<SEC-DOCUMENT>0000950170-24-029673.txt : 20240312
<SEC-HEADER>0000950170-24-029673.hdr.sgml : 20240312
<ACCEPTANCE-DATETIME>20240312083457
ACCESSION NUMBER:		0000950170-24-029673
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		108
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240312
DATE AS OF CHANGE:		20240312

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Inozyme Pharma, Inc.
		CENTRAL INDEX KEY:			0001693011
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				475129768
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39397
		FILM NUMBER:		24740312

	BUSINESS ADDRESS:	
		STREET 1:		321 SUMMER STREET
		STREET 2:		SUITE 400
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210
		BUSINESS PHONE:		857-330-4340

	MAIL ADDRESS:	
		STREET 1:		321 SUMMER STREET
		STREET 2:		SUITE 400
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Inozyme Pharma, LLC
		DATE OF NAME CHANGE:	20161222
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>inzy-20231231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:inzy="http://www.inozyme.com/20231231">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_76a60ac7-93d6-4c32-bfce-f6d2d8cea252" name="us-gaap:AccountingStandardsUpdateExtensibleList" contextRef="C_4ee9c018-375e-4d0f-ab9e-435246e8b7ce">http://fasb.org/us-gaap/2023#AccountingStandardsUpdate201912Member</ix:nonNumeric><ix:nonNumeric id="F_a15aaf36-3d5b-4787-b975-a3a77b3b6827" name="dei:AmendmentFlag" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric id="F_1cbeff8c-ad11-4b0e-bbd2-c155d4757782" name="dei:CurrentFiscalYearEndDate" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3">--12-31</ix:nonNumeric><ix:nonNumeric id="F_5309203e-500a-4126-b22b-ec8d64db6d1d" name="dei:EntityCentralIndexKey" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3">0001693011</ix:nonNumeric><ix:nonFraction id="F_0fc9b8f5-e2f0-43c6-b068-1c4c8f53dfd8" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="C_01add2ad-475c-4cb0-a885-6e7db27bc554" unitRef="U_pure" decimals="4" scale="0" format="ixt:num-dot-decimal">0.1338</ix:nonFraction><ix:nonNumeric id="F_e90451bb-00b0-4267-9f72-24a543a3e860" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" format="ixt:fixed-true">true</ix:nonNumeric><ix:nonNumeric id="F_e1dd4c93-e457-45e0-b6c0-ca83dbd27efa" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" contextRef="C_260e3568-2332-4710-9a63-9553a3e1f87f" format="ixt:fixed-true">true</ix:nonNumeric><ix:nonNumeric id="F_026d8e7b-ffcc-47b8-ac91-c8959a4e7883" name="dei:DocumentFiscalPeriodFocus" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3">FY</ix:nonNumeric><ix:nonNumeric id="F_dce1800e-309e-4f55-9e0c-343addd78c00" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" format="ixt:fixed-true">true</ix:nonNumeric><ix:nonFraction id="F_6360d63f-17d5-4de6-a919-fd4922754e06" name="us-gaap:CommitmentsAndContingencies" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_639d92d0-6f7f-4b32-af29-72c21c77075a" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_163a734f-613d-45f6-b523-f3a90ba56209" name="us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" contextRef="C_532bce2f-a513-4807-8f8f-ebc5cb9d4a86">http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentNet</ix:nonNumeric><ix:nonFraction id="F_8196d8a8-372d-4a07-a143-8661735a221d" name="us-gaap:NumberOfOperatingSegments" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" unitRef="U_Segment" decimals="INF" format="ixt:num-dot-decimal">1</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="inzy-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="C_471a56d8-9599-49a3-ac22-3a686ca9ff8d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0ff899d6-441a-422c-b0bd-1738ae7e6c26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e9fc3ff4-5b7b-4b15-a31d-763d0bfe62db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inzy:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4c84ce21-27ad-466f-a52b-53d2b027d662"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_be56dd08-7be1-43d7-b997-dbab1bf7f427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inzy:YaleUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d18b316d-5084-434e-a439-1915ad6efe10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inzy:K2HvMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_196b61ab-ba69-4401-87d4-819541ae1871"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inzy:YaleUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ce440ee2-4c72-4b3f-867c-b18a4779f0de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fc80a413-7ca1-4fd4-9918-01e35939d5b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9cdf7217-5d9d-4e8f-a508-7e31ed97b29e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_db0a0e7f-8b7b-448c-940d-e857265ac0d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inzy:YaleUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cad8e074-adf8-454f-b55e-9b9e5c164673"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1bb0cd98-9386-44b8-b7ca-6ea13928be77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1b475cba-fda5-4a60-90f8-717eba9366b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e6f1df46-623b-42c5-95a7-877ba9f99313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bdaa54b5-eb56-4511-8115-339fb1fdafab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inzy:K2HvMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5bc7e1b8-abf2-44b5-9b32-535f64c92fa2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inzy:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a654e8a2-be67-4c8a-a856-140b00703ba3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aa1d3c56-5369-4d66-b7ef-2331a4328983"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_53f07547-6128-43d4-94ec-d5cd4d0f51e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inzy:JefferiesLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cf58a586-baf1-45e2-afe5-cc909b0ac57a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_909f663f-1f61-4e6b-b9d6-919c23e28089"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0e40adfd-e61b-4fd5-8fdb-f07aeb03f570"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">inzy:ShareBasedPaymentArrangementTrancheFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-25</xbrli:startDate><xbrli:endDate>2022-07-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_afa7e7f7-939c-4d45-98c6-aac2333bb8a1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ecaeeeb0-1d3a-46e8-a993-a422899cf67d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inzy:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-23</xbrli:startDate><xbrli:endDate>2020-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fd818a77-dcd6-4172-b69f-ef9f6f65f940"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ebb0e8ce-192c-4794-b110-e57d539bd7f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4ee9c018-375e-4d0f-ab9e-435246e8b7ce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_41e6d162-5110-43e5-831b-9b8060b23a84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inzy:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bbdbd94c-6c63-4c85-99b0-648d3794ad11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b8ef8150-b682-4318-bd34-79e0eb945521"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inzy:K2HvMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-25</xbrli:startDate><xbrli:endDate>2022-07-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_580be68e-23a1-4156-859f-97d143db13e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3d6d281a-1b18-436a-aaa0-c7bcf2e894fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cc2d588b-2f3b-4c9e-8375-5d861c028af1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_52088c66-3520-4604-9fd3-bc8ff48b99dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inzy:K2HvMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_095b17b0-4474-4132-8919-5e9087e56021"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8f92c86f-a41e-44a3-8900-38efa4b160f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_93d69508-3aa9-4327-a66a-00b902adeda8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inzy:K2HvMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">inzy:ShareBasedPaymentArrangementTrancheFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c1e93c7a-08ea-4229-9081-72bf42fdc58f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inzy:JefferiesLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-14</xbrli:startDate><xbrli:endDate>2022-04-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9c13b456-85ec-4115-a24f-2f8c865d0abb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f4d73906-7252-43b1-b4b1-204a7275742a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_560a8eac-a2ea-4e9e-8e4c-468159d80f18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_94c35e60-92f5-4512-bce8-5ad4b2e3d95d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3f4c43df-91a9-4dcb-a518-2b872f3cab86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inzy:USGovernmentAgencyDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9dcd98d2-cef7-49c2-a825-548d1468b4ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inzy:USGovernmentAgencyDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6218f8b0-72c4-4511-8848-700fe16326a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f2eb39b0-33a2-4aff-a77e-446a7f20b7ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dac8f012-8074-43e0-b610-ec3ed404d713"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b766d812-c104-4ba8-94cb-06af03d52200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_02f9e665-ab6c-4248-ac91-2158ec322783"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inzy:K2LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_405879f4-cccf-412e-9ad8-4013cd3d818b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f5346b4d-f225-4d76-a62e-df2c1fef5d1f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_58e1da8f-d797-45d5-94a7-e1c0672c5b37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8bc77b63-43ca-4a39-8474-2b255355a3eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inzy:JefferiesLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c7103008-51fd-4024-8f26-143b54185554"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b5a7dbf5-13da-420d-8cd7-0ede5acf17cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inzy:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_263cecd1-5504-45b5-bec1-fb7bb72fed3f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inzy:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_08242d46-09fa-4d0f-acdd-9a2a331c3f18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f468c3aa-9d5e-4348-b6a5-6d3b6072b370"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ca6446c0-a789-468c-9c42-d76f1a43d7b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">inzy:OfficeSpaceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ba3b1d97-e28d-4318-9ed8-6d65ffffa8e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_da086e8a-c936-404a-b841-ba2c9c0e2bfa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_01add2ad-475c-4cb0-a885-6e7db27bc554"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-17</xbrli:startDate><xbrli:endDate>2020-07-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6f3ac30a-0134-4683-b65a-b99db351909d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inzy:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_031bf463-89a7-40b9-950c-5f55540d3e85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inzy:YaleUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e8c0a014-c50e-4051-b4de-b6a88a7006fe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_577acb1e-1a50-479e-a43c-9ea32fcb780c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a74fde5d-3b11-4279-84b0-6eaf17b9fed8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-17</xbrli:startDate><xbrli:endDate>2021-05-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_86c60b96-dc4e-40d1-8dc6-75af50996958"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_36317d60-ef8e-4485-8be4-dbe28ed900be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2ad74538-b479-4925-9f60-b6af61969b3d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inzy:YaleUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c219104e-7f65-4cfb-a306-535fab73fbae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5ea75401-6aea-4087-a31b-3b37976549a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6f7932b9-17b8-423d-9f3d-1d9425caa7f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-30</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c0269d4f-7dd7-4002-9ff8-a6effc16399e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_46f9ae16-b8c7-4213-9f64-dc61525d4c66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bc04799a-6e65-4820-b17f-b1036be4e528"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d9d28d21-3347-4c53-a22e-f87f54964ee4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inzy:K2HvMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f9151e1c-1a1c-4fd2-91c3-dfd8900bd0f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b6643dbc-a9cd-41a0-9331-c15dc4781614"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">inzy:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fe23324a-e605-4ce7-a370-83d0da0161d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inzy:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b69eb069-0d70-4c35-82e1-af14e7470196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f1b17c7a-98c5-4dda-8775-61fdebd34c84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f619a243-7caf-4810-be59-b9733e6d8eae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inzy:YaleUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_93fed2f2-49b6-4337-8584-7a6a8c8c936e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d2a5c6ce-86e7-4875-bb49-7e9cb50c94fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f1c3e67f-9945-41f0-944d-8d830ba9739e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-27</xbrli:startDate><xbrli:endDate>2023-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bebe8a61-3f52-4590-a963-a6915fc4e374"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inzy:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a9bb1918-b1d7-45e7-8152-c53d74f19eda"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inzy:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_639eb17d-d451-4e67-9099-b216251b8867"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5f12b8c5-840c-4b80-aafb-3c8b57f8ed2e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f0ae2476-b345-490a-a86b-4a01fe48843b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inzy:K2HvMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-25</xbrli:startDate><xbrli:endDate>2022-07-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f33f58db-c8e7-4f41-ad0b-b1c08a56375f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5bb4c6de-83a3-4b5b-8ccc-2887ba662ad0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_82b79cc2-0604-4d40-bafb-f6f4b9a694c4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_18d66cf9-fa61-4466-8750-6ba204ccf660"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-25</xbrli:startDate><xbrli:endDate>2022-07-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d09f7ff2-1a27-45d2-8579-2c27a2426a27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerDurationAxis">inzy:SixtyDaysPriorWrittenNoticeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-06</xbrli:startDate><xbrli:endDate>2021-05-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3069d94b-0504-4b09-8332-ed3b1c11af61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cd4ff0c3-e817-48e8-b8c3-ca0078eec69f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_23e7c97e-bcf3-4add-9b14-99d3a9ed6274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inzy:BofaSecuritiesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-27</xbrli:startDate><xbrli:endDate>2023-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a8a74a9f-0187-449d-bd71-ff493500514a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5ebf2fa0-40a8-42d4-9daa-b0340f2d221d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inzy:K2HvMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5fadef3d-5895-480b-9d9e-def33be1c27e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inzy:BofaSecuritiesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_16876f16-aca9-4cb2-b583-baf263afbd49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b8d04e02-0ef5-4212-8c55-26c32b719e5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inzy:YaleUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7521ee38-3522-499f-9163-aff0538685b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-25</xbrli:startDate><xbrli:endDate>2022-07-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0fef7786-5c9f-4661-84e2-6bd709ef1859"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dd2554f0-5fa2-4094-bb5c-964fac0c425e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8f452f4f-2469-461f-b6e0-17cef1221fa3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inzy:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f51cc874-6545-4fcf-a041-fffaa4e330ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_034c291a-b985-4a6b-bfa0-cd3fc75a6bbe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6a51238e-3618-4c6f-834a-a5b8760a5cab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">inzy:LaboratorySpaceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eeb4217e-fc77-4296-9ee9-2a609ec3e2d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">inzy:FederalAndStateTaxAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6180172f-c35b-4d20-961c-b44a3488a278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_26d33768-49f2-4d59-a581-db63d9838d45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a5581986-e14e-4e34-a7f8-7bba69e2c058"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7127e8c7-8b18-4fcc-9ba4-6bd21fc208d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inzy:K2HvMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-25</xbrli:startDate><xbrli:endDate>2022-07-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_18a731bb-67c4-4ab0-8890-db73d8f7acd7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5d4682fc-b7e8-4bc8-a04e-f170756de070"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inzy:K2HvMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b61af113-eb50-4b3e-aef8-307431908b88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inzy:YaleUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_35debf45-eff8-4880-842d-b7923517d412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inzy:K2HvMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">inzy:ShareBasedPaymentArrangementTrancheFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-25</xbrli:startDate><xbrli:endDate>2022-07-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6eef9496-93b0-48ca-b3cf-47eb906b4a01"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inzy:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-23</xbrli:startDate><xbrli:endDate>2020-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_18e79562-699d-4e71-9f51-f6b59fe5e488"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inzy:YaleUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_83b501bf-9deb-493d-89d6-5fbc9e9ca049"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inzy:YaleUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_68e0a225-f316-48f6-9fd5-63d50781b73b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a4ab63bc-07be-46e6-aa82-1e04ab169eca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_31d32f64-dc44-41d7-bce8-ff6cf58b79cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inzy:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1bd944ab-7162-429e-a0bf-1e98d8b5d629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e2f25e47-2422-40ab-810a-92c03b89c3a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bb47b565-7017-4ae4-8380-7d7bb5c73132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_67c9227f-23fa-4d03-94ed-39eb46d276a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inzy:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_85011284-cdc9-4bd4-845f-74414084de51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">inzy:RestrictedCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b153501c-2297-4e17-905e-f0f97a1348d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cabacfd7-585b-4a2b-88ce-edec24c747f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_12de314a-d4b0-494b-813f-351304fba130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_809272a0-4381-416d-b6c1-4926d329a113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_38923768-4f8c-4cf5-8568-d7b648fc7393"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a82024c8-742d-4976-8c8e-41e2b8b05ebd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2b1ba612-eaf7-4255-9f94-845320672517"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_260e3568-2332-4710-9a63-9553a3e1f87f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e4451f72-2b2b-4b91-8f5a-e4ab0f0244ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inzy:YaleUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_edffafaf-bcb8-4571-af95-10f388d3cb08"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0502b5cf-19d3-4a39-bb6c-6e6617f1dc75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inzy:JefferiesLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e462903e-5095-4918-b351-d475a954fa3c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inzy:TwoThousandSeventeenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_10590ddc-665f-42d2-b77b-89cf6c383211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">inzy:LaboratorySpaceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_532bce2f-a513-4807-8f8f-ebc5cb9d4a86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_627d9b19-c97f-4990-affb-d25c50839022"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8f668d05-5207-4a0e-8751-b2c77362080c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0c02063f-a103-4d30-8717-1985a331947e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inzy:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-25</xbrli:startDate><xbrli:endDate>2022-07-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cf7fde27-55f9-4b69-9589-3dfbcd890c64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inzy:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_578990c4-7b65-4722-8ca8-59f878771332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inzy:JefferiesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inzy:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_072e744e-d8a8-4b95-9e11-fd60fc749ad1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ba5b64e4-70b0-4502-8294-ad245be4038c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c2b667bf-badf-46cf-be28-9653192a233b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0bbdd3e1-67b1-4179-a2ad-34d654b46a8f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inzy:UnderwritingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inzy:BofaSecuritiesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-27</xbrli:startDate><xbrli:endDate>2023-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f0e6584f-b5b7-4d58-a88c-80a7eadaaae3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6f8af799-609d-4c14-b3ec-0e9bdd4c588e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">inzy:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e7cf70aa-36bc-46ec-bfe0-94356e1da198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerDurationAxis">inzy:ThirtyDaysPriorWrittenNoticeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-06</xbrli:startDate><xbrli:endDate>2021-05-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_65370ce0-f82e-4e38-acd5-1026ec007a18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">inzy:OfficeSpaceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_18a01e41-ea42-4897-ac23-422f3897a169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3c60cddf-e6e6-40e7-af29-5142f2416154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c5b05844-1535-4e7e-bc09-618ad8076340"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inzy:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1d9a39c0-b43f-460b-b719-403d215c02a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inzy:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ad70b717-7bb2-4c61-9bb0-95099842631c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e5909b1a-428c-48ad-8908-9d3d49539a18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0492ee51-d379-44b0-9b36-2dde4f604d4e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-06</xbrli:startDate><xbrli:endDate>2021-05-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>inzy:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_b26c1e5b-e21a-4bc2-827a-a1536cde1c95" fromRefs="F_212880b3-7bbd-414d-81a7-6f5c3c25b8a3 F_34c25793-e274-4a98-b618-192bea48ea94 F_5d11eac6-1566-416a-92bc-7160911079e4 F_8286ff25-fc6a-4473-a014-fe4d629b6f5c"></ix:relationship></ix:resources></ix:header></div>
  <div style="min-height:0.5in;"></div>
  <p style="border-top:2.25pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:15pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:15pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">WASHINGTON, DC 20549</span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:15pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:15pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f278e65e-c398-4424-8d50-5cf351e37555" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:15pt;font-family:Times New Roman;min-width:fit-content;">10-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Mark One)</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"/>
    <td style="width:96%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_6a001ff8-4155-4fa2-a9ee-cfd84c040447" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_653ef210-8a83-4ead-b54a-948a56abda1f" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">December 31, </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a760ab20-4c5c-4045-9b24-256e453c780f" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2023</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">OR</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"/>
    <td style="width:96%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_62537e37-6b72-42c2-9ee7-2558ed6cdc6e" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">For the transition period from _____________________ to _____________________</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commission File Number: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_277007f2-0d5d-43b7-9a2a-f337d54a6178" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">001-39397</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b97f3883-7cf4-4d2e-8548-4fdf31e64d66" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">INOZYME PHARMA, INC.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"/>
    <td style="width:50%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_87264056-918c-4bd6-8018-94564b77fd7d" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_99e44061-cdd8-4a60-956a-8a19af040ea2" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">38-4024528</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(I.R.S. Employer<br/>Identification No.)</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_a7f215a8-4c6e-4d16-8c69-6d64b541cba1" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">321 Summer Street</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;min-width:fit-content;">, </span><span style="font-size:8pt;"><ix:nonNumeric id="F_a0c5ac81-134e-4cbc-accd-eccebe1b81d3" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Suite 400</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_0f8b07b4-af4e-4c40-a953-5f6663a172eb" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Boston</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;min-width:fit-content;">, </span><span style="font-size:8pt;"><ix:nonNumeric id="F_664124fe-4006-445f-836d-56820ea2b8ca" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Massachusetts</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_187d31e5-e20b-4ed3-9b04-db1391605b5c" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">02210</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8cedc9e8-e996-4a4c-bc54-bb934f8e04ef" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">857</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">) </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ba79b74c-4c34-41cb-a708-cbdfb268c839" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">330-4340</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:39%;"/>
    <td style="width:1%;"/>
    <td style="width:20%;"/>
    <td style="width:1%;"/>
    <td style="width:39%;"/>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title of each class</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading Symbol(s)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7pt;"><ix:nonNumeric id="F_5511138e-b5fa-4e5f-811d-4850f93b3132" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock, par value $0.0001 per share</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7pt;"><ix:nonNumeric id="F_451fb127-7a81-4079-b2d2-ff928d2f777d" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">INZY</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7pt;"><ix:nonNumeric id="F_73209754-dbbc-404e-b1d0-421f79af32f9" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">None</span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_38b52897-a0b8-4c87-a76c-467cd985ab2d" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="dei:EntityWellKnownSeasonedIssuer"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">N</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">o</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> &#9746;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.  Yes &#9744; </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3e66591f-1ae1-4cec-ab3c-567885755591" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="dei:EntityVoluntaryFilers"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">N</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">o</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> &#9746;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4225b9f8-c637-4acb-9a0c-705b346f6450" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">  &#9746;    No  &#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).     </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_15c20643-f09c-4ad1-b6ef-5a22abff57ea" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Yes </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> &#9746;    No  &#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:15.537%;"/>
    <td style="width:1.1%;"/>
    <td style="width:3.299%;"/>
    <td style="width:55.989%;"/>
    <td style="width:20.096%;"/>
    <td style="width:1%;"/>
    <td style="width:2.979%;"/>
   </tr>
   <tr style="height:10.8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:3.6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_bb473025-22f3-4948-a56b-048025ff2b2f" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_d3826418-3c33-4508-b291-7417b51770f5" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_a3b8ea53-a5d8-4e69-87bf-eef1299373e1" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_948ff013-8b4d-4601-a484-fef62528f69b" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_15618657-b7c0-4424-9245-514029b365be" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.&#8195;</span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a0041ef5-58be-4ef5-a309-115a15f86284" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;&#8201;240.10D-1(b).&#8195;&#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).     Yes </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_56c65502-2b6a-4efd-abff-ee9d133257da" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> &#9744; </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">   No  &#9746;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2023, the last business day of the registrant&#8217;s most recently completed second fiscal quarter, the aggregate market value of the registrant's common stock held by non-affiliates of the registrant, based on the closing price of the registrant&#8217;s common stock on the Nasdaq Global Select Market on June 30, 2023, was </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29433588-2711-41a8-86de-4b0fb02745d0" contextRef="C_82b79cc2-0604-4d40-bafb-f6f4b9a694c4" name="dei:EntityPublicFloat" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">199,465,749</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">As of March 7, 2024, the registrant had 61,771,977 shares of common stock, $0.0001 par value per share, outstanding.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p>
  <div style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6d693039-939f-4fb6-99c3-3542c4ac4cf7" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">The registrant intends to file a definitive proxy statement pursuant to Regulation 14A within 120 days of the end of the fiscal year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">. Portions of such definitive proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K.</span></p></ix:nonNumeric></div>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TABLE OF CONTENTS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3%;"/>
    <td style="width:1%;"/>
    <td style="width:88%;"/>
    <td style="width:1%;"/>
    <td style="width:7%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">PART I</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_business"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 1. Business</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 1A. Risk Factors</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">59</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 1B. Unresolved Staff Comments</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">117</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="ic"><a href="#item_1c_cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 1C. Cybersecurity</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">117</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_properties"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 2. Properties</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">118</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 3. Legal Proceedings</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">118</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_safety_disclosure"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 4. Mine Safety Disclosures</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">118</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">PART II</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_market_for_registrants_common_equ"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">119</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_selected_financial_data"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 6. [Reserved]</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">120</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7_managements_discussion_analysis_f"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">121</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7a_quantitative_qualitative_disclos"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 7A. Quantitative and Qualitative Disclosures about Market Risk</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">131</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_8_financial_statement_supplementary"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 8. Financial Statements and Supplementary Data</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9_changes_in_disagreement_with_acco"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">118</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9_a_control_procedure"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 9A. Controls and Procedures</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">118</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9_b_or_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 9B. Other Information</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">119</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9c_disclosures_regarding"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">119</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">PART III</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10_director_executive_ficers_corpor"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 10. Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">120</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11_executive_compensation"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 11. Executive Compensation</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">120</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_12_security_ownership_certain_benef"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">120</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_13_certain_relationship_related_tra"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 13. Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">120</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_14_principal_accountant_fees_servic"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 14. Principal Accountant Fees and Services</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">120</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">PART IV</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15_exhibits_financial_statement_s_1"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 15. Exhibits and Financial Statement Schedules</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">121</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16_form_10k_summary_1"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 16. Form 10-K Summary</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">123</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signatures_1"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Signatures</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">124</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">i</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Annual Report on Form 10-K contains forward-looking statements, which reflect our current views with respect to, among other things, our operations and financial performance. All statements, other than statements of historical fact, contained in this Annual Report on Form 10-K, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;outlook,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and the negative version of these words and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such forward-looking statements are subject to various risks and uncertainties. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. We believe these factors include but are not limited to those described under the heading &#8220;Summary of Material Risks Associated with Our Business&#8221; and the &#8220;Risk Factors&#8221; section and include, among other things</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ongoing Phase 1/2 clinical trials of INZ-701 for adults with ENPP1 and ABCC6 Deficiencies, our ongoing Phase 1b clinical trial of INZ-701 for infants with ENPP1 Deficiency (the "ENERGY-1 trial"), our ongoing pivotal trial of INZ-701 in pediatric patients with ENPP1 Deficiency (the "ENERGY-3" trial), and our ongoing Phase 1 clinical trial of INZ-701 in patients with end-stage kidney disease receiving hemodialysis (the "SEAPORT-1 trial"), including statements regarding the timing of enrollment and completion of the clinical trials and the period during which the results of the clinical trials will become available;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing, design, and conduct of our planned clinical trials of INZ-701 for patients with ENPP1 and ABCC6 Deficiencies, including our planned pivotal clinical trials of INZ-701 for infants (the "ENERGY-2 trial"), and in adolescents and adults with ENPP1 Deficiency (the "ENERGY-4 trial"), and our planned Phase 3 clinical trial of INZ-701 for patients with ABCC6 Deficiency;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our plans to conduct research, preclinical testing, and clinical trials of INZ-701 for additional indications;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our plans to conduct research, preclinical testing, and clinical trials of other product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our plans to engage in regulatory interactions with the U.S. Food and Drug Administration, the European Medicines Agency and other regulatory authorities;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our plans with respect to regulatory filings;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing of, and our ability to obtain and maintain, marketing approvals of INZ-701, and the ability of INZ-701 and our other product candidates to meet existing or future regulatory standards;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expectations regarding our ability to fund our cash flow requirements with our cash, cash equivalents and short-term investments;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the potential advantages of our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the rate and degree of market acceptance and clinical utility of our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our estimates regarding the potential market opportunity for our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our commercialization and manufacturing capabilities and strategy;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our intellectual property position;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to identify additional products, product candidates or technologies with significant commercial potential that are consistent with our commercial objectives;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to comply with the covenants under our loan agreement;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the impact of government laws and regulations;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our competitive position; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expectations regarding the time during which we will be an emerging growth company under the Jumpstart our Business Startups Act of 2012.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Annual Report on Form 10-K, particularly in the &#8220;Risk Factors&#8221; section, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, collaborations, joint ventures or investments we may make or enter into.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">You should read this Annual Report on Form 10-K and the documents that we have filed as exhibits to this Annual Report on Form 10-K completely and with the understanding that our actual future results may be materially different from what we expect. The forward-looking statements contained in this Annual Report on Form 10-K are made as of the date of this Annual Report on Form 10-K, and we do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Annual Report on Form 10-K includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties as well as our own estimates of potential market opportunities based on our analysis of these data, research, surveys and studies. All of the market data used in this Annual Report on Form 10-K involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. Our estimates of the potential market opportunities for our product candidates include a number of key assumptions based on our industry knowledge, industry publications and third-party research, surveys and studies, which may be based on a small sample size and fail to accurately reflect market opportunities. While we believe that our internal assumptions are reasonable, no independent source has verified such assumptions.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Summary of Material Risks Associated with Our Business</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business is subject to a number of risks that if realized could materially affect our business, prospects, operating results, and financial condition. These risks are discussed more fully in the &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K. These risks include the following:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred significant losses since our inception. To date, we have not generated any revenue from product sales. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future and may never achieve or maintain profitability. Our net losses were $71.2 million for the year ended December 31, 2023 and $67.1 million for the year ended December 31, 2022.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will need substantial additional funding. If we are unable to raise capital when needed or on attractive terms, we may be required to delay, limit, reduce or terminate our research and development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have a loan agreement that requires us to meet specified funding conditions for future draw downs and operating covenants and places restrictions on our operating and financial flexibility. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have a limited operating history and are early in our development efforts. We are heavily dependent on the success of our lead product candidate, INZ-701. If we are unable to commercialize INZ-701 or experience significant delays in doing so, our business will be materially harmed.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot be certain of the timely completion or outcome of our preclinical testing and clinical trials. The results of preclinical studies may not be predictive of the results of clinical trials, and preliminary interim topline results of clinical trials do not necessarily predict final results. The results of any early-stage clinical trials we conduct may not be predictive of the results of later-stage clinical trials and our product candidates could be associated with serious adverse events or undesirable side effects.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interim topline and preliminary results from our clinical trials that we announce or publish from time to time, such as interim data we have disclosed from our ongoing Phase 1/2 clinical trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency, may change as more participant data become available and are subject to audit and verification procedures, which could result in material changes in the final data. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to obtain required marketing approvals for, commercialize, manufacture, obtain, maintain and enforce patent protection for, gain market acceptance of or obtain and maintain coverage, adequate pricing and adequate reimbursement from third-party payors for our product candidates, or experience significant delays in doing so, our business will be materially harmed and our ability to generate revenue from product sales will be materially impaired.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The design and conduct of our clinical trials for the treatment of ENPP1 or ABCC6 Deficiencies or calciphylaxis may take longer, be more costly or be less effective as a result of the novelty of development in these diseases. We may use new or novel endpoints or methodologies and regulatory authorities may not consider the endpoints of our clinical trials to provide clinically meaningful results.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are conducting clinical trials for our product candidates at sites outside the United States. If the FDA determines that any such trial did not comply with all applicable U.S. laws and regulations, the FDA may not accept the data from that trial, in which case we would likely need to conduct one or more additional clinical trials.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We focus our research and product development on treatments for rare diseases. Given the small number of patients who have the diseases that we are targeting, it is critical to our ability to grow and become profitable that we continue to successfully identify patients with these rare diseases and capture a significant market share.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely, and expect to continue to rely, on third parties to conduct our clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, which may prevent or delay our ability to seek or obtain marketing approval for or commercialize our product candidates or otherwise harm our business. If we are not able to maintain these third-party relationships or if these arrangements are terminated, we may have to alter our development and commercialization plans and our business could be adversely affected.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely, and expect to continue to rely, on third parties for the manufacture of our product candidates for preclinical testing and clinical trials, as well as for commercial manufacture if any of our product candidates receive marketing approval. This reliance on third parties may increase the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to obtain, maintain, enforce and protect patent protection for our technology and products or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be adversely affected.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are highly dependent on the research and development, clinical, financial, operational and other business expertise of our executive officers, as well as the other principal members of our management, scientific and clinical teams. Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.</span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The summary risk factors described above should be read together with the text of the full risk factors set forth in the section titled &#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report on Form 10-K and the other information set forth in this Annual Report on Form 10-K, including our audited consolidated financial statements and the related notes, as well as in other documents that we file with the Securities and Exchange Commission. The risks summarized above or described in full below are not the only risks that we face. Additional risks and uncertainties not precisely known to us, or that we currently deem to be immaterial may also harm our business, financial condition, results of operations and future growth prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART I</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Unless the context otherwise </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">requires</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">, we use the term &#8220;Inozyme,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and similar designations in this Annual Report on Form 10-K to refer to Inozyme Pharma, Inc. and its wholly owned subsidiaries.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_business"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1. B</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">USINESS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. Through our in-depth understanding of a key biological pathway, we are pursuing the development of therapeutics that address pathologic mineralization and intimal proliferation, or smooth muscle cell overgrowth that leads to narrowing and the obstruction of blood vessels, to improve the underlying causes of these debilitating diseases. It is well established that low levels of plasma pyrophosphate ("PPi") drive pathologic mineralization and low levels of adenosine drive intimal proliferation in a number of rare diseases. We are initially focused on developing a novel therapy for diseases characterized by pathologic calcification and intimal proliferation, including ENPP1 Deficiency and ABCC6 Deficiency, as well as calciphylaxis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ENPP1 and ABCC6 Deficiencies are rare chronic, systemic, and progressive genetic diseases occurring over the course of a patient&#8217;s lifetime, starting as early as fetal development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and spanning into adulthood. These diseases represent a significant unmet medical need, with high mortality rates for infants with ENPP1 Deficiency and high levels of morbidity occurring for patients with these diseases throughout their lives. Calciphylaxis is a rare disorder with a high mortality rate that mostly affects patients with end-stage kidney disease ("ESKD"). There are currently no approved therapies for ENPP1 Deficiency, ABCC6 Deficiency, or calciphylaxis. Currently available treatments seek to minimize the manifestations of these diseases and do not address the underlying causes of these diseases.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our lead product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to cleave extracellular adenosine triphosphate ("ATP") to generate PPi and adenosine monophosphate ("AMP"), which can be processed to phosphate and adenosine. This process is central to the regulation of calcium deposition throughout the body and is further associated with the inhibition of intimal proliferation. We have generated robust proof of concept data in preclinical models of ENPP1 Deficiency, ABCC6 Deficiency, and chronic kidney disease ("CKD") demonstrating that INZ-701 prevented pathologic mineralization and skeletal abnormalities, led to improvements in overall health and survival, and prevented intimal proliferation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are currently conducting clinical trials of INZ-701 for the treatment of ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis. The U.S. Food and Drug Administration ("FDA") has granted orphan drug designation and the European Medicines Agency ("EMA") has granted orphan designation to INZ-701 for the treatment of ENPP1 Deficiency and ABCC6 Deficiency. The FDA has also granted fast track designation for INZ-701 for the treatment of ENPP1 Deficiency and rare pediatric disease designation for INZ-701 for the treatment of ENPP1 Deficiency. Refer to the "Clinical Development of INZ-701 for ENPP1 Deficiency" and "Clinical Development of INZ-701 for ABCC6 Deficiency"</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">sections below for further details on our clinical programs.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We retain worldwide, exclusive development and commercialization rights to our pipeline and programs, including INZ-701. Our current development programs are protected through exclusive intellectual property rights, including filed and issued patents covering composition of matter for ENPP1-Fc fusion proteins, including INZ-701, and methods of treatment. We obtained an exclusive, worldwide license to our foundational intellectual property rights from Yale University ("Yale") in January 2017. In July 2020, we entered into an intellectual property asset purchase agreement with Alexion Pharmaceuticals, Inc. ("Alexion") pursuant to which Alexion sold and assigned to us its right, title, and interest in and to specified patent rights and other specified assets solely related to ENPP1.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To date, we have funded our operations primarily with proceeds from the sales of convertible preferred stock, offerings of common stock and pre-funded warrants, and borrowings under our loan and security agreement (the "Loan Agreement") with K2 HealthVentures LLC ("K2HV").</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Strategy</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our goal is to develop and commercialize safe and effective therapies for the treatment of patients suffering from a broad range of genetic and non-genetic diseases of pathologic mineralization and intimal proliferation. The critical components of our strategy to achieve this goal include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Efficiently advance clinical development for our lead product candidate, INZ-701, with a focus on infants and children with ENPP1 and ABCC6 Deficiencies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Our initial studies of INZ-701 in adult patients with ENPP1 and ABCC6 Deficiencies provided safety, pharmacokinetic, and pharmacodynamic data supporting clinical development in infants and children with these diseases. We believe that these affected groups represent the most urgent unmet need in these disorders. In September 2023, we opened the first site for our ENERGY-3 trial, a pivotal trial in pediatric patients with ENPP1 Deficiency, and patient recruitment is underway. We are also currently enrolling infants with ENPP1 Deficiency in our ENERGY-1 Phase 1b clinical trial. We expect to begin treating infants with ABCC6 Deficiency as part of the ENERGY-1 trial. Pending appropriate financial resources, we may conduct additional clinical trials of INZ-701 in adolescents and adults with ENPP1 Deficiency. Subject to regulatory review and sufficient funding, we plan to initiate a Phase 3 clinical trial of INZ-701 in patients with ABCC6 Deficiency in the first quarter of 2025. We believe that our clinical strategy, subject to ongoing discussions with regulatory authorities, of linking the restoration of plasma PPi levels to measures of physiological and clinical efficacy may provide an efficient path for development and availability of clinical data. </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Build a patient-focused company to treat diseases of pathologic mineralization and intimal proliferation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We intend to continue to engage with patient advocacy groups, medical centers of excellence, and medical specialists to fully understand the physical and economic burden these diseases have on patients. We have completed a burden of disease study in ENPP1 Deficiency and ABCC6 Deficiency with GACI Global, a patient advocacy organization dedicated to bettering the lives of families affected by generalized arterial calcification of infancy ("GACI") and autosomal-recessive hypophosphatemic rickets type 2 ("ARHR2") to understand the progression of the disease from the perspective of a patient and caregiver. We have completed a retrospective, cross-sectional natural history study of patients who had GACI or any presentation of ENPP1 Deficiency. We have several ongoing programs, including a retrospective, longitudinal natural history study of patients with ENPP1 Deficiency and ABCC6 Deficiency and a prospective, longitudinal natural history study of patients with ENPP1 Deficiency and ABCC6 Deficiency. Finally, we have launched a registry for all patients with ENPP1 Deficiency and infantile-onset ABCC6 Deficiency in order to expand our understanding of the burden of disease and disease progression across the entire disease population. We believe that the findings from these studies and others like it have been and will be important in supporting ongoing and future trial design and patient enrollment. </span></div></div>
  <p style="margin-left:12.467%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are also building awareness and understanding of the disease by promoting, through physician networks and patient organizations, the systematic genetic diagnosis of at-risk mothers, infants, and children to best intervene as early as possible in the disease. We have worked with multiple public and private organizations to introduce routine testing for ENPP1 and ABCC6 variants. Our partnership with the Rady Children&#8217;s Institute for Genomic Medicine aims to expand newborn screening for genetic diseases to 1,000 diseases and sequence 3.7 million newborns annually. We successfully advocated for inclusion of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ENPP1 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ABCC6 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in the initial list of genes in the Genomic England&#8217;s Generation Study, which aims to sequence the genomes of more than 100,000 infants and pave the way for potential widespread implementation of whole-genome sequencing in newborn screening.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Establish commercialization infrastructure for the marketing and sale of INZ-701 for rare indications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We retain worldwide, exclusive development and commercialization rights to INZ-701. Our current efforts focused on disease awareness and diagnosis, through our interactions with physician networks and patient organizations, as well as our patient registry, are laying the groundwork for an independent commercial organization. Given the limited number of specialists who treat the rare diseases we are initially pursuing, we believe that we will be able to commercialize INZ-701, if approved, in these indications with a small, targeted, internal sales and commercial organization in the United States and other major markets. Our executives have a strong track record and experience in building and managing biopharmaceutical companies and in rare disease research and development, developing new markets, obtaining marketing approval for and commercializing therapies for previously unexplored rare diseases. We may explore the use of a variety of types of collaboration, co-promotion, distribution, and other marketing arrangements with one or more third parties to commercialize our product candidates in smaller markets outside the United States or for other situations in which a larger sales and marketing organization is required. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expand our research and development efforts for INZ-701 in additional diseases of pathologic mineralization and intimal proliferation and for other therapies beyond INZ-701.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Based on its mechanism of action, we believe that INZ-701 has the potential to increase plasma PPi levels and provide therapeutic benefit to patients beyond those with monogenic defects in the ENPP1 or ABCC6 gene, including patients with calciphylaxis. Although ENPP1 Deficiency was initially described in patients with biallelic ENPP1 Deficiency (homozygous or compound heterozygous mutations), many patients with monoallelic ENPP1 Deficiency (heterozygous mutations) have clinical symptoms, potentially increasing the worldwide prevalence. In February 2024, we initiated SEAPORT-1, a Phase 1 clinical trial designed to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of INZ-701 in up to 10 patients with ESKD receiving hemodialysis. We also plan to continue to apply our expertise to identify and develop new therapeutics for ENPP1 Deficiency, ABCC6 Deficiency, calciphylaxis, and other diseases of pathologic mineralization. For example, we are currently exploring the potential for development of a gene therapy for ENPP1 Deficiency. </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Continue to strengthen and expand our intellectual property portfolio and our rights to complementary technologies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We intend to continue to pursue new scientific and therapeutic insights to position ourselves as leaders in the treatment of diseases impacting the vasculature, soft tissue and skeleton as well as intimal proliferation. In our Company's laboratory and in collaboration with academic and research institutions, we plan to continue to conduct translational experiments, validate disease models and evaluate new treatment modalities in our area of focus. Our current development programs are protected through exclusive intellectual property rights, including with filed and issued patents covering composition of matter for ENPP1-Fc fusion proteins, including INZ-701, and methods of treatment. We have expanded and expect to continue to expand the breadth of our intellectual property portfolio over time to incorporate novel insights we obtain through our research. In addition, we may further expand our development pipeline by opportunistically in-licensing or acquiring the rights to complementary technologies and product candidates. For example, in July 2020, we expanded our intellectual property portfolio when we acquired specified patent rights and other specified assets related to ENPP1 from Alexion. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pipeline</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our lead development programs, for which we retain worldwide exclusive development and commercialization rights, are summarized in the table below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img187419207_0.jpg" alt="img187419207_0.jpg" style="width:720px;height:311px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Diseases of Pathologic Mineralization: A Significant Unmet Need</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Mineralization is a biological process during which an organism deposits hydroxyapatite, an organic extracellular matrix that gives rise to essential structures, such as bone and teeth in humans. In human development, this normal mineralization process begins as early as fetal development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and continues throughout life. Diseases of pathologic mineralization have high levels of morbidity and mortality and can have a genetic and non-genetic basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The Mineralization Pathway</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A metabolic pathway that has been conserved throughout evolution in higher organisms is the key to regulating mineralization in the human body. Multiple enzymes and other proteins perform sequential reactions in this pathway as part of a normal mineralization process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In a properly functioning mineralization pathway, the protein encoded by the ABCC6 gene (ATP-Binding Cassette in the C6 family) located on the cellular membrane is responsible for transporting ATP from inside a cell to outside the cell. The enzyme encoded by the ENPP1 gene (ectonucleotide pyrophosphatase/phosphodiesterase 1) then cleaves ATP into PPi and AMP. PPi is a potent regulator of mineralization and, in particular, controls the rate of calcium crystal deposition in bone. AMP is further metabolized into adenosine, a potent regulator of cellular proliferation that, in particular, modulates a blood vessel&#8217;s response to injury and is responsible for preventing intimal proliferation, or the overgrowth of smooth muscle cells inside blood vessels.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The normal function of this mineralization pathway is depicted in the figure below.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img187419207_1.jpg" alt="img187419207_1.jpg" style="width:720px;height:381px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pathology of Diseases of Pathologic Mineralization</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the proper function of the key mineralization pathway is altered or disturbed, then both genetic and non-genetic diseases and conditions involving pathologic mineralization can result. Genetic mutations affecting ENPP1, a critical enzyme in the mineralization pathway, result in low levels of PPi and AMP, a precursor of adenosine. Genetic mutations affecting ABCC6, a critical protein in the mineralization pathway, decrease the availability of extracellular ATP required for proper ENPP1 function and give rise indirectly to low levels of PPi and AMP, a precursor of adenosine.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Low levels of PPi lead to pathologic mineralization and pathological calcification in areas of the body where it should not occur, referred to as ectopic calcification. This ectopic calcification occurs in the vasculature and soft tissue, including multiple organ systems, and results in disease. The heart, kidney, and skin are especially vulnerable to the effects of pathologic mineralization and pathological, ectopic calcification. Pathologic, ectopic calcification in blood vessels inside bones can also interfere with normal skeletal mineralization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The mechanism of PPi and consequences of low levels of PPi are depicted in the figure below.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img187419207_2.jpg" alt="img187419207_2.jpg" style="width:720px;height:378px;"/>&#160;</p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Low levels of adenosine lead to the narrowing and obstruction of blood vessels caused by intimal proliferation and potential development of cardiovascular complications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The mechanism of adenosine and consequences of low levels of adenosine are depicted in the figure below.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img187419207_3.jpg" alt="img187419207_3.jpg" style="width:706px;height:357px;"/>&#160;</p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ENPP1 and ABCC6 Deficiencies are chronic, systemic, and progressive diseases occurring over the course of a patient&#8217;s lifetime, starting as early as fetal development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and spanning into adulthood.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consequences of genetic mutations affecting ENPP1 are depicted in the figure below.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img187419207_4.jpg" alt="img187419207_4.jpg" style="width:720px;height:360px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consequences of genetic mutations affecting ABCC6 are depicted in the figure below.</span></p>
  <p style="text-indent:9.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img187419207_5.jpg" alt="img187419207_5.jpg" style="width:720px;height:370px;"/><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ENPP1 Deficiency and Disease Manifestations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img187419207_6.jpg" alt="img187419207_6.jpg" style="width:720px;height:318px;"/>&#160;</p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ENPP1 Deficiency is a rare, inherited, genetic inborn error of metabolism caused by inactivating mutations in the ENPP1 gene. The condition is inherited as an autosomal recessive trait in which mutations in the ENPP1 gene result in decreased or absent activity of the ENPP1 enzyme. ENPP1 Deficiency results in low plasma levels of PPi, vascular calcification, and intimal proliferation, and is a single, chronic, systemic, and progressive disease with high mortality and morbidity. The spectrum of manifestations for ENPP1 Deficiency includes an infantile phase, a pediatric phase and an adult phase.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the acute infantile phase, which has been referred to as GACI in the medical literature, ENPP1 Deficiency is characterized by narrowing of large and medium arteries caused by severe and pathological vascular calcification and intimal proliferation, resulting in myocardial infarction, stroke, and dysfunction and potential failure of major organs, such as the heart and kidneys. The disease can be diagnosed prenatally when an ultrasound shows characteristic calcifications in the fetus. Infants with ENPP1 Deficiency have clinical signs of hypertension, heart disease and kidney disease even at birth. Mortality caused by ENPP1 Deficiency is at the highest during the infantile phase and occurs predominantly in the first 12 months of life. Approximately 50% of infants with ENPP1 Deficiency die within 6 months of birth. If they survive the crisis of infancy during the first 6 months of life, individuals with ENPP1 Deficiency are likely to survive through adolescence and beyond, but with significant morbidity and a low quality of life.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the pediatric phase, in addition to continuing vascular and organ calcification, ENPP1 Deficiency is characterized by the onset of rickets, which has been referred to in the medical literature as ARHR2. This is associated with an excess circulating concentration of a hormone known as fibroblast growth factor-23 (FGF23), which in turn causes the kidneys to waste phosphate, giving rise to rickets. ENPP1 Deficiency is also associated with severe skeletal deformities, short stature, and severe bone and joint pain. In addition, children with ENPP1 Deficiency may experience excess calcification in joints and ligaments and dental problems caused by disrupted tooth movement and exfoliation. Early onset of hearing loss has also been reported in these children. Patients with pediatric ENPP1 Deficiency experience impaired growth and development and generally decreased quality of life, including impaired ability to engage in normal childhood activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the adult phase following closure of the bone growth plates at the end of adolescence, in addition to continuing vascular and organ calcification, patients with ENPP1 Deficiency have osteomalacia, severe bone and joint pain, fatigue, muscle weakness and risk of recurring bone fractures. Adults with ENPP1 Deficiency experience significant functional and cognitive impairment and generally decreased quality of life, including impaired activities of daily living.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The graphs below, adapted from a third-party study, show that patients with ENPP1 Deficiency have decreased levels of PPi and elevated levels of ATP in the plasma. This study measured plasma levels of PPi and plasma levels of ATP in healthy volunteers between 19 and 40 years of age and in patients with ENPP1 Deficiency between the ages of one month and 19 years of age. A p-value is a conventional statistical method for measuring the statistical significance of clinical results. A p-value of less than 0.05 is generally considered to represent statistical significance, meaning that there is a less than 5% likelihood that the observed results</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">occurred by chance. Values are presented as the mean &#177; standard deviation ("SD"). In these graphs, the symbol ** represents a p-value of less than 0.005 and the symbol *** represents a p-value of less than 0.001.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img187419207_7.jpg" alt="img187419207_7.jpg" style="width:557px;height:212px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Source: Nitschke et al. Experimental &amp; Molecular Medicine (2018)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Retrospective Natural History Study</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We conducted what we believe is the largest retrospective, cross-sectional, natural history study of infants, children and adults who had GACI or any presentation of ENPP1 Deficiency, including subjects with the acute form of ABCC6 Deficiency who were diagnosed with GACI as infants. The U.S. National Institutes of Health ("NIH") and the University of M&#252;nster in Germany contributed data on 127 subjects across 18 countries to this natural history study. Preliminary results from the study suggest that ENPP1 Deficiency, regardless of its phenotypic manifestation or original diagnosis as GACI or ARHR2, appears to be a chronic, systemic, and progressive disease that occurs over the course of a patient&#8217;s lifetime.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As shown in the graph below, in our natural history study, arterial calcification preceded skeletal abnormalities, which preceded postnatal rickets. This data is shown using a Kaplan&#8211;Meier curve, also known as the product limit estimator, a non-parametric statistic used to estimate the probability of an event occurring given a defined time frame. While they occur at a defined rate, these manifestations occur simultaneously and concurrently following birth. The data indicate that the condition referred to as GACI in the medical literature is not independent of the condition referred to as ARHR2 in the medical literature. Preliminary results from our study suggest that arterial calcification and rickets are inseparable and dependent phenomena of ENPP1 Deficiency.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img187419207_8.jpg" alt="img187419207_8.jpg" style="width:614px;height:482px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The data also suggest that patients who survive their first 12 months of life continue developing a systemic, progressive disease involving arterial, skeletal, and other organ calcifications, leading to physiological dysfunction across many systems. The graph below shows the Kaplan&#8211;Meier curve demonstrating systemic progression of the disease. The following manifestations of disease occur in progression: arterial calcification, cardiac dysfunction, organ calcification, pulmonary dysfunction, and neurological dysfunction.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img187419207_9.jpg" alt="img187419207_9.jpg" style="width:616px;height:482px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The data suggest that arterial calcification, organ calcification, and organ dysfunction proceed in a progressive manner, with organ-specific symptoms emerging sequentially with time well into adulthood.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on our retrospective natural history study, we believe that ENPP1 Deficiency is characterized by concurrent onset of manifestations, albeit at different rates, and that ENPP1 Deficiency is a chronic, systemic, and progressive disease.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2022, we initiated a retrospective, longitudinal natural history study of patients with ENPP1 Deficiency and ABCC6 Deficiency and a prospective, longitudinal natural history study of patients with ENPP1 Deficiency and ABCC6 Deficiency. These studies are designed to test and validate our findings from our retrospective, cross-sectional natural history study. These studies are also designed to inform the design of pivotal trials and provide control data which may potentially be used in analysis of future therapeutic trials. We have completed a retrospective, cross-sectional natural history study of patients who had GACI or any presentation of ENPP1 Deficiency.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ENPP1 Deficiency Incidence and Prevalence; Current Standard of Care</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ENPP1 Deficiency is estimated to occur in approximately one in 64,000 pregnancies worldwide, and we believe there are approximately 37,000 patients in addressable markets worldwide with ENPP1 Deficiency. In North America, the European Union ("EU"), Japan, and Brazil, we believe there are approximately 9,400 patients with ENPP1 Deficiency. In 2022, an analysis of all published cases of ENPP1 Deficiency patients diagnosed with GACI or ARHR2, and two published natural history studies, reported a threefold increase in pathogenic/likely pathogenic </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ENPP1 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">variants compared to those identified as of 2020.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are currently no approved therapies for ENPP1 Deficiency. Currently available treatments seek to minimize the manifestations of this disease. Some retrospective studies have reported potential therapeutic effect in infants of the bisphosphonate etidronate, a first-generation bisphosphonate developed to treat osteoporosis. However, these findings have been controversial due to selection bias in the study. In addition, etidronate has been discontinued in the United States, and bisphosphonate use can be associated with longer term adverse effects on skeletal development. Administration of active vitamin D3 and oral phosphate are sometimes used to address the rickets of ENPP1 Deficiency, although use of oral phosphate may actually increase the risk of pathological calcification. In a third-party healthy volunteer study, treating PPi deficiency by adjusting the diet was an inefficient process, with only a small fraction of dietary PPi being absorbed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ABCC6 Deficiency and Disease Manifestations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ABCC6 Deficiency is a rare, autosomal recessive gene disease characterized by a progressive ectopic deposition of calcium phosphate crystals on various extracellular matrices which leads to fragmentation of elastic fibers affecting the elastin-rich tissues such as the skin, the retina, and the vascular wall. Clinically diagnosed as pseudoxanthoma elasticum ("PXE") in adults, ABCC6 Deficiency has a high morbidity and cardiovascular and ophthalmological manifestations. Ocular changes include angioid streaks reflecting mineralization of Bruch&#8217;s membrane behind the pigmented retinal epithelium, which allows neovascularization of the retina, leading to loss of visual acuity, hemorrhage, and blindness. Cardiovascular manifestations include intermittent claudication, gastrointestinal ("GI") hemorrhages associated with stenoses of GI arteries, and stroke. Ectopic mineralization has also been noted in kidneys, joints, and tendons in patients with ABCC6 Deficiency, demonstrating this is a systemic and heterogenous disease. Infants with ABCC6 Deficiency may present with symptoms nearly identical to infants with ENPP1 Deficiency, and this syndrome is referred to as GACI-2.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Older pediatric patients with ABCC6 Deficiency may develop or present with ischemic stroke secondary to cerebrovascular stenosis and insufficiency, as well as other signs and symptoms observed in adult patients. In our natural history study of early onset ABCC6 Deficiency, we observed four of nine (44%) patients with biallelic ABCC6 mutations who suffered stroke at an early age, ranging from in utero to four years. These patients suffered significant disability, including residual paralysis and seizure disorders. Herring et al, have reported on a two-month-old girl with ABCC6 Deficiency caused by biallelic mutations who presented with multiple cerebral infarcts as well as extensive vascular calcification. Yasuhara described a 14-year-old girl with PXE who had no overt neurological deficits but exhibited occlusion of the right internal carotid artery, as well as other cerebral arterial occlusions. Bertamino et al reported on two pediatric patients with PXE who presented with cerebral vasculopathy and early onset stroke. Imaging of both patients revealed prominent narrowing of cerebral arteries. One of these patients remained undiagnosed until overt PXE developed later in life. Grossi et al systematically evaluated 38 pediatric patients with stroke of unknown etiology and screened them using a customized gene panel including 15 genes associated with genetic disease related to pediatric stroke. Four of the 38 patients had either heterozygous or compound heterozygous ABCC6 mutations. In addition, through our physician outreach program, we are aware of multiple other unpublished pediatric patients with ABCC6 Deficiency with either stroke or neurological symptoms. We suspect that many pediatric patients with unexplained stroke due to heterozygous and biallelic ABCC6 Deficiency remain undiagnosed. This information suggests we have identified a patient population with a severe unmet need who are in need of definitive treatment.</span><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The graphs below, adapted from a third-party study, show that patients with PXE have decreased levels of PPi and ATP in the plasma. This study measured plasma levels of PPi and plasma levels of ATP in healthy volunteers with an average age of 45 years (SD &#177; 11 years) and in patients with PXE with an average age of 46 years (SD &#177; 13 years). A p-value is a conventional method for measuring the statistical significance of clinical results. Values are presented as the mean &#177; SD. In these graphs, the symbol ### represents a p-value of less than 0.005.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img187419207_10.jpg" alt="img187419207_10.jpg" style="width:489px;height:275px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Source: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Kauffenstein, et al. J Inv Derm </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2018</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ABCC6 Deficiency Incidence and Prevalence; Current Standard of Care</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ABCC6 Deficiency is estimated to affect approximately one per 25,000 to 50,000 individuals, with the disease being diagnosed twice as frequently in females as in males, and we believe there are more than 67,000 patients worldwide with ABCC6 Deficiency. In North America, the EU, Japan, and Brazil, we believe there are approximately 24,400 patients with ABCC6 Deficiency.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are currently no approved therapies for ABCC6 Deficiency. Currently available treatments seek to minimize the manifestations of this disease. Ophthalmic symptoms are typically treated with intravitreal injections of vascular endothelial growth factor inhibitors to slow the progression of choroidal neovascularization. However, damage to Bruch&#8217;s membrane in these patients leads to continued and recurring choroidal neovascularization, causing vision loss. The current treatment approach for slowing or limiting the cardiovascular manifestations of PXE is based on the reduction of cardiovascular risk factors through lifestyle changes or in some cases by taking cholesterol-lowering agents. In the event of severe vascular disease, patients may undergo standard surgical bypass or angioplasty procedures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Calciphylaxis and Disease Manifestations</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Calciphylaxis is a rare disease with a high mortality rate that mostly affects patients with ESKD. This disease is associated with low levels of PPi and is characterized by pathologic mineralization and intimal proliferation of the vasculature in the skin and fatty tissues leading to poor blood flow, blood clots, painful skin ulcers, serious infections, and death. Initial skin lesions typically present as extremely painful plaques and nodules, and progress to necrotic ulcers. This disease has a reported one-year survival rate of approximately 50%. The estimated incidence rate of calciphylaxis is approximately 3.5 per 1,000 patients with ESKD with approximately 5,000 new patients presenting annually across major geographies, including North America, the EU, Japan, and Brazil. There are currently no approved therapies for calciphylaxis, although use of sodium thiosulfate, a chelating agent intended to lower calcium content in the blood, reportedly improves wound healing. Patients also are often advised to maintain a low phosphate diet.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have collaborated with a major academic institution to confirm that PPi levels are low in patients with calciphylaxis and to investigate associated manifestations that may be treated with INZ-701. Evidence of low PPi in calciphylaxis is supported by a third-party exploratory study designed to measure PPi in patients with calciphylaxis and to examine whether PPi levels are predictive of clinical outcomes. In this study, PPi was measured in patients with calciphylaxis at different stages of CKD/ESKD and matched for age, sex, race, and CKD/ESKD stage in patients without calciphylaxis. Results from this study revealed that PPi was significantly decreased in patients with calciphylaxis (both in those with and without dialysis-dependent CKD/ESKD) as compared to matched CKD/ESKD controls. The median PPi value was 248 nM in CKD/ESKD patients with calciphylaxis as compared to a median PPi value of 661 nM in CKD/ESKD patients without calciphylaxis, p&lt; 0.0001. As shown in the graph below on the left, PPi levels in both</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CKD/ESKD populations with and without calciphylaxis were significantly lower than PPi levels in healthy volunteers. Furthermore, as shown in the graph below on the right, lower PPi levels were associated with increased 6-month mortality among patients with calciphylaxis.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img187419207_11.jpg" alt="img187419207_11.jpg" style="width:623px;height:278px;"/>&#160;</p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, a prospective cohort study conducted as part of the Partners Calciphylaxis Biorepository and Patient Registry (NCT03032835) enrolled 70 patients with calciphylaxis. Plasma PPi levels were measured using an ATP Sulfurylase/Luminescence-based method at enrollment (n=70) and at 6-week follow-up (n=30). In adjusted models, for every 10 nM decrease in PPi at enrollment, an approximately 25% increase in mortality was observed at 6 weeks. Reduction in PPi levels over 6 weeks since enrollment was associated with an increased 12-week mortality (p=0.04). In addition, low plasma PPi levels were correlated with higher numbers of skin lesions, suggesting a higher severity of calciphylaxis and predicting the mortality risk among patients with calciphylaxis (Chewcharat et al 2023).</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Solution: INZ-701</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Overview of INZ-701</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INZ-701 is a soluble, recombinant protein containing the extracellular domain of native human ENPP1 fused to the fragment crystallizable ("Fc") domain of the immunoglobulin IgG1. In its native form, ENPP1 is a transmembrane enzyme with a modular structure consisting of a short intracellular domain, a single transmembrane domain and an extracellular domain that contains a conserved catalytic site responsible for enzymatic activity. ENPP1 is expressed predominantly in the liver and, to a lesser extent, in the kidney and bone. INZ-701 contains the extracellular soluble domain of ENPP1 fused to the Fc domain of IgG1 to minimize immunogenicity, stabilize the construct, increase the plasma half-life, and allow ease of purification.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The construction and presumed structure of INZ-701 is depicted in the figure below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img187419207_12.jpg" alt="img187419207_12.jpg" style="width:720px;height:338px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INZ-701 is designed to mimic the function of native ENPP1 protein, thus increasing PPi and adenosine, for ENPP1 Deficiency and providing therapeutic effect to treat other diseases, like ABCC6 Deficiency and calciphylaxis, involving low PPi levels. In contrast to native ENPP1, INZ-701 is a soluble protein that is designed to circulate throughout the body and access extracellular ATP and other nucleotide proteins. Like native ENPP1, INZ-701 cleaves ATP into PPi and AMP, a precursor of adenosine. Pharmacologically, INZ-701 is designed to have prolonged distribution and elimination phases, leading to steady-state concentrations in the blood over time and making dosing possible at infrequent intervals, potentially once-weekly dosing. INZ-701 is formulated for subcutaneous delivery.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In our preclinical studies conducted in Enpp1-deficient mouse models, dosing with INZ-701 resulted in increased plasma PPi levels, prevention of ectopic calcium deposits in a variety of tissues, prevention of calcification in the heart, aorta, lung, kidney, liver and spleen, prevention of skeletal abnormalities and improvements in overall health. In Abcc6-deficient mouse models, dosing with INZ-701 also increased plasma PPi levels and reduced calcification in key tissues. In addition to increasing levels of PPi, in preclinical studies, INZ-701 prevented intimal proliferation in both wild-type and Enpp1-deficient mice, which we believe is attributable to increased levels of adenosine. The nonclinical INZ-701 toxicology studies that we conducted in two animal species showed no systemic adverse effects at doses that significantly exceeded potential human doses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA has granted orphan drug designation, fast track designation, and rare pediatric disease designation to INZ-701 for the treatment of ENPP1 Deficiency and has granted orphan drug designation to INZ-701 for ABCC6 Deficiency. The EMA has also granted orphan drug designation to INZ-701 for the treatment of ENPP1 Deficiency and ABCC6 Deficiency.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">INZ-701: Preclinical Results and Data</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We demonstrated preclinical proof of concept for INZ-701 using multiple mouse models containing inactivated genes for ENPP1. In these Enpp1-deficient mouse models, the animals have an increased propensity for vascular calcification and replicate key aspects of human disease due to ENPP1 Deficiency. For example, an </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">asj</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mouse contains a missense mutation in the ENPP1 gene and develops severe vascular calcification and skeletal abnormalities. In these mice, vascular calcification develops in newborn pups beginning around two weeks of age to fourteen weeks of age. This vascular calcification resembles that seen in human disease in infants due to ENPP1 Deficiency, although in humans, extensive vascular calcification begins as early as fetal development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In another preclinical model of ENPP1 Deficiency in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ttw/ttw </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">mice, INZ-701 prevented intimal proliferation from developing and maintained proper vessel integrity.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In our preclinical studies, we also used an ABCC6 mouse model with targeted ablation of the ABCC6 gene. In these mice, ectopic calcification in tissues resembles that seen in human disease due to ABCC6 Deficiency. ABCC6 is primarily expressed in the liver. In mice, ABCC6 is responsible for approximately 90% of the levels of extracellular ATP, the primary source of extracellular PPi. Mice in which the gene for ABCC6 has been inactivated exhibit significantly reduced levels of extracellular PPi in blood.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Increase in PPi</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result of an ENPP1 gene mutation,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> asj</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mice have very low or nondetectable levels of circulating PPi. Treatment of these mice with 0.2 mg/kg, 1 mg/kg or 5 mg/kg of INZ-701 by subcutaneous injection every other day for a period of eight weeks led to significant increases in ENPP1 enzyme activity and PPi levels in plasma to approximately wild-type levels. These increases compensated for the loss of ENPP1 activity in this strain of mice. Mice treated with vehicle control lacked any ENPP1 activity and plasma PPi, as expected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The results of these initial studies are shown in the graphs below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img187419207_13.jpg" alt="img187419207_13.jpg" style="width:463px;height:253px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These initial studies showed that it is possible to administer doses of INZ-701 to increase PPi levels in mice and we believe that increasing the amount of ENPP1 enzymatic activity by administration of INZ-701 could lead to further increases of PPi. We further believe this suggests that INZ-701 has the potential to provide therapeutic benefit in non-genetic diseases that involve ectopic calcification.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also believe that our preclinical findings provide strong support for the eventual use of INZ-701 to treat patients with ABCC6 Deficiency. Individuals with PXE have dysfunctional ABCC6 and decreased levels of plasma PPi due to deficiencies in exporting ATP from within the cell. In studies in mice with defects in the ABCC6 gene, plasma PPi levels are significantly reduced relative to wild-type mice but still higher than those seen in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">asj</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mice, which have an inactivated ENPP1 gene. In other studies, overexpression of ENPP1 in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">asj</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mice containing inactivated ENPP1 normalized plasma PPi levels. Addition of the same transgene of ENPP1 in ABCC6 mutant mice normalized PPi levels, suggesting that even in the case of limiting extracellular ATP, an increase in ENPP1 activity led to the formation of additional PPi.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Studies in mice with a genetic defect in ABCC6 led to the hypothesis that low levels of plasma PPi in patients with ABCC6 Deficiency contributes to ectopic calcification. In studies in Abcc6-deficient mice, vascular calcification was correlated with plasma PPi level and overexpression of ENPP1 through transgene expression led to high levels of PPi resulting in significant reductions in cardiac calcium deposits. We believe these findings confirm the link between ABCC6, PPi and calcification. It also suggests that increasing plasma PPi in PXE patients offers potentially significant therapeutic benefit.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To further illustrate the potential of our approach, we dosed Abcc6-deficient mice with 1 mg/kg of INZ-701 and vehicle control for eight weeks. Treatment with INZ-701 resulted in an increase in plasma PPi levels consistent with those in normal healthy mice. The increase in plasma PPi levels was also associated with a decrease in pathological calcification of the eye, a target organ for ABCC6 Deficiency and patients with PXE. The results of this study are shown in the graphs below. We believe these data support the use of INZ-701 in patients who carry mutations in the gene for ABCC6 and have soft tissue calcification due to low PPi levels.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img187419207_14.jpg" alt="img187419207_14.jpg" style="width:463px;height:324px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">19</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The above findings in Abcc6-deficient mice were also observed in another study, as shown in the graph below, where doses of INZ-701 ranging from 2 mg/kg to 10 mg/kg increased plasma PPi levels to wild-type levels. In the graph below, the symbol * represents a p-value of less than 0.05, and the symbol **** represents a p-value of less than 0.001 relative to Abcc6-deficient mice treated with vehicle. We believe that the data from these two studies in Abcc6-deficient mice suggest the potential of ENPP1-Fc fusion proteins to increase plasma PPi levels and thereby reduce pathologic tissue calcification.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img187419207_15.jpg" alt="img187419207_15.jpg" style="width:281px;height:387px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reduction of Calcification</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Asj</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mice fed a diet rich in phosphorous and low in magnesium, referred to as an acceleration diet, develop a number of complications due to calcification defects. These defects limit their locomotion, restrict their growth, cause calcium deposits in the vasculature and soft tissues and lead to a shortened lifespan. We dosed mice on the acceleration diet, starting at week two, with both INZ-701 and vehicle control every other day for eight weeks. INZ-701 delivered to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">asj</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mice at doses of 0.2 mg/kg, 1 mg/kg and 5 mg/kg significantly reduced ectopic calcification in the kidney, spleen, lung and liver. As shown in the graphs below, treatment with as little as 0.2 mg/kg of INZ-701 reduced calcium deposits in all tissues, and mice treated with 5 mg/kg of INZ-701 showed no differences in calcification compared to wild-type controls.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img187419207_16.jpg" alt="img187419207_16.jpg" style="width:617px;height:242px;"/>&#160;</p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We obtained evidence of changes in vascular calcification in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">asj</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mice on the acceleration diet by carrying out scans of the heart and aorta using a technique known as high resolution micro computed tomography ("micro CT"). All nine </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">asj</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mice dosed with vehicle control showed variable but extensive calcification in the aorta, coronary artery and heart. All nine </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">asj</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mice dosed with 0.2 mg/kg of INZ-701 showed a pattern and intensity of calcification signals similar to that shown when mice were dosed with vehicle control. In almost all cases, increasing the dose of INZ-701 to 1 mg/kg or 5 mg/kg completely prevented calcification in the heart and in the aorta. Only one out of nine mice from the 1 mg/kg group showed some evidence of cardiovascular calcification. Treatment with 5 mg/kg of INZ-701 completely prevented calcification in the heart and aorta in all eight mice dosed in the 5 mg/kg group. The dose response and degree of calcification measured by micro CT of the heart and aorta for each mouse in this study are illustrated below in increasing shades of blue and green. We believe these results suggest that INZ-701 may have the ability to significantly reduce the extent of ectopic calcification due to ENPP1 Deficiency. In the study represented by the illustration below, the p-value for the degree of calcification for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">asj </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">mice dosed with INZ-701 compared to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">asj </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">mice dosed with vehicle control was 0.5341 for the 0.2 mg/kg group and 0.0004 for both the 1 mg/kg group and 5 mg/kg group.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img187419207_17.jpg" alt="img187419207_17.jpg" style="width:720px;height:307px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">21</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To investigate whether increasing plasma PPi levels would prevent ectopic calcification in Abcc6-deficient mice, we dosed Abcc6-deficient mice with 2 mg/kg of INZ-701, 10 mg/kg of INZ-701 or vehicle control from two weeks of age for eight weeks every other day. At 10 weeks of age, all of the mice were euthanized and the mineralization and blood biochemistry was measured. In this study, Abcc6-deficient mice exhibited low plasma PPi levels and significantly increased muzzle skin calcification. However, treatment of Abcc6-deficient mouse with INZ-701 caused a significant increase in plasma PPi at doses of 2 mg/kg and 10 mg/kg and a significant reduction in the extent of calcification noted in the muzzle skin to wild-type levels.  This increase in plasma PPi levels in the Abcc6-deficient mice contributed to the reduction in pathological tissue calcification.  We believe that these data suggest that ABCC6 Deficiency contributes to increased ectopic calcification and that ENPP1, through PPi, may be able to reduce the extent of calcification. In the graph below, the symbol **** represents a p-value of less than 0.001 relative to Abcc6-deficient mice treated with vehicle.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img187419207_18.jpg" alt="img187419207_18.jpg" style="width:368px;height:446px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Overall Health and Survival</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the measured changes in calcium deposition, treatment of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">asj </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">mice with 0.2 mg/kg, 1 mg/kg, or 5 mg/kg of INZ-701 and vehicle control every other day also led to improvements in overall health. Mice treated with INZ-701 had a dose-dependent increase in body weight compared to mice treated with vehicle control, whose average weight at 27 to 56 days was only 60% that of wild-type mice. Compared to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">asj</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mice treated with vehicle control, mice treated with INZ-701 at 1 mg/kg and 5 mg/kg showed significant increases in body weight. The results of this study are shown in the graph below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span><img src="img187419207_19.jpg" alt="img187419207_19.jpg" style="width:465px;height:269px;"/></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to body weight, treatment of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">asj</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mice with INZ-701 at 1 mg/kg and 5 mg/kg every other day led to improvement in a number of clinical signs associated with ENPP1 Deficiency in mice, including pinned ear, hunched back, stilted and stiff legs, dehydration and rough hair coat. Treatment with INZ-701 also prevented </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">asj </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">mice from early mortality associated with becoming moribund.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In another experiment, we treated mice with either 1 mg/kg of mENPP1-Fc, a research version of INZ-701 containing a mouse Fc domain, or vehicle control starting on the fourteenth day of life and until day 55. In this experiment, all eight mice treated with mENPP1-Fc survived the full 55 days of the trial (represented by the blue line in the graph below), while the median lifespan of the untreated mice decreased from 58 days to 35 days (represented by the black hatched line in the graph below).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img187419207_20.jpg" alt="img187419207_20.jpg" style="width:359px;height:248px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">23</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In another experiment, we treated </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">asj</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mice with 0.2 mg/kg, 1 mg/kg, or 5 mg/kg of INZ-701 and vehicle control for 56 days to analyze by micro CT the femora and tibiae bones and measure both trabecular number and cortical thickness, which are two important contributors of bone strength. The strength of a bone and its ability to resist fracture is dependent upon these two structural parameters. Treatment of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">asj</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mice with INZ-701 corrected the bone defects, leading to a dose-dependent increase in bone length, trabecular number and cortical thickness as compared to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">asj</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mice treated with vehicle control.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img187419207_21.jpg" alt="img187419207_21.jpg" style="width:330px;height:303px;"/>&#160;</p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intimal Proliferation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intimal proliferation resulting from ENPP1 Deficiency was also replicated in corresponding animal models. In animal models, intimal proliferation is accelerated during conditions of injury including ligation of the artery. The exact mechanism linking ENPP1 Deficiency to intimal proliferation is under investigation but is believed to directly involve the adenosine pathway.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The increase in intimal proliferation can be observed in a strain of Enpp1-deficient mice known as </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ttw/ttw</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mice in a carotid artery ligation model. These mice have a single base pair change in the ENPP1 gene producing ENPP1 Deficiency. The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ttw/ttw</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mice were treated with 10 mg/kg of INZ-701 or vehicle control every other day for seven days before carotid artery ligation surgery and for 14 days following carotid artery ligation surgery. Vehicle control-treated </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ttw/ttw</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mice showed a significant increase in intimal proliferation in the area of the artery at the sites of ligation. We believe these data, shown in the graph below, confirm that the INZ-701 treatment aligns with the earlier published findings indicating that ENPP1 treatment in mice inhibited ligation-induced intimal proliferation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:8.96%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Importantly, as shown in the graph below, INZ-701 also inhibited ligation-induced intimal proliferation in wild-type mice without ENPP1 Deficiency. These important findings in wild-type mice suggest that increasing levels of ENPP1 above normal may be useful in diseases in which vascular intimal proliferation is increased.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img187419207_22.jpg" alt="img187419207_22.jpg" style="width:362px;height:350px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To further evaluate INZ-701&#8217;s effects on intimal proliferation, we conducted a pilot study in a swine model. In this study, three pigs underwent surgery in which stents were inserted into the coronary, profunda, and femoral arteries. At day 14, the stents were re-injured with balloon dilation to initiate additional intimal proliferation at the stented arterial sites. The sites were then evaluated with angiography and optimal coherence tomography ("OCT"). We dosed the pigs with vehicle control and 10 mg/kg of INZ-701 every four days, with the first dose administered on day 10. At day 42, the pigs again underwent angiography and OCT, and quantification of intimal proliferation was performed in the OCT images and compared to the day 14 OCT evaluation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In this study, INZ-701 significantly (p&lt;0.05) inhibited stenosis or intimal proliferation in the profunda artery over 28 days. These results in a large animal model of intimal proliferation support the results from the studies in the mouse model of intimal proliferation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Safety and Toxicology</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We evaluated INZ-701 in toxicology studies in rats, mice, and non-human primates. In single and multiple administration studies in rats and non-human primates, the maximum tolerated doses of INZ-701 were determined to be 180 and 100 mg/kg, respectively. In these studies, no systemic adverse effects or pathological effects were noted with INZ-701. Because both non-human primates and mice are relevant species, based on gene sequence homology and biologic activity, we subsequently conducted 28-day good laboratory practices ("GLP") investigational new drug application ("IND")-enabling studies in each species. In these studies, there were no adverse events and we observed normal histopathology and clinical pathology. In addition, we conducted a 28-day GLP cardiovascular study in non-human primates and a 28-day GLP central nervous system and respiratory risk study in mice. There were no adverse observations in any of these studies at doses up to 30 mg/kg of INZ-701, which was the highest dose tested. The 28-day studies were followed by three-month GLP IND enabling toxicology studies in mice and non-human primates. There were no adverse observations in these studies at doses up to 60 mg/kg of INZ-701 in mice and 30 mg/kg of INZ-701 in non-human primates, which were the highest doses tested in each species.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">25</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, two GLP dose range-finding studies of INZ-701 were conducted in juvenile C57BL6 mice. In both studies INZ-701 was given by subcutaneous injection for 21</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">days every other day at doses up to 30 mg/kg. There were no adverse clinical observations, mortality, or moribundity in mice that received INZ-701; no test article-related changes in body weight, body weight gain, or food consumption; and no test article-related changes in hematology or coagulation in mice that received INZ-701 as compared to the concurrent control groups of the same sex (in either study).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A GLP multiple dose toxicity study of INZ-701 was also conducted in juvenile C57BL6 mice. The mice were given INZ-701 by subcutaneous injection every other day at doses of 5, 10, or 30&#8239;mg/kg from post-natal day&#8239;10 to post-natal day 100 and were followed for 4&#8239;additional weeks after dosing. Toxicokinetics, clinical observations, clinical chemistries, anti-drug antibodies, neuro-assessment, macro and micropathology with the addition of neurohistological parameters, and reproductive endpoints were evaluated during the study. The study concluded there were no adverse findings related to INZ-701 throughout the study period at any dose level. The no-observed-adverse-effect level for the study was the highest dose tested, 30 mg/kg.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overall, in our nonclinical toxicology studies, INZ-701 exhibited a good safety profile and an acceptable therapeutic index.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Development of INZ-701 for ENPP1 Deficiency</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Phase 1/2 Clinical Trial in Adults with ENPP1 Deficiency</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2021, we initiated our Phase 1/2 clinical trial of INZ-701 in adult patients with ENPP1 Deficiency. The Phase 1/2 clinical trial of INZ-701 is an open-label, first-in-human, multiple ascending dose trial. The trial will primarily assess the safety and tolerability of INZ-701 in adult patients with ENPP1 Deficiency, as well as characterize the pharmacokinetic and pharmacodynamic profile of INZ-701, including evaluation of levels of plasma PPi and other biomarker levels. In the Phase 1 dose-escalation portion of the trial, we assessed INZ-701 for 32 days at doses of 0.2 mg/kg, 0.6 mg/kg, and 1.8 mg/kg administered via subcutaneous injection, with three patients planned per dose cohort. Patients received a single dose and then began twice-weekly dosing one week later. The trial initially enrolled nine patients with ENPP1 Deficiency at sites in North America and Europe. The Phase 1 dose-escalation portion of the trial sought to identify a safe and tolerable dose that increases PPi levels, and that can be used for further clinical development. The Phase 1 dose-escalation portion of the trial is complete. The ongoing open-label Phase 2 portion of the trial is assessing long-term safety, pharmacokinetics, and pharmacodynamics of continued treatment with INZ-701 for up to 48 weeks, where patients may receive doses of INZ-701 at home depending on site-specific protocols. Exploratory endpoints include evaluations of ectopic calcification, skeletal, vascular, and physical function, patient-reported outcomes, and exploratory biomarkers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In April 2022, we announced preliminary biomarker, safety and pharmacokinetic data from the 0.2 mg/kg cohort of the Phase 1 dose escalation portion of this trial. At the 0.2 mg/kg dose level of INZ-701, all three patients showed rapid, significant, and sustained increases in PPi levels. Preclinical findings demonstrated PPi being a key predictive biomarker of therapeutic benefit in ENPP1 Deficiency. The range of PPi levels across the three patients at screening was 132-333 nM. At the 0.2 mg/kg dose level of INZ-701, the mean PPi level observed during the 32-day dose evaluation period across the three patients was 1356 nM, an approximately 5-fold mean increase from screening across the three patients. The range of peak PPi levels observed during the 32-day dose evaluation period across the three patients was 1082-2416 nM and was comparable to data from our study of healthy subjects (n=10) (1002 nM to 2169 nM). Increased PPi levels observed after dosing of INZ-701 were associated with systemic exposure and activity of INZ-701. Pharmacokinetic analysis showed INZ-701 nearing steady-state by Day 29 with an approximately 4-fold accumulation from Day 1, based on AUC0-72HRS. We believe that the half-life of INZ-701 observed in this trial suggests the potential for once-weekly dosing. All three patients from the first cohort enrolled in the open-label Phase 2 portion of the trial. At week 12, low titers of anti-drug antibodies were observed in two out of three patients in the first cohort. The significantly increased PPi levels observed during the 32-day dose evaluation period were sustained in all three patients through week 12 of the Phase 2 portion of the trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2022, we announced the first self-administration of INZ-701 in the open-label Phase 2 portion of the trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">26</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2023, we reported interim pharmacokinetic, pharmacodynamic, and safety data from this trial. A rapid, significant, and sustained increase in PPi was observed in all dose cohorts and in all patients, with a target PPi threshold observed from the lowest dose of 0.2 mg/kg. PPi increased in all patients to levels comparable to those observed in our study of healthy subjects (n=10) (1002 nM to 2169 nM). The mean baseline PPi across all three cohorts in the trial was 426&#177;407 nM. PPi levels observed after INZ-701 administration are shown in the table below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.648%;"/>
    <td style="width:4.556%;"/>
    <td style="width:13.676%;"/>
    <td style="width:4.556%;"/>
    <td style="width:14.704%;"/>
    <td style="width:17.917%;"/>
    <td style="width:1%;"/>
    <td style="width:19.083%;"/>
    <td style="width:13.861%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="4" style="border-top:0.75pt solid #000000;vertical-align:bottom;border-bottom:0.75pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Mean PPi (nM) &#177; SD</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cohort 1 (0.2 mg/kg)*</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cohort 2 (0.6 mg/kg)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cohort 3 (1.8 mg/kg)</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td rowspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Phase 1</span></p></td>
    <td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Single Dose</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Day 1-8</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1229&#177;410</span></p></td>
    <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1438&#177;715</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1220&#177;426</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="border-top:0.5pt solid #ffffff03;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2x/Week Dose</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Day 11-32</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1494&#177;498</span></p></td>
    <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1745&#177;780</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1341&#177;330</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Phase 2</span></p></td>
    <td colspan="3" style="vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2x/Week Dose</span></p></td>
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Day 32-338</span></p></td>
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1299&#177;490</span></p></td>
    <td colspan="2" style="vertical-align:top;border-bottom:0.75pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1472&#177;516</span></p></td>
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1462&#177;233</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">*Cohort 1 &#8211; n=2 post week 12</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> In February 2023, we also reported patient reported outcome data as measured by global impression of change ("GIC"). The measurement is performed by the clinician ("C-GIC") and the patient ("P-GIC") and assesses overall change in health from baseline on a 7-point scale as measured from &#8220;very much worse&#8221; (-3) to &#8220;very much improved&#8221; (+3). GIC is an exploratory endpoint in the trial and an early indicator of potential clinical outcomes. Six of eight patients showed concordant improvements on overall health on C-GIC and P-GIC. Five of eight patients showed &#8220;much improved&#8221; (+2) or &#8220;very much improved&#8221; (+3) on P-GIC. No patients showed a deterioration in overall health from baseline on C-GIC or P-GIC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> In the second quarter of 2023, we dosed two patients in a fourth cohort at 1.2 mg/kg to investigate the potential for once-weekly dosing of INZ-701 in the ongoing trial. We completed enrollment of this fourth cohort in the fourth quarter of 2023.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2023, we reported positive interim safety, pharmacokinetic, pharmacodynamic, and exploratory efficacy data from this trial. A rapid, significant, and sustained increase in PPi was observed in all dose cohorts and in all patients, and a significant elevation in PPi was maintained for up to 18 months. INZ-701 activity increased in proportion to dose level and a long half-life of approximately 126 hours, and drug accumulation as shown by a greater-than-dose proportional exposure suggests the potential for once-weekly dosing. Exploratory biomarker data were collected to provide evidence of the potential for disease modification with ongoing treatment with INZ-701. Notable changes in key biomarkers support our clinical hypothesis. Clinical outcome measures were also collected to assess potential clinical benefit with ongoing treatment with INZ-701 and to inform the design and patient selection of future trials. Notable changes in patient reported outcomes and functional outcomes were observed in all cohorts, including concordant improvement in GIC scores reported by patients and clinicians, and no patient showed a deterioration from baseline. INZ-701 was generally well-tolerated and exhibited a favorable safety profile, with no serious or severe adverse events attributed to INZ-701 and no adverse events leading to study withdrawal. Three of the nine patients experienced mild adverse events related to INZ-701 including injection site reactions (bruising or pain) occurring in two of nine patients, and other mild adverse events included decreased appetite and fatigue. There were two serious adverse events not related to INZ-701. INZ-701 exhibited a favorable immunogenicity profile with low titers of non-neutralizing anti-drug antibodies observed in seven of the nine patients. All nine patients enrolled in the Phase 2 portion of the trial and two of them subsequently withdrew for personal reasons not related to adverse events. The anti-drug antibody levels were transient in three of seven patients. Seven patients remain in the trial and continue on home self-administration of INZ-701 treatment. PPi levels observed after INZ-701 administration are shown in the table below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.648%;"/>
    <td style="width:4.556%;"/>
    <td style="width:13.676%;"/>
    <td style="width:4.556%;"/>
    <td style="width:14.704%;"/>
    <td style="width:17.917%;"/>
    <td style="width:1%;"/>
    <td style="width:19.083%;"/>
    <td style="width:13.861%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="4" style="border-top:0.75pt solid #000000;vertical-align:bottom;border-bottom:0.75pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Mean PPi (nM) &#177; SD</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cohort 1 (0.2 mg/kg)*</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cohort 2 (0.6 mg/kg)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cohort 3 (1.8 mg/kg)</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td rowspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Phase 1</span></p></td>
    <td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Single Dose</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Day 1-8</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1229&#177;410</span></p></td>
    <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1438&#177;715</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1220&#177;426</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="border-top:0.5pt solid #ffffff03;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2x/Week Dose</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Day 11-32</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1494&#177;498</span></p></td>
    <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1745&#177;780*</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1352&#177;326</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Phase 2</span></p></td>
    <td colspan="3" style="vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2x/Week Dose</span></p></td>
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Day 32-504</span></p></td>
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1032&#177;292</span></p></td>
    <td colspan="2" style="vertical-align:top;border-bottom:0.75pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1251&#177;539</span></p></td>
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1512&#177;973</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">*P&lt;0.05 vs 1.8mg/kg; Cohort 1 &#8211; n=2 post week 12</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to report topline data from the first three cohorts of the ongoing Phase 1/2 clinical trial of INZ-701 in adults with ENPP1 Deficiency in April 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ENERGY-1 Clinical Trial in Infants with ENPP1 Deficiency</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2023, we dosed the first infant patient in our Phase 1b, single arm, open-label ENERGY-1 clinical trial of INZ-701 (the "ENERGY-1 trial"), designed primarily to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of INZ-701 in infants with ENPP1 Deficiency. The ENERGY-1 trial is expected to enroll up to eight infants between the ages of birth to 12 months across multiple sites in the United States and Europe. Patients will receive subcutaneous doses of INZ-701 during the treatment period of 52-weeks and may continue to receive INZ-701 in an extension period beyond 52 weeks. Doses range from 0.2 mg/kg once weekly through 0.6 mg/kg twice weekly, and plan to increase the dose further depending on the results of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">27</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">pharmacokinetics, pharmacodynamics, and safety data. Other outcome measures include evaluation of plasma PPi levels, survival, growth, development, functional performance, cardiac function, and exploratory biomarkers. We expect to report interim data from the ENERGY-1 trial in the second half of 2024.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Global Development Strategy of INZ-701 for the Treatment of ENPP1 Deficiency</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We initiated pivotal trial meetings with the FDA in the first quarter of 2023. In July 2023, we announced a regulatory update for our global development strategy of INZ-701 for the treatment of ENPP1 Deficiency following meetings with the FDA and the Paediatric Committee of the EMA. Also in July 2023, we completed a scientific advice procedure and reached alignment with the Committee for Human Medicinal products (&#8220;CHMP&#8221;) regarding our global development strategy.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We plan to conduct pivotal clinical trials of INZ-701 designed to support registration, in infant, pediatric, and adult patient populations with ENPP1 Deficiency. Many companies pursuing marketing approval for enzyme replacement therapies in rare diseases have followed a similar clinical development strategy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We anticipate initiating the ENERGY-2 trial, a pivotal trial of INZ-701 in infants with ENPP1 Deficiency, outside of the United States in the second half of 2024.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have reached agreement with the EMA on a Paediatric Investigational Plan for a pivotal trial of INZ-701 in pediatric patients with ENPP1 Deficiency. We have finalized the design for a global pivotal clinical trial of INZ-701 in pediatric patients with ENPP1 Deficiency (the "ENERGY-3 trial"). In September 2023, we opened the first site for our ENERGY-3 trial, and patient recruitment is underway. We anticipate reporting topline data from the ENERGY-3 trial in mid-2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pending appropriate financial resources, we also plan to conduct a pivotal trial in adolescents and adults with ENPP1 Deficiency.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis for Planned Marketing Applications</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on regulatory feedback from the FDA and EMA, positive data from the ongoing and planned clinical trials of INZ-701 in patients with ENPP1 Deficiency, including comprehensive data demonstrating clinical impact of plasma PPi, could provide the basis for our submission of marketing applications in both the United States and the European Union. These data will include final results from our ongoing Phase 1/2 clinical trial in adult patients with ENPP1 Deficiency, available results from our ongoing ENERGY-1 trial, available results from the planned pivotal ENERGY-2 trial in infants to be initiated outside of the United States, and final results from the pivotal ENERGY-3 trial in pediatric patients.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If these marketing applications are approved, we expect to commercially launch INZ-701 for infant and pediatric patients as early as the second half of 2026. Data from the planned clinical trial in adolescent and adult patients with ENPP1 Deficiency may provide a basis for a supplemental marketing application.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Development of INZ-701 for ABCC6 Deficiency</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In April 2022, we initiated our Phase 1/2 clinical trial of INZ-701 in adult patients with ABCC6 Deficiency. The Phase 1/2 clinical trial of INZ-701 is an open-label multiple ascending dose trial, which initially enrolled nine adult patients at sites in the United States and Europe. The trial will primarily assess the safety and tolerability of INZ-701 in adult patients with ABCC6 Deficiency, as well as characterize the pharmacokinetic and pharmacodynamic profile of INZ-701, including evaluation of plasma PPi and other biomarker levels. In the Phase 1 dose-escalation portion of the trial, we assessed INZ-701 for 32 days at doses of 0.2 mg/kg, 0.6 mg/kg, and 1.8 mg/kg administered via subcutaneous injection, with three patients per dose cohort, which doses were selected based on preclinical studies and pharmacokinetic/pharmacodynamic modeling. Patients received a single dose and then began twice weekly dosing one week later. The Phase 1 dose-escalation portion of the trial seeks to identify a safe and tolerable dose for further development that increases PPi levels for further clinical development. The open-label Phase 2 portion of the trial will assess long-term safety, pharmacokinetics, and pharmacodynamics of continued treatment with INZ-701 for up to 48 weeks, where patients may receive doses of INZ-701 at home depending on site-specific protocols. Exploratory endpoints will include evaluations of ectopic calcification, vascular and retinal function, patient reported outcomes, and exploratory biomarkers.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Beginning in January 2023, self-administration of INZ-701 in the open-label Phase 2 portion of the trial was available.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2023, we reported interim pharmacokinetic, pharmacodynamic, and safety data from this trial. A rapid, significant, and sustained increase in PPi was observed in all cohorts with a dose response observed. PPi showed sustained increase in the highest dose cohort to levels comparable to those observed in our study of healthy subjects (n=10) (1002 nM to 2169 nM). Mean</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">28</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">baseline PPi across all three cohorts in the trial was 947&#177;193 nM. PPi levels observed after INZ-701 administration are shown in the table below:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.648%;"/>
    <td style="width:4.556%;"/>
    <td style="width:13.676%;"/>
    <td style="width:4.556%;"/>
    <td style="width:14.704%;"/>
    <td style="width:17.917%;"/>
    <td style="width:1%;"/>
    <td style="width:19.083%;"/>
    <td style="width:13.861%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="4" style="border-top:0.75pt solid #000000;vertical-align:bottom;border-bottom:0.75pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Mean PPi (nM) &#177; SD</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cohort 1 (0.2 mg/kg)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cohort 2 (0.6 mg/kg)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cohort 3 (1.8 mg/kg)</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td rowspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Phase 1</span></p></td>
    <td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Single Dose</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Day 1-8</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1087&#177;796</span></p></td>
    <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1326&#177;330</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1589&#177;1065</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="border-top:0.5pt solid #ffffff03;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2x/Week Dose</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Day 11-32</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1023&#177;454</span></p></td>
    <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1119&#177;216</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1415&#177;509</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Phase 2</span></p></td>
    <td colspan="3" style="vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2x/Week Dose</span></p></td>
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Day 32-252</span></p></td>
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">900&#177;253</span></p></td>
    <td colspan="2" style="vertical-align:top;border-bottom:0.75pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1011&#177;121</span></p></td>
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1498&#177;465*</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">*P&lt;0.05 vs 0.2 mg/kg &#8211; Cohort 3 &#8211; n=2 post day 18.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2023, we reported positive interim safety, pharmacokinetic, pharmacodynamic, and exploratory efficacy data from this trial. A dose-dependent response in plasma PPi levels was observed, with a sustained increase in the highest dose cohort to levels comparable to those observed in our study of healthy subjects. INZ-701 activity in a greater-than-dose proportional manner was observed, and drug accumulation as shown by a greater-than-dose proportional exposure suggests the potential for once weekly dosing. Clinical outcome measures were collected to provide evidence of clinical benefit and to inform the design of future trials in adults. All patients showed improvements on clinician-reported GIC scores and seven of the nine patients showed improvement from baseline on patient-reported GIC scores at the last follow-up. INZ-701 was generally well-tolerated and exhibited a favorable safety profile, with no serious or severe adverse events attributed to INZ-701. Seven of the 10 patients experienced adverse events related to INZ-701(including mild injection site reactions (discoloration, erythema, induration, pain, or pruritus) occurring in seven of the 10 patients and other adverse events included erythema, fatigue, night sweats, and urticaria). All adverse events were mild to moderate in severity. One patient from the highest dose cohort (1.8 mg/kg) was withdrawn from the Phase 1 portion of the trial at day 18 due to a moderate adverse event (erythema/urticaria) related to INZ-701. One patient withdrew from the trial during the Phase 2 portion for personal reasons not related to an adverse event. INZ-701 exhibited a favorable immunogenicity profile with low titers of non-neutralizing anti-drug antibodies observed in eight of the 10 patients. The anti-drug antibody levels were transient in three out of eight patients. Eight patients remain in the trial, and seven continue on home self-administration of INZ-701 treatment. PPi levels observed after INZ-701 administration are shown in the table below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.648%;"/>
    <td style="width:4.556%;"/>
    <td style="width:13.676%;"/>
    <td style="width:4.556%;"/>
    <td style="width:14.704%;"/>
    <td style="width:17.917%;"/>
    <td style="width:1%;"/>
    <td style="width:19.083%;"/>
    <td style="width:13.861%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="4" style="border-top:0.75pt solid #000000;vertical-align:bottom;border-bottom:0.75pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Mean PPi (nM) &#177; SD</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cohort 1 (0.2 mg/kg)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cohort 2 (0.6 mg/kg)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cohort 3 (1.8 mg/kg)</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td rowspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Phase 1</span></p></td>
    <td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Single Dose</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Day 1-8</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1087&#177;796</span></p></td>
    <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1326&#177;330</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1540&#177;960</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="border-top:0.5pt solid #ffffff03;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2x/Week Dose</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Day 11-32</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1023&#177;454</span></p></td>
    <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1119&#177;216</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1312&#177;573</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Phase 2</span></p></td>
    <td colspan="3" style="vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2x/Week Dose</span></p></td>
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Day 32-420</span></p></td>
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1004&#177;341</span></p></td>
    <td colspan="2" style="vertical-align:top;border-bottom:0.75pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1041&#177;434</span></p></td>
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1466&#177;824*</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">*P&lt;0.05 vs 0.2 mg/kg</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to report topline data from the ongoing Phase 1/2 clinical trial of INZ-701 in adults with ABCC6 Deficiency in the April 2024.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subject to regulatory review and sufficient funding, we plan to initiate a Phase 3 clinical trial of INZ-701 in patients with ABCC6 Deficiency in the first quarter of 2025. We intend to design this Phase 3 clinical trial as a pivotal trial for registrational purposes. Prior to initiating this Phase 3 clinical trial, we plan to engage with the regulatory authorities in the United States, Europe, and other jurisdictions to determine appropriate primary efficacy endpoints and other requirements for potential marketing approval. In particular, if we propose new or novel endpoints or methodologies for our clinical trials, regulatory authorities will ultimately need to conclude that the endpoints of our clinical trials have provided clinically meaningful results before we are able to obtain potential marketing approval. If successful, the Phase 1/2 clinical trial would allow us to obtain evidence of the restoration of plasma PPi levels and inform the design of our planned Phase 3 clinical trial. Our clinical strategy, subject to ongoing discussions with the regulatory authorities in the United States, Europe, and other jurisdictions, is to pursue registration of INZ-701 for ABCC6 Deficiency by linking the restoration of plasma PPi levels to measures of physiological and clinical efficacy in this patient population.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Development Plan for Calciphylaxis</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2024, we initiated SEAPORT-1, a Phase 1 clinical trial designed to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of INZ-701 in up to 10 patients with ESKD receiving hemodialysis. Patients will receive 1.8 mg/kg of INZ-701 once weekly coinciding with their hemodialysis treatment for a total of 30 days. The trial&#8217;s primary endpoint will assess safety and change from baseline plasma PPi concentration, with secondary endpoints including pharmacokinetic and pharmacodynamic parameters. We plan to report topline data from SEAPORT-1 in the fourth quarter of 2024 and expect data from this trial to inform our study design for patients with calciphylaxis in the future.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expanded Access Program</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">29</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2023, we dosed our first pediatric patient with ENPP1 Deficiency with INZ-701 under our expanded access program ("EAP"). Under an EAP, we are using INZ-701 outside of our clinical trials to treat infant or pediatric patients with serious or immediately life-threatening diseases or conditions when there are no comparable or satisfactory alternative treatment options and when other criteria are met. Other criteria include, but are not limited to, lack of success from standard treatments, ineligibility for participation in any ongoing clinical study of INZ-701 (including lack of access due to geographic limitations), and having a disease for which there is sufficient evidence of a projected benefit from the use of INZ-701. We expect that data collected from patients treated under our EAP program will provide further support for the potential safety and clinical benefits of INZ-701.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Future Development Plans; Other Potential Indications for INZ-701</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subject to successfully completing clinical development of INZ-701 in ENPP1 and ABCC6 Deficiencies, we plan to seek marketing approvals for INZ-701 on a worldwide basis. Beyond our development focus on INZ-701, we believe that our therapeutic approach has the potential to benefit patients suffering from additional diseases of pathologic mineralization and intimal proliferation.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on its mechanism of action, we believe that INZ-701 has the potential to increase plasma PPi levels and provide therapeutic benefit to patients beyond those with monogenic defects in the ENPP1 or ABCC6 gene. We intend to explore the potential of INZ-701 as a therapy in other, non-genetic diseases of pathologic mineralization associated with low levels of PPi, such as calciphylaxis or calcifications as a result of ESKD.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Diseases of intimal proliferation include diseases without a clear genetic basis. In preclinical studies, INZ-701 prevented intimal proliferation in both wild-type and Enpp1-deficient mice, which we believe is attributable to increased levels of adenosine. We plan to continue to explore the potential of INZ-701 in non-genetic diseases in which arteries have been damaged or disrupted by insertion of a stent, bypass graft occlusion, transplant vasculopathy or inflammation known as arteritis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ENPP1 Gene Therapy</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We plan to continue to develop new and innovative therapies to treat ENPP1 and ABCC6 Deficiencies. We believe we are well-positioned to do so because of our in-depth knowledge of the biological pathways involved in mineralization and of diseases of pathologic mineralization. For example, we have identified a gene therapy construct having an optimized ENPP1-Fc sequence driven by a tissue specific promoter in our enzyme replacement therapy program that has shown restoration and sustained enzyme activity leading to an increase of plasma PPi levels in preclinical experiments without adverse effects. Our results to date encourage us to continue to optimize our gene therapy construct as a potential new modality to treat diseases of pathologic mineralization impacting the vasculature, soft tissue and skeleton, in furtherance of our mission to become leaders in the treatment of such diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Treatment of asj/2j mice with, ENPP1 Deficiency with an AAV vector containing a modified ENPP1-Fc driven by a tissue specific promoter at three different doses by a single intravenous injection for a period of ten weeks led to a dose dependent increase in PPi levels. Mice treated with vehicle control lacked any plasma PPi, as expected.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The results of this initial study are shown in the graph below:</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img187419207_23.jpg" alt="img187419207_23.jpg" style="width:299px;height:310px;"/>&#160;</p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In another study in asj/2j mice, we evaluated lower doses of an AAV vector containing a modified ENPP1-Fc driven by a tissue specific promoter at three different doses by a single intravenous injection for a period of ten weeks. These studies demonstrated increases in plasma PPi with corresponding prevention of calcification in various tissues, including the aorta, spleen and lung, as well as prevention of skeletal abnormalities such as rickets in the growth plate and ectopic calcification in the vertebrae as shown in the figures below. These studies suggested that gene therapy is a potential therapeutic modality for ENPP1 Deficiency.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The results of this study are shown below:</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img187419207_24.jpg" alt="img187419207_24.jpg" style="width:532px;height:202px;"/>&#160;</p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">31</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img187419207_25.jpg" alt="img187419207_25.jpg" style="width:520px;height:240px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img187419207_26.jpg" alt="img187419207_26.jpg" style="width:544px;height:220px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Manufacturing and Supply</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While we have personnel with substantial manufacturing experience, we do not own or operate, and currently have no plans to establish, any manufacturing facilities. We rely, and expect to continue to rely, on third parties for the manufacture of both drug substance and finished drug product for INZ-701 and any future product candidates for preclinical testing and clinical trials, as well as for commercial manufacture if any of our product candidates receive marketing approval. We also rely on these third parties for packaging, labeling, sterilization, storage, distribution and other production logistics. We have only limited supply agreements in place with respect to our product candidates, and these arrangements do not extend to commercial supply. We obtain supplies of drug substance and finished drug product for INZ-701 on a purchase order basis. We do not have long-term committed arrangements with respect to any of our product candidates or other materials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Manufacturing biologics is complex, especially in large quantities. Biologic products must be made consistently and in compliance with a clearly defined manufacturing process. We have obtained from our third-party manufacturers a supply of INZ-701 that we believe is sufficient for our ongoing clinical trials of INZ-701 for ENPP1 Deficiency, ABCC6 Deficiency, and ESKD. However, we are continuing the process of scaling up our manufacturing processes and capabilities with our third-party manufacturers to support longer term clinical development. In addition, if we receive marketing approval for any of our product candidates, we will need to establish an agreement for commercial manufacture with a third party. If any of our current contract manufacturers cannot perform as agreed, we may be required to replace such manufacturers. Although we believe that there are several potential alternative manufacturers who could manufacture our product candidates, we may incur added costs and delays in identifying and qualifying any such replacement or be unable to reach agreement with an alternative manufacturer.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commercialization</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We retain worldwide exclusive development and commercialization rights to our pipeline and programs, including INZ-701. At this stage, we have not yet established our own commercial organization or distribution capabilities. We believe that we will be able to commercialize INZ-701, if approved, for ENPP1 or ABCC6 Deficiency with a small, targeted, internal sales and commercial organization in the United States and other major markets. We may explore the use of a variety of types of collaboration,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">32</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">co-promotion, distribution and other marketing arrangements with one or more third parties to commercialize our product candidates in smaller markets outside the United States or for other situations in which a larger sales and marketing organization is required.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We intend to continue to engage with patient advocacy groups, medical centers of excellence, and medical specialists in an effort to expeditiously bring our therapy to patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Competition</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. While we believe that our technology, expertise, scientific knowledge and intellectual property provide us with competitive advantages, we face and will continue to face competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research organizations that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. Moreover, our industry is characterized by the existence of large numbers of patents and frequent allegations of patent infringement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The key competitive factors affecting the success of our product candidates, if approved, are likely to be their efficacy, safety, convenience and price, the level of competition and the availability of coverage and adequate reimbursement from third-party payors. If any of our product candidates are approved and successfully commercialized, it is likely that we will face increased competition as a result of other companies pursuing development of products to address similar diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are currently no approved therapies for the treatment of either ENPP1 or ABCC6 Deficiency. Currently available treatments are only seeking to minimize the manifestations of these diseases. Although a number of companies generally are pursuing development of different enzyme replacement therapies or treatments for vascular calcification disorders and many other companies are focused on rare disease markets, we are not aware of any product candidate currently in clinical development for ENPP1 Deficiency. DS-1211b, a tissue-nonspecific alkaline phosphatase inhibitor, is currently in Phase 2 clinical development for PXE by Daiichi Sankyo Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may pursue the in-license or acquisition of rights to complementary technologies and product candidates on an opportunistic basis. The acquisition and licensing of technologies and product candidates is a competitive area, and a number of more established companies also have similar strategies to in-license or acquire technologies and product candidates that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources, and greater development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to in-license or acquire the relevant technology or product candidate on terms that would allow us to make an appropriate return on our investment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic products. Because of our primary focus on rare diseases, if our product candidates achieve marketing approval, we expect to seek premium pricing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">33</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Yale University License Agreement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2017, we entered into a license agreement with Yale, which was amended in May 2020 and July 2020, pursuant to which Yale granted us (1) an exclusive, worldwide license, with specified rights to sublicense, under Yale&#8217;s interest in specified intellectual property rights and materials for specified therapeutic and prophylactic products, (2) a nonexclusive, worldwide license under Yale&#8217;s interest in the same intellectual property rights and materials for specified diagnostic products, and (3) a nonexclusive, worldwide license under Yale&#8217;s interest in specified know-how for specified products, in each case that use any ectonucleotide pyrophosphatase/phosphodiesterase enzymes ("ENPPs"), or an agonist or antagonist of ENPP, its receptors, substrates, or ENPP enzymatic products, subject to certain exceptions. These licensed intellectual property rights, materials and know-how arose, and may in the future continue to arise, primarily from research conducted by Dr. Demetrios Braddock and members of his laboratory at Yale. During the period in which Professor Braddock serves as a member of our scientific advisory board or has another arrangement with us pursuant to which he provides regular advice to us or has an active consulting arrangement with us, and so long as he is an employee or faculty member (including emeritus faculty member) at Yale, Yale is restricted from granting any third party any rights for any therapeutic or prophylactic uses for any ENPP technology made, created, developed, discovered, conceived or first reduced to practice by or on behalf of Professor Braddock or his laboratory. Under the license agreement, we are obligated to use commercially reasonable efforts to pursue development and commercialization of specified ENPP products and licensed methods.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the license agreement, as partial upfront consideration, we paid to Yale approximately $0.1 million which amount reflected unreimbursed patent expenses incurred by Yale prior to the date of the license agreement. We are responsible for paying Yale an annual license maintenance fee in varying amounts throughout the term ranging from the low tens of thousands of dollars to the high tens of thousands of dollars. As of December 31, 2023, we have incurred a total of $0.4 million in license maintenance fees to Yale. We are required to pay Yale $3.0 million, based on the achievement of a specified net product sales milestone or specified development and commercialization milestones, for each therapeutic and prophylactic licensed product developed. In January 2022, we paid Yale an approximately $0.3 million milestone payment following dosing of the first patient in our Phase 1/2 clinical trial of INZ-701 in adult patients with ENPP1 Deficiency in November 2021. In March 2022, we paid Yale an approximately $0.3 million milestone payment following completion of the first cohort of our Phase 1/2 clinical trial of INZ-701 in adult patients with ENPP1 Deficiency. In addition, we are required to pay Yale an amount in the several hundreds of thousands of dollars, based on the achievement of a specified net product sales milestone or specified development and commercialization milestones, for each diagnostic licensed product developed. While the agreement remains in effect, we are required to pay Yale low single-digit percentage royalties on aggregate worldwide net sales of certain licensed products, which may be subject to reductions. Yale is guaranteed a minimum royalty payment amount (ranging in dollar amounts from the mid six figures to low seven figures) for each year after the first sale of a therapeutic or prophylactic licensed product that results in net sales. Yale is guaranteed a minimum royalty payment amount (ranging from the low tens of thousands of dollars to the mid tens of thousands of dollars) for each year after the first sale of a diagnostic licensed product that results in net sales. Such minimum royalty payment amounts are summed for each year after the first sale of both a therapeutic or prophylactic licensed product and a diagnostic licensed product has occurred. We must also pay Yale a percentage in the twenties of certain types of income we receive from sublicensees. We are also responsible for costs relating to the prosecution and maintenance of the licensed patents. Finally, subject to certain conditions, all payments due by us to Yale will be tripled following any patent challenge or challenge to a claim by Yale that a product is a licensed product under the agreement made by us against Yale if Yale prevails in such challenge.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have also agreed to pay for ENPP research support from Yale pursuant to a sponsored research agreement that we entered into with Yale in January 2017 and amended in February 2019, February 2022, May 2022, May 2023, and January 2024. Under the sponsored research agreement, as amended, we agreed to pay Yale an aggregate of $3.0 million over eight years, ending in December 2024. The research was performed by and under the supervision and direction of Professor Braddock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The license agreement remains in effect until the latest of, on a country-by-country basis, (a) the date on which the last claim of the licensed patents in such country expires; (b) 10 years after the last licensed know-how, licensed materials or licensed methods have been provided to us by Yale; and (c) 10 years after the first sale of a specified ENPP product; but in no event later than the date that is 30 years after the effective date of the agreement. We may terminate the agreement for Yale&#8217;s uncured material breach of the agreement, we may terminate the agreement for convenience upon six months&#8217; prior notice, and Yale may terminate the agreement for our uncured material breach of certain provisions or if we fail to make a payment when due, fail to obtain or maintain adequate insurance coverage or fail to engage in specified development and regulatory activities. The agreement will automatically terminate if we become insolvent or the subject of a bankruptcy event. Upon termination for any reason other than Yale&#8217;s breach of the agreement, in certain circumstances, Yale is permitted to use all regulatory approvals of, or clinical trials or other studies conducted by or on behalf of us on, and all filings made by or on behalf of us with regulatory agencies with respect to, certain licensed technology.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">34</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Alexion Intellectual Property Asset Acquisition</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2020, we entered into an intellectual property asset purchase agreement with Alexion pursuant to which Alexion sold and assigned to us Alexion&#8217;s right, title and interest in and to specified patent rights and other specified assets solely related to ENPP1. We issued 8,294,360 shares of our Series A-2 Convertible Preferred Stock to Alexion in consideration for the sale and assignment to us of such assets, which shares of preferred stock converted into 1,109,910 shares of our common stock in connection with our IPO. Under the intellectual property asset purchase agreement, we also granted a non-exclusive license to Alexion and its affiliates to continue to use the assets we acquired for Alexion&#8217;s and its affiliates&#8217; internal, non-clinical research purposes. In addition, subject to certain specified qualifications set forth in the intellectual property assets purchase agreement, Alexion is obligated to assign to us its rights with respect to any other assets owned by it that are solely related to ENPP1.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We strive to protect and enhance the proprietary technology, inventions and improvements that are commercially important to the development of our business, including by seeking, maintaining and defending patent rights, whether developed internally or licensed from third parties. We also rely on trade secrets, know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen and maintain our proprietary position in our field. Additionally, we intend to rely on regulatory protection afforded through rare drug designations, data exclusivity and market exclusivity as well as patent term extensions, where available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our future commercial success depends, in part, on our ability to: obtain, maintain and enforce patent and other proprietary protection in the United States and other countries for commercially important technology, inventions and know-how related to our business; defend and enforce in our intellectual property rights, in particular our patents rights; preserve the confidentiality of our trade secrets; and operate without infringing, misappropriating or violating the valid and enforceable patents and proprietary rights of third parties. Our ability to stop third parties from making, using, selling, offering to sell or importing our products may depend on the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patent positions of pharmaceutical and biotechnology companies like ours are generally uncertain and can involve complex legal, scientific and factual issues. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. We also cannot ensure that patents will issue with respect to any patent applications that we or our licensors may file in the future, nor can we ensure that any of our owned or licensed patents or future patents will be commercially useful in protecting our product candidates and methods of manufacturing the same. In addition, the coverage claimed in a patent application may be significantly reduced before a patent is issued, and its scope can be reinterpreted and even challenged after issuance. As a result, we cannot guarantee that any of our products will be protected or remain protectable by enforceable patents. Moreover, any patents that we hold may be challenged, circumvented or invalidated by third parties. See &#8220;Risk Factors&#8212;Risks Related to Our Intellectual Property&#8221; for a more comprehensive description of risks related to our intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We generally file patent applications directed to our key programs in an effort to secure our intellectual property positions with respect to these programs. As of March 12, 2024, we owned or possessed exclusive rights to 22 issued U.S. patents, one pending U.S. provisional patent application, 17 pending U.S. non-provisional patent applications, 24 issued foreign patents (including three issued European patents), 165 pending foreign patent applications, and three pending Patent Cooperation Treaty applications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, as of March 12, 2024, we owned one allowed U.S. trademark application, one pending foreign trademark application, and 13 foreign registered trademarks.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">INZ-701</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The intellectual property portfolio for INZ-701, our most advanced program, as of March 12, 2024, is summarized below. Prosecution is a lengthy process, during which the scope of the claims initially submitted for examination by the U.S. Patent and Trademark Office may be significantly narrowed before issuance, if issued at all. We expect this may be the case with respect to some of our pending patent applications referred to below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">35</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Currently, our patent protection includes patents and patent applications that we have exclusively licensed under our license agreement with Yale. This licensed patent portfolio includes:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A patent family that includes seven issued U.S. patents relating to: (1) reducing and/or preventing progression of pathological calcification, (2) reducing or preventing ectopic calcification of soft tissue, (3) reducing or preventing pathological ossification, (4) treating, reversing or preventing progression of ossification of the posterior longitudinal ligament, (5) treating aging-related hardening of arteries (6) reducing or preventing progression of chronic kidney disease, end-stage renal disease, calcific uremic arteriolopathy, and calciphylaxis, and (7) reducing pathological calcification of vascular tissue in a human subject in need thereof having reduced ENPP1 activity or a loss of function mutation in the gene encoding ENPP1. All such methods of treatment involve administration of soluble ENPP1 that lacks a bone targeting domain. These U.S. patents are expected to expire in 2034, absent any term adjustments or extensions. Corresponding foreign applications have been filed and are pending in Europe, Japan, and Hong Kong, and one patent has been granted in Japan. </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A patent family that includes one issued U.S. patent covering certain compositions that contain ENPP1, including INZ-701. This U.S. patent is expected to expire in 2036, absent any term adjustments or extensions. Corresponding foreign applications have been filed and are pending in Europe, Japan, Australia, Canada, Brazil, India, Hong Kong, South Korea, Mexico, New Zealand, and Russia, and one patent has been granted in Australia, Mexico, Russia, and Japan. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Through our acquisition of intellectual property assets from Alexion, we have acquired, among other assets:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A patent family that includes one issued European patent relating to polypeptides comprising ENPP1 and the therapeutic use of such polypeptides, such as in the treatment of generalized arterial calcification of infancy. This European patent is expected to expire in 2031, absent any term adjustments or extensions. </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A patent family that includes two issued U.S. patents relating to compositions and fusion proteins comprising ENPP1 and a targeting moiety. These U.S. patents are expected to expire in 2031, absent any term adjustments or extensions.  </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A patent family that includes one U.S. reissue patent application relating to methods for treating a subject having PXE by administering to the subject soluble ENPP1.</span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20 years from the earliest date of filing a non-provisional patent application.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, the term of a patent covering an FDA-approved drug may, in certain cases, be eligible for a patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984 as compensation for the loss of patent term during the FDA regulatory review process. The period of extension may be up to five years, but cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. Only one patent relating to an approved drug may be extended among those patents eligible for an extension and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. Similar provisions are available in Europe and in certain other jurisdictions to extend the term of a patent that covers an approved drug. It is possible that issued U.S. patents covering the use of INZ-701 and products from our intellectual property may be entitled to patent term extensions. If our use of product candidates or the product candidate itself receives FDA approval, we intend to apply for patent term extension, if available, to extend the patent term that covers the approved use or product candidate. We also intend to seek patent term extensions in any jurisdictions where available, however, there is no guarantee that the applicable authorities, including the FDA, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to patent protection, we rely upon unpatented trade secrets and confidential know-how and continuing technological innovation to develop and maintain our competitive position. However, trade secrets and confidential know-how are difficult to protect. We seek to protect our proprietary information, in part, using confidentiality agreements with any collaborators, scientific advisors, employees and consultants and invention assignment agreements with our employees. We also have agreements requiring assignment of inventions with selected consultants, scientific advisors and collaborators. These agreements may not provide meaningful protection. These agreements may also be breached, and we may not have an adequate remedy for any such breach. In addition, our trade secrets and confidential know-how may become known or be independently developed by a third party, or misused by any collaborator to whom we disclose such information. Despite any measures taken to protect our intellectual property, unauthorized parties may attempt to copy aspects of our products or to obtain or use information that we regard as proprietary. Although we take steps to protect our proprietary information, third parties may independently develop the same or similar proprietary information or may otherwise gain access to our proprietary information. As a result, we may be unable to meaningfully protect our trade secrets and proprietary information. See &#8220;Risk Factors&#8212;Risks Related to our Intellectual Property&#8221; for a more comprehensive description of risks related to our intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government Regulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions, including the European Union, extensively regulate, among other things, the research, development, testing, manufacture, pricing, reimbursement, sales, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, and import and export of pharmaceutical products, including biological products. The processes for obtaining marketing approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Licensure and Regulation of Biologics in the United States</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, our product candidates are regulated as biological products, or biologics, under the Public Health Service Act ("PHSA") and the Federal Food, Drug and Cosmetic Act ("FDCA") and its implementing regulations and guidance. A company, institution, or organization which takes responsibility for the initiation and management of a clinical development program for such products, and for their regulatory approval, is typically referred to as a sponsor. The failure of a sponsor to comply with the applicable U.S. requirements at any time during the product development process, including preclinical testing, clinical testing, the approval process, or post-approval process, may subject a sponsor to delays in the conduct of the study, regulatory review, and approval, and/or administrative or judicial sanctions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A sponsor seeking approval to market and distribute a new biologic in the United States generally must satisfactorily complete each of the following steps:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preclinical laboratory tests, animal studies, and formulation studies all performed in accordance with the FDA&#8217;s GLP regulations and standards and other applicable regulations; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">completion of the manufacture, under current Good Manufacturing Practices ("cGMP") conditions, of the drug substance and drug product that the sponsor intends to use in human clinical trials along with required analytical and stability testing; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">design of clinical protocol and submission to the FDA of an IND application for human clinical testing, which must become effective before human clinical trials may begin; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">approval by an independent institutional review board ("IRB") representing each clinical site before each clinical trial may be initiated; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">performance of adequate and well-controlled human clinical trials to establish the safety, potency, and purity of the product candidate for each proposed indication, in accordance with current Good Clinical Practices ("GCP"); </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preparation and submission to the FDA of a biologics license application ("BLA"), for a biologic product requesting marketing for one or more proposed indications, including submission of detailed information on the manufacture and composition of the product in clinical development and proposed labelling; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">review of the product by an FDA advisory committee, where appropriate or if applicable; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities, including those of third parties, at which the product, or components thereof, are produced to assess compliance with cGMP requirements and to assure that the chemistry, methods, and controls ("CMC") are adequate to preserve the product&#8217;s identity, strength, quality, and purity; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">satisfactory completion of any FDA audits of the preclinical studies and clinical trial sites to assure compliance with GLP, as applicable, and GCP, and the integrity of clinical data in support of the BLA; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">payment of user fees pursuant to the Prescription Drug User Free Act ("PDUFA"), securing FDA approval of the BLA and licensure of the new biologic product; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">approval of a BLA licensing a biologic product for marketing for particular indications in the U.S.; and </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">37</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy ("REMS"), and any post-approval studies or other post-marketing commitments required by the FDA. </span></div></div>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preclinical Studies</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Before testing any biologic product candidate in humans, the product candidate must undergo preclinical testing. Preclinical tests include laboratory evaluations of product chemistry, formulation and stability, as well as studies to evaluate the potential for efficacy and toxicity in animal studies. These studies are generally referred to as IND-enabling studies. The conduct of the preclinical tests and formulation of the compounds for testing must comply with federal regulations and requirements, including GLP regulations and standards and the U.S. Department of Agriculture's Animal Welfare Act, if applicable. The results of the preclinical tests, together with manufacturing information and analytical data, are submitted to the FDA as part of an IND application.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Investigational New Drug Application</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An IND is an exemption from the FDCA that allows an unapproved product candidate to be shipped in interstate commerce for use in an investigational clinical trial and a request for FDA authorization to administer such investigational product to humans. The IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions about the product or conduct of the proposed clinical trial, including concerns that human research subjects will be exposed to unreasonable health risks and issues surrounding CMC for the proposed product. In that case, the IND sponsor and the FDA must resolve any outstanding FDA concerns before the clinical trials can begin or recommence. As a result, submission of the IND may result in the FDA not allowing the trials to commence or allowing the trial to commence on the terms originally specified by the sponsor in the IND.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Following commencement of a clinical trial under an IND, the FDA may also place a clinical hold or partial clinical hold on the study if the FDA raises concerns or questions. Clinical holds are imposed by the FDA whenever there is concern for patient safety and may be a result of new data, findings, or developments in clinical, preclinical, and/or CMC. This order issued by the FDA would delay either a proposed clinical trial or cause suspension of an ongoing trial, until all outstanding concerns have been adequately addressed and the FDA has notified the company that investigations may proceed. This could cause significant delays or difficulties in completing our planned clinical trial or future clinical trials in a timely manner.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Following the issuance of a clinical hold or partial clinical hold, a clinical investigation may only resume once the FDA has notified the sponsor that the investigation may proceed. The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying the FDA that the investigation can proceed or recommence. Occasionally, clinical holds are imposed due to manufacturing issues that may present safety issues for the clinical study subjects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expanded Access to an Investigational Drug for Treatment Use</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expanded access, sometimes called &#8220;compassionate use,&#8221; is the use of investigational products outside of clinical trials to treat patients with serious or immediately life-threatening diseases or conditions when there are no comparable or satisfactory alternative treatment options. The rules and regulations related to expanded access are intended to improve access to investigational products for patients who may benefit from investigational therapies. FDA regulations allow access to investigational products under an IND by the company or the treating physician for treatment purposes on a case-by-case basis for: individual patients (single-patient IND applications for treatment in emergency settings and non-emergency settings); intermediate-size patient populations; and larger populations for use of the investigational product under a treatment protocol or treatment IND application.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">When considering an IND application for expanded access to an investigational product with the purpose of treating a patient or a group of patients, the sponsor and treating physicians or investigators will determine suitability when all of the following criteria apply: patient(s) have a serious or immediately life-threatening disease or condition, and there is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition; the potential patient benefit justifies the potential risks of the treatment and the potential risks are not unreasonable in the context or condition to be treated; and the expanded use of the investigational drug for the requested treatment will not interfere initiation, conduct, or completion of clinical investigations that could support marketing approval of the product or otherwise compromise the potential development of the product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is no obligation for a sponsor to make its drug products available for expanded access; however, as required by the 21st Century Cures Act, (the "Cures Act"), passed in 2016, if a sponsor has a policy regarding how it evaluates and responds to expanded access requests, sponsors are required to make such policies publicly available upon the earlier of initiation of a Phase 2 or Phase 3 clinical trial, or 15 days after the investigational drug or biologic receives designation as a breakthrough therapy, fast track product, or regenerative medicine advanced therapy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">38</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to and separate from expanded access, on May 30, 2018, the Right to Try Act was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a manufacturer to make its investigational products available to eligible patients as a result of the Right to Try Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Human Clinical Trials in Support of a BLA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical trials involve the administration of the investigational product candidate to healthy volunteers or patients with the disease or condition to be treated under the supervision of a qualified principal investigator in accordance with GCP requirements. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, inclusion and exclusion criteria, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, each clinical trial must be reviewed and approved by an IRB either centrally or individually at each institution at which the clinical trial will be conducted. The IRB will consider, among other things, clinical trial design, patient informed consent, ethical factors, the safety of human subjects, and the possible liability of the institution. An IRB must operate in compliance with FDA regulations. The FDA, IRB, or the clinical trial sponsor may suspend or discontinue a clinical trial at any time for various reasons, including a finding that the clinical trial is not being conducted in accordance with FDA requirements or that the participants are being exposed to an unacceptable health risk. Clinical testing also must satisfy extensive GCP rules and the requirements for informed consent.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board ("DSMB") or data monitoring committee ("DMC"). This group may recommend continuation of the trial as planned, changes in trial conduct, or cessation of the trial at designated check points based on certain available data from the trial to which only the DSMB or DMC has access.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical trials typically are conducted in three sequential phases, but the phases may overlap or be combined. Additional studies may be required after approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Phase 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> clinical trials are initially conducted in a limited population to test the product candidate for safety, including adverse effects, dose tolerance, absorption, metabolism, distribution, excretion, and pharmacodynamics in healthy humans or, on occasion, in patients, such as cancer patients. </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Phase 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> clinical trials are generally conducted in a limited patient population to identify possible adverse effects and safety risks, evaluate the efficacy of the product candidate for specific targeted indications, and determine dose tolerance and optimal dosage. Multiple Phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and more costly Phase 3 clinical trials. </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Phase 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> clinical trials proceed if the Phase 2 clinical trials demonstrate that a dose range of the product candidate is potentially effective and has an acceptable safety profile. Phase 3 clinical trials are undertaken within an expanded patient population to further evaluate dosage, provide substantial evidence of clinical efficacy, and further test for safety in an expanded and diverse patient population at multiple, geographically dispersed clinical trial sites. A well-controlled, statistically robust Phase 3 trial may be designed to deliver the data that regulatory authorities will use to decide whether or not to approve, and, if approved, how to appropriately label a biologic; such Phase 3 studies are referred to as &#8220;pivotal.&#8221; </span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In some cases, the FDA may approve a BLA for a product but require the sponsor to conduct additional clinical trials to further assess the product&#8217;s safety and effectiveness after approval. Such trials are typically referred to as post-approval clinical trials. These studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication and to document a clinical benefit in the case of biologics approved under accelerated approval regulations. If the FDA approves a product while a company has ongoing clinical trials that were not necessary for approval, a company may be able to use the data from these clinical trials to meet all or part of any post-approval clinical trial requirement or to request a change in the product labeling. The failure to exercise due diligence with regard to conducting post-approval clinical trials could result in withdrawal of approval for products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A clinical trial may combine the elements of more than one phase and the FDA often requires more than one Phase 3 trial to support marketing approval of a product candidate. A company&#8217;s designation of a clinical trial as being of a particular phase is not necessarily indicative that the study will be sufficient to satisfy the FDA requirements of that phase because this determination cannot be made until the protocol and data have been submitted to and reviewed by the FDA. Generally, pivotal trials are Phase 3 trials, but they may be Phase 2 trials if the design provides a well-controlled and reliable assessment of clinical benefit, particularly in an area of unmet medical need.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">39</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2022, with the passage of Food and Drug Omnibus Reform Act ("FDORA") Congress required sponsors to develop and submit a diversity action plan for each Phase 3 clinical trial or any other &#8220;pivotal study&#8221; of a new drug or biological product. These plans are meant to encourage the enrollment of more diverse patient populations in late-stage clinical trials of FDA-regulated products. Specifically, action plans must include the sponsor&#8217;s goals for enrollment, the underlying rationale for those goals, and an explanation of how the sponsor intends to meet them. In addition to these requirements, the legislation directs the FDA to issue new guidance on diversity action plans. In January 2024, the FDA issued draft guidance setting out its policies for the collection of race and ethnicity data in clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2023, the FDA issued draft guidance with updated recommendations for GCPs aimed at modernizing the design and conduct of clinical trials. The updates are intended to help pave the way for more efficient clinical trials to facilitate the development of medical products. The draft guidance is adopted from the International Council for Harmonisation&#8217;s (&#8220;ICH&#8221;) recently updated E6(R3) draft guideline that was developed to enable the incorporation of rapidly developing technological and methodological innovations into the clinical trial enterprise. In addition, the FDA issued draft guidance outlining recommendations for the implementation of decentralized clinical trials.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Finally, sponsors of clinical trials are required to register and disclose certain clinical trial information on a public registry (clinicaltrials.gov) maintained by the NIH. In particular, information related to the product, patient population, phase of investigation, study sites and investigators and other aspects of the clinical trial is made public as part of the registration of the clinical trial. Although the FDA has historically not enforced these reporting requirements due to the U.S. Department of Health and Human Services&#8217; ("HHS&#8217;s") long delay in issuing final implementing regulations, those regulations have now been issued and the FDA has issued several pre-notices for voluntary corrective action and several notices of non-compliance during the past two years. While these notices of non-compliance did not result in civil monetary penalties, the failure to submit clinical trial information to clinicaltrials.gov, as required, is a prohibited act under the FDCA with violations subject to potential civil monetary penalties of up to $10,000 for each day the violation continues.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Studies Outside the United States in Support of FDA Approval</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with our clinical development program, we may conduct trials at sites outside the United States. When a foreign clinical study is conducted under an IND, all IND requirements must be met unless waived. When a foreign clinical study is not conducted under an IND, the sponsor must ensure that the study complies with certain regulatory requirements of the FDA in order to use the study as support for an IND or application for marketing approval. Specifically, the studies must be conducted in accordance with GCP, including undergoing review and receiving approval by an independent ethics committee ("IEC") and seeking and receiving informed consent from subjects. GCP requirements encompass both ethical and data integrity standards for clinical studies. The FDA&#8217;s regulations are intended to help ensure the protection of human subjects enrolled in non-IND foreign clinical studies, as well as the quality and integrity of the resulting data. They further help ensure that non-IND foreign studies are conducted in a manner comparable to that required for IND studies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The acceptance by the FDA of study data from clinical trials conducted outside the United States in support of U.S. approval may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the U.S., the FDA will generally not approve the application on the basis of foreign data alone unless (1) the data are applicable to the U.S. population and U.S. medical practice; (2) the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations; and (3) the data may be considered valid without the need for an on-site inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, even where the foreign study data are not intended to serve as the sole basis for approval, the FDA will not accept the data as support for an application for marketing approval unless the study is well-designed and well-conducted in accordance with GCP requirements and the FDA is able to validate the data from the study through an onsite inspection if deemed necessary. Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials are subject to the applicable local laws of the foreign jurisdictions where the trials are conducted.</span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interactions with FDA During the Clinical Development Program</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Following the clearance of an IND and the commencement of clinical trials, the sponsor will continue to have interactions with the FDA. Progress reports detailing the results of clinical trials must be submitted annually within 60 days of the anniversary dates that the IND went into effect and more frequently if serious adverse events occur. These reports must include a development safety update report (&#8220;DSUR&#8221;). In addition, IND safety reports must be submitted to the FDA for any of the following: serious and unexpected suspected adverse reactions; findings from other trials or animal or in vitro testing that suggest a significant risk in humans exposed to the product; and any clinically important increase in the occurrence of a serious suspected adverse reaction over that listed in the protocol or investigator brochure.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, sponsors are given opportunities to meet with the FDA at certain points in the clinical development program. Meetings at other times may also be requested. There are five types of meetings that occur between sponsors and the FDA. Type A meetings are those that are necessary for an otherwise stalled product development program to proceed or to address an important</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">40</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">safety issue. Type B meetings include pre-IND and pre-BLA meetings, as well as end of phase meetings such as EOP2 meetings. A Type C meeting is any meeting other than a Type A or Type B meeting regarding the development and review of a product, including, for example, meetings to facilitate early consultations on the use of a biomarker as a new surrogate endpoint that has never been previously used as the primary basis for product approval in the proposed context of use. A Type D meeting is focused on a narrow set of issues, which should be limited to no more than two focused topics, and should not require input from more than three disciplines or divisions. Finally, INTERACT meetings are intended for novel products and development programs that present unique challenges in the early development of an investigational product. The FDA has indicated that its responses, as conveyed in meeting minutes and advice letters, only constitute mere recommendations and/or advice made to a sponsor and, as such, sponsors are not bound by such recommendations and/or advice. Nonetheless, from a practical perspective, a sponsor&#8217;s failure to follow the FDA&#8217;s recommendations for design of a clinical program may put the program at significant risk of failure.</span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pediatric Studies</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Pediatric Research Equity Act of 2003 ("PREA"), a BLA or supplement thereto must contain data that are adequate to assess the safety, potency, and purity of the product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. Sponsors must also submit pediatric study plans prior to the assessment data. Those plans must contain an outline of the proposed pediatric study or studies the sponsor plans to conduct, including study objectives and design, any deferral or waiver requests, and other information required by regulation. The sponsor, the FDA, and the FDA&#8217;s internal review committee must then review the information submitted, consult with each other, and agree upon a final plan. The FDA or the sponsor may request an amendment to the plan at any time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA may, on its own initiative or at the request of the sponsor, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. A deferral may be granted for several reasons, including a finding that the product or therapeutic candidate is ready for approval for use in adults before pediatric trials are completed. The FDA is required to send a PREA Non-Compliance letter to sponsors who have failed to submit their pediatric assessments under PREA, have failed to seek or obtain a deferral or deferral extension or have failed to request approval for a required pediatric formulation. Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan designation, although FDA has taken steps to limit what it considers abuse of this statutory exemption in PREA. The FDA also maintains a list of diseases that are exempt from PREA requirements due to low prevalence of disease in the pediatric population. In May 2023, the FDA issued new draft guidance that further describes the pediatric study requirements under PREA.</span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compliance with cGMP Requirements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA's regulations require that pharmaceutical products be manufactured in specific approved facilities and in accordance with cGMPs. The cGMP regulations include requirements relating to organization of personnel, buildings and facilities, equipment, control of components and product containers and closures, production and process controls, packaging and labeling controls, holding and distribution, laboratory controls, records and reports, and returned or salvaged products. Manufacturers and others involved in the manufacture and distribution of products must also register their establishments with the FDA and certain state agencies. Both domestic and foreign manufacturing establishments must register and provide additional information to the FDA upon their initial participation in the manufacturing process. Any product manufactured by or imported from a facility that has not registered, whether foreign or domestic, is deemed misbranded under the FDCA. Establishments may be subject to periodic unannounced inspections by government authorities to ensure compliance with cGMPs and other laws. Inspections must follow a &#8220;risk-based schedule&#8221; that may result in certain establishments being inspected more frequently. Manufacturers may also have to provide, on request, electronic or physical records regarding their establishments. Delaying, denying, limiting, or refusing inspection by the FDA may lead to a product being deemed to be adulterated. Changes to the manufacturing process, specifications or container closure system for an approved product are strictly regulated and often require prior FDA approval before being implemented. The FDA&#8217;s regulations also require, among other things, the investigation and correction of any deviations from cGMP and the imposition of reporting and documentation requirements upon the sponsor and any third-party manufacturers involved in producing the approved product.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The PREVENT Pandemics Act, which was enacted in December 2022, clarifies that foreign drug manufacturing establishments are subject to registration and listing requirements even if a drug or biologic undergoes further manufacture, preparation, propagation, compounding, or processing at a separate establishment outside the United States prior to being imported or offered for import into the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Submission and Filing of a BLA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The results of product candidate development, preclinical testing, and clinical trials, including negative or ambiguous results as well as positive findings, are submitted to the FDA as part of a BLA requesting license to market the product. The BLA must contain extensive manufacturing information and detailed information on the composition of the product and proposed labeling as well as payment of a user fee. Under federal law, the submission of most BLAs is subject to an application user fee, which for</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">41</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">federal fiscal year 2024 is $4,048,695 for an application requiring clinical data. The sponsor of a licensed BLA is also subject to an annual program fee, which for federal fiscal year 2024 is $416,734. Certain exceptions and waivers are available for some of these fees, such as an exception from the application fee for products with orphan designation and a waiver for certain small businesses.</span></p>
  <p style="text-indent:9.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Following submission of a BLA, the FDA has 60 days to conduct a preliminary review of the application and it must inform the sponsor within that period of time whether the BLA is sufficiently complete to permit substantive review. In the event that FDA determines that an application does not satisfy this standard, it will issue a Refuse to File determination to the sponsor. The FDA may request additional information and studies, and the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing.</span></p>
  <p style="text-indent:9.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Once the submission has been accepted for filing, the FDA begins an in-depth review of the application. Under the goals and policies agreed to by the FDA under the PDUFA, the FDA has ten months in which to complete its initial review of a standard application and respond to the sponsor, and six months for a priority review of the application. The FDA does not always meet its PDUFA goal dates for standard and priority BLAs. The review process may often be significantly extended by FDA requests for additional information or clarification. The review process and the PDUFA goal date may be extended by three months if the FDA requests or if the sponsor otherwise provides additional information or clarification regarding information already provided in the submission within the last three months before the PDUFA goal date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with its review of an application, the FDA will typically submit information requests to the applicant and set deadlines for responses thereto. The FDA will also conduct a pre-approval inspection of the manufacturing facilities for the new product to determine whether the manufacturing processes and facilities comply with cGMPs. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and are adequate to assure consistent production of the product within required specifications. The FDA also may inspect the sponsor and one or more clinical trial sites to assure compliance with IND and GCP requirements and the integrity of the clinical data submitted to the FDA. With passage of FDORA, Congress clarified the FDA&#8217;s authority to conduct inspections by expressly permitting inspections of facilities involved in the preparation, conduct, or analysis of clinical and non-clinical studies submitted to the FDA as well as other persons holding study records or involved in the study process.</span></p>
  <p style="text-indent:9.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA may also refer the application to an advisory committee for review, evaluation, and recommendation as to whether the application should be approved. In particular, the FDA may refer applications for novel biologic products or biologic products that present difficult questions of safety or efficacy to an advisory committee. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates, and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span></p>
  <p style="text-indent:9.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The FDA's Decision on a BLA</span></p>
  <p style="text-indent:9.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the PHSA, the FDA may approve a BLA if it determines that the product is safe, pure, and potent, and the facility where the product will be manufactured meets standards, including cGMP requirements, designed to ensure that it continues to be safe, pure, and potent. Specifically, the FDA must determine that the expected benefits of the proposed product outweigh its potential risks to patients. This &#8220;benefit-risk&#8221; assessment is informed by the extensive body of evidence about the proposed product in the BLA. The FDA will also consider the severity of the underlying condition and how well patients&#8217; medical needs are addressed by currently available therapies; uncertainty about how the premarket clinical trial evidence will extrapolate to real-world use of the product in the post-market setting; and whether risk management tools are necessary to manage specific risks.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On the basis of the FDA&#8217;s evaluation of the application and accompanying information, including the results of the inspection of the manufacturing facilities and any FDA audits of preclinical and clinical trial sites to assure compliance with GCPs, the FDA may issue a complete response letter ("CRL") or an approval letter.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the application is not approved, the FDA will issue a CRL, which will contain the conditions that must be met in order to secure final approval of the application, and when possible will outline recommended actions the sponsor might take to obtain approval of the application. Sponsors that receive a CRL may submit to the FDA information that represents a complete response to the issues identified by the FDA, withdraw the application or request a hearing. The FDA will not approve an application until issues identified in the CRL have been addressed. If a CRL is issued, the sponsor will have one year to respond to the deficiencies identified by the FDA, at which time the FDA can deem the application withdrawn or, in its discretion, grant the sponsor an additional six-month extension to respond. For those seeking to challenge FDA&#8217;s CRL decision, the agency has indicated that sponsors may request a formal hearing on the CRL or they may file a request for reconsideration or a request for a formal dispute resolution. The FDA has committed to reviewing resubmissions in response to an issued CRL in either two or six months depending on the type of information included. Even with the submission of this additional information, however, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An approval letter, on the other hand, authorizes commercial marketing of the product with specific prescribing information for specific indications. The FDA may limit the approved indication(s) for use of the product. It may also require that contraindications, warnings, or precautions be included in the product labeling. In addition, the FDA may call for post-approval</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">42</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">studies, including Phase 4 clinical trials, to further assess the product&#8217;s efficacy and/or safety after approval. The agency may also require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms, including REMS, to help ensure that the benefits of the product outweigh the potential risks. REMS can include medication guides, communication plans for healthcare professionals, and elements to assure safe use ("ETASU"). ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patent registries. The FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. After approval, many types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expedited Review Programs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.173%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA is authorized to designate certain products for expedited review if they demonstrate the potential to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. The purpose of these programs is to provide important new drugs to patients earlier than under standard review procedures. None of these expedited programs changes the standards for approval but each may help expedite the development or approval process governing product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:9.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Fast Track program, the sponsor of a product candidate may request the FDA to designate the product for a specific indication as a Fast Track product concurrent with or after the filing of the IND. Candidate products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to the combination of the product candidate and the specific indication for which it is being studied. In addition to other benefits, such as the ability to have greater interactions with the FDA, the FDA may initiate review of sections of a Fast Track application before the application is complete, a process known as rolling review.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any product candidate submitted to the FDA for marketing, including under a Fast Track program, may be eligible for other types of FDA programs intended to expedite development and review, such as breakthrough therapy designation, priority review and accelerated approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Breakthrough therapy designation. To qualify for the breakthrough therapy program, product candidates must be intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence must indicate that such product candidates may demonstrate substantial improvement on one or more clinically significant endpoints over existing therapies. The FDA will seek to ensure the sponsor of a breakthrough therapy product candidate receives intensive guidance on an efficient drug development program, intensive involvement of senior managers and experienced staff on a proactive, collaborative and cross-disciplinary review and rolling review. </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Priority review. A product candidate is eligible for priority review if it treats a serious condition and, if approved, it would be a significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention compared to marketed products. FDA aims to complete its review of priority review applications within six months as opposed to 10 months for standard review. </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accelerated approval. Drug or biologic products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval. Accelerated approval means that a product candidate may be approved on the basis of adequate and well controlled clinical trials establishing that the product candidate has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity and prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug or biologic product candidate receiving accelerated approval perform adequate and well controlled post-marketing clinical trials. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials. With passage of FDORA in December 2022, Congress modified certain provisions governing accelerated approval of drug and biologic products.  Specifically, the new legislation authorized the FDA to: require a sponsor to have its confirmatory clinical trial underway before accelerated approval is awarded, require that a sponsor of a product granted accelerated approval to submit progress reports on its post-approval studies to FDA every six months (until the study is completed); and use expedited procedures to withdraw accelerated approval of an NDA or BLA after the confirmatory trial fails to verify the product&#8217;s clinical benefit.  Further, FDORA requires the agency to publish on its website &#8220;the rationale for why a post-approval study is not appropriate or necessary&#8221; whenever it decides not to require such a study upon granting accelerated approval.</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Regenerative advanced therapy. With passage of the Cures Act, Congress authorized the FDA to accelerate review and approval of products designated as regenerative advanced therapies. A product is eligible for this designation if it </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">43</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">is a regenerative medicine therapy that is intended to treat, modify, reverse or cure a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product candidate has the potential to address unmet medical needs for such disease or condition. The benefits of a regenerative advanced therapy designation include early interactions with the FDA to expedite development and review, benefits available to breakthrough therapies, potential eligibility for priority review and accelerated approval based on surrogate or intermediate endpoints.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></div></div>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Post-Approval Regulation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If regulatory approval for marketing of a product or new indication for an existing product is obtained, the sponsor will be required to comply with all regular post-approval regulatory requirements as well as any post-approval requirements that the FDA have imposed as part of the approval process. The sponsor will be required to report certain adverse reactions and production problems to the FDA, provide updated safety and efficacy information and comply with requirements concerning advertising and promotional labeling requirements. Manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including cGMP regulations, which impose certain procedural and documentation requirements upon manufacturers. Accordingly, the sponsor and its third-party manufacturers must continue to expend time, money, and effort in the areas of production and quality control to maintain compliance with cGMP regulations and other regulatory requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A product may also be subject to official lot release, meaning that the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official lot release, the manufacturer must submit samples of each lot, together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#8217;s tests performed on the lot, to the FDA. The FDA may in addition perform certain confirmatory tests on lots of some products before releasing the lots for distribution. Finally, the FDA will conduct laboratory research related to the safety, purity, potency, and effectiveness of pharmaceutical products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fines, warning letters or holds on post-approval clinical trials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product seizure or detention, or refusal to permit the import or export of products; or </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although physicians may prescribe legally available products for unapproved uses or patient populations (i.e., &#8220;off-label uses&#8221;), manufacturers may not market or promote such uses. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2021, the FDA published final regulations which describe the types of evidence that the agency will consider in determining the intended use of a biologic product.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a company is found to have promoted off-label uses, it may become subject to adverse public relations and administrative and judicial enforcement by the FDA, the Department of Justice, or the Office of the Inspector General of the Department of Health and Human Services, as well as state authorities. This could subject a company to a range of penalties that could</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">44</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes drug products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It may be permissible, under very specific, narrow conditions, for a manufacturer to engage in nonpromotional, non-misleading communication regarding off-label information, such as distributing scientific or medical journal information. Moreover, with passage of the Pre-Approval Information Exchange Act in December 2022, sponsors of products that have not been approved may proactively communicate to payors certain information about products in development to help expedite patient access upon product approval. In addition, in October 2023, the FDA published draft guidance outlining the agency&#8217;s non-binding policies governing the distribution of scientific information on unapproved uses to healthcare providers. This draft guidance calls for such communications to be truthful, non-misleading, factual, and unbiased and include all information necessary for healthcare providers to interpret the strengths and weaknesses and validity and utility of the information about the unapproved use.</span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Orphan Drug Designation and Exclusivity</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Orphan drug designation in the United States is designed to encourage sponsors to develop products intended for rare diseases or conditions. In the United States, a rare disease or condition is statutorily defined as a condition that affects fewer than 200,000 individuals in the United States or that affects more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making available the biologic for the disease or condition will be recovered from sales of the product in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Orphan drug designation qualifies a company for tax credits and market exclusivity for seven years following the date of the product&#8217;s marketing approval if granted by the FDA. An application for designation as an orphan product can be made any time prior to the filing of an application for approval to market the product. A product becomes an orphan when it receives orphan drug designation from the Office of Orphan Products Development at the FDA based on acceptable confidential requests made under the regulatory provisions. The product must then go through the review and approval process like any other product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A sponsor may request orphan drug designation of a previously unapproved product or new orphan indication for an already marketed product. In addition, a sponsor of a product that is otherwise the same product as an already approved orphan drug may seek and obtain orphan drug designation for the subsequent product for the same rare disease or condition if it can present a plausible hypothesis that its product may be clinically superior to the first drug. More than one sponsor may receive orphan drug designation for the same product for the same rare disease or condition, but each sponsor seeking orphan drug designation must file a complete request for designation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a product with orphan designation receives the first FDA approval for the disease or condition for which it has such designation or for a select indication or use within the rare disease or condition for which it was designated, the product generally will receive orphan drug exclusivity. Orphan drug exclusivity means that the FDA may not approve another sponsor&#8217;s marketing application for the same product for the same indication for seven years, except in certain limited circumstances. If a product designated as an orphan drug ultimately receives marketing approval for an indication broader than what was designated in its orphan drug application, it may not be entitled to exclusivity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The period of exclusivity begins on the date that the marketing application is approved by the FDA. Orphan drug exclusivity will not bar approval of another product under certain circumstances, including if a subsequent product with the same drug for the same condition is shown to be clinically superior to the approved product on the basis of greater efficacy or safety, or providing a major contribution to patient care, or if the company with orphan drug exclusivity is not able to meet market demand. Under Omnibus legislation enacted in December 2020, the requirement for a product to show clinical superiority applies to drugs and biologics that received orphan drug designation before enactment of the FDA Reauthorization Act of 2017 but have not yet been approved or licensed by FDA. In addition, the FDA may approve a second application for the same product for a different use or a second application for a clinically superior version of the product for the same use.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2021, the Court of Appeals for the 11th Circuit held that, for the purpose of determining the scope of market exclusivity, the term &#8220;same disease or condition&#8221; in the statute means the designated &#8220;rare disease or condition&#8221; and could not be interpreted by the FDA to mean the &#8220;indication or use.&#8221; Thus, the court concluded, orphan drug exclusivity applies to the entire designated disease or condition rather than the &#8220;indication or use.&#8221; Although there have been legislative proposals to overrule this decision, they have not been enacted into law. On January 23, 2023, FDA announced that, in matters beyond the scope of that court order, FDA will continue to apply its existing regulations tying orphan-drug exclusivity to the uses or indications for which the orphan drug was approved.</span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pediatric Exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pediatric exclusivity is another type of non-patent exclusivity in the United States and for biologics, if granted, provides for the attachment of an additional six months of regulatory exclusivity to the term of any existing regulatory exclusivity, including orphan exclusivity. This six-month exclusivity may be granted if a BLA sponsor submits pediatric data that fairly respond to a written</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">45</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#8217;s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity that cover the product are extended by six months.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Biosimilars and Exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2010 Patient Protection and Affordable Care Act, which was signed into law in March 2010, included a subtitle called the Biologics Price Competition and Innovation Act of 2009 ("BPCIA"). The BPCIA established a regulatory scheme authorizing the FDA to approve biosimilars and interchangeable biosimilars.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the BPCIA, a manufacturer may submit an application for licensure of a biologic product that is &#8220;biosimilar to&#8221; or &#8220;interchangeable with&#8221; a previously approved biological product or &#8220;reference product.&#8221; In order for the FDA to approve a biosimilar product, it must find that there are no clinically meaningful differences between the reference product and proposed biosimilar product in terms of safety, purity, and potency. For the FDA to approve a biosimilar product as interchangeable with a reference product, the agency must find that the biosimilar product can be expected to produce the same clinical results as the reference product, and (for products administered multiple times) that the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. To date, the FDA has licensed a number of biosimilar products, as well as a few interchangeable biosimilar products.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An application for a biosimilar product may not be submitted to the FDA until four years following the date of approval of the reference product. The FDA may not approve a biosimilar product until 12 years from the date on which the reference product was approved. Even if a product is considered to be a reference product eligible for exclusivity, another company could market a competing version of that product if the FDA approves a full BLA for such product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity, and potency of their product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. There have been recent government proposals to reduce the 12-year reference product exclusivity period, but none has been enacted to date.  At the same time, since passage of the BPCIA, many states have passed laws or amendments to laws, which address pharmacy practices involving biosimilar products. In December 2022, Congress clarified through FDORA that the FDA may approve multiple first interchangeable biosimilar biological products so long as the products are all approved on the first day on which such a product is approved as interchangeable with the reference product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Federal and State Data Privacy and Security Laws</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the federal Health Insurance Portability and Accountability Act of 1996 ("HIPAA"), HHS has issued regulations to protect the privacy and security of protected health information used or disclosed by covered entities including certain healthcare providers, health plans, and healthcare clearinghouses. HIPAA also regulates standardization of data content, codes, and formats used in healthcare transactions and standardization of identifiers for health plans and providers. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 ("HITECH"), and their regulations, including the omnibus final rule published on January 25, 2013, also imposes certain obligations on the business associates of covered entities that obtain protected health information in providing services to or on behalf of covered entities. In addition to federal privacy regulations, there are a number of state laws governing confidentiality and security of health information that are applicable to our business. In addition to possible federal civil and criminal penalties for HIPAA violations, state attorneys general are authorized to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. Accordingly, state attorneys general (along with private plaintiffs) have brought civil actions seeking injunctions and damages resulting from alleged violations of HIPAA&#8217;s privacy and security rules. New laws and regulations governing privacy and security may be adopted in the future as well.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, California recently enacted legislation that has been dubbed the first &#8220;GDPR-like&#8221; law in the United States. Known as the California Consumer Privacy Act ("CCPA"), it creates new individual privacy rights for consumers (as that word is broadly defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households. The CCPA went into effect on January 1, 2020 and requires covered companies to provide new disclosures to California consumers, provide such consumers new ways to opt-out of certain sales of personal information, and allow for a new cause of action for data breaches. The CCPA could impact our business activities depending on how it is interpreted and exemplifies the vulnerability of our business to not only cyber threats but also the evolving regulatory environment related to personal data and protected health information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2020, California voters passed a ballot initiative for the California Privacy Rights Act ("the CPRA"), which went into effect on January 1, 2023, and significantly expanded the CCPA to incorporate additional GDPR-like provisions including requiring that the use, retention, and sharing of personal information of California residents be reasonably necessary and proportionate to the purposes of collection or processing, granting additional protections for sensitive personal information, and requiring greater disclosures related to notice to residents regarding retention of information. The CPRA also created a new enforcement agency &#8211; the California Privacy Protection Agency &#8211; whose sole responsibility is to enforce the CPRA, which will further increase compliance risk. The provisions in the CPRA may apply to some of our business activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">46</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to California, 11 other states have passed comprehensive privacy laws similar to the CCPA and CPRA. These laws are either in effect or will go into effect sometime before the end of 2026. Like the CCPA and CPRA, these laws create obligations related to the processing of personal information, as well as special obligations for the processing of &#8220;sensitive&#8221; data, which includes health data in some cases. Some of the provisions of these laws may apply to our business activities. There are also states that are strongly considering or have already passed comprehensive privacy laws during the 2024 legislative sessions that will go into effect in 2025 and beyond. Other states will be considering similar laws in the future, and Congress has also been debating passing a federal privacy law. There are also states that are specifically regulating health information that may affect our business. For example, the State of Washington passed the My Health My Data Act in 2023 which specifically regulated health information that is not otherwise regulated by the HIPAA rules, and the law also has a private right of action, which further increases the relevant compliance risk. Connecticut and Nevada have also passed similar laws regulating consumer health data, and more states are considering such legislation in 2024. These laws may impact our business activities, including our identification of research subjects, relationships with business partners and ultimately the marketing and distribution of our products.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available under such laws, it is possible that some of our current or future business activities, including certain clinical research, sales, and marketing practices and the provision of certain items and services to our customers, could be subject to challenge under one or more of such privacy and data security laws. The heightening compliance environment and the need to build and maintain robust and secure systems to comply with different privacy compliance and/or reporting requirements in multiple jurisdictions could increase the possibility that a healthcare company may fail to comply fully with one or more of these requirements. If our operations are found to be in violation of any of the privacy or data security laws or regulations described above that are applicable to us, or any other laws that apply to us, we may be subject to penalties, including potentially significant criminal, civil, and administrative penalties, damages, fines, imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements, and/or oversight if we become subject to a consent decree or similar agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. To the extent that any of our product candidates, once approved, are sold in a foreign country, we may be subject to similar foreign laws.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent Term Restoration and Extension</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, a patent claiming a new biologic product, its method of use or its method of manufacture may be eligible for a limited patent term extension under the Hatch-Waxman Act, which permits a patent extension of up to five years for patent term lost during product development and FDA regulatory review. Assuming grant of the patent for which the extension is sought, the restoration period for a patent covering a product is typically one-half the time between the effective date of the IND clearing clinical studies and the submission date of the BLA, plus the time between the submission date of the BLA and the ultimate approval date. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14 years from the product&#8217;s approval date in the United States. Only one patent applicable to an approved product is eligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent for which extension is sought. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals. The USPTO reviews and approves the application for any patent term extension in consultation with the FDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">FDA Approval of Companion Diagnostics</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2014, the FDA issued final guidance clarifying the requirements that will apply to approval of therapeutic products and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> companion diagnostics. According to the guidance, for novel drugs, a companion diagnostic device and its corresponding therapeutic should be approved or cleared contemporaneously by the FDA for the use indicated in the therapeutic product&#8217;s labeling. Approval or clearance of the companion diagnostic device will ensure that the device has been adequately evaluated and has adequate performance characteristics in the intended population. In July 2016, the FDA issued a draft guidance intended to assist sponsors of the drug therapeutic and in vitro companion diagnostic device on issues related to co-development of the products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2014 guidance also explains that a companion diagnostic device used to make treatment decisions in clinical trials of a biologic product candidate generally will be considered an investigational device, unless it is employed for an intended use for which the device is already approved or cleared. If used to make critical treatment decisions, such as patient selection, the diagnostic device generally will be considered a significant risk device under the FDA&#8217;s Investigational Device Exemption, or IDE, regulations. Thus, the sponsor of the diagnostic device will be required to comply with the IDE regulations. According to the guidance, if a diagnostic device and a product are to be studied together to support their respective approvals, both products can be studied in the same investigational study, if the study meets both the requirements of the IDE regulations and the IND regulations. The guidance provides that depending on the details of the study plan and subjects, a sponsor may seek to submit an IND alone, or both an IND and an IDE.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">47</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In April 2020, the FDA issued additional guidance which describes considerations for the development and labeling of companion diagnostic devices to support the indicated uses of multiple biological oncology products, when appropriate. The 2020 guidance expands on the policy statement in the 2014 guidance by recommending that companion diagnostic developers consider a number of factors when determining whether their test could be developed, or the labeling for approved companion diagnostics could be revised through a supplement, to support a broader labeling claim such as use with a specific group of oncology therapeutic products (rather than listing an individual therapeutic product(s)).</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the FDCA, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> diagnostics, including companion diagnostics, are regulated as medical devices. In the United States, the FDCA and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post market surveillance. Unless an exemption applies, diagnostic tests require marketing clearance or approval from the FDA prior to commercial distribution.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA previously has required </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> companion diagnostics intended to select the patients who will respond to the product candidate to obtain pre-market approval ("PMA") simultaneously with approval of the therapeutic product candidate. The PMA process, including the gathering of clinical and preclinical data and the submission to and review by the FDA, can take several years or longer. It involves a rigorous premarket review during which the sponsor must prepare and provide the FDA with reasonable assurance of the device&#8217;s safety and effectiveness and information about the device and its components regarding, among other things, device design, manufacturing and labeling. PMA applications are subject to an application fee. For federal fiscal year 2024, the standard fee is $483,560 and the small business fee is $120,890.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Regulation and Procedures Governing Approval of Medicinal Products in the European Union</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In order to market any product outside of the United States, a company must also comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety, and efficacy, and governing, among other things, clinical trials, marketing authorization, commercial sales, and distribution of products. Whether or not it obtains FDA approval for a product, a sponsor will need to obtain the necessary approvals by the comparable foreign regulatory authorities before it can commence clinical trials or marketing of the product in those countries or jurisdictions. Specifically, the process governing approval of medicinal products in the European Union generally follows the same lines as in the United States. It entails satisfactory completion of preclinical studies and adequate and well-controlled clinical trials to establish the safety and efficacy of the product for each proposed indication. It also requires the submission to the relevant competent authorities of a marketing authorization application ("MAA") and granting of a marketing authorization by these authorities before the product can be marketed and sold in the European Union.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Trial Approval</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 31, 2022, the new Clinical Trials Regulation (EU) No 536/2014 ("CTR") became effective in the EU and replaced the prior Clinical Trials Directive 2001/20/EC. The new regulation aims at simplifying and streamlining the authorization, conduct and transparency of clinical trials in the EU. Under the new coordinated procedure for the approval of clinical trials, the sponsor of a clinical trial to be conducted in more than one Member State of the European Union ("EU Member State") will only be required to submit a single application for approval. The submission will be made through the Clinical Trials Information System, a new clinical trials portal overseen by the EMA and available to clinical trial sponsors, competent authorities of the EU Member States and the public.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The main characteristics of the regulation include: a streamlined application procedure via a single entry point, the &#8220;EU Portal and Database&#8221;; a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications for clinical trials, which is divided in two parts. Part I is assessed by the appointed reporting Member State, whose assessment report is submitted for review by the sponsor and all other competent authorities of all EU Member States in which an application for authorization of a clinical trial has been submitted, or concerned member states. Part II is assessed separately by each concerned member state. Strict deadlines have been established for the assessment of clinical trial applications. The role of the relevant ethics committees in the assessment procedure will continue to be governed by the national law of the concerned member state. However, overall related timelines will be defined by the Clinical Trials Regulation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The new regulation did not change the preexisting requirement that a sponsor must obtain prior approval from the competent national authority of the EU Member State in which the clinical trial is to be conducted. If the clinical trial is conducted in different EU Member States, the competent authorities in each of these EU Member States must provide their approval for the conduct of the clinical trial. Furthermore, the sponsor may only start a clinical trial at a specific study site after the applicable ethics committee has issued a favorable opinion.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">48</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The CTR foresees a three-year transition period. The extent to which ongoing and new clinical trials will be governed by the CTR varies. Clinical trials for which an application was submitted (i) prior to January 31, 2022 under the Clinical Trials Directive, or (ii) between January 31, 2022 and January 31, 2023 and for which the sponsor has opted for the application of the Clinical Trials Directive remain governed by said Directive until January 31, 2025. After this date, all clinical trials (including those which are ongoing) will become subject to the provisions of the CTR.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Parties conducting certain clinical trials must, as in the United States, post clinical trial information in the European Union at the EU Clinical Trials Registry.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">PRIME Designation in the European Union</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2016, the EMA launched an initiative to facilitate development of product candidates in indications, often rare, for which few or no therapies currently exist. The PRIority MEdicines ("PRIME") scheme is intended to encourage drug development in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation reviewed under the centralized procedure. Products from small- and medium-sized enterprises may qualify for earlier entry into the PRIME scheme than larger companies. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and accelerated marketing authorization application assessment once a dossier has been submitted. Importantly, a dedicated EMA contact and rapporteur from CHMP or Committee for Advanced Therapies are appointed early in the PRIME scheme facilitating increased understanding of the product at the EMA&#8217;s Committee level.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Marketing Authorization</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To obtain a marketing authorization for a product under the European Union regulatory system, a sponsor must submit an MAA, either under a centralized procedure administered by the EMA or one of the procedures administered by competent authorities in EU Member States (decentralized procedure, national procedure, or mutual recognition procedure). A marketing authorization may be granted only to a sponsor established in the European Union. Regulation (EC) No 1901/2006 provides that prior to obtaining a marketing authorization in the European Union, a sponsor must demonstrate compliance with all measures included in an EMA-approved Pediatric Investigation Plan ("PIP") covering all subsets of the pediatric population, unless the EMA has granted a product-specific waiver, class waiver, or a deferral for one or more of the measures included in the PIP.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid for all EU Member States. Pursuant to Regulation (EC) No. 726/2004, the centralized procedure is compulsory for specific products, including for medicines produced by certain biotechnological processes, products designated as orphan medicinal products, advanced therapy products and products with a new active substance indicated for the treatment of certain diseases, including products for the treatment of cancer. For products with a new active substance indicated for the treatment of other diseases and products that are highly innovative or for which a centralized process is in the interest of patients, the centralized procedure may be optional. Manufacturers must demonstrate the quality, safety, and efficacy of their products to the EMA, which provides an opinion regarding the MAA. The European Commission grants or refuses marketing authorization in light of the opinion delivered by the EMA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Specifically, the grant of marketing authorization in the European Union for products containing viable human tissues or cells such as gene therapy medicinal products is governed by Regulation 1394/2007/EC on advanced therapy medicinal products, read in combination with Directive 2001/83/EC of the European Parliament and of the Council, commonly known as the Community code on medicinal products. Regulation 1394/2007/EC lays down specific rules concerning the authorization, supervision, and pharmacovigilance of gene therapy medicinal products, somatic cell therapy medicinal products, and tissue engineered products. Manufacturers of advanced therapy medicinal products must demonstrate the quality, safety, and efficacy of their products to EMA which provides an opinion regarding the application for marketing authorization. The European Commission grants or refuses marketing authorization in light of the opinion delivered by EMA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the centralized procedure, the CHMP established at the EMA is responsible for conducting an initial assessment of a product. Under the centralized procedure in the European Union, the maximum timeframe for the evaluation of an MAA is 210 days, excluding clock stops when additional information or written or oral explanation is to be provided by the sponsor in response to questions of the CHMP.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Conditional Approval</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In particular circumstances, EU legislation (Article 14&#8211;a Regulation (EC) No 726/2004 (as amended by Regulation (EU) 2019/5 and Regulation (EC) No 507/2006 on Conditional Marketing Authorizations for Medicinal Products for Human Use) enables sponsors to obtain a conditional marketing authorization prior to obtaining the comprehensive clinical data required for an application</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">49</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for a full MA. Such conditional approvals may be granted for product candidates (including medicines designated as orphan medicinal products) if (1) the product candidate is intended for the treatment, prevention, or medical diagnosis of seriously debilitating or life-threatening diseases; (2) the product candidate is intended to meet unmet medical needs of patients; (3) a marketing authorization may be granted prior to submission of comprehensive clinical data provided that the benefit of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required; (4) the risk-benefit balance of the product candidate is positive; and (5) it is likely that the sponsor will be in a position to provide the required comprehensive clinical trial data. A conditional MA may contain specific obligations to be fulfilled by the marketing authorization holder, including obligations with respect to the completion of ongoing or new clinical trials and with respect to the collection of pharmacovigilance data. Conditional MAs are valid for one year, and may be renewed annually, if the risk-benefit balance remains positive, and after an assessment of the need for additional or modified conditions or specific obligations. The timelines for the centralized procedure described above also apply with respect to the review by the CHMP of applications for a conditional MA.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exceptional Circumstances</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A MA may also be granted &#8220;under exceptional circumstances&#8221; when the applicant can show that it is unable to provide comprehensive data on the efficacy and safety under normal conditions of use even after the product has been authorized and subject to specific procedures being introduced. This may arise in particular when the intended indications are very rare and, in the present state of scientific knowledge, it is not possible to provide comprehensive information, or when generating data may be contrary to generally accepted ethical principles. This MA is close to the conditional MA, as it is reserved to medicinal products to be approved for severe diseases or unmet medical needs and the applicant does not hold the complete data set legally required for the grant of a MA. However, unlike the conditional MA, the applicant does not have to provide the missing data and will never have to. Although the MA &#8220;under exceptional circumstances&#8221; is granted definitively, the risk-benefit balance of the medicinal product is reviewed annually and the MA is withdrawn in case the risk-benefit ratio is no longer favorable. Under these procedures, before granting the MA, the EMA or the competent authorities of the member states make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety, and efficacy. Except conditional MAs, MAs have an initial duration of five years. After these five years, the authorization may be renewed on the basis of a reevaluation of the risk-benefit balance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pediatric Trials</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to obtaining a marketing authorization in the EU, sponsors have to demonstrate compliance with all measures included in an EMA-approved PIP covering all subsets of the pediatric population, unless the EMA has granted a product-specific waiver, a class waiver, or a deferral for one or more of the measures included in the PIP. The respective requirements for all marketing authorization procedures are set forth in Regulation (EC) No 1901/2006, which is referred to as the Pediatric Regulation. This requirement also applies when a company wants to add a new indication, pharmaceutical form, or route of administration for a medicine that is already authorized. The Pediatric Committee of the EMA (&#8220;PDCO&#8221;) may grant deferrals for some medicines, allowing a company to delay development of the medicine in children until there is enough information to demonstrate its effectiveness and safety in adults. The PDCO may also grant waivers when development of a medicine in children is not needed or is not appropriate because (a) the product is likely to be ineffective or unsafe in part or all of the pediatric population; (b) the disease or condition occurs only in adult population; or (c) the product does not represent a significant therapeutic benefit over existing treatments for the pediatric population. Before a marketing authorization application can be filed, or an existing marketing authorization can be amended, the EMA determines that companies actually comply with the agreed studies and measures listed in each relevant PIP.</span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Regulatory Data Protection</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the European Union, new chemical entities approved on the basis of a complete independent data package qualify for eight years of data exclusivity upon marketing authorization and an additional two years of market exclusivity pursuant to Regulation (EC) No 726/2004, as amended, and Directive 2001/83/EC, as amended. Data exclusivity prevents regulatory authorities in the European Union from referencing the innovator&#8217;s data to assess a generic (abbreviated) application for a period of eight years. During the additional two-year period of market exclusivity, a generic MAA can be submitted, and the innovator&#8217;s data may be referenced, but no generic medicinal product can be marketed until the expiration of the market exclusivity. The overall ten-year period will be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to authorization, is held to bring a significant clinical benefit in comparison with existing therapies. Even if a compound is considered to be a new chemical entity so that the innovator gains the prescribed period of data exclusivity, another company may market another version of the product if such company obtained marketing authorization based on an MAA with a complete independent data package of pharmaceutical tests, preclinical tests and clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">50</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Periods of Authorization and Renewals</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A marketing authorization is valid for five years, in principle, and it may be renewed after five years on the basis of a reevaluation of the risk-benefit balance by the EMA or by the competent authority of the authorizing member state. To that end, the marketing authorization holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization was granted, at least six months before the marketing authorization ceases to be valid. Once renewed, the marketing authorization is valid for an unlimited period, unless the European Commission or the competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal period. Any authorization that is not followed by the placement of the drug on the European Union market (in the case of the centralized procedure) or on the market of the authorizing member state within three years after authorization ceases to be valid.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Regulatory Requirements after Marketing Authorization</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Following approval, the holder of the marketing authorization is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of the medicinal product. These include compliance with the European Union&#8217;s stringent pharmacovigilance or safety reporting rules, pursuant to which post-authorization studies and additional monitoring obligations can be imposed. In addition, the manufacturing of authorized products, for which a separate manufacturer&#8217;s license is mandatory, must also be conducted in strict compliance with the EMA&#8217;s good manufacturing practice requirements and comparable requirements of other regulatory bodies in the European Union, which mandate the methods, facilities, and controls used in manufacturing, processing and packing of drugs to assure their safety and identity. Finally, the marketing and promotion of authorized products, including industry-sponsored continuing medical education and advertising directed toward the prescribers of drugs and/or the general public, are strictly regulated in the European Union under Directive 2001/83EC, as amended.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Regulatory Exclusivity</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the EU, new products authorized for marketing (i.e., reference products) qualify for eight years of data exclusivity and an additional two years of market exclusivity upon marketing authorization. The data exclusivity period prevents generic sponsors from relying on the preclinical and clinical trial data contained in the dossier of the reference product when applying for a generic marketing authorization in the EU during a period of eight years from the date on which the reference product was first authorized in the EU. The market exclusivity period prevents a successful generic sponsor from commercializing its product in the EU until 10 years have elapsed from the initial authorization of the reference product in the European Union. The 10-year market exclusivity period can be extended to a maximum of 11 years if, during the first eight years of those 10 years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies.</span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Orphan Drug Designation and Exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Regulation (EC) No 141/2000 and Regulation (EC) No. 847/2000 provide that a product can be designated as an orphan drug by the European Commission if its sponsor can establish: that the product is intended for the diagnosis, prevention or treatment of (1) a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the European Union when the application is made, or (2) a life-threatening, seriously debilitating or serious and chronic condition in the European Union and that without incentives it is unlikely that the marketing of the drug in the European Union would generate sufficient return to justify the necessary investment. For either of these conditions, the sponsor must demonstrate that there exists no satisfactory method of diagnosis, prevention, or treatment of the condition in question that has been authorized in the European Union or, if such method exists, the drug will be of significant benefit to those affected by that condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An orphan drug designation provides a number of benefits, including fee reductions, regulatory assistance, and the possibility to apply for a centralized European Union marketing authorization. Marketing authorization for an orphan drug leads to a ten-year period of market exclusivity. During this market exclusivity period, neither the EMA nor the European Commission or the member states can accept an application or grant a marketing authorization for a &#8220;similar medicinal product.&#8221; A &#8220;similar medicinal product&#8221; is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. The market exclusivity period for the authorized therapeutic indication may, however, be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan drug designation because, for example, the product is sufficiently profitable not to justify market exclusivity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pediatric Exclusivity</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">51</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a sponsor obtains a marketing authorization in all EU Member States, or a marketing authorization granted in the centralized procedure by the European Commission, and the trial results for the pediatric population are included in the product information, even when negative, the medicine is then eligible for an additional six-month period of qualifying patent protection through extension of the term of the Supplementary Protection Certificate (&#8220;SPC&#8221;) or alternatively a one-year extension of the regulatory market exclusivity from 10 to 11 years, as selected by the marketing authorization holder.</span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent Term Extensions in the European Union and Other Jurisdictions</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The EU also provides for patent term extension through SPCs. The rules and requirements for obtaining an SPC are similar to those in the United States. An SPC may extend the term of a patent for up to five years after its originally scheduled expiration date and can provide up to a maximum of 15 years of marketing exclusivity for a drug. In certain circumstances, these periods may be extended for six additional months if pediatric exclusivity is obtained, which is described in detail below. Although SPCs are available throughout the EU, sponsors must apply on a country-by-country basis. Similar patent term extension rights exist in certain other foreign jurisdictions outside the EU.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Approval of Companion Diagnostic Devices</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the European Union, medical devices such as companion diagnostics must comply with the General Safety and Performance Requirements ("SPRs") detailed in Annex I of the European Union Medical Devices Regulation (Regulation (EU) 2017/745) ("MDR"), which came into force on May 26, 2021 and replaced the previously applicable European Union Medical Devices Directive (Council Directive 93/42/EEC). Compliance with SPRs, and additional requirements applicable to companion medical devices, is a prerequisite to be able to affix the CE Mark of Conformity to medical devices, without which they cannot be marketed or sold.  To demonstrate compliance with SPRs, a manufacturer must undergo a conformity assessment procedure, which varies according to the type of medical device and its classification. The MDR is meant to establish a uniform, transparent, predictable, and sustainable regulatory framework across the European Union for medical devices.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Separately, the regulatory authorities in the European Union also adopted a new In Vitro Diagnostic Regulation (EU) 2017/746 ("IVDR"), which became effective in May 2022. The new regulation replaced the In Vitro Diagnostics Directive 98/79/EC. Manufacturers wishing to apply to a notified body for a conformity assessment of their in vitro diagnostic medical device had until May 2022 to update their Technical Documentation to meet the requirements and comply with the new, more stringent Regulation.  The regulation will, among other things: strengthen the rules on placing devices on the market and reinforce surveillance once they are available; establish explicit provisions on manufacturers&#8217; responsibilities for the follow-up of the quality, performance, and safety of devices placed on the market; improve the traceability of medical devices throughout the supply chain to the end-user or patient through a unique identification number; set up a central database to provide patients, healthcare professionals and the public with comprehensive information on products available in the European Union; and strengthen rules for the assessment of certain high-risk devices, such as implants, which may have to undergo an additional check by experts before they are placed on the market.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While the IVDR became effective in May 2022, it became clear in 2021 that Member States, health institutions, and economic operators were not ready to apply the IVDR as of that date. The European Commission therefore proposed a progressive or staggered roll-out of the rules of the IVDR. The current transition periods range from May 26, 2025 for high risk in vitro diagnostics to May 26, 2027 for lower risk in vitro diagnostics. Certain provisions for devices manufactured and used in health institutions would have to apply as of May 26, 2028. These transition periods only apply to so called &#8220;legacy devices,&#8221; meaning devices covered by a certificate or declaration of conformity issued under the previous legal framework.</span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Brexit and the Regulatory Framework in the United Kingdom</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The United Kingdom&#8217;s withdrawal from the European Union took place on January 31, 2020. As of January 1, 2021, the Medicines and Healthcare Products Regulatory Agency (the "MHRA") became responsible for supervising medicines and medical devices in Great Britain, comprising England, Scotland and Wales under domestic law whereas Northern Ireland continues to be subject to European Union rules under the Northern Ireland Protocol. The MHRA will rely on the Human Medicines Regulations 2012 (SI 2012/1916) (as amended) (the "HMR") as the basis for regulating medicines. The HMR has incorporated into the domestic law the body of European Union law instruments governing medicinal products that pre-existed prior to the United Kingdom&#8217;s withdrawal from the European Union.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 27, 2023, the UK government and the European Commission announced a political agreement in principle to replace the Northern Ireland Protocol with a new set of arrangements, known as the &#8220;Windsor Framework&#8221;. This new framework fundamentally changes the existing system under the Northern Ireland Protocol, including with respect to the regulation of medicinal products in the UK. In particular, the MHRA will be responsible for approving all medicinal products destined for the UK market (i.e., Great Britain and Northern Ireland), and the EMA will no longer have any role in approving medicinal products destined for Northern</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">52</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ireland. A single UK-wide marketing authorization will be granted by the MHRA for all medicinal products to be sold in the UK, enabling products to be sold in a single pack and under a single authorization throughout the UK. The Windsor Framework was approved by the EU-UK Joint Committee on March 24, 2023, so the UK government and the EU will enact legislative measures to bring it into law. On June 9, 2023, the MHRA announced that the medicines aspects of the Windsor Framework will apply from January 1, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">EU laws which have been transposed into UK law through secondary legislation continue to be applicable as &#8220;retained EU law&#8221;. However, new legislation such as the (EU) Clinical Trials Regulation will not be applicable in Great Britain. Since a significant proportion of the regulatory framework for pharmaceutical products in the UK covering the quality, safety, and efficacy of pharmaceutical products, clinical trials, marketing authorizations, commercial sales, and distribution of pharmaceutical products is derived from EU directives and regulations, Brexit may have a material impact upon the regulatory regime with respect to the development, manufacture, importation, approval, and commercialization of our product candidates in the UK. For example, the UK is no longer covered by the centralized procedures for obtaining EU-wide marketing authorizations from the EMA, and a separate marketing authorization will be required to market our product candidates in the UK. A new international recognition framework has been in place since January 1, 2024, whereby the MHRA will have regard to decisions on the approval of marketing authorizations made by the EMA and certain other regulators when determining an application for a new Great Britain marketing authorization.</span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General Data Protection Regulation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The collection, use, disclosure, transfer, or other processing of personal data regarding individuals in the European Union, including personal health data, is subject to the European Union General Data Protection Regulation ("GDPR") which became effective on May 25, 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. The GDPR also imposes strict rules on the transfer of personal data to countries outside the European Union, including the U.S., and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to &#8364;20 million or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. Compliance with the GDPR will be a rigorous and time-intensive process that may increase the cost of doing business or require companies to change their business practices to ensure full compliance. In July 2020, the Court of Justice of the European Union (the "CJEU") invalidated the EU-U.S. Privacy Shield framework, one of the mechanisms used to legitimize the transfer of personal data from the EEA to the United States. The CJEU decision also drew into question the long-term viability of an alternative means of data transfer, the standard contractual clauses, for transfers of personal data from the EEA to the United States. <br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Following the CJEU decision, in October 2022, President Biden signed an executive order to implement the EU-U.S. Data Privacy Framework, which would serve as a replacement to the EU-US Privacy Shield. The EU initiated the process to adopt an adequacy decision for the EU-U.S. Data Privacy Framework in December 2022, and the European Commission adopted the adequacy decision in July 2023. The adequacy decision permits U.S. companies who self-certify to the EU-U.S. Data Privacy Framework to rely on it as a valid data transfer mechanism for data transfers from the EU to the United States. However, some privacy advocacy groups have already suggested that they will be challenging the EU-U.S. Data Privacy Framework. If these challenges are successful, they may not only impact the EU-U.S. Data Privacy Framework, but also further limit the viability of the standard contractual clauses and other data transfer mechanisms. The uncertainty around this issue has the potential to impact our business.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On June 23, 2016, the electorate in the UK voted in favor of leaving the EU, commonly referred to as Brexit. As with other issues related to Brexit, there are open questions about how personal data will be protected in the UK and whether personal information can transfer from the EU to the UK. Following the withdrawal of the UK from the EU, the UK Data Protection Act 2018 applies to the processing of personal data that takes place in the UK and includes parallel obligations to those set forth by GDPR. While the Data Protection Act of 2018 in the UK that &#8220;implements&#8221; and complements the GDPR has achieved Royal Assent on May 23, 2018 and is now effective in the UK, it is unclear whether transfer of data from the EEA to the UK will remain lawful under the GDPR, although these transfers currently are permitted by an adequacy decision from the European Commission. The UK government has already determined that it considers all 27 EU and EEA member states to be adequate for the purposes of data protection, ensuring that data flows from the UK to the EU/EEA remain unaffected. In addition, a recent decision from the European Commission appears to deem the UK as being &#8220;essentially adequate&#8221; for purposes of data transfer from the EU to the UK, although this decision may be re-evaluated in the future. The UK and the U.S. have also agreed to a U.S.-UK &#8220;Data Bridge,&#8221; which functions similarly to the EU-U.S. Data Privacy Framework and provides an additional legal mechanism for companies to transfer data from the UK to the United States. In addition to the UK, Switzerland is also in the process of approving an adequacy decision in relation to the Swiss-U.S. Data Privacy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">53</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Framework (which would function similarly to the EU-U.S. Data Privacy Framework and the U.S.-UK Data Bridge in relation to data transfers from Switzerland to the United States). Any changes or updates to these developments have the potential to impact our business.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Coverage, Pricing, and Reimbursement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we may seek regulatory approval by the FDA or other government authorities. In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use any product candidates we may develop unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of such product candidates. Even if any product candidates we may develop are approved, sales of such product candidates will depend, in part, on the extent to which third-party payors, including government health programs in the United States such as Medicare and Medicaid, commercial health insurers, and managed care organizations, provide coverage, and establish adequate reimbursement levels for, such product candidates. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are increasingly challenging the prices charged, examining the medical necessity, and reviewing the cost-effectiveness of medical products and services and imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the approved products for a particular indication.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable marketing approvals. Nonetheless, product candidates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover any product candidates we may develop could reduce physician utilization of such product candidates once approved and have a material adverse effect on our sales, results of operations and financial condition. Additionally, a payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payor to payor. Third-party reimbursement and coverage may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. In addition, any companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to any companion diagnostics.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The containment of healthcare costs also has become a priority of federal, state and foreign governments and the prices of pharmaceuticals have been a focus in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement, and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#8217;s revenue generated from the sale of any approved products. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive marketing approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Outside the United States, ensuring adequate coverage and payment for any product candidates we may develop will face challenges. Pricing of prescription pharmaceuticals is subject to governmental control in many countries. Pricing negotiations with governmental authorities can extend well beyond the receipt of regulatory marketing approval for a product and may require us to conduct a clinical trial that compares the cost effectiveness of any product candidates we may develop to other available therapies. The conduct of such a clinical trial could be expensive and result in delays in our commercialization efforts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies (so called health technology assessments) in order to obtain reimbursement or pricing approval. For example, the European Union provides options for its member states to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. EU Member States may approve a specific price for a product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other member states allow companies to fix their own prices for products but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the European Union have increased the amount of discounts required</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">54</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">on pharmaceuticals and these efforts could continue as countries attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the European Union. The downward pressure on healthcare costs in general, particularly prescription products, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. Political, economic, and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU Member States, and parallel trade (arbitrage between low-priced and high-priced member states), can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products, if approved in those countries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Healthcare Law and Regulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Healthcare providers and third-party payors play a primary role in the recommendation and prescription of pharmaceutical products that are granted marketing approval. Arrangements with providers, consultants, third-party payors, and customers are subject to broadly applicable fraud and abuse, anti-kickback, false claims laws, reporting of payments to physicians and teaching physicians and patient privacy laws and regulations and other healthcare laws and regulations that may constrain our business and/or financial arrangements. Restrictions under applicable federal and state healthcare laws and regulations, include the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, paying, receiving, or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalties laws, which prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false, fictitious, or fraudulent or knowingly making, using, or causing to made or used a false record or statement to avoid, decrease, or conceal an obligation to pay money to the federal government;  </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Foreign Corrupt Practices Act, which prohibits companies and their intermediaries from making, or offering or promising to make improper payments to non-U.S. officials for the purpose of obtaining or retaining business or otherwise seeking favorable treatment; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal transparency requirements known as the federal Physician Payments Sunshine Act, under the Patient Protection and Affordable Care Act (the "ACA"), as amended by the Health Care Education Reconciliation Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the Centers for Medicare &amp; Medicaid Services ("CMS") within HHS, information related to payments and other transfers of value made by that entity to physicians, other healthcare providers, and teaching hospitals, as well as ownership and investment interests held by physicians, and their immediate family members.</span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring pharmaceutical manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures. In addition, certain state and local laws require drug manufacturers to register pharmaceutical sales representatives in the jurisdiction. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal, and administrative penalties, damages, fines, disgorgement, exclusion from government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, and the curtailment or restructuring of our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Healthcare Reform</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. There have been a number of federal and state proposals during the last few years regarding the pricing of pharmaceutical and biopharmaceutical products, limiting coverage and reimbursement for drugs and other medical products, government control and other changes to the healthcare system in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">55</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2010, the United States Congress enacted the ACA, which, among other things, includes changes to the coverage and payment for products under government healthcare programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, in August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2012 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of up to 2% per fiscal year, which will remain in effect through 2031 pursuant to the Coronavirus Aid, Relief and Economic Security Act (the "CARES Act").</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The American Taxpayer Relief Act of 2012, which was enacted in January 2013, among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers, and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used. Indeed, under current legislation, the actual reductions in Medicare payments may vary up to 4%.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since enactment of the ACA, there have been, and continue to be, numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, with enactment of the Tax Cuts and Jobs Act of 2017, which was signed by President Trump on December 22, 2017, Congress repealed the &#8220;individual mandate.&#8221; The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, became effective in 2019. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although the previous administration took executive actions to undermine or delay implementation of the ACA, those actions were rescinded with issuance of an Executive Order on January 28, 2021 by President Biden, which directs federal agencies to reconsider rules and other policies that limit Americans&#8217; access to health care, and consider actions that will protect and strengthen that access.  Under this Executive Order, federal agencies are directed to re-examine: policies that undermine protections for people with pre-existing conditions, including complications related to COVID-19; demonstrations and waivers under Medicaid and the ACA that may reduce coverage or undermine the programs, including work requirements; policies that undermine the Health Insurance Marketplace or other markets for health insurance; policies that make it more difficult to enroll in Medicaid and the ACA; and policies that reduce affordability of coverage or financial assistance, including for dependents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pharmaceutical Prices</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The prices of prescription pharmaceuticals have also been the subject of considerable discussion in the United States. There have been several recent United States congressional inquiries, as well as proposed and enacted state and federal legislation designed to, among other things, bring more transparency to pharmaceutical pricing, review the relationship between pricing and manufacturer patient programs, and reduce the costs of pharmaceuticals under Medicare and Medicaid. In 2020, President Trump issued several executive orders intended to lower the costs of prescription products and certain provisions in these orders have been incorporated into regulations. These regulations include an interim final rule implementing a most favored nation model for prices that would tie Medicare Part B payments for certain physician-administered pharmaceuticals to the lowest price paid in other economically advanced countries, effective January 1, 2021. That rule, however, has been subject to a nationwide preliminary injunction and, on December 29, 2021, CMS issued a final rule to rescind it. With issuance of this rule, CMS stated that it will explore all options to incorporate value into payments for Medicare Part B pharmaceuticals and improve beneficiaries' access to evidence-based care.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, in October 2020, HHS and the FDA published a final rule allowing states and other entities to develop a Section 804 Importation Program ("SIP") to import certain prescription drugs from Canada into the United States. That regulation was challenged in a lawsuit by the Pharmaceutical Research and Manufacturers of America (&#8220;PhRMA&#8221;), but the case was dismissed by a federal district court in February 2023 after the court found that PhRMA did not have standing to sue HHS. Nine states (Colorado, Florida, Maine, New Hampshire, New Mexico, North Dakota, Texas, Vermont, and Wisconsin) have passed laws allowing for the importation of drugs from Canada. Certain of these states have submitted Section 804 Importation Program proposals and are awaiting FDA approval. On January 5, 2023, the FDA approved Florida&#8217;s plan for Canadian drug importation.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 9, 2021, President Biden signed Executive Order 14063, which focuses on, among other things, the price of pharmaceuticals.  The Order directs HHS to create a plan within 45 days to combat &#8220;excessive pricing of prescription pharmaceuticals and enhance domestic pharmaceutical supply chains, to reduce the prices paid by the federal government for such pharmaceuticals, and to address the recurrent problem of price gouging.&#8221;  On September 9, 2021, HHS released its plan to reduce pharmaceutical prices.  The key features of that plan are to: (a) make pharmaceutical prices more affordable and equitable for all consumers and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">56</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">throughout the health care system by supporting pharmaceutical price negotiations with manufacturers; (b)  improve and promote competition throughout the prescription pharmaceutical industry by supporting market changes that strengthen supply chains, promote biosimilars, and increase transparency; and (c) foster scientific innovation to promote better healthcare and improve health by supporting public and private research and making sure that market incentives promote discovery of valuable and accessible new treatments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 16, 2022, the Inflation Reduction Act ("IRA") was signed into law by President Biden. The new legislation has implications for Medicare Part D, which is a program available to individuals who are entitled to Medicare Part A or enrolled in Medicare Part B to give them the option of paying a monthly premium for outpatient prescription drug coverage. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of the Department of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years.  <br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Specifically, with respect to price negotiations, Congress authorized Medicare to negotiate lower prices for certain costly single-source drug and biologic products that do not have competing generics or biosimilars and are reimbursed under Medicare Part B and Part D. CMS may negotiate prices for ten high-cost drugs paid for by Medicare Part D starting in 2026, followed by 15 Medicare Part D drugs in 2027, 15 Medicare Part B or Part D drugs in 2028, and 20 Medicare Part B or Part D drugs in 2029 and beyond. This provision applies to drug products that have been approved for at least 9 years and biologics that have been licensed for 13 years, but it does not apply to drugs and biologics that have been approved for a single rare disease or condition.  Further, the legislation subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing to comply with the legislation by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law or for taking price increases that exceed inflation. The legislation also requires manufacturers to pay rebates for drugs in Medicare Part D whose price increases exceed inflation. The new law also caps Medicare out-of-pocket drug costs at an estimated $4,000 a year in 2024 and, thereafter beginning in 2025, at $2,000 a year.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2023, Merck &amp; Co. filed a lawsuit against the HHS and CMS asserting that, among other things, the IRA&#8217;s Drug Price Negotiation Program for Medicare constitutes an uncompensated taking in violation of the Fifth Amendment of the Constitution. Subsequently, a number of other parties, including the U.S. Chamber of Commerce, Bristol Myers Squibb Company, the PhRMA, Astellas, Novo Nordisk, Janssen Pharmaceuticals, Novartis, AstraZeneca, and Boehringer Ingelheim, also filed lawsuits in various courts with similar constitutional claims against the HHS and CMS. We expect that litigation involving these and other provisions of the IRA will continue, with unpredictable and uncertain results.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. A number of states, for example, require pharmaceutical manufacturers and other entities in the supply chain, including health carriers, pharmacy benefit managers, wholesale distributors, to disclose information about pricing of pharmaceuticals. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the European Union, similar political, economic and regulatory developments to those in the United States may affect our ability to profitably commercialize our product candidates, if approved. In markets outside of the United States and the European Union, reimbursement and healthcare payment systems vary significantly by country and many countries have instituted price ceilings on specific products and therapies.  In many countries, including those of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control and access. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, pharmaceutical firms may be required to conduct a clinical trial that compares the cost-effectiveness of the product to other available therapies.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">57</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Human Capital</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had 59 employees, including a total of 20 employees with M.D. or Ph.D. degrees. Of these full-time employees, 44 are engaged in research and development activities. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our future success is dependent on attracting, motivating and retaining a diverse group of talented employees. We aim to create an inclusive and empowering work environment. Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and future employees. The principal purposes of our incentive plans are to attract, retain and motivate selected employees, consultants, advisors and directors through the granting of stock-based compensation awards and cash-based performance bonus awards, as applicable. We provide a comprehensive benefits package to help employees manage their health, well-being, finances, and life outside of work, including health insurance, dental and vision insurance, life insurance, accidental death and dismemberment issuance, short-term and long-term disability insurance, paid sick leave, a 401(k) plan, an employee stock purchase plan, a flexible spending account program, and paid vacation time. We value the health, safety, and wellbeing of our employees and their families.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Corporate Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our principal executive offices are located at 321 Summer Street, Suite 400, Boston, Massachusetts 02210, and our telephone number is (857) 330-4340. Our website address is http://www.inozyme.com. The information contained on, or that can be accessed through, our website is not a part of this Annual Report on Form 10-K. We have included our website address in this Annual Report on Form 10-K solely as an inactive textual reference.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We own or have rights to, or have applied for, trademarks, service marks and trade names that we use in connection with the operation of our business, including our corporate name, logos and website names. Other trademarks, service marks and trade names appearing in this Annual Report on Form 10-K are the property of their respective owners. Solely for convenience, some of the trademarks, service marks and trade names referred to in this Annual Report on Form 10-K are listed without the </span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#153;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> symbols.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Available Information</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Through our website, we make available free of charge our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Sections 13(a) and 15(d) of the Exchange Act of 1934, as amended (the "Exchange Act"). We make these reports available through our website as soon as reasonably practicable after we electronically file such reports with, or furnish such reports to, the Securities and Exchange Commission. We also make available, free of charge on our website, the reports filed with the Securities and Exchange Commission by our executive officers, directors and 10% stockholders pursuant to Section 16 under the Exchange Act as soon as reasonably practicable after copies of those filings are provided to us by those persons. The information contained on, or that can be accessed through, our website is not a part of this Annual Report on Form 10-K. We have included our website address in this Annual Report on Form 10-K solely as an inactive textual reference.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">58</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1a_risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1A. Ris</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">k Factors.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our future operating results could differ materially from the results described in this Annual Report on Form 10-K due to the risks and uncertainties described below. You should consider carefully the following information about risks below in evaluating our business. If any of the following risks actually occur, our business, financial conditions, results of operations and future growth prospects would likely decline. In addition, we cannot assure investors that our assumptions and expectations will prove to be correct. Important factors could cause our actual results to differ materially from those indicated or implied by forward-looking statements. See page 1 of this Annual Report on Form 10-K for a discussion of some of the forward-looking statements that are qualified by these risk factors. Factors that could cause or contribute to such differences include those factors discussed below. The risks and uncertainties described below are not the only ones we face. Additional risks not presently known to us or other factors not perceived by us to present significant risks to our business at this time also may impair our business operations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to our Financial Position and Need for Additional Capital</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have incurred significant losses since our inception. We expect to continue to incur significant expenses and operating losses for the foreseeable future and may never achieve or maintain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since inception, we have incurred significant operating losses. Our net losses were $71.2 million for the year ended December 31, 2023 and $67.1 million for the year ended December 31, 2022. As of December 31, 2023, we had an accumulated deficit of $285.9 million. To date, we have not yet commercialized any products or generated any revenue from product sales and have financed our operations primarily with proceeds from sales of convertible preferred stock, offerings of common stock and pre-funded warrants and borrowings under our Loan Agreement. We have devoted substantially all of our financial resources and efforts to pursuing research and development of our product candidates. We are still in the early stages of clinical development of our lead product candidate, INZ-701, and have initiated Phase 1/2 clinical trials of adults with ENPP1 Deficiency and ABCC6 Deficiency, a Phase 1b ENERGY-1 clinical trial of infants with ENPP1 Deficiency, and a Phase 1 clinical trial of patients with end-stage kidney disease ("ESKD") receiving hemodialysis.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to continue to incur significant expenses and operating losses for the foreseeable future. We anticipate that our expenses will increase substantially if and as we:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">conduct our ongoing Phase 1/2 clinical trials of INZ-701 for adults with ENPP1 and ABCC6 Deficiencies, our ongoing Phase 1b clinical trial of INZ-701 for infants with ENPP1 Deficiency, our ongoing pivotal trial of INZ-701 in pediatric patients with ENPP1 Deficiency, and our ongoing Phase 1 clinical trial of INZ-701 in patients with ESKD receiving hemodialysis; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">prepare for, initiate, and conduct our planned clinical trials of INZ-701 for patients with ENPP1 and ABCC6 Deficiencies, including our planned pivotal clinical trials of INZ-701 for infants, and in adolescents and adults with ENPP1 Deficiency, and our planned Phase 3 clinical trial of INZ-701 for patients with ABCC6 Deficiency;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">conduct research, preclinical testing, and clinical trials of INZ-701 for additional indications; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">conduct research, preclinical testing, and clinical trials of other product candidates; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">engage in regulatory interactions with the U.S. Food and Drug Administration ("FDA"), the European Medicines Agency ("EMA"), and other regulatory authorities;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">submit regulatory filings and seek marketing approval for INZ-701 or any other product candidate if it successfully completes clinical trials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">scale up our manufacturing processes and capabilities; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish a sales, marketing, and distribution infrastructure to commercialize any product candidate for which we may obtain marketing approval; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in-license or acquire additional technologies or product candidates; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">make any payments to Yale University ("Yale") under our license agreement or sponsored research agreement with Yale; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">59</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">maintain, expand, enforce, and protect our intellectual property portfolio; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">hire additional clinical, regulatory, quality control, scientific, and commercial personnel;  </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">add operational, financial, and management information systems and personnel, including personnel to support our research, product development, and planned future commercialization efforts and our operations as a public company; and</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">make any principal and interest payments when due under the terms of the Loan Agreement. </span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. Our expenses could increase beyond our expectations if, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we are required by regulatory authorities in the United States, Europe, or other jurisdictions to perform trials or studies in addition to, or different than, those that we currently expect; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">there are any delays in establishing appropriate manufacturing arrangements for or completing the development of any of our product candidates; or </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">there are any third-party challenges to our intellectual property or we need to defend against any intellectual property-related claim. </span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we obtain marketing approval for and are successful in commercializing one or more of our product candidates, we expect to incur substantial additional research and development and other expenditures to develop and market additional product candidates or to expand the approved indications of any marketed product. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have never generated revenue from product sales and may never achieve or maintain profitability.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are still in the early stages of clinical development of our first product candidate, INZ-701, and expect that it will be a number of years, if ever, before we have a product candidate ready for commercialization. We have no products that are approved for commercial sale and may never be able to develop marketable products. To become and remain profitable, we must succeed in completing development of, obtaining marketing approval for and eventually commercializing, one or more products that generates significant revenue. The ability to achieve this success will require us to be effective in a range of challenging activities, including completing clinical development of INZ-701 for ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis, completing research, preclinical testing, and clinical development of INZ-701 for additional indications or of other product candidates, scaling up our manufacturing processes and capabilities to support clinical trials of INZ-701 or of other product candidates we develop, obtaining marketing approval for INZ-701 or any other product candidates, and manufacturing, marketing and selling any products for which we may obtain marketing approval. We may never succeed in these activities and, even if we do, may never generate revenues that are significant enough to achieve profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our pipeline of product candidates or even continue our operations. A decline in the value of our company could also cause our stockholders to lose all or part of their investment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are heavily dependent on the success of our lead product candidate, INZ-701, which will require significant clinical testing before we can seek marketing approval and potentially launch commercial sales. If INZ-701 does not receive marketing approval or is not successfully commercialized, or if there is significant delay in doing so, our business will be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have no products that are approved for commercial sale and may never be able to develop marketable products. Our business currently depends heavily on the successful development, marketing approval and commercialization of INZ-701. We expect that a substantial portion of our efforts and expenditures for the foreseeable future will be devoted to advancing INZ-701. We cannot be certain that INZ-701 will achieve success in ongoing or future clinical trials, receive marketing approval or be successfully commercialized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">60</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we were required to discontinue development of INZ-701, or if INZ-701 does not receive marketing approval for one or more of the indications we pursue, fails to achieve significant market acceptance, or fails to receive adequate reimbursement, we would be delayed by many years in our ability to achieve profitability, if ever, and may not be able to generate sufficient revenue to continue our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We will need substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect our expenses to increase substantially in connection with our ongoing and planned activities, particularly as we conduct our ongoing and initiate our planned clinical trials of INZ-701 for ENPP1 Deficiency and ABCC6 Deficiency, continue research and development and initiate additional clinical trials of, and seek marketing approval for, INZ-701 and any other product candidates we develop. In addition, if we obtain marketing approval for INZ-701 or any other product candidate we develop, we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution. Furthermore, we have incurred and will continue to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital or obtain adequate funds when needed or on acceptable terms, we may be required to delay, limit, reduce or terminate our research and development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. In addition, attempting to secure additional financing may divert the time and attention of our management from day-to-day activities and distract from our research and development efforts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our future capital requirements will depend on many factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the progress, costs, and results of our ongoing clinical trials of INZ-701 for ENPP1 Deficiency, ABCC6 Deficiency, calciphylaxis, and any future clinical development of INZ-701 for these indications; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope, progress, costs, and results of research, preclinical testing, and clinical trials of INZ-701 for additional indications; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number of and development requirements for additional indications for INZ-701 or for any other product candidates we develop; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to scale up our manufacturing processes and capabilities;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to execute on our global development strategy;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs, timing, and outcome of regulatory review of INZ-701 and any other product candidates we develop; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential changes in the regulatory environment and enforcement rules; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to establish and maintain strategic collaborations, licensing, or other arrangements and the financial terms of such arrangements; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the payment of license fees and other costs of our technology license arrangements; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the extent of our debt service obligations and our ability, if desired, to refinance any of our existing debt on terms that are more favorable to us;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs and timing of future commercialization activities, including product manufacturing, sales, marketing, and distribution, for INZ-701 and any other product candidates we develop for which we may receive marketing approval; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the amount and timing of revenue, if any, received from commercial sales of INZ-701 and any other product candidates we develop for which we receive marketing approval; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential changes in pharmaceutical pricing and reimbursement infrastructure; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">61</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property and proprietary rights and defending any intellectual property-related claims; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the extent to which we in-license or acquire additional technologies or product candidates. </span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had cash, cash equivalents, and short-term investments of approximately $188.6 million, and we had $45.0 million of outstanding principal indebtedness under our Loan Agreement. We believe that our cash, cash equivalents, and short-term investments as of December 31, 2023 will enable us to fund our cash flow requirements into the fourth quarter of 2025. However, we have based this estimate on assumptions that may prove to be wrong, and our operating plan may change as a result of many factors currently unknown to us. In addition, changing circumstances could cause us to consume capital significantly faster than we currently anticipate, and we may need to spend more than currently expected because of circumstances beyond our control. As a result, we could deplete our capital resources sooner than we currently expect. In addition, because the successful development of INZ-701 and any other product candidates that we pursue is highly uncertain, at this time we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the development of any product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. We will not generate commercial revenues unless and until we can achieve sales of products, which we do not anticipate for a number of years, if at all. Accordingly, we will need to obtain substantial additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. Our ability to raise additional funds may be adversely impacted by general economic conditions, both inside and outside the U.S., including disruptions to, and instability and volatility in, the credit and financial markets in the U.S. and worldwide, heightened inflation, interest rate and currency rate fluctuations, and economic slowdown or recession as well as concerns related to health epidemics, such as COVID-19,</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and geopolitical events, including civil or political unrest. In addition, market instability and volatility, high levels of inflation and interest rate fluctuations may increase our cost of financing or restrict our access to potential sources of future liquidity. Alternatively, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have a loan agreement that requires us to meet specified funding conditions for future draw downs and operating covenants and places restrictions on our operating and financial flexibility.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently have $45.0 million of outstanding principal indebtedness, and we may in the future draw down up to $25.0 million of additional principal indebtedness under the Loan Agreement, subject to specified conditions and lender discretion. Our ability to draw down an additional tranche commitment of $25.0 million is subject to use of proceeds limitations and the lender&#8217;s consent in its discretion. As security for its obligations under the Loan Agreement, we granted the lenders a first priority security interest on substantially all of our assets (other than intellectual property), subject to certain exceptions. Because of the security interest, the lender&#8217;s rights to repayment from a liquidation of the assets subject to that security interest would be senior to the rights of other creditors.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Loan Agreement contains customary representations and warranties, events of default and affirmative and negative covenants, including covenants that limit or restrict our ability to, among other things, dispose of assets, make changes to our business, management, ownership or business locations, merge or consolidate, incur additional indebtedness, incur additional liens, pay dividends or other distributions or repurchase equity, make investments, and enter into certain transactions with affiliates, in each case subject to certain exceptions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We intend to satisfy our current and future debt service obligations with our existing cash and cash equivalents. However, we may not have sufficient funds or may be unable to arrange for additional financing to pay the amounts due under our outstanding debt. Funds from external sources may not be available on acceptable terms, if at all. In addition, a failure to comply with the conditions of our Loan Agreement, including a breach of any covenant, could result in an event of default thereunder. In the event of an acceleration of amounts due under our Loan Agreement as a result of an event of default, including upon the occurrence of an event or circumstance that could be expected to have a material adverse effect on our business, operations, properties, assets or financial condition or a failure to pay any amount due, we may not have sufficient funds or may be unable to arrange for additional financing to repay our indebtedness or to make any accelerated payments, and the lenders could seek to enforce security interests in the collateral securing such indebtedness. Any declaration by the lenders of an event of default could significantly harm our business and prospects and could cause the price of our common stock to decline.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">62</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, our outstanding debt combined with our other financial obligations and contractual commitments could have significant adverse consequences, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restricting the amount of our cash resources, after satisfaction of our debt service obligations, available to fund working capital, research and development efforts and other general corporate purposes;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">limiting our flexibility in planning for, or reacting to, changes in our business and our industry; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">placing us at a competitive disadvantage compared to our competitors that have less debt or better debt servicing options.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Until such time, if ever, as we can generate substantial revenues from product sales, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. We do not have any committed external source of funds, other than under our Loan Agreement. Our ability to borrow under our Loan Agreement is subject to our satisfaction of specified conditions and lender discretion. To the extent that we raise additional capital through the sale of equity or convertible debt securities or to the extent the lenders under our Loan Agreement elect to convert a portion of their outstanding principal into shares of our common stock or elect to purchase up to $5.0 million of shares of our common stock pursuant to the Loan Agreement, our stockholders&#8217; ownership interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#8217; rights as common stockholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our operations and ability to take specific actions, such as incurring additional indebtedness, making acquisitions, engaging in acquisition, merger or collaboration transactions, selling or licensing our assets, making capital expenditures, redeeming our stock, making certain investments or declaring dividends. The covenants under our Loan Agreement and the pledge of our assets as collateral limit our ability to take specific actions, including obtaining additional debt financing. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our limited operating history may make it difficult for stockholders to evaluate the success of our business to date and to assess our future viability.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, securing intellectual property rights, conducting research and development activities, conducting preclinical studies and clinical trials, establishing arrangements for the manufacture of INZ-701 and longer-term planning for potential commercialization. As a company, we have limited experience in clinical development, having only advanced INZ-701 into the early stages of clinical development. Our prospects must be considered in light of the uncertainties, risks, expenses and difficulties frequently encountered by companies in their early stages of operations. We have not yet demonstrated our ability to successfully complete any clinical trials, obtain marketing approvals, manufacture a commercial scale product or arrange for a third party to do so on our behalf, or conduct sales, marketing, and distribution activities necessary for successful product commercialization. Consequently, any predictions stockholders make about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing, obtaining marketing approval for and commercializing products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, as our business grows, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown obstacles. We will need to transition at some point from a company with a research and development focus to a company capable of supporting commercial activities. We may not be successful in such a transition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As we continue to build our business, we expect our financial condition and operating results to fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, stockholders should not rely upon the results of any quarterly or annual periods as indications of future operating performance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We hold a portion of our cash and cash equivalents that we use to meet our working capital and operating expense needs in deposit accounts, and our liquidity and operations could be adversely affected if a financial institution holding such funds fails.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We hold a portion of our cash and cash equivalents that we use to meet our working capital and operating expense needs in deposit accounts at multiple financial institutions. The balance held in these accounts typically exceeds the Federal Deposit Insurance Corporation ("FDIC") standard deposit insurance limit of $250,000 per depositor and per institution. If a financial institution in which we hold such funds fails or is subject to significant adverse conditions in the financial or credit markets, we could be subject to a risk of loss of all or a portion of such uninsured funds or be subject to a delay in accessing all or a portion of our funds. Any such</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">63</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">loss or lack of access to these funds could adversely impact our short-term liquidity and ability to meet our operating expense obligations, including payroll obligations.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For example, on March 10, 2023, Silicon Valley Bank ("SVB") was closed, and the FDIC was appointed receiver for the bank. The FDIC created a successor bridge bank, and all deposits of SVB were transferred to the bridge bank under a systemic risk exception approved by the United States Department of the Treasury, the Federal Reserve, and the FDIC. Access to and availability of deposits was delayed, though ultimately, in that case, restored. If financial institutions in which we hold funds for working capital and operating expenses were to fail, we cannot provide any assurances that the applicable governmental agencies would take action to protect our uninsured deposits or make deposits available in a similar manner.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also maintain investment accounts with one or more financial institutions in which we hold our investments and, if access to the funds we use for working capital and operating expenses is impaired, we may not be able to open new operating accounts or to sell investments or transfer funds from our investment accounts to new operating accounts on a timely basis sufficient to meet our operating expense obligations. In addition, to the extent that the financial institutions with which we hold securities fail or are associated with banks that fail, there may be delays or other access restrictions with respect to such securities, similar to those described above for deposit accounts.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Public health epidemics or pandemics may affect our ability to initiate and complete current, planned, or future preclinical studies and clinical trials, disrupt regulatory activities, disrupt our manufacturing and supply chain or have other adverse effects on our business and operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Public health emergencies or pandemics could adversely affect our business, financial condition, results of operations, and prospects. We and the third-party manufacturers and clinical research organizations that we engage may face disruptions that could affect our ability to initiate and complete preclinical studies or clinical trials or submit regulatory applications, including disruptions in our ability to obtain necessary site approvals or other delays at clinical trial sites, including recruitment or patient enrollment, or disruptions in procuring items that are essential for our research and development activities, such as, for example, raw materials used in the manufacturing of our product candidates, laboratory supplies for our ongoing and planned preclinical studies and clinical trials, or animals that are used for preclinical testing, in each case, for which there may be shortages because of ongoing efforts to address any pandemic. For example, as a result of the COVID-19 pandemic, we experienced delays with respect to initiating dosing in our Phase 1/2 clinical trials of INZ-701 for ENPP1 and ABCC6 Deficiency.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although the public health emergency declarations related to COVID-19 ended on May 11, 2023, the FDA retained a number of COVID-19-related policies. It is unclear how, if at all, these policies will impact our efforts to develop and commercialize our product candidates.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot be certain what the overall impact of any future health pandemic will be on our business, and it has the potential to materially and adversely affect our business, financial condition, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in tax laws or in their implementation may adversely affect our business and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in tax law may adversely affect our business or financial condition. The Tax Cuts and Jobs Act (the "TCJA"), as amended by the Coronavirus Aid, Relief, and Economic Security Act ("CARES Act") significantly reformed the Internal Revenue Code of 1986, as amended, or the Code. The TCJA, among other things, contains significant changes to corporate taxation, including a reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21% and the limitation of the deduction for net operating losses ("NOLs") to 80% of current year taxable income for losses arising in taxable years beginning after December 31, 2017 (though any such NOLs may be carried forward indefinitely). In addition, beginning in 2022, the TCJA requires corporations to capitalize and amortize research and development expenditures over five years for domestic expenditures and fifteen years for foreign expenditures.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the CARES Act, as part of Congress&#8217;s response to the COVID-19 pandemic, economic relief legislation was enacted in 2020 and 2021 containing tax provisions. The Inflation Reduction Act ("IRA") was also signed into law in August 2022. The IRA introduced new tax provisions, including a 1% excise tax imposed on certain stock repurchases by publicly traded corporations. The 1% excise tax generally applies to any acquisition by the publicly traded corporation (or certain of its affiliates) of stock of the publicly traded corporation in exchange for money or other property (other than stock of the corporation itself), subject to a de minimis exception. Thus, the excise tax could apply to certain transactions that are not traditional stock repurchases. Regulatory guidance under the IRA, the TCJA, and such additional legislation is and continues to be forthcoming, and such guidance could</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">64</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ultimately increase or lessen impact of these laws on our business and financial condition. In addition, it is uncertain if and to what extent various states will conform to the IRA, the TCJA, and additional tax legislation.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our ability to use our NOLs and research and development tax credit carryforwards to offset future taxable income may be subject to certain limitations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have a history of cumulative losses and anticipate that we will continue to incur significant losses in the foreseeable future. As a result, we do not know whether or when we will generate taxable income necessary to utilize our NOLs or research and development tax credit carryforwards. As of December 31, 2023, we had federal and state NOL carryforwards of  $164.5 million and $135.6 million, respectively, and federal and state research and development tax credit carryforwards totaling $17.3 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In general, under Section 382 of the Code and corresponding provisions of state law, a corporation that undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a three year period, is subject to limitations on its ability to utilize its pre-change NOLs and research and development tax credit carryforwards to offset future taxable income. We have not conducted a study to assess whether any such ownership changes have occurred. We may have experienced such ownership changes in the past and may experience such ownership changes in the future (which may be outside our control). As a result, if and to the extent we earn net taxable income, our ability to use our pre-change NOLs and research and development tax credit carryforwards to offset such taxable income may be subject to limitations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Research and Development of our Product Candidates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are early in our clinical development efforts. If we are unable to commercialize INZ-701 or experience significant delays in doing so, our business will be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are early in our clinical development efforts. Our ability to generate revenues from product sales, which we do not expect will occur for a number of years, if ever, will depend heavily on the successful development, marketing approval and eventual commercialization of INZ-701 or other product candidates we develop, which may never occur. The success of INZ-701 and any other product candidate we develop will depend on several factors, including the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">successfully completing preclinical studies and initiating clinical trials;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">successfully enrolling patients in and completing clinical trials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">scaling up manufacturing processes and capabilities to support our clinical trials of our product candidates; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">applying for and receiving marketing approvals from applicable regulatory authorities; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtaining and maintaining intellectual property protection and regulatory exclusivity for our product candidates; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">making arrangements for commercial manufacturing capabilities; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establishing sales, marketing and distribution capabilities and launching commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">acceptance of our product candidates, if and when approved, by patients, the medical community and third-party payors; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">effectively competing with other therapies; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtaining and maintaining coverage, adequate pricing and adequate reimbursement from third-party payors, including government payors; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">maintaining, enforcing, defending and protecting our rights in our intellectual property portfolio; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">not infringing, misappropriating or otherwise violating others&#8217; intellectual property or proprietary rights; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">maintaining a continued acceptable safety profile of our products following receipt of any marketing approvals. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">65</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully develop and commercialize INZ-701 or any other product candidate we develop, which would materially harm our business. As a company, we have limited experience in clinical development. Any predictions about the future success or viability of INZ-701 or any product candidates we develop may not be as accurate as they could be if we had a history of conducting clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Drug development involves a lengthy and expensive process, with an uncertain outcome. The results of preclinical studies and early clinical trials may not be predictive of future results. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of INZ-701 or any other product candidate. If our clinical trials do not meet safety or efficacy endpoints, or if we experience significant delays in clinical trials, our ability to commercialize INZ-701 or any other product candidates we develop and our financial position will be impaired.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have limited experience in clinical development. The risk of failure for INZ-701 is high. It is impossible to predict when or if INZ-701 or any other product candidate that we develop will prove effective or safe in humans or will receive marketing approval. Before obtaining marketing approval from regulatory authorities for the sale of INZ-701 or any other product candidate we develop, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical trials may fail to demonstrate that INZ-701 or any other product candidates we develop is safe for humans and effective for indicated uses. As our clinical trials may advance to self- and/or home-administration for select patients, we may face difficulties in patient compliance or see increases in user error. Even if the clinical trials are successful, changes in marketing approval policies during the development period, changes in or the enactment or promulgation of additional statutes, regulations or guidance or changes in regulatory review for each submitted product application may cause delays in the approval or rejection of an application.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In order to obtain regulatory approval to market a new biological product, we must demonstrate proof of safety, purity and potency or efficacy in humans. To satisfy these requirements, we will have to conduct adequate and well-controlled clinical trials. Before we can commence clinical trials for a product candidate, we must complete extensive preclinical testing and studies that support our applications to regulatory authorities in North America and Europe to allow us to initiate clinical development. We cannot be certain of the timely completion or outcome of our preclinical testing and studies and cannot predict if the outcome of our preclinical testing and studies will ultimately support the further development of our current or future product candidates or whether regulatory authorities will accept our proposed clinical programs. As a result, we may not be able to submit applications to initiate clinical development of the other product candidates we develop on the timelines we expect, if at all, and the submission of these applications may not result in regulatory authorities allowing clinical trials to begin. For example, in August 2020, our IND for INZ-701 for the treatment of ENPP1 Deficiency was placed on clinical hold, until we submitted our final study report for our three-month toxicology studies in mice and non-human primates. Furthermore, product candidates are subject to continued preclinical safety studies, which may be conducted concurrently with our clinical testing. The outcomes of these safety studies may delay the launch of or enrollment in future clinical trials and could impact our ability to continue to conduct our clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to the outcome. We cannot guarantee that any of our clinical trials will be conducted as planned or completed on schedule, or at all. A failure of one or more clinical trials can occur at any stage of testing, which may result from a multitude of factors, including, among other things, flaws in study design, dose selection issues, placebo effects, patient enrollment criteria and failure to demonstrate favorable safety or efficacy traits. The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and preliminary or interim results of a clinical trial do not necessarily predict final results. For example, our product candidates may fail to show the desired safety and efficacy in clinical development despite positive results in preclinical studies or having successfully advanced through initial clinical trials. As a result, we cannot assure stockholders that any clinical trials that we may conduct will demonstrate consistent or adequate efficacy and safety to support marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials even after achieving promising results in preclinical testing and earlier-stage clinical trials, and we cannot be certain that we will not face similar setbacks. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. Furthermore, the failure of any of our product candidates to demonstrate safety and efficacy in any clinical trial could negatively impact the perception of our other product candidates or cause regulatory authorities to require additional testing before approving any of our product candidates. In addition, results from compassionate use protocols or investigator-sponsored trials may not be confirmed in company-sponsored trials and/or may negatively impact the prospects for our programs.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">66</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize any product candidates that we develop, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulators or institutional review boards, or IRBs, may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site or at all; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulators may determine that the planned design of our clinical trials is flawed or inadequate; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be unable to establish clinical endpoints that applicable regulatory authorities consider clinically meaningful, or, if we seek accelerated approval, biomarker efficacy endpoints that applicable regulatory authorities consider likely to predict clinical benefit; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preclinical testing may produce results based on which we may decide, or regulators may require us, to conduct additional preclinical studies before we proceed with certain clinical trials, limit the scope of our clinical trials, halt ongoing clinical trials or abandon product development programs; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may decide, or regulators or IRBs may require us, to suspend or terminate clinical trials of our product candidates for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulators or IRBs may require us to perform additional or unanticipated clinical trials to obtain approval or we may be subject to additional post-marketing testing requirements to maintain marketing approval; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulators may revise the requirements for approving our product candidates, or such requirements may not be as we anticipate; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of clinical trials of our product candidates may be greater than we anticipate; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our clinical investigators, regulators or IRBs to suspend or terminate the trials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulators may withdraw their approval of a product or impose restrictions on its distribution. </span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive, if there are safety concerns or if we determine that the observed safety or efficacy profile would not be competitive in the marketplace, we may:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">incur unplanned costs; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">be delayed in obtaining marketing approval for our product candidates; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">67</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">not obtain marketing approval at all; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtain marketing approval in some countries and not in others; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtain approval for indications or patient populations that are not as broad as intended or desired; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">be subject to additional post-marketing testing requirements; or </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">have the product removed from the market after obtaining marketing approval. </span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product development costs will also increase if we experience delays in preclinical studies or clinical trials or in obtaining marketing approvals. We do not know whether any of our preclinical studies or clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. We may also determine to change the design or protocol of one or more of our clinical trials, including to add additional patients or arms, which could result in increased costs and expenses or delays. Significant preclinical study or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the FDA&#8217;s and other regulatory authorities&#8217; policies with respect to clinical trials may change and additional government regulations may be enacted.  For example, in December 2022, with the passage of Food and Drug Omnibus Reform Act, or FDORA, Congress required sponsors to develop and submit a diversity action plan for each Phase 3 clinical trial or any other &#8220;pivotal study&#8221; of a new drug or biological product.  These plans are meant to encourage the enrollment of more diverse patient populations in late-stage clinical trials of FDA-regulated products.  Specifically, action plans must include the sponsor&#8217;s goals for enrollment, the underlying rationale for those goals, and an explanation of how the sponsor intends to meet them.  In addition to these requirements, the legislation directs the FDA to issue new guidance on diversity action plans.  <br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Similarly, the regulatory landscape related to clinical trials in the European Union ("EU") recently evolved. The EU Clinical Trials Regulation ("CTR") became effective on January 31, 2022. The CTR aims to simplify and streamline the authorization, conduct, and transparency of clinical trials in the EU. We have not previously secured authorization to conduct clinical studies in the EU pursuant to the CTR and, accordingly, there is a risk that we may be delayed in commencing any such studies. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies governing clinical trials, our development plans may be impacted.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Because we are developing INZ-701 for the treatment of diseases in which there is little clinical experience and, in some cases, using new endpoints or methodologies, the FDA or other regulatory authorities may not consider the endpoints of our clinical trials to predict or provide clinically meaningful results.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are currently no therapies approved to treat ENPP1 or ABCC6 Deficiencies or calciphylaxis, and there may be no therapies approved to treat the underlying causes of other diseases that we attempt to address or may address in the future. As a result, the design and conduct of clinical trials of product candidates for the treatment of these diseases may take longer, be more costly or be less effective as a result of the novelty of development in these diseases. In some cases, we may use new or novel endpoints or methodologies, such as change in plasma PPi, which we are evaluating in our Phase 1/2 clinical trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency, and regulatory authorities may not consider the endpoints of our clinical trials to predict or provide clinically meaningful results. Any such regulatory authority may require evaluation of additional or different clinical endpoints in our clinical trials or ultimately determine that these clinical endpoints do not support marketing approval. For example, based on recommendations from the FDA, the sole primary endpoint of plasma PPi in our ENERGY-3 trial of INZ-701 in the United States should be supported by consistent trends in appropriate secondary endpoints. In addition, if we are required to use additional or different clinical endpoints by regulatory authorities, INZ-701 may not achieve or meet such clinical endpoints in our clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if a regulatory authority finds our clinical trial success criteria to be sufficiently validated and clinically meaningful, we may not achieve the pre-specified endpoint to a degree of statistical significance in any pivotal or other clinical trials we may conduct for our product candidates. Further, even if we do achieve the pre-specified criteria, our trials may produce results that are unpredictable or inconsistent with the results of other efficacy endpoints in the trial. Regulatory authorities also could give overriding weight to other efficacy endpoints over a primary endpoint even if we achieve statistically significant results on that primary endpoint,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">68</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">if we do not do so on our secondary efficacy endpoints. Regulatory authorities also weigh the benefits of a product against its risks and may view the efficacy results in the context of safety as not being supportive of approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we experience delays or difficulties in the enrollment of patients in our clinical trials for INZ-701 or any other product candidate we develop, our receipt of necessary marketing approvals could be delayed or prevented.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Identifying and qualifying patients to participate in clinical trials for INZ-701 and any other product candidate we develop is critical to our success. Successful and timely completion of clinical trials will require that we enroll a sufficient number of patients who remain in the trial until its conclusion. Because we primarily focus on rare diseases, we may have difficulty enrolling a sufficient number of eligible patients in future clinical trials of INZ-701 or any other product candidate. ENPP1 Deficiency is estimated to occur in approximately one in 64,000 pregnancies worldwide, and we believe there are approximately 37,000 patients in addressable markets worldwide with ENPP1 Deficiency. In North America, the EU, Japan, and Brazil we believe there are approximately 9,400 patients with ENPP1 Deficiency. ABCC6 Deficiency is estimated to affect approximately one per 25,000 to 50,000 individuals, and we believe there are more than 67,000 patients in addressable markets worldwide with ABCC6 Deficiency. In North America, the EU, Japan, and Brazil, we believe there are approximately 24,400 patients with ABCC6 Deficiency. The estimated incidence rate of calciphylaxis is approximately 3.5 per 1,000 patients with ESKD. In North America, the EU, Japan, and Brazil, we believe there are approximately 23,800 patients with ESKD receiving hemodialysis. We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside of the United States. We cannot predict how successful we will be at enrolling subjects in future clinical trials. Patient enrollment is affected by a variety of other factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the prevalence and severity of the disease under investigation; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the eligibility criteria for the trial in question and the process for identifying patients; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the perceived risks and benefits of the product candidate under trial; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the requirements of the trial protocols; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability of existing treatments for the indications for which we are conducting clinical trials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ability to recruit clinical trial investigators with the appropriate competencies and experience; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the efforts to facilitate timely enrollment in clinical trials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ability to identify specific patient populations based on specific genetic mutations or other factors; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the challenges in recruiting critically ill infants, and the extensive logistical support and transportation required;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the patient referral practices of physicians; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ability to monitor patients adequately during and after treatment; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain and maintain patient consents; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the proximity and availability of clinical trial sites for prospective patients; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the conduct of clinical trials by competitors for product candidates that treat the same indications or address the same patient populations as our product candidates; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost to, or lack of adequate compensation for, prospective patients; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the impact of any health epidemic, such as COVID-19. </span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any inability to locate and enroll a sufficient number of patients for our clinical trials would result in significant delays, could require us to abandon one or more clinical trials altogether and could delay or prevent our receipt of necessary regulatory</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">69</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">approvals. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If serious adverse events, undesirable side effects or unexpected characteristics are identified during the development of INZ-701 or any other product candidate we may develop, we may need to abandon or limit our further clinical development of those product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If INZ-701 or any other product candidate we develop is associated with serious adverse events or undesirable side effects in clinical trials or have characteristics that are unexpected in clinical trials or preclinical testing, we may need to abandon development of such product candidate or limit development to more narrow uses or subpopulations in which the serious adverse events, undesirable side effects or unexpected characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. In pharmaceutical development, many compounds that initially show promise in early-stage or clinical testing are later found to cause side effects that delay or prevent further development of the compound.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, if results of our clinical trials reveal undesirable side effects, we, regulatory authorities or the IRBs at the institutions in which our studies are conducted could suspend or terminate our clinical trials, regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications or we could be forced to materially modify the design of our clinical trials. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete any of our clinical trials. For example, one patient from the highest dose cohort (1.8 mg/kg) of our ongoing clinical trial of INZ-701 in adults with ABCC6 Deficiency was withdrawn from the Phase 1 portion of the trial at day 18 due to a moderate adverse event (erythema/urticaria) related to INZ-701. In addition, any treatment-related side effects could result in potential liability claims and may not be appropriately recognized or managed by the treating medical staff.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we elect or are forced to suspend or terminate any clinical trial of our product candidates, the commercial prospects of such product candidate will be harmed, and our ability to generate revenues from sales of such product candidate will be delayed or eliminated. Any of these occurrences could materially harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interim topline and preliminary results from our clinical trials that we announce or publish from time to time may change as more participant data become available and are subject to audit and verification procedures, which could result in material changes in the final data.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we may publish interim topline or preliminary results from our clinical trials. Interim results from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as participant enrollment continues or more participant data become available. For example, the interim biomarker, safety, pharmacokinetic, pharmacodynamic, and exploratory efficacy data that we have disclosed in connection with our ongoing Phase 1/2 clinical trials of INZ-701 may not be indicative of the full results of those trials obtained upon completion.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also make assumptions, estimations, calculations, and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully evaluate all data. Preliminary or topline results also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could be material and could significantly harm our reputation and business prospects and may cause the trading price of our common stock to fluctuate significantly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen and other clinical trial protocols, and the rate of dropout among clinical trial participants.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If any of our product candidates receives marketing approval and we, or others, later discover that the drug is less effective than previously believed or causes undesirable side effects that were not previously identified, our ability to market the drug could be compromised.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical trials are conducted in carefully defined subsets of patients who have agreed to enter into clinical trials. Consequently, it is possible that our ongoing, planned or future clinical trials may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any, or alternatively fail to identify undesirable side effects. If one or more of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">70</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our product candidates receives marketing approval, and we, or others, later discover that they are less effective than previously believed, or cause undesirable side effects, a number of potentially significant negative consequences could result, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">withdrawal or limitation by regulatory authorities of approvals of such product; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seizure of the product by regulatory authorities; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">recall of the product; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on the marketing of the product or the manufacturing process for any component thereof; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">requirement by regulatory authorities of additional warnings on the label; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">requirement that we implement a risk evaluation and mitigation strategy or create a medication guide outlining the risks of such side effects for distribution to patients; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">commitment to expensive post-marketing studies as a prerequisite of approval by regulatory authorities of such product; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the product may become less competitive; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">initiation of regulatory investigations and government enforcement actions; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">initiation of legal action against us to hold us liable for harm caused to patients; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">harm to our reputation and resulting harm to physician or patient acceptance of our products. </span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any of these events could prevent us from achieving or maintaining market acceptance of a particular product candidate, if approved, and could significantly harm our business, financial condition, and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. Failure to allocate resources or capitalize on strategies in a successful manner will have an adverse impact on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">71</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are conducting clinical trials for our product candidates at sites outside the United States, and the FDA may not accept data from clinical trials conducted in such locations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are conducting clinical trials of INZ-701 outside the United States, including our ongoing Phase 1/2 clinical trial of INZ-701 for adults with ENPP1 Deficiency in Europe and Canada, our ongoing Phase 1/2 clinical trial of INZ-701 for adults with ABCC6 Deficiency in Europe, and our ongoing Phase 1b clinical trial of INZ-701 for infants with ENPP1 Deficiency in Europe, and we expect to conduct clinical trials at other sites outside the United States in the future. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of these data is subject to conditions imposed by the FDA. For example, in cases where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the U.S., the FDA will generally not approve the application on the basis of foreign data alone unless (1) the data are applicable to the U.S. population and U.S. medical practice; (2) the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations; and (3) the data may be considered valid without the need for an on-site inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, even where the foreign study data are not intended to serve as the sole basis for approval, the FDA will not accept the data as support for an application for marketing approval unless the study is well-designed and well-conducted in accordance with GCP requirements and the FDA is able to validate the data from the study through an onsite inspection if deemed necessary. Thus, our clinical trial outside the U.S. must be well designed and conducted and be performed by qualified investigators in accordance with ethical principles. The trial population must also adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful. In addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will depend on its determination that the trials also complied with all applicable U.S. laws and regulations. If the FDA does not accept the data from any trial that we conduct outside the United States, it would likely result in the need for additional trials, which would be costly and time-consuming and could delay or permanently halt our development of the applicable product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the U.S. or the applicable jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which could be costly and time-consuming, and which may result in current or future product candidates that we may develop not receiving approval for commercialization in the applicable jurisdiction.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, there are risks inherent in conducting clinical trials in multiple jurisdictions, inside and outside of the United States, such as:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory and administrative requirements of the jurisdiction where the trial is conducted that could burden or limit our ability to conduct our clinical trials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">foreign exchange rate fluctuations; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">manufacturing, customs, shipment and storage requirements; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cultural differences in medical practice and clinical research;  </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the risk that the patient populations in such trials are not considered representative as compared to the patient population in the target markets where approval is being sought;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">diminished protection of intellectual property in some countries; and</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">interruptions or delays in our trials resulting from geopolitical events, such as war or terrorism. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Because gene therapy is novel and the regulatory landscape that governs any product candidates we may develop is uncertain and may change, we cannot predict the time and cost of obtaining regulatory approval, if we receive it at all, for any product candidates we may develop.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The regulatory requirements that will govern any novel gene therapy product candidates we develop are not entirely clear and may change. Within the broader genetic medicine field, we are aware of a limited number of gene therapy products that have received marketing authorization from the FDA and the European Medicines Authority ("EMA"). Even with respect to more</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">72</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">established products that fit into the categories of gene therapies or cell therapies, the regulatory landscape is still developing. Regulatory requirements governing gene therapy products and cell therapy products have changed frequently and will likely continue to change in the future. Moreover, there is substantial, and sometimes uncoordinated, overlap in those responsible for regulation of existing gene therapy products and cell therapy products. For example, in the United States, the FDA has established the Office of Therapeutic Products within its Center for Biologics Evaluation and Research ("CBER") to consolidate the review of gene therapy and related products, and the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its review. Gene therapy clinical trials are also subject to review and oversight by an institutional biosafety committee, or IBC, a local institutional committee that reviews and oversees basic and clinical research conducted at the institution participating in the clinical trial. Gene therapy clinical trials conducted at institutions that receive funding for recombinant DNA research from the National Institutes of Health, or NIH, are also subject to review by the NIH Office of Biotechnology Activities&#8217; Recombinant DNA Advisory Committee. Although the FDA decides whether individual gene therapy protocols may proceed, the review process and determinations of other reviewing bodies can impede or delay the initiation of a clinical trial, even if the FDA has reviewed the trial and approved its initiation. The same applies in the European Union. The EMA&#8217;s Committee for Advanced Therapies ("CAT") is responsible for assessing the quality, safety, and efficacy of advanced-therapy medicinal products. The role of the CAT is to prepare a draft opinion on an application for marketing authorization for a gene therapy medicinal candidate that is submitted to the EMA. In the European Union, the development and evaluation of a gene therapy medicinal product must be considered in the context of the relevant European Union guidelines. The EMA may issue new guidelines concerning the development and marketing authorization for gene therapy medicinal products and require that we comply with these new guidelines. As a result, the procedures and standards applied to gene therapy products and cell therapy products may be applied to any gene therapy product candidates we may develop, but that remains uncertain at this point.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Adverse public perception of genetic medicine, and gene therapy in particular, may negatively impact regulatory approval of, or demand for, our potential products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The clinical and commercial success of our potential products will depend in part on public acceptance of the use of gene therapy for the prevention or treatment of human diseases. Public attitudes may be influenced by claims that gene therapy is unsafe, unethical, or immoral, and, consequently, our products may not gain the acceptance of the public or the medical community. Adverse public attitudes may adversely impact our ability to enroll clinical trials. Moreover, our success will depend upon physicians prescribing, and their patients being willing to receive, treatments that involve the use of product candidates we may develop in lieu of, or in addition to, existing treatments with which they are already familiar and for which greater clinical data may be available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to the Commercialization of our Product Candidates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if any of our product candidates receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success, and the market opportunity for any of our product candidates, if approved, may be smaller than we estimate.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any of our product candidates receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. Efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may not be successful. If our product candidates do not achieve an adequate level of acceptance, we may not generate significant revenues from product sales and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the efficacy and potential advantages of our product candidates compared to the advantages and relative risks of alternative treatments; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effectiveness of sales and marketing efforts; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to offer our products, if approved, for sale at competitive prices; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to manage the complex pricing and reimbursement negotiations that may arise with marketing the same product at potentially different doses for separate indications;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the clinical indications for which the product is approved; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of treatment in relation to alternative treatments; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the convenience and ease of administration compared to alternative treatments; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">73</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the strength of marketing and distribution support; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing of market introduction of competitive products; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability of third-party coverage and adequate reimbursement, and patients&#8217; willingness to pay out of pocket for required co-payments or in the absence of third-party coverage or adequate reimbursement; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product labeling or product insert requirements of the FDA, the EMA or other regulatory authorities, including any limitations or warnings contained in a product&#8217;s approved labeling; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the prevalence and severity of any side effects; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">support from patient advocacy groups; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any restrictions on the use of our products, if approved, together with other medications. </span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our assessment of the potential market opportunity for our product candidates is based on industry and market data that we obtained from industry publications, research, surveys and studies conducted by third parties and our analysis of these data, research, surveys and studies. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. While we believe these industry publications and third-party research, surveys and studies are reliable, we have not independently verified such data. Our estimates of the potential market opportunities for our product candidates include a number of key assumptions based on our industry knowledge, industry publications and third-party research, surveys and studies, which may be based on a small sample size and fail to accurately reflect market opportunities. While we believe that our internal assumptions are reasonable, no independent source has verified such assumptions. If any of our assumptions or estimates, or these publications, research, surveys or studies prove to be inaccurate, then the actual market for any of our product candidates may be smaller than we expect, and as a result our revenues from product sales may be limited and it may be more difficult for us to achieve or maintain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to establish sales, marketing and distribution capabilities or enter into sales, marketing and distribution agreements with third parties, we may not be successful in commercializing our product candidates if and when they are approved.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not have a sales or marketing infrastructure and have no experience as a company in the sale, marketing or distribution of pharmaceutical products. To achieve commercial success for any product for which we have obtained marketing approval, we will need to establish a sales, marketing and distribution organization, either ourselves or through collaborations or other arrangements with third parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that we will be able to commercialize INZ-701, if approved, for ENPP1 Deficiency, ABCC6 Deficiency, or calciphylaxis with a small, targeted, internal sales and commercial organization in the United States and other major markets. There are risks involved with establishing our own sales, marketing and distribution capabilities. For example, recruiting and training a sales force is expensive and time-consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. These efforts may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. In general, the cost of establishing and maintaining a sales and marketing organization may exceed the cost-effectiveness of doing so.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Factors that may inhibit our efforts to commercialize our products on our own include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our inability to recruit, train and retain adequate numbers of effective sales, marketing, coverage or reimbursement, customer service, medical affairs and other support personnel; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our inability to equip sales personnel with effective materials, including medical and sales literature to help them educate physicians and other healthcare providers regarding rare diseases and our future products; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our inability to effectively manage a geographically dispersed sales and marketing team; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">74</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future products; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inability of reimbursement professionals to negotiate arrangements for formulary access, reimbursement and other acceptance by payors; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inability to price our products at a sufficient price point to ensure an adequate and attractive level of profitability; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restricted or closed distribution channels that make it difficult to distribute our products to segments of the patient population; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unforeseen costs and expenses associated with creating an independent sales and marketing organization. </span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to establish our own sales, marketing and distribution capabilities and we enter into arrangements with third parties to perform these services, our revenues from product sales and our profitability, if any, are likely to be lower than if we were to market, sell and distribute any products that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell, market and distribute our product candidates or may be unable to do so on terms that are acceptable to us. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish sales, marketing and distribution capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do, thus rendering our products non-competitive, obsolete or reducing the size of our market.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. We face and will continue to face competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions, government agencies and public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are aware of a number of companies generally pursuing the development of different enzyme replacement therapies or treatments for vascular calcification disorders and many other companies are focused on rare disease markets. For example, DS-1211b, a tissue-nonspecific alkaline phosphatase inhibitor, is currently in Phase 2 clinical development for pseudoxanthoma elasticum by Daiichi Sankyo Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our development programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic products. Because of our primary focus on rare disease, if our product candidates achieve marketing approval, we expect to seek premium pricing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Technology in the pharmaceutical and biotechnology industries has undergone rapid and significant change, and we expect that it will continue to do so. Any compounds, products or processes that we develop may become obsolete or uneconomical before we recover any expenses incurred in connection with their development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">75</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may pursue the in-license or acquisition of rights to complementary technologies and product candidates on an opportunistic basis. However, we may be unable to in-license or acquire any additional technologies or product candidates from third parties. The acquisition and licensing of technologies and product candidates is a competitive area, and a number of more established companies also have similar strategies to in-license or acquire technologies and product candidates that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources and greater development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to in-license or acquire the relevant technology or product candidate on terms that would allow us to make an appropriate return on our investment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If the market opportunities for our product candidates are smaller than we currently believe, our revenue may be adversely affected, and our business may suffer. Because the target patient populations of our product candidates are small, we must be able to successfully identify patients and capture a significant market share to achieve profitability and growth.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We focus our research and product development on treatments for rare diseases. Given the small number of patients who have the diseases that we are targeting, it is critical to our ability to grow and become profitable that we continue to successfully identify patients with these rare diseases. Our projections of the number of people who have these diseases are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including the scientific and medical literature, industry publications, third-party research, surveys and studies, patient registries, patient foundations, internal patient identification activities, or market research that we conducted, and may prove to be incorrect or contain errors. New studies may change the estimated incidence or prevalence of these diseases. The number of patients may turn out to be lower than expected. Our efforts to identify patients with diseases we seek to treat is in the early stages, and we cannot accurately predict the number of patients for whom treatment might be possible. Additionally, the potentially addressable patient population for each of our product candidates may be limited or may not be amenable to treatment with our product candidates, and new patients may become increasingly difficult to identify or gain access to, which would adversely affect our results of operations and our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, even if we obtain significant market share for our product candidates, because the potential target populations are very small, we may never achieve profitability despite obtaining such significant market share. For example, the estimated incidence of ENPP1 Deficiency is approximately one in 64,000 pregnancies worldwide. In North America, the EU, Japan, and Brazil we believe there are approximately 9,400 patients with ENPP1 Deficiency. ABCC6 Deficiency is estimated to affect approximately one per 25,000 to 50,000 individuals, and we believe there are more than 67,000 patients in addressable markets worldwide with ABCC6 Deficiency. In North America, the EU, Japan, and Brazil, we believe there are approximately 24,400 patients with ABCC6 Deficiency. The estimated incidence of calciphylaxis is approximately 3.5 per 1,000 patients with ESKD. In North America, the EU, Japan, and Brazil, we believe there are approximately 23,800 patients with ESKD receiving hemodialysis. In addition, while we are pursuing marketing approval for ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis indications, the FDA may only grant approval for more narrow, specific disease indications that would result in a smaller market than we initially sought.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because there are currently no products approved for the treatment of our target indications, such as ENPP1 and ABCC6 Deficiencies and calciphylaxis, the pricing and reimbursement of our product candidates, if approved, is uncertain, but must be adequate to support commercial infrastructure. In addition, while we are pursuing additional diseases of pathologic mineralization and intimal proliferation, including those without a clear genetic basis, such as calciphylaxis or calcifications as a result of end stage kidney disease, we may not receive approval for such indications or such indications may not expand the target population for INZ-701 in an amount sufficient to achieve profitability. Furthermore, if we are unable to obtain adequate levels of reimbursement, our ability to successfully market and sell our product candidates will be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if we are able to commercialize any product candidates, the products may become subject to unfavorable pricing regulations, third-party coverage or reimbursement practices or healthcare reform initiatives, which could harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drug products vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost effectiveness of our product candidate to other available therapies. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues, if any, we are able to generate from the sale of the product in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">76</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to commercialize any product candidates successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. The availability of coverage and adequacy of reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford medical services and pharmaceutical products, including our product candidates. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Coverage and reimbursement may not be available for any product that we commercialize and, even if these are available, the level of reimbursement may not be satisfactory. Reimbursement may affect the demand for, or the price of, any product candidate for which we obtain marketing approval. Obtaining and maintaining adequate reimbursement for our products may be difficult. We may be required to conduct expensive pharmacoeconomic studies to justify coverage and reimbursement or the level of reimbursement relative to other therapies. If coverage and adequate reimbursement are not available or reimbursement is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or similar regulatory authorities outside of the United States. Reimbursement agencies in Europe may be more conservative than the Centers for Medicare &amp; Medical Services ("CMS") in the United States. For example, a number of cancer drugs have been approved for reimbursement in the United States and have not been approved for reimbursement in certain European countries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution expenses. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">No uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases on short notice, and we believe that changes in these rules and regulations are likely.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There can be no assurance that our product candidates, even if they are approved for sale in the United States, in Europe or in other countries, will be considered medically reasonable and necessary for a specific indication or cost-effective by third-party payors, or that coverage and an adequate level of reimbursement will be available or that third-party payors&#8217; reimbursement policies will not adversely affect our ability to sell our product candidates profitably.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">77</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our future growth depends, in part, on our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties that, if they materialize, could harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our future profitability will depend, in part, on our ability to commercialize our product candidates in markets outside of the United States and Europe. We are not permitted to market or promote INZ-701 or any other product candidates we develop before we receive approval from the applicable regulatory authority in that foreign market, and we may never receive such regulatory approval for any of our product candidates. To obtain separate marketing approvals in other countries we may be required to comply with numerous and varying regulatory requirements of such countries regarding the safety and efficacy of our product candidates and governing, among other things, clinical trials and commercial sales, pricing and distribution of our product candidates. If we commercialize our product candidates in these foreign markets, we will be subject to additional risks and uncertainties, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">economic weakness, including inflation, or political instability in particular economies and markets; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements, many of which vary between countries; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">different medical practices and customs in foreign countries affecting acceptance in the marketplace; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">tariffs and trade barriers, as well as other governmental controls and trade restrictions; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">other trade protection measures, import or export licensing requirements or other restrictive actions by U.S. or foreign governments; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">longer accounts receivable collection times; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">longer lead times for shipping; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">workforce uncertainty in countries where labor unrest is common; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">language barriers for technical training; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reduced protection of intellectual property rights in some foreign countries, and related prevalence of generic alternatives to therapeutics; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">foreign currency exchange rate fluctuations and currency controls; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">differing foreign reimbursement landscapes; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">uncertain and potentially inadequate reimbursement of our products; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute. </span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If risks related to any of these uncertainties materializes, it could have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">78</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical trial and product liability lawsuits against us could divert our resources and could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We face an inherent risk of clinical trial and product liability exposure related to the testing of our product candidates in human clinical trials and use of our product candidate through compassionate use, and we will face an even greater risk if we commercially sell any products that we may develop. While we currently have no products that have been approved for commercial sale, the ongoing, planned and future use of product candidates by us in clinical trials, and the sale of any approved products in the future, may expose us to liability claims. These claims might be made by patients that use the product, healthcare providers, pharmaceutical companies or others selling such products. On occasion, large judgments have been awarded in class action lawsuits based on products that had unanticipated adverse effects. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">decreased demand for any product candidates or products that we may develop; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">termination of clinical trials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">withdrawal of marketing approval, recall, restriction on the approval or a &#8220;black box&#8221; warning or contraindication for an approved drug; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">withdrawal of clinical trial participants; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">significant costs to defend any related litigation; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">substantial monetary awards to trial participants or patients; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">loss of revenue; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">injury to our reputation and significant negative media attention; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reduced resources of our management to pursue our business strategy; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">distraction of management&#8217;s attention from our primary business; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inability to commercialize any products that we may develop. </span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently hold $10 million in product liability insurance coverage in the aggregate, with a per incident limit of $10 million, which may not be adequate to cover all liabilities that we may incur. We may need to increase our insurance coverage as we expand our clinical trials or if we commence commercialization of our product candidates. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. If a successful clinical trial or product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to our Dependence on Third Parties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We rely, and expect to continue to rely, on third parties to conduct our clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, which may prevent or delay our ability to seek or obtain marketing approval for or commercialize our product candidates or otherwise harm our business. If we are not able to maintain these third-party relationships or if these arrangements are terminated, we may have to alter our development and commercialization plans and our business could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely, and expect to continue to rely, on third-party clinical research organizations, in addition to other third parties such as research collaboratives, clinical data management organizations, medical institutions and clinical investigators, to conduct our ongoing clinical trials, our planned clinical trials, and any other clinical trials we conduct in the future. We do not plan to independently conduct clinical trials of INZ-701 or any other product candidate that we may develop. These contract research organizations and other third parties play a significant role in the conduct and timing of these trials and subsequent collection and analysis of data. These third-party arrangements might terminate for a variety of reasons, including a failure to perform by the third parties. If we need to enter into alternative arrangements, our product development activities might be delayed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">79</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our reliance on these third parties for research and development activities reduces our control over these activities but does relieve us of our responsibilities. For example, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with standards, commonly referred to as good clinical practices, or GCPs, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. Regulatory authorities in Europe and other jurisdictions have similar requirements. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our contract research organizations or trial sites fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within specified timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully develop and commercialize our product candidates. Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected the interpretation of the trial, the integrity of the data generated at the applicable clinical trial site may be questioned, and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of any marketing application we submit to the FDA. Any such delay or rejection could prevent us from commercializing our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative third parties or do so on commercially reasonable terms. Switching or adding additional contract research organizations, investigators and other third parties involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new contract research organization commences work. As a result, delays can occur, which could materially impact our ability to meet our desired clinical development timelines. For example, the COVID-19 pandemic and government measures taken in response have also had a significant impact on many contract research organizations. Although we plan to carefully manage our relationships with our contract research organizations, investigators and other third parties, we may nonetheless encounter challenges or delays in the future, which could have a material and adverse impact on our business, financial condition and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Manufacturing biologic products is complex and subject to product loss for a variety of reasons. We contract with third parties for the manufacture of our product candidates for preclinical testing and clinical trials and expect to continue to do so for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not own or operate, and currently have no plans to establish, any manufacturing facilities. We rely, and expect to continue to rely, on third parties for the manufacture of both drug substance and finished drug product for INZ-701 and any future product candidates for preclinical testing and clinical trials, as well as for commercial manufacture if any of our product candidates receive marketing approval. We also rely on these third parties for packaging, labeling, sterilization, storage, distribution and other production logistics. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts. We may be unable to establish any agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reliance on the third party for regulatory compliance and quality assurance; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the possible breach of the manufacturing agreement by the third party; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the potential failure to manufacture our product candidate or product according to our specifications; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the potential failure to manufacture our product candidate or product according to our schedule or at all; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">80</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the possible misappropriation of our proprietary information, including our trade secrets and know-how; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us. </span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have only limited supply agreements in place with respect to our product candidates, and these arrangements do not extend to commercial supply. We obtain supplies of drug substance and finished drug product for INZ-701 on a purchase order basis. We do not have long-term committed arrangements with respect to any of our product candidates or other materials. We are continuing the process of scaling up our manufacturing processes and capabilities with our third-party manufacturers to support ongoing and future clinical trials. In addition, if we receive marketing approval for any of our product candidates, we will need to establish an agreement for commercial manufacture with a third party.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We or our third-party manufacturers may encounter shortages in the raw materials or active pharmaceutical ingredients necessary to produce our product candidates in the quantities needed for our clinical trials or, if our product candidates are approved, in sufficient quantities for commercialization or to meet an increase in demand, as a result of capacity constraints or delays or disruptions in the market for the raw materials or active pharmaceutical ingredients, including shortages caused by the purchase of such raw materials or active pharmaceutical ingredients by our competitors or others. The failure of us or our third-party manufacturers to obtain the raw materials or active pharmaceutical ingredients necessary to manufacture sufficient quantities of our product candidates, may have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our third-party manufacturers are subject to inspection and approval by regulatory authorities before we can commence the manufacture and sale of any of our product candidates, and thereafter subject to ongoing inspection from time to time. Third-party manufacturers may not be able to comply with current good manufacturing practices, or cGMP, regulations or similar regulatory requirements outside of the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in regulatory actions, such as the issuance of FDA Form 483 notices of observations, warning letters or sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Manufacturing biologic products, such as INZ-701, is complex, especially in large quantities. Biologic products must be made consistently and in compliance with a clearly defined manufacturing process. Accordingly, it is essential to be able to validate and control the manufacturing process to assure that it is reproducible. The manufacture of biologics is extremely susceptible to product loss due to contamination, equipment failure or improper installation or operation of equipment, vendor or operator error, inconsistency in yields, variability in product characteristics and difficulties in scaling the product process. We have not yet scaled up the manufacturing process for any of our product candidates for potential commercialization. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects, and other supply disruptions. If microbial, viral, or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which could harm our results of operations and cause potential reputational damage. Our product candidates and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities. As a result, we may not obtain access to these facilities on a priority basis or at all. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. If any of our current contract manufacturers cannot perform as agreed, we may be required to replace such manufacturers. Although we believe that there are several potential alternative manufacturers who could manufacture our product candidates, we may incur added costs and delays in identifying and qualifying any such replacement or be unable to reach agreement with an alternative manufacturer. In addition, a health epidemic, such as the COVID-19 pandemic, may impact our ability to procure sufficient supplies for the development of our product candidates.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our current and anticipated future dependence upon others for the manufacture of our product candidates or products may adversely affect our future profit margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">81</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may enter into collaborations with third parties for the development or commercialization of our product candidates. If our collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates and our business could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While we retain worldwide, exclusive development and commercialization rights to our pipeline and programs, including INZ-701, we could in the future enter into development, distribution, marketing or funding arrangements with third parties with respect to our existing or future product candidates. Our likely collaborators for any sales, marketing, co-promotion, distribution, development, licensing or broader collaboration arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies. We are not currently party to any such arrangement. However, if we do enter into any such arrangements with any third parties in the future, we will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate revenues from these arrangements will depend on our collaborators&#8217; abilities and efforts to successfully perform the functions assigned to them in these arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Collaborations that we enter into may not be successful, and any success will depend heavily on the efforts and activities of such collaborators. Collaborations pose a number of risks, including the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators have significant discretion in determining the amount and timing of efforts and resources that they will apply to these collaborations; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may not perform their obligations as expected; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may not pursue development of our product candidates or may elect not to continue or renew development programs based on results of clinical trials or other studies, changes in the collaborators&#8217; strategic focus or available funding, or external factors, such as an acquisition or business combination, that divert resources or create competing priorities; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may not pursue commercialization of any product candidates that achieve marketing approval or may elect not to continue or renew commercialization programs based on results of clinical trials or other studies, changes in the collaborators&#8217; strategic focus or available funding, or external factors, such as an acquisition or business combination, that may divert resources or create competing priorities; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may not have access to, or may be restricted from disclosing, certain information regarding product candidates being developed or commercialized under a collaboration and, consequently, may have limited ability to inform our stockholders about the status of such product candidates on a discretionary basis; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates and products if the collaborators believe that the competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates; a collaborator may fail to comply with applicable regulatory requirements regarding the development, manufacture, distribution or marketing of a product candidate or product; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a collaborator may seek to renegotiate or terminate their relationship with us due to unsatisfactory clinical results, manufacturing issues, a change in business strategy, a change of control or other reasons; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve marketing approval may not commit sufficient resources to the marketing and distribution of such product or products; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">82</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">disagreements with collaborators, including disagreements over intellectual property or proprietary rights, contract interpretation or the preferred course of development, might cause delays or terminations of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may not properly obtain, maintain, enforce, defend or protect our intellectual property or proprietary rights or may use our proprietary information in such a way as to potentially lead to disputes or legal proceedings that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">disputes may arise with respect to the ownership of intellectual property developed pursuant to our collaborations; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may infringe, misappropriate or otherwise violate the intellectual property or proprietary rights of third parties, which may expose us to litigation and potential liability; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborations may be terminated for the convenience of the collaborator, and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates. </span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner, or at all. If any collaborations that we enter into do not result in the successful development and commercialization of products or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, our development of our product candidates could be delayed and we may need additional resources to develop our product candidates. All of the risks relating to product development, regulatory approval and commercialization described herein also apply to the activities of our collaborators.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, subject to its contractual obligations to us, if a collaborator of ours is involved in a business combination, the collaborator might deemphasize or terminate the development or commercialization of any product candidate licensed to it by us. If one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators and our perception in the business and financial communities could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are not able to establish or maintain collaborations, we may have to alter our development and commercialization plans and our business could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may decide to collaborate with pharmaceutical or biotechnology companies for the development and potential commercialization of one or more of our product candidates. We face significant competition in seeking appropriate collaborators, and a number of more established companies may also be pursuing strategies to license or acquire third-party intellectual property rights that we consider attractive. These established companies may have a competitive advantage over us due to their size, financial resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. We may also be restricted under future license agreements from entering into agreements on certain terms with potential collaborators. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical and biotechnology companies that have resulted in a reduced number of potential future collaborators.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">83</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms or at all, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them to market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have agreements with Yale to supplement our internal research and development program. If Yale decides to discontinue or devote less resources to such research, our research efforts could be diminished.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our set of arrangements with Yale provide us with access to certain of Yale&#8217;s intellectual property and to Professor Demetrios Braddock&#8217;s laboratory in a manner that we believe closely aligns our scientific interests with those of Yale. We are a party to both a license agreement and a sponsored research agreement with Yale. While Yale has contractual obligations to us, it is an independent entity and is not under our control or the control of our officers or directors. The license agreement is structured to provide Yale with license maintenance fees, development and regulatory milestone payments, royalties on net sales of products, and a portion of sublicense income that we receive. Upon the scheduled expiration of the Yale sponsored research agreement in December 2024, we may not be able to renew the research agreement or any renewal could be on terms less favorable to us than those contained in the existing agreement. Furthermore, either we or Yale may terminate the sponsored research agreement for convenience following a specified notice period. If Yale decides to not renew or to terminate the Yale sponsored research agreement or decides to devote fewer resources to such activities, our research efforts would be diminished, while our royalty obligations to Yale would continue unmodified.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our license agreement with Yale also provides that so long as Professor Braddock remains meaningfully involved in our company by serving as a member of our scientific advisory board or has a similar advisory arrangement or has an active consulting arrangement with us, and so long as he is an employee or faculty member (including emeritus faculty member) at Yale, any future invention by Professor Braddock&#8217;s laboratory in the license agreement&#8217;s field is included in the licensed intellectual property. If Professor Braddock were to leave Yale or no longer be meaningfully involved with us, we would no longer have access to future inventions in the license agreement&#8217;s field from Yale.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, the license granted under the license agreement terminates after a specified period following a qualifying change of control, unless we elect or our successor or assignee elects to continue the agreement. If the license is terminated after such a change of control, royalty payments would continue to be paid on certain licensed products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Any acquisitions or in-license transactions that we complete could disrupt our business, cause dilution to our stockholders or reduce our financial resources</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may enter into transactions to in-license or acquire other businesses, intellectual property, technologies, product candidates, or products. If we determine to pursue a particular transaction, we may not be able to complete the transaction on favorable terms, or at all. Any in-licenses or acquisitions we complete may not strengthen our competitive position, and these transactions may be viewed negatively by customers or investors. We may decide to incur debt in connection with an in-license or acquisition or issue our common stock or other equity securities to the stockholders of the target company, which would reduce the percentage ownership of our existing stockholders. We could incur losses resulting from undiscovered liabilities that are not covered by the indemnification we may obtain from the seller. In addition, we may not be able to successfully integrate the acquired personnel, technologies and operations into our existing business in an effective, timely and nondisruptive manner. In-license and acquisition transactions may also divert management attention from day-to-day responsibilities, increase our expenses and reduce our cash available for operations and other uses. For example, we completed an acquisition of specified patent rights and other specified assets related to ENPP1 from Alexion Pharmaceuticals, Inc. in July 2020. We cannot predict the number, timing or size of additional future in-licenses or acquisitions or the effect that any such transactions might have on our operating results.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to our Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to obtain, maintain and enforce patent protection for our technology and product candidates or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully develop and commercialize our technology and product candidates may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">84</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our success depends in large part on our ability to obtain, maintain and enforce protection of the intellectual property we may own solely and jointly with others or may license from others, particularly patents, in the United States and other countries with respect to any proprietary technology and product candidates we develop. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our technologies and product candidates that are important to our business and by in-licensing intellectual property related to such technologies and product candidates. If we are unable to obtain, maintain or enforce patent protection with respect to any proprietary technology or product candidate, our business, financial condition, results of operations and prospects could be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patent prosecution process is expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain, defend or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we do not have the right to control the preparation, filing and prosecution of patent applications, or to maintain, enforce and defend the patents, covering technology that we license from third parties. Therefore, these in-licensed patents and applications may not be prepared, filed, prosecuted, maintained, defended and enforced in a manner consistent with the best interests of our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patent position of pharmaceutical and biotechnology companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. In addition, the scope of patent protection outside of the United States is uncertain and laws of foreign countries may not protect our rights to the same extent as the laws of the United States or vice versa. For example, European patent law restricts the patentability of methods of treatment of the human body more than United States law does. With respect to both owned and in-licensed patent rights, we cannot predict whether the patent applications we and our licensors are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors. Further, we may not be aware of all third-party intellectual property rights potentially relating to our product candidates. In addition, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not published at all. Therefore, neither we nor our licensors can know with certainty whether either we or our licensors were the first to make the inventions claimed in the patents and patent applications we own or in-license now or in the future, or that either we or our licensors were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Moreover, our owned or in-licensed pending and future patent applications may not result in patents being issued which protect our technology and product candidates, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents and our ability to obtain, protect, maintain, defend and enforce our patent rights, narrow the scope of our patent protection and, more generally, could affect the value or narrow the scope of our patent rights.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, we or our licensors may be subject to a third-party preissuance submission of prior art to the United States Patent and Trademark Office ("USPTO") or become involved in opposition, derivation, revocation, reexamination, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize drugs without infringing third-party patent rights. If the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">85</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our owned or licensed patent estate includes patent applications, many of which are at an early stage of prosecution. The coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if our owned or in-licensed patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and in-licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. Such proceedings also may result in substantial cost and require significant time from our management and employees, even if the eventual outcome is favorable to us. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. Furthermore, our competitors may be able to circumvent our owned or in-licensed patents by developing similar or alternative technologies or products in a non-infringing manner. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing technology and products similar or identical to any of our technology and product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to obtain licenses from third parties on commercially reasonable terms or fail to comply with our obligations under such agreements, our business could be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our products, in which case we would be required to obtain a license from these third parties. If we are unable to license such technology, or if we are forced to license such technology on unfavorable terms, our business could be materially harmed. If we are unable to obtain a necessary license, we may be unable to develop or commercialize the affected product candidates, which could materially harm our business and the third parties owning such intellectual property rights could seek either an injunction prohibiting our sales or an obligation on our part to pay royalties and/or other forms of compensation. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected technology and product candidates, which could harm our business, financial condition, results of operations and prospects significantly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, if we fail to comply with our obligations under any license agreements, our counterparties may have the right to terminate these agreements, in which event we might not be able to develop, manufacture or market, or may be forced to cease developing, manufacturing or marketing, any product that is covered by these agreements or may face other penalties under such agreements. Such an occurrence could materially adversely affect the value of the product candidate being developed under any such agreement. Termination of these agreements or reduction or elimination of our rights under these agreements, or restrictions on our ability to freely assign or sublicense our rights under such agreements when it is in the interest of our business to do so, may result in our having to negotiate new or reinstated agreements with less favorable terms, cause us to lose our rights under these agreements, including our rights to important intellectual property or technology or impede, or delay or prohibit the further development or commercialization of one or more product candidates that rely on such agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our product candidates may face competition from biosimilars approved through an abbreviated regulatory pathway.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively the "ACA"), includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 ("BPCIA") which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-approved reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">86</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">until four years following the date that the reference product was first approved by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first approved. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full biologics license application, or BLA, for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of the other company&#8217;s product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2022, Congress clarified through FDORA that the FDA may approve multiple first interchangeable biosimilar biological products so long as the products are all approved on the same first day on which such a product is approved as interchangeable with the reference product and the exclusivity period may be shared amongst multiple first interchangeable products.  More recently, in October 2023, the FDA issued its first interchangeable exclusivity determination under the BPCIA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that any product candidate of ours that may be approved as a biological product under a BLA should qualify for the 12-year period of exclusivity. Nonetheless, the approval of biosimilar products referencing any of our product candidates would have a material adverse impact on our business due to increased competition and pricing pressures. Moreover, there is a risk that any exclusivity we do receive could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for biosimilar competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. The ultimate impact, implementation, and meaning of the BPCIA are subject to uncertainty, and any new regulations, guidance, policies, or processes adopted by the FDA to implement the law could have a material adverse effect on the future commercial prospects for our biological products.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we do not obtain patent term extension for any product candidates we may develop, our business may be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, the term of a patent that covers an FDA-approved drug may, in certain cases, be eligible for a patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, as compensation for the loss of a patent term during the FDA regulatory review process. The Hatch-Waxman Act permits a patent term extension of up to five years, but patent extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. Only one patent among those eligible for an extension and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. Similar provisions are available in Europe and certain other non-United States jurisdictions to extend the term of a patent that covers an approved drug. While, in the future, if and when our product candidates receive FDA approval, we expect to apply for patent term extensions on patents covering those product candidates, there is no guarantee that the applicable authorities, including the FDA, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions. We may not be granted patent term extension either in the United States or in any foreign country because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the term of extension, as well as the scope of patent protection during any such extension, afforded by the governmental authority could be less than we request. If we are unable to obtain any patent term extension or the term of any such extension is less than we request, our competitors may obtain approval of competing products following the expiration of our patent rights, and our business, financial condition, results of operations and prospects could be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in either the patent laws or interpretation of patent laws in the United States, including patent reform legislation such as the Leahy-Smith America Invents Act, or the Leahy-Smith Act, could increase the uncertainties and costs surrounding the prosecution of our owned or in-licensed patent applications and the maintenance, enforcement or defense of our owned or in-licensed issued patents. The Leahy-Smith Act includes a number of significant changes to United States patent law. These changes include provisions that affect the way patent applications are prosecuted, redefine prior art, provide more efficient and cost-effective avenues for competitors to challenge the validity of patents, and enable third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent at USPTO-administered post-grant proceedings, including post-grant review, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> review, and derivation proceedings. Assuming that other requirements for patentability are met, prior to March 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March 2013, under the Leahy-Smith Act, the United States transitioned to a first-to-file system in which, assuming that the other statutory requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">87</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">claimed invention. As such, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our patent rights and our ability to protect, defend and enforce our patent rights in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The federal government retains certain rights in inventions produced with its financial assistance under the Bayh-Dole Act. The federal government retains a &#8220;nonexclusive, nontransferable, irrevocable, paid-up license&#8221; for its own benefit. The Bayh-Dole Act also provides federal agencies with &#8220;march-in rights&#8221;. March-in rights allow the government, in specified circumstances, to require the contractor or successors in title to the patent to grant a &#8220;nonexclusive, partially exclusive, or exclusive license&#8221; to a &#8220;responsible applicant or applicants.&#8221; If the patent owner refuses to do so, the government may grant the license itself. We collaborate with a number of universities with respect to certain of our research and development. While it is our policy to avoid engaging our university collaborators in projects in which there is a risk that federal funds may be commingled, we cannot be sure that any co-developed intellectual property will be free from government rights pursuant to the Bayh-Dole Act. If, in the future, we co-own or in-license technology which is critical to our business that is developed in whole or in part with federal funds subject to the Bayh-Dole Act, our ability to enforce or otherwise exploit patents covering such technology may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Although we or our licensors are not currently involved in any litigation, we may become involved in lawsuits to protect or enforce our patent or other intellectual property rights, which could be expensive, time-consuming and unsuccessful.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Competitors and other third parties may infringe, misappropriate or otherwise violate our or our licensor&#8217;s issued patents or other intellectual property. It may be difficult to detect infringers who do not advertise the components that are used in their products. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor&#8217;s product. To counter infringement or misappropriation, we or our licensors may need to file infringement, misappropriation or other intellectual property related claims, which can be expensive and time-consuming and can distract our management and scientific personnel. There can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Any claims we assert against perceived infringers could provoke such parties to assert counterclaims against us alleging that we infringe, misappropriate or otherwise violate their intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, in a patent infringement proceeding, such parties could counterclaim that the patents we or our licensors have asserted are invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may institute such claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post-grant review, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions, such as opposition proceedings. The outcome following legal assertions of invalidity and unenforceability is unpredictable. Similarly, if we or our licensors assert trademark infringement claims, a court may determine that the marks we or our licensors have asserted are invalid or unenforceable, or that the party against whom we or our licensors have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks, which could materially harm our business and negatively affect our position in the marketplace.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An adverse result in any such proceeding could put one or more of our owned or in-licensed patents at risk of being invalidated or interpreted narrowly, could put any of our owned or in-licensed patent applications at risk of not yielding an issued patent, and could limit our or our licensor&#8217;s ability to assert those patents against those parties or other competitors and curtail or preclude our ability to exclude third parties from developing and commercializing similar or competitive products. A court may also refuse to stop the third party from using the technology at issue in a proceeding on the grounds that our owned or in-licensed patents do not cover such technology. Even if we establish infringement, a court may not order the third party to stop using the technology at issue and instead award only monetary damages to us, which may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information or trade secrets could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. Any of the foregoing</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">88</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">could allow such third parties to develop and commercialize competing technologies and products and have a material adverse impact on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same technology. Our defense of litigation or interference or derivation proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development partnerships that would help us bring our product candidates to market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial success depends upon our ability and the ability of our collaborators to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property and proprietary rights of third parties. There is considerable patent and other intellectual property litigation in the pharmaceutical and biotechnology industries. We may become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our technology and product candidates, including interference proceedings, post grant review, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> review, and derivation proceedings before the USPTO and similar proceedings in foreign jurisdictions, such as opposition proceedings before the European Patent Office. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are pursuing development candidates. As the pharmaceutical and biotechnology industries expand and more patents are issued, the risk increases that our technologies or product candidates that we may identify may be subject to claims of infringement of the patent rights of third parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The legal threshold for initiating litigation or contested proceedings is low, so even lawsuits or proceedings with a low probability of success might be initiated and require significant resources to defend. Litigation and contested proceedings can also be expensive and time-consuming, and our adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we can. The risks of being involved in such litigation and proceedings may increase if and as our product candidates near commercialization and as we gain the greater visibility associated with being a public company. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of merit. Even if we diligently search third-party patents for potential infringement by our products or product candidates, we may not successfully find patents our products or product candidates may infringe. We may not be aware of all such intellectual property rights potentially relating to our technology and product candidates and their uses, or we may incorrectly conclude that third party intellectual property is invalid or that our activities and product candidates do not infringe such intellectual property. Thus, we do not know with certainty that our technology and product candidates, or our development and commercialization thereof, do not and will not infringe, misappropriate or otherwise violate any third party&#8217;s intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations or methods, such as methods of manufacture or methods for treatment, related to the discovery, use or manufacture of the product candidates that we may identify or related to our technologies. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that the product candidates that we may identify may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Moreover, as noted above, there may be existing patents that we are not aware of or that we have incorrectly concluded are invalid or not infringed by our activities. If any third-party patents were held by a court of competent jurisdiction to cover, for example, the manufacturing process of the product candidates that we may identify, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize the product candidates that we may identify. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">89</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may choose to take a license or, if we are found to infringe, misappropriate or otherwise violate a third party&#8217;s intellectual property rights, we could also be required to obtain a license from such third party to continue developing, manufacturing and marketing our technology and product candidates. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us and could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or product. In addition, we could be found liable for significant monetary damages, including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent or other intellectual property right and could be forced to indemnify our customers or collaborators. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. In addition, we may be forced to redesign our product candidates, seek new regulatory approvals and indemnify third parties pursuant to contractual agreements. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While we seek to protect the trademarks and trade names we use in the United States and in other countries, we may be unsuccessful in obtaining registrations or otherwise protecting these trademarks and trade names, which we need to build name recognition in our markets of interest and among potential partners or customers. We rely on both registration and common law protection for our trademarks. Our registered or unregistered trademarks or trade names may be challenged, infringed, diluted or declared generic, or determined to be infringing on other marks. At times, competitors may adopt trademarks and trade names similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks. If we are unable to protect our rights to trademarks and trade names, we may be prevented from using such marks and names unless we enter into appropriate royalty, license or coexistence agreements, which may not be available or may not be available on commercially reasonable terms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During trademark registration proceedings, we may receive rejections. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. Effective trademark protection may not be available or may not be sought in every country in which our products are made available. Any name we propose to use for our products in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA objects to any of our proposed product names, we may be required to expend significant additional resources in an effort to identify a usable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA, and such an effort may significantly delay our ability to market our products. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intellectual property litigation or other legal proceedings relating to intellectual property could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and may also have an advantage in such proceedings due to their more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of intellectual property litigation or other proceedings could compromise our ability to compete in the marketplace.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">90</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Periodic maintenance, renewal and annuity fees and various other government fees on any issued patent and pending patent application must be paid to the USPTO and foreign patent agencies in several stages or annually over the lifetime of our patents and patent applications. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In certain circumstances, we rely on our licensing partners to pay these fees to, or comply with the procedural and documentary rules of, the relevant patent agency. With respect to our patents, we rely on an annuity service, outside firms and outside counsel to remind us of the due dates and to make payment after we instruct them to do so. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, potential competitors might be able to enter the market with similar or identical products or technology. If we or our licensors fail to maintain the patents and patent applications covering our product candidates, it would have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to comply with our obligations in our current and future intellectual property licenses and funding arrangements with third parties, or otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights that are important to our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are party to a license agreement with Yale that provides us with the foundational intellectual property rights for our lead product candidate, INZ-701. This license agreement imposes diligence, development and commercialization timelines, and milestone payment, royalty, insurance and other obligations on us. If we fail to comply with such obligations, including achieving specified milestone events, Yale may have the right to terminate the license agreement or require us to grant them certain rights, in which event we might not be able to develop, manufacture or market any product that is covered by the intellectual property we in-license from them and may face other penalties. Any such occurrence could materially adversely affect the value of any product candidate being developed under any such agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For a variety of purposes, we will likely enter into additional licensing and funding arrangement with third parties that may impose similar obligations on us. Termination of these agreements or reduction or elimination of our rights under these agreements may result in our having to negotiate new or reinstated agreements with less favorable terms, or cause us to lose our rights under these agreements, including our rights to important intellectual property or technology, which would have a material adverse effect on our business, financial condition, results of operations and prospects. While we still face all of the risks described herein with respect to those agreements, we cannot prevent third parties from also accessing those technologies. In addition, our licenses may place restrictions on our future business opportunities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the above risks, intellectual property rights that we license in the future may include sublicenses under intellectual property owned by third parties, in some cases through multiple tiers. The actions of our licensors may therefore affect our rights to use our sublicensed intellectual property, even if we are in compliance with all of the obligations under our license agreements. Should our licensors or any of the upstream licensors fail to comply with their obligations under the agreements pursuant to which they obtain the rights that are sublicensed to us, or should such agreements be terminated or amended, our ability to develop and commercialize our product candidates may be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disputes may arise regarding intellectual property subject to a licensing agreement, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope of rights granted under the license agreement and other interpretation related issues; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the sublicensing of patent and other rights under our collaborative development relationships; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">91</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the priority of invention of patented technology. </span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected technology and product candidates, which could have a material adverse effect on our business, financial conditions, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, licensors could retain the right to prosecute and defend the intellectual property rights licensed to us, in which case we would depend on our licensors to control the prosecution, maintenance and enforcement of all of our licensed and sublicensed intellectual property, and even when we do have such rights, we may require the cooperation of our licensors and upstream licensors, which may not be forthcoming. For example, under the license agreement with Yale, any patent applications and issued patents under the agreement remain the property of Yale, and Yale has the right to choose patent counsel. Licensors may determine not to pursue litigation against other companies or may pursue such litigation less aggressively than we would. Our business could be adversely affected if we or our licensors are unable to prosecute, maintain and enforce our licensed and sublicensed intellectual property effectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our current or future licensors may have relied on third-party consultants or collaborators or on funds from third parties such that our licensors are not the sole and exclusive owners of the patents and patent applications we in-license. If other third parties have ownership rights to patents or patent applications we in-license, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In spite of our best efforts, our licensors might conclude that we have materially breached our license agreements and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize product candidates and technology covered by these license agreements. If these in-licenses are terminated, or if the underlying intellectual property fails to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, products and technologies identical to ours. This could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be able to protect our intellectual property and proprietary rights throughout the world.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Filing, prosecuting and defending patents on product candidates and trademark applications for our company name and product names in all countries throughout the world would be prohibitively expensive, and the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States, and even where such protection is nominally available, judicial and governmental enforcement of such intellectual property rights may be lacking. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection or licenses but enforcement is not as strong as that in the United States. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. In addition, certain jurisdictions do not protect to the same extent or at all inventions that constitute new methods of treatment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">92</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or in-licensed patents, trade secrets or other intellectual property as an inventor or co-inventor. For example, we or our licensors may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or our or our licensors&#8217; ownership of our owned or in-licensed patents, trade secrets or other intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be subject to claims by third parties asserting that our employees, consultants or contractors have wrongfully used or disclosed confidential information of third parties, or we have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of our employees, consultants and contractors were previously employed at universities or other pharmaceutical or biotechnology companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Litigation may be necessary to defend against these claims.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, while it is our policy to require our employees, consultants and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our intellectual property assignment agreements with them may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial conditions, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could have a material adverse effect on our competitive business position and prospects. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products, which license may not be available on commercially reasonable terms, or at all, or such license may be non-exclusive. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our management and employees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to seeking patents for some of our technology and product candidates, we also rely on trade secrets and confidentiality agreements to protect our unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect our trade secrets and other proprietary technology, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract research organizations, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants, but we cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary technology. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Detecting the disclosure or misappropriation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">93</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of a trade secret and enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside of the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be materially and adversely harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intellectual property rights do not necessarily address all potential threats.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">others may be able to make product candidates that are similar to ours but that are not covered by the claims of the patents that we own; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we, or our license partners or current or future collaborators, might not have been the first to make the inventions covered by the issued patent or pending patent applications that we license or may own in the future; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we, or our license partners or current or future collaborators, might not have been the first to file patent applications covering certain of our or their inventions; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or in-licensed intellectual property rights; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">it is possible that our owned or in-licensed pending patent applications or those we may own or in-license in the future will not lead to issued patents; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we cannot ensure that any of our patents, or any of our pending patent applications, if issued, or those of our licensors, will include claims having a scope sufficient to protect our product candidates; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we cannot ensure that any patents issued to us or our licensors will provide a basis for an exclusive market for our commercially viable product candidates or will provide us with any competitive advantages; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the U.S. Supreme Court, other federal courts, Congress, the USPTO or similar foreign authorities may change the standards of patentability and any such changes could narrow or invalidate, or change the scope of, our or our licensors&#8217; patents; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we cannot ensure that our commercial activities or product candidates will not infringe upon the patents of others; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we cannot ensure that we will be able to successfully commercialize our product candidates on a substantial scale, if approved, before the relevant patents that we own or license expire; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may not develop additional proprietary technologies that are patentable; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">94</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the patents of others may harm our business; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property. </span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Regulatory Approval and Other Legal Compliance Matters</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process of the FDA, the EMA and comparable foreign authorities is expensive, time-consuming, and uncertain and may prevent us from obtaining approvals for the commercialization of any product candidates we develop. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize, or will be delayed in commercializing, product candidates we develop, and our ability to generate revenue will be materially impaired.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any product candidates we develop and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, and distribution, are subject to comprehensive regulation by the FDA and other regulatory authorities in the United States, the EMA and other regulatory authorities in the European Union and by comparable authorities in other countries. Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate in a given jurisdiction. We have not received approval to market any product candidates from regulatory authorities in any jurisdiction. We have only limited experience in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third-party contract research organizations to assist us in this process. Securing regulatory approval requires the submission of extensive preclinical and clinical data and supporting information, including manufacturing information, to the various regulatory authorities for each therapeutic indication to establish the biologic product candidate&#8217;s safety, purity, and potency. Any product candidates we develop may not be effective, may be only moderately effective, or may prove to have undesirable or unintended side effects, toxicities, or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The process of obtaining marketing approvals, both in the United States and abroad, is expensive, may take many years if additional clinical trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity, and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. The FDA, the EMA and comparable authorities in other countries have substantial discretion in the approval process and may refuse to accept any application or may decide that our data is insufficient for approval and require additional preclinical, clinical, or other studies. In addition, varying interpretations of the data obtained from preclinical testing and clinical trials could delay, limit, or prevent marketing approval of a product candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to develop and market products may be threatened by the results of ongoing litigation challenging the FDA&#8217;s approval of another company&#8217;s drug, mifepristone. Specifically, in April 2023, the U.S. District Court for the Northern District of Texas invalidated the approval by the FDA of mifepristone, a product which was originally approved in 2000 and whose distribution is governed by various measures adopted under risk evaluation and mitigation strategy ("REMS"). In reaching that decision, the district court made a number of findings that numerous representatives of the pharmaceutical and biotechnology industry believe will chill the development, approval, and distribution of new drug and biologic products in the United States. Among other determinations, the district court substituted its scientific judgment for that of the FDA and it held that the FDA must provide a special justification for any differences between an approved drug&#8217;s labeling and the conditions that existed in the drug&#8217;s clinical trials. Further, the district court read the jurisdictional requirements governing litigation in federal court so as to potentially allow virtually any party to bring a lawsuit against the FDA in connection with its decision to approve a new drug application or a biologics license application or establish requirements under a REMS. The U.S. Court of Appeals for the Fifth Circuit declined to order the removal of mifepristone from the market, finding that a challenge to the FDA&#8217;s initial approval in 2000 is barred by the statute of limitations. But the Court of Appeals for the Fifth Circuit did hold that changes allowing for expanded access of mifepristone that the FDA authorized in 2016 and 2021 were arbitrary and capricious in violation of federal law. In December 2023, the Supreme Court announced that it will review the appeals court decision. Depending on the outcome of this litigation and the regulatory uncertainty it has engendered, our ability to develop product candidates is at risk, and our efforts to develop and market new products could be delayed, undermined, or subject to protracted litigation.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">95</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Finally, under the Pediatric Research Equity Act, a new drug application ("NDA"), a BLA or supplement to an NDA or BLA for certain drugs and biological products must contain data to assess the safety and effectiveness of the drug or biological product in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective, unless the sponsor receives a deferral or waiver from the FDA. A deferral may be granted for several reasons, including a finding that the product or therapeutic candidate is ready for approval for use in adults before pediatric trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric trials begin. The applicable legislation in the European Union also requires sponsors to either conduct clinical trials in a pediatric population in accordance with a Pediatric Investigation Plan approved by the Pediatric Committee of the EMA, or to obtain a waiver or deferral from the conduct of these studies by this Committee. For any of our product candidates for which we are seeking regulatory approval in the United States or the European Union, we cannot guarantee that we will be able to obtain a waiver or alternatively complete any required studies and other requirements in a timely manner, or at all, which could result in associated reputational harm and subject us to enforcement action.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we experience delays in obtaining approval or if we fail to obtain approval of any product candidates we develop, the commercial prospects for those product candidates may be harmed, and our ability to generate revenues will be materially impaired.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Failure to obtain marketing approval in foreign jurisdictions would prevent any product candidates we develop from being marketed in such jurisdictions, which, in turn, would materially impair our ability to generate revenue.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In order to market and sell any product candidates we develop in the European Union and many other foreign jurisdictions, we or our collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. We or these third parties may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. The failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval elsewhere. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our products in any jurisdiction, which would materially impair our ability to generate revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, we could face heightened risks with respect to seeking marketing approval in the United Kingdom as a result of the withdrawal of the United Kingdom from the European Union, commonly referred to as Brexit. The United Kingdom is no longer part of the European Single Market and European Union Customs Union. As of January 1, 2021, the Medicines and Healthcare Products Regulatory Agency (the "MHRA") became responsible for supervising medicines and medical devices in Great Britain, comprising England, Scotland, and Wales under domestic law, whereas Northern Ireland will continue to be subject to European Union rules under the Northern Ireland Protocol. The United Kingdom and the European Union have however agreed to the Windsor Framework which fundamentally changes the existing system under the Northern Ireland Protocol, including with respect to the regulation of medicinal products in the United Kingdom. Once implemented, the changes introduced by the Windsor Framework will result in the MHRA being responsible for approving all medicinal products destined for the United Kingdom market (Great Britain and Northern Ireland), and the EMA will no longer have any role in approving medicinal products destined for Northern Ireland. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, may force us to restrict or delay efforts to seek regulatory approval in the United Kingdom for our product candidates, which could significantly and materially harm our business.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, foreign regulatory authorities may change their approval policies and new regulations may be enacted. For instance, the European Union pharmaceutical legislation is currently undergoing a complete review process, in the context of the Pharmaceutical Strategy for Europe initiative, launched by the European Commission in November 2020. The European Commission&#8217;s proposal for revision of several legislative instruments related to medicinal products (including potentially reducing the duration of regulatory data protection and revising the eligibility for expedited pathways) was published on April 26, 2023. The proposed revisions remain to be agreed and adopted by the European Parliament and European Council, and the proposals may therefore be substantially revised before adoption, which is not anticipated before early 2026. The revisions may however have a significant impact on the pharmaceutical industry and our business in the long term.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect that we will be subject to additional risks in commercializing any of our product candidates that receive marketing approval outside the United States, including tariffs, trade barriers and regulatory requirements; economic weakness, including inflation, or political instability in particular foreign economies and markets; compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; foreign currency fluctuations, which could result in increased operating</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">96</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expenses and reduced revenue, and other obligations incident to doing business in another country; and workforce uncertainty in countries where labor unrest is more common than in the United States.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fast track designation, breakthrough therapy designation and/or priority review designation by the FDA may not actually lead to a faster development or regulatory review or approval process, and does not assure FDA approval of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a product candidate is intended for the treatment of a serious or life-threatening condition and the product candidate demonstrates the potential to address unmet medical need for this condition, the sponsor may apply to the FDA for fast track designation. For fast track products, sponsors may have greater interactions with the FDA and the FDA may initiate review of sections of a fast track product&#8217;s application before the application is complete. This rolling review may be available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a fast track product may be effective.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, a sponsor may seek designation of its product as a breakthrough therapy, which is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs and biologics that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, if the FDA determines that a product candidate offers major advances in treatment or provides a treatment where no adequate therapy exists, the FDA may designate the product candidate for priority review. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting product reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, and evidence of safety and effectiveness in a new subpopulation. A priority review designation means that the goal for the FDA to review an application is six months, rather than the standard review period of 10 months.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2020, we received fast track designation from the FDA for INZ-701 for the treatment of ENPP1 Deficiency. We may seek other designations for that and other product candidates. The FDA has broad discretion with respect to whether or not to grant fast track designation, breakthrough therapy designation and/or priority review designation to a product candidate, so even if we believe a particular product candidate is eligible for such designation or status, the FDA may decide not to grant it. Moreover, a fast track designation, breakthrough therapy designation or priority review designation does not necessarily mean a faster regulatory review process, review or approval compared to conventional FDA procedures, or necessarily confer any advantage with respect to approval compared to conventional FDA procedures. Receiving priority review from the FDA does not guarantee approval within the six-month review cycle or thereafter. In addition, the FDA may withdraw these designations if it believes that the designation is no longer supported by data from our clinical development program.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accelerated approval by the FDA or comparable foreign regulatory authorities, even if granted for our product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A product may be eligible for accelerated approval if it treats a serious or life-threatening condition and generally provides a meaningful advantage over available therapies. In addition, it must demonstrate an effect on a biomarker efficacy endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, or IMM, that is reasonably likely to predict an effect on IMM or other clinical benefit. The FDA or other applicable regulatory agency makes the determination regarding whether a biomarker efficacy endpoint is reasonably likely to predict long-term clinical benefit.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may seek approval of our product candidates using the FDA&#8217;s accelerated approval pathway. Prior to seeking such accelerated approval, we will seek feedback from the FDA and otherwise evaluate our ability to seek and receive such accelerated approval. As a condition of approval, the FDA may require that a sponsor of a drug or biologic product candidate receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. These confirmatory trials must be completed with due diligence and we may be required to evaluate different or additional endpoints in these post-marketing confirmatory trials. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">97</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There can be no assurance that the FDA will agree with any biomarker efficacy endpoints that we propose, or that we will decide to pursue or submit an NDA for accelerated approval or any other form of expedited development, review or approval. Similarly, there can be no assurance that, after feedback from FDA, we will continue to pursue or apply for accelerated approval or any other form of expedited development, review or approval, even if we initially decide to do so. Furthermore, if we decide to submit an application for accelerated approval or under another expedited regulatory designation, there can be no assurance that such submission or application will be accepted or that any expedited review or approval will be granted on a timely basis, or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, as noted above, for drugs granted accelerated approval, the FDA typically requires post-marketing confirmatory trials to evaluate the anticipated effect on IMM or other clinical benefit. These confirmatory trials must be completed with due diligence. We may be required to evaluate additional or different clinical endpoints in these post-marketing confirmatory trials. These confirmatory trials may require enrollment of more patients than we currently anticipate and will result in additional costs, which may be greater than the estimated costs we currently anticipate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">With passage of FDORA in December 2022, Congress modified certain provisions governing accelerated approval of drug and biologic products. Specifically, the legislation authorized the FDA to: require a sponsor to have its confirmatory clinical trial underway before accelerated approval is awarded, require a sponsor of a product granted accelerated approval to submit progress reports on its post-approval studies to FDA every six months (until the study is completed; and use expedited procedures to withdraw accelerated approval of an NDA or BLA after the confirmatory trial fails to verify the product&#8217;s clinical benefit. Further, FDORA requires the agency to publish on its website &#8220;the rationale for why a post-approval study is not appropriate or necessary&#8221; whenever it decides not to require such a study upon granting accelerated approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA may withdraw approval of a product candidate approved under the accelerated approval pathway if, for example, the trial required to verify the predicted clinical benefit of our product candidate fails to verify such benefit or does not demonstrate sufficient clinical benefit to justify the risks associated with the drug. The FDA may also withdraw approval if other evidence demonstrates that our product candidate is not shown to be safe or effective under the conditions of use, we fail to conduct any required post approval trial of our product candidate with due diligence or we disseminate false or misleading promotional materials relating to our product candidate. A failure to obtain accelerated approval or any other form of expedited development, review or approval for our product candidates, or withdrawal of a product candidate, would result in a longer time period for commercialization of such product candidate, could increase the cost of development of such product candidate and could harm our competitive position in the marketplace.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the European Union, a &#8220;conditional&#8221; marketing authorization may be granted in cases where all the required safety and efficacy data are not yet available. A conditional marketing authorization is subject to conditions to be fulfilled for generating missing data or ensuring increased safety measures. A conditional marketing authorization is valid for one year and has to be renewed annually until fulfillment of all relevant conditions. Once the applicable pending studies are provided, a conditional marketing authorization can become a &#8220;standard&#8221; marketing authorization. However, if the conditions are not fulfilled within the timeframe set by the EMA, the marketing authorization will cease to be renewed.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we do receive accelerated approval, we may not experience a faster development or regulatory review or approval process, and receiving accelerated approval does not provide assurance of ultimate FDA approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be able to obtain or maintain orphan drug exclusivity for INZ-701 or any other product candidates we develop for one or more indications, and even if we do, that exclusivity may not prevent the FDA or the EMA from approving other competing products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug or biologic intended to treat a rare disease or condition. A similar regulatory scheme governs approval of orphan products by the EMA in the European Union. Generally, if a product candidate with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA from approving another marketing application for the same product for the same therapeutic indication for that time period. The applicable period is seven years in the United States and ten years in the European Union. The exclusivity period in the European Union can be reduced to six years if a product no longer meets the criteria for orphan drug designation, in particular if the product is sufficiently profitable so that market exclusivity is no longer justified.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">98</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA and the EMA have granted orphan drug designation to INZ-701 for the treatment of ENPP1 Deficiency and ABCC6 Deficiency.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In order for the FDA to grant orphan drug exclusivity to one of our products, the agency must find that the product is indicated for the treatment of a condition or disease with a patient population of fewer than 200,000 individuals annually in the United States or that affects more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making available the biologic for the disease or condition will be recovered from sales of the product in the United States. In order for the EMA to grant orphan drug designation, we must establish that the product is intended for the diagnosis, prevention or treatment of (1) a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the European Union when the application is made, or (2) a life-threatening, seriously debilitating or serious and chronic condition in the European Union and that without incentives it is unlikely that the marketing of the drug in the European Union would generate sufficient return to justify the necessary investment. For either of these conditions, we must demonstrate that there exists no satisfactory method of diagnosis, prevention, or treatment of the condition in question that has been authorized in the European Union or, if such method exists, the drug will be of significant benefit to those affected by that condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA or the EMA may conclude that the condition or disease for which we seek orphan drug exclusivity does not meet the applicable standard. Even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different products can be approved for the same condition. In addition, even after an orphan drug is approved, the FDA can subsequently approve the same product for the same condition if the FDA concludes that the later product is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. Under omnibus legislation signed by President Trump on December 27, 2020, the requirement for a product to show clinical superiority applies to drugs and biologics that received orphan drug designation before enactment of the FDA Reauthorization Act of 2017, but have not yet been approved or licensed by the FDA. Orphan drug exclusivity may also be lost if the FDA or the EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of the patients with the rare disease or condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA may further reevaluate the Orphan Drug Act and its regulations and policies. This may be particularly true in light of a decision from the Court of Appeals for the 11th Circuit in September 2021 finding that, for the purpose of determining the scope of exclusivity, the term &#8220;same disease or condition&#8221; means the designated &#8220;rare disease or condition&#8221; and could not be interpreted by the FDA to mean the &#8220;indication or use.&#8221; Although there have been legislative proposals to overrule this decision, they have not been enacted into law.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 23, 2023, the FDA announced that, in matters beyond the scope of that court order, the FDA will continue to apply its existing regulations tying orphan-drug exclusivity to the uses or indications for which the orphan drug was approved. We do not know if, when, or how the FDA or Congress may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA or Congress may make to its orphan drug regulations and policies, our business could be adversely impacted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may seek a Rare Pediatric Disease Designation for one or more of our product candidates. However, a BLA for one or more of our product candidates may not meet the eligibility criteria for a priority review voucher upon approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">With enactment of the Food and Drug Administration Safety and Innovation Act in 2012, Congress authorized the FDA to award priority review vouchers ("PRVs") to sponsors of certain rare pediatric disease product applications that meet the criteria specified in the law. This provision is designed to encourage development of new drug and biological products for prevention and treatment of certain rare pediatric diseases. Specifically, under this program, a sponsor who receives an approval for a drug or biologic for a &#8220;rare pediatric disease&#8221; may qualify for a voucher that can be redeemed to receive a priority review of a subsequent marketing application for a different product. The sponsor of a rare pediatric disease drug product receiving a PRV may transfer (including by sale) the voucher to another sponsor. The voucher may be further transferred any number of times before the voucher is used, as long as the sponsor making the transfer has not yet submitted the application.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In order to receive a PRV upon BLA approval, the product must receive designation from the FDA as a product for a rare pediatric disease prior to submission of the marketing application. A &#8220;rare pediatric disease&#8221; is a disease that is serious or life-threatening, in which the serious or life-threatening manifestations primarily affect individuals aged from birth to 18 years and affects fewer than 200,000 people in the United States, or affects more than 200,000 people in the United States but there is no reasonable expectation that the cost of developing and making available in the United States a product for such disease or condition will be recovered from sales in the United States of such product.  In addition to receiving rare pediatric disease designation, in order to receive a PRV, the BLA must be given priority review, rely on clinical data derived from studies examining a pediatric population and dosages of the product intended for that population, not seek approval for a different adult indication in the original rare pediatric disease product application and be for a product that does not include a previously approved active ingredient.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">99</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2020, we received rare pediatric disease designation from the FDA for INZ-701 for the treatment of ENPP1 Deficiency. However, the FDA may determine that a BLA for INZ-701 or one or more of our other product candidates does not meet the eligibility criteria for a PRV upon approval. The Rare Pediatric Disease Priority Review Voucher program was scheduled to expire after September 30, 2020. After that, only drugs designated as rare pediatric treatments and approved by the FDA by October 1, 2022, could receive a voucher. In December 2020, however, Congress renewed the program as part of the 2021 Coronavirus Response and Relief Supplemental Consolidated Appropriations Act through the federal fiscal year 2024. Thus, under the current statutory sunset provisions, FDA may only award PRVs for approved rare pediatric disease product applications if sponsors have rare pediatric disease designation for the drug granted by September 30, 2024. The FDA may not award any rare pediatric disease PRVs after September 30, 2026. If we do not obtain approval of our BLA for INZ-701 by these dates, and if the program is further extended by congressional action, we may not receive a PRV.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The FDA, EMA, or other comparable foreign regulatory authorities could require the clearance or approval of a companion diagnostic device as a condition of approval for any product candidate that requires or would commercially benefit from such tests.  Failure to successfully validate, develop and obtain regulatory clearance or approval for companion diagnostics on a timely basis or at all could harm our product development strategy and we may not realize the commercial potential of any such product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If safe and effective use of any of our other product candidates depends on an in vitro diagnostic, then the FDA generally will require approval or clearance of that diagnostic, known as a companion diagnostic, at the same time that the FDA approves our product candidates. The process of obtaining or creating such diagnostic is time consuming and costly. Companion diagnostics, which provide information that is essential for the safe and effective use of a corresponding therapeutic product, are subject to regulation by the FDA, EMA, and other comparable foreign regulatory authorities as medical devices and require separate regulatory approval from therapeutic approval prior to commercialization. The FDA previously has required in vitro companion diagnostics intended to select the patients who will respond to a product candidate to obtain pre-market approval ("PMA") simultaneously with approval of the therapeutic candidate. The PMA process, including the gathering of preclinical and clinical data and the submission and review by the FDA, can take several years or longer. It involves a rigorous pre-market review during which the sponsor must prepare and provide FDA with reasonable assurance of the device&#8217;s safety and effectiveness and information about the device and its components regarding, among other things, device design, manufacturing, and labeling. After a device is placed on the market, it remains subject to significant regulatory requirements, including requirements governing development, testing, manufacturing, distribution, marketing, promotion, labeling, import, export, record-keeping, and adverse event reporting.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Given our limited experience in developing and commercializing diagnostics, we do not plan to develop companion diagnostics internally and thus will be dependent on the sustained cooperation and effort of third-party collaborators in developing and obtaining approval for these companion diagnostics. We may not be able to enter into arrangements with a provider to develop a companion diagnostic for use in connection with a registrational trial for our product candidates or for commercialization of our product candidates, or do so on commercially reasonable terms, which could adversely affect and/or delay the development or commercialization of our product candidates. We and our future collaborators may encounter difficulties in developing and obtaining approval for the companion diagnostics, including issues relating to selectivity/specificity, analytical validation, reproducibility, or clinical validation. Any delay or failure by our collaborators to develop or obtain regulatory approval of the companion diagnostics could delay or prevent approval of our product candidates. In addition, we, our collaborators or third parties may encounter production difficulties that could constrain the supply of the companion diagnostics, and both they and we may have difficulties gaining acceptance of the use of the companion diagnostics by physicians.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that adoption of screening and treatment into clinical practice guidelines is important for payer access, reimbursement, utilization in medical practice and commercial success, but both our collaborators and we may have difficulty gaining acceptance of the companion diagnostic into clinical practice guidelines. If such companion diagnostics fail to gain market acceptance, it would have an adverse effect on our ability to derive revenues from sales, if any, of any of our product candidates that are approved for commercial sale. In addition, any companion diagnostic collaborator or third party with whom we contract may decide not to commercialize or to discontinue selling or manufacturing the companion diagnostic that we anticipate using in connection with development and commercialization of our product candidates, or our relationship with such collaborator or third party may otherwise terminate. We may not be able to enter into arrangements with another provider to obtain supplies of an alternative diagnostic test for use in connection with the development and commercialization of our product candidates or do so on commercially reasonable terms, which could adversely affect and/or delay the development or commercialization of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">100</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if we, or any collaborators we may have, obtain marketing approvals for any product candidates we develop, the terms of approvals and ongoing regulation of our products could require the substantial expenditure of resources and may limit how we, or they, manufacture and market our products, which could materially impair our ability to generate revenue.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any product candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, advertising, and promotional activities for such product, will be subject to continual requirements of and review by the FDA, the EMA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements relating to quality control and manufacturing, quality assurance and corresponding maintenance of records and documents, and requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the product, including the requirement to implement a REMS. We must also comply with requirements concerning advertising and promotion for any product candidate for which we obtain marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accordingly, assuming we, or any collaborators we may have, receive marketing approval for one or more product candidates we develop, we, and such collaborators, and our and their contract manufacturers will continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance, and quality control. If we and such collaborators are not able to comply with post-approval regulatory requirements, we and such collaborators could have the marketing approvals for our products withdrawn by regulatory authorities and our, or such collaborators&#8217;, ability to market any future products could be limited, which could adversely affect our ability to achieve or sustain profitability. Further, the cost of compliance with post-approval regulations may have a negative effect on our business, operating results, financial condition, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Any product candidate for which we obtain marketing approval could be subject to restrictions or withdrawal from the market, and we may be subject to substantial penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products, when and if any of them are approved.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA and other regulatory agencies closely regulate the post-approval marketing and promotion of products to ensure that they are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA and other regulatory agencies impose stringent restrictions on manufacturers&#8217; communications regarding off-label use, and if we do not market our products for their approved indications, we may be subject to enforcement action for off-label marketing by the FDA and other federal and state enforcement agencies, including the Department of Justice. Violation of the Federal Food, Product, and Cosmetic Act and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription products may also lead to investigations or allegations of violations of federal and state health care fraud and abuse laws and state consumer protection laws.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2021, the FDA published final regulations which describe the types of evidence that the agency will consider in determining the intended use of a biologic product. In addition, in October 2023, the FDA published draft guidance outlining the agency&#8217;s non-binding policies governing the distribution of scientific information on unapproved uses to healthcare providers. This draft guidance calls for such communications to be truthful, non-misleading, factual, and unbiased, and include all information necessary for healthcare providers to interpret the strengths and weaknesses and validity and utility of the information about the unapproved use. We will need to carefully navigate the FDA&#8217;s various regulations, guidance, and policies, along with recently enacted legislation, to ensure compliance with restrictions governing promotion of our products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, later discovery of previously unknown problems with our products, manufacturers, or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on such products, manufacturers or manufacturing processes; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on the labeling or marketing of a product; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on the distribution or use of a product; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">requirements to conduct post-marketing clinical trials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">receipt of warning or untitled letters; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">withdrawal of the products from the market; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">101</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">refusal to approve pending applications or supplements to approved applications that we submit; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">recall of products; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fines, restitution, or disgorgement of profits or revenue; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">suspension or withdrawal of marketing approvals; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">suspension of any ongoing clinical trials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">refusal to permit the import or export of our products; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product seizure; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Similar restrictions apply to the approval of our products in the European Union. The holder of a marketing authorization is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of medicinal products. These include: compliance with the European Union&#8217;s stringent pharmacovigilance or safety reporting rules, which can impose post-authorization studies and additional monitoring obligations; the manufacturing of authorized medicinal products, for which a separate manufacturer&#8217;s license is mandatory; and the marketing and promotion of authorized drugs, which are strictly regulated in the European Union and are also subject to European Union Member State laws.  The failure to comply with these and other European Union requirements can also lead to significant penalties and sanctions.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accordingly, any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize any product candidates we develop and adversely affect our business, financial condition, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our relationships with healthcare providers, physicians and third-party payors will be subject to applicable anti-kickback, fraud and abuse, and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, and diminished profits and future earnings.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Healthcare providers, physicians, and third-party payors play a primary role in the recommendation and prescription of any product candidates that we develop for which we obtain marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell, and distribute our products for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations include the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal healthcare anti-kickback statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving, or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order, or recommendation of, any good or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal False Claims Act imposes criminal and civil penalties, including civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval from Medicare, Medicaid, or other government payors that are false or fraudulent or making a false statement to avoid, decrease, or conceal an obligation to pay money to the federal government, with potential liability including mandatory treble damages and significant per-claim penalties, currently set at $11,181 to $22,363 per false claim. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act; </span></div></div>
  <div style="margin-left:9.167%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.472%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.8223993482544887%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal civil monetary penalties laws, which impose civil fines for, among other things, the offering or transfer of remuneration to a Medicare or state healthcare program beneficiary if the person knows or should know it is likely to </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">102</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:9.167%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.472%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.8223993482544887%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">influence the beneficiary&#8217;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state healthcare program, unless an exception applies;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></div></div>
  <div style="margin-left:9.167%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.472%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.8223993482544887%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as further amended by the Health Information Technology for Economic and Clinical Health Act, which imposes certain requirements, including mandatory contractual terms, with respect to safeguarding the privacy, security, and transmission of individually identifiable health information without appropriate authorization by entities subject to the rule, such as health plans, health care clearinghouses, and health care providers; </span></div></div>
  <div style="margin-left:9.167%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.472%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.8223993482544887%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal false statements statute, which prohibits knowingly and willfully falsifying, concealing, or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items, or services; </span></div></div>
  <div style="margin-left:9.167%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.472%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.8223993482544887%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Federal Food, Drug and Cosmetic Act, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices; </span></div></div>
  <div style="margin-left:9.167%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.472%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.8223993482544887%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal transparency requirements under the federal Physician Payment Sunshine Act, which requires manufacturers of drugs, devices, biologics, and medical supplies to report to the U.S. Department of Health and Human Services, or HHS, information related to payments and other transfers of value to physicians, other healthcare providers, and teaching hospitals, and ownership and investment interests held by physicians and their immediate family members and applicable group purchasing organizations; </span></div></div>
  <div style="margin-left:9.167%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.472%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.8223993482544887%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; </span></div></div>
  <div style="margin-left:9.167%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.472%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.8223993482544887%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">analogous state laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, and certain state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to payments to physicians and other health care providers or marketing expenditures; and </span></div></div>
  <div style="margin-left:9.167%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.472%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.8223993482544887%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">similar healthcare laws and regulations in the European Union and other jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers and laws governing the privacy and security of certain protected information, such as the General Data Protection Regulation, or the GDPR, which imposes obligations and restrictions on the collection and use of personal data relating to individuals located in the European Union (including health data). </span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. If our operations are found to be in violation of any of the laws described above or any other government regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from participation in government health care programs, such as Medicare and Medicaid, imprisonment, and the curtailment or restructuring of our operations, any of which could adversely affect our business, financial condition, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices, including our relationships with physicians and other healthcare providers, may not comply with current or future statutes, regulations, or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal, and administrative penalties, damages, fines, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. Further, defending against any such actions can be costly, time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. If any of the physicians or other providers or entities with whom we expect to do business are found to be not in compliance with applicable laws, they may be subject to criminal, civil, or administrative sanctions, including exclusions from government funded healthcare programs. Liabilities they incur pursuant to these laws could result in significant costs or an interruption in operations, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">103</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Current and future legislation may increase the difficulty and cost for us and any collaborators to obtain marketing approval and commercialize our product candidates and affect the prices we, or they, may obtain.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could, among other things, prevent or delay marketing approval of our drug candidates, restrict or regulate post-approval activities, impact pricing and reimbursement and affect our ability, or the ability of any collaborators, to profitably sell or commercialize any product candidate for which we, or they, obtain marketing approval. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we, or any collaborators, may receive for any approved products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other legislative changes have been proposed and adopted since the ACA was enacted. These changes include the Budget Control Act of 2011, which, among other things, led to aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which will remain in effect through the first half of 2032. The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under current legislation, the actual reductions in Medicare payments may vary up to 4%. The Consolidated Appropriations Act, which was signed into law by President Biden in December 2022, made several changes to sequestration of the Medicare program. Section 1001 of the Consolidated Appropriations Act delays the 4% Statutory Pay-As-You-Go Act of 2010 (PAYGO) sequester for two years, through the end of 2024. Triggered by enactment of the American Rescue Plan Act of 2021, the 4% cut to the Medicare program would have taken effect in January 2023. The Consolidated Appropriations Act&#8217;s healthcare offset title includes Section 4163, which extends the 2% Budget Control Act of 2011 Medicare sequester for six months into 2032 and lowers the payment reduction percentages in years 2030 and 2031.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since enactment of the ACA, there have been and continue to be, numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, with enactment of the TCJA in 2017, Congress repealed the &#8220;individual mandate.&#8221; The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, became effective in 2019.  Further, on December 14, 2018, a U.S. District Court judge in the Northern District of Texas ruled that the individual mandate portion of the ACA is an essential and inseverable feature of the ACA and therefore because the mandate was repealed as part of the TCJA, the remaining provisions of the ACA are invalid as well. In June 2021, the U.S. Supreme Court dismissed this action after finding that the plaintiffs do not have standing to challenge the constitutionality of the ACA. Litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Trump Administration also took executive actions to undermine or delay implementation of the ACA, including directing federal agencies with authorities and responsibilities under the ACA to waive, defer, grant exemptions from, or delay the implementation of any provisions of the ACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. On January 28, 2021, however, President Biden issued an executive order which directs federal agencies to reconsider rules and other polices that limit Americans&#8217; access to healthcare, and consider actions that will protect and strengthen that access. Under this executive order, federal agencies are directed to re-examine policies that undermine protections for people with pre-existing conditions, including complications related to COVID-19; demonstrations and waivers under Medicaid and the ACA that may reduce coverage or undermine the programs, including work requirements; policies that make it more difficult to enroll in Medicaid and the ACA; and policies that reduce affordability of coverage or financial assistance, including for dependents. The executive order also directs HHS to create a special enrollment period for the Health Insurance Marketplace in response to the COVID-19 pandemic.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the European Union, on December 13, 2021, Regulation No 2021/2282 on Health Technology Assessment ("HTA"), amending Directive 2011/24/EU, was adopted. While the HTA entered into force in January 2022, it will only begin to apply from January 2025 onwards, with preparatory and implementation-related steps to take place in the interim. Once applicable, it will have a phased implementation depending on the concerned products. The HTA intends to boost cooperation among European Union member states in assessing health technologies, including new medicinal products as well as certain high-risk medical devices, and provide the basis for cooperation at the European Union level for joint clinical assessments in these areas. It will permit European Union member states to use common HTA tools, methodologies, and procedures across the European Union, working together in four main areas, including joint clinical assessment of the innovative health technologies with the highest potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual European Union member states will</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">104</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">continue to be responsible for assessing non-clinical (e.g., economic, social, ethical) aspects of health technology, and making decisions on pricing and reimbursement.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect that these healthcare reforms, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product and/or the level of reimbursement physicians receive for administering any approved product we might bring to market. Reductions in reimbursement levels may negatively impact the prices we receive or the frequency with which our products are prescribed or administered. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. Accordingly, such reforms, if enacted, could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain marketing approval and may affect our overall financial condition and ability to develop or commercialize product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action in the United States, the European Union or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The prices of prescription pharmaceuticals in the United States and foreign jurisdictions are subject to considerable legislative and executive actions, which could impact the prices we obtain for our products, if approved.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The prices of prescription pharmaceuticals have also been the subject of considerable discussion in the United States. There have been several recent U.S. congressional inquiries, as well as proposed and enacted state and federal legislation designed to, among other things, bring more transparency to pharmaceutical pricing, review the relationship between pricing and manufacturer patient programs, and reduce the costs of pharmaceuticals under Medicare and Medicaid.  In 2020, President Trump issued several executive orders intended to lower the costs of prescription products and certain provisions in these orders have been incorporated into regulations.  These regulations include an interim final rule implementing a most favored nation model for prices that would tie Medicare Part B payments for certain physician-administered pharmaceuticals to the lowest price paid in other economically advanced countries, effective January 1, 2021. That rule, however, has been subject to a nationwide preliminary injunction and, on December 29, 2021, CMS issued a final rule to rescind it. With issuance of this rule, CMS stated that it will explore all options to incorporate value into payments for Medicare Part B pharmaceuticals and improve beneficiaries' access to evidence-based care.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, in October 2020, HHS and the FDA published a final rule allowing states and other entities to develop a Section 804 Importation Program, or SIP, to import certain prescription drugs from Canada into the United States. That regulation was challenged in a lawsuit by the Pharmaceutical Research and Manufacturers of America ("PhRMA"), but the case was dismissed by a federal district court in February 2023 after the court found that PhRMA did not have standing to sue HHS. Nine states (Colorado, Florida, Maine, New Hampshire, New Mexico, North Dakota, Texas, Vermont, and Wisconsin) have passed laws allowing for the importation of drugs from Canada. Certain of these states have submitted Section 804 Importation Program proposals and are awaiting FDA approval. In January 2024, the FDA approved Florida's plan for Canadian drug importation.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The final rule would eliminate the current safe harbor for Medicare drug rebates and create new safe harbors for beneficiary point-of-sale discounts and pharmacy benefit manager service fees. It originally was set to go into effect on January 1, 2022, but with passage of the IRA, it has been delayed by Congress to January 1, 2032.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The IRA has implications for Medicare Part D, which is a program available to individuals who are entitled to Medicare Part A or enrolled in Medicare Part B to give them the option of paying a monthly premium for outpatient prescription drug coverage. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Specifically, with respect to price negotiations, Congress authorized Medicare to negotiate lower prices for certain costly single-source drug and biologic products that do not have competing generics or biosimilars and are reimbursed under Medicare Part B and Part D.  CMS may negotiate prices for ten high-cost drugs paid for by Medicare Part D starting in 2026, followed by 15 Part D drugs in 2027, 15 Part B or Part D drugs in 2028, and 20 Part B or Part D drugs in 2029 and beyond. This provision applies to drug</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">105</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">products that have been approved for at least 9 years and biologics that have been licensed for 13 years, but it does not apply to drugs and biologics that have been approved for a single rare disease or condition. Nonetheless, since CMS may establish a maximum price for these products in price negotiations, we would be fully at risk of government action if our products are the subject of Medicare price negotiations. Moreover, given the risk that could be the case, these provisions of the IRA may also further heighten the risk that we would not be able to achieve the expected return on our drug products or full value of our patents protecting our products if prices are set after such products have been on the market for nine years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The legislation subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing to comply with the legislation by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law or for taking price increases that exceed inflation. The legislation also requires manufacturers to pay rebates for drugs in Medicare Part D whose price increases exceed inflation. The law also caps Medicare out-of-pocket drug costs at an estimated $4,000 a year in 2024 and, thereafter beginning in 2025, at $2,000 a year. In addition, the IRA potentially raises legal risks with respect to individuals participating in a Medicare Part D prescription drug plan who may experience a gap in coverage if they required coverage above their initial annual coverage limit before they reached the higher threshold, or &#8220;catastrophic period&#8221; of the plan. Individuals requiring services exceeding the initial annual coverage limit and below the catastrophic period, must pay 100% of the cost of their prescriptions until they reach the catastrophic period. Among other things, the IRA contains many provisions aimed at reducing this financial burden on individuals by reducing the co-insurance and co-payment costs, expanding eligibility for lower income subsidy plans, and price caps on annual out-of-pocket expenses, each of which could have potential pricing and reporting implications.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On June 6, 2023, Merck &amp; Co. filed a lawsuit against the HHS and CMS asserting that, among other things, the IRA's Drug Price Negotiation Program for Medicare constitutes an uncompensated taking in violation of the Fifth Amendment of the Constitution. Subsequently, a number of other parties, including the U.S. Chamber of Commerce, Bristol Myers Squibb Company, the PhRMA, Astellas, Novo Nordisk, Janssen Pharmaceuticals, Novartis, AstraZeneca, and Boehringer Ingelheim, also filed lawsuits in various courts with similar constitutional claims against the HHS and CMS. We expect that litigation involving these and other provisions of the IRA will continue, with unpredictable and uncertain results.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accordingly, while it is currently unclear how the IRA will be effectuated, we cannot predict with certainty what impact any federal or state health reforms will have on us, but such changes could impose new or more stringent regulatory requirements on our activities or result in reduced reimbursement for our products, any of which could adversely affect our business, results of operations and financial condition.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription product and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the European Union, similar political, economic and regulatory developments may affect our ability to profitably commercialize our product candidates, if approved. In some countries, particularly the countries of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control and access. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our products candidate to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed, possibly materially.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to continuing pressure on prices and cost containment measures, legislative developments at the European Union or member state level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare in the European Union, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than European Union, law and policy. National governments and health service providers have different priorities and approaches to the delivery of healthcare and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most European Union member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing European Union and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to commercialize our product candidates, if approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">106</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Finally, in markets outside of the United States and the European Union, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Inadequate funding for the FDA, the SEC, and other government agencies, including from government shut downs, or other disruptions to these agencies&#8217; operations, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. In addition, government funding of the Securities and Exchange Commission (the "SEC") and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compliance with global privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and the failure to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition or results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The regulatory framework for the collection, use, safeguarding, sharing, transfer and other processing of information worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. Globally, virtually every jurisdiction in which we operate has established its own data security and privacy frameworks with which we must comply. For example, the collection, use, disclosure, transfer, or other processing of personal data regarding individuals in the European Union, including personal health data, is subject to the GDPR, which took effect across all member states of the European Economic Area ("EEA") in May 2018. Beyond GDPR, there are privacy and data security laws in a growing number of countries around the world. While many follow GDPR as a model, other laws contain different or conflicting provisions. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. The GDPR increases our obligations with respect to clinical trials conducted in the EEA by expanding the definition of personal data to include coded data and requiring changes to informed consent practices and more detailed notices for clinical trial subjects and investigators.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the GDPR also imposes strict rules on the transfer of personal data to countries outside the European Union, including the United States and, as a result, increases the scrutiny that clinical trial sites located in the EEA should apply to transfers of personal data from such sites to countries that are considered to lack an adequate level of data protection, such as the United States. There are ongoing concerns about the ability of companies to transfer personal data from the European Union to other countries. In July 2020, the Court of Justice of the European Union ("CJEU") invalidated the EU-U.S. Privacy Shield, one of the mechanisms used to legitimize the transfer of personal data from the EEA to the United States. This CJEU decision has resulted in increased scrutiny on data transfers generally and may increase our costs of compliance with data privacy legislation as well as our costs of negotiating appropriate privacy and security agreements with our vendors and business partners.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The GDPR also permits data protection authorities to require destruction of improperly gathered or used personal information and/or impose substantial fines for violations of the GDPR, which can be up to 4% of global revenues or 20 million Euros, whichever is greater, and it also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. In addition, the GDPR provides that European Union member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric, or health data.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">107</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, in October 2022, President Biden signed an executive order to implement the EU-U.S. Data Privacy Framework, which would serve as a replacement to the EU-U.S. Privacy Shield. The European Commission initiated the process to adopt an adequacy decision for the EU-U.S. Data Privacy Framework in December 2022, and the European Commission adopted the adequacy decision on July 10, 2023. The adequacy decision will permit U.S. companies who self-certify to the EU-U.S. Data Privacy Framework to rely on it as a valid data transfer mechanism for data transfers from the EU to the U.S. However, some privacy advocacy groups have already suggested that they will be challenging the EU-U.S. Data Privacy Framework. If these challenges are successful, they may not only impact the EU-U.S. Data Privacy Framework, but also further limit the viability of the standard contractual clauses and other data transfer mechanisms. The uncertainty around this issue has the potential to impact our business internationally.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Following the withdrawal of the United Kingdom from the European Union, the United Kingdom&#8217;s Data Protection Act 2018 applies to the processing of personal data that takes place in the United Kingdom and includes parallel obligations to those set forth by GDPR. In relation to data transfers, both the United Kingdom and the European Union have determined, through separate &#8220;adequacy&#8221; decisions, that data transfers between the two jurisdictions are in compliance with the United Kingdom&#8217;s Data Protection Act 2018 and the GDPR, respectively. In October 2023, the United Kingdom and the United States implemented a US-UK "data bridge," which functions similarly to the EU-U.S. Data Privacy Framework and provides an additional legal mechanism for companies to transfer data from the United Kingdom to the United States. In addition to the United Kingdom, Switzerland is also in the process of approving an adequacy decision in relation to the Swiss-U.S. Data Privacy Framework (which would function similarly to the EU-U.S. Data Privacy Framework and the U.S.-UK &#8220;data bridge&#8221; in relation to data transfers from Switzerland to the United States). Any changes or updates to these developments have the potential to impact our business.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Similar actions are either in place or under way in the United States. There are a broad variety of data protection laws that are applicable to our activities, and a wide range of enforcement agencies at both the state and federal levels that can review companies for privacy and data security concerns based on general consumer protection laws. The Federal Trade Commission and state Attorneys General all are aggressive in reviewing privacy and data security protections for consumers. New laws also are being considered at both the state and federal levels. For example, the California Consumer Privacy Act ("CCPA"), which went into effect on January 1, 2020, is creating similar risks and obligations as those created by the GDPR, though the CCPA does exempt certain information collected as part of a clinical trial subject to the Federal Policy for the Protection of Human Subjects (the Common Rule). In November 2020, California voters passed a ballot initiative for the California Privacy Rights Act ("CPRA"), which went into effect on January 1, 2023, and significantly expanded the CCPA to incorporate additional GDPR-like provisions including requiring that the use, retention, and sharing of personal information of California residents be reasonably necessary and proportionate to the purposes of collection or processing, granting additional protections for sensitive personal information, and requiring greater disclosures related to notice to residents regarding retention of information. The CPRA also created a new enforcement agency &#8211; the California Privacy Protection Agency &#8211; whose sole responsibility is to enforce the CPRA, which will further increase compliance risk. The provisions in the CPRA may apply to some of our business activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to California, 11 other states have passed comprehensive privacy laws similar to the CCPA and CPRA. These laws are either in effect or will go into effect sometime before the end of 2026. Like the CCPA and CPRA, these laws create obligations related to the processing of personal information, as well as special obligations for the processing of &#8220;sensitive&#8221; data, which includes health data in some cases. Some of the provisions of these laws may apply to our business activities. There are also states that are strongly considering comprehensive privacy laws during the 2024 legislative sessions that will go into effect in 2025 and beyond, including New Hampshire and New Jersey. Other states will be considering similar laws in the future, and Congress has also been debating passing a federal privacy law. There are also states that are specifically regulating health information that may affect our business. For example, Washington state passed a health privacy law in 2023 that will regulate the collection and sharing of health information, and the law also has a private right of action, which further increases the relevant compliance risk. Connecticut and Nevada have also passed similar laws regulating consumer health data, and more states (such as Vermont) are considering such legislation in 2024. These laws may impact our business activities, including our identification of research subjects, relationships with business partners, and ultimately the marketing and distribution of our products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A broad range of legislative measures also have been introduced at the federal level. Accordingly, failure to comply with federal and state laws (both those currently in effect and future legislation) regarding privacy and security of personal information could expose us to fines and penalties under such laws. There also is the threat of consumer class actions related to these laws and the overall protection of personal data. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our reputation and our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Given the breadth and depth of changes in data protection obligations, preparing for and complying with these requirements is rigorous and time intensive and requires significant resources and a review of our technologies, systems and practices, as well as those of any third-party collaborators, service providers, contractors or consultants that process or transfer personal data</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">108</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collected. The GDPR and other changes in laws or regulations associated with the enhanced protection of certain types of sensitive data, such as healthcare data or other personal information from our clinical trials, could require us to change our business practices and put in place additional compliance mechanisms, may interrupt or delay our development, regulatory and commercialization activities and increase our cost of doing business, and could lead to government enforcement actions, private litigation and significant fines and penalties against us and could have a material adverse effect on our business, financial condition or results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot assure stockholders that our third-party service providers with access to our or our customers&#8217;, suppliers&#8217;, trial patients&#8217; and employees&#8217; personally identifiable and other sensitive or confidential information in relation to which we are responsible will not breach contractual obligations imposed by us, or that they will not experience data security breaches or attempts thereof, which could have a corresponding effect on our business, including putting us in breach of our obligations under privacy laws and regulations and/or which could in turn adversely affect our business, results of operations and financial condition. We cannot assure stockholders that our contractual measures and our own privacy and security-related safeguards will protect us from the risks associated with the third-party processing, storage and transmission of such information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Laws and regulations governing any international operations we may have in the future may preclude us from developing, manufacturing, and selling certain product candidates outside of the United States and require us to develop and implement costly compliance programs.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to numerous laws and regulations in each jurisdiction outside the United States in which we operate. The creation, implementation and maintenance of international business practices compliance programs is costly and such programs are difficult to enforce, particularly where reliance on third parties is required.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Foreign Corrupt Practices Act (the "FCPA") prohibits any U.S. individual or business from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. The anti-bribery provisions of the FCPA are enforced primarily by the Department of Justice. The SEC is involved with enforcement of the books and records provisions of the FCPA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. Our expansion outside of the United States has required, and will continue to require, us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit our growth potential and increase our development costs. The failure to comply with laws governing international business practices may result in substantial penalties, including suspension or debarment from government contracting. Violation of the FCPA can result in significant civil and criminal penalties. Indictment alone under the FCPA can lead to suspension of the right to do business with the U.S. government until the pending claims are resolved. Conviction of a violation of the FCPA can result in long-term disqualification as a government contractor. The termination of a government contract or relationship as a result of our failure to satisfy any of our obligations under laws governing international business practices would have a negative impact on our operations and harm our reputation and ability to procure government contracts. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions. For example, the provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order, or use of medicinal products is prohibited in the European Union. The provision of benefits or advantages to physicians is also governed by the national anti-bribery laws of European Union Member States. Infringement of these laws could result in substantial fines and imprisonment. Payments made to physicians in certain European Union Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217; s employer, his or her competent professional organization, and/or the regulatory authorities of the individual European Union Member States. These requirements are provided in the national laws, industry codes, or professional codes of conduct applicable in the European Union Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines, or imprisonment.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">109</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we or any third-party manufacturer we engage now or in the future fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs or liabilities that could have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We and third-party manufacturers we engage now are, and any third-party manufacturer we may engage in the future will be, subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we maintain general liability insurance as well as workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we may incur substantial costs in order to comply with current or future environmental, health, and safety laws and regulations. These current or future laws and regulations may impair our research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties, or other sanctions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, with respect to the operations of our current and any future third-party contract manufacturers, it is possible that if they fail to operate in compliance with applicable environmental, health and safety laws and regulations or properly dispose of wastes associated with our products, we could be held liable for any resulting damages, suffer reputational harm or experience a disruption in the manufacture and supply of our product candidates or products. In addition, our supply chain may be adversely impacted if any of our third-party contract manufacturers become subject to injunctions or other sanctions as a result of their non-compliance with environmental, health and safety laws and regulations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Employee Matters and Managing Growth</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are highly dependent on the research and development, clinical, financial, operational and other business expertise of our executive officers, as well as the other principal members of our management, scientific and clinical teams. Although we have entered into employment agreements with our executive officers, each of them may terminate their employment with us at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees. Recruiting and retaining qualified scientific, clinical, manufacturing, accounting, legal and sales and marketing personnel will also be critical to our success.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain marketing approval of and commercialize products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. Our success as a public company also depends on implementing and maintaining internal controls and the accuracy and timeliness of our financial reporting. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">110</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We expect to expand our development and regulatory capabilities and potentially implement sales, marketing, and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of drug development, clinical, regulatory affairs, commercial, manufacturing, and quality control and, if any of our product candidates receives marketing approval, sales, marketing and distribution. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Future growth will impose significant added responsibilities on members of management, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">identifying, recruiting, integrating, maintaining and motivating additional employees; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">managing our internal development efforts effectively, including the clinical and regulatory review process for INZ-701 and any other product candidate we develop, while complying with our contractual obligations to contractors and other third parties; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">improving our operational, financial and management controls, reporting systems and procedures. </span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our future financial performance and our ability to advance development of and, if approved, commercialize INZ-701 and any other product candidate we develop will depend, in part, on our ability to effectively manage any future growth. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. If we do not effectively manage the expansion of our operations, we could experience weaknesses in our infrastructure, operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. The expansion of our operations also could lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of the pharmaceutical and biotechnology companies that we compete against for qualified personnel and consultants have greater financial and other resources, different risk profiles and a longer history in the industry than we do. If we are unable to continue to attract and retain high-quality personnel and consultants, the rate and success at which we can develop product candidates and operate our business will be limited.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our internal computer systems, or those of our collaborators, vendors, suppliers, contractors, or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our internal computer systems and those of any collaborators, vendors, suppliers, contractors or consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. Such systems are also vulnerable to service interruptions or to security breaches from inadvertent or intentional actions by our employees, third-party vendors and/or business partners, or from cyber-attacks by malicious third parties. Cyber-attacks are increasing in their frequency, sophistication and intensity, and have become increasingly difficult to detect. Cyber-attacks could include the deployment of harmful malware, ransomware, denial-of-service attacks, unauthorized access to or deletion of files, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information. Cyber-attacks also could include phishing attempts or e-mail fraud to cause payments or information to be transmitted to an unintended recipient.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we experience any material system failure, accident, cyber-attack, or security breach that causes interruptions in our operations, it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed and the further development and commercialization of our product candidates could be delayed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">111</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our employees, independent contractors, including principal investigators, consultants and vendors and any third parties we may engage in connection with research, development, regulatory, manufacturing, quality assurance and other pharmaceutical functions and commercialization may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading, which could cause significant liability for us and harm our reputation.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are exposed to the risk of fraud or other misconduct by our employees, independent contractors, including principal investigators, consultants and vendors and any other third parties we engage. Misconduct by these partners could include intentional, reckless or negligent conduct or unauthorized activities that include failures to comply with FDA regulations or similar regulations of comparable foreign regulatory authorities, provide complete and accurate information to the FDA or comparable foreign regulatory authorities, comply with manufacturing standards, comply with federal and state data privacy, security, fraud and other healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, report complete financial information or data accurately or disclose unauthorized activities to us. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. This could include violations of HIPAA, other U.S. federal and state law, and requirements of non-U.S. jurisdictions, including the European Union Data Protection Directive. We are also exposed to risks in connection with any insider trading violations by employees or others affiliated with us. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws, standards, regulations, guidance or codes of conduct. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid, other U.S. federal healthcare programs or healthcare programs in other jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to our Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our executive officers, directors and principal stockholders, if they choose to act together, have the ability to control or significantly influence all matters submitted to stockholders for approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 7, 2024, our executive officers and directors and our stockholders who owned more than 5% of our outstanding common stock, in the aggregate, owned shares representing approximately 54% of our capital stock. As a result, if these stockholders were to choose to act together, they would be able to control or significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would control the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This concentration of ownership control may:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delay, defer or prevent a change in control; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">entrench our management and board of directors; or </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delay or prevent a merger, consolidation, takeover or other business combination involving us that other stockholders may desire. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">112</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Provisions in our corporate charter documents and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current directors and members of management.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Provisions in our certificate of incorporation and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of our company that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish a classified board of directors such that only one of three classes of directors is elected each year; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">allow the authorized number of our directors to be changed only by resolution of our board of directors; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">limit the manner in which stockholders can remove directors from our board of directors; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">limit who may call stockholder meetings; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">require the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to cast to amend or repeal specified provisions of our certificate of incorporation or bylaws. </span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law (the "DGCL") which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The price of our common stock is volatile and fluctuates substantially, which could result in substantial losses for our stockholders.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The trading price of our common stock has been, and is likely to continue to be, volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. The stock market in general and the market for smaller biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The market price for our common stock may be influenced by many factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.66525540221037%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">results of or developments in preclinical studies and clinical trials of our product candidates or those of our competitors or potential collaborators; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.66525540221037%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our success in commercializing our product candidates, if and when approved; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.66525540221037%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the success of competitive products or technologies; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.66525540221037%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory actions with respect to our product candidates; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.66525540221037%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory or legal developments in the United States and other countries; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.66525540221037%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in physician, hospital, or healthcare provider practices; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">113</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.66525540221037%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">developments or disputes concerning patent applications, issued patents or other intellectual property or proprietary rights; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.66525540221037%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the recruitment or departure of key personnel; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.66525540221037%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the level of expenses related to any of our product candidates or clinical development programs; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.66525540221037%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the results of our efforts to discover, develop, acquire or in-license products, product candidates or technologies, the costs of commercializing any such products, and the costs of development of any such product candidates or technologies; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.66525540221037%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.66525540221037%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">variations in our financial results or the financial results of companies that are perceived to be similar to us; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.66525540221037%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">announcements by us, our partners or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations, or capital commitments; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.66525540221037%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">sales of common stock by us, our executive officers, directors or principal stockholders, or others; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.66525540221037%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in the structure of healthcare payment systems; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.66525540221037%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">market conditions in the pharmaceutical and biotechnology sectors; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.66525540221037%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">general economic, industry, and market conditions; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.66525540221037%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the other factors described in this &#8220;Risk Factors&#8221; section. </span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class-action litigation has often been instituted against that company. Any lawsuit to which we are a party, with or without merit, may result in an unfavorable judgment. We also may decide to settle lawsuits on unfavorable terms. Any such negative outcome could result in payments of substantial damages or fines, damage to our reputation or adverse changes to our offerings or business practices. Such litigation may also cause us to incur other substantial costs to defend such claims and divert management&#8217;s attention and resources. Furthermore, negative public announcements of the results of hearings, motions or other interim proceedings or developments could have a negative effect on the market price of our common stock.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">An active trading market for our common stock may not be sustained.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although our common stock is listed on the Nasdaq Global Select Market, an active trading market for our shares may not continue to develop or be sustained. As a result, it may be difficult for our stockholders to sell their shares without depressing the market price for the shares, or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If securities analysts do not publish or cease publishing research or reports or publish misleading, inaccurate or unfavorable research about our business or if they publish negative evaluations of our stock, the price and trading volume of our stock could decline.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The trading market for our common stock relies, in part, on the research and reports that industry or financial analysts publish about us or our business. There can be no assurance that existing analysts will continue to cover us or that new analysts will begin to cover us. There is also no assurance that any covering analyst will provide favorable coverage. Although we have obtained analyst coverage, if one or more of the analysts covering our business downgrade their evaluations of our stock or publish inaccurate or unfavorable research about our business, or provide more favorable relative recommendations about our competitors, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price and trading volume to decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">114</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If a significant portion of our total outstanding shares are sold into the market, the market price of our common stock could drop significantly, even if our business is doing well.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sales of a substantial number of shares of our common stock in the public market, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. Holders of a significant portion of our common stock have rights, subject to specified conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders.  We have also filed registration statements registering all shares of common stock that we may issue under our equity compensation plans. These shares can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently have on file with the SEC a universal shelf registration statement on Form S-3 which allows us to offer and sell up to $300.0 million of a variety of securities, including common stock, preferred stock, debt securities, depositary shares, subscription rights, warrants or units from time to time pursuant to one or more offerings at prices and terms to be determined at the time of sale. In addition, we have also entered into an Open Market Sale Agreement with Jefferies LLC, as sales agent, pursuant to which we may offer and sell shares of our common stock under a registration statement with an aggregate offering price of up to $50.0 million under an &#8220;at-the-market&#8221; offering program. To date, we have sold</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$21.2 million of securities pursuant to the Open Market Sale Agreement.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company,&#8221; and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are an &#8220;emerging growth company,&#8221; ("EGC") as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. We may remain an EGC until December 31, 2025, although if the market value of our common stock that is held by non-affiliates exceeds $700 million as of any June 30 before that time or if we have annual gross revenues of $1.235 billion or more in any fiscal year, we would cease to be an EGC as of December 31 of the applicable year. We also would cease to be an EGC if we issue more than $1 billion of non-convertible debt over a three-year period. For so long as we remain an EGC, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not EGCs. These exemptions include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reduced disclosure obligations regarding executive compensation; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7367350305163027%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, even after we no longer qualify as an EGC, we may still qualify as a &#8220;smaller reporting company,&#8221; which would allow us to take advantage of many of the same exemptions from disclosure requirements allowed for an EGC, including reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. In addition, if we are a smaller reporting company with less than $100 million in annual revenue, we would not be required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, or Section 404.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">115</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may choose to take advantage of some or all of the available exemptions. We cannot predict whether investors will find our common stock less attractive if we rely on certain or all of these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the JOBS Act permits an EGC to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have elected to use the extended transition period for complying with new or revised accounting standards and will do so until such time that we either (1) irrevocably elect to &#8220;opt out&#8221; of such extended transition period or (2) no longer qualify as an EGC. As a result of this election, our consolidated financial statements may not be comparable to companies that comply with public company Financial Accounting Standards Board standards&#8217; effective dates.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have incurred and will continue to incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a public company we have incurred, and particularly after we are no longer an EGC or a smaller reporting company, will continue to incur significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of the Nasdaq Global Select Market and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs, particularly as we hire additional financial and accounting employees to meet public company internal control and financial reporting requirements, and will make some activities more time-consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance, which in turn could make it more difficult for us to attract and retain qualified members of our board of directors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are evaluating these rules and regulations, and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 404, we are required to furnish a report by our management on our internal control over financial reporting. However, while we remain an EGC or a smaller reporting company with less than $100 million in revenue, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section 404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, including through hiring additional financial and accounting personnel, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section 404. If we identify one or more material weaknesses in our internal control over financial reporting, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be our stockholders&#8217; sole source of gain.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, our ability to pay cash dividends is currently restricted by the terms of our Loan Agreement, and future debt financing arrangements may contain terms prohibiting or limiting the amount of dividends that may be declared or paid on our common stock. As a result, capital appreciation, if any, of our common stock will be our stockholders&#8217; sole source of gain for the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">116</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our certificate of incorporation designates the state courts in the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could discourage lawsuits against the company and our directors, officers and employees.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery of the State of Delaware does not have jurisdiction, the federal district court for the District of Delaware) will, to the fullest extent permitted by law, be the sole and exclusive forum for (1) any derivative action or proceeding brought on our behalf, (2) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, employees or stockholders to our company or our stockholders, (3) any action asserting a claim arising pursuant to any provision of the DGCL or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware or (4) any action asserting a claim arising pursuant to any provision of our certificate of incorporation or bylaws (in each case, as they may be amended from time to time) or governed by the internal affairs doctrine. These choice of forum provisions will not apply to claims arising under the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, or any other claim for which federal courts have exclusive jurisdiction. Furthermore, our certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolution of any claims arising under the Securities Act of 1933, as amended.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These exclusive forum provisions may limit the ability of our stockholders to bring a claim in a judicial forum that such stockholders find favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees. If a court were to find such provisions contained in our certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could materially adversely affect our business, financial condition and operating results.</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1B. Unresolve</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">d Staff Comments.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1c_cybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1C. Cybersecurity.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have certain processes for assessing, identifying, and managing cybersecurity risks, which are built into our overall information technology function and are designed to help protect our information assets and operations from internal and external cyber threats, protect information from unauthorized access or attack, as well as secure our network and systems. Such processes include physical, procedural, and technical safeguards, response plans, regular tests on our systems, incident simulations, and routine review of our policies and procedures to identify risks and improve our practices. We engage certain external parties, including consultants, computer security firms and risk management, peer companies, industry groups, and governance experts, to enhance our cybersecurity oversight. We consider the internal risk oversight programs of third-party service providers before engaging them to help protect us from any related vulnerabilities. As part of our overall risk mitigation strategy, we also maintain cyber insurance coverage; however, such insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyber attacks, and other related breaches.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Audit Committee of our Board of Directors provides direct oversight over cybersecurity risk and provides periodic updates to the Board of Directors regarding such oversight. The Audit Committee receives periodic updates from management regarding cybersecurity matters and is notified between such updates regarding significant new cybersecurity threats or incidents.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Executive Director of Information Technology leads the operational oversight of company-wide cybersecurity strategy, policy, standards, and processes and works across relevant departments to assess and help prepare us and our employees to address cybersecurity risks. The Executive Director of Information Technology has over 25 years of experience working with life science companies and venture capital firms in the information technology field, a certificate from HarvardX (Cybersecurity: Managing Risk), and an active membership in Health-ISAC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have also established a cross-functional Cybersecurity Steering Committee, led by our Chief Executive Officer serving as the chair and consisting of other executive-level leaders, that is responsible for</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">providing leadership in the protection of information assets and technology. The committee members advise on and prioritize the development of information security initiatives, projects, and policies as advocates for our stakeholders. This committee is also charged with helping to resolve security and compliance risk issues affecting us.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In order to help deter and detect cyber threats, we provide all employees, including part-time and temporary employees, with a monthly data protection, cybersecurity, and incident response and prevention training and compliance program, which covers timely</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">117</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and relevant topics, including social engineering, phishing, password protection, confidential data protection, asset use, and mobile security, and educates employees on the importance of reporting all incidents immediately. We engage third-party vendors for 24/7 monitoring and comprehensive incident response measures. We also use technology-based tools to mitigate cybersecurity risks and to bolster our employee-based cybersecurity programs.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not believe that there are currently any known risks from cybersecurity threats that are reasonably likely to materially affect us or our business strategy, results of operations, or financial condition.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_properties"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2. Pr</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">operties.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our principal facilities consist of office and laboratory space in Boston, Massachusetts. We occupy approximately 8,499 square feet of office space under a lease that expires in October 2025. In addition, we occupy approximately 6,244 square feet of laboratory space under a lease that expires in December 2025. We do not own any real property. We believe that this office and laboratory space is sufficient to meet our current needs and that suitable additional space will be available as and when needed.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 3. Legal </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Proceedings.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are not currently a party to any material legal proceedings.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4_safety_disclosure"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 4. Mine Safety</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Disclosures.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">118</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART II</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_5_market_for_registrants_common_equ"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 5. 	Market for Registrant&#8217;s Common Equity, Related Sto</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ckholder Matters and Issuer Purchases of Equity Securities</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Market Information</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our common stock commenced trading under the symbol &#8220;INZY&#8221; on the Nasdaq Global Select Market on July 24, 2020. Prior to that time, there was no public market for our common stock.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Holders of Our Common Stock</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 7, 2024, there were approximately 31 holders of record of shares of our common stock. This number does not include stockholders for whom shares are held in &#8220;nominee&#8221; or &#8220;street&#8221; name.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dividend Policy</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings to fund the development and expansion of our business.  We do not anticipate paying any cash dividends for the foreseeable future. In addition, our ability to pay cash dividends is currently restricted by the terms of our Loan Agreement, and future debt financing arrangements may contain terms prohibiting or limiting the amount of dividends that may be declared or paid on our common stock. Any future determination to declare and pay dividends will be made at the discretion of our board of directors and will depend on then-existing conditions including our results of operations, financial condition, contractual restrictions, capital requirements, business prospects and other factors our board of directors may deem relevant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unregistered Sales of Equity Securities and Use of Proceeds</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent Sales of Unregistered Equity Securities</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We did not issue any securities that were not registered under the Securities Act of 1933, as amended (the "Securities Act"), during the 12 months ended December 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Proceeds from Initial Public Offering</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 28, 2020, we completed our IPO, pursuant to which we issued and sold 7,000,000 shares of our common stock at a public offering price of $16.00 per share, and on July 30, 2020, we sold an additional 1,050,000 shares of our common stock at a price of $16.00 per share pursuant to the exercise by the underwriters of their option to purchase additional shares.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The offer and sale of all of the shares of our common stock in our IPO were registered under the Securities Act pursuant to a registration statement on Form S-1 (File No. 333-239648), which was declared effective by the Securities and Exchange Commission (the "SEC") on July 23, 2020. BofA Securities, Inc., Cowen and Company, LLC, and Piper Sandler &amp; Co. acted as joint book-running managers for our IPO. Wedbush Securities Inc. acted as lead manager for our IPO. The offering commenced on July 23, 2020 and did not terminate until the sale of all of the shares offered.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We received aggregate gross proceeds from our IPO, inclusive of the exercise by the underwriters of their option to purchase additional shares, of approximately $128.8 million, or aggregate net proceeds of approximately $115.9 million after deducting underwriting discounts and commissions and offering expenses. None of the underwriting discounts and commissions or offering expenses were incurred or paid to directors or officers of ours or their associates or to persons owning 10% or more of our common stock or to any of our affiliates.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we have used all of the net proceeds from the IPO to fund clinical development of INZ-701, to fund our preclinical research and development activities, and for working capital and other general corporate purposes. There was no material change in our planned use of the net proceeds from our IPO as described in our final prospectus filed pursuant to Rule 424(b)(4) under the Securities Act with the SEC on July 24, 2020.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Issuer Purchases of Equity Securities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We did not purchase any of our registered securities during the period covered by this Annual Report on Form 10-K.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">119</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_6_selected_financial_data"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 6. [R</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">served].</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">120</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7_managements_discussion_analysis_f"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 7. Management&#8217;s Discussion and Analysis of </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial Condition and Results of Operations.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The following discussion and analysis of our financial condition and results of operations should be read together with our consolidated financial statements and the related notes appearing elsewhere in this Annual Report on Form 10-K. This discussion contains forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K, our actual results could differ materially from the results described in or implied by these forward-looking statements. For convenience of presentation some of the numbers have been rounded in the text below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. Through our in-depth understanding of a key biological pathway, we are pursuing the development of therapeutics that address pathologic mineralization and intimal proliferation to improve the underlying causes of these debilitating diseases. It is well established that low levels of plasma pyrophosphate ("PPi") drive pathologic mineralization and low levels of adenosine drive intimal proliferation in a number of rare diseases. We are initially focused on developing a novel therapy for diseases characterized by pathologic calcification and intimal proliferation, including ENPP1 Deficiency and ABCC6 Deficiency, as well as calciphylaxis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ENPP1 and ABCC6 Deficiencies are rare chronic, systemic, and progressive genetic diseases occurring over the course of a patient&#8217;s lifetime, starting as early as fetal development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and spanning into adulthood. These diseases represent a significant unmet medical need, with high mortality rates for infants with ENPP1 Deficiency and high levels of morbidity occurring for patients with these diseases throughout their lives. Calciphylaxis is a rare disorder with a high mortality rate that mostly affects patients with end- stage kidney disease (&#8220;ESKD&#8221;). There are currently no approved therapies for ENPP1 Deficiency, ABCC6 Deficiency, or calciphylaxis. Currently available treatments seek to minimize the manifestations of these diseases and do not address the underlying causes of these diseases.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our lead product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to metabolize extracellular adenosine triphosphate ("ATP") to generate PPi and adenosine monophosphate ("AMP"), which can be processed to phosphate and adenosine. This process is central to the regulation of calcium deposition throughout the body and is further associated with the inhibition of intimal proliferation, or narrowing and obstruction of blood vessels. We have generated robust proof of concept data in preclinical models of ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis demonstrating that INZ-701 prevented pathologic mineralization and skeletal abnormalities, led to improvements in overall health and survival, and prevented intimal proliferation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are currently conducting clinical trials of INZ-701 for the treatment of ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis. The U.S. Food and Drug Administration ("FDA") has granted orphan drug designation and the European Medicines Agency ("EMA") has granted orphan designation to INZ-701 for the treatment of ENPP1 Deficiency and ABCC6 Deficiency. The FDA has also granted fast track designation for INZ-701 for the treatment of ENPP1 Deficiency and rare pediatric disease designation for INZ-701 for the treatment of ENPP1 Deficiency.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2021, we initiated our Phase 1/2 clinical trial of INZ-701 in adult patients with ENPP1 Deficiency. In February 2023, we reported positive interim pharmacokinetic, pharmacodynamic, and safety data from this trial. In September 2023, we reported positive interim safety, pharmacokinetic, pharmacodynamic, and exploratory efficacy data from this trial. We expect to report topline data from the first three cohorts of the ongoing Phase 1/2 clinical trial of INZ-701 in adults with ENPP1 Deficiency in April 2024.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In April 2022, we initiated our Phase 1/2 clinical trial of INZ-701 in adult patients with ABCC6 Deficiency. In February 2023, we reported positive interim safety, pharmacodynamic, and pharmacokinetic data from this trial. In September 2023, we reported positive interim safety, pharmacokinetic, pharmacodynamic, and exploratory efficacy data from this trial. We expect to report topline data from the ongoing Phase 1/2 clinical trial of INZ-701 in adults with ABCC6 Deficiency in April 2024. Subject to regulatory review and sufficient funding, we plan to initiate a Phase 3 clinical trial of INZ-701 in patients with ABCC6 Deficiency in the first quarter of 2025.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2023, we initiated our Phase 1b, single arm, open-label clinical trial of INZ-701 (the "ENERGY-1 trial") designed primarily to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of INZ-701 in infants with ENPP1 Deficiency. We expect to report interim data from the ENERGY-1 trial in the second half of 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">121</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2023, we opened the first site for our pivotal trial of INZ-701 in pediatric patients with ENPP1 Deficiency (the "ENERGY-3 trial"), and patient recruitment is underway. We anticipate reporting topline data from the ENERGY-3 trial in mid-2025. Pending regulatory discussions and appropriate financial resources, we also plan to conduct a pivotal trial in adolescents and adults with ENPP1 Deficiency (the "ENERGY-4 trial"). We anticipate initiating a pivotal trial of INZ-701 in infants with ENPP1 Deficiency outside of the United States (the "ENERGY-2 trial") in the second half of 2024.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2024, we initiated SEAPORT-1, a Phase 1 clinical trial designed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of INZ-701 in up to 10 patients with ESKD receiving hemodialysis. Patients will receive 1.8 mg/kg of INZ-701 once weekly coinciding with their hemodialysis treatment for a total of 30 days. The trial&#8217;s primary endpoint will assess safety and change from baseline plasma PPi concentration, with secondary endpoints including pharmacokinetic and pharmacodynamic parameters. We plan to report topline data from SEAPORT-1 in the fourth quarter of 2024 and expect data from this trial to inform our study design for patients with calciphylaxis in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subject to successfully completing clinical development of INZ-701 in ENPP1 and ABCC6 Deficiencies, we plan to seek marketing approvals for INZ-701 on a worldwide basis. Beyond our development focus on INZ-701, we believe that our therapeutic approach has the potential to benefit patients suffering from additional diseases of pathologic mineralization and intimal proliferation, including those without a clear genetic basis. We are also exploring the potential for development of a gene therapy for ENPP1 Deficiency.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Executive Summary</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the three months ended December 31, 2023, we continued to advance our ongoing clinical trials of INZ-701 in patients with ENPP1 and ABCC6 Deficiencies. Key highlights and accomplishments during the year ended December 31, 2023 through March 12, 2024, as well as upcoming anticipated milestones, include:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Key Highlights</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We initiated the clinical development program of INZ-701 for the treatment of calciphylaxis and launched the Phase 1 SEAPORT-1 trial of INZ-701 in up to 10 patients with ESKD receiving hemodialysis. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We launched a global patient registry in partnership with GACI Global to advance the understanding of ENPP1 Deficiency and infantile-onset ABCC6 Deficiency.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We initiated the ENERGY-3 pivotal trial of INZ-701 in pediatric patients with ENPP1 Deficiency.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We announced the inclusion of ABCC6 and ENPP1 in the initial list of genes selected for the Genomic England Generation Study, which was developed to advance early detection of rare genetic conditions, with the goal of setting a new standard for newborn screening programs.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We announced positive interim data from the ongoing Phase 1/2 trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency (pseudoxanthoma elasticum). Data suggested clinical benefit for ENPP1 Deficiency, including improvement in key bone biomarkers, patient reported outcomes, and functional outcomes. Improvement in the Global Impression of Change was observed in all three dose cohorts in the ABCC6 Deficiency trial.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Following meetings with the U.S. FDA and the Paediatric Committee of the EMA, we announced our global development strategy of INZ-701 for the treatment of ENPP1 Deficiency. Change in PPi will serve as the primary endpoint in the U.S and co-primary endpoint in the EU for the ENERGY-3 pivotal trial in pediatric patients. Based on regulatory feedback from the FDA and EMA, positive data from the ongoing and planned clinical trials of INZ-701 in patients with ENPP1 Deficiency, including comprehensive data demonstrating clinical impact of plasma PPi, could provide the basis for the our submission of marketing applications in both the U.S. and EU. These data will include final results from our ongoing Phase 1/2 trial in adult patients with ENPP1 Deficiency, available results from our ongoing ENERGY-1 trial, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, available results from the planned pivotal ENERGY-2 trial in infants to be initiated ex-U.S., and final results from the ongoing pivotal ENERGY-3 trial in pediatric patients.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Select Anticipated Milestones for INZ-701</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ENPP1 Deficiency</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to report topline data from the first three cohorts of the ongoing Phase 1/2 clinical trial of INZ-701 in adults with ENPP1 Deficiency in April 2024.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">122</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We anticipate initiating the ENERGY-2 trial, a pivotal trial of INZ-701 in infants with ENPP1 Deficiency, outside of the United States in the second half of 2024.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to report interim data from the ENERGY-1 trial, our ongoing Phase 1b clinical trial of INZ-701 for infants with ENPP1 Deficiency, in the second half of 2024.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We anticipate reporting topline data from the ENERGY-3 trial in mid-2025. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ABCC6 Deficiency</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to report topline data from the ongoing Phase 1/2 clinical trial of INZ-701 in adults with ABCC6 Deficiency in in April 2024.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subject to regulatory review and sufficient funding, we plan to initiate a Phase 3 clinical trial of INZ-701 in patients with ABCC6 Deficiency in the first quarter of 2025.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Calciphylaxis</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We initiated SEAPORT-1, a Phase 1 clinical trial designed to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of INZ-701 in up to 10 patients with ESKD receiving hemodialysis in February 2024, and we plan to report topline data in the fourth quarter of 2024. We expect data from this trial to inform our study design for patients with calciphylaxis in the future.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our Operations</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not yet commercialized any products or generated any revenue from product sales. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, securing intellectual property rights, conducting research and development activities, conducting preclinical studies and early-stage clinical trials, establishing arrangements for the manufacture of INZ-701, and longer-term planning for potential commercialization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since inception, we have incurred significant operating losses. Our ability to generate revenue from product sales sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of INZ-701 or one or more of our future product candidates and programs. Our net losses were $71.2 million and $67.1 million for the years ended December 31, 2023 and 2022, respectively. As of December 31, 2023, we had an accumulated deficit of $285.9 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our total operating expenses were $75.6 million and $68.7 million for the years ended December 31, 2023 and 2022, respectively. We expect to continue to incur significant operating expenses for the foreseeable future. In addition, if we obtain marketing approval for INZ-701 or any other product candidate we develop, we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing, and distribution. We have incurred and expect to continue to incur additional costs associated with operating as a public company.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result, we will need to obtain substantial additional funding to support our continuing operations. Until such time, if ever, as we can generate significant revenues from product sales, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, and marketing, distribution and licensing arrangements. We do not have any committed external source of funds, other than under our loan and security agreement with K2 HealthVentures LLC ("Loan Agreement"). Our ability to borrow under our Loan Agreement is subject to our satisfaction of specified conditions and lender discretion. If we are unable to raise capital or obtain adequate funds when needed or on acceptable terms, we may be required to delay, limit, reduce, or terminate our research and development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. In addition, attempting to secure additional financing may divert the time and attention of our management from day-to-day activities and distract from our research and development efforts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our pipeline of product candidates, or even continue our operations.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 14, 2022, we entered into an underwriting agreement with Jefferies LLC and Cowen and Company, LLC, relating to an underwritten offering of 16,276,987 shares of our common stock (the "April 2022 Shares"), and, in lieu of common stock to certain investors, pre-funded warrants to purchase 3,523,013 shares of common stock. The closing of the offering took place</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">123</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">on April 19, 2022. The offering price of the April 2022 Shares was $3.69 per share, and the offering price of the pre-funded warrants was $3.6899 per share underlying each pre-funded warrant. Net proceeds from the offering were approximately $68.3 million, after deducting underwriting discounts and commissions and offering expenses. As of February 2023, all of the pre-funded warrants had been exercised by means of cashless exercise.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 25, 2022, we entered into the Loan Agreement with K2HV (which we refer to, together with any other lender from time to time party thereto, as the Lenders), K2HV, as administrative agent for the Lenders, and Ankura Trust Company, LLC, as collateral agent for the Lenders. The Loan Agreement provides up to $70.0 million principal in term loans consisting of (subject to certain customary conditions): (i) a first tranche commitment of $25.0 million, of which $5.0 million was funded at closing and of which the remaining $20.0 million was funded at our election on February 15, 2023, or collectively, the First Tranche Commitment, (ii) two subsequent tranche commitments totaling $20.0 million in the aggregate to be drawn at our option during certain availability periods, subject to the achievement, as determined by the administrative agent in its sole discretion, of certain time-based, financial, clinical and regulatory milestones relating to INZ-701, which were funded during June and December 2023, and (iii) a fourth tranche commitment of $25.0 million available to be drawn at our option through August 31, 2025, subject to use of proceeds limitations and Lender&#8217;s consent in its discretion.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The facility carries a 48-month term with interest only payments for 36 months and then interest and equal principal payments for the next 12 months. The term loan will mature on August 1, 2026 and bears a variable interest rate equal to the greater of (i) 7.85% and (ii) the sum of (A) the prime rate last quoted in The Wall Street Journal (or a comparable replacement rate if The Wall Street Journal ceases to quote such rate) and (B) 3.85%; provided that the interest rate cannot exceed 9.60%. We may prepay, at our option, all, but not less than all, of the outstanding principal balance and all accrued and unpaid interest with respect to the principal balance being prepaid of the term loans, subject to a prepayment premium to which the Lenders are entitled and certain notice requirements. We paid the Lenders certain customary fees and expenses at closing and are required to pay the Lenders additional fees that may be due upon maturity or prepayment such as final payment fees and prepayment fees. As security for its obligations under the Loan Agreement, we granted the Lenders a first priority security interest on substantially all of our assets (other than intellectual property), subject to certain exceptions. The Lenders may elect, prior to the full repayment of the term loans, to convert up to $5.0 million of outstanding principal of the term loans into shares of our common stock, at a conversion price of $6.21 per share, subject to customary adjustments and 9.99% and 19.99% beneficial ownership limitations.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subject to certain conditions, we granted the Lenders the right, prior to repayment of the term loans, to invest up to $5,000,000 in the aggregate in our future offerings of common stock, convertible preferred stock, or other equity securities that are broadly marketed and offered to multiple investors, on the same terms, conditions, and pricing afforded to others participating in any such financing.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 27, 2023, we entered into an underwriting agreement with BofA Securities, Inc., Cowen and Company, LLC, and Piper Sandler &amp; Co., as representatives of the several underwriters named therein, relating to an underwritten public offering of 14,375,000 shares of our common stock, which included 1,875,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares (the "July 2023 Shares"). The closing of the offering took place on August 1, 2023. The offering price of the July 2023 Shares was $4.80 per share. Net proceeds from the offering were approximately $64.4 million, after deducting underwriting discounts and commissions and offering expenses.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had cash, cash equivalents, and short-term investments of approximately $188.6 million and we had $45.0 million of outstanding principal indebtedness under our Loan Agreement. We believe that our existing cash, cash equivalents, and short-term investments as of December 31, 2023 will enable us to fund our cash flow requirements into the fourth quarter of 2025. We have based this estimate on assumptions that may prove to be wrong, and our operating plan may change as a result of many factors currently unknown to us. See &#8220;Liquidity and Capital Resources.&#8221;</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To finance our operations beyond that point, we will need to raise additional capital, which cannot be assured. We anticipate that our expenses will increase substantially if and as we:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">conduct our ongoing Phase 1/2 clinical trials of INZ-701 for adults with ENPP1 and ABCC6 Deficiencies, our ongoing Phase 1b clinical trial of INZ-701 for infants with ENPP1 Deficiency, our ongoing pivotal trial of INZ-701 in pediatrics with ENPP1 Deficiency, and our ongoing Phase 1 clinical trial of INZ-701 in patients with ESKD receiving hemodialysis; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">prepare for, initiate, and conduct our planned clinical trials of INZ-701 for patients with ENPP1 and ABCC6 Deficiencies, including our planned pivotal clinical trials of INZ-701 for infants, and in adolescents and adults with ENPP1 Deficiency, and our planned Phase 3 clinical trial of INZ-701 for patients with ABCC6 Deficiency; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">conduct research, preclinical testing, and clinical trials of INZ-701 for additional indications; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">conduct research, preclinical testing, and clinical trials of other product candidates; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">124</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">engage in regulatory interactions with the FDA, the EMA, and other regulatory authorities;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">submit regulatory filings and seek marketing approval for INZ-701 or any other product candidate if it successfully completes clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">scale up our manufacturing processes and capabilities;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish a sales, marketing, and distribution infrastructure to commercialize any product candidate for which we may obtain marketing approval; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in-license or acquire additional technologies or product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">make any payments to Yale University ("Yale") under our license agreement or sponsored research agreement with Yale; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">maintain, expand, enforce, and protect our intellectual property portfolio; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">hire additional clinical, regulatory, quality control, scientific, and commercial personnel;  </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">add operational, financial, and management information systems and personnel, including personnel to support our research, product development, and planned future commercialization efforts and our operations as a public company; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">make any principal and interest payments when due under the terms of the Loan Agreement.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial Operations Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development activities are central to our business model. Research and development costs consist of direct and indirect costs related to specific projects as well as fees paid to other entities that conduct certain research and development activities on our behalf and primarily relate to costs incurred in connection with the discovery and development of our lead product candidate, INZ-701.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expense research and development costs as incurred. These expenses include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fees and expenses incurred in connection with the in-license of technology and intellectual property rights; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expenses incurred under agreements with third parties, including contract research organizations ("CROs"), and other third parties that conduct research, preclinical, and clinical activities on our behalf as well as third parties that manufacture our product candidates for use in our preclinical studies and clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">manufacturing scale-up expenses and the costs of acquiring and manufacturing preclinical trial materials, including manufacturing validation batches; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">personnel-related expenses, consisting primarily of salaries, related benefits, and stock-based compensation expense for employees engaged in research and development functions; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs of acquiring laboratory supplies and developing preclinical studies and clinical trial materials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">costs related to compliance with regulatory requirements; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">an allocation of facilities costs, which include depreciation of equipment and expenses for rent, information technology, utilities, and other operating costs. </span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recognize external development costs based on an evaluation of the progress to completion of specific tasks using information provided to us by our service providers. We do not currently track research and development expenses by specific indication.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are currently conducting our Phase 1/2 clinical trials of INZ-701 for adults with ENPP1 Deficiency and ABCC6 Deficiency, our Phase 1b ENERGY-1 trial for infants with ENPP1 Deficiency, our pivotal ENERGY-3 trial of INZ-701 for pediatric patients with ENPP1 Deficiency, and our Phase 1 SEAPORT-1 clinical trial of INZ-701 for up to 10 patients with ESKD receiving hemodialysis. Product candidates in later stages of clinical development generally have higher development costs than those in preclinical development or in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect that our research and development costs will continue to increase substantially for the foreseeable future as we execute on our global development strategy, prepare for and conduct our ongoing and planned clinical trials of INZ-701, further</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">125</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">scale our manufacturing processes, advance development of INZ-701 for additional indications, and potentially develop additional product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses consist primarily of salaries, related benefits, travel, and stock-based compensation expense for personnel in executive, finance, and administrative functions. General and administrative expenses also include professional fees for legal, consulting, accounting, tax, and audit services, and an allocation of facilities and information technology infrastructure costs. We incur, and anticipate that we will continue to incur, costs associated with being a public company, including costs of accounting, audit, legal, regulatory, compliance, and tax-related services related to maintaining compliance with requirements of Nasdaq and the Securities and Exchange Commission (the "SEC"); director and officer insurance costs; and investor and public relations costs. Additionally, we may experience an increase in payroll expense as a result of our preparation for potential commercial operations, especially related to sales and marketing costs. We expect that our general and administrative expenses will increase in future periods as we expand our operations and execute on our global development strategy.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest Income</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest income consists of income from bank deposits and investments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest Expense</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest expense consists of interest expense related to our Loan Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Expense, net</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other expense, net primarily consists of realized gains and losses on marketable securities and foreign exchange gains or losses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comparison of the Years Ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our results of operations for the years ended December 31, 2023 and 2022 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.477%;"/>
    <td style="width:1.399%;"/>
    <td style="width:1%;"/>
    <td style="width:10.776%;"/>
    <td style="width:1%;"/>
    <td style="width:1.399%;"/>
    <td style="width:1%;"/>
    <td style="width:10.776%;"/>
    <td style="width:1%;"/>
    <td style="width:1.399%;"/>
    <td style="width:1%;"/>
    <td style="width:10.776%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Increase<br/>(Decrease)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">54,847</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47,849</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,998</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,798</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,826</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(28</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75,645</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">68,675</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,970</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(75,645</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(68,675</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,970</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income (expense):</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,837</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,195</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,642</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(3,333</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(262</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(3,071</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other expense, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(28</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(319</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">291</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,476</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,614</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,862</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(71,169</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(67,061</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,108</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expense</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our research and development expenses for the years ended December 31, 2023 and 2022 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">126</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.477%;"/>
    <td style="width:1.399%;"/>
    <td style="width:1%;"/>
    <td style="width:10.776%;"/>
    <td style="width:1%;"/>
    <td style="width:1.399%;"/>
    <td style="width:1%;"/>
    <td style="width:10.776%;"/>
    <td style="width:1%;"/>
    <td style="width:1.399%;"/>
    <td style="width:1%;"/>
    <td style="width:10.776%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Increase</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">INZ-701-related research and development expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,564</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,336</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,228</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unallocated expenses:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Personnel-related expense (including stock-based compensation)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,563</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,637</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,926</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Facilities and administrative expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,720</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,876</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">844</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">54,847</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47,849</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,998</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expense increased $7.0 million for the year ended December 31, 2023 compared to the year ended December 31, 2022 primarily due to increases of $4.2 million in INZ-701-related research and development expense and $1.9 million in personnel-related expense.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INZ-701-related research and development expense increased $4.2 million primarily due to a $3.6 million increase in chemistry, manufacturing, and controls expense to support our ongoing clinical trials and prepare for potential commercialization and a $0.6 million increase in non-clinical research and development expense to support our ongoing clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Personnel-related expense increased $1.9 million primarily due to increased headcount needed to support our ongoing clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative Expense</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expense remained relatively flat for the year ended December 31, 2023 compared to the year ended December 31, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest Income</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest income increased $5.6 million for the year ended December 31, 2023 compared to the year ended December 31, 2022 primarily due to higher interest rates and a larger cash balance on which we were earning interest in 2023.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest Expense</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest expense increased $3.1 million for the year ended December 31, 2023 compared to the year ended December 31, 2022 primarily due to additional borrowings in 2023 under our Loan Agreement.</span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Expense, net</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other expense, net remained relatively flat for the year ended December 31, 2023 compared to the year ended December 31, 2022.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Liquidity and Capital Resources</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sources of Liquidity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since our inception, we have not generated any revenue and have incurred significant operating losses and negative cash flows from our operations. To date, we have funded our operations primarily with proceeds from the sales of convertible preferred stock, offerings of common stock and pre-funded warrants, and borrowings under our Loan Agreement. Until such time, if ever, as we can generate substantial revenues from product sales, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, and marketing, distribution, or licensing arrangements.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 11, 2021, we filed a universal shelf registration statement on Form S-3 (the "2021 Registration Statement"), which was declared effective on August 23, 2021. Under the 2021 Registration Statement, we may offer and sell up to $200.0 million of a variety of securities, including common stock, preferred stock, depositary shares, debt securities, warrants, subscription rights or units from time to time pursuant to one or more offerings at prices and terms to be determined at the time of the sale. In connection with the filing of the 2021 Registration Statement, we entered into an Open Market Sale Agreement with Jefferies LLC, as sales agent, pursuant to which we may offer and sell shares of our common stock with an aggregate offering price of up to $50.0 million under an &#8220;at-the-market&#8221; offering program. During</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the year ended December 31, 2023, we sold 3,553,995 shares of our common stock pursuant to the Open Market Sale Agreement for aggregate net proceeds of $21.2 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">127</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In April 2022, we closed an underwritten offering in which we sold 16,276,987 shares of common stock and pre-funded warrants to purchase 3,523,013 shares of common stock under the 2021 Registration Statement. Net proceeds from the offering were approximately $68.3 million, after deducting underwriting discounts and commissions and offering expenses.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2022, we entered into a Loan Agreement with the Lenders, which provides up to $70.0 million principal in term loans consisting of (subject to certain customary conditions): (i) a First Tranche Commitment of $25.0 million, of which $5.0 million was funded at closing and of which the remaining $20.0 million was funded at our election in February 2023, (ii) two subsequent tranche commitments totaling $20.0 million in the aggregate to be drawn at our option during certain availability periods, subject to the achievement, as determined by the administrative agent in its sole discretion, of certain time-based, financial, clinical, and regulatory milestones relating to INZ-701, of which $7.5 million was funded in June 2023 and the remaining $12.5 million was funded in December 2023, and (iii) a fourth tranche commitment of $25.0 million available to be drawn at our option through August 31, 2025, subject to use of proceeds limitations and Lender&#8217;s consent in its discretion. We have an aggregate of $45.0 million principal in term loans outstanding. The Lenders may elect to purchase up to $5.0 million of shares of our common stock pursuant to the Loan Agreement. Additional information on the Loan Agreement is described in Note 8 to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2023, we closed an underwritten offering in which we sold 14,375,000 shares of common stock under the 2021 Registration Statement. Net proceeds from the offering were approximately $64.4 million, after deducting underwriting discounts and commissions and offering expenses.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 7, 2023, we filed a universal shelf registration statement on Form S-3 (the &#8220;2023 Registration Statement&#8221;), which was declared effective on November 15, 2023. Under the 2023 Registration Statement, we may offer and sell up to $300.0 million of a variety of securities, including common stock, preferred stock, depositary shares, debt securities, warrants, subscription rights, or units from time to time pursuant to one or more offerings at prices and terms to be determined at the time of the sale.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash in excess of immediate requirements is invested primarily with a view to liquidity and capital preservation. The following table provides information regarding our total cash, cash equivalents, and short-term investments at December 31, 2023 and December 31, 2022 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34,588</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32,915</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">154,001</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">94,951</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash, cash equivalents, and short-term investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">188,589</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">127,866</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Flows</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table provides information regarding our cash flows for the years ended December 31, 2023 and 2022 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.953%;"/>
    <td style="width:1.6%;"/>
    <td style="width:1%;"/>
    <td style="width:12.903%;"/>
    <td style="width:1%;"/>
    <td style="width:1.6%;"/>
    <td style="width:1%;"/>
    <td style="width:12.943%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(70,675</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(57,761</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(53,646</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(5,403</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">125,969</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72,788</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net increase in cash, cash equivalents, and restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,648</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,624</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Cash Used in Operating Activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in operating activities increased approximately $12.9 million for the year ended December 31, 2023 compared to the year ended December 31, 2022 primarily due to a $4.1 million increase in our net loss, a $3.7 million adjustment for non-cash items, and a $3.1 million increase in payments against accounts payable and accrued expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Cash Used in Investing Activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in investing activities increased approximately $48.2 million for the year ended December 31, 2023 compared to the year ended December 31, 2022, as a $117.3 million increase in purchases of marketable securities exceeded a $69.0 million increase in maturities of marketable securities in the year ended December 31, 2023.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">128</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Cash Provided by Financing Activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash provided by financing activities increased approximately $53.2 million for the year ended December 31, 2023 primarily due to a $35.9 million increase in net proceeds received from the issuance of long-term debt and a $17.4 million increase in combined net proceeds received from the issuance of common stock and pre-funded warrants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Funding Requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to devote substantial financial resources toward our ongoing and planned activities, particularly as we execute on our global development strategy, conduct our ongoing clinical trials of INZ-701 for ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis, and continue research and development and initiate additional clinical trials of, and seek marketing approval for, INZ-701 and any other product candidates we develop. We expect our expenses to increase substantially in connection with our ongoing and planned activities. In addition, if we obtain marketing approval for INZ-701 or any other product candidates we develop, we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing, and distribution. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital or obtain adequate funds when needed or on acceptable terms, we may be required to delay, limit, reduce, or terminate our research and development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. In addition, attempting to secure additional financing may divert the time and attention of our management from day-to-day activities and distract from our research and development efforts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had cash, cash equivalents, and short-term investments of approximately $188.6 million, and we had $45.0 million of outstanding principal indebtedness under our Loan Agreement. We believe that our existing cash, cash equivalents, and short-term investments as of December 31, 2023 will enable us to fund our cash flow requirements into the fourth quarter of 2025. However, we have based this estimate on assumptions that may prove to be wrong, and our operating plan may change as a result of many factors currently unknown to us. In addition, changing circumstances could cause us to consume capital significantly faster than we currently anticipate, and we may need to spend more than currently expected because of circumstances beyond our control. As a result, we could deplete our capital resources sooner than we currently expect. In addition, because the successful development of INZ-701 and any other product candidates that we pursue is highly uncertain, at this time we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the development of any product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. We will not generate commercial revenues unless and until we can achieve sales of products, which we do not anticipate for a number of years, if at all. Accordingly, we will need to obtain substantial additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms. Our ability to raise additional funds may be adversely impacted by general economic conditions, both inside and outside the U.S., including disruptions to, and instability and volatility in, the credit and financial markets in the U.S. and worldwide, heightened inflation, interest rate and currency rate fluctuations, and economic slowdown or recession as well as concerns related to health epidemics and geopolitical events, including ongoing wars or civil or political unrest. In addition, market instability and volatility, high levels of inflation and interest rate fluctuations may increase our cost of financing or restrict our access to potential sources of future liquidity. In addition, market instability and volatility, high level of inflation and interest rate fluctuations may increase our cost of financing or restrict our access to potential sources of future liquidity.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Contractual Obligations, Commitments, and Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently lease office and laboratory space. Additional information about these leases and our commitments under them can be found in Note 7 to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have entered into a license agreement with Yale under which we are responsible to pay annual license maintenance fees, milestone payments and royalties. The amount, timing and likelihood of such milestone and royalty payments are not known. We have also entered into a sponsored research agreement with Yale under which we agreed to provide research support funding in the aggregate amount of $3.0 million over the eight year period from contract inception through December 2024. Additional information about these arrangements can be found in Note 6 to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have a Loan Agreement with K2HV under which we have borrowed $45.0 million as of the date of this Annual Report on Form 10-K. We are obligated to make interest only payments for the first 36 months and then interest and equal principal</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">129</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">payments through the maturity date, August 1, 2026. The loan bears a variable interest rate equal to the greater of (i) 7.85% and (ii) the sum of (A) the prime rate last quoted in The Wall Street Journal (or a comparable replacement rate if The Wall Street Journal ceases to quote such rate) and (B) 3.85%; provided that the interest rate cannot exceed 9.60%. Additional information about the Loan Agreement and our commitments under it can be found in Note 8 to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Critical Accounting Policies and Estimates</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While our significant accounting policies are described in more detail in the notes to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K, we believe that the following critical accounting estimates are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accrued Research and Development Expenses</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing purchase orders and open contracts, communicating with our personnel and suppliers to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the services when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly in arrears for services performed or when contractual milestones are met; however, some require advance payments. We make estimates of our accrued expenses as of each balance sheet date in our consolidated financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. The significant estimates in our accrued research and development expenses include the costs incurred for services performed by CROs and contract manufacturing organizations ("CMOs"), among others, in connection with research and development activities for which we have not yet been invoiced.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We contract with CROs and CMOs to conduct clinical and manufacturing and other research and development services on our behalf. We base our expenses related to CROs and CMOs on our estimates of the services received and efforts expended pursuant to quotes and contracts with them. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our CROs or CMOs will exceed the level of services provided and result in a prepayment of the research and development expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or amount of prepaid expense accordingly. Non-refundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in us reporting amounts that are too high or too low in any particular period. To date, there have been no material differences between our estimates of such expenses and the amounts actually incurred.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recently Issued Accounting Pronouncements</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 3 to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">130</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Emerging Growth Company Status</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Jumpstart Our Business Startups Act of 2012 permits an &#8220;emerging growth company&#8221; such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have elected to use the extended transition period for complying with new or revised accounting standards and will do so until such time that we either (1) irrevocably elect to &#8220;opt out&#8221; of such extended transition period or (2) no longer qualify as an emerging growth company.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7a_quantitative_qualitative_disclos"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 7A. Quantitative and Qualitati</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ve Disclosures About Market Risk</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are exposed to market risk related to changes in interest rates. As of December 31, 2023, our cash equivalents consisted primarily of short-term money market funds and U.S. Treasury securities. As of December 31, 2023, our short-term investments consisted of U.S. Treasury securities and U.S. government agency debt securities with maturities of less than one year. As of December 31, 2022, our short-term investments consisted of commercial paper and U.S. Treasury securities with maturities of less than one year. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. Due to the short-term nature of the investments in our portfolio and the low risk profile of our investments, an immediate change of 100 basis points in interest rates would not have a material effect on the fair market value of our investment portfolio or on our financial position or results of operations.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the aggregate principal amount outstanding under the Loan Agreement was $45.0 million, which bears interest at a variable rate equal to the greater of (i) 7.85% and (ii) the sum of (A) the prime rate last quoted in The Wall Street Journal (or a comparable replacement rate if The Wall Street Journal ceases to quote such rate) and (B) 3.85%; provided that the interest rate cannot exceed 9.60%. Of the $45.0 million aggregate principal amount outstanding, $5.0 million was funded at closing, and we borrowed an additional $20.0 million in February 2023, $7.5 million in June 2023, and $12.5 million in December 2023 under the Loan Agreement. The interest rate as of December 31, 2023 was 9.60%.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are not currently exposed to significant market risk related to changes in foreign currency exchange rates; however, we have contracted with and may continue to contract with foreign vendors that are located in Europe. Our operations may be subject to fluctuations in foreign currency exchange rates in the future.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inflation generally affects us by increasing our cost of labor and clinical trial costs. We do not believe that inflation had a material effect on our business, financial condition, or results of operations during the years ended December 31, 2023 and 2022.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">131</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_8_financial_statement_supplementary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 8. Financial Statemen</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ts and Supplementary Data.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:90%;"/>
    <td style="width:1%;"/>
    <td style="width:9%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Report of Independent Registered Public Accounting Firm (PCAOB ID: </span><span><ix:nonNumeric id="F_81ae238e-c3bd-4352-a75f-39950655b221" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="dei:AuditorFirmId"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">42</span></ix:nonNumeric></span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:36pt;vertical-align:top;text-align:center;"><p style="text-indent:-36pt;padding-left:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Balance Sheets</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:36pt;vertical-align:top;text-align:center;"><p style="text-indent:-36pt;padding-left:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_operations_compr"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:36pt;vertical-align:top;text-align:center;"><p style="text-indent:-36pt;padding-left:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_convertible_pref"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Stockholders&#8217; Equity</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:36pt;vertical-align:top;text-align:center;"><p style="text-indent:-36pt;padding-left:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Cash Flows</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:36pt;vertical-align:top;text-align:center;"><p style="text-indent:-36pt;padding-left:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_consolidated_financial_statemen"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:36pt;vertical-align:top;text-align:center;"><p style="text-indent:-36pt;padding-left:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the Stockholders and the Board of Directors of Inozyme Pharma, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Opinion on the Financial Statements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Inozyme Pharma, Inc. (the Company) as of December 31, 2023 and 2022, the related consolidated statements of operations and comprehensive loss, stockholders' equity and cash flows for each of the two years in the period ended December 31, 2023, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2023, in conformity with U.S. generally accepted accounting principles.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e0a6b3ff-9811-477f-9229-bf2454e25a20" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ernst &amp; Young LLP</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have served as the Company&#8217;s auditor since 2017.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f6d7f264-e60a-460c-a79b-72db2bf850db" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Boston, Massachusetts</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 12, 2024</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INOZYME PHARMA, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_balance_sheets"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED BA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">LANCE SHEETS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(amounts in thousands, except share and per share data)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:63.36%;"/>
    <td style="width:1.84%;"/>
    <td style="width:1%;"/>
    <td style="width:15.7%;"/>
    <td style="width:1%;"/>
    <td style="width:1.84%;"/>
    <td style="width:1%;"/>
    <td style="width:13.26%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current assets:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e87668de-7fbe-4f13-b70c-a39444163d40" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,588</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_48b79c04-2545-4109-a95c-6649004d0d72" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,915</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1afc5b19-36fb-4032-a596-25e307cfdeed" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">154,001</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f3213c74-a2c3-4a72-ae77-7cab01e0e54d" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,951</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_53dfb213-bcf3-4f8c-9649-ed73d2f60580" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,661</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_87fa15d8-e895-4c59-a47e-e12e2f48744f" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,527</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_492262ee-37c4-429c-8ae4-653d18f70fe9" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">196,250</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d0ef99c4-dd29-43b9-a688-9118400f992c" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">131,393</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d455e92d-a0af-4f20-a70b-a0903544179e" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,466</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_20cd13dd-eaef-428b-9739-486d70783746" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,018</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a3024496-de63-471c-8115-8be10c656cef" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,126</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_96bb6b0c-75a0-486d-a6cb-2a911e3c3249" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,620</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6d480a6a-cd5b-458f-9130-9a13e7af5815" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">311</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d702e491-3906-421c-abea-71594a95d803" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">354</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses, net of current portion</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3cc8d760-cab7-4e49-8a8f-c3e95e0662d4" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:PrepaidExpenseNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,694</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a061735-0c48-46af-b459-517772b19028" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:PrepaidExpenseNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,810</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_54f195f5-e4c5-4572-a0bd-8812370959cb" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">200,847</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ffd40d43-f450-47fb-9ffd-5eea7106e28e" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">139,195</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Liabilities and stockholders&#8217; equity</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_02a22c66-9872-45a2-afa4-674485502ae0" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,166</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6c08b599-0a12-4f42-9242-8bec07389748" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,544</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aca09502-86ff-4394-8649-c095da1d84c1" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,610</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_593f29be-f298-44d2-8120-851a966cad67" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,355</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa29ef63-0318-4457-b6e7-dd2f252a46d6" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">910</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_65b5cbc2-79f9-4adc-aa0f-9ae752d5d180" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">816</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ecc6f7d-bacb-47d3-b903-74d2c9ab0b9a" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,686</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bee10824-20bd-4675-8d7d-6ec1696bbb08" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,715</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities, net of current portion</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7531cb34-c39f-4f51-b7ed-3229e11a235d" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">913</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_110b6d65-37a3-4bca-ae36-f7e3e8f19fe2" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,823</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term debt, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd7ccee9-b828-4bb8-8182-451fa54ec280" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,769</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_967f9abc-ddc1-4ce0-9aca-9008d9c1eb41" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,139</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other long-term liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_689539cd-f0c7-4d21-aacd-6150cefcfc11" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0ff3e796-513b-4f0a-83cf-24365d365e09" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">124</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c6d3e260-4364-44e0-9745-185194c597ab" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60,368</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af3e8487-4f15-4092-aa0e-6b0b39e92a86" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,801</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9.5pt;"><span style="-sec-ix-hidden:F_6360d63f-17d5-4de6-a919-fd4922754e06;"><span style="-sec-ix-hidden:F_639d92d0-6f7f-4b32-af29-72c21c77075a;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commitments and contingencies (Note 7)</span></span></span></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stockholders&#8217; equity:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;min-width:fit-content;">Preferred Stock, $</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_606c3ac6-4c39-407b-944e-08a1c9db856a" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c2ed5047-0821-4ecc-9cbb-4a3aa9d727aa" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;min-width:fit-content;">&#160;par value - </span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4e405eab-416f-4c71-a1b4-9ed05b24a10a" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_f61499b0-ddee-4f23-b561-c216e2fc455a" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;min-width:fit-content;">&#160;shares authorized at December 31, 2023 and December 31, 2022; </span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc1e19b9-79af-4ca9-b71d-e1aac2af5d59" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_f144b5da-225b-43c8-9593-a37cf02c122b" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_a4572e8a-f8a9-49e0-9fa6-e399b29aa9b2" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_c20a6f0b-af7e-44c1-a687-6b60c8bbab35" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;min-width:fit-content;">&#160;shares issued and outstanding at December 31, 2023 or December 31, 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e41c39a3-3064-4010-8db3-4a694d0ea4d1" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2767c2f2-b9c9-4164-8094-2dd3e2497b22" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;min-width:fit-content;">Common Stock, $</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_845648c7-7088-490f-8d2b-498e35805cf6" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal"><ix:nonFraction id="F_9160af8c-5bd3-4693-91c9-dfbfb4428fb8" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;min-width:fit-content;">&#160;par value &#8211; </span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4cfeaf90-a3de-435f-95c2-c20b3d41ed30" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_db642a05-ba43-431e-878f-2f1d5b68ef19" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">200,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;min-width:fit-content;">&#160;shares authorized at December 31, 2023 and December 31, 2022; </span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ac81c27-fc95-4ec1-a7e6-84215eb316bc" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_d8ed6275-9c4d-4a76-b470-ff7284a4c4d8" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">61,768,771</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;min-width:fit-content;">&#160;shares issued and outstanding at December 31, 2023 and </span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_44e268ea-16b7-4097-8f74-6e8dd700f25d" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_7d40ae9c-02f8-466d-853a-8c2307a56966" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">40,394,363</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;min-width:fit-content;">&#160;shares issued and outstanding at December 31, 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_662a5fea-b9fb-41c2-acf7-bf1c4d674966" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ebc340e0-ccfb-410d-9347-6854569138ba" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additional paid in-capital</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8c7c30c8-c676-4ebf-b1a5-04430d4f88b3" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">426,362</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f54d4b9-cb69-4e0e-9502-e0daa4cff21d" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">333,356</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated other comprehensive income (loss)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a22a98a-8bc6-4603-9a05-37172c4d116c" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_db1cfa16-d27f-4a27-8b94-dcc425388e6b" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">205</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d5d76e65-9d85-4fca-91a1-f733554f243f" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">285,930</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_93cde37f-2e0d-4cf1-bebb-331eb8cfe310" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">214,761</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stockholders&#8217; equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d466fa9e-039f-49e8-8328-1e2a0ed9eca7" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">140,479</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_60f2d72e-e385-4ab3-a3f7-0da3ac09790e" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">118,394</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities and stockholders&#8217; equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_10666dca-8343-48da-843c-9dac5b3fbbd0" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">200,847</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1da499e2-bf09-453d-b169-831406b88acd" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">139,195</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INOZYME PHARMA, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_operations_compr"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED STATEMENTS OF OPERA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TIONS AND COMPREHENSIVE LOSS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(amounts in thousands, except share and per share data)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:65.52%;"/>
    <td style="width:1.72%;"/>
    <td style="width:1%;"/>
    <td style="width:12.66%;"/>
    <td style="width:1%;"/>
    <td style="width:1.72%;"/>
    <td style="width:1%;"/>
    <td style="width:12.66%;"/>
    <td style="width:1%;"/>
    <td style="width:1.72%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="8" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_127f0459-376d-4eea-89b4-ff072a47a6a8" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">54,847</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_44126002-cbe5-42fc-bf5b-6751c112dd14" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,849</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11940b97-832a-46b6-b1d5-31d6f4f5d715" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,798</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f16ea773-c439-4a78-896f-36c1504b820e" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,826</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f9dcb64-9ef6-4de2-a75d-f4c9fdb90f0b" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75,645</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5a2bba18-ca30-4fb8-91b7-8bf2146d326e" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,675</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_735165d3-f545-4b22-b454-408652d30a16" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">75,645</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b863e69b-df4a-4df2-ab57-eeacd3221b5a" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">68,675</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income (expense):</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0d19c8fb-5d4e-49bb-a4fa-8ea07293b97b" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,837</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7fa7c9db-8a18-4080-bece-17e1d16cc4e9" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,195</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_74e1b48d-d4f5-407d-919a-433271f4eb3f" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,333</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5bd157e9-182c-45f8-8e48-0f9f4dbaf3eb" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">262</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other expense, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b95b1d97-7456-457a-9037-ba0f87533657" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">28</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e43e834-f835-4511-9ae9-669fe079d311" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">319</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_efb5c671-d799-4eb2-8a9f-56ed2659ab30" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,476</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_767d9b5a-083c-43b6-96b1-913f3a017bed" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,614</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_326ad914-556d-4a3a-8e7e-eebe4d6863e1" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">71,169</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6fa7983e-d11d-4581-9586-9a74c16394ad" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">67,061</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other comprehensive income (loss):</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized gains (losses) on available-for-sale securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7192d4c1-3a23-4c2e-8d15-ba6e4893e3d7" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">264</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f3f5a970-87e0-49a9-86e9-0c11ab11a03f" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">198</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign currency translation adjustment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a3bc603-68f9-4b8a-9106-d1763903a032" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">18</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a3669cf6-a8dd-4276-9289-98ec6f552638" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">25</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total other comprehensive income (loss)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e25f2ff4-ef61-4c17-ae3b-59341f66e8d8" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">246</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c7751aee-4fa5-491d-a73f-309f419a8b81" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">223</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Comprehensive loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_32657b80-ca26-4890-b79c-a7c8bbf0bc70" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">70,923</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ba8c427-3555-44cf-852d-9da09d6289aa" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">67,284</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss attributable to common stockholders&#8212;basic<br/>&#160;&#160;&#160;and diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d248df69-7094-4f33-be1f-c8ff75b18397" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">71,169</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5167bdbb-d435-4124-aa47-415cf4ba5c7c" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">67,061</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share attributable to common<br/>&#160;&#160;&#160;stockholders&#8212;basic and diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_45a8b82d-64de-4a11-9eea-9b62cdb2335d" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_202dbc0b-b402-4f3e-a55b-009855c54ba2" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.37</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_15d1915c-e993-4389-8a9b-187f082ee295" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_28b1feea-9f96-47b1-a195-056e4818f172" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.78</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average common shares outstanding&#8212;basic<br/>&#160;&#160;&#160;and diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7be21c9b-a21c-4b89-b8f2-dd56f4a1bc6d" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_fa58d197-3b71-4a7f-a9c6-cb8be1da4145" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">51,839,131</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4d9452b4-d9fe-42ae-9e0c-d268efda91bc" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_9d0cf1b0-a4f8-410f-9982-994df02e64ed" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">37,763,168</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INOZYME PHARMA, INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_convertible_pref"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED STATEMENTS OF </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">STOCKHOLDERS&#8217; EQUITY</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(amounts in thousands, except share data)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:24.27%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.896%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.556%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.556%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.556%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.556%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.616%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Additional<br/>Paid-in</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated<br/>Other<br/>Comprehensive</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total<br/>Stockholders&#8217;<br/>Equity</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Capital</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Income (Loss)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deficit</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Deficit)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bd80d53d-3fb4-4a14-a608-174d023864d5" contextRef="C_ba3b1d97-e28d-4318-9ed8-6d65ffffa8e5" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">23,668,747</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_df435f95-f36f-42ee-96cc-699d77aeb68c" contextRef="C_ba3b1d97-e28d-4318-9ed8-6d65ffffa8e5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0f81fa93-6ec5-4812-b191-bf34ce9ec983" contextRef="C_b69eb069-0d70-4c35-82e1-af14e7470196" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">256,948</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b94b75e9-4578-4af5-8e83-e9ae1443d3dd" contextRef="C_471a56d8-9599-49a3-ac22-3a686ca9ff8d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4fa5713e-aab7-44b3-bac7-9b8aac459d4b" contextRef="C_0ff899d6-441a-422c-b0bd-1738ae7e6c26" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">147,700</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_27ae67b9-a672-4e13-92ed-4bd11c168875" contextRef="C_f9151e1c-1a1c-4fd2-91c3-dfd8900bd0f6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">109,268</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f24179ed-6493-4003-8da6-ba188776df15" contextRef="C_6180172f-c35b-4d20-961c-b44a3488a278" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,672</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5a3c7630-bf5c-4d79-88a5-23dd43f3b8b9" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,672</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise of stock options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_379369d9-afa5-4b22-b513-5332fe506cff" contextRef="C_5f12b8c5-840c-4b80-aafb-3c8b57f8ed2e" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">210,977</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8620f425-f1f0-4f42-933e-e0802764e1d8" contextRef="C_6180172f-c35b-4d20-961c-b44a3488a278" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">359</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ea4d9ac3-5e4b-4471-95eb-d2789990766a" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">359</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock, net of issuance costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ef83508-e517-46c5-8f74-d73fa32667fb" contextRef="C_5f12b8c5-840c-4b80-aafb-3c8b57f8ed2e" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">16,276,987</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_99e21bd4-7be7-4fa8-ab38-1f3da141da49" contextRef="C_5f12b8c5-840c-4b80-aafb-3c8b57f8ed2e" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0f852d1f-a800-47d0-816b-023ea46a3646" contextRef="C_6180172f-c35b-4d20-961c-b44a3488a278" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56,135</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_60cf068b-ac72-4ecb-a916-caf60a1b081a" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56,137</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of pre-funded warrants, net of issuance costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_efeedcbe-3607-4bec-9742-52ed56297357" contextRef="C_6180172f-c35b-4d20-961c-b44a3488a278" name="inzy:IssuanceOfPreFundedWarrantsNetOfIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,150</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_08162773-9aab-4964-8260-eafb4d951e83" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="inzy:IssuanceOfPreFundedWarrantsNetOfIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,150</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise of pre-funded warrants</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_097e73a4-1827-4225-9a5d-7dadd7c29ac6" contextRef="C_5f12b8c5-840c-4b80-aafb-3c8b57f8ed2e" name="inzy:ExerciseOfPreFundedWarrants" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">197,240</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares purchased in Employee Stock Purchase Plan</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_426fbe2b-60ed-4f49-abfd-aaee768a7740" contextRef="C_5f12b8c5-840c-4b80-aafb-3c8b57f8ed2e" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">40,412</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b89d57b5-d921-4274-9f44-4a6b5200fa89" contextRef="C_6180172f-c35b-4d20-961c-b44a3488a278" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f05c5888-3c71-44cc-b60b-21e1864016fa" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other comprehensive loss:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized loss on investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e9fdc45f-4eb7-4198-9367-f31e9c3a9e99" contextRef="C_94c35e60-92f5-4512-bce8-5ad4b2e3d95d" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">198</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b28e338b-9428-4895-8abc-a316a2da644f" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">198</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign currency translation adjustment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_757e0bd8-552c-4da2-bdac-20e2dd2b7cbf" contextRef="C_94c35e60-92f5-4512-bce8-5ad4b2e3d95d" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">25</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dfd45012-4d83-4417-b5a7-442e130c081c" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">25</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_79306643-c87f-4ed9-8f06-d7ff83cd9e38" contextRef="C_4c84ce21-27ad-466f-a52b-53d2b027d662" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">67,061</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b23fb535-fd40-47da-8b7a-c83dd66683f1" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">67,061</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bd397cde-5007-45a0-a1eb-ba6a48a06d01" contextRef="C_c0269d4f-7dd7-4002-9ff8-a6effc16399e" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">40,394,363</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f528d80-007b-4832-b534-427d57342747" contextRef="C_c0269d4f-7dd7-4002-9ff8-a6effc16399e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_996760ad-2e2e-4c05-9dab-72c419b72d44" contextRef="C_577acb1e-1a50-479e-a43c-9ea32fcb780c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">333,356</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5973a9a1-adbf-4630-844c-171b70b42b4b" contextRef="C_ba5b64e4-70b0-4502-8294-ad245be4038c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">205</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e290c9f-f210-420e-9de0-41206c0ae7b1" contextRef="C_f33f58db-c8e7-4f41-ad0b-b1c08a56375f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">214,761</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a52f98bf-e2dc-4416-9a47-88340aeac0e8" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">118,394</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fab1bbfc-5ac9-4a16-b247-28a0913c5cca" contextRef="C_e5909b1a-428c-48ad-8908-9d3d49539a18" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,037</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6f88dc4d-f69e-476c-8094-3f4c62d4de61" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,037</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise of pre-funded warrants</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_665d6f54-1411-4d1b-bf37-35b4fe842fc9" contextRef="C_3069d94b-0504-4b09-8332-ed3b1c11af61" name="inzy:ExerciseOfPreFundedWarrants" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,325,644</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares issued in at-the-market offering</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a3d67d61-1bbe-4995-bdcb-1a42c108b256" contextRef="C_3069d94b-0504-4b09-8332-ed3b1c11af61" name="inzy:StockIssuedDuringPeriodSharesIssuedInAtTheMarketOffering" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,553,995</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_faa9cbbe-aca6-4313-96e4-580b2bffe55d" contextRef="C_3069d94b-0504-4b09-8332-ed3b1c11af61" name="inzy:StockIssuedDuringPeriodValueSharesIssuedInAtTheMarketOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d2423a1-8612-439a-b18c-c0112d5e39d5" contextRef="C_e5909b1a-428c-48ad-8908-9d3d49539a18" name="inzy:StockIssuedDuringPeriodValueSharesIssuedInAtTheMarketOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,235</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f2a740af-8d8e-48dd-bc0a-aa92db88071a" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="inzy:StockIssuedDuringPeriodValueSharesIssuedInAtTheMarketOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,236</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise of stock options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_015a0ada-46c6-4854-876a-047ff3df746d" contextRef="C_3069d94b-0504-4b09-8332-ed3b1c11af61" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">43,209</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ae56836-4449-42aa-b772-d5cbcd351183" contextRef="C_3069d94b-0504-4b09-8332-ed3b1c11af61" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_beb07fce-0b97-4bf9-8cb6-855f6347c7cb" contextRef="C_e5909b1a-428c-48ad-8908-9d3d49539a18" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_89793a84-da66-47da-aaff-3a28079af62f" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">117</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock, net of issuance costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f1b32b55-5ab4-4984-b4a6-eb008acf4491" contextRef="C_3069d94b-0504-4b09-8332-ed3b1c11af61" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">14,375,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c0281e41-7a72-4d4d-85f4-40868afd27f7" contextRef="C_e5909b1a-428c-48ad-8908-9d3d49539a18" name="inzy:IssuanceOfPreFundedWarrantsNetOfIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,412</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_371a11a3-619d-4634-8406-a1f13a3be007" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="inzy:IssuanceOfPreFundedWarrantsNetOfIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,412</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares purchased in Employee Stock Purchase Plan</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_609bab41-509c-499e-bdad-b77723b637f9" contextRef="C_3069d94b-0504-4b09-8332-ed3b1c11af61" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">76,560</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1fba7cf7-0c43-4218-a2ec-026997a566a5" contextRef="C_e5909b1a-428c-48ad-8908-9d3d49539a18" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">206</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e3d418c3-8e2e-43b3-91c5-78b85be3a05a" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">206</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other comprehensive income (loss):</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized gain on investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8bccd545-45d7-4fee-9552-28a3a46f2a7d" contextRef="C_46f9ae16-b8c7-4213-9f64-dc61525d4c66" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">264</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5b71a7b4-d4ff-46cd-a349-79a2a9c25435" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">264</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign currency translation adjustment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f3c0ed44-541c-4159-9f3d-d205006ec392" contextRef="C_46f9ae16-b8c7-4213-9f64-dc61525d4c66" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">18</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_840543b8-ce7d-4803-a78d-a5ec527686a4" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">18</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_06302b53-4e35-478a-91e4-2f28d505544b" contextRef="C_8f92c86f-a41e-44a3-8900-38efa4b160f5" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">71,169</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11b129ab-6eea-4b16-9279-130ba9052d43" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">71,169</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4c41c10d-be39-49d9-bdc9-a6462fb1ab30" contextRef="C_b153501c-2297-4e17-905e-f0f97a1348d3" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">61,768,771</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e3d4e7ff-84e3-48f0-a4c0-a45f816d9c03" contextRef="C_b153501c-2297-4e17-905e-f0f97a1348d3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_46794457-acaa-48ad-af9e-728fb743e113" contextRef="C_dac8f012-8074-43e0-b610-ec3ed404d713" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">426,362</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd2bf402-dff6-40e5-b6c9-ccd92919b054" contextRef="C_c2b667bf-badf-46cf-be28-9653192a233b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_54d81ea0-00bb-4646-8a1a-20138937b2c0" contextRef="C_5ea75401-6aea-4087-a31b-3b37976549a7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">285,930</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ca3ec5f6-37b7-4a76-adb9-3e859ab27a07" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">140,479</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an in1tegral part of these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INOZYME PHARMA, INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED STATEME</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NTS OF CASH FLOWS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(amounts in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.673%;"/>
    <td style="width:1.74%;"/>
    <td style="width:1%;"/>
    <td style="width:12.923%;"/>
    <td style="width:1%;"/>
    <td style="width:1.74%;"/>
    <td style="width:1%;"/>
    <td style="width:12.923%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8dabfdcf-b136-4481-b943-342b1c4d3d4e" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">71,169</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b655c7dd-89fa-4ab9-9d03-7d2d7dd18865" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">67,061</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bf9466bb-6f33-42fa-bb59-8aab48c53983" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">833</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_99ab82f2-994e-478a-8b01-597d67954897" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">744</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss on disposal of fixed assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_94270ef3-1871-4e4e-9398-42b84a90de6b" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="inzy:LossOnDisposalOfFixedAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_68fedc62-4604-4864-b2e9-c02889e621a3" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="inzy:LossOnDisposalOfFixedAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c9d6dd90-6188-46c1-a7f0-48ebce27e68e" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,037</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f9e4b251-7e8e-4d73-bdab-4c24500a93ca" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,672</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization of premiums and discounts on marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_adea295a-8386-4273-b197-31e06ccf51bf" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,438</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_55efbf99-9b39-4288-bf64-b29b57c247cb" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,671</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reduction in the carrying value of right-of-use assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34bc10a9-d6f0-45f4-af44-b227e31bac04" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:OperatingLeaseImpairmentLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">494</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_88ad3e15-de9e-4aac-8552-1b64bd3138f4" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:OperatingLeaseImpairmentLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">433</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-cash interest expense and amortization of debt issuance costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51ade35b-80ed-4daf-a9c4-dc1ab5b58ff7" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:AmortizationOfDebtDiscountPremium" unitRef="U_USD" scale="3" decimals="-3">630</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c078f9f9-1eb8-4353-8177-e615b7b1ec48" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:AmortizationOfDebtDiscountPremium" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">93</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f840f3a8-0b74-4bf8-8ecc-4ccf3183be22" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,134</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f48eac49-4999-42e8-aee6-8a6b4edaab04" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0f67f21d-5071-4647-9651-0866cea42980" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,378</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d0c29e5f-25a4-4ebf-8fe7-7f78d54b8066" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">150</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f5dc8449-43da-4a08-b357-95322622242d" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,255</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb473435-4aad-497d-adb6-b67982f9ba9d" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,857</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9357950b-ee0c-4ddf-93ee-37e1838ef381" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">816</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e1dfe9d0-3210-49e9-a73b-870d7fe8ca8a" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">732</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses, net of current portion</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f53353dc-5c28-4ffb-97cd-c06b9cb8443e" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="inzy:IncreaseDecreasePrepaidExpensesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,115</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f4b5de5d-95a4-46d4-ab09-d3542a13a50f" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="inzy:IncreaseDecreasePrepaidExpensesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">401</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other long-term liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_62d25b03-8105-4ef7-b22f-5e47d08c2091" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">124</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e4fba57d-a289-496a-8551-781ca2039fe7" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">124</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_36300ebe-9936-454b-93bc-c536c5b62de1" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">70,675</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1a265017-ebdf-464a-8d25-e4baec885b55" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">57,761</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Investing activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_85bb95c4-5b9c-41b2-b629-23c19a3a339a" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">269,330</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d6a134a7-cc27-466c-b251-4e0b56970ea4" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">151,993</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Maturities of marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c25100d3-bc9c-4604-be6d-e64d4b0dd751" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">215,982</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc7745f5-f64f-4650-aa63-bcda120db6a3" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">147,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of property and equipment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5a6b276e-1cb8-442a-96c3-55dc67953044" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">298</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e4c5abc1-0998-4b0d-b267-f87a731b4029" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">410</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_82766f4c-1aa7-407d-a899-438a11879db8" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">53,646</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_507c22a3-4266-4c2e-ab6f-ee7022786daf" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,403</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financing activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net proceeds from issuance of common stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_50fe506b-ed4c-48bf-b26e-16ac8067599e" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">85,647</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_40050ddd-5f1c-4182-b540-b1e265ce494b" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56,137</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net proceeds from issuance of pre-funded warrants</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_444a1e2c-6d67-4e0e-9f1d-d45dfe8abd94" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b813e302-47c8-4891-8da3-0336678ddf7c" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,150</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net proceeds from issuance of long-term debt</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f3c7cf18-0af5-4c8e-bf77-af07da47b1ec" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f9f7c57-70f8-4957-9a51-6efc45410348" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,050</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from exercise of stock options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f66bb3fc-ddab-4c78-ac7d-c7e88d9b56be" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_84d46bc4-9641-4498-9e54-1db02b7112d2" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">359</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from issuance of common stock for cash under employee stock purchase plan</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b268e79b-e3fd-4405-801a-a0ab3acbc454" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="inzy:ProceedsFromIssuanceOfCommonStockForCashUnderEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">206</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9bfc398d-ba9f-4644-98e3-890e29833503" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="inzy:ProceedsFromIssuanceOfCommonStockForCashUnderEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0bbd4335-0191-41c7-b6fd-24ed337ab01b" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">125,969</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_829c4724-d72e-4b1d-8942-45ce29299658" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">72,788</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net increase in cash, cash equivalents, and restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d6c5b588-52b0-4232-9733-7206df1b3f62" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,648</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf375bd0-2c0a-49b1-9c2d-22079358773b" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,624</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Effect of foreign currency exchange rate in cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a31d13a5-d68d-4945-bbeb-b442cc51326a" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">18</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf08d0c6-3a87-41b1-a7f5-eed05450b555" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">25</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash, cash equivalents, and restricted cash at beginning of period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_12f05863-c917-40a5-a679-d3ea1f384155" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,269</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fdf27bd8-dd25-4853-85ab-a1ee3d609848" contextRef="C_f9151e1c-1a1c-4fd2-91c3-dfd8900bd0f6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,670</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash, cash equivalents, and restricted cash at end of period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d2c3e0ab-47c7-46aa-b6df-edb6b9eee35c" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,899</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d70cb0f9-371b-415b-a2e0-3489e9d90518" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,269</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Supplemental cash flow information:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41381aed-caa6-43f3-8b20-b4d831f9b58d" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,588</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_420775c4-0a6d-4051-890b-3bd52ca487c6" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,915</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1a607bd5-f6c9-4299-874e-a0641817d997" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:RestrictedCashAndCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">311</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2a4a4edc-86c9-4479-84af-0e96abb81d64" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:RestrictedCashAndCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">354</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash, cash equivalents, and restricted cash at end of period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_36886876-c2e1-4df9-bdd2-5d7db500a066" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,899</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_21351119-5ca3-4a4a-add8-d89b215dbb55" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,269</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment unpaid at end of period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ae2b523f-7412-4c4e-a9d3-d76bb90b3df8" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f9fdb78-21f1-467b-bb98-ea0a8b35a6e5" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash paid for interest</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d8e96d7-b577-42e9-a066-aa4b76078f9d" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,347</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_50c38078-d1d6-4b19-a641-c61fc4c8f897" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">170</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inozyme Pharma, Inc.</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_to_consolidated_financial_statemen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FINANCIAL STATEMENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_eabf6ce2-b078-40e9-a6bb-ba06695ad864" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Organization and Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inozyme Pharma, Inc. (the &#8220;Company&#8221;) is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Through the Company&#8217;s in-depth understanding of a key biological pathway, the Company is pursuing the development of therapeutics that address pathologic mineralization and intimal proliferation to improve the underlying causes of these debilitating diseases. It is well established that low levels of plasma pyrophosphate drive pathologic mineralization and low levels of adenosine drive intimal proliferation in a number of rare diseases. The Company is initially focused on developing a novel therapy to treat for ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s lead product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to metabolize extracellular adenosine triphosphate to generate plasma pyrophosphate and adenosine monophosphate, which can be processed to phosphate and adenosine. This process is central to the regulation of calcium deposition throughout the body and is further associated with the inhibition of intimal proliferation, or narrowing and obstruction of blood vessels.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_972cff08-2c4e-4d4b-b78e-248b51f6b2b2" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true" continuedAt="F_972cff08-2c4e-4d4b-b78e-248b51f6b2b2_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p></ix:nonNumeric></div><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:continuation id="F_972cff08-2c4e-4d4b-b78e-248b51f6b2b2_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity, Capital Resources, and Going Concern</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since the Company&#8217;s incorporation in 2017 and through December 31, 2023, the Company has devoted substantially all of its efforts to raising capital, building infrastructure, developing intellectual property and conducting research and development. The Company incurred net losses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0a9d7e65-378a-4a61-b692-775f5ae008b8" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">71.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f431a06-b3bd-45d2-89ce-77ba6fe1c3e7" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">67.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in the years ended December 31, 2023 and 2022, respectively, and had an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8cb0867c-4733-49bb-b654-b275715db2f8" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">285.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of December 31, 2023. The Company had cash, cash equivalents, and short-term investments of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a52cc5c6-dc9d-495a-9622-18e6f33acc81" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">188.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of the numerous risks and uncertainties associated with product development, the Company is unable to predict the timing or amount of increased expenses or when or if the Company will be able to achieve or maintain profitability. Even if the Company is able to generate revenue from product sales, the Company may not become profitable. If the Company fails to become profitable or is unable to sustain profitability on a continuing basis, then the Company may be unable to continue its operations at planned levels and be forced to reduce or terminate its operations.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets, and the satisfaction of liabilities and commitments in the ordinary course of business. The Company has incurred recurring losses and negative cash flows from operations since inception and has primarily funded its operations with proceeds from the issuance of convertible preferred stock, offerings of common stock and pre-funded warrants, and its loan and security agreement (the "Loan Agreement") with K2 HealthVentures LLC (see Note 8). The Company expects its operating losses and negative operating cash flows to continue into the foreseeable future as it continues to expand its research and development efforts.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company believes that its cash, cash equivalents, and short-term investments as of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> will be sufficient to fund its cash flow requirements for at least 12 months from the date of filing this Annual Report on Form 10-K. Management&#8217;s expectations with respect to its ability to fund current and long-term planned operations are based on estimates that are subject to risks and uncertainties. The Company will need additional funding to support its planned operating activities. However, there is no guarantee that any financing opportunities will be executed on favorable terms, or at all, and some could be dilutive to existing stockholders. If the Company is unable to obtain additional funding, it would be forced to delay, reduce or eliminate some or all of its research and development programs, portfolio expansion, or commercialization efforts, which could adversely affect its business prospects.</span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:nonNumeric id="F_c27a5c50-8d22-40ab-8e08-0e78ecf1d1b6" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2. Summary of Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d6107755-60f2-46fe-82bc-95779d65a9c1" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:ConsolidationPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Principles of Consolidation</span></p><p style="text-indent:9.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Inozyme Securities Corp., which is a Massachusetts subsidiary created to buy, sell, and hold securities; Inozyme Ireland Limited; and Inozyme Pharma Switzerland GmbH. All intercompany transactions and balances have been eliminated.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8e4c76b5-cc5c-4f7f-9973-24c9689bbd9e" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:UseOfEstimates" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the Company&#8217;s financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and judgments are based on historical information and other market-specific or various relevant assumptions, including, in certain circumstances, future projections that management believes to be reasonable under the circumstances. Actual results could differ materially from estimates. Significant estimates and assumptions are used for, but not limited to the accruals for research and development expenses. The Company evaluates its estimates and assumptions on an ongoing basis. All revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_eedb7b0a-805b-4d1b-8bdc-cf386849f8a3" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk, Significant Suppliers, and Off-Balance Sheet Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and short-term investments and, from time to time, long-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits and limits its exposure to credit risk by placing its cash with high credit quality financial institutions. The Company&#8217;s investments are composed of U.S. Treasury and U.S. government agency debt securities and commercial paper of corporations. The Company mitigates credit risk by maintaining a diversified portfolio and limiting the amount of investment exposure as to institution, maturity, and investment type.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is dependent on third-party manufacturers and contract research organizations ("CROs") to supply product candidates and provide services for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. The Company also relies on CROs to conduct its clinical trials. The Company&#8217;s programs could be adversely affected if a third-party manufacturer or a CRO is unable to successfully carry out their contractual obligations or meet expected deadlines. If a third-party manufacturer or a CRO needs to be replaced, the Company may not be able to complete its program development on its anticipated timelines and the Company may incur additional expenses as a result, which could be significant.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1f249596-1768-4942-956d-a0289ed24f1e" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd53fb91-72d2-4a9d-bf37-34f41f2db4f7" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="inzy:ConcentrationRiskCreditRiskOffBalanceSheetRisk" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> significant off-balance sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cdab6c2d-c273-4bd4-9b8b-4827278c7364" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts, money market accounts, and certain marketable securities. Cash is carried at cost, which approximates its fair value. Cash equivalents are carried at fair market value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7862449a-f5fd-46c9-927d-6e50d63f4075" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" escape="true" continuedAt="F_7862449a-f5fd-46c9-927d-6e50d63f4075_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Cash</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:continuation id="F_7862449a-f5fd-46c9-927d-6e50d63f4075_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted cash is composed of amounts held to collateralize the letters of credit related to the Company&#8217;s lease arrangements. Restricted cash is classified as either current or non-current based on the terms of the underlying lease arrangement.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1ca69b15-13b1-4abe-9587-eea7b8525626" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:InvestmentPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Short-Term and Long-Term Investments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company classifies its investments as available-for-sale and records such assets at estimated fair value on the balance sheet, with unrealized gains and losses on marketable securities, if any, reported as a component of accumulated other comprehensive (loss) income. Realized gains and losses are calculated based on the specific-identification method and are recorded as a component of interest income. There have been </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4caf2bb2-0fd5-456e-8896-e3375b1186f2" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_0e50a852-f9d2-46b6-9e43-9be55d6dcbe3" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> realized gains and losses for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022. The Company periodically reviews available-for-sale securities for other-than-temporary declines in fair value below the cost basis whenever events</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Marketable securities with a maturity date of one year or less from the balance sheet date are classified by the Company as short-term investments. Marketable securities with a maturity date of greater than one year from the balance sheet date are classified as long-term investments and are available to fund operations as needed. As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6e800d23-b1d6-40f5-98e1-eff482fb8b38" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:LongTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t have any long-term investments. In accordance with the Company&#8217;s investment policy, at the time of purchase, the final maturity of each security within the portfolio shall not exceed </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a5fabd00-4fea-4de6-9b45-325e57fe2224" contextRef="C_a5581986-e14e-4e34-a7f8-7bba69e2c058" name="us-gaap:DebtSecuritiesHeldToMaturityThresholdPeriodPastDueWriteoff" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> months and the weighted average maturity of the portfolio will be no greater than </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ba748a34-72a7-46e6-94eb-4e571aa72cdf" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:DebtSecuritiesHeldToMaturityThresholdPeriodPastDueWriteoff" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> months.</span></p></ix:nonNumeric></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fa219f20-0467-4aac-b831-4c2de6b83bf6" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the related asset. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d2f16701-f627-425a-a1a2-b8e31ac5b7a5" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="inzy:PropertyAndEquipmentEstimatedUsefulLivesTableTextBlock" escape="true" continuedAt="F_d2f16701-f627-425a-a1a2-b8e31ac5b7a5_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The estimated useful lives of the Company&#8217;s property and equipment are as follows: </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_d2f16701-f627-425a-a1a2-b8e31ac5b7a5_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:73.34%;"/>
          <td style="width:1%;"/>
          <td style="width:24.66%;"/>
          <td style="width:1%;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Useful Life (In Years)</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory equipment and manufacturing equipment</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_1a500c19-a89d-497d-bb5b-295521e84e68" contextRef="C_f1b17c7a-98c5-4dda-8775-61fdebd34c84" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></ix:nonNumeric></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_c1e78596-3a49-4d9a-9e2d-b8566f98bad1" contextRef="C_ad70b717-7bb2-4c61-9bb0-95099842631c" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></ix:nonNumeric></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_9f5b3fb7-1708-40ea-b5b0-100d8e64f3af" contextRef="C_6f8af799-609d-4c14-b3ec-0e9bdd4c588e" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></ix:nonNumeric></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="-sec-ix-hidden:F_163a734f-613d-45f6-b523-f3a90ba56209;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lesser of asset life or lease term</span></span></span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:continuation></div></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a6f6a2cf-c8e9-4316-bef8-8a1b04d24b4a" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Impairment of Long-lived Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As required under the applicable accounting guidance, the Company periodically reevaluates the original assumptions and rationale used in the establishment of the carrying value and estimated lives of all of its long-lived assets, including property and equipment. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. An impairment loss is recognized when the total of estimated future undiscounted cash flows, expected to result from the use of the asset and its eventual disposition, are less than its carrying amount. Impairment, if any, would be assessed using discounted cash flows or other appropriate measures of fair value. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc9b1d3e-7386-4ab4-b63d-b297d8a6dfa0" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:AssetImpairmentCharges" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_e78542c8-f710-4714-af37-c253f76b4603" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:AssetImpairmentCharges" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> impairments for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4195e7fc-7d3c-41cb-bfc4-dce56ae94fd0" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="inzy:AccruedResearchAndDevelopmentCostsPolicyTextBlock" escape="true" continuedAt="F_4195e7fc-7d3c-41cb-bfc4-dce56ae94fd0_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accrued Research and Development Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company records accrued liabilities for estimated costs of research and development activities conducted by service providers for sponsored research, preclinical studies, clinical operations, and contract manufacturing activities based upon the estimated amount of services provided but not yet invoiced and includes these costs in accrued expenses in the accompanying consolidated balance sheets and within research and development expense in the accompanying consolidated statements of operations and comprehensive loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:continuation id="F_4195e7fc-7d3c-41cb-bfc4-dce56ae94fd0_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with service providers. The Company makes significant judgments and estimates in determining the accrued liabilities balance in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. The Company has not experienced any material differences between accrued costs and actual costs incurred since its inception.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_51526752-1537-4b00-b05a-bbc22a0685d7" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development costs are expensed as incurred. Research and development costs consist of direct and indirect internal costs related to specific projects as well as fees paid to other entities that conduct certain research and development activities on the Company&#8217;s behalf.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f176e6a1-c03c-4acd-bdd6-0b803bf9905e" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="inzy:PatentCostsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company expenses all costs as incurred in connection with patent applications, including direct application fees, and the legal and consulting expenses related to making such applications, and such costs are included in general and administrative expenses within the Company&#8217;s consolidated statements of operations and comprehensive loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d4268b36-b7af-4ba4-8a46-b82e48202a73" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compensation expense represents the cost of the grant date fair value of employee and non-employee stock option grants recognized over the requisite service period of the awards on a straight-line basis. For service-based awards that are</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">subject </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">to graded vesting, the Company has elected to recognize compensation expense on a straight-line basis. The Company has elected to recognize forfeitures as they occur.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3019682d-b2e2-4cdc-9fa5-ce9ad873197a" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income taxes have been accounted for using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates applicable to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. A valuation allowance against deferred tax assets is recorded if, based upon the weight of all available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for income taxes in accordance with authoritative accounting guidance which states the impact of an uncertain income tax position is recognized at the largest amount that is &#8220;more likely than not&#8221; to be sustained upon audit by the relevant taxing authority. There are </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_58ffbc56-102e-48cf-9b3e-86eb02652968" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_99158650-21ab-43f8-8f2d-3b0b1a909dcb" contextRef="C_f9151e1c-1a1c-4fd2-91c3-dfd8900bd0f6" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> unrecognized tax benefits included in the Company&#8217;s consolidated balance sheets at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 or 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company&#8217;s policy is to recognize interest and penalties related to income tax matters in income tax expense. The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_87988723-f5e6-4f4f-afa2-b825e435b044" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t recognized any interest or penalties in its consolidated statements of operations and comprehensive loss since inception.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5a01ffdd-c19e-431b-8dc6-2bebc3e1e235" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company determines if an arrangement is a lease at contract inception based on the facts and circumstances present in the arrangement. If a lease is identified in an arrangement, the Company recognizes a right-of-use asset and liability on its balance sheet and determines whether the lease should be classified as a finance or operating lease. Short-term leases, or leases that have a lease term of 12 months or less at the commencement date are excluded from this treatment and are recognized on a straight-line basis over the term of the lease. Additionally, the Company does not separate lease and non-lease components for all leases.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded as operating leases.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Finance and operating lease assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount rate implicit in the lease. If the rate implicit is not readily determinable, the Company utilizes an estimate of its incremental borrowing rate at the lease commencement date. Operating lease assets are further adjusted for prepaid or accrued lease payments. Operating lease payments are expensed using the straight-line method as an operating expense over the lease term. Finance lease assets are amortized to depreciation expense using the straight-line method over the shorter of the useful life of the related asset or the lease term. Finance lease payments are bifurcated into (i) a portion that is recorded as imputed interest expense and (ii) a portion that reduces the finance liability associated with the lease. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_deda3c33-cb12-4b09-8b34-60d877a69f06" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:FinanceLeaseImpairmentLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_dfc005fe-171b-40fe-9130-e881ad0e4872" contextRef="C_4ee9c018-375e-4d0f-ab9e-435246e8b7ce" name="us-gaap:FinanceLeaseImpairmentLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t have any finance leases recorded on its consolidated balance sheet as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5abb3292-254a-4a4e-a12d-4006932e1e0c" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:DeferredChargesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Deferred Issuance Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company capitalizes certain legal, professional accounting, and other third-party fees that are directly associated with in-process equity financings as deferred issuance costs until such financings are consummated. After consummation of such an equity financing, these costs are recorded as a reduction of the proceeds generated as a result of the offering. Should a planned equity financing be abandoned, the deferred issuance costs would be expensed immediately as a charge to operating expenses in the consolidated statements of operations and comprehensive loss. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e0426bf3-9df9-4a82-8dd7-f6a2678f6d78" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_0863ccc8-da7e-48d6-a424-50e328eb5025" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t have any deferred issuance costs recorded at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 or December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_191f2df2-b8b6-4721-bee5-5a8ddccaad92" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss Per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock and pre-funded warrants outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock and pre-funded warrants and potentially dilutive securities outstanding during the period determined using the treasury-stock and if-converted methods. The Company has generated a net loss in all periods presented; therefore, the basic and diluted net loss per share attributable to common stockholders are the same as the inclusion of the potentially dilutive securities would be anti-dilutive.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c19f391d-5cc2-4061-89cd-f3dbd58d2651" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true" continuedAt="F_c19f391d-5cc2-4061-89cd-f3dbd58d2651_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:continuation id="F_c19f391d-5cc2-4061-89cd-f3dbd58d2651_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (&#8220;CODM&#8221;) in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#8217;s CODM is its Chief Executive Officer. The Company has determined it operates in a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_8196d8a8-372d-4a07-a143-8661735a221d;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">single</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> operating segment and has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d7a62e7b-a6af-47a6-b05e-f6b39cd5f030" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:NumberOfReportableSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reportable segment. All long-lived assets of the Company reside in the United States.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4e6a5d23-d51f-46ae-944c-ddaeb576b0e8" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comprehensive</span><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Loss</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is required to report all components of comprehensive loss, including net loss, in the financial statements in the period in which they are recognized. Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Comprehensive loss consists of the Company&#8217;s net loss, unrealized gains and losses on the Company&#8217;s investments, and foreign currency translation adjustments and is presented within the consolidated statements of operations and comprehensive loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_88772189-974d-4be8-bccb-a3a89831d570" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Foreign Currency Transactions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company maintains foreign bank accounts denominated in euros and Swiss francs and enters into transactions which are denominated in various currencies. Foreign currency transactions are initially recorded by the Company using the exchange rates prevailing at the date of the transaction. At the balance sheet date, recorded monetary balances denominated in foreign currencies are adjusted to U.S. dollars using the period-end rates of exchange. Exchange gains and losses arising from the translation of foreign currency items are included in other expense, net in the consolidated statements of operations and comprehensive loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d0f3ccb1-04ab-492a-956a-8c33bac2f91d" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company categorizes its assets and liabilities measured at fair value in accordance with the authoritative accounting guidance that establishes a consistent framework for measuring fair value, and expands disclosures for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.66525540221037%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1 &#8211; Unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets or liabilities; </span></div></div><div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.66525540221037%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2 &#8211; Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; or </span></div></div><div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.66525540221037%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3 &#8211; Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). </span></div></div></ix:nonNumeric></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ba1065b9-f609-4e91-9414-a711b40960e2" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="inzy:EmergingGrowthCompanyStatusPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Emerging Growth Company Status</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is an &#8220;emerging growth company&#8221; (&#8220;EGC&#8221;) as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and the Company may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs. As an EGC, the Company can elect to take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to use the extended transition period for complying with new or revised accounting standards, and as a result of this election, the Company&#8217;s consolidated financial statements may not be comparable to companies that comply with public company FASB standards&#8217; effective dates. The Company will remain an EGC until December 31, 2025, although if the market value of the Company&#8217;s common stock that is held by non-affiliates exceeds $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0af2b15f-cccc-4e7d-90dd-bc3bb65c5529" contextRef="C_cf58a586-baf1-45e2-afe5-cc909b0ac57a" name="inzy:EmergingGrowthCompanyMarketValueOfCommonStockHeldByNonAffiliates" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">700</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of any June 30 before that time or if the Company has annual gross revenues of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e4d63ed6-cc0d-4cd6-bedd-52ff30f7fc51" contextRef="C_ce440ee2-4c72-4b3f-867c-b18a4779f0de" name="inzy:EmergingGrowthCompanyAnnualGrossRevenues" unitRef="U_USD" scale="9" decimals="-6" format="ixt:num-dot-decimal">1.235</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> billion or more in any fiscal year, the Company would cease to be an EGC as of December 31 of the applicable year. The Company would also cease to be an EGC if it issued more than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b869a52-cb12-4f53-96d6-73ac73058303" contextRef="C_ce440ee2-4c72-4b3f-867c-b18a4779f0de" name="inzy:EmergingGrowthCompanyStatusIssuanceValueOfNonConvertibleDebt" unitRef="U_USD" scale="9" decimals="-9" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> billion of non-convertible debt over a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5c153743-1110-4c5c-ad66-e2b1226470f1" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="inzy:EmergingGrowthCompanyStatusIssuancePeriodOfNonConvertibleDebt" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> period.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ee33bed4-fab4-463a-8233-52228d81e7c8" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:DebtPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt and Debt Issuance Costs</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Debt issuance costs are presented on the consolidated balance sheet as a direct deduction from the related debt liability. Debt issuance costs represent legal and other direct costs incurred in connection with the Company&#8217;s term loan under the Loan Agreement. These costs are amortized as a non-cash component of interest expense using the effective interest method over the term of the loan. Any final payments are included in the cash flows to determine the effective interest rate and are recognized using the effective interest method over the term of the loan.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b72f35d5-9d0a-43b0-b424-521afad43418" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="inzy:WarrantsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Warrants</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company determines the accounting classification of warrants that are issued, as either liability or equity, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting for Certain Financial Instruments with Characteristics of Both Liabilities and Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and then in accordance with ASC 815-40, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#8217;s Own Stock</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Under ASC 480-10, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate the issuer to settle the warrants or the underlying shares by paying cash or other assets, or must or may require settlement by issuing variable number of shares.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If warrants do not meet liability classification under ASC 480-10, the Company assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability classification under ASC 815-40, in order to conclude equity classification, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable U.S. GAAP. After all relevant assessments are made, the Company concludes whether the warrants are classified as liability or equity. Liability classified warrants are required to be accounted for at fair value both on the date of issuance and on subsequent accounting period ending dates, with all changes in fair value after the issuance date recorded in the statements of operations as a gain or loss. Equity classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dbd09f33-c1bf-4344-b794-5d396792e3c1" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3. Recent Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f675882e-d3f9-4b10-a718-ec7cb74d6d79" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently Adopted Accounting Standard</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (&#8220;Topic 326&#8221;): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 and its subsequent related updates establish a new forward-looking &#8220;expected loss model&#8221; that requires entities to estimate current expected credit losses on accounts receivable and financial instruments by using all practical and relevant information. The Company adopted this standard effective January 1, 2023. There was no impact to the Company's financial statements upon adoption.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_75615bea-0589-4e84-ad57-3569ce57b8e0" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4. Balance Sheet Details</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ba561aad-8a59-4dd1-97fd-9e8f32df55fb" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Short-term investments consisted of the following (dollar amounts in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.24%;"/>
        <td style="width:1%;"/>
        <td style="width:9.9%;"/>
        <td style="width:1.08%;"/>
        <td style="width:1%;"/>
        <td style="width:8.3%;"/>
        <td style="width:1%;"/>
        <td style="width:1.08%;"/>
        <td style="width:1%;"/>
        <td style="width:8.3%;"/>
        <td style="width:1%;"/>
        <td style="width:1.08%;"/>
        <td style="width:1%;"/>
        <td style="width:8.120000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.08%;"/>
        <td style="width:1%;"/>
        <td style="width:7.82%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="16" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Maturity</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_6a4f7699-70ea-4c01-8193-7cedaeef4501" contextRef="C_afa7e7f7-939c-4d45-98c6-aac2333bb8a1" name="inzy:InvestmentMaturityPeriod"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1 year or less</span></ix:nonNumeric></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a324e0c-3823-400e-913f-afc7f1f70b28" contextRef="C_38923768-4f8c-4cf5-8568-d7b648fc7393" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80,160</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b76c4797-6fd1-465b-aa45-39d443751694" contextRef="C_38923768-4f8c-4cf5-8568-d7b648fc7393" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8db0e6fb-5812-4b1e-b6fb-57c6391d0f12" contextRef="C_38923768-4f8c-4cf5-8568-d7b648fc7393" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a6b57b33-69b2-49c7-a87d-69c4c6a657c3" contextRef="C_38923768-4f8c-4cf5-8568-d7b648fc7393" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80,218</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government agency debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_95760b22-3931-4e62-bf1b-ddcd87235066" contextRef="C_3f4c43df-91a9-4dcb-a518-2b872f3cab86" name="inzy:InvestmentMaturityPeriod"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1 year or less</span></ix:nonNumeric></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2dc854df-1b93-401f-ad1b-52e114e6a34c" contextRef="C_9dcd98d2-cef7-49c2-a825-548d1468b4ee" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73,774</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6cf4046f-6294-443c-9fe1-17aa84ce3b84" contextRef="C_9dcd98d2-cef7-49c2-a825-548d1468b4ee" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cbaf0672-e391-4e6a-b16a-c505f81cee16" contextRef="C_9dcd98d2-cef7-49c2-a825-548d1468b4ee" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a9a6c309-d83d-4d33-aea3-7c1d80bbd60d" contextRef="C_9dcd98d2-cef7-49c2-a825-548d1468b4ee" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73,783</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f0c6589-a71e-4c33-b69e-3bf7f2ea153c" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">153,934</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_03247cdf-2651-492d-9cd9-7d4bc2c10dd9" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2517baed-2492-481c-8171-e4a39a46174c" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28702be3-1b85-46bd-b37d-8f1c3536e9c1" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">154,001</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.269%;"/>
        <td style="width:1%;"/>
        <td style="width:9.902%;"/>
        <td style="width:1.08%;"/>
        <td style="width:1%;"/>
        <td style="width:8.282%;"/>
        <td style="width:1%;"/>
        <td style="width:1.08%;"/>
        <td style="width:1%;"/>
        <td style="width:8.282%;"/>
        <td style="width:1%;"/>
        <td style="width:1.08%;"/>
        <td style="width:1%;"/>
        <td style="width:8.122%;"/>
        <td style="width:1%;"/>
        <td style="width:1.08%;"/>
        <td style="width:1%;"/>
        <td style="width:7.822%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="16" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Maturity</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_6549c39a-5101-42d7-ad05-5dd6d67d88b5" contextRef="C_5bb4c6de-83a3-4b5b-8ccc-2887ba662ad0" name="inzy:InvestmentMaturityPeriod"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1 year or less</span></ix:nonNumeric></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d98ba3f-46e0-467f-b9af-9b5a777ed751" contextRef="C_580be68e-23a1-4156-859f-97d143db13e7" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">78,451</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0ea408cb-ac80-4657-bf2c-0e8cc9bafd06" contextRef="C_580be68e-23a1-4156-859f-97d143db13e7" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_273171c0-4b36-496b-8e56-9f20e1d1c3db" contextRef="C_580be68e-23a1-4156-859f-97d143db13e7" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">119</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aba0dec2-9076-40b5-b6c2-90e5cf1e8632" contextRef="C_580be68e-23a1-4156-859f-97d143db13e7" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">78,336</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_43a69409-ed43-4003-b770-0fe1a5b7c65b" contextRef="C_627d9b19-c97f-4990-affb-d25c50839022" name="inzy:InvestmentMaturityPeriod"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1 year or less</span></ix:nonNumeric></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aaba097a-20fd-478c-bd5f-d0791542c02a" contextRef="C_fd818a77-dcd6-4172-b69f-ef9f6f65f940" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,698</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_12bf9d0e-d901-4d1c-90bb-3ae19f858785" contextRef="C_fd818a77-dcd6-4172-b69f-ef9f6f65f940" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b625c180-430f-4f0d-9e0d-8f21c6546056" contextRef="C_fd818a77-dcd6-4172-b69f-ef9f6f65f940" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">83</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_33e56427-115c-4446-a4e3-811e1db929ec" contextRef="C_fd818a77-dcd6-4172-b69f-ef9f6f65f940" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,615</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5194c989-4edd-4ece-ae7a-5d2de8832ce1" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">95,149</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6010e46b-88d6-4739-a79d-295971ec7474" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cadcd1bc-df01-4d58-ba06-8cd179e09a9b" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">202</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_20447c2a-da39-459c-96fd-75518c32b138" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,951</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company concluded that the declines in market value of available-for-sale securities were temporary in nature and did not consider any of the investments to be other-than-temporarily impaired. In accordance with its investment policy, the Company invests in investment grade securities with high credit quality issuers, and generally limits the amount of credit exposure to any one issuer. The Company evaluates securities for other-than-temporary impairment at the end of each reporting period. Impairment is evaluated considering numerous factors, and their relative significance varies depending on the situation. Factors considered include the length of time and extent to which fair value has been less than the cost basis, the financial condition and near-term prospects of the issuer, and the Company&#8217;s intent and ability to hold the investment to allow for an anticipated recovery in fair value. Furthermore, the aggregate of individual unrealized losses that had been outstanding for 12 months or less was not significant as of December 31, 2023 and December 31, 2022. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before a recovery of their amortized cost bases, which may be maturity. The Company also believes that it will be able to collect both principal and interest amounts due at maturity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7944f43b-f4a5-4fa2-a054-6b018fe537a2" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="inzy:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prepaid expenses and other current assets consisted of the following (dollar amounts in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">At December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">At December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest receivable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6e9c4371-6635-4932-8f60-0af4811fe786" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:InterestReceivableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">385</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1a0493f-fabc-4781-b940-5283367227fd" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:InterestReceivableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">115</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid insurance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ea9a0431-7e22-439b-8292-6d336f4b1cb7" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,067</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_54d5e46a-5d0c-496d-9129-52a718b6db20" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,293</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid research studies</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cced3f7f-0470-4e3f-ae6a-e0f4d27eb842" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="inzy:PrepaidResearchStudies" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,339</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d061d5a-19f1-4e5f-b644-f5aff50919b1" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="inzy:PrepaidResearchStudies" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,397</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a7ab929-3f25-4068-a81f-5e57498ae18d" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:OtherPrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">870</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a738084-a9b2-46c6-877c-add1e93c623a" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:OtherPrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">722</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1db435db-5a8a-4758-8aae-852d2710d4bc" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,661</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_33fb43e0-7aab-4054-81f1-12b1ad35899b" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,527</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9d84b2d6-94a4-4406-9766-a5eced1dcda3" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment consisted of the following (dollar amounts in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">At December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">At December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory equipment and manufacturing equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a180909-4acb-4ee5-abc6-60a9f238cd0c" contextRef="C_f1b17c7a-98c5-4dda-8775-61fdebd34c84" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">947</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6b89f4bb-01a1-4028-88e8-b07755258f79" contextRef="C_dd2554f0-5fa2-4094-bb5c-964fac0c425e" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">805</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0af0e3a-5a1f-4ebb-aa04-bd76e87d4b92" contextRef="C_ad70b717-7bb2-4c61-9bb0-95099842631c" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">284</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_247135a4-e80d-448f-8a90-895064342e80" contextRef="C_e8c0a014-c50e-4051-b4de-b6a88a7006fe" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">258</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8241500-6190-49f7-934b-08683cb3b851" contextRef="C_6f8af799-609d-4c14-b3ec-0e9bdd4c588e" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">491</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5a7c6270-220d-4816-8b1e-b4a99206db71" contextRef="C_b6643dbc-a9cd-41a0-9331-c15dc4781614" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">558</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a5840710-747f-4d1f-a4b7-6e59d791c598" contextRef="C_1b475cba-fda5-4a60-90f8-717eba9366b4" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,157</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4d4c6845-d089-4127-9d7f-92003d5dcf92" contextRef="C_93fed2f2-49b6-4337-8584-7a6a8c8c936e" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,129</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f02bc506-c512-466a-9021-d2a523bc299d" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,879</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7cf7afe2-b5f7-417d-8539-5e8af6ce2f22" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,750</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less accumulated depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c001e5f5-c3cf-4b12-8e08-5a389c4b8d13" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,413</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_45483f42-3ae5-465c-bfd6-c67aceeb7acc" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,732</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a9186b7f-6ad7-4010-9896-1195815b5d0b" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,466</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b925a626-57f4-45eb-ad3d-d59df68f7af8" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,018</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation expense for the years ended December 31, 2023 and 2022 totaled </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a1d40243-a74f-45e4-ab5f-cff2d2350176" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ac468cb-4640-4965-8b86-73bc37436eb7" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7b7be5af-6de9-4272-9898-c53130a8e84e" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses consisted of the following (dollar amounts in thousands):</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">At December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">At December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Payroll and related liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f23e1aab-3397-4bd8-9c11-2f19056efef1" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,838</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_45b79002-86cd-475f-8ba0-a08a20d30db3" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,229</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other professional fees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c530eb52-8f6d-4a14-a6d6-864f774b8932" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,377</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f343e244-87e6-431e-8511-f8c76ff1b25f" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,310</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Clinical expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b34f705-b6e4-4f3d-8f24-6f80e51ebe09" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="inzy:ClinicalExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,595</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf396902-0662-40fc-bc7c-40c3c0f7c646" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="inzy:ClinicalExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,986</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_01b16efc-a2c4-44ad-bc9b-9aec6231e1e8" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="inzy:AccruedResearchAndDevelopmentCostsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,917</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_add3af88-af7f-4cad-bc22-24b897829a2f" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="inzy:AccruedResearchAndDevelopmentCostsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,345</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6cd3c4b3-b5d5-4ae7-84a1-b336b5519cde" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">883</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_86258d39-85c8-44e1-a3ef-e399bcfcd6e4" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">485</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_985c80d7-ec1d-4222-9d66-18e346aada6f" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,610</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_217bac8a-02bf-412e-8906-f90768cd1279" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,355</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_98567677-f8bc-466f-9b1f-be4fa4336db4" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5. Fair Value Measurement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0b2a973c-6f03-46a0-b781-1344da8be933" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables represent the Company&#8217;s financial assets measured at fair value on a recurring basis and indicate the level of fair value hierarchy utilized to determine such fair values (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements at Reporting Date<br/>Using</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted<br/>Prices in<br/>Active<br/>Markets for<br/>Identical<br/>Assets<br/>(Level 1)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds (included in cash and cash<br/>&#160;&#160;&#160;equivalents)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_85f9b5c4-783c-4d4a-b617-a83eb90f48ed" contextRef="C_2b1ba612-eaf7-4255-9f94-845320672517" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,830</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a10c747-5c81-4998-b750-0991fb836596" contextRef="C_aa1d3c56-5369-4d66-b7ef-2331a4328983" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,830</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c7085863-ef18-4ccf-af1b-583b004052d2" contextRef="C_0fef7786-5c9f-4661-84e2-6bd709ef1859" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_16d35fb0-3ef0-4087-8d8c-2cd87a4a1669" contextRef="C_ebb0e8ce-192c-4794-b110-e57d539bd7f5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government agency debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b7420a3-9507-497a-96bb-6a69cfa9df31" contextRef="C_f468c3aa-9d5e-4348-b6a5-6d3b6072b370" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73,783</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_808acd06-4993-4d76-9314-97a90b2164ff" contextRef="C_08242d46-09fa-4d0f-acdd-9a2a331c3f18" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_600a88bf-0579-4d98-b852-9ab776b4a712" contextRef="C_f4d73906-7252-43b1-b4b1-204a7275742a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73,783</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1a27c44a-df52-4809-a90d-1918c9ab5aec" contextRef="C_b766d812-c104-4ba8-94cb-06af03d52200" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_03e0ec99-bb1e-44f1-b83c-76b6907f160f" contextRef="C_639eb17d-d451-4e67-9099-b216251b8867" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80,218</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_274c5d66-3707-4aae-bddc-836e424e1495" contextRef="C_f2eb39b0-33a2-4aff-a77e-446a7f20b7ba" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80,218</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_edfcca4f-470b-43db-85d5-0f8cbcdcb04e" contextRef="C_a8a74a9f-0187-449d-bd71-ff493500514a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_711319d2-ffe9-4372-b681-b06279dc393b" contextRef="C_58e1da8f-d797-45d5-94a7-e1c0672c5b37" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a15cff4-ea8f-4228-8b4e-b8d4f85768ed" contextRef="C_cc2d588b-2f3b-4c9e-8375-5d861c028af1" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">187,831</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b6ef7c01-4d95-4d24-9ae7-4ae9ab94de70" contextRef="C_c219104e-7f65-4cfb-a306-535fab73fbae" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">114,048</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0628ab97-fd1b-4b3a-a53e-a15a31abfe28" contextRef="C_560a8eac-a2ea-4e9e-8e4c-468159d80f18" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73,783</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f423c01e-c523-48bf-82e1-45d61264a646" contextRef="C_edffafaf-bcb8-4571-af95-10f388d3cb08" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements at Reporting Date<br/>Using</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted<br/>Prices in<br/>Active<br/>Markets for<br/>Identical<br/>Assets<br/>(Level 1)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds (included in cash and cash<br/>&#160;&#160;&#160;equivalents)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_875506a5-dcb4-4422-82cd-c27672b6ff23" contextRef="C_e2f25e47-2422-40ab-810a-92c03b89c3a7" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,587</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aea5b585-e44f-42b0-b260-4f653500dd23" contextRef="C_68e0a225-f316-48f6-9fd5-63d50781b73b" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,587</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a1e21df-8435-43ad-bed9-3feb541ee405" contextRef="C_1bd944ab-7162-429e-a0bf-1e98d8b5d629" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd67773d-c830-4e8b-b171-85bbd5bf0fa3" contextRef="C_cabacfd7-585b-4a2b-88ce-edec24c747f6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1dcfe138-524f-46f9-9077-5dbdbb76a5cd" contextRef="C_a82024c8-742d-4976-8c8e-41e2b8b05ebd" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">78,336</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b43b7102-0e0c-4366-a5ff-aea8983180b3" contextRef="C_12de314a-d4b0-494b-813f-351304fba130" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22beddd1-5c4a-4a26-b27d-f158107e8110" contextRef="C_86c60b96-dc4e-40d1-8dc6-75af50996958" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">78,336</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4fc0dafb-dd31-49d5-b4bd-96553bf7b1cc" contextRef="C_072e744e-d8a8-4b95-9e11-fd60fc749ad1" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fe9ebe8b-6bea-4e62-adb5-0c9c1e6e4c72" contextRef="C_da086e8a-c936-404a-b841-ba2c9c0e2bfa" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,615</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9388960f-2f94-4b6f-b421-8946fddf01ca" contextRef="C_26d33768-49f2-4d59-a581-db63d9838d45" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,615</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e2e18ada-37a5-4a2b-b470-77af1129a55d" contextRef="C_f51cc874-6545-4fcf-a041-fffaa4e330ec" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d7fce6db-9c1c-45bb-80a5-29ee0eddf60f" contextRef="C_e6f1df46-623b-42c5-95a7-877ba9f99313" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc56f26a-e898-4b91-8dd2-0cf783f59586" contextRef="C_9c13b456-85ec-4115-a24f-2f8c865d0abb" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">121,538</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bd6353f9-34a4-4b95-8b26-acae2d77145f" contextRef="C_6218f8b0-72c4-4511-8848-700fe16326a0" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,202</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c3406394-ccde-4b41-986d-d13479841c31" contextRef="C_18a01e41-ea42-4897-ac23-422f3897a169" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">78,336</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3423adb9-7d96-4dd0-8cab-dd188875c96b" contextRef="C_9cdf7217-5d9d-4e8f-a508-7e31ed97b29e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There have been </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_04fff231-739d-4832-b1c1-6cde6ca29b32" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_5b6c5793-03a8-4a6f-8d0a-5196c92f098a" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d02c0538-2140-4d22-85f6-8476295af697" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_0b65395b-951b-4b8c-b917-0cdb46c5d6e0" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> transfers between fair value levels during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2a455ab1-3fba-4afa-bfd8-21627ffedc4f" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6. License and Sponsored Research Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2017, the Company entered into a license agreement with Yale University (&#8220;Yale&#8221;), which was amended in May 2020 and July 2020, under which the Company licensed certain intellectual property related to ectonucleotide pyrophosphatase/phosphodiesterase enzymes that is the basis for the Company&#8217;s INZ-701 development program. Pursuant to the license agreement, as partial upfront consideration, the Company made a payment of approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e9bde8b-b499-4ea6-8ee5-69d1f738cc06" contextRef="C_b61af113-eb50-4b3e-aef8-307431908b88" name="inzy:PartialUpfrontConsiderationPaymentUnderLicenseAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to Yale, which</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">amount reflected unreimbursed patent expenses incurred by Yale prior to the date of the license agreement. The Company is responsible for paying Yale an annual license maintenance fee in varying amounts throughout the term ranging from the low tens of thousands of dollars to the high tens of thousands of dollars. For the years ended December 31, 2023 and 2022, the Company incurred a total of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_99329919-954f-4f28-8128-99bb3db7ba48" contextRef="C_be56dd08-7be1-43d7-b997-dbab1bf7f427" name="us-gaap:CostMaintenance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a0d0311-9185-44b9-862b-e2fb1d1efb42" contextRef="C_196b61ab-ba69-4401-87d4-819541ae1871" name="us-gaap:CostMaintenance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, in license maintenance fees to Yale.  The Company is required to pay Yale up to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_204af1a8-0052-4ec5-9347-e0bd6070a7ef" contextRef="C_e4451f72-2b2b-4b91-8f5a-e4ab0f0244ad" name="inzy:LicenseAgreementPaymentUponAchievementOfSpecifiedProductSalesOrDevelopmentAndCommercializationMilestones" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, based on the achievement of a specified net product sales milestone or specified development and commercialization milestones, for each therapeutic and prophylactic licensed product developed. In January 2022, the Company paid Yale an approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_89f8baf6-ab8a-4163-901a-7e0a1778daed" contextRef="C_83b501bf-9deb-493d-89d6-5fbc9e9ca049" name="inzy:LicenseAgreementPaymentUponAchievementOfSpecifiedProductSalesOrDevelopmentAndCommercializationMilestones" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million milestone payment following dosing of the first patient in Company&#8217;s Phase 1/2 clinical trial of INZ-701 in adult patients with ENPP1 Deficiency in November 2021. In March 2022, the Company paid Yale an approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c6a7806f-857d-4dc1-94aa-67cb2b47ff9e" contextRef="C_18e79562-699d-4e71-9f51-f6b59fe5e488" name="inzy:LicenseAgreementPaymentUponAchievementOfSpecifiedProductSalesOrDevelopmentAndCommercializationMilestones" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million milestone payment following completion of the first cohort of the Company's Phase 1/2 clinical trial of INZ-701 in adult patients with ENPP1 Deficiency in January 2022. In addition, the Company is required to pay Yale an amount in the several hundreds of thousands of dollars, based on the achievement of a specified net product sales milestone or specified development and commercialization milestones, for each diagnostic licensed product developed. While the agreement remains in effect, the Company is required to pay Yale low single-digit percentage royalties on aggregate worldwide net sales of certain licensed products. Yale is guaranteed a minimum royalty payment amount (ranging in dollar amounts from the mid six figures to low seven figures) for each year after the first sale of a therapeutic or prophylactic licensed product that results in net sales. Yale is guaranteed a minimum royalty payment amount (ranging from the low tens of thousands of dollars to the mid tens of thousands of dollars) for each year after the first sale of a diagnostic licensed product that results in net sales. The Company must also pay Yale a percentage in the twenties of certain types of income it receives from sublicensees. The Company is also responsible for costs relating to the prosecution and maintenance of the licensed patents. Finally, subject to certain conditions, all payments due by the Company to Yale will be tripled following any patent challenge or challenge to a claim by Yale that a product is a licensed product under the agreement, made by the Company against Yale if Yale prevails in such challenge.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2017, the Company also entered into a corporate sponsored research agreement with Yale (the "Sponsored Research Agreement"), which was amended in February 2019, under which the Company agreed to provide research support funding in the aggregate amount of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0d3e6b8a-8467-4b2a-8970-f95d308b5d6a" contextRef="C_031bf463-89a7-40b9-950c-5f55540d3e85" name="inzy:ResearchSupportFundingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million over the </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c64c2000-7860-4660-93c2-1b072c7f2fda" contextRef="C_f619a243-7caf-4810-be59-b9733e6d8eae" name="inzy:ResearchSupportFundingPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> period from contract inception through </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_56879eb2-4668-4b58-a909-3a7844dfff6f" contextRef="C_cad8e074-adf8-454f-b55e-9b9e5c164673" name="inzy:ResearchSupportFundingExpirationMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 2021</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Sponsored Research Agreement was amended in February 2022, under which the contract was extended through June 30, 2022 subject to the terms of the existing agreement. The Sponsored Research Agreement was amended again in May 2022, March 2023, and January 2024, such that the agreement now extends through December 2024, with approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_69e5ef67-55f6-47e3-b0e1-d80d29936555" contextRef="C_db0a0e7f-8b7b-448c-940d-e857265ac0d7" name="inzy:ResearchSupportFundingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of Company-provided research support funding for the most recent extension. The aggregate amount of agreed upon research support funding under the Sponsored Research Agreement is </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_818c3757-7176-4ac5-9cda-1a508464a0a1" contextRef="C_f0e6584f-b5b7-4d58-a88c-80a7eadaaae3" name="inzy:ResearchSupportFundingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company recorded research and development expenses associated with this arrangement of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d5f3d3c5-6cce-4901-b475-905305e3e401" contextRef="C_2ad74538-b479-4925-9f60-b6af61969b3d" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_6f908250-7a40-4bd4-9a6a-6576d7ffcfdf" contextRef="C_b8d04e02-0ef5-4212-8c55-26c32b719e5f" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in each of the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span></p></ix:nonNumeric></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c6932093-232f-4c81-8cd3-a1ead01f2db6" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7. Commitments and Contingencies</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Leases</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company held the following significant operating leases of office and laboratory space as of December 31, 2023:</span></p><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An operating lease for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c7f2470c-8dae-488c-b977-7007f81c8865" contextRef="C_65370ce0-f82e-4e38-acd5-1026ec007a18" name="inzy:AreaOfLeasedSpace" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">8,499</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of office space in Boston, Massachusetts that expires in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d02c98e5-f1fc-4880-839b-4ff6be5d137f" contextRef="C_ca6446c0-a789-468c-9c42-d76f1a43d7b9" name="inzy:LesseeOperatingLeaseExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, with an </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1a27f382-16bc-4613-976d-026eaf8cd0c7" contextRef="C_ca6446c0-a789-468c-9c42-d76f1a43d7b9" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">option to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_93b402af-d0d7-49a3-be2e-a1b7c49ff76b" contextRef="C_ca6446c0-a789-468c-9c42-d76f1a43d7b9" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">extend</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> the term for </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_802216cf-b36f-4d46-bdae-18b1a357ac5e" contextRef="C_65370ce0-f82e-4e38-acd5-1026ec007a18" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exercise of the option was determined not to be reasonably certain and thus was not included in the operating lease liability on the consolidated balance sheet as of December 31, 2023 or 2022; and</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An operating lease for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c021174-0dba-465d-a96a-0bcdfb83c4f0" contextRef="C_10590ddc-665f-42d2-b77b-89cf6c383211" name="inzy:AreaOfLeasedSpace" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">6,244</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of laboratory space in Boston, Massachusetts that expires in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_32fffb91-3851-4278-8d33-23553bb51f40" contextRef="C_6a51238e-3618-4c6f-834a-a5b8760a5cab" name="inzy:LesseeOperatingLeaseExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, with an </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_667d5b6c-bdf9-49c4-b446-69194c0641b4" contextRef="C_6a51238e-3618-4c6f-834a-a5b8760a5cab" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">option to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_820996fc-7505-4562-b2b7-4db8f4a08da9" contextRef="C_6a51238e-3618-4c6f-834a-a5b8760a5cab" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">extend</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> the term for </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0244c1ad-87f3-4579-9acd-65cb9370d989" contextRef="C_10590ddc-665f-42d2-b77b-89cf6c383211" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exercise of the option was determined not to be reasonably certain and thus was not included in the operating lease liability on the consolidated balance sheet as of December 31, 2023 or 2022.</span></div></div><p style="text-indent:10.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Both leases are subject to yearly rent escalations. In connection with the Company&#8217;s leases of office space and laboratory space, the Company provided security deposits to the landlords in the form of letters of credit totaling $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_006beaca-571b-414c-97cd-91742860dac8" contextRef="C_85011284-cdc9-4bd4-845f-74414084de51" name="us-gaap:SecurityDeposit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023. The cash collateralizing the letters of credit is included in restricted cash in the accompanying balance sheets as of December 31, 2023 and December 31, 2022.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">        </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the weighted average incremental borrowing rate and the weighted average remaining lease term for the operating leases held by the Company were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d8f71af-2b2a-4d72-bde2-182da70af6c7" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="inzy:OperatingLeaseWeightedAverageIncrementalBorrowingRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bccd7aff-ed31-4e1e-b442-b317757c0e6d" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years, respectively.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2023, cash paid for amounts included for the measurement of lease liabilities was $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_08e8e5c0-14e2-4226-932b-e3dcf9a7ea77" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and the Company recorded operating lease expense of $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_dc03371e-6d7a-4e33-9fa1-4982fad45963" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. During the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, cash paid for amounts included for the measurement of lease liabilities was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8676f171-80dd-4ef9-8323-6e28cb660d0a" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and the Company recorded operating lease expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cfb65d33-f648-4129-9c09-3fa96055d714" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bae67349-64df-4f65-8da4-b2e2268c27ba" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future lease payments under non-cancelable leases as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 are as follows (dollar amounts in thousands):</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.48%;"/>
        <td style="width:2.68%;"/>
        <td style="width:1%;"/>
        <td style="width:15.84%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">Year Ending December 31,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4aa02391-e389-44dc-94b3-ad59f8f7b15a" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,016</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8f42ac1-e12d-4b2c-9728-765ccbbb0c4b" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">944</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de57d7f6-afc7-4d2b-aabe-e5e686c865c1" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="inzy:LesseeOperatingLeaseLiabilityPaymentDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,960</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company did not have any finance leases recorded on its consolidated balance sheet as of December 31, 2023 and 2022.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Indemnification Agreements</span></p><p style="text-indent:10.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters arising out of the relationship between such parties and the Company. In addition, the Company has entered into indemnification agreements with members of its board of directors and senior management that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any claims under indemnification arrangements, and it has not accrued any liabilities related to such obligations as of December 31, 2023 or December 31, 2022.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Legal Proceedings</span></p><p style="text-indent:10.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is not currently a party to any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses the costs related to its legal proceedings as they are incurred. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e888f09d-64fd-4d18-b5a3-c0751f9cb208" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:LegalFees" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_60a28c2c-6763-443b-a63e-520aa3a8681b" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:LegalFees" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> such costs have been incurred during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></ix:nonNumeric></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d78c51bd-29f8-4cf7-9023-653e04fec1f6" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:DebtDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8. Convertible Debt</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Loan Agreement with K2 HealthVentures LLC</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 25, 2022, the Company, as borrower, entered into the Loan Agreement with K2 HealthVentures LLC (&#8220;K2HV&#8221;, together with any other lender from time to time, the &#8220;Lenders&#8221;), K2HV, as administrative agent for the Lenders, and Ankura Trust Company, LLC, as collateral agent for the Lenders. The Loan Agreement provides up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_998c31ae-760d-48ee-af60-e68058727f99" contextRef="C_d9d28d21-3347-4c53-a22e-f87f54964ee4" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">70.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million principal in term loans, subject to certain customary conditions. The Company received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3b4e20b9-7826-4ed5-9456-5a74a9f214e8" contextRef="C_bdaa54b5-eb56-4511-8115-339fb1fdafab" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from the first tranche commitment upon closing. The first tranche commitment contained an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a2921ab7-834f-4c37-a610-591367ab4d8b" contextRef="C_bdaa54b5-eb56-4511-8115-339fb1fdafab" name="inzy:AdditionalLoanAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million available to be drawn at the Company&#8217;s option through March 31, 2023. The Company elected to borrow the remaining $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_abeb86ca-0b0a-4b13-b34b-f8ad95eac97b" contextRef="C_bdaa54b5-eb56-4511-8115-339fb1fdafab" name="inzy:AdditionalLoanAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in February 2023. Two subsequent tranche commitments totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51f2f0fb-42d8-48e7-b18a-6eefc010ead0" contextRef="C_d18b316d-5084-434e-a439-1915ad6efe10" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in the aggregate were available to be drawn at the Company&#8217;s option during certain availability periods, subject to the achievement of certain clinical and regulatory milestones relating to INZ-701. The Company elected to borrow $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_02e3d740-ed94-43c3-a5ce-d6d91010ada5" contextRef="C_5ebf2fa0-40a8-42d4-9daa-b0340f2d221d" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million under the second tranche commitment in June 2023 and elected to borrow $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_efef1339-66a8-4468-896b-87567cac8ea6" contextRef="C_52088c66-3520-4604-9fd3-bc8ff48b99dc" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million under the third tranche commitment in December 2023.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A fourth tranche commitment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_33db14f9-2722-4550-8ae9-c6e19b142746" contextRef="C_93d69508-3aa9-4327-a66a-00b902adeda8" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million may be made available to be drawn down at the Company&#8217;s option through August 31, 2025, subject to use of proceeds limitations and Lender's consent at its discretion. The fourth tranche commitment is subject to an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_73a46437-81be-45f2-9ef7-ce4c2d6a2890" contextRef="C_35debf45-eff8-4880-842d-b7923517d412" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.75</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% facility fee.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cb770ce7-f985-443a-9197-ee327eacbffe" contextRef="C_5d4682fc-b7e8-4bc8-a04e-f170756de070" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of borrowing capacity remained available under the Loan Agreement, subject to the terms and conditions set forth therein. As security for its obligations under the Loan Agreement, the Company granted the Lenders a first priority security interest on substantially all of the Company&#8217;s assets (other than intellectual property), subject to certain exceptions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The term loan matures on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2b2f008e-eb72-4c66-bf46-e1a2a5b4a33b" contextRef="C_d9d28d21-3347-4c53-a22e-f87f54964ee4" name="us-gaap:LongTermDebtMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">August 1, 2026</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_24b62f6b-6a74-42d6-a04f-c94fe3c36c65" contextRef="C_7521ee38-3522-499f-9163-aff0538685b8" name="us-gaap:DebtInstrumentPaymentTerms"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Company is obligated to make interest only payments for the first 36 months and then interest and equal principal payments through the maturity date. The term loan bears a variable interest rate equal to the greater of (i) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_da091b37-4c25-494d-98e8-9d8257e273d8" contextRef="C_7521ee38-3522-499f-9163-aff0538685b8" name="us-gaap:DebtInstrumentInterestRateBasisForEffectiveRate"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7.85</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, and (ii) the sum of (A) the prime rate last quoted in The Wall Street Journal (or a comparable replacement rate if The Wall Street Journal ceases to quote such rate) and (B) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a43b16a9-4c3c-4961-83ab-a47a5220c4b9" contextRef="C_1bb0cd98-9386-44b8-b7ca-6ea13928be77" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.85</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%; provided that the interest rate cannot exceed 9.60%</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The interest rate as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0adea806-885e-4459-a7d9-103ef315688f" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:DebtInstrumentInterestRateBasisForEffectiveRate"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9.60</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%. The Company has the option to prepay all, but not less than, the outstanding principal balance and all accrued and unpaid interest with respect to the principal balance being repaid of the term loans, subject to a prepayment premium to which the Lenders are entitled. The prepayment fee is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_852ae480-acab-4ba0-b22c-e47de35067c2" contextRef="C_7127e8c7-8b18-4fcc-9ba4-6bd21fc208d5" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% prior to the second anniversary of the July 25, 2022 funding date, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6af69d8c-8c5f-4cfa-a410-907505f75ed1" contextRef="C_18d66cf9-fa61-4466-8750-6ba204ccf660" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% after the second anniversary but prior to the third anniversary of the funding date, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c462e082-c86c-4956-836c-ff7653160aec" contextRef="C_0e40adfd-e61b-4fd5-8fdb-f07aeb03f570" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">thereafter if prior to the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">maturity </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">date. Upon final payment or prepayment of the loans, the Company must pay a final payment equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd230d24-1d82-4e25-ae1f-0d0f927dc8b3" contextRef="C_7521ee38-3522-499f-9163-aff0538685b8" name="inzy:PrepaymentOfLoans" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">6.25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the loans borrowed ("Final Fee"), which is being accrued as interest expense over the term of the loan using the effective interest method.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Lenders may elect, prior to the full repayment of the term loans, to convert up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_083f3f2b-5306-471f-a9be-3bf5f3f827b8" contextRef="C_b8ef8150-b682-4318-bd34-79e0eb945521" name="us-gaap:DebtConversionConvertedInstrumentAmount1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of outstanding principal of the term loans into shares of the Company&#8217;s common stock, at a conversion price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2e834631-c57b-4a61-85c6-c90506f843ad" contextRef="C_d9d28d21-3347-4c53-a22e-f87f54964ee4" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.21</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, subject to customary adjustments and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3edefc12-d9ad-4a5e-8f87-fe9015f87d34" contextRef="C_f0ae2476-b345-490a-a86b-4a01fe48843b" name="inzy:CustomaryAdjustmentsPercentageOnConversion" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">9.99</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9f2ff211-b7b6-4eaf-bf2b-681d04a001b6" contextRef="C_f0ae2476-b345-490a-a86b-4a01fe48843b" name="inzy:PercentageOfBeneficialOwnershipLimitation" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">19.99</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% beneficial ownership limitations. The Company determined that the embedded conversion option was not required to be separated from the term loan. The embedded conversion option met the derivative accounting scope exception since the embedded conversion option is indexed to the Company&#8217;s own common stock and qualifies for classification within stockholders&#8217; equity.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Loan Agreement contains customary representations and warranties, events of default and affirmative and negative covenants, including covenants that limit or restrict the Company&#8217;s ability to, among other things, dispose of assets, make changes to the Company&#8217;s business, management, ownership or business locations, merge or consolidate, incur additional indebtedness, incur additional liens, pay dividends or other distributions or repurchase equity, make investments, and enter into certain transactions with affiliates, in each case subject to certain exceptions. Upon the occurrence of an event of default, a default interest rate of an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_769de3fa-e0e5-4e49-ab1d-8b02d06a8224" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">5.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% per annum may be applied to the outstanding loan balances, and the Lender may declare all outstanding obligations immediately due and payable and exercise all of its rights and remedies as set forth in the Loan Agreement and under applicable law. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, the Company was in compliance with all covenants under the Loan Agreement.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subject to certain conditions, the Company granted the Lenders the right, prior to repayment of the term loans, to invest up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_86899b80-b051-4b52-8916-e04f395b5f87" contextRef="C_b8ef8150-b682-4318-bd34-79e0eb945521" name="inzy:FutureOfferingsOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in the aggregate in future offerings of common stock, convertible preferred stock or other equity securities of the Company that are broadly marketed and offered to multiple investors, on the same terms, conditions and pricing afforded to others participating in any such financing.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company incurred debt issuance costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c382ed12-d132-460b-b27a-ed21fdcdc5e6" contextRef="C_a9bb1918-b1d7-45e7-8152-c53d74f19eda" name="us-gaap:DeferredFinanceCostsGross" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in connection with the term loan. In addition, at the time of closing the Company paid to the Lenders a facility fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0a57bcbb-5f64-488f-864d-1c3a2dd7731a" contextRef="C_0c02063f-a103-4d30-8717-1985a331947e" name="us-gaap:LineOfCreditFacilityCommitmentFeeAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, as well as $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc329e81-1afe-4e36-8865-001c86346ae1" contextRef="C_0c02063f-a103-4d30-8717-1985a331947e" name="inzy:LendersReimbursedAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of other expenses incurred by the Lenders and reimbursed by the Company ("Lender Expenses"). At </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, the carrying value of the Loan Agreement approximates the fair value of the term loan, considering that it bears interest that is similar to prevailing market rates.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d19eac8d-4ebd-4303-a0c4-5aae2ac47f49" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="inzy:SummarizesOfImpactTermLoanTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the impact of the term loan on the Company&#8217;s consolidated balance sheet at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023:</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.64%;"/>
        <td style="width:5.36%;"/>
        <td style="width:1%;"/>
        <td style="width:38%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gross proceeds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e801b7e0-1800-4b92-b79d-f332bd7bfb1d" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unamortized debt issuance costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1083c65f-c5bb-448c-ab4c-0da930814a33" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">231</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Carrying value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_97db1235-9947-4364-b1ad-ae37ceb63633" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,769</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_daba7b32-e06a-49d7-a908-f246d696727f" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future principal payments, which include the Final Fee, in connection with the Loan Agreement as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 are as follows (dollar amounts in thousands):</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.64%;"/>
        <td style="width:5.36%;"/>
        <td style="width:1%;"/>
        <td style="width:38%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fiscal Year</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fcf118ce-e866-49a2-a75a-0462e537f6d0" contextRef="C_02f9e665-ab6c-4248-ac91-2158ec322783" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8727c29f-01ab-421c-aa92-93db0d4d00fb" contextRef="C_02f9e665-ab6c-4248-ac91-2158ec322783" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,508</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a3a7d43-2f6c-48f2-99f9-9f6f6523acc4" contextRef="C_02f9e665-ab6c-4248-ac91-2158ec322783" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,305</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2087345f-a4dc-4de3-8eb1-dd06e2f10c95" contextRef="C_02f9e665-ab6c-4248-ac91-2158ec322783" name="us-gaap:LongTermDebtMaturingInYearsTwoAndThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,813</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:line-through;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;text-decoration:line-through;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_21d9503d-5f33-4944-8bf9-9665cb79f6e2" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9. Stockholders&#8217; Equity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">July 2023 Underwritten Offering</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 27, 2023, the Company entered into an underwriting agreement with BofA Securities, Inc., Cowen and Company, LLC and Piper Sandler &amp; Co., as representatives of the several underwriters named therein (collectively, the &#8220;Underwriters&#8221;), relating to an underwritten public offering of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e75a49a8-f91c-4bcc-9a9d-51cd2826b99b" contextRef="C_0bbdd3e1-67b1-4179-a2ad-34d654b46a8f" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">14,375,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company's common stock, which included </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a91c1123-fe00-4903-87ae-7683056ed697" contextRef="C_f1c3e67f-9945-41f0-944d-8d830ba9739e" name="inzy:AdditionalSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,875,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">issued upon the exercise in full by the underwriters of their option to purchase additional shares (the "July 2023 Shares"). The closing of the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">offering </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">took place on August 1, 2023. All of the July 2023 Shares were sold by the Company. The offering price of the July 2023 Shares was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7447e331-8697-46c3-a6c1-d76be72d9404" contextRef="C_5fadef3d-5895-480b-9d9e-def33be1c27e" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.80</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. Net proceeds from the sale and issuance of the July 2023 Shares were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_214d47c8-9558-4310-8be5-0a236f58d127" contextRef="C_23e7c97e-bcf3-4add-9b14-99d3a9ed6274" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">64.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, after deducting underwriting discounts and commissions and offering expenses.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">April 2022 Underwritten Offering</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 11, 2021, the Company filed a universal shelf registration statement on Form S-3, which was declared effective on August 23, 2021, (the "Registration Statement"). Under the Registration Statement, the Company may offer and sell up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a71adbc9-3726-499a-afbf-79dda4bfd72c" contextRef="C_8bc77b63-43ca-4a39-8474-2b255355a3eb" name="inzy:AvailableForDebtSecuritiesEquitySecuritiesNonCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">200.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of a variety of securities, including common stock, preferred stock, depositary shares, debt securities, warrants, subscription </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> rights or units from time to time pursuant to one or more offerings at prices and terms to be determined at the time of the sale. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 14, 2022, the Company entered into an underwriting agreement with Jefferies LLC and Cowen and Company, LLC, relating to an underwritten offering under the Registration Statement of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d5b7e299-7149-4eef-abfc-bbec95990387" contextRef="C_c1e93c7a-08ea-4229-9081-72bf42fdc58f" name="inzy:UnderwrittenOffering" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">16,276,987</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock (the "Shares") and, in lieu of common stock to certain investors, pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_991516bf-b9aa-40af-9987-4634eb21227b" contextRef="C_578990c4-7b65-4722-8ca8-59f878771332" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,523,013</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock. The closing of the offering took place on April 19, 2022. The offering price of the Shares was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e3ff73a-d9c0-4dfe-b43c-fe57e7112f44" contextRef="C_53f07547-6128-43d4-94ec-d5cd4d0f51e5" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.69</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and the offering price of the pre-funded warrants was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d92e8396-1f84-4546-8e97-e9494f19bac6" contextRef="C_578990c4-7b65-4722-8ca8-59f878771332" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">3.6899</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share underlying each pre-funded warrant. Warrants must be exercised by means of a cashless exercise. Net proceeds from the offering were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4b58815-1011-4dd9-9dba-437be07a3b26" contextRef="C_c1e93c7a-08ea-4229-9081-72bf42fdc58f" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">68.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, after deducting underwriting discounts and commissions and offering expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On June 10, 2022, the Company and each holder of the pre-funded warrants entered into amended and restated pre-funded warrants solely to eliminate the seven-year expiration date of the pre-funded warrants. Each amended and restated pre-funded warrant is now exercisable for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6d2f30b9-8e6a-4305-a856-b278517f6f5e" contextRef="C_bb47b565-7017-4ae4-8380-7d7bb5c73132" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share of common stock from the original date of issuance until the date the pre-funded warrant is exercised in full. All other terms of the pre-funded warrants remain unchanged. The pre-funded warrants contain standard adjustment provisions if certain corporate events were to happen.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The pre-funded warrants are classified as a component of permanent equity and were recorded at the issuance date using a relative fair value allocation method. The pre-funded warrants are equity classified because they are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the holders to receive a fixed number of shares of common stock upon exercise. In addition, such pre-funded warrants do not provide any guarantee of value or return. As of December 31, 2022, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_576f0f3d-e449-4bdb-92f1-9203e52eca56" contextRef="C_67c9227f-23fa-4d03-94ed-39eb46d276a9" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:num-dot-decimal">197,251</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> pre-funded warrants had been exercised by means of cashless exercise in exchange for the issuance of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f722c15-673a-4228-aaaf-d7609a139eeb" contextRef="C_67c9227f-23fa-4d03-94ed-39eb46d276a9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">197,240</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company's common stock. As of December 31, 2023, the remaining </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_53d108af-805d-4e58-9b9a-6c25ca66f252" contextRef="C_1d9a39c0-b43f-460b-b719-403d215c02a3" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:num-dot-decimal">3,325,762</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> pre-funded warrants had been exercised by means of cashless exercise in exchange for the issuance of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_31136318-ae9f-4321-85ce-7027551a8273" contextRef="C_1d9a39c0-b43f-460b-b719-403d215c02a3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,325,644</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company's common stock.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Open Market Sale Agreement</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the filing of the Registration Statement on August 11, 2021, the Company entered into an Open Market Sale Agreement with Jefferies LLC, as sales agent, pursuant to which the Company may offer and sell shares of its common stock with an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_202c9b84-d883-4d98-a57a-7a9344dc8a29" contextRef="C_8bc77b63-43ca-4a39-8474-2b255355a3eb" name="us-gaap:CommonStockSharesSubscriptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million under an &#8220;at-the-market&#8221; offering program. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ea51f265-b41a-425f-8d81-385adbbd44eb" contextRef="C_0502b5cf-19d3-4a39-bb6c-6e6617f1dc75" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,553,995</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock pursuant to the Open Market Sale Agreement for aggregate net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1726532e-bb0a-44c4-845d-030264d24fd9" contextRef="C_0502b5cf-19d3-4a39-bb6c-6e6617f1dc75" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">21.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity Incentive Plans</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2017, the Company&#8217;s board of directors and stockholders adopted the 2017 Equity Incentive Plan, which was amended and restated in July 2017, (as so amended and restated, the &#8220;2017 Plan&#8221;), which provided for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards and other stock awards. The maximum number of shares of common stock that were authorized for issuance under the 2017 Plan was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f394a5ba-8f67-47fd-b8fd-d07a8a231f66" contextRef="C_bebe8a61-3f52-4590-a963-a6915fc4e374" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,730,496</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_29802e4b-9def-4267-9561-f1e6310a9710" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 17, 2020, the Company&#8217;s stockholders approved the 2020 Stock Incentive Plan (the &#8220;2020 Plan&#8221;), which became effective on July 23, 2020. The 2020 Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock units, and other stock-based awards. The number of shares of the Company&#8217;s common stock reserved for issuance under the 2020 Plan</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_03c0a04a-1ea2-4469-8360-3e9de5452b0d" contextRef="C_6f3ac30a-0134-4683-b65a-b99db351909d" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,588,315</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares, plus the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22a4276e-8641-46e2-baef-b1e4ba0668bf" contextRef="C_e462903e-5095-4918-b351-d475a954fa3c" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">426,065</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock remaining available for issuance under the 2017 Plan as of July 23, 2020. The number of shares reserved under the 2020 Plan will be annually increased on each January 1 through January 1, 2030 by the lower of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_414d9d84-ec40-4d1f-85ce-18a19b901c2a" contextRef="C_ecaeeeb0-1d3a-46e8-a993-a422899cf67d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the number of shares of common stock outstanding on the first day of such fiscal year and (ii) an amount determined by the Company&#8217;s board of directors.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of the effective date of the 2020 Plan, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2a9c101e-678b-4167-9acf-8278e6bcc45c" contextRef="C_c5b05844-1535-4e7e-bc09-618ad8076340" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> further </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">awards will be made under the 2017 Plan. Any options or awards outstanding under the 2017 Plan are governed by their existing terms. The shares of the Company&#8217;s common stock subject to outstanding awards under the 2017 Plan that expire, terminate, or are otherwise surrendered, cancelled, forfeited, or repurchased by</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company at their original issuance price pursuant to a contractual repurchase right will be added back to the shares of common stock available for issuance under the 2020 Plan. No more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_baa2f23a-1454-4d79-b8df-767c14e736e0" contextRef="C_6f3ac30a-0134-4683-b65a-b99db351909d" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,588,315</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock may be granted subject to incentive stock options under the 2020 Plan. On January 1, 2024 and 2023, the number of shares of common stock reserved under the 2020 Plan was increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8aaa1ce0-78de-45b4-8efb-b4829a3300a4" contextRef="C_5bc7e1b8-abf2-44b5-9b32-535f64c92fa2" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,470,750</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2dd33430-c1b7-455c-8d96-8de3605eb4ff" contextRef="C_31d32f64-dc44-41d7-bce8-ff6cf58b79cc" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,615,774</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 27, 2023, the Company's board of directors adopted the 2023 Inducement Stock Incentive Plan (the "Inducement Plan"). The Inducement Plan provides for the grant of non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock units, and other stock-based awards to persons who (a) were not previously an employee or director or (b) are commencing employment with the Company following a bona fide period of non-employment, in either case, as an inducement material to such person</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8217;s entry into employment with the Company and in accordance with the requirements of the Nasdaq Stock Market Rule 5635(c)(4). As of December 31, 2023, the maximum number of shares of the Company's common stock reserved for issuance under the Inducement Plan is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_346207fa-f98f-41ea-a412-8fc780f07f4d" contextRef="C_e9fc3ff4-5b7b-4b15-a31d-763d0bfe62db" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the years ended December 31, 2023 and 2022, the Company recognized stock-based compensation expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7be9dce1-e3d1-4f12-abec-34400967ce0f" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f8ad34b8-7279-4e38-b242-d357f8d94dc6" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. The fair value of shares vested for the years ended December 31, 2023 and 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ba5979b9-d669-40da-a411-345fd6b12648" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de172955-7615-4661-bd1c-b75554e29536" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Options</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_daa4ccaa-c364-4d34-9bad-612142fa100a" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes stock option activity under the Company&#8217;s equity incentive plans since </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.11%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.662%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:8.942%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.662%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.182%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Options<br/>Outstanding</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value (1)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in years)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f434c12-d687-4baa-94c8-c60a8c2843f5" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,687,811</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_91e36684-c288-4bef-976d-6d313ef002b0" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.53</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_49c62019-4213-4431-9f3a-1b152c902b27" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.06</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_212880b3-7bbd-414d-81a7-6f5c3c25b8a3" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8b566164-6bd3-45d2-ad61-ebe864595bbf" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,019,590</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_93b814d2-98bf-4865-a529-66058165491f" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.53</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b96d059a-55cf-4b85-b1ad-f2c2f18d0eff" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">43,209</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d724af64-dac3-4617-9196-f02134e0826b" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.70</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e96a3b2-30ac-4833-8be4-3ec7d3eef215" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">627,526</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a9cb34c-cba6-4f22-92d5-121ee07f8215" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.43</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_09ca56cb-9fdd-4d28-a19c-9170fd0de9c0" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,036,666</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_40ed48fa-de60-4afa-a347-0ca5cc3a8e9d" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.68</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_9cd50fe9-9e2d-455e-b4ad-7f69cb055ea3" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.71</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8286ff25-fc6a-4473-a014-fe4d629b6f5c" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,615</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_566225b0-2e32-4d22-8134-9a270e41da65" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,370,210</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dc8900e4-109f-4b69-856a-a71d51fb9de6" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.05</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_84c591d6-4dc6-4aa5-862c-487ea244c898" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.37</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d11eac6-1566-416a-92bc-7160911079e4" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,007</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested and expected to vest at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_17935371-a703-406d-a3ba-6f9fbef32384" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,036,666</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dda6459c-1e3e-4e23-ba20-758679f9d638" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.68</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_d3cd3473-47a5-4cdc-8b8e-0d3fa50ace31" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.71</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34c25793-e274-4a98-b618-192bea48ea94" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,615</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(1) </span><ix:footnote id="FNT_b26c1e5b-e21a-4bc2-827a-a1536cde1c95" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#8217;s common stock.</span></ix:footnote></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted average grant date fair value of stock options granted in the years ended December 31, 2023 and 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9725b4f1-8389-4576-af55-c27a17f9c0aa" contextRef="C_909f663f-1f61-4e6b-b9d6-919c23e28089" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.47</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_503757dd-a258-460f-a34e-64ff99b1bd88" contextRef="C_cd4ff0c3-e817-48e8-b8c3-ca0078eec69f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.45</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, respectively. The aggregate intrinsic value of stock options exercised during the years ended December 31, 2023 and 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_311f19dc-32dc-4d85-9829-6b974259d819" contextRef="C_909f663f-1f61-4e6b-b9d6-919c23e28089" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b93bc725-3f79-406c-b01f-e82657d3450f" contextRef="C_cd4ff0c3-e817-48e8-b8c3-ca0078eec69f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The total unrecognized compensation cost related to outstanding employee option awards as of December 31, 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_96c2e989-4dc2-49fa-94a0-213232ff9de2" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and is expected to be recognized over a weighted average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_af7ec8d1-b036-43a4-8e4e-400b68d221bb" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.8</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For purposes of calculating stock-based compensation expense, the Company estimates the fair value of stock options using the Black-Scholes option-pricing model. This model incorporates various assumptions, including the expected volatility, expected term, and interest rates. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b0deff98-ee90-44e0-a82e-3a868f7f0bbb" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true" continuedAt="F_b0deff98-ee90-44e0-a82e-3a868f7f0bbb_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The underlying assumptions used to value stock options granted to participants using the Black-Scholes option-pricing were as follows: </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_b0deff98-ee90-44e0-a82e-3a868f7f0bbb_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:14.883%;"/>
        <td style="width:1.62%;"/>
        <td style="width:14.883%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate range</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_76111b75-6fad-4cfb-b2cc-5b1260497528" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.36</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% to </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d579463-fb19-48c4-978b-f8e06cb87550" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.67</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f863a87-cc34-40c4-bcd1-5d0c5639ec99" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">1.59</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% to </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0f50d03f-efa6-4aa8-a24a-ea2e1a1bc035" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.30</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a4fe7cbf-6b16-4a14-86df-d3ba96d0a5c1" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_07244c18-368b-4f2d-8bf2-eb1c017bc529" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term of options (years)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_37da54b5-c4a0-4940-8f5f-6831086aad29" contextRef="C_ce440ee2-4c72-4b3f-867c-b18a4779f0de" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;to </span><span><ix:nonNumeric id="F_cb862c2e-67a7-46cb-b544-ca3ad52b9b51" contextRef="C_fc80a413-7ca1-4fd4-9918-01e35939d5b6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.48</span></ix:nonNumeric></span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_47d38b36-1388-48f6-a7a8-33f49778d360" contextRef="C_8f668d05-5207-4a0e-8751-b2c77362080c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.08</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;to </span><span><ix:nonNumeric id="F_516d44c8-0d75-42cb-beee-6b686b2b766f" contextRef="C_809272a0-4381-416d-b6c1-4926d329a113" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.48</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Volatility rate range</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_572fbc7a-2486-4da1-9d1e-d7aff73557f9" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">87.26</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% to </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c876b390-23ee-4f1c-8dab-707ddcba5b7e" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">89.67</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_12b595ea-1c1c-482e-9da4-b7286b1d69d8" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">84.50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% to </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_975293f8-77c9-4c0d-8b45-61bbeabc01e0" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">87.15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">19</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected Term &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The expected term of stock options represents the weighted average period the stock options are expected to be outstanding. The Company uses the simplified method for estimating the expected term, which calculates the expected term as the average time-to-vesting and the contractual life of the options for stock options issued to participants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected Volatility &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Due to the Company&#8217;s limited operating history and lack of company-specific historical or implied volatility, the expected volatility assumption was determined by examining the historical volatilities of a group of industry peers whose share prices are publicly available. The Company expects to continue using this approach until such time as it has adequate historical data regarding the volatility of its own traded stock price.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk-Free Interest Rate &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The risk-free rate assumption is based on U.S. Treasury instruments, the terms of which were consistent with the expected term of the Company&#8217;s stock options.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected Dividend &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The expected dividend assumption is based on the Company&#8217;s history and expectation of dividend payouts. The Company has not paid any dividends to date and does not intend to pay dividends.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Following the Company's initial public offering, the fair value of the Company&#8217;s common stock has been determined based on the closing price of the Company&#8217;s common stock on the Nasdaq Global Select Market on the grant date, with consideration of whether there is material nonpublic information that could impact that estimated fair value when it is released.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">RSUs</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bbf3a3f3-9d4d-4980-9ac1-327a9b82958d" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Activity related to restricted stock units ("RSUs") for the year ended December 31, 2023 is summarized in the table below:</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.22%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1%;"/>
        <td style="width:16.3%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of January 1, 2023</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dbf05ff7-8344-4dc5-b37f-b513960ad11c" contextRef="C_c7103008-51fd-4024-8f26-143b54185554" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4e1a1a1e-609e-42f1-aa65-b7685c7a7783" contextRef="C_095b17b0-4474-4132-8919-5e9087e56021" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">100,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Canceled / Forfeited</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e6e2e8e8-f793-4430-8e64-04a5ea581530" contextRef="C_095b17b0-4474-4132-8919-5e9087e56021" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested / Settled</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a5841c09-1984-4925-90ec-0210e403dfce" contextRef="C_095b17b0-4474-4132-8919-5e9087e56021" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b15311a0-263a-46f0-bb11-4897616eeeeb" contextRef="C_36317d60-ef8e-4485-8be4-dbe28ed900be" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">100,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted-average grant date fair value of RSUs granted in the year ended December 31, 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_1a2d3a8c-83fa-4d0b-8a79-557d0233d8a7" contextRef="C_095b17b0-4474-4132-8919-5e9087e56021" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.73</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. The total unrecognized compensation cost related to outstanding RSUs as of December 31, 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_c1e67522-781b-4371-867c-0ffcc7fec9ed" contextRef="C_36317d60-ef8e-4485-8be4-dbe28ed900be" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and is expected to be recognized over a weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6094ef1a-6359-44fe-8c10-0ac18c6292cd" contextRef="C_095b17b0-4474-4132-8919-5e9087e56021" name="inzy:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Employee Stock Purchase Plan</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 17, 2020, the Company&#8217;s stockholders approved the 2020 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;), which became effective on July 23, 2020. The ESPP initially provided participating employees with the opportunity to purchase up to an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7684a5d9-c6d8-4e6d-87e8-7e1fc9cad2a2" contextRef="C_41e6d162-5110-43e5-831b-9b8060b23a84" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">198,539</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5ab628ea-25bc-43d9-b34d-af552c7c07bc" contextRef="C_6eef9496-93b0-48ca-b3cf-47eb906b4a01" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The number of shares of common stock reserved for issuance under the ESPP will increase each January 1 through January 1, 2031, in an amount equal to the lowest of (1) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_24f8c329-e27b-4b27-ab27-92a041df5326" contextRef="C_6eef9496-93b0-48ca-b3cf-47eb906b4a01" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">397,079</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock, (2) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_62df0eb3-b31c-4b80-895a-b7a138489765" contextRef="C_6eef9496-93b0-48ca-b3cf-47eb906b4a01" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the number of shares of the Company&#8217;s common stock outstanding on the first day of such fiscal year, and (3) an amount determined by the Company&#8217;s board of directors.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> On January 1, 2024 and 2023, the number of shares of common stock reserved under the ESPP was increased by </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_4f066e64-94c9-4d85-854b-dcbf2531890d" contextRef="C_b5a7dbf5-13da-420d-8cd7-0ede5acf17cc" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">397,079</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_e18de26a-adc5-4835-a769-7a35b3ba3714" contextRef="C_fe23324a-e605-4ce7-a370-83d0da0161d5" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">397,079</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares, respectively. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company activated its first six month offering period under the ESPP on April 1, 2022. As of December 31, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_0a6226ed-59fb-4248-bb93-3422fc39076d" contextRef="C_263cecd1-5504-45b5-bec1-fb7bb72fed3f" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">116,972</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares have been purchased by employees under the ESPP.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:nonNumeric id="F_61095702-f03a-48ca-96e2-0b215a58b6a7" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10. Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">   </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the years ended December 31, 2023 and 2022, the Company recorded pre-tax net losses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1470d594-ffef-44bd-9e05-d7f4e197b539" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">71.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_97362368-b5cf-4591-952c-66fff35a8fd2" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">67.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. Since it maintains a full valuation allowance on its deferred tax assets, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4250fd7a-fbea-4648-9a25-a9111075a3f8" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen"><ix:nonFraction id="F_37f06261-6c64-43fd-b727-3787addba09f" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t record an income tax provision for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022.</span></p><p style="text-indent:9.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ac29af33-b8a0-4c3a-adf5-087a20f7b7e5" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:9.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</span></p><p style="text-indent:9.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.088%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:16.277%;"/>
        <td style="width:1%;"/>
        <td style="width:1.44%;"/>
        <td style="width:1%;"/>
        <td style="width:16.277%;"/>
        <td style="width:1%;"/>
        <td style="width:1.92%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="8" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal income tax at statutory rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e1cb889b-fd85-40a0-98dc-fb49ffbd3af1" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_410d9c31-72b7-4734-9640-2f3fbac3848c" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Permanent differences</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b9615d6a-10d9-424c-8ba5-c7539021006d" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="inzy:Effectiveincometaxratereconciliationpermanentdifferences" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c092843-27b3-42dc-a555-697c906a70a8" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="inzy:Effectiveincometaxratereconciliationpermanentdifferences" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.6</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State income tax, net of federal benefit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1778e033-aa70-4498-bad2-e4676eb77999" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">8.1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f3a5c87-a571-49cd-b4e4-2e1d1ff12f78" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">5.4</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal and state research and development tax credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e6d33a90-246d-47ec-8234-f3dc21a258e7" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">9.1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0905f88e-c54c-4211-9ffb-9c5b77e3b4ab" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">5.5</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4cfba11d-da0b-4ee8-8fdb-b8d2af288ab9" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">37.2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d4a0203-b219-46bf-88af-4e584981b346" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">30.3</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Effective income tax rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_35590ff5-b7c1-4fcc-884d-171819bad8cd" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff1adfeb-dee5-4445-a580-16ad2715d442" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">     </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred taxes are recognized for temporary differences between the bases of assets and liabilities for financial statement and income tax purposes. </span><span style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f9eb7fec-181d-49b7-8945-18d89b9a184e" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true" continuedAt="F_f9eb7fec-181d-49b7-8945-18d89b9a184e_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The significant components of the Company&#8217;s deferred tax assets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 are composed of the following (dollar amounts in thousands): </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_f9eb7fec-181d-49b7-8945-18d89b9a184e_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating losses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd8528d7-ae94-4242-b663-10ce29275bdc" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,999</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3fc847ab-859c-4549-bfa4-8b488188b890" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,144</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d7ca8458-4c47-44b9-9c6f-ab6190118d71" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,903</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d1729eb1-e084-49d4-b729-a86fbca90587" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,220</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_671de964-2d70-4a26-b893-162d82f750b5" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,930</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d1bb6a57-017a-4ef5-a531-5c5a253372cb" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,604</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ed4e904-62fb-4e05-9825-8192bbfc69e8" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">916</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af5c5921-5240-4f79-ab92-ce130eaa3745" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">758</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e5e67ee-ce68-4202-9a2c-fb34456e3a4e" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="inzy:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,759</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_56796d58-be4f-49a7-b046-40cc5602e301" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="inzy:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,899</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a179603-7970-452a-8d48-c06bfecc2999" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:LeaseIncentiveReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">499</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_71cd708a-a0fd-4304-bce5-5d67297d43ff" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:LeaseIncentiveReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">688</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized research and experimental expenditures</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e3736e8b-2b4f-4867-87a9-06138ddde595" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,959</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5e59960d-1fa9-4ff7-86d6-99345eb17ca6" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,467</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb29c884-f53b-4239-aa61-88312757fd42" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">351</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d684b46-d5fb-4e6d-80ce-82fca8aba04f" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">297</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gross deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_75b390b9-db00-4322-be0e-119cb0a099ec" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89,316</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_83a4afd0-5b00-4e32-816b-c40c9802d052" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,077</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_641decec-727b-47ff-afb7-748d244e665a" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">88,906</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ffefd55-6bbf-4371-a171-997acff86831" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62,468</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ae4c811-83ba-4d94-ae1f-a19a7833478b" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">410</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fdb837a3-f8e5-4e3b-a2bb-0785e944b9b0" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">609</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation of fixed assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cabb3f4e-9bf3-4fd9-8edd-4cdc67cff1b1" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_214c807f-b62a-42af-bd58-59bce2b35d9f" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">184</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right of use assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c07ce8d7-bb3a-476a-af7e-222d8b190f34" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="inzy:DeferredTaxLiabilitiesRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">308</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_20e4102f-ecc2-4552-8007-af750722b42b" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="inzy:DeferredTaxLiabilitiesRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">422</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_203fbbf8-6168-4c27-ac7f-90c394781003" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="inzy:Others" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">38</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_db506265-853a-4098-b749-fe84119a8bdd" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="inzy:Others" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gross deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c4e06f93-0e8c-410f-b70c-0610a3147a7c" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">410</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_757a50d1-43c1-4613-907c-a3d700f8ade4" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">609</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-current net deferred tax assets (liabilities)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_56e5d483-9eab-403d-85c4-2d5936db432a" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e0f8fe0-a82a-428d-a236-d46cf399ee12" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company had gross federal net operating loss carryforwards ("NOLs") of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_f86a9473-44a9-4f9e-bdad-b08a65345ffd" contextRef="C_bbdbd94c-6c63-4c85-99b0-648d3794ad11" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">164.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which may be available to offset future taxable income. Of the federal NOLs, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_c5c3960d-0d05-4789-8297-6a96de9fcb65" contextRef="C_bbdbd94c-6c63-4c85-99b0-648d3794ad11" name="inzy:OperatingLossCarryforwardsWithExpirationPeriod" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_39322d91-0126-4af2-9f63-91f89fce511b" contextRef="C_18a731bb-67c4-4ab0-8890-db73d8f7acd7" name="inzy:OperatingLossCarryforwardsExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2037</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_882adb88-7dee-4bfc-b213-e135c6551933" contextRef="C_bbdbd94c-6c63-4c85-99b0-648d3794ad11" name="inzy:OperatingLossCarryforwardsWithNoExpirationPeriod" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">158.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million do not expire. As of December 31, 2023, the Company had gross state NOLs of  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_beb8b4c4-b8ab-4dd6-a4e6-a08165659de2" contextRef="C_3c60cddf-e6e6-40e7-af29-5142f2416154" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">135.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which may be available to offset future taxable income and which begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b88aa229-9331-4b54-887e-60698f0f82b0" contextRef="C_a4ab63bc-07be-46e6-aa82-1e04ab169eca" name="inzy:OperatingLossCarryforwardsExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2037</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As required by FASB ASC Topic 740, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, management of the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, which are composed principally of capitalized research and experimental ("R&amp;E") expenditures, NOLs, and research and development credits. Under the applicable accounting standards, management has considered the Company&#8217;s history of losses and concluded that it is more likely than not that the Company will not recognize the benefits of federal and state deferred tax assets. Accordingly, a full valuation allowance of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_535af447-7cf3-4536-b3ee-90e095c99aa3" contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">88.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_e7dd0d9b-dbcb-4e30-84cd-5e6e91b90fc5" contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">62.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million has been established at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and December 31, 2022, respectively. The increase in the valuation allowance of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_30b3294a-33b0-4c05-9768-354b123221e1" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">26.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023 was primarily due to increases in capitalized R&amp;E expenditures, NOLs, and research and development credits generated by the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company also has federal and state research and development credit carryforwards totaling </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_8ea1b5ae-4e6b-4bf7-ae16-e206a5f34c8f" contextRef="C_eeb4217e-fc77-4296-9ee9-2a609ec3e2d5" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">17.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The federal research and development credit carryforwards will begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0ab2d1d2-9328-4c04-8db2-fe34692ab2e5" contextRef="C_d2a5c6ce-86e7-4875-bb49-7e9cb50c94fc" name="inzy:TaxCreditCarryForwardExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2038</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, unless previously utilized. The state research and development credit carryforwards will begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8181dcd0-b9f9-4841-96a6-955a6d8a9e54" contextRef="C_3d6d281a-1b18-436a-aaa0-c7bcf2e894fc" name="inzy:TaxCreditCarryForwardExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2032</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unless previously utilized. The Company has generated research and development credits but has not conducted a study to document the qualified activity. This study</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">21</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">may </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">result in an adjustment to the Company&#8217;s research and development credit carryforwards; however, until a study is completed and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#8217;s research and development credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the deferred tax asset established for the research and development credit carryforwards and the valuation allowance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective January 1, 2022, a provision of the Tax Cuts and Jobs Act ("TCJA") changed the treatment of R&amp;E expenditures under Section 174 of the United States Internal Revenue Code (the "Internal Revenue Code"). Prior to the TCJA being effective, businesses have had the option of deducting Section 174 expenses in the year incurred or capitalizing and amortizing the costs over five years. The new TCJA provision, however, eliminates this option and requires Section 174 expenses associated with research conducted in the United States to be capitalized and amortized over a five-year period. For expenses associated with research outside of the United States, Section 174 expenses will be capitalized and amortized over a 15-year period.</span></p><p style="text-indent:9.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s ability to use its NOLs and tax credit carryforwards to offset taxable income is subject to restrictions under Sections 382 and 383 of the Internal Revenue Code. Under the Internal Revenue Code provisions, certain substantial changes in the Company&#8217;s ownership, including the sale of the Company or significant changes in ownership due to sales of equity, have limited and may limit in the future, the amount of NOLs which could be used annually to offset future taxable income. The Company has not yet conducted an analysis of ownership changes. The Company may also experience ownership changes in the future as a result of subsequent shifts in its stock ownership, some of which may be outside the Company&#8217;s control. As a result, the Company&#8217;s ability to use its pre-change NOLs to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to the Company. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. Under the TCJA, the use of federal NOLs arising in taxable years beginning after December 31, 2017 is limited to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec767be5-4a6c-4a52-bf88-0fa8991140bb" contextRef="C_405879f4-cccf-412e-9ad8-4013cd3d818b" name="inzy:TaxCutsAndJobsActFederalNetOperatingLossPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">80</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of current year taxable income and NOLs arising in taxable years ending after December 31, 2017 may not be carried back (though any such NOLs may be carried forward indefinitely).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company establishes reserves for uncertain tax positions based on management&#8217;s assessment of exposures associated with tax positions taken on tax return filings. The tax reserves are analyzed periodically and adjustments are made as events occur that warrant adjustment to the reserves. The Company does not have any reserves for uncertain tax positions as of December 31, 2023 and any change in position would result in a change in the valuation allowance maintained against its net deferred tax assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest and penalty charges, if any, related to unrecognized tax benefits are classified as income tax expense in the accompanying consolidated statements of operations and comprehensive loss. As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had no accrued interest related to uncertain tax positions. Since the Company is in a loss carryforward position, the Company is generally subject to examination by the U.S. federal, state, and local income tax authorities for all tax years in which a loss carryforward is available.</span></p></ix:nonNumeric></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_b183568c-cf0f-4405-92df-3396c7e7a78b" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11. Net Loss per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss per Share Attributable to Common Stockholders</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_0fe4cb27-d04d-4909-b902-5c661e2339f1" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth the computation of basic and diluted net loss per share for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 (in thousands, except share and per share amounts):</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.92%;"/>
        <td style="width:1.6%;"/>
        <td style="width:1%;"/>
        <td style="width:12.64%;"/>
        <td style="width:1%;"/>
        <td style="width:1.6%;"/>
        <td style="width:1%;"/>
        <td style="width:12.64%;"/>
        <td style="width:1%;"/>
        <td style="width:1.6%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="8" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss attributable to common stockholders&#8212;basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6e96a55b-238a-4b4d-8c61-3622ba2710c6" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">71,169</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ae90facc-7ab7-452d-ab76-6b3b07e69b4f" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">67,061</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share attributable to common stockholders&#8212;basic and diluted</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f72099f-1e51-4f94-9d9e-ce8646b0ff14" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b42c5abb-0d95-42ac-8cd6-d32059308b83" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.37</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1922eb0d-b145-4e0c-8f98-1104e2089471" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_86410aed-2ea6-4869-a9cd-7639abdd4444" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.78</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average common shares and pre-funded warrants outstanding&#8212;basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_18b1f359-72c3-475d-98d7-880dc26c0bde" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_822da900-f4b0-493d-b8ac-3e450ba2b470" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">51,839,131</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a75c828d-a601-47f9-a9f2-8df988da3001" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_6f2eb53e-f55e-44b5-b55c-38937da66a04" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">37,763,168</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has generated a net loss in all periods presented; therefore, the basic and diluted net loss per share attributable to common stockholders are the same as the inclusion of the potentially dilutive securities would be anti-dilutive. Since the shares underlying the pre-funded warrants are issuable for nominal consideration, they are considered outstanding for both basic and diluted earnings per share from the date of issuance. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7efa4164-af8b-4c52-98d3-f4460bc8c708" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true" continuedAt="F_7efa4164-af8b-4c52-98d3-f4460bc8c708_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company excluded the following potential dilutive securities, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated: </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_7efa4164-af8b-4c52-98d3-f4460bc8c708_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.357%;"/>
        <td style="width:1%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.357%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_30004a71-86e0-46b2-852a-cded42cab0a1" contextRef="C_bc04799a-6e65-4820-b17f-b1036be4e528" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,036,666</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6be484a5-654a-4557-b576-a9729a48414f" contextRef="C_16876f16-aca9-4cb2-b583-baf263afbd49" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,687,811</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested RSUs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_201a8c3e-a6f3-4838-8b9e-fc4b62b57656" contextRef="C_8f452f4f-2469-461f-b6e0-17cef1221fa3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">100,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0f203645-9b6b-4b17-8437-120a581a7551" contextRef="C_cf7fde27-55f9-4b69-9589-3dfbcd890c64" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_157f482a-561a-4a60-907d-3cf644cf3101" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,136,666</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_904e492d-22a7-43f8-aab6-831a28222613" contextRef="C_4ee9c018-375e-4d0f-ab9e-435246e8b7ce" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,687,811</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b330207d-078a-4874-a796-79424cdcd5b0" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12. Employee Benefit Plans</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company established a defined contribution savings plan in 2018 for all eligible U.S. employees under Section 401(k) of the Internal Revenue Code. Employees can designate the investment of their 401(k) accounts into several mutual funds. Effective January 1, 2021, the Company implemented a matching policy under which the Company matches </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f01628e-5fb7-4123-ae4a-7fda08762212" contextRef="C_f5346b4d-f225-4d76-a62e-df2c1fef5d1f" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of an employee&#8217;s contributions to the 401(k) plan, up to a maximum of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_efc76103-aa48-4600-be1f-f8c7803f624d" contextRef="C_034c291a-b985-4a6b-bfa0-cd3fc75a6bbe" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the employee&#8217;s base salary and bonus paid during the year. For each of the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, the Company made employer contributions to the 401(k) plan of $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_2124cae2-dbc8-43ae-a9f9-eba99f6e613f" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_dfa4490e-b40d-4d92-a57a-1a61953bf441" contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p></ix:nonNumeric></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fc735d02-8587-409e-8f06-c608191fa5cb" contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13. Related Party Transactions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 6, 2021, the Company entered into an amended and restated consulting agreement (the &#8220;Consulting Agreement&#8221;) with Danforth Advisors, LLC (&#8220;Danforth&#8221;), pursuant to which Danforth, in addition to providing finance, accounting and administrative functions, provided interim chief financial officer services to the Company by Stephen J. DiPalma, Managing Director of Danforth. The Company paid Danforth an agreed upon hourly rate for such services and reimbursed Danforth for expenses. The Consulting Agreement could be terminated by the Company or Danforth with cause, upon </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0a2a6272-1c8b-4b4e-8a89-ef7b78fcd6f9" contextRef="C_e7cf70aa-36bc-46ec-bfe0-94356e1da198" name="us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1" format="ixt-sec:durday"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> days prior written notice, and without cause, upon </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6bb996db-13ee-41bc-89d7-d5a7b63ddcca" contextRef="C_d09f7ff2-1a27-45d2-8579-2c27a2426a27" name="us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1" format="ixt-sec:durday"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">60</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> days prior written notice. Mr. DiPalma ceased serving as the Company's interim chief financial officer on March 21, 2022 in connection with the appointment of Sanjay S. Subramanian as the Company's Chief Financial Officer ("CFO"). The Company incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b77ca4f-460b-41eb-8014-6e602c14e1d2" contextRef="C_0492ee51-d379-44b0-9b36-2dde4f604d4e" name="us-gaap:ManagementFeeExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of expense for services provided by Danforth during the time Mr. DiPalma was the Company's interim CFO in 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, on May 17, 2021, the Company granted Mr. DiPalma an option to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_116f1246-90ff-4a5c-826e-e5b1978cc3ba" contextRef="C_a74fde5d-3b11-4279-84b0-6eaf17b9fed8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">15,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock (the &#8220;Option&#8221;) under the Company&#8217;s 2020 Stock Incentive Plan at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_832cc156-748a-4086-a8b8-82a6b712de9d" contextRef="C_a74fde5d-3b11-4279-84b0-6eaf17b9fed8" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.90</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The shares underlying the Option vested in full in 2022.</span></p></ix:nonNumeric></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">23</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9_changes_in_disagreement_with_acco"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9. Changes in and Disagreements wit</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">h Accountants on Accounting and Financial Disclosure.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9_a_control_procedure"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9A. Contro</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ls and Procedures.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer (our principal executive officer and principal financial officer, respectively), evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2023. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December 31, 2023, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Management&#8217;s Annual Report on Internal Control Over Financial Reporting and Attestation Report of Registered Public Accounting Firm</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting for our company. Internal control over financial reporting is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act as a process designed by, or under the supervision of, a company's principal executive officer and principal financial officer, or persons performing similar functions, and effected by a company's board of directors, management, and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of a company's assets;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that a company's receipts and expenditures are being made only in accordance with authorizations of a company's management and directors; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">provide reasonable assurance regarding prevention or timely detections of unauthorized acquisition, use or disposition of a company's assets that could have a material effect on the financial statements.</span></div></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the supervision of and with the participation of our principal executive officer and principal financial officer, our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2023 based on the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control - Integrated Framework (2013 framework). Based on this assessment, management concluded that our internal control over financial reporting was effective as of December 31, 2023.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm due to an exemption established by the JOBS Act for "emerging growth companies".</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the three months ended December 31, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">118</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9_b_or_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9B. Other</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Information.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(b)Director and Officer Trading Arrangements</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None of our directors or officers adopted or </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3941164c-636b-4268-815d-adb0047ba30f" contextRef="C_6f7932b9-17b8-423d-9f3d-1d9425caa7f3" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_8afd13af-2d96-4a9e-9a88-d0f8c21990be" contextRef="C_6f7932b9-17b8-423d-9f3d-1d9425caa7f3" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">terminated</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d1ae1f4d-c3ca-4615-a0f2-73d8549ca2d7" contextRef="C_6f7932b9-17b8-423d-9f3d-1d9425caa7f3" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Rule 10b5-1</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> trading arrangement or a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a56a17e5-3f46-4166-83c0-e053126f6806" contextRef="C_6f7932b9-17b8-423d-9f3d-1d9425caa7f3" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">non-Rule 10b5-1</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> trading arrangement (as defined in Item 408(c) of Regulation S-K) during the fourth quarter of 2023.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9c_disclosures_regarding"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <p style="text-indent:5.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">119</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Part III</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_10_director_executive_ficers_corpor"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 10. Directors, Executive Off</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">icers and Corporate Governance.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Except to the extent provided below, the information required under this Item 10 is incorporated by reference to our definitive proxy statement for our 2024 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission not later than 120 days after the end of the fiscal year ended December 31, 2023.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We post our Code of Business Conduct and Ethics, which applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions, in the &#8220;Governance&#8221; sub-section of the &#8220;Investors&#8221; section of our corporate website at http://www.inozyme.com. We intend to disclose on our website any amendments to, or waivers from, the Code of Business Conduct and Ethics that are required to be disclosed pursuant to the disclosure requirements of Item 5.05 of Form 8-K.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_11_executive_compensation"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 11. Executi</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ve Compensation.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required under this Item 11 is incorporated by reference to our definitive proxy statement for our 2024 Annual Meeting of Stockholders, which proxy statement we intend to file with the Securities and Exchange Commission not later than 120 days after the end of the fiscal year ended December 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_12_security_ownership_certain_benef"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 12. Security Ownership of Certain Beneficial Own</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ers and Management and Related Stockholders Matters.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required under this Item 12 is incorporated by reference to our definitive proxy statement for our 2024 Annual Meeting of Stockholders, which proxy statement we intend to file with the Securities and Exchange Commission not later than 120 days after the end of the fiscal year ended December 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_13_certain_relationship_related_tra"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 13. Certain Relationsh</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ips and Related Transactions, and Director Independence.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required under this Item 13 is incorporated by reference to our definitive proxy statement for our 2024 Annual Meeting of Stockholders, which proxy statement we intend to file with the Securities and Exchange Commission not later than 120 days after the end of the fiscal year ended December 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_14_principal_accountant_fees_servic"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 14. Principal Accou</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ntant Fees and Services.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required under this Item 14 is incorporated by reference to our definitive proxy statement for our 2024 Annual Meeting of Stockholders, which proxy statement will be filed with the Securities and Exchange Commission not later than 120 days after the close of the end of the fiscal year ended December 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">120</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART IV</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_15_exhibits_financial_statement_s_1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 15. Exhibits and Finan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cial Statement Schedules.</span></p>
  <div style="margin-left:13.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:3.8457544394060026%;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial Statements</span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For a list of financial statements included herein, see Index to the Consolidated Financial Statements on page F-1 of this Annual Report on Form 10-K.</span></p>
  <div style="margin-left:13.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:3.8457544394060026%;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial Statement Schedules</span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All financial statement schedules have been omitted because they are not applicable, not required, or the information required is shown in the consolidated financial statements or the notes thereto.</span></p>
  <div style="margin-left:13.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:3.8457544394060026%;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibits</span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following is a list of exhibits filed as part of this Annual Report on Form 10-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.1%;"/>
    <td style="width:1.02%;"/>
    <td style="width:88.88%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit<br/>Number</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description of Exhibit</span></p></td>
   </tr>
   <tr style="height:4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;2.1&#134;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1693011/000119312520195044/d919364dex21.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Intellectual Property Asset Purchase Agreement, dated July 17, 2020, by and between the Registrant and Alexion Pharmaceuticals, Inc.  (incorporated by reference to Exhibit 2.1 to Amendment No. 1 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-239648) filed with the Securities and Exchange Commission on July 20, 2020).</span></a></p></td>
   </tr>
   <tr style="height:4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;3.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1693011/000119312520195044/d919364dex33.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-39397) filed with the Securities and Exchange Commission on July 28, 2020).</span></a></p></td>
   </tr>
   <tr style="height:4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;3.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1693011/000095017023027987/inzy-ex3_1.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-39397) filed with the Securities and Exchange Commission on June 14, 2023).</span></a></p></td>
   </tr>
   <tr style="height:4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;4.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1693011/000119312520195044/d919364dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Specimen Stock Certificate evidencing the shares of common stock (incorporated by reference to Exhibit 4.1 to Amendment No. 1 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-239648) filed with the Securities and Exchange Commission on July 20, 2020).</span></a></p></td>
   </tr>
   <tr style="height:2.9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;4.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1693011/000156459021015250/inzy-ex42_239.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Description of the Registrant's Securities Registered under Section 12 of the Exchange Act (incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-39397) filed with the Securities and Exchange Commission on March 25, 2021).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;4.3</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1693011/000095017022011473/inzy-ex4_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Amended and Restated Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-39397) filed with the Securities and Exchange Commission on June 10, 2022).</span></a></p></td>
   </tr>
   <tr style="height:4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1693011/000119312520195044/d919364dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Second Amended and Restated Investor Rights Agreement, dated as of November 9, 2018, by and among the Registrant and the other parties thereto, as amended (incorporated by reference to Exhibit 10.1 to Amendment No. 1 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-239648) filed with the Securities and Exchange Commission on July 20, 2020).</span></a></p></td>
   </tr>
   <tr style="height:4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001693011/000119312520186800/d919364dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Registration Rights Agreement, dated as of June 1, 2016, by and among the Registrant and the other parties thereto (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-239648) filed with the Securities and Exchange Commission on July 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.3#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001693011/000119312520186800/d919364dex103.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated 2017 Equity Incentive Plan, as amended (incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-239648) filed with the Securities and Exchange Commission on July 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.4#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001693011/000119312520186800/d919364dex104.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Stock Option Agreement Granted under Amended and Restated 2017 Equity Incentive Plan (incorporated by reference to Exhibit 10.4 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-239648) filed with the Securities and Exchange Commission on July 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.5#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1693011/000119312520195044/d919364dex105.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">2020 Stock Incentive Plan (incorporated by reference to Exhibit 10.5 to Amendment No. 1 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-239648) filed with the Securities and Exchange Commission on July 20, 2020).</span></a></p></td>
   </tr>
   <tr style="height:4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.6#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1693011/000119312520195044/d919364dex106.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Stock Option Agreement under the 2020 Stock Incentive Plan (incorporated by reference to Exhibit 10.6 to Amendment No. 1 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-239648) filed with the Securities and Exchange Commission on July 20, 2020).</span></a></p></td>
   </tr>
   <tr style="height:4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">121</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.1%;"/>
    <td style="width:1.02%;"/>
    <td style="width:88.88%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.7#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1693011/000119312520195044/d919364dex107.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Restricted Stock Unit Agreement under the 2020 Stock Incentive Plan (incorporated by reference to Exhibit 10.7 to Amendment No. 1 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-239648) filed with the Securities and Exchange Commission on July 20, 2020).</span></a></p></td>
   </tr>
   <tr style="height:4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.8#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1693011/000119312520195044/d919364dex108.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">2020 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.8 to Amendment No. 1 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-239648) filed with the Securities and Exchange Commission on July 20, 2020).</span></a></p></td>
   </tr>
   <tr style="height:4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.9#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1693011/000095017023019176/inzy-ex10_5.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Summary of Non-Employee Director Compensation Policy (incorporated by reference to Exhibit 10.5 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-39397) filed with the Securities and Exchange Commission on May 9, 2023).</span></a></p></td>
   </tr>
   <tr style="height:4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.10&#134;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001693011/000119312520186800/d919364dex1010.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">License Agreement, dated January 6, 2017, by and between Yale University and the Registrant, as amended by Amendment No.  1 to License Agreement, dated May 2, 2020, by and between Yale University and the Registrant and Amendment No. 2 to License Agreement, dated July 1, 2020, by and between Yale University and the Registrant (incorporated by reference to Exhibit 10.10 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-239648) filed with the Securities and Exchange Commission on July 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.11*&#134;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="inzy-ex10_11.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Corporate Sponsored Research Agreement, dated January 6, 2017, by and between Yale University and the Registrant, as amended by Amendment No. 1 to Corporate Sponsored Research Agreement, dated February 19, 2019, by and between Yale University and the Registrant, as amended by Amendment No. 2 to Corporate Sponsored Research Agreement, effective December 31, 2021, by and between Yale University and the Registrant and as amended by Amendment No. 3 to Corporate Sponsored Research Agreement, dated May 31, 2022, by and between Yale University and the Registrant and as amended by Amendment No. 4 to Corporate Sponsored Research Agreement, dated March 24, 2023, by and between Yale University and the Registrant, and as amended by Amendment No. 5 to Corporate Sponsored Research Agreement, dated January 24, 2024, by and between Yale University and the Registrant.</span></a></p></td>
   </tr>
   <tr style="height:4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.12#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1693011/000119312520186800/d919364dex1012.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Restricted Stock Agreement between the Registrant and Axel Bolte (incorporated by reference to Exhibit 10.12 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-239648) filed with the Securities and Exchange Commission on July 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.13</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1693011/000119312520186800/d919364dex1013.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Lease, dated December 13, 2019, by and between 321 Summer Street LLC and the Registrant (incorporated by reference to Exhibit 10.13 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-239648) filed with the Securities and Exchange Commission on July 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.14</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001693011/000119312520186800/d919364dex1014.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Lease, dated May 13, 2020, by and between RREF II 451D, LLC and the Registrant (incorporated by reference to Exhibit 10.14 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-239648) filed with the Securities and Exchange Commission on July 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.15#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1693011/000119312520195044/d919364dex1015.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Indemnification Agreement between the Registrant and each of its Executive Officers and Directors (incorporated by reference to Exhibit 10.15 to Amendment No. 1 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-239648) filed with the Securities and Exchange Commission on July 20, 2020).</span></a></p></td>
   </tr>
   <tr style="height:4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.16#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1693011/000156459021015250/inzy-ex1016_1007.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Employment Contract, dated March 24, 2021, between Inozyme Pharma Switzerland GmbH and Axel Bolte (incorporated by reference to Exhibit 10.16 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-39397) filed with the Securities and Exchange Commission on March 25, 2021).</span></a></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.17#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1693011/000095017023019176/inzy-ex10_2.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Transition and Separation Letter Agreement, dated March 21, 2023, by and between the Registrant and Axel Bolte (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-39397) filed with the Securities and Exchange Commission on May 9, 2023).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.18#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1693011/000095017023019176/inzy-ex10_3.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consulting Agreement, dated April 30, 2023, by and between the Registrant and Axel Bolte (incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-39397) filed with the Securities and Exchange Commission on May 9, 2023).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.19#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1693011/000095017022008727/inzy-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Employment Agreement, dated March 2, 2022, by and between the Registrant and Sanjay Subramanian (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-39397) filed with the Securities and Exchange Commission on May 10, 2022).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.20</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1693011/000119312521242618/d172637dex12.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Open Market Sale Agreement</span><span style="color:#0000ff;top:-4.6899999999999995pt;white-space:pre-wrap;text-decoration:underline;font-size:6.7pt;position:relative;min-width:fit-content;">SM</span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">, dated August 11, 2021, by and between the Registrant and Jefferies LLC (incorporated by reference into Exhibit 1.2 to the Registrant&#8217;s Registration Statement on Form S-3 (File No. 333-258702) filed with the Securities and Exchange Commission on August 11, 2021).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="text-indent:8.45pt;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">122</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.1%;"/>
    <td style="width:1.02%;"/>
    <td style="width:88.88%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.21#&#134;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1693011/000095017022017233/inzy-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Loan and Security Agreement, dated July 25, 2022, by and among the Registrant, K2 HealthVentures LLC, as lender, K2 HealthVentures LLC, as administrative agent, and Ankura Trust Company, LLC, as collateral agent (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-39397) filed with the Securities and Exchange Commission on August 15, 2022).</span></a></p></td>
   </tr>
   <tr style="height:4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.22#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1693011/000095017023019176/inzy-ex10_1.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Employment Agreement, dated March 21, 2023, by and between the Registrant and Douglas Treco (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-39397) filed with the Securities and Exchange Commission on May 9, 2023).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.23#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1693011/000095017023019176/inzy-ex10_4.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Employment Agreement, dated March 14, 2023, by and between the Registrant and Matthew Winton (incorporated by reference to Exhibit 10.4 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-39397) filed with the Securities and Exchange Commission on May 9, 2023).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.24#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1693011/000095017023009054/inzy-ex99_3.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">2023 Inducement Stock Incentive Plan (incorporated by reference to Exhibit 99.3 to the Registrant&#8217;s Registration Statement on Form S-8 (File No. 333-270733) filed with the Securities and Exchange Commission on March 22, 2023).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.25#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1693011/000095017023019176/inzy-ex10_7.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Nonstatutory Stock Option Agreement under 2023 Inducement Stock Incentive Plan (incorporated by reference to Exhibit 10.7 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-39397) filed with the Securities and Exchange Commission on May 9, 2023).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.26#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1693011/000095017023019176/inzy-ex10_8.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Restricted Stock Unit Agreement under 2023 Inducement Stock Incentive Plan (incorporated by reference to Exhibit 10.8 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-39397) filed with the Securities and Exchange Commission on May 9, 2023).</span></a></p></td>
   </tr>
   <tr style="height:4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="text-indent:8.45pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.27*#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="inzy-ex10_27.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Restricted Stock Unit Agreement under the 2020 Stock Incentive Plan.</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="text-indent:8.45pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="text-indent:8.45pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.1*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="inzy-ex21_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Subsidiaries of the Registrant</span></a></p></td>
   </tr>
   <tr style="height:4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="text-indent:8.45pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23.1*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="inzy-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consent of Ernst &amp; Young LLP, independent registered public accounting firm</span></a></p></td>
   </tr>
   <tr style="height:4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="text-indent:8.45pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="text-indent:8.45pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.1*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="inzy-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.2*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="inzy-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32.1+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="inzy-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32.2+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="inzy-ex32_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97.1*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="inzy-ex97_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Dodd-Frank Compensation Recovery Policy.</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.INS</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Instance Document</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.SCH</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.CAL</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.DEF</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.LAB</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.PRE</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.1%;"/>
    <td style="width:1.02%;"/>
    <td style="width:88.88%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101).</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">* Filed herewith.</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">+ Furnished herewith.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"># Indicates a management contract or any compensatory plan, contract or arrangement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#134; Certain portions of this exhibit have been omitted because they are not material and contain information that the Registrant customarily and actually treats as private or confidential.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_16_form_10k_summary_1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 16. Form </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10-K Summary</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">123</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="sig"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNA</span><span id="signatures_1"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TURES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Date: March 12, 2024</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:41.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:9.681%;"/>
    <td style="width:3.679%;"/>
    <td style="width:86.641%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">INOZYME PHARMA, INC.</span></p></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Douglas A. Treco</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Douglas A. Treco</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:30.06%;"/>
    <td style="width:2.3%;"/>
    <td style="width:46.64%;"/>
    <td style="width:2.34%;"/>
    <td style="width:18.66%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Signature</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Douglas A. Treco</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Executive Officer and Chairman</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 12, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Douglas A. Treco</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Sanjay Subramanian</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Financial Officer</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 12, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sanjay Subramanian</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Financial Officer and Principal Accounting Officer)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Sarah Bhagat</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 12, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sarah Bhagat</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Axel Bolte</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 12, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Axel Bolte</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Reinaldo Diaz</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 12, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reinaldo Diaz</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Martin Edwards</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 12, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Martin Edwards</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Robert Hopfner</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 12, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Robert Hopfner</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Edward Mathers</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 12, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Edward Mathers</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Lynne Sullivan</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 12, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lynne Sullivan</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">124</span></p></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>2
<FILENAME>inzy-ex10_11.htm
<DESCRIPTION>EX-10.11
<TEXT>
<html>
 <head>
  <title>EX-10.11</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.11</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Certain identified information has been marked in the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Double asterisks denote omissions.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">INOZYME PHARMA, INC. CONFIDENTIAL</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">YALE UNIVERSITY</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CORPORATE SPONSORED RESEARCH AGREEMENT</font></p>
  <p style="text-indent:7.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This RESEARCH AGREEMENT (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) is entered into as of January 6, 2017 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), by and between </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Yale University</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, a non-profit corporation organized and existing under and by virtue of a special charter granted by the General Assembly of the Colony and State of Connecticut (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">University</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Inozyme Pharma, LLC</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, a Delaware limited liability company, having its principal offices at 240 Bluff View Drive, Guilford, Connecticut 06347 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Sponsor</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">W I T N E S S E T H :</font></p>
  <p style="text-indent:7.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WHEREAS, in pursuit of its educational purposes, which include research and training, the University undertakes scholarly, research, and experimental activities in a variety of academic disciplines including the biology of the modulation of inorganic pyrophosphate and calcification by ectonucleotide pyrophosphatase/phosphodiesterases (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ENPPs</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;); and</font></p>
  <p style="text-indent:7.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WHEREAS, the Sponsor wishes to fund and desires that the University undertake a research program in the field of ENPPs, as described more fully in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> attached hereto; and</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:7.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WHEREAS, in furtherance of its scholarly, research, and instructional interests, the University is willing to undertake such research upon the terms and conditions set forth below; and</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:7.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">NOW, THEREFORE, in consideration of the premises and the mutual covenants herein contained, the parties hereto agree as follows:</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <div style="text-indent:7.6%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:7.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.465%;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Scope of Research</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">During the term of this Agreement, the University shall use reasonable efforts to perform the research program described in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, attached hereto and incorporated herein (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Research</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) using the levels of diligence, care and skill applicable to academic research typically conducted at the University. Notwithstanding the foregoing, the University makes no warranties or representations regarding its ability to achieve, nor shall it be bound hereby to accomplish, any particular research objective or results.</font></div></div>
  <div style="text-indent:7.6%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:7.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.465%;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Personnel.</font></div></div>
  <div style="text-indent:7.6%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:7.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.465%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Research shall be performed by and under the supervision and direction of Dr. Demetrios Braddock, while employed by the University, who shall be designated the Principal Investigator (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Principal Investigator</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) together with such additional personnel as may be assigned by the University and who are employees or agents of the University. If Dr. Braddock ceases to be available to act as Principal Investigator, the University shall give Sponsor written notice of any proposed change in the Principal Investigator, subject to Sponsor&#x2019;s approval, which the Sponsor may withhold in its sole discretion. In case a replacement Principal Investigator cannot be found who is acceptable to the University and the Sponsor, then the Sponsor may terminate the Term (as defined herein) on 30 days&#x2019; notice to the University.</font></div></div>
  <div style="text-indent:7.6%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:7.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.465%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">It is understood that the University and the personnel performing the Research hereunder may be involved in other activities and projects which entail pre-existing commitments to other sponsors. The University will use reasonable efforts to avoid conflicts with the terms of this Agreement; however, it is agreed that unless provided to the contrary herein, this Agreement is subject to the University&#x2019;s pre-existing commitments to such other sponsors. [**].</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <div style="text-indent:7.6%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:7.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.465%;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">University Policies and Procedures</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">All Research conducted hereunder shall be performed in accordance with established University policies and procedures, including, but not limited to, policies and procedures applicable to research involving human subjects, laboratory animals, and conflicts of interest.</font></div></div>
  <div style="text-indent:7.6%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:7.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.465%;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Reimbursement of Costs.</font></div></div>
  <div style="text-indent:7.6%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:7.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.465%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Sponsor shall reimburse the University for all direct and indirect costs incurred by the University in connection with the Research, in accordance with the budget set forth as Exhibit B, in the amount of [**] Dollars ($[**]), attached hereto and which hereby is incorporated herein; provided, however, that the University may submit to Sponsor at any time, and Sponsor may at its discretion approve in writing, a revised budget or budgets requesting additional funds. Indirect costs shall be equal to the facilities and administration rate for indirect costs negotiated between the University and the Federal Government.</font></div></div>
  <div style="text-indent:7.6%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:7.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.465%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Sponsor shall make quarterly advance payments to the University to fund estimated reimbursable costs, as determined in advance by Yale in good faith, it being understood that Yale&#x2019;s estimate is not a guarantee of actual reimbursable costs for the applicable quarter. All checks shall be made payable to Yale University, shall include reference to the Principal Investigator, and shall be sent to:</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Yale University</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Office of Sponsored Projects</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">P.O. Box 1873</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">New Haven, CT 06508-1873</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Contacting email: [**]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Or wired to:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[**]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Reference: Demetrios Braddock, Principal Investigator; [**]</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">3</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <div style="text-indent:7.6%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:7.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.465%;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Research Reports</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The University shall furnish to Sponsor during the term of this Agreement periodic informal reports regarding the progress of the Research. A final report setting forth the significant research findings shall be prepared by the University and submitted to Sponsor within a reasonable period following the expiration of the Term or the effective date of early termination. The University shall hold such reports in confidence subject to its rights under Section 6. The Sponsor shall hold such reports in confidence pursuant to Section 7.</font></div></div>
  <div style="text-indent:7.6%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:7.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.465%;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Publication.</font></div></div>
  <div style="text-indent:7.6%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:7.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.465%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Part of the University&#x2019;s mission is to publish and disseminate research results developed under sponsored research projects. Consistent with this Agreement, University, the Principal Investigator and other University employees and/or students may disseminate or publish the results of the Research without prior approval by the Sponsor. The University shall provide the Sponsor with a copy of any proposed publication 45 days in advance of submission to third parties. The Sponsor shall determine whether any of its Confidential Information is included in the proposed publication. The Sponsor may reasonably require that any of its Confidential Information be removed from the proposed publication. The Sponsor may reasonably require that submission of the proposed publication to third parties and publication be W I delayed to permit the filing of patent applications. The Sponsor shall make such determinations within forty-five (45) days of receipt of the proposed publication. Submission of the proposed publication shall not be delayed more than ninety (90) days after receipt of the proposed publication by the Sponsor. The Sponsor at its election shall be entitled to receive an acknowledgment of its sponsorship of the Research in any such publication.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">4</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <div style="text-indent:7.6%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:7.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.465%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The University shall have the final authority to determine the scope and content of any publications or presentations made by its students and employees in accordance with the limitations of this section.</font></div></div>
  <div style="text-indent:7.6%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:7.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.465%;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Confidential Information.</font></div></div>
  <div style="text-indent:7.6%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:7.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.465%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Confidential Information consists of information that has been reduced to writing and marked &#x201c;Confidential,&#x201d; or, if disclosed orally, has been reduced to writing and marked &#x201c;Confidential&#x201d; within [**] of oral disclosure. Subject to the following exceptions, all Confidential Information of either party disclosed by or on behalf of it to the other party in connection with the Research hereunder will be treated by such other party as confidential throughout the term hereof or for [**] from the time of disclosure, whichever is longer. Each party will use reasonable efforts to safeguard the confidentiality of the other Party&#x2019;s Confidential Information, and will require its employees, agents, students and associates to adhere to such obligation of confidentiality. The following shall be exceptions to confidentiality:</font></div></div>
  <p style="margin-left:7.6%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(i)Information that is now in the public domain or subsequently enters the public domain through no fault of the receiving party;</font></p>
  <p style="margin-left:7.6%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(ii)Information that is presently known or becomes known to the receiving party from its own independent sources;</font></p>
  <p style="margin-left:7.6%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(iii)Information that the receiving party receives from any third party not under any obligation to keep such information confidential;</font></p>
  <p style="margin-left:7.6%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(iv)Information that is required to be disclosed by law.</font></p>
  <p style="margin-left:7.6%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(v)Information that is developed independently by persons who had no direct or indirect access to the information.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">5</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Neither party will use any Confidential Information of the other party provided under this Agreement for any purpose other than carrying out the Research and performing the parties&#x2019; respective obligations under this Agreement.</font></p>
  <div style="text-indent:7.6%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:7.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.465%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Neither party shall knowingly convey Confidential Information that is subject to federal export control restrictions under the EAR or the ITAR without first so disclosing to the other party and providing the other party the opportunity to decline receiving such information.</font></div></div>
  <div style="text-indent:7.6%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:7.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.465%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the foregoing in this Article 7, the Sponsor may disclose or release the results of the Research in connection with obtaining necessary regulatory approvals by a governmental authority for any ENPP product or ENPP product candidate of the Sponsor that is the subject of any license agreement between the University and the Sponsor pertaining, in part or in whole to such ENPP products or ENPP product candidates (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Regulatory Disclosure</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) to the extent that such Regulatory Disclosure is necessary or appropriate in the Sponsor&#x2019;s judgment to obtain such approvals [**].</font></div></div>
  <div style="text-indent:7.6%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:7.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.465%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[**] under this Section 7.</font></div></div>
  <div style="text-indent:7.6%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:7.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.465%;">8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Intellectual Property.</font></div></div>
  <div style="text-indent:7.6%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:7.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.465%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Definition of Invention. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Invention</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean any discovery, concept or idea, whether or not patentable, first conceived, discovered or first reduced to practice in whole or in part in performance of this Agreement. For purposes of this Agreement, &#x201c;Invention&#x201d; shall also include any software written, created, and utilized in performance of this Agreement.</font></div></div>
  <div style="text-indent:7.6%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:7.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.465%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Ownership of Inventions. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The University shall be entitled to ownership of any Invention first conceived or discovered solely by its employees, students, or agents in the performance of the Research (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">University Inventions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). Sponsor shall own any Inventions first conceived or discovered solely by Sponsor&#x2019;s employees or agents (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Sponsor </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">6</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:7.602%;text-align:left;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Inventions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). Inventions first conceived or discovered jointly by University employees, students or agents and Sponsor employees or agents in the performance of the Research shall be owned jointly (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Joint Inventions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></div></div>
  <div style="text-indent:7.6%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:7.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.465%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Disclosure and Right to Patent Inventions. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The University and Sponsor shall promptly disclose to each other in writing any Invention first conceived or discovered in the performance of the Research [**], and reported to the University&#x2019;s Office of Co-operative Research (&#x201c;OCR&#x201d;) if a University Invention or Joint Invention or Sponsor&#x2019;s Intellectual Property Authority (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">IPA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) if the Invention is a Joint Invention (see Article 11 &#x201c;Notices&#x201d;), respectively. Such disclosure shall be considered Confidential Information. The University may elect to file and prosecute a patent application on any University Invention described in any such Invention disclosure. Should the University elect not to do so it will so notify the Sponsor and the Sponsor may at its own cost file and prosecute any such patent application on behalf of the University. The Sponsor shall have the sole right to file and prosecute a patent application on any Sponsor Invention and Joint Invention. If Sponsor elects not to file or to prosecute an application for a Joint Invention or if after filing such an application, Sponsor elects not to prosecute such application, then in any such case Sponsor shall notify the University promptly and, if University elects to file and prosecute such an application on a Joint Invention, Sponsor shall not grant rights to such Joint Invention to any third party without University&#x2019;s prior written permission. [**].</font></div></div>
  <div style="text-indent:7.6%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:7.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.465%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[**] &amp; Option.</font></div></div>
  <div style="margin-left:14.926%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.333004208101182%;display:inline-flex;justify-content:flex-start;">i.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[**]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, the Sponsor shall have [**]; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided, however,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> that [**].</font></div></div>
  <div style="margin-left:14.926%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.333004208101182%;display:inline-flex;justify-content:flex-start;">ii.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. For each University Invention or University&#x2019;s interest in a Joint Invention that, at the time the University makes written disclosure thereof to the Sponsor, [**], the Sponsor will have the option, for a period of three (3) months from the date of such disclosure to Sponsor, </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">7</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <div style="margin-left:14.926%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:5.333004208101182%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">to elect to negotiate for a royalty-bearing, exclusive or non-exclusive, world-wide license to University&#x2019;s rights in such Invention, including the right to sublicense, to make, have made, use, lease, sell, import and export products embodying or produced through the use of such Invention (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). In the event that the parties are unable to reach agreement on the terms of the license described above in this Section 8(d)(ii) for such Invention after three (3) months of good faith negotiations, and the parties therefore do not execute such license, the University may enter into an agreement relating to such Invention with any third party [**].</font></div></div>
  <div style="text-indent:7.6%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:7.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.465%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">New License. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Any license to Sponsor as provided herein [**] will be granted by a separate license agreement signed by the parties which shall include at least the following terms and conditions: (a) an appropriate field of use; (b) mutually agreeable license fees and royalties; (c) mutually agreeable minimum royalties and/or other requirements of due diligence to develop and effectively commercialize the Invention; (d) reimbursement of University&#x2019;s cost of patent filing, prosecution and maintenance; (e) retention by University of a royalty-free right, sublicensable to its research partners, to use the Invention for teaching, research, or other educational or academic purposes; and (f) indemnification of the University.</font></div></div>
  <div style="text-indent:7.6%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:7.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.465%;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Data. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">University will retain ownership of the data arising out of the Research that University generates. Subject to other provisions of this Agreement, including those pertaining to Confidential Information and intellectual property, Sponsor will have access to the data and may use such data in connection with its internal research, subject to the applicable confidentiality provisions of this Agreement.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">8</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <div style="text-indent:7.6%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:7.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.465%;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tangible Research Property. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">University shall retain ownership of property that is developed solely by University&#x2019;s employees, students, and agents, including, but not limited to, prototypes, biogenic materials, samples, lab notebooks graphs, maps, drawings, and documents created or acquired under this Agreement (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tangible Research Property</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), except the University shall not retain ownership of any such Tangible Research Property that is a deliverable under this Agreement. [**]. University shall retain the right to use and distribute copies of all deliverables for educational and/or research purposes.</font></div></div>
  <div style="text-indent:7.6%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:7.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.465%;text-indent:0;display:inline-flex;justify-content:flex-start;">(h)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Copyrightable material. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">As between University and Sponsor, University shall own all right, title and interest in and to any and all copyrights and copyrightable materials, including data and excluding software, that is created solely by University employees, students or agents in performance of this Agreement (collectively &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">University Copyrights</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). As between University and Sponsor, Sponsor shall own all right, title and interest in and to any and all copyrights and copyrightable materials, including data, created solely by Sponsor employees or agents in performance of this Agreement (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Sponsor Copyrights</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). As between University and Sponsor, University and Sponsor shall jointly own all right, title and interest in and to any and all copyrights and copyrightable materials, including data, created jointly by University employees, students, or agents and Sponsor employees or agents in performance of this Agreement (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Joint Copyrights</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). University shall have the sole right to determine the disposition of University Copyrights, provided that Sponsor shall have option rights, in accordance with Section 8, in computer software and databases developed and delivered under the Statement of Work.</font></div></div>
  <div style="text-indent:7.6%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:7.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.465%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Background IP. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Neither party shall, by virtue of this Agreement, acquire rights to Inventions, copyrights, technical information, or tangible property concurrently created or acquired outside of this Agreement or that are owned by the other party prior to </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">9</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:7.602%;text-align:left;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">entering into this Agreement, including any background technology required to practice Inventions. Such rights may or may not be available for licensing.</font></div></div>
  <div style="text-indent:7.6%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:7.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.465%;">9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Ownership of Property</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Title to any equipment purchased or created in the performance of the work funded under this Agreement shall vest in the University.</font></div></div>
  <div style="text-indent:7.6%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:7.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.465%;">10.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Term and Termination.</font></div></div>
  <div style="text-indent:7.6%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:7.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.465%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Agreement shall be effective for the term January 6, 2017 through January 6, 2020 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Term</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and may be extended thereafter by mutual agreement of the parties in writing; provided, however, that the termination of this Agreement shall not relieve either party of any obligation of such party accrued prior to such termination hereunder. In particular, the provisions hereof relating to rights in patents and ownership of property shall survive such termination.</font></div></div>
  <div style="text-indent:7.6%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:7.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.465%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the foregoing, this Agreement may be terminated by either party at any time upon 180 days advance written notice to the other party; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided, however,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> that Sponsor may also terminate this Agreement pursuant to Section 2(a). Upon receipt of notice of early termination by Sponsor, the University shall use reasonable efforts promptly to limit or terminate any outstanding commitments prior to the effective termination date. All allowable costs associated with such termination and up through the date of termination, shall be reimbursed by Sponsor, including non-cancelable commitments, such as, where applicable, committed salary and benefits [**] for personnel shall be non-cancelable commitments. In case of such termination, such amounts for such non-cancellable obligations shall be the limits of the Sponsor&#x2019;s liability for payments to the University hereunder.</font></div></div>
  <div style="text-indent:7.6%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:7.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.465%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If Sponsor breaches its obligation of payment and fails to remedy such breach within thirty (30) days after receipt of notice in writing of such breach, then if such payment breach is not remedied in such thirty (30) day period, the University may, in addition to any other remedies that the University may have at law or in equity, terminate this Agreement by </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">10</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:7.602%;text-align:left;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">sending written notice of termination to Sponsor. Termination for material breaches will be effective from the date of notice to Sponsor and does not affect any of University&#x2019;s other rights under this Agreement.</font></div></div>
  <div style="text-indent:7.6%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:7.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.465%;">11.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notices</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Any notices given under this Agreement shall be in writing and shall be deemed delivered when sent by first-class mail, postage prepaid, addressed to the parties as follows (or at such other addresses as the parties may notify each other in writing):</font></div></div>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:59.16%;"></td>
    <td style="width:40.84%;"></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="text-indent:40.8pt;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.007in;vertical-align:top;padding-bottom:0.01in;padding-right:0.007in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">The University</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Yale University</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Office of Sponsored Projects (OSP)</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25 Science Park - 3rd Floor</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">P.O. Box 208327</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">New Haven, CT 06520-88327</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ATTN: [**]</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contract Manager</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.007in;vertical-align:top;padding-bottom:0.01in;padding-right:0.007in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">Sponsor</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inozyme Pharma, LLC</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[**]</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ATTN: Chief Executive Officer</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[**]</font></p></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.007in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Yale University</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Office of Cooperative Research</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">433 Temple Street</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">New Haven, CT 06511</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ATTN: Managing Director</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.007in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[**]</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided, however,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> that Invention Disclosures shall be addressed to the parties as follows:</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:59.64%;"></td>
    <td style="width:40.36%;"></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:110.15pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.007in;vertical-align:top;padding-bottom:0.01in;padding-right:0.007in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">Yale University</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Yale University Office of Cooperative Research</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Attn: Director of Intellectual Property</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">433 Temple Street</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">New Haven, CT, 06511</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">P: [**]</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">E: [**]</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CC: [**]</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.007in;vertical-align:top;padding-bottom:0.01in;padding-right:0.007in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">Sponsor IPA</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[**]</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:7.6%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:7.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.465%;">12.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Use of Name</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Neither party shall employ or use the name of the other party in any promotional materials or advertising without the prior express written permission of the other party.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">11</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <div style="text-indent:7.6%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:7.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.465%;">13.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Relationship of the Parties</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The relationship of Sponsor and the University established by this Agreement is that of independent contractors. Nothing in this Agreement shall be construed to create a relationship of employment or agency, nor shall either party&#x2019;s employees, servants, agents, or representatives be considered the employees, servants, agents, or representatives of the other. Nothing in this Agreement shall be construed to constitute the parties as partners or joint venturers, or allow either of the parties to create or assume any obligation on behalf of the other party.</font></div></div>
  <div style="text-indent:7.6%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:7.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.465%;">14.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Indemnification</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The following indemnification obligation applies only to the extent of Sponsor&#x2019;s use of the Research or any University intellectual property or Research Results. The Sponsor shall therefore defend, indemnify and hold harmless University, the Principal Investigator, in his capacity as such, and any of University&#x2019;s faculty, students, employees, trustees, officers, affiliates, and agents (hereinafter referred to collectively as the if &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Indemnified Persons</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) from and against any and all liability, claims, lawsuits, losses, damages, costs or expenses (including attorneys&#x2019; fees), which the Indemnified Persons may hereafter incur, or be required to pay, unless determined with finality by a court of competent jurisdiction to result solely from an Indemnified Person&#x2019;s gross negligence or willful misconduct. University shall notify Sponsor upon learning of the institution or threatened institution of any such liability, claims, lawsuits, losses, damages, costs and expenses and University shall cooperate with Sponsor in every proper way in the defense or settlement thereof at Sponsor&#x2019;s request and expense. Sponsor shall not dispose or settle any claim admitting liability on the part of the University without University&#x2019;s prior written consent.</font></div></div>
  <div style="text-indent:7.6%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:7.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.465%;">15.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">NO WARRANTIES</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">THE UNIVERSITY MAKES NO WARRANTIES EITHER EXPRESS OR IMPLIED, AS TO ANY MATTER, INCLUDING, WITHOUT LIMITATION, THE RESULTS OF THE RESEARCH OR ANY INVENTIONS OR PRODUCT, TANGIBLE OR INTANGIBLE, CONCEIVED, DISCOVERED, OR </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">12</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:7.602%;text-align:left;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">DEVELOPED UNDER THIS AGREEMENT; OR THE OWNERSHIP, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE OF THE RESEARCH RESULTS OR OF ANY SUCH INVENTION OR PRODUCT. Neither party shall be liable for any indirect, consequential, lost profits, or other damages suffered by the other party or by any Licensee or any others resulting from the use of the research results, including any Invention, program, or product.</font></div></div>
  <div style="text-indent:7.6%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:7.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.465%;">16.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Export Controls</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The University complies with all applicable laws and, regulations, including, where applicable, federal export control regulations. Many of the University employees (faculty and staff) and students are residents of foreign countries, including individuals who may work on this contract and/or have access to information conveyed to the University pursuant hereto. The University does not screen its employees or students based on nationality. In most situations, the University relies on the fundamental research exclusion from export control laws, but makes no representation as to whether Sponsor&#x2019;s conveyance of information or material to the University pursuant hereto would be covered by the export control laws. Each party agrees that before knowingly providing the other with export-controlled materials or data, it will provide written notice, including a description of the materials or data, and, if known, the appropriate ECCN or MCL designation. No such materials or data shall knowingly be shared without prior written approval.</font></div></div>
  <div style="text-indent:7.6%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:7.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.465%;">17.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Force Majeure</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The University shall not be liable for any failure to perform as required by this Agreement, to the extent such failure to perform is caused by any reason beyond the University&#x2019;s control, or by reason of any of the following: labor disturbances or disputes of any kind, accidents, failure of any required governmental approval, civil disorders, acts of aggression, acts of God, energy or other conservation measures, failure of utilities, mechanical breakdowns, material shortages, disease, or similar occurrences.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">13</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <div style="text-indent:7.6%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:7.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.465%;">18.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Assignment</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Neither the University nor the Sponsor shall assign this Agreement to any other person without the prior written consent of the other, and any purported assignment without such consent shall be void [**].</font></div></div>
  <div style="text-indent:7.6%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:7.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.465%;">19.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Severability</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In the event that a court of competent jurisdiction holds any provision of this Agreement to be invalid, such holding shall have no effect on the remaining provisions of this Agreement, and they shall continue in full force and effect.</font></div></div>
  <div style="text-indent:7.6%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:7.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.465%;">20.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Entire Agreement: Amendments</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Agreement and the Exhibits hereto contain the entire agreement between the parties. No amendments or modifications to this Agreement shall be effective unless made in writing and signed by authorized representatives of both parties.</font></div></div>
  <div style="text-indent:7.6%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:7.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.465%;">21.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Similar Research</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Nothing in this Agreement shall be construed to limit the freedom of the University or of its researchers who are not participants under this Agreement, from engaging in similar research made under other grants, contracts or agreements with parties other than the Sponsor.</font></div></div>
  <div style="text-indent:7.6%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:7.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.465%;">22.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Governing Law</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Agreement shall be governed by and construed in accordance with the laws of the State of Connecticut.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">14</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <p style="text-indent:7.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">IN WITNESS WHEREOF, the parties hereto have executed this Agreement by their duly authorized officers or representatives.</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:51.02%;"></td>
    <td style="width:48.98%;"></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">YALE UNIVERSITY</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">/s/ Jeffrey E. McGuinness</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Associate Director</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">January 10, 2017</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">INOZYME PHARMA, LLC</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">/s/ Axel Bolte</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Chief Executive Officer</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">January 10, 2017</font></p></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Read and acknowledged:</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Principal Investigator</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Demetrios Braddock</font></p><p style="border-top:0.5pt solid;padding-top:1pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Demetrios Braddock, MD PhD</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">01/09/2017</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">15</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">YALE UNIVERSITY</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AMENDMENT NO. 1 TO</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CORPORATE SPONSORED RESEARCH AGREEMENT</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This AMENDMENT NO. 1 TO CORPORATE SPONSORED RESEARCH AGREEMENT, dated as of February 19, 2019 (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Amendment</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), by and between Yale University, a non-profit corporation organized and existing under and by virtue of a special charter granted by the General Assembly of the Colony and State of Connecticut (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">University</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inozyme Pharma, Inc.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, a Delaware corporation, having its principal offices at 280 Summer Street, Floor 5, Boston, Massachusetts 02210 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sponsor</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), amends the RESEARCH AGREEMENT, entered into as of January 6, 2017 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), by and between the University and the Sponsor.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">W I T N E S S E T H:</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">WHEREAS</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Sponsor has funded a research program in the field of ENPPS.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">WHEREAS</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Sponsor now wishes to continue to fund for an extended period (years 3-5) research programs in the field of expertise of the Principal Investigator, as described more fully in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, attached to this Amendment; and</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">WHEREAS</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Sponsor wishes to allow for a broader research program and to amend the the budget for the research to take place during the Extended Term (as defined herein) as provided in the Agreement, and the University is willing to agree to such modifications and to undertake such research upon the terms and conditions set forth below and in the Agreement;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOW</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">THEREFORE</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, in consideration of the premises and the mutual covenants herein contained, the parties hereto agree as follows:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Scope of Research</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Upon the effectiveness of this Amendment, the Agreement is hereby amended such that during the Extended Term, the University shall use reasonable efforts to perform the research program described in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, attached hereto and incorporated herein and incorporated in the Agreement to allow for expansion of the original Research, and otherwise in accordance with the terms and limitations provided in the Agreement. The Research provided for in this Amendment shall be in lieu of the portion of the Research for the third year of the Term as provided in the Agreement and shall also extend for the Extended Term. Any additional research requested by Sponsor that is supplemental to the research selected by the Principal Investigator &#x2013; relating to ENPPs within the amended program described in Exhibit A attached hereto, shall be the subject of a separately negotiated financial agreement between the University and Sponsor.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Reimbursement of Costs</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Agreement is hereby amended such that the Sponsor shall reimburse the University for all direct and indirect costs incurred by the University in connection with the Extended Research, in accordance with the budget set forth as </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">hereto (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Extended Budget</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">), </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in the amount of [**] Dollars ($[**]), attached hereto and which hereby is incorporated herein and incorporated in the Agreement. The first year of the Extended Budget shall be in lieu of $[**] of Total Grant Budget for Year 3 as shown in the budget attached as Exhibit B to the Agreement. Nothing in this Amendment modifies the Total Grant Budget shown for each of Year 1 and Year 2 in the Agreement. Once the parties execute and deliver this Amendment, the Total Grant Budget and Extended Budget under the Agreement, as amended by this Amendment, will be:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:64%;"></td>
    <td style="width:2%;"></td>
    <td style="width:1%;"></td>
    <td style="width:32%;"></td>
    <td style="width:1%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Year 1</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$[**]</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Year 2</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$[**]</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Year 3</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$[**]</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Year 4</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$[**]</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Year 5</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$[**]</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:20pt;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="border-top:0.5pt solid;vertical-align:bottom;border-bottom:2.25pt double;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</font></p></td>
    <td style="border-top:0.5pt solid;vertical-align:bottom;border-bottom:2.25pt double;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,409,708</font></p></td>
    <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indirect costs for the Extended Budget shall be as shown in the Extended Budget.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">16</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Amendment to Term</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The first sentence of Section 10(a) of the Agreement is hereby amended by deleting the words &#x201c;January 6, 2020&#x201d; and substituting in lieu thereof &#x201c;December 31, 2021&#x201d;. The period of the New Research shall be referred to as the &#x201c;Extended Term.&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Defined Terms</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Capitalized terms used in this Amendment and defined in the introductory paragraph of, or recitals to, this Amendment shall have the respective meanings provided therein. Capitalized terms used in this Amendment and not defined in this Amendment shall have the respective meanings provided in the Agreement except as otherwise expressly provided herein.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effectiveness</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. This Amendment shall become effective as of the date first set forth above once this Amendment or counterparts hereof shall have been executed and delivered by University and the Sponsor.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Confirmation of Original Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Except as amended by this Amendment, the Agreement shall remain in f&uuml;ll force and effect in accordance with its terms. From and after the date this Amendment becomes effective, any reference in the Agreement to the &#x201c;Agreement&#x201d;, the &#x201c;Research&#x201d; or the &#x201c;Term&#x201d; shall be deemed a reference to the Agreement, as amended hereby, the Research, as defined hereby, or the Extended Term, as defined hereby, respectively. </font></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Governing Law</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. This Amendment shall be governed by and construed in accordance with the laws of the State of Connecticut.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">[signature page follows]</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">17</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IN WITNESS WHEREOF, the parties hereto have executed this Agreement by their duly authorized officers or representatives.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9.08%;"></td>
    <td style="width:1%;"></td>
    <td style="width:35.52%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1%;"></td>
    <td style="width:12.14%;"></td>
    <td style="width:1%;"></td>
    <td style="width:38.26%;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">YALE UNIVERSITY</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="3" style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">INOZYME PHARMA, INC.</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ James Cresswell</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">/s/ Henric Bjarke</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sr. Contract Manager</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">COO</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date:</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 19, 2019</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date:</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2/22/2019</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Read and acknowledged:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Principal Investigator</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="text-indent:20pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">/s/ Demetrios Braddock</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Demetrios Braddock, MD PhD</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date:</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">&#160;February 19th, 2019</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit B: Extended Budget</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Amendment No. 1 to Corporate Sponsored Research Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:47.219%;"></td>
    <td style="width:1%;"></td>
    <td style="width:12.825%;"></td>
    <td style="width:1%;"></td>
    <td style="width:12.825%;"></td>
    <td style="width:1%;"></td>
    <td style="width:12.825%;"></td>
    <td style="width:1%;"></td>
    <td style="width:10.304%;"></td>
   </tr>
   <tr style="height:7.9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year 3</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year 4</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year 5</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</font></p></td>
   </tr>
   <tr style="height:10.1pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total Direct Costs</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[**]</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[**]</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[**]</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">[**]</font></p></td>
   </tr>
   <tr style="height:10.1pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Indirect Rage</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[**]</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[**]</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[**]</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[**]</font></p></td>
   </tr>
   <tr style="height:10.1pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total Indirect Costs</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[**]</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[**]</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[**]</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">[**]</font></p></td>
   </tr>
   <tr style="height:10.1pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total Grant Budget</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">[**]</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">[**]</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">[**]</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">[**]</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit B: Budget</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:48%;"></td>
    <td style="width:14.36%;"></td>
    <td style="width:13.74%;"></td>
    <td style="width:11.1%;"></td>
    <td style="width:12.8%;"></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Year 1</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Year 2</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Year 3</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Total</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">YALE TOTAL DIRECT COSTS - Grant</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">[**]</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">[**]</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">[**]</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">[**]</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total Indirects</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">[**]</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">[**]</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">[**]</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">[**]</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="border-top:0.5pt solid;background-color:#ffff00;padding-top:0.01in;border-left:0.5pt solid;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</font></p></td>
    <td style="border-top:0.5pt solid;background-color:#ffff00;padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</font></p></td>
    <td style="border-top:0.5pt solid;background-color:#ffff00;padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</font></p></td>
    <td style="border-top:0.5pt solid;background-color:#ffff00;padding-top:0.01in;border-right:0.5pt solid;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total Grant Budget</font></p></td>
    <td style="background-color:#ffff00;padding-top:0.01in;border-left:0.5pt solid;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">[**]</font></p></td>
    <td style="background-color:#ffff00;padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">[**]</font></p></td>
    <td style="background-color:#ffff00;padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">[**]</font></p></td>
    <td style="background-color:#ffff00;padding-top:0.01in;border-right:0.5pt solid;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">[**]</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">18</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Second Amendment to Corporate Sponsored Research Agreement</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Second Amendment (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Amendment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), effective as of December 31, 2021 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Amendment Effective</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), is entered into by and Inozyme Pharma, Inc., a Delaware corporation, having its principal offices at 321 Summer Street, Suite 400, Boston, MA 02210 (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Inozyme</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and Yale University, a non-profit corporation organized and existing under and by virtue of a special charter granted by the General Assembly of the Colony and State of Connecticut, (</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Yale&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">), and is made to that certain Research Agreement with an Effective Date of January 6, 2017, as amended by a First Amendment effective February 19, 2019 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Whereas</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, the Parties desire to modify the terms of the Agreement to extend the term thereof on a no-cost basis as set forth herein.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Now Therefore</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, the Parties agree as follows:</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">1.1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">All capitalized terms used in this Amendment but not defined herein shall have the meaning given such term in the Agreement.</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">1.2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The first sentence of Section 10(a) of the Agreement is hereby amended by deleting the words &#x201c;December 31, 2021&#x201d; and substituting in lieu thereof &#x201c;June 30, 2022.&#x201d;</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">1.3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Except as amended by this Amendment, the Agreement shall remain in full force and effect according to its terms.</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">1.4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Amendment may be executed in two counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument.</font></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In Witness Whereof</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, the Parties hereto have caused this Amendment to be executed by their respective duly authorized officers as of the Amendment Effective Date.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:10%;"></td>
    <td style="width:33.343%;"></td>
    <td style="width:7.143%;"></td>
    <td style="width:10%;"></td>
    <td style="width:39.514%;"></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Yale University</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Inozyme Pharma, Inc.</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ James Cresswell</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Axel Bolte</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name:</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">James Cresswell</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name:</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Axel Bolte</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title:</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sr. Contract Manager</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title:</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CEO</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">19</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">THIRD AMENDMENT TO CORPORATE SPONSORED RESEARCH AGREEMENT</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Third Amendment (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Amendment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), effective as of May 31, 2022 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Third Amendment Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), is entered into by and Inozyme Pharma, Inc., a Delaware corporation, having its principal offices at 321 Summer Street, Suite 400, Boston, MA 02210 (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Sponsor</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and Yale University, a non-profit corporation organized and existing under and by virtue of a special charter granted by the General Assembly of the Colony and State of Connecticut, (</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;University&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">), and is made to that certain Research Agreement with an Effective Date of January 6, 2017, as amended by a First Amendment effective February 19, 2019 and a Second Amendment effective December 31, 2021 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Whereas</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, the Parties desire to modify the terms of the Agreement to extend the term and to provide additional funding as described herein in support of experiments associated with investigating [**].</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Now Therefore</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, the Parties agree as follows:</font></p>
  <div style="text-indent:4.533%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.53%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">All capitalized terms used in this Amendment but not defined herein shall have the meaning given such term in the Agreement.</font></div></div>
  <div style="text-indent:4.533%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.53%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 8(d)(ii) of the Agreement is hereby amended by addition of the following at the end of the Section:</font></div></div>
  <div style="margin-left:16%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.935%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.1130952380952381%;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the foregoing in this Section 8(d)(ii), Inventions that are: (i) related to (a) [**] and/or (b) the use of such [**] and (ii) not otherwise already subject to a license from University to Sponsor, including a license under the License Agreement (Yale Ref. [**])) (such inventions ((i) and (ii)), &#x201c;[**] Inventions&#x201d;) shall not be subject to the Option granted herein. Sponsor shall not seek or require the disclosure of any future [**] Inventions from University.</font></div></div>
  <div style="margin-left:16%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.935%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.1130952380952381%;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Sponsor hereby acknowledges that University has disclosed to Sponsor the [**] Inventions set forth on Exhibit 8(d)(ii)(2) (&#x201c;Existing [**] Inventions&#x201d;). Further, Sponsor hereby acknowledges and agrees that its Options to such Existing [**] Inventions have expired without exercise.</font></div></div>
  <div style="margin-left:16%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.935%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.1130952380952381%;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">University represents that, to the actual knowledge of Yale Ventures (fka Yale Office of Cooperative Research; &#x201c;Yale Ventures&#x201d;), the [**] Inventions set forth on Exhibit 8(d)(ii)(2) are all of the patentable [**] Inventions that have arisen under this Agreement that have been reported to Yale Ventures as of the Third Amendment Effective Date.</font></div></div>
  <div style="text-indent:4.533%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.53%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The first sentence of Section 10(a) of the Agreement is hereby amended by deleting the words &#x201c;June 30, 2022&#x201d; and substituting in lieu thereof &#x201c;April 30, 2023.&#x201d;</font></div></div>
  <div style="text-indent:4.533%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.53%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A is hereby modified to include the additional components of the Research identified in Exhibit A-1, attached hereto and incorporated herein.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">20</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <div style="text-indent:4.533%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.53%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Extended Budget of the Agreement is hereby modified to include the following:</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:92.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:50.02%;"></td>
    <td style="width:49.98%;"></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="border-top:0.5pt solid;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Funds for the performance of Research as set forth in Exhibit A-1 (for the time period beginning on the Third Amendment Effective Date and ending on April 30, 2023)</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="border-top:0.5pt solid;border-left:0.5pt solid;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total Direct Costs</font></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[**]</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="border-top:0.5pt solid;border-left:0.5pt solid;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Indirect Rate</font></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[**]</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="border-top:0.5pt solid;border-left:0.5pt solid;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Indirect Costs</font></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[**]</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="border-top:0.5pt solid;border-left:0.5pt solid;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total Budget</font></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">[**]</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">For clarity, the total funding under the Agreement, inclusive of the original Budget and the Extended Budget, is $2,549,708.00, of which University acknowledges that $2,409,708 has already been paid by Sponsor and received by University as of the Third Amendment Effective Date.</font></p>
  <div style="text-indent:4.533%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.53%;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Except as amended by this Amendment, the Agreement shall remain in full force and effect according to its terms.</font></div></div>
  <div style="text-indent:4.533%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.53%;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Amendment may be executed in two counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument.</font></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In Witness Whereof</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, the Parties hereto have caused this Amendment to be executed by their respective duly authorized officers as of the Third Amendment Effective Date.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8%;"></td>
    <td style="width:1%;"></td>
    <td style="width:39%;"></td>
    <td style="width:4%;"></td>
    <td style="width:7.66%;"></td>
    <td style="width:1%;"></td>
    <td style="width:39.34%;"></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">YALE UNIVERSITY</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Inozyme Pharma, Inc.</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ James Cresswell</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Henric Bjarke</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name:</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">James Cresswell, JD</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name:</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Henric Bjarke</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title:</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Senior Contract Manager</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title:</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">COO</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Josh Geballe</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name:</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Josh Geballe, MBA</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title:</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Managing Director, Yale Ventures</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Read and acknowledged</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Demetrios Braddock</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dr.</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Demetrios Braddock, Yale Faculty</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">21</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">F</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">OURTH </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">A</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">MENDMENT TO </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">C</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">ORPORATE </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">S</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">PONSORED </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">R</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">ESEARCH </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">A</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">GREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Fourth Amendment (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Amendment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) effective as of March 24, 2023 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Amendment Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), is entered into by and Inozyme Pharma, Inc., a Delaware corporation, having its principal offices at 321 Summer Street, Suite 400, Boston, MA 02210 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(&#x201c;Inozyme&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> and Yale University, a non-profit corporation organized and existing under and by virtue of a special charter granted by the General Assembly of the Colony and State of Connecticut, (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Yale</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and is made to that certain Research Agreement with an Effective Date of January 6, 2017, as amended by a First Amendment effective February 19, 2019, a Second Amendment effective December 31, 2021, and a Third Amendment effective April 22, 2022 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">W</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">HEREAS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, the Parties desire to modify the terms of the Agreement to extend the term and to provide additional funding as described herein.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">N</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">OW </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">T</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">HEREFORE</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, the Parties agree as follows:</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">1.1 All capitalized terms used in this Amendment but not defined herein shall have the meaning given such term in the Agreement.</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">1.2 The first sentence of Section 10(a) of the Agreement is hereby amended by deleting the words &#x201c;April 30, 2023&#x201d; and substituting in lieu thereof &#x201c;March 31, 2024&#x201d;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">1.3 Exhibit A of the Agreement is hereby supplemented, but not replaced, by Exhibit A-2, attached hereto and incorporated herein.</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">1.4 That Section of the Agreement referencing &#x201c;Reimbursement of Costs&#x201d; is hereby amended to add an additional $167,500.00 in funding. For clarity, the total funding now available under the Agreement is increased to $2,717,208.00.</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">1.5 Except as amended by this Amendment, the Agreement shall remain in full force and effect according to its terms.</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">1.6 This Amendment may be executed in two counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">I</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">N </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">W</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">ITNESS </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">W</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">HEREOF</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, the Parties hereto have caused this Amendment to be executed by their respective duly authorized officers as of the Amendment Effective Date.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8%;"></td>
    <td style="width:37%;"></td>
    <td style="width:10%;"></td>
    <td style="width:8%;"></td>
    <td style="width:37%;"></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">YALE UNIVERSITY</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">INOZYME PHARMA, INC.</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">\S\ Doug Treco</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name:</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">James Cresswell</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name:</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Doug Treco</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title:</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assistant Director, Contracts</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title:</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CEO</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Read and acknowledged</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">\S\ Demetrios Braddock</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dr. Demetrios Braddock</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">22</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">F</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">IFTH </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">A</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">MENDMENT TO </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">C</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">ORPORATE </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">S</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">PONSORED </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">R</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">ESEARCH </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">A</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">GREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Fifth Amendment (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Amendment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), effective as of January 24, 2024 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Amendment Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), is entered into by and Inozyme Pharma, Inc., a Delaware corporation, having its principal offices at 321 Summer Street, Suite 400, Boston, MA 02210 (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Inozyme</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and Yale University, a non-profit corporation organized and existing under and by virtue of a special charter granted by the General Assembly of the Colony and State of Connecticut, (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Yale</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and is made to that certain Research Agreement with an Effective Date of January 6, 2017, as amended by a First Amendment effective February 19, 2019, a Second Amendment effective December 31, 2021, a Third Amendment effective April 22, 2022, and a Fourth Amendment effective March 24, 2023 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">W</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">HEREAS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, the Parties desire to modify the terms of the Agreement to extend the term and to provide additional funding as described herein.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">N</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">OW </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">T</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">HEREFORE</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, the Parties agree as follows:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">1.1 All capitalized terms used in this Amendment but not defined herein shall have the meaning given such term in the Agreement.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">1.2 The first sentence of Section 10(a) of the Agreement is hereby amended by deleting the words &#34;March 31, 2024&#34; and substituting in lieu thereof &#34;December 31, 2024&#34;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">1.3 That Section of the Agreement referencing &#34;Reimbursement of Costs&#34; is hereby amended to add an additional $323,156.00 in funding. For clarity, the total funding now available under the Agreement is increased to $3,040,364.00.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">1.4 Payments commencing for the year 2024 shall be made on an equal quarterly installment basis, as follows:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Payment shall be made in 4 installments paid quarterly upon invoicing in 2024 at the start of each quarter.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.102%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"></td>
    <td style="width:50%;"></td>
   </tr>
   <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:1.125pt solid #000000;padding-top:0.049in;border-right:1.125pt solid #000000;border-left:1.125pt solid #000000;padding-left:0.074in;vertical-align:top;border-bottom:1.125pt solid #000000;padding-right:0.08in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Payment 1 (signing of contract)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">  </font></p></td>
    <td style="border-top:1.125pt solid #000000;padding-top:0.049in;border-right:1.125pt solid #000000;padding-left:0.074in;vertical-align:top;border-bottom:1.125pt solid #000000;padding-right:0.08in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$80,789</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:15.1pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.049in;border-right:1.125pt solid #000000;border-left:1.125pt solid #000000;padding-left:0.074in;vertical-align:top;border-bottom:1.125pt solid #000000;padding-right:0.08in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Payment 2 (April 1, 2024)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.049in;border-right:1.125pt solid #000000;padding-left:0.074in;vertical-align:top;border-bottom:1.125pt solid #000000;padding-right:0.08in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$80,789</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.049in;border-right:1.125pt solid #000000;border-left:1.125pt solid #000000;padding-left:0.074in;vertical-align:top;border-bottom:1.125pt solid #000000;padding-right:0.08in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Payment 3 (July 1, 2024)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.049in;border-right:1.125pt solid #000000;padding-left:0.074in;vertical-align:top;border-bottom:1.125pt solid #000000;padding-right:0.08in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$80,789</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.049in;border-right:1.125pt solid #000000;border-left:1.125pt solid #000000;padding-left:0.074in;vertical-align:top;border-bottom:1.125pt solid #000000;padding-right:0.08in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Payment 4 (October 1, 2024)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.049in;border-right:1.125pt solid #000000;padding-left:0.074in;vertical-align:top;border-bottom:1.125pt solid #000000;padding-right:0.08in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$80,789</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:15.1pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.049in;border-right:1.125pt solid #000000;border-left:1.125pt solid #000000;padding-left:0.074in;vertical-align:top;border-bottom:1.125pt solid #000000;padding-right:0.08in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.049in;border-right:1.125pt solid #000000;padding-left:0.074in;vertical-align:top;border-bottom:1.125pt solid #000000;padding-right:0.08in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$323,156</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">1.5 Exhibit B, the Budget, is hereby supplemented, but not replaced, by Exhibit B-5, appended hereto and which is fully incorporated herein.</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">1.6 Except as amended by this Amendment, the Agreement shall remain in full force and effect according to its terms.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">1.7 This Amendment may be executed in two counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">23</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">I</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">N </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">W</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">ITNESS </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">W</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">HEREOF</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, the Parties hereto have caused this Amendment to be executed by their respective duly authorized officers as of the Amendment Effective Date.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8%;"></td>
    <td style="width:37%;"></td>
    <td style="width:10%;"></td>
    <td style="width:8%;"></td>
    <td style="width:37%;"></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">YALE UNIVERSITY</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">INOZYME PHARMA, INC.</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">\S\ Douglas A Treco</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name:</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">James Cresswell</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name:</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Douglas A Treco</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title:</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assistant Director, Contracts</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title:</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CEO</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Read and acknowledged</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">\S\ Demetrios Braddock</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dr. Demetrios Braddock</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">24</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.27
<SEQUENCE>3
<FILENAME>inzy-ex10_27.htm
<DESCRIPTION>EX-10.27
<TEXT>
<html>
 <head>
  <title>EX-10.27</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.27</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inozyme Pharma, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RESTRICTED STOCK UNIT AGREEMENT</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Granted under 2020 Stock Incentive Plan</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inozyme Pharma, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) hereby grants the following restricted stock units to the recipient named below pursuant to its 2020 Stock Incentive Plan (as amended through the date hereof, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). The terms and conditions attached hereto are also a part hereof and incorporated herein by reference.</font></p>
  <p style="font-size:10pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notice of Grant</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"></td>
    <td style="width:1%;"></td>
    <td style="width:49%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name of recipient (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Participant</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x201d;):</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Grant Date:</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Number of restricted stock units (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">RSUs</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x201d;) granted:</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vesting Start Date:</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Vesting Schedule:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:51%;"></td>
    <td style="width:1%;"></td>
    <td style="width:48%;"></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vesting Date:</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Number of RSUs that Vest:</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">All vesting is dependent on the Participant remaining an Eligible Participant, as provided herein.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This grant of RSUs satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:42%;"></td>
    <td style="width:1%;"></td>
    <td style="width:4%;"></td>
    <td style="width:1%;"></td>
    <td style="width:3%;"></td>
    <td style="width:1%;"></td>
    <td style="width:5%;"></td>
    <td style="width:1%;"></td>
    <td style="width:42%;"></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="5" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inozyme Pharma, Inc.</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;border-bottom:0.75pt solid #000000;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Signature of Participant</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;border-bottom:0.75pt solid #000000;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;border-bottom:0.75pt solid #000000;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Street Address</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name of Officer:</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;border-bottom:0.75pt solid #000000;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title:</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">City/State/Zip Code</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">ActiveUS 198334837v.2</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inozyme Pharma, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted Stock Unit Agreement</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Granted under 2020 Stock Incentive Plan</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Incorporated Terms and Conditions</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For valuable consideration, receipt of which is acknowledged, the parties hereto agree as follows:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"></td>
    <td style="width:5%;"></td>
    <td style="width:91%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Award of Restricted Stock Units</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In consideration of services rendered and to be rendered to the Company, by the Participant, the Company has granted to the Participant, subject to the terms and conditions set forth in this Restricted Stock Unit Agreement (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and in the Plan, an award with respect to the number of restricted stock units (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RSUs</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) set forth in the Notice of Grant that forms part of this Agreement (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notice of Grant</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). Each RSU represents the right to receive one share of common stock, $0.0001 par value per share, of the Company (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) upon vesting of the RSU, subject to the terms and conditions set forth herein.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:18pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"></td>
    <td style="width:5%;"></td>
    <td style="width:91%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Vesting</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The RSUs shall vest in accordance with the Vesting Schedule set forth in the Notice of Grant (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Vesting Schedule</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). Any fractional shares resulting from the application of any percentages used in the Vesting Schedule shall be rounded down to the nearest whole number of RSUs. Upon the vesting of the RSU, the Company will deliver to the Participant, for each RSU that becomes vested, one share of Common Stock, subject to the payment of any taxes pursuant to Section 7. The Common Stock will be delivered to the Participant as soon as practicable following each vesting date, but in any event within 30 days of such date.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:18pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"></td>
    <td style="width:5%;"></td>
    <td style="width:91%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Forfeiture of Unvested RSUs Upon Cessation of Service</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the event that the Participant ceases to be an employee, director or officer of, or consultant or advisor to, the Company or any other entity the employees, officers, directors, consultants, or advisors of which are eligible to receive awards under the Plan (an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Eligible Participant</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) for any reason or no reason, with or without cause, all of the RSUs that are unvested as of the time of such cessation shall be forfeited immediately and automatically to the Company, without the payment of any consideration to the Participant, effective as of such cessation. The Participant shall have no further rights with respect to the unvested RSUs or any Common Stock that may have been issuable with respect thereto. If the Participant provides services to a subsidiary of the Company, any references in this Agreement to provision of services to the Company shall instead be deemed to refer to service with such subsidiary.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:18pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"></td>
    <td style="width:5%;"></td>
    <td style="width:91%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Restrictions on Transfer</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Participant shall not sell, assign, transfer, pledge, hypothecate, encumber or otherwise dispose of, by operation of law or otherwise (collectively &#x201c;transfer&#x201d;) any RSUs, or any interest therein. The Company shall not be required to treat as the owner of any RSUs or issue any Common Stock to any transferee to whom such RSUs have been transferred in violation of any of the provisions of this Agreement.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"></td>
    <td style="width:5%;"></td>
    <td style="width:91%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Rights as a Stockholder</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Participant shall have no rights as a stockholder of the Company with respect to any shares of Common Stock that may be issuable with respect to the RSUs until the issuance of the shares of Common Stock to the Participant following the vesting of the RSUs.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:18pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"></td>
    <td style="width:5%;"></td>
    <td style="width:91%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Provisions of the Plan</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Agreement is subject to the provisions of the Plan, a copy of which is furnished to the Participant with this Agreement.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">ActiveUS 198334837v.2</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:18pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"></td>
    <td style="width:5%;"></td>
    <td style="width:91%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Tax Matters</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(a) </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Acknowledgments; No Section 83(b) Election</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Participant acknowledges that he or she is responsible for obtaining the advice of the Participant&#x2019;s own tax advisors with respect to the award of RSUs and the Participant is relying solely on such advisors and not on any statements or representations of the Company or any of its agents with respect to the tax consequences relating to the RSUs. The Participant understands that the Participant (and not the Company) shall be responsible for the Participant&#x2019;s tax liability that may arise in connection with the acquisition, vesting and/or disposition of the RSUs. The Participant acknowledges that no election under Section 83(b) of the Internal Revenue Code of 1986, as amended (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Code</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), is available with respect to RSUs.</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(b) </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Withholding</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Participant acknowledges and agrees that the Company has the right to deduct from payments of any kind otherwise due to the Participant any federal, state, local or other taxes of any kind required by law to be withheld with respect to the vesting of the RSUs. To the extent the Participant has not previously executed and delivered to the Company effective durable sell-to-cover instructions that by their terms would cover any taxes required by law to be withheld with respect to the vesting of the RSUs, at such time as the Participant is not aware of any material nonpublic information about the Company or the Common Stock and is not prohibited from doing so by the Company&#x2019;s insider trading policy or otherwise, the Participant shall execute the instructions set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Schedule A</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> attached hereto (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Durable Automatic Sell-to-Cover Instruction</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) as the means of satisfying such tax obligation. If the Participant is required to but does not execute the Durable Automatic Sell-to-Cover Instruction prior to an applicable vesting date, then the Participant agrees that if under applicable law the Participant will owe taxes at such vesting date on the portion of the award then vested the Company shall be entitled to immediate payment from the Participant of the amount of any tax required to be withheld by the Company. The Company shall not deliver any shares of Common Stock to the Participant until it is satisfied that all required withholdings have been made.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:18pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"></td>
    <td style="width:5%;"></td>
    <td style="width:91%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Miscellaneous</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(a) </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">No Right to Continued Service</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Participant acknowledges and agrees that, notwithstanding the fact that the vesting of the RSUs is contingent upon his or her continued service to the Company, this Agreement does not constitute an express or implied promise of continued service relationship with the Participant or confer upon the Participant any rights with respect to a continued service relationship with the Company or any affiliate of the Company.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(b) </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 409A</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The RSUs awarded pursuant to this Agreement are intended to be exempt from or comply with the requirements of Section 409A of the Code and the Treasury Regulations issued thereunder (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 409A</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). The delivery of shares of Common Stock on the vesting of the RSUs may not be accelerated or deferred unless permitted or required by Section 409A.</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(c) </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Participant&#x2019;s Acknowledgments</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Participant acknowledges that he or she: (i) has read this Agreement; (ii) has been represented in the preparation, negotiation and execution of this Agreement by legal counsel of the Participant&#x2019;s own choice or has voluntarily declined to seek such counsel; (iii) understands the terms and consequences of this Agreement; (iv) is agreeing, in accepting this award, to be bound by any clawback policy that the Company has in place or may adopt in the future; and (iv) is fully aware of the legal and binding effect of this Agreement.</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(d) </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Governing Law</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. This Agreement shall be construed, interpreted and enforced in accordance with the internal laws of the State of Delaware without regard to any applicable conflicts of laws provisions.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">ActiveUS 198334837v.2</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Schedule A</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">DURABLE AUTOMATIC SELL-TO-COVER INSTRUCTION</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Durable Automatic Sell-to-Cover Instruction (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Instruction</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), which is being delivered to Inozyme Pharma, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) by the undersigned on the date set forth below (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adoption Date</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), relates to the Covered RSUs (as defined following my signature below). This Instruction provides for &#x201c;eligible sell-to-cover transactions&#x201d; (as described in Rule 10b5-1(c)(1)(ii)(D)(3) under the Securities Exchange Act of 1934 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)) and is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c)(1) under the Exchange Act.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I acknowledge that upon vesting and settlement of any Covered RSUs in accordance with the applicable RSU&#x2019;s terms, whether vesting is based on the passage of time or the achievement of performance goals, I will have compensation income equal to the fair market value of the shares of the Company&#x2019;s common stock subject to the RSUs that are settled on such settlement date and that the Company is required to withhold income and employment taxes in respect of that compensation income.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I desire to establish a plan and process to satisfy such withholding obligation in respect of all Covered RSUs through an automatic sale of the number of the shares of the Company&#x2019;s common stock that would otherwise be issuable to me on each applicable settlement date in an amount sufficient to satisfy the applicable withholding obligation, with the proceeds of the sale delivered to the Company in satisfaction of the applicable withholding obligation.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I understand that the Company has arranged for the administration and execution of its equity incentive programs and the sale of securities by participants thereunder pursuant to a platform administered by a third party (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Administrator</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and the Administrator&#x2019;s designated brokerage partner.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon the settlement of any of my Covered RSUs after the 30</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> day following the Adoption Date (or if I am an officer of the Company on the Adoption Date, after the 120</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> day following the Adoption Date) (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cooling-Off Period</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), I hereby appoint the Administrator (or any successor administrator) to automatically sell such number of shares of the Company&#x2019;s common stock issuable with respect to such RSUs that vested and settled as is sufficient to generate net proceeds sufficient to satisfy the Company&#x2019;s minimum statutory withholding obligations with respect to the income recognized by me in connection with the vesting and settlement of such RSUs (based on minimum statutory withholding rates for all tax purposes, including payroll and social security taxes, that are applicable to such income), and the Company shall receive such net proceeds in satisfaction of such tax withholding obligation.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I hereby appoint the Chief Executive Officer, the Chief Financial Officer and the Chief Operations Officer, and any of them acting alone and with full power of substitution, to serve as my attorneys-in-fact to arrange for the sale of shares of the Company&#x2019;s common stock in accordance with this Instruction. I agree to execute and deliver such documents, instruments and certificates as may reasonably be required in connection with the sale of the shares of common stock pursuant to this Instruction.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unless the third and final box in the definition of Covered RSUs below is checked, if I have previously adopted an automatic sale or sell-to-cover instruction relating to Covered RSUs, this Instruction shall be void </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ab initio</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I hereby certify that, as of the Adoption Date:</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(i)  I am not prohibited from entering into this Instruction by the Company&#x2019;s insider trading policy or otherwise;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (ii) I am not aware of any material nonpublic information about the Company or its common stock; and</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">ActiveUS 198334837v.2</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (iii) I am adopting this Instruction in good faith and not as part of a plan or scheme to evade the prohibitions of Rule 10b-5 under the Exchange Act.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <table style="margin-left:40%;border-spacing:0;table-layout:fixed;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:15%;"></td>
    <td style="width:15%;"></td>
    <td style="width:70%;"></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Print Name:</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date:</font></p></td>
    <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Covered RSUs:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following restricted stock units (&#x201c;RSUs&#x201d;) are covered by this Instruction.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Check all applicable boxes:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#9744;  The first award of RSUs granted to me on or after ______________ [</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">insert date of grant of current RSUs the grant of which is triggering the execution of this Instruction; if instruction is being executed in advance of a grant of RSUs, insert the Adoption Date</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">] and any RSUs that may, from time to time following such date, be granted to me by the Company, other than any future granted RSUs which by the terms of the applicable award agreement require the Company to withhold shares for tax withholding obligations in connection with the vesting and settlement of such RSUs, and therefore do not permit sell-to-cover transactions.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#9744;  Any outstanding RSUs that were granted to me by the Company prior to the Adoption Date that (1) are </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">not</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> subject to any prior automatic sale or sell-to-cover instruction and (2) for which the next vesting date is after the Cooling-Off Period, other than any previously granted RSUs which by the terms of the applicable award agreement require the Company to withhold shares for tax withholding obligations in connection with the vesting and settlement of such RSUs, and therefore do not permit sell-to-cover transactions.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#9744;  With respect to any RSUs, whether or not granted to me by the Company prior to the Adoption Date, that already are subject to an automatic sale or sell-to-cover instruction (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior Instruction</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), I elect to have such sales effected pursuant to this Instruction and confirm that doing so does not modify or change the amount, price, or timing of such sales from those provided by the Prior Instruction (and, as a result the Cooling-Off Period is not applicable to sales pursuant to this Instruction that were previously subject to the Prior Instruction).</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">ActiveUS 198334837v.2</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>inzy-ex21_1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html>
 <head>
  <title>EX-21.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">Exhibit 21.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:44.225%;"></td>
    <td style="width:3.75%;"></td>
    <td style="width:52.025%;"></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="3" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Subsidiaries of the Registrant</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="3" style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Name of Subsidiary</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Jurisdiction of Incorporation</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:2pt solid;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2pt solid #ffffff03;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2pt solid;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Inozyme Securities Corp.</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Massachusetts</font></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Inozyme Pharma Ireland Limited</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Ireland</font></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Inozyme Pharma Switzerland GmbH</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Switzerland</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>inzy-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 23.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#333333;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We consent to the incorporation by reference in the following Registration Statements:</font></p>
  <div style="margin-left:5.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5108231948175064%;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-8 No. 333-240146) pertaining to the Amended and Restated 2017 Equity </font></div></div>
  <p style="margin-left:8.387%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Incentive Plan, as amended, 2020 Stock Incentive Plan and 2020 Employee Stock Purchase Plan of Inozyme Pharma, Inc.;</font></p>
  <p style="margin-left:8.387%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:5.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5108231948175064%;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-8 No. 333-254685) pertaining to the 2020 Stock Incentive Plan and 2020  </font></div></div>
  <p style="margin-left:8.387%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Employee Stock Purchase Plan of</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inozyme Pharma, Inc.;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:8.387%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:5.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5108231948175064%;display:inline-flex;justify-content:flex-start;">(3)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-8 No. 333-263586) pertaining to the 2020 Stock Incentive Plan and 2020 Employee Stock Purchase Plan of Inozyme Pharma, Inc.;</font></div></div>
  <p style="margin-left:8.387%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:5.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5108231948175064%;display:inline-flex;justify-content:flex-start;">(4)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-8 No. 333-270733) pertaining to the 2020 Stock Incentive Plan, 2020 Employee Stock Purchase Plan and 2023 Inducement Stock Incentive Plan of Inozyme Pharma, Inc.;</font></div></div>
  <p style="margin-left:8.387%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:5.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5108231948175064%;display:inline-flex;justify-content:flex-start;">(5)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-3 No. 333-258702) of Inozyme Pharma, Inc.; and</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:5.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5108231948175064%;display:inline-flex;justify-content:flex-start;">(6)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-3 No. 333-275364) of Inozyme Pharma, Inc.;</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of our report dated March 12, 2024, with respect to the consolidated financial statements of Inozyme Pharma, Inc. included in this Annual Report (Form 10-K) of Inozyme Pharma, Inc. for the year ended December 31, 2023.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:13.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ Ernst &amp; Young LLP</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Boston, Massachusetts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:13.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 12, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:13.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:13.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>inzy-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Doug Treco, certify that:</font></p>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Inozyme Pharma, Inc.;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(c)	Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(d)	Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></p>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.44%;"></td>
    <td style="width:1.02%;"></td>
    <td style="width:4.04%;"></td>
    <td style="width:49.5%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: March 12, 2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Douglas A. Treco</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Douglas A. Treco</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Executive Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>inzy-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Sanjay Subramanian, certify that:</font></p>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Inozyme Pharma, Inc.;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(c)	Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(d)	Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></p>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.44%;"></td>
    <td style="width:1.02%;"></td>
    <td style="width:4.04%;"></td>
    <td style="width:49.5%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: March 12, 2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Sanjay Subramanian</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Sanjay Subramanian</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Financial Officer</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Financial Officer and Principal Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>inzy-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Annual Report of Inozyme Pharma, Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(1)	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:48.51%;"></td>
    <td style="width:1%;"></td>
    <td style="width:3.241%;"></td>
    <td style="width:47.249%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: March 12, 2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Douglas A. Treco</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Douglas A. Treco</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Executive Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>inzy-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32.2</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Annual Report of Inozyme Pharma, Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(1)	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:48.51%;"></td>
    <td style="width:1%;"></td>
    <td style="width:3.241%;"></td>
    <td style="width:47.249%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: March 12, 2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Sanjay Subramanian</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Sanjay Subramanian</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Financial Officer</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Financial Officer and Principal Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>10
<FILENAME>inzy-ex97_1.htm
<DESCRIPTION>EX-97.1
<TEXT>
<html>
 <head>
  <title>EX-97.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:0.04%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 97.1</font></p>
  <p style="margin-left:0.04%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">INOZYME PHARMA, INC.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:0.08%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Dodd-Frank Compensation Recovery Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Compensation Recovery Policy (this &#x201c;Policy&#x201d;) is adopted by Inozyme Pharma, Inc. (the &#x201c;Company&#x201d;) in accordance with Nasdaq Listing Rule 5608 (&#x201c;Rule 5608&#x201d;), which implements Rule 10D-1 under the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;) (as promulgated pursuant to Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010). This Policy is effective as of October 2, 2023 (the &#x201c;Effective Date&#x201d;).</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Definitions</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:6.533%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.53%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Accounting Restatement&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> means a requirement that the Company prepare an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the U.S. federal securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period. Changes to the Company&#x2019;s financial statements that do not represent error corrections are not an Accounting Restatement, including: (A) retrospective application of a change in accounting principle; (B) retrospective revision to reportable segment information due to a change in the structure of the Company&#x2019;s internal organization; (C) retrospective reclassification due to a discontinued operation; (D) retrospective application of a change in reporting entity, such as from a reorganization of entities under common control; and (E) retrospective revision for stock splits, reverse stock splits, stock dividends or other changes in capital structure. </font></div></div>
  <div style="text-indent:6.533%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.53%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Committee&#x201d; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">means the Compensation Committee of the Company&#x2019;s Board of Directors (the &#x201c;Board&#x201d;). </font></div></div>
  <div style="text-indent:6.533%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.53%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Covered Person&#x201d; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">means a person who served as an Executive Officer at any time during the performance period for the applicable Incentive-Based Compensation. </font></div></div>
  <div style="text-indent:6.533%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.53%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Erroneously Awarded Compensation&#x201d; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">means the amount of Incentive-Based Compensation that was Received that exceeds the amount of Incentive-Based Compensation that otherwise would have been Received had the amount of Incentive-Based Compensation been determined based on the restated amounts, computed without regard to any taxes paid by the Covered Person or by the Company on the Covered Person&#x2019;s behalf. For Incentive-Based Compensation based on stock price or total shareholder return, where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in an Accounting Restatement, the amount of Erroneously Awarded Compensation will be based on a reasonable estimate by the Committee of the effect of the Accounting Restatement on the stock price or total shareholder return upon which the Incentive-Based Compensation was Received. The Company will maintain documentation of the determination of that reasonable estimate and provide such documentation to Nasdaq. </font></div></div>
  <div style="text-indent:6.533%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.53%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Executive Officer&#x201d; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">means</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the Company&#x2019;s officers as defined in Rule 16a-1(f) under the Exchange Act.  </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">1</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:6.533%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.53%;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Financial Reporting Measures&#x201d; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">means (A) measures that are determined and presented in accordance with the accounting principles used in preparing the Company&#x2019;s financial statements, and any measures that are derived wholly or in part from such measures (whether or not such measures are presented within the Company&#x2019;s financial statements or included in a filing made with the U.S. Securities and Exchange Commission), (B) stock price and (C) total shareholder return.   </font></div></div>
  <div style="text-indent:6.533%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.53%;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Incentive-Based Compensation&#x201d; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">means any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a Financial Reporting Measure. </font></div></div>
  <div style="text-indent:6.533%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.53%;text-indent:0;display:inline-flex;justify-content:flex-start;">(h)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Incentive-Based Compensation is deemed to be </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Received&#x201d; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">in the Company&#x2019;s fiscal period during which the Financial Reporting Measure specified in the applicable Incentive-Based Compensation award is attained, even if the payment or grant of the Incentive-Based Compensation occurs after the end of that period or is subject to additional time-based vesting requirements. </font></div></div>
  <div style="text-indent:6.533%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.53%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Recovery Period&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> means the three completed fiscal years immediately preceding the earlier of: (A) the date the Board, a committee of the Board, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement; or (B) the date a court, regulator, or other legally authorized body directs the Company to prepare an Accounting Restatement. In addition, if there is a change in the Company&#x2019;s fiscal year end, the Recovery Period will also include any transition period to the extent required by Rule 5608. </font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Recovery of Erroneously Awarded Compensation</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <p style="text-indent:6.573%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Subject to the terms of this Policy and the requirements of Rule 5608, if the Company is required to prepare an Accounting Restatement, the Company will attempt to recover, reasonably promptly from each Covered Person, any Erroneously Awarded Compensation that was Received by such Covered Person during the Recovery Period pursuant to Incentive-Based Compensation that is subject to this Policy.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Interpretation and Administration</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:6.533%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.53%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Role of the Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. This Policy will be interpreted by the Committee in a manner that is consistent with Rule 5608 and any other applicable law and will otherwise be interpreted in the business judgment of the Committee. All decisions and interpretations of the Committee that are consistent with Rule 5608 will be final and binding.  </font></div></div>
  <div style="text-indent:6.533%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.53%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Compensation Not Subject to this Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. This Policy does not apply to Incentive-Based Compensation that was Received before the Effective Date. With respect to any Covered Person, this Policy does not apply to Incentive-Based Compensation that was Received by such Covered Person before beginning service as an Executive Officer. </font></div></div>
  <div style="text-indent:6.533%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.53%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Determination of Means of Recovery</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Subject to the requirement that recovery be made reasonably promptly, the Committee will determine the appropriate means of recovery, which may vary between Covered Persons or based on the nature of the applicable Incentive-Based Compensation, and which may involve, without limitation, establishing a deferred repayment plan or setting off against current or future compensation otherwise payable to the </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.537%;text-align:left;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Covered Person. Recovery of Erroneously Awarded Compensation will be made without regard to income taxes paid by the Covered Person or by the Company on the Covered Person&#x2019;s behalf in connection with such Erroneously Awarded Compensation.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></div></div>
  <div style="text-indent:6.533%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.53%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Determination That Recovery is Impracticable</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The Company is not required to recover Erroneously Awarded Compensation if a determination is made by the Committee that either (A) after the Company has made and documented a reasonable attempt to recover such Erroneously Awarded Compensation, the direct expense paid to a third party to assist in enforcing this Policy would exceed the amount to be recovered or (B) recovery of such Erroneously Awarded Compensation would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of Section 401(a)(13) or 411(a) of the Internal Revenue Code and regulations thereunder. </font></div></div>
  <div style="text-indent:6.533%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.53%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Indemnification or Company-Paid Insurance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The Company will not indemnify any Covered Person against the loss of Erroneously Awarded Compensation and will not pay or reimburse any Covered Person for the purchase of a third-party insurance policy to fund potential recovery obligations. </font></div></div>
  <div style="text-indent:6.533%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.53%;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Interaction with Other Clawback Provisions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The Company will be deemed to have recovered Erroneously Awarded Compensation in accordance with this Policy to the extent the Company actually receives such amounts pursuant to any other Company policy, program or agreement, pursuant to Section 304 of the Sarbanes-Oxley Act or otherwise. </font></div></div>
  <div style="text-indent:6.533%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.53%;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Limitation on Other Remedies</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Nothing in this Policy will be deemed to limit the Company&#x2019;s right to terminate employment of any Covered Person, to seek recovery of other compensation paid to a Covered Person, or to pursue other rights or remedies available to the Company under applicable law. </font></div></div>
  <p style="font-size:10pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Adopted by the Board on October 30, 2023.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">3</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img187419207_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img187419207_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '3!#@# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MP"BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 9'_",Z1_S[/_ -_Y/_BJ/^$9TC_GV?\ [_R?_%5K
MT4 9'_",Z1_S[/\ ]_Y/_BJ/^$9TC_GV?_O_ "?_ !5:]% &1_PC.D?\^S_]
M_P"3_P"*H_X1G2/^?9_^_P#)_P#%5KT4 9'_  C.D?\ /L__ '_D_P#BJ/\
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M_/L__?\ D_\ BJ/^$9TC_GV?_O\ R?\ Q5:]% &1_P (SI'_ #[/_P!_Y/\
MXJC_ (1G2/\ GV?_ +_R?_%5KT4 9'_",Z1_S[/_ -_Y/_BJ/^$9TC_GV?\
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M '_D_P#BJ/\ A&=(_P"?9_\ O_)_\563J?C_ $BUMK*ZL;NTO+:6_2TN)EF
M6 ,"2Q/T%=%IVIV.KV:WFG745U;L2!)$VX9'44.+6K I_P#",Z1_S[/_ -_Y
M/_BJ/^$9TC_GV?\ [_R?_%5KT4@,C_A&=(_Y]G_[_P G_P 51_PC.D?\^S_]
M_P"3_P"*K7HH R/^$9TC_GV?_O\ R?\ Q5'_  C.D?\ /L__ '_D_P#BJUZ*
M ,C_ (1G2/\ GV?_ +_R?_%4?\(SI'_/L_\ W_D_^*K7HH R/^$9TC_GV?\
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M)M5M([UI!%Y#2C>'P#MQZ\BFMXIT8W=S8P:C;37\".QMED&[*C)'U'?TI<K
M=_PC.D?\^S_]_P"3_P"*H_X1G2/^?9_^_P#)_P#%5D:+X^T[6?#C7T<MM_:,
M=FUU+8+-EDP"<'\O3O4FE>-(;R*&>^CM[.W;38K]Y6N0=F\XVE<9Q_M4^206
M-/\ X1G2/^?9_P#O_)_\51_PC.D?\^S_ /?^3_XJB+Q5H$UG<WD6KV;V]JP6
M:19050GH#]>WK5G3-9T[6H&GTV]ANHD;:S1-D ]<&E9@5O\ A&=(_P"?9_\
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M_P 51_PC.D?\^S_]_P"3_P"*K7HH R/^$9TC_GV?_O\ R?\ Q5'_  C.D?\
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MVLPZK:.+,9N")!B,=,D^F12LP&_\(SI'_/L__?\ D_\ BJ/^$9TC_GV?_O\
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M UT+>+O#R:8FI-K%G]CD<QI+YHPS#J![TW"2Z!8?_P (SI'_ #[/_P!_Y/\
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M%:;K^FZEK4FK6%K!#J%TUX&BN?,*LP4;,;1QQG-=G114R=W<04444@"BBB@
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M]L^>3M ^;H#7:6,,UOI]M!<3&>>.)4DE/\; 8)_$U8HJ7)M6$%%%%2 4444
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M*;_KI%_Z,6M:LGQ+_P @*;_KI%_Z,6M:@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ K-\0?\BYJ7_7K)_P"@FM*LWQ!_R+FI?]>LG_H)
MH O0?\>\7^X/Y5)4<'_'O%_N#^524 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %9'AC_ )%VT^C?^A&M>LCPQ_R+MI]&_P#0C0!KT444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9.@?\>]Y_U_
M7'_HPUK5DZ!_Q[WG_7]<?^C#6M0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 45RWQ$U"ZTSP5>75G=/:S*\0\Z,X9074$C\":S+"[L5T
M?7+S2/%M_JTMO8R';-,KB)MI*L,*.?EJU"ZN.QWE%>4Z3XIUA/ FLV.IWDG]
MLVNF_;K6[Z-+"Z95Q[J>#^%7;F[NM0\36UG=>);O2[9=$BNM\4R1AI2V"3N&
M#Q3]FPL>DT5Y0OB'6-3\)^'&N-6FMC=:NUI)?08C,\ W@/R,#. :V/#VH:S+
MJOB+1M/UE-4BM(XVM;ZZ <1R-G*,4P&QUH=-H+'?T5R'@.XU&3^W;;4M1EOY
M;34GA6:10O 53P!P!DGBF>+6O;GQ3X<TJWU.[L(+O[09FM6"LVQ 1R0>]3RZ
MV"QV5%</9:KJ'ACQ3)HVLZFU_I\ME)>P7<R!9(A&?G5]H (P<@XJW9^.1<3V
M/GZ+?6EMJ.187$I3$S8+*I .4+ <9IN#Z!8ZVBO&[34)IK;Q%K^J6^MVLT=\
M81<6]XH,2^8BB$+N(R.YQCK@UW^I^+6M-7FTS3M'O=5N;:-9;K[.541*WW1E
MB,L0,X%#IM!8Z6BN1@\26-EJ'B6]NY]02&RBMI98IR"D8:/(6-1R&/0@]ZGL
M?&#3:A%9:AH]YILUS \]KYS(PF51EA\I.U@.<&ER,5CIZ*XFP^(T-ZFG7+Z)
MJ-OIU]*MNE[(%V"5C@#&<D9XW8Q5ZX\8L-6NK/3M$O\ 4H[*017<]OM"QN>=
MH!(+D C.*.20['445RQ\<V2^%[[6GM9T:SN&M9+0X\PRA@H4=N<C'UKIXV+1
MJS*5) )4]O:DTUN(=1112 **** "BBB@ HHHH **** "BBB@ K)U;_D*:+_U
M]-_Z*>M:L37[A+2YTNYE.(X9I)&^@AD-"5P&>)?%FG>&8%-R3)<.,QV\?WF]
MSZ#WKSJ[^*VMRR$VUM:6Z=@5+G\3D5R&JZG<:SJ<^H7+%I)FSC^Z.RCV I=*
MTNYUG4HM/LPAGESMWMM' )//T%?04<#2I0O45WU/;I8.E3C>>K.E_P"%H>)/
M[UG_ -^#_C1_PM#Q)_>L_P#OP?\ &L9_"^J1Z#+K7EQM91.R.ROEAM;:3CTR
M*GC\&ZF[1JTUA$9($N%\ZY"91\XZ]^*MT\(E>R+Y,,NB-+_A:'B3^]9_]^#_
M (T?\+0\2?WK/_OP?\:Y_7-"O?#UXEK?^4)7C\T"-]WRY(_I6M;^ =9NX5DA
MDL'!02;1<C<!C/(Q3=/"**DTK,'##)*32LRU_P +0\2?WK/_ +\'_&C_ (6A
MXD_O6?\ WX/^-9T/@G6I],6^2.##Q&9(3*!*\8_B"^G^-5AX9U3_ (1U]=>%
M8[!0&#.V&<$@ @>G-'L\(^B[!R8;LC:_X6AXD_O6?_?@_P"-'_"T/$G]ZS_[
M\'_&N-HK3ZK0_E1I]6I?RH[+_A:'B3^]9_\ ?@_XT?\ "T/$G]ZS_P"_!_QK
MC:*/JM#^5!]6I?RH[+_A:'B3^]9_]^#_ (T?\+0\2?WK/_OP?\:XVBCZK0_E
M0?5J7\J.R_X6AXD_O6?_ 'X/^-'_  M#Q)_>L_\ OP?\:XVBCZK0_E0?5J7\
MJ.R_X6AXD_O6?_?@_P"-'_"T/$G]ZS_[\'_&N-HH^JT/Y4'U:E_*CLO^%H>)
M/[UG_P!^#_C1_P +0\2?WK/_ +\'_&N-HH^JT/Y4'U:E_*CJ[SXBZ_?6S6\S
M6GEL5)VPX/!!'?U J?\ X6AXD_O6?_?@_P"-<;11]5H?RH/JU+^5'9?\+0\2
M?WK/_OP?\:/^%H>)/[UG_P!^#_C7&T4?5:'\J#ZM2_E1V7_"T/$G]ZS_ ._!
M_P :/^%H>)/[UG_WX/\ C7&T4?5:'\J#ZM2_E1V7_"T/$G]ZS_[\'_&C_A:'
MB3^]9_\ ?@_XUQM%'U6A_*@^K4OY4=E_PM#Q)_>L_P#OP?\ &C_A:'B3^]9_
M]^#_ (UQM%'U6A_*@^K4OY4=E_PM#Q)_>L_^_!_QH_X6AXD_O6?_ 'X/^-<;
M11]5H?RH/JU+^5'9?\+0\2?WK/\ [\'_ !H_X6AXD_O6?_?@_P"-<;11]5H?
MRH/JU+^5'9?\+0\2?WK/_OP?\:/^%H>)/[UG_P!^#_C7&T4?5:'\J#ZM2_E1
MV7_"T/$G]ZS_ ._!_P :/^%H>)/[UG_WX/\ C7&T4?5:'\J#ZM2_E1V7_"T/
M$G]ZS_[\'_&C_A:'B3^]9_\ ?@_XUQM%'U6A_*@^K4OY4=E_PM#Q)_>L_P#O
MP?\ &HKKXC^(+RTFMI6M/+F0HV(<'!&#WKDJ*/JM#^5!]6I?RH[%?B=XD50H
M:SP!@?N/_KTO_"T/$G]ZS_[\'_&N-HH^JT/Y4'U:E_*CLO\ A:'B3^]9_P#?
M@_XT?\+0\2?WK/\ [\'_ !KC:*/JM#^5!]6I?RH[+_A:'B3^]9_]^#_C1_PM
M#Q)_>L_^_!_QKC:*/JM#^5!]6I?RH[+_ (6AXD_O6?\ WX/^-'_"T/$G]ZS_
M ._!_P :XVBCZK0_E0?5J7\J.R_X6AXD_O6?_?@_XT?\+0\2?WK/_OP?\:XV
MBCZK0_E0?5J7\J.R_P"%H>)/[UG_ -^#_C1_PM#Q)_>L_P#OP?\ &N-HH^JT
M/Y4'U:E_*CLO^%H>)/[UG_WX/^-'_"T/$G]ZS_[\'_&N-HH^JT/Y4'U:E_*C
MLO\ A:'B3^]9_P#?@_XT?\+0\2?WK/\ [\'_ !KC:*/JM#^5!]6I?RH[+_A:
M'B3^]9_]^#_C1_PM#Q)_>L_^_!_QKC:*/JM#^5!]6I?RH[+_ (6AXD_O6?\
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MP\,_\\+G_P "&H_X5AX9_P">%S_X$-78T4?6J_\ ._O#ZQ5_F9QW_"L/#/\
MSPN?_ AJ/^%8>&?^>%S_ .!#5V-%'UJO_._O#ZQ5_F9QW_"L/#/_ #PN?_ A
MJ/\ A6'AG_GA<_\ @0U=C11]:K_SO[P^L5?YF>?:S\._#UCI<EQ##<"17C S
M.QX+J#^A-:'_  K#PS_SPN?_  (:MOQ+_P @*;_KI%_Z,6M:E]:K_P [^\/K
M%7^9G'?\*P\,_P#/"Y_\"&H_X5AX9_YX7/\ X$-78T4_K5?^=_>'UBK_ #,X
M[_A6'AG_ )X7/_@0U'_"L/#/_/"Y_P# AJ[&BCZU7_G?WA]8J_S,X[_A6'AG
M_GA<_P#@0U'_  K#PS_SPN?_  (:NQHH^M5_YW]X?6*O\S.._P"%8>&?^>%S
M_P"!#4?\*P\,_P#/"Y_\"&KL:*/K5?\ G?WA]8J_S,X[_A6'AG_GA<_^!#4?
M\*P\,_\ /"Y_\"&KL:*/K5?^=_>'UBK_ #,X[_A6'AG_ )X7/_@0U'_"L/#/
M_/"Y_P# AJ[&BCZU7_G?WA]8J_S,X[_A6'AG_GA<_P#@0U'_  K#PS_SPN?_
M  (:NQHH^M5_YW]X?6*O\S.._P"%8>&?^>%S_P"!#4?\*P\,_P#/"Y_\"&KL
M:*/K5?\ G?WA]8J_S,X[_A6'AG_GA<_^!#4?\*P\,_\ /"Y_\"&KL:*/K5?^
M=_>'UBK_ #,X[_A6'AG_ )X7/_@0U4]6^'/AVST>]N8H;@20P.Z$SL1D D5W
MM9OB#_D7-2_Z]9/_ $$TOK5?^=_>'UBK_,SG8OAEX:>)&,%SDJ"?](:G_P#"
ML/#/_/"Y_P# AJZV#_CWB_W!_*I*/K5?^=_>'UBK_,SCO^%8>&?^>%S_ .!#
M4?\ "L/#/_/"Y_\  AJ[&BG]:K_SO[P^L5?YF<=_PK#PS_SPN?\ P(:C_A6'
MAG_GA<_^!#5V-%'UJO\ SO[P^L5?YF<=_P *P\,_\\+G_P "&H_X5AX9_P">
M%S_X$-78T4?6J_\ ._O#ZQ5_F9QW_"L/#/\ SPN?_ AJ/^%8>&?^>%S_ .!#
M5V-%'UJO_._O#ZQ5_F9QW_"L/#/_ #PN?_ AJ/\ A6'AG_GA<_\ @0U=C11]
M:K_SO[P^L5?YF<=_PK#PS_SPN?\ P(:C_A6'AG_GA<_^!#5V-%'UJO\ SO[P
M^L5?YF<=_P *P\,_\\+G_P "&H_X5AX9_P">%S_X$-78T4?6J_\ ._O#ZQ5_
MF9QW_"L/#/\ SPN?_ AJ/^%8>&?^>%S_ .!#5V-%'UJO_._O#ZQ5_F9QW_"L
M/#/_ #PN?_ AJ/\ A6'AG_GA<_\ @0U=C11]:K_SO[P^L5?YF<=_PK#PS_SP
MN?\ P(:L_1/AYX?O](@N9X;@R/NSB=@.&(_I7H-9'AC_ )%VT^C?^A&E]:K_
M ,[^\/K%7^9F+_PK#PS_ ,\+G_P(:C_A6'AG_GA<_P#@0U=C13^M5_YW]X?6
M*O\ ,SCO^%8>&?\ GA<_^!#4?\*P\,_\\+G_ ,"&KL:*/K5?^=_>'UBK_,SC
MO^%8>&?^>%S_ .!#4?\ "L/#/_/"Y_\  AJ[&BCZU7_G?WA]8J_S,X[_ (5A
MX9_YX7/_ ($-1_PK#PS_ ,\+G_P(:NQHH^M5_P"=_>'UBK_,SCO^%8>&?^>%
MS_X$-1_PK#PS_P \+G_P(:NQHH^M5_YW]X?6*O\ ,SCO^%8>&?\ GA<_^!#4
M?\*P\,_\\+G_ ,"&KL:*/K5?^=_>'UBK_,SCO^%8>&?^>%S_ .!#4?\ "L/#
M/_/"Y_\  AJ[&BCZU7_G?WA]8J_S,X[_ (5AX9_YX7/_ ($-1_PK#PS_ ,\+
MG_P(:NQHH^M5_P"=_>'UBK_,SCO^%8>&?^>%S_X$-1_PK#PS_P \+G_P(:NQ
MHH^M5_YW]X?6*O\ ,SCO^%8>&?\ GA<_^!#4?\*P\,_\\+G_ ,"&KL:*/K5?
M^=_>'UBK_,SS_2OAWX>O(;AI8;@F.ZEB7$[#Y58@?I5__A6'AG_GA<_^!#5M
MZ!_Q[WG_ %_7'_HPUK4OK5?^=_>'UBK_ #,X[_A6'AG_ )X7/_@0U'_"L/#/
M_/"Y_P# AJ[&BG]:K_SO[P^L5?YF<=_PK#PS_P \+G_P(:C_ (5AX9_YX7/_
M ($-78T4?6J_\[^\/K%7^9G'?\*P\,_\\+G_ ,"&H_X5AX9_YX7/_@0U=C11
M]:K_ ,[^\/K%7^9G'?\ "L/#/_/"Y_\  AJEM_AOX9@D#FR>7'\,LS,/RS76
M44GBJS^V_O#ZQ5_F9%;6T%G L%M#'#$HPJ1J% _ 5+116#=S'<**** "BBB@
M HHHH **** ,X:'IPQ^X/$9B'[U_NGMU_6C^P].  \@\1>2/WK_<].OZ]:T:
M* ,[^P].X_<'B/RO]:_W?3K^M']A:=C'D'_5>3_K7^YZ=?UZUHT4 9W]AZ=_
MSP/^J\K_ %K_ '?3K^M']A:=C'D'_5>3_K7^YZ=?UZUHT4 9W]AZ=_SP/^J\
MK_6O]WTZ_K1_86G$$>0>8O)_UK_<].OZ]:T:* ,[^P]..?W!YB\H_O'^[Z=?
MUH.A:<<Y@/,0B/[U_NCMU]NM:-% &<=#TXYS >8Q$?WK_=';K[=:#H6G'=F
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M'?\ >-RPZ'K[UHT4 9SZ%ITGF[H"?-<._P"]?DCIW]Z'T/3I/,W0$^8XD?\
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MIT?E;("/*<NG[Q^">O?VH30].C\K9 1Y3%D_>/P3U[\]*T:* ,Z/0].B\K9
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M(Q3:M.\9()4A>H.1V]0*D_X3;Q-_T&;C\E_PK!HH]C2_E7W(/94_Y5]QO?\
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MDUB6,.E#X>W>E3^(M.AN[R6.ZVL3^[QM)0^_!%<=1FL_J26TOZ6IG]42V?\
M2$5MZAL$9YP:6BBNTZPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ]MQL4,V9!\H/0G\Q0VK:>F_=>VXV ,V9!\H/0GZY% %RBJ;:MIR;]U];C8
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MMQM?RS^\'#>GUH.JZ>,YO;<8?RS^\'WO[OU]J+A<I>)(HQH4Q$: ^9%_"/\
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MZ4?9;<Y_<1<C:?D'3TJ6B@"+[-;G.8(^1@_(.1Z4?9;<YS!%R,'Y!T]*EHH
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MS#&=W7*CF@V\)SF*,YZY4<U)10!&;>$YS#&=W)RHYH-O"<YAC.3D_*.:DHH
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M+(,%GDX_B(VXYP*NQ:-KD>L:SJX@T]KB^L+:)8)9&,9D7.]6X^[S@']*7NV
MV/#VJZAJULT][IL5I&RJ\#Q72SK(ISW &"/ZULUQ_@WPY?:-J.IW<UM;:=:W
M6SR].M9FDCC89W/D@ $YZ =J["HE:^@@HHHJ0"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ K"\1726,NFW<GW()9)#^$,AK=KF/&ML][86]M'R\IF50.
MY\F2J@DY),J*3DDSQ"^OI]2OI[VY<M-.Y=B??M]!TJSH>C7&OZHFGVTD:2NK
M,&D)VX SVK.'2NK^'#JGC.W9V51Y,O+' ^[7U-:3ITFX]$?156X4VX]$4/\
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M[K5'3BT]7]S_ .&-75J.FK/7\'_PQ#;^!M3N-.2Y6XLUN)8#<QV32?OGC_O
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M'_HPUK5DZ!_Q[WG_ %_7'_HPUK4 %%%% !1110 4444 %%%% !1110 4444
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M-:7_  A_AS_H"V7_ 'Z%']JT_P"5A_:,.S/GRBOH/_A#_#G_ $!;+_OT*/\
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MZ%'_  A_AS_H"V7_ 'Z%']JT_P"5A_:,.S/GRBOH/_A#_#G_ $!;+_OT*/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU XYS[UH44 9[V5^WF[=6E3>04Q#&=@[@<<Y]Z)+*^;S=NK2IO8%,0QG8!U
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M#XE_Y 4W_72+_P!&+6M0!G_8K[_H+2_ZW?\ ZF/[O]WIT]^M'V*^X_XFTO\
MK=_^IC^[_<Z=/?K6A10!GBRON/\ B;2_ZS?_ *F/[O\ =Z=/?K0+*^X_XFTI
MQ+O/[F/E?[O3I[]:T** ,\65\,9U:4XDWG]S'RO]WIT]^M LKX;<ZM*<2;C^
MYCY7^[TZ>_6M"B@#/6ROAMSJTIQ)N/[F/E?[O3I[]:%LKX;,ZM*<2%C^YC^9
M?[O3I[]:T** ,];*^&S.K2MB3<?W,?S+_=Z=/?K0ME?#9G5I6VR%F_<Q_,O]
MWI^O7FM"B@#/6ROEV;M6E;;)N;]S'\R_W>GZ]>:$LKY?+W:M*VURS?N8QN7^
M[TX^O7FM"B@#/2ROE\O=JTK;7+-F&,;U_N]./J.>:$LK]?+W:M*VURS9AC&\
M?W>G'X>M:%% &>EE?+Y>[5I7VN6;,,8WC^[TX_#UH2ROU\K=JTK;6);,,8WC
ML.G&/;UK0HH STLKY?*W:M*^UR6S#&-X].G'X4)97Z^5NU:5]K$OF&,;QV'3
MC'M6A10!GQV5\OE;M6E?8Q+YAC&\=@>.,>U9VMV5\GAZ\+ZK+($MY2X,*#S!
MMX!P./P]:Z&LWQ!_R+FI?]>LG_H)H 2VLKX06Q.JRL%&6!AC&\$<#IQCVIZ6
M5^OE;M6E?83OS#&-^>F>.,>U7(/^/>+_ '!_*I* ,^.ROE\K=JTK["2^88QO
MST!XXQ[4)97Z^5NU:5]F=^88QOSTSQQCVK0HH STLK]?*W:M*^S._,,8WYZ9
MXXQ[4)97Z^5NU:5]F=^88QOSTSQQCVK0HH STLKY?*W:M*^W._,,8WYZ9XXQ
M[4)97Z^5NU:5MH(?,,8WYZ=N,>U:%% &>EE?+Y6[5I7VAM^88QOST[<8]J$L
MK]?*W:M*VT$/F&,;R>AZ<8]JT** ,]+*_7R]VK2MM#!LPQC>3T/3C'MZ4)97
MZ^7NU:5MJD-^YC&\G.#TXQ[>E:%% &>EE?+Y>[5I6VJP;,,?SDYP>G&/;TH6
MROU\O=JTK;5(;]S'\Y.<'IQCCIZ5H44 9ZV5\/+W:M*VU6#?N8_F)S@].,<?
ME0ME?CR\ZM*VU"K?N8_F)SANG&./RK0HH SULKX;,ZM*VU"K?N8_F)SANG;C
M\J%LK\;,ZM*=J%6_<Q_,QSANG;CCIQ6A10!GK97PV9U:4X0JW[F/YF.<-T[<
M<=.*!97XV9U:4XC*G]S'\S<X;IVXXZ<5H44 9ZV5^-F=6E.(RI_<Q_,QSANG
M;CCIQ69X>M;M]#M'CU&2-/+==@B0_-N;YLD9_#I71UD>&/\ D7;3Z-_Z$: )
MQ97XVYU:4XC*G]S'RW.&Z=O3IQ0+*_&W.K2G$94_N8^6_O=.OMTXK0HH SQ9
M7XVYU:4XC*G]S'RW][IU]NE LK_C_B;2\1[3^YCY;^]TZ^W2M"B@#/%E?\?\
M3:4XC*']S'RW][IU]NE'V*_X_P")M+_J]G^IC^]_>Z=?;I6A10!G_8K_ (_X
MFTO^JV?ZF/[W][IU]NE'V*^_Z"TO^JV?ZF/[W][IU]NE:%% &?\ 8K__ *"T
MO^JV?ZF/[W]_IU]NE'V*_P#^@M+_ *O9_J8_O?WNG7VZ5H44 9_V*_Y_XFTO
M^JV?ZF/[W][IU]NE!LK_ )_XFTO^K"?ZF/AO[W3K[=*T** ,\V5_S_Q-I>8]
M@_<Q\-_>Z=?;I0;*_.<:M*,QA1^YCX;^]TZ^W2M"B@#/-E?G=C5I1F,*/W,?
M#?WNG7VZ<T&ROCNQJTHS&%'[F/AN[=._ITYK0HH SS97YW8U:49C"C]S'PW'
MS=.OMTYH-E?'=C5I1F,*/W,?RMQENG?GCIS6A10!GFROSOQJTHS&%'[F/Y6X
MRW3OSQTYH:ROCOQJTHR@5?W,?RL,9;IWYXZ<UH44 <UH=E?-;7VW595S=3*/
MW*<,)#ENG?GCIS6JUE?G?C5I5W(%7]S'\I&,MT[\_G4.@?\ 'O>?]?UQ_P"C
M#6M0!GM97Y\S&K2KN0*O[F/Y2,9;ISGG\Z&LK\^9MU:5=R@+^YC^4C&3TYSS
M^=:%% &>UE?GS-NK2KN50O[F/Y",9/3G//7UH>ROV\S;JTJ[E 7]S'\A&,GI
MSGGKZUH44 9[V5^WF;=6E7<JA<0Q_(1C)Z<Y]_6A[*^;S=NK2KN"A<0QG81U
M/3G/OZUH44 9[V5^WF[=6E7<%"XAC.PCJ>G.??UH>ROV\W;JTJ;@-F(8SLQU
MQQSGWK0HH SWLKYO-VZM*NX*$Q#&=F.O;G/O0]E?MYNW5I4WXV8AC.S'7''.
M?>M"B@#/>ROF\W;JTJ;MNS$,9V8ZXXYS[T265^WF[=6E3?C9B&,[,=<<<Y]Z
MT** ,][*^;S=NK2IOQLQ#&=F.N..<^]$EE?MYNW5I4WD;,0QG9CKCCG/O6A1
M0!GR65\WF[=6E3>04Q#&=F.N..<^]$EE?MYNS5I4WD%,0QG8.X''.?>M"B@!
M%!"@$Y..3ZT4M% '.^.-7O-#\*7-]8,B7*O&B-(FX#<ZJ3COUK+N=6\1^%M0
ML#K5Q9ZCI=Y<+:M/# 89(';A21D@J3Q5WXB6=U?>"[N"RMI;F?S(F$42Y9@L
MBDX'T%9FJ/J?C6ZTVQCT2]T_3;>[CN[FXOE$;,$.0B)DDY..36L4K:C-2W\3
MVMC:ZO=:AJ9N8[?4FM42.U*LC<;8E R7//7OFK;>+M*BT8ZI<?:;>(3>0(IK
M=UE:3LH3&23VQ7*-I072_$*:KI&J30SZ\\\)LE/G(, K,G.< CJ,]>E9]UIG
MB74M TZ\O(]5N%T[56DB7"QWKVI7:&P.-X)/N13Y(L+'<V_C'1[C3[V[WW$7
MV(J+B"6W=9HRWW?DQDYSQCK26/C/1[U;W=)/:/91>?<1WD#0ND?]_##D<=JY
M/[/>P:7K6J^';/Q!_:LB0Q&;4U!D>,,<^6K=64$XR.]0:=8W,VNZM>76DZ_?
M:=+H_D$:@J^=.=_S(HXQP3@<>U')$+';6/B[2[VSNKMOM5I;VT0F>2[MWA4Q
MG.&!8<CCM3--\9Z/J4[0*]Q;R"$W"B[MWA\R(=77<!D"N&.CZ]JWAS7]'L4U
M5M*^SQ&Q35E"3>8KAFC4GDKA0 3WK2TNSM;O4([NXTGQ7<7-K:S8CU(CRQN3
M#1@D@,6Z#''TH<(A8ZW1?%&GZ_*R64=X%\OS4DFMGC25,XW(Q&"*76?%&FZ'
M<0VUR9Y;N92\=M;0M+(5'5MJC@>]<UX*CU"UUN2ULH-7A\.I;?+#JL>UH9=W
M"1D\E<9ZY JQJ7VW0?'\FN'2[R_L;NP6VW6<?F/"ZL3@KUP<]?45/*N:P%;Q
M;XY@/A2TNM#N[@?;KI+?[1#;LS0C< X((^5\' !Y)Z5O&[FT_P !SWL%S=3S
M0V<DT<U]'ME) )&]<#D<<8'2N/?0M7D\/O=-ILT4U_XCAU#[(HW-!%O7EL=#
M@9/I7>^)89;GPOJL$$;22R6DJ(BC)8E2 !3=E9(#&B\<Z?9:9I"ZI)*VHWUC
M'<K%!;LYE) R%"@\YSQZ57UOXB65GX=L]6TR.2[2YNE@P87^3Y@'#8'RL,\
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M)K96DD;JQ]:WJP/ ]K<67@C1[:ZA>&>*V57CD&&4^A%;]9RW8@HHHI %%%%
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M "BBB@ HHHH **** "LCPQ_R+MI]&_\ 0C6O61X8_P"1=M/HW_H1H UZ***
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MT_PYIUI(,/%;HK ]CCD5IU\C-)2=MCYF=N9VV"BBBI)"BBB@ HHHH R?$O\
MR IO^ND7_HQ:UJR?$O\ R IO^ND7_HQ:UJ "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "LWQ!_P BYJ7_ %ZR?^@FM*LWQ!_R+FI?]>LG
M_H)H O0?\>\7^X/Y5)4<'_'O%_N#^524 %%%% !1110 4444 %%%% !1110
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M8B!A(\6Z*5H^S+GE3Z5V%%+G8KG%Z=X+O5NM9N-1O;0G4[(6ICL[?RDAQN'
MR<_>[\TMOX3UA]'T6QU#4K25M*OH)XWBA9=\4:D!3D_>.>O2NSHI\['<X>7P
M=K=NNJ6&E:U;V^DZE-)+(LEN7FA,GWQ&V<8/.,CC-:NG>%ETOQ#:WUM*HM+;
M2ETZ.$CYOE?<&S]*Z.BDYMBN8OAG0Y-!LKR"6=9C/>SW0*KC D;<!]16U112
M;N[L HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !63JW_(4T7_KZ
M;_T4]:U9.K?\A31?^OIO_13T >?^.? 5RMY+JNCPF6*4EYK=!\R-W91W!]*\
MW<%&*N"K#@JPP1^%?3U5;C3;"[;=<V5M,WK)$K']17IT,RE"/+-7/0HX^4(\
MLU<^:LKZBC*^U?1_]@Z/_P! FQ_\!T_PH_L'1_\ H$V/_@.G^%=']JP_E-O[
M1C_*?.&5]11E?45]'_V#H_\ T";'_P !T_PH_L'1_P#H$V/_ (#I_A1_:L/Y
M0_M&/\I\X94^E&5]J^C_ .P='_Z!-C_X#I_A1_8.C_\ 0)L?_ =/\*/[5A_*
M']HQ_E/G#</44;AZBOH_^P='_P"@38_^ Z?X4?V#H_\ T";'_P !T_PH_M6'
M\H?VE'^4^<5!=@J LQX 7DFO1? _@&YEO(=4UB PP1$/%;N/FD;L6'8#T[UZ
M?;Z986C;K:QMH6]8XE4_H*M5A7S*4X\L%8QK8^4X\L%8****\L\\**** "BB
MB@ HHHH R?$O_("F_P"ND7_HQ:UJR?$O_("F_P"ND7_HQ:UJ "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "LWQ!_R+FI?]>LG_H)K2K-\
M0?\ (N:E_P!>LG_H)H O0?\ 'O%_N#^525'!_P >\7^X/Y5)0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5D>&/^1=M/HW_H1K7K(\,?
M\B[:?1O_ $(T :]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% &3H'_ ![WG_7]<?\ HPUK5DZ!_P >]Y_U_7'_ *,-:U !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !16>)]6XS8VW^K)/^DG[_
M *?=Z>_Z4>?JV!_H-M_JLG_23]_^[]WI[_I0!H45G^?JW'^@VW^KS_Q\G[_I
M]WI[_I1Y^K?\^-M_JL_\?)^__=^YT]_TH T**S_/U;_GQMO]7G_CY/W_ .[]
MWI[_ *4>?JV/^/&V_P!5G_CY/W_[OW>GO^E &A16?Y^J_P#/C;?ZO/\ Q\G[
M_P#=^[T]_P!*//U;G_0;;_59'^DG[_\ =^[T]_TH T**S_/U7G_0;;_5Y'^D
MG[_I]WI[_I09]6P<6-M_JP1_I)^_W7[O3W_2@#0HK/,^K<XL;;_5@C_23R_I
M]WIUY_2@SZM\V+&V_P!6"/\ 23R_<?<Z=>?TH T**SS/JOS8L;8_NP1_I)Y?
MN/N].O/Z4&?5OFQ8VQQ&"O\ I)Y?C(^YTZ\_I0!H45GF?5?FQ8VQQ&"O^DGE
M^,C[G3KS^E#3ZM\^VQMCB,%<W)Y;C(/R<#KS^E &A16>T^K#?ML;8X0%<W)Y
M;C(/R<#KS0T^K#?ML;8X0%<W)&6XR#\O Z\^U &A16>T^K#?ML;8X0%,W)&6
MXR#\G Z\T-/JP\S;8VQPBE,W)&6XR#\O '//M0!H45GM/JP\S;8VQPH*9N2-
MS<9!^3@=>:'GU4>9ML;8X52F;DC<W&0?DX YY[T :%%9[SZL/,V6-L<*"F;D
MC<>,@_+QWH>?5AYFRQMCA5V9N2-QXR#\O&.?K0!H45GO/JP\W98VQPH\O-R1
MN/<'Y.._K0\^JCS=EC;-@+Y>;DC<>^?EXQSZYH T**SWGU8>;LL;8X \O-R1
MN/?/R<?K0\^JCS=EC;-@+Y>;DC=ZY^7C'XYH T**SWGU8>;LL;9L8\O-R1N]
M<_)Q^M#SZJ/-\NQMFQM\O-R1N]<_+QC\: -"LG5O^0IHO_7TW_HIZF>?5AYN
MRQMFQCR\W)&[US\G'ZUEZO-J?]IZ9BSMR5N3Y6;@_/\ NGSGY>._K0!TE%9[
MSZL/-V6-LV"/+S<D;O7/R<?K1)/JH\WR[&V;!'EYN2-P[Y^7C]: -"BL]Y]6
M'F[+&V;!'EYN2-P[Y^3C]:))]5'F^78VS88"/-R1N'<GY>/UH T**SWGU8>;
MLL;9L,/+S<D;AW)^3C]:'GU4>;LL;9L,!'FY(W+W)^7@]..: -"BL]Y]6'F[
M+&V;# 1YN2-P[D_)Q].:'GU4>;LL;9L.!'FY(W+W)^7@]..: -"BL]Y]6'F;
M+&V;#@)FY(W+W)^3@]..:'GU4>9LL;9L. F;DC<O.2?EX/3B@#0HK/>?5AYF
MRQMCAP$S<D;E[D_)P>G%#SZJ/,V6-L<2 )FY(RGJ?EX/3C]: -"BL]I]6&_9
M8VQPX"9N2,KZGY.#TX_6AI]5&_;8VQQ)A<W)&4]3\O!Z<?K0!H45GM/JPW[;
M&V.) %S<D93U/R<'IQ^M#3ZJ-VVQMCB3"YN2,IZ_=Z]./UH T**SVGU8;MMC
M;'$F%S<GE/7[G7V_6@SZK\V+&V/[S S<GE/[WW>OM^M &A16>9]6^;%C;']Y
M@?Z2>4]?N]?;]:#/JO.+&V_UN!_I)^Y_>^[U]OUH A\2_P#("F_ZZ1?^C%K6
MKG=?EU!M'F$UI D?VB,;EG+'9YBX.-HYSCC]:TO/U7_GQMO];C_CY/W/[WW>
MOM^M &A16?Y^K?\ /C;?ZW'_ !\G[G][[G7V_6CS]5X_T&V_UN/^/D_<_O?=
MZ^WZT :%%9XGU7C-C;?ZS'_'R?N?WON]?;]:!/JO&;&V_P!9@_Z2?N?WON]?
M;]: -"BL\3ZKQFQMA^\P?])/"?WON]?;]:!/JORYL;8?O,-_I)X3U^[U]OUH
M T**SUGU4[=UC;#,F&Q<GA/7[O7V_6A9]5.S=8VPS(0V+D\)Z_=Y/7C]: -"
MBL]9]5.S=8VPS)AL7).$]1\O)Z\?K0L^JG9NL;89D(?%R3A.Q'R\GKQ^M &A
M16>D^JG9OL;89DP^+DG">H^7D]>/UH2?53Y>^QMAER'Q<D[5[$?+R>O'ZT :
M%%9Z3ZJ?+WV-L,N0^+DG:OJ/EY/7C]:$GU4^7OL;89<A\7).U>Q'R<GKQ0!H
M45GI/JI\O?8VRY<A\7).U>Q'R\GKQQ0D^K'RM]C;+EB),7).U>Q'R\GKQQ0!
MH45GI/JI\K?8VRY<B3%R3M7L1\O)Z\<4)/JI\K?8VRY8B3%R3M'8CY.?TH T
M*S?$'_(N:E_UZR?^@FG1SZL?*\RQMERQ$F+DG:.Q'R\_I6=K<VJ-X>O/-LK9
M0UO*)2MP3M&W@CY>3UXXH W8/^/>+_<'\JDK,M9M5,%MNLK8 C#XN"=HQP1\
MO-/2?5CY6^QMER3YF+DG:.V/DY_2@#0HK/CGU4^5YEC;+DGS,7).T=L?)S^E
M"3ZL?*WV-LN<^9BY)V^F/DY_2@#0HK/2?5CY6^QMESGS,7).WTQ\O/Z4)/JQ
M\K?8VRYSYF+DG;Z8^3G]* -"BL])]5/E;[&V7.?,Q<D[?3'R\Y_"A)]6/E;[
M&V7(/F8N2=I[8^3G]* -"BL])]5/E;[&V7(;S,7).T]L?+SG\*$GU8^5OL;8
M9!\S%R3M/;'R<YX]* -"BL])]5/E[[&V&0V_%R3M/;'R<YX]*$GU8^7OL;89
M4F3%R3M/. /DY[>E &A16>D^JGR]]C;#*L7Q<D[3S@#Y><\4+/JQ\O=8VPRI
M+XN2=K<X ^3D=.: -"BL]9]5/E[K&V&58OBY)VMS@#Y>0>.:%GU8^7NL;890
ME\7).&YP!\G(Z<^] &A16>L^K'9NL;890E\7).&YP!\O(Z<T+/JQV;K&V&4)
M;%R>&YP!\G(Z<T :%%9ZSZJ=FZQMAE"6Q<GAN< ?)R.G- GU;Y,V-L,QDMBY
M/#\X ^7D=.?TH T*R/#'_(NVGT;_ -"-3B?5OES8VPS&2V+D\/S@?=Y'3G]*
MS/#LNH+H=H(K6!X_+<[FG(._<W&-IX]_TH Z.BL\3ZM\N;&V&8R6_P!)/#\X
M'W.G3G]*!/JWRYL;;_5DG_23P_8?<Z=.?TH T**SQ/JWRYL;;_5DG_23P_8?
M<Z=.?TH$^K<9L;;_ %>3_I)^_P"GW.GO^E &A16>)]6XS8VW^K)/^DG[_P#=
M^[T]_P!*//U;C_0;;_5Y_P"/D_?_ +OW>GO^E &A16?Y^K<?Z#;?ZK/_ !\G
M[_\ =^[T]_TH\_5O^?&V_P!5G_CY/W_[OW>GO^E &A16?Y^K?\^-M_JL_P#'
MR?O_ -W[G3W_ $H\_5O^?&V_U>?^/D_?_N_=Z>_Z4 :%%9_GZM_SXVW^JS_Q
M\G[_ /=^YT]_TH,^K<XL;;_5@C_23]_^[]WI[_I0!H45G^?JW.+&V_U>1_I)
M^_\ W?N=/?\ 2@SZMSBQMO\ 5@C_ $D\OW'W>G7G]* -"BL\SZM\V+&V_P!6
M"/\ 23R_<?<Z=>?TH,^K?-BQMC^[!7_23R_<?=Z=>?TH T**SS/JWS8L;8XC
M!7_23R_&1]WIUY_2@SZM\V+&V.(P5S<GE^,C[O3KS^E &A16>9]6^?%C;'$8
M*YN3R_&1]S@=>?TH:?51OVV-L<("N;D\MQD'Y>!UYH AT#_CWO/^OZX_]&&M
M:N:T.;5!;7VRRMC_ *5,1FX(R_F'(^[TZ\_I6JT^JC?ML;8X0%,W)&6XR#\O
M Z\T :%%9[3ZL-^VQMCA 4S<D9;C(/R<#KS0T^K#S-MC;'"@IFY(W-QD'Y>
M.>: -"BL]I]6'F;;&V.%!3-R1N;C(/R< <\T//JP\S98VQPJE,W)&X\9!^7C
M'- &A16>\^K#S-EC;'"J4S<D;CQD'Y>,<T//JP\W98VQP!Y>;DC<>^?EXQSZ
MT :%%9[SZJ/-V6-L<!?+S<D;CWS\G&.?6AY]6'F[+&V; 'EYN2-Q[Y^3C]:
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M* "BBB@ HHHH **** ,GQ+_R IO^ND7_ *,6M:LGQ+_R IO^ND7_ *,6M:@
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MV]S"-R_/$ICW-U[8/OQ71Z=IEY#XN\4WDD!6WO([<0/D8D*QD-^1/>F^7?\
MKH!+<^,M-CL--N;5+F^DU)-]I;VT>Z210,DX., =R:KS_$#1[;1#JD\=Y&B7
M8LYH&A_>PR_W67/\L]17'Q^$-5MM'\*W=QI=S<M86DMM=V=O<B*9-S9#*P8
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M %_7'_HPUK4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1G_1[WB,2_\ 'J_3TZ=?;K6A10!GG6(1G_1[WB,2?\>K]/3IU]NM!UB$;O\
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MA10!GMK$*[O]'O?ED\LXM7Y/J..1[]*#J\*[O]'O?ED\KBU?KZ].GOTK0HH
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MM_T>]YC,G_'J_3TZ=>.G6M"B@#/&L0G;_H][S&9/^/5^@[=.O'3K0-8A./\
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MY%%+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% "4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
,0 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img187419207_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img187419207_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .T!OX# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
M/2O!9O%?B[5?$$MG#?3PR7$QA%NG'EC.,<#(QZ_6NK#866(ORNUB)S4+7.X\
M:_$:3P]JPTS3[6.>9%#3/(3A<]  /;^=='X1\2IXHT5;SRUBG5BDL0;.TCH?
MH17*0?""S>W#WNJ7+WK-NDDC VGU'/.>O.?PK+\1>![WP?!+K7A_4IEBA +H
MQ^<#.#R!AA]174Z>$J05*F_?[ZZF=ZB?,]CUZBO'?A[XI\0:AXKAM;J[FN[>
M97,H<9$8"D@Y[<X'XU[%7'B<-+#SY),TA-35T%%%%<Y84444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW"BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !117/\ C#Q1%X5T;[8T0FFD
M<1PQ9QN;KS[ "JA"4Y*,=V)M)79T%%<)X)^(+>)K^6QO+6*VG"&2,HQPX!&1
MSWYS7=U=:C.C+DFK,49*2N@HHHK(H**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\S^!WA6[\->!VEOXGANM0F^T&-Q@HFT!01V/!/XUZ90 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ***S[[54LIUC,9?C+'.,?XU48N3LAI7V-"BFQNLD:NOW6&13JD04444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M $!G_P# A* -.BLS[?J?_0&?_P "$H^WZG_T!G_\"$H TZ*S/M^I_P#0&?\
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M>5W=ZO50L]*ALY?,#,[#(&[M5^N2?+?W=B':^@4445 @HHHH **** "BBB@
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M3+7^PX+>.1[V!C*[D_(AX& ._7\N];4*,JU10B3*2BKLH>!]3T[7/B/K6I9
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M$1".5S_,^@[UNT5K[5N2=35(GELM#R'P[XWL-(\8ZG:_8VM-.O;K<?.^1H'
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M"S1114 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXM+GB$%S,VYRDD8;8S?Q%3GD\X(JQ?>$8;C4/[0LM3U#3;QXUCGEM9%_?A>
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MNN)KBW\2---)(V^WY=B3TD]:]VH **** "BBB@ HHHH **** "BBB@ HHHH
M*;(J/&RR*K(1R&Z4ZD90RE3R",&A <S8:DUA//%'%)-8*[;60;MGX^E6+OQ%
ME0;%"VTY<NAX%,,G]@:B8TB9K.?#,<9*'H:@2_M['6LV \^VN /,1,DJWL/I
M7H\D9OF4;Z??Z^9E=K2YT-I>17D"2QN/F&2N>0>XJQ7+6"0W7B)I+0M%$GSX
M*;<]B *WKW4([%X%D5R)6VAAT'UKEJT>6:C'J6I:79;HHHK H**** "BBB@
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MW_?R#_XY1_:5Y_T [[_OY!_\<H TJ*S?[2O/^@'??]_(/_CE']I7G_0#OO\
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M %'_ ,"FH_L5/^?_ %'_ ,"FK3HH S/[%3_G_P!1_P# IJ/[%3_G_P!1_P#
MIJTZ* ,S^Q4_Y_\ 4?\ P*:C^Q4_Y_\ 4?\ P*:M.B@#,_L5/^?_ %'_ ,"F
MH_L5/^?_ %'_ ,"FK3HH S/[%3_G_P!1_P# IJ/[%3_G_P!1_P# IJTZ* ,S
M^Q4_Y_\ 4?\ P*:C^Q4_Y_\ 4?\ P*:M.B@#,_L5/^?_ %'_ ,"FH_L5/^?_
M %'_ ,"FK3HH S/[%3_G_P!1_P# IJ/[%3_G_P!1_P# IJTZ* ,S^Q4_Y_\
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M^H_^!34?V*G_ #_ZC_X%-6G10!F?V*G_ #_ZC_X%-1_8J?\ /_J/_@4U:=%
M&9_8J?\ /_J/_@4U']BI_P _^H_^!35IT4 9G]BI_P _^H_^!34?V*G_ #_Z
MC_X%-6G10!F?V*G_ #_ZC_X%-1_8J?\ /_J/_@4U:=% &9_8J?\ /_J/_@4U
M']BI_P _^H_^!35IT4 9G]BI_P _^H_^!34?V*G_ #_ZC_X%-6G10!F?V*G_
M #_ZC_X%-1_8J?\ /_J/_@4U:=% &%JFF&UTF]N(M0U 210.ZDW+'!"DBMF
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M 98W211V5E YQT[&N]NM6\5ZS\%O%-WXKTM;"9XF:W0(8SY9QP4/*X([\G-
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MY25[U7A_[.FFW^GVOB'[;97-MYCV^SSHF3=@29QD<]1^=>X4 %%%% !1110
M4444 %%%% !1110 4444 %%%% !UJM;V-M:RRR0Q!'D/S'-6:*:;2L@,C6+-
MD07MDA6Z1LEHQR1WR.]4(M,N];LTN[F^(<@^4@4;1VYQ]*Z4C((]:PFTN^TZ
M"1K"\9\\F(IU]Q[UU4JKY;7L^C?Y$218TC55NO\ 1)$9+F(%7'!!QQP<UK5Q
M%M=7NGWQ9H?](F(+*RY/)Z>V:[922H)&"1TJ<324)76S"$KH6BBBN8L****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM=R9J6BN>OT445Y9N%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!C:+_ ,A7
MQ%_V$$_])8*V:QM%_P"0KXB_[""?^DL%;- !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4-<_Y
M&I?]>LO_ *":MV__ ![1?[@_E537/^0!J7_7K+_Z":MV_P#Q[1?[@_E0!)11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<[8Z/;ZBMS<W-SJ
M1D-W.O[O4KB-0%E90 JN , #H*Z*LW0_^/*?_K\N?_1ST 0_\(S8?\_&K?\
M@WNO_CE'_",V'_/QJW_@WNO_ (Y6Q10!C_\ ",V'_/QJW_@WNO\ XY1_PC-A
M_P _&K?^#>Z_^.5L44 8_P#PC-A_S\:M_P"#>Z_^.4?\(S8?\_&K?^#>Z_\
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M_P"#>Z_^.5%-X1TNX4+-)J;@'(#:K='_ -J5NT4)VV Q(_"FFPQB..;5%4=
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M6C7MU!=:JLT,#R(QU6Y8!@"1P9,'\:Z6LWQ#_P BWJ?_ %ZR?^@F@#2HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$HI/;)!%<3=7=WJ5EIFH3/XBU&YBN[:XOLVKPV]KB0;E6+:"Y'L'/<FO8Z*
M.%AD:U\>^)K">"[1M7CM_LDR6[M&0(2K$N!A<$=R.HKG=.M- M="BT/7-%\0
M-J4$0MI;*+[5)'<8&W<C ^7L;KR0!T/2O7** .9N +_QSIL$/$>E6TDTV.=K
MR (B'WV[S^7K6]97BWT+R)%/$%E>/$T90G:Q&0#V.,@]Q3X+6"V,I@A2,RN9
M)"HP78]2?4U+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %#7/
M^0!J7_7K+_Z":MV__'M%_N#^55-<_P"0!J7_ %ZR_P#H)JW;_P#'M%_N#^5
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M%?$7_803_P!)8*V: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M 'E&M>(I=4\*>);&ZNK#6+:S-HW]H6"?),&F7,;*"06 '8G[PK4\8:]H.O\
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MS8[#+#U>6+NB*L%"5D%%%'2N,S"BFK(CYV.K8ZX.:=0 4444 %%%% !1110
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M,?15*K:,;(*4N:.X4445Q&H4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !6;XA_Y%O4_^O63_P!!-:59OB'_ )%O4_\ KUD_]!- &E1110 4444
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M_P"@OJ/_ 'VG_P 16G10!F?V3+_T%]1_[[3_ .(H_LF7_H+ZC_WVG_Q%:=%
M&9_9,O\ T%]1_P"^T_\ B*/[)E_Z"^H_]]I_\16G10!F?V3+_P!!?4?^^T_^
M(H_LF7_H+ZC_ -]I_P#$5IT4 9G]DR_]!?4?^^T_^(H_LF7_ *"^H_\ ?:?_
M !%:=% &9_9,O_07U'_OM/\ XBC^R9?^@OJ/_?:?_$5IT4 9G]DR_P#07U'_
M +[3_P"(H_LF7_H+ZC_WVG_Q%:=% &9_9,O_ $%]1_[[3_XBC^R9?^@OJ/\
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M/3O1IU 8T[R90#K_ "JR@(10>N*CD0)AT7YAV J8<BA^0PHHHJ0#M3(XQ&"
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "LWQ#_ ,BWJ?\ UZR?^@FM*LWQ#_R+>I_]
M>LG_ *": -*BBB@ HHHH **** *YCD60R*0?;UH$[2':B\^N>E6*0*H)( !/
MM3OW CAC:,$,<Y-2T44F 4444 %%%% !1110 4444 %(S*B,[L%51DDG  I:
MS/$6B1>(] O-(GN+BWAND"/);/M<#() /OC!]02* /"_'?QRN1XLL[?PW/\
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MN9+:&:6[N$;:([:(ON/^R1P:SA2G/X5<IR2W-FUUS3;W4[G3K>Z62[M?];&
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M?^>^J?\ @UN?_CE:]% &1_PCEC_SWU3_ ,&MS_\ '*/^$<L?^>^J?^#6Y_\
MCE:]% &1_P (Y8_\]]4_\&MS_P#'*/\ A'+'_GOJG_@UN?\ XY6O10!D?\(Y
M8_\ /?5/_!K<_P#QRC_A'+'_ )[ZI_X-;G_XY6O10!D?\(Y8_P#/?5/_  :W
M/_QRC_A'+'_GOJG_ (-;G_XY6O10!D?\(Y8_\]]4_P#!K<__ !RC_A'+'_GO
MJG_@UN?_ (Y6O10!D?\ ".6/_/?5/_!K<_\ QRC_ (1RQ_Y[ZI_X-;G_ ..5
MKT4 9'_".6/_ #WU3_P:W/\ \<H_X1RQ_P">^J?^#6Y_^.5KT4 9'_".6/\
MSWU3_P &MS_\<H_X1RQ_Y[ZI_P"#6Y_^.5KT4 9'_".6/_/?5/\ P:W/_P <
MH_X1RQ_Y[ZI_X-;G_P".5KT4 9'_  CEC_SWU3_P:W/_ ,<H_P"$<L?^>^J?
M^#6Y_P#CE:]% &1_PCEC_P ]]4_\&MS_ /'*/^$<L?\ GOJG_@UN?_CE:]%
M&1_PCEC_ ,]]4_\ !K<__'*/^$<L?^>^J?\ @UN?_CE:]% &1_PCEC_SWU3_
M ,&MS_\ '*/^$<L?^>^J?^#6Y_\ CE:]% &1_P (Y8_\]]4_\&MS_P#'*1_#
M&G2(R22:C(C##(^IW+*P]"#)@BMBB@ K,U;49+/8D0&YAG)&<5IUSGB0I)-#
M$%!=5SUP>M;4(J51)E05V:6DW[WL;B3!9,?,!C(-:-4]-LDL;1$4?.5&\GJ3
M5RHJ<O,^784K7T"BBBH$%%%% !1110 4444 %%%% !1110 4444 %(2%!).
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M[Q#?>'ITDCBNOWMN)1M977L1[J<_\!]Z].\(^!=)\%K=#39+F5KDKO>X968
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M7$:NCC![9Y%35SM-:,V3NKH****0PHHR#T/2B@ HHHH **** "BBB@ HHHH
M*XWXDV+2^&_MMM;.][:S))'+$OSQX/)XYQ7945I2J>SFI]A25U8\VM?B/JUM
MX?\ MFI^';IF XN$4I&W.,G/2KG@S0[36HV\5:K;I/?WDC,@=?DB4'  !X/
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@!DDL<*[I'55]2:2.>*52T<BLH
MX)!Z5A:XSF]"M]P*-M9D=M/<RJENA9A@GG'%=,,.I1NW8T4-+G0ZGJT5K&J1
M2(TSM@8.<>M<X[F>?SY27DR#DD]NU6IO#UVMHSEHP5;=M!Z#.:H"&XG5EMXG
M=QV49_S_ /6KKHPIQ7N/U9<4EL=I:7"W=JDR\;AR/0U/7)Z=J4^F8MY%+H#R
MK<%?I_\ 7K?BU:QEC#BX49['J*XJM"47HM#.46F7:*165U#*P(/0BEK @***
M* "BBB@ HHHH **** "BBB@ HHHH *Y[QY(8?A_X@D!P5T^8Y_X :Z&N:^(8
M)^''B, 9/]G3?^@&@#G_ ('1B/X5Z<0I&^25C[_.1G]*]%KS[X)N'^%.D@9^
M4RJ?^_C5Z#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !15:ZU"ULBHN)@A;H.M$NH6D,1D:XCV@9X8$GZ"JY)/H*Z.5UG
M4I;F>6-VQ#&Y 0#TXS]:O&YTB^TR*"X)A:, X5<'(';UJEI_V?7?$MQ)-S$H
M)$3# ;L/KQR<5I:[I=K%8M<P1K%(A'W1PV2!7I2<$XTG=/R,E?5FCI$=G%9X
MLV+)GDGKFK]8_ARW$6F^=NRTQR?;!Q6Q7!65JC5[FL=@HHHK(8445!=W<-E
M99FPN<# Y)II-NR GHJK9:C;WZDPL<KU5A@BK5$HN+LP"BBBD 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3;"#2M-MK"VW>1;QB--QR<#IDU:KA>^AB%%%%( HHHH **** "BBB@ HHHH
M**** "BBB@#EI[#Q0^N7,L%_'%:-_J\\@#L-OK[UR?BK1O$2:M'?W<\DUO"H
M*SPG B_#L<]Z]5I&574JP!4]01UKOHX^5*:DHK:VQK&JT[V.=\.>*HM=F>V\
MAXI8T#$DY#=C71U5MM-LK*626VMHHGE.79%P35JN6O*G*=Z2LB)--^Z%%%%9
M$A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% %>YOK2S9!<W,,)D.$$CA=Q]
MLU8KB/&O@*7Q7J-M=Q:@+;RX_*970L,9)R.1SS7/Z_J_C7P5;P0274-Y;-\L
M5QY.X\=%/H?\YKLIX:%515.:YGNGH9N;C>ZT+_Q0FTF>]T.PO6 D-R'E;)&R
M$G#9/O\ TK9U[P1X=N]!E\JR@MS#"S0S1<;<#.3ZCCO5/3/A]9ZC:IJ'B1YK
M_4KA \A=RHCR/N@#TS_^JN<\8>'-1T)K2QT_5+K^Q;V586ADE)",3T_W<5T0
M<9.%*G-IQ^Y^A#NKR:W-+PU\3E;3-FJ6%T[6ZA#<6T6]6P/XO0\5SVK:UK'Q
M+D2ST_3"(;3=(RI*.IR%))Q_G->IZII]W;>%I;#0$AAN%B$<((  '0_CCUIG
MA/P_#X>T*WMA;PQW113<O'SO?USWJ8XBC"]6$;2OIK^(W"3]UO0X?X8:#;6V
MIWCZI:F'6K5AY4;D@I&5QN"]#W&:]5KGM7\*Q:KXATW6!=S6\MFV66+CS0#D
M G]/H370URXFJJLE.^KZ=BX1Y58****YRPHHHH **** "BBB@ HHHH ****
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M$>UEBMY&H^5&)RP&/0_,/^!"@#WFBF12QSQ)+$ZO&ZAE=3D,#T(-/H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJG?:
ME#8X#@LY&0JTXQ<G9#2OL,UF9(=+F+DY(PH'4G-<>Q62$E3FM)9+C7+_ !RJ
MCJAZ(/\ /^?3I;:RM[2(1Q1* .<XY)]:[HS6'C9ZLT34#C=/<V,\<LT)>0\E
M6.,5U,>N6,B ^8P)ZC:>*LW5E!>)MF0$X(#=Q7*36[VLIA<$%3@9]*'*&(U>
MC#29V,<B2H'C8,IZ$4ZLO0XW2T=F!"NV5!'MUK4KBG'EDT9M684445(@HHHH
M **** "BBB@ HKR'XC_&VP\.>?I7A\QWNK+\KS=88#W_ -]O8< ]>A%=S\/]
M>N?$W@72M6O"ANIXCYI1=H+ E2<>^,T =+1110 4444 1QV\,))CC52>I J2
MBBAN^XDDM@I&.%)P3@=!2T4#/#]*\ ZMXT\6ZOK&OC4-)5GW0$+M<Y.  3V"
M@"E;P9K?@3XA:?J.BP7VJV38,\FS>VUCAU;'?'(_#TKV^BNKZW._E:UC3VK^
M1X+<:;XMT3XHZCK^F>';F[4W,WE%HFV.KY&<CZU?B\(^,?'WBBVU/Q3;II]E
M:D 1# RH.2JKDGGN37M=%-XN71*]K7'[5]CQ+QII/B.V^*8UW2M"GOHH%C*?
MNBT;$+@CBNETG6?%>NZ?K=EJOAC^SHVTZ;R62)@9)",!>?J:](HJ'B+Q2<5I
MU%SW6QY)X%\"2:A\-=1T37[&:TFDOGEA,B;7C/EQA7'X@CWYK*^&_@;5]'\:
M:C;ZQILHL7LYK9IBO[N4%E'!]QFO<**IXJ;YEW#VCU\SPVPT7QC\+M=NVTK3
M&U?2[@8R@)R >"0.58=.F#G\I+3POXG^(GC"#6?$MB=/TZWVXB8;2R@YV*#S
MR>I/_P!:O;J*;Q<M[+F[A[5[VU/+O$.K>,].UF_M[KPK;ZYH\DFZTVQ[A&N,
M < \^N1U)P<5A>%/!6N0:1XMU.YTLV)O[">&UL$'S$L"0 O4 < 9YKVZBI6)
M:CRI)![2RLD>'Z-X8UR'X/ZWILNE727LUTK1P&,[V'R\@?@:VW^'C^(/A5I5
ME<0-:ZU91,8?,&T@[F.QO8Y_ X]\^JT4/%3;NM-;@ZC/$_"'AG6[+X9^*["Y
MTNZBN[D#R86C(:3Y>P[U2\)W?CCPEH[:=!X+DN4:9I=\T#;LD 8X[<5[S15/
M%-WYHIWU#VE[W12TBXNKO2+2XOK?[/=21*TL."-C$<CFKM%%<KW,PHHHI %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %<-\5IS%X15/*+;[A!O[)C)S_3\:[FFNB2(4=5
M93U##(-:T:BIU%-J]B9*ZL<'X>^)6DOHT*ZM*;2\B0!U*,0X'0CZBL?Q5J]W
MX\2*Q\,6<]Q!:R"66X("#?C@ GTS_GK7=>(_"NG>);$6]TGER*08YXU&]/;/
MI[5/X>T"T\-Z2FGV9=D#%V=_O.QZD_I^5=4:U"'[V"]Z^SV(<9/W7L6M+CNX
MM*M([^19+Q85$SKT+XY_6K=%%<+=W<U"BBBD 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%9>O>(+#PY8"[
MOW8(S;45%RSGT IGA[Q+IWB6S>XL'?Y&VR1R##(>V1[UI[*?)[2VG<7,KVZF
MO11168PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %>'>._$'B&S\87<)O;RUBC8?9TBD9%*8X(QUS_.O<:\D
M^*M[:'Q%I4:RHTUMS,HY* D$9_#FO0RUVK6Y;W1E67N[ESPE\.K74-.35=?>
M:YFNU\P0N2NT'NQSDGH:O:O\+;#R4FT&62QO8N4)<D,1[]0?<?E7=VEU;WMI
M%<VLJRP2+N1T/!%35E+&5_:.5[>0U3C:QX1IGC[QBVH+912FXNG/E+!+$,[O
MTP?K^-+XO\/^,9(O[;UJ-951=K['4^4,]P.W/;-=1X+-O=_$WQ!<QE'V[MC#
MGJP&17>Z_+%#X>U&298GC6VDRDOW6^4\'V/2NZIBO8UHJG!)Z7^9FJ?-%W95
M\'W*W7A#2Y5F\[_1U5G[Y'!!^A&*VZ\+^&&IZQ'XEALK5I9+-R3<1GE%&/O>
MQR!]>E>Z5PXVA[&JU>]]32G+FB%%%%<AH<MXU\<V/@FVM9+J"2XEN6(2*,@'
M ZGGMR/SJ&^\?V=KX+L_$T%G/=P73*@AB(+*3G(/T*D5Y-XLU[1?$GQ/F.L7
M3QZ+9H]LCQH6+$ C(Q_MDG/H!70? _7T274/#LDX9=QN+4GC=V; /X''UKOE
MAE&DIM:K5FSII1N:!^.=@)?*.@7_ )G]PLN?RK1F^+MG!X=76)=&O$1KK[,(
MF8!L[=V?IVKE-4_Y.)M?^NT7_HNMSX\?\BOIO_7[_P"R-3]E2<H14?BUW'RQ
MNE;<L0?&K31<6ZZAHVHV,$^"L\@!7'][W'TKTR-TEC62-@R, RL#D$'O7S]>
M6/B[QSH6@:5#X>-O:6L:A+MSPX*@;B3T&!T%>\Z;9C3]+M+(/O%O"D6['7:H
M&?TK'$TZ<$N7?UN14BEL6J***Y3,**** "BBB@ HHHH **** "O.O&6EW,.J
MR7JQN;>8 [P,A6]_2O1:P/%^I1V&B2QLP\R<;%'MW/Y5M0E)37*:T9.,]#S-
M9XPNU\[NWO[4D5P4N59QA2,56\X2S]. N?K4I?,97%>NDIIW9US=C7$T)R3(
MIXY&>HJMYQ,K/&>#Q[$5E !,DDGTYX%313LA 7!'\JY&W&UG<J$$BU)@N2 !
M["GQP>8"-V=W;%0"0G&<9/I5VS8 \#YNH-=D'S*[0YOE6A8@MRG"<'')J9(W
MB8EB.G05-!(I3!4YZDT2KNC)&"#W-:1GKRVL<O,[W("TC JJ^Q/K4D9Q%EB<
MYQ@CFH@3E5;@ 8-7 BL.#^%5)I%-V#<#$O' Z^]1N 4(/?I4BJ%)!&0::T8_
MA-1SQ7429BW\!.UU&0.3GTK)N+96PX7\JZAX>.>:Q;NR!M'5B<;@1Z]:SK8Z
M--<J=A2@G=F.(BKG/%3Q(!N)QU[=JF,>U.Y]S4"W"^<=HX PP-84LQ<I71RR
MI:6L/>-6&1@'\/SJ":=I@8WD;9C@9S3Y9VE!VH8QU-0-$RKG.0#7J46JJO8Y
MY+E(U*" <%7S@C':HF>0G,8(7'0T2LP*CM3@RE,8Q]*U<(OW6R4WN1I(\0#A
M5/N?2K:WK.-JJ5;TJB0QR>2!W-03710E8R ?4=O:N>M0@]MRHR?4U)+IHCPP
M^A]:3[?*5Y"Y]A60&(.2>O/-6K9Q*""O.,YSTK.-*$5>2N6^QZ9\+5#-J,NX
M[OE7'YUWU_J%GI=G)>7]U%;6T8+/+*X50/J:^=M*^)Z^%+V6#2[4ZI>7($2P
M1DXWYXY&<GV'7VKH].^''BGXAWRZQ\0[Z6VM!S!I<#;<#W X7]6/<BO'QK3K
MMIW-(;$FK?$OQ%X\U!]"^'%E(L0R)]5E&T*/52>$_'+'L!BNG\#_  DTGPO(
MNIZD_P#:VO,QD>\G&X(Y.<H#W_VCSG)XZ5V^E:1I^B:?%8:9:16MK$,+'$N!
M]3ZGW/-7:Y"@HHHH **** "BBFJZL2 >G!H =1110 45%-N!0AL#/-2T %%-
M616) 8$BG4 %%%% ')?$'P+9>._#SV4P6.]B!>TN,<QOZ'U4]"/\*Y#X6^.K
MV*^E\"^+-\6MV),<$LS9\]1VR>IQR#SN%>N5YQ\4_AS_ ,)99)JVD?N/$-B
M]O*AVF4 Y"$]CGD'L: /1Z*\X^%OQ&_X2NTDTC5P+?Q#8Y2:)OE,H'!8#U'<
M=OQKT>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *\:^.7SZWX&C7ECJ)P/^!15[+7C'Q3)O_BSX$TQ3G;,)B/3YQ_\30![/111
M0 4444 %%%% !1102 "2< =2: $9E12S$!0,DD\ 5X1XLU_4OBWXH_X0WPO*
M\6BV[9U"^'W7 .,^Z@]!GYCST%3>-_&NH_$+7#X%\$L'MWXOK]&^4J#R 1_
M.Y_BZ#W]0\&>#M-\$Z#'IFG*6).^>=OO3/W)]/8=J +_ (>T#3_#&B6VDZ9%
MY=M N!GEF/=F/<D\FM.BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MDZOH^G2PR/)JDSPQLN,(50OD_E5O5]1CT?1;_4Y49X[.WDN'1>K!%+$#WXH
MFNKJ&RM)KJYD$<$*%Y'/15 R32VUS#>6L-U;R+)!,BR1NO1E(R"/J#7-:UJ<
M>M?"^_U.&-XX[O2Y)E1\94-&3@XJ_P"#/^1&\/\ _8-MO_12T ;=%<EJ'BW6
M4O[BTTCP=J5\+=S&T\\B6T3$?W"V2P]P,59\,^+X?$%U>Z?/8W&FZM8X^T65
MS@LJM]UE(X93ZB@#I**Y/6O&<]CX@;0=*T"\U;44MUN'$<B11HA.!N=CZ^@-
M:F@:IJNI1SG5="DTF2,J%5KA)A)D<X*^GN.] &Q1110 4444 %%%% !1110
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M14#.,\'_  XTSPM:W,<QCU*:XD#-+/ N0 .  <^I/XU!/\-+5?','B?3;[[
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MO*W]YCW/Z"@"KX&\#Z9X%T1;&Q427#@&YNF7#S-_0#L.U=/69J6K?V?<11F
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M/!/45AW'A+Q?8^+];UGP_J^E00ZH\3-'=V[NR[$"]CCL:MVVG_$E;N$W.N:
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M[OH(IYQ!$[?-(1G:/6O9/"WA;2=(S>V5P;N1QM$Q(( [@8KR.S'R@#J!7<>
MIKU=9:%#(;0QL9%S\JGL:Y,6FXNTMC?E?+<]+HHHKR2 HHHH **** "BBB@
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MR?AG-;T4\4Z;H9%=?53FN;L=3$,-Q;FUFGL,MY<BJ3A3V.?QJ?PQ NR:Y5F
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS' AD8(N6('I7G[?%"ZNVQIGANZG)Z%B<'\A39)OB/XEB:%;&VTRUD4HQD4
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MUU,#P2.OY=![U;\2^(KFYN1X?T3]Y>S';)(AXB'<9[>Y[5N^'O#\'AS25@A
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M]14\C,GAYHU\T9K,.I+BGIJ"'J:7*R?8S[%]D1_O*K?49K)O/"GAS49?-OM
MTJYDQC?-9QNWYD596_C+8S3OMT><;J.5D^SGV.9NOA/X$NYC+)X;M%8CI$6C
M7\E('Z5QOC'X5> ]+L@T6GSPW$G$8BN&P,=2<YKUIKR-0#NKB_'MHUW;P7\)
M#" ;9!WP>A_.KIQ7,N8NE3;DKK0\9_X5[H;R8 N5';][_P#6IX^&^B9P9+O'
MM(/\*Z02[&]:G5E(&#76E!;Q.N5"/1'+-\-]!7HUTP]Y/_K4Z/X?: O_ "QF
M;_>E-=477 6D89Z=J<J4&KQ1,80ZHQK;P7X;A()TM'/J[L?TS6Y9:7H]DP-O
MI5I$1T98ES^>*8#ZU*LG!XSFN6=/0U4(WT1IK<PK@*F!WP*NK-'M&&%8L*NW
MW1D>O:KQ@8JG/;FO/K4GW+<8DL<5LMU)<111++* ))0@#/C@9/4U=CE*],BL
MT!E)4GMGCI4L<NTGO7!4I7U-U&RT-99<CKT]Z0R J>.>U41,=O4?@:0S C.[
MIU/I6,:-W8ANVX\L*8S<'@FJZW W,I.3V%3[@8_K54Z5W84YV*C%5#)CWJ)W
MR"V>:6Y;<3S57:9&VYQBO1H04&KG-4E=7*=R[.>YJJ96C.&'4<&M!X6#X.#W
MS3+NU3:I[XYKWJ&LM#CJSB9TOS)QBLZ4'?L/UJ[,S1DJ!N Y!JG(V^3)')P*
M]*^ECG2UN=)X%U--,\2V[/$KB;]R#W3<>HKW#->)>";03^)(9V(\NV!D;W/0
M#\Z]:.I+VKQ\9[U30W5*3V1IY%&X5DMJ8["F'4C7+R,M8>9L[A1N%8G]ID<Y
MIIU0D\&CD8_JTS<W#U%&X>M8)U0YQFFG4RW1L4_9L%AI&_Y@I/- [USQOV/\
M51M?,3]XT*FR_JKZLZ/SU_O"D-PH_B%<TU[CJW-,-X?7BG[,?U5=SI_M2?WA
M2?:D_O"N8-YSC)I&NR#P:.0KZK'N=2+E#_$*7[0O]X5R37K9ZG\#3A>..=QH
MY!?58]&=:)E/<4[S!7)+J#JN2Q-.75)3C%+D)>%L[7.LWCUHW"N:&K.O7.*E
M36.YS2Y&2\-(Z'-&:PUUE6]?Q%2+J\9[T<C(]A,V,U6U"_ATZREN9W"JBY )
MQN/8#WJH-4B/<<^]</X_>2:>UN/,S;A2@0#[K9SG\>/RK.I[L6S2CA93J*,M
M$<=<R_:+Z:ZEDR\Q)<'OD^GX_K3-Y"*3]XY%94]P0[/VSQ[5:@F#QA&)# \#
MU]J\:HX<Z9]'RM(O*1U([=,U+QCCCCBH5P ,_H*8)D+[00>WXUO);7ZDH?-<
M+"C!L\]@:Y_4/#]EKT(-S$$F4;4GCX?\?7\:N:BLHG!!&U^,]Q5V!$6&/V7C
M-<<8S=?F;M856$90M+6YR"7/B;P:,./[3TI#C/4JO\U_45V/A_QAI.N8C@F$
M=P1DP2\-^'K^%6HBI&&&01T([5AZOX%TK5R)H$-E=9R)(1@$^Z]/RK>-52?[
MS3S7ZHX73G2_ANZ[/]&=O)<VMC:FXN9XX(EQNDD<*H[<DU="AV5EY)Y![$5X
M)XM;Q!HUI'H6HZBMW9R$31'.6P,C!)Y ]N>E=)\,?'3Q3P^']28O&YV6LN,E
M3V0^WIZ5U58-T[K5&,<6O:<K5CV"-3NP2>>1SGZ5:VG(!.5]*JO*$.0 1C_/
M^?:B-?M +2<D]!VKQJF(<7RQ.EJ^I<7 /7GTSFE(P:;%$B+\B[?6GY(']:RA
M*3=R&9FO1Q/8>;L'F(0 <=B:YVW,BRX1-Q(QC%=J!NZ\CWJ*:T27+ !7/\0'
M6LL1&\N:^IM2J\L>6QSS0;3DK\V/KWK@O%6O7[:B- T6WD-\X&^;& BD9R/\
M:]-EA:)MKC_Z]4)H8D<RLJ@JN"Q_N_7KZUKA:\8R]]7(JJ4E[KL<AX:\-P>'
MK9N1+=RC,TQ')/H/:N@W9[_C7+ZUXYT?3 T<,GVRXS@1PGC/NW3\LUS\G_"5
M>*6Q(?[,L#R1RK,/YG]!7I*E4F^>;LO,Q]K3BN2FKOR.CUOQII6CN\0D^TW(
M_P"64)S@]@3V_P \5S1M?$GC%P]V_P#9VGMSL&02OTZG\>*VM(\)Z9I*AUC\
MZ?O+*,G\!T%=$@ 7)/6KYH4_X:U[L7LISUJ/3LC.T7P]IVAHPMH1YA!#2OR[
M>V>WX5>EDYZ\8YR*=-(#D*?I4<,@2X1WC$BHP+*W1O:L]9.\F;QBHK1':^ -
M&2\G.K72G9 VV!2, MZ_AG\Z](\]<]1^=<C%=NEM&D8$:*HPJC&!Z4TW,O)\
MPU[%."IQ44<53"RJ2<FSKFN%7JPIANXP,EAQ7)-.\AR9"?QIADQU8Y^M:"6"
M5M6=8;^#_GHGYBDEU*&-<EQSZ&N2\[)&2<]:8TQY[T#^IP[G5+J\)!.X\5"-
M;CW$;3BN;$P9?2F!RJD#O1J7]5I(Z:36T##"Y%,.O(",J/?YJYEI#MJ,DD9-
M&H?5Z78Z+4-4AO;(PK,4;(/#9!]B/2DTO6H+2S%O,-NQC\RC(-<V%=P2. #0
M)50E22RX].]=U&%X6J:1_4X*\()VI*[.AN-<N9[H&T+)&O&"/O?6MU-2MWX\
MQ1]>*X"1FC.\,=N>.V*A:]DB(P6_ UC75GRJ-K%TJ$)1YN;<],2YCD&5=2/4
M&G+*IZ$?G7G":E<8^60@=^*>-9N(#D-D_E_*L.5EO#+HST;S!2[QZUY\FO39
M+Y.<GN:M6_B"82 ECCT)S2>FXOJC>S.WW"ER*XY_$DI((^7'L*G3Q..,CZG%
M!+PLT=7FBLFVUJVF0'S I/&#5^.X25=R$%?446,)0E'=$]%-!I<_G2)%HHS1
MF@ HHS1F@ HHR*,T %%&:* "BC-)F@!:*3-)N]Z '49JO+<QPC+L%'O6==ZY
M:P*<2 OZ9IV+C"4MD;&12;A7*2>)OE8+C/8XZU%'XDE&<Y/X _X4&RPLV=AO
M%)Y@]:X>77YRQ;<P_P"!55;79T.0>?;-"UV*^J-;L] ,J@XR,TQ[F./[[JOU
M->?'5[B7YMV&]<?XU%)J4_5I&/IVI\K&L*NK._;4K=3@R#\*B?6+=3]XX]>E
M<"MY)*"Q8_B:7SF/<T^5EK#TSN9-;@0<D_C43^((%SSS]17$[G))%/C=FZ@T
M<K*5"D=B->0YPH]OFI\>MQ\Y4BN3R5YJ3S"14ZFGU:D=3_;<7FA>GO4S:O".
MYQ7)%BVTYZ>M/,P & 2>]&H?5:3.Q34(73<)%P/>E%_ 1GS$_,5QPF^N*=YN
M!P301]3AW.R%W&0"'%2+.K#AA7&"0GD,?SIZW,D? D(H)>"5M&=B)E)ZC\Z4
M2#UKCUN9@0=YZYJ9;^=%X;GU-&A+P3Z,ZOS!2AP>]<FNHSCJYYJ5-5FC;GD4
M:$O!3[G3[Q2[JYP:M(6R5_6I/[9)!PAHL0\)4-_<,49%8::P/+^92&I\>L1G
M[V?RHL2\-470V<T9K*DU6('"G/N*%U6(KGI]:+"]A4WL:N:,UE+JL6.31'JD
M;L1GBGRA["IV-7-&160^K1JW<CVYIK:L,C HY1K#U'T-G<*-PK%.K#=W_*D.
MK<'@_A1RC^K5.QM[A1N'K6#_ &J=N-IS1_:KX^Z:.4?U6H;VX4;A6"NJ-W!I
MYU7*9 .>]'*+ZK4-O</6C(/>L8:H"OO2KJH'6CE8OJU3L<R+HCIG%(;KT)JN
MJ$?+BD\I@W7@^]=O(=?,RP;D'&32FZ.,@FJSP,XI-CXVXHY6MPYNQ9-TS#@_
M2FBZ;&,G\ZKK!*IX/'O4PB+#T-"5UL)R=Q_V\J<'/Y4271"[LG%0M"6^5AT[
MTXQMC&,BIY.A7.2Q79=3@TU;UO,*5&D&Q>./:D$9WY*\^M/E=Q<UD7&N64 F
ME%UN&15=@0N#R*:L17G-'+?0?.T6UN"1G Q3_M [CBJH'&#Q]*=[&DXL?,3B
MX'I4@E4]:H;65B5Z>E2YXS3<>H<Y:\Q<4@E!..:KJQ/2@-S0HASEL2X&>U.$
MOTJFTC"E5B1TI<@_:%OS 3T%'F'VJF793Z4[>W7]*.0/:%KS.>M*9*JEFVC'
M6E4Y!R>:?(+VA8,A]:7>2.M5\@GK3@>,YHY ]H2[R#C-*'J'(]>:<"/6ER![
M5$H?'O1YA!R*CW 4%E(Q3]F'M42>:<@TOF_6HPP(Z4;A2]F/VJ'><V>M+YS'
MI3,@49%'('M$2><0.M,,KY^\::6 /(H+BER![1"^8_8FE\QQQDFF;_:@OWIN
M!*JH7<Q/&<TJAAU-1F0]J3S6HY+C]I8E8,1@FD"X'6HS(Q-1F4L<<TK(',M8
M]Z <?Q54,C8ZT;V"C!-59$^T+@*@YKROXJZE-K>JZ5X*TXDS74JR7)'15SQG
MZ#+'Z"O0Y;H6\$D\S[8HU+LQ/0 9)_*O,/AS#)XC\5:SXPND*J\AAM@>=H/7
M\EVC\3436MEU,ZE2ZY>YZIIEG;:3IEM86J[8;>,1J!Z 5;%PN<51+E3@4S?\
M_)XJE9EN=C2,X],4S[0":ILQ X-1L21P#FEZ"]IW-$W( ]:8+M2>N*J D+EC
MS4.?,;*]*:WV$ZC-+[0#WI!<Y[U1\W;QC-(0_53U]:4M-D"JLT//W#K1]J4#
M%9BR-DCT]*<[_)CO5<MU=$^V:W-+[2I&10MR&.*R8G?')_.GR%@/DR30X:#5
M>1J&= <=37/:YXOM-$N3;-;R33;-^%( &>F35LRO$ S<FLV]T>PUBZ2ZND8L
MGR\-C<!V-:484^>]5:>1%2O-QM3>ISLWA_6?%DAU.Y:*W+*%B1P1E>3P.O?O
M6=?>&M2T9XHEA%VLV"62+> P/3ID?UKT,W)1MO.WUJ7SB1E>:Z8XNI%I)*W8
MYG0A)7;U[EVR6.'3X8A$D("#,:=%..0*EC\L=,5E&:11NY/J*59S(.&Q7(XZ
MG6JVEC7,B*1W-+YJCFLP2$'DYI[2'&TFH:>QHJJ-#S@3BE\T5G&0HF?UIX+;
M0V:$NC!U=="]YM'F"J<;E^G6G%PO4T[(%49:\SVI=]5U.><TX'FCE6Y7/T)1
M)GM3MXJ($ 4H8$<T<H^?J2;QGBEW5"7&[ I^\8SC%+E#G)-Y/&34=Q$MQ;R0
MO]UU*G\:19!UH:7 SVI<H^=(\PO+:2SN9;>1<,C8/O[U$&QTX^E;7B:1I-0?
M<!\N ..U8>/>MHK0N]QXD)P#R*F63Y<#'UJKWZTN332ML2U<LH^#@^O-3J1N
M JCOQ3UDP01G\:REK%@E[QKQR!  #CWJRDWKP/6LOSB?F^G%2"0[3SBN-1<D
M5R]S4\]>O&?6FQ[I6$:*2Q/'-4$);UKI-(LU6!;@D-(W0@]*R5#GGRE.2A$I
M/I]\@8^7E1SPP)-4&E8$C85['([UUVUC574$B73Y?-/!'&.N>U%; I1O!VL9
M1JW>J.6:3<>3DU(9_E&.IZU7!&2<\=LT"15//'OBO.I1DW<*KLK$ID&3D?AF
MH'GP0>@(ZXZ5'--G.&''2JDL^<9/X5[%.DDK,Y).Y::8\$FHY<NI)88%4_M:
M#JF2*<LB7((#?45V0J2A))HY9ZLISR;E<J>,C\:C5 V#U/UJ:5 C'C&:B50J
M\$X[5ZZBM^YES/8]%\+:4=+L/-E ^T3X+?[*]A6\7)Z5C>'I'D\/VI8_PD#Z
M9.*TU;WXKR*B]]IGK0G[JL2\XZFF'.:0R8'!YIHE)ZU/6P<VER3%1LK-P#B@
MOCFA9,\]J+*]@YNH%#CK32C'C--^T#S-M/:7:/>C3=$WZ# C@FF;'W=ZD6??
MT'XTXR8QQ196%>_4KLLC'ITIZJV,FI!(.]+O!Z4.*!2*^&).*;ABI!ZU:#!1
MTIA93SQ2<0NB*.,A<GK3AGGO4H=0,8I,H!CI1R70U)(K*&E8J1QZU/CRQQ4F
MY.V!2@I@YZ4..EBE)7N1 ;N>U+C&:D&W;@4I*8]Z.70=]2'D#VI>=@QUJ5=N
M.?I2;ESP/K2Y1\R(TSG&:R?$L$MSH\WEQ-(\?SJ ,GCTK;)1#GUI"Z>V:B=)
M3BXLN-3EDFCQL@@\C\"*BDD,3C/*D?E7IFL>&K75G\]7,$^W&Y5&&],BO.[Z
MRFM+E[6ZC*NAZ^ON/:O!Q6%G3W^3/7H5X51_VIY%&6R#UQWIFXJ^Y.*I%7A;
M*YQZU<C(R,]#6%)R;Y6:RBH[;$]P1< $GE1D>U-BDSM!Q@#T[4QOD.TGIQT_
MSZU&&"$+NY[<TJR::FB)1NC6MRV <Y!.1[_YP:TX6 8="!VK$MY0"%')ZX]\
M5IQ,%P,DD8SSS7&ZG*TEL9.">HS4/!VC:Y?1W^H12RR+&$">80F ?0?6MG3=
M!TC2"&L=-MX'' D6,;_S/-%K-E5' Q[UIQ(/*).,@<<_I7=*;Y+7T.9TX)\U
MM1TB(PR,< 8X]O\ ZW\JDMG3[I/3H34D*JPQ@@87G-)Y$<.6)XQR/:O,KP;M
M40KK8M[T!"YY_.G991CJ#5=?F ; Y.<CG/Z5,C;@<XX-9TZTHNY#BA5IU(:.
M:4O>=Q%/4&7:JY^8'./:O,?%?A;5M<U:0W&MF/2S@I;H#GMD$=/Q->AWR$2A
M@3M((;'7-<\9<RNY);.>M%&M.C4O'<V5&-2-I;'.6'AC3=$*R6EK&TB_\M9?
MF?\ /M^ J]%.TBE7&'&035VYE 0*,Y]:S)9MF=HY^E>EJW[23'%)+D2+*X!Y
MZ4YAGD=:IP2EW^8U?C< C(]JWBU)7.>JY1>A"^<8&>M/M4<RQJH^8L /K1.1
MA6'TP*T+'2[V2YCWPM$F02S#H*UA!R=D0YMQT.R56 '/-(^XFAGP>#S3=Y#<
MCBO?]FC/VH] 0*8VXR"AIAD8S3-S%L_RJ' ?M25E'7BDVY[BFYYS3"W7%6H1
MV)=7J/VKD'BC@^]0[LTI; QWI.FD@]L2%0&XQ2-C&?2H]Q(^M,=R*.1=P]L3
M\ 4UBHZXJ$2'O3&;-7RNVK(]I%.Z1*Q5B W2F,D<AQC@>U,)![T@Z<5+BV"J
M12T0YD11@#@5$P1CC^=#%NE,93D<TG!@JJ)-BJ.*;D#H:3+"H7,@.0..]'()
MU"QD'O03\IP>:@ /?FA2<D=!2Y2^>^Q+&^T\-SUR.M:=CK,]HQ^8L*Q 2N:?
MDB//-'(B7.ZLSM8?%,!3]XC!AV'>I!XHM2< -U]*X2W=GSU'UJ=1@C!^M+D1
MBZ<3N3XBM0@/SY[C::5/$5J1R6'X5Q2LSGH23^.:6,R.Y7L!ZY[]Z3BD)4XL
M[1/$5JS8R1SVITOB"U0 AC]37&@%0,=,?EVI =W#=.,_E_\ 7H]F')"^QV'_
M  D=J(F8[L@=*A?Q79JH/SD]QCI7)98(QSR>O//^>*ILK%L]:.0I4X,[R+Q1
M9N"264?3-,/BJS#$ ,0.]<-_$,#!I^S/UQ0X#]E"YVS>*[13T<T[_A*+/9_%
MN["N"^??BI _S;>E"BF#I1.U_P"$KM"VT*P(J.?Q5%MQ%&2WO7'A!NSWJ&9V
M210!P:?(K"]G!,V+O5+BZE+&0@9XP:SW;+##<_6HV)"@]*:,LP-/D1KSV5BS
MD8Y-&X"H"3NYZ4-NZBCE*Y[(FX/7K3BBL.:KQESRPQ4I+'UI\I*J#E"#.!^5
M3!$8<U653SS3T+=*%!@ZJ1.B(IVD"G*5!/RC%0GZTH/'6GR,?M46@5/(Q^%+
MA0.GZ565]HI3(<\<TW3!5D65 Q2A03]*@1B13MQ J>1%>U)N/I0%&>U1;LCB
MDW\TU33#VQ8VX[_K2@>E1!OFYZTXGFAPB"JL6/=NYZTYU)]:B#E33UF'?(^M
M2H%.J/3<,Y/ZTC*Q!P::'.?NX^E.5\CKGZ57LU87M1ZL549.:4OD@#-,R&'%
M&[;2Y(VN5[1WL/,I49I1*V,CK3&(9<49' />CE2%SMCQ*V#S2+,Y[<4?C2 8
MHY4'.P-P0^W-/$S'D&H]@9@1UIVTX-'*'..^T'.#ZT\2=QCFH A+8IVT].E+
MEUU'SV1()F)Z#%(+G#8(J-5()R:0 AB6YS34&+VI.MR&.,8I_FXZU3>,9W*<
M"E4C/!S^-/V;%[9%OS5'<9I/.R<8JNVUSG!S2F4*0#WHY+;@ZU]B<3<G H69
MLGI41?H12-,HQQUIN*2U%[6[)A,P'2@3N3T_2HQ(0,GD4X.".,4<HW4MH9YD
M4<DT><O8U0$AZ-G%&XY^7M72<7.S0\T#DFE$@(Z@UG>:<X85(K$#<M#NV'.6
MVN C[2,>AI?/XR#S5"1A,I /S=JC6X:( ..1[TKV>NP.>FY?%Z"V,=*D%SCO
MCZUG"+SFW@X)J0@,#&3@CTH=[:[]!*;O<N?:E8'!Y]131<C.#\I]#6:C-!*R
M,"<G@GTJ67Y]KH<D=JE2;5^J#G+DEPZC(&5]:<EQW)JJK.#AAA?K0Z;1YB_E
M1%V5RFVV6GN]I&[IVI?/)!*_E50CS8]N:17:,[&'/J*I*VA+FRV+I3]:&NMG
M7FJ!A*EY-_OC%2*P>/<Q!!I7L[2T#F=BXEPSY*\"E^TC."<&H(@=I(^Z*BDB
M65]ZOM)]:))H:DV7O//0C(I#.!W -5HTD3EOF^E$@649# ,/6ILT/FN63.2/
M7Z4&7C!;%5H&;.TCD=Z2>/>0 2&I[ZH7,T3>>PX'('<"GF9MNY:B5&1 %;/U
MI3C;AAC-5T%=DBSEAG'-.CG+>M0^65&0WR^E$;^9D[< =ZE6NE?4=V3R3[.O
M'O2QS9YS4+J&&"P(]*0>A4CWH6X<S+/F @Y--,[@\<CUJ$LBIDG(]142[ADJ
MP*]LT6:8<UT7UN2>O%.,P]:I*#CD?,:25S'@%./6B[MJ.Y=^T$<9!IZS@]L5
M01=PW D4NYB2"",=ZJ[M=BYM30:48ZT+*"*SI)#&F>J^M-BE\PYSQ0D/GZ&H
M9%%-WH?:JBMDXP12%V#;6'!Z4N;N._8O@J>!1QFJ@D  .?PH64EL=!1=!S%S
M"TQD!.14)E./:D64 ]><T:!S$_EBD*$X J-I2#TZ\"@S;1C'S4*S"YQWQ3UC
M^Q_!%Q$A_?WK"WCQ[\L?^^01^(K6\$Z"="\(:?9.NV?RA)*/1VY(_#./PKB/
M'SG7?B%X:T'[R*WG2+[$Y/Z(:]6#GTK.-G-R)3]X1HSQCFFFW4D>M.WD+G]*
M:KF0X (JM+V+NK7'+$2?FZ4&'GMBFR%^B<GTH1I'&&!'X4)*]K WH*8EQAC0
M( I 3 %.P2<$?E2.KCDGY13EHA)JXTVJ,V<TX0@#&ZFQNTI( .!WIS<G:335
MFKH5T,%L QVN.:<+=5[\TCYB^;:<>M.RQ7IGVIQ[";6XAMMQYQ]::8F7Y5^;
MWH61I&V'(/I3O,9#C'XBBU_0&T1^0SH5D4<U7-I*H.P''I5U&+$DG-#3,3M4
M9QWI+W4#LV55ML18=3FI5BR@"C@5.C\8/6CS.=N!2=NHU8K^7C@\@^U(EH(]
MS=NH%6V=46E!Z<=:;7<%;H5H8R2P(('O2K!B0DG/H*G,P!P!DTH//;-)+LRM
M.I%Y))YZ4_RP1@\@4OF#=M[T[H?2J207$4  X%1^26D#$Y'I3\\$]J5&&.*F
MR;L/FT%8X'- [8Y%1*6>0\' I[?(<Y[=*6F[!RZ#]PSR:,U&HWY(I6R%YX^E
M/S8.5M 8XD!S4A(*],5"%*D%QDFG'/<&G%JUR92'1D 8H8Y4XIH /RYYICR@
M$H.M3HEJ/GNSC?$4L;ZA(J9RN-V?6L4?,P K:UC2;Y[^:9(6E1VRI3G]*R)[
M>:TD\N:)HWZX85I&UD=*>FXXQ[4#9S49 [4"1F4+R?UIADQU_6JE8(M]1U&\
MYZ<4P..]!88''&?6L*RM&YK!IRL68VW;5Z]JL1LTK!47\ZH1O\QQWK5M2YQL
M7)QVK"DY/2P5&HZW+L $:;?XL<UI6EP;4$@81CSBLE)<OR,>U3&XP!G..GI3
M5)N5^IDW=&W/J\$-NTF_<1V'6N8O=6FO6S(P 'W5%22;903N.6X(%4[BQDC7
M="VXC&5/7\*FM"I/W>@+E@KK<CDGPQYSW%*\HR #@GO59HIMN]H7 /\ $1TJ
MN\N3[ UC0H^_9HYI3NRP\@CR1G'\ZJNYZTDDQ;M@5!++\W/IBN[D<=;&<Y!+
M)CC'UID4SQ2 KWX/TJ(R,[!(U)9C@ <UT$'A34Y(\M"J<9P[#)KIF^6.JW,H
MQ<VS*ENXW7'EG=ZDU7:1B/0>E;T?A+5)& ,2H">2SBMNS\$VD85KN9IG[A>%
M%.G626H_9-%KPI=/+HL:/&5$;%5/J*W^2.*BBM(;>V2"(;(T& !4GW5P.@K"
M6LFS=:) @/>F.K=5-2;@<4F[#;?;FD[+0:=QK#<@&[!IZIL 7-(0 ,G\Z;YP
M48/6G9+5BOT&26X$GF!L&I#$"H]:0ON SUH,F, ]:6P770>L2X]J7:IJ"639
M@C]*3S?,<8!!'6IYK2L5I8G:-.I.*4 8]JAD?=P.30) B<G+>E5=)BO=$NU
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MRJKG:K$ FN[MI"$\M1\J@ ?2N-TGP]?7<R33QF.#/S;^"1Z 5W*HD6 H"KZ
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M485P*@F8R-NA89Z$&I4X0LF6]C21HLF1@@DYP>U*LDTHO8(MW".'R@.3G'+
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M@'@;?K211S6\0>7!8_>QSBB>+SD) .[MD<5$6VN9;]C%[CGD(4[<9/I2"3(
MW$D5# KPKNG8;CT%17DI$3.N<]J)-QBY+5@GK9EQ92Q)1<C.#0&8@E2-V>E5
MX62&,#))'7/K4DN]E4QD*?[WI52;4+VNQ)ZDRRMC!4AN_M3A(VW)<8 [U4:1
M8^3\X/5@>0:=G=$6'SJ1UK-5+JRTD5Y]"5)RY)()QW%/\X %2<&J,)$48 D)
M/6I"^U"YC(_VJVYFH78KZZ%I)>.^?I4?FL_S$%5]:@1V8 EBN?3FCSV\WR@P
MQCK6:J-NZ&W8M+,<E<AO>D,C#Y<UF3/)%*!M=@QX9>E75!.%*X..M2ISE=;6
M*;1(^\KN#8(]30+D%0,EB?2HV&V-B&.X G!K-TVY$V6QD[B,#M3E4M.PKZ&R
M29(R.%/;-9_VIO-\EVPP["K#R;& '(-0SVJS2^8"4E'WL>E*5[O6W8.8NH^8
MAA^::6RN&..>I-5W_=1&17.X#I4!\VYMV=< _P (/>E.\D^578E*SU+JRA4P
MS]/X0:0RDN G!QGDU6A=0!%LS+W]:=Y>P,V\B0] W:A727D)N]R6281$ LP8
M^W!I%G /!VEO[W>J,EQ)/*EHF 6.2<<@"KPVHGER8VCI13?.F_S"6F@TKDY5
MQ]!3_,B4@,&W=LU3GD:&=!$V0W;WI]P)5A#R -CKCJM+FB[\NE@NT6)IPD9V
M'(J!+M=H0#GM3(@GV<;T)W?Q'BEM8(H7)#[R!GYNU.S4KWW%>Z)W+R(8G.T$
M8XZT*C00B,@L".6[U*R+-TZCG(JM<K(FWRU)).",T**3UW_$&W8:(I"_I$>0
M33ML<).YF9FY!S3E255&6!7N*>\:J-^ I'/-4W_-I8$NQ2D$\4<CE"P49 SR
M:\UU*<7.H22MP7;)QVKU%EDG 9<*/?O6#J?A.RF<S(9D<]2N,&N+'T*E>"Y-
MEW/0RW%4L/-^TZ]3BC"A3@8XZTV @'</H:U-0T22S0F*XW*.JGK^E946!&#D
M$'H?_P!=>/5P\X2M.-CW*>+I5HM0E?\ ,U(+PQQA2-P4\5;CN\\*V>YK&612
M=JD$]:E1\$$8-9*+9G*G9F]'=[?N*<'U[U$TWSY.2QZU2WYB+DG&.HX-"W2G
MY5#L>@KIMRI(GEL6Y[D*H=@2/0"J;ZB\D@)'R+P!W^M9U_=.]P5#85>, \9J
M"&8H&!&2>17+7JW]V)O[!\O,SHDN0XX.<?X4DDQ. .I(-9*2;N5!'O5B*4JW
M.3FM$<3C9W)+@MM&P')...IK7TS2;JS"WT\95E( 3KM!ZFK'AVW,XDF49D4@
M<]A75^66BVCE>AXKU,%A%)>TE\CS\3BI:TXB0R*T(<MQZ9ICA'&$#%OK47V=
M8F 1F('\)JVI=\!4V#U(Q7J/56D><@+XPBA@Q&<&B0?)TP<<U')#)YJ%I1@=
MQ5K#;<H PK*#:NI/3^NAH]=B"'Y(P<Y^O4U(H$G0-]*61!MW X;]*="ID!)S
M]<5HGJDQ:B@<D\^_'%-=P@PH&3V'>GE?*;<&)]C3 QED_=KD^U1)O:10FXM\
MN#FG(C!<DDGUJ8V[[MS-CW%#;3A0_-+VG*[S>H[=B$;B,L<"D7'103GO5@VZ
M,.&8&F,P3Y21Q5.JM7+85AC*%7!;FEC7>,CG'6JTDH>145P,GO6E"8PH7/'J
M*A8A/5/0;B5BA(P< 4HBP,A>*;<S+%/MW U*ERK+QT-*.)5VEN#CI<B$8<G!
MH\D'C&:2XG2(Y%0+J@+A<"HEC5#W7JRE3;U)_LS9Z<5&ULF?>K*7"LN:S;F^
M$$_X]:;QEHW2%R:V+/V4L#BH3:8;DY^E6H;P.N3TJ">Y5'!)ZFJ6,3C="=/4
MB:S([4QK4CK5U9MRBJL]T(V^[FM7BE%79')?8K&VW'"CFFFU9.3^5:$$Z,,\
M4Z9HCC<:/K,&A\K,DPDGY1FH7MWW9;@5N!4V_*!6?)@S%#3=:#6@N7N5%4#H
M*4Q'=QUK4%N@7I522,^;M)[U;E!B( =PZ=:01$KN;('7GO5PVVV(L"2<9J'&
M]L =^*3LAK4J./FX%!7Y?F_(_P"?K5TJJ#.!GK^M0%=W Z9_K196 IY"N @)
MYYQ3RH8Y9>:E"A7 (SDU.T <Y%2XL$T5V0A<KTIBC/!ZU<0%<C'%2?9U<9QS
M5.,;70[]REY>W&.:'X&,5:$1\P+U&:M-:HR\BFI1>PC-2%B U#)NX(YK0@B!
M;:#P*FEMTV\>E"G"UD+4RH[=P3@<5*(B.HYJ>!@9BO85=98]OS8^M1[:FEJ-
M1?0SA:.PR.:>+?!P1S6C&\80X(-0W$Z)SWI?68)!R,B6T..*>+,XR1BG6]PL
MG(&#4SSA5)/2CZTG'F0^2SL0)9DMD&IC:XX-);7*M\V:?<7HC0G]:REC$HW9
M2IZ@ELI/'6G?9FYR.*J65Z)I"W8&K\ETJ+FI^N>[=CY-;#!".@&#1Y>UL=35
M;^U5+%1BK=O,CJ3WI0QBGHM&#IV!HN 67% 0],9ITMR ASTQ3;.597;)Z5<L
M2N:SW%RZ7&R+MX/!I=@*@ANG:IKC8Z$ X]#5&"=<D%@2/2F\0EN] 4>Q*V#U
M!%*=PQW%2KB4;1BG^0BK]XY'<U?M5NMA6*SQMQAB#_.D+D# !R.V*L_*<KOY
M!IHMY.64YSW/>I]I=WB%NY"CJXSP2.*4KGCG)]1Q2*XCDPP^;/0T]8P[%BQ&
M:<6[VB!$2(ST8_C4,_S*"3SGM5B8&,X&?KCBA4 3<.6_G5-WO%?U\B2/!\O@
M9;M32WF(Z[6+#C J9@=OSX7(_&JT,,HW8D7!.<^M1-MM)/0:T$3RD #;@1UR
M<4V\E$<!?=P1^53.S*"K1[O<#-54MEE/SN3SD+6NRLC.^HRR!D@5IU82,,^E
M66)&<C<OHO6G/&WE[2<$].*9"IC0>9_K.<T*+^&/X= OU9'#(\H+N"%!XSVJ
MK=3-#.J1_,7Y&*ONN$);)##M44",L9<H"PS@GJ:(148I)7"5VQ(RA 1TPW?-
M-<;267E1U]J8V^=\A&XXI=J3CRU.PCUZ5/,VK1"ROJ/$H=,OG9ZTS./NMQU&
M:0031N2<2KCM21E7N/\ 4D =:T=TU<D"[0L&92P;IQ3[:X$CO\G3]*6^^: @
M#<#QA3R*BTRWE@A*R94'^$G)H<6JEEL"V);A@TB D$9R,&I-R2*.<?2LK5)C
M#+&@5RLC8!4=*OI;R[ Q(QC[O>E9NH]-!WT([F9K=T5^5<X!]Z>8YVP5& 1G
MK4KV:W"(70JR'*DTJ^9"OS#=D]C4QBXW;V_(;U,JZ"H@*]!68LXDN@OO6C<M
MNA;Z5A6/_'ZQ;UXHJZ23(CL=4D*/$ 1VK-G58[L)FK8N"J>O%<]/?,=57.1S
MBE5D]!QLSK[:!9(,YX(K F'V6_>-QC)R#6W:7:+;J,9K"\1-N>*5> 3M--S<
MHCL;%ENE7U!JW+8F*(R1 \#.VL_2I3;Q 2=#W]*OWFH+%:N5.6VG&*AU6E:1
M228EM"EW%F0#';-5;ZT%DHD4G:3CV%2:9=K):A0,$=:EU!7N+-XE(RW<TX2]
MI$'H1VKHH!8D^E7DMEE^<,5)YXKE]*GE+-;R'A2<<UU,5R$0!EP,>M1&<I*T
MU>Q6FZ(KA7M "2I4_P!VGVE@'D-P_P P?G'I6#K.IAM1CC!(4"M?2;_%J S$
MD''-0ZK4KM#23)M07[&%DC_U9X(]#4-M(9WX8$YXJ35+D264J<'*DUS^F78W
M!HR<@9()ZU4JC5^E^@NIV:6RE<O@D=P<51#&.=T8;BIXIT=]\@QG%<_-<S?V
MHXDW!';Y6SVJ*E2HXII:E+E3.GBC2:02,HS27L,$064-MYQCM5"&Y:%0H)93
M536;EWMEVG 5@2*=YJ+8<R-ZW*R_(SC9_.I[J&,6C(NT$+\IZ8KF=.O9&<R8
MSV-:5S.T]J\70L"![5-.57J.3B5K>[\V15=\$\5T%NL2QX)P>^17$VI:.Z:W
MF'SJ.H-;D%U*(E!)..^>HIQG-OW1:=22_F\F^$2-D-R/:M.WD^11T KE9M_]
MKI,7W!ST/:MF.4;=QZBB#:G:^H7TN.U&X6&Z"KA>,M6E:D)$OEQC![@=:XO6
M[IH;Y7WY5Q@"MJUN)5A3<6' Z&IYYN5DMAZ6U+6JW<43Q$C!.1[46-V7E))S
MCIZ55U:5&T^5I #@9&>M4M&GW6@;.0QXP:*CM46H)Z'42NC1.SJ"%&>>U4K:
MYBF8-NVDCH!5>X=6M)$W$;T(KF+&]G$PC#Y*GK[5.(E5O%QD5!QU31W98%2N
M%/'I7/W5T+:?RG4 9SGOBIFNY&0 <GU!KG]9O LR G+XY'M3E*7(I2T)NKV1
MT\;JJ_( ?I61=3M%<E3P&Y7/2H(KF3RE4$\#KFH+O-VL<6<'=R?;O1^\E 5U
M<U+-WE7)((]<YK4CQ@ 5G6,:0Q+&@ 45>S@#'3UKKH>[&SW(GN%P,#OFH(WF
MSL5=W/X4LKG=C.<TZ(<5$DIN[92FXZ(>JW#=, ?6F%WY5P<^]6%8#BGI,2,]
MO?O5QC%;,3D^J,@2,\FT\\\U>:))K=X)1NCD4HZ^H(P:?)#$S-( %8]<=*C,
MH6/WI1@X[L)3YB'PAH&F^%K"2PL?-\D,9=TC;CN;_P"L *V"Q:5GZ G(K.M"
M7+,2<9Z8S5_SE7KCH#D^E7"FK\S^1Y^(Q-_W<=B>.8*W.<=ZJW^JB*01J>@R
M<5&+^"1V6)@2.^.*B*%P\@P7('*^GY>U1B*/ME9-HG#XQ45[UF41?"XD. QY
MXQTJXLK)&58':1U-8MM')'<.P.5+E@?K6A)+NBV+\S'D"NB"M&QXTZDO:N=]
M1DDSVDJR2!MA[CG-7HM2!4'/!%5IH!=VCQ!P&."I[9K!$_EY3."O&/2N"K0<
M9+E>A]%@\9[:G>6YLQZ@!?%@,*6]:VX[Y" 0<#O7 37"?;(P'QGD@&MJVN<K
M@,1FL5%J>CLCLYM-32N=06WO< G]YT-:UK?*R\G+#J/2N.U*?R[VW8'(;@?6
MM6&4LP;=M/K1[+WVXNS'SZ:FWJ6I1Q"$C:K[L9%)97D<OSDAB*Y[5F5K0L6Y
M3Y@:=9R.0CJ=I"\^]*5.2J74M1J:Y;6.CU6ZBCL?-)P4(.<]:@LKY+@$D*1Q
MT%9-Z/M-J8V<COGWJI8RD01A#AE.*J<)J2?-J*,U:UCKKEXI+1V+8PI(/IBL
MNSO5N"&4#'9JJSRR2P/&6V[E(XK.T=UC@$3-DHQS@]ZIJ:FI2=F+F5K(ZF62
M,1%G_A&<^E1V5RLX9G99$/3!W"L;59Y7L&6%\'OD]JJ:%-/$#N)6-CD#UHK3
MJ*::V''E:L;]^D21-<0MM"\LO:BTNO-=$$B[2.W(J)RDL;1R [&X(KGX+MX+
M@119.UB/PJJTG&THBCKH=L+6WV'$8.>]8TL^V7R9#TZCH*GCOG\L;20<5BZO
M=[;Q=QY=>:GWIQ3:MZ!=19TMG*L@P0,=N:-06.*U:56";>H7O63:2BWAQ$Q(
M'7/>H-7OY%L\K]W<,BB]5PM+7S'>-[HV[":)8QTPW3O46J$1*LR?*&X(]:RM
M+F86W[S 8DFEUN9%TF69G.8_F&:N,W[,E[D]I<*JD\;CZFMRWE&P!B,8R37$
M6&H)-/&&Y7&<"N@6Y^3Y>GI4QE-N\7\F/W;699U&YAAN4$;DY&6X_I5RTNHG
M12N!['O7$:O?-;:@2QZJ&%:>FW$C0!F?.[D>E9<\N;ECH^H]+79L:K-Y!6?J
MOW64-^55;6[$DH9688YP3574[A;>Q<RX(/&/>LO3KP"1N3SCGM53CR/G;]4"
ME?W4=K'=(4R6/ Y-87]K?.Y#D_,>IX-3+=9CQV/!KD;FZ%O>2Q<X5L<U-=*4
M(MO0<96;L=M;7;JF]U SZ<U/>ZFT=@X$C$$?=SQ6%:3L85W'((I=1GC33IF+
M8 4T_8KDNV[6$YZ[%NQO/.^;/?&,UH75X8[&5G!QM[5R.ESRB!&8?*W*D5N>
M:TJ%2>HP0>E%"*:Y$ASEU91M[XM(D0;<.BDUS7B#Q#/J8%GY8C@B<X&>21QS
M5B"Z87^P<[7(.#TK%U.%HM1G# C<V02.H-:8:$.=RMJ:4VY:,I8IO(/3CM@U
M)M(':G1[=XWC(]*]))6;'-M"E2L:,3G<,\'M2;OEQNXJQE9G)V_=X H%JLAP
MN1FLZ%26H*DYQ4F5*[+P:!;Q23$J'D.!GJ!7)7,(M+<R._4[5'?-;>D2E0@)
M'&,8I8JO*2Y(&4X^S>IV/G);7#J6 #?,HSBM2SN4DAR3WKDM7O0EO!D_,35O
M3+J1;<,I^5A7GS=12O!Z"BXVLSI;R39&C!E!)Q]::3#(F!D-ZUA7SRW,<;(W
MSIR.:L17&[!W8)[UO&=1-<S)TZ%C&RY<3(I (V@_SJPUJDC!CA#VXKGM5O&M
M;@%7+;UR5/M6G9:GOB3<3R.]9O$SIRY;712C&2N2W=LC_NRQ+CD&G06<AC!*
M@-ZDU3OM0$,L$@"@9VDYZBKL5XA7+-@=B.:M8A1E9K<GDNKE81)&S$,&R<G-
M-F#QVYE2%@@ZD<<57NKH6NH(1EHY.1[5I+<!TVO(A!&"#5RKK2#T$H=3-MYQ
M=MM3:N!UQ5F6%VB* ,01C<M9:S)IDTD+_P![=D]Q6U!=!\&-AM(XR:'B()\D
MT*,&U=%6)2L?E@J O&#U-+#:)EF*EB?3M5+59FMI@ZL-K\Y'K5FTO%>",AP"
M1^-3[2,6KC46RE<W;171A5OD'('K5VW63 >1BO< U2UD;_)N% #*WS'V]ZCM
M]0\UL*YR>2*3J.C9;W$ES7->5)BC' 8@< 5FZ2"BRF>/:V[[N,5?M[E2.3@^
MIK N]3VWDA1P5W=^]7*:7O=?,5CI&C,JY60J,]^E0W6ZS5"Q#JW\7H:I:=J@
M>+G( ."#5G4ITDL)>Y W CM64*WM%R-6+E'EU3N(;A90=^-OIWJS9P Y+-_N
MJ#TKDK:Z$LX02L 1DUOP7F&"GH.F*<ZDKZ:K^MQ12ZZ$UR&M+\O,P^=<1X/)
M JY$\;H-P#@^M<MXCU!OM$)8$+MX/O5G2[R1;1"Q))Z$>E2ZE2+48[=AI1W9
M;NT^RZF\Z<)(H"'TQU%(M_$[B(O\S'%-U.<OITK2-\R ,">U<W8W@FNF7&?E
MR#Z5<Y):/2Y"ONCOK=8-NU,#UR.M9-Y/]GU)80P*L<GG]*9;74BH%8\^OK67
MJ$,IOC.[Y1CD>WM4WJ\FO0IN-]#IA.'0*PRI[=:QKBX6UNI47) /2I;6;]V!
MGM69XDG$5O Z\,S;21WK2+O#FEN3+>R-RRNRT0.<!N>>*FO;U+>"-]X!9L5A
MV-R!#$N0<* :777#Z9N YC8-D>E9J7-!I,K9ILT(=1$\P88 !K3\Y3"7(!4#
M)S7%Z'>(Z'G)W<BMR5VGM9(D?8S+C-/#MM-)ZBGO=HFBU:-BJEE.\X48S5J2
M>-82O:N.TF91=3*V&9#M!]*V)9FVG:<\5%/G3=G<<FFM48VHW$37DD2OT[9K
M.>PCNRL:@JPZ$5FW4TB:U,",X)R?K6[IK[K028&<D5S8RORP?M%='5@8-U4X
M.S,J[TQK67"YDB[-CIZYJ)(]H^4&ND^M+Y.&,C$# [U\]0Q#E*W*?1N;MJ<Y
MSP#^&:M1VX>)@Q8$C&0<54U"^AGU+; V0@P6]35B.?:@)YKZ##T4US21X>+Q
MTV^2&ENJ,EU*.RGJ#@U-!#SO8 \<#-(TJW%Z 5'?.15L#'%>5B*7L*BC>]ST
MZ6->(I7M87:=NX+^-*"3]<5(TRQ6[,QXQ3;.%'= TIVGKQR!73&G.>J1QU*\
M(Z2.W\) KH\TQ7&Z4C=CL *V#-O=%1UWL<#-9%E>);::+>!2$4?_ *S3K*:*
M:<R,QRC?*,]*].$I1IJ%['ES:E-LZ:"WA5,$@/U+>IJ"Z=(2RRMG;Z&H(K@K
MC)Z5SVJ:A(EZ5!R6?YJJ5:MRVM85H'2Z>UO*!+(23V!YJY<E88]ZL./05@VL
MS!MR#Y0.E3W;RS6WRMD@Y(]:2=6S4=@O%:LM17L+R8(5JNK.KK@'CTKB[.=O
MM;[FX%;<4[%>#GZU%/VJ=FQN46MB>XNQ&K#//04:5>D(03C=S]:Y[7)I49T&
M<C!'-6M/DVV\:N?G &33E!W>HE/8Z6YO$^SEB/;BL=+_ 'W)08V@<XJ7*RQE
M&Z&L,$K=2F/D!MII2IO1WNT'/T.HAN3QC!'I5"]O<22<X-06\IQW_.LW5I!&
MY8MG<N2,U4DIT[O07,T]"QIEVL\SR2<NK8'TK9%SMZ$D#WKD-%N4?SB#GYL5
MNK< +NS@"BE&,HH)2:8R[N2\Y1F.:N6UP @&>E<N]Y]HU4$'&<C&:VX0/+'/
M-.$&Y/E$Y6W+M],/(S6-"ZFXW;OUJQ>2XMF^E<U97<CWLBYPHJ:UTT$6CMH9
MLI@&L[4F F7)ZU%!<E<=<5'J)\R,..HJE=Q:L#-&UFP@ /%.NG& 36+;7++@
MYJ\\PEC&33I-OW6A2=M47H;G*C#&JM]/\RU&A 6JE]-@J,<YK247&&I*E=FE
M%/E14=W.XP<G%4X9^*J7>H S>5GFLY*/)=E)NYN07A*X)ICRD3;C6=;3\#FI
MII00#FBG%*-D$I-N[-*.\.>35=[AO.+$\?E56*48X[U#-,'?"MTZU:@DA<QK
MQW6X'<?UIIN%#< U2A8;*@EEQ+\IK5+E5V/F-&>Y"Q$CK5**](!!J*60M$0>
MPJI&^.I[TIWNFF),U_.4D'/Z5<$ZJ.M88DZ$?_JI[RE1UIU$[73$I:EZ>_0.
MH]ZNK=(8@5-<G-(7F'/>M))RL0%<]-2UDV5*2V-J*[429-+->XZ,*Q(9PS<G
MFGRR<4W%R7,F'-;0TK>Z9922>#4DMY\W7BLB"X7.,\T^644<B:N'/T+L4I$A
M;-%S>-M.#56*4*AR>M5+F<8)J:L4U9A&36QJ6L[>4<DG-$\_R'/-9%CJ =C'
MW%3SS\&J2CR70KN]C2L)_D/Z5+/<94C)K+LIMT6!4\F"*M0<HH7-9E^V8"/@
MU7NYLK@FHO/$<?!K-N+EFSSUK*JVO=2+CW9KZ6X*G!Z5:N)N,$UF6#>3;@]S
M3)[DMG!HE=))($^HGF*EP2&Y-;MK,HMU]<5PSW;C4]AZ5U,,NZ%<=Q2HW=PD
MTBU>3AT*DU%I]T5EVJQ..M07  CXZBLBPOA!J$@8\%L4Y0:DE(%+30Z\W.[J
M3CTS6+=WJV]]&(OEW\M4[SC'7-<_JMRBWT.3@D'BIJQC&-N@XR;=SL+&\!E&
M#NX]:L377!W8QZ5S^E/N#N&[8QFK-S*<<?E3MR036H7N]2PFH 7+1MTZBMN*
M\C\E2O?U%<?;@/?H)3RP[?RK:9PJA1P!P,U,:3L[.S8^?7874KXF5".<'!JQ
M;W*RLHSQWKGM5D9K1O*/S#FGZ),[KMQC:N2#3C!J2LP<UJ=8\Z!<,<CTJBU[
M&LI5=J^U4YIV Y/2L5YG-^ K9ST]Z4_:N7Q#4HI;';0A&B#L0?8C)K.O6MX'
M#(6VE@"!Q4,$LD-LJL^6YZ51O)F&]F&?ERH-7*53:6PKQZ&[;D3':C[5 SS2
MW%O$1^[*B0=&KF=$OY))ER?F&1U[5M27.3QT[TU6K<MF@M :EP-I)<9#;36@
MEJL\(>1/E(X).*YJ66*&Z&PG#DL0?6ME+XFW56R/EYJXUI*.CN39-]ADY:W=
M8RPVL<#FK:1K)%QTZ5S]]>'_ %N[:8_N_P#UZLZ=J@>0J<D,N>:4,1-/;<;C
M$T+F$10%HB=R^OI45KMD^7:H!&>11/<9!(( Z &L>RO_ "KYE)+ -T]JU=5\
MVI%ET-\Q0H"RKM/UXI@"2K@D+GC/>H)KC>O!VC^=83ZC)%J B0;CD$#UJ*M>
MI&RBM^@XQB]SIT@AB7#*6/<DUGK+BZ,0!+YX/6I9[HE2VX+QTK.AG+ZB&7.=
MA''UK1U'?E9-E:Z-V6.%P-R+D?Q=Z@AFMC>M$9-Q49P#UJC<7K>4<Y]ZP-/N
M)GU]P1MP"WU%9^VJ.IRO0IJ-KG97$J, <<#IQTK)?5U/*,N.X]Z;/.V3N/'I
M7*:I<I'?$+\N1D@=,UG4YVTW*S&I+HC5>1F0XZ5E0I(EX2.F:TV^Z:K J'XZ
MUZ$X)V.9.Q>WD)S7/W,R-K"*#VK4EF(C(]JY-F8ZUG-15OLAQ/0+5@8EK(\1
M"5H5:/[BG)I]M<-&%!/%3W,J20,IY!'>E9N-@V99LW+0+GN!3KAE\O!X]:IV
MC$1J W(Z&J>M7+HL:%L;SCZTFOW8U\1NV<BPCY>GH*L27:D'!_"LS2Y5FME(
M.2HP?K4][D("GWJJ$5RW0-N]C&M;F1-4;:,@.<_2NF65F& >*YK3XWS(Q/SE
MR2?QK:5R$^8\UG36MQR?0Q==D"7]NN.2#D^M;M@56!0!VKB/$4\BZ] N\LI3
M('IS74V)9;5!N.=HK.+<JC16B1MNRR1,#TP17.:1$()Y0S9=6V_A5V2X9 =Q
M)K-T^X6YU"YVYV@C)]#55$[JXD]SI@^!UK(O[N/[;;QEP&+]*EG?$1P?UKD!
M?&[\40VS<+&"1CJ316;2L$>YWT4BXX;D>M9'B+5H[*UVE@9'. M78CN3+#I7
M ^,YS_:Z!6. @(HJI\ED$7J=QH]RKVBLO&1DBM1KE53)8<5S7AQ]VDQ2-_%T
M]JOWC[(RXITXM10.6I%'<JVN73$9^5<>PK86<"/(?Y<5R.CSR3ZG<2-SG -=
M%)(JH5''%*FM&T#>Q5^T#4KUO+8^7'T8<<UJ0S,HVN^2/6N:\/W:R+<1A0I6
M0GZ@UODKMR>II4(*45)[CG)IV,CQ)=I'+:)MRQ8D-6WIVHI>VT<B'V8>AKD_
M%3[&MN<$M\OY4OAV^:(L@;C/S U,I.,[C5FK'2ZVTATRX8%FPI.WUJ'2X6M[
M&+:Q4[02*FFND>W=",Y4]:2VE$D:,,;2.@K5QA*?R)NTB^9LQX+9%<;;ZJBZ
MZX(*!I"N,UU#D=!^%><FYB'B5U)X6?!^O_ZZY\5#2*+IRU;/1X[I&& XK \1
M0J\)O$R)8NI'=:FW8PZ'GUJK?73"UD9\$ $GBM/9OE:>Q/-J6;+4$N;1&5AD
M@'!IEW-(@6>%OWD9) /0^U<YI5UYELKK@%216F]TQB)8?7%3"/NV>PV];HZ6
MQUF)U4NK(2,^HK6\_>N >#7!:5?"XMB<8(8J#ZC-=;97)GA5NAZ$547>*:#=
MNY=0Y&3S5E&!. 0!BJ);YP,X!ZU.I51D&FKL-">0X&=QIZOE 35-I%)SGI47
MVK)*C&*I"N6Y9P!UYJKN+,&;[GI4,LX ZY-5$OUEE>$-\T9 ;'YTV^Y$VE%M
MFX)E#?3TJ&]F>>T\B/*[AC/8#O5?S$"Y+ #ZTD5ZOEL1\WI6L'?0\*O)Q5T.
MC5K0(K,#N;H/I6@DYC7.1M[YZ5D*LMQ*"-OJ2U42-0FN9+<Q,L:'[Q/WA["M
M;V.-)WW-QC;D,T>P'KP1P:A@AD1O,?&#SFJ/E%+4&<.IR<L.OT]JTQ<PQV6Y
M2#A>!FF)HCGNRC*J;2&S@UA:ZHM)1-"P(DR2/0]_YUHIJ$26V& )[ ]17.>(
M+LL[Y78BKA01C.>]8UK.)WY<I*MIMU,*+4WGUD%3N4#'-=+;Z@RXW#Z&N TN
M8B_W#GJ,UUD<GRC)KCIP4KGON5C;O;D211OD%U<$8K3M[ESC<,CL17)2EF$(
M0X_> D>U=';N4CP.HZ9K11]^Q+>AD^(M<99UM$(X8%ZW[2Y)4;AVX85YSJT[
M2>)9T&,M*JUZ!;GRH57N!BLH)NJRV_=&:SK!LK.4IPX7@FG:5>B2R@<C[Z@Y
M'K7*^-9BIMNPR<BN@T5?+TZ -TV#%5K[6PK^Z:.HZM'86Y9B2Q&$4=S5;3%D
M@):23YY/F8?[58WB.X0:KI*/PC2MGZXXK<M]FT$\M5.'--I]!*5E<M:A=16^
MG32R'"A"2U1:+>B^TZ*=3UXJKK(4Z3<JY 0QMDGZ5SG@#63Y)L)B-BY=&[_2
ME5?+43EL.&J:1Z#))+$02WR^M<P+D1ZX7##:25S71RR+(@'\-<.\I75I(7 $
M:S$AAWJZL8J-ELQ)N]SO+6ZR.H]C6)XD+QE+Q3\N0C^W/6FQN8F#H<CTI]_=
M))8NDR95^,5"4E%IO0;:;1I6TT8B7YAR!@]JS/$>IK!;16H(,L[@*/;/6I+8
M_*%Q\H&*Y;Q9=+'JUJ%/,:9/MS1.ZI FG([BV200A@><=#3KR1)-/F24 J4.
M5_"H+*]CN;.&6,G8ZAAFHM5.--N/+^_Y9(K2,(J/-$3D]F8&CW+&[CW?*%'2
MNN2==O/'O7&: ZR OC+$XS741,5!+=,5G13UU')F'KES]IN' &3&-M6M(U4"
MUA#Y3 QS6-+-YL\\@R!DD9IVERB6TP0/E)%*I34FNX1DU<[&Y9+RW>)^0PX]
MJIZ?$(;;8W+GDUGQ32A2-Y( X!J;3IY#$K2C#9-:?#92W%>][&U'*RX#+CZ5
MY_JEU<S:O<D2?O?,V@#ICM7<I+N//6O.]5N?+\23NR[ ) /P'>LZ]-<B[#C)
MW.\LI)/)16?YPH!(Z9K'\4WTJS6ED90D,IRX['FM:U!\M67GBN/\5&2Y\0VT
M"Y)$>/Q)I3A:D"E[QVUKM$21H<!0 *LL6"-\V1CK65:,\,*([<A0,FK<<^]"
M >HX-:P2:2>XF['.::F;F4[BK!L$]S6MJ,$=U9YD.'C&5(_E7/6MP+:^F25C
MN,A!S5ZYOGGR@("#L.]10C[S\C:*DW=%'RL%2FU:8^-H/ .><4WS,2$C^=-F
M4FV9EX.<\"N^:2IW1M)W31>"A1@"K,(XZ8%4;:<3PA^-W\0]#5R-QD?E7'2;
MO8]%\LHIQV,KQ3O2PB9">).3^%2Z!>^>J$GY@ #4/B@NVE.$!.UE)Q63X=F.
M$8$@G@UEB;PJ<R/+K:S=SN]6BWZ>;E3AH2#]14^GW8,0YP/2JLTSOI=Q'@;6
M0CI4-E*%B13U"@$UI)<TUTT.9.R-J34452H;+$8 I\,DJ1*200:YJ^O5M=2M
MRW^K9MK8_G70K(&4+GBDHJ4W%] <FE=%+7I%*VSLQ#%]@QZ5=M9U\L8X%<_X
MI8J;%%)VF7!(_"K5O(P0$-4SC)U.5#325V;6I;9+1".S@\>E+:S95?FP .@K
M,DO0ELYD?H.IZ54L-0??L?&#WJ)MQFIM>I2LTTC0U6[/]I6D!SMZAL=?:M.)
MV7JP8UD:A&+JR)3_ %B?.A'J*;I^H?:EW$;6SR*M\L:GO:I["5W'3H+XANQ]
MMAC4Y)3GVYJ_:2,(D16X P<US_BB#%JE[&2'C8!L>E/TS5 ZHC@JS#]:FJ^2
M:NM C[RT-/7;R..TBA=L.[_)4MH1&$4-G:.]4]2MEO[!T_Y:I\R'N#5/1;TW
M=IN? D4[''H16DXQYU?9_@2F[>ATES,HLY2<$;#_ "KEM.NOWK'L1C/O6KJ#
M&+39I(TW-L(QFL/2AMM$!Y9AN-55@W:-Q1DMSJH;DE!SG/!%<EK#+::@\48*
MJ #@^];]N[*!N&#[5QOB&:9M6E,C @<*!Z=JB:?LE=:E)KF.HTN4"WC&>2,D
MULG$MM*O4LA /O7)Z7(RV</S'.W-;EO=$##''TI4N?1M;A*VQS^DRD:B\;D9
M0$$=\UU%O*.HY!'6N4(B;Q+=/$P. #A3T)ZUT$1"Q%LX.W.**?QN*"6URAXM
MU"*.WB@!!E)W#V%3:+J*RV\?S#(4#\:XF^GFO99[AN6![>E:.CR9MHRO#*:S
MK*?.FF5!JUF=K?QM>Z>\6[WQZ^U<II,I2>8!<8.#Z@5TMM=Y7<PQGTK$01#7
M+TQ\1Y''^UWK:I+F@I=2(JS:-Z"X 3);Y:S[_5@^IVMF -LA)+?RJ96'E-QQ
MBO/[N]G:_EEWL"K';ST ]*5>\8674(:L]-M@6!^8J:SM:82O9VY;+&0D_A4F
MFW1DM(F88)0'/K53Q!*\8LI(A\_G;3[@]:TYXRI.6Q-FI6-"-50!EZ^@IVIS
MM'I%R8U!;9@ ^]0VTHQFC49,:9.X!.!T%-15G*/8+O9E#3$6V$:C+,5PQ'K6
MZ;D06LDK#(12Q [UBV+XC7&.><UIS.BVDCR'"!"6^F*BA#[2ZCF^C.=\/7*S
M3W4@4C<V1GTK?EF A9CQM'(K T)5^QJ8Q@,Q/UK:NW6.R<_[-9X;6Y50X(WO
MVG4;B4Y!9N![5MZ7?"-Q&Q_=L>#Z&N:4J+N4@?Q<5MZ18SW$\<^PB%6RSGIQ
MSBN7$4H5*4U4>AT8>4XU(N&YU2QG/S#BGSA1;R!N5VG)'I34F1C@]1^-+*RM
M&Z')&"#[\5XM&G&FER['T4M4SSR '[?(RL"A8BMB+.WK@5FV\2^>XZ!6.*VD
MB_= U]'!--M'RS[%2.SD6],Y=2"N-HJ_ H92",G.>G^?6H*GBD6,$=?7-?.S
MKNI6YGH?10HQIT^6)#JB*M@3NV@$=._M4%E.!C!]JNW4"7]F\9R#U7GH>U8\
M'R'#<-C!KUL$[Z'DXV-I7.RT^]5$RYP .?I4FD72S27$BGY2YPOH*Y2:\,(6
M,'_6?RK=T4@6RE1]XYS795:T1QQ[G717 12^X!0.2>U<GJ&I)/JBLO7S!@>M
M;-VZQZ=,V>2E<8S%M3M8QR6?)]@.:5>Z@@A9L[BSN=W7*GN*GNM16UM9)<[M
MBYQ5&&11C'(-8WB*X98C&"0A'('>KBFJ?,#?O6':5>-.\C8/)SFNAM[LY .>
MO2N)\/S/Y;D#C?BNG1NG-84*7,GKJ5.=F1>*I6CM$G1L'.*L64C>4ASD,H(K
M'\1O-*MM;C_5NW3U-:-ON4*HXP  *U</WI/-[II27IA&YV"JHR36787:SIYD
M;9#,>:BUI]UA*BM\Q6JNCP&WM(PQYZGZTYIQJ)1$G>-V=-%\HX.2:Q-=<B0X
M/\-7XI06P#TK-UU3G?G@KBM)1BXNQ*;OJ,T@!+5=@ W')K5N91%92.3_  UC
M>'RQM &.<-BK>OOY&E2'/4@5%&/[MR*F_>L<_'/(+R,J><UV=O,2BYX.*Y/3
M(O.NXLC@<YKK  J>^*G#P?,Y)A.6EB/4GS:N1P<5RFFO(;R4XX)ZUTTQ\R%U
M/<&L*R 4D=^]:5H*5F3!V-J-\"HM2DD6 ;"<9YJ$R[&4'C-6SB6(@\Y%5:[<
M.H7MJ4;=SL&3S5U')3@UFSYB0G.,4^TN0X R*(QLU%@WU-:*0[1DU!>G>!4V
M0(L\9JJQW=:T=-\G*2GK<?"=L>3Z5A33!]2;V-;CG; 3[5SENF^Y=SS\QK"K
M&U-(N+NVS9B<@5.9B5Q5(2!%%3*VY0:U4+Z+<ELDEF,<+$']:IV,KR,2Q)YI
M+^39;M[TFF9*+CT)-34CJHCB^IJR2F.,X[U625F;)R:2X?Y1D]NG>HXVQ@9Y
MJFKNS"Y9N)&6!L<&LV&=CN)/)/85<G;,#'VK*MF+,V?6BHE=($V:BRYYS39[
MH@8S5?..:AD;/>E.%U8$^I%+<N)EP>]:ZREH0>^*YR=F$R8&>:W(W_<+VXJ*
M,5:0Y/88T[Q2;LXJX)FECZ]JS)WR/>K-JY:+'>G&.KB)OJ5YIWBF!5L<UJ+*
M7B5B3TK&U$[1GI5^UD\RW4CTI4HMIQZA)]2YYQVU6FDX-*[;$J%G#K6DH:-=
M1)E;3I@NH$'J:V;C)7-<\H\K48V'0FNC;_5?6LH1YJ5BF[2)+0[(O>GRR-CB
MJRL5P*LOCR\\5O[-\O*1?6Y!)(0,9JC<N=N5.33+NZ . PS3X$\T+6<H\UXH
MI.VI>LG<VJE_PHE?Y33G81QX' %4UEWJ><\T-:\@7ZF-.[C5%.,?UKLK1\6Z
MYZXKF)562ZC Z[A70*VW !P*5&*BKH)N['7DS+ ^W[V.*Y""Y?[07;^]DUV<
MBAD(XKC+Y/(DF7& I-8UX-3YFRX2TL=EO#0AE/45@:P 520@;E;@^E:FF/YV
MFPR9SE!6/K^[,"@X!;)JL1'W4Q0>MC7T1R0Y)[ "M*4Y&=W(K*T4$1O(3P<
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M4L,A7&6QVR*M:EX;NM)LY;Y;E)EC7+ C!Q[5=\>>([G0[2WBM&V2S[B9,?=
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M.E3Y6_,J4KV./OIX_LC-G'!''>IM'00Z?& /4FM"]\.1#6K'[-(WE%CNC;D
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M2P?TJF[;+1G/0+FMN2\U)=B;Z6)KB);NREB!QN'!]ZH6Q( #X##@U8LKH31
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M2+.X.B[N/?%6-(T^]U64VME;O+<*I9D& 0!QSGW(KU+PIXYDU[6Y]-N+:-"
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M+$PZX-<EI5ZVI>*K>.<[@A+ =L@5#JN4U%#Y;*YU=VX5#N('UK)BU..!\Y.
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MV .#4^CZTET]U"NY_+?[ZCBLOQ'<N]O+!!S(P.*RJM.,9/<J/5'H-D1+812
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M1YG2UW%*W,4]/N?/LXG( +CFNPL+I8K=8^ JKCBN)\,;'MS'(,F)C74H"%+
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MIQW_ ,BA01[K:1R:6$NG!$==^5X(%3W&DSZA!&?)^XP8;JZX1!A@@''M4HC
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MWS57?LM-Q:<VIEZ5-F)0PVD=:Z."4X(!SBL^VL#;>6LJD,1FM"6,B(F(-O\
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MKE::5IZ"*<UK',FUD!'TJI!I%M;R^8J#-:Q04FRC0"NT2NNTCBHX[.&)MRH
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MK<?-S]*O! L84#  P *SM<YJWNNQS-OI*VBLTNR1SC!QT^F:?,X5>O-:5R,
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MET>71S 5/+H\LU;\ND\OFCF J;*/+]JM^6:3RZ.8"IL]J39[5;\LTGE^U/F
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M41XZU8V4NRES 5_+I?+JQLHV4N89!Y?M1Y8]*L;*-E',!7\L4OEBI]E&RCF
M@\NC95C91LHY@(-E&P5/MI=M',!7V"EV5/MHVBE<"#9[4;*GV^U&WVHY@(-E
M&SVJ?;1M]J+@0;*-E6-M)MHN!#L]J-GM4^WVHV^U',!!L]J-GM4^WVI=OM1<
M"#;1LJ?:?2C;1<"#92[#4VTT;?I2N!#LHV<5-LHVT7 AV4;*GVT;*+@0[*-E
M3;* E%P,_4+#[=9209P2,J?0UPUU"]I-)!* )$X('->E;/K61JGAZ#4I1-YA
MBEQ@L!G</>JC.QE4I\VJW/-+I7WE\GKG'3%307,K81_F!'#=Z[VW\'Z?&RO<
M;KAU.?F.%_*N#U+9IVI7-MC(AE*CZ=J+HYJU*22;&7"Y1L?A7-:@DB2%OX"?
M3D5U65EC# 'D9P>WM6;>6X8$8Z\9IM=3FC*S.7>/C.,XJE,,9ZUMSQ *RL "
M*QKHB-,XR:5S:%V[(H6[F/4^#U%=%;R'<,GD5RT;A)Q-(>=P'YUM02K&T91]
MV!ZTZ;L/$PU.CN+>2XM]J'!)_/VJWI>G&*'+8![D=S5.SF$X"-G&,D^U:XG6
M&-54\]L]JZ$EN>9-R2Y3-N9'MKE08F-KCYY_^>9]"*TK"YMU!>.3Y>JMGK3)
MVB\AXN&W_>!Y^M*EA#$B[,H!_"O04^I#::U(-3NFGE\U5W;<U6MF=R&RZOD
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M'+<D4]%K<"WMHV^U5-,BE66;,NZ)"4 /J*TMHJ9:.P(@VT;/:I]HI&VJI+$
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %5-3O1IVG3W97=Y:Y ]3VJW
M4%[:1WUG+;2DA)%VDCJ*:WU!^1YNWBG67G>3[65#9^0*-H&.U94<KKD,V\MR
M">M=)J7@V>QL9+F.X$Y3!*+'@X[GKVKF=IR#CCO6OH<-52;M(E9L@$5$MI=:
MC.;:UA>9]N2J#I]:1@Q'!Q7I'A'3;:QT6.:)O,EN 'DD(Y)]/PH;LA8>FG*[
MZ&'IWP]0VBM?7+I*R\QQ@84^Y[UJZ#X)L-$N_M6?/G'W"5P$^@]:Z:N8\?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 BHJ+M50H] ,55U***2PE\T9"J6'..>U6ZKW-J+EXBSL%
MC;<5'1OK51>MP,T7T\.E@26;J-NP'MCIS6C80)!91JBE<J&.>N2.]27$/GV[
MQ;MNX8SC.*6",Q0)&SERHQN/>G*2:T%8DHHHJ!A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-?$K>-=.CNK22QT^[D6-;>:, $'@G<1G/?\ *O5*XZU"5&W-U-(R4M@HHHK
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M +9(Q->"17W&7S!EA_=QC&*YO98:#<9S;?=;%<TWJD=V\T441EDD18P,EV8
M#\:XS0?$FL:SXUOX(5AET.$M&)47@$="&[D_E6)XK^'$=GX>NKC2+VZ'DJ99
M()ILHR*"3VZ^E9O@/P3K7VG2]=%W'#:%O-*!SO*CMC&.:TI4:"I2GS>2NOZU
M%*4^9*Q['1117FFP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH " 001D'J#
M45O:V]G%Y5M!%!'DG9$@49^@J6BB_0 HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
@B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img187419207_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img187419207_2.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 1P"',# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#"\3^)/^$<_
ML;_1/M']I:I!I_\ K-GE^9GY^ASC'3C/K6[7"?$W_F3O^QGLO_9Z[NGT%U"B
MDS12&+1244 +1244 +1244 +1244 +1244 +1249H 6BDS2YH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI"
MPSCJ:3=0 ZBF;Z:7H'8XCXFG_D3O^QGLO_9Z[CS5]:X'XG/\GA$^GB6S/_H=
M=-]I]Z&]!QA=LV/,7U%)Y@]:R1<>]+]H]Z5R_9FIYB^HH\Q?[PK+^T>]'G^]
M%PY#4\Q?[PH\U?[PK+\_WH\_WHN'(:GF+_>%'F+_ 'A69YU+YU%PY#2\Q?[P
MI?,7^\*S1-2B;WHN+D-'S%]:7S!ZUGB;WI1-1<.0O[QZTN\>HJB)J<):+BY2
MYO7UI=P]:IB6GB2F+E+.X>M+GWJN'IP:@5B;-+FH@U*&H$244W-.H **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH ***S9M2,I,=EM?L9F&4'T_O'Z<
M=><C%)L:BWL7I9XX0"[8)Z <D_0=ZA\YY.OR+_=!Y_$_X53C7:Q=F9Y&ZNQR
M3[>P]AQ4GF8J>8T4"SY@ P.!33+54R^])OS2YBN0M>92;ZK[Z7?3N'*<7\46
M_P! \.?]A^T_]FK9$U8/Q/;-AX=_[#UK_P"S5J;JI[(JFM66_-/K2^<?6JFZ
MC=4FO*7/.-'G&JFZC=0'*7/./K1YU4]YHWF@.4N^=2^=5+>:-YH%REX3TX3U
M0\RE\R@.4T!/2B;WK/$E.$OO0+E- 34X3>]9PE]Z<):!<II":GB:LT2^].$W
MO3N+E--9O>I!-66)Z>)_>@EQ-59:D5\UDK<>]7[+,Y)_@7@GU/I3,Y*Q?7D4
MZCI13,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<>AJWX9^(WAWQ5<_9;*XDANB,K!<J$9_7;@D'Z YKS+X\?\ (QZ7_P!>A_\
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MZ#J.A_;O#UG':V<\K%HTA$7SC@D@<=A3?'O_ "(6N?\ 7G)_*LVES6#J5?\
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M'FC-9WN78DS2@U'FG U206) :4&H\TN:M(5B3-+NJ/=1NJA6..^))_T'P_\
M]ARU_P#9JUZQOB.<V6@?]ARU_P#9JV:TZ(SC\3#-&:,T4BPS1FC-&: #-&:,
MT9H ,T9HS10 9I<TE% "T4E% "T4E(30,:S5'NI7-,'6@"3=Q4,GF2LL,/\
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MRR-H SN&<X Z5[%;)%%:PQP#$*HJH/10./TJ)Q22:$R6BBBLQ!1110 4444
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M32<=+H#K+N1HK*>1#ADC9@?0@5R'PMUW4O$/A WNJW)N+D7+IO**OR@# PH
M[FL3X=WMW>)XS%S=33B.Z<()9"VT?/P,].E+\(XKB?X87<-G.+>YDGG6*8KN
M\MRJ@-CO@\U;C9->@6/3Z*\9UWPOI^F:7=W4OQ$NGU^WC:10^H*NYU&=H3.X
M$XP.:TY_$.H:I\ Y=5EN9%O_ "@C31L58E9@N<CN0.?J:7L]K,+'J=%>5>"?
M"&M:K!I'B?5_$5[YP\N2&V5R4,*@8#<]6 R?KSDDUZK4R23M<3"BBBI ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8OB[Q;X5GL+&X32[;48TCNIDV^=(SH2 /0!1^?:O<6574JP#*>H(R#1M4 #
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M+M&W;@8]*;JWZ=0N87@C_D1="_Z\8?\ T 5O445FW=W$%%%%( HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M444 %%%% !6=J^I?V?:CR]K7,IVPH?7N3[#J?P'4BKLTT<$,DTKA(XU+,QZ
M#DFN2,LNI7KW<H9=WRQQG^!.PQZGJ??CG J9.QK2I\SN]A;*VV#))9B2S.W5
MF)R2?<FK,T@1<"G\11^]4)I-S5C)V1VQ7,QCN2:929HK'<W%HHHJD@%HS245
M:$+FC-)FES3 ,T9I,X&334E24D1;I<=?+4N!]2.E #\T9IR0W4A.+9D'8R.
M#^63^E/6PNV/S201#T"E_P#XFG8GFB1YHJP=-+#FZD7W15'\P:<NEQ#[\T\G
MU<#_ -! HL+VB*M&:N_V?;?W9/\ O\_^-']GVW]V3_OZ_P#C187M$<%\0S_Q
M+-(_["UO_,UTM8GQ*LX8='TEU#@#5K;<3(QXR?>MH6T8[R?]_6_QK5+W48.:
MYV+133;)V>53Z^83_/-(MNZG_CYE;V8+_04A^T0^BF-'<#E9(C[%"/US_2D)
MG5<F -[1N#_/% ^>))141N%5<R*\?KN4X'X]/UIZ.DB[D967U4Y%!0ZBBB@
MHHHH **** "D-+10 TBG**2GJ*!,@G'!KI/!4QDT26$_\L+J1!]"=_\ [/7/
MSCY:T?!=P$U'4;,G[ZI<*/?E6_DM-;F557@=E1115'(%%%% !11574-2L=*M
M3=:A=PVL ./,F<*,^G/>@"U167I/B31==+KI>IVUTZ#+)&X+ >N.N/>H=3\7
M>'M'N#;ZAK%I!..L;2 L/J!R/QIV=[ ;5(&#?=(/;BJ]AJ-EJEHMU874-S;M
MP)(G##/ID=Z\Z^"7_(N:M_V$G_\ 0$IJ.C?8#TZBL74/%_AW2KO[)?:S9P7
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** %7AA]:L57'458JHDR"BBBJ)"D;[I^E+2-]T_2@"O1116
M9H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %3
MI]P5!4Z?<%.),AU%%%62%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(2
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 *.HJQ5<=15BJB3(****HD*1ONGZ4M(WW3]* *]%%
M%9F@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 $]!2[
M3Z&@0E%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBEP3T!H$)12D$=0:2@84444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5.GW!4%3I]P4XDR'44459(4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ J.7H*DJ.7H*3V&MR*BBBH+"BBB@
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MC=>6HW2FNAT]%%%>>9A1110 4444 %5[Z^MM-M'NKN410IU)[GT [FK' Y)
M'<FO'_%.OOKFJ,48BTA)6!?;NQ]S_A7?E^!>+J6>D5N:4Z?.[&GJ_C^_NG:/
M30+2#H&(#2,/KT'X?G7+SW]Y='-Q=SS'UDD+?SJO17V-'"T:*M3BD=L81CLB
MU;ZE?69!MKVXA[_)(176Z-\0KF*18M703Q$_ZZ-0KK]0."/R-<112KX2C75J
MD?\ ,4H1ENCWFWN(;NWCN+>5989!E74\$5)7E'@[Q*-%U!+.ZDQ97<@3D\)(
M> WL.Q]OI7J]?&8[!O"U>2]UT.*I#D=@HHHKC("BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ J=/N"H*G3[@IQ)D.HHHJR0HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBJ.L7IL-+FF1@LI&R(D9^=N%X[C)R?8&@:5W9'.7]S]OUB>56!
MBB/DQX']T_,?^^LC_@(H9MJ57MHQ%$J#.%  SUHD+RRK!%CS'Z9Z*.['V'^
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MS,<3,H\AFWC&<D$'D <'HIR<<IM SH]*NK.TW0ND$EXTCL#YF1,YQRF> 2<
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M-TI(Z.BBBJ.8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0[?W4YK&O-5FN043]W&>P/)^M8UJM**L]?+T)E**'ZM?"YD$,1S&AZC^(U]
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M@IQ)D.HHHJR0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MAK.KV^B:<]Y<?-CA(P<&1NP'^-7Z\J\=:J;_ %][9'S!:?NU /&[^(_7/'_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "CJ*L57'
M458JHDR"BBBJ)"D;[I^E+2-]T_2@"O11169H%%%% !1110 4444 %%%% !11
M10 5!>6JWUC<6CL56>-HRP[9&,U/13C)Q::Z >#3PR6\\D$JE)(V*LIZ@C@B
ML[3M,@TQ;@0-(PGF:=]Y!PS8SC ''%>G^./##S,VKV,99L?Z3&HYX_C _G^?
MK7GM?=X6O3Q5.-5;K\'U/0A)35RKJ6GQ:II\ME.SK%* &*$ \$'C(/I4\4:P
MPI$I)5%"C/7 I]59]1M8 =TH9O[J\FNA\D7SO1E:)W&SZ;#<:G:W[M();8.$
M (VG<,'/%9FKWPG<01'*(<DCN:9>:M+<@I&/+C/7GDUV/PW\$2ZM?1:QJ$)7
M38&W1*X_U[CIQW4'J>_3UQY>+Q=.$)<NSW\S&<TEH>G^"M)DT7P?IUG,")O+
M\V0$8*LY+8(]1D#\*WZ**^1G)SDY/J<84445(!T->5>,O#C:3?M=VZ'[#.V1
M@<1MW4_T_P#K5ZK3)H8KB%X9HUDB<89&&017;@<;+"5.9:I[HNG-P=SP6BNU
M\1?#B\D=I_#][%&IY^S7 Z?[K\_D1^-<#>^$/&<1VSZ7>N#VAQ(/_'":^HCF
MV'FKQ?Z'4J\6.GO+>V'[V0 _W1R?RK$O=6DN08X@8XCP?4UJ6GP_\57C#9HT
M\8)Y,Y$>/^^B*[[PW\([>TE2YUZX2Z=3D6T.?+]MS'!/TP/QKDQ.9QM:_P!Q
M$JQC?"[P?)>7T>OWT3+:6[9ME88\V0?Q#V7U]?H:]FIJ(D<:QQHJ(H"JJC
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M-9[V*]I(\[\/_"73=/D2XU:<ZA*I!$(79$#[]VY^@]17H:(L:*B*JHH"JJC
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH IZL VC7RGH8''_CIK-) S]:U-2YTRY'K&164_4?
M6HD=%'8;*<+_ ,"7^8I:CGYC'^^G_H0J2I-A$P;VV'<,S?\ CI'_ +-6G67%
MSJUN.WDRG]4_QK4J693W&RQI-$\3C*.I5AZ@UB7%K-=:5-*SM-<QR$ XZK&Y
M& !W(!/N3Z8 W:KVNU7N8U_AF)_[Z ;^;&D).QR&[*J4&\L0$"_Q$] *Z8VZ
MQ6FG64K GS$!QW9 7S^:5:2RM8[@W"6T*S-G,BH QSUYJK/MDU>W8CBW.W=V
MRZMQ]>%_[ZJF[E.5S(U:-QK$HVG,NQD]#P%_F/Y5?M;<6T.P'+'ECZFM&[M4
MN8P3&K2QG=&Q R#['MGI5"1LPD@$YXQT([4T]!<UR'>@<S.Y"1AW;VQQ_(-7
MFOCQ[/7=#MM?MXWAECG-JPDP"ZXW#H>W]37I)DCMWG>=D6**W4NQX4 ;L_AQ
M7B_B[Q)#K,T5IIUNMMI=J3Y,:H%W$]6('3_Z_O4R>AU8>+NFCFJ***S.]"TM
M(*<*12 4M%**1:0 4M%+2*0"EHI12*"E H I0*  "G 4H%. H&9NMC_B6-_O
MK_,5J 5FZX/^)6W^^O\ ,5K*M6_@7S_0QA_&EZ+]1%6I%6E5:D5:@Z1 M2JM
M*JU(JTAB*M2!:4"G 4#$ IX%*!3@*!B 4X"@"G 4@ "G 4 4X"@#JO"]Y?17
M%E:P6H:QF#F>8(25<9ZMT' 3KUR?PZR/*7;*6R,G&?0X;C\2?R'I7G6D:O<:
M1<^9%\T;8\R,]&']#[UW=O?PWR)=6\F4= 3&>H*G&#Z'+#\JZ:<DU8\7&T91
MDY=&:L$+S$S+)M9&(52,C\14YE\QO+D0I(/FVYX.#U![C_)'-00[A=)L)!/W
ML="H]?T_/ZTLUS97SO9K<J)QG:5)!# =CZCG.#GK5/<\\X;Q#X@ATWQ8Z;XQ
M<?9%_=$G+#).WH06R.!UY]*Y.R\3M'$_V.%XYVW.$4@<R,3C)&."?3&0*ZKQ
M%86CP--<1+.\TDCS>;@NH78-O&!]Y5Q@= /7->6?:FM;RX68JJ!B(&=P?E!.
M <=>H.>O%;4[=0<;'I/A_1-/CU&X3SKB:>2/,ZRREA*2?G;GGNH_*NC?3G1I
M9+=%C2 ^;''&I3>_&<D<'(RO?KVQ7':-JMM8/+=7#SS_ -ISHMLD<N45T#8P
MX P#M4'!.<\BNGTW5I9]09[A@\<@6/B/;Y9W=1GGDGD'L <\<RQV9T,%]% )
M;FX.$,@2,CYMV!C _'?^'M3-1O(-0TPR0EMT$T9*L,%=QV_J":SIT$>D6"JQ
M(5I(RQ[L"0?_ $%JK(<;P.ZKN^@D3^N/SJ+=2N4O_P 2_0_TJ"<?+4P/*_0_
MTJ*;[M,I;$47*BN@\(Y%MJ"GI]K+#Z&-/ZYKGH?N_P# C_,UO^$B=VI#/ F7
M'_? JD95-F=)1115'.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5'+T%25'+T%
M)[#6Y%1114%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% "CJ*L57'458JHDR"BBBJ)"D;[I^E+2-]T_2@"O11169H%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$BG4MOE0& <@PQ\#D]6[G</3IFM:2OH%S5LM5B31XD668I;3!V01EL*P.WD
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 *.HJQ5<=15BJB3(****HD*1ONGZ4M(WW3]* *]%%%9F@
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5.GW
M!4%3I]P4XDR'44459(4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 (ZAT9&&588(KF[9BU
MI"QZM&I/X@5TM<Y'&8O,B(QLD=0/1=QV_IBHD;T7N"_>=".^?J#_ /7S3E^Z
M,]<4UOEE1L\'Y3_3_/O3ZDW&AMMY:9X!D(/_ 'PW]<5%JVDR3S&ZM0ID(Q)&
M3C?CH0?7MSUXY&.77 &Q'SC9*CY] &&?TS6O4O1D2=G=&!I>DW NH[BZC$2Q
MDE8R0S%NQ."1@=?KCICG8MQB6Z/]Z;/_ (XH_I4]4[.54M9II75$\Z4EF.
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M HHHH 4=15BJXZBK%5$F044451(4C?=/TI:1ONGZ4 5Z***S- HHHH ****
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M_@-=-5+2+'^S=)MK0G+(GSGU<\L?S)J[5(XY.["BBBF2%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5'+T%25'+T%)[#6Y%1114%A1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!SWCW_ ))[XD_[!EQ_Z+:G>!O^2?\ AO\ [!5K_P"BEIOCW_DGOB3_ +!E
MQ_Z+:G>!O^2?^&_^P5:_^BEHZ"-^BBB@84444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 HZBK%5Q
MU%6*J),@HHHJB0I&^Z?I2TC?=/TH KT445F:!1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5Y_P#&S_DDVL?[T'_HY*] KS_XV?\ ))M8_P!Z#_T<E"W$ST"BBB@84444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5.GW!4%3I]P4XDR'44459(4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% &3JT7ESPW0.%;]S)Z>JG/UR/^!U5K;N8%NK:2!B5#KC<O53V(]QU
MK!C9RN)%VR*2KC&,,.#CV]/;%1)'32E=6%Z2]/O#K]/_ -?Z4 8=O0X/X_Y
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M<9'J34HFK(V:***LY0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.<A7]GQP?Q Q^"^M;-1W$"7-N\,F=KC&0<$>X]Q2:N5"7*[F!]V3IPW\Q_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ J.7H*DJ.7H*3V&MR*BBBH+"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBL#QGJ>L:-X7N]2T.U@NKJU7S6@F#$/&/O8VD'('/X&@0WQ[_
M ,D]\2?]@RX_]%M3O W_ "3_ ,-_]@JU_P#12U\_:S\>=>UK1+[2YM*TU(KR
MW>!W0/N4,I4D9;KS2Z1\>]>T?1;#2X=*TUXK.WCMT9Q)N944*"<-UXIV8KGT
M_16%X/U'6-6\,6>HZY:P6MY<KYH@A# (A^Z#N).<<GZX[5NTAA1110,****
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M'44459(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M  #_ -#6MT53^!>K_0PC_'EZ1_.0HIPI!2U!T"THI*DBB>:5(HU+.Y"J!W-
MMAM%;MEX>GDU@V5S:7(A1<O=*=J9QGY<K\W/'7^5:L/A6Q68XDEN0.Q(5!]2
M.OT'Z5I[.1RO&TEU,/0-.%_J :4 6T'SRENGL/Q_QKK[/2[*SO;B[LK<B><D
MO-(21R<D 'MG'3\^*G@T^WL86\F),YW 8P ?8=OY^]2!B=LC8+,WR#)P./\
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M>0?T7^?TKEDTB^M;GRM !>(J7EL2V%1>[1D\(Q/ 7[I)[<FO0-"O]/O+$16
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MZ?I0!7HHHK,T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!&574JRAE88((X(KX_^*'@I
MO!7BZ:WA1O[-NLS6;'. A/*9]5/'KC![U]@UR?Q!\#VOCO0%L)7$%S%*LD%Q
MMR8^<,/H1GCU /:FG831Y5\ ? YEN)/%]]$=D6Z&P# C<W1Y/< 94>Y;N*^@
M:J:7IEIHVE6NFV,0BM;:,1QH/0>OJ3U)[FK=)NX(****!A1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%3I]P5!4Z?<%.),AU%%%62%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1
MSP1W,+PRKN1A@C./R/8^]244 <Y)&\,QM9VS(HW(^,;U_O#WYP1_0BE'S AA
MSW]#6U>VB7D&PG:ZG=&XZHWK_P#6[BL4;UD:*5=DR?>7L?0CU!_Q'4&LVK'5
M3GS+S#.SJ?E]?2G44S_5].4]/2D:%:"4Z+)M.?[-8]/^?8^O^X?_ !WZ=+MP
M7AOF^7SK>XC.^'&<D<$CU)! V]PIQTP6\,.Q!_6JKL]A !&"T$3>9& ,F(C^
M'_<()'^SGT^[+1+C?4ADT4R*9-.GCDCSC9,2"OJ-V">/0C/J:T-)TR2R+RSN
MK2N-NU/NJ/J>N>/3I5GRH;M$N[>0HTB!DFC_ (E(XR.A'U_#%+]HEA.+F/*Y
MXEB!*_B.J_J/>B[(<FU8#^YU $L0LZ8P>F]>?S()_P"^*=+:JSF6)FAF(Y=.
M_P#O#H?Q_#%),OVJU#V\BEN'B<'()'3GT/0^Q-203+/"LB@C/53U4C@@^X/%
M(DB^T30G%S%E<X$L0)7\1U'ZCWILP-TD4D#I)%R<JW!]#GOWJE>Z[]GN7@@M
MQ,8SAV:38,^@X.:ACN+:^NEEM]]M?8YC+E5F'/&1P3]1GU&*=GN5RO<MRQO$
M(_,"'>V-HYQP3G/X?K4<\?FQD#&[^$G/!_"I/)GNDS'=DM&2"DJ .IX^4D<#
MMS@_B*#%+'@M;R*3G<4<R+GMCOZ]@*:8BJ[QAQ'<-&I"@@[\$?0]>U/:%\@Y
M27:<J)5Y!]B.GY4CS;EV! 2PYB+%9 IZG9C)_#FE5B%CE\TF,C)+[<8(XZ50
MTVCF?$OA9=7E%Y$#!=[0K$#>CXZ9QR#[XKFK7P9JTY( @4@X(:49'U'6O4JB
MF,0QYL89?[Q P.<=_K4.";.NGC:D(\IPE[X:TW0=/CN=5GNY2[;#]E50%./]
MK_/M5&?0&ET^+4M*,MS9R9X9,2)@D'('4<=17H9943Y'G1.Q&",>N6SQ2B1>
M2;Q\+WVJ!^>.>AZ4.FK%1QLT[MGDF,$@C!':M&RT>\O8FF1!';HI9YY3M10.
MIS7I4VG6UPZM-$KLIR&903G\J>8&*&/S \9&TI+&&7'I@8XJ%2[F\LQNO=5F
M>*^+[2(^$M2DM[VWN!"(RZH'4@&11D!E&1DCIZUIBM_XF:=:V'PXUC[-;6D!
M80Y\J$*Q'G)WSTKI[GPY8W3LSP0HS=6B0J?_ $+'Z54J?NJW];&='')592GV
M7Z_YG"Z?I]QJ5R(+=,MW8]%'J36I9Z+97>I3:<DU[]HAR'E-N!$"/J<_3IFN
MT@L_L\0CA=84'\,4:J/ZTZ08&V1IW4<D[@ /KC&:4::6X5<?*3]W1'%R^$[V
M*;R_.MSGD?,<D?[N,UL:#H$EA)]IE1&GY"ENB#U ZDGWQBMU"=C>1"BJ?NL.
M ?<CT_G3C%G+3,& '3& ![\U2II.YC4QM6<>4/)+Y\V0N#_"!M7_ !_,TC)*
M.$=0I([8VCVJU;P"<AV'[H?='9O_ *W\Z2]6ULH_/DN([6/.#OX4GV&1S]*J
MYR-ME9;::Z?RV<*J8)8<Y].,=?\ &H;BUDO'*Q2_N(P59T&W)Z87D^X)[=!S
MRKH[@W,8CCCG:%_F.U"K2_4G"JO3C.?7'.:4FO-%=FP>*&UE$;21*[%@RJ=O
M\(  Y7C/?C-"O?0+%*^OTTW3[M'AF-O'&8V^SIO*DC&-HZ8&#Z8KE=8U:XBW
MPH(E\M5D,BRL2<GD8(&./7'X<$IX@U"S=5O)+=9;Q'D=(=QC",V%=CMY(*@<
M<\^N:I%;NYTN0^7"N^13#,L7^K!^ZPP<$\?Q'^>*V47NQIV*UI+8:8+N\6>*
M27:T<HE<,-S# &T#);KVQCTY)R;W3+E[U7E<WDS_ #N<'=P.1Z__ %@:T9K6
M+^TI9%M8)I+D,Z%9/WDCD_,  .>,G_#M9\-Z,RZA%=(UP2K-')L._((P>!GC
M'<8ZCWPTWN-H6WMKRXO+.W6.<^>VPA?NQA>I'8''&[&>W>NW;2K5)69EN%+0
M"#]V"55<@CY1P#GG(';G ZS65LRV!@BL$CPYWQLZ@<\C. 6!P5., CCGBKC0
MR.6-S.=G4JGR+^)Z_J![5#=R3$?3(K1V5;B2;9QA$ /)S@G)P<XZC)W<9YJ:
M1$T^.)ID66[.3! /N1^K'U]V.3Z=:FN+Q(&7RHE,F,V\&-H4'_EHWIGG'?'U
M.*<4+L[22.9)7Y=SW_P'M32'=L2*)V=I)'+RN<NY[G^@]!5Z&'/4?+_.EBA]
M>E3LX08'7M2E(TA#J.)"\"F%F9DCC0O+(=L:#JQ]/Z^P!-,9]HR<DDX  R6)
MZ #N3Z5U&AZ.;-3=7('VMQC&<B)?[H]_4_T J4A5)I(M:1IBZ;:E20\\AW2R
M#^(^@] .@']2:BU70H=1E2[AE>SU*(8BO(1\X']UAT=?]ELCZ'FM6BK6AR-W
MW,*TUR>VNX].UV%+6[D;9!<1Y^SW)]%)^ZW^PQSZ%JW:@O+.VU"UDM;RWCG@
MD&'CD4,I'T-<]C5O"S<"?5M%&?E WW5J/;O*@_[['^UTIDG4457L;^TU.SCO
M+&XCN+>0922,Y!_^O[=JL4AA1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M4<O05)4<O04GL-;D5%%%06%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 *.HJQ5<=15BJB3(****HD*1ONGZ4M(WW3]* *]%%%9
MF@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD\1Z'#_K=9TZ/_>ND']:IQ>%]!A<2#2+-Y1_RUEB$DG_ 'TV3^M7HM/LH/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[:]\8_[4>#R&N$D9H\YVGR\'G\*UC2Y5*_8#WFBBBN< HHHH **** "BBB@
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MT= %X48[8 _'BK"QS&".$SR"./[JQXC _P"^<'%*PK%VSTZ*T6-SM81* K.
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M/_7(?^AK755ROQ(_Y)YK/_7(?^AK7+#XD!YSX"^)>B^%O"BZ=>P7LEPLKO\
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M **** "BBB@ HHHH *G3[@J"IT^X*<29#J***LD**** "BBB@ HHHH ****
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M/Q[G\\'TK>HIV,W4;(XH8H(ECBC2.->BHH 'X"I***9F%%%% !1110 4444
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M:G/<1_V?>Q0R6R^2L-ON+-DY#MCC'''O736=S/;:9IFG0P-)J+6T:^4>JD*
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MBJB3(****HD*1ONGZ4M(WW3]* *]%%%9F@4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !2-RI'M2T4 >7?!S0-5T--9_M2PF
MM/-,/E^:N-VW?G'YC\Z]1HHJIRYY<S ****D HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *G3[@J"IT^X*<29#J***LD**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH JMIMDS,WV6)7;EF1=K'\1S4!T: 9\N6XCS_TTW_^A9K1HI612G);,R)-
M'F_Y8W8Q_P!-8MW\BM,.E707AX7;\4']:VJ*.5%*K/N8#:=J Z16Q'_7=O\
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MBBB@ HHHH **** "BBB@ HHHH **** "BBN2U;QU;Z3XTL/#;V4LDEWLQ,'
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MA3Z"ZEBBBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *Y_4C]K\6Z9:@Y2SADO)!Z,W[N/]
M#+^5=!7/:6?M.O:]>$DXGCM(SVV1QJW_ *'))1T;&C8HHHK,L**** "BBB@
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M'2_A9KEB\FV[M#LM@3@XER./]T[FI6]I#3>_Y@;_ (0\2:SXI^)^H217\O\
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MXA_M/[+:2S*ZVOG&,&+/4)@C&/7D]>:/CK_K?#__ &\?^TZ]B5510J@*H&
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M/RY/_?->BZ+I,&BZ;':0C.T?,W=CW-?7T;JG%/L>!7M[65NY>1%CC5$4*JC
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MN[6 *QM0\*:-JFN6FLWEH9+^TV^3+YC#;M8LO .#@DGD5LT4)M; %(RAE*L
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#B_BRI;X7:Z!_SR0_E(IKJM-8/I=FXZ- A&?]T5S'
MQ6_Y)AKO_7%?_0UKI=(_Y MA_P!>\?\ Z"*?074N4444AA1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO!^M5#J)[&]1115$!4<O05)4<O04GL-;D5%%%06%%%% !1110 4444 %%%%
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M=$DELP"BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5.GW!4%3I]P4XDR'44459(4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 444A('4XH 6BH_/B+;1(I/IFCST]Z!V9)17#>*?B(WAAHH9='DEGD&1^](
MCQG^]MY/L*RM!^*E_KVM6]A;Z"-LC@2.DI?RTSRQ^7@"IYU>QLL-4<>:VAN_
M%;_DF&N_]<5_]#6NETC_ ) MA_U[Q_\ H(KD_BG.6^&6N @<PK_Z&M<UI'Q0
MU--/MXY=+ME5(E5?WC9( QD^E4Y*QG&E*3=CUVBN2TWQJNH62W M0O.'7?\
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M:***9(5'+T%25'+T%)[#6Y%1114%A1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% "CJ*L57'458JHDR"BBBJ)"D;[I^E+2-]T_2@
M"O11169H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5\[_$WPM-H&K6DDNK37HOY)742J1Y/S#@?,<_>]NE?1%>-_''_C^\
M/_\ ;;^<=;8=M3L!UGAGPA)X(:_U2^\07-_ MLQ=)(R @7YBWWCDX%<+ID?B
M3XL:M>7$FJ2Z=I,#;0D>=HST4*" S8ZDG^@KU;QE')+X)UM(B0YLI>G<;3D?
MB*XSX'W,+^%;^V4CSX[PNZ]]K(H!_P#'6_*JC)\KGU YGQ!H/B/X7O:ZKI>M
MRW-DTGELK@A03D[63)!! //\N*[7QIK?]K?!Z?5[-GA^T1P.-K$%294##(]\
MBE^,5S##X#DAD8>9//&L8[D@[C^@-8%W#);_ +.2))G<8T<9]&N0P_0BFGS*
M,GO<# \,^%O$GQ"TN.6[U>2UTRS7R;<N"^]AUPN1GW8GV'3CH_B3:WOA_P"&
M&C6)OI'G@NHXGF1F4O\ ))[YQT_*NJ^%G_)-](^DO_HUZP_CA_R)ME_V$$_]
M%R4<[=7EZ7 P=,\#>)O'6DQ:KK.N2VJ-$OV. J6&T#AB,C /'/)/6L/0=7\;
MR7-SX)L+Q_/\YHWE=B6MU0D/A^JK^OIUY]O\*?\ (G:'_P!@^#_T6M>9>#/^
M2X^(/^WG_P!&+3C4;YKK8#(\4^$=;^'D%KKECK\\[-,$E8 H0Y!(R,D,IP>O
M]:];AU#4->\"1W^ELD.HW=D'B+?=20K^/0YK ^,?_(@R?]?,7]:9IFOGPS\%
M[+55C626*V58T8\%F?:,^PSG\*EMS@GUN!CI\(-3U*,W&M^*+B2];D[ TBJ?
MJQ!/Y"H?AUJFL:+XZO?"&I7CW4*!Q&78G:R\@KGD KDXIOAW0O&?C?3%UF\\
M7W5A;W!;RHX,C< 2#\JLH R#Z]*S/"&GRZ5\;6L9KZ2^EA$BM<R9W.?*SSDG
MZ=>U7NI*3N [XO>&)M.E.MOJLUQ'>76U;5U.V+Y2>#N]O0=:Z;P3\/;JPFTC
M7&\1W4T7DK+]D,9"X9/NYWG@9].U,^./_(KZ=_U^C_T!J[SPT0?"VD$'(-E#
M_P"@"HE.7LD!YLEW<_\ #1+6_P!HE\C&/+WG;C[+GITZ\UJ_%/QG?:(MIHNC
M,R:A>C<TBC+(A.T!?]HG//;%8B?\G(M_G_ETJO\ $65;'XP:#>7;8MD%M(6/
M1565L_ER:I13E&_8"Y'\']8GLUN[KQ1,-4*[L$,RJW]W?NS^./P-6/AEXKU9
M==N_">O2O-<6^X0O(=S*R'YE+?Q#'(/M]*]7KQ30W74?V@+NYM#NAB>8NR]#
MB/8?_'C4QFZD9*0%3Q3?^(5^,&H6>@W$WVN<)#$H;A084)(!X&!DY[=:D\1_
M#G7/#FB2>(8O$4]Q>P8>X"EE;&>2K[LG&>X'&?I5]/\ DY%O\_\ +I7H?CD9
M\"ZWG_GSD_E5.;BXI=D!6^'OB"X\2>#[6]NSNNE9H9F  W,IZ_B,5U->=?!;
M_D1I/^OV3_T%*]%K"HDIM( HHHJ "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "IT^X*@J=/N"G$F0ZBBBK)"BBB@ HHHH **** "BBB@
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MG)JZ.UHID,T5Q$LL$J2QL,JZ,&!^A%/ID!1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M 4444 %%%% !1110 4444 %%%% !4Z?<%05.GW!3B3(=1115DA1110 4444
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M%1114%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M65&RA4L>@&1U/'%>F45$9<KN)'CGB+Q)XK\8Z)_PC4'A&^L[NX94NII%81*
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MS7J%[:0WUK-:3@F*52C;6*G'L1T/O7EFJ6$^N^,='L85+PV\JR3CL%R"Q/X
M#\?>O62<G--$5GMKJ>,>-/"?B+0_"^K-'JJ7VDB(EEN"?-49'KZ>Q_"IO!D[
M:UX-.G9W3)$UMCJ=K+\O\\?\!KMOB7_R3C7/^O?^HKD=,\6Z)H5Y8:3HMA!
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M23S3$44TJ_\ $3+/KZ"VL,Y324?<'&!C[0PX<]?D'R>I>ND5510J@*H&  ,
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 *.HJQ5<=15BJB3(****HD*1ONGZ4
MM(WW3]* *]%%%9F@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5.GW!4%3I]P4XDR'44459(4444 %%%% !1110 4444 %%%%
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MCW_R-:=)SUZ'J\OB/186*OJEL&'4!]W\JGM=8TV]8+;7]O*QZ*L@S^76O#Z
M<'(KUGD%*VDW<U^K+N>^T5Y3H/C.^TN18;IVN;3H5<Y9!['^E>H6EW!?6L=S
M;2"2*095A7AXW 5<(_>U3ZF$Z;AN34445Q$!1110 4444 %%%% !1110 444
M4 %%%% !1110 4448)[4 %%+@CM24 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5.GW!4%3I]P4XDR
M'44459(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%1SS);PO+(
M<(HR: ,;Q9XHM/"NCM>7&'F?*P09P9&_H!W/]2*^=[R[U/Q-K$EQ+YEU>3G)
M"C.!Z =@*]8U[2;+Q%JIOM0264@;8XS*0B+Z #'UJ,IIWA_399DACM[>)=S;
M%Y;T^I/3FLI)R]#T\/RTHZ*\F+\/M$NM$T^ZCNI5+S.K^4O(C.".O<GC\JZ2
M]LS*?-C^_P!QZUSG@'4;W6;?4=1N2%A>8101#H@49/U^\.?:NPH6VA-1OG=S
MF5N(6G: 2IYR_>CS\P^HZUHZ2I;4HL=MQ/Y&H]4O] #;-0GMFD3ICYG0^Q7D
M5=\.W6GZB)KJP#[(SY9+ C)X/&:JY$G[ISWQ4_M&?0K>SL(WDC>3?<!.6VC[
MHQW&>?P%=+X4LDT_PKIENBXQ KGW+#<?YU!XE$*V[RREP?)?;CID#/\ 6MNU
MC\FTAB_N1JOY#%1):D2E^[426JU]?PV$(DFW$L<(B#+,?;_$\59KE=8=GUJ8
M/TC153_=/)/XGC_@(]*25V1%79+)K]\_,45M%[.&D/Y@K_*I(?$-PC#[3;QR
M)_$T.5(^BDG/YC\:RJ*OE1KRH[*">*YA2:%P\;C*L*Y3QUH\\]G'K.G'9J%A
M\V1_''U(/J!SQZ$UH>&W?S;V''[H;''^\<@_HJG\:WZC9F?P2.$TNXBUL:5K
M$6Z*:UD;>@/.&4JZ'VZ'WP/6NLU"]-K:;D_UC':I]/>N;&DIX?UJ2*!-MI>N
M7B(Z*^.4]NY'M]*V[R"*^M@DN_:,C*.5(S[CI5K8J33:[!9EFM49R2QR22<D
M\FLZ]MO(DW*/W;=/8^E:D,<<$*0Q*$C10JJ.@ Z4LL:S1M&_W3Z4%W/(?B'8
MLMS:7ZJ=C*8G/8$'(_,$_E7$5[GK.A?;--FM+CYXI!@2 <J>S8]0:\3O;.:P
MO);6X7;+$VUA_4>QZUE-:W.ZA-.-C.U+_D'3_P"[7>ZE;MJGPL\/ZND>9K M
M93.!SLR=F?8<#ZM7!:E_R#I_]VO>OAQH<5Q\+X;2_CW0WV^0J>H!.%(]_E!'
MX525XV,:\^2IS>GZGD^HRRS31V, )DD(! _B)X KW#2;+[-I,5O)AOW85O<8
MQ7)>'O 5UIGB>ZO=4"R)"Y%JPY$@QPWMQQCUS[&N]IKN14FFDHGGUUH&C6<[
M137;1LIQM:9<_J,U EOX7L+C[0%BEG_O$&3_ .L#[U>\;:$1,=7MTR' 6X [
M$# ;\L#\!7(VUM->7,=O;Q-+-(=JHHR2:8)Z7N=]H?B.QEU=,&151'D=Y %5
M5"DDDD\#W-:'B[7['3+L!X8[N>&V>9+5GR)'#* I'0<%SD\YQ@,1BJ$\-AX"
MT&0XCN=:NHB@5CQR.1[(#^>/R\KO)=3U2]M]0NH"T$[/,\WF+N*HPWN#SA0>
M,XQU&#B@P:4GS=#TL^(_$3:GI<FFPJ]K=0-<737:'R[;&6\LS X' VY([ G)
MRM,\8RZEY<::':V;&[==]R;<J2S$QE_, VG)((Y#=<@@8KR>Y\02NL%O:A;6
MTACV".,8\PY!+.?XB3SSP.V*UO">M"+5W^W7<@@6W9K>-40IO'(!![<'H1G
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M J=/N"H*G3[@IQ)D.HHHJR0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3FY&+XEA%QI+I_&S+&OU=@G_ +-6V>M9<^;O5K>V7[EN1<3<<=PB_7.6_P"
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M=Z]4^$>KV=NFI:=-.C3R%)X[<CE\?+P3@9)9,<]_R\UD6""XA1WE60.&W!0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ J.7H*DJ.7H*3V&MR*BBBH+"BBB@ HHHH ****
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MNN[Z6UTM\C17Y&_)AJ)U#0$M[Q=3FNH6F6.2&=0<@]P0.M:R.I\0.OV^0MY
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M^H[5TG@_66TK68T9C]GN"(Y!VSV->1F674Z]-U*:]Y?B85:2DKK<]=HHHKY
MXPHHHH **** "BBB@ J=/N"H*G3[@IQ)D.HHHJR0HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %1R]!4E1R]!2>PUN14445!84444
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M_P 1^%?293B)5*3A-[?D>/CZ"A)3CLS$\-:Y)H&K)<C+0-\DZ#^)?7ZCJ/\
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MDOF _.5/S$ ')&<]#T&>*RVF\S.%PH!(XZT,Z*:5M1'W #.!&>V<9'K[4_\
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M 4444 %%%% "CJ*L57'458JHDR"BBBJ)"D;[I^E+2-]T_2@"O11169H%%%%
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MBBB@!"< FJ9Y8U8N7,=NS+U[54C?S$#5+-(+2XZBN!\;?$5-!GDTS3(UFOU
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M/X=\/P>'[%H4?S9I#NEEQC<>P ]!_C35Q57!74=38KG-8E>2^*GA$&%_J?\
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M%W:K 95E"R!U*R'9O*'.0<*WS#((.<CC.Z[G%&\JGF<-K=_!H.G2Z+YDDEW
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M@ HHHH **** "BBB@ HHHH **** "BBL7Q/KT>@:4T_#7,GR0(>[>I]AU/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "IT^X*@J=/N"G$F0ZBBBK)"BBB@ HHHH **** "BBB@
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ME7[Y)I-/NH[<XG:%UC/HQ!Q^M>6V?B>2-_*OX>AP7488'W%6<U.*>YW::Y<
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MC,[C.>''3I]TC&<<5P5[=M<21;8V10V2 <Y[<GOQ7J7Q!T9;'P)HUO;HL9L
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M) [9/./>J3UL16A^[YO,Z6BBBK.0**** "BBB@ HHHH **** "BBB@ HHHH
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MG2_])TC4+,#+X$JCUQU_D/SK&K''U76<*W=?DV=.$IJDI4UT?Z"K]X?6O*O
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MBK7Q7,ZE3FHVMU.NHHHK0X@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*I1\SQ<3B/;.RV1KV5G!I]G%:6R!(8E"JH_SUJ>BBMSG"BBB@ HHHH ****
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M&S^AK8MKN"[3?!(' ZCN/J*PHXNC6TA*[,ZE"I3^)$U%%%=)D%%%% !1110
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M1VW1PU(\LF@HHHKB("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MLE]J#/-/,PRQ.XC&?3C]:Z26Q%A!>W&D65L+Z< X/R+(PZ%B/3)K@O#GB9_
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M.2%90P!0H<@X;'S9(ZUQ4]U<1W2ZA:7DBR&=Q976QF!W,#Y;D@ GGJ<DC:,
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M.-O8&9EPT@W$^I;'] M=V.E=$3Q:[7-H%%%%68!1110 4444 %%%% !1110
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M,H@SM!]^23[G':JBM1K17,G6;H1R+I;7-Q9-<K^[GC^4O_LJQ! /MU]*Y@>
M+1KCSWU"[9RVXL=NXGZXKU/['!=6YAN88YHFZI(H93^!IPTBQ  $) '^V?\
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M\._O^%=)112*"BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%05.GW!3B3(=1115DA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBO9_#:D6,A]9#C\A6L4<6)=TV;5%%%:G %%%% !1110 4444 %%%% !1110
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MX130B^[^SHL]>K8_+.*OVVFV-FH6VM((@#GY(P#^=<9;:O?VK I<R,!_"YW
M_G76Z5JT6IPG V3+]],_J/:A6-&WU9H5U.G.9-.@8G)VX_+C^E<M73:2,:9%
M[Y/ZFF8U-ANJ:8FH&SD)(DM+@3I[G:RD?DQ_(5!<SI:6LUQ+G9$A=L=< 9K6
MJK?Z?!J-G-:S;@DJE&9#@XHL9QE;1G@'BO7;K6=38S,0J](P>%'8"N?KV.Z^
M$&GSW#2QZM=(&.2K1JQ_/C^5:6E?##P[IT@EFCEOY!R/M+#8/^ @ '\<UDX-
ML[XXFE&-D>7^%O!6I>)YU:-3;V(/SW3K\ON%'\1_3U(KW31=&L]!TN+3[%"L
M4?)8\L['JS'N3_GBKI,5O!T6.*,< # 4>PK#N]9EE8K;YC3^]_$?\*N,4CEJ
M59UGY&\SJ@R[!1ZDXJ WUJ.MS%_WV*\O\6^*6TA5M[<B2^E7=N?GRU]3ZGT^
MGY\)'XCU3[3YLU_<R ]1YA 'T X%#FD[%QPKDKGT<ES!*"4E1ATX-+F'_IG^
ME<?X9N&M/#"WVI71"2DR*\IZ(<!?<YQD?45;M/$NG7[.MLSN4/(*X./4 ]J=
MS'V9TX=.S+^!IU9$5U#-PCC/H>#4X)!X)!]J=Q<AH5SU[>:C::R86TP/IS)N
M6\2;E3_=*8ZY]\8K C^*.G1:M<6=TLJ1QRM&)63C@XSD9/;N*[>QO[74K5;F
MSG2:%^C(P(I73&XRIZM'/>)R)_ NORH<I_9MSS[^4U<#\,O$&KIK^C:9<MMM
M);)8UCV #:(@RMGJ3P/S->F>,A_Q0OB  ?\ ,-N< ?\ 7)JY?P)IT6HV_AG6
M+5U*6VG)#<CN)%B"C\>?R ]:;7NBC-7E==#8\8^'7OOWZV"7]JP_?0*,3(?[
M\9[^XX/IGI7D?B#PK<Z/FXA$DUD>CLA#Q^SCMZ9_ETKW+Q-XKTWPM9K-?,S2
MR9\J"/EY/7Z >IK@%^,@FNMESH4?V-CM8>?N8#\5P?I6<K=3HP\JMM%='E=>
MI_#S1M>T@VM[)IR1VEU*WG-,,21J$^1PI(X)8CVX.,5VMK?Z/);>=I]I:VLD
MJ;HKA+=2H)'!.W!(Z<<9JUJ.IF?2[M+>/S"(G5Y%=MJ/Y>X#Y>3]Y>!SR>XP
M2,;:BKXB4ERVL>0>.]9;7=?N(KJ\:&RMML0MRX+!@,,6"\9W;N:Y*.>T5)XD
MQ)&W21%PPY[Y]O:J>H,8;FXMY)5EEB=D+QME7()'!'!'O51)64!=F,D'DX%!
MHK))/8](\+&.71[R^BM8Y+:T>-WB,AC=7&"K(1GGY5!/!P3CG@[4MS;OIEW>
M6EM)>[Y#<%2!(R2<9 !.0PSD>W0UQV@ZQ)9^#=6MDCC=FFRP=PA8.% (/4["
M@XX'SCN14?AR\^P^+1MD66"53&6)P(1MR6'88V_EQ5)D6NW8],LM0;3O#LNI
M^([T1PW\:3B)$5VA0LH*8VX8,-N>,C![C-=M&1+9-]DF78P4P[$ \M=JX&./
MKVX-<!9BWL+J6?5K-Y=,EA>W,[_,(8V.XH>?DY8X;KCCC:*[O3ELT4FR:T-N
MX'E_9V&T*.@&.".6/Y5+.:2LR_1112("BBB@ J*XF,$#2!&<@@849/) S]!G
M)]AWZ5+2$CH2!GUH X[QMI;76D.EA.]C>R7<;[X#\TA"\;LX]#CGJ.O45Y'=
M8O\ QGJ%S=H4BMS(TB3Y;"I\H#9/3.!C/0X&>*])\<:Q):Z9%>-]H@MX[R.1
M"T8+ABC_ "J0_P W7<1\N 0.<G'G+WD*W=Y=O?,E_<A9&24, T6S<1NZ[^%&
M,#!Q@]<4D;TW8@\0//::P8[RWM) 65FB)==[%@&(8X;E5 SG&#GJ:S+ZRTS?
M]JANU6W= 5B ;S-P4Y#9R 2PQP2/F!' -9TUQ+<3F=R')[E0"?J<#)]Z%C=T
M!&"".C=.*&S6,+EX+IGV.*:*YG5E7=) Z;BS!@, @<9&3GG' ]ZNVD>E7&M2
MA9V^Q*K"(R')8\[2WW<<XS]?J:Q,NKER-H'#+GKQUJS;+_H$]R=HRRJ,''?]
M>@Y-(T\KGNEA:Q1PQ);Q(NY0,1]#_C]:] LK86EG'".JCD^I[UX_\&[2_N;Z
MYG>1O[.MU&$;D&4],>F!DG'M7L]:P=U<XL3I+D"BBBJ.8**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *CEZ"I*CEZ"D]AK<BHHHJ"PHHHH **** "BBB@
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MX&O&N_#4:N<M YC_  X(_F:Z2O@\12=&K*F^C//DN5V"BBBL1!1110 4444
M%%%% !1110 4444 %%%% !1110 HZBK%5QU%6*J),@HHHJB0I&^Z?I2TC?=/
MTH KT445F:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8/BKQ
M-"T[]W@W<V1$#V]6_"MZO(/&&H-?^([@YS'"?*0>PZ_K7I95A%B*_O;+5FE*
M'-+4Q9II;F9YIG9Y'.69CDDU'6 VKZI/JM[:6-G;2+:E03)*5)R,^E2V^O\
MGZ1J%T;<QW-BK^; S9PR@GKZ'%?61Q5+9:;].V]CL4XFU17-?V_JL&FQ:G=:
M= ;)T5V,,I+JK8P<$>];!N+N2[M3;11O92)NDE+88>F!50Q,)[7Z='UZ^@U-
M,[KP;XFDTZZ2PNG+6<IPI/\ RS8^GM7J%>!5[+X7OVU'P]:S.<R*OEL?4CBO
M SS"1C:O%;Z,YL1!+WD;%%%%?/'.%%%% !1110 4444 %%%% !1110 4444
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M&64\$%<@BN8O? VGSW EA,MN,Y:)>5/T[BM+'*JE]S(\+PM'IC2,"/,D)7W
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MU9U$?B2U8XDAE3W&#6E;7EO=KF"57]1T(_"N%IT<CQ.'C8JPZ$&LZ6;UHO\
M>*Z^X53+Z;7NZ'?T5DZ1J_VT>1/@3@<'^_\ _7K6KWJ-:%:"G!Z'E5*<J<N6
M04445L0%%%% !1110 4444 %%%% !1110 HZBK%5QU%6*J),@HHHJB0I&^Z?
MI2TC?=/TH KT445F:!1110 4444 %%%% !1110 4444 %%%% !2,0JEF(51U
M).!3)YTMH6ED/ Z#U/I7-W=[+=OESA>RCH*:C<YJ^(C2TW9MR:M9QG&]G/\
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M+_CPM_\ KFO\J[;XAZ#<$W6KVZ&6&2$F;;R4(7&[Z8 YKB;+_CPM_P#KFO\
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MI-;L@MT,PGS0=XR1GV&01D^AI^I^+O#VCW!M]0UBT@G'6-I 6'U Y'XT<K[
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M.U>J:?9KI^GP6J_\LUP3ZGO7T&74'36IP8^HN11[EFBBBO5/*"BBB@ HHHH
M**** "BBB@ HHHH 4=15BJXZBK%5$F044451(4C?=/TI:1ONGZ4 5Z***S-
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MNZNC6%&,9-25SI=*^,JE@FK:844_\M;5\X_X W^->DZ9JMCK-DMYI]REQ W
M9>Q]"#R#[&OF*:SN;>[:TFMY4N5;:8F4[L^F*](^'NF:IH%XU_<R-##*NU[3
MJ7'8MZ$<X[_3D%1;9-?#4U&\=&=5JEO)_P )9?74@(011Q1<]1M#$_F<?G7&
MZ]K4]U(UM97,D$*G!DB.&<_7L/I75?$:Y:TL8+J(D6]R-LDH[8&0/Q'\C7CE
MUJ4TY(C)CC] >3]352E85"#DDT:B-/9R^8NL7,3^IF(S]>>:W]-\7/"!'>7$
M5VO][*J_Z<'_ #S7G];_ (9\'ZMXIN=ME#LMU.)+F3A$_P 3["H4G?0Z9P25
MY,Z23P?IVM7"76E#<DK@20*<;<]<#MZX_*O4[#PG:VWB6[UR54>XEPD*@<1H
M%"C\<"E\+>$=/\*6/DVQ:6=A^]N).K>P'\(]OYUT%;1C8\NM7<G9/0****LY
MPHHHH **** "BBB@ HHHH **** "BBB@ HHHH *\V^-__(BP_P#7]'_Z"]>D
MUQ'Q4T#4_$?A.*RTFV^T7"W:2%-ZK\H5@3EB!W%73=I(:W.<\8?#_0-(^&-S
M-;6@-];QI+]K<YD=BPW9/H03QTIVA^ M"NOAA)J-W;&YU&\LFN6NYF)='VDC
M:>V,#Z]Z[3QII=YJO@/4--LH?-NY855(]P&2&4GDD#L:31=*O;7X=6VE3P[+
MU=/,+1;@</L(QD''7WJ^=\N_4+G*>"+F6Y^!UZ)6+>5:W<:D_P!T!B!^M8]G
M_P FVW'_  +_ -*:Z?P?X;U;3/A7?:->6GE:A+%<JD)D4Y+J0O(..?K5&V\*
M:W'\$)O#[61&JMNQ;^8G_/;=][.WISUIW5_F,9X;^'?AZX^'$=Q<68GO;VR\
MXW,AR\;%,C;Z <?7'-4O!^N7FG_ K4;R*1A-:&6*!NI3)&"/H7)KT/0-/NK+
MP1I^G7$6RZBL$A>/<#APF",CCK7+^!O!M[!\-[[P_KENUK)=22@@.K%0R@!O
ME)'49_"ES7O?N%SBO"DN@0>%8X;WP'K&J7%PK-->K8^9OR3]Q\Y QCD8K>\#
M0ZI:?#+Q/97]I>6T$4=P;5;N(HVQHR2 #[\_4FIM#/Q#\&Z>NBIX?M]7M(&(
MM[B.Y5/E)S@Y.<<]P*ZRW3Q+JO@O5HM;L[6#4KB*:."WMWR ICPH))(SG/.<
M=*J4OZN#.*^%?@70]1\)1ZMJ5HMY<7,C!?,SB)48@!<'KD$Y]ZLW^H?#O3=?
MU&W30)M;U*69Y+KR+7[25<G+ ;C@<G^'I75?#C2+_0O ]EI^I0>1=1M(7CW!
ML9=B.02.A%<;HVD>-_ VJ:M;Z7H=OJMM?3>9%<M.J8ZXW9(/0\CUZ&E>\GJ
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M14445!84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%86<5M#&B)&,;4&!GJ>/K3C"SN+$5^:/*CE+ZTOK/Q\E["JFTNHU6<LV.Q7
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M%% !1110 4444 %%%% !1110 4444 %1R]!4E,E'R_C2>PUN0T445!84444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 HZBK%5U&6
M%6*J),@HHHJB0HHHH AD&'^M,J=UW+[U!4-%IA1112&%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4V
M2-98GB;[KJ5-.HH$U=69R4L3PRM&XPRG!JO<VMO>0-!<PQS1-]Y)%# _@:ZC
M4-/6\7>F%F X/9AZ&N.U'5[32[EK>[,B2KU7RS6G,K'BUJ,J4O(98:!I&ERF
M6PTRTMI#U>*)5/YBA] TB2^-Z^F6C71ZS&%=Q_'%9=QXQME!^SV\DA_VR%']
M:P[[Q%?WH*>8(8S_  Q\?KUI.HD9>]W-_5=:M=)M?L.G+&'4;0L8 6/\JB\
MZ3)J.N_;Y03#;'>6/=^W^/X5E:#X8O\ 7IQY2&.V!^>=Q\H^GJ:]@TO3+;2-
M/CL[5<1IU)ZL>Y-9W<G=G9AJ#E+F>Q<HHHIGJ!6+XBLS+;I<H,M'PWTK:I"
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M12@%N@H$)4D:=S3EC Y/)I]4D)L****HD**** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH KW]HFH:=
M<V4C,J7$3Q,R]0&!!(_.JV@Z/%X?T&RTF"1Y(K2(1*\F-Q ]<5HT4 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %! /4444 ,
M,:GVI/*'K4E%*R'=D?E#UH\H>M2446079'Y0]:/*'K4E%%D%V1^4/6CRAZU)
M119!=D?E#UH\H>M2446079'Y0]:/*'K4E%%D%V1^4/6CRAZU)119!=D?E#UH
M\H>M2446079'Y0]:/*'K4E%%D%V1^4/6CRAZU)119!=D?E#UH\H>M2446079
M'Y0]:/*'K4E%%D%V1^4/6CRAZU)119!=D?E#UH\H>M2446079'Y0]:/*'K4E
M%%D%V1^4/6CRAZU)119!=D?E#UH\H>M2446079'Y0]:/*'K4E%%D%V1^4/6C
MRAZU)119!=D?E#UH\H>M2446079'Y0]:/*'K4E%%D%V1^4/6CRAZU)119!=D
M?E#UH\H>M2446079'Y0]:/*'K4E%%D%V1^4/6CRAZU)119!=D?E#UH\H>M24
M46079'Y0]:/*'K4E%%D%V1^4/6CRAZU)119!=D?E#UH\H>M2446079'Y0]:/
M*'J:DHHL@NQH11T%.HHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0]#7503)<0K+&<JPR*1W4:ZJKS)****#<**** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M**RNOW@MF@V93/.TY)##/1LXXR.:](^(_P 1HO!6A6MQ:PI<WU_G[*CDA0H
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M"@D#Z@D_\!I*YVWG,7Q+LBG4.B'_ ($N#^AJ).UAT)<M1,];HHHIGLA1110
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M]B^;N>OT5\Y>(OASXH\'^%AXI7Q/=/?0^6]U$CNK1[B!P^X[L$C/ [UNZO\
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MP]I7AK3A8:/9I:VVXN54DEF/<DDDG@=?2E)IZCBFM#S+]H;_ )%'2_\ K_\
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M):,WP$\'L!D*+,GV_P!&:K+:YIWB+X"3:'I=V)M4M-,CDGMD4[T6*1-Y/'3
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M5UG1?[26[N?]/M3C$2R!C\V00<!5!!P,GK7K:00QR-(D2*[_ 'F50"WU-2$
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<EXG\$0:SONK%D
MMK\\DL/W<A_VL=#[C]:ZVBM:->I1ESTW9E1DXNZ/GG6-#\6Z3(4GTB39SB6W
MC,JD>N1G'XX-<U(VI7+F-EN&8\;%0C/X"OJNBN_^U:LE:6OS-?K$NI\VZ/\
M#_Q+K,H$6FRV\60&FN@8E'OSR?P!KV+P;\/M/\*@7+L+K4B,&=EP$SU"#M]>
MI]NE=A17+6Q=2HK;(B51R"BBBN4S"BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
=BB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img187419207_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img187419207_3.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 1)"'L# 2(  A$! Q$!_\0
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MX]*OD?+S#L=71114""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU6-O9>.8WMXDC^TV:32!1C+[G7/Y**TY8<W)8>E['O>L:U8Z'HT^K7LN+6%
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M&NBN+Q-0N/#=W']R:5G'MF)N*])3N:\Q?M=:CGOA8W%M/9W9!9(YP,2 ==K
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<22.,\!4 P,#O@_A6OXFTK4-$^ ^GZ?J<7E745V"8]P)4%W8 D<=#6I\"+6
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MD:Y*!22'QU(P2#Z8%>RT4O:/GY@OK<\#T7XVZCIFD06-WI45Y) @C6;SC&2
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M4.K%ZN.H[GGOQC,DGPY1Y$VN;B$N!_"<'/ZU4^!(/_")Z@<<&^/_ * E>I$
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M(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P VKO*;V$MPHHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MD<!G).!@?7BK] !1110 4444 %%%% !1110 54U748=)TF[U&X/[JVA:5O<
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M$*,$*YZ'D#):L3X(^'M,N-%N]9GM4FO1=- CR ,(U"HWR@]"2QY]J7)%)M]
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M_'/F/R0?IG'X4SXB?\D^UO\ Z]C_ #%)6Y] ZG"^#OB3X>\*^ -'LKV6::[
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M;3>28C'\\C<\J >G'4XJSX9^)'A[Q7>_8K*6:&[(++#<H%+@==N"0>.<9S7
M?"K0--U7Q9XCOKZV2XELK@"!9 "JEVDR<'J?E&/3FK?CFRM],^+_ (3N[.)(
M9+J:)9?+&W=^]"DG'?#8_"K<(WY1V1Z=KWB'2_#6GF]U6Z6"+.%'5G/HH')-
M<I8?&/PG>WJVS27=J';:LMQ$%3ZY!.![G%<=\2[YKCXJZ5:3:?<:G:V<*.+"
M%2QE8Y8X&#G.%SQT6K'C'7K_ ,5>&Y-,'P]UF&9=IMYC:N?)((Z83H1D8]Z(
MTU97ZA8]G5@RAE(*D9!'0U3U?5+?1=)N=2N]_P!GMD+OL&3CV%9/@)+Z/P-I
M$>I0S0W<<.QXY@0Z@$A<@\CY0*C^(G_)/M;_ .O8_P Q627O6),:[^,GA2TB
MMG#7DYG3>4BB!:(9_BRP /L,UU&K>)](T/1X]4U&Z$-O(H:,$9=\C( 7J37%
M_"3POI*^"(-2FLX;BYOS)YK31A\*KLH49Z#Y<^Y/TKFOB3>F;XIZ392:;/J-
MI90HRZ? N3*3EC@ '(P%SQT6M.2+ERKH.RN=E8?&/PG>WJVS27=J';:LMQ$%
M3ZY!.![G%=XTL:PF9I%$07<7)^4#KG/I7C7C'7K_ ,5>&Y-,'P]UF&9=IMYC
M:N?)((Z83H1D8]ZNZ]>:IIOP#MHKQ)[>]DC2UD60%75-Y&"#R,HH'XT.FM+:
M!8VKWXS>$[.\:W1[RY"MM,L$(*?@202/H*[#2-=TW7-)34]/N5EM&!RY^7;C
MJ"#TQ6!\/O#^FV7@/3%6T@<WELD\[,@8R%QN(;UQG'X5E_$2VM?"OPQU&UT:
MW%G%<2A"L6<#>PW_ $! (QTYJ6HM\J#0EOOC'X3LKQK=9+NZ"MM:6WB!3\R1
MD>XKK-"\0:9XDTX7VEW*SPYVL,89&]&!Y!KRKP=XHFT+PI;6-KX U:ZCDCW2
MW$=NQ6Y+<[L[#D<\>U6_A39:I9^+M=D?1+[2]+ND,D45Q$R*IW_*HR!G 9NE
M5*FDGY T=-)\5_"L-O>2RW,R/;3&$PF/YY&&?NC/3CJ<5/X;^)GASQ1?"QM)
M9H+I@2D5R@0OCT()!/MG-<'\*=!T[4_%OB._O;99YK*X @$@RJEVDRV/7Y1C
MTYJ7XPV4&C:_X>URPC6"\:5MYC7&\H5*GCOR1^5/DAS<H[+8T/B[XV2PM/[#
MTZ\O;754ECE>2!C&/+*GC<#GN.*W_!7Q#TCQ$;/287NWU!+56E:6/AF50&.[
M//-9GQNBC_X0F*7RU\S[9&-^.<;7XS7:>&K:"+P[I<D<,:.;.++*H!/R#O4O
ME]FM!="EXF\=Z!X4=(M2NB;AQN%O"N]\>I'8?7%9NA?%7PQKU]'913SVMQ*=
ML:W2! Q[ $$C)^M<?\.K.#Q-\1/$NMZG&MQ+;2XA649";F8 X/\ =5 !Z9K1
M^-FBV7_".6^L1PI%?0W*IYJ##,I!X)'7! (].?6GR1ORO<=EL=SXE\6:9X4B
MM9=2,H6YE\I#&F[!]3R,"L:R^*7AS4?$L>AV;74TTLGEI.L8\IF]CG...N*X
M?XK74NH?#WPE=SDF6X1)')ZEFB!/ZFO5-$\+:/H.GVMI:6,&;<969HP9"V.7
M+8SD_P#UNE)QBHW>XC$\0?%'PYX=U%]/G>YN;J/B1+6,-L/H22!GZ5L^&?%6
ME^+=/>\TMY"D;[)$E3:R-C.#VZ'L37EBW&J_"[QKK.I7VC27VF:C*SB\C&2J
MEBP^;H#SRIQD@<\5Z?X3UO0/$%A-?Z$L2"23-P@B$;A\?Q@=3COS]:)Q25T#
M1OUP7P\3PHNHZZ/#<-TDT<JI=>?TZO@)STR&_2N]KR7X-?\ (:\8?]?4?_H4
MM3%>ZP.LO/B5X:T[4M1L+VYD@FL/]9OCX<\<)CECSZ57T+XJ^&=?U2/3X);B
MWGE;;%]IC"K(W8 @GD]LXKBM'T+3]=^.FO)J, GBM@]PD;<JS@HHW#N/F)Q]
M*L?&S3[6PCT34[2"."Y28Q[XU"D@ %>GH1Q]:TY(W4>X[(]CHHHK D**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#@_BE_QY^%_^QCL_YM7>
M5P7Q4.W3O#DG]SQ!9MCUY:N]IO82W"BBBD,**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%X?&GPH;D1$:@(BV//-N-GUZ[OTK7^(+>'I?"!F\0+<2:=YL;J;;[^X_=(_
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M$'AWQ;=O^XU.\E5V/]W=L<G_ +[)_"N[U%?^$J^/-I:_?M=%B$CXZ;E^;/\
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M"&.W<=V"0#M(8G&1@@_ED^./^$T\916NH3>'KJUT^&81P6:Q,\N2,EV&,XX
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MRQRS[&& 2,8;D CGFN@:T\1?$_QAIMWJ&C3Z7HM@0^V<,-PR"<$@;BV .!@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3T"PBTFT;2+FU@7RX9I#RJCH.Q_,&MGP3X&U#1]:O?$7B"_CO-8NU*GRA\B
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#@OBM_R"-
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MI+A6:T\^$NH.TG'!'J.1^%>>:-XL^)/C&R670UMX8[5=DT[H@$\G7 W#'3'
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M>NH^.7FKX=T3SBIE$YWE>A;9SCVI_P #R-OB->XN8\C_ +[I?CO_ ,@71_\
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MTNYT^Y+B"YC,<FQMIVGK@T.3EN%SQKX(Z%'-K.IZX%8P6X^SVQ<<DMR3]0H
M_P"!5[A67X?\/:?X8TI=.TR-D@#%SO;<S,>I)_+\JU*=27-*X-W"BBBH$%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '!?%CY
M=#T63_GGK=HV/7DUWM<#\6O^1=TK_L,VO_H1KOJ;V%U"BBBD,**** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#@?BU_
MR+NE?]AFU_\ 0C7?5P/Q:_Y%W2O^PS:_^A&N^I]!=0HHHI#"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X'XM?\B[I7_89M?_0C
M7?5P/Q:_Y%W2O^PS:_\ H1KOJ?074****0PHHHH **** "BBB@ HHS1F@ HH
MS1F@ HHS1F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:*2ES0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 44C,%ZFF[B?8?K0 _-)FF[
M@*3=0.P_-(6IA:FEJ5PL<-\7#GPG:?\ 83MO_0Z[S)KS_P"+39\)VG_83MO_
M $.N\!XIO8$M6/S13:*0[#J*;10%AU%-YHR:!V'44W<:-U K#J/PI-U&Z@+"
MTM-W4NZ@+"\>E&1Z4F:* L+D>E+D4VB@0[CTI>/2F49IA8?Q2\4S-&: L/HI
MF:7- #J*;FC- AU%-S1F@!U&:;FDS0 _-+FH\TFZ@"7-%1@EN@X]:<%]30 Z
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BH+F]MK-<W$R1\9 )Y/T
M'4UG-XFTY3@-(WN$_P :TC2G+6*&HM[&Q16;!KVFSL%%P$/_ $T!7]3Q6B""
M 0<@]"*F4)1^)6!IK<6BBBI$%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)W=1S4.DW,\WA-4NI3+-%*T!D/\ %M8@'\A4D \36MDFGI;64C1J(TO#,0,
M8!*8SG'O426L>F:=;Z9%(91!DR2'^)R<D_F35TU[RLBHK4]>\+R&7PS8,W41
M;?P!(_I6O5+1[1K'1K.V< /'$H<#^]CG]<U=KP:C3FVNYRRW84445 @HHHH
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MRK$VZEW5#NIP--,5B7=1NJ/-+FJ0K'%_%0Y\+6O_ &$K;_T*NZ#<5P7Q3/\
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 <]XL<BSMT[&0G\A_\
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M825FM9X<<?ZDC]<56CT_4KUP8[2ZF8\9$;']:]!6M>YMH3W>J[@4M\@'J_\
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MWCR?TQ^9IDMV5S3CC6*-8T&%48%.HHJC$**** "BBB@ HHHH **** "BBB@
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445C:GK1AF:RL
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M096"&,R.1ZX':GZ=J]GJ@D^S2-YD1VR1.A1T/N#S69H.)/$&ORR<SB=$YZA
MOR_A1,(T\>V[QD"1K!_.'^R'&T_GG\J.9[CNSO\ P%?/+9WEA(Q8VTNY23_"
MV>/S!/XUU]>>?#YF?6+]Q]QH\GZ[N/ZUZ'7DXV*C6=C"JK2"BBBN4S"BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %0W5K%>6[P3+E&'XCW%344TVG= >?ZOILND9DFR
MUOGB4#C\?0UBOJMJO1F;Z+_C7K) 92K $$8(/>L2Z\(:'=N7-DL3'O"Q0?D.
M/TKTJ6/5K5%]QO&JNIYM+K#D8BC"^[<U3'VF^N%11)-*QPJJ,D_0"O2X_ FB
M(V62>0>C2_X8K:L=*L=,3;9VL4.1@LH^8CW/4_C6LLPIQ7N*[*=:*V.;\*>$
M3ISK?Z@ ;K'[N+J(_<^I_E_+L***\NK5E5ES2,)2<G=A11169(4444 %%%%
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MX$,L,[JS<<%!BI+VYBU#Q;I$-HR3FU\V6=T8$1J5V@$^Y[5JRZ)I<\$,$MA
M\4((C5D!" ]<58M+&UL8S':6T4"'J(T"Y^N*OE8[,P_"4B0VM[8R,JW4%W+Y
MB$_,03D-CT([U'974<_B#6[Z AK=(HX!(IRLD@!)P>^,@5K:AHNE:@WG7UG#
M(RC_ %C#!Q[FLZ>2$(EK9PI%;1_=1%P"?7%5"#NET0*+.Z^',9%A?2_PM*JC
MZ@?_ %Z[6L?PQIATG08()% F;,DO^\>Q]P,#\*V*\3$S4ZLI(YIN\FPHHHK
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK3,SM-%YT+3SC&;:,_\ CHJ]5#0O^1?TW_KUB_\ 0!5^MCSWN%%%% @HHHH
M**** "BBB@ HHHH **** "BB@D 9)P* "BD!! (((/<4M !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!2UC4X=%T6^U6Y61X+.![B18P"Q55+$ $@9P/44NDZE#K
M.C6.J6ZR+!>V\=Q&L@ 8*ZA@#@D9P?4UD^/_ /DG7B7_ +!=S_Z+:G>!/^2>
M>&O^P5:_^BEH Z"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% '.^/_\ DG7B7_L%W/\ Z+:G>!/^2>>&O^P5
M:_\ HI:;X_\ ^2=>)?\ L%W/_HMJ=X$_Y)YX:_[!5K_Z*6@#H**** "BBB@
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M?Q^7=6DICD'.#CH1GJ",$'N"#2Z'HUYXAURSTBP3?=7<HC0'.!ZL<=@,DGL
M: /N>RO[/4H//L;N"ZA#;?,@D#KGTR#UJQ63X:\/V?A;P[9:-8KB&VC"[B,%
MVZLQ]R<G\:UJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-YHDGW=1*^5/_ 1A?TIV(=1(S7N84?89 9/[B_,Q_P" CFI%%Q(X$=G.5/\
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MD HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !6+XMT5?$/A74=+P"\T)\K/:0<K_ ./
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MG!Y&.>PJEJ/AWQ7X-\0ZKX@\+_9[^ROY#/=64H^?.2QQTSC<V,'/.,&MG0_
M%W;^)8O$'B#79=7OX$*0 Q"-(\@CIGGJ?3KFJUUX"\2B>[CT_P ;W<%A<N[&
M&2'S&C#$DA6W>_;%%XWT SO$OBP>+/@MJ6JVD+0.62&>,MG8?,3< >X((_ T
MSPS;>/G\'Z;#IH\,G39+5?+202EBK#G?CC<<G/OFNST;P7I>C^$G\.;6N+69
M6$[2=9"W4^W;&.F!7,6WPW\0Z/&UIH?C:YM=/+$K#);AS&#Z'/\ ("A2C9I
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(/H<F*A9J1<HHHJSD"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *Y;69WEU!U)^6/Y5%=37(ZG_ ,A*?_>IHX\:_<154E6!4D$="*T;
MN"-Y$EFF6)W0%TQD[N_ JOIX!O%9AD(K/@]\ D57=VD<NY)8G))IG"FE'7J7
MGA5=+<12K*!*&.WJ!@CD4EK$%LYC,XB650$+=3@@]/PJ"QD,=Y%W#,%8>H/!
MHOI#)>2]E5BJCT X%(KF5N;Y$\%C#-*-MPKH,EE (8@>@J.34)\[86,$8^ZD
M?&/KZU61VC<.A(93D$58U *+MF4 !U5\#MD TQ<WNWCH:FDZI)-,+>X;<3]U
MN_T-;=<AIIQJ5O\ [XKKZ3._"3<H:A1112.H**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_(2G_P!ZNNKD=3_Y"4_^]31QXWX%ZB:?_P ?#_\ 7)__ $$U5JUI_P#Q\/\
M]<G_ /0356F<#^%?,EMO^/J'_?7^=%S_ ,?<W^^W\Z2#BYB_WU_G2W/_ !]S
M?[[?SI!]CYD56;[_ %L?_7&/_P!!%5JL7G+Q?]<8_P#T$4Q+X6+I_P#R$;?_
M 'Q785QU@<:A;_\ 71?YUV-)GH8+X'ZA1112.P**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBHVEQPOYTF[ 24TR*.^?I4))/4TE+F*Y24R^@I/-/8"HZ*5V.R'^:WH
M*/-;T%,HI7860_S6]!1YK>@IE%%V%D/\UO04>:WH*911=A9#_-;T%'FMZ"F4
M47860_S6]!1YK>@IE%%V%D/\UO04>:WH*911=A9#_-;T%'FMZ"F447860_S6
M]!1YK>@IE%%V%D/\UO04>:WH*911=A9#_-;T%'FMZ"F447860_S6]!1YK>@I
ME%%V%D/\UO04>:WH*911=A9#_-;T%<OJ?_(2G_WJZ6N:U/\ Y"4_^]5Q9PX[
MX%ZB:?\ \?#_ /7)_P#T$U5JUI__ !\/_P!<G_\ 0356K//?PKYCXN+B'_KH
MO\Q3KG_C[F_WV_G4<9Q/#_UU3_T(5)<_\?<W^^W\Z0?8^9%4]UR8#_TPC_\
M014%37'2W_Z]XO\ T 4 OA?R%LO^0C:_]=5KK/-;T%<E9G_B96?_ %V%=54R
M9Z&!^!^H_P UO04>:WH*91479W60_P UO04>:WH*911=A9#_ #6]!1YK>@IE
M%%V%D/\ -;T%'FMZ"F447860_P UO04>:WH*911=A9#_ #6]!1YK>@IE%%V%
MD/\ -;T%'FMZ"F447860_P UO04>:WH*911=A9#_ #6]!1YK>@IE%%V%D/\
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M]!2@5'GS'R?N(>/<_P#UOY_059D*N<EV^\>@]!Z4$T$TRD-(1LD8!Q[T  #
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M)VCI4=%%9MW+"BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %<UJ?_(2G_P!ZNEKFM3_Y"4_^]50.#'_
MO433_P#CX?\ ZY/_ .@FJM6M/_X^'_ZY/_Z":JUH>>_A7S!>)H?^NT?_ *&*
MEN?^/N;_ 'V_G4.<2P?]=XO_ $,5-<_\?<W^^W\Z74/L?,A8X4GVJ>?[MO\
M]>\7_H JM*<0N?\ 9-69_NV__7O%_P"@"CJ"^!_(;:'_ (F=E[SC^1KK*Y*V
M/_$TL/\ KX'\C76U$ST<#\#]0HHHJ3N"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!Z/M.#TJ:JU6%.5%5%DL
M6BBBJ)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?^>J?*__ 'T,']:XCXHQ0VWPEU.PCF5F@BMTP2-V%ECZCZ"N^CD66))$.58
M@^U2_A7]=CG6DG8J"VNX"/(NS(@S^[N!N_ ,,$?4[J47LL95;JSF0GC?"/-3
M/X?-^)45-/=6]L5$\\<9?[H9@"WT'>HEO_,+>3:74@'<Q^6/_'RN?PJ2]R.=
M;+6K5X8[A'*-D-&P+1.._L?8]B16!<:=?6C8DMVF3.!);J6!^J_>'ZCWK<EB
MN+[ N=*LV0<CSILL#^"'!_&FM9WJX-NYA/H+UG!]L/&P'X8IIV*3L8'DS_\
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MHHHK8\X**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP4XDR'44459(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_:H66&(9+>4"?X7* G\.M.#1QL(QM4MS@=Z=AMWW.1^*"JGPTU=5  "Q<?\
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MD3> 0<,.5..E"/O7D8(."/0TB,<E'^\._J/6AU(.]1\PZC^\/2@95U*Q^V0
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MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KFM3_P"0E/\
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M%1 L<4:@ = J@?RQ57^T#./] A-QGI*3LB_[Z[_\!!_"D3N7:S+K6[:"?[-
M&NKK_GE""VW_ 'B,X'Z\]*CNH;BXE%J]P9)7!9E1=D42=,L,Y8GD $X/)Q@&
MK]G96]A (;>,*O&3W8XQD_@/PZ#B@=DMRA#%J,TJ74MO&)NWG/Q"/]E%R#]2
MP)]AQ4]P+E2OG:G' IZ>5" 3Z_>+5))?^7.ZF/\ =(0'<MC'&<X]!D=_7TYC
MN0OVULC+>6OY9;_Z]-(+W"\MI!:$->7$F64$-L7(+ '[JCMFJ\L*R2*[*CX!
M!5QE3GU'?']34OFL]O#"593'C>3T; P,?7K2$A022 !R2>U4D)#8HEAA2)
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M444 %%%% !7-:G_R$I_]ZNEKG=6C9-1D)'#X93ZBJ@<..7N+U(]/_P"/A_\
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MQ7PVM2FDW=T1S--MSZA1_BQKM:,8Z44F 4444#"BBB@ HHHH **** "BBB@
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MT"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-MN/1/[W_ L _0#WK3J6S.<N@R:&.XA>&9 \;C#*>]92^&[0,-T]TR YV&3
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M[U;_ )!<WT'\Q7M?@ZY8>#-.CSP%?_T8U;4_A^_]#S\7&\G\O_;CJU\0RQ2
M7-LKQ_Q/"3D?\!/7\#GV-7K.:%K^8P,&BND6X1U.0Q'R-^0$?YFN:)R<U/IL
M[6U\@RWE!O,PO/WB$8?3+(W_   GO3:.9Q5M#KJJSV2RR^?$Y@N<8\Q!]X=@
MPZ,/K^!%6@*D"U*1C>Q0CO&258+Q!%*QPC@_)(?]D]C_ +)YZXR!FK=$\$<T
M312HKQL,,K#((J@6ETX_O&>:S_ODEGA_WN[+[]1WR,D%A[E\5AWMXXU.='!
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MUF*Q11J,,L#,=HV(TJ,?9@/T(!]JIV\-N\SW>@W"1RX!EM'!5'';*D90\8#
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MIB@[Y1YI7_:QG'YN:]-P#U%& >U%QV(;2W%K906Z_=BC5!^ Q4U%%(84444
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M++(N<[0"/E'T /XD^M35%+'(UO)"MS*B.K*PR&P#UP3R/SXI&<16H:/]Z%
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M:O'6Y9HHHJSG"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ J.7H*DJ.7H*3V&MR*BBBH+"BBB@ HHHH ****
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M#J***LD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;*EMPR,9Y)[58Z57C(-TYBYC89<]MXP.#]!@^F!2N[S2-%"=H7AY,=/8>_\
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M+$<,?KV;\0:DL!Y)FLB#B @Q\8'EMG:!],,O_ :L/'FHDGT&G;0IK=W%L?\
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M 4444 %%%% !4Z?<%05.GW!3B3(=1115DA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %<7K8DNO&441;]PB1 #T92\C'\<1
MBNTKB;<_:?%VJSEB1&^U0>V0B?SB;\ZF6QO0^)LU9!E0F1\[8Y[CJ1^0-3&H
MAS../NK_ #__ %'\ZD)J#88:CESY1 ."WRY';/&:D-1L-TJC (7YL^AZ#^M
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MI&"#W%;%A++?Z1+;[M]Y:$&,L>6QRA)]\%2>^&]:;5AN-M4;?F@VWG*,@IO
M]>,UQ,"[;>,;MQVC+'^(]S^-=9HTGG:%I\A_BMHR<_[HKF);9K"X>S?/[O\
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M!@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M"CJ*L57'458JHDR"BBBJ)"D;[I^E+2-]T_2@"O11169H%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1165XDUK_A'M N=4^S_:/(V?N]^S=N<+UP?7/2@#5HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH ***B\[_2O)V_P;\Y]\4 2T444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 *.HJQ5<=15BJB3(****HD*1ONGZ4M(WW3]* *]%%%9F@4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %<K\2/^1!U+ZP_^C4KJJY7XD?\B#J7UA_]&I0(ZJBB
MB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5.GW!4%3I]P4XDR'44459(4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %>_<Q:==2+U6)V'X
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %<K\2/^1!U+ZP_P#HU*ZJO"?'WQCLYK'5/#4^AWMO>)*L;EW4
M@%)%8_@0O'UH0F>[45YYX'^*]MX[UF33['1KR%8HS)+/(ZE4'0#CN3_6O0Z
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !5;_ )B?_;'_ -FI]U<?9;=IMA<+U ]*R/[;B^U^=Y3X
M\O;C(]<T"-VBH;6?[3;K-L*!N@/I4U PHHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!1U%6*KCJ
M*L5429!1115$A2-]T_2EI&^Z?I0!7HHHK,T"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M KPGX_>"6F2#Q780EI%VP7BHN<CHC_\ LO\ WS7NU-=%D4JZAE/4,,BA.PF<
M3\*_!@\&^#X8ITQJ-WB>[)'(8CA/^ CCZYKN*** "BBB@84444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!4Z?<%05.GW!3B3(=1115DA1110 4444 %%%% !1110 4444 %%%% !1110
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M(S]*T:6.Y6ZO @9,^5$ISM)XW$^N#C X&3R>,3(!_9$4P.1+=I,#_LM."/\
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M% !1110 4444 %%%% !1110 HZBK%5QU%6*J),@HHHJB0I&^Z?I2TC?=/TH
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MD)XW)&/H$!_FQJ63&W![G%0:?AK9I@<B>1YE/JK,2O\ X[BIFSO [<FJ1M%
M>M$ ^7.,;CFF/RN.>>.*G08K2)4MATDJP0O*Q 6-2Q/L!FMG2HI(-(LHIAB5
M($5_]X*,_K6#>@/:F$@D3LD! ]'8*?YUU-:Q..L]D%%%%6<X4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5'+T%25'
M+T%)[#6Y%1114%A1110 4444 %%%% !1110 4444 %%%% %/4I=D 0=7/Z4Z
MWMQ]A\L]7&3^-4[HM<WWEICCY1_6I?LM[_SW_P#'C5=">HW3G*3/"W&>WN*M
MWLIBMF*\$\9K-D26TN4=SEL[L@]:NZC\]HK+R-P-#W#H1V5G')#YD@W9Z#-0
MWMJ+=@R'Y6['M5ZP<-:(!U7(-5]3=2$0'Y@<D47U#H6?,\K3U<=1&,?E5*SB
MADW23NI.> S8_&K,R[M+ ']Q3_*JUE;0W$;%RVX'H#VI+8 O8H$57A9<YP0K
M5=60RV!<]2AS3/[-@_V_SJ5HUBM&1>@4T7 S;*V%PQ+'Y%ZCUJ:^M(XHA)&-
MO.",T[2_NR_45-J/_'H?J*=]0MH1%3<:6I/+*,C\*=ILNZ%HSU4\?0U)8?\
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M+N+8Z< !<^YR?:NC^&G@O4O!]OJ2:C+;2-<NA3R&9L!0W7('K7>442JR:MT
MX7XC> 9/&,%M/97$4-]; JOFYV2*>Q(SC';CO6?X,\*^-M-UVVN-<UDRZ?;1
ML@MQ<N^_*X'&,<=<GTKTJBDJDN7E \U\:_"PZYJIUG1;U;/4'8-(KDA&8?Q
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M8OF^7GY\;L>U.JM_S$O^V/\ 6@19HHHH&%%%% !1110 4444 %%%% !1110
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M]A^'6UZ\BQ?ZDH,>>L<'4?3=U^F*]:I,$%%%% PHHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"IT^X*@J=/N"G$F0ZBBBK)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-02:%J4;[8C;3+CAV<QG\1@_S_"A/H*Z6@:3;K>1ZC8S$^1/&IP.H;D%@?7
M3'TK0T^\D^SK:ZEM9B3"9#@JS#@JWH3VS]X$=SBI=)TMK 222R!YY0 VW[J@
M9X'KR3SW]!4DT:1W^V1 ]O>+Y;JP!7>!QD>ZY!S_ '5%2]R&TV(-$TP/N^Q1
M$?W#DH/HI^4?E5^J&VYL!^[#W-L/X"<RQCV)^^/8\^YX%6H+B&YCWPR!U!*G
M'52.H(Z@^QYI$NY!'_HVI21'_5W \U..C# 8?B-I^NXU<JM>P/- #%CSXF$D
M1/3<.WT(RI]B:EMYTN;=)H\[7&<,,$>H([$'@B@3[E&["?:&$H&&P5W#@XQ^
MN:B>1MI,4,D^.HC&<?Y]!D^U:%W=0V=LTUPV$'&,9)/8 =S6:OB.VR ]K=1I
M_>VJV/P5B?R!JDQI-["Q3I,/E8'CJ#W[CU!'<$ TDL3;_.A(64#!ST<>A_H>
MWY@SW/V:2--1@,;Y 4NF#O4D#&>^#_44E-#3LRK'!9SW0O/LL0NT^4NT8\Q.
M,8SUZ'Z8->*>*K"33_$U]%(N TID0^JL<@U[=(JRR$Q2!9X^,CG&>S#N*Y?Q
M?H3^(8K:.*$1:BA(#.2$*XR1NQS[=^N<5,XW1VX6JHRUZGD8%.Q6W=>#]>L\
M^9ILSJ.K1?./TK(E@E@;;+$\9]'4BL&FCU8RC+9D=+12BD4**<*0"G+0,>HI
MX%-%2**!CU%3**C45*HI#'J*>*:*>!0,<!3A2"E% RAKO_(!OO\ KBW\JFTT
M?\2RT_ZX)_Z"*BUW_D WW_7%OY5-IG_(+L_^N"?^@BK^Q\SG_P"7_P OU+8%
M/%(*<*S.@44M%+0,*6DI: )()6M[B.9/O1L'&?4'-=-X9TNY^V7TQN!+IMVK
M-D29;S"P()'9P,Y/<X//;EA5BTOKFPF$EM*T;=\=#]1WK2$^4Y<3A_:JZW1Z
MSI]TUQ 4F(^T1'9+CC)[,/8CGVZ=C3+ARVJ6L6,@1R2Y]"-JC]':N>TS7EN4
M2\V[+F/$<T(_Y;+_ +([D=0.>X_BS6UQJMTD]I.ZVR(R--&PQ+G'"G';'+#Z
M#G.-7J>%.FX2LR2:X8S&WMU$D_?^[&/5C_3J?IDB$6B_;(K<MYLA(GN9&ZD*
M?D&.PW<@?[+=R2=*&WCMXQ'"@1,YP/4]3[GWJM8.)(Y;PG/VAMR?]<QPN/8C
MYO\ @1J%%+4GF[%[A1S4$DO84UY"QP*J3W20-Y:J9K@C(B4]/0L?X1QU/X9/
M%2Y-Z(%'N2S3Q6L)GN) B#N>Y] .Y]JSI/MES=0W!F-N "(K=$#L"1]XGD;L
M9'0@9/7J5AADFN)+B:X+2!BB;%&U!CD+D'OD$]3BK=L$M)80JXB5?*]2H.,<
M_@!^/M6L8<J!R[' ^#$CCM?%=Q=JTN/$-VABD?\ UC?+QL'REO?&/H!6[OED
M)+,T<9.1 C?(O ';&>G?\*YGPN%&H>*Y'?A=?O,;CPO*Y/MG S]!75V]J;J(
MSS.8+!1EYSD%QZ)W.?4>O&3TUDE>["G\*9<TV5Y+..*XE#6_VAI@\DG*Q1[2
M3D]O,P.>V>U:H5]3YE5H[+M&PPTWNP[+_L]3WXR#2CA@AE%]J;QVT1V):VKD
M*$5?N@CNW4X[>Y (U[>[M[M"]M/'*JG:Q1@<'T/H:S"3ZHEJE"1<:A-<<%(1
MY$?'?@N?S"CZH:GNYS;6LDJKO<#"+_>8G"C\20*2V@%M;1P[RY4<NW5CW)]R
M<G\:1*V([RQM[Y%6="2ARK*<,OT(_ET-9LFFV=F\9*RW5P3^ZCD8<GU(  P.
MN2#CMS@5HW%WY<@@A7S;@C(3. H_O,>PX/N<<9IL%L(2TCN9)WQOD(QGV [+
MZ#^9))ALJ-TBI+ <K"[^9/<MNF<<?(O) ']WD+C_ &B>I-7)H8ITV31I(F<[
M74$9_&H;8^=/-<]5)\N/C^%2<G\6S]0!2WMVME;&4KO<D+'&#@NYZ*/\\#)[
M5F49UY# \XTZWBCC1@)+HHH&5_A4^N[G\ ?6KAJ"TMV@B)D??/(V^5_[S'T]
MAP![ 5*[  DG@5:1JD1R,>@ZGI0H"K2*#G<W!/Z5(HR<]NU6C1:#XUP.>IY-
M.2#[=>QVA&8EQ+/P"-H/"G_>(_)6%->188FD?.U1G@9)]@.YK8TJT>UM2TP'
MVB8^9+@YP>R@^@&![XSWK2*.>M.R+U%%%:G$%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5'+T%25'+
MT%)[#6Y%1114%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5'Y$?G^?M'F;=N?:I** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@!1U%6*KCJ*L5429!1115$A2-]T_2EI&^Z?I0
M!7HHHK,T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BLS7/$.E>'+1+K5KM;:%WV*2C,2V,X
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M%3D<ECQ] 14NGP(KSSE2)Y&&\E]^!@$+N))( /?OD\#%9RAS,-$2RSW$D3,
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M3]* *]%%%9F@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?ZU[366(MS@%%%%8@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9'0CJ* *E]:RL\=Y9,J7T .PM]V1>\;?[)_0\BM/3-2AU.U\V-6C=&V2PO\
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MG-JLLA"65NV#C]],A"@>H7@G'OM'H35)=T<H#[I;N0['E="V5QG@#&!P/E&
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MM4O[J"BBBK.<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *CEZ"I*CEZ"D]AK<BHHHJ"PHHHH
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MDA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2T45H<84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !4<O05)4<O04GL-;D5%%%06
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !3?,3S?*S\^W=CVIU5?^8I_VP_]FH$6J***
M!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% "CJ*L57'458JHDR"BBBJ)"D;[I^E+2-]T_2@"O1
M1169H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !7*_$C_D0=2^L/_HU*ZJN5^)'_ "(.
MI?6'_P!&I0(ZJBBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5.GW!4%3I]P4XDR'44459(
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% &7?Z69)6NK,JEP<>8C'"2X]?1O]KZ
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M **** "BBB@ HHHH **** "BBB@ HHHH *G3[@J"IT^X*<29#J***LD****
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M#!'!$L44:QQJ,*BC  ^E2UJHV..=5R #%%%%49!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5'+T%25'+T%)[#6Y%1114%A1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!%/<1VT1DE)"#@D#-9O\ :MG]O\WS3L\K;G:>N:U)8UFB:-QE6&"*
MY3^S9?[2^Q]\_>_V?6@1U4$\=S$)(B2AZ$C%24V.-8HEC0851@"G4#"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** %'458JN.HJQ51)D%%%%42%(WW3]*6D;[I^E %>BBBLS0**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "J]]8VNI6CVE[;QW%N^-T<BY4X((R/J :L44
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M** "BBB@ HHHH **** "BBB@ INQ?,\S:-^-N[OBG44 %%%% !1110 4444
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MYF;=++;1R.V,98J"3Q[U=I %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !4<O05)4<O04GL-;D5%%%06%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445DAK
MB>Z=$F8')_B(%"0FS6HK+D6]MAO,A9?7.?YU=M;C[1%N(PPX(HL%R>BLWS9/
M[4V[VV[NF>.E6[JX%O%GJQ^Z*+!<GHJC8+,Y,TDC%3T!/6KU# **Q9KF5YF=
M)'"YXP>*UX9!+"CCN*&K F/HHHH&%%%% !1110 4444 %%%% !1110 4444
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MG#_Z *TJS?#W_(M:5_UYP_\ H K2KG>Y(4444@"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "HY>@J2HY>@I/8:W(J***@L**** "BBB@
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M=/TH KT445F:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBC14U[PSJ&F%1NGA(C)[..5/_?0%;%%8W=[@>+_!'5I(;_4]"F# ,OVA%/\
M"RD*P^IRO_?->T4@10Q8* 3U('6EJJD^>7-8 HHHJ "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "IT^X*@J=/N"G$
MF0ZBBBK)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,+QHN[P)XA4=
M3IER/_(34SP,0_@#PZ1G_D&6X_*-14WC'_D2-?\ ^P;<?^BVJOX"_P"2?>'?
M^P=!_P"@"GT%U.BQ1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 F!G.!GUI:** $P,DX&3UIK11N%#1JP4Y (SBGT4
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MVA+!-3 Z<",,P'OA@/\ @)K<^%>@0:GX1U'4=8MH[DZU=M+(LJY#JK'!(/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% "CJ*L57'458JHDR"BBBJ)"D;[I^E+0>1B@"M11THK,T"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ KG_ !MXG_X0[PG>:[]C^U_9C&/)\WR]VYU7[V#C&[/3M705
MY_\ &S_DDVL?[T'_ *.2A"/0****!A1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4Z?<%05848
M4"G$F0M%%%62%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO$/B&2-M8U$X:.,Y$29SMST[+TS@*.:Y3Q9\.-9U+XA//8VY.B:A-#+=N)5
M7!P^03DGJ>!_%7LM%4JC3N%SRCXI^"=;UG6;/4O#]L97>V:UN0LB)A<\9W$9
M!#$?@*](T/3(]%T*QTV/&VV@2+([D#D_B<G\:OT5+FVD@N>3>&])\:^#-=OM
M/LM'@O=+O+P2"Y:8 (F>6QNSG;VQU'&:WK+P]JD/QCU+77M<:;-9"*.?>O+8
MC&,9S_">W:N[HINHV%SA/&'A[5-4\=>%-1L[7S;2QF+7$F]1L&Y3T)R>AZ9K
MNZ**ENZ2$>9:UX:\3>'_ !Q<>*/"MO#?1WJ;;JSDD"G/&2,D=P",'.<\8ID7
MA[Q5XS\4Z;J?BBR@TS3=.;S8;1)0[2-D'G!/<#.<<# ')->H45?M&.YPGC7P
M]JFK>,?"-]8VOFVUA=&2Y?>J^6N]#G!()X4],]*[NBBH<KI(04444@"BBB@
MHHHH **** "BBB@ HHHH **** "HY>@J2HY1\H-)[#6Y%1114%A1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 9'BO_D3M<_[!\__ *+:J'P[_P"2=>'_ /KQB_\ 0:O^*_\ D3M<
M_P"P?/\ ^BVJA\._^2=>'_\ KQB_]!I]!=3IJ***0PHHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** .#^)7AC5=;&D:GH\<-Q=
M:5.91:S8VR@E3WX/*#CC()I?"GCBTUW7VT[5-%;2_$,417;*F2R\$A6(! XS
MCI@=36IXIL?%DMU:7?AG4;6'RE99K6Z7Y)<D8.0#S^7UK'\/>#]>D\9#Q5XH
MO+-[R*$PP068.U 01R2!V+>O7KVK5-<NH^AA>!]'L-0^*/C"\O+9)Y;2[;R/
M,&0A9WR<>ORCFH$\.:3=?'R[MIK*)K9;<70AV_)YFU>2.AY)./6NR\*>%+_0
M_%?B75+J6W:#4YQ) L;$L!N<_-D#'WATS1#X4OX_BG<>)S+;_89+00J@8^9N
MPHZ8QC@]ZKGU>O0+G-^)[6#3_C5X6GM(DA>>,K)Y:[=WWEYQ[''X"FZE;Q:Y
M\>K>RU)!+:V5H'AAD&59MN[IWY;/_ 172^(/"=_JOCW0-=@EMUM=/!$RNQ#G
MDGY0!@]?45!XR\#WVK:W9^(?#]_'8ZS:C8&E!V2+SU(![$CH<@XI*2TUZ#N9
M'QITRR3PM;:G'$D-[;W2+%-& K8(/&1] ?;%4/&3-KWC3P/I>I FTGB2>:,_
M==VZ@_\ ?./QK1E\#^*_%=_9MXRU2R.G6K^8+2S!_>,/7@=1WR>"<8S6[XZ\
M$-XI@LKFPNA8ZII[[[:;''8X..1R 0><>G--22LK@5OBAHNFS?#Z_D:UAC>T
M17MW5 IC(8# ]B#C'O7-^(Y7O?V?[.ZNEWW A@7>PRV!( #GW %7;[P?X]\4
MPQ:;XCUK3XM,5P9A9J=\N.1_"!_(=\'%==XB\*0:QX)F\.6C+;1^4D<!(R$V
M$%<^WRX/UI)J-E?J(=HL$,7@6R>.*-&;3(\LJ@$_NA7%?!70]-?PM/J<EG%+
M>2W#Q&210Q" #@9Z#DY]:W?"&B^,M/LI--UV]L);"&S-M;+#DMD8"DG:. O'
MK5WX=^&+WPGX8.FW\D$DYG>7,#%EP0,<D#TI-V35P.9^&$,=AXU\;:?;J$MH
MKM?+C'1 'D  _#C\!7I6H?\ (-NO^N+_ ,C7+>%?"E_H?BSQ+JMU+;M!J<XD
M@6-B6 W,?F! Q]X=":ZRYB,]I-$I 9T903TY&*F;O*X,\N^"VA:9+X4N-1EL
MH9;J:X>)I)%#?( /E&>@Y.?6J?PJ\/:6?%/BB62TCD>PNS!;;QN$:[GZ ]_E
M'-=M\._#%[X3\,'3;^2"2<SO+F!BRX(&.2!Z5%X*\*7_ (<U;Q'=7DMN\>I7
M?G0B)B2%W.?FR!@_,.F:N4_BU'<YWPK;1:=\<O$]G:HL5N;02^6@PNX^4QX^
MKM^=2_#<_P#%P/'@[_;1_P"C):W=-\*7UG\4=8\322VYLKRU6&-%8^8& C'(
MQC'R'OW%8VI>"?$^F>,+[7O"6HV<2Z@/](AN@<!CU/0YYY[$9(YHNGI?HA$5
MQ_R<):_]@X_^@M5?5;#Q%X*\=:GXHL-)76-.OES*J'][$.,@=2.G4 C'7%7?
M#WP^UW3/'D'B/4M5AOW:!_M3DD-YC C"#&-H&W'([\"KM_I_Q(M]3O?[*U32
MY[&>5G@%VI#VZD\+PO./?/3I3NKV3Z#,GQ%XJTW6/@_J^HZ!";422+%<1J@1
MD9G4/NQP<@XSWS73^#O#VD+X TNU-C;RPW-G'+,'C#>8SJ&)/KR?PXJCH'PY
MAT_P1J&@ZC<BXFU%FDN)HQ@*_&W;GT(!YZFL6Q\)_$G2-/&B:?KVFC3ERL4[
M ^9&A/0?*<'\3CL:3LU9/J(/B5:P6.L> K2VC$4$-\L<:+T50T0 JC\1)KRY
M^+&@V46F#5%@M?.BL9)0B2OER3D\?P#KUVXKIO$/@G5-4/A$17T<[:/,CW,]
MRS!YL%,L.#DG8>I[]:L^-_!-QXAN['5](OEL=:L#^YE<95AG(!ZXP<]CU((Y
MIQDE;YCN<=XOL/&GBQ;!D\%I87EG,)(KI+Z)F '\/4<9P?;%>R#..>M<!;V/
MQ.NKF!+W5='M+9)%,LEO&6>10>0 5QS^%=_43>B0F>4W\$6M?'R"UU!!+;V5
MF'ABD&5+;=V<?5L_\!%>C2:1IRWZZHMA";Z&-E254 ?!'3/?\:Y3QEX(U'5-
M=LO$?AV_BLM8M5V9E!V2+SU(!YP2.AR#[5+X=T?QJVNQZEXEUFW-O#&RI96>
M0CDC&6X'3J.OX4W9I-,#SWX;:EXACM]2U73O"R:Q<W5TPGO7NTC8' 8IAN?X
MLY[Y]JZOP)H>OV7CS5]6O=#72-.OH,_9TN$=1*"O3:?]\].,T+X(\4^%M8O;
MGP=J%B+"\?S'LKP'"'/08!X'KD<>N*Z?PO9>+8KFYN?$VI6<RR*!#;6D>%C.
M>3D@'^=5.2=VK:C;.7^$O_(4\8?]A'_V9ZROAOI+Z[\-_$VEQRB*2YNY$5ST
M!V)C/MGK79>!O"E_X:O=>FO9;=UU"[\Z+R6)(7+'YL@8/S#UK-\,^"=?T#P;
MJ^F0ZE;6VI75T9[>XA)=4'R<'*CKM(Z'K0Y*[L^P&!I'B6Y\%:?9^&_&GAM4
MT]&V17J()(FYR"1R">^0<^V:]A5@RAE(((R".]>7:GX0\>>+8;?3/$6HZ5%I
ML<HDE>U4F23&1D9&,\GT^E>H1QK#$D:#"(H51Z 5%2WS$QU%%%9B"BBB@ HH
MHH **** "FE%/:G44 1^4/4T>5_M?I4E%*R'=D?E?[7Z4>5_M?I4E%%D%V1^
M5_M?I1Y7^U^E2446079'Y7^U^E'E?[7Z5)119!=D?E?[7Z4>5_M?I4E%%D%V
M1^5_M?I1Y7^U^E2446079'Y7^U^E'E?[7Z5)119!=D?E?[7Z4>5_M?I4E%%D
M%V1^5_M?I1Y7^U^E2446079'Y7^U^E'E?[7Z5)119!=D?E?[7Z4>5_M?I4E%
M%D%V1^5_M?I1Y7^U^E2446079'Y7^U^E'E?[7Z5)119!=D?E?[7Z4>5_M?I4
ME%%D%V1^5_M?I1Y7^U^E2446079'Y7^U^E>>_"F/,7C'GIXHO1_Z!7HU>>_"
M?_5>,O\ L:;W_P!DHL@NSOO*_P!K]*/*_P!K]*DHHL@NR/RO]K]*/*_VOTJ2
MBBR"[(_*_P!K]*/*_P!K]*DHHL@NR/RO]K]*/*_VOTJ2BBR"[(_*_P!K]*/*
M_P!K]*DHHL@NR/RO]K]*/*_VOTJ2BBR"[(_*_P!K]*/*_P!K]*DHHL@NR/RO
M]K]*/*_VOTJ2BBR"[(_*_P!K]*/*_P!K]*DHHL@NR/RO]K]*/*_VOTJ2BBR"
M[(_*_P!K]*/*_P!K]*DHHL@NR/RO]K]*/*_VOTJ2BBR"[(_*_P!K]*/*_P!K
M]*DHHL@NR+RO]K]*41#N:DHHL@NQ@B7W-."@=!2T4[""BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** ,+Q-XPT/P?;P7&NWCVL,[E(W$
M$D@+ 9P=BG!QZ]<'TKRKXI_%+P=XD^'6IZ5I.KFXO9S"8X_LTJ9VRHQY90.@
M/>O5?&'ABU\8>%[W1;K"B=,Q28R8I!RK#Z'\QD=Z^)]3TV[T?5+K3KZ(Q75M
M*T4J'G# X//<>_>@#ZT_X7=\//\ H/G_ , I_P#XBNUTO4[36M+MM2L7:2TN
M4$D3M&R%E/0X8 X/TKX_^&/@J3QOXPM[.1&_LZWQ/>N.@C!^[GU8\>O4]J^R
MHXTBC6.-51$ 5548  Z 4 .HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** ,CQ7_R)VN?]@^?_ -%M5#X=_P#)
M.O#_ /UXQ?\ H-7_ !7_ ,B=KG_8/G_]%M5#X=_\DZ\/_P#7C%_Z#3Z"ZG34
M444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2N.^&7@M/!'@ZWL75?M\W[^]<<YD(^[GT487\">]=C0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7@?[07@4R
MB'Q=I\)9QM@OE0<D=(Y.GT4_\!]Z]\IKQI*A21%=3U##(H X;X3^"%\%>#HH
MIXPNJ7F)[QNX./E3/HH./J6]:[NBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,CQ7_R)VN?]@^?_ -%M
M5#X=_P#).O#_ /UXQ?\ H-7_ !7_ ,B=KG_8/G_]%M5#X=_\DZ\/_P#7C%_Z
M#3Z"ZG34444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 97B=0_A/65/0V,X_\AM69\-V+_#CP^3_ ,^:#\ABM3Q+_P BKJ__
M %Y3?^@&LGX:_P#)-] _Z]%I]!=3JJ***0PHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MR0,$]>>E.$(S;:V!),]*M?CU=B7_ $S0H7C)_P"6,Y4@?B#G]*]:\/>(=/\
M$^D1ZEILI>%B596&&1AU5AZ\UXIXV\>>$?$OAM[&RT6YMKV,J;:4PQH$P1D9
M5LX(SQZXK2^ MW(+S6;/+&)HXY0.P()'ZY'Y43IKEYK6!K0X.U_Y*C#_ -AI
M?_1U>I_'C_D7-+_Z^S_Z :\LM?\ DJ,/_8:7_P!'5ZG\>/\ D7-+_P"OL_\
MH!JY?'$?5$OP)_Y%'4/^O\_^BTKU*O+?@3_R*.H?]?Y_]%I7J585?C9+W.%^
M('Q$;P1<6,*::+QKE6<EIM@4 @>ASUKG-5^.=I#:6W]FZ89[J2)7F\R0A(F(
MR5!QEL=,\5E_'K_D*:+_ -<9/_0A6E\*/ >AWWA=-:U*TCOI[IG54F7*1*K%
M>!W)QG/Y>^BC!04FAV5B;PM\:H-4U.*QUJQCLA,=J7$3DH&/0,#T'OG_ !KK
M/'WC0^"M+MKM;$7;3S>4%,NP+P3GH<]*\%^(>@VWASQK>V%D-MK\LL29SL#
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MUXJN6GS<E@TV/99;RWU#P_+>6DJRV\ULTD<B]&4J<&OF_P"%O_)2=&_WY/\
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MEB._7&.G]%&$%#FD%E8U-#^.D=Q?10:SIB6\#M@W$$A(3W*D<CUP?PKV$$,
M000>017S%\4-!LO#WC6:VT^(0VTL23+$#PF<@@>V03^-?07@V9KCP3H<C\L;
M&')]2$ S4U8Q24H]0:-RBBBL20HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK\3]+T#0/[&UE7A2 L\$T:%]X8EBI Z')X/3Z8Y=\>O^0IHO_7&3_P!"%/\
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M;HHHK(04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4N-+T6Y:[N+P!&;RF18TR"<[@,DCCBLOX%:-.^K:AK3)BWCA^S(Q[NQ5CCZ
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ KFO&?@VU\::;!:7-U-;^1+YB/& ><$8(/UKI:*:;3N@.<
M\&^$+7P9I,MA;7,MP)9C,SR@#D@#  [<5T=%%#;;NP"BBBD 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
<% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img187419207_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img187419207_4.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )5!*D# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!A77_(Z:?\ ]>LG\ZW:PKK_ )'33_\ KUD_G6[5SV7H-] IC31K
M*(F<!V&0#WI]5KQ;=HP+E<J3@''0_7M4"*FL:E!I]G*]W&?*"Y4@_>/I[&O)
MM5U2XU:[:>=R>RJ3PHK5\7:JUW?_ &*.9I+>V) +'.37.5QUJG,[+8]W!894
MX\\MV%=OX3EGU&T-ML8F'HYZ8],UC>&O#DNN76Y\I:QGYW]?85ZK9V5O86ZP
M6T2QQJ.@%50@[\QEF%>'+[/=_D4H=&0#,KDGT%6ETVU _P!5GZFK=%=1XY3;
M3+5A_J\?0U4FT;C,+_@U:]% '+W,;Q.(V4J%Z9[U#74W%O'<1E77/H?2N=NK
M5[64HW(['UH GLKI0Z1SY:-3E1GH:VXYMT1DD7RA_M'MZURU:EL\%Q&'NY&;
MR\*(ST/H<=Z -B.1)4#HVY3T(IU(N HP,#' I: "L[7O^0'=?[H_F*T:SM>_
MY =U_NC^8JZ?QKU''=%Z'_41_P"Z/Y4^F0_ZB/\ W1_*GU+W$%%%%( HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M&%=?\CII_P#UZR?SK=K"NO\ D=-/_P"O63^=;M7/9>@WT()VN01Y"1L.^\XK
M#U_0;OQ!;0QR2Q0&)RPQDYXK>6X@:3RUFC+_ -T,,_E0UQ DGEM-&K_W2P!_
M*LW&ZLRH3E"2E'<X+_A7$_\ S_Q_]\&NA\,>&WT 3[YUE,N,%1C%;K7$*SK
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M/!QWXK9LO #:9?[[#7+R"Q\XR_9%52N2<D9ZXJ:]^'^GWOC.'Q&T\BR1D,8
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 8VN1R0RVNIPH7:V8^8HZE#UK3MKJ&\@6:"17
MC89!!J8@$8/2LB7P_;&8S6TLUI(>3Y+8!_#I5IIJS&:]%8_]BW7_ $&KW\Q1
M_8MU_P!!J]_,4<J[A9&Q16/_ &+=?]!J]_,4?V+=?]!J]_,4<J[A9&Q16/\
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M2S2#HTAXP/I6[4=O;PVL*PP1K'&O15%24I.^P,****D04444 %%%% !1110
M4444 %%%% !1110 4PQ(0?E ]Z?37?8N<9]J ((G\HE&Z9ZU,TJ(,DU!$GG%
MF?.,]*?+"-I93@]Z &9DE#,B\=CFG+<$ AT.13X'0Q  CBHI"KW*@'CO[T 2
M1RO(Q^0A>V:FHZ44 %%-D#%#MZU1,C-)UVC&.* -"BHXNAYJ2@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J.6)9
MDVM^=244 10P+"#C))[FI: <]** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ I&4,,&EH/2@"JCF!V5N5SUJ26=!&<-G-(D.23)
MSD]*<8$[#% $4=OO 9N,CH*5[<JN4/3G%60,#%-=MJDXR?2@"%;I2,'(;%)%
M,53=(<Y[U7C0RRE3QZ^U6&MRD9VMN]C0!(]Q&JYW9/H*BCMUD)<DX/:JZ(TF
M=HRPZU<MF/EA6&".E "QP+$Q*D\U+110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4R9PD+L3C"FGTV2-98RC?=/
M6@#"L]0E@?:V70GIW%;RL'4,.A]:SIH8[2Z@DC0*A.TUI4 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $:1!
M'9AU;K3G.$)IU!&1@T 5K8A-RL0&)JP !T%1M;QLP;;@BI ,#% "T444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M..;Y?)P"XSU(ICZ7<-:3Q87+S!QSVH DL+J?^T3;--Y\>S=O]#6Q4-O;16R
M1QJAQS@5-0 4444 %%%% !1110 4444 %%%% !16?J5U);&(QGOR/6I;2_CN
MAC[LG]TT 6Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH 1V"(6/0#-58D,S^8__ .KVJ6Z_U!^H_G3H?]4#W/6@ 9XH
M< D GVH5HYEW*0P]:)?, !C52?\ :J"RP/-!!$F[YA0 2*8)/,7\1ZBK0(8
MCH:CG^X/K26O_'LGTH FJG9#9+<1^CYJY5.WXO[C\* +E%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %.[L1=R
MJSN0%&,"HM-C2,RQE!YB-U[D5HU0E_<:G')_#*-I^M %^BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHKSKQSKFMV/B&SM--E95= RI%R7.>XK:A1=:?(G8F4N57/1:*AM&F
M>TA:X4+,4!<#L<<U-635G8H****0!1110 4444 %%%% !1110 4444 %%%%
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MILRHI9B. *K6VF)%!YS%WF\L@!CTXK5HH H:-&\6G(KJ5;)X-7Z** "BBB@
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M7=Z!&H0?=SZUI^\C*#<%=[NWY_(7NN^IV=A.+G3[>8.'WQJ2PZ$XJQ7+^"-
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M:7+<7L2HR2; RC ;\*YJF$G3BY-II=F6IINQT]%%%<I84444 %%%% !1110
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M:>]2/&''O5617M8U9)B0"!M/>KHZ4@*UNQ1S$>G5<]O:K-51_P ?BX_VJM4
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M5I1"K&*8]%?O705XQX+TN35M:5HY JVQ#OSS^%>SC@5E))/004445(!1110
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M= 6)[8'7FN3.G:C?S:K>)ISVA-J(K>,  G_Z^*G,-Y=>%);*VTB2WEBB"[V
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M2Z;HD"R0A+EAND)'S9/:@#;HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MDLY.[N*\E2"1EW8XK2-RUL6HW8(#@U9CD!7GK55"VS[I(IID91DC%5L(OK*
M>*:\O/6J(GH1][9HN%C4TW6;O2;G[19RF-^^.X]Z]T\-ZJVM:%;WK@!W&& ]
M17@2(#VK=TSQ/J^C0""UN"(1G"$9 HE"X,]LN=1L[-@MQ<QQL>@9L58CD29
M\;AE/0@Y%>!7-_=ZC.US=3-)(W=C7<_#C6I'FFTN5BP"[TSV]14.%E<D]&HK
MEO&7BQO#5O$(H?,FE^Z3T%<5_P +8U!82IM83+G[U*,&]@*_Q3@U%=?6=T<V
M90"-OX0>]<"S%<>E;?B7QAJ7B-DCG<+&O_+-.!GUK%\M?+ZY-;Q32LR6PW^8
MI!%4G8AMHZU(7\O// J!6,SLZCBE<!Y#GA2<U-%#+@DBFPJP)9JL!F(II(#V
MCX6:BUYX>>"3E[=]H..U=Y7EOPMUZSBC?23'MNG8N&_OUZ?F0] !6$MRA]%1
ME)#_ !X^E(82>LC&I EHR/6H?LZ_WF_.D^RIZM^= $]%5_LB?WG_ #H^RX^[
M*Z_C0!8(R,4BJ%& ,"J_DW"G*SY_WA2;KQ,DHCCV.* +5%5/MH3B6)T_#-3Q
MW$4OW)%/XT 24444 %%%% !1110 4444 %%%% !1110 5#=/LMW/?&!4U5KC
M][-'%VSN- $ELGEVZ+[5+110 4A(49)P*KR766V0KO;]!31:O*=UQ(6_V1TH
M 5[Z,';&&D;T44W-[-T"1+[\FK21I&,(H ]J=0!3^PESF6>1C['%/73[9?\
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ME7<_WJVZHBERI:%ZBBBN U"BBB@ HHHH **** "BBB@ HHJ*>0QI\OWF.!0
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M=SE_^$\TK_GVU+_P$:C_ (3S2O\ GVU+_P !&KJ**.>E_*_O_P" %I=SE_\
MA/-*_P"?;4O_  $:C_A/-*_Y]M2_\!&KJ**.>E_*_O\ ^ %I=SA;KQ=I\VM6
MEVMOJ'EQ*0V;5L\UI?\ ">:5_P ^VI?^ C5U%%'/2_E?W_\  "TNYR__  GF
ME?\ /MJ7_@(U'_">:5_S[:E_X"-7444<]+^5_?\ \ +2[G+_ /">:5_S[:E_
MX"-1_P )YI7_ #[:E_X"-7444<]+^5_?_P  +2[G+_\ ">:5_P ^VI?^ C4?
M\)YI7_/MJ7_@(U=111STOY7]_P#P M+N<O\ \)YI7_/MJ7_@(U'_  GFE?\
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M#&!CI4-Q+M7RT&9'X HAF4K@\8XY_E0UI&TADRX8^C4 /@C\F%(\YP*CN_\
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MK+)Y;],"KL<_%9KRC;BA)F"_UIW)-0OO&.]0M(<;13().,GK3I7!<$=:+W$
M0CEJ"P/ IS2;HZT- TZRO[\17]]]CA(_UFW//I3&CJ? 7@6]URZM]1EV)I\;
MY);G?CMBO?D18XU1  JC  [5D^%])M-%T&WM+*7S80-PD_O9[UL5@W<84444
M@*]SP\1(R,G^53H<H"/2FS1^;&5S@]0?0U#%-M^1Q@CJ* (I6D$TC- [  A2
M.@'K4MBQ:T3*D8&.>]6 58$ @CO3-\<:X&,#L*8$5Y_J_P #Q5A 0B@]0*JJ
M#<2AC]P')/K[5;I %%%% !63K.NQ:0%5D+R,,@"M:O*?%5_>RZQ-'.I41G"#
M':LZM6-*/-)G7@Z"K5+/9%VYUN>[8M),X5OX0<"LZ6,."P&Y>^:S+:X9D.X9
M /%7HKO;U^[6'MH5(^^>UR<FD40EY(3F/+)W4FKUO?Q2C@<CJ#UJ"0+.2Z<5
M0.#*2IVNO>LW-TY+I<&DU<W%D9VPB$TI:4-MVD$=JS[74)#((V&U^WH:T&+E
M@SX.?0UTWYH[F3>I(@8GYS2^:$;!-.7!X(J&6$R,-M8U'[O+%CB[O4T-/OYK
M>Z2568H#R,\&NMBUJTDMO-:58SG&&-<1#&PPOI2RP"16'Y5E2Q/*N5ZLPKX:
M-1WV-G6/$_D'R;%@6/WI/\*YX>(;\EU-RS!A@@UG3AHF8'DBJ6XALUC/&RO[
MH0PL8QM8TQ,P;))R>].N+N29%#R.P7H">E9XGR!4R2*PYJ(UDW>Y7);4D7YL
M[7(SUI1#S]\FH0P5CBGK/1*M*]F#3)6&U<9KK?#GB.SAM!:7.(63HW9JXMY2
M^<5 )3OY%72K.,N:QC.DIQLSVB.1)HP\;!E/0BG5PG@N\NI+YX Y, 7+*3TK
MNZ].G452/,CS*D.25@HHHK0@**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%5&U*U4X,JYI?[1MO^>B_G3L'*RU1112$%%%% !1110 4444 %%%% !1110
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M2:FQ5R)AGJ2:D\Q<;<TB(=N&%1B((^2#2MU'<5Y'#  =:D!*C-(1SP,FHWW
MC)_"DURZE)W%FEV#(Y-5_M3_ -PU.ZM@$=/>FX/M4/5ZCN>F4445S&(4444
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MC%TFFS4U_48H[ Q-R6%<3-"T6R1/]6XR*U/$=SYCLHZJN*I7MPB:?!; _O%
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M$N9[-@IYQ0HJ[ON#9'97K8&:TOM@]:YZW_<KAC5KSQ6<8V6KL-N[/>J***D
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH CG_ ./>7_</\J\"\0S16UTK
M]6WXXKWV?_CWE_W#_*O%+VT@EOAYJ@_.>M;4[\KL2]PL+F(HA9P ?6M*^O[>
MTM0Y<8/'6J%_I<4T2B,;?<57NK&+[&(Y/F^M;7EKH3H;-KJ_EP#G=&1P1VJK
M_:+)J,<R'Y"0&%16EBL=D%[8J"XM6@(4G&>AKII6DM3AK1Y9:';-=9AR/2MC
M1$BCL1<W6 )6"1AN]<'H*W^IW\=@DWR9^8^B]Z[;6Y-",MG;W>K?96LY 5C5
ML9;MFN>M'E?*:45?WF<QXMG>#Q!+96X.]]I08X&:W_$_A^WG\'2JD$8NH(0^
MY1SD#FF>(K1)_%>E;/\ EXQEL=@>*EFUN)?'LFES?ZF:W$7)XW'G%8N;:21M
M&*4G<Q=-BM-,^&UI=>3'YUQ@ER.>3Z_A74Q:9YVCV4:1(LC@,\F.0.M<_P"-
M[- VAZ1:@QPK)D1IW'2NAO\ 7HM)U:PTU@OE2)M=R>5["IYG9%<L>9W,O6-6
MLK<"PLE5G!VO)C//H*E\1[[2PL8[:V9G89<JN3T[UC:CHSV?C"V@09@N90Z'
M\<D5H^)O%.H:7K\-C:",QL%!W+DY)IIZJQ-M'<GU!DL/"]L[1A9Y2,DCGWK'
MT^XWRY<]>E6/B#<S&;3K4$#@R-CUZ5B0I.L8D4]!DUI!W1E56MNQU5TZ+:LQ
MP.*\Y\1:DPO8+.,[V8$[1S73VKR7=PIDD+(O1>U0ZKI-E#K5M>I$BRE"&P.O
M/6JFFE9!0DN;4RO#-H+%93(C)+(V64UD^-K>:<QEH6\H2#YNV*W]4O%M[JUD
MQ@;\$UHWBQ7UJ(Y(PZ$@XJ+;P1U^9GBX,.A@VZ\K%\@]:R='O7O[A)9XBIC.
MTY]:Z"XD2&U$(4#C 7%4[>U6W@9L 9.XU<H7M<294\5:DMO9Q*59EDD"D 5>
MN=2@T_0VG521'&"$ YJ26"&^MU#*KC.15'7D2UT68$#)7 I.Z;EY NB+6F:C
M#?V"/T:5?NFL*\T^?2[R*Y9E:'<2=HZ59\/P^9%!-V1:=XLO L$4'0OS4)WC
M=CV>AO6\\=W DL7S8'6LR'6%;5YK:9?+"#*D]_6I]&5H+"W4<97)K&OU\W6D
M7C>V0:?.W"X6UL;L^CIJ%TE]'+L9$(48ZU2T.WFOKVZ!DV^2=I]S6M'*+.P(
M!X1>M8_A*Z<+= MDM(6W>N:SE?F0ULQFK6T\LTD8&UHOXO[U:EAIQCTV">20
M[E&67M3-8E:.WFFZX&:=I=VUUI,3$D;TY%:/XO-BZ%B::&^:.W1\JWWL>E)'
M:VND,P0D"4]3S6)>2MIUY;NHSO?;\M;3C[0%RU.*O)]P>Q8N;3?;M-&Q+]<4
MMMO6-<U##<'88\GY>,U/#("<#I5W5KLJ-]2W$0K'MFM72K875T7DYBC&YL]*
MS%CR0,<FND5+/3M+%O=7 A:8?,V<&L9/E5B;W9F^)UA2TMKF$ *Q(X'6I-/,
M5IX;6\DM?/=CD*%R>:B\1I;OX25[23S8X6&U^N?6K-VNL6FAV$6AQQM)M&_S
M.PQG^=1?074P_%MGI=SX?MM4NK<65RDJ^5V+9[?C6CYEGX;T.WNIH/.N)@,
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M]@6O]Q:KWI_(6B/HJBBBLB@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM:=Y&ATJ<%N-AK+\+2B6QVL?N';6MU&48DK5-E[7&:/3"RG']:R/#D)97=@
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M7[4>7[59\NCRZ+@:=%%%8%!1110 4444 %%%% !1110 4444 %%%% !1110
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MC@=_I0!LT5CP>)]*N+IH(YR2N?GVG9QUYHM?$VEWMV+:&9M[ E2RD!L>A[T
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M(!MXCN/U["E*2BG(Z:-"4ZBB;&D>"[=H%GO]S3,<E5;C%=;##';PK%$H5%&
M!3P J@ 8 Z4M>;*<I;L^FI484U[J"BHKBY@M8S)<31Q(/XG8 5E_\)7H?_00
M0^X1B/Y5*39J;-%5++4['45W6EU%-[*W(_#K5ND 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7UJ>L^YT]YM7M;P.H6%2"IZG-:% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MIM;#N5=-TZVTG3H+&SCV6\*[47T%6J**@04444 %%%% !1110 4444 %%%%
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M,>E>A?V5I_V3[*+.'R-NW9L'2K:JJ*%4!5'  ' I:Y*V(G5?9+9%Q@HGF2^
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J
MU[86NH6[P74*2HP(^89Q]*LUR_C75-8TZQB&E0%S*2KNJ[BOIQ6E&$IS48NS
M%)I*[//KCQ;JWA/5KO1[*59+6"8K&LJ;B![5J?#Z\N+SQ++)<:BQ=D9C"V?F
M)]/I75^'?"-C:Z?%/?VRW%_)^\DDF&2&]*W(-%TVUOGO8+.*.Y?[TBK@FO1J
MXRCRRA&.K5KZ:F*IRNFV7J***\HW"BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
***** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img187419207_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img187419207_5.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0V"#,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBN7\2:]=Q7D.BZ.-VHSXW/C/E+Z_ESGL*J$7)V0TKFMJ6O:9I'
M%[=I&^,B,?,Q_ <UAO\ $;1E; AO''JL:_U:K.C^"]/L5$U\@OKUN9))OF7/
M? /\SS]*Z-(XXEVQHJ#T48J_W<=-_P "O=1R/_"R-'_Y]K[_ +]I_P#%4?\
M"R-'_P"?:^_[]I_\57844<U/^7\17CV./_X61H__ #[7W_?M/_BJ/^%D:/\
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M #[7W_?M/_BJ/^%D:/\ \^U]_P!^T_\ BJ["BCFI_P OXA>/8X__ (61H_\
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MC_\ /M??]^T_^*KL**.:G_+^(7CV./\ ^%D:/_S[7W_?M/\ XJC_ (61H_\
MS[7W_?M/_BJ["BCFI_R_B%X]CC_^%D:/_P ^U]_W[3_XJC_A9&C_ //M??\
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M_A9&C_\ /M??]^T_^*H_X61H_P#S[7W_ '[3_P"*KL**.:G_ "_B%X]CC_\
MA9&C_P#/M??]^T_^*H_X61H__/M??]^T_P#BJ["BCFI_R_B%X]CC_P#A9&C_
M //M??\ ?M/_ (JC_A9&C_\ /M??]^T_^*KL**.:G_+^(7CV./\ ^%D:/_S[
M7W_?M/\ XJC_ (61H_\ S[7W_?M/_BJ["BCFI_R_B%X]CC_^%D:/_P ^U]_W
M[3_XJC_A9&C_ //M??\ ?M/_ (JNPHHYJ?\ +^(7CV./_P"%D:/_ ,^U]_W[
M3_XJC_A9&C_\^U]_W[3_ .*KL**.:G_+^(7CV./_ .%D:/\ \^U]_P!^T_\
MBJ/^%D:/_P ^U]_W[3_XJNPHHYJ?\OXA>/8X_P#X61H__/M??]^T_P#BJ/\
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M"T:XD-ND *Q%CM!PG('XFB6&DF]>E_D#IM?=<ZFBL/Q=<SVGANXFMY7BE#(
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MTO4_+(AF/RGH_P#C7><INT50@N+NZOF*Q>39QDKF1?GE/L.R^_>K] !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!GZ]_R+NI_]>DO_ * :S_!'_(GV'_;3
M_P!&-6AKW_(NZG_UZ2_^@&L_P1_R)]A_VT_]&-6O_+KYE?9.@HHHK(D****
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M_;9P<K$!B&+_ '5[_4Y/TK9  & , 4 %%%% !1110 5R'B__ )&'PQ_U]_\
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M_P"OO_V>2NPK6M\?W?D5/<****R)"BBB@ HHHH **** "BBB@ HHHH ****
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MXEU%-+O;-M/OY"5C!?>DA';. 0?8C\<UT7C'QEI_@W2UN[Q7EEE)6"!#AI&
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MG=KY?YZEQ@G&W5FYXHUN;0M-CN8(HY'>41X?. ,$]OI67+X@\2V49GO-"C,
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% &?KW_(NZG_UZ2_^@&L_P1_R)]A_VT_]&-6AKW_(NZG_ ->DO_H!K/\
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MCUK>O=4@N/"MSJ$198GMW*;Q@YP0/UK7K$\4:;>ZMI:V=F47?*IE+MCY1_\
M7Q^5)3I3J+2VNNO_   O&4EI8K>!H##X9C8C'FR.X^F<?TKI*AM+:.RLX;:(
M?NXD"+] *FK&K/GJ.7=D3?-)L****S)"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** ,_7O^1=U/_KTE_P#0#6?X(_Y$^P_[:?\ HQJT->_Y%W4_^O27_P!
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M!/ASK5QKMM>ZG92V5G;N)#YZ[6<CH IY_&O?* "BBB@ HHHH *H:PF[3W/\
M=(-7ZBN8?M%N\6<;AUH Y"BMG^P3_P ]Q_WS1_8)_P">X_[YH SK%MM] ?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+0L/,B//'J,]#7K]>)Z-I%SK-_';P(^TL!)*%RL8]3^1^M>U1HL<:QH,*H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#/U[_ )%W4_\ KTE_
M] -9_@C_ )$^P_[:?^C&K0U[_D7=3_Z])?\ T UG^"/^1/L/^VG_ *,:M?\
MEU\ROLG05Q_Q1N)K;X<:O+!*\4@$0#HQ! ,J \CV)%=A7%_%C_DF6L?]L?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MLA&&9 SD@%CQ_P#7KD2;=D=#=BY14<$PN(%E7HWO4E)JV@%'4K22>!GMSB<
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.C_] FQ_\!T_PH_L'1_^@38_^ Z?X5H44<TNX79G_P!@Z/\ ] FQ_P# =/\
M"C^P='_Z!-C_ . Z?X5H44<TNX79G_V#H_\ T";'_P !T_PH_L'1_P#H$V/_
M (#I_A6A11S2[A=F?_8.C_\ 0)L?_ =/\*/[!T?_ *!-C_X#I_A6A11S2[A=
MF?\ V#H__0)L?_ =/\*/[!T?_H$V/_@.G^%:%%'-+N%V9_\ 8.C_ /0)L?\
MP'3_  H_L'1_^@38_P#@.G^%:%%'-+N%V9_]@Z/_ - FQ_\  =/\*/[!T?\
MZ!-C_P" Z?X5H44<TNX79G_V#H__ $";'_P'3_"C^P='_P"@38_^ Z?X5H44
M<TNX79G_ -@Z/_T";'_P'3_"C^P='_Z!-C_X#I_A6A11S2[A=F?_ &#H_P#T
M";'_ ,!T_P */[!T?_H$V/\ X#I_A6A11S2[A=F?_8.C_P#0)L?_  '3_"C^
MP='_ .@38_\ @.G^%:%%'-+N%V9_]@Z/_P! FQ_\!T_PH_L'1_\ H$V/_@.G
M^%:%%'-+N%V9_P#8.C_] FQ_\!T_PH_L'1_^@38_^ Z?X5H44<TNX79G_P!@
MZ/\ ] FQ_P# =/\ "C^P='_Z!-C_ . Z?X5H44<TNX79G_V#H_\ T";'_P !
MT_PH_L'1_P#H$V/_ (#I_A6A11S2[A=F?_8.C_\ 0)L?_ =/\*/[!T?_ *!-
MC_X#I_A6A11S2[A=F?\ V#H__0)L?_ =/\*/[!T?_H$V/_@.G^%:%%'-+N%V
M9_\ 8.C_ /0)L?\ P'3_  H_L'1_^@38_P#@.G^%:%%'-+N%V9_]@Z/_ - F
MQ_\  =/\*/[!T?\ Z!-C_P" Z?X5H44<TNX79G_V#H__ $";'_P'3_"C^P='
M_P"@38_^ Z?X5H44<TNX79G_ -@Z/_T";'_P'3_"C^P='_Z!-C_X#I_A6A11
MS2[A=F?_ &#H_P#T";'_ ,!T_P */[!T?_H$V/\ X#I_A6A11S2[A=F?_8.C
M_P#0)L?_  '3_"C^P='_ .@38_\ @.G^%:%%'-+N%V9_]@Z/_P! FQ_\!T_P
MH_L'1_\ H$V/_@.G^%:%%'-+N%V9_P#8.C_] FQ_\!T_PH_L'1_^@38_^ Z?
MX5H44<TNX79G_P!@Z/\ ] FQ_P# =/\ "C^P='_Z!-C_ . Z?X5H44<TNX79
MG_V#H_\ T";'_P !T_PH_L'1_P#H$V/_ (#I_A6?XYU!=+\"ZY=M*8F6SD2-
MQU#L-J8_X$PKQ7X;_%R70$@T;7V>?2UPD-QRSVR]@>[(/3J!TR,"CFEW"[/>
MO[!T?_H$V/\ X#I_A1_8.C_] FQ_\!T_PJY!/#=6\=Q;RI-#(H=)(V#*RGD$
M$<$5)1S2[A=F?_8.C_\ 0)L?_ =/\*/[!T?_ *!-C_X#I_A6A11S2[A=F?\
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ML%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ3:6H6/>:*AM+F.\LX+J+/ES1K(N>N",C^=35D(**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR^8>27QQR,8(R,<=L#L:F?Q,1S.N6, UVW,PS::S!)I=X@.-QV.\;?@!*O\
MP,>E9_PONK@^&)M)O&S=:/=RV+G.<A3D?AS@?[M;?BD#^R[9\?.FHV14^F;F
M-3^A(_&N>\#_ ">-O'$*']T+V)Q_O,K%OUJEK%@=Y11168%/5K87FC7UJ<8F
MMY(SGW4C^M>4_ :1C#KT)/R*T##ZD2 _R%>P2#,3CU!KQWX#C']O_2V_]J4
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M1GL=4USPS=B1)(_]($1 Q&Z-Y<F?<Y0?\!KW"@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M([!449)/85S0G*$KQ>I32>YS&AZVEK&]E>%U\HX4E3\OJOKQ70-J%DB[FNX
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M(SPZ-P\;?W6'8_S[9%2XM :M%%%2!P?QCTY+_P"&U^Y1GDM'CN(\=B&"D_\
M?+-3?@WJ(O\ X;V49<O):226[Y[8;<!_WRRUUGB&QDU/PUJMA%CS+FSEA3/J
MR$#^=>6?L_7Q?2]:T\\"*:.<>^]2I_\ 0!^= 'LM%%% !1110 4444 %%%%
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M]2:X7X@9UGQGIFD(PVJ$C)_NM(W/Z!37J6,# H **** "BBB@ HHHH ****
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M*%55'   Z"DY7BH@/HHHJ!!1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP9%9AO$&G*L:.ZI<0(@55R,;^.F3@'W.:Z?QYXZG\*S6]I9VL<EQ*GF%YLE
MN2,8!!SD>M<AXG^)=IKW@Q].^PRI?SE-YX\I<,&)!SD].F._7CG7!4:\)1JP
M6C_(524&FF=O\,;*WM/!-M+ SL;EWEE+'H^=I ]OE%=A7A7@?XA7>BRVFEWB
MQ-I9D()"?/'N).0<],G)SGBO=:RQ]"I2JMSZZH=*<91TZ!1117$:A1110 44
M44 %%%% !1110 4F*6B@ HHHH **** "BBB@ HHHH **Y'5M8O[?QE9V,5P5
MMI&C#)M'.3SSC-==0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MVJ/4**SM,UJTU0$0/E@.5-:->;*+B[2184445(!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
MF>L6MOX>\>74=\-N@>*H?(F<<"&Y P#GMG.<^K$_PUZ969K^@V/B31I]+U",
MM#*.&7AD8=&4]B/_ *QX-5%V8$7A_4;BXADT_4>-4L<1W'  E'\,R_[+@9]B
M&7^&M&\LX-0LI[.ZC$EO/&T4B$D;E(P1D<CBO,DU.YT&_M]%\67;6>H0 II/
MB)5S'/&2/DFSP>VX,?0Y! <]G'XDET]%7Q!9M:X4'[=;JTMH_3YMP&8QS_&
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6A%XM\.S8VZW8 GH'G53^IH V:*CAN(;A \,T<BGNC C]*DH **** "BBB@
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M444 %%%% !163=^(;2SUB'3)(YC/*5"E5&WYC@9.:UJ "BBB@ HHHH ****
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MC%<U=7BF3-:%V\NX[*U>>4X51FN)NO%E_<L?( B3MW-==J]I]MTV6'')&17
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M?$BC^R]2AFEQDPL=D@_X"<'\>E &Y1110 4444 %%%% !1110 4444 %%%%
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M(M/B2WE2.X@<LF_.T@]0<=.WY5RDG@#Q!>62+=:C"S0@)#"\C,JK]<<=N@H
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MHHH *XW7/'BP:F^B>';"36M:7(>*(XB@QQF1^@P3T_ D&H?%^NZC>ZQ!X/\
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MQ2HLD;J5='&0P/!!'<5YQXH^#.A:SON-*/\ 95V<G$:[H6/NG\/_  $@#T-
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M:;FQ)<./W<6>ON?04 +KVOV>@67G7!W2-D10J?F<_P!!ZG^N!7G]MI6L>/\
M4A>:A(T&G(2%('R@=U0'J>.6_P  *T-(\.W?BB__ +6UEW-L3PO0R ?PCT7_
M "/6O0XXTBC6.-%1$ 5548  Z "@"II>E66C62VEC L42\G'5CZD]S5VBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1E5U*N
MH93P01D&EHH I?V18YSY _[Z/^-7%144*BA5'0 8%+15.4I;L=VPHHHJ1!11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M HHK(\0^(]/\,Z=]KOG/S';'$G+R-Z ?UJHQE-J,5=B;25V:LD:2QM'(BNC
MAE89!'H152PTC3M*\S[!8V]KYAR_DQA=WIG'U-<' _CSQ<HN8IXM#TZ3!C&/
MWC*>X.-Q_P#'0:L?\(!XB;EO'FI!CR0!)C/_ '\KJ]A&"Y9U$O+5_D1S-ZI'
MH-%>??\ "OO$'_0^ZG^4G_QVC_A7WB#_ *'W4_RD_P#CM3[&C_S]7W/_ "#F
ME_*>@T5Y]_PK[Q!_T/NI_E)_\=H_X5]X@_Z'W4_RD_\ CM'L:/\ S]7W/_(.
M:7\IZ#17GW_"OO$'_0^ZG^4G_P =H_X5]X@_Z'W4_P I/_CM'L:/_/U?<_\
M(.:7\IZ#17GW_"OO$'_0^ZG^4G_QVC_A7WB#_H?=3_*3_P".T>QH_P#/U?<_
M\@YI?RGH-%>??\*^\0?]#[J?Y2?_ !VC_A7WB#_H?=3_ "D_^.T>QH_\_5]S
M_P @YI?RGH-%>??\*^\0?]#[J?Y2?_':/^%?>(/^A]U/\I/_ ([1[&C_ ,_5
M]S_R#FE_*>@T5Y]_PK[Q!_T/NI_E)_\ ':/^%?>(/^A]U/\ *3_X[1[&C_S]
M7W/_ "#FE_*=3=^';:\UJ'5'FE66(J0JXVG:<CM6Q7GW_"OO$'_0^ZG^4G_Q
MVC_A7WB#_H?=3_*3_P".T>QH_P#/U?<_\@YI?RGH-%>??\*^\0?]#[J?Y2?_
M !VC_A7WB#_H?=3_ "D_^.T>QH_\_5]S_P @YI?RGH-%>??\*^\0?]#[J?Y2
M?_':/^%?>(/^A]U/\I/_ ([1[&C_ ,_5]S_R#FE_*>@T5Y]_PK[Q!_T/NI_E
M)_\ ':/^%?>(/^A]U/\ *3_X[1[&C_S]7W/_ "#FE_*>@T5Y]_PK[Q!_T/NI
M_E)_\=H_X5]X@_Z'W4_RD_\ CM'L:/\ S]7W/_(.:7\IZ#17GW_"OO$'_0^Z
MG^4G_P =H_X5]X@_Z'W4_P I/_CM'L:/_/U?<_\ (.:7\IZ#17GW_"OO$'_0
M^ZG^4G_QVC_A7WB#_H?=3_*3_P".T>QH_P#/U?<_\@YI?RGH-%>??\*^\0?]
M#[J?Y2?_ !VC_A7WB#_H?=3_ "D_^.T>QH_\_5]S_P @YI?RGH-%>??\(#XC
M3E/'>HLWHP?'_HPU!-JWC+P6PDU=4UC2EX:>, .@]^,Y^N1[TUAHSTIS3?;5
M?F'.UNCTBBJ6DZM9ZWIT5_82B2"3H<8(/<$=B*NURM.+L]S3<****0!1110
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MG+7PT6[K1GN-%<UX5\1'6(VAE&)XUR3ZUTM=L9*2NCSI1<79A1115$A1110
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M.@Z7%INFP^3:0EC''N+;=S%CR23U)J]0(**** "BBB@ KS73;=/''Q OK^\
MFTO26\FWB/*.V3S[\@L?^ @\5Z57GWPA^?PS?3-R[WS;CZ_(A_J:Z\.^2E4J
M+?1??_PQG/621Z#1117(:!1110 4444 %%%% !1110 44A( R3@>II001D'(
M- !1110 4444 %%%(S*HRQ 'N: %HHHH **** "BBB@ HHHH **** "BBB@
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M4M.MM7TRYT^\C$EO<1F.1?8]QZ$=0>QJU10!Y5I<ESHFI6OA/6;E;?4;)B=
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M.:(XWD;(!-=48\L=25K(L6L6X@XKT[PIXJATZ*&RFMHU3<!Y@'(]S7G5I\I
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MD0[VACX*GU3_  _+TK*U/QMJ&I:.EB0(F88GE0X,H],=@>_K[#BO7ARN/NG
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M%%%%;&(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.L>W 1L@#Y>.AKHJ*)3OT"Y\Z:=\)/%!U^VMKZPQIB7(\V83H5,>1N8#=G)
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M9/3<=Q.3W]*] HI*;5K= N>1Z)X8\5ZYXVT?6O$&G1:?;Z5;I"H$BL92F[&
M">I;)[8'%>N444I2<A!1114@>??$'_D;?!7_ %_'_P!&0UZ#7GWC_P";Q?X+
M4<L+XD@=<;XO\#7H-=5;^#2]'^;(C\4@HHHKE+"BBB@ HHHH **** "BBB@
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M2*!+\;M9A+*MQ;Q-V*V]NP_/#5[S10!X'_PJ[XDZU"#JWB(*I/,-Q?RR$?@
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M /%T?\+A\/\ _/GJ?_?J/_XNE]1Q'\C%[6'<]!HKS[_A</A__GSU/_OU'_\
M%T?\+A\/_P#/GJ?_ 'ZC_P#BZ/J.(_D8>UAW/0:*\^_X7#X?_P"?/4_^_4?_
M ,71_P +A\/_ //GJ?\ WZC_ /BZ/J.(_D8>UAW/0:*\^_X7#X?_ .?/4_\
MOU'_ /%T?\+A\/\ _/GJ?_?J/_XNCZCB/Y&'M8=ST&BO/O\ A</A_P#Y\]3_
M ._4?_Q='_"X?#__ #YZG_WZC_\ BZ/J.(_D8>UAW/0:*\^_X7#X?_Y\]3_[
M]1__ !='_"X?#_\ SYZG_P!^H_\ XNCZCB/Y&'M8=ST&BO/O^%P^'_\ GSU/
M_OU'_P#%T?\ "X?#_P#SYZG_ -^H_P#XNCZCB/Y&'M8=ST&BO/O^%P^'_P#G
MSU/_ +]1_P#Q='_"X?#_ /SYZG_WZC_^+H^HXC^1A[6'<]!HKS[_ (7#X?\
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M2IR%3J:0*'Y'-5>ZOLS-U81W97GC"J64<UBZO<[-"U%MV"+=U'U(Q_6ND$8
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YYJ;8U2[_Z[/\
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M !1110 4444 >&^,VQX@OL]IW_G2Z9(C0+CTJGXZD*^(=1'_ $W?^=9NB7Q
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M5?7$+$@20V[NIQUY Q7NWQ$O#8^ M6D5@K/&(1SU#L%(_(FN(\*?%#P]X?\
M#%CIDUMJ#2P*=YCC0J6+%CC+CN:8'"-X:\0X_P"0#JO_ (!R?_$U$?#7B/\
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MQ^85Z9/4['XY7XM_!]I:!\27-XOR^JJK$_J5KY^#[5R*]=^/-]YFL:/IV/\
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MI?\ R%4'\//\JSQ,6VFBJ<M&=8@R"/:O+];C:/6;HCN]>GK(J\YKS>:YBO\
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M3O?$/F.D<'//-.$N2%GN)J[.E#9SBL2\_=WI]QFK=M<LT(;!!Q6'JD\QU%2
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MD5P_PFW7FLWMU_!#;A/Q9AC]%-:0ORRD95%><8G>>*A-<6UI8VP+37$W3_9
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MZG+9R:[@>'$>'H,UCW/AZ03[5 HN[!9%73];>!,-FB[U^9V.W(%7X_#,@&6
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M4I&;IG KKXD/>LZ:4ILJ6B13UV;&ES+G[RD5A^%&-O/+#GY6&15GQ/<&*WV
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MO/&VIR(DOV;3[?!N+DKDY/15'=C^0'/H#[79_"KP;8P*DFF_:6Z&6YF8LWX
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M@L+M99X'C0N5 4LI&3@]LUS/@WQG8>#UO7O+2>9KC8%,6W@+NSU(]:48^[=
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MI!P<<548MR<V3+L9^H7(GU"1T^[G%;.DOY5NN.IY-<KI)%U$A<Y)ZUU$ "J
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M<IIDK1:BJ@Y#<&LZZ]],N'PG7P.Z-AR/:KCW(\HJV,$566 /W.:BO4,$)=G
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MY"XQBB,;*P<VMSRT:9>+B8PL%'8BKD14#!R#Z5Z(;9&7!48^E4)M#M9GW&,
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M1R0.E$X<S4D"=M#T.BBBN4H**** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ_Q7UA_O1?\ H5=QBJD^C6%SJ$=]-;[KF,@J^]AC'3@'%7\4 1XHQ4F*,47
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M,48HN!'BC%28HQ1<"/%&*DQ1BBX$>*,5)BC%%P(\48J3%&*+@1XHQ4F*,47
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MHQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10
MF*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4
M )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M
M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%
M+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8H
MQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F
M*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4
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M>,G*G49S<2@?[0V-^CD"NRTS2K/2+8P6<6P,Q>1V)9Y7/5G8\LQ]3S5VAS[
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M^7Y><[3GKG^E;U%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ Z
MU75?(E_V35BFLH84 .HI%R!@TM !1110!YSK5S#J?Q03[6Q_LWPQ8M?3 KQY
MS#(/X+M8>ZFNN\-64UKHZS7887]ZQN[O=G(D<#Y?HJA4'L@KS_<9]0^([2')
MEN+6U8^D9^3_ -!/Z5ZQ6D]$D,*XCQ/XNUA=6F\/>%M(DO-41%,US(,06VX9
M&2>"<9/) Z?>Y%=O2-]T_2H32$<#\)?$.J^(_#EY=:M=FYFCO#&K%%7"[%./
ME [DUW]>6_ K_D4M0_Z_V_\ 1:5ZE55%:3 HZQIB:OI-Q8M(T32 &.9/O12
M[D<>ZL 1]*\^2_:S\=>&_$+((#KL#:=J404@)<Q_+CKUWC8/93ZUZ?7E/BAC
M%I-H%/\ Q[>+PT9]"S,Y_5S3AV&>K4445F(**** "BBB@ HHHH XG6;NYC\=
MV,"7$JQ,T68U<A3EN>*[:N7U/0;V[\66FI1>7]GB,9;+8/RG)XKJ* "BBB@
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M* "BBB@ HHHH **Y+5=:U"V\8V=A#/MMI&C#)L4YR<'G&:ZV@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBB@ HHHH XO6;&[E\<V-S':S/ K1;I%C)48;G)KM*** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHK?>E?J?I_G\JM0PI FU!]2>II[ /50JA0, # %+112 **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>']/OID*RSP*[@KM^;') ]">1[$5I5\Y*+C)Q?0[$[JX4445(PHHHH ****
M"BBB@ HHHH X/7/^2@Z?_O0_^A5WE9]QHEA<ZE'J$L):YC*E7WD8QR.,XK0H
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH X/QI\.;7Q)*;R%VBN\8R "#^9%<[8_!6'&;R]D^BJ!_6O7J* L96@:!
M9>'=-2SLH]JC[S'JQ]36K110 4444 %%%% !1110 4444 %%%% !2,H888 C
MWI:* (&M$/W25_6F>5/']ULCV-6J* *OGRKC>G'N,4\7(/52/H:GI"JGJH/U
M% $8N%/8THF4]C3O+3^Z/RHV+_=%  '![&E!S1@>@I: "BBB@ HHHH ****
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M_P"]#_Z%7>4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,$#N,=??\^:ME]2E2]JVFBXU4Y<IWM%%%<!J%%%% !137D2*-I)'5$499F.
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MYSM.>N:W:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MMIFJ=]0HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVC)>O=SH&$/[O8$R,$]3DX)'ISTKLHU**P\X3>KV,Y*7,FCMZ***XC0****
M"BBB@ HHHH *\>^+UY?'6+2RD+KIXA$D:C[KR9()/') P,<XSVS7L-5[RPL]
M0A\F]M8;B/.=DJ!AGZ&NG"UU0JJ;5R*D>:-CBOA+//)X4EBD0^5%<,(6(Z@@
M$CWP2>??VKO:CAABMXEB@B2*->%1%"@?0"I*SKU%5J.:5KCBK*P4445D4%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>/?$$2*\EM8P(#)L8@*.Y^I/3V^AJAXNTR5/%JV*W33^>5\M6S^ZW':%Y//
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M?45XA?K!90VMQ::[+=:BQS*(PP$?T?N<UT'C74[X:+H=O/))'=/#YTX!*G.
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %!.!D]**S?$%W]B\/:A<9P5@;:?]HC
M_4B@#SGPG=V]UXZN=2NKB*%/WLRM*X498X &?9C6A\2=6MKJUL+6UN8IAO:1
M_+<-C  &<?4UE^$/!\'B*RN+FYGFB6.01IY>.3C)ZCW%4M3T"WL_&,.C6TDD
MJ&2)&9\9RV">GL: /1HM2LO"GA/3_MK$$0J!&HRSOC) 'U-8T?Q-MO.3S]+G
MC@;I('!./7&!_.L3QTUQJ?C.+3HRN46.*)6.%W-S^N0/PK4N/"/B/79;9=8O
M+6*U@X1(@,J.,@  #L.IH Z#Q!XOM-"BLY/):Y%TI=-C ?+QSSZYK'E^)]BM
MWLCL)W@!P9=P!^H7_P"O6'XQBCNO%]AH\;^7#!'#; D_=R>OY$5;^(BV%A9Z
M9I5I%&C1;GVJ.57  S]3G\J .XU'Q!I^F:0FIS2$P2J#$%'S29&0 /I7+Q?%
M"R9G$NG3H "4*N&W'T/3'ZUSOBA)C<:!H\S%!%9Q*P/\+L<'^0_*M7XAR:=9
M:=8:1:Q1++$=V% S&@&,'ZYS^% &IJ'CN-?#*7T=I-'+=F2*$;A\I48W9^I%
M87@;Q/+;Z@;&Z-S=27DJ*C-*6$?7)P?K^E7==4:9\+]/M" 'G\O(QR,YD/ZU
MHZ$ATGX;/=QJ!<>1+,& Y!.<'\L4 3:S\0-/TN\>T@A>\F0[7V,%4'TSSD_A
M4WAWQM9Z_=_8S ]M<D%E5F#!L=<'U_"L'X965NRWVHRA6F1A&K-U08R3^/K[
M5G:/(E]\2I[VT7-O')-,2HX*A2,_B2/SH [#Q!XWT_0KDVOEO<W(&61" $^I
M]?:JEG\0K>ZTV]NCI\RO:*KM&'!# L%Z_CZ5SWP_@CU7Q-=W]YMEF13*H;GY
MV;EOP_K7<:S9V=]H>KFV2!II(761XP"2ZC(#$=P?6@!VD>([?5="EU7RVABB
MW^8K')&T9/Z5SY^)%N^G3W"Z?,I1UC7+@Y+!B#^&W]:XFTUYK3PG>:1'G?<S
MAB?1,#/YX _.NJN]/_X1WX8R12H!=7;*7R.06(X_!1CZYH RO!WBF>SU1HKM
MKN\>[=(D!E)"DGDX/U%=CKGCFPTB\-E%#)>72G#)&<!3Z$^OT%4_!<0T[P++
M?A%,A\V<$CGY1@?^@UR'A.TUR\OKF^TE[<W"<223X)&[G(R#SP>: .\\/>-K
M37;TV36TEK<X)56;<&QU&>.?PJE>_$:UBNY(+&PFO1'G=(K;0<=2.#Q[TOA[
MP=<V.IS:MJ]XDMU(&XB/ +<$DX'//:N6EM]<^'^H&:,QO;S':'QE)0.0".H/
M^>: /3-#U>/7-)BOXXGB60D;7[$''7O6C532[M+_ $JUNXX_+6>-9-G]W(SB
MK= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !7DOQ$NA)XK2-U)C@B12N<9R2Q_GBO6J* .'TWXBQZCJ5M9)I;H9I
M F[S0=H/?&.U8NIWESX\\2QZ=9,RZ? 2=V.,=W/\@/\ $UZE2  = !0!Y?X%
MFET;Q==Z/-G][NC/^^F2#^6[\ZJ^)+Q]-^(S7UU TB121R(N<;E"C&#]?UKU
MK SG SZTCQI(0716QTR,XH \Q\?:J^I:?HN(6B,\;3F(G)&<!?Z_G7;7FFR)
MX-ETVW7,JV1B51_$0F,?C6R0#U'2EH \<\-^)+O1+.[T^TL6EO;A_P!VW.5;
M&.5QSBM3X:6AN=3U&\E!<+%Y9+=RYR?_ $']:]-$:!RX10YZMCDTX #H* ,$
M>"O#H(/]F1_]]M_C7&WB_P!K?%:.';F.&5!C' $:[C^H->H4F!G..: /,O'Q
M;4O%^GZ:F?N(GXNW/Z8IGQ#M);;Q!:7S6YDL_*1<8^7Y6.4/IQ_.O4,#.<<T
M,H92K $'J#0!YUI'B+0I=3L[?3/#2BXDD52[!<Q@GE@<$\=>U9/CN],OC,A4
M\T6B(NS&0<?.?YUZS'%'$,1QJ@_V1BN+TGPSJ4?CFYUB]CC6#?*\9#@DYR%X
M^AH YK6-<OO'-W:6%E9-&J'<5W;OF/&YCC@ ?S-3^/=)?3%T@1H6MH;<0;\<
M;@<G/USG\Z]32-(P0B*H/)VC%*RJZE6 93U!&0: /'?%/BB[\16]OBT:VL4;
M@9W!WQZX'0=O>NF\26<UE\,[.VC1OD$1F '3C)_\>Q7>!%"A0H '0 =*4C(P
M>E 'G?@SQ&L7AZYLDM&4V-K+<//NR&;)(&,=>?TJK\/].DNM-UN51^\EA^SQ
ML?4@Y_\ 9:],2-(QA$51Z 8IP  P!B@#QSPSXD?PG-?0W%@\CR[05+;&5ESP
M<CWKU'0;Z[U+1X;R]MQ;RR[CY8!&%R<=?;!K0,<;,&9%+#H2.13J .+^)8F/
MAV#RU)C%P#(0.@VMC/MG^E9^@>(P?!5]:Q6CQ_8;1AYN[(9VSCC'J<UZ&0""
M" 0>QI%1$7:B*J^@&!0!YEX-N6T/PKJNM+;&=O-2,(#C('4YQP/G_2LC7[_3
M?$-U VD:5/%?2,?-"@$.?8#J??BO9@ !@#BF)%'&24C52>NT8S0!P^HZ]!H%
MG8:'K6G/=PFS3S7R#\PXP >#C'7-87@ZR:\\9B^TVVF@TZ%G;+G.U2I 7/<G
M/3TKU9XTD7:Z*P]&&:4 * %  '0"@#QR#59O#OC6_N[BT::?S)0$)VG+'@]/
M\YJQX<6\U?XA1W%^C+.'::52N-N%^48[8^45ZT8T9PY12PZ,1R*=@9SCF@#Q
M_6D31_'-S<:I8FYM))7D"-P'5NA!]LC\JZGPQKNE7NK&#2= %NBQLSW 50PQ
MVX'?ZUVKQI(NV1%<>C#-"HJ+M10H] ,4 >4Z_P"*=)UZPD6ZT>6+5%&V.16'
MR\]SP3]"*ZSX>Z?=V'AY_M:/'YTQD2-Q@A< 9QVSBNI\J,R>9Y:[_P"]CG\Z
M?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
9BB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img187419207_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img187419207_6.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $^ M # 2(  A$! Q$!_\0
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M@>Y3/XUTL0RXH!;EBBBB@V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT#;S\UH_X7'I7_0-O/S6CZI6[?D'(SO=/TVUTS3X+*VC"PP($4=_J?4GK5H
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M'AB.72(=4U/5[73+:Y<I;>>"3*1U.!T'O574M!DT_3]-NUN([@:@9!$L8/\
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MYO\ RKC*[/X7?\CM;_\ 7-_Y5G5_AR]&)['M6N_\@#4/^O=_Y&OF*OIW7?\
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M]1Z?_P @VU_ZXI_(5P8[X8F=38^>/&?_ "..J_\ 7PW\ZPJW?&?_ "..J_\
M7PW\ZPJ[8_"C0****H HHHH **** "BBB@"WINF7FKWJ6=A;M/._15[#U)["
MK]MX8UBYU*]TN)%6:W(6Y4SA%'/ )S@\TWPO#--X@M?*N8[=4=7E>2<1*4#
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M>I;/QSI$]_/8SRF"X@>.)B02C2-_"IQV/'-'UBIV0<S//?\ A6GB/_GE;_\
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M1_\ /*W_ ._PH_X5IXC_ .>5O_W^%>T44?6I]E_7S#F/%_\ A6GB/_GE;_\
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MB/\ YY6__?X5[112^M3[+^OF',>+_P#"M/$?_/*W_P"_PH_X5IXC_P">5O\
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M/#^O6GB/2UO[,2+&6*E9!@@BM2D\5-:-+^OF+F9XO_PK3Q'_ ,\K?_O\*/\
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MCG;UYKJ--N[B]M6EN;*6S<2.@CD8$D X#<=B.:3BUN(N4445(!1110 4444
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MW /2NGHHYI=PN4]/TVWTU9UMS(1/,TS^9(6^9NN,]![5<HHJ0"BBB@ HHHH
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M_P ?5I_OM_Z":4=P+-%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^^W_ *":4=P+-%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO@D)R=H(VY]\9%6-5G6:&73H!YES.A7:.B _Q,>PJ-O^)G(EK$2;*!AYTO\
MSU9>BCU&>2:1+[&J#E0?49I87\F^B;M)\C?THIK?ZZW'<RK5%[69L5S/C/Q#
M/X<MM-N(AF.6]2*8",NQ0YSM [UTU9VJZ-;:P;,W#2*;2X6YCV'&67IGVYI1
MM?4] Y"V^(\:MJUQ<1.UNEY%:V431^2[%DR=V[IT)R>U6I_B39QZ'!JR:?,]
MN^\2 RHIC*-A@,GYS]*T;_P1I>H27LLDEPLUU<I=>8CC,4B+M!7CT]<U5O\
MX=Z;J44*W-[?M)'"\#2>8NZ1&.2#\N.OIBM+TQZ%+5_'Q:TUA+"SO(DL(T+W
MP5&52VTJ I/)(:KC^/K>#5S8/IMX8H[I+.6\&WRUD< KQG/.:N-X)TQM-U2Q
M,EQY6I&,S'>,C8J@;>..%%+/X,TZ?[2?,G#3WD=Z?F'$D8 7MTXYHO -"MH7
MCF#7]<.G6VGSJ@1Y//9U("JVWE0<@D]C5"U\97-KJ&JVLT,VH7+:J]K8VT05
M3L5 QY.!@<\FF>#/!NL^'=6,T]W"+4JXFCC<OYS%LJV"HVX^IK7N? VG7$L\
MZ7-Y;W4EXUXMQ#(%>)V4*0IQT('0T/D3#0J6_P 0[.[NM-MH+&?S;PL&61U3
MRF5MK+DGYF!["M+P_P"*8O$%[>P06LD26KM&7=UW$@XY3JOKS51O &E-!8VW
MGW@MK202^3Y@(EDW;M['&=Q/4@BK^E>%[32M9N]5%Q<W%W<H(R\[@[4!R ,
M=^YR:3Y+:!H;E%%%9B"BBB@ HHHH **** &3?ZB3_=/\JBL?^0?;?]<E_D*E
MF_U$G^Z?Y5%8_P#(/MO^N2_R%5]D!NG_ /'I_P!M)/\ T,TZ^E,-G(Z_>Q@?
M4\4W3_\ CT_[:2?^AFFZG_QZ9[!U)_.B7Q,BJVH-HIH@C14'84ZBH;N=;6TF
MG9E4(A.6Z9[4'%LC+GU2^%G<7UO#;_9HF*@2,=S8.TGC@#-3-8W5Q&J7>I[H
MY1S'&@3?[ YSBLN*QW:/!<6EO<-J$YW.6)4;OXMX/&T\U)9P/;ZI));::/-1
M &MVE&8\YPR$\8/3\*@RN^I):1JCO;:9(LMP>)[S;\L*]E4>OH/Q-;=O MM
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M44 %%%% !1110 4444 %%%% !52]_P!;9_\ 7<?^@M5NJE[_ *VS_P"NX_\
M06JH[@/OO^0?<_\ 7)OY&I(/^/>/_='\JCOO^0?<_P#7)OY&I(/^/>/_ '1_
M*C[(#I(Q+$\;=&!!K(BW*#$_WX_E/OZ&MFJEY:&8B6(A9E&.>C#T-)&%:#?O
M+<J50DM;N*]EN;1H6\Y5#I+G@CH01_*K@D^?9(#'(.JM_3UJ"XL(YY?.$DT,
MN,;XG(R/ITH9RO78CAB&G6=S/<RAI')DFDQ@9QP![#H*71XGAT>UC==K"/)'
MIGG^M(NEQ&17N)I[DH<JLSY4'UP/ZU>) &2<#U-"!+J%.LT\Z\\S^"'C/JQ_
MPJ.-);L[8<JG\4I''X>M:L,*01+&@PHH9K2ASN_0?1112.P**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@!DW^HD_W3_*HK'_ )!]M_UR7^0J6;_4
M2?[I_E45C_R#[;_KDO\ (57V0&Z?_P >G_;23_T,U-<0B>W>(_Q#%0Z?_P >
MG_;23_T,U:HE\3"23NF8T3$KM<8=3M8>]9%ZPAD^V:H0P1C]FM$.03_>/J?T
M%='=V;2-YT.!*!@@]'%9D]O:WK!+J &1?X7&"/;W%)ZGGS@X^ZS.L9]6U&,R
MB6."(DE7,>[=[ 'L/4]:G&CLTKSRZA<F>0!7:-@@*CH !T[_ )UJ8P, 8 [4
M46$H]R.""*U@2"%=L:#"BI*0D*,L0!ZFDCBDO#B/*0_Q2'O]/\:8_)$UBGFW
M+3_P1C8I]3WK2IL<:Q1K&@PJC %.J3LIPY(V.1\865Y=:SH$MK;RR+"]P7>-
M2=F8B!D]LFO-KJ>Z6_TZTU6>]@AM+2T%R^YRT#%B2, CEN <YKW>J5QH^FW5
MXEW<6%M+<IC;*\2EACIR16L:EM&:W/+H;?Q!)XBO)H=,U"UCDM[Q)!F1E8[3
MY9W$X)/;:!BHI/"NK1V<[Q_VT95TJ"X0>?(<W>?F&/4#^&O8Z*/:L+GE=O8>
M(G\;M/>/?QO]H5XY$A=HWA\O[A;=M49SG(SFJ-EX9UAM.MHIH=4=K[2+I;Q)
MI'(\X']TIS]T^@[U[%11[5A<\^%GJ*_"2*UTFTO[>[6-%D@DRLV P\P+DYY&
M[%9.I64SQ6/D:5XA_L7[/,([=6?SEN2?E9OFR%QTR<5ZO1252P7/'M0T'Q+<
M6MY-<_VFU_;:;9F P2,%:?=A\ <,P7K3=9LKO1KS^SW&K/IC:S$(425S+,A@
M)<(V<GYO>O8ZBFM;>X>)YH8Y&A??&67)1O4>AIJJ^H7/(H]'\0_V;"YL]0W+
MI]^MN),M+&K$>6K'KNQT'6M:SM=2BU]I-1T[6+F<6L/V!H7984 B^97.<!MV
M<YKTRBDZE^@7/#O[#UO4='UJ.32M12%K6"6.V/F#,RR?.!N)+';GZ^E;NHV.
MLLNHMIUIJJ:>T=C^YRPF:$?ZQ5R<[L=>]>J44_:OL%SR>TT+5KZ6SMWAU>#1
MI-2F:.-Y'66.#R^ YSD MG -16UCKT,GAMI;74[F:!C$\$RN$5/-.)"X/#!0
M/O=17KM%'M6%PHHHK(16L_N3?]=G_G5FJUG]R;_KL_\ .K-5+< JM<?\?5I_
MOM_Z":LU6N/^/JT_WV_]!-*.X%FBBBD 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 54O?];9_]=Q_Z"U6ZJ7O^ML_
M^NX_]!:JCN ^^_Y!]S_UR;^1J2#_ (]X_P#='\JCOO\ D'W/_7)OY&I(/^/>
M/_='\J/L@24445($<L$4Z[945A[BJK:8@_U4TJ>V<C]:O44$2IQEJT9XTV3/
M-V^/914B:; IW/NE/^V<C\JN447)5&"Z   , 8%%%%!J%%%% !1110 4444
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MJ#)JQ#8R3L'N1MC'(B!Z_7_"K\<4<0Q&BJ/]D8I]%S2-#^8.E%%%(Z HHHH
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M]_V_QH^Q1_\ /6X_[_M_C5FBGS/N!6^Q1_\ /6X_[_M_C1]BC_YZW'_?]O\
M&K-%',^X%;[%'_SUN/\ O^W^-'V*/_GK<?\ ?]O\:LT4<S[@5OL4?_/6X_[_
M +?XT?8H_P#GK<?]_P!O\:LT4<S[@5OL4?\ SUN/^_[?XT?8H_\ GK<?]_V_
MQJS11S/N!6^Q1_\ /6X_[_M_C1]BC_YZW'_?]O\ &K-%',^X%;[%'_SUN/\
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E?\]9_P#O\W^-6**.9]P(X84@0HF[!)8[F)))]S4E%%2W<#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img187419207_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img187419207_7.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1:J4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %HZ^5W0X0DE-! 0      &D< 5H  QLE1QP!6@ #&R5'' (   )P!QP"
M4  (<G(Q-3$Q.#$< @4 0$UI8W)O<V]F="!0;W=E<E!O:6YT("T@-%\@-5]0
M4&D@86YD($%44"!I;B!'04-)7W8R7TY%5U\P-2XP,RXR,#( .$))300E
M   0VKI(YWBV]#<D(E5L6YP@)SA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU
M  (  CA"24T$)@      #@             _@   .$))30/R       *  #_
M______\  #A"24T$#0      !    !XX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          (X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      S4    &
M  **   &JP         !                          $
M!JL   **                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   **     %)G:'1L;VYG   &JP    9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   "B@    !29VAT
M;&]N9P  !JL    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     <X0DE-! P     "_     !    H    #T   '@  !R8   "]0
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M[9LVY-G^#24ZZ22!
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ T (B P$1  (1 0,1 ?_$ !X
M 0 " @,! 0$            ("08' 04*! (#_\0 61    8#  $! P4)"P4,
M"04  @,$!08'  $("1$3%!42%A<A,1@9.$%1>):WU H:5EA987&7F-;7(C='
M@;$C)RA55W>'D:'1T_ E)DA4A(65X?$R4V>&E/_$ !T! 0$  @,! 0$
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MK;,JFT^>?:$-19I>WV3./N!9@&QLTC:$2!"F<XYW^\J<YY0LFP!@# & , 8
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M$ID+E+G!P;92;[1,U,S#[J(Y4)GXJGEGZ&TH=Y<+2>.\JDYY$RT+8]&79?\
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M?K2"!? QMH<GMTD2Q(&121XECIHYW>E*QR5^V>GUQ/+]X4&>P*- F*^0246
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M &:UK_5K*O9ZT^:D3A[7?%2[_(48 P!@# & , 8 P!@# & , 8 P!@# & ,
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M@# & :<M_H2D.?VYG=KKM*%U@W2%QVTL:J8OB-F ZKP%Z./)0@4C":H"D)$
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MR"DJ5.7]!36+Y!"<@!910/E"$+Y( !U\H6]^GKO*O9ZTS[U"</:OQ4O(R%&
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M26DKBYWZ&KQLBU9W9=SG<#@GIV05T12=%-BM9([65((7;LDLEFB4D<@-46A
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MF6E8QBT2H]9)849*[K6+&QW6-:]&JU?US0?97T9T"])&D*ZOZ3;O7U.H]/\
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M& LL 1#&88+0   '6Q"$(0MZ"$(=:WL0M[UK6M;WO?IK"(JKA$RJ[D1.*KW
MZOX^P[^Q[:-__,D?_C9R]1-_$R_S;_H!\?8=_8]M&_\ YDC_ /&QU$_\3+_-
MO^@&W]AWK>M/;1]>O^,D?X_J_P#WL=1/_$R_S;_[(/.-6? A$:\RLPLPV[2E
MD?CB8_K-/L8M_'G$ZV9//XL57JIW&OVE]S9G1&Z[7+@^V$OBNV]HV@(-5JE2
M3]"7+7;JGH>I+8EEV)ZE[-)KA/[GC;:::WU:W!D*1[6W-$Z+JXUPD=7UDVVY
MK&-?I<%E5FIY:GTE7-8W[Q1N%ZQRU3ZB%(5=G&Q&YCM^-\:L9LY57)Z.?C[#
M]GQMH]?R?$D?_C9^>^HG_B9?YM_T-T'S@8?^.VC_ .I(_P#QL=1/_$R_S;_H
M!\X&'_CMH_\ J2+_ ,;'43?Q,O\ -O\ H#M];UO6MZWK>MZ]=;U]>MZW]F];
M_'K><0& , 8 P!@# & , 8 P!@# & , 8 P!@# & , B;W7-K"KCD2^YQ5+;
M:KO8,;@BQQC3=1S"QR>W5*D*Q$2KU7C')8U,F!=*"VTU:<W?%HI(4:8PO:LU
MI6>[Z*$!Y?\ C:V'GK>X(G$H/*?)M7=B/#PW))K8TF\NG/\ (+#KI,8<,2AW
MFW'LD$(!B1",O8E4&W0Z0?L2AID[61LG?R!.=W.[S^1[#(6S/D>B$889-*UD
MZD3,PM+8^S5Q:VED<):[H4)"9PDBYG8$R)C;%CTJ*-<5*%G1I&Q*<H&0A2IT
MH"B@"E?EI>/A->4C\A3C:$W3+$/:=&PCG*&K&MG,V_4]5<5@DH0*&U.8X*CD
M3FH66A.I98@RTH$"588>V(EX3!H"CP!SS[B&7WIGI3:KZ>=](4S]V0*V5$R-
MD7T-2WZ!C8*HY*UQV*(_,?Z2OGH6]AA803[4D#,MD;F8--6F?4?&/>Q./J\/
MR\T-"^5CQ,\=0?Q62V8R: J9_='#_![?4=.VTXRF;,B]$WU>VGGM;HJB3#*$
M<.6GJ7UV>GL9#NSNP0&.8D)IJE&E2EEBE]G)'X*7,GYO=+_JWC6 2$P!@# &
M , 8 P!@# & , 8 P!@# /C<&] ZHE;:Z(TKBW+TRA$N0+B"E2):C5E#(5)%
M:4\(R%*9208,D\@X RC2AB+, ((MZW\O8U[7,>U'L>U6N8Y$<US7)AS7-7*.
M:Y-RHJ*BHJHJ853FIZB>DG@JJ6>:FJJ:6.>FJ:>1\,]//"]LD4T$T;FR12Q2
M-:^.2-S7L>UKFN1R(J5S];4M4U)\ER]BJ.NXA730[6W03NYM\28T3,G<'(R^
MZP*VL6!1E%B4&ED@ 01LP0M)DP )TVBB0A!K1]2VJVVG3-5!;*&EH(9+G999
M(Z6%D+7R+>[<BO<C&IM.PB-3/[UJ(UN&HB'Z?Z%]=:RU[TT62XZTU/>]3UM'
MHOI(HJ2IO5QJ*^6EI&='&K7]3 L[W)$QSU=))L(U997.EE5[W*Y;(P_9K^C6
M;T?EHYP!@# & , 8 P#R%^19]Y(IGM>Q*;-@7A[YV:VVNH#91L@Z8X$F5ZSN
MT);93E,ULM<U3W5R)D96?348U-J@]([&+GEV,>MO UAH33B45\^'?SN]1.?=
MQ3X=GU]2KRS2J5T8O8*QF[17TOD59#:H18C1$BW5DASRZQC25BES+"'-<B(6
M(610>F=FB..2XHC9:=,A7#&4$T X4J>@OB*G4$J:M(LR]+1=IN&F;>E-S0>]
M&JA3ULAE\RM"KIA4]TR:_P!),[AESI<DVLECF)[J=+E$HC2EC>65A(0(QQMM
M3Q\%1??Q\T7Y$5,Y1>"GTP[PHUK7LEJ1OAUR2M'1T&UR8^SZJ'*)1MR>+1L3
MB^&N\,J&7*+"+-1*XPD=$[BW.E@,"%@7@?7".MH&AQCJ)4XIE,5<\JOKYW^\
MIL+F3Q&5;33/-8G<TTWTY!7CG&M^.(A#9O!6&/,[%S!4TJELPAL&E93.M5:G
M<H^*RT9;],C0,)3JE8F/V,>0*2UJA6!';PW557-']<>92IZCAS)7];P?J>G6
MF)0V.)M(F)@;3*41KQHVU)K8O=R!+%BI2('RQ^IQY@_77RO357L\/FO/;\DB
M;_-?<JH7_9"C .GD4?998P/<6DC:E>8[)&AR87YG7%^U1.K,[HSF]S;5A7KK
MVJ5<B4'IE!>]ZT,HT8?7Z\YJ>>:EG@JJ>1\-1331SP31KLOBFA>V2*1B]CV/
M:US5[%1%/E[&R,<Q[4<Q[7,>UR9:YKD5'-5%XHJ*J*G:BD+OO97 >O\ V3Z>
M_1O7[1_V9N7ZRM>?RJO'])7^R8S[CL_^#:/CG^\L^AS][+X#_BGT[_KC>M_[
M3\?K*UY_*J\?TE?[(^X[/C'W;1X_^@SZ<\#C[V7P'_%0I[]&]?T_^\?^?L^S
M'ZRM>?RJO'])7OS_ .CW[_$)8[.G_)M'W?WEGT(:,? _&:CR V/6A_.-7FP)
MKY+JJ:MT4&PAVT))4\6Q:3*Z/Q";VOJ!Q7-;0V(%)WM/0:9"F!L'^1K>;?-K
MS6+=!V^Y-U'<TKY=5W6BEJDJ%ZY]+#:;5/% YV-\<<LTLC4QN=(Y<[S'MM%L
M6[3P^@4O5-MU+*V/JF;"2/J:MKWHW&$<YK&(J]J-1%X$R_O9? ?\5"GOT;U^
M+_XC_P#/X\U#]96O/Y57C^DK_9,A]QV?_!M'_,L^GGW]IS][+X#_ (J%._HW
MK]HQ^LK7G\JKQ_25_LC[CM'#[MH_YAGCW'&_&5P%OZM\GT[O6_Q?-O7Y?7_W
MC_S]GV8_65KU?_*J\?TE?[(2QV=/^3:/N_O+/H3B2IDZ),G1I"2TZ1(02F3)
MR0Z 40G(+"4224#7IH!918 @ '7U!"'6M?5K-)<YSW.>Y5<YSE<YRKE7.<N5
M557>JJJJJKVJ95$1$PB81-R(G!$[C^^?(& , 8 P!@# & , 8 P!@# & , 8
M P!@# & :(Z=B%W3Z@K2AO-]EM=.WE(HNH;:UL]Z9DL@:X5(CE";Y#VK9EK6
M])5P24@51191S4N" XTL[1/RBPC"!Y%^,"0O??\ 1[Y='1'-_;%Q1*W/F"&Z
M9-SUY-;*E:%]8GY4UO8:BM&9/*WDFNG!L=T*M&BD$6C3#!FY408I(V$ MFFN
MSNQQWCASW_5?>>U[?U:WO\FMX!Y=[)\PO15=6[VA)'7VC77--R/N2H:+K=UH
MU*XUW8EA<E4T38[<F-NQJLA'/FRQEH&J26#*6EX@7T:.%8!!'8P^I; 0J3<8
MYYX>WO0F_NY\N?4F\R07>?=@;&'QUNYZ]^E -V*VO?38J690!W DWC^!V3J)
MEUG\X!1+;\*;& AFWP:GVH:[",[2$4H%I_ Y]_TWCZ]F_P!7EGV]^XUYY)/*
M.CL#Q$!CTYYUZ4<;#[-\>4:M5=/JIIAUDW.=</%CLII3D@G%DG/>M0M*WNC4
MM<S$R]*Z*&V,N3$M4J50EGK@IZ).2/P4^9/Q?\'NE_JW]O\ FXC?V_9_LU@$
MA, 8 P!@# & , 8 P!@# & , 8 P!@$*/(/OTYB?_M_SE<__ &;]-_Y_JR_'
MZ;S4];?P?G3_ -_LB^5\MOU/>?LU?[[5M[/]RG25_HVU836U]FOZ-9MAX,<X
M P!@# & , 8!5W+^0.[$DH>3Z6\G$SBL >WAT<R(C<7-=*WC(H<G=5XEPV6(
MV",B"/*EG:]G'(V$F;)9>O0(-$IE;FY"3@-Q[.?C\/$F/;SN]OS)K4!54JI^
M!!BTXO&S>A9:K=W!^?;(M,$/1/:U:X@2EB;F=A@,8B$2B\6;@)  9H^TLH I
M/:*3U:UQ7JE2TX4W=@# & 4@>,+\/OS??G;TU^HEJRKP;X?-2)P]KOBI=_D*
M, 8 P!@'&]_5O?\ -O[< H^@7=E /_EWL"OVYY>AN#]3T9YJ:7DQH^3'5MM5
MG8%D2N2LA:L*L:L"79;W\#;'0Y 6C<) V+T19@4QK6M<O9Z[1%_@Z);?<98(
M49!>*G4DT*2_W1':+G06VEIJA6*U&*[,"3RQ)(KXZ>6.145S9HX]8BN]$_44
M],U[E>ZEBHFNV/W-:FGFJI98]K.4PDFRCE;LK(QS47]XKLB\KWDJM3@]TI^/
MUE6L8DJBP$\@>G633PA_.CA*%@5-R0<=: ,+LR&"?C??PKEJM2O,*;$1B#86
MU;M<,Q)P=%O1Q:]=1WB>YW*IIFV]U/!%2T"PMJ7/J&R.2HE6>*9.H;U:LC8R
M-%E?UB+(SJT1_P!:AOD]G6E2"GCE6?K'.DFV]A&QJS+&HQ6JKW([.554:B(N
MR[.ZTFB;)4W'2U4VPLC3C#5=CU_$YJIBKKL0E[ =)&5&ZF-9Q@RB!G!2B5;+
M(4&)TQBA/HH\Q,F&8(@OS*]6YMGO%TM3:J.M;;KA5T3:J+^]U"4T[XDD:B.<
MC=K9WM1SD:[+4<Y$VESU+,M334]0K'1+/#%,L;OWS.L8U^P[<F]N<+N3AP3@
M;7S&'., 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P# ;1E[] :_E,RC->
M2BV'R.M@W-#74)51M'+I9L@TK:ALCATO>XU&A.^TNSST29W?VE*L.)"D]])-
M/+W@'F=Y[LR24--V!D@ML>:64M3!8LFG!_%*_P <,-CT:,)ETN>I@]0L^Q%]
M.,,3BT%4OCVM F<6>[&MC;$9Y>VAU2-_R/D7L^?/9SD^>"^/K[N/%>/?A/'O
M3T\PM[>)-#XQ(9!%'2"/K['VEV>(4]K69R>8DYN* A4MC;LOCK@[,"UR95)I
MC<M5,CJY-1ZE.8:WKU:411XX?1%-3R+PPY7W-;075-3;K?4]99"S3@QQV@<W
M=\;Y;$$<5ERIQ@ZQ>H9BW>5P!&DC4IDA4=(?Y%#BBV9Z=%S'ZI=AN^?[?,P+
M7CW\<H*+#50:4J<-):L#5AEZU('319=B!8M5WI_)L/4FU*2G?43_ -[O0"I0
M$.HCL4&]A\WA":-OF3*=_#U_$UMY@8Y'XAX@^VHI%&9KCT8C/*LM8(ZPLJ%.
MVL[(Q,S,D;FAI:F](64E0MK:@3D(T"-,460E2DE$D@"6 (="DU>2/P4N9/S>
MZ7_5O&L D)@# & , 8 P!@# & , 8 P!@# & , A1Y!]>O,,@_FLGG_?V^FO
M\_U9?;O\GIFJ:U_@]/\ X_8_\^6X]Z^S4N.ENV+_ /"O25_HWU636#]FOZ-?
M[,VL\%.< 8 P!@# & , \QK?R[XO;5LNT*3Y]<Y!V=UK")=:<DN**/W<W2])
MN*06I))U;X>VK8J[$UP[((=8+M&*K=&^ ,0TL13KTASZ;\40'I7,3YKSQ7GN
M+>?'9SJ]\STS,(.\0!YJXE]MV6SAD@3O?KUT@&,,SXSQ5&2W--CR6/L,D,9]
M+&E<>F9GT3VX(3SE1XWQ02M(2(@3._*8[N<KVY)\X*, 8!2!XPOP^_-]^=O3
M7ZB6K*O!OA\U(G#VN^*EW^0HP!@# (W]>QBY9GS3<D6Y[?Q1FY7N&+T<#>"G
M'3,J)=!&$&*4C>]"&5ID=75K O:6A[V>FTS.:U(Z;5)=)-J"L_I6JL]%J.S5
M5_I_2K/!71OKX%CZYKHD:]&OD@3*SQ0RK'-- C7+-%&^-&/5VRO3N#*F6BJH
MZ-_5U3X7)"_.RJ/]3D5-ASDRUK\IL.5'93&4@!X=:3[0I:L+.:^M7"3)4+Q)
MVM36D,FDO33621\M.F7 E;I\22O$@*;6:0*SVOW!F^*;V%8V.;M[@E^+;4N.
M^=+MZT;>KM;I-)QTKGPTLK;E6T5&ZBIJASGQK21=4Z&G66:G8V7;FZK>R6.'
MK'=4K8\1INENM+33I<W/R^5%@CEF2>2-$14D7;1\F&/795K$>NRJ.=A.LW_P
M@_'7/+-Y<+(L!N@2<A_:J"AU]-H-.#EMI0VW8EB67$I9,R&G:GW'2]Q:V4H\
M"<PL;>D>5KB^(TA+J<4J3_=9JV_R]$]NM\E>]U/+?JRQ2+L1I+):;=;[95TE
M$^;8ZQ8XY9U;M(J2/ACB@>]T35:Y%;:)FH9ZAL*)(E'#5I^)RM2IJ)ZJ*69&
M*NRCW,C3LPCG/>B(]=HU=YJ.6^S>D/H*#SB@<)A!XLZ.2V10MBDC+%W-NG9J
MI&"-3E6<^/#(F7)&U -6@1JR%NU$;/-6+=DA3N!RI/DNAO5&CM-NOBZB?'1U
MU7%&RFK9Z::IBDH$8Y:J@8V"&=['RR(Q[VNC1M2U(X]I71M:O7U/072M2C2@
M1TD<;WNEB9*R)R2_A6*95>^-%1B(Y&X<KF.7*)ORER%$,MD1NEJJC]POZ.4V
MHRU_%&RPY&@]=I'J8(F9(G?W$DW9*?WG2EQ+/,&L]V2Z6F;&KTD2Z.TG+\BO
M4]NJ;Q=*BST[Z2U3U]5+;Z:3&W!1R3/=3QN1%<C=F-6HC-I_5IAFV[9VEV2F
M;,RG@94/22H9#$V>1O[U\K6-21Z;DW.>BKG"9SG"<$VOF,.<8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@$=.M["M>J.;;ALBCH_!91:L+AZN01%ELZ0
MH(E7IZE H3&N*N929SD$50,<>:F;XD[.3BJD+64F3H1CVHWOT+, J_JOH'RX
M7U C[+H*>^&F\X8 ]T;TK_54^Z0F#,M>VDL(U3"6\M1Y[0F> B,3EC2+UJ3:
M?2M*>J$0F/+.%]?@_P#:]Q/Q=R>O>J[O)"WJDGNSY'3=62"[(FUP.XGJO(@Z
MVG"61:2XL\1L%>P(%4OC;4O3.KXG6-[*_&KVY&J(>G4H].G+-+<5@!A4&?)3
MRW=(\V=*N?6/=+ES)3]X.EMWU&^R4,]F-N\W5@RL40CBGE!HAM 2[E;L-F9R
MIBI6S^3LL;JIIK8FUE2A"TKILNEE:PUQ:CI"O<YY_,G/;W]WS_(U2+E]:(G<
MU!PY<FO'W]TZK>R.61\PR_;DGDP_&;NG";.%RU\WAR,3$'I8P32*4:B)B8,W
M$78FC?AX-RPM[<X]WJ*IOGO^DO)?$?#(Q-[C>M8PRL:R\;<)C/5]/S^O%,SM
MZ63I@BX2)HG9K,)=!I69:!J$QL S3"UVBWEF<W'WA4!:'>R<_MXY!Z.^2/P4
M^9/S>Z7_ %<1K )"8 P!@# & , 8 P!@# & , 8 P!@# (4^0?\ !@D'_.5S
M]]?V?Z?ZR_'O[/\ [9J>M?X/S_X]9-W_ .<MO/M/>?LU)GI;MG_17I+_ -&N
MK4[-_;V;R:NOLU_1K-L/!CG & , 8 P!@# /('RU&;RD/7:>H.2^Z..7FQ.2
MG3N$R LD[Y0Z0"FD$7O;H%+);Q3;L0R=Q*&6^IJVQ3V:(KE=>.A:!B<1;TO2
MN8M 7D">2*O/JSN0]<9*LQG8"ETI<6L@UM:0*I"[!WIL923$:/1SLXZ$N4&:
M;VLL12A5\I8K'I(D#ZJ% M%C,V*0)-\IG&1U-HKWC-@R&Q:_?;CF=$PHVK:\
MF]E2&Q[ KY&^NTN*KJ+PQD>'V8QUGCD8D4K-EK.B/CAT79U3VG<348T@U(';
MIO)KQHX614U9,]HK'UPNABK!^A4M981-W*L2@W<PO4GIEDEEEIV 4-A$JM1@
MCKTYPB+RQW:'QW)1:!I$2>M;BE8<\^9FW,7=W-G7[K+F:C9:^O:^(M;))Q%R
M."32"@E5?RAR?V:*6C7YLQ8V4N=5C*':+2-O89O&A.#(O5,ZLL*@/JGV>! +
MQA?A]^;[\[>FOU$M6_\ 9E7L\/FI$X>UWQ4N_P A1@# & =%(I/&XBW;>)4_
MLD::0GE)MN;^ZH&9O"I4;%H@C:UR4)4VCCMA%HHK9NC#-ZWH 1;UO.:"FJ*J
M1(J6GGJI517=53PR3R;+=[G;$;7.V6\57&$W9/E[V1IM/>UC<HFT]R-3*[D3
M*JB95=R)VE+'DR\L[KR*Y59'>?V>K[6<)FG>'R0R-T>S)'&FIL9EB!'I@2$P
MZ0(5!<@7[5C5&*ERT*= C"F$4WN(U8Q(_8^C?HJCU;'=*B_37.UQT3H8*>FB
M@2GJ999F2/Z][JRGD8M/'L(U&1LVGO5V9(T8B/UB_P"H'VI:9E+'#.Z;K'/>
M]RNC8C-E$9B-[5VW[64551&HF<.SNU@[^06,1FP+2[-:6=B7R!S\;'.\H::N
M52UKVL!,I!<5C;-BJM0E/VJ/#&QR!,[/A29(6\EQP@2T:!$:> L&1BT%5U-!
M:]'2RS1P1](^HJ6:Z-HY=A:*GL]NV:MC7ILM])2G=# Y[UA6I<C$>]K55?B2
M[,BDJ;FC6JY;%03-IED;M=8^IJU6)53*JK-M'/PFTC&J[93.Z0/C-\HHNO89
M9"B_BJNJ>60%^94B)>AD (U&I4UR%*X*""VYOE\@7.('9D,;#2G;V+BL2&$+
MVP\&DIAIA.8/I)Z,TTE66YMB=<[K25]/,]\;Z=:FII9:=\;7+))20,C6*=)$
M6+:C8]'1RM7;1$<=FPWQ;I#.ZI9#3R0O:W+7JV-[7M5R;*2.5R.;LKM)M*F'
M-7=G"6^,;\QR9L3/4<>&M_9UFC-HW9E<$CHV*]%&F$&[2KT)RA*HT4>4:29L
MHT>@'%F%"]!@$'7DLT,U/*^"HAE@FCQMQ31NBD9M)M-VF/1KFY:J.3*)EJHO
M!38FN:Y$<UR.:O!6JBHN%PN%3*+A=WB=MG&48 P!@# & , 8 P!@# & , 8
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M8]*BUZ)B)>E9<87NIL9"[(V63!:WX"AO+#V8YX$S< 8 P!@# & , 8 P!@#
M(A][45'^F./[YHF66 RU9&+'A>V9_L&1%D&,<6:$SLV.Z]R=-*7F/$ 1^[-I
MA!QYKTV@3A.]X$I#HKT$!3+03=X$VOKZJ(#QC5CG>O1D?EZ)Z;)3SPY= V[
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MJ-1SU?E&IP3#7(GMQE=V5W(:]-\8/"I"8S15#(BPDD#T6$$]M,(0:++W\@(
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MA%OT@:?VO 'SYA/\,(M^D#3^UX ^?,)_AA%OT@:?VO 'SYA/\,(M^D#3^UX
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M6<#LD&M;3-3B6W@3Z]NC4F 7.#B  CE(21",T\-V.>>' <^TAUOQ0]0;<!=
M[OZCONP1VT?+C5>JLFWT &0(_D/7' HQ\VMSO<[!(/FH$-C?'-2,2/YUZU'-
MM?P/8G';G\B8]N.>[W<,HG#LD:?X1?'K/:LYM@?0]'M=]27FN@*]Y[BD_D4D
ML&,.JJ)P)*I&4(;9#)HR-A'Q!]<WM[V684K4IAN@T7OQZ9,GT 4QC?[GL\.
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M),$L:EO6Z(,,]U7)PG%".2'^S4%!-+V,L.AA]0/OP!@# & , 8 P!@# & ,
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(K6 , 8!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img187419207_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img187419207_8.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1#R17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $UA<G1I;B!"
M;WEL90    60 P "    %   $*:0!  "    %   $+J2D0 "     SDW  "2
MD@ "     SDW  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                       R,#(S.C R.C(S(# Y.C4P.C,T #(P,C,Z,#(Z
M,C,@,#DZ-3 Z,S0   !- &$ <@!T &D ;@ @ $( ;P!Y &P 90   /_A"Q]H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTG
M[[N_)R!I9#TG5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED)S\^#0H\>#IX;7!M
M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(CX\<F1F.E)$1B!X;6QN<SIR
M9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN
M<R,B/CQR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2)U=6ED.F9A9C5B9&0U
M+6)A,V0M,3%D82UA9#,Q+60S,V0W-3$X,F8Q8B(@>&UL;G,Z9&,](FAT=' Z
M+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(B\^/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M8F$S9"TQ,61A+6%D,S$M9#,S
M9#<U,3@R9C%B(B!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"\B/CQX;7 Z0W)E871E1&%T93XR,#(S+3 R+3(S5# Y.C4P.C,T+CDW
M,CPO>&UP.D-R96%T941A=&4^/"]R9&8Z1&5S8W)I<'1I;VX^/')D9CI$97-C
M<FEP=&EO;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M8F$S9"TQ,61A+6%D
M,S$M9#,S9#<U,3@R9C%B(B!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C
M+V5L96UE;G1S+S$N,2\B/CQD8SIC<F5A=&]R/CQR9&8Z4V5Q('AM;&YS.G)D
M9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS
M(R(^/')D9CIL:3Y-87)T:6X@0F]Y;&4\+W)D9CIL:3X\+W)D9CI397$^#0H)
M"0D\+V1C.F-R96%T;W(^/"]R9&8Z1&5S8W)I<'1I;VX^/"]R9&8Z4D1&/CPO
M>#IX;7!M971A/@T*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" \/WAP86-K970@
M96YD/2=W)S\^_]L 0P '!04&!00'!@4&" <'" H1"PH)"0H5#Q ,$1@5&AD8
M%1@7&QXG(1L=)1T7&"(N(B4H*2LL*QH@+S,O*C(G*BLJ_]L 0P$'" @*"0H4
M"PL4*AP8'"HJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ_\  $0@#7@1* P$B  (1 0,1 ?_$ !\   $% 0$! 0$!
M           ! @,$!08'" D*"__$ +40  (! P,"! ,%!00$   !?0$" P $
M$042(3%!!A-180<B<10R@9&A""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ
M-#4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(
MB8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8
MV=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$        !
M @,$!08'" D*"__$ +41  (! @0$ P0'!00$  $"=P ! @,1! 4A,08205$'
M87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#
M1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66
MEYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7F
MY^CIZO+S]/7V]_CY^O_:  P# 0 "$0,1 #\ ^D:*** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q?$7C#0?"B0'7M12U>X)6
M"$(TDLI'7;&@+-CV%;5>:^$T34OCQXZO=0"O=Z9%96=F&',,#QEVV_[S<T =
MEX>\6:)XJAGDT&^6Y^SL$F0QO')$2,@,C@,N1ZBMBL;Q5='3?#=]>P:I8Z+*
MJJ&U&]C#QPKN&21D;C@G:,_>(KSOP/\ $-]0^)47A^U\91>+K&ZLI9FE^PK;
MR6LJ%>,HJAE8$]B<CK0!Z-X<\26?BBQN+O3XYHTM[R:S<3* 2\3E&(P3QD<?
MR%7-4U.ST72;K4]3F\BSLXFFGDVEMB*,DX )/'H*\?T3Q%J6@> )X="\E=3U
MCQE<Z9;33IO2!I)W)D*Y&=JJQQZXZ]*[#4X?%GA3P7XGU&[\5?VNUOI-Q<6D
MDMA%%);S)&S _(-K+P."O;J<T ;&N^.-,T/2M,O1#>:BVK.J6%M8P[YK@LN\
M85BN!M&26(Q5O2O%&G:MJ#:=%Y]OJ4=K'=3V5Q"R20))G;N_ASD$8!/2O)_%
MD.N:YXJ^%EXGB*>SFU"%G4QVL+""7[,&>0!E();=C!X'8"NNNO%VHZ%XT\16
M]_=->:?HOAJ/4?+\M%9Y%,F]L@9RP0<=!V% 'H5%<%X0M?&^I66C^(=6\4PM
M'?1)<W&D+I\8ACCD7<$20?/N7(Y+,"0>*XKQS\2[CPS-J-U:_$G3;C4K.8F/
M0(=/1H74/CR6E&YP^WJ=PY'04 >UR7]I%?0V4MU"EW.K/% T@$DBKC<57J0,
MC)'3(JM#KVFW'B&YT.&YW:C:PI/-!Y;#8CDA3NQM.<'@'->9>*M,UC4_C=X:
METWQ-=::+O3+J2WV6D$GV90(MRC<IW;B<G=G';%;MYXOO]#\;^)(+ZX:ZTW1
MO#<>I>3Y:*S2*9-[9 SE@@XZ#L* /0**\BN=3^(5C\.%\?2>([61UM%U&30_
ML$8M_)(#&,2#]YN"'KN(SQBM/4]>\2Z]\1M,T3PUK$>D6%]X?&IR226J321_
MO0N4##&XAE'S94#)P3B@#TJBN+^'NM:S>7/B'1/$=W'J%YH=^+=;U(1%Y\;1
MJZ%D7@-\W..*[2@#DM3^*'@_2-2N+"^UC$]JVRX\JVFE2!O1W1"J'V)&*UCX
MDLU\:IX7,<_VY]/;40^T>7Y8D$9&<YW98<8QCO7G:S>(/@Y+J]Q<Z8-<\(7-
M]+?O=VC8N['S&RWF(?\ 6*#W!SCDXZ"EXU\;VWAGXN6>NVL?VP7GA7RK,D[8
MB\MW'Y;2.?N1\@EC].I% 'M%%>8^,/%'B#P+X1T.SO-5^WZYJ]Z()=02P\Q8
M%(+.8X(P"^T *H.2<Y)IO@3Q;KEWXV?1[N[U36M+FLVG2_O]$:P>WE5@/+.$
M56# D@X!&,4 =SX6\26?B[PY;ZUIL<\=M</(BK.H5P8Y&C.0"1U0]^F*UZ\&
MT+QI=^$O@=X6@TQO*N]6U2[M5N!:M<F!/M4[.ZQ+R[8& OO[5T7A+Q/XBU3Q
M-=:!_:VKWUE=:?))!K%YH/V.2RG! "X,8CD!!W#*]5QS0!ZA9W]IJ-N9]/NH
M;J$.R&2"0.NY3AAD=P001V(J>O(O@YI^L67@F\U"3Q,7MEGOU2UNK:)8(Y1.
M_P"^9U ?&021NQR>F!6?9?$R2U\;Z#8V?Q#M/%8U&_6SO+&+3DA6(.IQ+$ZC
MH& !!9NM 'JVF>)+/5?$>M:+;QSK<Z*\*7#.H",98Q(NP@DG@\Y YK0OKVVT
MW3[B^OI5AMK:)I9I&Z(BC)/X 5P_@W_DKWQ'_P"N^G?^DBU5^-6O:?8^'M-T
M'5+^.Q@UZ^2WN9G;;LM4(>8Y]P G_ Q0!V_A_P 0Z7XIT.#6- NUO+"XW>7,
M$9<X8J>& (Y!ZBHO#GB2S\46-Q=Z?'-&EO>36;B90"7B<HQ&">,CC^0KSWX5
M^)-!_P"$^\5>'/#6H6MWIEPZZO8BV/RQ[\+/'C&  X4@#L]97@_3_&4_A;Q)
M>^'O$EOI<5KK.HR6UJ+%)?M#"9B1*[Y(!(P-F,=<GH #VZBO)[CQOXE\06OP
M[/AV[M]+G\3PSFZ,L F2,I"'+ 'DD8;:,@$XSD5>T[Q5K?A;6O%FE^*-1_MV
M+1M)75[>[^SI!*T>)-T;*@"DY3@@#WH ]*HKR*YU/XA6/PX7Q])XCM9'6T74
M9-#^P1BW\D@,8Q(/WFX(>NXC/&*T=4U[Q+K_ ,1M+T3PUK*Z1I]]H U.65K6
M.:2/]Z!E PQN.Y5^;( R<9Q0!Z917FVIWOBZ[^*4?A/3/$4=C:IX?AO+BZ-E
M')*9?.DC9D4C:"V%R#E0!P,G-8VE:G\1-<T'Q&__  D]G93^&+RYLEEBTY&;
M49(0'W2ALJBE6480 YR<\8(![%5'6]5@T'0-0U>\21[?3[62ZE6( NRHI8A0
M2!G XR17":GXUDN?ASX<UZ\\5V/A%-2M4GN)7MUFD=B@.R%6)'!).2K'&.*Y
M_3?&L_BKX7_$JRFUF+7H=+T^X6VU6.W$!N(Y+5V^9   RD,I( !Q0!Z?;>+=
M(N;C1K;SWBNM;M3=V4#QMN>,*K-D@%00&'!/TS6G:W]I?-.+*Z@N#;2F"<0R
M!_*D !*-CHP!!P>>17G=AK6IVFH?#+1K*[,%GJFC7!N4$:L6:.VA,9R02,%B
M>.N><UG_  BT?68==\57$_B>YN+:V\27<5S:M:0*MW)Y4?[UF"[E/*\*0/E'
M')H ]*T'7]-\3Z';ZOH=S]JL+G=Y4OELF[:Q4\, 1RI'([5HUXM_PM#7+;X3
M>&[V:Y\S6-<U*XLVO!9&8PQI/*"ZPQ@;V"(H  Y/)[UK>"?%^OW/C";2);G4
M]=L);%YXKW4=%;3V@G4@>42$565@<YQD8[T >IT5Y;\._$NKZSK44?B/Q8T.
MK[7:\\,W.EI;&(\_ZICAW4<'=EP1Z=NT\9ZB^E^&9KI-=LM "LH?4+V,2+$I
M/.%) +'H ?R- &]17E'PX^($FM?$*]\.P>*X_%E@-,^W1WOV-;>2%UD5&C(5
M55@0ZL#CV^N/9>(OB%=_"6?QV/$]LOV$3R)I_P#9T96YCAE=6\U\9#':<;-H
M  SDDT >WUD:?XDL]2\4:QH,$<ZW6CK;O<,Z@(PF5F7:0<GA3G('XUR&L>)-
M;\0^.M(\+>&M3&A^?HQUJ[N_LZ3R",N$2- X*@[B<D@\=,56^'$.JVWQ8\?P
MZ]=P7MY'%IBFY@B\H2KY<NUBF3M;'4#C/2@#LO$OC/0O"'V0:_>/;M>NR6Z1
MVTLS2%1D@+&K'@&G>'/&.@>+%N/[ U%;I[9@L\31O%)$3TW1N PS@]17#_%:
M>_MOB%\/)M(LH[^\6\N_*MI)_)60^2,@OM;'&3T/2E^'4EYKOQ.\4Z]K]O'I
M.LVL,.FR:/&WF>3%_K$E:3@2;^<$ # H ]!T'7]-\3Z';ZOH=S]JL+G=Y4OE
MLF[:Q4\, 1RI'([4SQ+K]KX6\-7VN:A'-);6,1ED2!07('H"0,_B*\TTOQWX
MFU+X=>%([:\A.O>(M3N;(W\T"E;>*.6;+B,85F"1@ =">M7O'^EZ_I?P?\8Q
MZ]XA_MR%[$&WDDLXX)8SGYPWEX5A]W' (YSF@#TZ&59X(Y4SMD4,,^A&:?7G
MG@;Q-J/BZ^N=7@O/L/AW25:R%@8E,]Q,@&^27(W1@?PH,$]3Z5P,/Q4\3ZQH
M#^(],U+4DN69Y;70X/#<DUK(BL0L;7 0L6('+*P )Z<4 >]27]I%?0V4MU"E
MW.K/% T@$DBKC<57J0,C)'3(J>O'O$=AK6L_&3PK=6/B&\TAK[2;F:&/['"[
M68VQ;TPZ<[B<G=D@CC%7/%/B37-/\;RZ;JGBM_"FEQP0_8+]],2:&^D(/F>;
M*XVQD,,;04R#P: /5:Y76/B9X1T'4YM/U'5Q]KMQF>*WMY;@PCK\_EJVSC^]
MBM^\GEM]&GG@(GFCMV="!P[!<C\S7%?!"TMXOA+I%Y#MDN=1#W=Y<=7GF9VW
M,Q[GM^% '9Z1K&G:_I<.I:->0WMG.,QS0MN5NQ_$'C':KM>))XBD\ :I\6[C
M1K6.2UL;JQFL[?\ Y9_:[F-5?.".-[(2./K7=6=IXJ\,V\^L>(O%2ZU:6]G+
M-=6G]GQP[65=V8G3!QP1AMV0>M '9T5Y[X-C\;Z]I>C>*+_Q/!'#J*1W<FCI
MI\?DI!(-P19/]9OVD'<21GM4W@'Q+JNMV'C234[KSGTOQ#?65H?+5?+AC"[%
MX SC)Y.2>YH [RBO'O\ A,O%UY\/?AY=:=J<$>JZ_=+;W=Q/;HR,&BD)8J .
M05# +C)4#H37J6B65_I^E1V^K:J^K72EMUW) D3."<@%4 7@<<"@"_1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %<?K_@6XO?%"^)O#.N2:#K!@%M<2"W6XANH@<@21$C)'
M9@00.*["B@#A=5^'NI>(_"UWIGB7Q3-?7,T\,\%PEC''%;/$VY<1<[@3U#,<
M^U/TOP)JT7C+3O$>O^)_[4N+"VFMD@CT]+>(+)MQM 8D$;3G);.1C;CGMZ*
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M%FN65AJ>GZ3XXN+2QU:YN)[N$Z>DA7S78D1,6S&=I"D_,"1N !->ET4 <D/
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#(#YZ?PU[=7FWA?PGK6F_#SQEIEY9^7>:G?ZE-:1^:A\Q)01&<@X&?<C'?%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *STT'38_$DFO+;?\3.6
MV6T:X+L3Y0;<$ )P!N.>!SWK0HH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#/
MMM"TVTUZ]UJWMMNH7\<<=Q.79MRQ@A0 3A0,GH!GJ<UH444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %<+X:\-6>N:9<W^I7>L27$FIWZ$IK5W&H5+N5% 5)0H 50
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M^>^M?^#Z^_\ CU'_  @FC_\ /?6O_!]??_'JZ.B@#G/^$$T?_GOK7_@^OO\
MX]1_P@FC_P#/?6O_  ?7W_QZNCHH YS_ (031_\ GOK7_@^OO_CU'_"":/\
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M .>^M?\ @^OO_CU'_"":/_SWUK_P?7W_ ,>KHZ* .<_X031_^>^M?^#Z^_\
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MX:B\>?\ /OHW_@*__P <H_X:B\>?\^^C?^ K_P#QR@#Z^HKP'X,?&SQ1X_\
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MLW"=ODE+\D>JP0K;V\<*,[+&H4&1R[''JQY)]S4E%%>@8MMN["BBB@04444
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M^M(RC)7B[HX:U&K0FZ=6+C)=&K,****HR"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** .?\??\ )-O$O_8)NO\ T2U;D'_'M%_N#^58?C[_ ))MXE_[!-U_
MZ):MR#_CVB_W!_*@"2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *\6^$<,=_P"/?'"WT:W(36;T()EW
M[0)A@#/2O::\/^$%V8?B;XOMP@87&MZ@"V?NXES7)B>7W.;^9?J<.,Y;T^;^
M9?J=_P"(L#XH># .!LO@/^_2UV.<]*\V^(-CKM[X@T'5+/38A'I-\ AEN0//
M,DD:IP!D#(Y^M0_#G6=6FCU?RM%69XKOR9-ETJA67KUZ]:4:O+5<6MW^B/LJ
MN7NME].O":]R-FKK=SD][]FCT^BBBNP^;"BBB@ HHHH **** "BBB@ HHHH
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M^4$ 97!QU/SMS37GY_K_ , 3\OZV_K_([6BBBD 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% '->,/\ C]\,?]AJ/_T3-72U
MS7C#_C]\,?\ 8:C_ /1,U=+0 444=.M !13?-C_OK^='FQ_WU_.@!U%-#JQP
MK*3[&G4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '/^/O\ DFWB
M7_L$W7_HEJW(/^/:+_<'\JP_'W_)-O$O_8)NO_1+5N0?\>T7^X/Y4 24444
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MV.F.3*K3<X5(N5K[Z;V[=OQ/8****[#YP**** "BBB@ HHHH **** "BBB@
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MCBC5BQ53AMASTZ55\+WGF^,O",XFA""UN+>2WL[%XH[-V16$,DCEF>3(.22
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ME%SM7##/YD#\:ZBN*C'EKU->S_#T\CSL/#EQ-7WGT?3M;MY!1117:>B%%%%
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M , ;7_XW0!TM%<U_PCOB#_H=;_\ \ ;7_P"-T?\ ".^(/^AUO_\ P!M?_C=
M'2T5S7_".^(/^AUO_P#P!M?_ (W1_P ([X@_Z'6__P# &U_^-T =+17-?\([
MX@_Z'6__ / &U_\ C='_  COB#_H=;__ , ;7_XW0!TM%<U_PCOB#_H=;_\
M\ ;7_P"-T?\ ".^(/^AUO_\ P!M?_C= '2T5S7_".^(/^AUO_P#P!M?_ (W1
M_P ([X@_Z'6__P# &U_^-T =+17-?\([X@_Z'6__ / &U_\ C='_  COB#_H
M=;__ , ;7_XW0!TM%<U_PCOB#_H=;_\ \ ;7_P"-T?\ ".^(/^AUO_\ P!M?
M_C= '2T5S7_".^(/^AUO_P#P!M?_ (W1_P ([X@_Z'6__P# &U_^-T =+17-
M?\([X@_Z'6__ / &U_\ C='_  COB#_H=;__ , ;7_XW0!TM%<U_PCOB#_H=
M;_\ \ ;7_P"-T?\ ".^(/^AUO_\ P!M?_C= '2T5S7_".^(/^AUO_P#P!M?_
M (W1_P ([X@_Z'6__P# &U_^-T =+17-?\([X@_Z'6__ / &U_\ C='_  CO
MB#_H=;__ , ;7_XW0!TM%<U_PCOB#_H=;_\ \ ;7_P"-T?\ ".^(/^AUO_\
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MYHR<!XW##\Q275I;WMNT%Y!'/"V-T<JAE.#D<&N?\"(L6@3I&H1%OK@*H&
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 <_X^_Y)MXE_[!-U_P"B6K<@_P"/:+_<'\JP_'W_ "3;Q+_V";K_
M -$M6Y!_Q[1?[@_E0!)1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %>=_!__ (]/&/\ V-NH_P#H:UZ)
M7G?P?_X]/&/_ &-NH_\ H:T >B5RGA^RATWQOK=K:;UA,4,NQG+ ,Q8L1GU-
M=77+K&]M\4&*2MLO-.WR1X&,HP4?S/YURXA)2IRML_S37^1Q8I)3I3MM+\TU
M^=CJ****ZCM"BBB@ HHHH **** "BBB@ HHHH Y7XF@M\-=9 !)\E>!_OK63
MJ/Q6\-Q:#+_9FJG[:L0$8-G+C=QZIBO0*H:WI[ZKHMU8QR"-IDVAV&0.:PJ0
MG=R@^G;U\T>MA,3AE"%'$0;2E>ZDEORIW3C*^WD<O9?$_P .7GB9[5=9C2T>
MV0PF:%XAYN7+Y9E&/E"=>/3FNUBECGA26%UDCD4,CJ<A@>00?2N$\16+)\:/
M".H;QLEAN8 F.05C=B?_ !\?E7>T47-N2GT?_!%F-/#0C2GATUS1N[M/JX]$
MNVX4445N>4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '
M/^/O^2;>)?\ L$W7_HEJW(/^/:+_ '!_*L/Q]_R3;Q+_ -@FZ_\ 1+5N0?\
M'M%_N#^5 $E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5YW\'_^/3QC_P!C;J/_ *&M>B5YW\'_ /CT
M\8_]C;J/_H:T >B5R^I/+:_$C1YO+#175K+;!MV-I'SDX_ ?G745R_BB;[)X
ME\,W4D<C1+=/$S(N=K2+M7/XG]#7+BM*:EV<?S1Q8W2DI=I1_P#2E^AU%%%%
M=1VA1110 4444 %%%% !1110 4444 %%%% '%>/HYK?7O"&J6T_ER0ZNEJ5V
M [EF&UN3T^52/^!=L5VM<9\29HK:W\-SW$BQ11^(+5W=VPJJ-Q))/05V=8P_
MB2^7Y'IXF[P=!O\ O+\;_J_O"BBBMCS HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH Y_Q]_R3;Q+_ -@FZ_\ 1+5N0?\ 'M%_N#^58?C[
M_DFWB7_L$W7_ *):MR#_ (]HO]P?RH DHHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O._@__P >GC'_
M +&W4?\ T-:]$KSOX/\ _'IXQ_[&W4?_ $-: /1*X_QOJVGQ1Z8KWL&^WU6"
M29!("R*I))*CGBNPJGJ=C]MM5CCV*PGAD)8=DD5R/R4USXB$ITG&)S8JG.I1
ME&&_]>@W2]9T_6H'ETNZ2X1&VL5R"I]P>:O5RG@VZ1;K5K38=[ZE=2A@.,!U
M&/UKJZ>'J.I34GN&%JNM24Y;^04445N=(4444 %%%% !1110 4444 %%%% '
M&_%B*.3X:ZBSHK-&\#(2,E3YR#(]#@D?B:[*N<\?:1>Z]X'O].TR-9+J8Q%$
M9PH.V56/)]@:I_VYXX_Z$ZU_\&J__$USN7)5;:>J71^9[$*3Q&!A",HWC*>C
ME%:-0MNUV9U]%<-J7BWQ?I.F7%_>^$;9+>W0R2,-44D >VVNSLY_M5C!<%=I
MFC5]N<XR,XK2-2,G9?DT<5?!U:$%.5FGII)2U7HWW)J***T.0**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH Y_Q]_R3;Q+_ -@FZ_\ 1+5N0?\
M'M%_N#^58?C[_DFWB7_L$W7_ *):MR#_ (]HO]P?RH DHHHH **** "BBB@
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M445UGSP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MPR ?*-H( '4?D =Y1110 4444 %%%% !7C7P-_Y'CXG_ /8??_T9-7LM>-?
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'/\ C[_DFWB7_L$W7_HEJW(/^/:+_<'\JP_'W_)-O$O_ &";K_T2U;D'_'M%
M_N#^5 $E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 <_X^_Y)MXE_[!-U_P"B6K<@_P"/:+_<'\JP_'W_ "3;Q+_V
M";K_ -$M6Y!_Q[1?[@_E0!)1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MLE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 &!Z48'I110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKQ;0X(E^,'A>=8D$TAU]7D"C<P6^DP">I R<>F3ZT >TT444 %%%% !1110
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M.;>!8]V(3C.T#-=Y54Y2=U+I_D<^+HTJ:ISI-VDKZ[_$UT] HHHK4X0HHHH
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M7C9:/R]$%%%%=1VA1110 4444 %%%% !1110 4444 %%%% '(>*/^2A>#/\
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M\3  _P"F8KD:E3KIWTE^B9PM3I8E--6G]^B?6_EV.DHHHKK.X**** "BBB@
MHHHH **** "BBB@ HHHH **** ./^'_^N\5?]C!<_P#H*5V%<?\ #_\ UWBK
M_L8+G_T%*["L:/\ #1Z.9_[W+Y?D@HHHK8\X**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH Y_Q]_P DV\2_]@FZ_P#1+5N0?\>T7^X/Y5A^/O\ DFWB7_L$W7_HEJW(
M/^/:+_<'\J )**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"0"S%QR>@'0TSP_XNU2>?P$E]-'<+XBT,SW(\L*ZSK#%(9!CC:=[ C& =N*
M._HHHH **** "BBB@ KR3Q9_R;IXK_Z^=2_].$M>MUY)XM_Y-T\5_P#7UJ7_
M *<): /4=+_Y!%G_ -<$_P#015JJ&@W4%[X=T^YLYDF@EMHVCD0Y5@5&"#5^
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q
M_%W_ ")NK?\ 7I)_Z#5W2?\ D#67_7O'_P"@BI;RTAO[*:TNDWPS(4D7)&0>
MHR.:P1\/_#@Z64G_ (%2_P#Q5<LXU55YX)/2VKM^C..I"LJWM*:3TMJVNOHS
MI*K:C_R"[O\ ZXO_ .@FL3_A /#G_/E)_P"!4O\ \51_PK_PX>ME)_X%2_\
MQ5-RQ%OA7_@3_P#D2HU,5&2?)'_P)_\ R!G> =?T>V\ :/#<ZM8Q2I; ,DER
MBLI]"">*Z+_A)M!_Z#>G?^!<?^-9/_"MO"G_ $"A_P!_Y/\ XJC_ (5KX3_Z
M!0_[_2?_ !591^M1BH\L=/-__(G;7Q,ZU:55TK<S;^/N[_\ /LMZ;XPT>\M9
M)+C5-/@9;B:(*;M.521D5N3W"@_C4MSXLT.WB5UU6QF)D1-J72$@,P4MUZ#.
M3[ UAZ;\-=!^S2?VEI:F7[1-LQ,_^J\QO+Z-_<V^_KS3M1^'/AR.U0V6DYD\
M^$';+(?D,BA_XO[I:DYXM0ORQV[O_P"1,L34E'GY*:ZVM._W?N]3H/\ A)M!
M_P"@WIW_ (%Q_P"-'_"3:#_T&]._\"X_\:R?^%:^$_\ H%#_ +_2?_%4?\*U
M\)_] H?]_I/_ (JM.;%?RQ^]_P#R(O:2_P"?7_D__P!S-;_A)M!_Z#>G?^!<
M?^-'_"3:#_T&]._\"X_\:R?^%:^$_P#H%#_O])_\51_PK7PG_P! H?\ ?Z3_
M .*HYL5_+'[W_P#(A[27_/K_ ,G_ /N9K?\ "3:%_P!!O3O_  +C_P :TE97
M4,A#*PR"#D$5P?B7P#X:T_PSJ%W:::(YX8&=&\US@@>A.*[33?\ D%6G_7!/
M_0154JE5S<*B2TOH[_HB8UN:HZ;A9I7^*_\ [;'L6:***Z34**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .?\??\ )-O$O_8)
MNO\ T2U;D'_'M%_N#^58?C[_ ))MXE_[!-U_Z):MR#_CVB_W!_*@"2BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FNXCC9VR0H).!DTZB@
M#S#QSJWA7Q/X;TBYU6P\2XN5DELKG2[*9;FV_@?)493<#C##!':J'POM/">F
M>((8=+@\7W>H"U-M;7?B"VEVVT"C/E(Q541>!@ =@*L:OX\\76OQ-L[*W\':
MK):+:70^RI<P8N]LD868$MP .QP?GZ=:VM)UCQGK_C33I+GPW=>'M%M89C=_
M:KJ&0W3L (U"H21M(SGZCZ@'>4444 %%%% !1110 5P=K&DOPB\1)*BNIEUG
M*L,@_P"E7!Z5WE<9H=G+J/PVUFRMMIFN;K5X8]QP-S7=P!D_4T 6/A;_ ,DE
M\+?]@JW_ /0!75UPOP6U"74/A!H1GB6)[6)K,A6R#Y+M%G\=F?QKNJ "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@#%\8_P#(EZM_U[/_ "K1TW_D%6G_ %Q3_P!!
M%9OC,A?!6K%B% MGR2< <5SUG\5O"T%C!$]V^Z.-5.%'4#'K7#.M3I8ANH[:
M+\V<=^7$N3VY5^;.\HKD-$\>Z7J^I7A@N)GMU5#$! 6P>=WW0?;K77@Y%=%*
MM"LKP=S>E6A53Y7L%%%%;&H4444 %%%% !1110 4444 %%%% !1110 4444
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MTM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% ",H92& (/4$=:C^RV__/"/_O@5+10-
M-K8X/PDH3XF>*U0!5$B8 &/X4KO*X3PG_P E.\6?]=$_] 2N[KDPGP2_Q2_-
MD+XY^K"BBBNLH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%M7\5:-I:>'9[*&^TW5K?48S?;_*8Q;B =HSU(].,\T =C17G?E_&?\ Y^/
MW_?J[_\ BJ/+^,__ #\>!O\ OU=__%4 >B45YWY?QG_Y^/ W_?J[_P#BJR]=
M\2?%/PG'87NNGPC-97&H6]I(MG#<^9B1PN1N8#O0!ZQ1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% 'D#^-;#P=\2/$CWR-(9YE 53@CY$YK2_X7AH?_ #Z3?]]C_"O2C#$S
M9:-"3W*BD\B'_GDG_?(KSUAJ\6^2I9-M[+J;.&%;<O?3>]I0M?RO3;_%F?X=
MUR+Q%HL6I01-"DI8!7.3P<5J5S?@3CPQ_P!O4_\ Z,:NDKIP\I3HQE+=I'#A
MINI0A.6[2"BBBMSH"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH Y_P ??\DV\2_]@FZ_]$M6Y!_Q[1?[@_E6'X^_Y)MXE_[!-U_Z):MR#_CV
MB_W!_*@"2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *YSP)_P BU-_V%=2_]+IZZ.N<\"?\BU-_V%=2
M_P#2Z>@#HZ*** "BBB@ KSSXZ6AG^$>IW4=Q+;SZ<T5[ \1 (D1QM_4Y_"O0
MZAN[.VO[22UOK>*YMY1B2&9 Z./0@\&@#F;3XE>"C90>=XQT+S/+7=NU*'.<
M<Y^:NIBECGA2:!UDBD4,CH<A@>00>XK@/B)X&\/CX;>(/[(\+:;]N^P2^1]E
MTZ/S=^TXV[5SGTQS7.R_%J+3O!FE6=OH?BBUNK=["&61]'<*5$T2RH">I9=R
MCN2P Y- 'LE%>>_\+DTO_H6?%O\ X)):/^%R:7_T+/BW_P $DM 'H5%>:_#G
MXJV'B22QT*]35%UF:&6</=V+1I*BN>00,8 XSP,C&<\'TJ@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M YSP)_R+/_;U/_Z,:NCKS30/&J>'X?[+O=&U-C]HF8/';,2^6+?*I +=><?6
MMJ3XE:=#$TDNCZ\D:*69FTUP% ZDGL*X,+7I^QC%O5*S%EF#Q-?#QC"#O&R:
MLTT[)VL_)I_,[&BJVG7T.J:7:W]KN\FZA6:/<,':P!&1]#5FNY.ZNBY1<6XR
MW04444R0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y_Q]_R3;Q+_
M -@FZ_\ 1+5N0?\ 'M%_N#^58?C[_DFWB7_L$W7_ *):MR#_ (]HO]P?RH D
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "N<\"?\BU-_P!A74O_ $NGKHZYSP)_R+4W_85U+_TNGH Z
M.BBB@ HHHH **** "L[7-*_MG3X[4S&'9=VUSN"[L^3.DNWJ.OEXSVSGFM&B
M@ HHHH ^>_%EIJ/A;QKI=Q9Z)K.J6.GV]M9/=0VA0/*=4BG"KN.#N V @\LP
M]\>@_P#"T=3_ .B;>+O_  %C_P#BZ[75]*BUBQ2UGD>-4N;>Y!3&=T,R2J.>
MQ* 'V)J]0!YY_P +1U/_ *)MXN_\!8__ (NC_A:.I_\ 1-O%W_@+'_\ %UZ'
M10!SO@KQA;^-=&N+^VL+NP-O=R6<MO>*JR))'C<" 3W./PKH'D2, R.J!F"C
M<<9)Z#ZUY5HWASXH>%9]8@T!/"<]C?:K<W\;7LUSY@$KY .U<=,?XU6\5R?%
M@V>G_P!HVO@[9_:EIY7DRW1/F^<NS.1]W=C/?'2@#V"BO._-^,W_ #Z^!_\
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MZ/P[XATWQ5H%MK.B7'VBSN5RC8P00<%2#T((((H TZYSP)_R+4W_ &%=2_\
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M5SGVOQA_T"]+_P# I_\ XFC[7XP_Z!>E_P#@4_\ \31]8C_*_N8?6H_RR_\
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MW/F 2.6P=J@=Z /6**\[\SXS_P#/#P+_ -_;S_"CS/C/_P \/ O_ ']O/\*
M/1*:\L<6WS'5-S!5W'&2>P]Z\]\SXS_\\/ O_?V\_P *PO%#_%D_V/\ VC!X
M,_Y"D'D>3)=?ZWG;NR/N]<XYH ]AHKSOS/C/_P \/ O_ ']O/\*/,^,__/#P
M+_W]O/\ "@#T2BO._,^,_P#SP\"_]_;S_"CS/C/_ ,\/ O\ W]O/\* /0I)$
MAB:25U2-%+,[' 4#J2>PIU>0^,W^+9\!Z^-5@\&"Q.FW'VG[/)=&3R_*;=LR
M,;L9QGC-;7F?&?\ YX>!?^_MY_A0!Z)17G?F?&?_ )X>!?\ O[>?X4>9\9_^
M>'@7_O[>?X4 >B45YWYGQG_YX>!?^_MY_A45S=_&6UM)KB2W\#E(49V"R7>2
M ,\<4 >DT5S_ (#\07/BKP'I&N7T445Q?6XED2$$(I/IDD_K704 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5R/PY).B:D#T75[L#_OX:ZZN1
M^''_ "!=3_["]W_Z,K&7\2/S_0[Z48O"56UJG'_VXZZBBBMC@"BBB@ HHHH
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MOF%%%%;G0%%%% !1110!S_C[_DFWB7_L$W7_ *):MR#_ (]HO]P?RK#\??\
M)-O$O_8)NO\ T2U;D'_'M%_N#^5 $E%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5SG@3_D6IO\ L*ZE
M_P"ET]='7.>!/^1:F_["NI?^ET] '1T444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '(M\*/ 3,6;P
MCI)).2?LJTG_  J?P#_T*.D?^ JUU]% '(?\*G\ _P#0HZ1_X"K1_P *G\ _
M]"CI'_@*M=?10!YAX]^&7@G3_AQXDO++PMI<%S;Z5<RQ2I;*&1UB8A@>Q!&:
M[#P'Q\.?#>/^@3:_^B5J_P"(-(C\0>&M2T>:5H8]0M);5Y$&2@="I(SW&:X>
MS^&'B'3[&"SL_B5KD5O;QK%%&+>#"(HP!]WL!0!Z117GO_"N_%'_ $4[7?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/^/:+_<'\J )**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO0-B?W5_*C8G]U?RH \__P"%\?#7_H:(?_ :;_XBC_A?'PU_Z&B'_P !IO\
MXBO0-B?W5_*C8G]U?RH \_\ ^%\?#7_H:(?_  &F_P#B*/\ A?'PU_Z&B'_P
M&F_^(KT#8G]U?RHV)_=7\J //_\ A?'PU_Z&B'_P&F_^(H_X7Q\-?^AHA_\
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M^P3=?^B6K<@_X]HO]P?RH DHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^B6K<@_X]HO]P?RH DHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH \S^")(T7Q3%*1]JC\3WPN!C!WY7K3O@L
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M_&@#I:*YK^W_ !+_ -";/_X,8/\ &C^W_$O_ $)L_P#X,8/\: .EHKFO[?\
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M@_QH_M_Q+_T)L_\ X,8/\: .EHKFO[?\2_\ 0FS_ /@Q@_QH_M_Q+_T)L_\
MX,8/\: .EHKFO[?\2_\ 0FS_ /@Q@_QH_M_Q+_T)L_\ X,8/\: .EHKFO[?\
M2_\ 0FS_ /@Q@_QH_M_Q+_T)L_\ X,8/\: .EHKFO[?\2_\ 0FS_ /@Q@_QH
M_M_Q+_T)L_\ X,8/\: .EHKFO[?\2_\ 0FS_ /@Q@_QJIJ'C'7-,6W-WX/N%
M%S<);Q[;^ Y=S@#KTH ["BN:_M_Q+_T)L_\ X,8/\:/[?\2_]";/_P"#&#_&
M@#I:*YK^W_$O_0FS_P#@Q@_QH_M_Q+_T)L__ (,8/\: .EHKFO[?\2_]";/_
M .#&#_&C^W_$O_0FS_\ @Q@_QH Z6BN:_M_Q+_T)L_\ X,8/\:/[?\2_]";/
M_P"#&#_&@#I:*YK^W_$O_0FS_P#@Q@_QH_M_Q+_T)L__ (,8/\: .EHKFO[?
M\2_]";/_ .#&#_&C^W_$O_0FS_\ @Q@_QH Z6BN:_M_Q+_T)L_\ X,8/\:/[
M?\2_]";/_P"#&#_&@#I:*YK^W_$O_0FS_P#@Q@_QH_M_Q+_T)L__ (,8/\:
M.EHKF3X@\2 $GP;-@?\ 41@_QJMIGB_7=7TFTU*R\'W#6UY D\):_@!*.H9<
MC/'!% '7T5S7]O\ B7_H39__  8P?XT?V_XE_P"A-G_\&,'^- '2T5S7]O\
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M7-?V_P")?^A-G_\ !C!_C1_;_B7_ *$V?_P8P?XT =+17-?V_P")?^A-G_\
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M_&@#I:*YK^W_ !+_ -";/_X,8/\ &C^W_$O_ $)L_P#X,8/\: .EHKFO[?\
M$O\ T)L__@Q@_P :/[?\2_\ 0FS_ /@Q@_QH Z6BN:_M_P 2_P#0FS_^#&#_
M !H_M_Q+_P!";/\ ^#&#_&@#I:*Y#4/&&NZ7;)/>>#[A8WGAMU*W\!^>618T
M'7^\Z_2K7]O^)?\ H39__!C!_C0!TM%<U_;_ (E_Z$V?_P &,'^-']O^)?\
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M%1CCOBMFBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX1T^SU:;1V\/32QV5JLY22U+H"R)DY48$9Z\9&.M $/A32O$,6I?:[_XA?\
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M;4KNXOHX9!AECDD)3/U7!^A%>@T %%%% !1110 4444 %%%% !1110 4444
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M2<F.T@6)2?7"@"H+[PQH&J:A'?:GH>FWEY%CR[BXM(Y)$QTPQ!(K4HH  ,#
MX%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@*WS;CSQTH X;P[X9\2>-_ :^(X])TN;6;PRS)XAGUJ:.YMI [8PH0A F,;
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
5BB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img187419207_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img187419207_9.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1#R17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $UA<G1I;B!"
M;WEL90    60 P "    %   $*:0!  "    %   $+J2D0 "     S4X  "2
MD@ "     S4X  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M]]LEG'EL"X3>5VYQR,-R,+C)H Z32/$-CX4UOXH:YJK,+2QOX)) @RS?Z-&
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MRW4FH1PM* NYC%'ABV!Z[<D<5A>#;3QKX'T6#PE#X9CU.TLYW2UU?^T(XXS
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M-]]O2*2<1DAWAB*G>!@XRPSCBK>J_$Z*"#PO-H&CW&MCQ-'(UG'%(L;@K&'
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MQ?NUZMM' 'SL0$@[G(!..!CO65\&;QM0MO&5V]K-:/-XINF:WN !)$?*ARK
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M3LVX2/\ ,H8;2%P&XP>/6C:_#?Q#:_!+QKX<@T>.WO=4U-KBQLH[T2KY3"#
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MNZ<C%7-!OK&VO/"T.C^,-4DLK^6\V6FK6TLT^HE8^5,LJAXA&59QG[V<#C%
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M]1\S<>Y]:XW39O[*\(_"#Q)JOF?V%I:3B^D\LNL+20E(9& S@*P//;->_44
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M &SJ/_(+NO\ KB__ *":\2TF".?X?_!N.>)9$_M*-MKKD<0RD'!]" :]UHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !112,RHI9R%51DDG@"@!:*YT?$'P>0"/%&D$'H1>
MQ\_K2_\ "P/"'_0SZ3_X&1_XT =#17/?\+ \(?\ 0SZ3_P"!D?\ C1_PL#PA
M_P!#/I/_ (&1_P"- '0T5SW_  L#PA_T,^D_^!D?^-'_  L#PA_T,^D_^!D?
M^- '0T5SW_"P/"'_ $,^D_\ @9'_ (T?\+ \(?\ 0SZ3_P"!D?\ C0!T-%<]
M_P + \(?]#/I/_@9'_C1_P + \(?]#/I/_@9'_C0!T-%<]_PL#PA_P!#/I/_
M (&1_P"-'_"P/"'_ $,^D_\ @9'_ (T =#17/?\ "P/"'_0SZ3_X&1_XT?\
M"P/"'_0SZ3_X&1_XT =#17/?\+ \(?\ 0SZ3_P"!D?\ C1_PL#PA_P!#/I/_
M (&1_P"- '0T5SW_  L#PA_T,^D_^!D?^-'_  L#PA_T,^D_^!D?^- '0T5S
MW_"P/"'_ $,^D_\ @9'_ (T?\+ \(?\ 0SZ3_P"!D?\ C0!T-%<]_P + \(?
M]#/I/_@9'_C1_P + \(?]#/I/_@9'_C0!T-%<]_PL#PA_P!#/I/_ (&1_P"-
M'_"P/"'_ $,^D_\ @9'_ (T =#17/?\ "P/"'_0SZ3_X&1_XT?\ "P/"'_0S
MZ3_X&1_XT =#17/?\+ \(?\ 0SZ3_P"!D?\ C1_PL#PA_P!#/I/_ (&1_P"-
M '0T5SW_  L#PA_T,^D_^!D?^-'_  L#PA_T,^D_^!D?^- '0T5SW_"P/"'_
M $,^D_\ @9'_ (T?\+ \(?\ 0SZ3_P"!D?\ C0!T-%<]_P + \(?]#/I/_@9
M'_C1_P + \(?]#/I/_@9'_C0!T-%<]_PL#PA_P!#/I/_ (&1_P"-'_"P/"'_
M $,^D_\ @9'_ (T =#17/?\ "P/"'_0SZ3_X&1_XT?\ "P/"'_0SZ3_X&1_X
MT =#17/?\+ \(?\ 0SZ3_P"!D?\ C1_PL#PA_P!#/I/_ (&1_P"- '0T5SW_
M  L#PA_T,^D_^!D?^-'_  L#PA_T,^D_^!D?^- '0T5SW_"P/"'_ $,^D_\
M@9'_ (T?\+ \(?\ 0SZ3_P"!D?\ C0!T-%<]_P + \(?]#/I/_@9'_C1_P +
M \(?]#/I/_@9'_C0!T-%<]_PL#PA_P!#/I/_ (&1_P"-'_"P/"'_ $,^D_\
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MPNZ*:)LJP_SQCM2ZG_R";S_K@_\ Z": */@__D1]"_[!UO\ ^BUK8K'\'_\
M(CZ%_P!@ZW_]%K6Q0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %8'CW_DF_B7_L$W7_ *):M^L#Q[_R
M3?Q+_P!@FZ_]$M0!OT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %1S\6\G^X?Y5)4<_\ Q[2_[A_E0!C>!O\ DGGAS_L%6O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK203B9E+*ACV[@2!D<<T ='17/1^+M/2RGN9YWEVWAM8X8K.02F3&?+V<LS
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MHY_^/:7_ '#_ "H QO W_)//#G_8*M?_ $4M;M87@;_DGGAS_L%6O_HI:W:
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *K:B,Z7= YYA?H,G[IJS5?4"!IMT2< 0ODXSV- '#^"M:
M2T\/V$'VS2X_,A@PMQ=[)&_=H.%QSTQ]<BO0*\M\)^&-)U6RLU.GP22VEK;N
MDS00Y167*E=T;$'()P#QGUR:]2 PH&<^Y[U=1)3T=_N_1L\O*ZL*E#W4]Y;_
M .)[:+YA1114'J!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !6!X]_Y)OXE_[!-U_Z):M^L#Q[_P DW\2_]@FZ
M_P#1+4 ;]%%% $<__'O)_N'^5?G!7Z1TSRH_^>:_]\T ?F_7U#^R9_R+GB+_
M *^XO_0#7O\ Y4?_ #S7_OFG*JK]U0/H* %HHHH YCQ-X;G\3:]I45VTD>D6
M):Z=H+EXI'N!\L8!0A@%!8Y!ZXKGKSP'J5CJ]W%HA>XTN_N;*^D-Y>/))'/#
M,N_YG)8AHP#UZKCO7I%%"T_K^OZ0'G/B#P;J^I:MK$L,.8GU"UU*U>.\,+2F
M.)8VBW+AD;@D,..E/M/"%\U_97ZZ6]E(FJP7$YN]5DO)GBCBD7)+D@8+\ 'I
M7H=%"T_KM;_(;U_(\^O?#.O1Q7)MD>2*77);R6"UO3;RS0-'M7$HP5(;!(!&
M0,9J#PMX,UC2IM*%U:6UO%9:M>W16&?>!%,AVXR,D@MM.?3->D44+3^O3_(&
M[_UZ_P"9S&H:=J>E^*Y==T6S34%O+=+>[M3,(G!0L4=2W!^\00<=B*RM3TOQ
MAJ-G#<WK%PU\99-,L;L6[Q6_EE503K@EMQ#-R,\@<=>\HH_K]1?U^AY/:?#G
M69="CTFY@MK*/[5J1+0S>8J1W,;!",C)P7P0?3/>M^]L?$VM>&HM*NM(MK,V
MTEFQD%V&$IBGC9BH X7:A/.#T&*[FBC_ ('X;!_P?Q.&M_"FJ1ZM;3ND7EQ^
M(+F_8B3GR7B=5/URPXJ/3=*\5Z9X/D\+V=G:Q&WM9H+?5&G!5\AO+81X)W<C
M(/'!ZUWM%*VEOZVL.^M_ZWO^IY./ ^O7$NLRKIWV?^T=#:Q#7>IM<S&<-D%W
M;/RG.!@\8Z#-:TWA/6KR/5+TV\4%U)>6-];6[S@AV@B0-&S <9*D9^AKT*BG
M_7XW_,7]?DOT//Y?#.N:KXD37KJTALV:_LW-J9@[1PPK+EBPX+%I. .PKH_#
MFE76F7FN272H%O=1:XAVMG*%$'/H<J:W:*%IM_6W^0/7^O7_ #"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J.?_ (]I?]P_RJ2H
MY_\ CVE_W#_*@#&\#?\ )//#G_8*M?\ T4M;M87@;_DGGAS_ +!5K_Z*6MV@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "JVI';I5V< XA<X/?Y35FJVI$KI5V0<$0.0?^ F@#S3P5
MHE_J-O;^1XAO[#R=/LVE^S)%^_#*Q"ME3@  @8QP:]3 PH')P.IKS'P);VUW
MJ5O:7=K#-&VC6\V77)# +T^N\Y_"O3@ J@ 8 & *SC\4M#QLG_W=Z;2G_P"E
M,6BBBM#V0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ K \>_\ )-_$O_8)NO\ T2U;]8'CW_DF_B7_ +!-U_Z)
M:@#?HHHH 0D*I). !DFN4'Q3\#$ CQ3II!Z$3"NHN/\ CVE_W#_*OB[3O^07
M:_\ 7%/_ $$5R8K$_5TG:]SZ+(LE6;5)P<^7E2>U]_FCZI_X6EX'_P"AHT[_
M +_"MC1/$VB^)(YGT'4[>_6 A93 ^[83TS7R/7LW[/?^I\1?]=8/_06K'#8U
MUY\G+8]#.N&8Y7A?K"J\VJ5K6W^;/9J***]$^-"BL3Q%K=QITVGZ?ID<4FHZ
MG,T4'G$^7&%4L\C8Y( '08R2!D=:A@O]9T>2[?Q1+8S:=#;^>-0MHFAVD'!C
M:(LYZ<A@>>F/4 Z&BN8/C[2(;'4+B^BO;(Z<D<EQ!<6Y60)(=J.%&<@G(X]#
M4.K?$"ST_3[ATL=0-U!:M<S0FU+&U7G:TH!X!VDX!)P,TF[*XTKG6T5R&A^-
MX;G0FO\ 5)5\V.WM'D@M[=@1)-&K!%RQWEBW XQT.>M74\<:2=*NKV474#VM
MPMK+:2P$3B9L%$"=RP92,=C5-6=A+5)G145FZ=K*:I8SSQVMW:O"2KQ7D!C8
M$#/T(Y'()KCK/Q/XJ'@6'Q==3Z7<VHB^T3V,5E)$XB!^;;(96&0.>5YQCCK2
M ]#HK#'C#2#'(YF<>7>)9LI0@^8Z*ZX'<%6#9],UC:K\1X(/#%_J>EZ9J,QC
MLWNK.22T80W*@<,&S]WD'G!(Z4GHKC6KL=K17+:=XQ@C\/W=UK+R?:--2)KW
M;:-%M,BAE 0LW9A_$:?;^/='N=5%DBW:@WCV'VE[<K#]H3.8]WK\IQV]ZIZ.
MPNESIJ*XK5OB3:6WA^_U'2]-U"\2"WDFMIOLK>1<;#@D/Z=\G&0"1FK]OXRL
MTM-1NK^22-;/R ]N;5EE1Y(U94QN.]B6& ,8SCGK2 Z:BN7E^(&CV]LSW,5]
M#<+<QVK63VQ\]9) 3&-H[-C@YQ^M:VB:[::_:2SV8FC:&9H)H9X]DD4B]58>
MO(/XT :5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!4<__'M+_N'^525'/_Q[2_[A_E0!C>!O^2>>'/\ L%6O_HI:W:PO W_)//#G
M_8*M?_12UNT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9^0H@YXX.5-;=%"T_KT_R!Z_U_7<**** "BBB@ HHHH **** "BBB@ HHHH
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M.=\VW(]OE %5B+K&55_A_P#2(_Y'A90VG65M/:3?_DS_ ,B:BBBI/="BBB@
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M&90' ) .TG&><5N4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1113/H HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)!ZYXI3X>URQFBU"+3_M;VWB&XOC;1S1J\L,B,@92S!<_-G#$<"O0Z*?6_\
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M//#G_8*M?_12UNUA>!O^2>>'/^P5:_\ HI:W: "BBB@ HHHH **** "BBB@
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MS_\ 'M+_ +A_E0!C>!O^2>>'/^P5:_\ HI:W:PO W_)//#G_ &"K7_T4M;M
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !6!X]_Y)OXE_[!-U_Z):M^L#Q[_P DW\2_
M]@FZ_P#1+4 ;]%%% $=S_P >LO\ N'^5>"^'?$NA0>%]*BFUG3XY([.%71[I
M 5(0 @C/!KWZBNK#XAT&VE>YX6<9-3S:$(3FX\K;T\SQ/_A*O#__ $'=-_\
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M"">.>W-;O@W2;G0O!NF:9?;/M%K (Y/+;*Y]C6W11LK %%%% !1110 4444
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MHPPDW*BE)6:T=^Z"BBBN@ZPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@#H**Y__ (3[P?\ ]#7HG_@QB_\ BJ/^$^\'_P#0UZ)_X,8O_BJ .@HKG_\
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M .03>?\ 7!__ $$U:JKJ?_()O/\ K@__ *": /GWPE#%<_'[3K>?[DN@6RD
MX)_T)*]XT(%(;R(N[K%=NBEV+$  8&37S?ICLO[1GAK:Q7-AIH.#C@VJYKZ/
MT5QY^I1'(=;QV((['I_*O4Q#O1@UU@G]TI1_0X,3&*Q.'J/?WH^MES?JS5HH
MHKRSO"BBB@#F-<M-8L]?DU[25LI(X]/,,B7+N#PQ<D;1].];>CWKZCHEE>RJ
MJ/<0)*RKT!90<#\Z?J,+W&EW4$0R\D+HH)QDE2!7G-Y-K^G):6,VG+$UMH\\
M/R7@PRJJ@R<#@CJ![]:\ZK4^JS<K-I_G?T/)K5?J=1SLW%_-7NO(]/HK'\.Z
MU<:U;327-A]D:&9H3B82 LI(.",'MZ5L5W0G&I%2CLSTJ=2-6"G'9A1115F@
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1S_P#'M)_N
M'^525'/_ ,>TO^X?Y4 8W@;_ ))YX<_[!5K_ .BEK=K"\#?\D\\.?]@JU_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI8=L$495H\Y^89&<^PK7(!!!&0>HK+L%":_J:J %"0@ =OE-<_M.>$N9:_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[S2DTV2"^>-@+F1PR[4"] N.QJ;S/&/_ #[:+_W^E_\ B:Z&BN98=*]I-?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %1S_\>TO^X?Y5)4<__'M+_N'^5 &-X&_Y
M)YX<_P"P5:_^BEK=K"\#?\D\\.?]@JU_]%+6[0 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %1S_\>TO^X?Y5)4<__'M+_N'^5 &-X&_Y
M)YX<_P"P5:_^BEK=K"\#?\D\\.?]@JU_]%+6[0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %8NO^*+#PZ^GI>-N:^OHK)51ERC2
M9PS9(PO%;5><_$OP/X5OQ#KVK>%;[6;U+J(R+I5NLD\ZJ" KAB 8\#!Y!Z4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"W$;VFO6YG>+R_FC,"(@^;/?)-92DX3A-='_ %^-CTL&E.C7I/=QNO6+3?\
MY+</@_/+<_"/P_)<2O*_V=DW.V3A795'T   ]A7:UP5I\(M'L+5+6PUOQ):V
M\8PD,.K2(B\YX X%3?\ "K;#_H8_%/\ X.I?\:]W%+!5\1.K&HTI-NW+W=^Y
MY,>9)*QV]%<1_P *ML/^AC\4_P#@ZE_QH_X5;8?]#'XI_P#!U+_C7/['"?\
M/U_^ _\ !'>78[>BN(_X5;8?]#'XI_\ !U+_ (UFV&BMX8^+>DV%IK&L7=M=
MZ;<RRQ7]^\Z[E:, @,<=S51PN'J*7LZMVDW\-ME?N',UNCTFBBBO-+"BBB@
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MV"K7_P!%+6[6%X&_Y)YX<_[!5K_Z*6MV@ HHHH **** "BBB@ HHHH ****
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M_P#Q-'_";:3_ '+[_P  9?\ XFKW]B?]1/4?^_\ _P#6H_L3_J)ZC_W_ /\
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M_B:/^$VTG^Y??^ ,O_Q-=#11RU_YE]W_  0Y,1_.O_ ?_MCGO^$VTG^Y??\
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MF7OJWIZ?WBOI.M6>MPRR6#2$0OY;B2-D*M@'&"/0UH5S_AK_ )"WB'_L(?\
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MRU!Z[CU+?I79US7C3P[8:OI<E_=^>MSI]M.]O)#.T90E<G[I&?NBKG@Z1YO
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M_P .[8332S,EU=('FD+L0MPX&2>3P!76Q7]O/J%S91L3/;*C2KM/ ?.WGO\
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M44OJL.:]W_X%+_,GZE3YG*\O_ I?YG._V)XB_P"AMD_\%\-']B>(O^AMD_\
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y[P/_ ,BK'_U\3_\
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M^/?%7ZTJU,O=27+3E:[^VO\ Y6"4[;_U]YPI^,W@3!QK,N?^P?<__&ZIZ/\
M&KPC+H5A)JNKLE\]M&URJ:?<;1(5&X#"$8SGH37HQY!JCHFG?V/X?T_3#+YW
MV*UBM_,V[=^Q N<9.,XZ4*IE_LW^[E>Z^VO/_IV%IWW_ *^\K>'/%6C>+;&6
M\\/WGVN"&4PR,8GCVN #C#@'HPK7KS[P+J=A8ZSXT2]OK:W=O$$I"S3*A(\J
M+G!/2O0000"#D'H16&-H1H5G&"?+I:_FD][*^_8<7=!1117$4%%%% !1110
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ML[P;_P!!V#_OA_\ "NJV+_='Y4;%_NC\J+5>Z^[_ ((_:8'_ )]S_P# U_\
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M.)IJTE)+YF4\IQ\9./L9.W]U_P"1R/COX?Z'IG@KQGJ7]A:=&Y02V4J0KOC
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MTJBI%1E9'1@JLZM!2J;W:^YM?H%%%%9G6%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7/:!_R,_B3_KYB_\ 12UT-<]H'_(S^)/^
MOF+_ -%+7/5_B4_7]&<M?^)2]7_Z3(Z&BBBN@Z@HHHH **** "BBB@ HHHH
M**** "HY_P#CVE_W#_*I*CG_ ./:7_</\J ,;P-_R3SPY_V"K7_T4M;M87@;
M_DGGAS_L%6O_ **6MV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *\8>WTKQAXI\17?BOQU>:/)8:E)8:?96NKK:"W2,*/-V_Q,
MQ+<G([5[/7-7_P .?!NJ7\U[J/AC2KFZG8O+-+:H6=O4G')H QOAQXZLM2\*
M6L&M^(M/N-5AN9K(NUS&KW7ERM&C[<]74*>.N>.M=]7+VWPS\$6=U%<VOA32
M8IX7$D<B6B HP.01QU!%=10 4444 %%%% !574_^03>?]<'_ /035JJNI_\
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M.(R]NM)T'#EZ?O(;?.5_O-:^\(^&]3O'N]2\/Z7>7,F-\UQ91R.V!@98C)X
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M VS_ ._"_P"%1_M/,]OQ)7UOG>L;:=_,@_X2C0?^@UI__@4G^-'_  E&@_\
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MBB@ K-\/_P#((7_KI)_Z&:TJS?#_ /R"%_ZZ2?\ H9K6/\*7JOU."I_OU/\
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MY6)[@[#R^?XQV[T >R4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7]QM_:6"_P"?T?\ P)?YFC16=_PD&E?\_L?Y'_"C_A(-*_Y_8_R/^%'L:O\
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M)=2#)!\JK)@]CM-;^HWOB[^S+H-H6C!?)?)&LRDXVGM]FH T?!__ "(^A?\
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M\8:W-9^$Y$L9TFOD26Y))%M#@1\#(V[>I'.>V*]IM93/9PS, #)&K$#MD9H
MEHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH 1T61&210RL,,I&01Z5Y;XO\(Z1H_CWP-J&BZ98:</[4:"5;2U2
M(R;HRP)*@9QL/7UKU.O/_BG/>6<WA6\TZS6]GM]8$BP/<+"'_<R#&]N!UKT,
MOJN%;E<N5-/=V6SM>]EOW&HSD[05WZ7]?P/0**\[_P"%@>+O^A&M?_"DMO\
M"C_A8'B[_H1K7_PI+;_"E]0J_P T/_!E/_Y(.6?\K^Y_Y'HE%>7ZI\4_$FC:
M7/J&H>"+=+:W7=(R>(('('LJJ2?PKTV&59H(Y4(*NH8$'(((]:RK86I0BI2L
MT[[2C+:U_A;[H6J=FK#Z***Y0"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "DVKZ#\J6B@!-J_W1^5&U?[H_*EHH%9";5_NC\J-J_W1^5+
M10%D)M7^Z/RHVK_='Y4M% 61#=6XN+.6%<*9$*@XZ9%2[5_NC\J6BG=VL3[.
M*DY6U?Z?\.)M7^Z/RHVK_='Y4M%(JR(5MP+R2;C#QJF,=,%C_P"S5+M7^Z/R
MI:*;;9,:<8JR7]/43:O]T?E1M7^Z/RI:*15D0VUOY$94X),COD#^\Q/]:FHH
MIMMN[)A",(J,=D%1S_\ 'M+_ +A_E4E1S_\ 'M+_ +A_E2+,;P-_R3SPY_V"
MK7_T4M;M87@;_DGGAS_L%6O_ **6MV@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ JEJNC:7KMH+76]-M-1MU<.(;
MN!94# $!MK C.">?>KM% &%9>!O"6FWL5YIWA?1;2ZA;='/!I\2.A]0P7(-6
MM4\-Z'KDT4NM:+I^HR0_ZM[NU24IWX+ XK3HH 1$6.-4C4(B@!548 'H*K:G
M_P @F\_ZX/\ ^@FK55=3_P"03>?]<'_]!- %'P?_ ,B/H7_8.M__ $6M;%8_
M@_\ Y$?0O^P=;_\ HM:V* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M *=_X(5_^.5W,UK!<R023PI(]O)YL+,,F-]I7</0[68?0FI: .!_X1OXF?\
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MH1FVFG=:.^JM?\T1)13LI7^_]4@HHHKE)"BBB@ HHHH **** "BBB@ HHHH
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MC+_R2G5/^NUK_P"E,5=S7"_&?=_PJ;5=F-WFVNW/3/VF*KOF?$3_ )]_#/\
MW^N/_B:[:TN7 4M/MS_*F;4*#K2E[R5K;NW<ZVBN2\SXB?\ /OX9_P"_UQ_\
M31YGQ$_Y]_#/_?ZX_P#B:\WVOD_N.KZB_P#GY#_P)'6T5R7F?$3_ )]_#/\
MW^N/_B:/,^(G_/OX9_[_ %Q_\31[7R?W!]1?_/R'_@2.MHKDO,^(G_/OX9_[
M_7'_ ,31YGQ$_P"??PS_ -_KC_XFCVOD_N#ZB_\ GY#_ ,"1UM%<EYGQ$_Y]
M_#/_ '^N/_B:/,^(G_/OX9_[_7'_ ,31[7R?W!]1?_/R'_@2.MHKDO,^(G_/
MOX9_[_7'_P 31YGQ$_Y]_#/_ '^N/_B:/:^3^X/J+_Y^0_\  D=;17)>9\1/
M^??PS_W^N/\ XFM'P?K5UX@\,PZA?Q117#22QND.=H*2,G&>?X:<:B<N6S(J
MX.=.FZO-%I-+1WWO;\F;E%%%:'$%%%% !1110 4444 %%%% !1110 4444 %
M%%% !4<__'M+_N'^525'/_Q[2_[A_E0!C>!O^2>>'/\ L%6O_HI:W:PO W_)
M//#G_8*M?_12UNT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 55U/_ )!-Y_UP?_T$U:JKJ?\ R";S
M_K@__H)H H^#_P#D1]"_[!UO_P"BUK8K'\'_ /(CZ%_V#K?_ -%K6Q0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>!O^2>>'/^P5:_\ HI:W: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *JZG_R";S_K@_\ Z":M55U/
M_D$WG_7!_P#T$T 4?!__ "(^A?\ 8.M__1:UL5C^#_\ D1]"_P"P=;_^BUK8
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O/\ X%?\D3\/
M?]<YO_1\E>@5YMIOP:CT?3XK#2?'7B^SM(<^7!#?1*B9))P/*]230!Z317 ?
M\*MNO^BB^-/_  81?_&J/^%6W7_11?&G_@PB_P#C5 '?T5P'_"K;K_HHOC3_
M ,&$7_QJC_A5MU_T47QI_P"#"+_XU0!W]%<!_P *MNO^BB^-/_!A%_\ &J/^
M%6W7_11?&G_@PB_^-4 =_17 ?\*MNO\ HHOC3_P81?\ QJC_ (5;=?\ 11?&
MG_@PB_\ C5 '?T5P'_"K;K_HHOC3_P &$7_QJC_A5MU_T47QI_X,(O\ XU0!
MW]5-6!.BWH R3;R8 _W37%_\*MNO^BB^-/\ P81?_&J/^%6W7_11?&G_ (,(
MO_C55%\K3 Q_ OQ,\,:+X!T73=2N+R*[M;..*:/^S;AMK <C(0@_A70?\+@\
M&_\ /[>_^"NY_P#C=5_^%6W7_11?&G_@PB_^-4?\*MNO^BB^-/\ P81?_&J]
M*KB,%5J2J2I2NVW\:Z_]N$)22M<L?\+@\&_\_M[_ ."NY_\ C='_  N#P;_S
M^WO_ (*[G_XW5?\ X5;=?]%%\:?^#"+_ .-58^$%_?:C\-K2;5+VXO[E;JZB
M-Q<OND<)<2*N3] !6?M,#_S[E_X&O_D M+O_ %]X?\+@\&_\_M[_ ."NY_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?\)/\2_^B=67_A0)_P#&Z[^B@"AH=UJ=YHT$^NZ='IE^^[S;2.X$ZQX8@?.
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MXS_Z VA?^#:;_P"1J/M7C/\ Z VA?^#:;_Y&H Z&BN>^U>,_^@-H7_@VF_\
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M;N%9H9!_$C#(/Y&@"S1110 4444 %%%% !1110 4444 %%%% !116;XCU?\
MX1_PMJNLF'[0-.LIKKR=VWS/+0MMS@XSC&<&@!MEI4EKXDU34FE5DO8X$5 .
M5\L,#GZ[JU*X/P]XQ\;:V^G3W'@&"STV]$<ANQKD<ACB< [MGE@G@].*[R@
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M_"OX+?2]16&;[7_;L;F.&3!W[/+!)"G.W@]J /0:*** "BBB@ HHHH ****
M"BBB@ HHHH **IZM?OIFDW%[%97-^\*;EMK50TDI[*H) _.N'@^)NJV'BC2=
M(\9^#Y]!CUF3R;&Z6^CN5:7LCA0-A.0.IZ^Q( .RTO3'L-1UFY>1774;U;E%
M Y0"WABP??,1/XBM*N+\1>/;NQ\4?\(UX5\/2^(=8CMQ<W,8NDMH;:,G"EY&
M!^8]E S5SP3XV3Q=%J$%SITVDZMI4_D7^GSNKM"Q&5(9>&4CH>^#0!U%%%%
M!1110 4444 %%%% !1110 4444 %%%<?XB\5^)M/U.>U\-^![K6H[9 TMS)>
MQVL;Y&=L>X$N1GT SD9H W-$TJ32CJ/F2K)]LOI+I=HQM#8X/OQ6I7$67Q-L
M=4^%%[XVT^RF9+.WFDDLIF\MUDC!W1EL''3K@\'IVH\/^*_&VK7=BU_X#AL-
M.N@KO=C7(Y3&A&0VP1@GMQF@#MZ*** "BBB@ HHHH **** "BBB@ HHHH **
M*\WU[XG>(- M;G5[GX?WX\/VLF)KR2]B2<)G'F"WY.WZL#CDX% ';:#ICZ1I
MTMO+(LC27MU<@J,8$MQ)*!]0' _"M*N4\3>/K+0-#TN\L[2?5;K6G2/3+*WP
MKW+.NX<MPJ@<DGI5+0/B#?W/BZ+PSXN\-2>'=3NH&N++_3$NHKE5^^ Z@88=
M<8Z ^V0#N**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "L3QJL[^ ?$"6?_'PVF7(BP,_-
MY38Z>];=! 92&&0>"#WH \X\(7%HO[-UC-*\8M4\/MYK'[HQ$0^?Q!S6K\(H
MY(_@_P"&%F!#'3XV /H1D?H168?@EX<'F6L6HZY#HLLIE?0HM0*V1).2-F-V
MTGG&[%>A0PQV\$<,$:QQ1J$1$& J@8  ]* 'T444 %%%% !1110 4444 %%%
M% !1110 51US28=>\/:CH]R[QPZA:RVLCQXW*LB%21GC.#5ZL_7-%M?$.BW&
MEZ@91;W  9H9#&ZD$,"K#D$$ _A0!YAXIM-:^$NDZ3JNB^*=4U33X;NWLIM+
MU,12B2)CM C944JP'3K_ $KU^N&L/A1I4.L6FHZQK.O>(9+&02VD6L7_ )T<
M$@Z.J@ %AZMDUW- !1110 4444 %%%% !1110 4444 %%%% ",H92K $$8((
MZUYQ> +^TMI048 \,S  =OWXKT:5/-A>,.R;U*[T.&7/<>]>;M\%K9]835F\
M<>,3J$<)@2Y.H1;UC)R5SY73/.* &V9*?M0:BMP0&D\,1FWR.2@G^;!_WO\
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M9YX% '5T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW('X9(_"O0Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *Q_#OABR\,KJ/V*2>:34KZ6_N);APS-(^
M,C( ^4   =@*V** /,OB9X%:70_$NI:#:WEY>ZX+-+ZT@9<E(9%/FQ+@9F5>
MF6QP..,'*T!-7?QIHI\*_P#"<I9+*QU8^)FE\CR=AP%$WS%]V,;./7BO8J*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
/!1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img187419207_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img187419207_10.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +0!0 # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[1(5'LJB@#[,HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7ES?#GX]_P#!3KXT^'M9\<>&;CP3\.=+.W?);R6]O;VY8-*L/F?---)@#=C
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444E "T444 %
M%)10 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%?-?[8'[8!_9S
M;PUX9\->')/&OQ*\52^3HVA1L57&X+YDA'.W<< #J0>0 30!]*45\!^-/VB/
MVP_@7X=;QSX]^&?@_7/!]MMEU&ST&Z?[990D_,S'>W0=6 8#J>.:^QO@S\6M
M"^.GPTT#QSX;D=]*U>W\Z-)0!)$P)#QN!T96!4_2@#MJ*0U\$>,/VV/COXB_
M: ^(W@'X/_"_1O&>G^#[E+:>ZN+DQR#*XRQ,BK]\. !V6@#[XHKY!^#/QF_:
ML\2_$[0],\??!C1O#7A"XE9=0U6VOE>2W0(Q4JHF;.6"CH>M?7U !1244 +1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ:#\4-1TN2?QGH<!MK&^^T2!8XR'&/+SM/\ K'YQGFO2*^=_VQOVNM-_9?\
M"MA!9:>WB7Q_KSFWT'P] "SSR9 \QPOS>6&(''+$X'<@ S/^"@'[17A_X&?
M'Q#87DD=[XF\46,^D:1HZ_-+.\R&-I-O78@8DGN<#J:N_P#!/GX/ZS\#_P!E
M7PAX=\0Q/;:U,)M2N;23[UL9W+B(^C!2N1V)([5YE^R]^Q7XAU3QPGQO_:#O
MO^$I^)]V1/8Z1-AK31%ZHH3[N]<\ ?*G;+?-7VSG&>U $5]=QV%G/<S'$4,;
M2N?15&3_ "K\B?V*?C!\:([SXMZW\*OA$WC/6?$_B22_O=;UBY%K:6\>7:.
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ML=->.:??(9"&83Y(W'./:NG_ .&#?C]_T=KXI_[\2_\ R10!]X5YC^T;\5?
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P""KG_)EGBO_K\L?_2A:^>/^"'/_(#^+?\ U\:;_P"@W% 'ZC4444 %%%%
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M_P $H?\ DRGPG_U^W_\ Z4O7V!0 4444 %%%% !1110 4444 %%%% !1110
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MH+X9?#CP1XJUK0+B>T0W$.CWTML99+FX\N/=L8;B!&<9Z;J_3_1=/;2='L+
MS/<&UMXX3-*Q9GVJ%W$GDDXSDT 7>U&?:ORR^%7Q-\9_&K_@J_X@TZU\6ZXO
M@O0;Z\D;28=0E%DT5K#Y"@Q!MF&EVMTY)JIX\^*/C7XK?\%9-.\$:+XJURP\
M+Z7JEM;W&F6.HS1VTD=K )Y]T:L%.6#J<B@#]6:*0'-+0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7Y:_P#!<3_D%_"7_KMJ/_H,%?J57Y:_\%Q/^07\
M)?\ KMJ/_H,% 'T5_P $H?\ DRGPG_U^W_\ Z4O7V!7Q_P#\$H?^3*?"?_7[
M?_\ I2]?8% !1110 4444 %%%% !1110 4444 8/C#Q[X;^'NGQ7_B?7M-\/
M64LGDQW&IW26\;.03M#.0"< G'L:_/7]J+XP> _BU^W=^S]ID?C+0+GPAX96
M;6K[4CJ,1M$FW%U1I-VT-^XCXSGYA7W/\:/@+X'_ &@O#MGH?CS1%UW2[2Z%
MY# TTD>R4*R!LHP/W78?C7YR?L__ +'?PD^+7[;7QOT&3P@C_#SP;##I]IIR
M74VP7;%59RX;<3F*?C/>@#MO^"D'QF\"?%[7/@=X T?QIH6IZ1J'BA+W6;JW
MU&*2WMK>,HF9F#$*"LLA&?[M?=-Y\=/AMHNBZ5J-UXZ\.66E:BK_ &"ZEU.%
M(;D1D*_EL6PVTX!QTS7YP?\ #'7PD\4?\%(!\,](\()#X%\/^&_M^KV*7<S+
M+<,N4)8ON',T/ /:OM[Q%^PK\$/$G@WPSX:U7P7%<:%X86X&EVQNYU%N)G#S
M<AP3N90>2>E 'RK8?&'P%X^_X*F:AXLU#QGH$'A;P?X8%II^HW-_$MO/,R@,
M(Y"VUB#<2]#_  FC]HCXP> _BM_P4*^!5NOC+09O"'A*RFUBZU1M1B-F+@EW
M5/,W;=^88>,YYKB_^"?_ .QO\)OV@)/BYXH\1^$%OO#L/B:33O#]M]IF1(+>
M/<QVLK ME9(ADD_=I/V:OV._A+\8/VO_ ([Z9<>$(YOA[X1>+2]/L$NIMB7)
M;:S[PVXG]U*<$_Q4 ?I+KWQP^'GA4:>=9\<>']*&H6ZW=F;S4HHOM$+?=D3<
MPW*<'##CBO@_X ?&'P'XG_X*(?&_XD:[XQT'3])L+*+1=&O+W48HTN%&Q&>%
MF8!EQ"3D?WQZU]1_&+]COX)>+?#=CJGB[P=%J-KX1T+[%9;KN:,064"LZQ_*
MXR!\W)R>:^-_^"<G[$/PJ^.'P-U+QOXY\()J4NIZY=#34:ZFC%O:1[5"#:XS
M\^\9//% '2ZU\8O ?Q&_X*F:/KUYXRT$>$?!7A@BTU*;4(A:O=2(V1'(6VLW
M^D=C_ ?2OTDAFCN(8Y8G62*10R.IR&!&01[5^4_["_['?PD^/GCCXW:[K7A!
M;OPAIOB)M+\/V;7,RI!&C.S88,"WRF+J3UK]5;&SAT^RM[6W3RX((UBC7T51
M@#\A0!/1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]#_\%7/^3+/%?_7Y8_\ I0M?/'_!#G_D!_%O_KXTW_T&XH _4:BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
MAZ4M% 'AWQ\_;-^%/[-VH6VF>,?$##7+E0\>C:; UU=[3T9D7[H/;<1GMFLC
MX)_M[?!WX\^*AX7T#7;G3_$C_P"ITK6[1[.:?C)$>[Y6..=H.?:N<_9Y_8UN
M_AW\>OB;\5O'U]I/BWQ)XCOC+I-U'$S-I]N68E '7Y6"^4@*Y^5,5X?_ ,%<
MM,\/Z3;?"C5M#@AM?BQ)XBC32I[-0MU+"HYW%>2!*8=N>A)QU- 'Z-"DD8(A
M9F"JHR6)P *@TW[0VFVOVOBZ\I?-Q_?P-WZYKYH_X*3?$W4/A;^R#XSO]*G>
MVU#4O)TB.:-BK(L[A)"".A\O?^= &;XR_P""G_P%\&^);[1CKVI:VU@_EW5]
MHNFR7-I$<X/[T8# 'NN1QQFOHGX9_$_PO\8/!]EXI\'ZS;:[H=YGR[JV;@,/
MO(P/*L.ZD BO+_V/_@7X:^%?[,O@WP]!H]E(=0TB"[U9I(%?[9/-&'D,F1\P
MRQ4 ]  *^;_V+[=/@3^W9\=/@QI0:V\(742:_IEB&RELW[LE4'8;9]OTB7TH
M _0FORU_X+B?\@OX2_\ 7;4?_08*_2C4_B-X3T.]DLM1\4:-87D7W[>ZU"&.
M1?JK,"*_,'_@M1XNT+Q1I?PJ&C:WINKF&;4/-%A=QSE,K!C=M)QGGKZ4 ?4'
M_!*'_DRGPG_U^W__ *4O7V!7Q_\ \$H?^3*?"?\ U^W_ /Z4O7V!0 4444 %
M%%% !1110 4444 %%%% 'BW[5WPGUCXM?#=+;1_B+J_PS;29SJ=QJFC[O,DA
MCBDW1MM=#MY#=?X17YR?L)_L<^.?CI\-=;^(6F?&WQ-X$;5]9GBE_LT.7U Q
MD$SRN)5+,6=^N>_-?JK\7?!=]\1OA?XJ\+:;J:Z->ZUIL^GQW[1>:(/-0H6V
MY&>">,BN0_9V^ I_9[_9^T;X<Z?JJ7M[I]M.AU7[/Y:R3R.[^9Y>X\ N.,_P
M]: /S._9)_9-\:?'[XD_%_Q#IGQN\3>'[C1-7.A'Q';[WN]6",V3(WF@@ 1Q
M$#)ZCTKZ<_:D_9S\:> _V5K6_;X]>*K6X\!Z5J-Q>WT32))KC2L&B28B7(VG
M$8R6X<U[W^QS^S#_ ,,I_"^\\+RZVOB34+[5)M3N]36V,'FLX4 ;2S= HYS6
MU^U=\#]1_:,^".M> -.\01^&GU5X?.OI+8W \I)%=DV!EZ[0,YH _/C]F/\
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MXS^-<W\(?AY;?"7X7^%?!EG()[?0M.@L%F"[?,*( 7QDXR<G&>]==0 4444
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M+< 9?  [#FOUDK^?[]M>-9/^"A'C5'571O$=F&5AD$%(."* .E_X>X?M%?\
M0<T7_P $T/\ A1_P]P_:*_Z#FB_^":'_  K]L(?A7X*:)"?!^@9VC_F%P?\
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MBO1/V-OVW/CA>?M0^!?#GB7QOJVO:5JVJQZ5?Z9K#;UVR-L)P1E74\@^HP:
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MV7AKPG9S"86"D,"[L"0" []R2SD\  5]NTF*6@#Y _X*N?\ )EGBO_K\L?\
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ML:OZ"*_GV^"W_*1SP_\ ]E";_P!+&H _H)HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** /D#_ (*N?\F6>*_^ORQ_]*%KYX_X(<_\@/XM_P#7
MQIO_ *#<5]#_ /!5S_DRSQ7_ -?EC_Z4+7SQ_P $.?\ D!_%O_KXTW_T&XH
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M** "BBB@ HHHH **** /Y^K7_E)4W_92W_\ 3@:_H%K^?JU_Y25-_P!E+?\
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M*^AJ2@#R;]EW]GG2?V7_ (.Z7X#TG4)]62VDDN;B_N%"-/-(V78*.%'0 9/
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M ?S]6O\ RDJ;_LI;_P#IP-?T"U_/U:_\I*F_[*6__IP-?T"T %%%% !1110
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M3444 %%%% !1110 4444 %%%% !1110 4444 %%%% '\_5K_ ,I*F_[*6_\
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ME!\-_'7Q:^)'_!2+X3>(OBOI#>&9=1T^YN]$\.LQ_P")?9-#.%#(>5=BI)+
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MGA__ +*$W_I8U ']!-%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M ?S]6O\ RDJ;_LI;_P#IP-?T"U_/U:_\I*F_[*6__IP-?T"T %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-?
M.QL=<<4ZB@#\N->_9]_;\N==U*;3_B08;"2YE>WC_MY!MC+DJ,;..,51_P"&
M=_\ @H1_T4P_^#]/_C=?JI7P+^VU^WWXK\$_$J#X,_!#2/\ A(/B-,5CN[M+
M?[2;5V&Y88H^C2!3N9F^51U!YP >2_\ #.__  4(_P"BF'_P?I_\;I#^SO\
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M#!0!]%?\$H?^3*?"?_7[?_\ I2]?8%?'_P#P2A_Y,I\)_P#7[?\ _I2]?8%
M!112&@ I:^$/VO\ _@J=X>_9W\<77@GPMX>_X3+Q+I[JNI2S7/D6EJQ )B#
M,SN 1G@!3QDG(&S^QC_P4O\ #?[4?B;_ (0[6]%_X0_QE(CRVD*W'G6MZJ\L
ML;D B0#)VD<@'!XQ0!]JU\[?MQ_M70_LE_!QO$-O:1:EXDU*X%CI%G/GRFF(
M+-))CG8B@G /)VCC.1]%5\=?\%//V9?$/[1OP,LG\)0M?^(O#5XVH0:8F-UY
M&R%)$3_; PP'?:1U(H _,W2_^"HW[16G^*H]8E\:QW\(F,KZ7<:?!]D=2?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK]B+]J#Q%\;+?Q?X*^(NG6^D?%'P1>?8M7@MUVQW*$E5F5>WS*P../ND<-@
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M#_T5>3_P3C_X[7U1_P //?V;O^BA+_X++O\ ^-4?\//?V;O^BA+_ ."R[_\
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M8[20!P.<U]P5\L?\//?V;O\ HH2_^"R[_P#C5'_#SW]F[_HH2_\ @LN__C5
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M/VD_V)?'O[)NKZ!J'C7Q-=ZMX U&Z%K-X@T!W:2W8@G:T,C##8!(YPVTC.:
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M'P?_ ."0_P +_B%\*?!_B>]\4>)H+S6-*MKZ:.%X BO)&KL%S&3@$\<U\_\
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M)+#3;S^S]4MK%/-N+>4J'5Q&/F:,J1R <$'/:KMM^R!\5U^'WBGQMJOA*_\
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M(? >N:=XN\2:UJMLTMQ:3H;6R5&R-TQ(0,S$#KP-Q.*Z#_AR=\+?^AX\5_\
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M4?V7=&_9,^'=YX1T/6+[6[6ZU"34&N-01%D#,B)M^0 8P@_.O:Z** "BBB@
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M['^WQ\8]2\ ^+O!GB?Q1/XQT#Q)8/93Q:R?,DMR>1)%(,,",=#E3Z=Z^EO\
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MCC8\$H@!_2@">BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\
MM?\ @N)_R"_A+_UVU'_T&"OU*K\M?^"XG_(+^$O_ %VU'_T&"@#Z*_X)0_\
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M!>.)+B/2K-+<2L!@%MH&2!75T44 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% 'R!_P %7/\ DRSQ7_U^6/\ Z4+7SQ_P0Z_Y ?Q;_P"OG3?_ $&X
MKZ'_ ."KG_)EGBO_ *_+'_TH6OGC_@AS_P @/XM_]?&F_P#H-Q0!^HU?ES_P
M7"_Y ?PI_P"OF^_]!BK]1J_+G_@N%_R _A3_ -?-]_Z#%0!]$_\ !*3_ ),F
M\'_]?>H?^E<E?7M?(7_!*7_DR;P?_P!?>H?^E<E>+_\ !0[_ (*4>(?@KX\N
M/AI\,1:P:W8QQOJVMW40F-O(ZAE@B0_+NVE2S$'&X #()H _23%%?CW^R7_P
M5F\>I\2]*\/_ !9N+37?#6K7*6IU2.V6"XL'<[5?Y %=,D9!&0,D'L?UWUC6
MK#P_I5SJ>IWUOI^G6T9EGN[J58XHD'5F8G 'UH N[:\UO/V9_A-J'B=O$5S\
M-_"\^N-,+AK^3283(T@YWD[>6SSGK7(>%?V[/@-XT\46_A[2?B7H\^J7$GE0
MQR%XDE?LJR.H4D]N>>U>\T (J!5 48 X ':DDA25<.JN,YPPS3Z0T  7 Q1M
MKR3XX?M7?"W]G,6J>//%=MI%Y=#=#81JT]TZ]-_E("P7/\1 %6?@A^TY\-?V
MB[&ZN/ /BFUUJ2U/^D6A5H;F$9P&:)P&VG^]C'O0!RO[>W_)G/Q9_P"P))_Z
M$M?GI_P1&_Y+)\1/^P!'_P"E"5^A?[>W_)G/Q9_[ DO_ *$M?GI_P1&_Y+)\
M1/\ L 1_^E"4 ?L11110 4444 %%%% 'YD_M&?\ !6SQ3\%/CAXR\"V/P_TC
M4;30KYK..[N+V59)0 #N(48&<]*Y/P/_ ,%H?%_BCQIH&C7'PVT2&#4=0M[.
M22._FW*LDBH2,C&1G-?&O[>W_)XWQ9_[#<O_ *"M>8?"'_DK'@K_ +#=E_Z/
M2@#^GNBO/?BI^T#\.O@C)IT?COQAIOA>34 [6J7TA4S!,;B  >!N'YUP?_#?
M'[/7_16?#W_?YO\ XF@#WZBN/LOB]X,U#X=Q^/8/$VFMX,DA\]=;:<+;>7NV
M;MYQCY@5Y[\5QX_; ^"7_15/"G_@TB_QH ]?KB[KXW?#JQN9K:X\?>%[>XA<
MQRPRZS;*Z,#@JP+Y!!XP:D^'_P 8/!'Q5:]_X0[Q7I/B4V6W[2-,NTF,.[.W
M=M/&=IQ]#7\VOQ>_Y*SXU_[#=[_Z/>@#^DW2/C!X#\0:E!IVE>-O#NIZA.=L
M5I9ZM;RRR'&<*BN2> >@KK17\[7_  3_ /\ D\OX3_\ 887_ -%O7]$U !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** /D#_@JY_R99XK_ .ORQ_\
M2A:^>/\ @AS_ ,@/XM_]?&F_^@W%?0__  5<_P"3+/%?_7Y8_P#I0M?/'_!#
MG_D!_%O_ *^--_\ 0;B@#]1J_+G_ (+A?\@/X4_]?-]_Z#%7ZC5^7/\ P7"_
MY ?PI_Z^;[_T&*@#Z)_X)2_\F2^#_P#K[U#_ -*Y*^ O^"K/[,_BWP3\?-<^
M),-A<ZEX/\2F*X_M""(LEG.L:QM#*1]W.P,I/!#8Z@U]^_\ !*3_ ),F\'_]
M?>H?^E<E?7%Q;Q74+Q31I-$XPT<BAE(]"#UH _G-_9'_ &:_&'[1GQ<T+3-
MTZX&DVMY%/J>L-$?L]E"K!F+-TW$#"KU)([9-?H1_P %K/&VN:%\./A[X4L;
MF2WT'5KNXFOD3(\]H%C\I&/H"[-CN0#VK])[/3[738S':6T-K&3DI#&$&?7
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-_QV_P"?OPM_X,7_ /C= 'UK_P ,=_L*_P#0Q^'O_"S'_P >I1^QW^PKD?\
M%1^'O_"S'_QZODG_ (<W_';_ )^_"W_@Q?\ ^-T?\.;_ ([?\_?A;_P8O_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 ?GQ_P31V^.OCI^TK\0[W]_JUUXB^P),W)2'S9FV#
MT&%C&/15]*T/^"P&FC2_@KX&\<VBB/6O#7BFWDMKA>'4.CL0#VRT49_"J/\
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MY,I\)_\ 7[?_ /I2]?8% 'XC?\%EO^3KM._[%JT_]&SU^M7[+_\ R;C\,?\
ML7+#_P!$)7Y*_P#!9;_DZ[3O^Q:M/_1L]?K5^R__ ,FX_#'_ +%RP_\ 1"4
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M,\9?M$_'[PUX!U?P9H6E:?JHN/,N[.:8RQF.!Y 0&)!Y3'XU^0EY_P ?D_\
MOM_.O6_V59)8?B9J,D+O%*OAK6V5XR58$:=/R".E '](/VRW_P">\?\ WV*^
M:O\ @H]#)JW[&'Q(M[&-[VX:WMR(;93(YQ=1$\+D],_E7X!?\)%JW_03O/\
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MA[_R'/BM_P!>UA_Z%-7ZQT %%%% !1110 4444 %%%% !1110 4444 %%%%
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M"C_KRO\ _P!&0U]I_P#!-O\ Y,G^&'_7I<?^E4U 'XU?M[?\GC?%G_L.2_\
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MN/\ TKFKWWQMXD'@WP;KVOM ;I=*T^XOC &VF3RHV?;GMG;C/O0!MT5^4_\
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MV?\ Q9H^DVD=AI>G^&;NUM;6$82&)+5U1%'H  *_&_\ X)#?\GDZ=_V!;_\
M] 6@#]U**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ_6K]E__ )-Q^&/_ &+EA_Z(2@#T^BBB@ HHHH **** "BBB@ KYN_X*,?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **\@^/G[6'PS_9IM[(^.=?%G?7W-II=I$UQ=SKG&Y8UY
M"YXW' SQFLKX"_MJ?"?]H[5KC1_"&OR#7X$,K:/JENUK=%!U94;[X&>=I..]
M 'NE%%(S!5))P!R30 M%?*GC;_@IM\ _ _BJ\T*;Q+>:M-92>5=7>CZ?)<VL
M# X(,JC!P0>5R.*^A?AS\2O#/Q:\(V/BCPAK%MKNA7JDPWEJV1D<%6!Y5@>J
ML 1Z4 =-7Y:_\%Q/^07\)?\ KMJ/_H,%?J57Y:_\%Q/^07\)?^NVH_\ H,%
M'T5_P2A_Y,I\)_\ 7[?_ /I2]?8%?'__  2A_P"3*?"?_7[?_P#I2]?8% 'X
MC?\ !9;_ ).NT[_L6K3_ -&SU^M7[+__ ";C\,?^Q<L/_1"5^2O_  66_P"3
MKM._[%JT_P#1L]?K5^R__P FX_#'_L7+#_T0E 'I]%%% !1110 4444 %%%%
M !7S=_P48_Y,K^*/_7A%_P"E$5?2-?-W_!1C_DROXH_]>$7_ *414 ?#?_!#
M_P#Y*!\4?^P79_\ HV2OUUK\BO\ @A__ ,E ^*/_ &"[/_T;)7ZZT %%%% !
M7Y2_\%Q/^/SX3?\ 7/4/YP5^K5?E+_P7$_X_/A-_USU#^<% 'U7_ ,$M_P#D
MR7P'_OWW_I7+7U?7RA_P2W_Y,E\!_P"_??\ I7+7U?0 5\G_ /!0+]CG7OVP
M?"GA+2] U_3M"GT6]FN9&U))&6170+@; 2",?K7UA10!^.G_  Y'^)'_ $4'
MPM_WZN?_ (BOT2_8I_9WU7]EWX$V/@76-6M-9OH+VXNWNK%&6+$C9"C=@G'K
MBO>:* "BBB@ HHHH XSXU?\ )&_'G_8!O_\ TGDK\7O^"0W_ ">3IW_8%O\
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M* .8^&OPW\/_  C\$:3X1\+6']FZ!I<9BM;7S&DV*6+'YF)))9B>3WKIZ**
M"BBB@ KY>_X*9_\ )DOQ(_ZY6O\ Z5PU]0U\O_\ !3)2W[$OQ(P,XAM2?;_2
MX: /CS_@A[_R'/BM_P!>UA_Z%-7ZQU^3O_!#T'^W/BL<<?9[#_T*:OUBH **
M*2@!:*2EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ I*6DH _.W]C#1;+]HG]LSX\_%GQ-;1:S)X?U(:)H27:^8EG
M&KR(&0'@,$B'('!=SU-6/^"HGA6Q^$-]\+?CSX9LXM)\4:#XBAM+N\LXPC74
M#JSA9<?>_P!6Z\]I".E2_P#!*J/^Q?%_[1NA7!VW]IXM)DC;[V-\ZY/X@UL?
M\%CKM/\ AEW1M,0;[O4/$]I%!&.K$13$X_3\Z /N33+^/5--M+V+_57$*3+]
M&4$?SKYK_P""DGQ/U#X4_LA>--0TJ=[;4=1$.D13Q,5>,3N$<@]CY>_\Z^A?
M!MG)IW@_0K248E@L((G'NL:@_P J^1?^"NVGRWO[&VIRQ*S+:ZQ8S2;>RERF
M3^+B@#U/]D#]G_PI\+_V9O!_A]="T^>34])@N]7>:W20WD\T8>3S"P^8#=M
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M]HO_ *%O2_\ P;P?XT?\.FOVB_\ H6]+_P#!O!_C0!^WW_"S?!__ $->A_\
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MWB?XH?MO>,O@Y9:#IB^$O#:7!FU96D-RQB"+Z[>97QTZ"OL"@ HHHH ****
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M\::G9?%7X46_P^T"VL3-!> OOGGWJ!&,N1]TL3]* /J2BDI: "BBB@ HHHH
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M444 %%%% !7P]_P4F_:N\>?L_P!W\-_#OPUOK6T\2^)+N99%N+1+C?&#&D8
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MOTXKX[_X)0^ _P#A"_V._#]Y)$$N/$%[=:H[ <LI?RT)_P" Q"OL2@ HHHH
M**** "BBF33);PO+(P2-%+,QZ  9)H _+_Q</^%Y_P#!8_1-/7,^G>";>)Y
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M3/A[_P $AO@K?^ ?#5SX@3Q&VNSZ;;RWYAU,(GVAHU,FU=G W$X'I0!]H_\
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M**3RRL_F.!_P"-J[K_@G_P" _P#A7G['_P -=/:+RKBZTT:G,,8):X8S _\
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M1EB+25ADQ_-SE<X.>^:ZR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.O#=OX!/@F+1K2#PG]A.F#2HXPL(MBFPQX]-I/OSFOS@_9!NM>_8;_;!\4_
MS7X[VY\ >);A9M%U)HF:))6&;>0L!@;U_=/_ +:+Z5^H=,>%)&!=%<CH64$B
M@#\G_P#@K9XO>^_:-^%6CS:1J.LZ%X;MTU+4+>SA9O,\VX!>-3C;N,< Z_WJ
M]87_ (+#>'%4*OP>\; #@#9'7Z#M;QR-EHT8^K*":/LL/_/&/_OD4 ?GR?\
M@L1X>[?![QL3_NQU]Y^#]>?Q3X4T;6GLIM-;4;.&[-G<$&2#S$#[&QQN&<'W
M%:7V6'_GC'_WR*E'% "T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=W*L<42CNS,0 /K7B%C^WI^S]J6M+I5O\5= -VSB-6>9DB9B< "0J$Z]\XH
M]]HJ&UNH;VUBN+>:.XMY4#QS1,&1U(R&!'!!'>N1^)'QF\"_!^&QE\;>+-)\
M+1WS,EJVJ72P^<5 +!<]<9&?J* .THKQ+_AMCX"G_FK?A/\ \&<?^->G^"/'
M7A_XD>';?7_"^L6FO:+<%A#?V,HDBDVL5;##K@@C\* -ZBBB@ HHHH ****
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M-1\2_L/Z%X]\93375QHNG7@O+N0YDN8K0N Y)ZL40 GN03WKYC^-WQD\9?\
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M/]I;X\?#?X6Z;I6M6'PB:2.YUO7+./\ T9Y"S%M[#C*1IA0W&Z3/T]I\2?\
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MY5]4_MZ^(M4\*_L?_%+4=&DDAOETHPB6(X9(Y)$CD(QT^1VY[4 ? <WQ;O\
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MT%XT\1Z!^S[XQ\5?#I[74?$%CI<E]IKA1<0R[/F8@ X?Y ^.>M>9_P#!/_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
2HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img187419207_11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img187419207_11.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'V!&4# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7L?S"4_>!C+ D#C(9>OI27EC??%OXQ:MI%UJEQ;:1I0<*D+= I"\ \9+<DT
M==K/C#7;7X_:5X<AOBNDS1J9+?8N&)1R><9Z@=Z];KYGT[P_=^&/VAM#TFZU
M*74%AQY$TI^<1&-]JGZ<U]'ZC))%IEW)",RI"[(/]H XH \J\5?&2[C\2MX;
M\&:1_:^H1N4ED8$H&'4*!UQW)(%:'@WQWXPN_$]OH/BWPP;!KF)WAN8P0I*C
M)!Y(_(UQG[-D,,UYXCO9</> 0IO;[P5BY;GW('Y5] T >9_#[XEWWBSQ-XAT
MW4+6TMK;3-Q22,L#@.5^;)QT&:A\+?$W5O&GQ NM.T73;9O#MH3YM])NWD=
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M,6X26\;A?M+'&/KC'H>M>.6FH:)X8^*&@-X&UV\N[&XFCBNXY2V#E@I4Y W
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M8W&&4Y/!KIZ* /.OC7HNIZ]\/S9Z592WES]KB?RHAEMHW9./Q%=-X'L[C3_
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M?52,&IJ* /E?3/AAXP;Q);^&[O3;I?#\>J&9YRO[LJ."X/NH_6O6OC%X"O\
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M\LJM(QX]>#2> ?#OBGX=?$:\T>+3[J\\,7LGRW*C*Q]U<GL0/E;_ /57M]%
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MPZ_(^YT(P?< UA:;H/BOX7^)=52U\*#Q%H][)YD3HH9E )QV.TX.",5]!44
M<'X.U/Q!K4>JOJ7A&+0;8Q;;9>!+*Q!SNZ<=.PKG/@-X;UKP[9:ZNL:;<633
MSQF,3+C< &SC\Q7K]% 'CWPR\-:UI/Q1\6ZAJ&FW%M9W1D\B:1<+)F7(P>_'
M-<WINF>.?AW\1M<N-+\,R:I;:E*VR49V;6?<&R.A&3D&OH6B@#ROQIK_ (D7
M4M0TB\^'@U_27_X])8_F!R/XN#@YSTP:=\$/!NL>%-!U&76(3:R7\RR1VA;)
MB50>3Z$YZ>PKU*B@#A_BSX9F\5?#^]L[2 S7L++/;HHY9E/('U!->>?#?X?:
M[?Z9XJF\3V4]O=7U@NGVXN!M.T+P?H"L?Y5[W10!\Z?"CP'XH3QY8WWB/3;F
MWM-)MF6W,ZX&<D*J^O+,:Z;Q1X8UN[^/^AZU;Z9<2:9"L/F7*K\BXW9R?Q%>
MRT4 >(?$_P .^)K+XG:3XST'29-32"- T48R0REN"!S@@]:B^*FE>+/&_@7P
MU<_\([.FI>=*]S9P@L80>%SGGD &O=** /-OBWH>IZS\+DT_3;*:ZO!) 3#$
M,M@=>/:NI\"V5SIW@/0K.\A:&Y@LHDEC?JC!1D&N@HH \8^,?A77;[Q5H7B'
M3]).LV5D )K$#=G#[CE>X8<?A7/ZWHWB_P 4^,_#6LCP4VDZ=:W*(L,84NBA
MU+/)@# ].!T-?0]% 'C?C_PSK>I?&GPIJMEIEQ/86S6YFN$7*Q[9B3D]L#FI
M/CEX;UKQ _AXZ1IMQ>^1,YE\E<[ =N,_D:]@HH \7^*GA#Q'%XTTCQMX8M&O
M+FU"++ @RV5)P<=U()!Q7+>.=-^)'CZ/3=3O?#36MO;3>7%91 F49P6D;/..
M .<5](T4 %>(?&GP?X@NO$^E>(O#%C<7%T('@F-NN63&<$_4,P_"O;Z* / =
M<^&^LVWP@\,+IEA,VO:;<?:GA09D4R'+?B"$_*NM^"/A34O#WA[4;W6K62WU
M/4;HO(LHP^U>F?J2Q_&O4:* /&_@CX8UOP_K/BB75M,N+-+EX_):5<!\-)G'
MYC\ZY[P?IOCKX<^,]4LK7PS)?V>HW2+]IY\M4#GYPP_V6Y!Z8KZ%HH \;@\,
MZVO[2+ZZVF7 THHV+O;\G_'OMZ_7BI/''AO6M0^-GA;5K33;B;3[8P^=<(N4
MCQ(2<GZ5[!10!X?XK\+^*_"7Q3?QMX7TPZK;W:_O[=>6!*@,"!S@X!!&>:@C
M\/>,/B=X^TO6/$6BG1=(TPJRQ2$[GP=V!GDDD#)P !7N]% 'AWQ#\.>*]&^*
MMEXW\.:6VI)L4/%&NXA@I0A@.<%3UK+N]"^('B+XD^%O$^MZ*881=1?N(!G[
M)$D@)+GL3DFOH6B@#Q;XN>&O$@\=:#XNT#3)-1^PJ@>&,9(9'+#('.""1D5Z
M;X2U/5M8\.6]]K>E_P!F7TC-NM<G**&(7.?48-;E% 'G/Q=^'<_CO1+9]/>-
M-4L69H1(<+(K8W+GL> 0?:N.TOQA\7=*TR'1Y/!S7=S$GE1W<L;=!P"Q!VG'
MK7N]% '@_P 1O"/C75]-\)ZQ=Z>FK7M@I.H6,6""Q<-]T=00-IQZ5E^*=(\7
M^,-7\/ZC#X&;2+"RN5188POF<E2S, !A1CCCUKZ,HH \:^*WAC6]9^(_A.^T
M[3+BYM;5X_/EC7*QXF!.?3CFH?B'X2\3Z1\2+3QWX6L3J# *)[9>6!"[3QU*
ME>XZ&O:Z* /-O#FM^.O% U9M:\/+I.G?8)(X(6!\R68]#SSC&>P'2N(\%^'=
M8\._!CQO#K&G3V4LL;LBS+@L/+QD5] 5F^(=(77_  [J&DM,81>0-"9 ,E=P
MQG% 'SK\.?$'C_0? \B^']"75-/NIY%A=%+/;RX )('8Y!&?2NN\$_#K6M#^
M&7BF2_MF.LZQ;.$M007 VG /^T2QX^E>B?#[P:/ OA@:/]M-V?.>8R[-G+8X
MQD^E=50!YG\&-"U70_AS<6.J6,UI=-=3.L4HPQ!50#^8-9?P0\+ZKHVG^([?
M7-+GM$NYTVI.N/,7# X_.O8** /D:R\&W9^+2^!VE9["+4C,R Y7RP-V[Z[,
M"O8?COX<U;Q!X8TNVT73IKR2&[W-' N2J[",X]*V/!_PR7PWXPU7Q->:HVH7
M]\7VDQ;!&&;)[G)X KT"@#PSXG>#O$-X/"&K66DMJD.F6T27.G]3N&TD%>X.
M,''I61XDT?Q?XM\2>'-5C\$-I&GV=RB+#& 9 -RLSN !A>../6OHJB@#Q_XD
MZ'XB\=>.=(\/)I]S%X;MI%ENKPC"2'&3@^P^4>Y-4/#'A;7_ (>?%VYBTO2[
MJX\+ZD0K21C<D*GE2?\ <.1]#7M]% 'BOP_\->(M'^*'C'5)M*FBBN([C[)+
M,,1RN90R@'T.*Q/&DGBWQUI2Z5=_#-X=9\Q0-17[J 'G#$=#[L17T+10!A>#
M=&N/#W@W2=)NY1+<6MNL<C Y&?0>PZ#Z5NT44 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%-9U4J&8 L< $]:&=5(#, 6.!D]: '44A(4$L0 .I- 8,
M 5((/0B@!:*:KJQ(5@2IP<'I3J "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BN7^(7BFX\&^#KK6K:WCN)86
M11'(2%.Y@.WUKEHOB/XBTC5- A\3Z)8QV6N,J6UQ8W#.49MN RL/]H4 >HT5
MP/A/QK=:AKGC*'69K6"QT6Z\N.7&P(GS9+$GV'-;6E>/_"FN:B-/TW7+6XNV
MSMB!(+_[N0,_A0!TE%<[?^._"VEZL-+O=<M(;W(4Q,W*D] Q'"_C4^I^,/#N
MBRW$6I:Q:6TMNJO+&\GS*&^[\O4Y]J -NBN7F^(W@ZWL[:[E\16(@N<^4P?.
M<'!R!R.?7%7]6\5Z!H=C!>ZEJUK;V]P,PNSY\T8SE0.6X(Z4 ;-%96A^)=&\
M2VSW&C:C!>Q(VUS&>5/H0>1^-<W\1?&FI^$Y=#MM+LK6YN-4N3;K]I<JJGC'
M3W- '<T5Y[H7CW5SXV?PCXDTFWM=1-L;F"6SF,D4B@$X.1D=#^5<Y9?%7QA>
M>&]0\31>']*ETG3YVBG47+K-A<9(!&.C"@#V6BN)L_'$VJZEX:-BFGII^L6Q
MG9+JYV7(X/")_%C'7ZUUU]?VFF64M[?7,5M:PKNDEE8*JCW)H L45SNC>._"
M_B&^-EI6M6US= $B)20Q ZD @9_"DU#Q]X4TL2F\UZRB,4Q@D7S,LKCJ"HYX
MH Z.BLN?Q)HMKH:ZU-J=LFF,H9;HR#8P/3![_2N)'Q+CU3XE:#I&@WUG>:1>
MV\CSNBDNKKNP/5>@X([T >E45B^*_$EKX2\-7FM7BL\=NN1&O5V)PJCZDBL#
MPSJWCG5+JSNM3M="M]/N%\R2VBE<W$*D97)Z$],CB@#N:*0D*"2< <DUS,WQ
M%\'6_P!G\SQ%8#[02(R),@X..<=.1WQ0!T]%8$7C?PS/K@T6+6[-]1)P(%DR
M2?0'H3[9S2ZYXU\-^&IDAUC6+:TF<;EC<DMCUP,G'O0!O45DCQ/H;:'_ &V-
M5M3I?&;H2#8"3C!/8Y(%5;7QSX7O=:&CVVN6<M^>!"DF=Q] >A/L#0!T%%<)
M#\6/#<GC2Y\./=11^2 %NVE7RY)"0#&/]H$X_ UF6?Q0BLO'OBC2_$5_96>F
M:<T:VK,I#L3U]2WX#B@#TZBJFFZG8ZQ817VG745U:RC*2Q-E35'4_%GA_19Y
MH-2U>TM9H8Q*\<D@#!"< XZG)]* -FBN6D^(_@Z+3H+]_$-D+:=BL;!R22.O
MRXR,>XK6O/$>C:?HZ:O=ZG:PZ>ZADN&D&QP>F#WS[4 :=%8>A>,/#WB9Y$T;
M5K>\DC&7C0D.H]=IP<>]1?\ "=>%OM,-L-=LFFF9T1%DR24^]G'3&#UH Z&B
MN'\*_%+P_P"*M7O--@GCAGAG,-NKR@FZ S\Z =N,U?7XD^#'U%;!?$5B;AGV
M !SM+9QC=C;^M '4T5PUWXLU*'XPZ?X73R?[.GL'N'RGS[QNQ@YZ<"JH^):Z
M7X4U/6]<;2V-M=-;P0Z?=^9YQ'\.3T?J<>@H ]#HKEM*^(?AG5-$M=3_ +6M
M8$G9(RDDHS'*PR(V/][K^5;=WK.FV-_:6-U>PPW=X2+>%VPTI'7:.] %ZBBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+VI^*7>'^S[FP2W10QW[ALSD8Z?*:P]$^'FM:?X#\7Z+-):FZU>XFDMRKDJ
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MJPNWM+F"0Y*,IZ^X(Y!K=KS+PD6A^-_C>"/(AD@MI7';?M S^IKTV@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *@NK*UO4
M"7=M#.@Y"RQAP/SJ>B@"."WAMHA%!%'%&.B1J% _ 4CVMO)<1W#P1--&"$D9
M 67/7!ZBI:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQF@#U*BO)/AI]OL/B7XMT*XUG4=1M;&.(0F]G,A&>2?3O7K= !1110 4444
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M]8?_ $4:^@*^?_$7_)TVE?6'_P!%&OH"@ HHHH **** "BBB@ HHHH ****
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M>- D\G,DRY(5?=B1@?6J7AG5/%O_  M?1XM=U&X5-5L9KU]-S^[MU.[8F/4
M#/O0![117A_BO7)K7XDZU#K/B+Q%I6CPPPFV;3XV,>XJ-V2%( KU7PC<6=SX
M8LI;#5Y=6MBIVWDS[GDY/WN!R.G3M0!MT444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% '%>+] L/B):IIEMXB>UDL+G?,M
MHRLZNO3<,Y4@]#6;!\,];@DB8_$7Q ZQL#M9@=P'8\UI>(/A9X9\0:B^I/#<
M6.HN=S75C,8G8^IQP3[XS62/@U9S934/%7B6]M_^>,E\=O\ *@#T"TU.POIY
M[>TO()Y;<@3+&X8H3T!QT/%6ZQ_#OA;1?"EDUIHMA':QN=TA!):0^K,>36Q0
M 4444 %%%% !1110!YE>?\G'Z?\ ]@!O_1CUZ;7F5Y_R<?I__8 ;_P!&/7IM
M !1110!\_P#B+_DZ;2OK#_Z*-?0%?/\ XB_Y.FTKZP_^BC7T!0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%&110 4444 >4^!_P#DN'CW_=@_
MD*]6KRGP/_R7#Q[_ +L'\A7JU !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!X+X4_P"$M_X2;X@+X8BTZ<2:
M@T<J7;LA1COVNI'!QSD'VKN/#?PP@T[P#9^'=2O[LRQS-<RRV5PT.9&[ CD@
M#^6:[Z."&%G:**-&<Y<JH!8^I]:DH Y/1OA]I6AZG'?V]]J\TB!@$N;]Y4.1
M@Y4G!KAHO 7C?0]'UOPKHQTN;1M3F=H[R>5EDMT? 8;0.3BO9:* .(?PSXBT
M+POX?T7PIJ-K"MBZK=R729\V/JV!@X)))Q^M9NK^%?$VD?$.Y\6^%DL+O[?;
M""ZM+N0QX(QA@0/]D?K7I-% 'F.@_"6!_#5[:>*)S<7NHW_]HW#6DC(J2<X"
MGJ0,FJ__  I]8/B%INKV]_>-IEM"?,\Z^D:<R@D@ _W.F1GUKU:B@#A_$G_"
M?SR:A8:7I^AW%A<J4AGGF=6C5A@[TQ@D<]*O_#WP@?!'A&WT=[G[1,':660#
M"EVZA?8<5U-% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M *&G2/\ P+3_ !H Z:BN9_X6)X,_Z&G2/_ M/\:/^%B>#/\ H:=(_P# M/\
M&@#IJ*YG_A8G@S_H:=(_\"T_QK;TW5+#6+-;S3;R"[MF)42P.'4D=1D4 6Z*
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \X^)_@GQ!XIFT^
MZT/4V@%JK"2T^T/")LD<AEZ'CN*\WGL=)T"2.'QDGC;1&<[5N(]2%Q Q]F49
M_0UZ/\47\>--IUOX2BN39N&^V/:&-90<C !;IQGD5PEEX;U""<76H_#'5M:N
M^IFU/5EER?\ =Z?I0![7X6&GCPOIPTN]EO;'R1Y-S,Y9Y%]22 2:V*S= >1]
M!LFFTP:9(8ANL@01!_L\<5I4 %%%% !1110 4444 >4^!_\ DN'CW_=@_D*]
M6KRGP/\ \EP\>_[L'\A7JU !1110 4444 %%%9?B-=6;P]?+H31KJIC/V9I,
M;0_OGB@#4HKQ?[-\=_\ G\TK\HO_ (FC[-\=_P#G\TK\HO\ XF@#VBBOG#PS
MXT^+?BW4;^PTK4+%I['B8211J!R1P=O/(-=/]F^._P#S^:5^47_Q- 'M%%>9
M>$H/BPGB.V;Q/<V#Z3AO.6'R]V<'&,#/7%>FT %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!7>QM)'+O:P,Q.23
M&"32?V?9#G[);C'.?+7_  K@_BU>W45MX?T]-4GTNQU'4EM[R[@;:R(5) W=
MLG^5>5W&FP:3$YO?%6J7&J6&NK9RZ5->M_I,/F#:RJ.1E2#GD=: /IFJ]]--
M;6%Q-;V[7$\<;-'"IP9& X7/N:L#H** /"O#J^.['Q%<:]K/@*74M8N)-JW<
MEY&%MHO[D:9.T#GGJ?SK6US0O&7A[Q?XBU#PYHL6JVGB*!5;=.J&UD"[22">
M1R37K]% 'C=W\.]=\.^&_!EWHD$.H:MX>=WFMC(%$PD.YPK'C@DCZ4ZR^'^N
M^)M'\9ZAKUM%INI^(5C6"V\S>(1$04W$>I5?R_"O8J* /'M"T+QGX@\3>&'\
M2:+#IECX;0_O%F5S<R!0JD $X' ->AZEX*\,:Q?27VHZ#875U)C?-- K,V!@
M9)]@!6]10!Y':Z)I>@_M"6-KI-A;V4#:&\C1P(%4L9&&<#O@#\J]<KS*\_Y.
M/T__ + #?^C'KTV@#SKXP>"=6\<:#I]GI#6XFM[KSG,\A08VD<8!YR:\P_X4
M_P#%'_H,6W_@:_\ \37TI10!\@7>A>-K+QQ!X1EU<_VG/MV%;EC'\R[AEL>@
M]*ZO_A4'Q1_Z#-M_X&O_ /$UJ>(O^3IM*^L/_HHU] 4 >-?"7X9>)/!OBR^U
M76I+22.XM&BW0S%V+ET;)R!Z&O9:** .,UGX4^#?$&KW&JZGI+37EP099!<R
MKN(  X# #@"J'_"D/A]_T V_\"YO_BZ]"HH \]_X4A\/O^@&W_@7-_\ %T?\
M*0^'W_0#;_P+F_\ BZ]"HH \]_X4A\/O^@&W_@7-_P#%T?\ "D/A]_T V_\
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M_M1J]^KP'X"?\CQXP^O_ +4:O?J "BBB@ HHHH **** "BBB@ HHHH ****
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MZA+\+KV,3W&F2:E=336TRK\\2-@!@#]#7J%Q9VUVJK<V\4RJ<J)$# 'VS4H
M4  8 [4 >-_"ZQN--^+/C2SN]0FU">*.$/=3##R>Y _*O9:\I\#_ /)</'O^
M[!_(5ZM0 4444 %%%% !1110 4444 > _ 3_ )'CQA]?_:C5[]7@/P$_Y'CQ
MA]?_ &HU>_4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBHK6YAO;2&ZMI%D@F021NIX92,@C\*EH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#S?XEW\S:MHN@Z5H&F:KK-_YC1/J,8>."-0"Q_P ^G>J/
M@FULM1UK4O#GBCP=H=KK%A&DV^UME,4T;=&&>G-=5XL^'^F^+[^SOKJ\U"TN
M;1&2.2RG\MMK=1G%<\OP3T9;I[I=?\1"X=0K3"^^=E'0$XR10!Z1;6L%E;1V
MUK#'#!&-J1QJ%51Z #I4M4M(TU-'TFVT^.>>=+= @EN'WR-[L>YJ[0 4444
M%%%% !1110!Y3X'_ .2X>/?]V#^0KU:O*? __)</'O\ NP?R%>K4 %%%% !1
M110 4444 %%%% '@/P$_Y'CQA]?_ &HU>_5X#\!/^1X\8?7_ -J-7OU !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% 'F_Q>FD^R>'K.:_N;'2KS4TAOY[=RK!"#@9'0$_RKRF\TC1='WVU
MUJU[/KEAKRVQTV:Y9A=VYD!0[>WRD'/J*];U^^^(,U_=6EOX0T6_TP2_N&N;
MH9< Y4E2>#6;CQ]<ZW;ZE=_#_P .&[1E'VLW"M(B^H.<\#I0!ZJ.E% Z4V1!
M)&R-G# @XH YL>.]%D\;Q>$[>8W&H-$TDABPR1;1G:QS][':L_Q1\4=!\*ZN
M=,N8KVZN8XQ+<"TA\P6Z'^)SGCU_$5R5KX=TKPQ\=] T_2+1+> :5,S8)+.Q
MW99B>2:-$>&/X@?%,7;(K_9U/[S_ )Y^6?TP1^E '<ZU\0M T7PY8ZW)-)<6
M^H;19QVZ;I)R1D!5_GZ4NA?$#0M>T*_U:.66UBT[/VV*Z39) 0,_,/P/Y5XS
MX7\V.+X1M=DK;^?>;#)TR9#MZ]^F/PJ7Q6)9+[XN/99: 168<Q]-P=-WXX#9
M_&@#U+PS\5- \4:PFF6\=[:W$Z&2U^UP^6MRHZE#GGC)_ UW%>-:T\$WB'X3
M?8GB:7 (\LC/E^6N[IVZUUOB+4/B1!K<\?A_1=&N=, 7RI;F=ED;Y1NR P_B
MR/I0!E7G_)Q^G_\ 8 ;_ -&/7IM>+:#<>)+GX]V3^*+*RM+W^Q7"1V;EE,>\
MX)))YSN_(5[30 4444 %%%% !1110 4444 ?/_CS_DY7PS_VZ_\ H;5] 5\_
M^//^3E?#/_;K_P"AM7T!0 5XKX:OKH>$_BAXBBG:/4&N[H)*A^:/RD.S'TSQ
M7M5>:Z)X4DM=>\;^&[N&==(UL?:H+B-<*!("LB ] P)Z>G- ''7>L>*M(^'?
MACQDWBB^GN[B>&.6T<+Y#QL6ZC&2V!R<]^U6/&.OK:^+M2@_X37Q59;)<?9[
M33]\4? X5L\BO1+[X=:3?^#=-\,2SW0LM/='B=7&\E,XR<8[GM77X'I0!QOP
MSO1?^%WF&KZEJF+EU\_48/*D' ^7&3Q[^YJCXYL(M2T/Q#%X:GT6/5I("NIO
M)AI3$%/RG'W6XP"W2NONM=TZRDNHYK@*]JL33#!.T2,53\20:YCQ)\*?#OB7
M6)=4G:]M;FX4)=?9)_+6X4=G'?H/RH \YL[NQO\ 5/A"]C!)#IRB>-8IVW8D
M4 ')Z$[AD'WKH?#=M'=_$OXFVFT&SFAC255Z%F1@?QY:NRU?X=>'=8\-V.AO
M;/;VU@0;1[=RLD##N&]?7/6J8\-6?@#P+K0T&UN[N]EB>0LQ,LUQ,1M4D]^3
M_.@"G\$KV:]^%VG"8Y-N\L"G_95CC^>*]#KFO 'AU_"W@?2])EQ]HBBW3X_Y
MZ,=S?D3C\*Z6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,WQ!
M=7=CX=U*[L8_,NX+:22%,9RP4D<=Z\%;4M;BAT6^U3XC:E9V>KZ9)=+=!?W:
M7*D?N<#L,G\17T!JUS<6>D7ES:6QNKF*%WB@'61@"0OXUX_I5SXR\5Z!;WKZ
MWX.@MY26%C<6H8P,"05((X8=Z /1?AWJ5QJ_P_T:^NFN'GE@^=[@Y=R"1N)X
MX.,CV(KIZS]"6[30[-+ZXMKBZ6,"26U7;$Q]5'85H4 %%%<QXS\4/X?LH+73
MX1=:YJ#^386@_B?N[>B+U)H Z>BO$O WB36])\">.M2U.^DU#4-,NI0KRN64
M.J]@>B[N<5G27>O>&?"?A;QQ_P )'J5W<ZC<1?;K:XEW0O')DX5.BX [4 >_
M45Y'=-J7CKXG^(-$.MZCING:-;)Y26,OEEY6&=S'OWX]A6I\./&L]S\-[K5?
M$$[S2:5-+!/.J%FD5,8; ZG!_2@"CX'_ .2X>/?]V#^0KU:O&OA=J]IKWQ9\
M::I8,[6MQ'"T9="AQTY!Y'2O9: "BBB@ HHHH **** "BBB@#P'X"?\ (\>,
M/K_[4:O?J\!^ G_(\>,/K_[4:O?J "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_H*V/_?$?_Q-=#11_;N*[+[O^"'^LV-[1^[_ ()SW_"1_%[_ *"MC_WQ'_\
M$T?\)'\7O^@K8_\ ?$?_ ,370T4?V[BNR^[_ ((?ZS8WM'[O^"<GJ?C7XJZ3
MITM]=:M9B&( MMCC)Y..!M]Z]F^&.MW_ (B\ :=JFIS":[FW[W"A<X<@<#V%
M>0^//^1,O_HG_H0KT[X+?\DJT?Z2?^AM7OY7BZF*HN=3>]M/D?3Y-CJN-H.I
M5M=.VGHCOZ***](]<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S*\_Y./T_P#[ #?^C'KT
MVO,KS_DX_3_^P W_ *,>O3: "BBB@ HHHH **** /(/VC/\ DGUE_P!A*/\
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M%% !1110 4444 >4^!_^2X>/?]V#^0KU:O*? _\ R7#Q[_NP?R%>K4 %%%%
M!7SE\6O^2Y:-_P!<8/\ T)J^C:^:?C5'=2_&'3H[&40W36T(BD/16W-@UG65
MZ<EY,RKJ]*2VT?Y'6T5P?]B^/O\ H/6_^?\ @%']B^/O^@];_P"?^ 5\3]1I
M_P#/Z/X_Y'YU_9M+_H(A][_R.\HK@_[%\??]!ZW_ ,_\ H_L7Q]_T'K?_/\
MP"CZC3_Y_1_'_(/[-I?]!$/O?^1WE%<'_8OC[_H/6_\ G_@%']B^/O\ H/6_
M^?\ @%'U&G_S^C^/^0?V;2_Z"(?>_P#([RBN#_L7Q]_T'K?_ #_P"C^Q?'W_
M $'K?_/_  "CZC3_ .?T?Q_R#^S:7_01#[W_ )&QX\_Y$R_^B?\ H0KT[X+?
M\DJT?Z2?^AM7@OB/3/%]OH-U+J>KPSV:@>9&O5N1_LCOBO>O@K_R2K1_^VG_
M *&U?2Y/25*@XJ2EKT]$?7Y#0C1PSC&:EKNO1'?T445ZI[84444 %%%% !11
M10 445P.I?&;P5I.IW6G7FHSI<VTK12J+60@,#@\@<T =]7->./"DOC#0ETV
M'5)M-83++YT()8X!&."/7]*YS_A>W@'_ *"=Q_X"2?X4?\+V\ _]!.X_\!)/
M\* .=_X4-??]#UJ?_?+?_%UE>)O@]?\ A[PSJ.KKXTU.8V<#2B,[ANQVSOKM
M_P#A>W@'_H)W'_@))_A6#XU^,?@O6O!6L:;9:A,]U<VKQQ*;:106(XY(P* .
M0^'GPWU'QSX7&L/XNU*T8S/%Y2LS_=QSG</6NK_X4-??]#UJ?_?+?_%UB_"/
MXG^%?"7@@:9J][+#=?:9)-JV[N-IQCD#':N\_P"%[> ?^@G<?^ DG^% %OP%
M\.;CP7J-W=3>(KO5!/$(Q'." G.<C+&N]KS?_A>W@'_H)W'_ ("2?X4?\+V\
M _\ 03N/_ 23_"@#TBBO-_\ A>W@'_H)W'_@))_A7H5I=17UE!=P,6AGC62,
MD8RK#(X^AH FHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /,KS_DX_3_ /L
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M%KQ/+>3K#&;J=0S>OF5G5OR.QV9>X+%0<]K]3?\ [$TG_H&VG_?H4?V)I/\
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MPQ_R*>C_ /7C#_Z *]##W]FN8^/SATWBVZ5K66VWX&K1116YY84444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !7*_$?Q%<>%? 6J:M9X^U1(J0DC(5F8*&_#.?PKJJY?XB^'+CQ7X
M$U/2+0J+J5%:'<< LK!@"??&/QH X/1+KQ%X0\9^%K34?$=WK-IXB@8S)='/
MDR[0P*>@R0*]9GU73K64Q7%_:Q2#JDDRJ1^!->3Z'8^)O%GC+PQ=ZOX=GT:T
M\.0,LCSMGSY=H4;/;@'O]:[;6_AEX/\ $6K3:IJNCK<7LP422^?(N[: HX5@
M.@ H Y6[U/3S^T+87(O[4P#064R^<NT'S&XSG&?:O2/[<TC_ *"MC_X$)_C7
M(_\ "E_A]_T+R_\ @3-_\71_PI?X??\ 0O+_ .!,W_Q= '7?VYI'_05L?_ A
M/\:/[<TC_H*V/_@0G^-<C_PI?X??]"\O_@3-_P#%T?\ "E_A]_T+R_\ @3-_
M\70!UW]N:1_T%;'_ ,"$_P :/[<TC_H*V/\ X$)_C7B^H_#;PE!\9]&T&/2%
M73+C3))Y8//D^9P7P<[L]AWKNO\ A2_P^_Z%Y?\ P)F_^+H Z[^W-(_Z"MC_
M .!"?XT?VYI'_05L?_ A/\:Y'_A2_P /O^A>7_P)F_\ BZ/^%+_#[_H7E_\
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M1)U)/T -7*XW2_A5X*T74[?4M/T18;NW??%)Y\K;3ZX+$5V5 !1110 4444
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MY+!XI_Z^+C_T96=9M4VT=N6QC+%TXR5U<O\ _"+:'_T#8?S/^-'_  BVA_\
M0-A_,_XUKT5Y7M)]V?>?4\/_ ,^X_<C(_P"$6T/_ *!L/YG_ !H_X1;0_P#H
M&P_F?\:UZ*/:3[L/J>'_ .?<?N1D?\(MH?\ T#8?S/\ C1_PBVA_] V'\S_C
M6O11[2?=A]3P_P#S[C]R,C_A%M#_ .@;#^9_QH_X1;0_^@;#^9_QK7HH]I/N
MP^IX?_GW'[D<%XVT?3M-TNWEL[1(7:;:67/(P?>OK#PQ_P BGHW_ %XP_P#H
M KY=^(G_ "!K7_KX_P#937U%X8_Y%/1_^O&'_P! %>EAFW339\9G5.,,8XP5
ME9;>AJT445N>2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MA.]H\TT0:1K23?$6Z':?3V[=*UZ "BBB@ HHHH **** "BBB@ HHHH ****
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MM/LYKR\\'W$%M"I>262-@JJ.I)KZHKE?B5_R37Q#_P!>4G\J/84^P?VMC?\
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M6_,?X4?\-"6?_0J:M^8_PH ]FHKQG_AH2S_Z%35OS'^%'_#0EG_T*FK?F/\
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MA_[\R_\ Q-'_  N+P!_T,</_ 'YE_P#B:ZS^QM+_ .@;9_\ ?A?\*/[&TO\
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M_L;2_P#H&V?_ 'X7_"C^QM+_ .@;9_\ ?A?\* .3_P"%Q> /^ABA_P"_,O\
M\31_PN+P!_T,</\ WYE_^)KK/[&TO_H&V?\ WX7_  H_L;2_^@;9_P#?A?\
M"@#D_P#A<7@#_H8X?^_,O_Q-5KWXV> [. 2IK!N3N V00.6^O('%=K_8VE_]
M VS_ ._"_P"%']CZ7_T#;/\ [\+_ (4 >=_\- >!_P#GKJ'_ ("__7K"\9?&
MOPAKG@W5]+LY+TW-U;/%'OM\#<1QDYKV'^Q]+_Z!MG_WX7_"J6L:1IBZ)?L-
M.M 1;2$'R%X^4^U 'A_PH^*OAGP=X+&E:J]V+K[1))B*#<,'&.<^U=S_ ,-
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M,(2!G*L!]#^77FN8\0>-O$SZ)'?V.L_8X]0\2R65K*8U*QVR_*"<C^\&)^E
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M5#8,>PL"#C_/>@#Z.HKRCQ?K%UJ7B/3]'@U;6X+S[$)[C2=&1$D#$9W/,YP
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC7144 <EXF\,SMX$F\->%[>VLTG46W)VK#$Q^=AW)QGZYK?T72K?0]%LM*M
M1;VD*Q)GJ0!C)]SUJ]10 4444 %%%% !7(:I\,O"FL:O<:K>:>[7MR099$N)
M$W8 '\+#L!77T4 8N@>$]#\,6\D.CZ=%:K*<R,N2TG^\QR360WPL\%MJ)OCH
M4'F&3S2FYO++^NS.W]*[&B@#F]<\ ^&?$5_%?:II<<UU&H02*S(2H_A.TC(]
MC4NF>"O#VCVNH6ECID4=KJ!S<V_)C?C'W3P./2M^B@#BH_A+X)B"A-$0%)!*
MC>:Y*$'( .>!GL*[0@,I!&01@BEHH X/PWX%;3-,U[PSJ$<=QX=NKAI;0"0A
MPC\M&P'3!'!!YK<O?!6@ZCH%GH=U9;].LRC01>8PVE>!R#DUT%%  !@ #M11
M10!DVOAK2K/Q%=Z]!;;=2NXQ%--O)W*,8&,X'0?E6;K7P[\*^(-3.HZEI$4M
MTV [AF3S .FX*0&Z=ZZBB@#C?&WA.Y\1Z/IOAVQ6"VT@W$9O2#M*P1\A$4>I
M ^F*[".-(HDCC4*B *H'8#I3J* "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "H+Z[BT^PN+R8D16\32OCT49/\JGJEK%A_:NBWVG[MOVF
MW>'=Z;E(S^M 'DN@>,]=\5M#J4GC?1M"%Q,?LFDM%'([1AL?.68$$XKV8=!G
MK7SJ/!6N2^!%\%GP*$UA;G_D-8C$>P/G?YGWCQQCTKUS_A7UC/?VNH7.IZN;
MJ%8MPBOG2)F10/N XP=O([T ,U/XH>&=+OKZPDFNI[VQ?9-;6]L\CCC)8 #[
MH'4]*IR_&/P=';0727=U-;2[=\\5J[) 6Z"0XPI]NM4O#/AK5[+XB>.M2N;(
MI::BJ"TE+*?,X.<<Y';K7.V'@KQ!#\ -2\/OI;KJTMPSI;;EW,/,4YSG'0'O
MVH ]*\0>.-"\-PV;WEP\DEZ,VL%M&999AZJHZCD<U'H'C[0?$27WV2:>*>Q4
MO<VUS"T<L:@9R5-<1J>@>(-$\3>$O%%MH\NJ1Z?I:V5U9PNOFQ-M(W*"<'K^
ME3Z-H.NZUXT\0^+KW29=*BNM--E:VDSJ993M W,!P.GZT ;#_&3P<MO!<K<W
M<EK*0KW*6CF.$D\!VQ@'VJOXR^*]IX6\3:1I:6S7$%UA[F98W.R,@%3'@?.3
MD\"N:M_!?B"/]GB;PZVEN-7:4N+;<NXCS@V<YQT]ZTO&.@:Y$? .K6FE3W[:
M+L^UVL!!D'RIG&>O*D4 +XB^(;:;\1?#4@OKF/0;W3FG>W%N2\K$L%^3&[=D
M#BNX\+^--'\7+=#39)EGM'"7%O<1&.2,GIE3]#^5<K>:1K&K_%CPMXD_LF:W
MLHM/<7'FLNZ!SNPK8/7D=*G\(^'M5T[XJ>,=6NK1HK"^\K[-*6&),#G !S^=
M '4^(O%NB^%!9MK-W]F2[D,<;E"1D#)SCI7/Q?%WPK+)<0,]_%=Q8*VDEFXF
MF!Z>6F,M5;XH>'M4UZ^\)OIMF;E+/5$FN,$ (@(R3GZ&D;P[JC?'>/Q!]C)T
ML:68?M.1C?Z8ZYH Z#1?'GA[7-!N]9MKWRK.S)6Z-PIC: CJ&!K*L_BYX5O+
MRV@,E];1W;[+>ZN;1XX9CVVN>*XU?A]X@OO#WQ"T]K;[--J>H_:+(NXVS*K%
MNQX!]Z36;+Q3XV\+Z)X2_P"$2NM+:UDA^TWMPZ"*-8Q@F/!R<T =_K_Q)\->
M&]3GTV_N9OM\2(_V>*%G=PW3;CKQR?2N<E^,VGP^/#HCV<_]GB -]H$$AE\T
MGILQ]WGK5NU\-:E'\<[G79+(G3/[+6&.Y8J?WGRC '7/!JEKUAK>C_&>#Q1:
MZ'=ZII\VG?9#]E*[HWS_ !9(P* .EUSXBZ+H&H3V4\&IW$MNH><VED\JQ C(
M+,!@<<US?Q$\<2_\(7H6M^%]3*0WNHQ1^:BC+(=V5((XY'/TK.\46?C2^\7:
MO:SV>MW6F3QA-,73+M;>!,C!\X]>O6LAO GB;_A4/A[1O[+<ZA:ZOY\T.]<I
M'N;YLYQCD4 >AW'BM[#XA:CI]SJT)L;333>-81VCM,H&,MO'#?0<\UD^#/C#
M8^(K;47O[2:UEM3+(!#"[J84 .2<?>Z_+UJS;^'M53X[W6OM:,-+?2A MQN&
M"^5XQG/8UG?"_3M9\.7FL^'M5T&Z$%S>S7"WV5,#(0 !UR2<>G>@#L)O'OAV
M#PA'XI>]/]E2X"2*A+%B<;=O7.0>/:MN74;6WTQM1GE$-HD7G/)(-NU,9R?3
MBO -+\,7K_$[_A7YD27P[INH'5]H.=J%050_B0,>Y->\:]%YV@7\7]GC4=\#
MJ;,N%\\$?<R>F>E &!I'Q+T'6I72VBU)4\A[B.66R=4F1!EBAQ\WTK&\"_%F
MU\7:K>Z?/:26TJ7#K;%(G*O&H)W.<85L#H:Q_ >E>)-.\86\>F:?K>E^%TA;
M[39ZO,LBH_.!#@DXSC]:G\"V'B/POKWBC2I-#N<:A>S75KJ.5-NN02N[G/)Q
MQ0!OGXN>&$N(EE&I0VTTGE1WLUC(D#-G'#D50\2?%NT\/>/K;0)+25[7RR;F
M=879T;&0$4#YATY'K[5YWK'AKQYXD\-M::AI>OW.L1W(DGDN+U%M"H;@11@X
M)_ES7=>,M+UNQ^(7A;Q-9:-=:G:V-JT$\5J5,BL0>Q/3YOTH [B'Q;I%QXCB
MT!)G_M&6U%VL9C(_=GN3V/M4$7CKP_-%K<HO2D6BN8[UW0@1GGIZ],<5QFNV
M>OZ5\5[+Q?:>'KO4K.?3/LTD-LR^9"_7#9./3GIUJIX<\-:W::=X[EU[PR;G
M^U;A9DT^.X7]\IR2%?U7/7CD4 =UX;\=Z3XHNS;64.H0R>5Y\9NK1XEECR!N
M0G@CD5T]>3_#C3O$UAXHECCM=8LO"B6VU+7695>1)>PCQDA17K% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%("
M&&001[4 +1110 444BLKC*L&'J#F@!:*1F"J68@ =232@@C(Z4 %%(K*Z[E8
M,/4'- 96) 8$C@@'I0 M%)D @$C)Z4M !1110 44A8 @$C)Z#UI: "BBB@ H
MI P894@CVH#!LX(.#@XH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** ,VQ\/Z5INI7NHV=C%#>WK;KF=1\TA]S6E110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!!>P-=6,\"2O$[H562-MK*>Q![5S_@SPQ>^&;.XAO=7
MGU!I)-ZES\JY)9L+Z[F;GN,5T]% '"7WB+Q==^,-8T/P_8Z4T>GQ0RFXOI)
M#O4G9A>Y(Z] !3G^(,A\,:9J2Z6T4U]N21[A]MM:2*2K"60 D#<#C Y]JH/X
M?UV]^(WB>[TS5[C2%DAM(_,^S++',NPY(W?Q*>A'3/(KM=#T.TT'0;;1[?=)
M;P(4)E.YI"22S-ZDDDGZT <;X@BU=O"\$-]KZ7?]M:E;6SR6:B***%F^98R"
M2<@8+$YY[5-I.DV7A+XE0Z5HL+6VG:AIDD\ML'9D$L;J X!)P2&(/KQ6Q>^
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MSM\HS^\W=S[5Y]X;?PC%I^D6-YIEPWC"*^#3I'"1>"?S#ND>3O'C)))P5XH
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M<=:]3H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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)%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>img187419207_12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img187419207_12.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &8 V0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC\ZWO#EV$N'@<G$G*C/0UP8O#IQYHK5'-7I)KF70Z>BBBO+.$**** "BBB@
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M"Y65,[E.1S7;Z?JD&H B/*NO537D8S#\CYHK0X,12Y7>*T+U%%%<)S!1110
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MXA(X1 X)8FNX!! (.1ZUYF+IQA)<O4Y*\%%Z"T445R& 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !137D2,?.ZK]3BE!!&001[4 +1110 4444 %%%% !1110
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MK2Y>*0=U-<V,PWUB'*G8J$N4]"^(3,VIVH\P%!&?E!Z'-<Y;0O,ZQQ*6=C@
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M[XJ-X-[;HV"'O4Z;.F>M)M\PE ?RI.S'8JO)/"IW(#C^+.175>%I&O-/<R(
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M!MH.>>E5H[P[CD%B>^:M6LN^7GM64??5I(VBN17Z%_3XICN+ *OJ:U4=43!
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MBB@ HHHH **** "BD) ZD4GF)_>'YTKH!U%(&4]"*6F 4444 %%%% !1110
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M8>[3R?51S6Q;^$[""<2DR28QA6/%=,\=0@M'<A4I,YF7PQ>0V*75O^]5EW%
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M,T5%<-MCP.II-V5QI7=BM(^]R:\JUNY2;Q'<RNI>-9MI .,@<8_2O4)"1&Q
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M\-:?-:06K+)Y4.2H#>O6KLFG6TNG?873,&T+CV%6Z*MU)O=CYF88\*:8+9H
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MZFIG7C:!4L,85>*YXQ;E=FC=D"*5ZU+28I16UK$"$5')&'4BI::QP*30(J)
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
&**** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>img187419207_13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img187419207_13.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )$!"0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.ISWZ@?@: /0Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% ' Z_P#%K0_#^OW&C2VFH7-U;A3)]FAWA<C/:NF\,>([;Q3HRZG:07,$
M3.R;+B/8^1[5Y?+\.?&\7B3Q%KVF>)K*RGO)3($B3>7 Y56)'R\5O^!_'VHZ
MU\,;_69[,7.JZ8LJ/#$"//=%R. ."?:@#TFBO#/^%W^+?^B>W7_D7_XBN@\!
M?%;4_%OBY]!U'P[_ &6ZVS7&7D;=P5 ^4J.#F@#U.BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBJU_=-9:?<726\MPT49<0Q#+N0.@]Z\Z?XIVH\30'SY4TXV+M+8M;'[2+@,
M$VXSG&?;O32;$VD>G452T_4&OM(AOVL[BW:2/S/L\JXD7V(]:X"]^*-NNLZ0
MIDETZ'?,NHV=W!B9<+E<>N3TV]:$FP;2/3**S="U?^W-+2_%E=6:NQ"QW2;'
M(!X;'H>M:5(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_J]R]1117L'E!1110 4444 %%%% !1110 4444 %%%% !1110 444A(4$DX
MY)H SM<U[3?#>E2ZGJMRMO:QX!<\Y)Z #N:GTO4[76=,M]1L9/,M;A \;X(R
M/H:^?/B;J[^/K/7+^"\6/0M!VQVJ!QF[N"ZJS8ZD $_YS7JG@?5H=.^#^GWZ
MHUU]CT_S'AM\,Y*@G:!Z^U '=5Y/;?\ )S5W_P!@0?S6E_X7E;?]"=XD_P#
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MF&RBU&ZL S@O+:MM<KW7/;-<%I/PP%MK.LS6[76CE;F-K"[M9\N\>P;PW/S
MD$\^M>HT4TVA-)B 8 &<^]+112&%%%% !2,RHI9V"J.22< 4M0W=K%>VDUK,
MNZ*5"C#V(IJU]1JU]1G]HV7_ #^6_P#W]7_&I8IXIU+0RI(H.,HP(_2OFO7-
M&N=&UZ?3)%8NCXC_ -M3]TCZU[SX.T(>'_#=M:,/W[#S)C_MGJ/PZ?A7J8W
M4\-2C4C._-MH=^+P=.A34U.]]C?HHHKRCSPHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MYGV<.T@\QMQR>O-:]?,8^O'$8JI5AM)MFT%:*04445QE!1110 4444 %%%%
M!1110 444@96) ()!P<'I0 M%%% !1110!@ZIX4LM5\0Z?J\P'F6F<KM_P!9
M_=S]#S6]115RJ2FDI/1;%RG*22;V"BBBH("BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!F:]KUCX;T[^T-1:1+4.$>1(R^S/<XZ#WKSJ_\'Z7XN\17'B72
MO'T\#7*JH%I.N%4 #'7..,_C7JSHDB,DBJR,,%6&017#ZG\'_!6J7+7+:5]F
ME8Y8VLK1 _@#B@#/T@Z1\.YKFZUGQW/J(FC")!<RB1@0<_*JY)/:O1+2Y6\L
MX+I%=4FC615==K $9P1V-<SH'PU\)>&YUN-/TB+[2O(GF)D<?0MG%=90 444
M4 %%%% !1110 4444 >3?"'_ )&_X@_]A8_^A25ZS7DWPA_Y&_X@_P#86/\
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M)I^D65E+.UQ);P)$TS#!D*J 6/UQF@"W1110 4444 %%%% !1110!Y-\(?\
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M /'GBUD\.W.H+>WN0RED"A2?]DYZT >G_"_QS>^+[*_M-8M%MM7TV7RKA5&
MW7G'8Y!KOZ^7/"OQ)U'PUXH\0:S_ ,(M=W']KR+)Y6YE\K!)QG8<]?:O>_ ?
MBZ;QGH#:G/I<FG.LS1>3(Q8G&.<D#UH ZBBB@].* (I;JWMV59IXHV;[H=P"
M?IFI:\1USX:6Z6OB7Q-X\U5I9,M)9203L!"N/E 4XYS@ >U=1\(=2O$^%=M?
M:[<E8HC(R3W#8Q IX))[=>: /1J\GMO^3FKO_L"#^:UV?_"P_!W_ $,VE_\
M@2O^-<#HFJV&L_M'75WIMY#=VYT;:)87#+D%<C(H ]CHHHH ***\R^)/Q5/@
M^\32]-MH[B_*!Y&ESLC!Z=.IKJP>#K8RJJ5%79,I**NSTVBO)_AU\7G\3ZLN
MCZO;10W<H/D2PYVN0,E2#T.,FO6*>-P5;!5?95U9A&2DKH****Y"@HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH \K^)>O:KHVM0#3=9>)9(AOMT(RA['\
M?Z5A^%?%>H:AK*Q:[KS)IP1C,DQ&)!C&W\<UZ?XE\):;X@M+EI+6/[<\6V.X
M(^92.G/I6%H7@33-(\+>;JVE1WE\J-+(N-S>NT?A7OT,7A%A%"4?>VV5_5'L
MTL3AUA^62][;97]3R#6+2VM-9N+>SN8Y[;S/W4J'(*GI^5>R>']5\)Z/X9AT
MEM6M&!C(G^;[[,/FKCIO$'@*2[AF_P"$?G3RMV8U4!7S_>&>U0>*=,T[4_#<
M'B/0M,:RMDD,,J$8W#LPY]>*[\0OK*A2JJ45WTWZ'967MU"G44HKOIN=OX0N
M?"OAVV:QM-9MIIKB<G=G!;)PJ_E7=5\Z^"-&EUOQ1:0IE8X7$TCJ/NA3G^>!
M7T57C9MAXT:R]YRD]7<\K,J,:57XKMZL*P?$/AR/5X_.AVQW:]&/1AZ&MZBO
M%KT(5X.G45TSDHUIT9J<'9F7HFBP:/:[$PTS?ZR3')]OI6I113I4H4H*$%9(
MFI4E4DYS=VRCJFEV^K6A@G7GJCCJI]13-'T:WT>U\N+YI&^_(1RW_P!:M&BI
M]A3]I[7E][N5[:I[/V5_=[!1116QD%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <YXXU?2-(\,
M3OKEK-=6%P1;R10Q[RV[/;\.M>&:EX9^&GAOQ5JEEJ=IK5S$IC\B&")\0@H"
M?GW?-G/X5]*E0PP0"/>O/_$/BGQ3X:UZYDG\+'5- )7RKBR.9HQM&=R]^<^G
MUH S_A/)X(6[U"W\*:9J%K-Y:O/)>(V67.  23W[5ZC7,>$?'7A_QBDO]CSG
MSX5!FMY(RDD?U'^%=/0 4444 %%%% !1110 4444 >3?"'_D;_B#_P!A8_\
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M5!C##/WB?[V>]'+I<.;6QZ'1114E!1110 4444 %%%% !1110 4444 %%%%
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M7 Z)JNGZS^T==7>F7L%Y;'1MHE@<.N05R,B@#V.BBB@ HHHH **** "BBB@
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MQR):KI!<"1RQR2F>37M]>3VW_)S5W_V!!_-: /6**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HJ."XAN49H9%D56*$J<X(X(J2A.^PDT]4%%-=U
MC1G<@*HR2>PKDO#'B\:UK=_9R$!-VZUXP2HX(_K64ZT(2C"3U>QE4KPISC"3
MUEL=?1116IL%%%% !1110 4444 %%%% ",H92K $'@@]ZYQ?!UDNK&ZSFW^\
M(,<!O\*Z2BL*V&I5K>TC>VQM2KU*5^1VN(    , = *6BBMS$**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** ,'QC?:]IOAZ6[\.V$-]?1,&,$I(W)WQCJ?:O.= \=_$WQ/
MI:ZCI7A[1IK<LR'-SM96!P006R#7J6NZ[I_AO1Y]5U2?R;6 99L9))X  [DU
MQ'@CXA^#=1UF33-*L+C2[J_<SJL\/EBX;N1R1F@#<\(W_C:[N[E?%6D6-C L
M8,+6TV\LV>0>3VKK:** "BBB@ HHHH **** "BBB@#R;X0_\C?\ $'_L+'_T
M*2O6:\F^$/\ R-_Q!_["Q_\ 0I*]9H **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBD+!>I ^IH 6BF^8G]]?SKP[QZ-8T#Q)*D
M6I7HM;C]["1,V #U'7L:[<%A/K53V?-9G5A<-]8GR7LSW.BO-OA5;:G<P7&K
MW][<RQ/^ZA221F!QU;!_+\Z])K+%4%0JNFG>QGB*2HU'"][!1117.8A1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %>;^./%G@+6]+U'PSJ^NI;R
M;MCE5;=%(IR"..Q%>D5X;X\U#X4Z)XEN;?4=!?4=5=O,N?(S\K'GD[@,^PH
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MVC01ARUW#L# G&!SUKKJ, 44 %%%% !1110 4444 %%%% 'DWPA_Y&_X@_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MD$&UL*-X ;([]*T0H484 #T%+10 4444 %%%% !1110 4444 %%%% !1110
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M>O)[;_DYJ[_[ @_FM>L5Y1;?\G-7?_8$'\UH ]7HHHH **** "BBB@ HHHH
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M,?\ 0Q:5_P"!D?\ C4"^$-,OO!VG^'M8M5N[6VAB0QLQ +(H .00:RO^%/\
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M*-XD_P"_I_\ BJL>,M.O;GXN>"+N"TGDMK?SO.F2,E(\CC<>@_&O2: /+O\
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M.6!3/##N1U&/6O8? GA7_A#_  O#ICS">X+M-<2J,!I&.3@>G;\* .EHHHH
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MSL3EF/N36M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-+%DX4MWP10!VO@[P[+X5\,VVD3:C-?M!D"67L,\*/8"MZBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MGSIA]HOY_EM+-.7E;^@]ZXGX,:@/$NH:OXCU'6)9]<F/E2V.2J6\0/RX7O\
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MLZ%9:EY#P&YA60Q..4)'(-:%   P!@44 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ7B+Q]#H6L6ME<0R6P:YV.9XB?/CVGF(@\G=@8KK+"Z:]L(;E[::V:1=QAF
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!SFM^#M/UBZ%VRHMR98
MFD>5?,!1#R@4G"Y[XK7TS2[31[(6=DC) K,RH7+;<G.!GM[=JN447"QR'Q)N
M"GA5;58WE^VW<%N4C7<S*7!; '4X!IFLM=>+-+&B66G7=M:3,BW5Q>0F()$"
M"0JGEB<8XX%:^L:+-JFM:+<^8@MK"9YW0DY9MI5<=N,FMNG<5BI?"[ATJ<:9
M'$]VD1$"2DA"P' )]*\_TH:5>:M'_P )I<7+ZVI^2VU%1';*?^F2@[&^N2:]
M'N#,L#FW1'F ^19&*J3[D X_*N?U&TU?5K1K74-"T6Y@;JDMX[#_ -$T(&=&
MJJJA5 "@8 '0"N3T)FD^(GBAI!\T<=K'&3_<VL?YDUT.DV8T_2;6S$8C$,80
M()3(%QVW, 3]367>Z/?P>(CK>DR0-++ (+FVN"560*258, 2K#)['(H0,HZB
MS)\4M$V#_6:?<K(1Z!E(_6G?$5F_X138!E)+NW20>J&5<UH:=H]T=;EUK5)(
M6NVA\B&*')2"/.2,G!8DXR<#H.*@;0M2U;PWJ&EZ]?12R7$C^3-;)M\I,Y3Z
MD8%,"]XEC1_"FK(R@H;.4$'IC8:C\)223>#]&DFSYC6<1;/KM%4+K2_$6JZ6
M=(OIK&*WD7R[B[@9S)*G<!",*2.,[CBMJ=+NSLH8=*M;:01@($FF,:JH&!@A
M6I 8'P[_ .1<N?\ L)7?_HYJV;73+N#Q!?:A)J<TUK<1QK%9L/DA*]2#[UE^
M$M*UK0[9[.]AL# ]Q-.98;ARP+N6QM*#.,XSFIM%U'4=3\2ZR_F*VBVY2WMO
MD +2K_K"#U(!P/J#3>[!&IJFD66L01P7T7FQ)() FX@$CID#J/8\5F>'?"-E
MH CE3#WBHT;S1@QAU+;AE <$C@9ZUT-%3<=CF=3\$:9J.IQ7IC3>;CSKD2J9
M/.785V#)^4=#QZ5NZ?80:980V5L'$$*[4#N7('U/)JS13N%CD?B3<-%X.EMT
MC>1KV>*UV(NYF#.,@#N< U'J[W7BC1SH>GZ;=VUO/MCN;B\A,0CB!&0H/+,0
M,#'2M?6]%EU;4]%F\Q!;6-R;F123EF"D+CZ$YK;HN*Q4NDN;?2I4TZ.-KF.(
MB!)3A2P'R@GTKS[3!IM[JT8\<7%P=94_N[:_41V@/_3( ['^I)->D3F58',"
M(\H'R*[%5)]R <?E6!?VVL:K:/:W^A:+<P/UCEO'8?K#0@9T**JHJH $ X"C
M@"N4\'%GUKQ;)(/WG]JE,]]HC3;70:19#3M(M;,1"(0QA BRM(%]@S $_C64
M^CZEINO7NIZ0UM+'?!3<6MR[(!(HP'5@#U& 1CMUH JQ%D^*]RB#"2:-&TF.
M["5@/T)I/'!8R>&XL9BDUF 2 ],#<1^H%:.E:-=6UW?ZI>SQR:E>*$^0'9"B
M@[47/)&223W)JK-H&J:MX4ALM7U"(ZM%()TNX(\*LBME#MXR,8!Z9YI]0#XA
MC_BW^ML!EEMBR_[PP1^M4?#3R3^.M:DG'SII]DJD]<%7)_6KM[I.M:];QV&J
MFR@L=ZM<?9I&=K@*<[<%1L!(YY/I4]]HM[#X@36])D@\XP"WN+:<E4E0'*D,
M 2I&3V/!HZ6%UN4M7+)\2_#10?ZRUNTD(_N@(1^M.\=?\>^B_P#87MO_ $*K
MUAH]W)KC:UJKPFY6'R+>" ED@0G+'<0"S' YP.E4O$FF:_K#VL=O;Z<L-K>Q
MW*/)=.&<(<X($?&?J:.H'5457LVNWMP;V&&*?)RL,A=<=N2H_E5BI*"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F
MHB1KM1549SA1BG44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
(% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>img187419207_14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img187419207_14.jpg
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MT>%"<A935).4TM7Q)#/4&$-55F.2EI?3_]H # ,!  (1 Q$ /P#OXP!@# &
M, 8 P!@# & , 8 P"@;Y,O8?J6L?>ODSRE2'J:D?)$%NJF+7GTPM.\(!$)E&
M1QR!N7*XIHHXE<ABB#+9E%MH0V2X.M]=/'*2O*+E76D>Q>,4XN33;32232Z_
M!E><H^9CVW'?"/R%RQI9-!V-;7C'U%2-,P/U?4\,:$*8N.)V?+$QIAVTCI @
M8C3HU&V+9;\R>@B&Q2;<^&Y:Z<=--'S8MR1YHK?$HN6'C*PFUX>./(E/2WR$
M>MJZ^06GO'MC^P?)GO2O[VIF[9N0L/SG! T?E/GLU5<(D,Q$%9H.ADWEL:7
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M7>BIGY1] WPZKGU3#5^R&P\#$^39H&6BM9,R+98</.MUYFY"!TTER\=']D6
MMNJ(<TTUO+;"YDLQZ?XD\OW86?UZI<&,8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M-R+P3$)<&)10(<%K )(_'O$0Y)1ZDV>\MU'"/?3;[%M@HM^'3X>_KY>)-W!
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & 838UEUU3\
M,.6-;$[A]9U_&6Z3J13:>R0/$HH#;N'*#)LJ5/GGC 6QY=/7+9DUTY=)].7C
MENT0THX723[!)O9++\D>:%V' ;'A86R*]FT3G->R,9^=Q^=1&1")'$#8?6U=
M=%!4C$.W8A^PXZ16Y4=M7BJ"?:*W'??/22FN0,,I[T30/H9E(25"7;4]U#XD
M6T"E#ZJ;"B=@-(Z9ZY443&&G$5+%4ACQ=)%59LB\Z1[=()]K-]*I<[[T)::Z
MIKQW6-O,W'@@8 P!@# & , 8 P!@# ,$LJSZ]IR&%["M*91R!PL'RVT1D4I,
M, @M-R_=(CQ8Y)T07;I.2QDFY:"0@IOTH0,EWC,6-;N7SMNW4!)OHL^XT#-?
M8]6M/(-H>PJA,Q>Z817M4RZS&K4'+V@MD4<Q6*J2A>(GCB ^0+PDVDGI!C(&
M98"Z-15PJJF5 [=ME&6Q.-TGMND:?K?Y#X&^D-D1BYGU*11U!&%4.A<CH.\2
M'IV%S<Y;SZRV$:JV,NA-3UU-BUX\\U<:-[J<! #YXG%28,^#6)I+$6XP2X[)
MK.^>JQTQOU>V_7WF02[W X!R3I(33,BW!8D#HZ47 ;GQ=]6\]@\<]"V]+ZB@
M+X'5SZ(FGLB>C%845GL[!2N15L:C<$>A>V#*03)V]AHQ\/KZ^O )9]^^/>EG
MKG^IE5Z^MGM/3Z11@;7#>71BJX#4]JWM*74UZC)*%5]<ME36MHH5A,9XB,@1
ML0L.7K*Q9+*@Y&10%(9'HZU_*BAXT::!^!"6WO>%[UCKY=5C^1\SS-[&WZ,L
MNS(:D!K6,AH:8LUA%DF]J2PS:TN"UO;)FJE)LZK<Q2L-C#&&&G0;1;DU#K7L
M?D!V=C("2(C#991LQ!K&/'9/W96<?6/9L3BP0, 8 P!@# *0OE_FEV-]5U4-
M">6K@G!"[HG-J\O+UE2U!CKCLBB?.TCTW:S: 5=I^X#-^[ M?M#3!NF5DK*/
MQ)FS3ESL27,<@.V O%+=MK;I%O&7[?8L_'IMU()>BJ#LZ%2*#G_"= _)/4'H
M5;R[X8JKR1*6,D:-?/(""UD<Y_'U3ZXB8WK0V&*UU'#!_5GQ^YR\O$24D]</
MX6FT+H[[?BR>V).+69-]7)MKJNG7;&&D_$MY]+^*[8GLEL^X(M\B/MVF&3H*
ML;%U55LBI9G6L96CT3;-/PH-G)J7DTD3:%G@KLR4Y>R1ZMV3)D.VJS5MVW;M
MQ1-)?=B_:^;/Y22_(SSXN+-GMS?'AX]M6T9.2FEASVC(9))A*R^T>B9\X09]
M*/23[INBW0VX<=Z^\IM)%/C[?^7&L":2G)+9)[$]<%1@# & , 8 P!@# & ,
M CC'_7/G&46%NJPMJ UYUW,I;7;00Z9'1;8M/8(Z/LIA# )XJ*91V0RB/.8I
M*$R0(&6($D?T<.]Z;=)B7_: G#QG&W]?%^2]IM&Q+0@%3@.I-84G'QH1^.&"
MT.W.G+M^1*FG>F(@0&##4'IHX7*._O(L!0<>^(.^DUMH-N^4%NN!&,GR"UX5
M($K,1<;Z?1[JLI$TC;R-S <[Z,C).G,EV36(HQC@.F^>21_*'9)@TCXL&U?D
MC#MXW:CVCAPKRGL,>!B'7JSSSLG7 =M:D<)D;;$A3U>-P?)(_J2!)$5_(PI=
M%<(P?MV T@8TJ,1>%E6#?EZU>MU5$U&+SE 3CK[//;]20>"!@# & , 8 P!@
M# & , 8!4)\R(8BK4OD2>O(X;E%34G\B/E*Y/13 )&"\U_ T9$2\G;R61FHB
M!'ERT@C<5D)>)R,ZR9B"G:3 6J^[9+),^_NBT.KWP^5X\-\>?F^GQP:&^-R<
MQ&LO)L[@UC539QF(^KK^^2*Y?-E%,Z<EBSR9^:6LRD,T;0WF.F!(>-P;=A1@
MRNXKZ(6*3A*$WYE+5L&^LDZ743$RW>4^B@F_)X2][W1JGXZ4.[']5>\))Y&2
M/U[6UH^4J'!U?<TP\MDJD8>3;'B:ED1Z%>5%Z;*ZAT/N-_2,<+B)3)S39[T0
M6>ZZB1V8NQSL(X0![)9><2EE<R><X;>=VL^'7/7"WSO.?F?DD\E>@?# ZV?=
M\#]&5MZ/]3"Z&F$''>.8/2[]J)(5E9,[Z,-)>,LF=/M*IN(,@Q_!MQ[%3KE[
MTX_,.=(;;.!*Y9*6(M8BW][/BEY+S+U\&,8 P!@# & , 8 P"IUU\K#QJZ<M
M?U9GRQN?PSA9#\2U\F U6KCZ*G2?UVRN[:XVHW5^[]1%3?'.^T^N>M\\_;]F
MA?D7XX?-_P!#6EL?(9%KMK>95+8WQ:?+F8@D_!NXW*Q+3R\W!K% C_7/#X=L
MF$NA@3;MWJ.NFKSAL[1_%,U5VB_U&RZR78<N/\</F_\ E-1O/4M5<>5Y7XZB
MWQ;_ # PBEY- IO6[88"\N!GQ**Q:=?G.G@V,O)/;)])HR!HFUV$5%O&SX0
M#M!8-BPX#C6C),3R[YYX9SG.7U_^TV](_D%KB7Q!_7TK^'WY+I)!"BG*Q*&'
M/#4#*19\OQUPHFX= 7MFK"UG*2B::J+CMKM=)5--5-3A1/CKD1R__4A\Y?\
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M=/NJ4I4HSDG4@G*?.^/'Q@# & , 8 P!@# & , 8!A=D?R=SW^I<I_R-]@$
M_AJ_98>#_P!W& ?X#K!>I]^7O+,,%!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P"N3Y6+3%U+XVE!>21"H9;"I99M#5?82WH"+?II24*@-FW3!
MH9+;&LV-;YVF1CL'$%G!Q'M?KAN/-MQ!-?2R3/MLN+067U::3:QURD\)>UOP
M\2L[X7O3DYNKT#8:A*NZ"B-?VYYM$W+5L9J:F!U:33S_ $5"[QFM1^9:;L"0
M!^>6LH!S6K&[VT*Z9.T&"H<=LTY%CFHLMQQH3))+QSG#;>4WC,FML[/9_#.^
M3I,P4& , I#^1>C*4C?L3XO;SCU05@!NN>?(7#P$XM\- XL,L^9 F'FZZFS$
M-*IXR%(2F0"F;:-QYNU'EBKMHW1!!TDDN.!C+E$9(-XFLO"@\+.W5>!=Y@QC
M & , 8 P!@# *(_FZC'LF1Q2F=><F5J&*[;$)-_"0'IQ.1NY&K(E-A/T0=R$
M;$]=GG\?1;\&^6722"PEB5ZZ5+:3=K N]>5=I]#B2O;Z:M%A?U;.,Z_IM/35
M7E6=9]UZ/*M"WS5G12[SEPG3A4WJ8DZ3/T2^P!J_87I6L\=OM2N.#K'B>K;:
M3_HK?<<STNCI4-,C^T/VW1TR[UKETVVU.=66GNXC4J0O;BS2A9<U&GJ,78-\
M=XST"(\@5 /]-JG5+:0&E_S+B6+JNIBVC_9\GW$&DO<.%%72LA;QKH8F]T_[
MZ+()Z0;&]_G:!'-OX.AJ]/AW3H:XZO[04*G.KAN5RJ+K5';QN&VY.LJ'(I<_
M[Q+$:O[U3/FC[3EWV:WW;=QO<]DL-.CP74N[+T26BTX4=#JZE'3;2.MUM$I4
MHPHQTRKJRNY4';Q5E4DZE;3UZ!4M2'<,^%BC(9ZS9^EV=@R]T!"6%S:<;J54
M8/38B9DW,[D8SE:6<.NGS^-!CVDGPX-T';OND6C-D2.$4>7>WFMVW9GI=MQ!
M'6XWEQ*C2O/3Z&GNG!0IW*J=]!.XYG*="E5Q*%/NHSQ&,9U9I2YO<=>^WIVA
MZ]V+U^R>OPUHE'4;_AE\'ZKQI"[NI7-[H56Q_9=VX:,Z*M[;5;_3>>WNKY7M
M6W4Z]>O:Z?:U)4>XN:STH^$Q@# & :,L'TS0-53 ) +%MB&Q"82'ENH,!&2G
M+=U]%XKT@S<D5.>.VP5H\6X[3:.S2X]LYZ34T@JI]/O[O3WNOZ+IMU1LK[4K
M6UNJZBZ=&K4498FW&$IO#C2C*2:C*JX1DT\-X9J6L\><'</:G::-K?$>EZ;J
M=ZH2M[.ZN%"IR59.%*I7DDZ=I3JR4HTJEU.C3J.,E"4N5XWGK>MZ^W6_MUO^
M/6]?\MZ_^>=P;:, 8 P!@# & , PNR/Y.Y[_ %+E/^1OL @'\-7[+#P?^[C
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M.,GCSPFWC=;GIM.ZMJTN2C<4*L\.7+3K4ZDN583?+&3>$VDWC&Z\SZ69#.,
MJV^3B1\4S6,:LZ"GOC7J>>2:S!$:/6'\B@M^PKV0A]PZ3NN8^ .Q5P)/OK#^
M^!$N!39^0<,.(F&D.OP_U&K/I$7CEO'KXQTBLOY96Q##X9_9RMB63[#IRZO3
M_B*=SMG=D,ZIJ*>3-12-U,>CLBJ1C,#'%*E7:X^;6NR%N4"HZ1,"[:12"!%(
ML:1<GW8$@)1'!-8QM);;N6<]7C.>GP>#H8P4& 879'\G<]_J7*?\C?8! /X:
MOV6'@_\ =Q@'^ ZP7J??E[RS#!08 P!@# & , 8 P!@# & , 8 P!@# & ,
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MU=5C"]MY4X6,Z%/T.W]#N[:-2=7TCFN57=6%.DZ3ITE5G"M2G3XT\Y>4+_\
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M7M(TW6+:E55>E0U*SH7E.E6BFE5IQKPFJ=3E;@Y0Y7*$I0;<9-/+!0H6"&L
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MZ3T^^_VV[_XFM_SG,[BA_J:7^[A_0?H#!/\ [*B7_AP/_P!'CT^^_P!MN_\
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M$X>K+-XK&X>72=\H/-#>A_*_*(2CC&V,Y_Q*7ETQNO;G)=A@H, 8!4M\F/\
M+C\2/_>0QG_RZ>A,%X=)_P"1_K$MIP4& , YV_DC^9ZUO'/J;5#5K4D%D8&'
MAXH8G1:>[DNB4GZE ML?TPA;D(7%L@;5D*>MFG1HD/DVE#7+U+8OA$=M-[]!
M=G78YI?%_"_[=U+5KZVKWE:ZHV-*Q5MW=LK6K*@ZEY&M2JSKRG5A*2HTZEMB
MCR/O7*IF&BZ_Q9<Z5J7H5O:T:D*4*4ZTJW><U3O(J?+2<)1C!*+2YY1J>OS+
MEQ'>_&N9FUL>O8'8;(>^$LIY#(O,V@HGQI,D,:R@(Q.-QY#CG6M</F:3[AL[
MXUK6N5TU-:U]FL\)U&SEIVH7VGSJ0JSL;RZLYU:;S3J2M:\Z$JE-^,)N#E%_
MA:-UH557H4:ZC*"K4J=51E]Z*J04U&7\23P_:C,\X9E& , 8 P!@# & , 8
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M+W07^5IY]_K/]$3U]Z^JY7Y5KBJ%JVAD<G=O^AO1U0^6Z>"S4X2CL$;6!;A
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M0LJ%'4KFRE5E:W-W2@J=6YI=]2H5(JX<>^E"5*/=SG*G'FC&,I9QG,.V& ,
M8 P!@# & , K+^7A6LT?#\V[M*P[=K(6E8E'.HC)?/\ !QMAWFI:8VX864JL
M/4<8)MUN%YZ5GC$$W OFBPXB+<?:08DV*[?E;0M'/-LD^O7IC#RWNMDO:1?^
M**<W7*K1LIG9TS^663B6M>-%Q;?Y"O*4(H" MWVY$-2VX@TBC"*;T_,^FW2G
M#@0\[Z1Y"]/7W\:J/.\"6-MHKK]UM_/+98+[B\FO_6U<5P'BMAHU5:=&WW5G
MI>EYX0BO,ZCP2T*E(/UPZ4LANCD87DD6-"#)Z/FAS.2 WO+<K^,;/OJ---G
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M)P@\-K,=F^IZ';QJPH4(5IJI6A1IQJU%TG5C"*J36RVE)-]%UZ&:YPC,, 8
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MG#J22A7AJER31X9C)![36%]Q[^/5>)?5@QC & , 8 P!@# & , 8 P!@# &
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M>+I[SW(_)(8 P!@# & , 8 P!@# & , 8!5W[!\:^E99Z%AGLSP]>L IST8
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M=<^7AU6WBO(C%\F/\N/Q(_\ >0QG_P NGH3!:'2?^1_K$MIP4& , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P"J;TK\4\!]'WS,+9>7+8L&@EW]^=._4
MU'Q\1#2$4]!;\IS1:<TM^9R,T'=RN$_EA)1$7)OT6?H_I''V31CQ^5/.%B2P
MLI;8QG&</RYEA^SHMO)[EK."HP!@# -">JX));1\O>D:RAC)(E,+%H.X8)%!
MR[QJ/1?R675Y(H^"9+/WRJ#)BDZ*$&J"CQXNBU;<*;6<*IH\=]\B5LT_)H]3
MR+7\HJ?R?YAJR<,4ADUK3SS2M?R\:@]:$4!\HAM;1J.2!BB08+.&#])H6&NV
MZ;UDX7:.N$]+MEE45..^H6R2\D@]V_>R0V20, 8 P" ?RE4/9?IWX_?4-"TX
M%:R*S;-KU,!#PKTP* -2!3F2 B.T%C!MVQ%,.--&+E3ZSUV@E]O&N/O_ '^^
M>=P]TUYIDQ>&FR>S;CI-LW3[U]G::"7'6OMUO[.N>.>>M?;K^+?V;UO^/7\6
M\D@\V , 8 P"OWY'Z$LWT13M21"J0K4Z=BGKWR9;1MJ[,"@B;:#55=T4FDU)
M\.3#MFW<KC8\*>NT!K=10@143Y:L&[ARIPET+1:3W_#)?%Q:7YLL"P5& , 8
M P!@# & , 8 P!@%8ORE4[;%F5WY<G]/P$S:YWRK[F\Z>J9%5L7?@&$QGT"K
M)U*!4P"PO]*B\?CCZ6,A<NZD8027/"$"CH'ID@]Y?+-$E1:+W:SC*:SX;^?L
M(B>?O._IEAXA]$><)71<OADP^1B3_)K9KPB]DT'5$^4>/0#:3N*?BUK="9&1
M7=&Y6A)&/7*4 XE#6/%DB;8XNR40^WH2VN9/.>7D7COA)/&?=ME+;P,6^/GR
M?Z/FE@3*87M55Q>/@D>^,+S/\<Z#EE/88$LXW858\RYQ8ULU'):TE$Q_1\)&
MG!0>A6LW?*CRCQ5R@38BDNF+M!N$FML-2]:4O'I+EPGE++VW)!2KX3JGG+^&
ME9G[?^4*5DZ[DZ4V@1"1^U9<:>PN8(#"05&4Q5T2C[E>/R%(08+"TS(GMH1X
M'DW[/ESIN\<)J IM9PH[K#V\#,?U2(/^D2^6O^_I8?\ I6".;^&/R'ZI$'_2
M)?+7_?TL/_2L#F_AC\A^J1!_TB7RU_W]+#_TK YOX8_(@EZR\.2:EKY\ UQ#
MOD.^4SN.^E?1LIJRQNC'N*RGQ!.,!Z.LNPFG4=<I(-$Q9/<@B8K2KM=!^GVP
MVZ;:;\=K<KIB4\J7JQV65M_%%?HV3M_5(@_Z1+Y:_P"_I8?^E8(YOX8_(?JD
M0?\ 2)?+7_?TL/\ TK YOX8_(?JD0?\ 2)?+7_?TL/\ TK YOX8_(?JD0?\
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MG9#*V<:<2LV7ETK58J2.832PIG(;&L&7E^!;,>)9NY1.I9(CVQ8A@R$"$R'
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M-:\?\*+,>/:MVJ''V]=:33UOOKKO?76QBZF58 P!@# & , 8 P!@# & , 8
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M8%@2MTQ:L6'1B3R8L_?=MA[)H/&M-M!;!!-FR1YP4D\O/3ILO!)82^"1)+!
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M*HQMMO+W?U]8\#:."!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P#7\#JFMZO<SQY7L
M*C\/=6A/2]HV&X!#TF*LPL,^Q%#3,P/=IZ^\^.$F 02U=/5-_?428-^=_P#P
M?;L#8& , 8 P#75O55"+SJRQ:9LH1P>K^TX7)(#,1'?7T^GT=E0ET&*)MW&N
M>NVCWEJ[458/D=:<,'J:#QMUPN@GWR)3:::V:W1]R#0T#7,)AU>Q9%XWC$$B
MT?AL<0(DR)L@@"C EH$$(OC)AT]+%WB0]BWX<DRCUV1?K<]NGKE=RJJKV(,I
1P!@# & , 8 P!@# & , _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>img187419207_15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img187419207_15.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &# 1D# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *I:OJMKH>D7>J7K,MM:QF64JN2%'7 J[7*?$S
M_DF?B/\ Z\9/Y4 96E?&CP7JVI06,5]/#+.P2-KB!D0L>@W=!FNITGQ)IVM:
MGJNGV;R&XTN40W(9, ,<XP>_0UY%H_@WQSXMT/P];:M/HEOH4 @N$>"/-P54
M J.G!(Z\_G52]U&+3[GXCB5)W^U:U:VRK%<F#+-NQN<<A>.<=J /?@0PR""/
M:@,I&000/>OGS2+/4+6[\=:!!K>GZ5BP@96MKJ0VMM(S#(#L202#M)Z\U;\+
M2G0K[4M$O=*DL-0N-$FD22SU(W%M<A5/[PKD[7.#SG\.: /> P/0@\9ZT @C
M(((]:^=]+\/6_P#8?PXO([N_CNM5N3;WDJ73@R1$$[.O P,<>M6)KN+0;'QC
MH"&[DL1K=O:6=N+UHEC,@)(:3DA..0/\: /H $,,@@CVKC_%/Q.\-^#]533=
M6EN5N7B$P$4!<;22.H^AKD/A/'<Z=X[\5:0]Q;&""*!Q;V4SR6\+G.0A<D_6
MJ_B^/Q%)\<HE\,"P-_\ V*-WVX$Q[/,;.,=\XH [+_A:_A)O#$GB".^DDLHI
ME@E58CYD;MG *]>QYI?#OQ6\*>*-3_L[3[R47;*62*>$H9,#)"YZG Z5YAXP
M\(ZUX=\ :EJ&K7%E)J^K:Q:RO':Q[88RNX+V'7//'YUUECX.\::GXHT[7/%D
M^CQ0Z2LCPQZ?&=\C,A&"2!QWH ])T;5X-;TY;VWBN(HV9E"W$1C?(./NFK]>
M>?!21Y?AK;-([.WVFXY8Y/\ K&KT.@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "J]]8VNIV,UC>PK/;3H4EB?HRGJ#5BB
M@"&UM8+&TAM;:)8H(4"1QKT51P *RYO"/A^XCU%)M)M9%U)Q)>!TSYS#H3[C
M-;5% &#9>"?#.GB1;31+.%98/LTBK'P\><[6'0\^M&E^"O#6BBY&FZ+:6WVF
M,Q3%$Y=#U7/I[5O44 9,?AG18H-.@CTZ!8M-??9J <0MZK^=1W'A'P_=QZA'
M<:3:RIJ,BRW8=,^:Z]&/N/:MJB@#'TGPKH6@W!GTK2[:SE,0A+0KMR@.0#Z\
M]ZM?V-IQUL:S]CB_M(0^1]IQ\WEYSM^F:O44 4=5T;3M<M%M=3M([J!9%E"2
M#@,.AJZRAE*L,J1@CVI:* *6E:1I^AV"V.F6D=K:JQ811C@$G)/YU=HHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ JEJNK6>BZ=/?7TOEP01F5R!D[1U( Y-7:XKXA^"#XTM["WC
M6VB*S;9KM\^=#">6$6.,M@ YXP: .OMKJ&\@2:!PR.JL/4 C(R.W!J:N4\ >
M%I?"F@-:74=L;QI6\RXA+$SJ#A'?/\6W&>U=70 4444 %%%% !1110 4444
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MC6G0 5Q'@'_D.>-O^PXW_HJ.NWKB/ /_ "'/&W_8<;_T5'0!V]%%% !1110
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M-/NWAB6%9;FV25]JC !9@37-_#>UM[+4_&5M:0106\>M,J11(%51Y4?  X%
M'>T444 %%%% !1110 444UW6-2SL%4=2QP* '44$@#)/%(CJZ!T8,IY!!R#0
M M%-5T?.QE;!P<'.#Z4*Z,S*K*2IPP!Z?6@!U%%% !3)5=HG6-PCD85BN<'U
MQWI]% '+:KIM[)J.D//?02RI<'RG:U&8SL8Y'S>U;]G#>0E_M5XMP#]W$(3'
MZG-5=4_Y"&D?]?)_]%M6I6]2I)PBGV[+NS:<VXI/^M0HHHK Q"BBB@ HHHH
M**** "BBB@ HHHH CN)X[6VEN)FVQ1(7=L9P ,DUP>K7]QKUPM[X>U#P?=6#
M1#Y[X&23/.>0>![&N]EDCAA>69U2)%+.S'  '4GVKAM3T[X77-Z9M1C\.&Y8
M!R7>-2P(R">><C% $GPZN;N&VN-$NM7T74/[/1%7^S"Y,8)8X<G@=L =A7<5
MGZ+:Z1;:9%_8D-G'8N,QFT50C#U&W@UH4 %<1X!_Y#GC;_L.-_Z*CKMZXCP#
M_P ASQM_V'&_]%1T =O1110 4444 %%%% !7F7QAL?$5WH^[13,+=8L70+AH
MG&]<#R\%B^<'(Q@ UWVL:UIV@:<^H:K=I:VB$*TKYP"3@=/>N;_X6SX$_P"A
MEM/R;_"@#+O-.\8GX>1VZ/>C7Q,S23/>1LF,'+-A<-&1T0#/(^M4/ .G>*(O
MAQ=17JW[7,EK&+#R+I(MJXX5 5'EL.^[.?TKH_\ A;/@3_H9;3\F_P */^%L
M^!/^AEM/R;_"@#C_  #IGC."ZUYM7:ZFC:2Y4?9+A(0;C RV"H))XVN.!@\4
MOP]TSQG;>.-1DUF2>2U$X$_ES*H,GE#:TGRCS1MP,KQN!.*Z_P#X6SX$_P"A
MEM/R;_"C_A;/@3_H9;3\F_PH [.BLK0O$NC>)K:6XT6_BO(8GV.T><*V,XY'
MI6K0 4444 9>J?\ (0TC_KY/_HMJU*R]4_Y"&D?]?)_]%M6I6D_ACZ?JRY?#
M'^NH4445F0%%%% !1110 4444 %%%% !1110!1UJY6ST+4+IH4F6&VDD,3C*
MN I.#['&*\L\,QROK?A[_A((M#U*#7[%YU0:=&AM6158*#W7:0.>XKU/69+>
M'0]0ENXO-MDMI&EC_OH%.1^(S7C/A?PSH]]J^CP:[X/TJWMM9M'N=/:TNIF>
M(* VQ\MCE2#D4 >WVUO;VMM'!:Q1Q0(,)'$H55'L!Q7'^-/&.L^')Y&L-!%U
M8VEK]KO+J>4Q)MW8V1G!!DZG!]JZO3M.M=)T^"PL8A#:P+MCC!)VCZGFN(\=
M^'/%GB#7+!M/71Y]%M,2FROII4$TP)PSA%.57@@9QG.: .WMK^"XM(+@L(O.
MC60)(0&4$9P1ZUR/@!@VM^-F4@@ZVV"#G_EE'6CJ/@/P[XBFBO\ 7]%L[K43
M$B2R MC('0<CC.<5B_#'3[32KSQA86$"P6L&LLD<2YPH\J/CF@#T&BBB@ HH
MHH **** .'^+$*W'@I8FC$B/J%H&0KD$><N01Z5L_P#"#>$O^A8T;_P!C_PK
M?HH P/\ A!O"7_0L:-_X Q_X4?\ "#>$O^A8T;_P!C_PK?HH P/^$&\)?]"Q
MHW_@#'_A1_P@WA+_ *%C1O\ P!C_ ,*WZ* /*_@K;K:CQ?"D(AB76YEC0+M
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MV6WEF4@_-RV[OR#_ "J7Q?X5M-:\0:'=S  B;RYAC_6( 6 _,?K798"I@#
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M_P#T8U=-7,_#[_D1=,_W7_\ 1C5TU:8O_>)^K_,O$_QI^K_,****YS$****
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M% !1110 4444 %%%<CXA\83Z%K0TRYM!;0WL!73]2D;,+7.#B.3^YDXP3UH
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MR"UEO[8LUS:O\K+,\1 _=[NW7'- $>J7OA[Q=JLMQ;WDZV=Q<+;R3#*3:;>
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MR^LJL/,\MCS&&=,MCJ*];I%547:BA5'8#%+0 5%<F9;69K=5><(QC5C@%L<
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M:UM]1LY!*]M<)RC;1\RMCD8!R#7LU<=_PA$*_$__ (2D16[PR691TDR62<$
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
G!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>img187419207_16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img187419207_16.jpg
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M 0$! 0$! 0'_P  1" #N ET# 1$  A$! Q$!_\0 '@ !  (" P$! 0
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M(GB)XB>(HM]C7A8G.E#RZW:TK<':QR&,2I\A##$FDL<<DH_'HT>DA1*.)Q&
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MY2.R*\H@T9PI^ 102K2USVS"1/"A]]'I(ON_CC;:6+5YH6 ::XD.^%;61@R
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M4L$E95O[N%LM1)_;A87'\TC_ ,K1N5JSF#J^G>OX.:L.E"9HK&8_*W4,)+G
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MCV2&SWS[]%(&3SQ[B3\E^N:[YEE[1\H8D]1*UUJ.7_+L)" M6K+GK"9J($C
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MZ_S7JY(V32OZ93]*7"XA-57>>+YF32LI%)(6NX$"OVX[FB$ZO&H7E=4IB08
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ML([6.UR@NET[.](3ZDH++4Q4=SJ(;I8J 4M3-":B.)S+M=*"60NA!?Q0LD8
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MNINSAW+]1"3B<<DTZ*GYW?E,R*41M4B-+/!D9K<#8,^:#!Y_ZQ=VHU$+R$H
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M;7;\RIKMG7.5L8S],X_E]UGKK5<FGJVW4[+30W$54$DADJV.>Z/AE#.!F <
M_J.>O1>]/PB?AWHNVC2VM+O5=I6K=#.L5XHZ)E'IVKBIX+@)K<ZI,]2V2:,N
MEC([II (##A74^[,7@M/$7 %E1AM@W*!R#(J-=Z[[M2 YTB\9N=4U-T=]D'+
M?=1%7&BJ:B6^=-\_:IIOIM]-M<XQ2.2.5C9(GLDC<,M?&X/8X D'#FD@X((.
M#L01S"^-/44]7"RHI9XJB"4$QS02,EBD <6DLD87-< YKFG!.' @[@KG^NOL
MGB)XB>(GB)XB>(GB*A&!MY%%?EE_*0TY81V+32VK7(63#8\T^2T# H=^+1<R
M=(SV9(S.;->!Y&W=R0-%(GH\CT7)KK2>0QAY%!N#K#<\#*_^7?AY;?HSS&VP
MXAS\?'IE8S\R4AC2M^\L0Z>26)@HT.K^V;*CZTILW@VE5A=@1^758*#G(Q8/
M;%2W"D[--AQ,A]P"OA\0)LM4&QUT6/:(8:@B-Y'GT&!D[;\\$> \5>.]D=5T
M?6&))*#]?U%5T2%-'1*0'S$5@L!C30@Y13PY?&EE D4%-WQ4BGKAUC=DS>$'
MVGX.,JNT]-BIN?-5Y_,6? ROXBNTY/%C8B2QJ1<X&#<?D( DS, SH8I@4]&%
MPY8<LY8$QA%FLB[8OV3A=H[;*I+MU5$E--\E>/\ 6WU5H8#_ '$%_LD=_@T?
M%1=MXB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(J$>;V\BBOR?3N/Q,Y84A@,AL
M#IZ03&,"6GR6@:YKPT4-EC^QPV,N:;:\2%MY+*"#QKDS5<8=8?RHBW*P0;H&
M?O38DKG](Y=/]&?#?'YO<<\OAAORS26-K=@\XQB;RJ*1\9$:L=67!7$CM/@>
MD"@2?;V2W#J'HA-.RJCMN02(ME@.'IN0U8?L=W%\LAI)<C(74C0TC)&YP=C@
MG!QGP)Q@$#'JO06#!!(P'&QZ-!A4>CX5F@.#@P8YH)#B1[73"39B-&,$6[)B
MS;IZZIH-6J"2".F,:)Z:ZXQCQ44*OD&_HDIK^_5\>/\ G<HCQ2.?N=]"IU>*
M$\1?S;;737;??;&NNN,[;;;9QKKKKKCZYVVSGZ8QC&,9SG.<XQC&/KGSES4@
M$D  DD@  9))V  &Y).P YJG/Y$N=>=._6]1MW/:%1U7_"I:<K:;H%H+-/US
M]ZZ1'3;7;52R(M^G?IO[4USKG&7WYO\ /9QG#;\MC*_6^LK-9M7"W ZFMU![
M :L[24M5WOM0IAUKJ?@X/9__ )\7'_EX=_<GX8>T_M0_#;+K66+L'UKK#_&,
M>GHW-DHM0V'^G_T%UZ<""W2UX]J]J_K!!!%/W/LXP9>]_MV6T_+:R=1>-P*"
MVA!K">0B(  [O>+2:/F'F[,(/9!M2SL:'+%%1Z#I5%//T4542256U0PX5V^W
M;;=[=44+H(:2EKZ6L=2T\,;C3SPR.+8F-B[QS(Y)"P.(',D G'$5Y1UO9=60
MW:Z:CU#I'4.F8+_>[E70B\6FY4,#9Z^IJ*\T<-574=(RIDA9(X?D8U[V1F0Q
M,&0.\D]K0.'3:NZ[D1]J.EUJ.9 TA E7/T5+JQ@3DR8^F^<XT1T0:9233RIG
M&7+MPW:H8465QKB]1<J.EJZ&AGF;'57%T[:.(\Y33Q][+@\APMP!G]3G-:W)
M*ZMK]16>V7:R62MK(X+EJ%];'::9Q_-4NM]-[55;\FAD?"&EV..5[(V9>X!:
M2Z5ZG#<Z'Z7"$ !,_BS9VD$D#@<R?NDX?"DT?RI68OE&2"^J6HTN2!9U:N-<
M9?C=#F[7.R[#Z8Q-^U%%8YK5$^&2?^H5@AG,;'O%+2!I;)5/+ [ CE?#^5P_
M/&)N'+F+5===H-+HFLTM2S4=16"_7=M+6O@BFD;;+4UG=U%TF,3'\(@J9Z,B
M-X_O4XK#%E\.%+'_ &_[/;(NQ4\1/$3Q$\1/$7GKZZ"1,7VF"'P6JVDVDA"3
M\^DJXDPJRI,1C ^PGW2\WE'3PJYU].GH0VKS43$RXHO"AZE:&4OU0BZ8A6<V
MV:(5N**XSP]<;Y], #I[MN6-\<U(KY4EK"AJ=?6-&6H#4:NLR@H%=7H/JL+-
MC=D//W.>&1R"\JTGRIUS +H,I1@=(I L=D-6FI(% "I$HY0:Q$00>8*&_>P_
M_P!$C'Q'S4U.6M\6_P <5EK+Y>/FZ-BU:X8GY97$E( 4BC&1HDF+Q2/RB%UA
MS2>C!MFR=;,%GP2JJ>E,7/M'.NH".'QV^R10=B?7K_V?J<JG-Y\3O2ZC7G"/
M@"E9196N:!B%6(V2UEAC:3T*8@AWK,F<5K9!.*J$BS.Z0M]5W$9,Y'&XZL@*
MKQUN<3*Z-0;5P5BX'TSGUV \=N6Q&^Y4EN<OCKZ+B= *5^CT5+^'RB]NE)XV
MA7)ZU92V,CHZI4-.UE^W5WMDU&^%Z-RLNK266OG6.1T(I@K91+!==\3_ #F^
M"%P)R1Q;8W)'4^!Z#;&3RRMC?!BENW^*CD=!5PHZ51C]DI*.EL:86<[IW796
MF[A7">NB>%%MM<J*83TTTQMMG&FNNOTQB!R'38*'_J/WT5LWI54\1:NNRV -
M%5)85Q2A@7*1ZMXL4EA@<!29K&GC 4CE==N,2(/1S%1XIICZ(Z.GS1'.W\FZ
M^F/Y?<"Z7"*U6ZLN4[))(:*!]1(R$-,KF1C)# ]S&%QZ<3VCQ*V_0.C+CVB:
MTTSH:T5-%1W/5-XI+-0U5R?/'005-9((XY*M]+3U50V!I.7F&GFD _3&X[+2
MG&79E==OUO(K.K..36,A(U-WL#>L9TT!,RBQ1@!CTA5=-4P!Z0M-A^[22,T4
M]U7B3G+E%SKLVU2U255QFFM2T>J**:NHH*F"*"J=2.95-B;(7MBAF+FB&69O
M 6S- RX'(=MC!.^]NW85JC\/^J[9I'5ETL%VK[KIZGU'!4:>FN,]''1U-RNE
ML9#,ZY6ZV3"I;-:IWN:R!\7=21$2EY>QDO/;$NDT\1/$3Q$\1/$3Q$\1/$3Q
M%Y^?E1"PX?9;E4'6*=DRJ55?9+X5@!84C6?B^I%V5+A:D96F :=04@VKRICE
M=PY5@7.:#E!&?QUI&Y,1DLWTWFQ7;GSQR.!TW/@<G?EMX==I?_)<A-0]*0NQ
M!3.(-1$(WT:2=V9Z9Z;J)1H<F)2$QV#@(?7W/M&] I=(2&23%5D"C<.G582)
MPD95$XB(5^3D!)-$H'KCW#IOS)&/<5MGXYIE)IQRG&)'+9.(F$AVD<^'$,A-
M%6+X*[!RDF(<0^1B2O-''AR.S*.NF*PJ0 Y71$-D0T@ELF7>'5,X//BAW,_]
M]/')^I5++_@?M"2Q#=S%^>IE2I$S;,_, :GS?E?'8G2LF(P^OX;0W1S"7ZW7
M,9%9$QKEO#9-+;ML,Z[2MJ<V#8KPC&8&<:L5'VY6)&>>V.8R,^(Q@;> V \>
MBLYZ7@5S!NK."I;*K\6F=:E^YC^L9J3:L(='DX@H]XX[#="E=9T+5VD9[]%'
MH/!>-"6FNI##_+UU]'#5'&2C;!VZ#KYCR_=6M^*J>(N 5'I%AA$4LX?M$2;!
MX/5="G[L43;)/6ZC91P.*,%F[\:_1T5RHS?LET7;-QJFX;+)K)Z;ZTD8)(WQ
MESVB1CF%T;W1R-#FEI<R1A#V/ .6O:0YKL.:00"N11U+Z*KI:R..GFDI*B"I
M9#64T-922O@E;*V.JI*EDE/54[RP-GIJB.2&>(NBE8^-SFGSR_)3>K[ARP:L
MAT.5OJ>M)_&"1Y\]D'7?2S)<<LQ-Z"]&[;07/,I*)J);95VV6_GXWQ],?S?=
M0:UNSM+5E!34QNU6VL@?*YTVHKVPL+91& !'5X((WWWROTU_"IV=T_X@]-:P
MOE\9V<Z<FTU=J2W4]/;>Q3LIJ(ZIE10.K'22NK-.\;7->T, 9L6[G=7J5K40
M6KU#"@B66K)LFM&.CC6RK7G]F)L\#]G>R6P=.;GS>@;=?+Q3#[<;AML_U1::
MN\JX:-\)]IT5OBH3(8ZBOG[T,!]MN%77!O!Q8[L54THB)XCQEG#QX;Q9X6X_
M/+56M:_5S:%M;9M'VD4!J'1G2NC=-Z3=.:D0!XKG:?MMO=7"/N&^SMJC**8R
M3F$,,\O%H&^>M:JA%D(<S&#=B ;!L2OY$\&'8%7TOF9V/.'Z&C*/KQX/'XT>
M?'S#Y']R$ASD,.,L@SR*+IG4D?QTM,X.\ZEMM)7MT_+-70UU=13OCFHJ&JJY
MH'/'!"Z"*"GF?-*\=_)&Z*.5D+J8B8#B 7GS6':/IZU7UF@JFKO5'>;W9JV2
M"LL]FN=TJZ%\S!%1/HJ6BH*R:MJ9F^W3P/I8*J*EEMSVUC6<;0HKU)T)3_%^
ME*<PBREYS(),IP9V4,VU4=AUX8KR.2--SJ(RQ&RB!Q)R?#%[$5VUU<,&KW06
MBZDSAXYUPU'M-M=ME[M>E!:=/127BKAJJN;,USME?12T,$X=W7"RHH:5TT,M
M<< L:[NPZH<]WY8V'KW3>L]-=EHTIH&GJ-6W2DNEVJBZJU'IN]V2ILE#7->*
M;N:>X6>W25E+4WMQ ?#'*VG;)7OE>.[AC-O?NS5Z53Q$\1/$3Q$\1/$7'=I-
MUVCI!W]/RJS=9)S]RFR.OY=1/;1;ZK:;I[I8_#SM]5--]-M,?SM=]<XQG!%Y
M^Z"$QL1\B<0"5U5;;\6.VK:C/>P&-C224UM_HO->:=P%6&(C)G_3<I;S"W<3
ML2@*E<9=U(H[0!S*6$7K -FO \ZD97.S=R>6<8/ZL[@G \SS/1<;Y+)5:--7
MPXDPHU H.QF8O>11J4$NB>I9^0%0R'Q^'"9]/K!YV5^/OMOG'GZLHP=?-!QZ
MQ?R<9BCY!9E)Y/(F,D(%4QK[^_BC>6Q]>0\< 'B!/UZ#;.;>.G(#<5G\\&X=
M11^L@MO$DX>[B$[L@.E)8Q$2PDX&+J3P Q1CAMCF; $62YFMC*T<=BX_,T0$
MD<AW[,7N'=E4;'["I+^5'@".PCXKK<E*UI=!P$K0/'HF"M*:J?IJWFW,Y;6#
MZIMDU9+7!-R.'V(Y+[/5%9$=EXG]7DRR35<MKLHW3^A7C)XQRW=G< GXXR/=
MA>CL!_N(+_9([_!H^+YKMO$3Q$\11?AO9W,U@78?YTB%HLC-SQ=_)Q9V$)QV
M9-'(]_#5UFTE;[%R$=:1Y?(M9NMIONU+KI.?L^YGNXUSKMG!4VI;)672:S4U
M<V6YP/GCEI1!4M<Q],2V<&1\+83W9!!+9"'?Y2[(7;E][".UC36@;;VHWO2$
M]!H.[TUIJ[=J!UTL4T533WV-DMIE;0TUTFND8K(Y&.:V:BC?$'8G;$00)0>S
MJZC3Q$\1/$3Q$\1/$3Q$\1=/(F(<I'SHR0Y3U $0Q-B<V5>K#$L!W;)=N3RH
M2;.&C@>GADHOG=Z@Z;+--?JNDX1W3U4U(J'.260M#Y %6T.JI 8^&2_J_><S
MAO/9!):Z(U"0+CTN;Y!6<A?]+3=I+YN:C3%%]8L?2JEBF#?325(.$H?BOP&\
MH*YV;@YZ8&.IR3S'3R/7KG;%OD%E5J4WTBL_'2.O*\;S3\&3B)44Z,Z>L[,?
MK]DH%!F9Y:5-2;X].RN<.9*Z;R5RJ*6E/ZM 86]7T<FW,J8%]) \$$;OM\MA
MGRSD$\^6_IA>B3Q44%?D&_HDIK^_5\>/^=RB/%(Y^YWT*G5XH3Q%_,XQMC.N
MV,;:[8SC;7.,9QG&<?3.,XS_ "9QG'\F<9_DSCQ2"0002"#D$;$$<B#T(50O
MR0=;UGP$VIYPVY6K6U/XJKSQ'?1=2/PS]#_92</WUVUV3@$I_4?U+]UYQG&<
M,?RGY'&<9<_F<X0Z[UIJ&ATD+<6V"BK_ &\U8.3#3=U[**;PI)^/C]H_^'#P
M?YN+\OMG\+/8KJS\24NN(I>V'56C_P#!T>G9&NC;<K]_4/Z\Z^-((=J2S^R^
MR_T<$$&H[[V@Y$7=?W++*J&PYU$8K.8Y!HO#7<RB,?..D (@6S601-C&1?(U
M5^P'CU7J#55?73&ZB*6BNZ6JWX"6V<:Z[M0,IG4\%5!2P4SJFGAE<(HXVD"5
MC9. O8QA>&DXR0 2,X')>4M85=\AO5XT_=-0W>^PV*]7*WQ27&MK)XY)+?5U
M%%[6RFJ:JI93R3,C+BUKWN8UYC[QXR3T,ZYTIJR[ A]IS:&ZFY] <CMH;(MC
M\H'KQ_<444-,E&#,4;8C=5="2NSA955DHH[QA-!YLNV111TXU98K5<*VEN-7
M2]]6T7![+/W]0QT!CD,K"QL4S(\B0EQ)82[9KBYH '4]WT1I>^WFV:ANMK%7
M>+,8#:ZTUEPA?1.IZAU5$Z&*GJHH X3N+W.=$YTN&LE+V-:T;M__ '__ *_V
M^RZVM/$3Q$\1/$3Q$\1>;CM*GFT@[-B5PT:;Y-%0@5TISS1DP9#XKQ>'DA7J
M*1RZ361:[&S+!M6B9I9B]CZPW^&B0L+ +%!3XD0E^-HLPVFX8@U-E<'8@YS@
MGKL,#&-P,$YSL?W$Y/E\/Z Z5HE%FD_'2P[TR$$0:P8XOT;O/*HD*=*WD:>3
M6 @>4!I>\96<?Q,/)J_, XN->#DH/.9:=E2&\8"E?H_=0W<G?IY '<;$NVQU
MWSN.65,#B<.*C_*5&APK!N-',(.S21;MX[<$5V55V=O%7A!Z$Z!;-+L;ERSU
M1P5-N[/0Q,"QAX^+F%%W#[*ZI0>9_P"#]-E*/Q0GB*J#X.OZK'D_^QK._P"M
M]F>AO(>@^BL_]1]WT"M?]*JGB*OSO_G1]:_/M^$8F2N@S/2=6&AL;KV(6;/F
M<3D!1!ANDQ'[UN*-H1@PJ0WS]KQLY%+8)[?3\WJMGVH:NLS[A:+M)3ON<M6^
M@D9!1T]=5MIYGAN&L-%'*V"0O_S!T9XS^K)7I7\-G:A3Z-[2^SBEO5+H2@TY
M2:PH*NZZFO>D]-SWFV4<E2'U%4W5-9;Y;O0LIFC,$L-8PT@SW)8H-?#SQQ8,
M I"6+W>+O^G)>SO)Z;#PY*P;#K@&;"-8C -VA8K# QL<$D#=\3:$A;UT28N?
MU)F/_2G6RK1IHCIJW9SINKI+94.ND=WMM0VZ.EBIA65M%%+$VGI"V22FCE9%
M,USVOC<Z1CN-K.[=EK<+T'^.'MSTUJ7M!LT?9_6=F^N;)/V>4]OKKZ_3.F-4
M7&WW":]ZE;/14=^K[?4W"VR4])-25E/#25$7LL]3[9"&3S.>;Z/=L+\YT\1/
M$48.PIQT'6E%26>\T12(SJR(L[%D5(;+@<A/I2&,[.?RAQN$9QJ3Q5]J='IN
M4#2&ZC]RW6'C"3+5BL\=M%4,YIVEL];=8*2]U%1244[9&>TT\L,)AGX>*)TK
MIX*AAB>6F(@,#@^1CN,-:X',6&FM=7<H::\3STU),U[/:()(HC%-CBB,CIH9
MF]TXM,9 :"'O8[B#6N!WG ]IKO"HGO9'[>Q8"D>$*S32)-7S.,(R=1BBH:;@
M&Y,F9(:"6Q#9=NQW>$WCA9NGHLJKC93.FN+J_9?:J@47?>QB:04QJ'-=.8 X
MB)TSF1Q,,CF8+^&-H!) &V5CJGV?VB?V3O?91+(*?ORUTQA#B(S*6,C9WA9@
MNX6- )( V66>XZ^">(GB)XB>(O.-\O51CYY-IC8-0'>4X\9IV"@,]&/)#$N+
MM[&VLJWC$3KGG)I;\^Z9I"T4XU&G0UQH9"J;GHHZ5A\2+ALKZN)%7Q8.5VD^
M!/@/S<ADG&"-_OTL9^3PNVB_#TD7+A&Q0G^]>> P=9B3MIJ6B,R)W=6XJ.6!
M!]J&'XN@S+JYD#AI-(H#K,>G+)"0!(#&+!PF[7%N2JWG\?#P/CM\5E?QKB6P
MCE*+Z:*NWY$C+K$.2*0EHITI$9)+I.;F)4F>E<K9=;C!%YD)&;(.57) Q)F2
M8QWK^ E%-48NV$MD"'<G_@_393U\4*"O8O\ 2U\<']^IQ_DF[1\4CD[T_<*=
M7BA/$73R*0!8E'SLJDI-H%CD9#DY ?,/U/P6(D*&9+D2I-XKG&<)-&#%LNZ<
M*9QG[$4M]OIGZ>^<TT5/#+/,]L<,$;YI9'G#8XHVE\CW'HUC&EQ/0 KG6RVU
M]ZN5OL]JI)J^Z7:NI+;;:&F9WE16U]?41TM'20,&[YJBHECAB9_F>]HZK5E5
M]&4A>(622&G;+B]DB8CMHE(G<3?ZDM!:ZS1=\@V<YQJGC1=PV;K*(Z9SC[\:
M;?RX^GN!07FUW2*>:W5T%;'38$SJ=_&(R6EP#N6Y:TD#KA;AK#LN[0.SZOM5
MLUQI2[Z5K;VUS[7#>J8TKJN-DT=/)+%DNXHXY96,D=_E+AL5HGD;Y!*#[6*S
M8/3*<YT>0$>%)GOW?'&H)++8\Y(-6/Y'=L8*9<*85&N?Q]-]4<)Z_AYQMO\
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M1&<^G+D2T9Y=7 CY94PN/AZXCF:F1;I<VX=,H8T265DL%NRLC^^WYIYG&Y2
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MK1-S%B*SUBXU9,C*[Y#75RW1WU[FL=31T=XMM57Q.EHX*N%\[6R2QO:P._\
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MBU!VA:AUM2T7:[0VK5]3;-,NUO8:&>HK;745;+'$-,3M-UJ#5Q1PN;%&[CK
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ML$:H$2A+M .+8,C N+C4F14<KOIOLTEJY@BR7_!=::Z[9<M31TM1=J33$?\
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MB+7?=6:OT#J'1!H?ZW'2]W<!-[--1U'M$1?3F/O8GDLC>R1K98W@.9PO:_\
M(YQ9(&;-:;W0WH3>Q&4NI^#O&21\#PV3BX7  N!:2UPR#D$;@9!.]/\ 6'\
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M5$,@KJZAFLUNMEAKI66]LH;!6,AJH6"..WTK!"\TTQJIY'15-3#53S2EE5Z
M[4_PSR31:<I^R[3$L7L-#717FX7._44;[@Z(NFHWS4LTA?)<*I_>M%1 *6G8
MV6GIYJ6"&(/I9QJ_(%P<W>*#G7:_)3,D@YW9.!CWHRGV1-J^25R@LP=CG4P1
M>M'Z"^NS=PR<H).D'&NZ"R.BVFVF/<%+54U=2TU=1SQ5-'64\-52U,+P^&HI
MJB-LT$\3VY:^*6)[9&/!PYK@1L5XCJJ.KH:FIHJRGFIJNCGFI:JGFC<R6"HI
MY'13PRL(RR2*1CF/:=VN:0=PI=>Y"XR>(GB)XB>(H]7WU/1W,FD,4N>7.HOI
M/2ST6 RQBLOE>4T!*;18_)#VL1!'=HM"8PD1&J2F<R7 J)1O0D.R9,,OSK;\
M0I )Y+378O\ 2U\<']^IQ_DF[1\0<G>G[A9-U[W9SOQ %B1>]I"98N9V[*M8
MC'HR =R$^:U!:CMSCU%LELV9-& G!<7J[<D2#/7=1^W1::N5L[IZ;?I+0^H-
M:SU<-CIX9&T+(GU=14SLIX(._,@@8YQXGODF[F7@;'&_ C<7\( )Q-TO-!9V
M1/K9'M,Q<(F1L,CW\'#QD 8 :SC;DN</U #)4'!_SY_'P\PMEP?M<3E+*6-,
M$*R?J9<X4WQKOLC^ED26-<(8SE17\QE#;;3&<(:K;_33.[2=A&OV</#!:I<Y
MSW=R8.' V#N]CC_5R'#Q#/ZBT;K#MUK8SG,E2W&/U4[CGS'"YW+KG!\ 5<'#
M9?&[!B$5GL.*H'8C-HX$EL7--M5DVY>/2(:V+A2:";A-%PFD^'/&SE--PBBO
MIJKC19)-3&VFO4=925-OJZJAK(G05=%434E5"XM+HJBGD=%-&XM+FDLD8YI+
M7%I(RTD8*VF*6.>*.>)P?%-&R6-XSA\<C0YCAD X<T@[@'?< K)/<9?1/$5=
M=I1M1WWA3$ATYH+RV/,(NX:R6^DAI=92*2==7=6$IBWZ)!%) -'-6KUK(4DF
M^PQPE.GSA^FLL)7U4T:XP<>LK5/_ $"6IACIG-GO0CE)IJ@DNI!&\/:!%!PO
M;. #&X5CR]I,1STGJ&A=)VO:6K1H2IN5%#;WQU^L&P5+W6ZO>YSK2VGF;,UK
M*6A[N6.M:UA@>V[ROF:Y],\.WG=',C>Y;3IRU'%GSZ'D*2)[FHH"C&P+0&[+
M.W:"A=T;3(BGCM]H8%M4(^];:N44OT?9XW0PEL0=[JYBZZ?;=;C:KBZXUM*^
MT2&:GAI^Y$+Y'.'>NF#XW.>)8VB![>(#NB]HQQN)VW5.@F:GU#IC4+[_ 'BV
M3:4J#5V^CH#2"DEJ)9&&IDJFS4\LDHJJ>-M%*P/:WV4RL9PF>4NR;IR]!W-M
M(3NY"@(Y(6L0%_C:, (S8LMH]>JZ,!KPFV3=LUD8\S(.&R\A((*[*C0^KM_J
MDIAOMCV[V.U/O5TI+;'+%"ZHDQQRO[L%K?S/:QQ:X&9S X0L< 'R<+,C*[2L
M]M?=[C36]DL43IWX+Y7\ X6CB>UAX7 RN:"(FD /DX69!(7E;%_)["2/:T7[
M%L/F(>E)0L%=0YVRC$Q6RHH4W;;L!L[T;F0*:3R3,(L\<Q)+#AXV;?HKIDZU
MVPZ%-,+]]2:%JF:9GTY1WUQAEJQ4M=/3  ,#@Z2E+HIB6P/G:)SAKCWH<TC$
MCL=T/T;4-T]-8:6\O,,E4VH:Z:G&. 'B?3$QRDMA=,ULYPTGO6N')[L>IKEW
MHV*=5T['KEA@:0@@IU5RSR/D;%1HY1(CL(IE$&;C;1- NQ8OE%QGZNQQEBZ?
M,7R;9131#\3;H>^V:HL-RFMM3+#++#AW' \.:6/R6%P!)C<Y@#^[?A[6N:7
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M_P#;YXG=N\!_N;_*?ZZKX_/^^E^?\DG;'_M\\3NW> _W-_E=2*^<CXWSN2>
M=G7,9R%+.P)G KC7LPCD2<8:H[O@I/#2@ELL"S+1PWV=CG7X3QMJNCLLCIA7
M3.Q.[=X#_<W^5VW^NJ^/S_OI?G_))VQ_[?/$[MW@/]S?Y74O/G(^-\<3#A2%
MG7,Q,R+=^G'Q+SC7LQJ3.[BVF7Y/0.P7H+1T3W',=<O7^K))?+1IC+AQA-'&
M=_$[MW@/]S?Y7;?ZZKX_/^^E^?\ ))VQ_P"WSQ.[=X#_ '-_E<9[\V_QWC6;
MLB1G]YL![!LN]?/GO%G:;5FR9M4MUW3MVZ7Y_30;-FR">ZRZZV^B2*6FZBF^
MNFN<X)W;O ?[F_ROP.^;OX[# ]@6$V'>!0449M2(PF.XN[1?#R(]\AHY9/V#
MUM0"K9XS=ME4G#5TW540<(*:*I;[I[Z[9)W;O ?[F_RMZT%\E/)735C,JIJ&
M2VL3FA 85+M6DMYGZ6K -LQ"MOS9#=666=4D0B;=?1#^5!FX-)/'N_\ V+)!
MPK_,\4%CFC)Q\6GY DJ>/BJGB)XB>(HG]?=6A^28'%I:^@<GLPU-Y>6A\5AD
M3? !1$F\C-569=TJ<JE),1&"&2 FM*AG15MJX<_>3+LQ8-+\#<IAXV*0,^&W
MCZ@?O\%!;O/N3D\E6U+ ,WC!ATJUZ@^.VW2,/*%4VDI!U[GI&@[B=R4X'_[1
M<</%UHKB8E5U<Y28A$UGJV^$4MM\%(:?#_4/?@_>>2EC_K-?C^_XNJ/_ /.C
M#Q.!WA\Q_*^&GR?_ !ZJ+KM4^PJ(4<MM4=W+?2<C=EV^CC&^6^RZ.NV5$M5\
M)*91V4UUPKA/?.F=OLV^A.!WA\Q_*^_^LU^/[_BZH_\ \Z,/$X'>'S'\KX+_
M "?_ !ZM=4]W785$-M%5T&R6R\Y&HZJ.72NJ#9NGLIMKC==PMOHB@EKG*BJN
M^J:>NV^V,9)P.\/F/Y7W_P!9K\?W_%U1_P#YT8>)P.\/F/Y3_6:_']_Q=4?_
M .=&'B<#O#YC^5\&_P G_P >KM/*S3L*B'26JSAOLJWG(U9/5PS<*M':&=T]
MMM<+-72*S9PEG/WH.$545==5$]]<$X'>'S'\K[_ZS7X_O^+JC_\ SHP\3@=X
M?,?ROAM\G_QZZ.$6>_85$:.W"2Z[=KM.1NKA=!KLAHZ610SMA55)MNZ:Z+J:
M:[:([.4-5-M<K)XV)P.\/F/Y7W_UFOQ_?\75'_\ G1AXG [P^8_E?)?Y//CW
M;(K.7/8%%-V[=)1=PX7G Y)%!%+3*BJRRJFVJ:226FNVZBF^VNFFFN=MLXQC
M.?$X'>'S'\K]Z_)Q\?>^NN^G7E&[Z;ZXVTWUFH_;7;7;&,Z[:[8SG&VNV,XS
MC.,YQG&<9QGZ>)P.\/F/Y7Z_UFOQ_?\ %U1__G1AXG [P^8_E3H\54\1/$6.
MS")@)[$I3!I6/T+1>9QTW$Y(+44613) )$,=!S _=5NHDNEH\'/'+?91!5-;
M353.R:FF^-=L$Y**=4\#<TUG7N]=G(*,O-FXESN<OI#T$ A=GR9[)7$4B,!0
M(;+OHHR#,5!\"@,(AS;80$&J. T7&;E%")79\2>%)<2<\O3;[YE9MGBSCG.F
M=,<G<U:ZYUSK_P!G1=8)[:XSC.,YTW3B^N^FW\OUQMIMKMKG^=KG&<8S[Z12
MR02QS0R/BFAD9+%+&XLDCEC<'LD8]I#FO8\!S7-(+7 $'(57 /:YCQQ,>TM<
MUV[7-<"'-<#L002"#L0<%5_7E\*?),V*4(I4U506MPL(O(=,[H'J/YZZ<VA3
M_P"UIJS.UJT?:R-=T,<OY<6AQYD12<,E!C*-KC&#MHR>*LW'83>UOM%87$:G
MJB7-8T\5+;7@"/ ;PA]$X,<<#C<P-=)N9"XDYP7^%[ 1@VV(XXL8EJ&X+N9)
M$H+@-\!V0W_+C 4QZ]^.?A6L ZX**\JTNNP<O-WZN\RAK"RB>7&^N-<_8<LC
M65FTF^NN/HFS2(:,T?KG\)#3ZY^NM:@U5J'5,L$U_ND]Q?2L>RG$C88HH&R<
M'>&*"GCA@8Z3NX^\>V,/DX&<;G<+<9"@MM#;&/90T[*=LA#I"TO<YY;GAXGO
M<]Y#>)W"TNPW)X0,E9Y_H7\=_P#"?S3_ /8FKO\ TM[7ES\GQ/Q*BMQ'\7_/
M_-W+-04C;-+\WV]8< "EALGL=Q2T*(K2EV_E!TVV=J/9+'71Q?+8>39CL;$'
M"JFN&>-$\X0U2UP4EQ))R=_-2I_T+^._^$_FG_[$U=_Z6\49/B?B5%C;XP>?
M\]M)=(8I;F_%3Z<L.*1VJ+^"T*_+[6(K;3:>)V/^G?MW]M96TC2*D8_.Y:_K
MF-%/P,./R&=D_%/$<8R>><Y\E*?_ $+^._\ A/YI_P#L35W_ *6\49/B?B5%
MKMCXPN?NC^5[HI"IZ5YOJ*Q+%BR02*V0WI:%#EXD0T-"B.Y)-[&XZU.-]MFC
M)RT^\:X27SASG7.WX>RF,E(<00221ZJ4FO%W'>-=<9Y/YISG&,8SG^!-7?RY
MQCZ?7_\ E;_Z^*,GQ/Q*YS/D/E,;MKL)YLHD'MARU=J; *H@X'9TJSRKEMH^
MV#@V62#73*RN=F+[+ADK]^?Q6^_\GTPMYTY8=1"@%]M%!=A:ZZ*Y6\5]-'4"
MDKH,]U4PB1IX7MSN-VOP.-KL#&:LVI+_ *>-<;'>+A:C<Z&6VUYH:F6G-70S
MX[VGF,;@7,<0"#L]AR6.;DYCG1'Q^P.OIUT?*;."0.R!EF7\1LRG@JX1RLUJ
MBNGD'KX*A72+$C]PW1FVEL9DLF28#F_Z,C^Y7&B"&F[I_HKIH[&NRL5$=4-!
M::[^.:2H:XVZ(M[V6I-6YSXCF*0"8GNV2,='##BFB:RF A&XN[9>U-U,ZD.O
M-2=P^".G>T7&4.[J.G]E:&RC$L;C"!WCXWMDFFS4RN?4N,ID%CC/C_"F%<<I
M<V85QOA3"F*+J_"F%,;?=C?&^(M]V-\;?SL;?7[ON_E^OU]V6         !@
M #8  ;  <@NM"YQ))<23DDDDDD\R<\\]5)/TJ$\1/$3Q$\10H[$XDA_8J4$2
MDTXED'Q$V4ZB1K,8:@7G[OJZU&\;:V7 WF#H]_\ I*DC1B$=_)287^&4![LU
M]FR;C#M374I!QGS^1'(KL9E\=_ ]BRL_.I_Q7RK-IK*B[V02>72N@JN/R21'
M2*JBY P<-E(NZ(E2;Y9519V^?.5W+A7?9153??.<^)D^)^)6O))\3_QN29@B
M.WXPH:*MT7R)#96KX6UIU^]7;I+I()E2M3[PLH98I:.5\Z#"SQZ-U54ROAI^
M/KJIKL>GM6ZBTI)52:?N<MN=6LCCJ@R*FG9,V(O=$7154,\0?$9).[D:P2,$
MDC6O#7N!Q]?;*"Z-B;7T[:@0N<Z+B?(QS"X .PZ-['<+N%O$TDM<6M)!+1B,
ME<_![Q4+F%U%+&I@%((P8N-C)*)$B;-N9):'5-I3]3""$+EB7[I%(D'ZMTB+
M=ER&R[F3+8C<GC[#,@3;-_VV$VT]LW:06EIU%L8^#(M5E#ATXPX6X.$G_P @
M>N<9 (Q7^$=/9!%!N#Q'-55D$Y.V._QP\ML=.>"09>[_ !A_' KOLJOP7Q^Z
M74VV46=/.=*F>/'*N^<[*+NGCJ*+.G;E;?.5%W+E55==7;9593=3?;;/6E1/
M-53S553*^>HJ99)YYI7%\DTTSW22RR/=DN?(]SGO<22YQ).Y6Q1M;$QD48#(
MXV-CC8W9K&, :UK0-@UK0  -@  M&7'\1'$TQD//Y"ON-N-HF)@%XM)Q:K#^
M U=!_P!\UHC5UIQ=>&_EP\&<MS_XLVE,(DGZ)(-V8/?]M_J>[K!06+0<?)?3
MB.^YY;;^86\?]5_\;?\ P"<;?\M=/?\ I#Q1D^)^)3_5?_&W_P  G&W_ "UT
M]_Z0\3)\3\2M'<V_$/Q+6])02$W#QMQM8%D FA9*3S#^ U=2/]:7=R$N18*_
MK4D@S(V^_*B7;!A][]JENE^5_+HXV;HH[[$+CT)^)6\]/C#^.%'?15MP=R$Q
M<I;:J-WH[G>J1Q!HOIG&R3IB08Q5N]8/&ZF-56SQFX0=-5]-%VZR2VFF^OTA
MED@EBGA>Z.:&1DL4C3AT<D;@]CVGHYKFAP/0@*\4TL,D<T4CHY8GMDC>TD.8
M]C@YC@?%K@"/,+3CKXI.4,].Q"TQO-_/ FH8_3LWBY*NAD%%BVQ>S)#,HF4#
MR(C$!X!&)&0;*.LI;ASH5<[[Z28N@93#N2*[HNADH;[>*=KVPW*LC$D$E.[A
MG>"(I:H5D@:X'B8Z2HS(][2'NXWM+N![FG(Q7NZPL>R*OJF=Y&^%Q$KN(1R5
M'M4@:[/$QSZC,CGM(>[B>TNX7.!W#CXPOCEWT2_.\+<G&'.B""*I20T)6DC.
MO\MT=$-7)<^=CA T9(*Z)Z[.B95^\(/5OO<.W*ZZFZFW JJJ>MJ)JNJE=-45
M$CY9I7G+GR/.7.., ;\@ &M& T  !<&HJ:BKGEJ:B5\T\[W22R//YGO<<DG&
M /( !K1@-   6)7S\==(GZ(M2'<YU55=06N_JN71FDRXUB^A]?U_.W$8)#8,
M:5B\39NP3$,$.N&!%^@RAQ7571ONMN((K_\ 8J]27_L3[+M3W.LO-ZTA055T
MN#N\K*N.HN%&^>;N^Z,SXZ*LIX3,YN'22]UQRR 2RE\OYCV98.VOM0TS;:*S
MV?5U?36NWM[NDI)*>WUC88>\$H@9)6T=1,(6G\L<7>\$41,,89%^1;-6^/;B
MDB.>!I/S;5T_#/U6+A<+9\>1LX+JY')83:NFH>?;2(8R=Z9RHKEVS:(.=U5E
MMME<XW^W'-TCV2=GFA:^:ZZ7TU2VZY30>S.K75%;6U$<!;&U\=.^OJ:GV43=
MVUTYIQ$9G%W>%S3A<+5O:UVAZYH(;7J?4M5<;=#,:AM$R"BH:>2?C>]DE0R@
MIJ7VHP]X6P"I,K8&@=T&').>TYQ_RASN?)RJ@^:*&I23&A&\?,2&J:F@L -%
M 2CUH1W#$"<6!BWKP7N0'L7VS!PLHUV=LVKC*654$M]>QUUUDGF2?>I&>*$\
M1/$3Q%@=F5A ;CA96O+-C ^7PXTN(=O@I'+A/3]0CQH?)(\69/&2[4B*-1Z1
M"!1\ ;%NV98(;&#RPMXT?LV[A,@.-PNWAD-BE=Q&+P&"Q\5$X5"@ B*Q., F
M:0\-'HX!8(# P86R0UU1:L!H]LW:-4$]<:IHI::X^OT^OB$Y))YG<K)?$4</
M]&N+_P"EUGL+]?/?O3/.&.:_VM]!_P"U_P!KXLW-H?K_ -?RGZM^O?JV?T[Z
M?GOT_P#3_P"7\I^9_P"V\4YVQYY4C_%"CCUOS7%^ON>;%YTF9\]%XU8Z,;0)
MG8Q@?L=8:QF8QZ9M<L,%6CYAG+A]'6S1Q^8:JX_*KK_A_8M^&IH4@X.5([Q0
MGB*./.O-<7YP5OQ6,GSQ[/0/1UC]*2+!W _& DHLIG&F10 %_3VC3.0(_2,-
M=V&7WYDAG=PX_,.U<?AXT*2<X\AA2.\4*.-H<UQ>T[]Y@Z"+'SPZ1\M$;@(Q
M,(.P/R$D:MQURM6YM.19<M%GV$Q0Q;9^+_373/;+_&,.\KM_JEDISL1XX^2D
M=XH6 VM7XZV:NLFJS#YZ,$V9 9C7Y0D-PADB/'3..D8X^?,,.DEVV7K1L257
M:X<(K(?CII_C)*)_=ID@V(/@NLHZJA%%4K4%(Q\D1,@:<JZOZJ"%S&&V"Y41
M7L3$Q$:2*X9(MF>"+YF(1=/L-&[=M^955_ 122^S34I)R2?$Y6T?%">(GB)X
MB>(M%=!\W5%U%"F4 N4 5.1\8<VD8I0!+YA SXDNO')%#"#D5*H(=CDD'8,P
MN82V'FD6A5%$K&9.<#O-%6K]73)2"1R^]\_4 K<@<0+CX@6!",&PL*$',1 @
M8R2U09CA8ULDR8,&B&F,:(MF;1%)N@EKC&J:2>FFN/IC'BA=CXBTM#J880^[
M;JNI X\>D+G!5*#?@E6B*3,&G5#&8,F3AF\T5V7=[F-9>NHZT622U:[,DL)9
M4PKOG4G3'K\\?PMT^(M+7E3+"[P$' D3CP"E";II6YF[ADT1>*/W],67'+)'
M@UM%U4M469QW'$A;QWIG=9HV<J.$$E54]=-BD''P(^(PMT^*$\1:6H*F&%"P
M(I QIQY(6Q2V^@+9W(/FB+)=)[?M\V1>Q,/J@W563V:QTE8[N/L76=\+/F(Q
MN]<)HKN%$= V^?S.5).?@!\!A;I\4+2LCI@?(N@:EOY4X\;$ZGJV\JO91U-H
MBHP,,[ODE%2,B6=/ME=7#9R!5HT<U9-D45$GB9]ZHNHELS0U5)TQZ?+/\K=7
MB+65UUHTNBFK:IT@4<@V%L5E/*T>FV;=)V[#M)W%2L6<E&K1=1)%TY'HE=W:
M#=95-)95'5-1333;.V"D'!!\#E9C& B<9C<>C:*^[I*/@Q(1)TIIJFHY3%,&
M[#1=1/7.VNFZVK?"F^FNVVNNVV=<9SC&,^*%WGB)XB>(GB)XB>(L L>T8%4D
M0E4YL"2,X_'(9&B$MD"^R3LD1;@1F=-'#MD $H/CQE=5TJW'CQP8:_)%2KMD
M)&-'9)ZU:JD5*,4M?Y(NA.J:T;1IR)@49IEO#<W *;L)9#*REHF3&R99W+BT
M5DPDS(&,DE%2R(4SDW.$ZD8^ZN?[;@,?PWW>UI:NEN[E;;'F<XZG;IG./'?<
M'U&%?&]?,AK-R0(O&H]@R04<O'SUPDU9M&R.F5%G#ERONFB@@EIKG=157?1-
M/3&=MML8QG/BJJ@.\>N;R'+3ZKN5E6)M=HJ"IZ4R0;%;#82ZN[O-Y'3]LRB\
MD:A3@JT(T\JQ-\$M]*F8]*K7YC:R(1=#\1( 862CHB5@.6>O+./CO\1G8^*G
MCR#'^@(M0$& =-'&DBMD6@^9E"B9!N8+. Z#Y=*.[2LVQ1;BR\NW$:-EC[L4
MDJQ2>*[,-2TF79+RHX4''3[^9^I_987V#V[6G&($8>L*,V!)4" &:RQYF%1U
M0LUC41@HUJH<ETC=;*I;)1X<?.0\$=5!MCQ:,#Y1F>GP["N8M-97'2 9Y<^@
M\3X#[^9 -8M!])=K6GUU ;;@@BU)WSU=4D?QXX$DL7G4<J*)4[J.@DJC?Z?'
MY34D!-4C=5,MYO,7DJF,]+%!'48W41'X#B1JX H4>4D#'0$>F<[YY'<9VQS'
M/;?-_))\D+'/R:Z3Q= <R=/ED1S%V3(+)-$%'"B3$:/1</R#Q31/;1LQ9-UW
M;M?.C=LBJLIIIL550A=?R3[]6JN>=.8Q70D,FWW5;+)<VBPHS!;)L2H;.7N<
M(W$U!=;*"V+4U720X'C=:7;74]D\M$BK A10_ 0AV+SL',<Q(K\.-R01N!OU
M&-B-CY? G\I!-F7 TZZ-L/E^OY!U1&U -NZ:D!)(BZBYN %)N'$N/R8:>G*X
MDP@!(J^.25LGLN5C)@%'W.':*AE",Q1@89Q8,57  G'['Y@D'[]5I[JOY,JE
MY@L/6HY%%+2<2@G(JJA V5AZTELRB3>66V:9,Q@Q(3"QIZ=20J,B[M_.@HT+
M%]A-E(PZPX7")0]FU<V"(BA2&D@G;;/4=/\ G;RR/$9T'\:<][E>VC)8I?0V
MP9A4DGJD1:#^S;'_ %)TV'W.4VBF'CBEY8I75:!R](78T+2B9Q2H$X\C+^<U
MH<[ S!I%1\VAT49D.,;<\[8\//S&V^^<^2NG\54\1/$3Q$\1/$3Q$\10'ZUZ
MW,U'^V1%)H +*G2(UI9<U@_Z0;>9(TD1_<$7:$HQ9B3X954(L0[,FR/\'P-I
M'QP>\3L5/55'7P8T8TEL:*0/OSY\N> .9'+;WX'\8(_LQ.H"\AZWF>LT3FZ<
M3EU>$"^YO27J?JPQ\I)BJX:0Q2%R"#PR2L-89( -;2\ SF4(FC^S1KAC&X:I
M!(1%"EV.G3_OXC)'A@#GS4\+-M: U!#Y/.)_(FX0%$@OZ\7RBT?FC'Y%5XB+
M8ZC(R#;$)&>(%C+EH$!B @Q^4.G'C(*):NR;MNV4*H&=OO[\U2W7MH_)'?W7
MU=;CG86$P2G!E=-KB#,&TGB]4RY@;E4G>2V6KQN0BC)U"2S:HS;$6\H.7R9G
M=7-%_5< 9FMW-438A/IX5L- ZYW_ &P/WSR(Y;\KZ/%54?\ 2?RCBY45D_,%
M!B+;A5Y2 9-7T2EA2OI@DU.BJHN6F(+-@L9.QNOK28P A8B$EN&GPEE6&&%M
M**NJ!HL[.C8IV9AZ1I]_?W^RL&XW."!]<$CPSXXSN.60I7?&Y*.GS%33>+]+
M1F<#\5O9<@A-2RZU6S]C;<QK08I_\G;V;N^$!$)K+X5KMK$2ES1X:VAUQKCM
MYA%EI"-6UFTL([&=NHSTQ\N6>>#N.16[^H>M*[Y-"Q.06*#G9@7*"A5JHO"8
MRO(=@ 2."53\LE19)-5!1R-B4>1=RP\& :FIGB#@II-A47*QJ S0B#* ,_?W
M_'Q"ISK;KOL^_+\ICI6@H[;,OI*WI-2PO^&QF-3@)3\3I&PZMK@W9<,F84[4
M<4*Q*YZPEY"6W+"^IGDI*5):U;K,JWC+@N0DD-B&I6P "#SP=_,$XP>H.P(Z
M'<<BO0#/YQ'ZS@\OL26*O6\7@T;,RR1.!PQ^9>M@@!@N3*.6XL6W=$'N[=DV
M66RBU;J*?9IMMG&--=ML%1>?WHWY#+0ZM_6*MY*$=(UC/*B4=E;.A,;BT@ 6
MWB:,ZV>65"$V,N&53;=8RL!74NCC K-*DBDL+E^F:S,LWU8_Q'@QMA%K+??V
M>2MC',C?E_T<8ZC)Q@@YQL1=WS-*[;G%#5E*[VBC2%6R9CNJ\Q L6) .V_.(
MO7C5@;TCA==V:A^\J#H#I2O!CCQ\=@JYE6'FWSXJ$=NUB@['GE;U\4)XB>(G
MB)XB>(GB*/?1MV#:AK"3EA4B%L[#(+IP.M!V\)F=LK/K>DXETZ@H)[6=8JZ3
M^3-E<IZR V* KC7Z,.8&#RI(8*8.2C8I R?+KCPZ[G8>]5M\B3OO>]NNY3<4
MJ=L8ES>,=N*_F%7N)'N<AX D&JX,U-#*N(LHZV#6@HM<# 18M<WG%3FP@S4U
MCV!!+1&A++B<=KZO"L0T#GD[$>F_/?;;F",Y (V.3<\Z>LF7Y?\ ..VK3\VZ
M19-?S3A)O^9>N,[80:-_Q=]/QG2^==L(MT_N55SKM]FFWTSXJ*B;J_J'JR\I
M0WISD0LY;1">6JH.KFV8(%F4#EQ4-6D9-1RY8@_)RH022P :V [&6%4/3<;8
M-.>9\6A!7G6?'0"YL-(++*X &YZ<P=^O\;$<QS'7ANDJE"QFM95^WM]W'G]J
M(P^.IV*[B>''[97F>HIKB1[@MW39BX7&?JOYG#1TJ/&9=I8U<X%C-5<,&Y4]
M%"WKKY):@X\EHV&SN&6F??/5JO0=F(I"#T@ "G%L62+@43'+ZQT<>E1 L<8H
MV ?BZ(.*%!<I*UJ:K<>93LDW%8R8*P:3\">G0$_MOX9"B?\ '_97=1/HLD.M
M5K8%B4E9U?.Y[*K#FPR0#X4)GP@X>C(::4&[*US7J<"KRP00.-"'O*\H9O[1
M@1YH5L(U^FC2*LJMXAQ@8QS/+]^>?(^'P%OMM6;'::K>7VA+-'^\<A8G<N6_
M3D-%EM&VJR+?\====5L.$C&ZBZ:YF1G7PN,Q<.F^D<I,!HZ+*%695YJ@>_._
M[EZR+F!/'3?I&MBG/1Z;AIQ#Q%7V PGPZX@E><^V/$)'/@:=/S4-;$"I^0S&
MS*BZ Y1@DN4LJ98< YI%D9,!+P<JF5P .>#G'7UY;\R-P2,>*OJH^1V1+Z<J
MZ4W##6=>6K(H%%C-B08>]V?L8G,B(9HZD )JYV5<;Y1'DE'"&B*CIZHUQK^5
M4?O]T=GBY4/,XW'0\LJJ[JOY3 (8U/>:J=&V5";[+YM:+5E8TAJV8&H6[/5>
MQ02D)<1B+5_;#H>R9R],E 2)N=P9%C EW,3M21Q8]5LWKE_/WW]Y5@WD3C&V
M=\8!^&<C<8SUZ@XWG\:\CZH<16V8!T5$[*'1BLIK^@4W+;J</G]P%(]N3E")
M&"SN5.Q 5A<3FO6(V++BK^BS9W%;)%S% 2W/S&0P>33>2D=CF#SY@#8>GAGP
MZ?(68>*J>(GB)XB>(GB)XBA;UGU$[IB/!&=5.85+;8(Z2R<,X1)TI#I%CE84
MN2%:7FM([1!??$*'3"(EF$886G:[A.O(]8!@ "E+?5L^?O1!2!GT_GEZ^G/&
M5'CXTU>VI%M:=D=+2,F2KBPC#\S70.<L2H"? B"$A(CEA^:_*@@A"JVXM@R6
M&2V'.W1Z/_N5%GI6[Q_%A#BR;:(<;>/7'+I]^_W"RF<6!"JUC,EF,\DXB+1J
M'Q&4SZ2E2SO1!(3#(2.P6ETD<(X^]UN)CH[9-T5=((*ZM-%F^JGTW<(:*%'-
M4:2BY_D:Z&Z1K>)TPNT@ 6O"LIFI)TL!G-;0V:0$P>BA>NU[@ALT EI=#9M$
MXH>$1RYN=Y\^C4Y/Q.4![9HO9TWGK&8T05P&@9.^?D>N,'?/0[C.Q&V]_?BH
MJ;^M?E'C4*.3WFNL&-B0B_#Z]L5S5EGR"J)G*H"QG4'JZ3R=Y)TAL.A%G'%!
ML.E@Z.")/F6P1!J!BLU@]WJ@Y=34JC!:5BK!IY[8V)W Z^H^\C.00-G?&Q)^
ML5T+KKWH2'V>/@$!D(+^#,LO!\\,6]NF>4DBLOK.53=2/QL1= Z!;#XZ<B=T
M14>L"-QN?CH,\-2"8U]+"&I0<;>_..N_/RSX>6>N%+_I+HV)\QP49.Y;&9[,
M$#$K$Q,;'JWC*TIDSUT];D"Y)PT':KLTG&XB,A#YML'2=;2*8/AK2#P 1*K$
MDL3B1P@&?^=O+Z_\[*C(SW#UOTI8L Z:XK#VM.:T9.(N#B%5MHS.1E7EDCKZ
MRALTBMRAR=0BW,C:6ZI!X02J?JR-SEY4]".DBJ$D?"ABDG$W25@T#(=\1\O7
M'4;$Y'D1Z/C)5N"#EC;Q%^X:!ACXJZ;B1K\R47;CVJKM=$:(%MW9,L_421VT
M9C1S1R_?.-DVK-NLX533V*BH.OCY(GG4SY3G;F09T1#9>P7K"9SEK"!I2'67
M9%2V:QOT6&'TY=8^!6;4, +D=(I3O0$ F)^6, MPUF7D%?QPV(E@J:,0A7#<
M9)QC?!Z9!','!ZXQC.X\LVC<)3CHBP^8*WDG4T;3CUR;MR@TZYQ&#L"<S$:'
M*.QH"P"5<2@:'DE<%9J(;-3I*%'1(@D'=NE,K@8UAQI&A!5< "<<O7/S&RE[
MXH3Q$\1/$3Q%AEAV##ZIA$FL:?&-0$.AXIP:/E<LR)-5NR;_ &X_#9B@[0@9
M,$G:VZ3(6%##R!@P2<-1@I@](.FS94B\]PAKTU\E\S69FSE<-:^"."(!O,PE
M'VI"X+8M%FA)L0L=/C[ >Y)2]S)CNLIK._\ AVZ$H;(H@./0R[:3LP4_"1NQ
MY05]F@$$YR.HV(]/#8M<,CF".85]M-TE6M!1#>#U<$(!P;@N^D!)P=E<PGLH
M/GB*;5N[-RF=6"?E,WEA?=DP'"TB4ED15ZU#"Q(5JNB)%#F;8J9RJM^Z>P9F
M[M;7E^AI'"Y&S=L7D6Z%&.N;[3N>95GJX; "K>7Q@.FJ$K.^8H*2ED.%WG54
M+.+7%6T%DCRRPC$OD&581\K ;9/NW&_/SR.1P<8R,'FMX<2<$#*.PQMFXVR4
MFZ&4?.7[8E^_["FXZ#H+PL7 4F.Q60FV0*U9D$B[(C!HYT)*ZX"7N\I5U'JM
MGLLEZP Q)Y5 ^]_O/J=T)SRV'NWW^73(Y9WZJ4?4?4-6<D525M:U"VC1BCEP
M/C@1)PT:DI;)=1K\FU L'9!9J)$H[-1SQ\9D\B?B8E$0;,A)98:#@!CX@A*@
M#)QXJC=N^[7Z4Z]JNPW<'NIA7V>C$!YJ'2/=O^S:K@$%5AJ1^-*#&L(?P*NI
MU&X7/[D:F;?0G]@PWM&D["3@\(>G%I%'-^?BM^4 CKXCKL3ZD<MML'&>1"]&
M<2B46@,7CT(@\<"1"'1(,.CL7BT:&,PL?CH$0T28B@P40.1;L!HP<S01:LF3
M1!)NV02T223UTUQC!45,_6W;QB\I :YDY,:VA(\A[-CU=6_952RT3!WS]0F*
ME&QVI(C/TF,DF50GS[9DL1K[H)Y#6512B6P&65 *M2,3)^S*-RL!@9./$ Y\
MM]N>!G(Y^16\OBSJ2PX_18^Q^AX&F,O@F<L!F.E<AA3:'S3%?3$O'97(F36/
MDHM&IG7H&=6@./62?@AYF+;O9T5+S8/#JXCDACM90@CN9QRVZYY<O@-OYYG<
M_6W;D(YI?P^NQH.0V=>%E.'+:'U;!-0#N6:C6\;ETF=2+5E)S\5"F"/Z9"I#
M^RJW:R%O/+8.C5X[ Q))1F=( R@ G/EU^'\C/0=55_P?4O2-M="-I'U)%I59
M]2&:!!3.0RVUD<RR'2ZR3!VM;"C;N'+R^J8&S*U?+I8@4NFK*@1BS"9<;3"+
M20 N0AH^VEJ_7??W]^JLXXY;8)Y>&,$<R01R)S^;W+T0>*B>(GB)XB>(GB)X
MB>(JU?D)[&E?/ J*06BS$/+=%2Y?=V$K&3P&P)4K*(T3 3AFPU"RR.J#:\K^
M<?K,>(RBOQ]RR6+Q.V]JYEU<LY!&%WCZ;Q%Z*0,\]AU/AN.G,\]\9(SE:%Y$
MX":2\TSOOH;+>9"E\1P_3D51%VK5+# +#Z,6+&Y$<J0B<B[VMH^5*-8^3F/&
M%DA[,J.N+Q@Q"TZH;P/26O(NU*2<9 \\G8^/7&_,[CQQOLK;K'L2'U/!Y+8L
M^,X 1&)CMR1DG@>4,+I)952;-FS *#9D#ITL1?.&HX.!!#R!LX5=LQ(A@\(O
M&S94JKSVQ45TK\G,I5UF!NN6U?AMT 3B7QREK5@D(G5-DX\72&RI=I.2&I.Q
M1-D29A.H5</']LK0*RJ((&Z_N*G+(9/8Y'+3LDK;#Q^6=O=MSV<"<^&^!?Q4
M--5W1,-2@=9!GXB/ZE"AQXJ;E$LG,F.GC;G+LL?E<YGIR33>8'WZN=-')R4R
M$P5W;-VC+\WAFR:((E!).Y_CX ;#W*MWMWO1R*)S_F#F;622&]A ^&;3:9Q)
M07L/J9O)YP!#ICG^JS"22S?24-=WE=R.U*_KVR@W,\HG<"FEJ#A0G9PHQ*0!
MC).!N/?^V-C@XR,X.5T?Q@T=:0MW<4RZ.KR4:&XE<!-*BI)<K-H8L\4R;1HC
M79\^O)C$8$2"0SHC7C6%UE8-W1_<9#KZ'0H/)!@Z0D=)-;-KOO[^^2.(VQU&
MX'+//TQORZ;^0%B_2/1U7<JU)*KDMLRH,C49&D7:#!BAEZ?DI)@*?ETX_'!N
MNVF7A1TS&O7*BSA5H("C&A"02,F&C8DL78E &3CQ5"DZE7;O4W0L6F\4A=T"
M(9MT;5$<90W)8<]@=70 )':TDQUXFO'8?(*Z9SB.'ERW1U6=<C[)G58W93,P
M7YV+@)"K)GU.L2ML 0? D'J3DXR/#;!','?IE>C>)Q"$UE$Q\3A$;C4"A$::
MN=14=C0H;&XR!9;N'!!WJQ%CD68P8TRY<.GBVJ"**.%%5EML8SMOMDJ*A_J[
MMVR>K=G5><4M[G<0N*G9WJZLZI3#"/O+1E=?5HWL00-B9<9#[/EP%Q!9"ZB$
M^Q4T^@$53ZTJK)W2M'5EQC1:"6)'N_@_?_65< #G]1L,X\>NXR.7/GRL:^/&
MGC%<\X5N;LJOA$1N\I$E(O*2&L;8@I#FNHQ/9\2IV'[-=F^TDBL)BT/E";B"
M5)*#$@,4X)-[UZ2-ERH,@5>RJNQDXR1GK\_7UZ\\#D)X^*$\1/$3Q$\1/$3Q
M%'3JJ^HISE24QL.33<5 'OZ48$0H^8K^>VNQ0FZL>-%@R[RM*O3WG\T#A6X<
MA*94*C"C%XWAP"0EW)8*-&OB[$I R53O2M&WYWU96MN="8"0N#(25PM8T2A(
MNSZZ9/2L2)@"M8-(',@AZ,O[-_$A#N"6)3?94!E-67[2LHCTYIRQ8HH&D+^J
MH$5M@-MR1Y<L<O(YY@@@C!!&Q-\=?P&'U9"HS7< !-8U#(<(: XZ$:*.5TF(
MYGI]J>JCM\NZ($'B^^5'1 H3=O"A5^NY(DWCM^Z<.52HJ+>E.E;=ZWN"4<[<
MY&H5.Z@PZ=,A$E&53?$3E@:VQ -'5O!)%;B&!Y2N83-!S">FZI[DH<5+(C!I
ML\AD7FP[<$N-4MXK@ #)R".8R-QGPZD;9:2#USSQ9MR5QI ^9!"AW.J<GN:2
M#B+6?V1E0\Q:F53$F?RPRK'X$O(BE?UHO*CCQ.366VJ&-5W$+%L31]/GD,$.
MGC(2'*I.?O[]V<KE]6=F5]RS^PH\0#%K%MJUCB8&L:?BQ6,!)+,G>F<[N=43
MTW-1N$@5G6J>XB)MY1) N\YFKH-!HOL_D!9)!(@&<^0SU_;*J!Y(K;IWH+IJ
M*2/I2)S>U*-G5-S _9).V 3EW7DFS,]24>6" (W.JNBS.!UO.EHC4AJ0<=OQ
MY">55:U6,K <'XZ)W./N@"L< 8!W!V.2,^X<R,D [9&>?3T7%BPJ/BB1PX18
MA@@4>[*%BQ-T@Q&BQ@]NHZ?$'[USNDV9LF35)5PY<KJ)HH()[J*;ZZ:YS@J+
MSP]4=B7!V5KN"Y!#W4QK&*AK[51D,2'HN=;0FM=2"%QL#*#$.#PNRY1*8C5T
MA:R)G;/%UDQN 6!?-47#!YO%0DK','PP(5P .>,Y'/.V?H2-P>A'0JV_A^IR
M%;\]5<0G<!'0J[Y'6->LK;4WU&OY6LZBH=9A$XM*)6V1W,2=.N8^\3A\<5E)
MJ6204$9(##4QEQ=$A)RY5/,[YW./C^_DHP]T]\YKY>=\Y<\[FSW0[:"%#1^5
M1ED*-#Z'0V<1%F,D4G!.V$@D<D8X7FD>TF)*N*^MM[2,>D(NS;'A.\:R.8'1
M^_O_ (/HI#3C/3/7KU\N@/49Y#=:[^-:B+:;SN\)3TK7$QVT@]@QK>C3-XJM
M9G8(J21L79M<DS;F;G8N+*61849J4C#ZYWZAC&[89;E:/(W!5B<Y=U8^L.7$
M=C;!YCD.G7W;],G'O5T7BJGB)XB>(GB)XB>(H#=^];$.7ZZ#IUW(*]TOJ8O4
MG-8P.RXO91N)SYF)DD2C9T,=EE<L7J%.L29J>0V)C+:L+*%<1Z7RN,#I.L@S
M,;OV!2!GT]1S/+;KZ#=0DYIX3(]&GW-X=4HNI% Y(/D[L77).+V709HL=FRP
MAG8R4XJ$9+Q/\(7SYY'3=>='5.%D5F\T]@,A<!N K%&LA;EC,R*2<;#TZ<@=
ML'KY'8@;9(5ULTF46KB&RRP9N;8QF%02,G)A+I$2WV2&Q^+QD6Z,GC+_ 'TT
MWW39"Q3)T]<[:)[[ZH(;YTTVVQC7)5YKSY&#_3/R.64>A08Y#AM<10]-PD$L
M070]MUQA_7;B9OX=9*LK7M-HX(#;'KETZAU=] <+WQ%&M:=.5HW*3:&2=H_<
M!2E61O\ ?WT]/X5]F^?+KOG'KRZAPW'R5X//_.U7\UPM:&5@!5$MBCUF9DK]
M]))S+RI\ZSCP2+-G3F061+9U,=Q@F.1P%&8H"?RHFPB$2"!(J"_+!A#)LG*J
M23S^^OUW]=U"3N[O=O4Z4VY^HI8P<Z.>558$C5DD8%"Y0RH%$6.C+(;/Y3%7
MB!0Y.T8Z2GL4DLPC%:PVU)= J[V?V7*J](1Y ,(EA2!G<\LC/I]C&Y SME::
M^.FB[D<6[>TCZ6K29[Q^%2&N7]+DKT>M+#F@Z= $;$$.G6T^.PX(XM*6UE$S
M+8%$>EH@W&)RJKK"!5$:.3M_3+<L((<8&.9SG&,8VQR\>H/7H,JVVV;9@%'0
M"06=9Q].-PV-(MU")#+-^3=K.'KM >,%B0XEJ^,'#9<DZ:C0X40Q>DRA!R@T
M9-5EE==,E5>;KH2Y>R>W3"$WHNO+L801T-J1&O:V9'A3Z';,9^+DD["2TX^K
MD#-H-*$K!+Q2L)C2_7 6VLB^1;-@IIC+1$>(!#<6N]S^_I_(5P .9&=SGPY
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MH\>+%H/,B@8T4$:#QC,JDY4..AOD[I&@[PJJF,(M[!4G4C.QB72:(RL,_;0
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MB>(GB)XB>(GB)XB>(H"?(U!.I)_06XCE60'F4KUD@1.3Q.)BJJ>R.?1$L29
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:*;/BA/$3Q$\1/$3Q$\1/$3Q$\1/$3Q%__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>img187419207_17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img187419207_17.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'S!)$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M 5:*** "MRWCCBM4RX9<9S6'5VRB$I0;SUY - &S"N] ^< ]*F*X6@+M4*.
M.E+C/>@ !_2EW$ ]/QIIX/6@K0 UER.OY5%);I("KJ&!]:F*\=>:869,>E '
M.W,#6T[1M]0?45#6AJ[!IX_7;6?0!<M?]4?K4]06O^J/UJ>NF'PHYY;A1115
M$A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MWL,&1MV/:M4XJ*%-L:J. !BI@IH 3C.<TG![T[;VHVXH ;CWI>/6EV^]+MH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!TOA#4+"UGN;?5)1':,$N5R
MI.98FW*O']X;U_X%5FYUZUN?";S27!;6I%-BZ$'/DF3S=^>G4[,>E<C12L.Y
MW::_I27J2RSB2-;O3Y" A/$=LR,V,<[6(X[XK)U6\!\*06,VKI?72W\DVU6=
MMB% ,[F'<@G%<U118+FO97T=OX;OX1-LNFN[>6(#.<()<D'V++^==I!=6\?B
M7P^;9@DNKW<.IW0"G]V>BKCN-QD;Z,M>:5+]JN//2;SY?-0 ))O.Y0!@8/;
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$D 'D9[UMG7M5CB\H6EJ%'*A2W!SGUY')X/%8>J7EU<QVD%S$B?9HA&A4?>
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M!P,G'85GJC,"54D#T%7M+U:?2'G,<4;^:FQED!Q^6>:/:L/9H=N7&=PQ]:5
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MIU#=W<V2L@HHHI#'QQ/*2$4L0,X%6!IMRRAE0-GT--L;A;:<NX)!&.*UAJL
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MH ***TK?1WFT2XU5[NV@ABE$*I(7WROC.%"J1T[D@4@,VBBBF 4444 %%%%
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MQ.< <*..IQZT7"Q@459OK"?3K@0W"KED61&5@RNI&0P(ZBJU,04444 %%%%
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M 4^&)IIEC49+&F5KZ)"I\V9NH^5>/SH TT@5$4 # & /2G@8Y&.*?VS1G\J
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M[1UQ'(!]UNX)]QC'TKQW6E N4;U6M.:$TI0V?]6)H2E*"<M_(SF=GV[F)VC
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M5;O_ #(/_<4_]I4F-&%6YH'B$:+!>QO;F8RJ'MSNQY,Z@A9/? 9N/IZ5AT4
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MV-_E_ND9% '7^;LRQ...2:P-3U;S%,%N?E/#/Z^PK/N+^YN1B20[?[HX%5J
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MHYX]@Y9=RY]FB_N_K1]FB_N_K5/>_P#>;\Z-[_WF_.CGCV#EEW+GV:+^[^M
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M]I]FEX'4[MP( V^]8&Q1K?TBS3[.LQ7+MWJ#^RH0F,L3ZYK2LU:*$)GA>,T
M7CLCMQ$B_.Q#,Q[=< ?G38BD4\<DD2S1JP+1DD!QZ&HSG&:4EFP.N!@<4V[B
ML,U/3K2^\.SWD<4<-[:3*N(UP)8WSU]P1U]#7'UVUY(GV6"*(,N$_>@-D.^3
M@_D0*XR4 2N ,#<>*<MPB,HHHJ1A1110 444=: "KFF1))?)YB[D7DBI+?3I
M)(F#H58X*M6CING-;!FD(+L.@[4 :<1&TC+ _P ('.:LEL*Q(+.1WXQ1Y+01
M12B.6-9!\LC@@-ZD'TI Z1NX9?-)&T%LC!^G>J [&QOTT:WN[6WD NI&BDC)
MC"LBD@L&/3T(Z_A7*?$\K<ZN]S)+)+=,J-*SCOTP/;%:MY:P:M>12V%Q$KR'
MYD 8X;C&1V].^<9KF?'UV7OX;>5T>\2,"X:,@J<<+C'MBNNK3BHRE;KH]]/)
M_<<E->^GUMJ<=1117$=8444X(S=%)^@H ;15NULFGD97RFWDC')%7'TE'0>4
M2&]SQ0!!I=D+F;?(N8E['N:Z2**"%!B($_W>@_'%1VUHT4&Y4(C7"[@. :F/
M!P.>*>J 8\:L20H4GL.E4KJRBF1@T8WXX(&#GZUI;D*J%1MXZ\\'TXK2TB.T
M@U>WN[M&ELH9=TP6,E3QE5R<#D^M%A7L>;,K(Y5AA@<$4E;^MV*W&H3W5LJQ
MK([/Y>>%YX K I#"KNF31Q7)$A 5EQDU2HH Z233;>9681=LEE&,5E7&ERPC
M*9<?3FHK:_GM6&UR4[J>AKHHI8KF#S$;.>V* *VGVL36<1\M6)&3D=ZN-"N!
M\H(^E/A18TVJ /:I. IZ[NWI0!5-NC')0>W%8^L6B0,DL:[0^0V/6NB ZY..
M,]*R==Q]D7_?XSWH Y^BBB@ HHHH ***<J,Y(12V!DX&<"@"1;69T#JA(//%
M=3\/=&34M>:6=%>*UC:1D89)/;'T)!K TZY(86Y&0QX/I7HW@>ROVU 7-EL1
M5!5W=<CGK_2MJ"O41CB).-*33L=SM2:SE=;6-W@'S)(I)E0#G'J>#P?PKP_Q
M?IUO8:[(UF"+6=1*@Q@+N&2OX&O?-3O;31[$22OL:1_*4QCN>I/H ,FO.M<M
M(]2PIBA9I>"V.5 Z8SZ^M=U=QK0?)TM:^_\ 7_!['!@)-OFM9,\IHK3U'1;F
MRGD54+1J>".3BLRO+:L>J%%%% !1110 5+;0M<7"1+U8U%3D=HW#H2&4Y!%
M&E>64"?N[:*5Y "6;/"UEUOV=X]WI]T97&]1\Q  XQ6!0 4444 %%%% !111
M0 4444 %;.B>'I-6+S33I:648^>XD&>?11U8_3I6-79Z;XC:7PQ!HXMDW6[,
M1*,9VDY[CKDG\!6E/DNW,B?-:T1G_"!:A%>"!HFE9S^XV8Q,.N0?3%6U^&NJ
MSWX62SGM;=FVF50)%7T[]/>NIT>RU">&T9KZ0QJ&1".1&0-Q'7TS[5WEM?06
MF@2:<X<W;6^+;M($*95L=L8Z^Q]:TJTN11E%==5Y?(YW6E=P;5[=GOT/F[6M
M*ET/5[C3IY(Y)8" S1G*DD _UQ5"MV^\/ZP\DU[<V\H5Y"?,D/S.<]<'D_6F
MIX:G/E&2Y@B5SR6)^4>OO^'-8N$D[-'3%Z;W,2BK5Y9_9& \Q6)[ \BJM24%
M%%% !1110 5=TVW\Z?+#]V" QQD@>U4P,D"NELX,1+'$O' ^IH N:?I,MY-Y
M5O;,\,A$;'RBV1U[<]L\5/X@T6UTG4I;%8F6)#R&7D C/:I['7=4T1)8M/NY
MK99!APIP3QC.>WX5GS3S,QEDD\UBY8AVW9;N3GKFJNK6)L[W.0/4XI*N7EF\
M69ARA/Y53J2@HHHH **** "MS188I+=F:(%MV"Q&:PZZO2T$>GQ#;@D9/'-
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M=VUK(2 "&X-5JO6&GM<L)&&(@>_\58&QJVJSW"FY;'V8MM0A3@D=1GUYJX"
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M6^YO\3"O)TYJ:VZGFQ0CIT[UB:\@ A?OR*WJP/$"$2POD[2",>]!UF-1110
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MI9S@#O7,ZE?F]F &1$OW0>_O0!3=VDD9V.68Y--I2K*%)! 89!]:2@ HHHH
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M@<@CMG(SWK)^U2>B_E1> 6F/^R#^_P#I1]D']_\ 2F?:I/1?RH^U2>B_E1>
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MW_TKH7T6S$9D77;,)T#,.IP,C@^_U]J:^G:9'9/)_:T;S!2< H-I )Z9.[D
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M%6/L-R5#>2V#TH KT59EL;B&-'>,@-T'>JY5E^\I'U% &KH]C'<*\DJAAG:
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M[N>.02"1FP>Y.*W=-O9[W)=,!1RP& 30!I@G'2KT&J-:P&**TLF;M*\ =_\
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MGSC^+:,?G0!TA5>QII';-/P2*3;0 F*._M2[?:C;[4 )C(ZBF,O%2A>:-F:
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M//1AZ&K6[Y=N3@]:  LQ !/ Z>U(32YQ4%Q<Q6\9>1@!_.@!MW=K;6[._P"
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MM=WT%G&6ED5?1>Y_"F S4KM;.T>8GYNBCU/:N)=R[ECU)R:NW^IO?3,S(/+
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M110 4444 %%%% !1110 4444 %%%% !1110 5N_\R#_W%/\ VE6%6[_S(/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5N_P#,@_\
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MPVL4<KGVJRU_K:*^ZYN\'J2Y)_ ULVT"P1")?NBIM@/;- '.PWFL,H>&YO"
M, K(WTJLLUY#&X62:-&R' 8@'/7/UQ^E=8$PH4#@4KPI(-KJ"/<4 <51717>
MAQ2G= ?+;TQP?\*PKBVEM93'*N#V]#0!%4MO_KUJ*I;?_7K3CNA2V+U%%%=1
MS!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6[_P R
M#_W%/_:585;O_,@_]Q3_ -I4F-&%1113$%%%% !1110 4444 %%%% !1110
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M2* ,4I.* &[:4KD<T@.<YI8P&D568(I."QS@>_% "'/:HG5LY J8<_2D;VH
MX[4EVZC,/]K-5:W-<LUVBZ3KG#^_O6'0 4444 36]NUPQ X4=35Z<BV@$,7^
ML<X'L*JVMRD$<@;.3@C%()VFO$=AWP !T% %^TLHT4%EW.#G=6BJX&::F"..
M!3QUR10 .3@ 8%-; '/-.(Z9H(SVH P+_!E#=ZJ5?U1-DJ>X-4* "BBB@ HH
MJ6WA:XN$B7JQQ0!+:V$]V<QKA.['I6W::7%;K]T._P#>/]*O10K$BHG"J, "
MI N,8% "1H.%R /4]J#G/0#%*5HP>IS0 !@2<@"H9)@ASVI[)T..M5;A&,3A
MON@'- $R2@G-9.NR96) ."2:HVMZ]I(XY=&///ZT:A=K=.A0$!1WH IT444
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M_6J=\'-I,HX8H<5H8%12Q++&5;.",<4 <315F\LY+65P1\@; /K5:@ HHHH
M<I7# J2Q^Z0>G^-=/IEF;6W^9BSMR?;VKF(SMD0^A!KMHU&/K0 H!S2\4N*,
M4 (!FG<<T@'%+C/- !BJ&K_\@N?/H/YUH$DJ <X'05F:UQIKY) R.E '*T44
M4 %%%201&:98UZD_E0!L641A@4=21DU.6Q^/I3D0*M.PIH 9P#TH#<T\X]:3
M;GO0 @P1[U4OD?RS*C,KKZ'J*N@#UI'174JW0\4 <Z\\LB[7<D>]1T^6,Q2M
M&>JG%,H **** "I;5BMU"1C(<=?K457-+M_M%\@(RJ_,?PH ZW!S2\TH-&:
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M!0@G@\4[!Z56OYOL]G(Y.#C ^IH Y1@ Q Z \4E%% !1110!J:',L=TT;?\
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M3W]16WS7%*Q5@RD@CD$5T6F:JMPHAG(68=">C?\ UZ -/I12\4I;)RQSZYH
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MH **** "BBB@ HHHH **** "BN[_ .%->/O^@#_Y.0?_ !='_"FO'W_0!_\
M)R#_ .+J>9=Q\K['"45W?_"FO'W_ $ ?_)R#_P"+H_X4UX^_Z /_ ).0?_%T
M<R[AROL<)17=_P#"FO'W_0!_\G(/_BZ/^%->/O\ H _^3D'_ ,71S+N'*^QP
ME%=W_P *:\??] '_ ,G(/_BZ/^%->/O^@#_Y.0?_ !=',NX<K['"45W?_"FO
M'W_0!_\ )R#_ .+H_P"%->/O^@#_ .3D'_Q=',NX<K['"45W?_"FO'W_ $ ?
M_)R#_P"+H_X4UX^_Z /_ ).0?_%T<R[AROL<)17=_P#"FO'W_0!_\G(/_BZ/
M^%->/O\ H _^3D'_ ,71S+N'*^QPE%=W_P *:\??] '_ ,G(/_BZ/^%->/O^
M@#_Y.0?_ !=',NX<K['"45W?_"FO'W_0!_\ )R#_ .+H_P"%->/O^@#_ .3D
M'_Q=',NX<K['"45W?_"FO'W_ $ ?_)R#_P"+H_X4UX^_Z /_ ).0?_%T<R[A
MROL<)17=_P#"FO'W_0!_\G(/_BZ/^%->/O\ H _^3D'_ ,71S+N'*^QPE%=W
M_P *:\??] '_ ,G(/_BZ/^%->/O^@#_Y.0?_ !=',NX<K['"45W?_"FO'W_0
M!_\ )R#_ .+H_P"%->/O^@#_ .3D'_Q=',NX<K['"45W?_"FO'W_ $ ?_)R#
M_P"+H_X4UX^_Z /_ ).0?_%T<R[AROL<)5&X_P!>U>D_\*:\??\ 0!_\G(/_
M (NC_A37C[_H _\ DY!_\74RM)6N5&\7>QYC17IW_"FO'W_0!_\ )R#_ .+H
M_P"%->/O^@#_ .3D'_Q=1R+N7SOL>8T5Z=_PIKQ]_P! '_R<@_\ BZ/^%->/
MO^@#_P"3D'_Q='(NX<[['G::E=Q@!9VP/7FFRWUS.,23,0>W05Z-_P *:\??
M] '_ ,G(/_BZ/^%->/O^@#_Y.0?_ !='(NX<[['F-%>G?\*:\??] '_R<@_^
M+H_X4UX^_P"@#_Y.0?\ Q='(NX<[['F-%>G?\*:\??\ 0!_\G(/_ (NC_A37
MC[_H _\ DY!_\71R+N'.^QYC17IW_"FO'W_0!_\ )R#_ .+H_P"%->/O^@#_
M .3D'_Q='(NX<[['F-%>G?\ "FO'W_0!_P#)R#_XNC_A37C[_H _^3D'_P 7
M1R+N'.^QYC6G::W<6R;' E4=-QY'XUW?_"FO'W_0!_\ )R#_ .+H_P"%->/O
M^@#_ .3D'_Q='(NX<[['$2^(;EUPB1I[]:S9[B:Y??-(7/OVKTG_ (4UX^_Z
M /\ Y.0?_%T?\*:\??\ 0!_\G(/_ (NCD7<.=]CS&BO3O^%->/O^@#_Y.0?_
M !='_"FO'W_0!_\ )R#_ .+HY%W#G?8\QHKT[_A37C[_ * /_DY!_P#%T?\
M"FO'W_0!_P#)R#_XNCD7<.=]CS&BO3O^%->/O^@#_P"3D'_Q='_"FO'W_0!_
M\G(/_BZ.1=PYWV/.+2[ELYA)&?J.Q%=59:M;78 #;)/[C'_.:W?^%->/O^@#
M_P"3D'_Q='_"FO'W_0!_\G(/_BZ.1=PYWV*&0>_%(\L<2%G=54=R<5H?\*:\
M??\ 0!_\G(/_ (NC_A37C[_H _\ DY!_\71R+N'.^QR&I:Z&!BM"?>3_  K!
MR=V[J<YYYKTW_A37C[_H _\ DY!_\71_PIKQ]_T ?_)R#_XNCD7<.=]CS)CN
M8DXY.>!BDKT[_A37C[_H _\ DY!_\71_PIKQ]_T ?_)R#_XNCD7<.=]CS&BO
M3O\ A37C[_H _P#DY!_\71_PIKQ]_P! '_R<@_\ BZ.1=PYWV/,:FMKE[:4.
MA^H]17I'_"FO'W_0!_\ )R#_ .+H_P"%->/O^@#_ .3D'_Q='(NX<[[',6MY
M#=+\C?-W4]:L<5O_ /"FO'W_ $ ?_)R#_P"+H_X4UX^_Z /_ ).0?_%T<B[A
MSOL8![<T"M__ (4UX^_Z /\ Y.0?_%T?\*:\??\ 0!_\G(/_ (NCD7<.=]CD
M-5OA%'Y:8$C#''8>M8%>G?\ "FO'W_0!_P#)R#_XNC_A37C[_H _^3D'_P 7
M1R+N'.^QYC17IW_"FO'W_0!_\G(/_BZ/^%->/O\ H _^3D'_ ,71R+N'.^QY
MC17IW_"FO'W_ $ ?_)R#_P"+H_X4UX^_Z /_ ).0?_%T<B[ASOL>>:?>M8W(
M?DH>''J*ZZ*5)HUDC8,K#(-:O_"FO'W_ $ ?_)R#_P"+H_X4UX^_Z /_ ).0
M?_%T<B[ASOL9V<49XK1_X4UX^_Z /_DY!_\ %T?\*:\??] '_P G(/\ XNCD
M7<.=]CGM3U%;. JK?OF'RCT]S7*,[.Y9F)8\DGO7IG_"FO'W_0!_\G(/_BZ/
M^%->/O\ H _^3D'_ ,71R+N'.^QYC17IW_"FO'W_ $ ?_)R#_P"+H_X4UX^_
MZ /_ ).0?_%T<B[ASOL>8T5Z=_PIKQ]_T ?_ "<@_P#BZ/\ A37C[_H _P#D
MY!_\71R+N'.^QYC17IW_  IKQ]_T ?\ R<@_^+H_X4UX^_Z /_DY!_\ %T<B
M[ASOL>=6-X]E<"1>5/#+ZBNKM+V"[3=$^3W4]16U_P *:\??] '_ ,G(/_BZ
M/^%->/O^@#_Y.0?_ !='(NX<[[&=D52O-3MK0$,X:3^XO)_^M6]_PIKQ]_T
M?_)R#_XNC_A37C[_ * /_DY!_P#%T<B[ASOL>>7=\UZ[/,#P/W84\+_C52O3
MO^%->/O^@#_Y.0?_ !='_"FO'W_0!_\ )R#_ .+HY%W#G?8\QHKT[_A37C[_
M * /_DY!_P#%T?\ "FO'W_0!_P#)R#_XNCD7<.=]CS&BO3O^%->/O^@#_P"3
MD'_Q='_"FO'W_0!_\G(/_BZ.1=PYWV//=.N&AN O\#G!%;P;BND_X4UX^_Z
M/_DY!_\ %T?\*:\??] '_P G(/\ XNCD7<.=]CFLTNX <UTG_"FO'W_0!_\
M)R#_ .+H_P"%->/O^@#_ .3D'_Q='(NX<[['"W]\C.L0&] PW@'&1Z9K-<J9
M&**50D[5)R0/3->F?\*:\??] '_R<@_^+H_X4UX^_P"@#_Y.0?\ Q='(NX<[
M['F-%>G?\*:\??\ 0!_\G(/_ (NC_A37C[_H _\ DY!_\71R+N'.^QYC17IW
M_"FO'W_0!_\ )R#_ .+H_P"%->/O^@#_ .3D'_Q='(NX<[['F-%>G?\ "FO'
MW_0!_P#)R#_XNC_A37C[_H _^3D'_P 71R+N'.^QYC3HY'B<.C%6'0BO3/\
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M*:\??] '_P G(/\ XNCF7<.5]CA**[O_ (4UX^_Z /\ Y.0?_%T?\*:\??\
M0!_\G(/_ (NCF7<.5]CA**[O_A37C[_H _\ DY!_\71_PIKQ]_T ?_)R#_XN
MCF7<.5]CA**[O_A37C[_ * /_DY!_P#%T?\ "FO'W_0!_P#)R#_XNCF7<.5]
MCA**[O\ X4UX^_Z /_DY!_\ %T?\*:\??] '_P G(/\ XNCF7<.5]CA**[O_
M (4UX^_Z /\ Y.0?_%T?\*:\??\ 0!_\G(/_ (NCF7<.5]CA**[O_A37C[_H
M _\ DY!_\71_PIKQ]_T ?_)R#_XNCF7<.5]CA**[O_A37C[_ * /_DY!_P#%
MT?\ "FO'W_0!_P#)R#_XNCF7<.5]CA**[O\ X4UX^_Z /_DY!_\ %T?\*:\?
M?] '_P G(/\ XNCF7<.5]CA**[O_ (4UX^_Z /\ Y.0?_%T?\*:\??\ 0!_\
MG(/_ (NCF7<.5]CA**[O_A37C[_H _\ DY!_\711S+N'*^Q]8T445S'2%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
6444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>img187419207_18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img187419207_18.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &^ 7 # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(]3CF@#QWPWX=\3B'PYK>D:1;V<QD26?47U?<UZC?>#HQP>,\=J]@^(@TE_
MNIPZW/+;Z?*@22:)-S1Y(P<?7%4=*^%7AG2-4M[Z!+R06SF2VMYKEGAA8]U0
M\"NNO["UU2PGL;V!)[:="DD;C(8'M0!X%J]UJV@>%;!M:D\.^*?#-OY9B\M_
M*G [%<8.<'_&LSQSJ>M+X_\ $4V@13"WN-+MWO)(A^\BMMBEL>AP0,UZ?:?
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5ZA0 4444 %%%% !1110 4AY!X!^M+5>]O;73;*6\O9X[>VA7=)+(V%4>I-
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MUM%%% !1110!Y_\ %?\ X]/"?_8RV7\VKT"O/_BO_P >GA/_ +&6R_FU>@4
M%%%% !1110 4444 %<-XY\>7/A*_M;:"QBN!-&7+.Y&.<=J[FN,\9^ QXMOK
M:Y^W&W\F,IMV;L\YK&O[3D_=[GHY4\(L2GC/@UOOVTVU.;E\77GC;P3KL9T]
M8Y($3:L)+ELGTKB_"6DZE%XMTMY-/ND1;A26:%@!^E>O>"_!0\(_:_\ 3#<>
M?M_@VXQ76USK#2J<LZCU7^9[4\\H8/VN'P<$Z<MG=K>*3W\PHHHKN/E HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH \C\7WUK;:UK,S>.O$=H+1HA):64:LBO)PL:<<MWQ77?#:/1X_!\?]C3
M7<T332-/)>KMG,V[Y]X[-GM7(^)-*\.6WC+4-3O/$Q@M;.>#4+W3A#N_TC;L
MB;/?/]VNS^'T&EQ>%DETK4WU..YGDGENY!AI)6;+9'8YXQ[4 =31110 4444
M >?_ !7_ ./3PG_V,ME_-J] KS_XK_\ 'IX3_P"QELOYM7H% !1110 4444
M%%%%  >G'%<_J,6M6=A<W2:PI\I&=5-JO;M705YO\3/%VH:%/#I]JD)ANH&W
MEUR>N.*QK3C"'-(]#+,/4Q.(5&FDV^Z6R]4SKK.VUB6*WGDU=65E5V06RC.1
MG&:VJX+X;>*[_P 1PW<5ZD(6U5%0QKCC&.?RKO:=&49Q4HDYA0JX>NZ-5)-=
MDNNO0****U.$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK:W+IMH>_4445Z9\,%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'!'7Y2 ?QH W:*** "BBB@#S_P"*_P#QZ>$_^QELOYM7H%>?_%?_ (]/"?\
MV,ME_-J] H **** "BBB@ HHHH \\^&/_']XH_Z_S_-JQ?BYJU]:ZG906E_/
M##) V](I2JMSW /-;7PR&;WQ0#T^WG^;5TMYX*\.7\@DN=)@=AGD%E_D17"J
M<JF'48_UJ?4U,70PF;RK5DVDEHDG]E=V>8>$VU?Q-X2U_33=RW4Q2,0)/-G'
M/0%CQ6;I'A?5- \=:);:C"D4DTP= '#9 Z]*]CL/!_A_3'WVFEPQMD')RQ!'
M3J37,>*_^2I^%?\ =;^9K.6&Y8Q<WJFOS.NAG*K5ZU/#QM"<9/5:IJ'D[=#T
M.BBD9E12S$!0,DGL*](^+%KF[/Q9!=^+;G1@%"(N(Y,_><?>'^?0U;OM;C_L
M-M1M 9K5HV)F1U79VSAN^>U</I7AI'U""\LQ>O*%2Z5_,C&X$G'?O@UPXBO-
M3BJ6O5^AYN*Q-13A&CKU?FO(]1HJ"UFGFC+3VS6[ X"EPV1Z\5/7:G=7/13N
MKA1113&<!\4;/4%TB+5M/N[B$VQVS)%(5!0]\#T/\ZU/A[I][:>&H[C4;F>:
MYN\2XE<ML7^$#/MS^-0^._%%QX;MX"=+BO;*Y!CD,C< ^A&.XS^57O!GB"[\
M2:2U]/8I:0[]D(5B=P'4].G:O4DZWU!)I<M]]+^G?<]"3J_4UHN6^^GW'1T4
M45Y9YX4444 %%%% !1110 4444 %%%% !1110 4444 %%%5[Y;M[&9;"2*.[
M*GRFF4L@;W YQ0!Y5?RRZEX\\16MUXZOM AL_+\BV,B*&!3)D7=_"#Q5?X<>
M(M6F\1:;:RZ_<ZM;7T=UYBSJ"!Y3 +-&<9"MTP:T];75)[E!X@\/^$-9GAXW
M+>"*4>V)!^F:Z_PM+I^H6XO8M(MM.O(U^SF*-XW9(P> "A("^U '1T444 %%
M%% 'G_Q7_P"/3PG_ -C+9?S:O0*\_P#BO_QZ>$_^QELOYM7H% !1110 444@
M(89!!'M0 M%%% 'GGPQ_X_O$_P#U_G^;5/X\\=WGA2_M;>VM(9A-&7)D)XYQ
MVJ#X8_\ ']XG_P"O\_S:M'QEX"7Q;>VUR;\V_DQE-HCW9YSGK7%%5'AU[/?_
M ()]-6EA8YQ)XSX+*^_\JML-\ ^,[KQ9]M%U;10F#;M,9/.?K5#Q7_R5/PK_
M +K?S-:_@SP4OA'[7B]-R;C;U3;MQ^-9'BO_ )*GX5_W6_F:;4U17M-[K\R:
M3PSS&H\)\')*V_\ (^_F>AU@^+AJ4FA26VEV[RS3G8Q4XVKW_P *WJY[QGK,
MFBZ"\D !GF;RDR>F0<D>XK;$-*E)R=E8^3Q3BJ$G)V5NAPEKH?BR709-(BL\
M6KR"7+2*/P!STSS52[N-8\,6$NE78\F:9$\MDD!*H&8D9!]35C1O&VI:%HQL
M39>:%+>7+(2-F?;'/-)=^-I;J1KJ72;1IWA6-9)5#@%222 1WSC%?/N5!03C
M-J5K>B[;'R[GAE33C4DI6MKK9=MCL(?'-I%X9L=0FP\TL@ADC4\J1]X_ES^(
MKKD=9$5T(96&01W%>*ZL-3\0*-1M]%-O8HA(%O'^[&/O,2 /3]*])\"32S^$
M+)YGWD;E4^BAB /TKT\'BYU*CIRVMH^_G\SV,!C:E6JZ4MK:.UKVW?S.CH/(
M(!Q[T5Y#KWBSQ=IWBZ71X;R!A),%@/EK@JQXR?;H?I7NX7"3Q,G&#2MKJ?08
M?#RKMJ+2MW.N\6:#<WOAB^2[U1YHTC,H4PJ.5Y'-6K>Q/AK1X'EUAHM/M$7<
MOD*!M_#UK,\9^+(-%T5;"Y1[N6[MFC\^ KMWXP<C.1US6AH?B;3/%NB77F0-
M;VN# PN74;^.<8-=/+7^KQE)>Y?LO):&_+6]BG)>[?R+=EXS\/ZC>1VEIJ4<
ML\IPB*#DFMZO,_A_X6M]&\07]U<7$$CHYAL\2 EE/)8<^F!^=>F5SXVE2I5.
M6BVUYF.*ITZ=3EINZ"BBBN0Y@HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH \7\0:;H-AX\UZ]\6^$KK4(KSRS8W%K;-*A4)AE.T\/GN?:F?#?P[=Z5XKT
MJ6'0I]+4VUT]SN!&Z%G'D+)V,@Y_"NV\4S:_'JX&F^+M&TJ#RQ_H]Y"K/GUR
M6'%0_"^^4Z'<Z?=:W#J.H17UP'=9@VX;LY09SLYX]* .@\5IK4F@3IH-Q;VU
MXW!GG!(B3!W,H'5O2O)M-O+^^^%OA'37U*[0:IJQM[JX24B5XP[D@-U&<"O<
M9HA-!)$3@.I4D>XKCE^&VF#P7:^'/M=T%M)S<6UVA"RQ2;BP8?3)H \YDO-0
ML[;4/!\6J7PLE\2PV"W#3$S+;N-QC#]>HZUU/A+68_",OC'3[VYO[G2]&NHC
M"\FZ>55D &T8R3@_SK:7X8:2?#<VES7=Y-<S78OWU%I/W_V@=) >@QZ=*V/"
MOA2V\*VMTD=U<WEU>3&>ZN[ELR2N1C)]!@=* /-O&GC_ $/Q3/X6L=-^V^>G
MB"SE/GVCQ+M#$'EAC/(XKVBO/_BO_P >GA3_ +&6R_FU>@4 <[XU\7VG@O0&
MU*YB:9F<10Q+QO<@GKV& 37GFG?M Z<]JS:EH]Q%<!L!;=PZE?7)Q7H?C3PC
M:>,]!;3;J1HF5Q)%*HR4<9&<=Q@D5XYJWP#UJWBA;3+^WO')Q(K_ +O;[CUK
MZ;**>3U*')C':=^[6GY?>8U'43]W8I>*_C7K&N6MU8Z= NGVLIVB1'/G;/KV
M)]JR/ WQ,U/PA>3&=IK^SF7YH))3\K9^\"<X/6NUTGX3Z'H.MB7Q%J7F065J
MEU<!L)$6+$8)Z[>!QWJYX@\">'?B3>#4?"6L6,$T*B.XA2/"8YPVT8(/\Z]U
M8K*(0>&C3_=/>5G:_2[W^9ERU+WOJ>G^%O$UCXMT*+5;#<(W)5T?[R,.JFMF
ML#P;X5MO!WAV+2K>5I2&,DLK#&]SU..PX _"M^O@\4J2K2]A\%]+]CJC>VIY
MY\,?^/[Q/_U_G^;5Z'7GGPQ_X_O$_P#U_G^;5Z'7#AOX2^?YGK9W_OT_^W?_
M $E!7GGBO_DJ?A7_ '6_F:]#KSSQ7_R5/PK_ +K?S-&(^%>J_,,G_CR_P3_]
M)9Z'7-^-/^0;8?\ 80@_]"KI*YOQI_R#K#_L(P?^A48G^%(\'%_P)%S6_#5A
MKZQ+>&8+$256)]H)/<\5S:?#_1&UB:T)NO+2!)!^]YR68'M["NSNX+F<)]GN
MS;XZXC#9_.N%L->FN_&UQ8KJ9"LGDQS>2OSLI)QC\37-B8T%.+G#5ORU.3&0
MPZJ1=2%VW;IKIZG1'1+70?"NJ6MFTQB:"5\2/NP=AZ5%\/\ _D3++_>D_P#0
MVK0U&&>'PYJ:W%R;AC;2D,4"X&P\<5G_  __ .1,LO\ >D_]#:KC%1Q$4E9<
MK_-&D8J.*A&*LN5Z?-'35\V:S:37OC74;.)?-GFOY(UP,98N:^DZ\!CUB71?
MB%J5U%I\=Y?&]E2%2Q 5BQ' []:^JR24HNHX*[L?3Y2Y)S<5=V-+QAX3\/\
MA73H(FCU![V>+]W.K@Q>8,9R/3_&M#PKX(\,>*=(>YAAU*)H\1F220!7?')
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M\\^&/_']XG_Z_P _S:O0Z\\^&/\ Q_>)_P#K_/\ -J]#KQL-_"7S_,]C._\
M?I_]N_\ I*"O//%?_)4_"O\ NM_,UZ'7GGBO_DJ?A7_=;^9HQ'PKU7YAD_\
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M]#KSSX8_\?WB?_K_ #_-J]#KQ<-_"7S_ #/8SO\ WZ?_ &[_ .DH*\\\5_\
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MX8_\?WB?_K_/\VKT.O//AC_Q_>)_^O\ /\VKT.O%PW\)?/\ ,]C._P#?I_\
M;O\ Z2@KSSQ7_P E3\*_[K?S->AUYYXK_P"2I^%?]UOYFC$?"O5?F&3_ ,>7
M^"?_ *2ST.N;\:?\@ZP_[",'_H5=)7-^-/\ D'6'_81@_P#0J,3_  I'@XO^
M!(Z2BBBMSI*&N?\ ( U+_KUE_P#0361\/_\ D3++_>D_]#:M?7/^0!J7_7K+
M_P"@FLCX?_\ (F67^])_Z&U<K_WI?X7^:.*7^^Q_PO\ -'35Y]\/_P#D:_&7
M_7Z/_0I*]!KS[X?_ /(U^,O^OT?^A25[&'_W>MZ+_P!*1[%#^#5]%^:/0:**
M*X3D//;W_DM^G?\ 8//\I*]"KSV]_P"2WZ=_V#S_ "DKT*N[&[4O\*_-G7BM
MJ?\ A7ZA1117"<@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!P'Q13[:GAS1YI9%LM0U6.*Z5'*&1 "=I([$XK+\$:B/"MMXSLX;6_O--T
MC4]MK;6RF>4*VW*("<G!.>O3-=[XB\-Z=XHTO[!J*.46198Y(G*/$Z]&5AT(
MIGAOPSIWA73GL]/$I\V0S333.7DFD/5F8]3Q0!Y?XW\:3>)(-#2S\'^+%-CK
M%O?2^;I;#,<9.X#!.3SQ74?\+7@_Z$SQE_X*3_\ %5Z#10!X5\3/%-SXR\/V
MMAIWA#Q5'+%=K.QGTQE7:%8<8)Y^85V@^*T(4#_A#/&73_H$G_XJO0:*WGB)
MSI1HO:-[?.U_R%97N>;CXR:<;XV(\+>+#>"/S3;_ -F_O F<;MN[.,\9I\_Q
M3BEMY8U\&>,<LA49TD]Q_O5JQ:)J*_&"XUTP?\2U]$6T6;>/]:)MVW&<].<X
MQ785BG9W&>&_#3Q9<>#O"SZ9J/A#Q5).;EY<P:8S+@A0.21SP:['_A:\'_0F
M>,O_  4G_P"*KT&BM<17GB*LJU3>3NQ)65D>*>#O&4WA^YUF2[\'^*V%[=&:
M/RM+8X7)ZY(YYKI;GXP6-G;27-UX3\6P01C<\LNF;54>I); KT:N<\>Z9>:U
MX$UG3=/B\Z[N;9DBCW!=Q],G@5SP@H1Y4=&(Q$\14=6IN_T5C 3XM6TL:R1^
M#_&#HP#*RZ42"#T(.ZN6UOQE-J7C71=8A\'^*Q;6((E5]+8,<YZ#/OZUZ]H\
M$MKHEA;S+MEBMHT=<YPP4 BKM$X*2LPP^(G0DY0W::^35F>??\+7@_Z$SQE_
MX*3_ /%5D^(?B'_:MI:Q0>#O%X:*ZCF;?I1'RJ<GOUKU>BB<%.+BSEJ052+C
M+9GGW_"UX/\ H3/&7_@I/_Q501_&33I;N:TC\+>+'N80IEA73<O&&Z%EW9&>
MV:](KC]%T34+3XF^*-7G@VV%[!:);R[P=Y1"&XSD8)[U19BZC\3X[O2[NVC\
M&^, \T+QJ6THXR5(&?FJAX7^(1T7P_;V%SX.\7-+&6),>E$CEB>Y'K7K-%1[
M.//S];6,W2BZBJ=4K'GW_"UX/^A,\9?^"D__ !5<MX6\9S:+K?B"]N?!_BQH
MM0N/-A$>EL2!N8_-DC!^85[516\*LH0E!;2W^3N;QJ2C%Q6S/-[SXR:=I]LU
MS>^%O%=M I :6?3=BC)P,DMCDD"I_P#A:\'_ $)GC+_P4G_XJM'XGZ)J/B'P
M#?:9I4'GW<LD+)'O"Y"RJQY) Z UV%9D'BMQXSFE^(]IXA7P?XL^QPVIA93I
M;;]V&Z#.,?,.]=3_ ,+7@_Z$SQE_X*3_ /%5Z#16E2K*IR\W16+G4E.U^BL<
MCH/CV+7]6CT]?#?B.Q+JS>??6!BB&!G!;)Y/:NNHHK,@**** "BBB@ HHHH
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M,""X%\@@F5F'S1+(<!V7N<<5[L0""",@U@^%?#$/A6SO+.VN'DMIKN2XBC8
M"$.<[1ZC- &5X*\ V?A=FO'GNKJ[=!'#]KD\PVD/41(?0=SWKLZ** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
L* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>img187419207_19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img187419207_19.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X6(E:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(^"B @(" @(" @(#QX
M;7 Z0W)E871E1&%T93XR,#(P+3 W+3$W5#$S.C4R.C4R*S U.C,P/"]X;7 Z
M0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!)
M;&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]X;7 Z0W)E871O<E1O;VP^"B @
M(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(P+3 W+3$W5#$S.C4R.C4R*S U
M.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A
M=&4^,C R,"TP-RTQ-U0Q,SHU,CHU,BLP-3HS,#PO>&UP.DUE=&%D871A1&%T
M93X*(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @(" @(" @(" \<F1F
M.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.G=I9'1H/C(U
M-CPO>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z
M:&5I9VAT/C$U,CPO>&UP1TEM9SIH96EG:'0^"B @(" @(" @(" @(" @(" @
M(#QX;7!'26UG.F9O<FUA=#Y*4$5'/"]X;7!'26UG.F9O<FUA=#X*(" @(" @
M(" @(" @(" @(" @/'AM<$=);6<Z:6UA9V4^+SEJ+S1!05%3:UI*4F=!0D%G
M14%304))04%$+S=107-51VAV9$<Y>F%'.7=)1$UU34%!-%%K;$Y!*S!!04%!
M04%"04%304%!04%%028C>$$[05%"24%!04%!44%"+RLT041K1FMB,DIL04=4
M04%!04%!9B]B04E104)G445"055%0F=51D)G:T="45E*0W=G1T)G9TQ$06]+
M0W=O2R8C>$$[1$)!341!=TU$07=11$$T4$5!.$]$0DU41D)15$5X=V)'>'-C
M2'@X9DAX.&9(>#AF2'=%2$)W8TY$03!914)!64=H55)&4F]F2'@X9B8C>$$[
M2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&9(>#AF+SA!04519T%M045!07=%4B8C>$$[04%)4D%135)!
M9B]%06%)04%!04A!445"05%%04%!04%!04%!04%11D%W24=!44%(0T%K2T-W
M14%!9TE$05%%0D%114%!04%!04%!028C>$$[05%!0T%W449"9V-)0U%O3$5!
M04-!44U$06=10T)G8T1"04E'06Y-0D%G35)"04%&25))>%%614=%,D5I8UE%
M54UP1VA">%=X46E00B8C>$$[571(:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY63-0
M0TY546YK-D]Z3FAD55I(5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y
M-"]0128C>$$[,4]4,%I85T9L85<Q>&18;#E76C)H<&%M='-B5S5V63-2,61N
M9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM#:S535FQP95EM6B8C>$$[
M<6)N2C)E;C5+:G!+5VUP-FEP<7%U<W)A-G9O4D%!24-!44E$0E%514)1645#
M04U$8E%%04%H141"0T53355%1E523FA)9UIX9UI%>28C>$$[;V)(=T9-2%(T
M4TY#1E9*:6-V17I*1%)$9VAA4U5Y5VE9-TQ#0C-04TYE2D5G>&15:W=G2D-H
M9UI*:EI&1VED:V1&53,X<4]Z=WEG<"8C>$$[,"M0>FA*4VMT3515-5!2;&19
M5U9P8EA&,658,5)L6FUD;V%7<')B1S%U8C)2,61N9#1E6' W9D@Q*V8S3T5H
M66%(:4EM2VDT>4YJ;R8C>$$[*T1L2E=7;#5I6FUP=6-N6C9F:W%/:W!A86YQ
M2VUQ<39Y=')Q*W8O84%!=T1!44%#15%-4D%$.$$Y531Q.'8X07I*,&(X=SE1
M.'A%*R8C>$$[5VPQ2T,R3VU4>$,K=#<R0T\S13=W>F]K670R;6=:5TQ3235M
M2W-W6E5#;$%'2E976#@S-6PK6%!Y,6LQ9C8W8C)6>F\Y<&181GI96"8C>$$[
M,%4R;WI41DI:2DEY,7DY-TLP6F%0:E9056Q#.4%X1TMV53A69&ER<U9D:7)S
M5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5B8C>$$[9&ER<U9D:7)S
M5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U99:BMB=B]K<B]!1%0O04YS>34O
M-4YN1E=867$W1EA9<3=&6%EQ-T98628C>$$[<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ:')V56)7,&MT-#5I+T\V9C T46MC:VQ704Q52E)7-"]#0V9I.$UL1T).
M,3!284IY2UA9<3=&6"8C>$$[67$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ
M-T9722]M-R\U2R]Z5"]W0G-Y-2\U3FY&5UA9<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ-R8C>$$[1EA9<3=&54AQ,3=C,F1Q<S%V0VLW=$Y$1'=K:TU1+V933$5$
M>4-39$,T-UI/15%4=6=L,G))2DY*=3%K2%=&>5%#9&E&2C));V5U3R8C>$$[
M32MO2U5U<T9N4S4P;3-J=4I%=$AS2DI*3&-C0T=D1$5!>&-Q6E X061X-DXR
M2'97>59623%V9C8O=T)306=(831T.5!T2DE*5V5A3"8C>$$[56(X>'9C=$IC
M8E)2,V%Q<#5V>6]&44-N3$II:51F.$%.2&PO3E%Y5%1P6C5B0S-L;DMT3DI'
M<G59,4M,5FA86E-Z:V9F;5!-044P>B8C>$$[0TEY2W5X5C)+=7A6,DMU>%8R
M2W5X5C)+=7A6,DMU>%8U=' S-6=E6C<S>E5D2FEF5$IN5UHT6G1/:71T52]D
M;45K>DPK;$1&.55:-"8C>$$[,55I;D%!<T].831Q>6Y7+U!V;%!1.5(O4BMQ
M,S1T8F=1;35D;FIK35-)16MK06565DUA<WE7.')+:&)K=U4P0GA6:FXU:RMA
M=DQU<28C>$$[9FQ.-6AU3$\O:5IB<E1R=%E)-4-96FDP665*,$U-;U-65U8P
M2VQ3=%%2:7(P4$9867$W1EA9<3=&6%EQ-T9867$W1E5.1G%.<DQF4R8C>$$[
M,E-&+W)%0W$X:71(27$X6$I#:T]Y:$=Q5E!1.6HT6DEW249O=$4U1DM#,4,K
M=7)A-'-9;UE%;$8S2UE76C5$1U5P1S!T44%J.'9H:B8C>$$[8G5.-F923TU1
M46(V24I3:5I:5D=O<3@X:WEP<71G:U-Y3GE#2UAT6DM,-$1L26-T2%0K<68P
M;U)0;5188F$R,"LK=')A3U153E-%128C>$$[;D14-U943$M35BM(;GAR-EE.
M97)5.7%N8DDT<UI*0D]W-WES:6MD;#5S:6DQ5%%B5SDP-BMT9%)L,#)F+U%Z
M07IS1R\P9'%C,#5**R8C>$$[=V5P1E R=4YC=FQG=4UI0T-/3'8Y-T54,T-2
M-G)Q=FUM9GDS0G%K9' K:&)+>G8W,C5V23<T9C93.$)--U-!4FUG6#DQ27='
M.5,S4R8C>$$[;7AA5G=H:T50<DTV07)K1%8O;U1'2FQ%;FQW-W91+TPQ-V$S
M,FAA9F0R:V=L=#5R94YO-48V16-2;4IL:5EY25!E>6EB0UE:5VPR2R8C>$$[
M=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W9!4$M.=W-F-3@S1G5L>% V8VUO
M86MW:FQ-:UE::71Z>4-X0R]D4W%.1S-X1S%P5&EX-"8C>$$[;#!*2W959DYF
M-5HV4C5O,558,G%8,38P271*8DPY1V\P2#%B:$]R3$I);V5&-45L268W84]$
M<T(P,G=+>"\X04U(>4PU8S!N.'%0328C>$$[9T9S;#EE>%=6.6-N53=Y3TM3
M-F%E8W902DM:06E"5V%2>69G0V=D:&ER,#=&6%EQ-T9867$W1EA9<3=&6%EQ
M:W5O87%,<7E:=%!U2B8C>$$[<F532SAT-V%75#!3:$AQ5'!%-F=815I",F9Q
M0C%Y-DU+3S0V2#=V2D)+13$K3TM64$U556]75E)P35):6$%/-$XP45-/;E56
M>65),28C>$$[=R\Q=C%)4%9K8TU-54U3>%%O<V-31&EK84%+;T$W04196FIK
M,GE3;GI$9C)6:E!P33DU3VQV0TQX:'IK64M#5&%4,$%R,4HW05IB:28C>$$[
M:5I!9V0S-E%X2EEN.51M.#%J5TET8T5U:S9,*VM)<%E)-$IA6$4U4T].66I)
M4E9O,2]D:'5"54YY-V=R:S5A=D9H04U:0U5G2U!7<B8C>$$[6D14>FYS45(Q
M.3=/0EDR9'!P<C(Y;D5T=D%Q35972#DS43!R5W$P3F9F351.27EI4U0P6C1T
M<$0S<4U-15)U-T=1<GEL1G)*4U9V:28C>$$[9G)(*S Q5"LP8WAO=TA&13EE
M13<Y96IF2UHT6D1P>$1B<#%3:EAD4U<S=#=#0S<T6%%V3'DT='8S.4)S16QJ
M56-5:EI7*VYV*T5*>B8C>$$[06AC-6(X4G)B,WA(2W4X3U)H>$=5:G=I=E1(
M.4)032LY:U9H1$9$63(X54M,2$5K84MK84%+;T%!,D%'=WI,>"]32$%Y9E56
M9DIS2"8C>$$[67%K3W$K8TQ05#=U>G1J639H8T<W;BMR;5-'>FY:27E&2C5-
M4V\U3#A0-T9D=#AV:&=-9U19,CAW>$UQ5&DR=6\W<4EY4D-24E5R4R8C>$$[
M5TM32G%J+TIK5D=P;$UO,'EE4C9B*V-8;74K,5<S,%9B0S!I=G)I-%13:&-T
M2$U95C%+,&Y186UP5#%!94UD=DIZ:EAN5V].5TY-5B8C>$$[6G8U03%J>DYQ
M,71Q3GAR5GA:4W)B6#DU<#A#5V1R3&)M=&IC>5<W4T\P;'IC,3E4,'=W54%C
M9D9S0W-E="]Z8G5B9&(V6%9R371(;R8C>$$[55 Q9E=O3$=#4U=D.55M=E1A
M,G1V8DQZ2R]V5FI,.%-4<SAF>$1U<6QX+U!U,TUT>EA4-VDR=%ID57-D3C!U
M964R-&M.8U(R.&LX3B8C>$$[>D,P.&-Q>7%*6F5,2W9#:6ID=&=Y<4IV=GHU
M,'DR,5A49W5L,S@R;39L6E,S1FY$0F)R3F4S36AE,DYU,$5C57)!4G9"3S=K
M4V-7,B8C>$$[-D$W1E8V5G!7<%<R<6%:86%L86AX8EAK2U1W:59':F9H26]:
M95--059.1#!/2V]R1EA9<2MF6G909'@U8S@Y86QD=T<U=F)A,S%(528C>$$[
M=E@P:CE,5W)/1EAM,'(O569Q2#%I3DA)0FE(<C!:*TDU1W4U5CE"6499:BMB
M=CA!-4LO>E0O,GI,;B]K,F-66F1I<G-69&ER<U9D:28C>$$[<G-6861I<4UY
M<5A+9VM)=$MK:G-/4D$S.7II1E-:=%1U-W=A3&17<&4P=#<V86MK37%2<S=X
M1T(U;#-6;D,Q.5!X-S5D=T%C44\Y9B8C>$$[<E)B2#E5,5A56F)7.7-03&M%
M5W V=6UQ<DI,0UI!<V-+47I)-6%::'-V>%(X94YE4C-)<E$U:U%G05%:-U(T
M9C!-0U0P6&$U-4]U8B8C>$$[3%1T8C%N5&)L<&9-3V]7<DIE3DY8-G9/06A8
M:C939SA!<6XT0W4T,C5%:FQ7=CA!3GA&8V8Y,TAU-6HX9%=58U)K86HY4E0R
M>'1F328C>$$[;#5:=U-A;&9P85-V1W!L9W-)471(22M*4SEZ-GA)*U-+8W$T
M-&9W:7@U+W$R4U%2>E%M<39$-4]I=G1,:S%A2C=M.5-F;G!S='<Y>B8C>$$[
M8TU*;$9D<6PQ6'AO84PS<'1H1W!K05%#26<K-$UO-%1,8T,V878X059B<3!H
M,4]A8U<T4TA5<E-*4S!J4DQ2:&)T>5II<CE!-')T-"8C>$$[-6E:27=!2DIO
M5T0X<2]5-65+2FM99T-Z=WDO,WE.,6TT=6)Z4G)S5S='>FA-3$4S>FMO4CA.
M9C-9*T)V.6MA93%C9UIY;CE/,&4X+R8C>$$[;T@V+W19=T5-4D)N=EA4.5HO
M2'=3:7<P;3-B53E$:V966C5B<&1/;#1T-FE(;G9'4'-K3GDK,B]7<#(V-UE2
M:2]P;2\X,WHV5BM+1"8C>$$[2U=T9U%127@Y4G9R*W1,3'%Y,#=43D9T-V4X
M=D%B<39V<C)+2S5M0G)50S1I54E!4G@K3FPV2#=2=R]L45%9>DIK6E)!=70K
M;GDV;"8C>$$[;DQ7:UI!66EH='1U9FXX4'-:=F]C36M':C)556MH;&1)54)K
M3F%N-%(T;'8Q-5!(:4=/26E,24<R+TYX8S)4:FU:5E9L1S5.<61I<B8C>$$[
M<U9D:7%%6%(Y25=D3&AB1S-794M74S1J;4530C%M;55P3$ER57%(9%-1>F13
M3W5+;V4S,#-Y-V1M,79,4TLS:T9N9%A&>&)Y,GA5228C>$$[=# O<7=83&XP
M>GA:>5I*1F9L6#1Q,2M,1E<R,#=Y,V-Y86IP-U=T;DY*9&A*9%=T0VM4=$M*
M1DUC8C--9$1Z1$Q&>%5U3G=T3S)+<B8C>$$[9CA+*U8K16%F;V5Y-%%Y>'IW
M<CE7:6]K<TM#3T]24G@R9$552W)$8T%51TMQ8F544$HW>%-1=&]7;G1&37IV
M3D=B4T%Q-U-S:GE&:"8C>$$[=V]3-WA)>E8V;%%E=WA61U%A;&\T:'1X0F17
M-&AL:V$P=$%K:6-8;&DU:&]9-D=H6E!397%J8V-4-$A&5F1,=3%E-6QT56U2
M<FU&528C>$$[96%!341):5-&9VI-;TY11S1.>$HV,%!H:7%R:7)Y6'DQ6BM1
M.5@X=U<O,5AY.35L=#%K;&M145@P96]185A$.58Y46AN:FQK1G5&-28C>$$[
M>#!33VAO>D0T1DYE2W(Q<D9722]M-R\U2R]Z5"]W0G-Y-2\U3FY&5UA9<3=&
M6%EQ-T9867%G3F9L=4ED178U-V55=WIW,CAK<U5Q:"8C>$$[5TE:1DQ$6G=Y
M.74T>65)07E!4&5G.&QL-W$P1VYX<F)C,W9T4S16:'150VUE53E!5T-+1E)3
M9&DU055967=-="M156QI5FI996(W+R8C>$$[044O>7=,*S14>39T;U%K.6=G
M13EX349H84@K.7!X:5IK63!!*WIY<E=O07DO3&YW-#5%9E5:8W9V4D1(3U%S
M9$]A95=&=C58.'(R128C>$$[-V%:8G!A47I822MS=$LW4FPU;DE7<E-4;7)E
M4%AX3UE78E=3;4PS;%<S8S-2=T-*.5)%8C-5.6-V-S93,C$V,FM)1G)$<#,Q
M:4-31B8C>$$[5U=4;$M*078W>$I72D%-6#AO.3EU<V508V=J6D=/6$1)16Y9
M5C-S:G1X1TE)>$AZ-&-2>#E1=5AP+VQC+VIR.#AS=3DR1C)K6&UZ5R8C>$$[
M3&)48G926&UL:E-T,#562$Y'62]6-4EW1C=B=$E&,S=K6D=::T)91G,X66M4
M438W9G O47AE,78Y075B8E8U2DQI1V5187)B3DLQ,B8C>$$[-4U10F5%3C9F
M<4@W2VQ'2$QU9TAB369&<'5D*W56,&5T6# K,FU8-758169#4$DX4%!Y2#ET
M9#ES;#AZ95IR1TA1<C0R:VE837=H:R8C>$$[54UM.$%B9V9H85=Q>&<O-5!,
M;#1!-6QY06E,;'-';DE20TIL23!'4&%F-6PQ6G11,$1K,6A$2$QP<V\T5%!0
M1U=$0TTQ16I2.$)U:28C>$$[,&]'1WIB-VEK4$=W,DYZ=3!J531366DO<4<S
M,DEE.71R>B]#<U=P-G1D2DIC=UAD>DYB=W=K=D%R>$=E4G%B,6M:,E%J;%A:
M96TO228C>$$[;5EY:7AW;FUA<RLT:'-'46)597 U+T9N=FPV-D8S;V1H8VEV
M1U=#3FQ*57!51E)1.%=Q8U-$93=09G%M1T)867%X<GI&-58Q;E9,<28C>$$[
M=VUS+TU6,W P9'!0-C P35E8:DML46944'!M2&)A;G@X+VQM3FMW4VM256E0
M>#A(86%06#1S55I#5TM-*TE50V5N;G9F,E5Y1S-I:R8C>$$[:6HT=DTX-U9R
M>FM#02],-$919FAL.%)85S-7>FM#9&A8>B]34SAM4#5F.$$U>$<S=3!0;5)$
M3&-834YW:$8Y94)&84UZ0GE"-EA.228C>$$[,D5K5&96,&-,5D]02VA*>6)&
M5V@X;BMF9%DX<C)N,6963&Y38GE)83AY<DI09%=J=&-85V]'6%1:6D5J*TEX
M>'A+5'AE=$%W2$5I;R8C>$$[=TLR9GDU+TUE3%8U<FU$6'I*67172T-#4R]V
M56Q73DQU-VQT-4AL0W4X<E%W5'A)63-01U%G.#(K1E-3<61E4G9,;FYZ>2]D
M,T,V,28C>$$[<54R=G<V:F-N,4IP8G-/3%I&4UHO6&IJ84-%>&E2+U1J.4)'
M64HY;TU29U9*=%,O3&8X04TR94="3&9Z9F-X9E8W<&A&-E8Q3D5X<R8C>$$[
M-#%#,G)Z3SA6>5IP5E!.<&M)06QQ2W8X24]&55!(*U98-6<R<6U(5&9-4S)C
M4G5B;3A5*W)024DU-3,Q3VMK8U1+15@T8C8R3$ET1B8C>$$[3$EZ57)1<T91
M,7HK5D@U;%-A<612<R]-3#98-CAD<VLX1G9Q3GI,2T1B>5A,25AU-VDS;&MU
M16I&=TM2=7%H-FM%<GA5:W$Y;%5%2R8C>$$[05-7249#>'!5*RLQ0F=6.'4V
M9G)E<RM6=GI*=DY:=C=F4F1B=4Q454Y31C5*15!2,6=Q:7EH<$9J6G!N:5%G
M.%EL4'=S3TM"=FE"=R8C>$$[<3EN+T%$0S%(.'=R4%5/4&QW1U=Z;#!F535%
M5TLQ37)26#A+>&96;F%5*V]R1G954'!X8T)8:3,R*VEH5TTK8G1A.#=4+VMZ
M<5EV="8C>$$[26YN33)M,V]V-RLK;6ET-3!!95)69C9U='1A;&Q-659K0FEJ
M86Q/4SAQ-'$Y:7A6,DMU>%8R2W5X5F=F;4]U<#-(;4118D\W;44P,"8C>$$[
M2T<W9%HU1U<Q9SE0;2]W8W5+=$QS<7)T545N;T-->510=W-9>5505%I',TUR
M0TEN4&@W,E<V4F\Q<'!M;G)A4D1M4V]&>&-.57EZ4"8C>$$[5&DP:W)K;&UD
M=35*>DAN27HK<CEN=U-+0C)1:5AD:F$R,FEI931J:6%:9U4Y4G=#-T="-C U
M2&9D<W<X569206IL>E K;$QM5$)-."8C>$$[;C0O:41%9%$X-C9F8C9:971&
M2$Y-,&5Q4DXX8C%3:U4V4V="*U5G*TPP>E1+0FXR4&AJ:DXS=&)H-65'03E2
M2DE)1D0Q4S5I.75L8R8C>$$[.38W:TQQ=7)E8TY4:SAW4&(V9%146G)31TM/
M-$%:,6%.0S5!:%E5.5AK,&HW<4MD3S):1U-%<4IL=#-X-C=E9DQF-W4U:$]-
M.$EL:R8C>$$[2FI)5G1%6%DK>CE39C9,<%=V6&UK5UIN:'0W4D1#;%5#:U-!
M.%)8*R]&,70W559V9DI1=S1G0G=W,B]P3C4Q,E-:-&A9=F9F8C=!<28C>$$[
M6%AK1DIR:7AK1#(O1S-N5V%C=$4W4W5O1D-I>79*27ED82]$44$P3DU-<V-T
M<7%).&A8,T]0;6QM;5)C.6=F,F0V23AZ*U(Y3S%05"8C>$$[1&)71G)A,FQW
M6%9V5DU10S!5,4E:5DAX5G!49DI39U%04C93,5I-2G(Y,S9*9#9D,G5K,E5#
M<69416MO54E:2E!J2490<W)8-TLO-28C>$$[2V=$,GE19T]:-71O9T]F5D5I
M0T%%15)Q0V]O<$%!24AS4C V-4MG>6]-93%$>4YO8F%5.799,E559'I&>FMS
M;F0U045N22M&,F(T>28C>$$[44<S;U%F;'9L171.2&AQ23,V3TQ04G<T86E.
M>'5096Y7;%$S8T=M5W-.,S9F,6U+2D5M.4=V<&QL54%L86AD='9$3&]8479M
M-4=-4R8C>$$[-%)X8S!6:VUB<U93,C@X>#9.6GI143-&=T5K=4IF4FE"5G0S
M;U14<#=5>7%784E.171-.#A):T%N;6%2,$9X1D]N3TIU4S%P5VA'+R8C>$$[
M,#590T,R9V=S02\U6&XU4$YV9%1R8C-Z4E=S<U-&>$A&=V5'651-=#!R*W)W
M14A',6M.6%I7,BMZ=4ML2S4O>F4P>7<P5S,Q0R]T8B8C>$$[;39&=S)R4VQR
M2T])3$AA-E)E9E9P6EA%<R]:5U4O0U-7,V]O,EA&5D<S+T]F4S,Q,C8P*U-X
M=39W=VE4-F]);U)00UE,;35T<C%P6B8C>$$[4')":5I9;G1G2U(W+W=!=D]V
M=W%S9SAL9FU&;S-M.#-N-DYT8C8S4S!+;%I,,C)E0DHT<$-Y>'I136%H,%EX
M=%1O9D59<6M6;"M:5R8C>$$[<EA&>'$V;3%T56IT-UA63'%X5U8R:#E%-E9D
M;7I+6#!J1FQ4,6TO94%H4GA52')3=4MQ9'(K8E4Q:71N838W<&QZ8U@K;U1/
M=6UY,B8C>$$[3G5,94\T:#E70S-H;#E'.6U34TPQ6C=P63%$12]W035O<'%&
M5S1F>G$P6%9R,U1D33AV,C%X3F8V=3!1<W!R:4U,8C=P8C-&>7)G4R8C>$$[
M97)Y:'1B;U-F6C1N;T<V-'%G3D$O4')4-VYY<$)Q*W!A8F-08W)A4&18<U9K
M27AW4S)I:&4U;$5D>$Q'5FI6<FU-24]43S1B:T)X*R8C>$$[3$950C52,41Y
M=U!Z5VTP5S$P4SAH=3=&,FIT-S)45DY1=68S85)Z>&UA83)M6F]E1$,S6&=3
M5R]V23(K,&1I<C)807)%9GID+W=$2B8C>$$[6"MA9BLR6F,O=T1*<S1Q>3=&
M6%EQ-T9867%K3W8V-4=M:G1F85IQ5G5I45A%161Z8T1J3VE*2DMS5#AQ3G-6
M1#AV;WEW44XP46U.2"8C>$$[;7@W,4Q$5$Q(>D1R6#%A3F1A,4)"3&-X.%%R
M:$A5.$DR3D)V2$9U.4]R06Y-4%<V9S%+1C=21D0T.#)E3U59:FHO;2MQ6'<U
M9G%:0B8C>$$[1G%36'5N<DIF6'E197!&>6UT-TYG-5AK3G<P<4=1+TQJ5#9C
M9T-:1#%32'5J*W9N.'%18RM+4# K<GHO049!9G!T:3)N+S193VME5R8C>$$[
M2DQ6:W5B-S%W26\U6D1Y.5IO6DLQ5V]00EIW=F(Y93E-34](:$A#0C5F9CDT
M=&](86-P>$)%>51,>D\K>#5O-U%D33!45U1F865K628C>$$[=61.=$PY<&11
M95)72'(S845C5DE91#=*2$]3;E@T4C!Q33(P8V9G:F)M4BM#,C0X27=J,#='
M6#1T;E=6261I<G-69&ER<U973E!!<R8C>$$[9VIA4E9K24Q"0U%#44]P<&=-
M:'E:0T))=71K22MR,G!.=CA!5F=B>$QM57=R2F)T1WEQ>7%84$EL,2]:53E+
M-5=C;S)R92LU=4=N;"8C>$$[=GAE;FA&-S,W=35(6F$T-W-69&EQ;DQB5SAX
M47EX2DE9>E9#-FAI<#A26'!G24(U;TE"-7%M1DM42'E4-4U)64A19$]O,&=M
M6696228C>$$[3C5!>&-/9F<K,7E*879J:7$S5%!*=FPK>#!T3D]E,5,K:%@V
M,U8W>$DU;EE8.'AU3&Q45E%V1U=2<7-O1DYH='1I<79.-54X<GIY928C>$$[
M<%!O.6I,2C9G;C5V8E%S,W%H,VM%;%-V,F<X,&IC=71763EZ:7)O=DLS;'E'
M-VEU-V948F4S=5ER:#=X6EE),6A*=4I);FAE5B]4-"8C>$$[.#)A3U9G959E
M=FII<G O2VYL931L=4I:.4AS6EIB<VQR<5(W849M;$IJ84EM46QA<U1(27EB
M+W-K:F]C5E=76&LS>6A9<6DR5V@V9B8C>$$[87)%+W%2<D1A=WAH6#5P2GE8
M:6]O,T]'3G$K2W%E=WA605=0-6,K5G),>E=033%V86AB*TLR1G!:>$)9>$1B
M4FA6:E!O2W%":W%I0B8C>$$[86-U22M,:4)Z9FMQ:'9-=C56951F3456<$1C
M,F$R,79A8D,S=%DT16IK:D-Q9U(Q84YW3TM*>%9K-'5O<49906UQ<GHS.' O
M2W9N4R8C>$$[=S@U4C,P*VXS,6YO25=29'!).4QS9#!F:"]U24)N:UDQ26]7
M9&%(96TR-58W:F=6:5 U=2]W1&MR+TY0+V)-=68K5%IX5FPR2W5X5B8C>$$[
M,DMQ13DQ-DTP15)I9"]88F=R<G@T9VA3,WA664AO<#9$26U614U42VE(:FUO
M,W-'=C9&3'!T;%HS8TYT8C8S2V)L231Y:S!Z+U<S6B8C>$$[541%3VEO:V-I
M<G5#961.<40T<F-U46%5:FAI2GIK3UAD='HO04(P84IZ-&AY;$MP8CEE=C9K
M,G9).5(Q1%=036QP*S=U.59E3E5S.28C>$$[3D5Q5'<X;55&=E58,49-87@P
M1D,Y0GEP,V]P>&10<%I(2G@U4C9F:"]A9C!U5EIY2&AN1&AX8F5F1C<O04Y6
M339T.4XQ<5A4;W)3-R8C>$$[=4QA>FHY25)3=S)%2D%!-#A3<V)Y<WEQ=F=0
M5#(X8WEV44]14T)%8D%B2F)A95(O2S)N=V%883,X>EAK,6\W9E9'=EHR8C%'
M9EEQ228C>$$[;6)G97$W0F5W>4]83$5Y<S!$,"]9;5=0>$1X0TXX3RMW-69Q
M5#,Q.4DP-C-:;U933T5Y2W),8E)L+S-J:TET5FA6:E4W1'!K2C5H>B8C>$$[
M2G8W5V-C335M=71D9'9V554X>F%/,F\S;&<Q>$A(3EE2<DQC;#594456>E%C
M;#4X,2\R4VIT-&I++TAJ6DAD-VTT-DA+25)N4DEM828C>$$[1W@O5E(K0E1/
M3U-/5TY:23)$>'5+<39K145(=4--=$)"-4]*2TI";S@R3RMA4$XK:S9*<4]L
M,FPQ<4LR<VPW355-6'!037I+1C(K=R8C>$$[1S1F1WE,=C0K,EDK9DU):T,V
M9&YO97IS;65%-5)H>$-)-3-8,S@Y<BM34E=V-6TR4EA66&YU6'-&=&(V2S-H
M8E5O47%M3FTT=G=74"8C>$$[,&U01VI..%)R4VU9,&1:>C,V:FXK>6Y96D]W
M-2MG06-F1D%K.$(V.4QU+TEB36<X=RMA3DET.4%V3&Q(3BM)-%-X:G-W6D=.
M96TV5B8C>$$[0SEF,FE->4TR94A!9#<Y>G)D2&]C<W,P66MC1FXK3&(W*V)(
M9$XX-U)Y879O4EA1-S!78S)N4W4Y*UEN9C!I,5<T='A6>E@O045E;B8C>$$[
M,G8R<W@X96-813A/,T-F>#EJ<S@O6EI'4$PK.&AX1$E05%DS*S<K9#EI5UAN
M;2]69%<X=C(K="M84CE8,&5W=G)M6%4W=34T27=J:R8C>$$[:U X061+1UIQ
M<DA/82LO4W56>GI3;$1I:G-!5&9,<B]!1W56:C=/>#1C>'A:.3AK-%)%4DAV
M038O1TPP:E$W>3-V3DET3'$S;BMS=R8C>$$[>E)+>7HQ<GIQ3GI8-35S<TUR
M9T1D=DUA<D=96EI2:T]%9SAK9&QJ:G5X5DET5S!R>E!D,U9N2F%A=DA:=W=4
M.#4T:W1Y9E9I-CA(2B8C>$$[:V%U-$$R-#=6>3)%;V='>&):1U52>D-C5WDS
M4W@P=5I%:VMR.7%.1$=T4#E6;FLO6&Q:<F]W3'EC>F8X-4)',W4O,T9*;G59
M6DQ:028C>$$[9$Y01D%::$Q#<VAA9V=*.4$X,U)P95!,64Y10E$S64@X>7)Z
M>6IA6$AL85E7-41E65HS16%765-A-4=P<V105#DK;%!4;%0Q2W5G1B8C>$$[
M4G570DE/0E<Q,'HX-7)B>D1D,U-6;70U;%<S1C='3DY&>DU,83AV9G%R5#AG
M:65K8F%32G!E0V@V=#A!0C5J0W%F.$%K5S4O374Q=B8C>$$[2C1F3V=A-U<Y
M=51(679B5S%U:U9T>%-A5GE8:&UK63(U16%,1S!Q:51K,4='0E5R,6YY+RM:
M1VU3*UDU=DM44TI.<4=Q:3=T6&UM:28C>$$[=4,X0S9/4GAR94Y*=U)T45)%
M-#=&5BMZ>%1&5U K6G9-=C5X84YR8V5J4EA46%8U9%A-4#9%5&A90G)Q1FUH
M3G@Y6DIJ6#1)*U5I2R8C>$$[659$24)Y:S(T<U-Q;F,V8C4T.&=46#!W=7!O
M9DQ%,3E#<3-C36QQ6G=O<S=A1C4R3C)7:#5Z4$1X0FYO<3A8+T%';E$T<3E8
M.&@S=28C>$$[<U@O:W91-S-7=5@V5W5R2T-A.35O23(Y5C!$3E9&0VA4=C!O
M2UE&95(K6"]!1$(U*S%4>G!C0WAU.5(X=C)M;U@R;U<Y:%I8.%5..28C>$$[
M85!C,C5K;&5/5U-3-FQL:#1I2G%X=TIX53=!,$=&6'5.>G%/;C)R:4\U=6]O
M2D1(2DU%:VM60UEO84=2-DU2.$MC:'E0460X0W-3+R8C>$$[32LO<V11+TM4
M>DIE5T9Z1F0R8RML,TQ1,TU$<DI'-BMM4E9846Q34&QI<DYC5F1I<7EE5DE9
M6DIN*WA'<&1U9S)55D\U;TU3=%!-+R8C>$$[4&9M4%-,,CDX<TYB33!6>F-4
M>5-#*T-,2CE7=#%J9%I*4U4U,%IE6$YD-D%R5G5M6&%8,5)L3&]",34K5%9+
M56E2141C+W!14&Q8428C>$$[3DPQ8GDW2DIC<D)D,DU7<$)93E!S*TU42E=5
M3$8V-W,P<D)J>4%+:'5813=S,4)40W<U>$%N2D0Q4VQS9FHK<S<O,D\Y>F%-
M8651>"8C>$$[>&HT44UE3&8K23%U96PK.4XU+T](;&YY+V5E84AS631X9E=#
M4F9716ET<%=D,E4X5CE2,FM#=%%V4W12.5!42W-U=D\T2BMN;'0K,28C>$$[
M>6-(63)42TU227%/5')X1#=.<BLY:VQR<C)P87@U8U,Y,'%X9'!,>3%-='1,
M8TUL=6A::W%U>5-43W!R+W="9&0X;#1S<'=U239E-R8C>$$[.4IC2$IP365(
M4'=:2D-O>6\Q8W5V;4%0>'E30W<X<B]!2F<S.7!O32MP87-.3G5T36YE5S=T
M;W5C>&U8:V](3U)P;D16:D1$+UI(2R8C>$$[65E-<$5B3E5F>#%D:&PQ,FEX
M>7EJ2&HT-'IJ44IO5C=H=VIR.7I1+TQ06$PS5&(V>#%8>D1.>'5,=UAC1#)Q
M<6A50W1&3E%'<G8R8B8C>$$[04Y&26=I575T<"]L>D9$2D=E4$505$1H4$5M
M;6\O;&YO33EV9G1:4$Y987)Q35-W,T=P<$Y/,&I+<%=T5DUN13%#8C5D4%)X
M23(R4"8C>$$[9G8X07)C5$0R-6UJ2U!(53AC1%EJ56$V*UAM;75L*U=,5S P
M,C)S-W5E8E589VI73U-7-6MK9%I#;W!Y84IN6E!W>7E';D%!0C,O2"8C>$$[
M8S1M9EA3;D]5;V=1<SE!3G9J5F]M6'DY;T5Z44Y,<&QP23%S>&4R6F]),DUB
M:V=L:W%V=VUQ:F-E1U0X2TAC4&LQ4C%M65A5-41I-28C>$$[*V\W*SEF<D=I
M851R3F],4%9,6DQU,D1#5#!P2VQE4S%!3S-Z=S5-8UII<$)J<'16:W=3-'-:
M-%I)>$56159&1D9504M0041*054P:R8C>$$[,F)B-C=(0VA#,V5L-F1D,DUT
M:&-7-E-78S0T>E%5;W)!*TE&36A,2$5I<3)B8V5E8TII8U-E26-I=G-,0WHP
M*WII<W)+2EE,5T)E328C>$$[34LO6E9F05E94452435)>35:6DI'56IC:GI+
M=FMM=#)+;T]F5W1)=#-22G(R1TXU2#E.5DQR6&PT9&1S;VYQ<U544FM.+TYV
M:'!C<R8C>$$[:%EI9FMI67 T6FPU=WE,26QA8VM)658K67DR37A)5T1B5DM"
M:6%)<&EX+TY8>4%"3B]U5U=T=F-*85-)25IY,W%Y0GEV0E)(>61#228C>$$[
M6%!Q2T-N=W1V<V-K>%=N.#!02S%R<'-&-W%T>#E51GI*9G!%26\W;318,#E.
M=6IB5'ES>5%G;W%N:5A,04MT97!!-5EQ<%%F;7HU428C>$$[;#%/87I.>592
M26]P26E)8F]Z171,4$)-2EE0441W<D$Y<U9D;3)5+V$T-U965%AY>#4W.&\K
M85I,,DQY+W%C5V]3864O<#-A>#AH=R8C>$$[2DI!235"95-N:6%-=%90631Q
M:U4S-7IE54Q05C<W5'16:G9D3%=Y;&QH5SEU;U S3G<P2% Q5W1X13!S<F]G
M:6-T25EW<6=B:U9'2R8C>$$[;S$O>EDX9V]A4'%427=L5T-65W1R<%=I:VM:
M56I%-$U665))6D8T1U1I1T<V,4=+<&)O4#5Y-D9F>5AD=G%&<E!P.3=A>7A)
M8DY%:R8C>$$[=35U3GAB>%A%5EDT14PX,SE6,4-)<D@Y,C=D06%+<S$P;E9D
M4#%F5$Q85DY/;#EE>'99,6UT<&='6&Y'-'%R8U=#<TMJ>$=+=D<O2B8C>$$[
M=7)A5F9F;E1E5#)*,#9A-VUM=D5U6F]&,#!Q8F%.5SE*-$IO;DXV.#<O0C9V
M3F5.3UAG34MS.3@W9FQN<'9M;E5"97EZ:7IL8E1,-R8C>$$[4W)I5TM*9E=K
M4SA%9G!L<&%G.%E#:D5)45%E6C9B,4-S53@K+VQV<&UM+VQ8-6=M=DQM-'4Y
M5'0W6%5B=WIW>C-.;F)'5S5K:W58028C>$$[<S1P:D1W1'E%0E@U8F138U9E
M=31Q-T95=CAW86Q"<&UH,S$O3S-'3S-G9'IU>3%02#12>50T:%4P1E)V:UI3
M249J;7908G9E3&549B8C>$$[2RMU96(U3D4Q;4M663E-,'533T]E5V%2>DQ+
M275.9E-"5U0T;#0P,TLP,D$V6D15>'EC6GAI:'=N,6-U=E%B9$EU-3=.>5E.
M3' U1R8C>$$[9#5-=5=0<')K4#9W=G%F9G-(;W5S9FQB<$4K;$-W,$\T;3!%
M=&-,8WI45W)Y<UI#<6M564=15C-)3F4Q36]N;V\Q5694.'HK;',P,R8C>$$[
M8C)73U1J>6=:9E1W9U-!,BMX;%9N<$]L,E1S.6YA43(X:FEK:VMC87%Z1"]!
M0VU!<3,P-6MW>%)J>4%$<4UM;WE:0E5P16IZ2TMY8B8C>$$[4S=&6%EQ-T98
M67$W1EA9<3=&6%EQ-T9867$W1EA9<7!Y,C%V33!B4WA,23!,8S1I=T(T<TYU
M4S$V2$EY:$=65TQP;$=C;S-2<3%42B8C>$$[35=(1#AO9GDX1G9,8FI3,D9V
M3G<Y5TE83C)%6EEY-5--<C9T4%1(<D]/2#)A35)3;3)+<CE0.$%Y>CAU>#9(
M2'!E<5)$565#86Q%,"8C>$$[=GAW1#!T5W548S--86]J+T%!<5<T9V)K9TPQ
M-C1Q<E,O;&PU26QV6DPU=$]+,V-Z=3AS.&,Y>$=Z*W!.3&-32WA34F%O.'1Z
M27I*.28C>$$[;'$W:6ER4E9&-EHU2S!04W)I2V)3>%!:3$A-6FUG:G5*5VEK
M0FIL:E=&;S5'9%)#:&Y:,&I4:7%T46=9<6=R,SAR9DEL.4Y.3F0V6"8C>$$[
M-GIZ=$]Z8W W:FEV,7!*16Y%4RMP>&E%;W5*0S9X9T%S95@R<4A&56XX>"]K
M=#5B,797;S<Q:CE8<UIP235T6'-6.5@O4S)H-&5N>28C>$$[9%I5055#1E9+
M<W)$=79":7I&5D@K6B]Y=3!45FUK=DQ#;6UA,4IC+U=Z<4M'9&U-:%-/2G%I
M2V$S9&%P0V<O9'E+4E0O2UE-<7E(>28C>$$[>F]6=&](;#=49$5T;F%31%1B
M84LR:FME;DIH16]8:S%.<713=4MS4CAS+VMX;VUG83%P=7)1-GAQ=#5*<%5A
M43)L=&135W)1:4]'0R8C>$$[93-I5FA(8GA/9E13-VLT+T8S,W)I<C!$1E=)
M+VTW+S5++WI4+W="<WDU+S5.;D976%EQ;&YM93@K<&58-RLW<GA-35):5T1T
M1U%2,"8C>$$[;WE";7)8-RMH,GEV3$E#2DHR83AP06=35%9"-7 U;'9(,6)Z
M:F)A4%HR,T-B53=*24)/6E-Z0DI!9E9M2T]/5D9T*V9%<T$Q94Q5>28C>$$[
M<T-%:GA!8W4X1&9U=F4O94\U>6-'1U))>45F=6\Y97!0-"LR;G%':6%,66%,
M<&M/;E=#8TQA1W9!1VQA<U-35%%!9%1K.$])46I6:R8C>$$[*UHS2V12;FQL
M;GA34C)7=$QS5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-6
M9&ER<U9D:7)S5F1I<G-69&ER<U9D:28C>$$[<G-69&ER169Z9"\X;&8U<"]W
M0S):8R\X;7II<4(O>$1Q<#!K>DQP9#)33E0Y1&MB:6-(:CE9-#EW1'@O,UA4
M>#DX=R]%3F)#6%!Z+R8C>$$[04)Y8U,U,71'5CA89C!V;C=U1FI(;B]Z0S!T
M:#5J<TDW8C W>')I1TLR9W1(5C5:6FHV9DEV>$%9:$%P4$=N,FTX4E5864E#
M95%I428C>$$[06IF.%A,.&11-6UL=S5":TTU=U!!3GA697)B.68V>&)*4$EV
M-69.8EAD:C5P,64T;FLQ=S)I4DQB4#A!0VM%6FE61FI:84%L,%A:=28C>$$[
M,64S9DQX23A01'1W,V5W.'$K-V\U3V9+3$EJ>35C*VPS,#(U<R]W3TLW1EA9
M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<28C>$$[-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3=&6%EQ;&9M<EA";U!L<E9.83E!,U(P-C%L=59T
M;%!%>71':%I9=S%'<'E)<%=H<#19<28C>$$[.#4X*V5F:S%8.'!.660Y3G50
M6'9T4'99-5=S-#4W:3)T-4DR:VAA3V5A5T<Q94XQ2V9'<GA+5B](1E5L8CAN
M=E!P,',R,S%I0W Q3"8C>$$[,7A%3&E12TEI94AQ,#1N96YX9GI5.3ES;G=X
M:V962V8P.65%*W%V=39U,DAA9D(Y34EC+S91.5!&9&,K9&)D>DTO2E U8S9N
M<$AM,R8C>$$[5DYD,64T:'9'=417>&1E8E-+>B]!1S-B;5!T8V9H<G5E=FIJ
M2U9X03-S6&0K+V%U-RMZ;E1I6G14>&EG04)T<T(U9#DW+VIV96<U0B8C>$$[
M>$A9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ<#-&=&(S3B8C>$$[=DIB6$U35#(X
M>6U/84=2439/:D-J2WET545%9%%C5EED*UIU;5<Q;"M5=FU05#E+=$ER83-J
M,#(T4S-T3&5-2D=O2T5L56IJ04$V;B8C>$$[;TU64EA$.#%V.2\V1B]Y2W90
M.$%Q<&EQ1S R6#@T3&UW=#4W=5!23$<V;&I6<').,'5:1VEC:F1#.&-R23-(
M>%4P>%9D85 K8G-Q4R8C>$$[1V-A2&)S<VIO:7-L,#-*1EEH2D)X;$Y!-"M+
M:#-(9D96<T5N-79Y6%9Z1DMM:5%W46Q"0F-&3&QH34=7<D965U5S=D9V:"M)
M9DQ&6"8C>$$[1U0X,R]W0DE#,S1A26)5>$=1,W9#-31I44U!275(<3@V:TAL
M5VQ-5E%U<#9V*V%D:'%E:C)"1VEY;E8W:5<S5U99<GIJ1C96=$QC8R8C>$$[
M;B]E9$0V4$@U;D955G%%=C5W5SET-FQR2&]L-TXV:U,K9VE835HT4$EQ3R]+
M4U96+V1O>&-J<6%51RM+<6PP9GIC:71:<%E4;V1X3B8C>$$[1VI.1F)R2&1+
M6D=!2E9!>E-H4GE/,51T:7$Y1B].:&M6;6PP2D=)0DM'2S=*0CA+:5=M2W%'
M;GEF;2]C5V-5,3!M:5=6=S1R2F%U;"8C>$$[>DEY1W1+1F\U5U4O46-69&%3
M9FTO36)G5'!O;'-)<%=J:$Q*8W8V<UE!26Q(0U4X47A*1D<S,GA60S)M<B]M
M;F-E64Y2,%E$4E5B5"8C>$$[-V4Q=4=U1$9E8T@K='1-;U9F,VY64'$K+W=!
M>&EQ360O=T$S:&91=TMU:'1B4$9+.&PS=W51<V)O,%E336]:95I-9V1I0T)1
M8V0K;R8C>$$[>%8Q>2]W0V)S8G=#26%(3W-K9U-:;%,V6#!K-'-F55!+56-H
M54)A3'9V:7$R+VLO3BLS=%=L=%4P4SAN57%&=#!3-6I,0FU!63AP2B8C>$$[
M5E@T5DIB<C)X5E9N+W=#5G1*1$DX8C9(3$EQ;&MI160R<%IG2VA15VQ!1F5M
M*TMT5W O3GE7,6AL;4]H,C@P:4LP='4P9#!X:EEG1B8C>$$[:TQ,2U9013=6
M1S)+<&XU23%R53E:.'5X6#)Q4E)W,S,Q:3AT-6MH1')(+V]T,TQB<7EH>5=O
M-GA"='HS>%908U9D:7)S5F1I<G-69"8C>$$[:7)S5F1I<G-69&ER<U9D:7)S
M5EDW-2]V4$U&<#5B96)1>$U,<C9X8DQ03&)1:35U27)6<#!7-6QG9TMY0U=2
M26EX5F5**U)X5D=E528C>$$[8FY83&YY=G!.>'(P270Y6FQT65@Q0T5#;D=C
M;T,T-&HW2G(Q2&)P:7%B67$W1EA9<3=&6&IN;F9Z3"M:;'8U>79R6%)8,59D
M1FDT0R8C>$$[-&UG,&MZ3$=H:E%Q8DIZ8C-!;EE49D1+5TQB4#A+05)L.%9E
M<"M86G16;3AV-EI.<3A9:#%A4S!G9E5)9T%!;'<P86U644)8;SE2:28C>$$[
M<5E9<3=&6%EQ,#5+<5-&3$5!:TM+5E!S2VM$1EAI3VAE85!Z>FXX,RMH<D9J
M95=6:S)Q44Q$6G):479B9E9*1VI.,&MT,4=K>3A,928C>$$[1FDP56=M6&TY
M4G52=U96-V9I<G-69&ER<U99>BM9.2\U;7-F2TXS8RM7-&YL,59:2498,&LY
M5U));6U26FY20D9C1FU727-24THO2"8C>$$[:3-1<7-6+TLW6&9Z3C%$6$I9
M+TY-3C-&82]62DAM:'5B4DQE3T=94WAI,45-<5)O2E=L9TQV34$W:%A&4&<K
M>FER,41&6%EQ-T98628C>$$[<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1E=.*V$O4$YP-6-V8D=Y:S V.3%'-'8T8G$T4DQ&
M64<T428C>$$[,EAP;5HS.6%72&]*;&]&-44W-UEQ:%0K8E U9G)E,E9K*W%H
M8FI556IK<S9W>BMN27-S4WI,4U52*VPO9'5P4'AB5D9E;WA62&%4-28C>$$[
M*SAP-G1Q34]M-F9E=$YE5'=2,U5C9F]4;U!3;6E%.&9*,VI61EIO;40X1TEA
M;F)&5U%9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98628C>$$[<3=&6%EQ-T98
M67$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<7AV>E@U1W10
M360W63-S;6\S=6Y4,D5.,6)O,6DP2R8C>$$[*W!$92MM2FMC>7A42&-1<E%P
M>$DS,WA6:&YM,SAG9$(Q1T-:.4IK;&=U-3%T-UI"3$YX:G0W94@V=719,E=*
M-6U+3%IO55)P3TEA="8C>$$[3U!),59:6D(K5VYL,D1Z;$(U<VEA9$PK,FA&
M=D)!<E)I1E5%4&]!8DHV<%5*,%%Y1D%F:30Q,WA6;&5+=7A6,DMU>%8R2W5X
M5C)+=28C>$$[>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMV.$$O.6L]
M/"]X;7!'26UG.FEM86=E/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+WAM<#I4:'5M8FYA:6QS
M/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP
M=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z<&1F/2)H='1P
M.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*(" @(" @(" @/'!D9CI0<F]D
M=6-E<CY!9&]B92!01$8@;&EB<F%R>2 Q,"XP,3PO<&1F.E!R;V1U8V5R/@H@
M(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P
M=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C.F9O<FUA
M=#YA<'!L:6-A=&EO;B]P;W-T<V-R:7!T/"]D8SIF;W)M870^"B @(" @(" @
M(#QD8SIC<F5A=&]R/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @
M(" @(" @/')D9CIL:3Y::&EL:6%N9R!#:&5N9SPO<F1F.FQI/@H@(" @(" @
M(" @(" \+W)D9CI397$^"B @(" @(" @(#PO9&,Z8W)E871O<CX*(" @(" @
M(" @/&1C.G1I=&QE/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @
M(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT(CYG,3%U,S,\+W)D
M9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.G1I
M=&QE/@H@(" @(" @(" \9&,Z9&5S8W)I<'1I;VX^"B @(" @(" @(" @(#QR
M9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI('AM;#IL86YG/2)X+7)E
M<&%I<B(^1FEL92!.86UE.B @(" @(" @(" @(" @(&<Q,74S,RYA:28C>$$[
M57-E<FYA;64Z(" @(" @(" @(" @("!R<C$Y-38W-B8C>$$[3&]C86P@5&EM
M93H@(" @(" @(" @(" @,3<M2G5L+3(P,C @,3,Z-3(Z-#8F(WA!.T535"!4
M:6UE.B @(" @(" @(" @(" @,3<M2G5L+3(P,C @,#0Z,C(Z-#8F(WA!.U-C
M<FEP="!697)S:6]N.B @(" @(" @(#(N-B8C>$$[26QL=7-T<F%T;W(@5F5R
M<VEO;CH@(" @,38N,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($QI
M;F4@0VAA<G0F(WA!.R8C>$$[*BHJ5&AE('!R969L:6=H="!C:&5C:R!I<R!C
M;VUP;&5T92X@4&QE87-E(&5N<W5R92!M86YU86P@8VAE8VMS(&%R92!C;VUP
M;&5T960@<&5R('!R;V-E<W,N*BHJ)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@
M9F]N=',@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @
M(" @($AE;'9E=&EC828C>$$[(" @(" @(" @($AE;'9E=&EC82U";VQD)B-X
M03LF(WA!.U1H92!F;VQL;W=I;F<@8V]L;W)S(&%R92!P<F5S96YT(&EN('1H
M92!D;V-U;65N=#HF(WA!.R @(" @(" @("!";&%C:R8C>$$[(" @(" @(" @
M($--64LF(WA!.R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM)B-X03L\+W)D9CIL:3X*(" @(" @(" @(" @
M/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.F1E<V-R:7!T:6]N/@H@(" @(" \
M+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z
M86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP5%!G/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C O="]P9R\B"B @(" @(" @(" @('AM;&YS.G-T
M1&EM/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1&EM96YS
M:6]N<R,B"B @(" @(" @(" @('AM;&YS.G-T1FYT/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1F]N=",B"B @(" @(" @(" @('AM;&YS
M.GAM<$<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G+R(^"B @(" @
M(" @(#QX;7!44&<Z3E!A9V5S/C$\+WAM<%109SI.4&%G97,^"B @(" @(" @
M(#QX;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC>3Y&86QS93PO>&UP5%!G
M.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD^"B @(" @(" @(#QX;7!44&<Z2&%S
M5FES:6)L94]V97)P<FEN=#Y4<G5E/"]X;7!44&<Z2&%S5FES:6)L94]V97)P
M<FEN=#X*(" @(" @(" @/'AM<%109SI-87A086=E4VEZ92!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(#QS=$1I;3IW/CDV,"XP,# P
M,# \+W-T1&EM.G<^"B @(" @(" @(" @(#QS=$1I;3IH/C4T,"XP,# P,# \
M+W-T1&EM.F@^"B @(" @(" @(" @(#QS=$1I;3IU;FET/E!O:6YT<SPO<W1$
M:6TZ=6YI=#X*(" @(" @(" @/"]X;7!44&<Z36%X4&%G95-I>F4^"B @(" @
M(" @(#QX;7!44&<Z1F]N=',^"B @(" @(" @(" @(#QR9&8Z0F%G/@H@(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1.86UE/DAE;'9E=&EC83PO
M<W1&;G0Z9F]N=$YA;64^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT
M1F%M:6QY/DAE;'9E=&EC83PO<W1&;G0Z9F]N=$9A;6EL>3X*(" @(" @(" @
M(" @(" @(" @/'-T1FYT.F9O;G1&86-E/DUE9&EU;3PO<W1&;G0Z9F]N=$9A
M8V4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT5'EP93Y4>7!E(#$\
M+W-T1FYT.F9O;G14>7!E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z=F5R
M<VEO;E-T<FEN9SXP,#$N,# P/"]S=$9N=#IV97)S:6]N4W1R:6YG/@H@(" @
M(" @(" @(" @(" @(" \<W1&;G0Z8V]M<&]S:71E/D9A;'-E/"]S=$9N=#IC
M;VUP;W-I=&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1FEL94YA
M;64^2%9?7U]?7RY01D([($A67U]?7U\N4$9-/"]S=$9N=#IF;VYT1FEL94YA
M;64^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @/'-T1FYT.F9O;G1.86UE/DAE;'9E=&EC82U";VQD/"]S=$9N=#IF
M;VYT3F%M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86UI;'D^
M2&5L=F5T:6-A/"]S=$9N=#IF;VYT1F%M:6QY/@H@(" @(" @(" @(" @(" @
M(" \<W1&;G0Z9F]N=$9A8V4^0F]L9#PO<W1&;G0Z9F]N=$9A8V4^"B @(" @
M(" @(" @(" @(" @(#QS=$9N=#IF;VYT5'EP93Y4>7!E(#$\+W-T1FYT.F9O
M;G14>7!E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z=F5R<VEO;E-T<FEN
M9SXP,#$N,# P/"]S=$9N=#IV97)S:6]N4W1R:6YG/@H@(" @(" @(" @(" @
M(" @(" \<W1&;G0Z8V]M<&]S:71E/D9A;'-E/"]S=$9N=#IC;VUP;W-I=&4^
M"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1FEL94YA;64^2%9"7U]?
M7RY01D([($A60E]?7U\N4$9-/"]S=$9N=#IF;VYT1FEL94YA;64^"B @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI"86<^"B @
M(" @(" @(#PO>&UP5%!G.D9O;G1S/@H@(" @(" @(" \>&UP5%!G.E!L871E
M3F%M97,^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \
M<F1F.FQI/D-Y86X\+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y-
M86=E;G1A/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^665L;&]W
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^0FQA8VL\+W)D9CIL
M:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<%109SI0
M;&%T94YA;65S/@H@(" @(" @(" \>&UP5%!G.E-W871C:$=R;W5P<SX*(" @
M(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \>&UP
M1SIG<F]U<$YA;64^1&5F875L="!3=V%T8V@@1W)O=7 \+WAM<$<Z9W)O=7!.
M86UE/@H@(" @(" @(" @(" @(" @(" \>&UP1SIG<F]U<%1Y<&4^,#PO>&UP
M1SIG<F]U<%1Y<&4^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP5%!G.E-W871C:$=R;W5P
M<SX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I
M<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X
M;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E
M+U)E<V]U<F-E4F5F(R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(^
M"B @(" @(" @(#QX;7!-33I$;V-U;65N=$E$/GAM<"YD:60Z,CA!.#5!14%&
M.4,W14$Q,4(U-C9%.$%#1D1"0S@Q1D$\+WAM<$U-.D1O8W5M96YT240^"B @
M(" @(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z,CA!.#5!14%&.4,W
M14$Q,4(U-C9%.$%#1D1"0S@Q1D$\+WAM<$U-.DEN<W1A;F-E240^"B @(" @
M(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#HR-4$X-4%%
M048Y0S=%03$Q0C4V-D4X04-&1$)#.#%&03PO>&UP34TZ3W)I9VEN86Q$;V-U
M;65N=$E$/@H@(" @(" @(" \>&UP34TZ4F5N9&ET:6]N0VQA<W,^9&5F875L
M=#PO>&UP34TZ4F5N9&ET:6]N0VQA<W,^"B @(" @(" @(#QX;7!-33I$97)I
M=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z,C=!.#5!14%&.4,W14$Q,4(U
M-C9%.$%#1D1"0S@Q1D$\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @
M(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z,C=!.#5!14%&.4,W14$Q,4(U
M-C9%.$%#1D1"0S@Q1D$\+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @(" @
M(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#HR-4$X-4%%048Y
M0S=%03$Q0C4V-D4X04-&1$)#.#%&03PO<W12968Z;W)I9VEN86Q$;V-U;65N
M=$E$/@H@(" @(" @(" @(" \<W12968Z<F5N9&ET:6]N0VQA<W,^9&5F875L
M=#PO<W12968Z<F5N9&ET:6]N0VQA<W,^"B @(" @(" @(#PO>&UP34TZ1&5R
M:79E9$9R;VT^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @
M(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I
M;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.FEN<W1A;F-E240^>&UP+FEI9#HR-4$X-4%%048Y0S=%03$Q0C4V-D4X
M04-&1$)#.#%&03PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @
M(" @/'-T179T.G=H96X^,C R,"TP-RTQ-U0Q,SHT-3HT,"LP-3HS,#PO<W1%
M=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E
M;G0^061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F
M='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^
M+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V
M=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$
M/GAM<"YI:60Z,CA!.#5!14%&.4,W14$Q,4(U-C9%.$%#1D1"0S@Q1D$\+W-T
M179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N
M/C(P,C M,#<M,3=4,3,Z-3(Z-3(K,#4Z,S \+W-T179T.G=H96X^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S
M=')A=&]R($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG
M960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D
M9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @/"]R9&8Z
M1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$(
M 0@!R ,!$0 "$0$#$0'_Q  ?  $  @(# 0$! 0          " D&!P0%"@,!
M @O_Q !$$  !! ,!  $$ 0(#!00'!@<% P0&!P ! @@)$1(3%!46(1<WN#%5
M>9;6(B-W>!@D-391MK<*)3)!87$S-#AU=K&U_\0 '0$!  $% 0$!
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MR::26.O#49(\N;6KNL.AA!](XW6I[-@L'P,T\K_F\K>QM+&-:Z1\KFC1DD#
M]Y_]3A$R.,$_'H8UOR 7<Y95:81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PB81,(F$3")A$PB81,(JC_ (:_\@/2/_$4][?ZB9=A5O\ 5O\ <9^P*W#"
MH3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"+@DWO\:-($=,WQ#8]B
M[>_H#$-.B3[]5!1?],>VWVEIP^<_C_"T0VHGI9?M-/??'W?=JN)GF21Q];(_
M,>QGF2NZ8V=;@WKD< >EC=]3W:.F@G1]%2YW2USM.=TM+NEHVYV@3IH^+CZ
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MQ?\ S'1C_2+Y8R<W_NSB'^';7_RWE"FG_M&5_P"?C_RO&I2W^;'KW_QRA?\
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M.O<B <]VR![H):#K>SLCL#]BPZF[9#W; @MCQV/3"/QN2,QQ6.=3,0V"OSH
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MSSVPO,&FV=AVM0$O]%V@FKKK;WBR_2D_6O::M"*W?/*KAX'.6 Z =*J?=OE
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MPR$O@9"UQ/F-)E?(UY!:\;#(7N:0=MT6DS^_@_5$Q_\ ;<XJNE!BOUY6%UR
M+6W,4>=_[%1UB6"A#8BT6UKZ[Z0?T<=2^_?/VK]<)=?L<%Y_%ZG^HI93,RCN
M)<C/%BJ9/RDQ] W+;AO^M'FX#H'W=N'1O.C)2_IS5JC3ZM@8ZU*/K;/.(HA]
MCJ;_ $'<]PN&0\EUA+F#UC<!6Q;XX)M'+$HVMB>&B,7(-W2/:"V^ZPB_<3J%
MFXVFHII-Z+KY@\0WU_W#A/7"6N*X^5Y.I(Q^(BQ^#,;VOB=BJ,,=F-S'!PUD
M[0M9=[=@;9+D)&.U[S3L[I=C*TK2VTZ>[U APM3/=&X$:.Z\?EU0='U; TCX
M$=ETWFCQQYU\012>,Z"@1,"UE;OF2RK?\J>F,E/=@FC_ /AA+58N]?/G" IN
M\?M@0EMUSOIR0=*=[</G[APM>Y+S#D/-+-*3/7H[#JC#7J@0P5*\ F<SSI7-
MA8Q@=,YD;IY7 ^[&P#ICC:ULXK#4<9U0T8Q +$C#(^65SMD$M9UR2./3'&''
M7H&@N<=DDGM?.-GAY5%;#=I 9N"9Q^S+A?/W4HB!D&DIKJSILJ\9L-.4-JD"
M(CIHLV+L&B:KAD[URVZXZ54XYZX'!\;R/'ZEFID'4S8O\BY+E*[*MR"S_H6:
MS][*8V61T3BV+VBE>KRAKR',ZRUX:YC@/0N9>7/D,2^">"<?T:XG1(CE:2)Z
M/',53GZ@==,9GB>(I3IDK!YC'%A!7*\Y6A")_P 64UBA9R2786=.'SOE8%(1
M/"+=\=7Y;_54R*'I=K[VGWI9HGWV[:[UK3I!'[N?KCX# Y;"0YCZ4INIF]RC
M/7J@?+ \ST[5PRU[#!%+(?*FC(?&\@!P]%5S-A$G'WAT;FQ\6P-1Y9+%)TV*
MU-K9HR&/<06..B[70X_HN*VG+K&"1]WN-,N"<EFSQI^9C#HF@W(R/E!?7::!
M)_IRL@)C0G:G/?*9V5OQ 11=/;5-XN[Z3:JXN7Y3C\59;C88K.9SLL8E@P&)
MC99R+XW'3)[?5+!5Q-%[@6C(Y>WCZ3G Q1V73EL3M?A^,7\I7=DIGUL1@H9#
M'8SN7DDJXT2, <^M5\N.:WE;S6EKCC\16O7VL<)GUV0!\K:__'\']B)S#T.I
M:5Y#'#4;9B<=V-<Q.-2198SU!H$;7-L7@1A"4&*B<?(Q\4CT_0,-U_Q//O$-
M%T?WG^BH8KQ),4,^1;P7BDN;J,S.8?@L9FLQ<N9TY#*XN22K)D^1FE1H,P&,
MX[#'&^G;EDN0VI"V$%QL^H<YS/A,:V!BP&$Y+EO9*;X:3[V5BQ->OBA*^6.M
M9BCH7;%N=^8FS5E[H;%,1P2UV-L3 ^77^/D[R[,:GMWU2<C-P;>/1]HCH6.0
ME<27D8K8<C5-1V/VHX'MI4 69N>.I6/$\I B EE^(+KO;?;=1BR%YW]&/$*A
M'C++_$DY)]S%69;,68XU4MU;]_\ I?RZ6#*WHL?>PTXO08*QA^/,%&W3KBCA
M:[3"8V5(:=KEO/>'Y[%<?J6. "E$VL+0DP^?DH6ZS(V-Q;Z56>WC<K"^K+?H
M9'+N=?J7+'M.5E/FB7VJ:YTGESS@=Z]'>GR-E02HA40C<]%BA8RO(^- #39!
M_7]7R)@S<LD6BYEW#DP^@\D)14Z9[#.)P14*NQIM^S3>C\1V,\2.2V\/%XE7
M<=>XQ!BKEXXG&SS,QN:Y!#S'D=?%7+U*9UBU=I4N,5\3NGE+<D#;[VAT%SV6
M*2IF<GY=Q'%\6P@X+8Y WD-UC1)D<W*ZU?Q.*%1T>0CJ6FNAIU<G9S<F1KQ9
M'&4F6AB8?*CL4669(;7&]<QLQ(./078).<-GH*WJ?*\&80RB3E43I:JH>!YX
M)+'Y7$2[-N][-<),U(R^<+*ODD4"S=,9VH[;9OB[X69+Q8X?QS!87D]?BF7H
M6Y,I1O68K!CE$-R]#9@\^C5FO5BVK++.QU:6 2R0QP3>9'(3':\'N;4.#YRE
M?RN+K9FA?P66Q]BC9EG:7EU^2W%)'%Y-BE8+9:K62MO0N$<,DDM9PG8(Y;/Z
M^_E]0>)\'M23^;1 #&Y7N8)Q]*4+/V[5-!TY/)15^4CB9-TLGTX=<!B+UCRH
MKO2+E76M];ZBC1FQE&GCK.4?F[%&K7JSYB5C8Y<G-!"R.6])&R"LUC[+VNE>
MUL$0:YQ ;H;/C>8L5K>6R5JG4J4*EF[9L5J-!]J2E3@FE?)%5JON_P"E/@KL
M<(HW3ZD+6 N ]!F&92UJ81,(F$3")A$PB81=3_ @_P"/?"?X83_%E.WRI,;_
M !S/^/(J$U%%22CYG^']=WV15555?=N$U.G:BJG;C:G7?6]D7)=C1S]BJ+?,
M&3T8NCINL.=M4'+%9OK6M:05:+)]MU$=:YYUI+M/?&M<Z^G/]M818U)(!%);
M(8!*) ,_D#-82$I*X0XZ=.T4PTB+Q&101Z5_7;K)(/5^HI+9()22?\.FJ')9
M9VDWY?MV3IJ3]ZRA\Q9$V;D>29M2#!ZBHV>,7S=)VS=MU>=\*H.6R_"B*Z*O
M&]\J)*\=\=\[WSUSO6_IA%Q"P((>$.X^<#"C0%^V_2?!"PYH1$/6?TYU^H[&
MO$5F;EM].>=?@61[2^G//_8_MKZ$7R'QN.B6H9B* !1C*.I=-X^S'BF+)J"0
M[;]->T0S=L@FB,2Z:]]MNDV7"''3?OI'?.T^M\[(ONB$#-W";MN(&(.TER+E
M)TBP:I.$W)=3A8LX36X2Y4X7**I)JD5>>M*/5$^.W/2O7'.]$73BH'!@30BP
M!PR*!F)@KR=+,A4=$#FA0WRX1=\F2+9HS11?%>739NYY(N>%7>G""*VEOR)<
M=<D7(W#HCN3:FNXK'-S+3#8K4MV#&?U-H7O?UV-T>_5_E=,-[_OMGIW^O]?[
M_CPBR/")A$PB81,(J5?E%I">>IB_G";^=ZQ\Z^W7'C2\Y::NWQI:$WA0<7/7
M4KK9W'0HLT>/-#@*+2J"N2K.9C(O/6: (QTX%'" \KL,)9/"K:0-[);L=G#U
M'?\ 5V/IV_BJ[*.^.FX(AZ9I;TI:?GWQEX,?V)[^@]P *I@\UKUQ+J=@D#\_
MG*Z>4S74NC F/M9X=]03@HU+3*OH1]T,&?Q#J6\B&Y<FY:(%)?L:VYP#2-GX
MDD'9&SK7S[DD#T&M>KW"MIA$PBJ/^&O_ " ](_\ $4][?ZB9=A5O]6_W&?L"
MMPPJ$PB81,(F$3")A$PB81,(F$6F_04?:R&FK&1<D92)4%Q"1GQY&'368P$X
MT*A09!\.71D$&.QTYRBDZ23468_R&V#W7&DGS5RE_P!WFXP%AU?,8YS8ZLHE
MMUX)([E*G?@=%-/''(TU[T%B#J+"0'^7YC-DL<T]UB7F!]2P"Z1I;%(]KHII
M8'AS&.<TA\+XWZ! );U=)^((6-UO'VD=\U"6[4C*2W9*J^#S\A,9K,)\<=E#
M402?$5UI!.3LB.]HJNE5%$67\C^BRYZVDQ;-D?HGK)R4[K'))G.CJQ"/*&".
M.G2IT(6Q0VS'&T5Z4%>#J#  Y_E^8_6WN<>ZHKQB.@T!TCNJMUETLTL[RY\6
MW$R3/D?HGN!U=(^ "CE9'J6,>.?CL@EYR,5J3*QZCZ>81Z&(F60,C+Y >CD5
M"L!;%X[2=]\)-=O^S)EPT'DW0^/C2I),>Z_4VEUT&-XQ9Y?X@WL)7E]F%C-9
M=]BX87SQU*\%BU,^61C7,!+_ "Q#"UTD;9+$L49D;U[&OL9*/%8*&Y(WS#'3
MJMCB#PQTLCXXV-8TD'TZNMY#7%K&N=TG6E&;P$_2^1;QS732W(^H"\^5W'(_
M2#JFF9,KTG;\@J^+QD:YF\[ES9K'G[F'IO.6CB-0&-Z;L&DA'/7DKD4I49CQ
M 3I>>1N\/>7Y%^*L"?/Y"S/FF9A\40.)KY.U9E;2HU'.L,;<+.IMF_8)D?7D
M:RK6JA\DT^OPCAGL5 +49CHP1LIFH'.U:?7CC:9II0(W&(.T8X(]-$C297RZ
M:UEI]'4'3_FR!-*PH^"":]@[-^]*\!!2I!WTY*D?Q:>E"10P])&2Y)PFW;-^
MWY4B]=Z:-&;/E;EJT;(I>89O.Y?D=]^3S=Z7(77QLB,THC9TQ1[Z(HXH61PP
MQM+G.$<4;&=;WO(ZGN)Z2G2JX^ 5J<+8(6N<X,:7';G?I.<YY<]SCH#J<XG0
M WH #,IXT D(;)1\H+M ,<("'; X5(?T_M@V%O4]M7O+[F5L"D<59ND%>VCI
M R.>,%T%^T5D.]*?3-)+!;LL,%"Y?QUUY::M[%B$Y&K,QP>R:G[16N0B=CF[
M8Z2M,&GW@WJ (VE)[&6H728^OE6!Q#\=;;:?6N-+2UT,S:5BK:=&X$]0@L1/
M.OT];!CUXSCU:QFF1HVKR4/6"*OGI!\%@P>LX^  EG;A7EPFD%J^-1@2S<D$
M4&[MSV0:."+GK?*NW&T?Q\<Z3C,_+KV'IY3FN>Y-G\WD(O,EL\H;6;<ACADE
MA9! *^-QSA7#6!X;,V9S7N<6O:TAHZ?G%+$8W/6<=@^.8OCF-ID,KP8H9/R;
M7F1QROL2.R60R!?('O='U5W11]+0',+P7&66;]<<NEDC<F\CIYH%<NF1AT%*
M-Q+QDY8LGC0DLQ738N6CPH(D UHY0==)*H.2 $VQ05YX5=B"2'"C-:W++-#%
M)-7K0W;$3'RP4[$TE:O:FC:71UI[$37RP0SO BEFC8]\3'.>QKG- .14%<VZ
MHMO,=4V(19>(76"ROYC?.>(&SUG3%L?41"VS7=(1T">(N$C8L>53ME*0>PY;
M<\Y*F&8NP;:C[4K*S\!4' @E56W:$)=K=]Q6L:T;C4F@B-C=&C!EV7;E^V'1
MEJUBR';H<KD7K=KVAPNX/$X"K!B<'>$U++W+XGGR&$IW\JVS[=%$VM!CKDDL
M-69CS[37)GF9 6B,;[ES>.XX5Y,;;#(8Z0N9"2Q2EQL->O)2J6X;4D]G,Y-C
MF2P22V9F$5F8\;@?-<#18&+^=/0-1]PZ?M8]-!$Z/?XY^ABC.*5^OJ;2D@Q,
M7-.2H,@W!QO1)\D%-,';1V/D;Q)M'5&;I)]V539;Z<<Z#D'.^,0R0NJ9)F:M
M.QN.BKXW QRYK)6IZ^)I"2.&IC6696L8]S8YK<S8J55SMVK,+&O<W&Q3*/-[
MFN.9WC60JXW%X(9?)0\CPKL;AQ-3$#!D;;;QBKSNDIW&Q423?LR59XJM6:9A
MC6!^1Y!>-MM;K8RB-DJ,C+.]K(<.W++2#R8G'Q,\X<%(N+*D?O:!$(]OA)H4
MD[ (_4,]/_MC1"//1JSO?)5\EX@<TFCKY?%VO#[%083 R32P"*?.7[%NEYEO
M$U+=KJBH,QG2R*WEJ^/L.OFR!BK&-L5))SZGS+&\ X9]#V,1E*OB!E9Z#8XH
MK'F082A!4#8JF6MU*O3-?DR0+IJF)L9"NVB*^\K7R=>TR$3]C,.CL*&+C8H)
M:C>%U57CI;OMPZ?%R:G&N>R9\P\4=%S9-QOGC3LJ5=OB3C7.MJN%-\\_3LL3
MA,7@:SZN)I15622.GG?U236;EEP ?;R%V=\UR_<ET/-N79[%F70\R5V@O(\Q
MF\MG; M9.X^W-'$(*T;@R&I3@9LQU*-*LR*ICZ49)\NI2KP5H@3Y<3=G<>O.
MG%B<S+T4I+F\+2:.;B[76_IMZ<<N>#W%55$T_"ER3'M$NA&Q;9NM^?OOEY^^
MHLE^#]?CA;O*K93(9%Y@N5Z4+,0P8QKJTT\CIG[&1\TMEBC#&=.0\O0)/5%O
MT=VX?"9S/YBSD*N6IX>M#Q^;Z%$F.LW9Y+-GR*N7\XLLUH6QP>5EQ#H.=)YD
M/5KI?V_GSZA8Z5E^G>Y>O"562UOA5'O,;;'476I#KSSYY1;;:]$W2R6@W\ B
MU_/PMST^V8VOVFIIE^-/5-;)9.^]U6['19%A6'&,=5]H\R=\KAF1*[S7%K6M
M;EG0%H!),+7[ <0(PN:Y%E;F2H9>+"QU^,S#!L?CA>\ZU/8J4.2-L.%E[HXX
M6Q<@?5=& YYDKMD#PUY:,QJ+_,[U/_XR1#_3E1F=)D/]AP7_ $VQ_G.57<7O
M]CPW_(3_ .:Y%5,P:P+,G=C^YAA1%9Q"8++8 /<RE"QM2L1)3&K&C,5B?8]B
MF 8H.>58]$"KM^YX(]=1=ZAQ%UT7KKEP\1R,5BV4<K&79G+7'0N;%3QUUD3(
MJM>Y@(<I<+^EC7];+ET,@ZO]9$\RM(8&M.GXSB'T>39+SN2<@R3:,U:OC\5D
MGP>S5*^2XS5S-TO:R%DCI(KUXLK%[O>@>7#W6M:;Y,T*NIA$PB81,(F$6OV=
ML580E/<&8677[Z;)O'PY2'LYE'',IX(#$W"I)CW'T279;EX/2:.E'S7III=H
MFV<=K\)\HJ;YPVY"@^P:C+U-UH.>PUFV876 ]@)>PPAYDZF!KB]O3MH:20-%
M=+/PSF%;#MY#9XIR6O@'05[3<Y/@LI%AW5K;HF5;#<G)5;2,%E\T+*\PG,<S
MI8FQN<9& [ S,7-+X.7+9DV</'CA!HS:(*N73IRJF@V;-D$^E5W#A=7KA)%!
M%+CM1553KE--/GKOOKGGG>]$6C*]]4^8;:#3>1U9Z,HNR8]6C=1Y8QV"6U I
M:'@3))L[>J/ID3 GW[*,L>68]^\_=-+LFNVK%XXTKM%JOWP4Z(UL$;].WK]B
MQH?ZXI*=1>(S2BK.IV^(I);>B=0O9'7UX58] !3,E<Z173X-:DBPT])AR"C=
MVUKX*X<S20IN4> @IUUWS]2:(]01\?3X?-;.M*\*7HX2F>NFW*RJ,*LV(/$"
MUF3R+P0<X:BNF/!-PW>2<H+0<(CNR8WAZHBIWRU[(,>%M\=.V^E" $^@)^Q8
M2#]9>:9H:?1"N?0-%6+8#>O^;/:0&(W'71>3D(,Y$H&A<M3&LI$Y<MXD5'O1
MSUK*UT>0&AY)B2[??HN45E":/KHZ]-Z^/R_ KJ=>OO/D<BE'FK@N>D*8DE]Q
M.)2.!PZ9WA5O+B2/94*%/^!$%.H27D)9;=N\*MQC*109R8 GU%6;L,[=-23'
MM8FCWT"=>O8^GS/R_6LV.>CO/<9M4#14DO6G@%VRE%%S&J@-67#!=GR!!SPJ
MJU5"P-\:0E!/AVD@NJTZ9BUM.DV[A1#\G""W7!-$@D D#U.NP^TK<^%"UZPM
MNJ2H.$R<99M>D8U99=O'ZYD+":1MX#GY]VV*O&H.$EFY)1A*B[EH"-NFXT$X
M?O5FP<JNFATD/=](E.C\BM%2GV[YM95]Z.F-<7!5%V2#S!6M@V/9M<5=:4&E
M4S!H5]'3)U\%.C I@F[C#YZN$<A4E3;1NDW*?>W7Y_,@LCR31[;!&_38TNK8
M^YJ#E]1V58E3V935H2NIH"UFE@5B&OFI19:".W@O1!*.V1(2TF0C]9+)N.7(
MQT6G*X06R>LGJ;M5'IJOPF31!&_CZ'7K]8^?ZEN8_P"C//D5M*.T;)[SI^.7
M3+D47$5J([94-$V;)$7.E>FRH*"OS+>3EN'7*#CIKMB+7TYY;N>D/R:;K;X)
MHZWHZ^?P^]:4A7O+SL_HJ+7];]DUSYPA\PGMH5X#4NNRX5"&I ]6%HS6L7S=
M@8D90,.(.2CF%.SK=BT44=-1CM+]GCZH+*X4])WH DCY GZU,0<1'EQ[$L)?
M,R@HHS;$1A,<Y0>CR(]ZAPY9OF+QMVJV=LW;95-PV<MU%$%T%.%4N^T^^>ME
M2N9A%6CZU^.7P7Z9L^,RNV!'-9^CIJ@_#1&S:BM8W1%XSMO&!/\ )%!B+Z&G
M0CRS?Z<C[33MPF=$2I>.@VG*J/0X>COK15!S@.Q[?6 0-_:"!M<#RE\;/@/S
M?;9Z65L/4MGTK7[06UD%@W3;QV^KKK=A+6#ET"33YF1XRI5^Y,)2?J#GP0#&
M'\B$?O<?N$1VE>.2%SG>O8'X  #8^SU_6K/<*E,(F$51_P -?^0'I'_B*>]O
M]1,NPJW^K?[C/V!6X85"81,(F$3")A$PB81,(HS>QQW;GS#>9IF=F<:-P>J+
M)GD8-P2>S:O#0Z3Q:!24@#=J%H)((Z1(L6K[E-TL!*.7L?(K(-NR0MYMLW_%
MTG$) WDV$A?!3LPW<KCJ-F&]1I9"&2M:O5HYV"*]7L1QO<PEK9XFLL1ASA'*
MSJ=O7Y5N\?<>'RQOAK6)HWPS30/;)'#(YA+H7QN<T'N6.+HW$#J:=#6[X3%1
MD+C N."'<E?,&*:RB+J7S.86#(%>GSE9^O\ O2R>G9)*2?/*[E3AKP2,N^&#
M/E <QY;#VK5JCI;MJ2Y:EL2LK,D>0"VI3J4*X#&B-O15HP5JL>VM!>8X6&1_
M5(_JD<YQRX8VQ1MC:9'- )!EEEG>>HEQZI9GR2.[DZZGGI&FMTT "&?R1^K(
MQY*\K6'-BXUO)I!)1;B#1&&?SS(&_-D94ET%=D$^UTGCQ4;&F#U<V5V/&OE?
MQ-DFRGZG#O\ >;]AX=<6L\KY1CZ4,KJT%:5MZW<\A\\<,=4B9L9#2Q@DLO8V
M&(22QC;BX=99T.U6?R4>,QMB9[1(^1IABBZPQSW2CH+AL$EL8)>[33V&NV]B
M#\9EGJ+Y-/C?8 Z+$1[S6TD\/8PO^M)/8$F<'I6^KPJU#F@D<2BL.:*!8/+>
M@2PHI+795V1_"N9CFX<_8_E+N.VLU>,^&WB+)/G);'(WUKDESV.M0K-@JQY"
M)TT$U@VK;Q-=J"<2Q5&1,CZFPV1;8_IB;IXY<ER' !E-D>/$L0A\V6>0OE,#
M@Q[(Q%$.B&4L+'2N<YVB]GE.'OF6'Q]>'"7F^A(]%?0[V,W'<B; \ ?R<DX+
MSP?%Z^*J_A955$"<Y;[=L86BPXTH6#"A($*2?NW"3@:^1:-7BW*\^YM'R+/6
M+7'V6</AS)!/'6B;%1DM7XAM^4MQ47=$EQTG:*:66>:.-C2V1CGO8-G@\.ZA
M2CBO.CM6PU['2.+YFQP//:M$Z;N(@W])K&L8XD@M( <9\I,H_7,328Q>)<#X
M^!030&1."Q]HW3;(+.^>=H!@ M-FT22X5<]NEDFR:7'*>G"^^=[UU]?,\OE)
MXH;.3M,R.5G'0^5E=DE_(V7.>R(%C'/\R9S0X.<2_;8F.=O3=+J,;09:L048
MIJ-!C^MK9;<K*=*$,C?)^<EZ2R(.Z>AGNZ=(YK?ZVUA6[/W)JL>6%"N/X--P
MQ'OX^_L( <0%NV)'@8[:%5!@?O9MT+>,2&M-56GV*[=?V4XY315^O,T.6T,M
MQS^DM9MW'8V2&"S6LY;&6F&:K9BK3U[D=.%_M,U:>.S&(WL+7=?7U- C<%M<
M_P 1Y!C,M/QFG/AK'(F235NB*TR]2K7:L\\-JI<?'8I-$\/LLP?&+,>B8G![
M@X-=BWG6Q35XU6SEDX0A#W4A09.?X>."I!P-9,WHYF]V,+)2O\W\@]165[WV
MX9:Z'J)?A^SZJ<][S-XSG6YND;L5F*26.41R>S5[=45Y?+8]T/59<YTKF]8/
MG0GRW!P [@[XSC_](GX3#Y?/1T:T^;Q];+468WK:V.G9C!8V1QO7'F42"0%Q
M,!Z0T&%IV3\?) H6,H"O=C1K ?MV/(+.OT6;=I^RMR<*I\JN/UTT_P RG*?/
M*?/:GW=:XYYXUO[=:UG;9V1[\I;ZWO?TO:&];B[I'EL.ALG0WWT.RZS.O>_*
M6^M[G=+F!O4XNT/*C.ALG0WWT/BI(YJ%J%PB71'@<0[#HLG);ADZZ%MR3I=D
M.<$>4%-L42#UJT(.6C)5SI)-TZ;L'J[=#I15%HY4XY1[HD,@C>8@QTH8XQMD
M<YD;I.D] >]K7N:PNT'.:Q[FMV0UQ&C:G,X@F-5D4ED12&NR>1\4#YPQQB9-
M+'%-)%$Z3I$DC(97L87.;%(X!A@S3<CGS"L9-"B(2"]RF>79Z='Q%FP+%9*/
M1T\]$6ZYLB13 <5CH!+B&0A4AKEGOEPKU+N7 <*\YCY:0LV?/%\BY1DLE69C
M8,=C3G,Z)>.XJDZ23)5&0X2/Z$S.<RT$M6J#B*$-9EN6$GINSVZ6&\V*S?@<
M[9^'%W)\JEO<JY-3JX/ \5LMI69L)EK=F];N<;NV^.P8^E8L8S'^RY+.7L'Y
MF-?"VS)2I.O92>+RL3,V3(O&M2PFHZYL-E7@ECV8<6Q;PYX0(/=INSVXA84L
MCL71+D6S1YTR8H,F?'/'# ;VU9]NR#UH,47=+\+87A[P? \)Q-RO@J+8[$UF
M6G:NV';M7V8-\V*QK+,[8],C@K0 -B@A9!%)-9FC@#YY.O!=S;DO,JF3LY:P
MV?R.9>)=S'8[J?6Q]2SFN<Y[*WFQZ9/(SVFY.!/:D;:M&&.!CC*RO#&,I\P+
MS[M"V>)?'X>':]7/9;I!:-S(U)7'99Q)%^RC%5L4@D332',]_CY8$^'2SDCK
MKOIP)%[XYY4[JOEKN5)=:HU:;:+&8UOL]^6X99*.X9)"),?2$;'Z#F &1W<A
MVM G083D&9Y ;;\GB,9BX\7,_"L-#-6LL^Q8Q;W5IY7LL8+$-@A?TM?"0^9[
MMEKV,T"9 R^:1& A'$CFTICT/!-^N$E#,F+,0PSAPM]>6[?]H@X;)*.7'>OL
M;M4U-N'*GT20X[4ZYYWL:]:Q;E$-6":S*[9$4$;Y7D#U/2QKB !W+B--'<D!
M=+!7GLR"*O#+/*=D1PL=(\@>IZ6@D ?%Q&FCN2 JOO'OJF[IO+O1:LH\P3;^
M%YM)5=B1@FT%>2LF3CD; N6:"EG/*T:,@VXQ'HW*V#PBN@\?-9D/WIHB@ATL
MKGC!8NM-F1!G:ID^FPUS+6P8X#@<%,UQ%%MUSY?:)IZ[VL!:QU9^W$G0P\3A
M<=7O<R$&9K>8>8:<RSL>7">(\2E#C[&VVYTGG2S0N:P%K37?[Q)T/[\IVS[.
M3M;U"K;_ )X)FH_NS&/*3.MN*G"R!"7)P*!C!_9M2;>CD0K9CW4H>M3"C",O
MI<V4D4E-_22HH#T!W4,H<;-C/-QV89',,[6V^Z;\L)KGB?&)'B,5<,92_P"D
M);L?5.VNX000_F"7ND3$TN/NR?.Q0RK(Y1S&@"ZW[;)$8#X=<">_RQ6Q)D+A
M>DN1ATS8'"&*+\R2\O6#>6*UOBS;I].!;1@0VAJ]&38:PDB46<G6L_GK(I&0
M'8V#-Y*PLV= (Y'RD($0R3V ]C!8M(_W9-W&8W+Q@]1YIACU*O&L+;RMG$2S
M9*_#?@JT39GDGI8ZO)@L%>LR-K6*\#Y)/I6U>]E;-#'%MCIY8'N(#]?Q_$\6
MP.;Y;;PWG7[U7-5*&/=9M6;-/&TY^)<3REORJMID9<YV9N7Y:[988V!_7/)"
MXNT[E>D [FL+#GY.OFD7C<;EYZHZ#+B7#54?'1R 6(06P*F4;,Q'ZZ YH"=1
MV91$8@FGPUVO8#5DGQRMVTUK5ULMDZQY1<K,K7+%"_1RCO;GV#+*+E&IB[GE
MR1]3G2/-NM;G,A),=%Q!WU%:(Y[/8FSX@93%Q8V]8QV8P60G9EI+G7*R_A\5
MB+'D2UNIQE+[U>W.90>J.F[1!V5;^#Z+]B!_9[L5V9Z;)[(]@]N=B.G7]_R;
M'[>;Z=;;?[/Q_GWM3_;]V\KB\T1L$_E^=TCS/*ZA'U_'HZ_?Z=^G5W^:ZRK[
M4*\(N^1[7T#VCV7S!7\W^MY/G?G>C?IU^]\UVN7%?3")A$PBU5-JD%3DND8>
MS&U0"R3%%AIE";/F4-$=IHK.%N7"HJ/E63%5\ITYZ36>]H[<K(I-T5%.DVZ7
M/.OM8Z.W()76<A"0P,Z*M^S6C(!<>HQPR-:7GJT7D=1 :"=-&NQP'-+G'J3Z
M-?!\.R3'V'V38S_$L%G;K721Q1F)ES)4[%AE=HB#F5VO$3)'RO:T.E>34- _
MAR*1#VF^]2.?0IIU'7=@6-,N8V,1E8>Q>6LW&2ABT:*VFA,.RZQ1GV?1[+F>
MFNESB"#UNXXXY(*;Y\\J>&[ZW)GYUV8E="ZW=L^3&+$5T-M1SL:TY 63(9&F
M8&23IW* YK@ \K[9Y'^7+3S?@+7\((O#*A#DX>-\6P9RMN3#7N+NFX_;Q%F:
M9G#Y,&VDRG.W&R-I41-Y>/DD@DB<XUF W#06LAL!<$'+&561(NB**""B4ZL.
M5S9NVTAWVIRH/0D9)^DP64VIOE=9KRGVOQSQPIOKGCG6O1:E!E-SW,L7INL
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ML0B,HJ"BW]<V7YXO"1R&6LW]<5^C/3"\_>S6+C):!>MS\G>">7\M BQ92!V
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MDAD=&'>6QP8.\Z?IKZ?;]-?3Z?3Z?37T^G_P^G^SZ?\ Z9SJTWKZIKGGG_\
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MU[ C]ZB38?QGI+>5?/E2S:6')S'O,GQK>BO',O$UG%$U; M!U9544;%$9)6
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M55.VJ"Z/.>CGA]S!$XPU:F,KTR6,$UNM5K-:X^:16-B5CK#&E[NU9LVG!S6
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M  7;4]_FEZO_ /&J'_Z:J%RYCO\ ;L__ -3K_P"2XE87-_\ A'P;_P !9O\
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M\;HX;DF'DO"/(S5,H8\UQXGJ?)7,M27&YJ\;->1Q=-<BQUH3QFG)':NO\RW
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M)--*X]W22/<]WQ)79Y6L1,(F$3")A$PB81,(F$6)RR=PZ"<1Y28R03&TY9+
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MF@)<(JN%VSO\=?5W]?P_BI 8=]W#0WWUW[@:^WNI%?L?/#_N?XC_ /F/V/\
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M7X8@^:RZY)L2F\J%CU0@0"V1 #3!)RT"-'39V3:,$TD2)0DZY4==E)).M_
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3PB81,(F$3")A$PB81,(F$7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>img187419207_20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img187419207_20.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1HX4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &AR^9H0X0DE-! 0      &8< 5H  QLE1QP!6@ #&R5'' (   )P!QP"
M4  (<G(Q-3$Q.#$< @4 /4UI8W)O<V]F="!0;W=E<E!O:6YT("T@,3-?(#$U
M7VEN="!P<F]L:69E<F%T:6]N7TY%5U\P,#)?+G!P='@X0DE-!"4      !!)
M>PJ_)0A]$P]N.,DXGSVO.$))300Z      #E    $     $       MP<FEN
M=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4
M    0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M
M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\
M;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N
M=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT
M   0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O
M;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP
M $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B
M;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P
M  ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0&HQH<
M   *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=0
M0P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M_P  .$))300-       $    'CA"24T$&0      !    !XX0DE- _,
M  D           $ .$))32<0       *  $          CA"24T#]0
M2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M    !@       0 U     0 M    !@       3A"24T#^       <   ____
M_________________________P/H     /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H   X0DE-! @      !     !   "0    D
M.$))300>       $     #A"24T$&@     #-0    8              A0
M  ,!          $                          0             # 0
M A0                      0                         0     0
M     &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M A0     4F=H=&QO;F<   ,!    !G-L:6-E<U9L3',    !3V)J8P    $
M      5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L
M;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O
M1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$
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MS_V!T;_N(S\?[TOV!T;_ +@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MYR_VG?@;_BFO_5SGJJMTNKXHR_*C^[W%I2H:% * 4 H!0"@% * 4 H!0"@%
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MTJD]05YU\C*D]K19H;G+IC6^<,E)GT:G$<;F((GXAM='P0:Z@R!H%M6@% *
M4!5K\Y?[3OP-_P 4U_ZN<]55NEU?%&7Y4?W>XM*5#0H!0"@% * 4 H!0"@%
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M 4!5K\Y?[3OP-_Q37_JYSU56Z75\49?E1_=[BTI4-"@% * 4 H!0"@% * 4
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M0"@% * 4 H!0%6OSE_M._ W_ !37_JYSU56Z75\49?E1_=[BTI4-"@% * 4
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M(F/H^T=&^$%EP78:#\%\.<.\H=Y]KR#ES:\9QGLEB^K&>>\K13"/ M7/C/D
MDZ YI-[=EFZ62F!*"+V@F9@/9MS-)P7R+R<!<T:VWO=[!))NWFNN!-)4** 4
M H!0"@% * 4 H!0"@% 5:_.7^T[\#?\ %-?^KG/55;I=7Q1E^5']WN+2E0T*
M 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0%9WQVVM_[0
M'YEK?_1VEOT?K]GL8H+[/T?\K^RM.UH^N_;W;S*\J7JZ/-WEF*LFA0"@% *
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M!0"@% * QWM3;FKM&PAWV5N78<,U9KU@Q0R>IK/Y(T1.,-F19"8@21;R^&!
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M4^L'S3/0.NH_M#6DBS$7<XO(D5[C_&MZV)+<ZMQX2XCLR/3:1CZS:]LI[>[
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M463*P]:UDD\E73;I>[BS*33DV]CO[^DF=M>U[>VU[7M_K;]-J&A0"@% * 4
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M6Q)65D9J+G'JGTN$I);%.5-6A*:5E*4=]WM;;;NVV25U"B@% * 4 H!0"@%
M8IWCI'5W1^J)OI'=$2;YSK+8C,HQ2N,.61"2#@%DJD4.JB6&L.<WN+<<.*Y-
M3HWDC.#6YB". )*!0R*N&9PC-)2OLE&2:;34HM2BTTT[II/@]S33:-1DX.ZM
MN:::334DU)-/8TTVFO.:#0OPT<$Q#5&ZM/FZTE&PH]O]GBT=V4^[1V=/9W.G
M"/0-5$F!,;/-7E\4?HNVP<P88V,HQTIMS!+&&544(N,A9/4KR@HMVM459RCX
MLY54K*I*2VN5MC3;BXN46FI23Q%:9:EM\1TTI;8JF]KA&.Z*OMV6::3332ML
M=R'POSWQ$R3=JT>QR6SKLR0C2?8DXGLSD>P]@S=V "Q;6I612^5''NI@S.WV
MS%:@,%4@@L5RE4D/B#"EEM.<G&,';3%RDDDE><VG.;LMLI65V^"M8BBDW+:Y
M-1C=MNT8WTQ5]T8W=EY^JVX-9-"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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CRM9"V*:.*8&T5 * 4 H!0"@% * 4 H!0"@% * 4 H!0'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>img187419207_21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img187419207_21.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '9 @,# 2(  A$! Q$!_\0
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MD/<P2_8I2JO)&."&QNVD$''X'-=6-=M-.TFU>]DF+FU65BL+OD;<DD@8_,T
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M(JV?'^@)>6]K++<Q2S>7N\RV=1 9.$$I(Q&6[!L=13NQ60G_  @ME_T%M?\
M_!K-_P#%4?\ ""V7_06U_P#\&LW_ ,54>H_$/1K#^TH]EY)<V-O)<>3]F=?/
M6/AO+)&& /4CIUZ4S_A9.@1V-E<W37=N;F 7#1O;.6@C)QODP/E7/\1X/6B[
M"R)_^$%LO^@MK_\ X-9O_BJ/^$%LO^@MK_\ X-9O_BJJ:Q\0+.UUVPTC3A]I
MN)=1AL[AS$_E('!8@2 ;2X&#C/>NSHNPLCE_^$%LO^@MK_\ X-9O_BJ/^$%L
MO^@MK_\ X-9O_BJZBBB["R.7_P"$%LO^@MK_ /X-9O\ XJC_ (06R_Z"VO\
M_@UF_P#BJZBBB["R.7_X06R_Z"VO_P#@UF_^*H_X06R_Z"VO_P#@UF_^*KJ*
M*+L+(Y?_ (06R_Z"VO\ _@UF_P#BJ/\ A!;+_H+:_P#^#6;_ .*KJ**+L+(Y
M?_A!;+_H+:__ .#6;_XJC_A!;+_H+:__ .#6;_XJNHHHNPLCE_\ A!;+_H+:
M_P#^#6;_ .*H_P"$%LO^@MK_ /X-9O\ XJNHHHNPLCE_^$%LO^@MK_\ X-9O
M_BJ/^$%LO^@MK_\ X-9O_BJZBLGQ'J&H:7HL]]IUI!=20*9)(YIC&-B@DD$
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MMMZUV0V_+<;3DC '88QQ[5C*M%5%3ZLUC2DX.?1'D?Q \,KX:\67&F_-<13
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MT]: /-M3^,<EAK%W!'HGG6,$IB%SY^,D<;B,=,UR.J_%OQ+J21BTN[33\LQ
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MDTWQ.MH6/E7J%&'^T.5/\_SKT,/B'3J*#>C.&O0YX.:6J/=****]<\L****
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MK-N%VRX.,<]17'2W:.JIM<)%5U^;ISUJ'3I!#*RG )Y Q4QPZ#//%06:"/4
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M?UI/8:W/DJV_UBUN6[=!^M8=N<.#6Y;'Y0>:\/$'L4#5@/&327"]\X&*2 G
MZYJ27T_.O.VD=^\1FGQM-<QQH"79L*H[GM7TGHFFQZ3I-O:HH#*H,A_O,>IK
MPWX>V/V[QM8IMRD1,S?\!'^.*^@J]G+:2UJOT/)S"J]*:]0HHHKU3S0HHHH
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M*!]U0 *Q;N/#%NN>!7;0>IR5EH>S?!9Q(\!YW+%(#QQ_#7M=>%_!,MYMO\Q
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MV\$9!!ZUD*-CR2S2R#8_R+'PQ_'L*Z:,M&SGJK5(](^"TI;5(X=V/+F; _X
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M52EL73:4DV>7_P!JZA_S^W'_ '];_&HX+VXMKM;J.5A,&W;L\DUVW_" 6O\
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M4,"W3YF.?Y"O/9V,6KWB32>84"J@' /3]*\/,<34KS<)/^KH[<.KVJRW_P"
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MAF>=HD\V9T "L.<*/Z5OZ?IEK;W0AGF\G[6NU4(S)L R>OW<U-248+FD[O\
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M:XU5K6W!=MZI@'.Y^G'XU=)-5'?<BH[P/H3X.^&_[)\,?VK*$$^IJDFU?X5
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M_P#"-:0SSY^V7>'E']P=E_#)_&NMHHKWZ<%"*BNAX<YN<G)]0HHHJR0HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MMY8 $G..PJ_XN%Q%I\-W;7]W;/\ :((L0N "KR*IR"#S@FCE=[,.96T.CHK
M@U*[AUN71XHA+!:6Z32W5Q/\[;BW&,=?EZ],5B:EXJN+S2M2AM_*-Q +>:.2
MTG;:X>8+MW$#!XZC((-"@V#DD=U17*7?BZ73Y)K.[MH$ODGCB4B1C$0Z%PQ.
MW/ 5AC'7'K4MEXFN]4>WM[.QB%R8GEF$TC*@57*?(=N3N()!('%'(PYD=-17
M/)XF=L_Z(!C5O[._UG;^_P!/T_6L2S\5S:3X3LKF>2&XDVRR2+-.WG.HE8?*
M,'MW) Z"CD8<R.\HK'T_5KJ_UO4+1;6)+6R=8S*9"6<LBN,+CC&[UK8I-6&G
M<****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW/HH=/#R*(E&XF-YAC)3/X\^XJ]X_O+GS]$TJ%)Y(KZY(FB@D"/*J@'9N)&
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M0?\ ?X__ !-'F7__ #[0?]_C_P#$T<K"Q;HJIYE__P ^T'_?X_\ Q-'F7_\
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MM5\C6;>P"J08)+B=V/\ JT7 !]\D_H:KKXNT%T+KJ414(),@-RA_B''*^I'
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
&**** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>img187419207_22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img187419207_22.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %> 6H# 2(  A$! Q$!_\0
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M9-H.<9&<9JW67X:_Y%C2_P#KUC_]!%:E !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 <[>>+HK.\EMCHVM2F-MN^&R+(WN#GD5#_P )O#_T ?$'
M_@ ?\:ZBB@#EO^$WA_Z /B#_ , #_C6'#<Z#;MJ#1>&_$B-J",ERPMGS("23
MD[NO)Y]*]%HH \TD'AJ338].;PMXB^QQ2/*D(M7VJS#!(&[CKD>AKH(_&EO%
M&L:Z#XAPH"C-BQ/'OFNKHH Y?_A-X?\ H ^(/_  _P"-:.D>((]8GDB33M2M
M2B[MUW;&-3ST!SR:UZ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH XC4O'%Y9>(I[>.RA?3+2Z@M+B8N1)OE&05'3 R!5KQIXP?PS)86T"6QN+
MLN0]RS"-50 G.WG)R!4>H>!3?>(9;X:F8[*XN(;JXM/)!+R1C"X?/ X!/%/U
MGP??:O+;W;:RB7UK-,8)6M RK%(,>65W<X&/FSVZ4 96H?$.]M@)H-/M9+>V
MM(;J^(FW$"0XQ&1P<=<FCXF^*M%C\,ZKH;WRC4I(4*0;&R<E6'.,=/>G2?"]
M!;Q6EOJ[Q6KVT=M>(8 QG5&+ @Y^4Y)'?BKWQ*L;0^ ]7N#:PF=85 E,8W#Y
ME'7K0!O^&O\ D6-+_P"O6/\ ]!%:E9?AK_D6-+_Z]8__ $$5J4 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !4-U<QV=I+<RYV1J6.*FIDL23PO%*H9'
M!5E/<4,3O;0Q-#\3PZU<R6X@:)U7>,G.1G_Z];U9NFZ%8:3*\EK$0[C!9FS@
M>@K2J(<UO>W)IJ:C[^X4445984444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 8-WXPT>RUU='GGD%R65"PC)1&8956;H"15C7/$5AX>
MCMWO?.8W#F.-(8C(S'&>@YZ"N*UCPWK,_B:^@@L6DM+_ %"UO/MF]0L2Q@;E
M(SG.1QBM'Q99W6M1V\LWAF[N#;S31H(KP(ZY&%D ! (/N<B@#5N_'.D6;6J2
M1WS2W,(G6*.U=G5,XRP R.?6H?B2<_#K63_TQ7_T-:X_4/"_B!M/L5;3;J?6
MQ91Q)J45]M\EPY.'&1G /7G-7_B7X2M9?#NI:]-=71O8H(P464B(D%5^[0!W
M'AO_ )%C2_\ KUC_ /016I67X:_Y%C2_^O6/_P!!%:E !1110 4444 %%%%
M!1110 4444 %%%% !1110 4449YQ0 45C^)M0NM-T@SVB_O"X4MC.P'O_3\:
MA\*:I>:II\CW8RR/M63&-PJ.=<W*9^T7/R=3>HHHJS0**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** &&6,2",R*)&&0I/)'THDECA7
M=)(B ]V.*\A\0,O_  G&H,[$:PNJ60LE!.[R=HW;1_=ZY]ZV_B#+INL)I_\
MQ.;"&"VGF#"X1GC>5%QL)! !'/!/YT >A>?#E/WJ?O/N?,/F^GK7,?$K_DG>
ML_\ 7)?_ $-:\MO[I;NQ-Q<6PL[W^S+4Z3 A(P_FD'RP><G@_0UV7Q-3Q0=
MU-XYK(:)Y">8C*?-ZKG!^M ';^&O^18TO_KUC_\ 016I67X:_P"18TO_ *]8
M_P#T$5J4 %%%9.L:Y_8[Q+_9FHWGF G-G;F4+CUQTH UJ*Y;_A-?^I;\0_\
M@ U'_":_]2WXA_\  !J +5_XTT+3-:CTFZO%CN7!SGHA^7 /N=W'T-5K?XA>
M&KB.]D34%"VA^<MCYAQ\PYZ98#G'-8MU?:7>:U'J\_A;Q(U['MV.+.0;0,\
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MY4%%%%46%%%% !1110 4444 %%%% !1110 4444 %%%% !2,=J%L9P,XI:*
M/(;_ %[1M:U(:N^L:[HMZT0@D@M(FQA6.,D+SUKL?!_B2VU*1]*M9+Z[2T@#
MF^NU*M*2QX(('(]:3Q%X[BT+6%TR+2;R_GVH6, &%+YVKSW.TUN:#JPUW1+;
M4EA: 3J6$;,"5Y(P<=^* .7U/P3J%YXBN)HKNV72[R[@O)T8'S0\0QM7L02
M:F\0^#;_ ,312RW>HB"ZB6>*T6W/[O8XP-^1G.."1VSBNAG\1:1;:O'I4U_"
ME])C;"3SST^A-.U;7=+T**.34[R.V60X3?U;UX% '"W'PXU5K9;2+4X'ANK.
M&UOGF!+@1MNRF!@\':,XX JW\3/#.C2>%=5UA["-M1CA0+<9.X8*@=\=*Z;4
M/%N@Z68!>:G!$9XQ+%DD[U/0C':L[XDG/PZUDC_GBO\ Z&M &OX:_P"18TO_
M *]8_P#T$5J5E^&O^18TO_KUC_\ 016I0 4444 %%%% !1110 4444 %%%%
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MM\2]#U>7P]J.J'7YH[18(_,TY8P48Y4'YL^O/2O3:Y3XE?\ ).]9_P"N2_\
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MM?E%V^T>8#Y>.>G;KC&*]-I5*?([7N-.X4445F,**** "BBB@ HHHH *B%M
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M-%*[M884444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "D;.TX.#C@TM% 'D6IZFMYJK07'B
MKPX;F"("66YL8V#'<W 8CJ!@$?XUZ#X.N4O/"EA.DL4JLA^>*$1*>3T0<"N
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M+D0 9XYXKEFT?6/^$R5C-IGVTVIF\W[+Q]X#./[WOZ5O_9/%G_04T[_P'/\
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MNJN?$VBVD]K!/J=O')=*&@!;[X/0_0UD_$K_ ))WK/\ UR7_ -#6@#7\-?\
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M:W_WV?\ &N]HH X+_A7^M_\ 0^:W_P!]G_&C_A7^M_\ 0^:W_P!]G_&N]HH
M\C/AWQ(/&RZ'_P )?K?V8VIG^T[V^]G[O7%;_P#PK_6_^A\UO_OL_P"-=[10
M!P7_  K_ %O_ *'S6_\ OL_XT?\ "O\ 6_\ H?-;_P"^S_C7>T4 <%_PK_6_
M^A\UO_OL_P"-'_"O];_Z'S6_^^S_ (UWM% '!?\ "O\ 6_\ H?-;_P"^S_C6
M!I7AWQ)?^*=:TF7Q?K<4%AY?ES[V_>[ER>^./:O5KN[M["UDNKN9(8(QEY'.
M H]ZD1UD171@RL,@@Y!% '"?\*_UK_H?-;_[[/\ C1_PK_6_^A\UO_OL_P"-
M=[10!P7_  K_ %O_ *'S6_\ OL_XT?\ "O\ 6_\ H?-;_P"^S_C7>T4 <%_P
MK_6_^A\UO_OL_P"-'_"O];_Z'O6_^^S_ (UWM% 'D?A?P[XDUU-2-SXOUNV^
MRWCVZ?.WSJ,?-R?>M_\ X5_K?_0^:W_WV?\ &N]HH X+_A7^M_\ 0^:W_P!]
MG_&C_A7^M_\ 0^:W_P!]G_&N]HH X+_A7^M_]#YK?_?9_P :/^%?ZW_T/FM_
M]]G_ !KO:* //;CP)KD-M+*OCK6V9$+!=YYP/K63X4\,^(O$'AZWU&Z\8ZW:
MRRE@8MYXP<=S7K%% '!?\*_UO_H?-;_[[/\ C1_PK_6_^A\UO_OL_P"-=[10
M!P7_  K_ %O_ *'S6_\ OL_XU/9>!]7M;Z"XD\::O<)%(':*1OE< ]#ST-=M
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !114=Q/%:V\EQ/(
ML<,:EG=C@*!U)H DKDO$7B6XTO4LV<T%U:P1'[=;1?-/ #TE [@=Q3=<\7V]
MO=6T>EWT5S=!?,%FHXN5(R%$F,!L<@9R:QM L+_5 [Z3>VW]CW%[]IEG.Y;M
M#G<T+#&#SQR>E %?P)8:TFL)>F.1H91^^O/.WPW,?)#CYB2[$CJ!@#%>H5!:
M6=M8VZV]I D,*DD(@P!DY-3T %%%% !4<\RV]O).X8K&I8A%+$@#L!U-)<W$
M=I:RW,S%8HD+N0"< #)X'6O*O$FOZAJ>J;;>^NX5N G]A&R8"&X8GEI&(ZCG
M*G&* +G_  D%WXRN+73)TMO[(UC>HAA?=<0)&<[I.P!(P1[UUF@:/J&@W\]C
M',)]#*[[82,3);MG_5CU7J1Z=*CL?":Z=XE76K.9('N(MM_"J K,V.&7^Z<_
MG734 %%%% !112,2%) R0.!ZT 17D[6MG-<+#).T:%A%&,L^.P]Z\^\0>/YG
M_LUM%NH+:&Z1F\VYC!'FJP!B<D@(0,DD\^E6M>\02:A!:HAO;>*WN-NKV]F<
MW$(*Y7H,E=Q&2M6/#^A0:G>SZY-:-;0SR.OV66/Y;E%.(Y75AE7QDYX)S0!T
MVBZC_:VCVM]L*><F[!&,^X'H>HJ_2 !5    X ':EH **** "LO6_$6E^';=
M)M3NA")#A% +,WK@#GBHO$WB"'PYI)O)(S)([K%"F<!G;IENBCW->=72^)-6
MU#5M3M4@75M/C%K<+;-YL<D3@DB/=TD7T[\?B =!_:.M:1?W7B(3-J7AV\E#
M"&(EV@CVKME3VZY6N]1@Z*ZYPPR,C%9OAVWM;3P[80644L5LD*^6DRD.!_M
M]ZTZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBF331
M6\#S32+'%&I9W8X"@=2: 'USGBKQ/;Z%:QIY,-U+.YB\N681H/E+'>V#CCH,
M<Y%7-.U?_A(=&FN]++0JY=+>>:/*OCC>!GE<Y].E<G;^&-4U#Q->)XBTRTFT
M^\@4S36\Q"M-&?E<#AD;!QQZ=: (/#OAV#4X;B%+5$T:[)>>R=_WVGW(Q@(P
M'H1Z8_2O1+:U@M(O+@C5 3EB!RQ]2>YXZU#INEV>D6:VEC#Y4();!8L23U))
M))/N:N4 %%%% !5+5=5L]%TZ6^OI1'!&.3W8GH .Y/I3M3U.TTBPEO;V4101
MC))ZD]@!W)]*P-&OK7Q[X=O!J%K%]FDF:,6^X^9&!TW_ -U\\\>U &!KNI>(
MM3AAO-+O'L;RU0RW6E1@2OY#'Y6((^_CG947AOPC/J8>XN-0LK[P_??OQ'#$
MT31S _>09_=MD'.#ZU>T;P7J]C=2:;-=HNC+/]H:>-B+B[[JCMU 7')'7BN^
M1$C4*BA5'0 8% "JH50HZ 8YI:** "BBB@ KS3Q3>PZIJ4IT?5I;^- !J&E1
M2$&2)#R8CZCN!UK8\<>*9M%M)4BAO('BV2K<>3NAF .6C+<[<CUQ]:J>&?!S
M07EIJ5OJ?FZ62+BV381*%8$B,MG&P%R<8Y.,T 3^'/":QWMKJRW\\EO&H:R<
M@K,86!_=2Y^\HR".]=O110 4444 %4=2U*.QC\M#$]]*CFVMGD"&9E&=H_QJ
MW++'!$TLKJD:C+,QP /<UYAXB74M"\3RWE_>!+#47"KJRH2]I$.3"HZ+GLW>
M@#*O_$6I:W-+J,7AB^:5/]%U&P#^?'(@[,N R,.H;%>@>!M'DT;1FB5V^Q3,
M)[:*6+9-$K#)60]R#^-+H%FFI7Y\1RZ?)8S2(8HLR$//%QAI5Z9X./8UTU !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 A('4XKR
MGQ3XST_4YHXYUN8K:PO3'>6-PNU;I 1D@CJ5X;:>HKTC6-'M-<T]K*\$GEE@
MRM'(496'0@CO7&Z?X)U6#Q'=)JDUKJNB7D.V<S+B0LO"DC'+8XW#'YT :FC:
M-/I.K1W.A312>'KY3*]LS<0L1D-%['TKK:@LK*WTZRAL[2(16\*A(T'10.U3
MT %%%% !4<L\4"AII4C4D*"[  D]!4E4]4TJQUJQ>RU"W2>W?DJW8]B".0?<
M4 >8Z_XYD>^6ZN=/N;1M(OFCDAD^>&X3(ZXX5P &7/X&NWM=%L[O6;7Q-I-V
MT"W,>;A(P-ETA'RDCLPXYK-TCP/=:1XCN+@ZD+S2+FW\F6VNDWN<?<!/\0 )
M&3SCBNQAABMH$A@C6.)%"HB# 4#L!0!)1110 444$@#)X% $<T\5O'YDTJ1I
MD#<[8&2< ?F17!>,?&(8C2-*=9VN"]M,T,WES0R$?(5SC()SST/3-9GB.36M
M:DN89)5N=-@4?;;.UQON("Q:.:'(/..#@]4K3\+^'O[5L+4:I9VMWI-J =.G
MFB:.ZPK?+O'&  /QXH ZGPU?76K^&[2XU*TD@NF3;/%,FT[AP3@]CC-:X 50
MJ@ #@ =J6B@ HHHH *I:KJUIHM@U]?2&.W1E5WP3MR<9..W-6W=8T9W("J"2
M3V%>77RZKK&I/<0W2ZE';QB5K$_+'J-J6+*1VW+D@C'4#UH ?XT\4W-XEI#:
M+)!I]VWE%[B#=!=1N,!@PY&#V.".M=GX9L[\>&+6RU^*&2XB&PC/F*ZJ?E)S
MWP!5+PCHKVEIYPDO8M.E!:WTN\52;;YL]>3[@9XS754 %%%% !1110 4444
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>img187419207_23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img187419207_23.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '. ;T# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHK,NO$>B6.J0Z9=ZO8P7\V/+MI9U61L],*3GGMZT :=%9MWXA
MT6PU.#3;S5K*WOI\>5;RSJLCY.!A2<\D$#UK2H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BN3\>>,QX-TB2Z>RN'#0R>5="+?
M#',!\BR8.X!CQG&/<4GAGQJWB/PQ+J]OI%_((859<1!!=OMRPA#-D@-D9.*
M.MHKS;PW\5H?$/BR]TBWT^\F42Q+"J6K(]NFW]XTY8X&U^./PS7I- !1110
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M* "BBB@#S_PE_P E>^(O_<,_])VKT"O/_"7_ "5[XB_]PS_TG:O0* "BBB@
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MB_\ <,_])VKT"O/_  E_R5[XB_\ <,_])VKT"@ HHHH **** "BBB@ HHHH
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M(\&Z/_:^_P#M#[)'Y_F9W[MH^]GG=Z^^:VZ** "BBB@ HHHH **** "BBB@
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M''*C&/N:=.G5W\CUJ6%PTL&ZLI>]K_P%;S.^HHHKV3R0HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .5^)<D\7PVU\V\C1RF
MT95*J6)SQ@ <Y.<9[9S7FWAV?P(EWI45KXC\:"821+%;SR3A-V1A6 3;C/![
M?A7J/CR_U+2_ NLWVD _;X+9GB*J&*^K 'K@9/X5Y=8>*M?U/Q#9ZCIFNW]U
MI_\ :EKI=C"(/W=]&JC[3,_'!_BW<8Y]. #W.BBB@ HHHH \_P#"7_)7OB+_
M -PS_P!)VKT"O/\ PE_R5[XB_P#<,_\ 2=J] H **** &211S(4EC5T/56&0
M:< %    '  I:RX_$NA2ZF=-CUBQ:^#%/LXG4ON'5<9Z^W6KC"<T^5-V U**
M**@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#GO'6
MLWGA_P $:OJVGHKW=M;EX]PR <@9([XSG\*\IA\0^);#7+:TO?'T-[&-3LX$
MLK>R@@>]MIQ&RRQ,JDE<L00/[I^8$BO0_'>OZSH7DM:2>&HM/F0I(VLW31%W
MYRJ@<,,5EZ7#XPOK_2]3;0_!,MO&$6&]MI'=XX#U\IMO3:3@ XH ](HHHH \
M=\2?$S4;/XB:AHT.L6>F:;9/;Q--<6+S*7=<MEUX0=LGW[ U[%7F/BOPEXSU
MN;6-%ANM-ET#5YHG:XGRLUH@(+*J@8?[O!/XGN.D\0?#CPIXIO(;S6M+-W<0
MP+;I(;B5,("2!A& ZL><=Z ,GPE_R5[XB_\ <,_])VKT"O+_ (;Z)IWASXC^
M/M)TFW^SV,']G>7%O9]NZ%V/+$D\DGDUZA0!S/COQ?%X*\-OJ;P^?,\@A@BS
M@,Y!/)[  $_ACO7FG@WXW:EJ7B2VT[6[.U%O=R"));=64Q,QP,Y)RN?Q'7/:
MO2_'?A"#QIX;;3)9S;R)()X9<9"N 1R.XPQ'XY[5XC8?#73]'@O=9\2:YI]Y
MIFGKF2WTJY,DLCDX5<X&S)(YZ_3K7U.4TLMJ8*<:RO5V6]]?AM\_^#H85'-2
M5MCWGQ@-1/@[5QI._P"W?97\K9G=G'.W'.<9QCOBOCV 3FZC$ D-P7&P)G=N
MSQCWS77Z+J_@VYUM(=5T&YMM/E?:)8M3G9H0>[9;YAZXQ_2N]CT3X+2:L;%+
M^7[0&*^8;RX"%N_[S.W\<X/K79ELL9DT)TJN'<N;6ZU^^U]"9\M35,]DT;[8
M-#T_^T?^/[[-']H_ZZ;1N_7-7:^5[O6O 46LM%;>'-1FTU7V^<=5F61Q_>"Y
MP/H3SZBOI7PX^G/X:TUM)=GT[[.@MRS%CL P,D\Y]<]Z^:QN78K"VJ5X<JEM
M_EY>AM&<9:)FG1117GEA1110 4444 %%%% !1110 4444 %%%% !14-W<K9V
M<URX)6)"Q [X[5P0\;:D+SS2L1@S_J=O;Z]<UQ8O,*.%:53J=F&P-7$INGT/
M0Z*J-J=K'IT=_-*(H'0."_7D9QCU]J;8:O8ZGN^R7"R%>JX((_ UT^VI\RCS
M*[Z7U.?V52SERNR+M%9.I>(].TN<03R,TO&5C7.WZU?M+R"^MEN+:021MT(I
M1KTIS=.,DVN@Y4:D8*<HM)]2>BBBM3(**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** /)_'=[HMA\5M(N?$EJ;G2XM)E"*UJUPBRM)C
M.T \[0>HJI\,?'6@Z1ITNA2->0^9JLXL(OL<NU89),QC.W"CD]>G>O8Z* "B
MBB@ HHHH \_\)?\ )7OB+_W#/_2=J] KS_PE_P E>^(O_<,_])VKT"@#SCXV
MW.HV_P /V^P-(L<ERB731]HB&Z^@+;1^..]?.NA:;=:UK5KI5F6\R\D6+@$@
M GJ<=AU/TK[-G@AN8'@N(DEAD4J\<BAE8'J"#U%96D>$M T&XDN-+TFVM9I.
M&D1/FQZ GH/85]/E6?PP&$E1Y+RU:?\ GZ&,Z7-*]SY_C^!_BXR70ECM42%&
M:-Q,&\X@'"J.HR<?>QUK@X-(U&YU5=+BLIVOS(8_L_EG>&'4$=L5]JTFU=Q;
M W$8SCG%;T.+\3'F]K!2[6TM^=R7AX]&?,<OP3\9)J:VJ6MM) Q'^E"X41@'
MJ2#\W'T^F:^A_#.AQ^&_#=AH\4AD6UB"%R,;FZL<=LDGBM:BO'S'.L3F$(PK
M6LNRW?=FD*<8:H****\DT"BBB@ HHHH **** "BBB@ HHHH **** (YX4N;>
M2"49CD4JP]C7'#P&WVOF]7[-G/"_/CT]/QKK;^.YFTZYBLIUM[MXG6&9DWB-
MR#M8KWP<''>N'_X1WXE?]#W8_P#@H3_&N7$X*AB6G5C>QTT,76PZ:INUR_XT
ML95L++[.C?9;<%"J\[> !G\O\YK)\'6US)KL<T:L(HPWF-VP00!^>*G_ .$=
M^)1&#X[L?_!0G^-(OAOXD(,+XZL%'H-'0?UKCJ95&>+6(YK6MIZ'53S*4,,Z
M'+>]]?4I^(],O+;6;B1XG>.>0O&ZC(()SCZCI76>#["YL=*<W*E#*^]4/4#&
M,FL#_A'?B5_T/=C_ ."A/\:ZGPY9ZW8Z<\6O:K%J=V92RS16XA 3 PNT>^>?
M>JP^5PH8AUU)N]]/4FOF4ZU!46MNOH:]%%%>H><%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'G_A+_DKWQ%_
M[AG_ *3M7H%>?^$O^2O?$7_N&?\ I.U>@4 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 45F:WK<&BVRR2(9))"1'&#C..O
M/8?XU2T3Q5#J]R;9X3!,02@W;@V.OXUS2QE"-547+WGT.B.$K2I.LH^ZNIT%
M%%%=)SA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M .%;'Q$\-WGB[P)J6AV$D$=U=>5L>=B$&V5'.2 3T4]JZB@#S_\ X2WXA_\
M1,/_ "OV_P#A1_PEOQ#_ .B8?^5^W_PKT"B@#S__ (2WXA_]$P_\K]O_ (4?
M\);\0_\ HF'_ )7[?_"O0** //\ _A+?B'_T3#_ROV_^%9]W\2/&5CK&G:3<
M_#C9?:EYOV2+^W(3YGEKN?D+@8!SR1GM7J%<OKGAN\U/QWX4UR&2!;72/MGV
MA'8AV\V((NT 8.".<D?C0!C_ /"6_$/_ *)A_P"5^W_PH_X2WXA_]$P_\K]O
M_A7H%% 'G_\ PEOQ#_Z)A_Y7[?\ PH_X2WXA_P#1,/\ ROV_^%>@44 >?_\
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M_$/_ *)A_P"5^W_PH_X2WXA_]$P_\K]O_A7H%% 'G_\ PEOQ#_Z)A_Y7[?\
MPK/UOXD>,_#FCSZMJWPX^SV,&WS)?[<A?;N8*.%4D\D#@5ZA7+_$3PW>>+O
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MNG>,].NKC[/;WB.EO<Q22,@CST;*J@RI)R.Q.1H>#--U=_B;-JRK/%/(\_\
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M)';HJ@9)/T J6O(O%WQ(TQM0T^)[FZLH8+MK;5M(U" P&XM908_-&X?,%^\
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M?BQ(],UW3[C[=87EC\UOJ,6QA(B;\E<J?F'7 XQQ7IL4,5O$L4,:1QKPJ(H
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M\.O';VYTZ-K._P##H@?3;6 ;;^X$RH@$?.68%ASGC/4]8=8O84@N[K1A!?\
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M/.<UUFGZ'INF7U]?VEE%#>:@XENY5Y,C  #D]O;@9).,DUHT %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
J4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>img187419207_24.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img187419207_24.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $\ T # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4D, V>@((SCZ9KKZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HKSSQ#\1KW2_%\^A66EV<K6R1NPO+X6[W._G$ 888CW(YK
M:U'X@^'])U":POYYX;BW6-[@?9W98%<?*7900!SC.: .IHKD(O'MG%=ZS'J$
M?E1V5\EE;^2&E>Y9HPX"J!DGD].PS5B?X@^'(+&UO/MDDL=RKNJPP.[JJ'$C
M.H&5"G@YQ@T =/17*7_Q'\,:=<M#/?2'9'%,\D<#O&L<GW'+ $!3QS[UU0(9
M0P(((R"* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MKF]0\>>&]+U&>PNM09;F @2HEO*^PD9 )52.A% '245R?_"RO"G_ $$)O_ *
M?_XBC_A97A3_ *"$W_@%/_\ $4 =97!>+_B%<>&?$VGZ5%I;74<_,DJL<*"#
MC)Q\N",YYX!XK1_X65X4_P"@A-_X!3__ !%1O\1/!\LD<DEV[/$28V:PF)0D
M8)'R<<$B@#KU.5!]12UR?_"RO"G_ $$)O_ *?_XBC_A97A3_ *"$W_@%/_\
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M*QM+\6^']:N_LFFZO:75QM+^7%("VT=3C\16S0 4444 %%%% !1110 4444
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MBB@ KF/&MM+=0:(L4#S!-8MG<*N["ACDGV%=/10!%]FM_P#GA%_WP*/LUO\
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MK7NE/X=OOLT44RF8%^^3AL8XP._/4<'%=O:K(EI"DI)D5%#9;<<XYYP,_7%
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MK4VNH&+RP0(Q# E2&P0.H.,<$<U:^'!S\.]$.",V^<'J.30!U-%%% !1110
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MD;4+@3LI& A"*F!_WSF@#&^T?$#_ *!WAS_P,F_^-T?:/B!_T#O#G_@9-_\
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M QP.A/N*[AEDN; JRF&26+!7.2A(Z9'I0!!IVLZ9J_G_ -G7]O=_9W\N7R9
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MI5_0?"^D>&8I8M(MFMXY,;D,SN.,XP&)QU/2@#8HHHH **** "BBB@ HHHH
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MEN0?^!;ACZ5TVE6]_;6*Q:E?+>W())F6$1 CL-H)JOH.CG1K-XFF\UG;<3C
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M^B);I--= 20DQ^<?F'WHSWKU?P)-K,_AM'UR#RKGS#MW1A&9.,%@._6ND$:
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M_$JE>5)Z9'09H T-.U.TUO1H-2L)/-M;F+S(FP1D'V/0UB_#G_DGNB_]</\
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MYWXH\ VUOHA?1O[7>\\^$ )J,['89%#\%_[NZMG_ (5WH/\ >U3_ ,&=Q_\
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MXKU?1=<\JPN(8H+2TBNY(7B#&ZWSB(ID\K@$G(YR10!K_$?_ )$6^_ZZ0?\
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M3%=[86OV'3K:T\QI/(B6+>W5MH R??BK%1SR&&WED5=S(A8+ZX'2@"2BO.O
MOBK5-1:X_M"^COA)I\.H)MC5/)>0N#"-O7&T8SSUJ'P9XQU:YCN9M1EEU97T
M^WU 0VENOF0-*SJ80%Z@;0>>>#F@#H=*_P"2D^(O^O.S_P#:E=57G-CX@NK?
MQAJ^J/X6\1?9[NWMXX\60SE-^[(W?[0K<_X38_\ 0K>)?_ #_P"RH ZJBN.A
M^(=O<7-Q;0^'O$3SVS*L\:V/,98;@#\W<$&I_P#A-C_T*WB7_P  /_LJ .JH
MKE?^$V/_ $*WB7_P _\ LJ@MOB';WAG%MX>\12F"4PRA+'.QP 2I^;KR/SH
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M5I87%S]HEA3:7"[1UX51_= P!WP!4NL2VD6C7K7]RMM:>2RRS,V-BD8)S^-
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M*:_"_N(YCA&;/\1]*XSPUINI+XD^WV-H;&*4.FKB\9GD,X<MA.@<$/\ *_\
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MPL*%W9CP H'4UHURNK0-)XKBFT[78%U)851])GE&R6'<2S%?O!N>& [8.0:
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MRR5DAEC.TA6&"IQU7O@\9YKD/^%,^%/[VJ_^#"3_ !H_X4SX4_O:K_X,)/\
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M*TS_ ,&8K6\.ZKXUO-5$6O>&[+3[+8Q\^&]$K;NPVT =;1110 4444 %%%%
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M&18%BMDM&C:!908D.5 W?=/)&>>O2G7?@FWNK9(?MLR!'N7!"C_EL<D?AVH
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M>XJ6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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I49*GRURARIQT^E/HHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>img187419207_25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img187419207_25.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (G!*@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[1K?_0/M/_ D_P#Q-'VC6_\ H'VG_@2?_B:/9ONOO0<K-2BLO[1K?_0/M/\
MP)/_ ,31]HUO_H'VG_@2?_B:/9ONOO0<K-2BLO[1K?\ T#[3_P "3_\ $T?:
M-;_Z!]I_X$G_ .)H]F^Z^]!RLU**R_M&M_\ 0/M/_ D__$T?:-;_ .@?:?\
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MM/\ P)/_ ,31]HUO_H'VG_@2?_B:/9ONOO0<K-2BLO[1K?\ T#[3_P "3_\
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M@?:?^!)_^)H]F^Z^]!RLU**R_M&M_P#0/M/_  )/_P 31]HUO_H'VG_@2?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>:C;Z@T2D1W%NQ9&CS\N">O%=10 4444 %%%% !1110 4444 %%%% !1110
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MT?R_[/$D?D>5]W;N?I[4 >TT444 %%%% !1110 4444 %%%% !1110 4444
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M%'GQ?\]4_P"^A7FNYMPY/YTIE?/WVX]Z:IDNM;='I NK<D@3Q$CMO%+Y\/\
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M:YP*S,P1FQGKFICAJ<E=2_ J>.JP=G#\?^ >V_:[;_GXB_[[%'VRU_Y^8?\
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M?,GZ]IL>E^?#_P ]8_\ OH4?:(?^>T?_ 'T*\P,C8X)_.F!W[EOSI^P\S/\
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MMVJ=M+-J0LC*P_V6S3<4]R'7ZV+E[JUM/I,UI;MG4C&$-V1UKFH]5UK2M/\
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M,VT9STK-FU"&-<JQQZ=ZO66F?;+=+K4+X6=LQ^49P35<R2(Y)/01KQ$X+8-
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M:;"^)5+'(STKUJ44HWL?/8B<I5.2Y5FL+F63>(BP]<4Q+:8+ATQBNO75+1(
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M1=;.T1KGH'F&<#VK4OY?$>KPRL\TDZX^=4'"BN(AUMUN,X95!^4XK?\ #OQ
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MUH.<4?2/A3'_  B6D8&!]DC_ /016Q6-X2.[P?HY];.+_P!!%;-?24_@7H?
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M:T,-M]T%W/<FB('<">M3W5C/I["7S4GB_B*]JE148!D[]*)>H0E%KW4,7*R
MD\TC!+C?$Y'/3-/F&UEP/K51(KNYE86EM+.P/(1<XJ:<6Y:%3J1BKR+6FZX-
M*0V-UIT=RJ_=W+\U)J>IP7Z[8--2WQSG;BF7%I>@![NTGM)!]V1D(_"JC),1
MF29CZ#UKKJ0<5J<=*$)3YH.X\N3"OJ>*KM!,6X=0#4TA(M 5ZJ:B6.X8AMH
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M6'N6:.2A5GSWD]!9)%120.,<FJIN[<#)?]*);2Z6(RR^6\?K&V<5K:#X.O\
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MLA+]_;DGG-0FS$74' Z8K0ER92&7H>*;([!0"0B9ZFNBE.3T0YQC:[$MR\.
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MR,0TK3+U[456\*9;Q/IA))'VA<?G17H8*_([G@9K&U2/H>^4445W'D!1110
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MRF?OSUKG-;NKGQ'?16T"^7:Q'. .":NZ-;#4K>.29^O48K?MX8[$F**WRO\
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M4D(V0IZ5ZU+;1S1JJMM'^S7F7@S7TBT2YTJ0[9HURE;OACQ$)X6M[R4K,K$
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MZM&:ZT36(U<'E.@8U3EU_P 262&+4M+\] ?];%SBO4;J15VCQ'"$YWB]R_\
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MK'E9[/&V^)&]0#3JC@&+>(>B#^525U' %%%% !1110 4444 %<IX^_Y D/\
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M/96>09W+LR]ZY/48V,4<A'W5)YK?OW-W>=3Y:=,UF7VR5VA8_*@PQ'\JFO\
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M>H6S&$@#+'D5V.H:9;ZO8F*=1M(^5NXJ;\KLQRBY*Z/+WBAQN ZUI>&RJ:B
M+<S;CR#VK6?P1,KC%P#$I[\5O:+HL&E$RH0S'J<YI\M."O$4:M:3M+8J:])'
M]@9;9(6;HT9 R*\[F\07EA<!"RP6X^^JC!Q6Q<:%K-MXUN+^>5QICG<6#9Q6
M=XG\,65S8R:M'/.D2G!).1]:B+L.<>B.E\)W\5ZDTD4;.I.5W<FM_4'EMK)[
MD<,HKB?"GB"W2Q6W\/J)I8L+*&ZD^U='XPU"2#PJ;ED*2$#>OH:<_(4;*)P^
MO6D^I6;3W,G[S/R*35#PGX$NKN\^U382,')S6CH&F2ZZRW,LS;1C"Y[5VNO:
M=<P^$7@TW(E+ ,V<'%;:0B9Q3D]2W'/;:? (OMD;!."%(XK(U'Q6))RMM*%A
M4<XZYKSVZM[S2+8+-.6DEY;GI51YM0CB1A#E2?O =:A4^;5EN=M$>A:;XCU&
M1RL<@=,_QFL[7[S5M4W*2J(O:,\UFZ-HFHZO$9[=73'4=!730^";]@CB5HFS
MDFDXV95[HH>#M4@M]UL\Q2=#R7XKH=5\92V<3?9K<S-C@J,BK5SX2MIWAF,2
MB=0%<CC=[FMM=.MQ9"V\B/[N,@<U$FKFBV-FW<R6T3L,%D!(_"I*:B[8U7T
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M+E9V8RSBI(J'XA+IFI?8[N+-N>$E'I7;V%_!J-LEU;N&C8<$&O+/&MI:PK%
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MU[-7C_Q+TR^NO%7GV]K/*@MD7*1EAG)]*PQ*;AH=V7V]MKV.4TJYCGA6"XR
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :[;(V?!.T$X R37*Z9XW
MM]1\03::MO< CRPB>0P="<[O,[ #CGWKK*S+?0-,M;Y;V&V"7(9V\P,<DO\
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MYS7M= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% &=9V-[!JM[<SZBT]M/M\FV* "' YP>^:B\3:+_ ,)%X9U'1_/\
MC[9 T/F[=VS/?&1FM:B@"II5C_9FD65AYGF?9H$AWXQNVJ!G'X5S^AZ%:^!X
MM?U*\U)3;7MVU[([IL$((Q@G)S]:ZNHYH(KF%X9XTEB<89'7(8>X- 'EGPQT
M6QN_&/B7Q78EWTZ6Y:#3R0=I!PTCKGL6XK-\%:'K]]>^*KG0O$/]F%]7FCFC
M>V$JG'1ESC#<U[-##%;PK#!&D<2#"HB@ #V I(K>&#?Y,21[VW-L4#<?4^]
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M[3SXG\2KJ5CI\JSPV\5HL)>1?NEV!YQZ5W]%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
L% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>img187419207_26.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img187419207_26.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'Y!-\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJCJV
ML:?H5@U]JEW%:VJD*TLIPH)X% %ZBJL.I65QIBZE#<QO9M'YHF!^4KUSGTJK
M#XDT:?1O[8CU*W.G<_Z1OPG'O0!J45B:/XP\.Z_.T&E:Q:7<JC)2.0$_E4UQ
MXET6UUR'1)]1@CU.8 QVS-\[ YQ@?@: -6BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(/[36@$=#!%_[/0![K1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 455U+4+;2=-N+^[?9
M;VZ%W8#)P/:O)W^.S?9VU*'PAJDFB+)L-_T7^6,^V: /8J*X_4_B3H6F>"(/
M%3M+)9W( @C5?G=C_#BN63XV-9W-J=>\):KI5C=,!%=2H2ISWP0,^O% 'JLM
MQ! 5$TT<>XX7>P&?IFEDECAC,DCJB#JS' 'XUY5\7=1\/Q2>&I-5TR;4%FN
M;9HKCR@F<<GCGM4_QIN3-X:TC0X21)JM]%%M!Y*#D_TH ]->>&.+S7E18S_&
MS #\Z(IXITWPRI(OJC C]*\>\7_#SQ-XO\76.F2S/:>$[6!4#12CDA>?ESR2
M?45A>#M/N_ 7QL3PMINHSWFFS1%I8W/"#;G)'0$?UH ]]2X@DE:))HVD7[R!
M@2/J*EKRCP9>Z#-\8O$UO9:3/!J2%_/NFN-RR?,,X7'%>KT ,EFB@3?+(D:#
M^)V %+'(DJ!XW5T/1E.0:\>^--Q/X@U;0/ MB^);^;SYB.RC./\ V8_@*L_
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBFM*DOO8IU74CTO)!3EU/4EY-Y(:A./[M&/6CV,>Q#Q.*CO4E][_ ,RT-7U
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M^OL?^@U[37BW[-__ "*>J_\ 7X/_ $&O::"PHHHH **** .(^+W_ "2S7?\
MKBO_ *&M?&]?9'Q>_P"26:[_ -<5_P#0UKXXH EMP&F0$X&17T_X?*QZ!9JI
M 40@X'TKY>C.UU/H:^CO >IQ:GX;@(8;E7:5],5O0^(^:XEA-T8R6R-V&9GF
M.>E7@,"JT0168@9-3[N,GBO0AHM3X9;CWBCEC*.,@C%<(/"8L/$ E\O=:EMV
M >A]Z[4SHO!88JI>70V @Y!K.I%,[:.)G"#C'J8=^D=O+MB4 =<*.*GL97EV
M\@ #I4%U(&D9U7@C&:KV4OESDEL[OEK+8)0<XZG3*RC!&>E87BOQ"V@6)C@3
M=),N,^E7H92)EW.W7&!6/XG.DRZ@JZI<%%"_*%ISEH:8&,56O)7L87A%HM\D
MMT !)R7/7)KNY]9T_2;'=+*,J.$[FLM+;0)M&!BD7RT^964\DUS DT6;55EN
M;\NF[ 5^U9J7*=SIQQ$^>2?W';:?>7&J1//,/+M)?N>M3W,AANH((%W#N:Y/
M4/%,EK(8[2#S-(BQF55X ^M7;'QYI$C!6A977E7;IBKC4[G+5R^JW=1T.N:&
M4[=K#'\0-2+9QIG:,$\G/2N=C\9:?<*3$)3@XX'%:]M>)>0JWF@#K@&MU),Y
M)T_8Z25BAJNC6<DD;B(@L>=G2K$NEVR:9+'"FPE"%QW-:0:,*$P2/6FW "QC
M8< ')H<(L:K;-,\KT3P;>WFL2?; RQQ-D!N]=7>7-QHDIBA@5,CI6\]S#YL<
MRCGH3534]4MA<1PGRY%)S(9.U9<J6QVO$RQ+]]:(RX?%LB@QW<+12'H&'!JO
M'XFBN;I\$KGCI75K;Z?>VZXCCDB;^+'3%5+9K6Y22%[2#S-Y3Y5' [9H:?<E
MSHN+O$CLKFV"B5IE_.M!;J-UW*<@UR^H^&[2>4*T[6;'A3&W!J?3[.\TBZB2
MXE\ZW/!;VJ5)[&-3#TK<T'J;18YW+]TU2OV6%U*\EJT;^/:BQQG"L>36;J30
M0Q*SMD] *;=CFC#74I!/-+;C\PYJI?7J_9_) .<=:1[G<2^=J@8K&N;D,X,9
M[XSZU#9Z%*E=7+4"YBR&P<\YJ;SC %$6&9^#5'(C*QDY=ADD=A1#<1Q%MQY'
M0U#9O[.Y-/+Y;D?Q53E?S.&.,#)J&[O TY8,#5":=@-[G@]*+G32HOJ60V,R
M%OE)XK7LY!'""2,CD5S<3O*0IX7-;4 'R)U>DF*M!)'2V$[S1_O"<N>*Z-9X
M[5$B+_,17*Q7$=NB* <K5NT<SW!E;.*Z(NQXM:%M3IEGWMC;QZTK@,>M0699
MD)8<>]3DITW"ME+0Y))C57#\GBN>\9ZBEA!$BOC<.U;TDR1@EC7G_BX_:=6M
M-Z-Y>1\GK6%66AWY=&,IOF1T'@^%A8O=L2/./ /;%="Q8+GC-9]DRQVT<<'$
M2KTQTJ>(;V=R9  .<]Z2LD<]>HJD[]#(U:5&#1YY([5C+-(#"I4>62.3UK5N
MRJW:RQ@.H)X;O6=<0DCY007['^E)H[J=K)'OD/\ J(_]T?RI]1V_%M$/]@?R
MJ2N(_1UL%%%% PHHHH ^8_VC?^1VT_\ Z\A_Z$:\<KV/]HW_ )';3_\ KR'_
M *$:\<H *4=125)"AED1!U8@4!>VK+%C:27MTD42%V8X %>_^#],?0/#2)<O
MM8'<5%/\'>$-,T_2K.Y:T4WC)EG^M:VM/!:H$;#%C]T&NB-+E5SXO.,Q^LOV
M4%I<Y+6-99I&\ARH]ZXR^NFE)WN"3Z5UVHJERY46^S'ZURNJ6R0+D)MYQGWH
M88*4$^7J8?VZ:&;]S(RD>AK5LO$NIP$;><]6/6M*V\,02VR.TFZX?DD=!6I/
MX8CT^*&9<2QN,-GL:A)G=6KT%HUJ7/#^I/J,,DLCA94['O76V,PD4!W7..M8
M&G:7:D)&$\MSU]ZGNK2;3I_E#F,?Q#I71&Z1\WB53JR]W0ZA)(\X S[T\D\Y
MZ=JP+?4F"#)&WN:L_;0V/+F!'I57.&5&2-"2=44AN:KQW(,NW=BA&CE&7/-5
MID13E 0?6G<7+H;,+DGDU:5QGBN>CDF1-Y)QVJ_#>JR#><-WJXSL1JC75N:D
M)S6>EPN/O5*+@XZUJI)FL:JM9D[>E(HQ48FR:L*5(K3F14;29&032HG-/.!W
MH! HN:65QP4BG#WJ-WXXIGF^AJ2U.*)70$57;@TC7('5A4$MV@'7FCFMU,:D
ME+8F-(!4"3JRYW4V6\2,<,,U/M$C#E9;!P*:SJHR3BL*YUG;D(^*S&U>0Y#2
M9!J954;PH3DM#HYM2AB/!R:RKJ_:1]Y.%%91OD[G-5+N]&PL#Q64JES6GAY7
MU'ZKJ.X,JG@U@3S&0*@/-,EF,Q.6J2'R@H+CI6#6IZD(*$;%N".-(@9>H]*@
M=T9B4! SWI[3IL+LIP?NU5>7<%!&TYS2945W(WE=I]BBF7DOV>V*_P ;4XSQ
M0R&1&^:LB^N_M,Y!;C%3<ZJ5*\B*.]$%TC#@J>379:=XA>:-0C,IST[&N#@C
M20,9>Q^4^M;-DS6\? V\=Z5S;%X>$X<IW[^(!&L*!CN[UEW6KQR7!\PY'I7)
MRW[ EM_(JJMW*\H(;YC5\YQ1P"M<[>#4C(WE*0$-:D-W;\#CBN/M;>X\DR-)
MCVJS"\H;:6P/YU2D<M;#);'9O>L+=]S *%.VO _%,[3ZU,2?XJ],O]9\NRD5
MEP5'%>0ZA.;B]DD/<UE49[F18:5-.;ZE:DHHK$^D"BBB@#ZE_9X_Y)W-_P!?
MTG_H*UZU7DO[/'_).YO^OZ3_ -!6O6J "BBB@#X HHHH 7-%)2T =7\/+G[/
MXOLB20I;FOH;EY=X&$)_.OF/P]/]GURUD5L8<5]&MK,$=M$3U" UTT)6/CN)
M:+=:,EV-@+M'3%,8D# K(_X2"%8MQY+=*JS:\%/[OFNIST/FHX:<F:5V=B%E
M.#WKG+V_6 %IF&VJ&L>(+A4+!QM^M>>ZKK]U=N4W';[5S3D>Q@<LE-W9OZUX
ML2/,=L,^C9KECJM_=2 >8W)[=:=IVE7&I2A1D#WKM]$\%2*_FE-V/6LN5RT/
M:J5<-A(6EJS-T/PS=7UU"9=YC8@L372ZGX8&DW1EA*21R#;LQR*[/2[+[)"%
M?&<=!4MY!;R#S96563DL:Z50M&[/G99I6JU/<V/']0\.W8/R1[D!W$ =JVSK
M%^?#FR#%K$'$)0<.?>NGAUS3V+?*N<E0W8^]9-HMMJMY,PA+A'^\!Q63@KG=
M'&U>2]2.Q>TB)=/M87X+-RQ/4_6NGMI_M*B16X^M<]=VC*@?<551TJ#2-6BM
MKL0S2$(>]:0Y4SQZ\/:^]%ZG9*68'N.G(ZUGWWA_3+Y-LUC#C.3A0#5V&Y@9
M!LD!!Z5*3GH:Z^2G8YU5JP6C9FVVGK8PB"U)5$^ZOI227%W;O\YRAZFKTC"/
MD]ZBD"S1LG7C@U+?*K(S4Y.3;ZD'DO*/,\TE37GOC00W!ETVX618"0X,:[CN
MKN8[ID+QD8*=,USD!C?6+J\NG4?+P&'%<U1)H]7*ZKH3]HMSS^U\&^:8I=)F
MNOM&[DRIM45Z)!:>(]"M(S+(+I0,MY?.T5NP1KD%%7!7<-HQ4S:B]L=DF,8X
MR*B-/E5T;XG-*N)GRU(JQBVOCZQ4@7+[2/O#N*T;7Q9I5TS*90I/0^M8CV-E
MJ&K(J644O\4A*^O>M2VTG2EO9+633HU5A\C5ISS2,Y1PUU9.Y0OK^R6\\VSF
M597XV9X)J.&821M)M_>YP17#^*]&U:WUN=-.M))+=3G<H.!71>&=$UN6Q\ZY
M<PN!@(1R16?,Y/8[*V$IPI*HI+4NW-P8U&4YQC(K.%P!%N!):IM2O(X56V;B
M=?E('>L:>Z*@Y(4CM0U8FC0<E<LW%P,C/+&GK-O 7^]UK&CN1,Y9FZ5HV[+E
M3D9:IN;3I<J.HTW"Q,KD$$8YYK;MK97A!MB XX!)Z5S%C)Y8.XDYKI;"XC5
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MX7V&'YGNQM%%%8GLGTM^S?\ \BGJO_7X/_0:]IKQ;]F__D4]5_Z_!_Z#7M-
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MUO[13@8#8Y-4Y(PC0K6]G'5FSIK+*,2A4/\ >J[JFHQZ38DB1<8]:X5_'&G
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MC%&* /J/]GG_ ))Y-_U_2?\ H*UZU7DO[//_ "3R?_K^D_\ 05KUJD,****
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MY(J$]*YV?;K742BBBD 4444 %%%% !3D_P!8OU%-IR?ZQ?J* /O:R_X\+?\
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M/J+]GK_DGD__ %_2?^@K7K->3?L]?\D\G_Z_I/\ T%:]9J2@HHHH ^ ****
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MIZK_ -?@_P#0:]IH **** "BBB@#B/B]_P DKUW_ *XK_P"AK7QO7V1\7O\
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MRPY(SM[CWJ98=\RD?+DXS33"6FAOPN@&%JTK# YK*C?[/AIF"JO%7HW!7/\
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MQ#7,>QP]3JPBY2V,T\+2445AU/I0HH%+0(2BEHH 2BEHH 2BEHH ^H?V>O\
MDGDW_7])_P"@K7K->3?L]_\ )/9O^OZ3_P!!6O6:DM!1110!\ 4444 %%%%
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MC$JO?E_]XYKJ(UVR;G.13KAE.T(/RK2-!1U(KYC7KQ]]G)ZC!]FGV.K,P'#
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M*6BF(3%&*6B@!,4Y!^\7ZBDIR?ZQ?J* /O2R_P"/"W_ZY+_(5/4%E_QX6_\
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MSEHR5XX-5C([6Y#$FG2,NTACTZ"HMQEB(5<'M57.%)+8JQJN"<A3FJKM),S
M-P#BK<-G$NXS2$N>@%1-Y-NTBJI(QG=4LZ4M+HK""YG;R+90K]Y#VJG?Z3+9
MVAWR%G4_,]:;7:I$#$<'N?6H+NYGOHC;,N$/)-2SIA*4;)[%;12D4VY_F &5
MJ>7=-=--<')/W!4,(CMY%(8*N.:BCU&"6]Y<%5/'UI)E<DI-M(W;1"EW'O<*
MR#-4O$=^+FY6WC(!0CD=VJ$7>^\+AAD=#5O1M/&H:BUU<Q_ND;(SZU2C<SC%
M1E=GGGQ1@ET\:? [D/+'OE7W[5YN,Y_G7M?Q#\,WGB2^>ZM&$GV==JH.U>:R
M>"];1#(]J0!6$XNY]GEV,P_U=1<K,YZBI9[>6WF,<B;6'7-15!ZE[ZA1110
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M_P#(ZV'_ %Y#_P!"->/5[#^T3_R.MA_UY#_T(UX]5(EA1113$%%%% !1110
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M*-7BW#YE(ZUU_A;Q;+'>B/6;0^9*,I*P/RU49RZG/C\HC).=)JQZ>S"-27D
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M6(WVK32O\A)RHK08K#(T28R>>E-@(699FX(-"5BI5;JR-$6["0X;[@Y%5K.
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M7"^(OA!<V-L]UIMP;@@_ZDK@XJ'1FMT>UA\ZPU=\K=CRV@5<U#3;K2[@V]Y
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MO^/"W_ZY+_(5/4E!1110 4444 ?-'[1'_(Z6'_7D/_0C7C]>P?M$?\CI8?\
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MNU.!8U,J*95'%3AL>83>!+B"5 D#29ZA7XJ23P9<Q/N>P67_ &1(:]-5 IR
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MTC?>ZX J(D"<G=SZ4Q&9O,+' ["HDPN.""4[BQ..U1.I?(3 QTI8!B-OK1(
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MU%)3D_UB_44P/N^R_P"/"W_ZY+_(5/4%E_QX6_\ UR7^0J>H+"BBB@ HHHH
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MZAJYW4N6+, :7-<7*01N[GJ?:NITC1I$"LT>R,<'/4U3T47,5_Y[?+&.F:Z
MZKN9QCYDYH2*Q%:3T1/;Z<MM<-.'WENF>U,O/+&NV1D;YRIP*8EXTMLUR6V(
MHSCUK L;][[6&OKHG9#\L>*OF2T,*5-M2G)G<E3*NS.*Y&XTFWU?Q8EG<R9C
MMU\T8]:TY-<2WC:9PP3GD]*XZ?QQIFF7$E_&!)<294 'M14FG8Z\#3JRNZ:N
MST:\2)[)H2VU=N!]*^<?&>GPZ?K\B0OO5CN+5U5]\6+J8,$@ XP#7GM]?RZA
M=274Q)9CWK"K)2>A])E6#K4&Y3V96HHHK(]D****8!1112 ^GOV?O^2?3?\
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M!T7)G7#'N@K4T<=H?AH2Z6&ETZ,-_"6')KHM.LXK0JDUM&K= =@K;B^2-4'
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M'O6L:<4B7.Z]TRY-+3*S/-)O ^XAX-0((X]JA%5LG%:GF;PPVD #@GO55[6
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MO^OV3_T%:]6J'N;1V"BBBD,^"****LR"BB@T &:,T4NWKUH'9"@<4N>W6DP
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M067_ !X6_P#UR7^0J>H-0HHHH **** /FK]H;_D=+#_KR'_H1KR&O7OVAO\
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M]?7.FZ 3J/R@MF,'[Y7WK)M/"]Q!=M>RP#9YI\J/VSP2*U]4M$N4S=2O&Q'
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MU"C2/#^\&#3$  ()W?6DZB+3:076HK%'LBC+'IG%54::1!,6VD=15A3N+9
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M28&>#G(S2US;(^YN%%%% !111B@0448HQ0!]-_ #_DG\W_7[)_Z"M>JUY5\
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M8\O9U4]0:\ZUJ^70=7+QG,+'E :QJ>Z=2I2J_#N==:I!$ JE^?4YK65$:,#
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M&L;4M5FMX1]DMV)<XW'I3T2.N,5%FY-)#&F^6154>IJG<WH1,PQ-+]*Y&?\
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MP7HL>K:FJO\ ZM.6-5%79E6K1HTI5)=#LO"/AJ/5M"2:4R1%./EQS[\UT*>
M[)R,7=QCN<"NCMH$CM8XK=!'%&, #^*M"*$!-P_&M?[/H3]Z4;L^9CQCG5%>
MSPM=QIK966GX'%W7@*V@A+I=3.>P.!FN=N-"WZC#9Z>[3.X^;/13[UZ-J,;W
M;!5)"C@@55TG3(M.M)/,4B4R9$G?%85,LH37+%6/8R[C[-L/-U*]5U-'9.UK
MO9NRZ;AH>DP:'&8  TIP7F/<^GTK,U*]%AK!GAE([N >#6SJMX!:2*("2W"D
M?SKBGT>:ZE_>3-&\O\9Y'TKIY8TXJ$%9(^5GB*N-K2Q&+GS2D[MO^O\ ACJS
MKUK=0@EMH(^;!XK*N;BQBO5O&MVN% P$<8!-+IWA-K9 \EQN ;[N/O5OOIUL
MS9D!D8= QI\C9SNK3I2O%G#?V5//?R3F/R(9CN$2<XKK;$3VJHMM (0J@,X^
MZWOCUK0C@&X[0%QQ@BK@0!/45<*1G6Q]2IHC+=/M;9N97E^G _*G"UD) B"H
MGKCFK^P*?04A?ABG'J:T48]3D<Y2W&06\,3 D;F]6JS(5D4CM5>&-9>,GG^*
MII!%#$79MJK_ !,:NT4M!PA)H8OR#:!GU-<OXRTS[5:K,C[9%Z@-BM^2ZFN
M$LX<*W65N*K2>&DN$)O+B1RW7:<5G*/,M#IPLO8RYCQZXLKEYE"3EI"< 9KH
M]"TQ+69/M#@O_$37<V_@W2K>Y68+(_\ O-6J-%T_D+:Q\]ZS]@]STZ^8JI#E
M@<U?>&X-5LG:%@+A>4;M]#4T%I'!I%O;7%LJ.$VNQ4=?:MAM*>(%[5]NWG8O
M1OK5>WO7G#0W5L3(#R,=!6?U:"FZEM61+-L=/!1P3FW",N9=UI:R\NMNYS]Q
MIR6Z;?*5F'*L!VJ"VDA68+-'&RG^(+TK>DCB\Q_+;,8&,'J*Y^\C:%N%RI/6
MIE%=C.E7J3]V4W][-&V6(QNR2*7W8">HIM]9Q3MY8C\K<,_*,BL.V:2T<R.>
M"W'-:YO'&T@9+=*I7,YQE3E<IV]O=10O#%+-%@\.C'FH(K:YGO"K74CN!P6;
M)S7331):0Q/*ZDMTYZUB:FIL9Q>QD+G^'-$HFM*M*?0SQ<:A%JR6AG,>SFMQ
M=0NS$T8FDD<'YE)PU9L@&I/!/:JXF# N<9Q[U=NHI='U$7'GP7'F@$@\%?P[
M4HW3-*L5)72U->&,2P)Y%K/&>KR%N?\ Z]4-5T[_ (2.R:TNQY13E<@!172V
M=Y:/9I-)=0H'Y&YL#Z5A>-HF?26;3G6664;0B'.?>M*D4D9X1U745]#Q'Q%H
M4V@ZBUO*.#RI!SN%8I'%:6J66IVTH^WQS(QX'FYZ>U9QX[5S'W5*_LU>5PQ2
M 4ZBI*&T4M% "4Y!^\7ZBDIZ?ZQ?J*!GW/9?\>-O_P!<E_E4]067_'C;_P#7
M)?Y5/69N%%%% !1110!\W_M!?\CE8?\ 7F/_ $(UY'7KG[07_(Y6'_7F/_0C
M7D=:+8PEN%%%%,D**** "BBB@ HHHH *,TE%  IP>G3BNT\#^);W1K]8HR7@
ME.'4UQ>,CTR:]:^&_AE5(O;R#>'&8B>E."?,<&93IPHMS.Z73;6=OM*Q>8S_
M #9;M6B&$4*J%V^U/SY.%1<9["DFQM!8CBO12Y4?GTVY,@N)$2)3-(%!-4Y;
MJYM_FCC#Q'N.]0:L/M>(X$,C@\X/2M&Q"_9DB/+J/F%1)MO0;I\JN9<E_J-T
M-L$9C!X)(JQ!8&"V(W9E?EF-:[(%&,8^@J,IQS3Y':[)E4=K6*UHA1\GDXQ5
MT@5 &"MM'YU(&[9IPE9&5[B.FXY' %(%^;VIWXBG <TT[B:N.09J3&/3-+&,
M4]T'WJUOH;QIZ#,<9II'-2,R1IN+#':JRW/FR82/@=6/:FY%>SL3D[1UJO-/
M^[;RQN8=A2&(N7WOD'IBG0A8W"@?B:ENXDU>QARPZMJ2EDE\E!T4]ZIPZ/=;
MR]W*5P>B]Z[$B/D C/M4!4;N>:S<+FLZKBK)&=:QS0OM 5H\=3UJ22>Y601Q
M1+SW-7?+ Y7K44MI]H_B97 [4<K2,5JRFW[N91-&VYNA7I4MV[00^;(F\#H%
MZT@AN(U\LDL>Q-)+'(T.905 _P!KK6;3+25]2L=6B(7:DF#ZBJEUJEK&PS*%
M8GN:RM:F;3XF9)]^[D =J\HUW6[B^O\ *RE0G'6L92>Q[&!RN.*WV/4[W5K.
M.[)>Y3<1W-8-[KU@<@RAR.F#7FDL\LS;GD8GZU8L+:2\E1%SUY)K*[N>W'*J
M-*-VST/3]1:[!:&)G Z^@KMM-426JNTH51RRFN7T.YM](CC@^7!P&-=8+>PD
M4R&0LK=EK2#/G,PTGRI:&C%?PC)A!8#OVKS?XE:?/=*FH\YZ8'2O0K6*"- (
MQB/WJ/6(X+C2;B(JLG'RCTJYZHRP%?ZO73/FYAM8C&/6BK>J1&#498SQANE5
M*Y7HS] B[I,****"PHHHH$%%%% 'TQ\ O^1 F_Z_7_\ 05KU2O*_@%_R($W_
M %^O_P"@K7JE9O<WCL%%%%(H^$<44M%:G,)R:>KM$RR*<,IS3:8>OXT#M<]<
M\'>*5U&U%G<R+Y_3:W\5:6LZ,E[NEMTQ*H^8 <5YAX2_Y&2V_P!ZO;;#[MY]
M*N&NY\EF%%8?$WI]3S+RQYAANH^,XR:@NO"<5TIELG'/10*T]9_X^G^M=#X9
M_P!5']:3WL:/%U*4%*)YC<^%M4@)S;G:.YXIVF^&KV>Z FB98@?F;' KUSQ9
M_JHZKZ7_ ,@&]_SVIV.F.959TMCI?"MC8V6C1V]F5*@9?W-:<ME$[<KS[5S_
M ()_X])/K75GI7=1^$^8KKFDY/<R9=#M93E\U$WAK3Y) [1!B!WK8I1VJYP3
M(C.2V9Q4_A_2OMLL5Y;HLA^:)^@QZ54N/"=E?VPFMW,$H.#L; K6\6](?K2:
M9_R"Q]:XI)'6J]2"34F<7J6@ZC"!$ES,R?[+FN4OM-U#3XC=-<RR1QO@JS$D
M5[%'_KJ\_P#%'^IO_P#>J6>MEV,G4DH26C-_1_B%IJZ?"D^I>2RJ!M8<T7_Q
M4TF [8#)<-ZCH:\.E_USU/:]:7,^YZ_]BX=SYW<]$U#XH:E<%EM;8(N.">:Q
M)O%GB:X&X3NJGNJXK+B_I74VO_(*A^M3=]R71HTE>,$8O]K>*YP"+FY(]B:<
M3XNEQN:^]LDUWNE_=B_WA7H$O_'K%^%-79Q5<P]GHH(\)$GC#3D\W;./]IN:
M:WBGQ6B%3+)@^J5[%XB_X\6^E<#>?<_"GJ*CBX5/BIHX:_U_5[TJ+V9WV]!B
MO0_#/CN.2U@M;N"0M&NU6 SQ7!7O_'T?K71>%O\ D)BI6YTXV-*=#6)WOVK4
M[M1_9T4B(>F>*AF'B&!%>6^56[K74:?_ *M?I6=J?W7_ -ZM]4?*QJJ,N511
ME-K=[$(HI;D9_B<5TNES6\UONB;<3RQ]:X6][?[QKH_"O_'O-]*TIR=R<3!<
MESIQDQ%D/2H[69&=QT8=:DM?]2:S[;_C_F^M;N3.-:6-&3;U%5VN(D!\P< >
ME2]C5*;_ %,W^[4MB;]\6RM(&M)_)*L9&RI89Q5B;2+*ZMO+G@C9L<E1CFJF
MA_\ 'E6O!_%2:5CKIR?,?/WC^U^P:N;56;RUY52>E<<#G KNOBG_ ,C,_P#N
MBN%3H*XI[GWF"_@1%(I,4XTE9G6?1?[/'_(K:I_U]C_T&O8J\=_9Y_Y%;5/^
MOL?^@U[%6;W-H[!1112*"BBB@#B_BS_R3#6_^N2_^AK7R'7U[\6/^28:Y_UQ
M7_T-:^0JN.QE/<****9 4444 *,[AQ7J/PJMXF:X8OC'.,=:\N7J*]2^%G2Z
M^E5'XD>5G/\ NLCU:WC#8(/ -6';8A]!4-E_J*D?H_TKTKV1\)#2-D48YXY;
MHJ&4-C@$\UHD1O#^\VD8YKDO^9F3_=-;[?\ 'L_UK*,M3=4TE<I2P2H'AVF:
M!B2,?PTB6<A,>_:L2<@#D_C6K_RZC_=JK'_JVI;LAR99)'D90 XYJE/.&EC$
M2ACGYO:K*?\ 'M^%95O_ *^?_>JC*R;-0-AN<%CZ4Z>X6&V(5"Q]!56Q[_6K
M#]6^E6B(NST*2&:=PN6'O5[]Q;KOD=44==QIMO\ >_&L7Q'_ ,?$7^\*AZ&E
M.*E+4UFU,2L%M(OE[RMP!6?:,MS(\HE\]XV/#GC'L*=J'_'HO^Z*R]._Y",7
MU%1=G79*+L=-:WB[666(P@G"EB*EN+N),#>",=16'XA^\G^_5FV_X\4JE-HB
M<;P1IP3Q/]^14/8.<4RXUJQA?RC,"P[H,URGBS_C\3_<%,T'[A^E)UI&GL8J
M-SI5\1:>'*^:V3UPIXJ%-2L;Z1Y;"ZB%POWF<XS69I?_ "$;S_KF:X1_^/J3
M_>/\ZF<W8WHT(R3.^E%RTS31- 03\^T]:HZG?0R6CP*NV51SGUI-*_Y LGUK
M(U+[_P#P&L+A""3(-,1[B=EE^[BNHTZP:\8G=M\KI7-Z5U-=KH7W6_"M*6I&
M-DUL7ETJWD4+.@8XZUQ-ZQN+NXLMFY5;"#UKT7M7G/\ S,9_ZZFJJ)$82329
M<M=/BLX"'EF4_P!Q>*M'2H);G%I(TI<#>S#)6M&__P"/B/\ W33=&_U2?[YJ
M4M13K22N)+X?M%MB)(LA>=V>!]!68D5G(!';W9WQ<@-D$5V4WW&^E<!)_P ?
M\W^]5S08><I/5G*_$>_N[L6L<Z+Y<8VK*!R?K7G9YSFO1O'/_((C_P!^O.!T
MKE>Y]S@OX*%HHHI'6-I:** "G)_K%^HIM.3_ %B_44 ?=%E_QXV__7)?Y5/4
M%E_QXV__ %R7^53UD= 4444 %%%% 'S?^T%_R.5A_P!>8_\ 0C7DE>M_M!?\
MCE8?]>8_]"->25HMC"6X4444R0HHHH **** "BBB@!#24IZT4QK40'H?0U[5
M\+_$,5U9-I]S*J,@_=@]37BG\)KK/ '_ ",$'^]50=I'!F5&,Z#YCWRXN5MH
MFEDC8A?2N3U/Q.LJLMM%)D<=*Z[4?^0<_P#N5Y];_?E_WJZJC9\93IQ3=T=#
MX8$WER32J?WHQS6C:K):WCH5S&QR#3M)_P"/8?2KC]1]*N&QR57[Q(K*X.&W
M4C)Q4-GU?ZU9:MMT9210F1EY6LYM3$;;"1N^M:TW4_2N(U3_ (^OQKEF[&U"
ME&3U-W^T4W[EDR5Z@&K:ZI&Z*^\+SR,UP^G_ .OFJR/OGZU*FT:U,/%2.XBU
M>$!F9L 4BZJ]XP6&,K$>/,;I7.?\NX^E;MK_ ,B^GUK2-1BY4HDLD*XW$M/C
M[H]*F\B:9%(;RR.H'>G67^J%6T_UGX5K$PNV]2#&W&[IWIQ"LF5."*)>GXTD
M72FG8BPJ1?Q,<'U-133;""(RV.N.]277W%^M'_+'\*JYI+9%*36?)CW?89G
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G_P"1 F_Z_7_]!6O4Z\L^ 7_(@S?]?K_^@K7J=9O<Z([!1112&?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>38
<FILENAME>inzy-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-03-12T08:26:53.9229+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.inozyme.com/20231231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:inzy="http://www.inozyme.com/20231231" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" namespace="http://xbrl.sec.gov/stpr/2023"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" namespace="http://xbrl.sec.gov/ecd/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" namespace="http://fasb.org/srt/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100030 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" id="StatementConsolidatedStatementsOfStockholdersEquityDeficit">
        <link:definition>100040 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" id="StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
        <link:definition>100050 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100060 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentation" id="Role_DisclosureOrganizationAndBasisOfPresentation">
        <link:definition>995455 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>995465 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureRecentAccountingPronouncements" id="Role_DisclosureRecentAccountingPronouncements">
        <link:definition>995475 - Disclosure - Recent Accounting Pronouncements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetails" id="Role_DisclosureBalanceSheetDetails">
        <link:definition>995485 - Disclosure - Balance Sheet Details</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurement" id="Role_DisclosureFairValueMeasurement">
        <link:definition>995495 - Disclosure - Fair Value Measurement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureLicenseAndSponsoredResearchAgreements" id="Role_DisclosureLicenseAndSponsoredResearchAgreements">
        <link:definition>995505 - Disclosure - License and Sponsored Research Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>995515 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebt" id="DisclosureConvertibleDebt">
        <link:definition>995525 - Disclosure - Convertible Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>995535 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>995545 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShare" id="Role_DisclosureNetLossPerShare">
        <link:definition>995555 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlans" id="Role_DisclosureEmployeeBenefitPlans">
        <link:definition>995565 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactions" id="DisclosureRelatedPartyTransactions">
        <link:definition>995575 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>995585 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureAcquisitionOfAssets" id="DisclosureAcquisitionOfAssets">
        <link:definition>995595 - Disclosure - Acquisition of Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>995605 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>995615 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables" id="Role_DisclosureBalanceSheetDetailsTables">
        <link:definition>995625 - Disclosure - Balance Sheet Details (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementTables" id="Role_DisclosureFairValueMeasurementTables">
        <link:definition>995635 - Disclosure - Fair Value Measurement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" id="Role_DisclosureCommitmentsAndContingenciesTables">
        <link:definition>995645 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtTables" id="DisclosureConvertibleDebtTables">
        <link:definition>995655 - Disclosure - Convertible Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityTables" id="DisclosureStockholdersEquityTables">
        <link:definition>995665 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>995675 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareTables" id="Role_DisclosureNetLossPerShareTables">
        <link:definition>995685 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" id="Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails">
        <link:definition>995695 - Disclosure - Organization and Basis of Presentation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>995705 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails">
        <link:definition>995715 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureRecentAccountingPronouncementsAdditionalInformationDetails" id="Role_DisclosureRecentAccountingPronouncementsAdditionalInformationDetails">
        <link:definition>995725 - Disclosure - Recent Accounting Pronouncements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfShortTermInvestmentsDetails" id="Role_DisclosureBalanceSheetDetailsScheduleOfShortTermInvestmentsDetails">
        <link:definition>995735 - Disclosure - Balance Sheet Details - Schedule of Short-Term Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails" id="Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails">
        <link:definition>995745 - Disclosure - Balance Sheet Details - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfLongTermInvestmentsDetails" id="Role_DisclosureBalanceSheetDetailsScheduleOfLongTermInvestmentsDetails">
        <link:definition>995755 - Disclosure - Balance Sheet Details - Schedule of Long-Term Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" id="Role_DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails">
        <link:definition>995765 - Disclosure - Balance Sheet Details - Schedule of Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfNoncurrentPrepaidExpensesDetails" id="DisclosureBalanceSheetDetailsScheduleOfNoncurrentPrepaidExpensesDetails">
        <link:definition>995775 - Disclosure - Balance Sheet Details - Schedule of Noncurrent Prepaid Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetails" id="Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetails">
        <link:definition>995785 - Disclosure - Balance Sheet Details - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails" id="Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails">
        <link:definition>995795 - Disclosure - Balance Sheet Details - Schedule of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementSummaryOfFinancialAssetsMeasuredAtFairValueDetails" id="Role_DisclosureFairValueMeasurementSummaryOfFinancialAssetsMeasuredAtFairValueDetails">
        <link:definition>995805 - Disclosure - Fair Value Measurement - Summary of Financial Assets Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails" id="Role_DisclosureFairValueMeasurementAdditionalInformationDetails">
        <link:definition>995815 - Disclosure - Fair Value Measurement - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureLicenseAndSponsoredResearchAgreementsAdditionalInformationDetails" id="Role_DisclosureLicenseAndSponsoredResearchAgreementsAdditionalInformationDetails">
        <link:definition>995825 - Disclosure - License and Sponsored Research Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>995835 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureLeasePaymentsUnderNonCancelableLeasesDetails" id="Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureLeasePaymentsUnderNonCancelableLeasesDetails">
        <link:definition>995845 - Disclosure - Commitments and Contingencies - Schedule of Future Lease Payments Under Non-Cancelable Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails" id="DisclosureConvertibleDebtAdditionalInformationDetails">
        <link:definition>995855 - Disclosure - Convertible Debt (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtSummarizesOfImpactOfTermLoanDetails" id="DisclosureConvertibleDebtSummarizesOfImpactOfTermLoanDetails">
        <link:definition>995865 - Disclosure - Convertible Debt - Summarizes of Impact of Term Loan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtFuturePrincipalPaymentDetails" id="DisclosureConvertibleDebtFuturePrincipalPaymentDetails">
        <link:definition>995875 - Disclosure - Convertible Debt - Future Principal Payment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" id="DisclosureStockholdersEquityAdditionalInformationDetails">
        <link:definition>995885 - Disclosure - Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityUnderEquityIncentivePlansDetails" id="DisclosureStockholdersEquitySummaryOfStockOptionActivityUnderEquityIncentivePlansDetails">
        <link:definition>995895 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity Under Equity Incentive Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfAssumptionsUsedToValueStockOptionsGrantedToEmployeesUsingBlackscholesOptionpricingDetails" id="DisclosureStockholdersEquitySummaryOfAssumptionsUsedToValueStockOptionsGrantedToEmployeesUsingBlackscholesOptionpricingDetails">
        <link:definition>995905 - Disclosure - Stockholders' Equity - Summary of Assumptions Used to Value Stock Options Granted to Employees using Black-Scholes Option-Pricing (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityRelatedToRestrictedStockUnitsRsusDetails" id="DisclosureStockholdersEquitySummaryOfActivityRelatedToRestrictedStockUnitsRsusDetails">
        <link:definition>995915 - Disclosure - Stockholders' Equity - Summary of Activity related to restricted stock units ("RSUs") (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfTotalCompensationCostRecognizedInStatementsOfOperationsDetails" id="DisclosureStockholdersEquitySummaryOfTotalCompensationCostRecognizedInStatementsOfOperationsDetails">
        <link:definition>995925 - Disclosure - Stockholders' Equity - Summary of Total Compensation Cost Recognized in Statements of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>995935 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUsFederalStatutoryIncomeTaxRateToEffectiveIncDetails" id="DisclosureIncomeTaxesScheduleOfReconciliationOfUsFederalStatutoryIncomeTaxRateToEffectiveIncDetails">
        <link:definition>995945 - Disclosure - Income Taxes - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate to Effective Inc (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails" id="DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails">
        <link:definition>995955 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureNetLossPerShareScheduleOfNetLossPerShareBasicAndDilutedDetails" id="DisclosureNetLossPerShareScheduleOfNetLossPerShareBasicAndDilutedDetails">
        <link:definition>995965 - Disclosure - Net Loss per Share - Schedule of Net Loss Per Share, Basic and Diluted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentialDilutiveSecuritiesFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" id="Role_DisclosureNetLossPerShareScheduleOfPotentialDilutiveSecuritiesFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
        <link:definition>995975 - Disclosure - Net Loss per Share - Schedule of Potential Dilutive Securities from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetails" id="Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetails">
        <link:definition>995985 - Disclosure - Employee Benefit Plans - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>995995 - Disclosure - Related Party Transactions (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="inzy-20231231.xsd#StatementConsolidatedBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="inzy-20231231.xsd#StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" xlink:href="inzy-20231231.xsd#StatementConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="inzy-20231231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" xlink:href="inzy-20231231.xsd#Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="inzy-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:href="inzy-20231231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureRecentAccountingPronouncementsAdditionalInformationDetails" xlink:href="inzy-20231231.xsd#Role_DisclosureRecentAccountingPronouncementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfShortTermInvestmentsDetails" xlink:href="inzy-20231231.xsd#Role_DisclosureBalanceSheetDetailsScheduleOfShortTermInvestmentsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfLongTermInvestmentsDetails" xlink:href="inzy-20231231.xsd#Role_DisclosureBalanceSheetDetailsScheduleOfLongTermInvestmentsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetails" xlink:href="inzy-20231231.xsd#Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementSummaryOfFinancialAssetsMeasuredAtFairValueDetails" xlink:href="inzy-20231231.xsd#Role_DisclosureFairValueMeasurementSummaryOfFinancialAssetsMeasuredAtFairValueDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureLicenseAndSponsoredResearchAgreementsAdditionalInformationDetails" xlink:href="inzy-20231231.xsd#Role_DisclosureLicenseAndSponsoredResearchAgreementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="inzy-20231231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails" xlink:href="inzy-20231231.xsd#DisclosureConvertibleDebtAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtFuturePrincipalPaymentDetails" xlink:href="inzy-20231231.xsd#DisclosureConvertibleDebtFuturePrincipalPaymentDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:href="inzy-20231231.xsd#DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfAssumptionsUsedToValueStockOptionsGrantedToEmployeesUsingBlackscholesOptionpricingDetails" xlink:href="inzy-20231231.xsd#DisclosureStockholdersEquitySummaryOfAssumptionsUsedToValueStockOptionsGrantedToEmployeesUsingBlackscholesOptionpricingDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityRelatedToRestrictedStockUnitsRsusDetails" xlink:href="inzy-20231231.xsd#DisclosureStockholdersEquitySummaryOfActivityRelatedToRestrictedStockUnitsRsusDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfTotalCompensationCostRecognizedInStatementsOfOperationsDetails" xlink:href="inzy-20231231.xsd#DisclosureStockholdersEquitySummaryOfTotalCompensationCostRecognizedInStatementsOfOperationsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="inzy-20231231.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentialDilutiveSecuritiesFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="inzy-20231231.xsd#Role_DisclosureNetLossPerShareScheduleOfPotentialDilutiveSecuritiesFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetails" xlink:href="inzy-20231231.xsd#Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="inzy-20231231.xsd#DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="inzy-20231231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="inzy-20231231.xsd#StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="inzy-20231231.xsd#Role_DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails" xlink:href="inzy-20231231.xsd#Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureLeasePaymentsUnderNonCancelableLeasesDetails" xlink:href="inzy-20231231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureLeasePaymentsUnderNonCancelableLeasesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails" xlink:href="inzy-20231231.xsd#DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="inzy-20231231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentation" xlink:href="inzy-20231231.xsd#Role_DisclosureOrganizationAndBasisOfPresentation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="inzy-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureRecentAccountingPronouncements" xlink:href="inzy-20231231.xsd#Role_DisclosureRecentAccountingPronouncements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetails" xlink:href="inzy-20231231.xsd#Role_DisclosureBalanceSheetDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurement" xlink:href="inzy-20231231.xsd#Role_DisclosureFairValueMeasurement" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureLicenseAndSponsoredResearchAgreements" xlink:href="inzy-20231231.xsd#Role_DisclosureLicenseAndSponsoredResearchAgreements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="inzy-20231231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebt" xlink:href="inzy-20231231.xsd#DisclosureConvertibleDebt" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquity" xlink:href="inzy-20231231.xsd#DisclosureStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="inzy-20231231.xsd#DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:href="inzy-20231231.xsd#Role_DisclosureNetLossPerShare" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlans" xlink:href="inzy-20231231.xsd#Role_DisclosureEmployeeBenefitPlans" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactions" xlink:href="inzy-20231231.xsd#DisclosureRelatedPartyTransactions" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureSubsequentEvents" xlink:href="inzy-20231231.xsd#DisclosureSubsequentEvents" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureAcquisitionOfAssets" xlink:href="inzy-20231231.xsd#DisclosureAcquisitionOfAssets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="inzy-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="inzy-20231231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables" xlink:href="inzy-20231231.xsd#Role_DisclosureBalanceSheetDetailsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementTables" xlink:href="inzy-20231231.xsd#Role_DisclosureFairValueMeasurementTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" xlink:href="inzy-20231231.xsd#Role_DisclosureCommitmentsAndContingenciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtTables" xlink:href="inzy-20231231.xsd#DisclosureConvertibleDebtTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityTables" xlink:href="inzy-20231231.xsd#DisclosureStockholdersEquityTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="inzy-20231231.xsd#DisclosureIncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareTables" xlink:href="inzy-20231231.xsd#Role_DisclosureNetLossPerShareTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails" xlink:href="inzy-20231231.xsd#Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfNoncurrentPrepaidExpensesDetails" xlink:href="inzy-20231231.xsd#DisclosureBalanceSheetDetailsScheduleOfNoncurrentPrepaidExpensesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails" xlink:href="inzy-20231231.xsd#Role_DisclosureFairValueMeasurementAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtSummarizesOfImpactOfTermLoanDetails" xlink:href="inzy-20231231.xsd#DisclosureConvertibleDebtSummarizesOfImpactOfTermLoanDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityUnderEquityIncentivePlansDetails" xlink:href="inzy-20231231.xsd#DisclosureStockholdersEquitySummaryOfStockOptionActivityUnderEquityIncentivePlansDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUsFederalStatutoryIncomeTaxRateToEffectiveIncDetails" xlink:href="inzy-20231231.xsd#DisclosureIncomeTaxesScheduleOfReconciliationOfUsFederalStatutoryIncomeTaxRateToEffectiveIncDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inozyme.com/20231231/taxonomy/role/DisclosureNetLossPerShareScheduleOfNetLossPerShareBasicAndDilutedDetails" xlink:href="inzy-20231231.xsd#DisclosureNetLossPerShareScheduleOfNetLossPerShareBasicAndDilutedDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_TemporaryEquityStockIssuedDuringPeriodSharesToAcquireInProcessResearchAndDevelopment" xlink:label="inzy_TemporaryEquityStockIssuedDuringPeriodSharesToAcquireInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityShareSubscriptions" xlink:label="us-gaap_TemporaryEquityShareSubscriptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_USGovernmentAgencyDebtSecuritiesMember" xlink:label="inzy_USGovernmentAgencyDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_AccruedResearchAndDevelopmentCostsPolicyTextBlock" xlink:label="inzy_AccruedResearchAndDevelopmentCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_ExerciseOfPreFundedWarrants" xlink:label="inzy_ExerciseOfPreFundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_EmergingGrowthCompanyStatusIssuancePeriodOfNonConvertibleDebt" xlink:label="inzy_EmergingGrowthCompanyStatusIssuancePeriodOfNonConvertibleDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseImpairmentLoss" xlink:label="us-gaap_FinanceLeaseImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_K2HvMember" xlink:label="inzy_K2HvMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="us-gaap_CommonStockSharesSubscriptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_InvestmentMaturityPeriod" xlink:label="inzy_InvestmentMaturityPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_SeriesAConvertiblePreferredStockMember" xlink:label="inzy_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_CustomaryAdjustmentsPercentageOnConversion" xlink:label="inzy_CustomaryAdjustmentsPercentageOnConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_PrepaymentOfLoans" xlink:label="inzy_PrepaymentOfLoans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_AdditionalLoanAmount" xlink:label="inzy_AdditionalLoanAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_AvailableForDebtSecuritiesEquitySecuritiesNonCurrent" xlink:label="inzy_AvailableForDebtSecuritiesEquitySecuritiesNonCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturityDate" xlink:label="us-gaap_LongTermDebtMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_PrepaidClinicalTrialAndOther" xlink:label="inzy_PrepaidClinicalTrialAndOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_StockIssuedDuringPeriodValueSharesIssuedInAtTheMarketOffering" xlink:label="inzy_StockIssuedDuringPeriodValueSharesIssuedInAtTheMarketOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_AdditionalTemporaryEquitySharesIssued" xlink:label="inzy_AdditionalTemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_AlexionPharmaceuticalsIncMember" xlink:label="inzy_AlexionPharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_ResearchSupportFundingExpirationYear" xlink:label="inzy_ResearchSupportFundingExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_LesseeOperatingLeaseLiabilityPaymentDue" xlink:label="inzy_LesseeOperatingLeaseLiabilityPaymentDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_ResearchSupportFundingAmount" xlink:label="inzy_ResearchSupportFundingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_Others" xlink:label="inzy_Others"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_TwoThousandTwentyStockIncentivePlanMember" xlink:label="inzy_TwoThousandTwentyStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="inzy_DeferredTaxLiabilitiesRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_PropertyAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:label="inzy_PropertyAndEquipmentEstimatedUsefulLivesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandImprovementsMember" xlink:label="us-gaap_LandImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_PercentageOfBeneficialOwnershipLimitation" xlink:label="inzy_PercentageOfBeneficialOwnershipLimitation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_ScheduleOfPrepaidExpensesNoncurrentTableTextBlock" xlink:label="inzy_ScheduleOfPrepaidExpensesNoncurrentTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_TwoThousandSeventeenEquityIncentivePlanMember" xlink:label="inzy_TwoThousandSeventeenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_Effectiveincometaxratereconciliationpermanentdifferences" xlink:label="inzy_Effectiveincometaxratereconciliationpermanentdifferences"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturingInYearsTwoAndThree" xlink:label="us-gaap_LongTermDebtMaturingInYearsTwoAndThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TimeDepositsAtCarryingValue" xlink:label="us-gaap_TimeDepositsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_EmergingGrowthCompanyAnnualGrossRevenues" xlink:label="inzy_EmergingGrowthCompanyAnnualGrossRevenues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_AdditionalSharesIssued" xlink:label="inzy_AdditionalSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_EmergingGrowthCompanyStatusIssuanceValueOfNonConvertibleDebt" xlink:label="inzy_EmergingGrowthCompanyStatusIssuanceValueOfNonConvertibleDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_InducementPlanMember" xlink:label="inzy_InducementPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_TermLoanMember" xlink:label="inzy_TermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostMaintenance" xlink:label="us-gaap_CostMaintenance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_ScheduleOfLongTermInvestmentsTableTextBlock" xlink:label="inzy_ScheduleOfLongTermInvestmentsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseIncentiveReceivable" xlink:label="us-gaap_LeaseIncentiveReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201815Member" xlink:label="us-gaap_AccountingStandardsUpdate201815Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:label="inzy_TwoThousandTwentyEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLoans" xlink:label="us-gaap_ProceedsFromLoans"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_LaboratorySpaceMember" xlink:label="inzy_LaboratorySpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_ProceedsFromIssuanceOfCommonStockForCashUnderEmployeeStockPurchasePlan" xlink:label="inzy_ProceedsFromIssuanceOfCommonStockForCashUnderEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_LesseeOperatingLeaseExpirationYear" xlink:label="inzy_LesseeOperatingLeaseExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_LoanAgreementMember" xlink:label="inzy_LoanAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_ClinicalExpenses" xlink:label="inzy_ClinicalExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1" xlink:label="us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="us-gaap_DebtInstrumentPaymentTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_SeriesATwoConvertiblePreferredStockMember" xlink:label="inzy_SeriesATwoConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_AccruedResearchAndDevelopmentCostsCurrent" xlink:label="inzy_AccruedResearchAndDevelopmentCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_UnderwritingAgreementMember" xlink:label="inzy_UnderwritingAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_PartialUpfrontConsiderationPaymentUnderLicenseAgreement" xlink:label="inzy_PartialUpfrontConsiderationPaymentUnderLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_TaxCreditCarryForwardExpirationYear" xlink:label="inzy_TaxCreditCarryForwardExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_OperatingLeaseWeightedAverageIncrementalBorrowingRate" xlink:label="inzy_OperatingLeaseWeightedAverageIncrementalBorrowingRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_OperatingLossCarryforwardsWithExpirationPeriod" xlink:label="inzy_OperatingLossCarryforwardsWithExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_OfficeSpaceMember" xlink:label="inzy_OfficeSpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Dividends" xlink:label="us-gaap_Dividends"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock" xlink:label="inzy_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_WarrantsPolicyTextBlock" xlink:label="inzy_WarrantsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_LendersReimbursedAmount" xlink:label="inzy_LendersReimbursedAmount"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_TwoThousandSeventeenStockIncentivePlanMember" xlink:label="inzy_TwoThousandSeventeenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:label="inzy_EmergingGrowthCompanyStatusPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_SixtyDaysPriorWrittenNoticeMember" xlink:label="inzy_SixtyDaysPriorWrittenNoticeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_K2LoanAgreementMember" xlink:label="inzy_K2LoanAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncollaborativeArrangementTransactionsMember" xlink:label="us-gaap_NoncollaborativeArrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_IncreaseDecreasePrepaidExpensesNoncurrent" xlink:label="inzy_IncreaseDecreasePrepaidExpensesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_TaxCutsAndJobsActFederalNetOperatingLossPercent" xlink:label="inzy_TaxCutsAndJobsActFederalNetOperatingLossPercent"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_OperatingLossCarryforwardsExpirationYear" xlink:label="inzy_OperatingLossCarryforwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_YaleUniversityMember" xlink:label="inzy_YaleUniversityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_LongTermInvestmentsMember" xlink:label="inzy_LongTermInvestmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_ComputerEquipmentAndSoftwareMember" xlink:label="inzy_ComputerEquipmentAndSoftwareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_PatentCostsPolicyTextBlock" xlink:label="inzy_PatentCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_ConcentrationRiskCreditRiskOffBalanceSheetRisk" xlink:label="inzy_ConcentrationRiskCreditRiskOffBalanceSheetRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeeAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_ResearchSupportFundingContractExtendedDate" xlink:label="inzy_ResearchSupportFundingContractExtendedDate"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_JefferiesLlcMember" xlink:label="inzy_JefferiesLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:label="inzy_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_FirstPatientInCompanyMilestonesMember" xlink:label="inzy_FirstPatientInCompanyMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesDomain"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_RestrictedCashMember" xlink:label="inzy_RestrictedCashMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:label="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_IssuanceOfPreFundedWarrantsNetOfIssuanceCosts" xlink:label="inzy_IssuanceOfPreFundedWarrantsNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_OperatingLeaseReversedLeaseLiability" xlink:label="inzy_OperatingLeaseReversedLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_TemporaryEquityStockIssuedDuringPeriodShareNewIssues" xlink:label="inzy_TemporaryEquityStockIssuedDuringPeriodShareNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_UnvestedRestrictedStockUnitsMember" xlink:label="inzy_UnvestedRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_UnderwrittenOffering" xlink:label="inzy_UnderwrittenOffering"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition2" xlink:label="inzy_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_Section174Adjustment" xlink:label="inzy_Section174Adjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_PrepaidResearchStudies" xlink:label="inzy_PrepaidResearchStudies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManagementFeeExpense" xlink:label="us-gaap_ManagementFeeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_BofaSecuritiesIncMember" xlink:label="inzy_BofaSecuritiesIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerDurationDomain" xlink:label="us-gaap_ContractWithCustomerDurationDomain"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_AreaOfLeasedSpace" xlink:label="inzy_AreaOfLeasedSpace"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_StockIssuedDuringPeriodSharesIssuedInAtTheMarketOffering" xlink:label="inzy_StockIssuedDuringPeriodSharesIssuedInAtTheMarketOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_FutureOfferingsOfCommonStock" xlink:label="inzy_FutureOfferingsOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_LicenseAgreementPaymentUponAchievementOfSpecifiedProductSalesOrDevelopmentAndCommercializationMilestones" xlink:label="inzy_LicenseAgreementPaymentUponAchievementOfSpecifiedProductSalesOrDevelopmentAndCommercializationMilestones"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_ThirtyDaysPriorWrittenNoticeMember" xlink:label="inzy_ThirtyDaysPriorWrittenNoticeMember"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_TemporaryEquityStockIssuedDuringPeriodValueToAcquireInProcessResearchAndDevelopment" xlink:label="inzy_TemporaryEquityStockIssuedDuringPeriodValueToAcquireInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_ResearchSupportFundingPeriod" xlink:label="inzy_ResearchSupportFundingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_FederalAndStateTaxAuthorityMember" xlink:label="inzy_FederalAndStateTaxAuthorityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_LossOnDisposalOfFixedAssets" xlink:label="inzy_LossOnDisposalOfFixedAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerDurationAxis" xlink:label="us-gaap_ContractWithCustomerDurationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk" xlink:label="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_ShareBasedPaymentArrangementTrancheFourMember" xlink:label="inzy_ShareBasedPaymentArrangementTrancheFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_TemporaryEquityShareSubscriptionsPricePerShare" xlink:label="inzy_TemporaryEquityShareSubscriptionsPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="us-gaap_OperatingLeaseImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_SummarizesOfImpactTermLoanTableTextBlock" xlink:label="inzy_SummarizesOfImpactTermLoanTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_ConvertiblePreferredStockAndStockholdersEquityAbstract" xlink:label="inzy_ConvertiblePreferredStockAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_TemporaryEquityPolicyTextBlock" xlink:label="inzy_TemporaryEquityPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_MA" xlink:label="stpr_MA"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization" xlink:label="inzy_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_PreFundedWarrantsMember" xlink:label="inzy_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesHeldToMaturityThresholdPeriodPastDueWriteoff" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityThresholdPeriodPastDueWriteoff"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_ResearchSupportFundingExpirationMonthAndYear" xlink:label="inzy_ResearchSupportFundingExpirationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_EmergingGrowthCompanyMarketValueOfCommonStockHeldByNonAffiliates" xlink:label="inzy_EmergingGrowthCompanyMarketValueOfCommonStockHeldByNonAffiliates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_OperatingLossCarryforwardsWithNoExpirationPeriod" xlink:label="inzy_OperatingLossCarryforwardsWithNoExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_NetProductSalesMilestoneMember" xlink:label="inzy_NetProductSalesMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_TemporaryEquityStockIssuedDuringPeriodSharesToAcquireInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of shares to acquire in-process research and development, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_TemporaryEquityStockIssuedDuringPeriodSharesToAcquireInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period shares to acquire in process research And development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_TemporaryEquityStockIssuedDuringPeriodSharesToAcquireInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares To Acquire In Process Research And Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term (in years), Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized research and experimental expenditures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, in Process Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long term liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">RSUs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSUs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Quoted Prices in Active Markets for Identical Assets (Level 1)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series A-2 Convertible Preferred Stock, net of issuance costs of $0.1 million</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityShareSubscriptions_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares available for issuance to investors</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityShareSubscriptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Share Subscriptions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IncomeTaxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Useful Life (In Years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total unrecognized compensation cost related to outstanding employee awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets, increase in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_USGovernmentAgencyDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government Agency Debt Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_USGovernmentAgencyDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">U S Government Agency Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_USGovernmentAgencyDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">U.S. government agency debt securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value measurement with unobservable inputs reconciliation recurring basis asset transfers into level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible preferred stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, net of current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Securities Available For Sale [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_AccruedResearchAndDevelopmentCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Research and Development Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_AccruedResearchAndDevelopmentCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Costs Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_AccruedResearchAndDevelopmentCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_ExerciseOfPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise of pre funded warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_ExerciseOfPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise of Pre Funded warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_ExerciseOfPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of pre-funded warrants, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_EmergingGrowthCompanyStatusIssuancePeriodOfNonConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance period of non-convertible debt cease to be EGC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_EmergingGrowthCompanyStatusIssuancePeriodOfNonConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Emerging growth company status issuance period of non-convertible debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_EmergingGrowthCompanyStatusIssuancePeriodOfNonConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Emerging growth company status issuance period of non-convertible debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Impairment Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based compensation options to purchase number of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Options Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Options Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_K2HvMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">K2HV [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_K2HvMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">K2HV [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_K2HvMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">K2HV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant date fair value of options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesSubscriptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate offering price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesSubscriptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Subscriptions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_InvestmentMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_InvestmentMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Maturity Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_InvestmentMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Investment maturity period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_SeriesAConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_SeriesAConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_SeriesAConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Goods and Nonemployee Services Transaction, Valuation Method, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_CustomaryAdjustmentsPercentageOnConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Customary adjustments percentage on conversion.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_CustomaryAdjustmentsPercentageOnConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customary Adjustments Percentage on Conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_CustomaryAdjustmentsPercentageOnConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customary percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Benefit Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation and Employee Benefit Plans [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Long-Term Debt Instruments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock reserved for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition of Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other comprehensive income (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency translation adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currency Transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Depreciation of fixed assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation of fixed assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_PrepaymentOfLoans_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepayment of Loans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_PrepaymentOfLoans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepayment of Loans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_PrepaymentOfLoans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayment of loans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_AdditionalLoanAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional loan amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_AdditionalLoanAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional loan amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_AdditionalLoanAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional loan amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease renewal term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Renewal Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_AvailableForDebtSecuritiesEquitySecuritiesNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offer and sell</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_AvailableForDebtSecuritiesEquitySecuritiesNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Debt Securities Equity Securities Non current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_AvailableForDebtSecuritiesEquitySecuritiesNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Available For Debt Securities Equity Securities Non current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan maturity date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_PrepaidClinicalTrialAndOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid clinical trial and other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_PrepaidClinicalTrialAndOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Clinical Trial And Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_PrepaidClinicalTrialAndOther_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid clinical trial and other.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, immaterial effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Carrying value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long term debt, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_StockIssuedDuringPeriodValueSharesIssuedInAtTheMarketOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued in at-the-market offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_StockIssuedDuringPeriodValueSharesIssuedInAtTheMarketOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Shares issued in at-the-market offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_StockIssuedDuringPeriodValueSharesIssuedInAtTheMarketOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Issued During Period, Value, Shares issued in at-the-market offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal income tax at statutory rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_AdditionalTemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_AdditionalTemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Temporary Equity Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_AdditionalTemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional temporary equity shares issued.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of warrant purchases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adopted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets fair value disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Assets, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee operating lease option to extend description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_AlexionPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Alexion Pharmaceuticals, Inc</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_AlexionPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Alexion Pharmaceuticals Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_AlexionPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Alexion Pharmaceuticals, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_ResearchSupportFundingExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research support funding expiration year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_ResearchSupportFundingExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Support Funding Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_ResearchSupportFundingExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research support funding expiration year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LegalFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Costs related to legal proceedings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LegalFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Accounting Pronouncements Or Change In Accounting Principle [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_LesseeOperatingLeaseLiabilityPaymentDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_LesseeOperatingLeaseLiabilityPaymentDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payment Due</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_LesseeOperatingLeaseLiabilityPaymentDue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee Operating Lease Liability Payment Due</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares purchased in Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_ResearchSupportFundingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research support funding amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_ResearchSupportFundingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Support Funding Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_ResearchSupportFundingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research support funding amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance or Sale of Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Issuance or Sale of Equity, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, Operating Lease, Existence of Option to Extend [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Existence of Option to Extend [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_Others_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Others</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_Others_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Others</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_Others_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Others</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_TwoThousandTwentyStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Stock Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_TwoThousandTwentyStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Stock Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_TwoThousandTwentyStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty stock incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right of use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Right of Use Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Liabilities, Right of Use Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental cash flow information:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_PropertyAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Estimated Useful Lives of Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_PropertyAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property And Equipment Estimated Useful Lives Table Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_PropertyAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Property And Equipment Estimated Useful Lives Table Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares purchased in Employee Stock Purchase Plan, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Lease, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LandImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LandImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Land Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Volatility rate range, minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government Agency Debt Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Agencies Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Employee Stock Option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of outstanding preferred stock converted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Shares Converted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adoption date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adoption Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Unamortized debt issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt and Debt Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gross deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Gross deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion, Converted Instrument, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, amount converted to common stock upon lender's choice</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net proceeds from issuance of shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of Series A-2 Convertible Preferred Stock, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds issuance of common stock, deducting underwriting discounts and commissions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net proceeds from issuance of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of awards available for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary, Sale of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Receivable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_PercentageOfBeneficialOwnershipLimitation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of beneficial ownership limitation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_PercentageOfBeneficialOwnershipLimitation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Beneficial Ownership Limitation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_PercentageOfBeneficialOwnershipLimitation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Beneficial ownership limitation percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock, $0.0001 par value - 200,000,000 shares authorized at December 31, 2023 and December 31, 2022; 61,768,771 shares issued and outstanding at December 31, 2023 and 40,394,363 shares issued and outstanding at December 31, 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Convertible, Conversion Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument conversion price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net foreign exchange gain (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Realized Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term (in years), Vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_ScheduleOfPrepaidExpensesNoncurrentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Noncurrent Prepaid Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_ScheduleOfPrepaidExpensesNoncurrentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Prepaid Expenses Noncurrent Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_ScheduleOfPrepaidExpensesNoncurrentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of prepaid expenses noncurrent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Health Care Organization, Revenue Sources [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_TwoThousandSeventeenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2017 Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_TwoThousandSeventeenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Seventeen Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_TwoThousandSeventeenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Seventeen Equity Incentive Plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Realized gain and losses on investments as available-for-sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Realized Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Realized Gain (Loss), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_Effectiveincometaxratereconciliationpermanentdifferences_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Permanent differences</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_Effectiveincometaxratereconciliationpermanentdifferences_lbl" xlink:role="http://www.xbrl.org/2003/role/label">EffectiveIncomeTaxRateReconciliationPermanentDifferences</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_Effectiveincometaxratereconciliationpermanentdifferences_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation permanent differences</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturingInYearsTwoAndThree_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturingInYearsTwoAndThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturingInYearsTwoAndThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year Two and Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Expense (Benefit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Issuance Costs, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt issuance cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Volatility rate range, maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TimeDepositsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Carrying value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TimeDepositsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Time Deposits, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_EmergingGrowthCompanyAnnualGrossRevenues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual gross revenues cease to be EGC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_EmergingGrowthCompanyAnnualGrossRevenues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Emerging Growth Company Annual Gross Revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_EmergingGrowthCompanyAnnualGrossRevenues_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Emerging Growth Company Annual Gross Revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment and Manufacturing Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2016-02</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2016-02 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares purchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-lived Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income (loss):</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_AdditionalSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_AdditionalSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_EmergingGrowthCompanyStatusIssuanceValueOfNonConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of non-convertible debt cease to be EGC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_EmergingGrowthCompanyStatusIssuanceValueOfNonConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Emerging Growth Company Status Issuance Value Of Non-Convertible Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_EmergingGrowthCompanyStatusIssuanceValueOfNonConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Emerging Growth Company Status Issuance Value Of Non-Convertible Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other expense, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of stock, price per shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Offering price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Nonproduction, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization, Nonproduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_InducementPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inducement Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_InducementPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inducement Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_InducementPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Inducement Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term Loan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Deferred Rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cash paid for interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostMaintenance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maintenance fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostMaintenance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost, Maintenance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Deferred Expense, Debt Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of shares vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized loss on investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Lease Payments Under Non-Cancelable Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_ScheduleOfLongTermInvestmentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Long-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_ScheduleOfLongTermInvestmentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Long Term Investments Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_ScheduleOfLongTermInvestmentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of long term investments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk, Sigificant Suppliers, and Off-Balance Sheet Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to common stockholders- basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per share attributable to common stockholder - basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 7)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonemployee [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseIncentiveReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseIncentiveReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Incentive Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201815Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2018-15</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201815Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2018-15 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Paper</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest or penalties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_TwoThousandTwentyEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_TwoThousandTwentyEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_TwoThousandTwentyEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for amounts included for measurement of lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to common stockholders- diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unrecognized Tax Benefits, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unrecognized Tax Benefits, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal and state research and development tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Long term liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recurring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reportable segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Reportable Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Common Stock, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Common Stock, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid in-capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase in cash, cash equivalents, and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future Principal Payment of Loan Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Non-current net deferred tax assets (liabilities)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employer matching contribution, percentage of employees base salary and bonus paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromLoans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Loans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_LaboratorySpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Space</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_LaboratorySpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Space [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_LaboratorySpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory space.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, and Short-term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents and short term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_ProceedsFromIssuanceOfCommonStockForCashUnderEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock for cash under employee stock purchase plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_ProceedsFromIssuanceOfCommonStockForCashUnderEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock for Cash Under Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_ProceedsFromIssuanceOfCommonStockForCashUnderEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock for cash under employee stock purchase plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Options Outstanding, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_LesseeOperatingLeaseExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee operating lease expiration year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_LesseeOperatingLeaseExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_LesseeOperatingLeaseExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease expiration year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_LoanAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Loan Agreement Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_LoanAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loan Agreement Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_ClinicalExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_ClinicalExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_ClinicalExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employer matching contribution, percentage of match</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GranteeStatusDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grantee Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GranteeStatusDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grantee Status [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Over-Allotment Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Investment Redemption, Notice Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Investment Redemption, Notice Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revision of Prior Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revision of Prior Period [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentPaymentTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Payment Terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentPaymentTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment description for debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_SeriesATwoConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A-2 Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_SeriesATwoConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Two Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_SeriesATwoConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A two convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_AccruedResearchAndDevelopmentCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_AccruedResearchAndDevelopmentCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Costs Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_AccruedResearchAndDevelopmentCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development costs current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_UnderwritingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_UnderwritingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwriting Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_UnderwritingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriting Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from issuance of pre-funded warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_PartialUpfrontConsiderationPaymentUnderLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Partial upfront consideration payment under license agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_PartialUpfrontConsiderationPaymentUnderLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Partial Upfront Consideration Payment Under License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_PartialUpfrontConsiderationPaymentUnderLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Partial upfront consideration payment under license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_TaxCreditCarryForwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit carryforward, expiration year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_TaxCreditCarryForwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carry Forward Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_TaxCreditCarryForwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carry forward expiration year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Employee [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_OperatingLeaseWeightedAverageIncrementalBorrowingRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average incremental borrowing rate for operating leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_OperatingLeaseWeightedAverageIncrementalBorrowingRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Incremental Borrowing Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_OperatingLeaseWeightedAverageIncrementalBorrowingRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease weighted average incremental borrowing rate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive income:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_OperatingLossCarryforwardsWithExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards with expiration period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_OperatingLossCarryforwardsWithExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards With Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_OperatingLossCarryforwardsWithExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards with expiration period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive (loss) income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Charges, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of foreign currency exchange rate in cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_OfficeSpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Space</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_OfficeSpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office Space [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_OfficeSpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Office space.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Stated Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Interest rate for debt instrument</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total unrecognized compensation cost related to outstanding employee awards, expected to be recognized over a weighted-average period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares authorized for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and Sponsored Research Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from the offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax penalties and interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination, Penalties and Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Examination, Penalties and Interest Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Temporary equity, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary equity, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Dividends_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Dividends, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Dividends_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividends declared on preferred stock or common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Dividends_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses - noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Prepaid Expense, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Prepaid expenses, net of current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Unobservable Inputs (Level 3)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Canceled / Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Options Outstanding, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Standards Not Yet Adopted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Recently Issued Accounting Standards Not Yet Adopted Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Recently issued accounting standards not yet adopted..</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Potential Dilutive Securities from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_WarrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_WarrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_WarrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Issuance of Long-Term Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Long-Term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from issuance of long-term debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letters of Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Letter of Credit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revision of Prior Period, Accounting Standards Update, Adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revision of Prior Period, Accounting Standards Update, Adjustment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less accumulated depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GranteeStatusAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grantee Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GranteeStatusAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grantee Status [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, liquidation preference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Liquidation Preference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common shares and pre-funded warrants outstanding - basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average common shares outstanding - basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Activity Related to Restricted Stock Units ("RSUs")</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_LendersReimbursedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lenders reimbursed amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_LendersReimbursedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lenders reimbursed amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_LendersReimbursedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lenders reimbursed amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_TwoThousandSeventeenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2017 Stock Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_TwoThousandSeventeenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Seventeen Stock Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_TwoThousandSeventeenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand seventeen stock incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity Under Equity Incentive Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Assumptions Used to Value Stock Options Granted Using Black-Scholes Option-Pricing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Emerging Growth Company Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Emerging Growth Company Status Policy Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Emerging Growth Company Status Policy Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating lease liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-Term and Long-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other professional fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_SixtyDaysPriorWrittenNoticeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">60 Days prior written notice</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_SixtyDaysPriorWrittenNoticeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sixty Days Prior Written Notice [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_SixtyDaysPriorWrittenNoticeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sixty Days Prior Written Notice [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive shares excluded from computation of earnings per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_K2LoanAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">K2 Loan Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_K2LoanAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">K2 Loan Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_K2LoanAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">K2 Loan Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncollaborativeArrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Arrangements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncollaborativeArrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Arrangement Other than Collaborative [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_IncreaseDecreasePrepaidExpensesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses - noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_IncreaseDecreasePrepaidExpensesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease Prepaid Expenses Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_IncreaseDecreasePrepaidExpensesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) prepaid expenses, noncurrent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_TaxCutsAndJobsActFederalNetOperatingLossPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax cuts and jobs act federal net operating loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_TaxCutsAndJobsActFederalNetOperatingLossPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Cuts And Jobs Act Federal Net Operating Loss Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_TaxCutsAndJobsActFederalNetOperatingLossPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax cuts and jobs act federal net operating loss percent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards expiration year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating  loss carryforwards expiration year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Components of Deferred Tax Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_YaleUniversityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Yale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_YaleUniversityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Yale University [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_YaleUniversityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Yale university.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Goods and Nonemployee Services Transaction, Valuation Method, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Total Compensation Cost Recognized in Statements of Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amortization of premiums and discounts on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_LongTermInvestmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_LongTermInvestmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Investments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_LongTermInvestmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term investments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock into common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_ComputerEquipmentAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment and Software</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_ComputerEquipmentAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment And Software [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_ComputerEquipmentAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Computer equipment and software.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_PatentCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patent Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_PatentCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Patent Costs Policy Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_PatentCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Patent Costs Policy Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value measurement with unobservable inputs reconciliation recurring basis asset transfers out of level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_ConcentrationRiskCreditRiskOffBalanceSheetRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Off-balance sheet concentrations of credit risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_ConcentrationRiskCreditRiskOffBalanceSheetRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk Off Balance Sheet Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_ConcentrationRiskCreditRiskOffBalanceSheetRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Concentration risk credit risk off balance sheet risk.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Accounting Pronouncements Or Change In Accounting Principle [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued and Adopted Accounting Standards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency translation adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested / Settled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instrument</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeeAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Commitment Fee Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeeAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lenders facility fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value of stock options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of common stock issued upon conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of outstanding preferred stock converted into common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_ResearchSupportFundingContractExtendedDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research support funding contract extended date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_ResearchSupportFundingContractExtendedDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Support Funding Contract Extended Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_ResearchSupportFundingContractExtendedDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research support funding contract extended date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_JefferiesLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Jefferies LLC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_JefferiesLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Jefferies llc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_JefferiesLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Jefferies LLC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Prepaid Expenses and Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Prepaid Expenses And Other Current Assets Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of prepaid expenses and other current assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_FirstPatientInCompanyMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First Patient in Company Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_FirstPatientInCompanyMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First Patient in Company Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_FirstPatientInCompanyMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First patient in company milestones member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Health Care Organization, Revenue Sources [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_RestrictedCashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_RestrictedCashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_RestrictedCashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted cash.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gross deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Basis for Effective Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual rate of interest for the debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred tax assets, valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term of options (years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sponsored Research Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity, reverse stock split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Reverse Stock Split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock, $0.0001 par value - 5,000,000 shares authorized at December 31, 2023 and December 31, 2022; No shares issued and outstanding at December 31, 2023 or December 31, 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Number of Shares Issued in Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional facility fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_IssuanceOfPreFundedWarrantsNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of pre-funded warrants, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_IssuanceOfPreFundedWarrantsNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of pre-funded warrants, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_IssuanceOfPreFundedWarrantsNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of pre-funded warrants, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-funded warrant exercisable price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Paper</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents fair value disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Details</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_OperatingLeaseReversedLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, reversed lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_OperatingLeaseReversedLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Reversed Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_OperatingLeaseReversedLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease reversed lease liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_TemporaryEquityStockIssuedDuringPeriodShareNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series A-2 Convertible Preferred Stock,net of issuance costs, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_TemporaryEquityStockIssuedDuringPeriodShareNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Share New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_TemporaryEquityStockIssuedDuringPeriodShareNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period share new issues.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_UnvestedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested RSUs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_UnvestedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Restricted Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_UnvestedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested Restricted Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Commitment Fee Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayment fee percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate range, minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized (losses) on available-for-sale securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate range, maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Debt Discount (Premium)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash interest expense and amortization of debt issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_UnderwrittenOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwritten offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_UnderwrittenOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwritten offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_UnderwrittenOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwritten offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service ShareBased Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period ForRecognition 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition2_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_Section174Adjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Section 174 Adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_Section174Adjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Section 174 Adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_Section174Adjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Section 174 Adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid insurance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Insurance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Other Observable Inputs (Level 2)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_PrepaidResearchStudies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid research studies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_PrepaidResearchStudies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Research Studies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_PrepaidResearchStudies_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid research studies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ManagementFeeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Management Fee Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ManagementFeeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Management Fee Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Temporary equity, balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary equity, balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_BofaSecuritiesIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bofa Securities Inc</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_BofaSecuritiesIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">BofA Securities, Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_BofaSecuritiesIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">BofA Securities, Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Financial Assets Measured at Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerDurationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Duration [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_AreaOfLeasedSpace_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area Of Leased Space</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_AreaOfLeasedSpace_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Area of leased space.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_AreaOfLeasedSpace_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of leased space</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Changes and Error Corrections [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_StockIssuedDuringPeriodSharesIssuedInAtTheMarketOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued in at-the-market offering, share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_StockIssuedDuringPeriodSharesIssuedInAtTheMarketOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares issued in at-the-market offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_StockIssuedDuringPeriodSharesIssuedInAtTheMarketOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Issued During Period, Shares issued in at-the-market offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_FutureOfferingsOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Future offerings of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_FutureOfferingsOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Future offerings of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_LicenseAgreementPaymentUponAchievementOfSpecifiedProductSalesOrDevelopmentAndCommercializationMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment upon achievement of certain milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_LicenseAgreementPaymentUponAchievementOfSpecifiedProductSalesOrDevelopmentAndCommercializationMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Payment Upon Achievement Of Specified Product Sales Or Development And Commercialization Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_LicenseAgreementPaymentUponAchievementOfSpecifiedProductSalesOrDevelopmentAndCommercializationMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement payment upon achievement of specified product sales or development and commercialization milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_ThirtyDaysPriorWrittenNoticeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">30 Days prior written notice</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_ThirtyDaysPriorWrittenNoticeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Thirty Days Prior Written Notice [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_ThirtyDaysPriorWrittenNoticeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Thirty Days Prior Written Notice [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_TemporaryEquityStockIssuedDuringPeriodValueToAcquireInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of shares to acquire in-process research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_TemporaryEquityStockIssuedDuringPeriodValueToAcquireInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period value to acquire in process research And development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_TemporaryEquityStockIssuedDuringPeriodValueToAcquireInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Value To Acquire In Process Research And Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_ResearchSupportFundingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research support funding period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_ResearchSupportFundingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Support Funding Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_ResearchSupportFundingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research support funding period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_FederalAndStateTaxAuthorityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal and State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_FederalAndStateTaxAuthorityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Federal And State Tax Authority [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_FederalAndStateTaxAuthorityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Federal and state tax authority.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employer contribution amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term (in years), Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average exercise price of options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_LossOnDisposalOfFixedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on disposal of fixed assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_LossOnDisposalOfFixedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss on Disposal of Fixed Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_LossOnDisposalOfFixedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Loss on Disposal of Fixed Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerDurationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Duration [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock into common stock, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Prepaid Expense, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash (used in) provided by investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Off-balance sheet concentrations of credit risk description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Financial Instruments, off-Balance-Sheet Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security deposits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_ShareBasedPaymentArrangementTrancheFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-Based Payment Arrangement, Tranche Four [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_ShareBasedPaymentArrangementTrancheFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Tranche Four [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_ShareBasedPaymentArrangementTrancheFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in additional number of shares to be issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_TemporaryEquityShareSubscriptionsPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares available for issuance, price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_TemporaryEquityShareSubscriptionsPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Share Subscriptions Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_TemporaryEquityShareSubscriptionsPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity share subscriptions price per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash and Cash Equivalents, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accrued Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduction in the carrying value of right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Impairment Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Short-term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Marketable Securities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_SummarizesOfImpactTermLoanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summarizes Of impact Term Loan Table Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_SummarizesOfImpactTermLoanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summarizes Of impact Term Loan Table Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_SummarizesOfImpactTermLoanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summarizes of Impact of Term Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other income, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_ConvertiblePreferredStockAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock And Stockholders Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_ConvertiblePreferredStockAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock and stockholders equity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment unpaid at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_TemporaryEquityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_TemporaryEquityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Policy Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_TemporaryEquityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary Equity Policy Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_MA_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Boston, Massachusetts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_MA_lbl" xlink:role="http://www.xbrl.org/2003/role/label">MASSACHUSETTS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets tax deferred expense reserves and accruals amortization.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairments of long-lived assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Impairment Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Asset Impairment Charges, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense):</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense) [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre Funded Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre Funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-funded Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income tax, net of federal benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Debt Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityThresholdPeriodPastDueWriteoff_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt securities held-to-maturity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityThresholdPeriodPastDueWriteoff_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Held-to-Maturity, Threshold Period Past Due, Writeoff</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common shares and pre-funded warrants outstanding - diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average common shares outstanding - diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate to Effective Income Tax Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_ResearchSupportFundingExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research support funding expiration year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_ResearchSupportFundingExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Support Funding Expiration Month And Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_ResearchSupportFundingExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research support funding expiration month and year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued, price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effective income tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Percent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining lease term for operating leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_EmergingGrowthCompanyMarketValueOfCommonStockHeldByNonAffiliates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Market value of common stock held by non-affiliates cease to be EGC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_EmergingGrowthCompanyMarketValueOfCommonStockHeldByNonAffiliates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Emerging Growth Company Market Value Of Common Stock Held By Non-Affiliates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_EmergingGrowthCompanyMarketValueOfCommonStockHeldByNonAffiliates_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Emerging Growth Company Market Value Of Common Stock Held By Non-Affiliates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Net Loss Per Share, Basic and Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common stock reserved for issuance increase percentage on stock outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_OperatingLossCarryforwardsWithNoExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards with no expiration period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_OperatingLossCarryforwardsWithNoExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards With No Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_OperatingLossCarryforwardsWithNoExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards with no expiration period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revision of Prior Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revision of Prior Period [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Initial public offering, net of issuance costs, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, net of issuance costs, Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payroll and related liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale and Maturity of Marketable Securities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturities of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale and Maturity of Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_NetProductSalesMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Product Sales Milestone [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_NetProductSalesMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Product Sales Milestone [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inzy_NetProductSalesMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net product sales milestone member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Loss Carryforwards, Total</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_TemporaryEquityStockIssuedDuringPeriodSharesToAcquireInProcessResearchAndDevelopment" xlink:to="inzy_TemporaryEquityStockIssuedDuringPeriodSharesToAcquireInProcessResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityShareSubscriptions" xlink:to="us-gaap_TemporaryEquityShareSubscriptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_USGovernmentAgencyDebtSecuritiesMember" xlink:to="inzy_USGovernmentAgencyDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_AccruedResearchAndDevelopmentCostsPolicyTextBlock" xlink:to="inzy_AccruedResearchAndDevelopmentCostsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_ExerciseOfPreFundedWarrants" xlink:to="inzy_ExerciseOfPreFundedWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_EmergingGrowthCompanyStatusIssuancePeriodOfNonConvertibleDebt" xlink:to="inzy_EmergingGrowthCompanyStatusIssuancePeriodOfNonConvertibleDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseImpairmentLoss" xlink:to="us-gaap_FinanceLeaseImpairmentLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_K2HvMember" xlink:to="inzy_K2HvMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesSubscriptions" xlink:to="us-gaap_CommonStockSharesSubscriptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_InvestmentMaturityPeriod" xlink:to="inzy_InvestmentMaturityPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_SeriesAConvertiblePreferredStockMember" xlink:to="inzy_SeriesAConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_CustomaryAdjustmentsPercentageOnConversion" xlink:to="inzy_CustomaryAdjustmentsPercentageOnConversion_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_PrepaymentOfLoans" xlink:to="inzy_PrepaymentOfLoans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_AdditionalLoanAmount" xlink:to="inzy_AdditionalLoanAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_AvailableForDebtSecuritiesEquitySecuritiesNonCurrent" xlink:to="inzy_AvailableForDebtSecuritiesEquitySecuritiesNonCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturityDate" xlink:to="us-gaap_LongTermDebtMaturityDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_PrepaidClinicalTrialAndOther" xlink:to="inzy_PrepaidClinicalTrialAndOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_StockIssuedDuringPeriodValueSharesIssuedInAtTheMarketOffering" xlink:to="inzy_StockIssuedDuringPeriodValueSharesIssuedInAtTheMarketOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_AdditionalTemporaryEquitySharesIssued" xlink:to="inzy_AdditionalTemporaryEquitySharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_AlexionPharmaceuticalsIncMember" xlink:to="inzy_AlexionPharmaceuticalsIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_ResearchSupportFundingExpirationYear" xlink:to="inzy_ResearchSupportFundingExpirationYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_LesseeOperatingLeaseLiabilityPaymentDue" xlink:to="inzy_LesseeOperatingLeaseLiabilityPaymentDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_ResearchSupportFundingAmount" xlink:to="inzy_ResearchSupportFundingAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_Others" xlink:to="inzy_Others_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_TwoThousandTwentyStockIncentivePlanMember" xlink:to="inzy_TwoThousandTwentyStockIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_DeferredTaxLiabilitiesRightOfUseAssets" xlink:to="inzy_DeferredTaxLiabilitiesRightOfUseAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_PropertyAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:to="inzy_PropertyAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandImprovementsMember" xlink:to="us-gaap_LandImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivableCurrent" xlink:to="us-gaap_InterestReceivableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_PercentageOfBeneficialOwnershipLimitation" xlink:to="inzy_PercentageOfBeneficialOwnershipLimitation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_ScheduleOfPrepaidExpensesNoncurrentTableTextBlock" xlink:to="inzy_ScheduleOfPrepaidExpensesNoncurrentTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_TwoThousandSeventeenEquityIncentivePlanMember" xlink:to="inzy_TwoThousandSeventeenEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_Effectiveincometaxratereconciliationpermanentdifferences" xlink:to="inzy_Effectiveincometaxratereconciliationpermanentdifferences_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturingInYearsTwoAndThree" xlink:to="us-gaap_LongTermDebtMaturingInYearsTwoAndThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsGross" xlink:to="us-gaap_DeferredFinanceCostsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TimeDepositsAtCarryingValue" xlink:to="us-gaap_TimeDepositsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_EmergingGrowthCompanyAnnualGrossRevenues" xlink:to="inzy_EmergingGrowthCompanyAnnualGrossRevenues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_AdditionalSharesIssued" xlink:to="inzy_AdditionalSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_EmergingGrowthCompanyStatusIssuanceValueOfNonConvertibleDebt" xlink:to="inzy_EmergingGrowthCompanyStatusIssuanceValueOfNonConvertibleDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_InducementPlanMember" xlink:to="inzy_InducementPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_TermLoanMember" xlink:to="inzy_TermLoanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostMaintenance" xlink:to="us-gaap_CostMaintenance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_ScheduleOfLongTermInvestmentsTableTextBlock" xlink:to="inzy_ScheduleOfLongTermInvestmentsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseIncentiveReceivable" xlink:to="us-gaap_LeaseIncentiveReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201815Member" xlink:to="us-gaap_AccountingStandardsUpdate201815Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:to="inzy_TwoThousandTwentyEmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLoans" xlink:to="us-gaap_ProceedsFromLoans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_LaboratorySpaceMember" xlink:to="inzy_LaboratorySpaceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_ProceedsFromIssuanceOfCommonStockForCashUnderEmployeeStockPurchasePlan" xlink:to="inzy_ProceedsFromIssuanceOfCommonStockForCashUnderEmployeeStockPurchasePlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_LesseeOperatingLeaseExpirationYear" xlink:to="inzy_LesseeOperatingLeaseExpirationYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_LoanAgreementMember" xlink:to="inzy_LoanAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_ClinicalExpenses" xlink:to="inzy_ClinicalExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1" xlink:to="us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPaymentTerms" xlink:to="us-gaap_DebtInstrumentPaymentTerms_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_SeriesATwoConvertiblePreferredStockMember" xlink:to="inzy_SeriesATwoConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_AccruedResearchAndDevelopmentCostsCurrent" xlink:to="inzy_AccruedResearchAndDevelopmentCostsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_UnderwritingAgreementMember" xlink:to="inzy_UnderwritingAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_PartialUpfrontConsiderationPaymentUnderLicenseAgreement" xlink:to="inzy_PartialUpfrontConsiderationPaymentUnderLicenseAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_TaxCreditCarryForwardExpirationYear" xlink:to="inzy_TaxCreditCarryForwardExpirationYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_OperatingLeaseWeightedAverageIncrementalBorrowingRate" xlink:to="inzy_OperatingLeaseWeightedAverageIncrementalBorrowingRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_OperatingLossCarryforwardsWithExpirationPeriod" xlink:to="inzy_OperatingLossCarryforwardsWithExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_OfficeSpaceMember" xlink:to="inzy_OfficeSpaceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Dividends" xlink:to="us-gaap_Dividends_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock" xlink:to="inzy_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_WarrantsPolicyTextBlock" xlink:to="inzy_WarrantsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LetterOfCreditMember" xlink:to="us-gaap_LetterOfCreditMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" xlink:to="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_LendersReimbursedAmount" xlink:to="inzy_LendersReimbursedAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_TwoThousandSeventeenStockIncentivePlanMember" xlink:to="inzy_TwoThousandSeventeenStockIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:to="inzy_EmergingGrowthCompanyStatusPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_SixtyDaysPriorWrittenNoticeMember" xlink:to="inzy_SixtyDaysPriorWrittenNoticeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_K2LoanAgreementMember" xlink:to="inzy_K2LoanAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncollaborativeArrangementTransactionsMember" xlink:to="us-gaap_NoncollaborativeArrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_IncreaseDecreasePrepaidExpensesNoncurrent" xlink:to="inzy_IncreaseDecreasePrepaidExpensesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_TaxCutsAndJobsActFederalNetOperatingLossPercent" xlink:to="inzy_TaxCutsAndJobsActFederalNetOperatingLossPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_OperatingLossCarryforwardsExpirationYear" xlink:to="inzy_OperatingLossCarryforwardsExpirationYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_YaleUniversityMember" xlink:to="inzy_YaleUniversityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_LongTermInvestmentsMember" xlink:to="inzy_LongTermInvestmentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_ComputerEquipmentAndSoftwareMember" xlink:to="inzy_ComputerEquipmentAndSoftwareMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_PatentCostsPolicyTextBlock" xlink:to="inzy_PatentCostsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_ConcentrationRiskCreditRiskOffBalanceSheetRisk" xlink:to="inzy_ConcentrationRiskCreditRiskOffBalanceSheetRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:to="us-gaap_LineOfCreditFacilityCommitmentFeeAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_ResearchSupportFundingContractExtendedDate" xlink:to="inzy_ResearchSupportFundingContractExtendedDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_JefferiesLlcMember" xlink:to="inzy_JefferiesLlcMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="inzy_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_FirstPatientInCompanyMilestonesMember" xlink:to="inzy_FirstPatientInCompanyMilestonesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_RestrictedCashMember" xlink:to="inzy_RestrictedCashMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:to="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:to="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_IssuanceOfPreFundedWarrantsNetOfIssuanceCosts" xlink:to="inzy_IssuanceOfPreFundedWarrantsNetOfIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_OperatingLeaseReversedLeaseLiability" xlink:to="inzy_OperatingLeaseReversedLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_TemporaryEquityStockIssuedDuringPeriodShareNewIssues" xlink:to="inzy_TemporaryEquityStockIssuedDuringPeriodShareNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_UnvestedRestrictedStockUnitsMember" xlink:to="inzy_UnvestedRestrictedStockUnitsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="us-gaap_LineOfCreditFacilityCommitmentFeePercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_UnderwrittenOffering" xlink:to="inzy_UnderwrittenOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition2" xlink:to="inzy_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_Section174Adjustment" xlink:to="inzy_Section174Adjustment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_PrepaidResearchStudies" xlink:to="inzy_PrepaidResearchStudies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManagementFeeExpense" xlink:to="us-gaap_ManagementFeeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_BofaSecuritiesIncMember" xlink:to="inzy_BofaSecuritiesIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerDurationDomain" xlink:to="us-gaap_ContractWithCustomerDurationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_AreaOfLeasedSpace" xlink:to="inzy_AreaOfLeasedSpace_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_StockIssuedDuringPeriodSharesIssuedInAtTheMarketOffering" xlink:to="inzy_StockIssuedDuringPeriodSharesIssuedInAtTheMarketOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_FutureOfferingsOfCommonStock" xlink:to="inzy_FutureOfferingsOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_LicenseAgreementPaymentUponAchievementOfSpecifiedProductSalesOrDevelopmentAndCommercializationMilestones" xlink:to="inzy_LicenseAgreementPaymentUponAchievementOfSpecifiedProductSalesOrDevelopmentAndCommercializationMilestones_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_ThirtyDaysPriorWrittenNoticeMember" xlink:to="inzy_ThirtyDaysPriorWrittenNoticeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_TemporaryEquityStockIssuedDuringPeriodValueToAcquireInProcessResearchAndDevelopment" xlink:to="inzy_TemporaryEquityStockIssuedDuringPeriodValueToAcquireInProcessResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_ResearchSupportFundingPeriod" xlink:to="inzy_ResearchSupportFundingPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_FederalAndStateTaxAuthorityMember" xlink:to="inzy_FederalAndStateTaxAuthorityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_LossOnDisposalOfFixedAssets" xlink:to="inzy_LossOnDisposalOfFixedAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerDurationAxis" xlink:to="us-gaap_ContractWithCustomerDurationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk" xlink:to="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_ShareBasedPaymentArrangementTrancheFourMember" xlink:to="inzy_ShareBasedPaymentArrangementTrancheFourMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_TemporaryEquityShareSubscriptionsPricePerShare" xlink:to="inzy_TemporaryEquityShareSubscriptionsPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseImpairmentLoss" xlink:to="us-gaap_OperatingLeaseImpairmentLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_SummarizesOfImpactTermLoanTableTextBlock" xlink:to="inzy_SummarizesOfImpactTermLoanTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_ConvertiblePreferredStockAndStockholdersEquityAbstract" xlink:to="inzy_ConvertiblePreferredStockAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_TemporaryEquityPolicyTextBlock" xlink:to="inzy_TemporaryEquityPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_MA" xlink:to="stpr_MA_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization" xlink:to="inzy_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_PreFundedWarrantsMember" xlink:to="inzy_PreFundedWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityThresholdPeriodPastDueWriteoff" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityThresholdPeriodPastDueWriteoff_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_ResearchSupportFundingExpirationMonthAndYear" xlink:to="inzy_ResearchSupportFundingExpirationMonthAndYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_EmergingGrowthCompanyMarketValueOfCommonStockHeldByNonAffiliates" xlink:to="inzy_EmergingGrowthCompanyMarketValueOfCommonStockHeldByNonAffiliates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_OperatingLossCarryforwardsWithNoExpirationPeriod" xlink:to="inzy_OperatingLossCarryforwardsWithNoExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inzy_NetProductSalesMilestoneMember" xlink:to="inzy_NetProductSalesMilestoneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="88.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_SeriesAConvertiblePreferredStockMember" xlink:label="inzy_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_SeriesATwoConvertiblePreferredStockMember" xlink:label="inzy_SeriesATwoConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="inzy_SeriesAConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="inzy_SeriesATwoConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermDebt" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PrepaidExpenseNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_SeriesAConvertiblePreferredStockMember" xlink:label="inzy_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_SeriesATwoConvertiblePreferredStockMember" xlink:label="inzy_SeriesATwoConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="inzy_SeriesAConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="inzy_SeriesATwoConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_9"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_SeriesAConvertiblePreferredStockMember" xlink:label="inzy_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_SeriesATwoConvertiblePreferredStockMember" xlink:label="inzy_SeriesATwoConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_TemporaryEquityStockIssuedDuringPeriodShareNewIssues" xlink:label="inzy_TemporaryEquityStockIssuedDuringPeriodShareNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_TemporaryEquityStockIssuedDuringPeriodValueToAcquireInProcessResearchAndDevelopment" xlink:label="inzy_TemporaryEquityStockIssuedDuringPeriodValueToAcquireInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_TemporaryEquityStockIssuedDuringPeriodSharesToAcquireInProcessResearchAndDevelopment" xlink:label="inzy_TemporaryEquityStockIssuedDuringPeriodSharesToAcquireInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_StockIssuedDuringPeriodValueSharesIssuedInAtTheMarketOffering" xlink:label="inzy_StockIssuedDuringPeriodValueSharesIssuedInAtTheMarketOffering"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_StockIssuedDuringPeriodSharesIssuedInAtTheMarketOffering" xlink:label="inzy_StockIssuedDuringPeriodSharesIssuedInAtTheMarketOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_15"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_IssuanceOfPreFundedWarrantsNetOfIssuanceCosts" xlink:label="inzy_IssuanceOfPreFundedWarrantsNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_ExerciseOfPreFundedWarrants" xlink:label="inzy_ExerciseOfPreFundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_23"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_24"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="inzy_SeriesAConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="inzy_SeriesATwoConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_NetIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="inzy_TemporaryEquityStockIssuedDuringPeriodShareNewIssues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="inzy_TemporaryEquityStockIssuedDuringPeriodValueToAcquireInProcessResearchAndDevelopment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="inzy_TemporaryEquityStockIssuedDuringPeriodSharesToAcquireInProcessResearchAndDevelopment" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="inzy_StockIssuedDuringPeriodValueSharesIssuedInAtTheMarketOffering" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="inzy_StockIssuedDuringPeriodSharesIssuedInAtTheMarketOffering" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_15" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="inzy_IssuanceOfPreFundedWarrantsNetOfIssuanceCosts" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="inzy_ExerciseOfPreFundedWarrants" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_23" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_24" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_SeriesATwoConvertiblePreferredStockMember" xlink:label="inzy_SeriesATwoConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="inzy_SeriesATwoConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_LossOnDisposalOfFixedAssets" xlink:label="inzy_LossOnDisposalOfFixedAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_IncreaseDecreasePrepaidExpensesNoncurrent" xlink:label="inzy_IncreaseDecreasePrepaidExpensesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="us-gaap_OperatingLeaseImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_ProceedsFromIssuanceOfCommonStockForCashUnderEmployeeStockPurchasePlan" xlink:label="inzy_ProceedsFromIssuanceOfCommonStockForCashUnderEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="inzy_LossOnDisposalOfFixedAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="inzy_IncreaseDecreasePrepaidExpensesNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseImpairmentLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="inzy_ProceedsFromIssuanceOfCommonStockForCashUnderEmployeeStockPurchasePlan" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureRecentAccountingPronouncements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurement" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureLicenseAndSponsoredResearchAgreements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebt" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlans" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactions" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/DisclosureAcquisitionOfAssets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_AccruedResearchAndDevelopmentCostsPolicyTextBlock" xlink:label="inzy_AccruedResearchAndDevelopmentCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_PatentCostsPolicyTextBlock" xlink:label="inzy_PatentCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_TemporaryEquityPolicyTextBlock" xlink:label="inzy_TemporaryEquityPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:label="inzy_EmergingGrowthCompanyStatusPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_WarrantsPolicyTextBlock" xlink:label="inzy_WarrantsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock" xlink:label="inzy_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="inzy_AccruedResearchAndDevelopmentCostsPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="inzy_PatentCostsPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="inzy_TemporaryEquityPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="inzy_EmergingGrowthCompanyStatusPolicyTextBlock" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="inzy_WarrantsPolicyTextBlock" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="inzy_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_PropertyAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:label="inzy_PropertyAndEquipmentEstimatedUsefulLivesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="inzy_PropertyAndEquipmentEstimatedUsefulLivesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_ScheduleOfLongTermInvestmentsTableTextBlock" xlink:label="inzy_ScheduleOfLongTermInvestmentsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:label="inzy_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_ScheduleOfPrepaidExpensesNoncurrentTableTextBlock" xlink:label="inzy_ScheduleOfPrepaidExpensesNoncurrentTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="inzy_ScheduleOfLongTermInvestmentsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="inzy_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="inzy_ScheduleOfPrepaidExpensesNoncurrentTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_SummarizesOfImpactTermLoanTableTextBlock" xlink:label="inzy_SummarizesOfImpactTermLoanTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="inzy_SummarizesOfImpactTermLoanTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_LoanAgreementMember" xlink:label="inzy_LoanAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLoans" xlink:label="us-gaap_ProceedsFromLoans"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inzy_LoanAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_NetIncomeLoss" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromLoans" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk" xlink:label="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_ConcentrationRiskCreditRiskOffBalanceSheetRisk" xlink:label="inzy_ConcentrationRiskCreditRiskOffBalanceSheetRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_EmergingGrowthCompanyStatusIssuancePeriodOfNonConvertibleDebt" xlink:label="inzy_EmergingGrowthCompanyStatusIssuancePeriodOfNonConvertibleDebt"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_EmergingGrowthCompanyMarketValueOfCommonStockHeldByNonAffiliates" xlink:label="inzy_EmergingGrowthCompanyMarketValueOfCommonStockHeldByNonAffiliates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_EmergingGrowthCompanyAnnualGrossRevenues" xlink:label="inzy_EmergingGrowthCompanyAnnualGrossRevenues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesHeldToMaturityThresholdPeriodPastDueWriteoff" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityThresholdPeriodPastDueWriteoff"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_EmergingGrowthCompanyStatusIssuanceValueOfNonConvertibleDebt" xlink:label="inzy_EmergingGrowthCompanyStatusIssuanceValueOfNonConvertibleDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseImpairmentLoss" xlink:label="us-gaap_FinanceLeaseImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="inzy_ConcentrationRiskCreditRiskOffBalanceSheetRisk" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetImpairmentCharges" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfReportableSegments" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="inzy_EmergingGrowthCompanyStatusIssuancePeriodOfNonConvertibleDebt" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="inzy_EmergingGrowthCompanyMarketValueOfCommonStockHeldByNonAffiliates" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermInvestments" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="inzy_EmergingGrowthCompanyAnnualGrossRevenues" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityThresholdPeriodPastDueWriteoff" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="inzy_EmergingGrowthCompanyStatusIssuanceValueOfNonConvertibleDebt" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseImpairmentLoss" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_ComputerEquipmentAndSoftwareMember" xlink:label="inzy_ComputerEquipmentAndSoftwareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandImprovementsMember" xlink:label="us-gaap_LandImprovementsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="inzy_ComputerEquipmentAndSoftwareMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LandImprovementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureRecentAccountingPronouncementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201815Member" xlink:label="us-gaap_AccountingStandardsUpdate201815Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_OperatingLeaseReversedLeaseLiability" xlink:label="inzy_OperatingLeaseReversedLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain" xlink:to="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="srt_RestatementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201815Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="inzy_OperatingLeaseReversedLeaseLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfShortTermInvestmentsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_InvestmentMaturityPeriod" xlink:label="inzy_InvestmentMaturityPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_LongTermInvestmentsMember" xlink:label="inzy_LongTermInvestmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_USGovernmentAgencyDebtSecuritiesMember" xlink:label="inzy_USGovernmentAgencyDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="inzy_InvestmentMaturityPeriod" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="inzy_LongTermInvestmentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_InvestmentTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inzy_USGovernmentAgencyDebtSecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_LongTermInvestments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RestrictedCash" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfLongTermInvestmentsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_InvestmentMaturityPeriod" xlink:label="inzy_InvestmentMaturityPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_LongTermInvestmentsMember" xlink:label="inzy_LongTermInvestmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_USGovernmentAgencyDebtSecuritiesMember" xlink:label="inzy_USGovernmentAgencyDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_InvestmentTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="inzy_InvestmentMaturityPeriod" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="inzy_LongTermInvestmentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inzy_USGovernmentAgencyDebtSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_PrepaidResearchStudies" xlink:label="inzy_PrepaidResearchStudies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_InterestReceivableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_PrepaidInsurance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="inzy_PrepaidResearchStudies" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfNoncurrentPrepaidExpensesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_PrepaidClinicalTrialAndOther" xlink:label="inzy_PrepaidClinicalTrialAndOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="inzy_PrepaidClinicalTrialAndOther" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PrepaidExpenseNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_ComputerEquipmentAndSoftwareMember" xlink:label="inzy_ComputerEquipmentAndSoftwareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="inzy_ComputerEquipmentAndSoftwareMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_ClinicalExpenses" xlink:label="inzy_ClinicalExpenses"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_AccruedResearchAndDevelopmentCostsCurrent" xlink:label="inzy_AccruedResearchAndDevelopmentCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="inzy_ClinicalExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="inzy_AccruedResearchAndDevelopmentCostsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementSummaryOfFinancialAssetsMeasuredAtFairValueDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureLicenseAndSponsoredResearchAgreementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_NetProductSalesMilestoneMember" xlink:label="inzy_NetProductSalesMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_PartialUpfrontConsiderationPaymentUnderLicenseAgreement" xlink:label="inzy_PartialUpfrontConsiderationPaymentUnderLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_YaleUniversityMember" xlink:label="inzy_YaleUniversityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncollaborativeArrangementTransactionsMember" xlink:label="us-gaap_NoncollaborativeArrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_FirstPatientInCompanyMilestonesMember" xlink:label="inzy_FirstPatientInCompanyMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostMaintenance" xlink:label="us-gaap_CostMaintenance"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_LicenseAgreementPaymentUponAchievementOfSpecifiedProductSalesOrDevelopmentAndCommercializationMilestones" xlink:label="inzy_LicenseAgreementPaymentUponAchievementOfSpecifiedProductSalesOrDevelopmentAndCommercializationMilestones"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_ResearchSupportFundingAmount" xlink:label="inzy_ResearchSupportFundingAmount"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_ResearchSupportFundingPeriod" xlink:label="inzy_ResearchSupportFundingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_ResearchSupportFundingExpirationMonthAndYear" xlink:label="inzy_ResearchSupportFundingExpirationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_ResearchSupportFundingExpirationYear" xlink:label="inzy_ResearchSupportFundingExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_ResearchSupportFundingContractExtendedDate" xlink:label="inzy_ResearchSupportFundingContractExtendedDate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="inzy_NetProductSalesMilestoneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inzy_PartialUpfrontConsiderationPaymentUnderLicenseAgreement" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inzy_YaleUniversityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_NoncollaborativeArrangementTransactionsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="inzy_FirstPatientInCompanyMilestonesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CostMaintenance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inzy_LicenseAgreementPaymentUponAchievementOfSpecifiedProductSalesOrDevelopmentAndCommercializationMilestones" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inzy_ResearchSupportFundingAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inzy_ResearchSupportFundingPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inzy_ResearchSupportFundingExpirationMonthAndYear" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inzy_ResearchSupportFundingExpirationYear" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inzy_ResearchSupportFundingContractExtendedDate" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_MA" xlink:label="stpr_MA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_OfficeSpaceMember" xlink:label="inzy_OfficeSpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_RestrictedCashMember" xlink:label="inzy_RestrictedCashMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_LaboratorySpaceMember" xlink:label="inzy_LaboratorySpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_AreaOfLeasedSpace" xlink:label="inzy_AreaOfLeasedSpace"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_LesseeOperatingLeaseExpirationYear" xlink:label="inzy_LesseeOperatingLeaseExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_OperatingLeaseWeightedAverageIncrementalBorrowingRate" xlink:label="inzy_OperatingLeaseWeightedAverageIncrementalBorrowingRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_MA" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_LetterOfCreditMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="inzy_OfficeSpaceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="inzy_RestrictedCashMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="inzy_LaboratorySpaceMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="inzy_AreaOfLeasedSpace" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="inzy_LesseeOperatingLeaseExpirationYear" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_CreditFacilityAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_SecurityDeposit" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="inzy_OperatingLeaseWeightedAverageIncrementalBorrowingRate" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LegalFees" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureLeasePaymentsUnderNonCancelableLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_LesseeOperatingLeaseLiabilityPaymentDue" xlink:label="inzy_LesseeOperatingLeaseLiabilityPaymentDue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="inzy_LesseeOperatingLeaseLiabilityPaymentDue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_TermLoanMember" xlink:label="inzy_TermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_K2HvMember" xlink:label="inzy_K2HvMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_AdditionalLoanAmount" xlink:label="inzy_AdditionalLoanAmount"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_ShareBasedPaymentArrangementTrancheFourMember" xlink:label="inzy_ShareBasedPaymentArrangementTrancheFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:label="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturityDate" xlink:label="us-gaap_LongTermDebtMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="us-gaap_DebtInstrumentPaymentTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_PrepaymentOfLoans" xlink:label="inzy_PrepaymentOfLoans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_CustomaryAdjustmentsPercentageOnConversion" xlink:label="inzy_CustomaryAdjustmentsPercentageOnConversion"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_PercentageOfBeneficialOwnershipLimitation" xlink:label="inzy_PercentageOfBeneficialOwnershipLimitation"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_FutureOfferingsOfCommonStock" xlink:label="inzy_FutureOfferingsOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeeAmount"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_LendersReimbursedAmount" xlink:label="inzy_LendersReimbursedAmount"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="dei_LegalEntityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="inzy_TermLoanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="inzy_K2HvMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VestingAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inzy_AdditionalLoanAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="inzy_ShareBasedPaymentArrangementTrancheFourMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturityDate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPaymentTerms" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityCommitmentFeePercentage" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inzy_PrepaymentOfLoans" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inzy_CustomaryAdjustmentsPercentageOnConversion" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inzy_PercentageOfBeneficialOwnershipLimitation" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inzy_FutureOfferingsOfCommonStock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsGross" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityCommitmentFeeAmount" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inzy_LendersReimbursedAmount" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtSummarizesOfImpactOfTermLoanDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TimeDepositsAtCarryingValue" xlink:label="us-gaap_TimeDepositsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_TimeDepositsAtCarryingValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebt" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtFuturePrincipalPaymentDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_K2LoanAgreementMember" xlink:label="inzy_K2LoanAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturingInYearsTwoAndThree" xlink:label="us-gaap_LongTermDebtMaturingInYearsTwoAndThree"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="inzy_K2LoanAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturingInYearsTwoAndThree" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_SeriesAConvertiblePreferredStockMember" xlink:label="inzy_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_TwoThousandTwentyStockIncentivePlanMember" xlink:label="inzy_TwoThousandTwentyStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_PreFundedWarrantsMember" xlink:label="inzy_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_BofaSecuritiesIncMember" xlink:label="inzy_BofaSecuritiesIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_UnderwritingAgreementMember" xlink:label="inzy_UnderwritingAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_SeriesATwoConvertiblePreferredStockMember" xlink:label="inzy_SeriesATwoConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_TwoThousandSeventeenStockIncentivePlanMember" xlink:label="inzy_TwoThousandSeventeenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_JefferiesLlcMember" xlink:label="inzy_JefferiesLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_AdditionalSharesIssued" xlink:label="inzy_AdditionalSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_TwoThousandSeventeenEquityIncentivePlanMember" xlink:label="inzy_TwoThousandSeventeenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_AlexionPharmaceuticalsIncMember" xlink:label="inzy_AlexionPharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_UnderwrittenOffering" xlink:label="inzy_UnderwrittenOffering"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:label="inzy_TwoThousandTwentyEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_InducementPlanMember" xlink:label="inzy_InducementPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityShareSubscriptions" xlink:label="us-gaap_TemporaryEquityShareSubscriptions"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_TemporaryEquityShareSubscriptionsPricePerShare" xlink:label="inzy_TemporaryEquityShareSubscriptionsPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_AdditionalTemporaryEquitySharesIssued" xlink:label="inzy_AdditionalTemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Dividends" xlink:label="us-gaap_Dividends"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_AvailableForDebtSecuritiesEquitySecuritiesNonCurrent" xlink:label="inzy_AvailableForDebtSecuritiesEquitySecuritiesNonCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="us-gaap_CommonStockSharesSubscriptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition2" xlink:label="inzy_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="inzy_SeriesAConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="inzy_TwoThousandTwentyStockIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="inzy_PreFundedWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="inzy_BofaSecuritiesIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="inzy_UnderwritingAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="inzy_SeriesATwoConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="inzy_TwoThousandSeventeenStockIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="inzy_JefferiesLlcMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inzy_AdditionalSharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="inzy_TwoThousandSeventeenEquityIncentivePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="inzy_AlexionPharmaceuticalsIncMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inzy_UnderwrittenOffering" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="inzy_TwoThousandTwentyEmployeeStockPurchasePlanMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="inzy_InducementPlanMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_TemporaryEquityShareSubscriptions" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inzy_TemporaryEquityShareSubscriptionsPricePerShare" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inzy_AdditionalTemporaryEquitySharesIssued" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_Dividends" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inzy_AvailableForDebtSecuritiesEquitySecuritiesNonCurrent" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesSubscriptions" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inzy_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition2" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" order="38" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="39" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="40" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityUnderEquityIncentivePlansDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfAssumptionsUsedToValueStockOptionsGrantedToEmployeesUsingBlackscholesOptionpricingDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityRelatedToRestrictedStockUnitsRsusDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfTotalCompensationCostRecognizedInStatementsOfOperationsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_ConvertiblePreferredStockAndStockholdersEquityAbstract" xlink:label="inzy_ConvertiblePreferredStockAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inzy_ConvertiblePreferredStockAndStockholdersEquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_FederalAndStateTaxAuthorityMember" xlink:label="inzy_FederalAndStateTaxAuthorityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_OperatingLossCarryforwardsWithExpirationPeriod" xlink:label="inzy_OperatingLossCarryforwardsWithExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_OperatingLossCarryforwardsWithNoExpirationPeriod" xlink:label="inzy_OperatingLossCarryforwardsWithNoExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_OperatingLossCarryforwardsExpirationYear" xlink:label="inzy_OperatingLossCarryforwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_TaxCreditCarryForwardExpirationYear" xlink:label="inzy_TaxCreditCarryForwardExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_TaxCutsAndJobsActFederalNetOperatingLossPercent" xlink:label="inzy_TaxCutsAndJobsActFederalNetOperatingLossPercent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="inzy_FederalAndStateTaxAuthorityMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="inzy_OperatingLossCarryforwardsWithExpirationPeriod" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="inzy_OperatingLossCarryforwardsWithNoExpirationPeriod" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="inzy_OperatingLossCarryforwardsExpirationYear" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="inzy_TaxCreditCarryForwardExpirationYear" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="inzy_TaxCutsAndJobsActFederalNetOperatingLossPercent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUsFederalStatutoryIncomeTaxRateToEffectiveIncDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_Effectiveincometaxratereconciliationpermanentdifferences" xlink:label="inzy_Effectiveincometaxratereconciliationpermanentdifferences"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="inzy_Effectiveincometaxratereconciliationpermanentdifferences" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="inzy_DeferredTaxLiabilitiesRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_Others" xlink:label="inzy_Others"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization" xlink:label="inzy_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseIncentiveReceivable" xlink:label="us-gaap_LeaseIncentiveReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_Section174Adjustment" xlink:label="inzy_Section174Adjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="inzy_DeferredTaxLiabilitiesRightOfUseAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="inzy_Others" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="inzy_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_LeaseIncentiveReceivable" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="inzy_Section174Adjustment" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/DisclosureNetLossPerShareScheduleOfNetLossPerShareBasicAndDilutedDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentialDilutiveSecuritiesFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_SeriesAConvertiblePreferredStockMember" xlink:label="inzy_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_SeriesATwoConvertiblePreferredStockMember" xlink:label="inzy_SeriesATwoConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_UnvestedRestrictedStockUnitsMember" xlink:label="inzy_UnvestedRestrictedStockUnitsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="inzy_SeriesAConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="inzy_SeriesATwoConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="inzy_UnvestedRestrictedStockUnitsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManagementFeeExpense" xlink:label="us-gaap_ManagementFeeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerDurationAxis" xlink:label="us-gaap_ContractWithCustomerDurationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerDurationDomain" xlink:label="us-gaap_ContractWithCustomerDurationDomain"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_ThirtyDaysPriorWrittenNoticeMember" xlink:label="inzy_ThirtyDaysPriorWrittenNoticeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_SixtyDaysPriorWrittenNoticeMember" xlink:label="inzy_SixtyDaysPriorWrittenNoticeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1" xlink:label="us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ManagementFeeExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ContractWithCustomerDurationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerDurationDomain" xlink:to="inzy_ThirtyDaysPriorWrittenNoticeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerDurationAxis" xlink:to="us-gaap_ContractWithCustomerDurationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerDurationDomain" xlink:to="inzy_SixtyDaysPriorWrittenNoticeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_SeriesAConvertiblePreferredStockMember" xlink:label="inzy_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_SeriesATwoConvertiblePreferredStockMember" xlink:label="inzy_SeriesATwoConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="inzy_SeriesAConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="inzy_SeriesATwoConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PrepaidExpenseNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_SeriesAConvertiblePreferredStockMember" xlink:label="inzy_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_SeriesATwoConvertiblePreferredStockMember" xlink:label="inzy_SeriesATwoConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="inzy_SeriesAConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="inzy_SeriesATwoConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_SeriesAConvertiblePreferredStockMember" xlink:label="inzy_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_SeriesATwoConvertiblePreferredStockMember" xlink:label="inzy_SeriesATwoConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_TemporaryEquityStockIssuedDuringPeriodShareNewIssues" xlink:label="inzy_TemporaryEquityStockIssuedDuringPeriodShareNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_TemporaryEquityStockIssuedDuringPeriodValueToAcquireInProcessResearchAndDevelopment" xlink:label="inzy_TemporaryEquityStockIssuedDuringPeriodValueToAcquireInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_TemporaryEquityStockIssuedDuringPeriodSharesToAcquireInProcessResearchAndDevelopment" xlink:label="inzy_TemporaryEquityStockIssuedDuringPeriodSharesToAcquireInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_StockIssuedDuringPeriodValueSharesIssuedInAtTheMarketOffering" xlink:label="inzy_StockIssuedDuringPeriodValueSharesIssuedInAtTheMarketOffering"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_StockIssuedDuringPeriodSharesIssuedInAtTheMarketOffering" xlink:label="inzy_StockIssuedDuringPeriodSharesIssuedInAtTheMarketOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_IssuanceOfPreFundedWarrantsNetOfIssuanceCosts" xlink:label="inzy_IssuanceOfPreFundedWarrantsNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_ExerciseOfPreFundedWarrants" xlink:label="inzy_ExerciseOfPreFundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="inzy_SeriesAConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="inzy_SeriesATwoConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inzy_TemporaryEquityStockIssuedDuringPeriodShareNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inzy_TemporaryEquityStockIssuedDuringPeriodValueToAcquireInProcessResearchAndDevelopment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inzy_TemporaryEquityStockIssuedDuringPeriodSharesToAcquireInProcessResearchAndDevelopment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inzy_StockIssuedDuringPeriodValueSharesIssuedInAtTheMarketOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inzy_StockIssuedDuringPeriodSharesIssuedInAtTheMarketOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inzy_IssuanceOfPreFundedWarrantsNetOfIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inzy_ExerciseOfPreFundedWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_SeriesATwoConvertiblePreferredStockMember" xlink:label="inzy_SeriesATwoConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="inzy_SeriesATwoConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_LoanAgreementMember" xlink:label="inzy_LoanAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLoans" xlink:label="us-gaap_ProceedsFromLoans"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inzy_LoanAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromLoans" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk" xlink:label="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_ConcentrationRiskCreditRiskOffBalanceSheetRisk" xlink:label="inzy_ConcentrationRiskCreditRiskOffBalanceSheetRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_EmergingGrowthCompanyStatusIssuancePeriodOfNonConvertibleDebt" xlink:label="inzy_EmergingGrowthCompanyStatusIssuancePeriodOfNonConvertibleDebt"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_EmergingGrowthCompanyMarketValueOfCommonStockHeldByNonAffiliates" xlink:label="inzy_EmergingGrowthCompanyMarketValueOfCommonStockHeldByNonAffiliates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_EmergingGrowthCompanyAnnualGrossRevenues" xlink:label="inzy_EmergingGrowthCompanyAnnualGrossRevenues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesHeldToMaturityThresholdPeriodPastDueWriteoff" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityThresholdPeriodPastDueWriteoff"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_EmergingGrowthCompanyStatusIssuanceValueOfNonConvertibleDebt" xlink:label="inzy_EmergingGrowthCompanyStatusIssuanceValueOfNonConvertibleDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseImpairmentLoss" xlink:label="us-gaap_FinanceLeaseImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inzy_ConcentrationRiskCreditRiskOffBalanceSheetRisk" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetImpairmentCharges" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfReportableSegments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inzy_EmergingGrowthCompanyStatusIssuancePeriodOfNonConvertibleDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inzy_EmergingGrowthCompanyMarketValueOfCommonStockHeldByNonAffiliates" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inzy_EmergingGrowthCompanyAnnualGrossRevenues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityThresholdPeriodPastDueWriteoff" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inzy_EmergingGrowthCompanyStatusIssuanceValueOfNonConvertibleDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseImpairmentLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inozyme.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_ComputerEquipmentAndSoftwareMember" xlink:label="inzy_ComputerEquipmentAndSoftwareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandImprovementsMember" xlink:label="us-gaap_LandImprovementsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="inzy_ComputerEquipmentAndSoftwareMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LandImprovementsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureRecentAccountingPronouncementsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201815Member" xlink:label="us-gaap_AccountingStandardsUpdate201815Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_OperatingLeaseReversedLeaseLiability" xlink:label="inzy_OperatingLeaseReversedLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="srt_RestatementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201815Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="inzy_OperatingLeaseReversedLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfShortTermInvestmentsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_InvestmentMaturityPeriod" xlink:label="inzy_InvestmentMaturityPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_default"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_LongTermInvestmentsMember" xlink:label="inzy_LongTermInvestmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_USGovernmentAgencyDebtSecuritiesMember" xlink:label="inzy_USGovernmentAgencyDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="inzy_InvestmentMaturityPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="inzy_LongTermInvestmentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inzy_USGovernmentAgencyDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfLongTermInvestmentsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_InvestmentMaturityPeriod" xlink:label="inzy_InvestmentMaturityPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_LongTermInvestmentsMember" xlink:label="inzy_LongTermInvestmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_USGovernmentAgencyDebtSecuritiesMember" xlink:label="inzy_USGovernmentAgencyDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="inzy_InvestmentMaturityPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="inzy_LongTermInvestmentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inzy_USGovernmentAgencyDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_ComputerEquipmentAndSoftwareMember" xlink:label="inzy_ComputerEquipmentAndSoftwareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="inzy_ComputerEquipmentAndSoftwareMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementSummaryOfFinancialAssetsMeasuredAtFairValueDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureLicenseAndSponsoredResearchAgreementsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_NetProductSalesMilestoneMember" xlink:label="inzy_NetProductSalesMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_PartialUpfrontConsiderationPaymentUnderLicenseAgreement" xlink:label="inzy_PartialUpfrontConsiderationPaymentUnderLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_YaleUniversityMember" xlink:label="inzy_YaleUniversityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncollaborativeArrangementTransactionsMember" xlink:label="us-gaap_NoncollaborativeArrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_FirstPatientInCompanyMilestonesMember" xlink:label="inzy_FirstPatientInCompanyMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostMaintenance" xlink:label="us-gaap_CostMaintenance"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_LicenseAgreementPaymentUponAchievementOfSpecifiedProductSalesOrDevelopmentAndCommercializationMilestones" xlink:label="inzy_LicenseAgreementPaymentUponAchievementOfSpecifiedProductSalesOrDevelopmentAndCommercializationMilestones"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_ResearchSupportFundingAmount" xlink:label="inzy_ResearchSupportFundingAmount"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_ResearchSupportFundingPeriod" xlink:label="inzy_ResearchSupportFundingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_ResearchSupportFundingExpirationMonthAndYear" xlink:label="inzy_ResearchSupportFundingExpirationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_ResearchSupportFundingExpirationYear" xlink:label="inzy_ResearchSupportFundingExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_ResearchSupportFundingContractExtendedDate" xlink:label="inzy_ResearchSupportFundingContractExtendedDate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="inzy_NetProductSalesMilestoneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inzy_PartialUpfrontConsiderationPaymentUnderLicenseAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inzy_YaleUniversityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_NoncollaborativeArrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="inzy_FirstPatientInCompanyMilestonesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CostMaintenance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inzy_LicenseAgreementPaymentUponAchievementOfSpecifiedProductSalesOrDevelopmentAndCommercializationMilestones" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inzy_ResearchSupportFundingAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inzy_ResearchSupportFundingPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inzy_ResearchSupportFundingExpirationMonthAndYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inzy_ResearchSupportFundingExpirationYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inzy_ResearchSupportFundingContractExtendedDate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_MA" xlink:label="stpr_MA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_OfficeSpaceMember" xlink:label="inzy_OfficeSpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_RestrictedCashMember" xlink:label="inzy_RestrictedCashMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_LaboratorySpaceMember" xlink:label="inzy_LaboratorySpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_AreaOfLeasedSpace" xlink:label="inzy_AreaOfLeasedSpace"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_LesseeOperatingLeaseExpirationYear" xlink:label="inzy_LesseeOperatingLeaseExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_OperatingLeaseWeightedAverageIncrementalBorrowingRate" xlink:label="inzy_OperatingLeaseWeightedAverageIncrementalBorrowingRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_MA" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_LetterOfCreditMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="inzy_OfficeSpaceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="inzy_RestrictedCashMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="inzy_LaboratorySpaceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="inzy_AreaOfLeasedSpace" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="inzy_LesseeOperatingLeaseExpirationYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_CreditFacilityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_SecurityDeposit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="inzy_OperatingLeaseWeightedAverageIncrementalBorrowingRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LegalFees" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_TermLoanMember" xlink:label="inzy_TermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_K2HvMember" xlink:label="inzy_K2HvMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_AdditionalLoanAmount" xlink:label="inzy_AdditionalLoanAmount"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_ShareBasedPaymentArrangementTrancheFourMember" xlink:label="inzy_ShareBasedPaymentArrangementTrancheFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:label="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturityDate" xlink:label="us-gaap_LongTermDebtMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="us-gaap_DebtInstrumentPaymentTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_PrepaymentOfLoans" xlink:label="inzy_PrepaymentOfLoans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_CustomaryAdjustmentsPercentageOnConversion" xlink:label="inzy_CustomaryAdjustmentsPercentageOnConversion"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_PercentageOfBeneficialOwnershipLimitation" xlink:label="inzy_PercentageOfBeneficialOwnershipLimitation"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_FutureOfferingsOfCommonStock" xlink:label="inzy_FutureOfferingsOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeeAmount"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_LendersReimbursedAmount" xlink:label="inzy_LendersReimbursedAmount"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="inzy_TermLoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="inzy_K2HvMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inzy_AdditionalLoanAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="inzy_ShareBasedPaymentArrangementTrancheFourMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPaymentTerms" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityCommitmentFeePercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inzy_PrepaymentOfLoans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inzy_CustomaryAdjustmentsPercentageOnConversion" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inzy_PercentageOfBeneficialOwnershipLimitation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inzy_FutureOfferingsOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityCommitmentFeeAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inzy_LendersReimbursedAmount" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtFuturePrincipalPaymentDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_K2LoanAgreementMember" xlink:label="inzy_K2LoanAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturingInYearsTwoAndThree" xlink:label="us-gaap_LongTermDebtMaturingInYearsTwoAndThree"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="inzy_K2LoanAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturingInYearsTwoAndThree" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_SeriesAConvertiblePreferredStockMember" xlink:label="inzy_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_TwoThousandTwentyStockIncentivePlanMember" xlink:label="inzy_TwoThousandTwentyStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_PreFundedWarrantsMember" xlink:label="inzy_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_BofaSecuritiesIncMember" xlink:label="inzy_BofaSecuritiesIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_UnderwritingAgreementMember" xlink:label="inzy_UnderwritingAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_SeriesATwoConvertiblePreferredStockMember" xlink:label="inzy_SeriesATwoConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_TwoThousandSeventeenStockIncentivePlanMember" xlink:label="inzy_TwoThousandSeventeenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_JefferiesLlcMember" xlink:label="inzy_JefferiesLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_AdditionalSharesIssued" xlink:label="inzy_AdditionalSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_TwoThousandSeventeenEquityIncentivePlanMember" xlink:label="inzy_TwoThousandSeventeenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_AlexionPharmaceuticalsIncMember" xlink:label="inzy_AlexionPharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_UnderwrittenOffering" xlink:label="inzy_UnderwrittenOffering"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:label="inzy_TwoThousandTwentyEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_InducementPlanMember" xlink:label="inzy_InducementPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityShareSubscriptions" xlink:label="us-gaap_TemporaryEquityShareSubscriptions"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_TemporaryEquityShareSubscriptionsPricePerShare" xlink:label="inzy_TemporaryEquityShareSubscriptionsPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_AdditionalTemporaryEquitySharesIssued" xlink:label="inzy_AdditionalTemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Dividends" xlink:label="us-gaap_Dividends"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_AvailableForDebtSecuritiesEquitySecuritiesNonCurrent" xlink:label="inzy_AvailableForDebtSecuritiesEquitySecuritiesNonCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="us-gaap_CommonStockSharesSubscriptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition2" xlink:label="inzy_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="inzy_SeriesAConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="inzy_TwoThousandTwentyStockIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="inzy_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="inzy_BofaSecuritiesIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="inzy_UnderwritingAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="inzy_SeriesATwoConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="inzy_TwoThousandSeventeenStockIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="inzy_JefferiesLlcMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inzy_AdditionalSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="inzy_TwoThousandSeventeenEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="inzy_AlexionPharmaceuticalsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inzy_UnderwrittenOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="inzy_TwoThousandTwentyEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="inzy_InducementPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_TemporaryEquityShareSubscriptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inzy_TemporaryEquityShareSubscriptionsPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inzy_AdditionalTemporaryEquitySharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_Dividends" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inzy_AvailableForDebtSecuritiesEquitySecuritiesNonCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesSubscriptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inzy_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="35" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="36" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="37" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="38" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="39" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="40" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfAssumptionsUsedToValueStockOptionsGrantedToEmployeesUsingBlackscholesOptionpricingDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityRelatedToRestrictedStockUnitsRsusDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfTotalCompensationCostRecognizedInStatementsOfOperationsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_FederalAndStateTaxAuthorityMember" xlink:label="inzy_FederalAndStateTaxAuthorityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_OperatingLossCarryforwardsWithExpirationPeriod" xlink:label="inzy_OperatingLossCarryforwardsWithExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_OperatingLossCarryforwardsWithNoExpirationPeriod" xlink:label="inzy_OperatingLossCarryforwardsWithNoExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_OperatingLossCarryforwardsExpirationYear" xlink:label="inzy_OperatingLossCarryforwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_TaxCreditCarryForwardExpirationYear" xlink:label="inzy_TaxCreditCarryForwardExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_TaxCutsAndJobsActFederalNetOperatingLossPercent" xlink:label="inzy_TaxCutsAndJobsActFederalNetOperatingLossPercent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="inzy_FederalAndStateTaxAuthorityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="inzy_OperatingLossCarryforwardsWithExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="inzy_OperatingLossCarryforwardsWithNoExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="inzy_OperatingLossCarryforwardsExpirationYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="inzy_TaxCreditCarryForwardExpirationYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="inzy_TaxCutsAndJobsActFederalNetOperatingLossPercent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentialDilutiveSecuritiesFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_SeriesAConvertiblePreferredStockMember" xlink:label="inzy_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_SeriesATwoConvertiblePreferredStockMember" xlink:label="inzy_SeriesATwoConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_UnvestedRestrictedStockUnitsMember" xlink:label="inzy_UnvestedRestrictedStockUnitsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="inzy_SeriesAConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="inzy_SeriesATwoConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="inzy_UnvestedRestrictedStockUnitsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inozyme.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManagementFeeExpense" xlink:label="us-gaap_ManagementFeeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerDurationAxis" xlink:label="us-gaap_ContractWithCustomerDurationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerDurationDomain" xlink:label="us-gaap_ContractWithCustomerDurationDomain"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_ThirtyDaysPriorWrittenNoticeMember" xlink:label="inzy_ThirtyDaysPriorWrittenNoticeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerDurationDomain" xlink:label="us-gaap_ContractWithCustomerDurationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_SixtyDaysPriorWrittenNoticeMember" xlink:label="inzy_SixtyDaysPriorWrittenNoticeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1" xlink:label="us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ManagementFeeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ContractWithCustomerDurationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContractWithCustomerDurationDomain" xlink:to="inzy_ThirtyDaysPriorWrittenNoticeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ContractWithCustomerDurationAxis" xlink:to="us-gaap_ContractWithCustomerDurationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ContractWithCustomerDurationAxis" xlink:to="us-gaap_ContractWithCustomerDurationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContractWithCustomerDurationDomain" xlink:to="inzy_SixtyDaysPriorWrittenNoticeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UsefulLifeDescriptionOfTermDomain" xlink:label="us-gaap_UsefulLifeDescriptionOfTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="us-gaap_AccountingStandardsUpdate201912Member"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UsefulLifeDescriptionOfTermDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201912Member" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermDebt" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PrepaidExpenseNoncurrent" order="7" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="inzy_LossOnDisposalOfFixedAssets" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="inzy_ProceedsFromIssuanceOfCommonStockForCashUnderEmployeeStockPurchasePlan" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseImpairmentLoss" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="7" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="9" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="10" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="inzy_IncreaseDecreasePrepaidExpensesNoncurrent" order="11" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="12" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_LossOnDisposalOfFixedAssets" xlink:label="inzy_LossOnDisposalOfFixedAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_ProceedsFromIssuanceOfCommonStockForCashUnderEmployeeStockPurchasePlan" xlink:label="inzy_ProceedsFromIssuanceOfCommonStockForCashUnderEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="us-gaap_OperatingLeaseImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_IncreaseDecreasePrepaidExpensesNoncurrent" xlink:label="inzy_IncreaseDecreasePrepaidExpensesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfShortTermInvestmentsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_InterestReceivableCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="inzy_PrepaidResearchStudies" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_PrepaidResearchStudies" xlink:label="inzy_PrepaidResearchStudies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="inzy_AccruedResearchAndDevelopmentCostsCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_AccruedResearchAndDevelopmentCostsCurrent" xlink:label="inzy_AccruedResearchAndDevelopmentCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureLeasePaymentsUnderNonCancelableLeasesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtFuturePrincipalPaymentDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtMaturingInYearsTwoAndThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtMaturingInYearsTwoAndThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtMaturingInYearsTwoAndThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturingInYearsTwoAndThree" xlink:label="us-gaap_LongTermDebtMaturingInYearsTwoAndThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="inzy_DeferredTaxLiabilitiesRightOfUseAssets" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="inzy_Others" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="inzy_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_LeaseIncentiveReceivable" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="inzy_Section174Adjustment" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="9" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="inzy_DeferredTaxLiabilitiesRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_Others" xlink:label="inzy_Others"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization" xlink:label="inzy_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseIncentiveReceivable" xlink:label="us-gaap_LeaseIncentiveReceivable"/>
          <link:loc xlink:type="locator" xlink:href="inzy-20231231.xsd#inzy_Section174Adjustment" xlink:label="inzy_Section174Adjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="inzy_RestrictedCashMember" name="RestrictedCashMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inzy_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization" name="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inzy_FutureOfferingsOfCommonStock" name="FutureOfferingsOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inzy_K2LoanAgreementMember" name="K2LoanAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inzy_LendersReimbursedAmount" name="LendersReimbursedAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inzy_K2HvMember" name="K2HvMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inzy_EmergingGrowthCompanyAnnualGrossRevenues" name="EmergingGrowthCompanyAnnualGrossRevenues" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inzy_NetProductSalesMilestoneMember" name="NetProductSalesMilestoneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inzy_SixtyDaysPriorWrittenNoticeMember" name="SixtyDaysPriorWrittenNoticeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inzy_OperatingLeaseWeightedAverageIncrementalBorrowingRate" name="OperatingLeaseWeightedAverageIncrementalBorrowingRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inzy_CustomaryAdjustmentsPercentageOnConversion" name="CustomaryAdjustmentsPercentageOnConversion" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inzy_Effectiveincometaxratereconciliationpermanentdifferences" name="Effectiveincometaxratereconciliationpermanentdifferences" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inzy_LossOnDisposalOfFixedAssets" name="LossOnDisposalOfFixedAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inzy_OfficeSpaceMember" name="OfficeSpaceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inzy_PreFundedWarrantsMember" name="PreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inzy_InducementPlanMember" name="InducementPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inzy_InvestmentMaturityPeriod" name="InvestmentMaturityPeriod" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inzy_PartialUpfrontConsiderationPaymentUnderLicenseAgreement" name="PartialUpfrontConsiderationPaymentUnderLicenseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inzy_ClinicalExpenses" name="ClinicalExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inzy_LesseeOperatingLeaseExpirationYear" name="LesseeOperatingLeaseExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inzy_PrepaymentOfLoans" name="PrepaymentOfLoans" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inzy_TaxCutsAndJobsActFederalNetOperatingLossPercent" name="TaxCutsAndJobsActFederalNetOperatingLossPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="inzy_AccruedResearchAndDevelopmentCostsPolicyTextBlock" name="AccruedResearchAndDevelopmentCostsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inzy_IssuanceOfPreFundedWarrantsNetOfIssuanceCosts" name="IssuanceOfPreFundedWarrantsNetOfIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inzy_TermLoanMember" name="TermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inzy_ScheduleOfPrepaidExpensesNoncurrentTableTextBlock" name="ScheduleOfPrepaidExpensesNoncurrentTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inzy_ConvertiblePreferredStockAndStockholdersEquityAbstract" name="ConvertiblePreferredStockAndStockholdersEquityAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inzy_PrepaidResearchStudies" name="PrepaidResearchStudies" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inzy_TemporaryEquityStockIssuedDuringPeriodShareNewIssues" name="TemporaryEquityStockIssuedDuringPeriodShareNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inzy_SummarizesOfImpactTermLoanTableTextBlock" name="SummarizesOfImpactTermLoanTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inzy_IncreaseDecreasePrepaidExpensesNoncurrent" name="IncreaseDecreasePrepaidExpensesNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inzy_EmergingGrowthCompanyStatusIssuancePeriodOfNonConvertibleDebt" name="EmergingGrowthCompanyStatusIssuancePeriodOfNonConvertibleDebt" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inzy_EmergingGrowthCompanyStatusIssuanceValueOfNonConvertibleDebt" name="EmergingGrowthCompanyStatusIssuanceValueOfNonConvertibleDebt" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inzy_FirstPatientInCompanyMilestonesMember" name="FirstPatientInCompanyMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inzy_DeferredTaxLiabilitiesRightOfUseAssets" name="DeferredTaxLiabilitiesRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inzy_ShareBasedPaymentArrangementTrancheFourMember" name="ShareBasedPaymentArrangementTrancheFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inzy_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" name="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inzy_LoanAgreementMember" name="LoanAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inzy_EmergingGrowthCompanyStatusPolicyTextBlock" name="EmergingGrowthCompanyStatusPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inzy_ProceedsFromIssuanceOfCommonStockForCashUnderEmployeeStockPurchasePlan" name="ProceedsFromIssuanceOfCommonStockForCashUnderEmployeeStockPurchasePlan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inzy_StockIssuedDuringPeriodValueSharesIssuedInAtTheMarketOffering" name="StockIssuedDuringPeriodValueSharesIssuedInAtTheMarketOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inzy_BofaSecuritiesIncMember" name="BofaSecuritiesIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inzy_PercentageOfBeneficialOwnershipLimitation" name="PercentageOfBeneficialOwnershipLimitation" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inzy_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition2" name="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition2" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inzy_Others" name="Others" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inzy_TaxCreditCarryForwardExpirationYear" name="TaxCreditCarryForwardExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inzy_EmergingGrowthCompanyMarketValueOfCommonStockHeldByNonAffiliates" name="EmergingGrowthCompanyMarketValueOfCommonStockHeldByNonAffiliates" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inzy_ScheduleOfLongTermInvestmentsTableTextBlock" name="ScheduleOfLongTermInvestmentsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inzy_ConcentrationRiskCreditRiskOffBalanceSheetRisk" name="ConcentrationRiskCreditRiskOffBalanceSheetRisk" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inzy_PatentCostsPolicyTextBlock" name="PatentCostsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inzy_OperatingLeaseReversedLeaseLiability" name="OperatingLeaseReversedLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inzy_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inzy_StockIssuedDuringPeriodSharesIssuedInAtTheMarketOffering" name="StockIssuedDuringPeriodSharesIssuedInAtTheMarketOffering" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inzy_TemporaryEquityStockIssuedDuringPeriodSharesToAcquireInProcessResearchAndDevelopment" name="TemporaryEquityStockIssuedDuringPeriodSharesToAcquireInProcessResearchAndDevelopment" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inzy_AlexionPharmaceuticalsIncMember" name="AlexionPharmaceuticalsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inzy_ResearchSupportFundingAmount" name="ResearchSupportFundingAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inzy_AdditionalTemporaryEquitySharesIssued" name="AdditionalTemporaryEquitySharesIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="inzy_OperatingLossCarryforwardsWithExpirationPeriod" name="OperatingLossCarryforwardsWithExpirationPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inzy_TemporaryEquityShareSubscriptionsPricePerShare" name="TemporaryEquityShareSubscriptionsPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="inzy_ThirtyDaysPriorWrittenNoticeMember" name="ThirtyDaysPriorWrittenNoticeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inzy_FederalAndStateTaxAuthorityMember" name="FederalAndStateTaxAuthorityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inzy_TwoThousandSeventeenEquityIncentivePlanMember" name="TwoThousandSeventeenEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inzy_UnderwritingAgreementMember" name="UnderwritingAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inzy_OperatingLossCarryforwardsWithNoExpirationPeriod" name="OperatingLossCarryforwardsWithNoExpirationPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inzy_ResearchSupportFundingExpirationYear" name="ResearchSupportFundingExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inzy_TwoThousandTwentyEmployeeStockPurchasePlanMember" name="TwoThousandTwentyEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inzy_ResearchSupportFundingContractExtendedDate" name="ResearchSupportFundingContractExtendedDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inzy_PropertyAndEquipmentEstimatedUsefulLivesTableTextBlock" name="PropertyAndEquipmentEstimatedUsefulLivesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inzy_PrepaidClinicalTrialAndOther" name="PrepaidClinicalTrialAndOther" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inzy_AvailableForDebtSecuritiesEquitySecuritiesNonCurrent" name="AvailableForDebtSecuritiesEquitySecuritiesNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inzy_ComputerEquipmentAndSoftwareMember" name="ComputerEquipmentAndSoftwareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inzy_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inzy_Section174Adjustment" name="Section174Adjustment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inzy_JefferiesLlcMember" name="JefferiesLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inzy_USGovernmentAgencyDebtSecuritiesMember" name="USGovernmentAgencyDebtSecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inzy_YaleUniversityMember" name="YaleUniversityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inzy_AdditionalLoanAmount" name="AdditionalLoanAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inzy_LesseeOperatingLeaseLiabilityPaymentDue" name="LesseeOperatingLeaseLiabilityPaymentDue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inzy_UnvestedRestrictedStockUnitsMember" name="UnvestedRestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inzy_AdditionalSharesIssued" name="AdditionalSharesIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inzy_TemporaryEquityStockIssuedDuringPeriodValueToAcquireInProcessResearchAndDevelopment" name="TemporaryEquityStockIssuedDuringPeriodValueToAcquireInProcessResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inzy_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock" name="RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inzy_TwoThousandSeventeenStockIncentivePlanMember" name="TwoThousandSeventeenStockIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inzy_AccruedResearchAndDevelopmentCostsCurrent" name="AccruedResearchAndDevelopmentCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inzy_ResearchSupportFundingPeriod" name="ResearchSupportFundingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inzy_ResearchSupportFundingExpirationMonthAndYear" name="ResearchSupportFundingExpirationMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inzy_LaboratorySpaceMember" name="LaboratorySpaceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inzy_WarrantsPolicyTextBlock" name="WarrantsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inzy_TemporaryEquityPolicyTextBlock" name="TemporaryEquityPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inzy_AreaOfLeasedSpace" name="AreaOfLeasedSpace" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="inzy_ExerciseOfPreFundedWarrants" name="ExerciseOfPreFundedWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inzy_LicenseAgreementPaymentUponAchievementOfSpecifiedProductSalesOrDevelopmentAndCommercializationMilestones" name="LicenseAgreementPaymentUponAchievementOfSpecifiedProductSalesOrDevelopmentAndCommercializationMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inzy_LongTermInvestmentsMember" name="LongTermInvestmentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inzy_SeriesATwoConvertiblePreferredStockMember" name="SeriesATwoConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inzy_TwoThousandTwentyStockIncentivePlanMember" name="TwoThousandTwentyStockIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inzy_UnderwrittenOffering" name="UnderwrittenOffering" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922023207120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INOZYME PHARMA, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001693011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">38-4024528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">321 Summer Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">330-4340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INZY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 199,465,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">The registrant intends to file a definitive proxy statement pursuant to Regulation 14A within 120 days of the end of the fiscal year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">. Portions of such definitive proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922023264960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 34,588<span></span>
</td>
<td class="nump">$ 32,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">154,001<span></span>
</td>
<td class="nump">94,951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">7,661<span></span>
</td>
<td class="nump">3,527<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">196,250<span></span>
</td>
<td class="nump">131,393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,466<span></span>
</td>
<td class="nump">2,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">1,126<span></span>
</td>
<td class="nump">1,620<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted Cash, Noncurrent</a></td>
<td class="nump">311<span></span>
</td>
<td class="nump">354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Prepaid expenses, net of current portion</a></td>
<td class="nump">1,694<span></span>
</td>
<td class="nump">3,810<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">200,847<span></span>
</td>
<td class="nump">139,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,166<span></span>
</td>
<td class="nump">2,544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">12,610<span></span>
</td>
<td class="nump">11,355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">910<span></span>
</td>
<td class="nump">816<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">14,686<span></span>
</td>
<td class="nump">14,715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">913<span></span>
</td>
<td class="nump">1,823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long term debt, net</a></td>
<td class="nump">44,769<span></span>
</td>
<td class="nump">4,139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long term liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">60,368<span></span>
</td>
<td class="nump">20,801<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, $0.0001 par value - 5,000,000 shares authorized at December 31, 2023 and December 31, 2022; No shares issued and outstanding at December 31, 2023 or December 31, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, $0.0001 par value - 200,000,000 shares authorized at December 31, 2023 and December 31, 2022; 61,768,771 shares issued and outstanding at December 31, 2023 and 40,394,363 shares issued and outstanding at December 31, 2022</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid in-capital</a></td>
<td class="nump">426,362<span></span>
</td>
<td class="nump">333,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive (loss) income</a></td>
<td class="nump">41<span></span>
</td>
<td class="num">(205)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(285,930)<span></span>
</td>
<td class="num">(214,761)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">140,479<span></span>
</td>
<td class="nump">118,394<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 200,847<span></span>
</td>
<td class="nump">$ 139,195<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922020782192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">61,768,771<span></span>
</td>
<td class="nump">40,394,363<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">61,768,771<span></span>
</td>
<td class="nump">40,394,363<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922017273008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 54,847<span></span>
</td>
<td class="nump">$ 47,849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">20,798<span></span>
</td>
<td class="nump">20,826<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">75,645<span></span>
</td>
<td class="nump">68,675<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(75,645)<span></span>
</td>
<td class="num">(68,675)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">7,837<span></span>
</td>
<td class="nump">2,195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(3,333)<span></span>
</td>
<td class="num">(262)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(319)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">4,476<span></span>
</td>
<td class="nump">1,614<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(71,169)<span></span>
</td>
<td class="num">(67,061)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Unrealized (losses) on available-for-sale securities</a></td>
<td class="nump">264<span></span>
</td>
<td class="num">(198)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income (loss)</a></td>
<td class="nump">246<span></span>
</td>
<td class="num">(223)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(70,923)<span></span>
</td>
<td class="num">(67,284)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (71,169)<span></span>
</td>
<td class="num">$ (67,061)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholder - basic</a></td>
<td class="num">$ (1.37)<span></span>
</td>
<td class="num">$ (1.78)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders- diluted</a></td>
<td class="num">$ (1.37)<span></span>
</td>
<td class="num">$ (1.78)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic</a></td>
<td class="nump">51,839,131<span></span>
</td>
<td class="nump">37,763,168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted</a></td>
<td class="nump">51,839,131<span></span>
</td>
<td class="nump">37,763,168<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922020252784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 109,268<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 256,948<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="num">$ (147,700)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,668,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Initial public offering, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,276,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">7,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">56,137<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">56,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs, Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,276,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_IssuanceOfPreFundedWarrantsNetOfIssuanceCosts', window );">Issuance of pre-funded warrants, net of issuance costs</a></td>
<td class="nump">12,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_ExerciseOfPreFundedWarrants', window );">Exercise of pre-funded warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Stock Issued During Period, Shares, Employee Stock Purchase Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Shares purchased in Employee Stock Purchase Plan</a></td>
<td class="nump">92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on investments</a></td>
<td class="num">(198)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(198)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(67,061)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(67,061)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">118,394<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">333,356<span></span>
</td>
<td class="num">(205)<span></span>
</td>
<td class="num">(214,761)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,394,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Initial public offering, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">7,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 117<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="nump">43,209<span></span>
</td>
<td class="nump">43,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_StockIssuedDuringPeriodValueSharesIssuedInAtTheMarketOffering', window );">Shares issued in at-the-market offering</a></td>
<td class="nump">$ 21,236<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">21,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_StockIssuedDuringPeriodSharesIssuedInAtTheMarketOffering', window );">Shares issued in at-the-market offering, share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,553,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs, Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_IssuanceOfPreFundedWarrantsNetOfIssuanceCosts', window );">Issuance of pre-funded warrants, net of issuance costs</a></td>
<td class="nump">64,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_ExerciseOfPreFundedWarrants', window );">Exercise of pre-funded warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,325,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Stock Issued During Period, Shares, Employee Stock Purchase Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Shares purchased in Employee Stock Purchase Plan</a></td>
<td class="nump">206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on investments</a></td>
<td class="nump">264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(264)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(18)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(71,169)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(71,169)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 140,479<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 426,362<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="num">$ (285,930)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,768,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_ExerciseOfPreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of pre funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_ExerciseOfPreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_IssuanceOfPreFundedWarrantsNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of pre-funded warrants, net of issuance costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_IssuanceOfPreFundedWarrantsNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_StockIssuedDuringPeriodSharesIssuedInAtTheMarketOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares issued in at-the-market offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_StockIssuedDuringPeriodSharesIssuedInAtTheMarketOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_StockIssuedDuringPeriodValueSharesIssuedInAtTheMarketOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Shares issued in at-the-market offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_StockIssuedDuringPeriodValueSharesIssuedInAtTheMarketOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922017435632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (71,169)<span></span>
</td>
<td class="num">$ (67,061)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">833<span></span>
</td>
<td class="nump">744<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_LossOnDisposalOfFixedAssets', window );">Loss on disposal of fixed assets</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">7,037<span></span>
</td>
<td class="nump">7,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premiums and discounts on marketable securities</a></td>
<td class="num">(5,438)<span></span>
</td>
<td class="num">(1,671)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Reduction in the carrying value of right-of-use assets</a></td>
<td class="nump">494<span></span>
</td>
<td class="nump">433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Non-cash interest expense and amortization of debt issuance costs</a></td>
<td class="nump">630<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(4,134)<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,378)<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">1,255<span></span>
</td>
<td class="nump">2,857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(816)<span></span>
</td>
<td class="num">(732)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_IncreaseDecreasePrepaidExpensesNoncurrent', window );">Prepaid expenses - noncurrent</a></td>
<td class="nump">2,115<span></span>
</td>
<td class="num">(401)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other Long term liabilities</a></td>
<td class="num">(124)<span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(70,675)<span></span>
</td>
<td class="num">(57,761)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(269,330)<span></span>
</td>
<td class="num">(151,993)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">215,982<span></span>
</td>
<td class="nump">147,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(298)<span></span>
</td>
<td class="num">(410)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(53,646)<span></span>
</td>
<td class="num">(5,403)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="nump">85,647<span></span>
</td>
<td class="nump">56,137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Net proceeds from issuance of pre-funded warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Net proceeds from issuance of long-term debt</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">4,050<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">359<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_ProceedsFromIssuanceOfCommonStockForCashUnderEmployeeStockPurchasePlan', window );">Proceeds from issuance of common stock for cash under employee stock purchase plan</a></td>
<td class="nump">206<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">125,969<span></span>
</td>
<td class="nump">72,788<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase in cash, cash equivalents, and restricted cash</a></td>
<td class="nump">1,648<span></span>
</td>
<td class="nump">9,624<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of foreign currency exchange rate in cash</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">33,269<span></span>
</td>
<td class="nump">23,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">34,899<span></span>
</td>
<td class="nump">33,269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">34,588<span></span>
</td>
<td class="nump">32,915<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">311<span></span>
</td>
<td class="nump">354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">34,899<span></span>
</td>
<td class="nump">33,269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment unpaid at end of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="num">$ (2,347)<span></span>
</td>
<td class="num">$ (170)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_IncreaseDecreasePrepaidExpensesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) prepaid expenses, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_IncreaseDecreasePrepaidExpensesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_LossOnDisposalOfFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss on Disposal of Fixed Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_LossOnDisposalOfFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_ProceedsFromIssuanceOfCommonStockForCashUnderEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock for cash under employee stock purchase plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_ProceedsFromIssuanceOfCommonStockForCashUnderEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479365/842-20-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922025635296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (71,169)<span></span>
</td>
<td class="num">$ (67,061)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922025621328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922115005696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Organization and Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inozyme Pharma, Inc. (the &#8220;Company&#8221;) is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Through the Company&#8217;s in-depth understanding of a key biological pathway, the Company is pursuing the development of therapeutics that address pathologic mineralization and intimal proliferation to improve the underlying causes of these debilitating diseases. It is well established that low levels of plasma pyrophosphate drive pathologic mineralization and low levels of adenosine drive intimal proliferation in a number of rare diseases. The Company is initially focused on developing a novel therapy to treat for ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s lead product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to metabolize extracellular adenosine triphosphate to generate plasma pyrophosphate and adenosine monophosphate, which can be processed to phosphate and adenosine. This process is central to the regulation of calcium deposition throughout the body and is further associated with the inhibition of intimal proliferation, or narrowing and obstruction of blood vessels.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p></div><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity, Capital Resources, and Going Concern</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since the Company&#8217;s incorporation in 2017 and through December 31, 2023, the Company has devoted substantially all of its efforts to raising capital, building infrastructure, developing intellectual property and conducting research and development. The Company incurred net losses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">71.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">67.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in the years ended December 31, 2023 and 2022, respectively, and had an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">285.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of December 31, 2023. The Company had cash, cash equivalents, and short-term investments of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">188.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of the numerous risks and uncertainties associated with product development, the Company is unable to predict the timing or amount of increased expenses or when or if the Company will be able to achieve or maintain profitability. Even if the Company is able to generate revenue from product sales, the Company may not become profitable. If the Company fails to become profitable or is unable to sustain profitability on a continuing basis, then the Company may be unable to continue its operations at planned levels and be forced to reduce or terminate its operations.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets, and the satisfaction of liabilities and commitments in the ordinary course of business. The Company has incurred recurring losses and negative cash flows from operations since inception and has primarily funded its operations with proceeds from the issuance of convertible preferred stock, offerings of common stock and pre-funded warrants, and its loan and security agreement (the "Loan Agreement") with K2 HealthVentures LLC (see Note 8). The Company expects its operating losses and negative operating cash flows to continue into the foreseeable future as it continues to expand its research and development efforts.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company believes that its cash, cash equivalents, and short-term investments as of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> will be sufficient to fund its cash flow requirements for at least 12 months from the date of filing this Annual Report on Form 10-K. Management&#8217;s expectations with respect to its ability to fund current and long-term planned operations are based on estimates that are subject to risks and uncertainties. The Company will need additional funding to support its planned operating activities. However, there is no guarantee that any financing opportunities will be executed on favorable terms, or at all, and some could be dilutive to existing stockholders. If the Company is unable to obtain additional funding, it would be forced to delay, reduce or eliminate some or all of its research and development programs, portfolio expansion, or commercialization efforts, which could adversely affect its business prospects.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922114924736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2. Summary of Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Principles of Consolidation</span></p><p style="text-indent:9.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Inozyme Securities Corp., which is a Massachusetts subsidiary created to buy, sell, and hold securities; Inozyme Ireland Limited; and Inozyme Pharma Switzerland GmbH. All intercompany transactions and balances have been eliminated.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the Company&#8217;s financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and judgments are based on historical information and other market-specific or various relevant assumptions, including, in certain circumstances, future projections that management believes to be reasonable under the circumstances. Actual results could differ materially from estimates. Significant estimates and assumptions are used for, but not limited to the accruals for research and development expenses. The Company evaluates its estimates and assumptions on an ongoing basis. All revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk, Significant Suppliers, and Off-Balance Sheet Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and short-term investments and, from time to time, long-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits and limits its exposure to credit risk by placing its cash with high credit quality financial institutions. The Company&#8217;s investments are composed of U.S. Treasury and U.S. government agency debt securities and commercial paper of corporations. The Company mitigates credit risk by maintaining a diversified portfolio and limiting the amount of investment exposure as to institution, maturity, and investment type.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is dependent on third-party manufacturers and contract research organizations ("CROs") to supply product candidates and provide services for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. The Company also relies on CROs to conduct its clinical trials. The Company&#8217;s programs could be adversely affected if a third-party manufacturer or a CRO is unable to successfully carry out their contractual obligations or meet expected deadlines. If a third-party manufacturer or a CRO needs to be replaced, the Company may not be able to complete its program development on its anticipated timelines and the Company may incur additional expenses as a result, which could be significant.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> significant off-balance sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts, money market accounts, and certain marketable securities. Cash is carried at cost, which approximates its fair value. Cash equivalents are carried at fair market value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Cash</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p></div><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted cash is composed of amounts held to collateralize the letters of credit related to the Company&#8217;s lease arrangements. Restricted cash is classified as either current or non-current based on the terms of the underlying lease arrangement.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Short-Term and Long-Term Investments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company classifies its investments as available-for-sale and records such assets at estimated fair value on the balance sheet, with unrealized gains and losses on marketable securities, if any, reported as a component of accumulated other comprehensive (loss) income. Realized gains and losses are calculated based on the specific-identification method and are recorded as a component of interest income. There have been </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> realized gains and losses for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022. The Company periodically reviews available-for-sale securities for other-than-temporary declines in fair value below the cost basis whenever events</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Marketable securities with a maturity date of one year or less from the balance sheet date are classified by the Company as short-term investments. Marketable securities with a maturity date of greater than one year from the balance sheet date are classified as long-term investments and are available to fund operations as needed. As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t have any long-term investments. In accordance with the Company&#8217;s investment policy, at the time of purchase, the final maturity of each security within the portfolio shall not exceed </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> months and the weighted average maturity of the portfolio will be no greater than </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> months.</span></p></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the related asset. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The estimated useful lives of the Company&#8217;s property and equipment are as follows: </span></span><span style=""></span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:73.34%;"></td>
          <td style="width:1%;"></td>
          <td style="width:24.66%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Useful Life (In Years)</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory equipment and manufacturing equipment</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="-sec-ix-hidden:F_163a734f-613d-45f6-b523-f3a90ba56209;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lesser of asset life or lease term</span></span></span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Impairment of Long-lived Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As required under the applicable accounting guidance, the Company periodically reevaluates the original assumptions and rationale used in the establishment of the carrying value and estimated lives of all of its long-lived assets, including property and equipment. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. An impairment loss is recognized when the total of estimated future undiscounted cash flows, expected to result from the use of the asset and its eventual disposition, are less than its carrying amount. Impairment, if any, would be assessed using discounted cash flows or other appropriate measures of fair value. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> impairments for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accrued Research and Development Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company records accrued liabilities for estimated costs of research and development activities conducted by service providers for sponsored research, preclinical studies, clinical operations, and contract manufacturing activities based upon the estimated amount of services provided but not yet invoiced and includes these costs in accrued expenses in the accompanying consolidated balance sheets and within research and development expense in the accompanying consolidated statements of operations and comprehensive loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with service providers. The Company makes significant judgments and estimates in determining the accrued liabilities balance in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. The Company has not experienced any material differences between accrued costs and actual costs incurred since its inception.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development costs are expensed as incurred. Research and development costs consist of direct and indirect internal costs related to specific projects as well as fees paid to other entities that conduct certain research and development activities on the Company&#8217;s behalf.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company expenses all costs as incurred in connection with patent applications, including direct application fees, and the legal and consulting expenses related to making such applications, and such costs are included in general and administrative expenses within the Company&#8217;s consolidated statements of operations and comprehensive loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compensation expense represents the cost of the grant date fair value of employee and non-employee stock option grants recognized over the requisite service period of the awards on a straight-line basis. For service-based awards that are</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">subject </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">to graded vesting, the Company has elected to recognize compensation expense on a straight-line basis. The Company has elected to recognize forfeitures as they occur.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income taxes have been accounted for using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates applicable to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. A valuation allowance against deferred tax assets is recorded if, based upon the weight of all available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for income taxes in accordance with authoritative accounting guidance which states the impact of an uncertain income tax position is recognized at the largest amount that is &#8220;more likely than not&#8221; to be sustained upon audit by the relevant taxing authority. There are </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> unrecognized tax benefits included in the Company&#8217;s consolidated balance sheets at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 or 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company&#8217;s policy is to recognize interest and penalties related to income tax matters in income tax expense. The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t recognized any interest or penalties in its consolidated statements of operations and comprehensive loss since inception.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company determines if an arrangement is a lease at contract inception based on the facts and circumstances present in the arrangement. If a lease is identified in an arrangement, the Company recognizes a right-of-use asset and liability on its balance sheet and determines whether the lease should be classified as a finance or operating lease. Short-term leases, or leases that have a lease term of 12 months or less at the commencement date are excluded from this treatment and are recognized on a straight-line basis over the term of the lease. Additionally, the Company does not separate lease and non-lease components for all leases.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded as operating leases.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Finance and operating lease assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount rate implicit in the lease. If the rate implicit is not readily determinable, the Company utilizes an estimate of its incremental borrowing rate at the lease commencement date. Operating lease assets are further adjusted for prepaid or accrued lease payments. Operating lease payments are expensed using the straight-line method as an operating expense over the lease term. Finance lease assets are amortized to depreciation expense using the straight-line method over the shorter of the useful life of the related asset or the lease term. Finance lease payments are bifurcated into (i) a portion that is recorded as imputed interest expense and (ii) a portion that reduces the finance liability associated with the lease. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t have any finance leases recorded on its consolidated balance sheet as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Deferred Issuance Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company capitalizes certain legal, professional accounting, and other third-party fees that are directly associated with in-process equity financings as deferred issuance costs until such financings are consummated. After consummation of such an equity financing, these costs are recorded as a reduction of the proceeds generated as a result of the offering. Should a planned equity financing be abandoned, the deferred issuance costs would be expensed immediately as a charge to operating expenses in the consolidated statements of operations and comprehensive loss. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t have any deferred issuance costs recorded at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 or December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss Per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock and pre-funded warrants outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock and pre-funded warrants and potentially dilutive securities outstanding during the period determined using the treasury-stock and if-converted methods. The Company has generated a net loss in all periods presented; therefore, the basic and diluted net loss per share attributable to common stockholders are the same as the inclusion of the potentially dilutive securities would be anti-dilutive.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p></div><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (&#8220;CODM&#8221;) in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#8217;s CODM is its Chief Executive Officer. The Company has determined it operates in a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_8196d8a8-372d-4a07-a143-8661735a221d;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">single</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> operating segment and has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reportable segment. All long-lived assets of the Company reside in the United States.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comprehensive</span><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Loss</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is required to report all components of comprehensive loss, including net loss, in the financial statements in the period in which they are recognized. Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Comprehensive loss consists of the Company&#8217;s net loss, unrealized gains and losses on the Company&#8217;s investments, and foreign currency translation adjustments and is presented within the consolidated statements of operations and comprehensive loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Foreign Currency Transactions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company maintains foreign bank accounts denominated in euros and Swiss francs and enters into transactions which are denominated in various currencies. Foreign currency transactions are initially recorded by the Company using the exchange rates prevailing at the date of the transaction. At the balance sheet date, recorded monetary balances denominated in foreign currencies are adjusted to U.S. dollars using the period-end rates of exchange. Exchange gains and losses arising from the translation of foreign currency items are included in other expense, net in the consolidated statements of operations and comprehensive loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company categorizes its assets and liabilities measured at fair value in accordance with the authoritative accounting guidance that establishes a consistent framework for measuring fair value, and expands disclosures for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.66525540221037%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1 &#8211; Unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets or liabilities; </span></div></div><div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.66525540221037%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2 &#8211; Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; or </span></div></div><div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.66525540221037%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3 &#8211; Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). </span></div></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Emerging Growth Company Status</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is an &#8220;emerging growth company&#8221; (&#8220;EGC&#8221;) as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and the Company may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs. As an EGC, the Company can elect to take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to use the extended transition period for complying with new or revised accounting standards, and as a result of this election, the Company&#8217;s consolidated financial statements may not be comparable to companies that comply with public company FASB standards&#8217; effective dates. The Company will remain an EGC until December 31, 2025, although if the market value of the Company&#8217;s common stock that is held by non-affiliates exceeds $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">700</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of any June 30 before that time or if the Company has annual gross revenues of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.235</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> billion or more in any fiscal year, the Company would cease to be an EGC as of December 31 of the applicable year. The Company would also cease to be an EGC if it issued more than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> billion of non-convertible debt over a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> period.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt and Debt Issuance Costs</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Debt issuance costs are presented on the consolidated balance sheet as a direct deduction from the related debt liability. Debt issuance costs represent legal and other direct costs incurred in connection with the Company&#8217;s term loan under the Loan Agreement. These costs are amortized as a non-cash component of interest expense using the effective interest method over the term of the loan. Any final payments are included in the cash flows to determine the effective interest rate and are recognized using the effective interest method over the term of the loan.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Warrants</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company determines the accounting classification of warrants that are issued, as either liability or equity, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting for Certain Financial Instruments with Characteristics of Both Liabilities and Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and then in accordance with ASC 815-40, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#8217;s Own Stock</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Under ASC 480-10, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate the issuer to settle the warrants or the underlying shares by paying cash or other assets, or must or may require settlement by issuing variable number of shares.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If warrants do not meet liability classification under ASC 480-10, the Company assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability classification under ASC 815-40, in order to conclude equity classification, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable U.S. GAAP. After all relevant assessments are made, the Company concludes whether the warrants are classified as liability or equity. Liability classified warrants are required to be accounted for at fair value both on the date of issuance and on subsequent accounting period ending dates, with all changes in fair value after the issuance date recorded in the statements of operations as a gain or loss. Equity classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922114924736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3. Recent Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently Adopted Accounting Standard</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (&#8220;Topic 326&#8221;): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 and its subsequent related updates establish a new forward-looking &#8220;expected loss model&#8221; that requires entities to estimate current expected credit losses on accounts receivable and financial instruments by using all practical and relevant information. The Company adopted this standard effective January 1, 2023. There was no impact to the Company's financial statements upon adoption.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -Publisher FASB<br> -URI https://asc.fasb.org//250/tableOfContent<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -SubTopic 20<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -SubTopic 20<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922114729520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Details</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4. Balance Sheet Details</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Short-term investments consisted of the following (dollar amounts in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.24%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.9%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.120000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.82%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="16" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Maturity</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1 year or less</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">80,160</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">59</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">80,218</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government agency debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1 year or less</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">73,774</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">73,783</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">153,934</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">154,001</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.269%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.902%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.282%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.282%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.122%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.822%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="16" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Maturity</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1 year or less</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">78,451</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">119</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">78,336</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1 year or less</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,698</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">83</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,615</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">95,149</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">202</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">94,951</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company concluded that the declines in market value of available-for-sale securities were temporary in nature and did not consider any of the investments to be other-than-temporarily impaired. In accordance with its investment policy, the Company invests in investment grade securities with high credit quality issuers, and generally limits the amount of credit exposure to any one issuer. The Company evaluates securities for other-than-temporary impairment at the end of each reporting period. Impairment is evaluated considering numerous factors, and their relative significance varies depending on the situation. Factors considered include the length of time and extent to which fair value has been less than the cost basis, the financial condition and near-term prospects of the issuer, and the Company&#8217;s intent and ability to hold the investment to allow for an anticipated recovery in fair value. Furthermore, the aggregate of individual unrealized losses that had been outstanding for 12 months or less was not significant as of December 31, 2023 and December 31, 2022. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before a recovery of their amortized cost bases, which may be maturity. The Company also believes that it will be able to collect both principal and interest amounts due at maturity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prepaid expenses and other current assets consisted of the following (dollar amounts in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">At December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">At December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest receivable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">385</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">115</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid insurance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,067</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,293</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid research studies</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,339</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,397</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">870</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">722</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,661</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,527</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment consisted of the following (dollar amounts in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">At December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">At December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory equipment and manufacturing equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">947</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">805</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">284</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">258</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">491</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">558</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,157</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,129</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,879</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,750</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less accumulated depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,413</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,732</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,466</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,018</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation expense for the years ended December 31, 2023 and 2022 totaled </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses consisted of the following (dollar amounts in thousands):</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">At December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">At December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Payroll and related liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,838</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,229</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other professional fees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,377</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,310</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Clinical expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,595</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,986</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,917</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,345</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">883</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">485</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,610</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,355</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922114924736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurement</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5. Fair Value Measurement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables represent the Company&#8217;s financial assets measured at fair value on a recurring basis and indicate the level of fair value hierarchy utilized to determine such fair values (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements at Reporting Date<br/>Using</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted<br/>Prices in<br/>Active<br/>Markets for<br/>Identical<br/>Assets<br/>(Level 1)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds (included in cash and cash<br/>&#160;&#160;&#160;equivalents)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,830</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,830</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government agency debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">73,783</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">73,783</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">80,218</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">80,218</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">187,831</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">114,048</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">73,783</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements at Reporting Date<br/>Using</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted<br/>Prices in<br/>Active<br/>Markets for<br/>Identical<br/>Assets<br/>(Level 1)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds (included in cash and cash<br/>&#160;&#160;&#160;equivalents)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,587</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,587</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">78,336</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">78,336</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,615</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,615</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">121,538</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43,202</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">78,336</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There have been </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> transfers between fair value levels during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922026965424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Sponsored Research Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License and Sponsored Research Agreements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6. License and Sponsored Research Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2017, the Company entered into a license agreement with Yale University (&#8220;Yale&#8221;), which was amended in May 2020 and July 2020, under which the Company licensed certain intellectual property related to ectonucleotide pyrophosphatase/phosphodiesterase enzymes that is the basis for the Company&#8217;s INZ-701 development program. Pursuant to the license agreement, as partial upfront consideration, the Company made a payment of approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to Yale, which</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">amount reflected unreimbursed patent expenses incurred by Yale prior to the date of the license agreement. The Company is responsible for paying Yale an annual license maintenance fee in varying amounts throughout the term ranging from the low tens of thousands of dollars to the high tens of thousands of dollars. For the years ended December 31, 2023 and 2022, the Company incurred a total of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, in license maintenance fees to Yale.  The Company is required to pay Yale up to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, based on the achievement of a specified net product sales milestone or specified development and commercialization milestones, for each therapeutic and prophylactic licensed product developed. In January 2022, the Company paid Yale an approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million milestone payment following dosing of the first patient in Company&#8217;s Phase 1/2 clinical trial of INZ-701 in adult patients with ENPP1 Deficiency in November 2021. In March 2022, the Company paid Yale an approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million milestone payment following completion of the first cohort of the Company's Phase 1/2 clinical trial of INZ-701 in adult patients with ENPP1 Deficiency in January 2022. In addition, the Company is required to pay Yale an amount in the several hundreds of thousands of dollars, based on the achievement of a specified net product sales milestone or specified development and commercialization milestones, for each diagnostic licensed product developed. While the agreement remains in effect, the Company is required to pay Yale low single-digit percentage royalties on aggregate worldwide net sales of certain licensed products. Yale is guaranteed a minimum royalty payment amount (ranging in dollar amounts from the mid six figures to low seven figures) for each year after the first sale of a therapeutic or prophylactic licensed product that results in net sales. Yale is guaranteed a minimum royalty payment amount (ranging from the low tens of thousands of dollars to the mid tens of thousands of dollars) for each year after the first sale of a diagnostic licensed product that results in net sales. The Company must also pay Yale a percentage in the twenties of certain types of income it receives from sublicensees. The Company is also responsible for costs relating to the prosecution and maintenance of the licensed patents. Finally, subject to certain conditions, all payments due by the Company to Yale will be tripled following any patent challenge or challenge to a claim by Yale that a product is a licensed product under the agreement, made by the Company against Yale if Yale prevails in such challenge.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2017, the Company also entered into a corporate sponsored research agreement with Yale (the "Sponsored Research Agreement"), which was amended in February 2019, under which the Company agreed to provide research support funding in the aggregate amount of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million over the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> period from contract inception through </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 2021</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Sponsored Research Agreement was amended in February 2022, under which the contract was extended through June 30, 2022 subject to the terms of the existing agreement. The Sponsored Research Agreement was amended again in May 2022, March 2023, and January 2024, such that the agreement now extends through December 2024, with approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of Company-provided research support funding for the most recent extension. The aggregate amount of agreed upon research support funding under the Sponsored Research Agreement is </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company recorded research and development expenses associated with this arrangement of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in each of the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922115005696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7. Commitments and Contingencies</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Leases</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company held the following significant operating leases of office and laboratory space as of December 31, 2023:</span></p><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An operating lease for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8,499</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of office space in Boston, Massachusetts that expires in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, with an </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">option to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">extend</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> the term for </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exercise of the option was determined not to be reasonably certain and thus was not included in the operating lease liability on the consolidated balance sheet as of December 31, 2023 or 2022; and</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An operating lease for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,244</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of laboratory space in Boston, Massachusetts that expires in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, with an </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">option to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">extend</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> the term for </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exercise of the option was determined not to be reasonably certain and thus was not included in the operating lease liability on the consolidated balance sheet as of December 31, 2023 or 2022.</span></div></div><p style="text-indent:10.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Both leases are subject to yearly rent escalations. In connection with the Company&#8217;s leases of office space and laboratory space, the Company provided security deposits to the landlords in the form of letters of credit totaling $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023. The cash collateralizing the letters of credit is included in restricted cash in the accompanying balance sheets as of December 31, 2023 and December 31, 2022.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">        </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the weighted average incremental borrowing rate and the weighted average remaining lease term for the operating leases held by the Company were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years, respectively.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2023, cash paid for amounts included for the measurement of lease liabilities was $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and the Company recorded operating lease expense of $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. During the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, cash paid for amounts included for the measurement of lease liabilities was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and the Company recorded operating lease expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future lease payments under non-cancelable leases as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 are as follows (dollar amounts in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.48%;"></td>
        <td style="width:2.68%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.84%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">Year Ending December 31,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,016</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">944</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,960</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company did not have any finance leases recorded on its consolidated balance sheet as of December 31, 2023 and 2022.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Indemnification Agreements</span></p><p style="text-indent:10.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters arising out of the relationship between such parties and the Company. In addition, the Company has entered into indemnification agreements with members of its board of directors and senior management that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any claims under indemnification arrangements, and it has not accrued any liabilities related to such obligations as of December 31, 2023 or December 31, 2022.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Legal Proceedings</span></p><p style="text-indent:10.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is not currently a party to any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses the costs related to its legal proceedings as they are incurred. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> such costs have been incurred during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922021717776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt Disclosure [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8. Convertible Debt</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Loan Agreement with K2 HealthVentures LLC</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 25, 2022, the Company, as borrower, entered into the Loan Agreement with K2 HealthVentures LLC (&#8220;K2HV&#8221;, together with any other lender from time to time, the &#8220;Lenders&#8221;), K2HV, as administrative agent for the Lenders, and Ankura Trust Company, LLC, as collateral agent for the Lenders. The Loan Agreement provides up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">70.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million principal in term loans, subject to certain customary conditions. The Company received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from the first tranche commitment upon closing. The first tranche commitment contained an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million available to be drawn at the Company&#8217;s option through March 31, 2023. The Company elected to borrow the remaining $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in February 2023. Two subsequent tranche commitments totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in the aggregate were available to be drawn at the Company&#8217;s option during certain availability periods, subject to the achievement of certain clinical and regulatory milestones relating to INZ-701. The Company elected to borrow $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million under the second tranche commitment in June 2023 and elected to borrow $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million under the third tranche commitment in December 2023.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A fourth tranche commitment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million may be made available to be drawn down at the Company&#8217;s option through August 31, 2025, subject to use of proceeds limitations and Lender's consent at its discretion. The fourth tranche commitment is subject to an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.75</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% facility fee.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of borrowing capacity remained available under the Loan Agreement, subject to the terms and conditions set forth therein. As security for its obligations under the Loan Agreement, the Company granted the Lenders a first priority security interest on substantially all of the Company&#8217;s assets (other than intellectual property), subject to certain exceptions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The term loan matures on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">August 1, 2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Company is obligated to make interest only payments for the first 36 months and then interest and equal principal payments through the maturity date. The term loan bears a variable interest rate equal to the greater of (i) </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7.85</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, and (ii) the sum of (A) the prime rate last quoted in The Wall Street Journal (or a comparable replacement rate if The Wall Street Journal ceases to quote such rate) and (B) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.85</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%; provided that the interest rate cannot exceed 9.60%</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The interest rate as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9.60</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%. The Company has the option to prepay all, but not less than, the outstanding principal balance and all accrued and unpaid interest with respect to the principal balance being repaid of the term loans, subject to a prepayment premium to which the Lenders are entitled. The prepayment fee is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% prior to the second anniversary of the July 25, 2022 funding date, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% after the second anniversary but prior to the third anniversary of the funding date, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">thereafter if prior to the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">maturity </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">date. Upon final payment or prepayment of the loans, the Company must pay a final payment equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the loans borrowed ("Final Fee"), which is being accrued as interest expense over the term of the loan using the effective interest method.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Lenders may elect, prior to the full repayment of the term loans, to convert up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of outstanding principal of the term loans into shares of the Company&#8217;s common stock, at a conversion price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.21</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, subject to customary adjustments and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.99</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">19.99</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% beneficial ownership limitations. The Company determined that the embedded conversion option was not required to be separated from the term loan. The embedded conversion option met the derivative accounting scope exception since the embedded conversion option is indexed to the Company&#8217;s own common stock and qualifies for classification within stockholders&#8217; equity.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Loan Agreement contains customary representations and warranties, events of default and affirmative and negative covenants, including covenants that limit or restrict the Company&#8217;s ability to, among other things, dispose of assets, make changes to the Company&#8217;s business, management, ownership or business locations, merge or consolidate, incur additional indebtedness, incur additional liens, pay dividends or other distributions or repurchase equity, make investments, and enter into certain transactions with affiliates, in each case subject to certain exceptions. Upon the occurrence of an event of default, a default interest rate of an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% per annum may be applied to the outstanding loan balances, and the Lender may declare all outstanding obligations immediately due and payable and exercise all of its rights and remedies as set forth in the Loan Agreement and under applicable law. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, the Company was in compliance with all covenants under the Loan Agreement.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subject to certain conditions, the Company granted the Lenders the right, prior to repayment of the term loans, to invest up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in the aggregate in future offerings of common stock, convertible preferred stock or other equity securities of the Company that are broadly marketed and offered to multiple investors, on the same terms, conditions and pricing afforded to others participating in any such financing.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company incurred debt issuance costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in connection with the term loan. In addition, at the time of closing the Company paid to the Lenders a facility fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, as well as $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of other expenses incurred by the Lenders and reimbursed by the Company ("Lender Expenses"). At </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, the carrying value of the Loan Agreement approximates the fair value of the term loan, considering that it bears interest that is similar to prevailing market rates.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the impact of the term loan on the Company&#8217;s consolidated balance sheet at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023:</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.64%;"></td>
        <td style="width:5.36%;"></td>
        <td style="width:1%;"></td>
        <td style="width:38%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gross proceeds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unamortized debt issuance costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">231</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Carrying value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44,769</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future principal payments, which include the Final Fee, in connection with the Loan Agreement as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 are as follows (dollar amounts in thousands):</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.64%;"></td>
        <td style="width:5.36%;"></td>
        <td style="width:1%;"></td>
        <td style="width:38%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fiscal Year</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,508</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,305</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47,813</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:line-through;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;text-decoration:line-through;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922026835536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9. Stockholders&#8217; Equity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">July 2023 Underwritten Offering</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 27, 2023, the Company entered into an underwriting agreement with BofA Securities, Inc., Cowen and Company, LLC and Piper Sandler &amp; Co., as representatives of the several underwriters named therein (collectively, the &#8220;Underwriters&#8221;), relating to an underwritten public offering of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14,375,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company's common stock, which included </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,875,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">issued upon the exercise in full by the underwriters of their option to purchase additional shares (the "July 2023 Shares"). The closing of the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">offering </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">took place on August 1, 2023. All of the July 2023 Shares were sold by the Company. The offering price of the July 2023 Shares was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.80</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. Net proceeds from the sale and issuance of the July 2023 Shares were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">64.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, after deducting underwriting discounts and commissions and offering expenses.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">April 2022 Underwritten Offering</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 11, 2021, the Company filed a universal shelf registration statement on Form S-3, which was declared effective on August 23, 2021, (the "Registration Statement"). Under the Registration Statement, the Company may offer and sell up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">200.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of a variety of securities, including common stock, preferred stock, depositary shares, debt securities, warrants, subscription </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> rights or units from time to time pursuant to one or more offerings at prices and terms to be determined at the time of the sale. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 14, 2022, the Company entered into an underwriting agreement with Jefferies LLC and Cowen and Company, LLC, relating to an underwritten offering under the Registration Statement of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">16,276,987</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock (the "Shares") and, in lieu of common stock to certain investors, pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,523,013</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock. The closing of the offering took place on April 19, 2022. The offering price of the Shares was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.69</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and the offering price of the pre-funded warrants was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.6899</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share underlying each pre-funded warrant. Warrants must be exercised by means of a cashless exercise. Net proceeds from the offering were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">68.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, after deducting underwriting discounts and commissions and offering expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On June 10, 2022, the Company and each holder of the pre-funded warrants entered into amended and restated pre-funded warrants solely to eliminate the seven-year expiration date of the pre-funded warrants. Each amended and restated pre-funded warrant is now exercisable for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share of common stock from the original date of issuance until the date the pre-funded warrant is exercised in full. All other terms of the pre-funded warrants remain unchanged. The pre-funded warrants contain standard adjustment provisions if certain corporate events were to happen.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The pre-funded warrants are classified as a component of permanent equity and were recorded at the issuance date using a relative fair value allocation method. The pre-funded warrants are equity classified because they are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the holders to receive a fixed number of shares of common stock upon exercise. In addition, such pre-funded warrants do not provide any guarantee of value or return. As of December 31, 2022, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">197,251</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> pre-funded warrants had been exercised by means of cashless exercise in exchange for the issuance of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">197,240</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company's common stock. As of December 31, 2023, the remaining </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,325,762</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> pre-funded warrants had been exercised by means of cashless exercise in exchange for the issuance of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,325,644</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company's common stock.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Open Market Sale Agreement</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the filing of the Registration Statement on August 11, 2021, the Company entered into an Open Market Sale Agreement with Jefferies LLC, as sales agent, pursuant to which the Company may offer and sell shares of its common stock with an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million under an &#8220;at-the-market&#8221; offering program. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,553,995</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock pursuant to the Open Market Sale Agreement for aggregate net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">21.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity Incentive Plans</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2017, the Company&#8217;s board of directors and stockholders adopted the 2017 Equity Incentive Plan, which was amended and restated in July 2017, (as so amended and restated, the &#8220;2017 Plan&#8221;), which provided for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards and other stock awards. The maximum number of shares of common stock that were authorized for issuance under the 2017 Plan was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,730,496</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 17, 2020, the Company&#8217;s stockholders approved the 2020 Stock Incentive Plan (the &#8220;2020 Plan&#8221;), which became effective on July 23, 2020. The 2020 Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock units, and other stock-based awards. The number of shares of the Company&#8217;s common stock reserved for issuance under the 2020 Plan</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,588,315</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares, plus the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">426,065</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock remaining available for issuance under the 2017 Plan as of July 23, 2020. The number of shares reserved under the 2020 Plan will be annually increased on each January 1 through January 1, 2030 by the lower of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the number of shares of common stock outstanding on the first day of such fiscal year and (ii) an amount determined by the Company&#8217;s board of directors.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of the effective date of the 2020 Plan, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> further </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">awards will be made under the 2017 Plan. Any options or awards outstanding under the 2017 Plan are governed by their existing terms. The shares of the Company&#8217;s common stock subject to outstanding awards under the 2017 Plan that expire, terminate, or are otherwise surrendered, cancelled, forfeited, or repurchased by</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company at their original issuance price pursuant to a contractual repurchase right will be added back to the shares of common stock available for issuance under the 2020 Plan. No more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,588,315</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock may be granted subject to incentive stock options under the 2020 Plan. On January 1, 2024 and 2023, the number of shares of common stock reserved under the 2020 Plan was increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,470,750</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,615,774</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 27, 2023, the Company's board of directors adopted the 2023 Inducement Stock Incentive Plan (the "Inducement Plan"). The Inducement Plan provides for the grant of non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock units, and other stock-based awards to persons who (a) were not previously an employee or director or (b) are commencing employment with the Company following a bona fide period of non-employment, in either case, as an inducement material to such person</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8217;s entry into employment with the Company and in accordance with the requirements of the Nasdaq Stock Market Rule 5635(c)(4). As of December 31, 2023, the maximum number of shares of the Company's common stock reserved for issuance under the Inducement Plan is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the years ended December 31, 2023 and 2022, the Company recognized stock-based compensation expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. The fair value of shares vested for the years ended December 31, 2023 and 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Options</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes stock option activity under the Company&#8217;s equity incentive plans since </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.11%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.662%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.942%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.662%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Options<br/>Outstanding</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value (1)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in years)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,687,811</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.53</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.06</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,019,590</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.53</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43,209</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.70</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">627,526</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.43</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,036,666</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.68</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.71</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,615</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,370,210</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.05</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.37</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,007</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested and expected to vest at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,036,666</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.68</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.71</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,615</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#8217;s common stock.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted average grant date fair value of stock options granted in the years ended December 31, 2023 and 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.47</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.45</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, respectively. The aggregate intrinsic value of stock options exercised during the years ended December 31, 2023 and 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The total unrecognized compensation cost related to outstanding employee option awards as of December 31, 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and is expected to be recognized over a weighted average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.8</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For purposes of calculating stock-based compensation expense, the Company estimates the fair value of stock options using the Black-Scholes option-pricing model. This model incorporates various assumptions, including the expected volatility, expected term, and interest rates. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The underlying assumptions used to value stock options granted to participants using the Black-Scholes option-pricing were as follows: </span></span><span style=""></span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:14.883%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:14.883%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate range</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.36</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% to </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.67</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.59</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% to </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.30</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term of options (years)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.5</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;to </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.48</span></span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.08</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;to </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.48</span></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Volatility rate range</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">87.26</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% to </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89.67</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84.50</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% to </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">87.15</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected Term &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The expected term of stock options represents the weighted average period the stock options are expected to be outstanding. The Company uses the simplified method for estimating the expected term, which calculates the expected term as the average time-to-vesting and the contractual life of the options for stock options issued to participants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected Volatility &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Due to the Company&#8217;s limited operating history and lack of company-specific historical or implied volatility, the expected volatility assumption was determined by examining the historical volatilities of a group of industry peers whose share prices are publicly available. The Company expects to continue using this approach until such time as it has adequate historical data regarding the volatility of its own traded stock price.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk-Free Interest Rate &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The risk-free rate assumption is based on U.S. Treasury instruments, the terms of which were consistent with the expected term of the Company&#8217;s stock options.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected Dividend &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The expected dividend assumption is based on the Company&#8217;s history and expectation of dividend payouts. The Company has not paid any dividends to date and does not intend to pay dividends.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Following the Company's initial public offering, the fair value of the Company&#8217;s common stock has been determined based on the closing price of the Company&#8217;s common stock on the Nasdaq Global Select Market on the grant date, with consideration of whether there is material nonpublic information that could impact that estimated fair value when it is released.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">RSUs</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Activity related to restricted stock units ("RSUs") for the year ended December 31, 2023 is summarized in the table below:</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.22%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.3%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of January 1, 2023</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Canceled / Forfeited</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested / Settled</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted-average grant date fair value of RSUs granted in the year ended December 31, 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;">5.73</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. The total unrecognized compensation cost related to outstanding RSUs as of December 31, 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and is expected to be recognized over a weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Employee Stock Purchase Plan</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 17, 2020, the Company&#8217;s stockholders approved the 2020 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;), which became effective on July 23, 2020. The ESPP initially provided participating employees with the opportunity to purchase up to an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">198,539</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The number of shares of common stock reserved for issuance under the ESPP will increase each January 1 through January 1, 2031, in an amount equal to the lowest of (1) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">397,079</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock, (2) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the number of shares of the Company&#8217;s common stock outstanding on the first day of such fiscal year, and (3) an amount determined by the Company&#8217;s board of directors.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> On January 1, 2024 and 2023, the number of shares of common stock reserved under the ESPP was increased by </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;">397,079</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;">397,079</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares, respectively. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company activated its first six month offering period under the ESPP on April 1, 2022. As of December 31, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;">116,972</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares have been purchased by employees under the ESPP.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922026922416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10. Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">   </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the years ended December 31, 2023 and 2022, the Company recorded pre-tax net losses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">71.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">67.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. Since it maintains a full valuation allowance on its deferred tax assets, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t record an income tax provision for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022.</span></p><p style="text-indent:9.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:9.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</span></p><p style="text-indent:9.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.088%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.277%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.44%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.277%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.92%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="8" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal income tax at statutory rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Permanent differences</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.6</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State income tax, net of federal benefit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal and state research and development tax credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30.3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Effective income tax rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">     </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred taxes are recognized for temporary differences between the bases of assets and liabilities for financial statement and income tax purposes. </span><span style="font-size:12pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The significant components of the Company&#8217;s deferred tax assets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 are composed of the following (dollar amounts in thousands): </span></span><span style=""></span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating losses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,999</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,144</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,903</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,220</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,930</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,604</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">916</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">758</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,759</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,899</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">499</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">688</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized research and experimental expenditures</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,959</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,467</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">351</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">297</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gross deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89,316</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,077</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88,906</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">62,468</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">410</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">609</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation of fixed assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">64</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">184</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right of use assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">308</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">422</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gross deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">410</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">609</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-current net deferred tax assets (liabilities)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company had gross federal net operating loss carryforwards ("NOLs") of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;">164.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which may be available to offset future taxable income. Of the federal NOLs, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;">5.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2037</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">158.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million do not expire. As of December 31, 2023, the Company had gross state NOLs of  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;">135.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which may be available to offset future taxable income and which begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2037</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As required by FASB ASC Topic 740, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, management of the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, which are composed principally of capitalized research and experimental ("R&amp;E") expenditures, NOLs, and research and development credits. Under the applicable accounting standards, management has considered the Company&#8217;s history of losses and concluded that it is more likely than not that the Company will not recognize the benefits of federal and state deferred tax assets. Accordingly, a full valuation allowance of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;">88.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;">62.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million has been established at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and December 31, 2022, respectively. The increase in the valuation allowance of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;">26.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023 was primarily due to increases in capitalized R&amp;E expenditures, NOLs, and research and development credits generated by the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company also has federal and state research and development credit carryforwards totaling </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;">17.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The federal research and development credit carryforwards will begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2038</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, unless previously utilized. The state research and development credit carryforwards will begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2032</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unless previously utilized. The Company has generated research and development credits but has not conducted a study to document the qualified activity. This study</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">may </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">result in an adjustment to the Company&#8217;s research and development credit carryforwards; however, until a study is completed and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#8217;s research and development credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the deferred tax asset established for the research and development credit carryforwards and the valuation allowance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective January 1, 2022, a provision of the Tax Cuts and Jobs Act ("TCJA") changed the treatment of R&amp;E expenditures under Section 174 of the United States Internal Revenue Code (the "Internal Revenue Code"). Prior to the TCJA being effective, businesses have had the option of deducting Section 174 expenses in the year incurred or capitalizing and amortizing the costs over five years. The new TCJA provision, however, eliminates this option and requires Section 174 expenses associated with research conducted in the United States to be capitalized and amortized over a five-year period. For expenses associated with research outside of the United States, Section 174 expenses will be capitalized and amortized over a 15-year period.</span></p><p style="text-indent:9.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s ability to use its NOLs and tax credit carryforwards to offset taxable income is subject to restrictions under Sections 382 and 383 of the Internal Revenue Code. Under the Internal Revenue Code provisions, certain substantial changes in the Company&#8217;s ownership, including the sale of the Company or significant changes in ownership due to sales of equity, have limited and may limit in the future, the amount of NOLs which could be used annually to offset future taxable income. The Company has not yet conducted an analysis of ownership changes. The Company may also experience ownership changes in the future as a result of subsequent shifts in its stock ownership, some of which may be outside the Company&#8217;s control. As a result, the Company&#8217;s ability to use its pre-change NOLs to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to the Company. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. Under the TCJA, the use of federal NOLs arising in taxable years beginning after December 31, 2017 is limited to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">80</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of current year taxable income and NOLs arising in taxable years ending after December 31, 2017 may not be carried back (though any such NOLs may be carried forward indefinitely).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company establishes reserves for uncertain tax positions based on management&#8217;s assessment of exposures associated with tax positions taken on tax return filings. The tax reserves are analyzed periodically and adjustments are made as events occur that warrant adjustment to the reserves. The Company does not have any reserves for uncertain tax positions as of December 31, 2023 and any change in position would result in a change in the valuation allowance maintained against its net deferred tax assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest and penalty charges, if any, related to unrecognized tax benefits are classified as income tax expense in the accompanying consolidated statements of operations and comprehensive loss. As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had no accrued interest related to uncertain tax positions. Since the Company is in a loss carryforward position, the Company is generally subject to examination by the U.S. federal, state, and local income tax authorities for all tax years in which a loss carryforward is available.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922026916816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11. Net Loss per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss per Share Attributable to Common Stockholders</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth the computation of basic and diluted net loss per share for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 (in thousands, except share and per share amounts):</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.92%;"></td>
        <td style="width:1.6%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.64%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.6%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.64%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.6%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="8" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss attributable to common stockholders&#8212;basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,169</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67,061</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share attributable to common stockholders&#8212;basic and diluted</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.37</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.78</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average common shares and pre-funded warrants outstanding&#8212;basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">51,839,131</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37,763,168</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has generated a net loss in all periods presented; therefore, the basic and diluted net loss per share attributable to common stockholders are the same as the inclusion of the potentially dilutive securities would be anti-dilutive. Since the shares underlying the pre-funded warrants are issuable for nominal consideration, they are considered outstanding for both basic and diluted earnings per share from the date of issuance. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company excluded the following potential dilutive securities, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated: </span></span><span style=""></span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,036,666</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,687,811</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested RSUs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,136,666</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,687,811</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922026835536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12. Employee Benefit Plans</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company established a defined contribution savings plan in 2018 for all eligible U.S. employees under Section 401(k) of the Internal Revenue Code. Employees can designate the investment of their 401(k) accounts into several mutual funds. Effective January 1, 2021, the Company implemented a matching policy under which the Company matches </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of an employee&#8217;s contributions to the 401(k) plan, up to a maximum of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the employee&#8217;s base salary and bonus paid during the year. For each of the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, the Company made employer contributions to the 401(k) plan of $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//710/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//712/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922026841392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13. Related Party Transactions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 6, 2021, the Company entered into an amended and restated consulting agreement (the &#8220;Consulting Agreement&#8221;) with Danforth Advisors, LLC (&#8220;Danforth&#8221;), pursuant to which Danforth, in addition to providing finance, accounting and administrative functions, provided interim chief financial officer services to the Company by Stephen J. DiPalma, Managing Director of Danforth. The Company paid Danforth an agreed upon hourly rate for such services and reimbursed Danforth for expenses. The Consulting Agreement could be terminated by the Company or Danforth with cause, upon </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> days prior written notice, and without cause, upon </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">60</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> days prior written notice. Mr. DiPalma ceased serving as the Company's interim chief financial officer on March 21, 2022 in connection with the appointment of Sanjay S. Subramanian as the Company's Chief Financial Officer ("CFO"). The Company incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of expense for services provided by Danforth during the time Mr. DiPalma was the Company's interim CFO in 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, on May 17, 2021, the Company granted Mr. DiPalma an option to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock (the &#8220;Option&#8221;) under the Company&#8217;s 2020 Stock Incentive Plan at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.90</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The shares underlying the Option vested in full in 2022.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922020900880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Principles of Consolidation</span></p><p style="text-indent:9.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Inozyme Securities Corp., which is a Massachusetts subsidiary created to buy, sell, and hold securities; Inozyme Ireland Limited; and Inozyme Pharma Switzerland GmbH. All intercompany transactions and balances have been eliminated.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the Company&#8217;s financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and judgments are based on historical information and other market-specific or various relevant assumptions, including, in certain circumstances, future projections that management believes to be reasonable under the circumstances. Actual results could differ materially from estimates. Significant estimates and assumptions are used for, but not limited to the accruals for research and development expenses. The Company evaluates its estimates and assumptions on an ongoing basis. All revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk, Sigificant Suppliers, and Off-Balance Sheet Risk</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk, Significant Suppliers, and Off-Balance Sheet Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and short-term investments and, from time to time, long-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits and limits its exposure to credit risk by placing its cash with high credit quality financial institutions. The Company&#8217;s investments are composed of U.S. Treasury and U.S. government agency debt securities and commercial paper of corporations. The Company mitigates credit risk by maintaining a diversified portfolio and limiting the amount of investment exposure as to institution, maturity, and investment type.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is dependent on third-party manufacturers and contract research organizations ("CROs") to supply product candidates and provide services for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. The Company also relies on CROs to conduct its clinical trials. The Company&#8217;s programs could be adversely affected if a third-party manufacturer or a CRO is unable to successfully carry out their contractual obligations or meet expected deadlines. If a third-party manufacturer or a CRO needs to be replaced, the Company may not be able to complete its program development on its anticipated timelines and the Company may incur additional expenses as a result, which could be significant.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> significant off-balance sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts, money market accounts, and certain marketable securities. Cash is carried at cost, which approximates its fair value. Cash equivalents are carried at fair market value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Cash</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted cash is composed of amounts held to collateralize the letters of credit related to the Company&#8217;s lease arrangements. Restricted cash is classified as either current or non-current based on the terms of the underlying lease arrangement.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Short-Term and Long-Term Investments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Short-Term and Long-Term Investments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company classifies its investments as available-for-sale and records such assets at estimated fair value on the balance sheet, with unrealized gains and losses on marketable securities, if any, reported as a component of accumulated other comprehensive (loss) income. Realized gains and losses are calculated based on the specific-identification method and are recorded as a component of interest income. There have been </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> realized gains and losses for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022. The Company periodically reviews available-for-sale securities for other-than-temporary declines in fair value below the cost basis whenever events</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Marketable securities with a maturity date of one year or less from the balance sheet date are classified by the Company as short-term investments. Marketable securities with a maturity date of greater than one year from the balance sheet date are classified as long-term investments and are available to fund operations as needed. As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t have any long-term investments. In accordance with the Company&#8217;s investment policy, at the time of purchase, the final maturity of each security within the portfolio shall not exceed </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> months and the weighted average maturity of the portfolio will be no greater than </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> months.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the related asset. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The estimated useful lives of the Company&#8217;s property and equipment are as follows: </span></span><span style=""></span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:73.34%;"></td>
          <td style="width:1%;"></td>
          <td style="width:24.66%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Useful Life (In Years)</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory equipment and manufacturing equipment</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="-sec-ix-hidden:F_163a734f-613d-45f6-b523-f3a90ba56209;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lesser of asset life or lease term</span></span></span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-lived Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Impairment of Long-lived Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As required under the applicable accounting guidance, the Company periodically reevaluates the original assumptions and rationale used in the establishment of the carrying value and estimated lives of all of its long-lived assets, including property and equipment. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. An impairment loss is recognized when the total of estimated future undiscounted cash flows, expected to result from the use of the asset and its eventual disposition, are less than its carrying amount. Impairment, if any, would be assessed using discounted cash flows or other appropriate measures of fair value. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> impairments for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_AccruedResearchAndDevelopmentCostsPolicyTextBlock', window );">Accrued Research and Development Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accrued Research and Development Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company records accrued liabilities for estimated costs of research and development activities conducted by service providers for sponsored research, preclinical studies, clinical operations, and contract manufacturing activities based upon the estimated amount of services provided but not yet invoiced and includes these costs in accrued expenses in the accompanying consolidated balance sheets and within research and development expense in the accompanying consolidated statements of operations and comprehensive loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with service providers. The Company makes significant judgments and estimates in determining the accrued liabilities balance in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. The Company has not experienced any material differences between accrued costs and actual costs incurred since its inception.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development costs are expensed as incurred. Research and development costs consist of direct and indirect internal costs related to specific projects as well as fees paid to other entities that conduct certain research and development activities on the Company&#8217;s behalf.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_PatentCostsPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company expenses all costs as incurred in connection with patent applications, including direct application fees, and the legal and consulting expenses related to making such applications, and such costs are included in general and administrative expenses within the Company&#8217;s consolidated statements of operations and comprehensive loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compensation expense represents the cost of the grant date fair value of employee and non-employee stock option grants recognized over the requisite service period of the awards on a straight-line basis. For service-based awards that are</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">subject </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">to graded vesting, the Company has elected to recognize compensation expense on a straight-line basis. The Company has elected to recognize forfeitures as they occur.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">IncomeTaxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income taxes have been accounted for using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates applicable to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. A valuation allowance against deferred tax assets is recorded if, based upon the weight of all available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for income taxes in accordance with authoritative accounting guidance which states the impact of an uncertain income tax position is recognized at the largest amount that is &#8220;more likely than not&#8221; to be sustained upon audit by the relevant taxing authority. There are </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> unrecognized tax benefits included in the Company&#8217;s consolidated balance sheets at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 or 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company&#8217;s policy is to recognize interest and penalties related to income tax matters in income tax expense. The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t recognized any interest or penalties in its consolidated statements of operations and comprehensive loss since inception.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company determines if an arrangement is a lease at contract inception based on the facts and circumstances present in the arrangement. If a lease is identified in an arrangement, the Company recognizes a right-of-use asset and liability on its balance sheet and determines whether the lease should be classified as a finance or operating lease. Short-term leases, or leases that have a lease term of 12 months or less at the commencement date are excluded from this treatment and are recognized on a straight-line basis over the term of the lease. Additionally, the Company does not separate lease and non-lease components for all leases.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded as operating leases.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Finance and operating lease assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount rate implicit in the lease. If the rate implicit is not readily determinable, the Company utilizes an estimate of its incremental borrowing rate at the lease commencement date. Operating lease assets are further adjusted for prepaid or accrued lease payments. Operating lease payments are expensed using the straight-line method as an operating expense over the lease term. Finance lease assets are amortized to depreciation expense using the straight-line method over the shorter of the useful life of the related asset or the lease term. Finance lease payments are bifurcated into (i) a portion that is recorded as imputed interest expense and (ii) a portion that reduces the finance liability associated with the lease. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t have any finance leases recorded on its consolidated balance sheet as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Issuance Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Deferred Issuance Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company capitalizes certain legal, professional accounting, and other third-party fees that are directly associated with in-process equity financings as deferred issuance costs until such financings are consummated. After consummation of such an equity financing, these costs are recorded as a reduction of the proceeds generated as a result of the offering. Should a planned equity financing be abandoned, the deferred issuance costs would be expensed immediately as a charge to operating expenses in the consolidated statements of operations and comprehensive loss. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t have any deferred issuance costs recorded at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 or December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss Per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock and pre-funded warrants outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock and pre-funded warrants and potentially dilutive securities outstanding during the period determined using the treasury-stock and if-converted methods. The Company has generated a net loss in all periods presented; therefore, the basic and diluted net loss per share attributable to common stockholders are the same as the inclusion of the potentially dilutive securities would be anti-dilutive.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (&#8220;CODM&#8221;) in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#8217;s CODM is its Chief Executive Officer. The Company has determined it operates in a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_8196d8a8-372d-4a07-a143-8661735a221d;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">single</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> operating segment and has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reportable segment. All long-lived assets of the Company reside in the United States.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comprehensive</span><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Loss</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is required to report all components of comprehensive loss, including net loss, in the financial statements in the period in which they are recognized. Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Comprehensive loss consists of the Company&#8217;s net loss, unrealized gains and losses on the Company&#8217;s investments, and foreign currency translation adjustments and is presented within the consolidated statements of operations and comprehensive loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Transactions</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Foreign Currency Transactions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company maintains foreign bank accounts denominated in euros and Swiss francs and enters into transactions which are denominated in various currencies. Foreign currency transactions are initially recorded by the Company using the exchange rates prevailing at the date of the transaction. At the balance sheet date, recorded monetary balances denominated in foreign currencies are adjusted to U.S. dollars using the period-end rates of exchange. Exchange gains and losses arising from the translation of foreign currency items are included in other expense, net in the consolidated statements of operations and comprehensive loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company categorizes its assets and liabilities measured at fair value in accordance with the authoritative accounting guidance that establishes a consistent framework for measuring fair value, and expands disclosures for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.66525540221037%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1 &#8211; Unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets or liabilities; </span></div></div><div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.66525540221037%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2 &#8211; Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; or </span></div></div><div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.66525540221037%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3 &#8211; Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). </span></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_EmergingGrowthCompanyStatusPolicyTextBlock', window );">Emerging Growth Company Status</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Emerging Growth Company Status</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is an &#8220;emerging growth company&#8221; (&#8220;EGC&#8221;) as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and the Company may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs. As an EGC, the Company can elect to take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to use the extended transition period for complying with new or revised accounting standards, and as a result of this election, the Company&#8217;s consolidated financial statements may not be comparable to companies that comply with public company FASB standards&#8217; effective dates. The Company will remain an EGC until December 31, 2025, although if the market value of the Company&#8217;s common stock that is held by non-affiliates exceeds $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">700</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of any June 30 before that time or if the Company has annual gross revenues of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.235</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> billion or more in any fiscal year, the Company would cease to be an EGC as of December 31 of the applicable year. The Company would also cease to be an EGC if it issued more than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> billion of non-convertible debt over a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> period.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt and Debt Issuance Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt and Debt Issuance Costs</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Debt issuance costs are presented on the consolidated balance sheet as a direct deduction from the related debt liability. Debt issuance costs represent legal and other direct costs incurred in connection with the Company&#8217;s term loan under the Loan Agreement. These costs are amortized as a non-cash component of interest expense using the effective interest method over the term of the loan. Any final payments are included in the cash flows to determine the effective interest rate and are recognized using the effective interest method over the term of the loan.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_WarrantsPolicyTextBlock', window );">Warrants</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Warrants</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company determines the accounting classification of warrants that are issued, as either liability or equity, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting for Certain Financial Instruments with Characteristics of Both Liabilities and Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and then in accordance with ASC 815-40, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#8217;s Own Stock</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Under ASC 480-10, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate the issuer to settle the warrants or the underlying shares by paying cash or other assets, or must or may require settlement by issuing variable number of shares.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If warrants do not meet liability classification under ASC 480-10, the Company assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability classification under ASC 815-40, in order to conclude equity classification, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable U.S. GAAP. After all relevant assessments are made, the Company concludes whether the warrants are classified as liability or equity. Liability classified warrants are required to be accounted for at fair value both on the date of issuance and on subsequent accounting period ending dates, with all changes in fair value after the issuance date recorded in the statements of operations as a gain or loss. Equity classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued and Adopted Accounting Standards</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently Adopted Accounting Standard</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (&#8220;Topic 326&#8221;): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 and its subsequent related updates establish a new forward-looking &#8220;expected loss model&#8221; that requires entities to estimate current expected credit losses on accounts receivable and financial instruments by using all practical and relevant information. The Company adopted this standard effective January 1, 2023. There was no impact to the Company's financial statements upon adoption.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_AccruedResearchAndDevelopmentCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_AccruedResearchAndDevelopmentCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_EmergingGrowthCompanyStatusPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Emerging Growth Company Status Policy Text Block</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_EmergingGrowthCompanyStatusPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_PatentCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Patent Costs Policy Text Block</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_PatentCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_WarrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_WarrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922026882416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_PropertyAndEquipmentEstimatedUsefulLivesTableTextBlock', window );">Schedule of Estimated Useful Lives of Property and Equipment</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The estimated useful lives of the Company&#8217;s property and equipment are as follows: </span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:73.34%;"></td>
          <td style="width:1%;"></td>
          <td style="width:24.66%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Useful Life (In Years)</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory equipment and manufacturing equipment</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="-sec-ix-hidden:F_163a734f-613d-45f6-b523-f3a90ba56209;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lesser of asset life or lease term</span></span></span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_PropertyAndEquipmentEstimatedUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property And Equipment Estimated Useful Lives Table Text Block</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_PropertyAndEquipmentEstimatedUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922026179296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Short-Term Investments</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Short-term investments consisted of the following (dollar amounts in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.24%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.9%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.120000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.82%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="16" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Maturity</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1 year or less</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">80,160</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">59</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">80,218</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government agency debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1 year or less</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">73,774</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">73,783</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">153,934</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">154,001</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.269%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.902%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.282%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.282%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.122%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.822%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="16" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Maturity</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1 year or less</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">78,451</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">119</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">78,336</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1 year or less</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,698</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">83</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,615</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">95,149</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">202</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">94,951</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prepaid expenses and other current assets consisted of the following (dollar amounts in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">At December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">At December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest receivable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">385</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">115</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid insurance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,067</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,293</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid research studies</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,339</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,397</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">870</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">722</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,661</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,527</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment consisted of the following (dollar amounts in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">At December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">At December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory equipment and manufacturing equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">947</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">805</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">284</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">258</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">491</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">558</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,157</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,129</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,879</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,750</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less accumulated depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,413</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,732</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,466</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,018</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses consisted of the following (dollar amounts in thousands):</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">At December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">At December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Payroll and related liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,838</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,229</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other professional fees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,377</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,310</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Clinical expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,595</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,986</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,917</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,345</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">883</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">485</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,610</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,355</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922026916816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Summary of Financial Assets Measured at Fair Value</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables represent the Company&#8217;s financial assets measured at fair value on a recurring basis and indicate the level of fair value hierarchy utilized to determine such fair values (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements at Reporting Date<br/>Using</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted<br/>Prices in<br/>Active<br/>Markets for<br/>Identical<br/>Assets<br/>(Level 1)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds (included in cash and cash<br/>&#160;&#160;&#160;equivalents)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,830</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,830</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government agency debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">73,783</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">73,783</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">80,218</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">80,218</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">187,831</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">114,048</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">73,783</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements at Reporting Date<br/>Using</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted<br/>Prices in<br/>Active<br/>Markets for<br/>Identical<br/>Assets<br/>(Level 1)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds (included in cash and cash<br/>&#160;&#160;&#160;equivalents)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,587</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,587</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">78,336</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">78,336</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,615</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,615</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">121,538</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43,202</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">78,336</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922026807232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Lease Payments Under Non-Cancelable Leases</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future lease payments under non-cancelable leases as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 are as follows (dollar amounts in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.48%;"></td>
        <td style="width:2.68%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.84%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">Year Ending December 31,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,016</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">944</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,960</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922026826144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_SummarizesOfImpactTermLoanTableTextBlock', window );">Summarizes of Impact of Term Loan</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the impact of the term loan on the Company&#8217;s consolidated balance sheet at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023:</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.64%;"></td>
        <td style="width:5.36%;"></td>
        <td style="width:1%;"></td>
        <td style="width:38%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gross proceeds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unamortized debt issuance costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">231</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Carrying value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44,769</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Future Principal Payment of Loan Agreement</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future principal payments, which include the Final Fee, in connection with the Loan Agreement as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 are as follows (dollar amounts in thousands):</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.64%;"></td>
        <td style="width:5.36%;"></td>
        <td style="width:1%;"></td>
        <td style="width:38%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fiscal Year</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,508</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,305</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47,813</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:line-through;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;text-decoration:line-through;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_SummarizesOfImpactTermLoanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summarizes Of impact Term Loan Table Text Block</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_SummarizesOfImpactTermLoanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922020753776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity Under Equity Incentive Plans</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes stock option activity under the Company&#8217;s equity incentive plans since </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.11%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.662%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.942%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.662%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Options<br/>Outstanding</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value (1)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in years)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,687,811</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.53</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.06</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,019,590</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.53</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43,209</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.70</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">627,526</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.43</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,036,666</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.68</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.71</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,615</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,370,210</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.05</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.37</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,007</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested and expected to vest at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,036,666</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.68</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.71</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,615</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#8217;s common stock.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Assumptions Used to Value Stock Options Granted Using Black-Scholes Option-Pricing</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The underlying assumptions used to value stock options granted to participants using the Black-Scholes option-pricing were as follows: </span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:14.883%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:14.883%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate range</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.36</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% to </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.67</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.59</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% to </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.30</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term of options (years)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.5</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;to </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.48</span></span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.08</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;to </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.48</span></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Volatility rate range</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">87.26</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% to </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89.67</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84.50</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% to </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">87.15</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Activity Related to Restricted Stock Units ("RSUs")</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Activity related to restricted stock units ("RSUs") for the year ended December 31, 2023 is summarized in the table below:</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.22%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.3%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of January 1, 2023</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Canceled / Forfeited</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested / Settled</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922026184592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate to Effective Income Tax Rate</a></td>
<td class="text"><p style="text-indent:9.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</span></p><p style="text-indent:9.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.088%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.277%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.44%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.277%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.92%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="8" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal income tax at statutory rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Permanent differences</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.6</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State income tax, net of federal benefit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal and state research and development tax credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30.3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Effective income tax rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Significant Components of Deferred Tax Assets</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The significant components of the Company&#8217;s deferred tax assets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 are composed of the following (dollar amounts in thousands): </span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating losses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,999</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,144</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,903</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,220</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,930</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,604</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">916</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">758</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,759</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,899</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">499</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">688</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized research and experimental expenditures</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,959</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,467</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">351</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">297</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gross deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89,316</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,077</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88,906</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">62,468</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">410</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">609</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation of fixed assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">64</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">184</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right of use assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">308</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">422</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gross deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">410</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">609</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-current net deferred tax assets (liabilities)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922023170496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Net Loss Per Share, Basic and Diluted</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth the computation of basic and diluted net loss per share for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 (in thousands, except share and per share amounts):</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.92%;"></td>
        <td style="width:1.6%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.64%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.6%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.64%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.6%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="8" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss attributable to common stockholders&#8212;basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,169</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67,061</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share attributable to common stockholders&#8212;basic and diluted</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.37</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.78</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average common shares and pre-funded warrants outstanding&#8212;basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">51,839,131</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37,763,168</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potential Dilutive Securities from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company excluded the following potential dilutive securities, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated: </span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,036,666</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,687,811</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested RSUs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,136,666</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,687,811</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922015760336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 17, 2020</div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split of common stock</a></td>
<td class="nump">0.1338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds issuance of common stock, deducting underwriting discounts and commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,647<span></span>
</td>
<td class="nump">$ 56,137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,169<span></span>
</td>
<td class="nump">67,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,930<span></span>
</td>
<td class="nump">$ 214,761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash and cash equivalents and short term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 188,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922021597136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk', window );">Off-balance sheet concentrations of credit risk description</a></td>
<td class="text">The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_ConcentrationRiskCreditRiskOffBalanceSheetRisk', window );">Off-balance sheet concentrations of credit risk</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Realized gain and losses on investments as available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairments of long-lived assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_EmergingGrowthCompanyStatusIssuancePeriodOfNonConvertibleDebt', window );">Issuance period of non-convertible debt cease to be EGC</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityThresholdPeriodPastDueWriteoff', window );">Debt securities held-to-maturity</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Income tax penalties and interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseImpairmentLoss', window );">Finance lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts', window );">Deferred issuance costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_EmergingGrowthCompanyMarketValueOfCommonStockHeldByNonAffiliates', window );">Market value of common stock held by non-affiliates cease to be EGC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_EmergingGrowthCompanyAnnualGrossRevenues', window );">Annual gross revenues cease to be EGC</a></td>
<td class="nump">1,235,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_EmergingGrowthCompanyStatusIssuanceValueOfNonConvertibleDebt', window );">Issuance of non-convertible debt cease to be EGC</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityThresholdPeriodPastDueWriteoff', window );">Debt securities held-to-maturity</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_ConcentrationRiskCreditRiskOffBalanceSheetRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Concentration risk credit risk off balance sheet risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_ConcentrationRiskCreditRiskOffBalanceSheetRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_EmergingGrowthCompanyAnnualGrossRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Emerging Growth Company Annual Gross Revenues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_EmergingGrowthCompanyAnnualGrossRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_EmergingGrowthCompanyMarketValueOfCommonStockHeldByNonAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Emerging Growth Company Market Value Of Common Stock Held By Non-Affiliates</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_EmergingGrowthCompanyMarketValueOfCommonStockHeldByNonAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_EmergingGrowthCompanyStatusIssuancePeriodOfNonConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Emerging growth company status issuance period of non-convertible debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_EmergingGrowthCompanyStatusIssuancePeriodOfNonConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_EmergingGrowthCompanyStatusIssuanceValueOfNonConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Emerging Growth Company Status Issuance Value Of Non-Convertible Debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_EmergingGrowthCompanyStatusIssuanceValueOfNonConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of financial instruments, excluding certain derivatives, with off-balance sheet credit risk (for example, standby letters of credit or financial guarantees), including (1) information about the (shared) activity, region or economic characteristic that identifies the concentration, (2) the face or contract amount of the instrument, (3) the nature and terms of the instrument, including the market risk, cash requirements and accounting policies for it, (4) the maximum amount of loss due to credit risk that would be incurred if the counterparties failed completely to perform according to the terms of the contracts, and any security or collateral that proved to be of no value, (5) the entity's policy of requiring collateral or other security to support financial instruments subject to credit risk, information about access to collateral or other security, and a brief description of the security supporting those financial instruments, and (6) the policy of entering into and a brief description of master netting arrangements to mitigate the credit risk, and the extent to which such arrangements would reduce the maximum amount of loss due to credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesHeldToMaturityThresholdPeriodPastDueWriteoff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold period for when investment in debt security measured at amortized cost (held-to-maturity) is considered past due to write off as uncollectible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesHeldToMaturityThresholdPeriodPastDueWriteoff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479365/842-20-25-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922015620880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Property and Equipment (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory Equipment and Manufacturing Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (In Years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (In Years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=inzy_ComputerEquipmentAndSoftwareMember', window );">Computer Equipment and Software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (In Years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration', window );">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</a></td>
<td class="text">Property, Plant and Equipment, Net<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482190/360-10-35-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=inzy_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=inzy_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922020757904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Accounting Pronouncements - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements Or Change In Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,126<span></span>
</td>
<td class="nump">$ 1,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (285,930)<span></span>
</td>
<td class="num">$ (214,761)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, accounting standards update, immaterial effect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible Enumeration]</a></td>
<td class="text">us-gaap:AccountingStandardsUpdate201912Member<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">ASU 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements Or Change In Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147477123/405-50-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 69: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 70: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 71: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 72: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147477123/405-50-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-5<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-5<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -SubTopic 20<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147477123/405-50-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-5<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 69: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 70: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 71: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 72: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 73: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 74: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-6<br><br>Reference 75: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 76: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 77: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 78: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 79: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 80: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 81: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 82: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 83: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 84: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 85: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 86: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 87: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 88: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 89: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 90: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 91: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 92: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922021659232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Short-Term Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Costs</a></td>
<td class="nump">$ 153,934<span></span>
</td>
<td class="nump">$ 95,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(202)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 154,001<span></span>
</td>
<td class="nump">$ 94,951<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_InvestmentMaturityPeriod', window );">Maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year or less<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,451<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(119)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,336<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_InvestmentMaturityPeriod', window );">Maturity</a></td>
<td class="text">1 year or less<span></span>
</td>
<td class="text">1 year or less<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Costs</a></td>
<td class="nump">$ 80,160<span></span>
</td>
<td class="nump">$ 16,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(83)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 80,218<span></span>
</td>
<td class="nump">$ 16,615<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=inzy_USGovernmentAgencyDebtSecuritiesMember', window );">U.S. Government Agency Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_InvestmentMaturityPeriod', window );">Maturity</a></td>
<td class="text">1 year or less<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Costs</a></td>
<td class="nump">$ 73,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 73,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_InvestmentMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment maturity period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_InvestmentMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inzy_USGovernmentAgencyDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inzy_USGovernmentAgencyDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922015313504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation expense</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922023312368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Long-Term Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Costs</a></td>
<td class="nump">$ 153,934<span></span>
</td>
<td class="nump">$ 95,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(202)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 154,001<span></span>
</td>
<td class="nump">$ 94,951<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_InvestmentMaturityPeriod', window );">Maturity</a></td>
<td class="text">1 year or less<span></span>
</td>
<td class="text">1 year or less<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Costs</a></td>
<td class="nump">$ 80,160<span></span>
</td>
<td class="nump">$ 16,698<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(83)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 80,218<span></span>
</td>
<td class="nump">$ 16,615<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=inzy_USGovernmentAgencyDebtSecuritiesMember', window );">U.S. Government Agency Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_InvestmentMaturityPeriod', window );">Maturity</a></td>
<td class="text">1 year or less<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Costs</a></td>
<td class="nump">$ 73,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 73,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_InvestmentMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment maturity period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_InvestmentMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inzy_USGovernmentAgencyDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inzy_USGovernmentAgencyDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922021626832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest receivable</a></td>
<td class="nump">$ 385<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">1,067<span></span>
</td>
<td class="nump">1,293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_PrepaidResearchStudies', window );">Prepaid research studies</a></td>
<td class="nump">5,339<span></span>
</td>
<td class="nump">1,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid other</a></td>
<td class="nump">870<span></span>
</td>
<td class="nump">722<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total</a></td>
<td class="nump">$ 7,661<span></span>
</td>
<td class="nump">$ 3,527<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_PrepaidResearchStudies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid research studies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_PrepaidResearchStudies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922023412480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Noncurrent Prepaid Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Prepaid expenses - noncurrent</a></td>
<td class="nump">$ 1,694<span></span>
</td>
<td class="nump">$ 3,810<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922006495760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 3,879<span></span>
</td>
<td class="nump">$ 3,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(2,413)<span></span>
</td>
<td class="num">(1,732)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total</a></td>
<td class="nump">1,466<span></span>
</td>
<td class="nump">2,018<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory Equipment and Manufacturing Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">947<span></span>
</td>
<td class="nump">805<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">284<span></span>
</td>
<td class="nump">258<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=inzy_ComputerEquipmentAndSoftwareMember', window );">Computer Equipment and Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">491<span></span>
</td>
<td class="nump">558<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 2,157<span></span>
</td>
<td class="nump">$ 2,129<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=inzy_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=inzy_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922026088560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and related liabilities</a></td>
<td class="nump">$ 3,838<span></span>
</td>
<td class="nump">$ 3,229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Other professional fees</a></td>
<td class="nump">1,377<span></span>
</td>
<td class="nump">1,310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_ClinicalExpenses', window );">Clinical expenses</a></td>
<td class="nump">3,595<span></span>
</td>
<td class="nump">3,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_AccruedResearchAndDevelopmentCostsCurrent', window );">Research and development costs</a></td>
<td class="nump">2,917<span></span>
</td>
<td class="nump">2,345<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">883<span></span>
</td>
<td class="nump">485<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 12,610<span></span>
</td>
<td class="nump">$ 11,355<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_AccruedResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development costs current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_AccruedResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_ClinicalExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_ClinicalExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922006352736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Summary of Financial Assets Measured at Fair Value (Details) - Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value disclosure</a></td>
<td class="nump">$ 187,831<span></span>
</td>
<td class="nump">$ 121,538<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents fair value disclosure</a></td>
<td class="nump">33,830<span></span>
</td>
<td class="nump">26,587<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,336<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value disclosure</a></td>
<td class="nump">114,048<span></span>
</td>
<td class="nump">43,202<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents fair value disclosure</a></td>
<td class="nump">33,830<span></span>
</td>
<td class="nump">26,587<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value disclosure</a></td>
<td class="nump">73,783<span></span>
</td>
<td class="nump">78,336<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Other Observable Inputs (Level 2) | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents fair value disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Other Observable Inputs (Level 2) | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,336<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Unobservable Inputs (Level 3) | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents fair value disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Unobservable Inputs (Level 3) | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value disclosure</a></td>
<td class="nump">80,218<span></span>
</td>
<td class="nump">16,615<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Treasury Securities | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value disclosure</a></td>
<td class="nump">80,218<span></span>
</td>
<td class="nump">16,615<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Treasury Securities | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Treasury Securities | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Government Agency Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value disclosure</a></td>
<td class="nump">73,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Government Agency Debt Securities | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Government Agency Debt Securities | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value disclosure</a></td>
<td class="nump">73,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Government Agency Debt Securities | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value disclosure</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922023513104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3', window );">Fair value measurement with unobservable inputs reconciliation recurring basis asset transfers into level 3</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3', window );">Fair value measurement with unobservable inputs reconciliation recurring basis asset transfers out of level 3</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922016490560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Sponsored Research Agreements - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2019</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Feb. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_ResearchSupportFundingAmount', window );">Research support funding amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_ResearchSupportFundingExpirationMonthAndYear', window );">Research support funding expiration year</a></td>
<td class="text">2021-12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,847<span></span>
</td>
<td class="nump">$ 47,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inzy_YaleUniversityMember', window );">Yale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_PartialUpfrontConsiderationPaymentUnderLicenseAgreement', window );">Partial upfront consideration payment under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_LicenseAgreementPaymentUponAchievementOfSpecifiedProductSalesOrDevelopmentAndCommercializationMilestones', window );">Milestone payment upon achievement of certain milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inzy_YaleUniversityMember', window );">Yale | Sponsored Research Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_ResearchSupportFundingAmount', window );">Research support funding amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_ResearchSupportFundingPeriod', window );">Research support funding period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inzy_YaleUniversityMember', window );">Yale | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostMaintenance', window );">Maintenance fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_LicenseAgreementPaymentUponAchievementOfSpecifiedProductSalesOrDevelopmentAndCommercializationMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement payment upon achievement of specified product sales or development and commercialization milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_LicenseAgreementPaymentUponAchievementOfSpecifiedProductSalesOrDevelopmentAndCommercializationMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_PartialUpfrontConsiderationPaymentUnderLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Partial upfront consideration payment under license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_PartialUpfrontConsiderationPaymentUnderLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_ResearchSupportFundingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research support funding amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_ResearchSupportFundingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_ResearchSupportFundingExpirationMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research support funding expiration month and year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_ResearchSupportFundingExpirationMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_ResearchSupportFundingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research support funding period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_ResearchSupportFundingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostMaintenance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of maintenance incurred and directly related to good produced and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostMaintenance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inzy_YaleUniversityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inzy_YaleUniversityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922021617104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jan. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_OperatingLeaseWeightedAverageIncrementalBorrowingRate', window );">Weighted average incremental borrowing rate for operating leases</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term for operating leases</a></td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 1,126,000<span></span>
</td>
<td class="nump">$ 1,620,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">900,000<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Costs related to legal proceedings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=inzy_RestrictedCashMember', window );">Restricted Cash | Letters of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposits</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=inzy_OfficeSpaceMember', window );">Office Space | Boston, Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_AreaOfLeasedSpace', window );">Area of leased space | ft&#178;</a></td>
<td class="nump">8,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_LesseeOperatingLeaseExpirationYear', window );">Lessee operating lease expiration year</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lessee, Operating Lease, Existence of Option to Extend [true false]</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lessee operating lease option to extend description</a></td>
<td class="text">option to extend the term for five years.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=inzy_LaboratorySpaceMember', window );">Laboratory Space | Boston, Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_AreaOfLeasedSpace', window );">Area of leased space | ft&#178;</a></td>
<td class="nump">6,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_LesseeOperatingLeaseExpirationYear', window );">Lessee operating lease expiration year</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lessee, Operating Lease, Existence of Option to Extend [true false]</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lessee operating lease option to extend description</a></td>
<td class="text">option to extend the term for five years.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">ASU 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_AreaOfLeasedSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of leased space.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_AreaOfLeasedSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_LesseeOperatingLeaseExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_LesseeOperatingLeaseExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_OperatingLeaseWeightedAverageIncrementalBorrowingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease weighted average incremental borrowing rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_OperatingLeaseWeightedAverageIncrementalBorrowingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147477123/405-50-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-5<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-5<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=inzy_RestrictedCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=inzy_RestrictedCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=inzy_OfficeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=inzy_OfficeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=inzy_LaboratorySpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=inzy_LaboratorySpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922017433968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Future Lease Payments Under Non-Cancelable Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 1,016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_LesseeOperatingLeaseLiabilityPaymentDue', window );">Operating lease liability, Total</a></td>
<td class="nump">$ 1,960<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_LesseeOperatingLeaseLiabilityPaymentDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating Lease Liability Payment Due</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_LesseeOperatingLeaseLiabilityPaymentDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922017775968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt (Additional Information) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 25, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long term debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Additional facility fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPaymentTerms', window );">Payment description for debt</a></td>
<td class="text">the Company is obligated to make interest only payments for the first 36 months and then interest and equal principal payments through the maturity date. The term loan bears a variable interest rate equal to the greater of (i) 7.85%, and (ii) the sum of (A) the prime rate last quoted in The Wall Street Journal (or a comparable replacement rate if The Wall Street Journal ceases to quote such rate) and (B) 3.85%; provided that the interest rate cannot exceed 9.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate', window );">Annual rate of interest for the debt</a></td>
<td class="text">7.85<span></span>
</td>
<td class="text">9.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Additional Interest rate for debt instrument</a></td>
<td class="nump">3.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_PrepaymentOfLoans', window );">Prepayment of loans</a></td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=inzy_TermLoanMember', window );">Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance cost</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeeAmount', window );">Lenders facility fee</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_LendersReimbursedAmount', window );">Lenders reimbursed amount</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Prepayment fee percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=inzy_ShareBasedPaymentArrangementTrancheFourMember', window );">Tranche Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Prepayment fee percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=inzy_K2HvMember', window );">K2HV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long term debt, net</a></td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturityDate', window );">Loan maturity date</a></td>
<td class="text">Aug.  01,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument conversion price</a></td>
<td class="nump">$ 6.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_CustomaryAdjustmentsPercentageOnConversion', window );">Customary percentage</a></td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_PercentageOfBeneficialOwnershipLimitation', window );">Beneficial ownership limitation percentage</a></td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=inzy_K2HvMember', window );">K2HV | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt instrument, amount converted to common stock upon lender's choice</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_FutureOfferingsOfCommonStock', window );">Future offerings of common stock</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=inzy_K2HvMember', window );">K2HV | Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long term debt, net</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_AdditionalLoanAmount', window );">Additional loan amount</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Prepayment fee percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=inzy_K2HvMember', window );">K2HV | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long term debt, net</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=inzy_K2HvMember', window );">K2HV | Tranche Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long term debt, net</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Additional facility fee</a></td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_AdditionalLoanAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional loan amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_AdditionalLoanAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_CustomaryAdjustmentsPercentageOnConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Customary adjustments percentage on conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_CustomaryAdjustmentsPercentageOnConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_FutureOfferingsOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future offerings of common stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_FutureOfferingsOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_LendersReimbursedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lenders reimbursed amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_LendersReimbursedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_PercentageOfBeneficialOwnershipLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of beneficial ownership limitation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_PercentageOfBeneficialOwnershipLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_PrepaymentOfLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepayment of Loans</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_PrepaymentOfLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of any adjustments made to the stated rate to determine the effective rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maturity date of long-term debt, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=inzy_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=inzy_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=inzy_ShareBasedPaymentArrangementTrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=inzy_ShareBasedPaymentArrangementTrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=inzy_K2HvMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=inzy_K2HvMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922021678336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Debt - Summarizes of Impact of Term Loan (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross proceeds</a></td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt issuance costs</a></td>
<td class="num">(231)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Carrying value</a></td>
<td class="nump">$ 44,769<span></span>
</td>
<td class="nump">$ 4,139<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922023180864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Debt - Future Principal Payment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 44,769<span></span>
</td>
<td class="nump">$ 4,139<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=inzy_K2LoanAgreementMember', window );">K2 Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2025</a></td>
<td class="nump">14,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2026</a></td>
<td class="nump">33,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturingInYearsTwoAndThree', window );">Total</a></td>
<td class="nump">$ 47,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturingInYearsTwoAndThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second and third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturingInYearsTwoAndThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=inzy_K2LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=inzy_K2LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922012827472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 27, 2023</div></th>
<th class="th"><div>Apr. 14, 2022</div></th>
<th class="th"><div>May 17, 2021</div></th>
<th class="th"><div>Jul. 23, 2020</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 01, 2024</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jun. 10, 2022</div></th>
<th class="th"><div>Aug. 11, 2021</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Jul. 17, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_AdditionalSharesIssued', window );">Additional shares issued</a></td>
<td class="nump">1,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Pre-funded warrant exercisable price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,768,771<span></span>
</td>
<td class="nump">40,394,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Plan description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On July 17, 2020, the Company&#8217;s stockholders approved the 2020 Stock Incentive Plan (the &#8220;2020 Plan&#8221;), which became effective on July 23, 2020. The 2020 Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock units, and other stock-based awards. The number of shares of the Company&#8217;s common stock reserved for issuance under the 2020 Plan<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,019,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost related to outstanding employee awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Total unrecognized compensation cost related to outstanding employee awards, expected to be recognized over a weighted-average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share based compensation options to purchase number of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,036,666<span></span>
</td>
<td class="nump">4,687,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.6<span></span>
</td>
<td class="nump">$ 9.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.0<span></span>
</td>
<td class="nump">$ 7.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=inzy_TwoThousandTwentyStockIncentivePlanMember', window );">2020 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,588,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,615,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Number of common stock reserved for issuance increase percentage on stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=inzy_TwoThousandTwentyStockIncentivePlanMember', window );">2020 Stock Incentive Plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,470,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=inzy_TwoThousandSeventeenStockIncentivePlanMember', window );">2017 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">426,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=inzy_TwoThousandSeventeenEquityIncentivePlanMember', window );">2017 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,730,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of awards available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=inzy_TwoThousandTwentyEmployeeStockPurchasePlanMember', window );">2020 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">397,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Number of common stock reserved for issuance increase percentage on stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Plan description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The number of shares of common stock reserved for issuance under the ESPP will increase each January 1 through January 1, 2031, in an amount equal to the lowest of (1) 397,079 shares of the Company&#8217;s common stock, (2) 1% of the number of shares of the Company&#8217;s common stock outstanding on the first day of such fiscal year, and (3) an amount determined by the Company&#8217;s board of directors.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share based compensation options to purchase number of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">198,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in additional number of shares to be issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">397,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=inzy_TwoThousandTwentyEmployeeStockPurchasePlanMember', window );">2020 Employee Stock Purchase Plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">397,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=inzy_InducementPlanMember', window );">Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.47<span></span>
</td>
<td class="nump">$ 3.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost related to outstanding employee awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition2', window );">Employee Service ShareBased Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period ForRecognition 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share based compensation options to purchase number of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=inzy_PreFundedWarrantsMember', window );">Pre-funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Pre-funded warrant exercisable price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,325,762<span></span>
</td>
<td class="nump">$ 197,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,325,644<span></span>
</td>
<td class="nump">197,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=inzy_BofaSecuritiesIncMember', window );">Bofa Securities Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price</a></td>
<td class="nump">$ 4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Net proceeds from the offering</a></td>
<td class="nump">$ 64.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=inzy_BofaSecuritiesIncMember', window );">Bofa Securities Inc | Underwriting Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Initial public offering, net of issuance costs, shares</a></td>
<td class="nump">14,375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=inzy_JefferiesLlcMember', window );">Jefferies LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_UnderwrittenOffering', window );">Underwritten offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,276,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Net proceeds from the offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of Stock, Number of Shares Issued in Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,553,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=inzy_JefferiesLlcMember', window );">Jefferies LLC | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_AvailableForDebtSecuritiesEquitySecuritiesNonCurrent', window );">Offer and sell</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscriptions', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=inzy_JefferiesLlcMember', window );">Jefferies LLC | Pre-funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrant purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,523,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.6899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_AdditionalSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_AdditionalSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_AvailableForDebtSecuritiesEquitySecuritiesNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available For Debt Securities Equity Securities Non current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_AvailableForDebtSecuritiesEquitySecuritiesNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition 2</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_UnderwrittenOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Underwritten offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_UnderwrittenOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscriptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481142/505-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscriptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=inzy_TwoThousandTwentyStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=inzy_TwoThousandTwentyStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=inzy_TwoThousandSeventeenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=inzy_TwoThousandSeventeenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=inzy_TwoThousandSeventeenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=inzy_TwoThousandSeventeenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=inzy_TwoThousandTwentyEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=inzy_TwoThousandTwentyEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=inzy_InducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=inzy_InducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=inzy_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=inzy_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=inzy_BofaSecuritiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=inzy_BofaSecuritiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=inzy_UnderwritingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=inzy_UnderwritingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=inzy_JefferiesLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=inzy_JefferiesLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922020280176">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Stock Option Activity Under Equity Incentive Plans (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 17, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Beginning Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,687,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Outstanding, Granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">3,019,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options Outstanding, Exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,209)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options Outstanding, Forfeited</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(627,526)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Ending Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,036,666<span></span>
</td>
<td class="nump">4,687,811<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Outstanding, Exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,370,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options Outstanding, Vested and expected to vest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,036,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding, Beginning Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 15.9<span></span>
</td>
<td class="nump">4.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding, Ending Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.68<span></span>
</td>
<td class="nump">$ 8.53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Vested and expected to vest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years), Outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 8 months 15 days<span></span>
</td>
<td class="text">8 years 21 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (in years), Exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 4 months 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (in years), Vested and expected to vest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 8 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,615<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#8217;s common stock.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922020606400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Assumptions Used to Value Stock Options Granted to Employees using Black-Scholes Option-Pricing (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate range, minimum</a></td>
<td class="nump">3.36%<span></span>
</td>
<td class="nump">1.59%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate range, maximum</a></td>
<td class="nump">4.67%<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility rate range, minimum</a></td>
<td class="nump">87.26%<span></span>
</td>
<td class="nump">84.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility rate range, maximum</a></td>
<td class="nump">89.67%<span></span>
</td>
<td class="nump">87.15%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of options (years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 29 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of options (years)</a></td>
<td class="text">6 years 5 months 23 days<span></span>
</td>
<td class="text">6 years 5 months 23 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922116789120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Activity related to restricted stock units ("RSUs") (Details) - shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 17, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,687,811<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">3,019,590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled / Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">627,526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,036,666<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled / Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested / Settled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922020747040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Total Compensation Cost Recognized in Statements of Operations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 7.0<span></span>
</td>
<td class="nump">$ 7.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922006359680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 27, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 71,169<span></span>
</td>
<td class="nump">$ 67,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets, valuation allowance</a></td>
<td class="nump">88,906<span></span>
</td>
<td class="nump">$ 62,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Deferred tax assets, increase in valuation allowance</a></td>
<td class="nump">26,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_TaxCutsAndJobsActFederalNetOperatingLossPercent', window );">Tax cuts and jobs act federal net operating loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Gross operating loss carryforwards</a></td>
<td class="nump">164,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_OperatingLossCarryforwardsWithExpirationPeriod', window );">Operating loss carryforwards with expiration period</a></td>
<td class="nump">5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_OperatingLossCarryforwardsWithNoExpirationPeriod', window );">Operating loss carryforwards with no expiration period</a></td>
<td class="nump">$ 158,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_TaxCreditCarryForwardExpirationYear', window );">Credit carryforward, expiration year</a></td>
<td class="text">2038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Gross operating loss carryforwards</a></td>
<td class="nump">$ 135,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_TaxCreditCarryForwardExpirationYear', window );">Credit carryforward, expiration year</a></td>
<td class="text">2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=inzy_FederalAndStateTaxAuthorityMember', window );">Federal and State | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Credit carryforwards</a></td>
<td class="nump">$ 17,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating  loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_OperatingLossCarryforwardsWithExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards with expiration period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_OperatingLossCarryforwardsWithExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_OperatingLossCarryforwardsWithNoExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards with no expiration period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_OperatingLossCarryforwardsWithNoExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_TaxCreditCarryForwardExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credit carry forward expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_TaxCreditCarryForwardExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_TaxCutsAndJobsActFederalNetOperatingLossPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax cuts and jobs act federal net operating loss percent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_TaxCutsAndJobsActFederalNetOperatingLossPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=inzy_FederalAndStateTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=inzy_FederalAndStateTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922020572064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate to Effective Inc (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal income tax at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_Effectiveincometaxratereconciliationpermanentdifferences', window );">Permanent differences</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(1.60%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income tax, net of federal benefit</a></td>
<td class="nump">8.10%<span></span>
</td>
<td class="nump">5.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Federal and state research and development tax credits</a></td>
<td class="nump">9.10%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(37.20%)<span></span>
</td>
<td class="num">(30.30%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_Effectiveincometaxratereconciliationpermanentdifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation permanent differences</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_Effectiveincometaxratereconciliationpermanentdifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922023356176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Significant Components of Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 42,999<span></span>
</td>
<td class="nump">$ 36,144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">16,903<span></span>
</td>
<td class="nump">9,220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock options</a></td>
<td class="nump">1,930<span></span>
</td>
<td class="nump">1,604<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">916<span></span>
</td>
<td class="nump">758<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization', window );">Amortization</a></td>
<td class="nump">3,759<span></span>
</td>
<td class="nump">3,899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseIncentiveReceivable', window );">Lease liability</a></td>
<td class="nump">499<span></span>
</td>
<td class="nump">688<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research and experimental expenditures</a></td>
<td class="nump">21,959<span></span>
</td>
<td class="nump">10,467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">351<span></span>
</td>
<td class="nump">297<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">89,316<span></span>
</td>
<td class="nump">63,077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Valuation allowance</a></td>
<td class="num">(88,906)<span></span>
</td>
<td class="num">(62,468)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">410<span></span>
</td>
<td class="nump">609<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation of fixed assets</a></td>
<td class="num">(64)<span></span>
</td>
<td class="num">(184)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_DeferredTaxLiabilitiesRightOfUseAssets', window );">Right of use assets</a></td>
<td class="num">(308)<span></span>
</td>
<td class="num">(422)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inzy_Others', window );">Others</a></td>
<td class="num">(38)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Gross deferred tax liabilities</a></td>
<td class="num">(410)<span></span>
</td>
<td class="num">(609)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Non-current net deferred tax assets (liabilities)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets tax deferred expense reserves and accruals amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_DeferredTaxLiabilitiesRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Right of Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_DeferredTaxLiabilitiesRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inzy_Others">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Others</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inzy_Others</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inzy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseIncentiveReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents a receivable for an incentive or inducement contractually stipulated between parties to a lease whereby the lessor has committed to provide the entity (lessee) with a cash payment as inducement to enter the lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481178/840-20-25-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481178/840-20-25-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseIncentiveReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922017789712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Schedule of Net Loss Per Share, Basic and Diluted (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (71,169)<span></span>
</td>
<td class="num">$ (67,061)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders- basic</a></td>
<td class="num">$ (1.37)<span></span>
</td>
<td class="num">$ (1.78)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders- diluted</a></td>
<td class="num">$ (1.37)<span></span>
</td>
<td class="num">$ (1.78)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares and pre-funded warrants outstanding - basic</a></td>
<td class="nump">51,839,131<span></span>
</td>
<td class="nump">37,763,168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares and pre-funded warrants outstanding - diluted</a></td>
<td class="nump">51,839,131<span></span>
</td>
<td class="nump">37,763,168<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922023532784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Schedule of Potential Dilutive Securities from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from computation of earnings per share</a></td>
<td class="nump">7,136,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,687,811<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from computation of earnings per share</a></td>
<td class="nump">7,036,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,687,811<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=inzy_UnvestedRestrictedStockUnitsMember', window );">Unvested RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from computation of earnings per share</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=inzy_UnvestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=inzy_UnvestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922023325536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer matching contribution, percentage of match</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employer contribution amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Employer matching contribution, percentage of employees base salary and bonus paid</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139922016360864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Additional Information) (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 17, 2021</div></th>
<th class="th"><div>May 06, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ManagementFeeExpense', window );">Management Fee Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Outstanding, Granted</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,019,590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">$ 15.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerDurationAxis=inzy_ThirtyDaysPriorWrittenNoticeMember', window );">30 Days prior written notice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1', window );">Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Investment Redemption, Notice Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerDurationAxis=inzy_SixtyDaysPriorWrittenNoticeMember', window );">60 Days prior written notice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1', window );">Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Investment Redemption, Notice Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notice period the entity is required to deliver before it can redeem an investment calculated using net asset value per share, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, investments calculated by per unit, per membership interest, other equity or ownership interest and alternative investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ManagementFeeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for investment management fee, including, but not limited to, expense in connection with research, selection, supervision, and custody of investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ManagementFeeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerDurationAxis=inzy_ThirtyDaysPriorWrittenNoticeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerDurationAxis=inzy_ThirtyDaysPriorWrittenNoticeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerDurationAxis=inzy_SixtyDaysPriorWrittenNoticeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerDurationAxis=inzy_SixtyDaysPriorWrittenNoticeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>101
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MX!%H?>_844?^3\PV).,H@;64&@-7/@6L.D:KCJ!Y>1(]42'/M;(9RR\/8"I
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ML2>Z2=4=?_G&*D(C'2_DJ2S^T4ME:P]0N)&*9Y4S(,B2O+S2UZHC=ARPU^%
M*@=RZ.!V.#B50]%S5HFLH'5!%9U.!']!0EM#-'U3]$WA#6R27 _C4@GXFH"?
MFLX6-\O%U>7%V?W\ BWOX7(]O[E?HL57M+B=WYW=7X(!.KNY0+/%]>W=_-O\
M9GGY?8ZN%LLE&J*'Y07Z_.D(?4))CNYCOI$TC^3$4@!--V"%%8SS$@;I@($)
MNN:YBB6:YQ&+]@-8P*DF1MZ(G9/>B!<L/$8._H*(31P#H-G[W4D/'*?N9Z>(
MYW3$6ZR9H"K)5XB]0@I*)D],O50&<<U!=$J?R#4-V>D <E8RL66#Z>^_8<_^
MP\3P@X+M\75KOFY?].D=1*0BC!',!TBK+=2+-62_,I$N(XV*2+KL;*<C-W#]
MB;7=9=.V<OW '==6>S!'-<Q1+\P_60[CDA8H:03YE4BEQVG+3$#+6-X.!&+[
MX^  J,DJ()X9J%<#]7J!WG,%,'EK%IE@>BT _LAS1P<PVU9>X/DC,TR_ANGW
MPKSB4J(GP;,WJ#PW0O1;C0]-& UF/2"#&F30GXLJ9@(*5L@SACY7/7EDS,?@
M(_/Q@X+M<1[7G,>] W.9*P91547;Q'7<GC:!<YB%;2."QQWC@>U&A.SWH:L&
MPR@@=GLR./ [ &@R(Q[I0+@CD[@783EG*GA?4,Z,E:P*LM_X87TP&3FXHY!A
MTB D[T!8#F\W0-)JVW5][Q!AVPI[V.U V$@@[E6<Z0VL2E,H$$9@CJ$B8.R-
M#Z$9[#S?]G 'N$:OL/N.H@"=!\D7ZV7JEM4E0H,VUP?<JX*_6B ^*MI^%S1:
MB/O%\"&'C4":_,.BDC*31TBOM+<T2>ECRH:P:QA*FC(D6;@1B4K,^H,-"NBY
MAP/9-AKB'2W=Y]#().[725C;P\H]AZ6S$"P/?R*0\URFM-PS1'_!BKIK&8+;
MBCC$K>0U&)&N^M>H)NZ7S4K=_VL*&E&W-9*XK80V""DA3@?L1D=QKV1-9WM0
M.U,[,*2V/2:MRFVP\WP2=-6=1OIPO_;ING-9]>-59S^.6^M+<P$RV/44(-)H
M(.G7P+?JB&#AA&1,!4-4*9$\;I1./J2XGAH93&/8%(;/,4\C,!SJ36P2FAA5
M[05[\_FXI>AF,[\C$TFCF*1?,?\7'SE$49)NU.$6L&*$W\?(:-;)J%%8TJ^P
M/XHS 18-Z1;6MBM6X]?D).(;)15L)/3RO&]8VN(ZPH$SQ@X^Y-&V='S?<[#7
M1:618M(OQ;]$I6]$VG+<1:9MV4'&VCG-R)A8%8<\$A!N<E7N_^NW]4'267%\
M<O#^')_,RN.@)DQY.G5-Q2K))4K9$X2TCWU(9U$>^)0/BJ^+,Y-'KA3/BMN8
M49B@V@"^/W&NWAYT _6QV_1?4$L#!!0    ( %E$;%BE@@$[)P@  (T^   8
M    >&PO=V]R:W-H965T<R]S:&5E=#4N>&ULM5MK<]NX%?TK&'6G36:BB #X
MD%+;,XE$S'J:C=W(::<?&0JRV/"A)2D[Z:\O2,FB\!!$[M[D0RQ*N.<"]Q"/
M>RYY]5R4WZH-YS7ZGJ5Y=3W:U/7VW612Q1N>1=7;8LMS\<NZ*+.H%I?EXZ3:
MECQ:M499.B&.XT^R*,E'-U?M=_?ES56QJ],DY_<EJG99%I4_/O"T>+X>X='+
M%Y^3QTW=?#&YN=I&CWS)ZR_;^U)<38XHJR3C>944.2KY^GKT'K]CU&\,VA;_
M2OAS=?(9-4/Y6A3?FHO;U?7(:7K$4Q[7#40D_CSQ.4_3!DGTX_<#Z.CHLS$\
M_?R"SMK!B\%\C2H^+])_)ZMZ<SV:CM"*KZ-=6G\NGG_EAP%Y#5Y<I%7[/WH^
MM'5&*-Y5=9$=C$4/LB3?_XV^'P)Q8H#I&0-R,"!]#>C!@"H&)#ACX!X,7,7
M]<\8> <#3_5P;M#^P: E<[(/5AOI151'-U=E\8S*IK5 :SZT=+76(L!)WMQ9
MR[H4OR;"KKZ9WWU:WGV\7;Q_"!=H^2#^_!9^>EBB.R:N[N;_^/7NXR+\O/P;
M"O_YY?;A/^C5(F2W\]N'UVB,OBP7Z-4OK]$O*,G1PZ;855&^JJXFM>A7@SZ)
M#WWXL.\#.=.'AZ*.4H/9W&XV+[),W)O+NHB_&:P7=NOWJU72W-M1BNZC9#46
M0YA'V\3<D_ "5ASOLET:U7R%[NH-+Y'HFYCHFV8&/G%TF\=%QM&KCT55O3;
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M7R]H+Q1O[!/Z6ZX4K^S'+26Z_3(&^O<-Y^KYPMQ@_Y+'\G]02P,$%     @
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M99#]F^]JLT$O..JM@U'@/:03%/HW*/""<(07#N6&EA=>X)TK\P;M7]&&9>1
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M=',O<VAE970Y+GAM;*U8:V_;.!;]*X1G,&@!QX[=1[)M$L!)VVDP;3=HMK/
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MZ4SW>A],-7:]E1X,S;D"I8[:0IOW8IEQKA"W9*1!Y!_F2\H'F7>,QO4W]"0
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M,1?:M)S]G+ Z,$0N81R'Z>/!O:ZSUU=<QFWEOA^F5 Z;?I<=_1?*T->&71=
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M#_S#V;LN^[O 3I9M^PD?WE0_GIR#(%O;LL<,AOZ[M=>VKC$1D?&;SGD2E\3
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M^IO#TTY30,(0UT3>Q62"VHWC]<,1(!+3HR[_<X6#S\^=%9* %C.4)(G2++R
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MSX=/"R%QE F7O@A2EKS:<BA&S_!IS(8GD0T?A/;69W7TWI:;QOTVA-2/@L)
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M'@_0[ZN6?)-^P +Q)=+/_Q=02P,$%     @ 641L6.=OM;[K P  Z @  !D
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M=CP0G0J(M@"*@349^@H6[ZWR_T\A)$JFI;9_!_M/&82#K5U/-L0$P>PM:+$
M@]PM:$R5C/"<CA*5*K@',Z$/$[TP>BUS),UR9&2*K5(F?\SI>;+BMLKA"&%
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MEX=ZCYK!RV;2"?,<?O&AV^0#Y=YOK.>!&#!+?_2*2_$I6/U)H N,6"X8H&?
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M?M'X=MFL$B>9RLNDR(56J]>GU^&+MQ,:SP-^3=2N['P6Q,FR*+[3EX_QZ].
M"%*IBBI:0>*_6_5.I2DM!#)^MVN>-EO2Q.YGM_H'YAV\+&6IWA7I;TE<;5Z?
M+DY%K%:R3JNOQ>X_E.5G2NM%15KR7[$S8\?S4Q'5955D=C(HR)+<_"_OK!PZ
M$Q;!@0DC.V'$=)N-F,J?927?O-+%3F@:C=7H [/*LT%<DI-2;BJ-MPGF56]N
MJB+ZOBG26.GR)_'^]SJI[E]=5EB9WE]&=I6W9I71@57"D?A;D5>;4KS/8Q7W
M%[@$20U=(T?7V]'1%7]6D2_&H2=&P6A\9+UQP^>8UQL_@T_QJ:B4^*_K95EI
M6,=_#_%M5IT,KTH>\Z+<RDB]/H5+E$K?JM,W/_XIG 4OC] \:6B>'%O]R;HY
MNLHPC5>^Z*[^XY\6HW#^TLGEESJ]9\&+;U"GWNFDJE0N/J]62B?Y6GS.[9"Y
MT8\GJHT2[XIL*_-[H?)*:16+)*\*(7-1NS5HJEQKI>#4%>R\VHBWQ>I:W*BH
MIM>J],3'//(]++7#?C*/W:*>^.M?W_&#+\E6:7&#CRG^_U%FVY<8A#FR1)!@
M#O-*DJN7HE@Q8:6Z55JF+2'@6.0R XUXK562BS/X$0>*6Y7>&W9()J/@Y;?.
M)'X4OCSWL%,JF9\]%DE,VWJ9)A$VM]("%>'$&\^G7A $HMQ(W9)FV?NI%%&1
M98A2)6G%$[M-$FT@P2BMX4\B]!;]Z4E9UGA>;S&%UE%W2D=)J3!%K.HT%<M[
M?MYCV>R9:%%L.2*"]FVMHPV"FI!QG-!#B,EN<4;S3UM3N.''I^>^^#M>1&E1
M6N9H7,-LA?@KMBG,36"'ZWJ-$":L&_OB&I39&?L+BQTT(4K8HZ/=RL;LUVRP
MU0FM?6@16,&?Q<1?!(+,A%GQQ2<DMZTN(J7B4JQTD1FSD*EBDR)AROS8JD2:
MW&*)NP2) ":"3683?X*(G*:0&JQO!1$C'<1UQ';1,_HX*:.BSJN2MR--8TM,
M,]\;UM0=4FVI2L@)7*9$PNBP!SK9&N&&?1]<)2G,0X(,6+0N6:LJ7<%NUPE%
M.]9_"3\QOH@OE./$S<78V1Y),E91*LF5%?9EY^@HE=S>;&PLY6MWZ1NW--D+
ML\#D#8_IDY[)>R,2%@[R-QQW2[;Z9VP7^(&3.6E+BENI$U71# QMPXCQ'))4
MWZ\0'[ RL60?Q&H+0ZZ 1ZS=TZ-EU5ML)[66T)X'Z+(L(YT8]]&4\.%5FJ1<
M.<,"8B%B^7]X%UE610^*7-'0K-"M,4/_E3%H8PDPH:RDP4L%*N@;8GE,@TA
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M!N#]JB@J]X4V:'XY^.9_ 5!+ P04    " !91&Q8!.-J2 H,  !:(0  &0
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MMA8NJ66JQI&]MG>J%XWWW6L%,-!;?4IZ*!?"J^_Z;OV/ S?A??E^>?BO@U^
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M+-DI4%< )@2@X"M>"(3;^"8&' ):Z.@R&+@92G":9J_N7H.NP5'LC\JA44S
M-:Y1=5Y,A;_56B@I4(66KQ1S&%RX6I/2<(8]A)L=E)6E[A2=*5=.@R6D(;3L
M7$>OFG180M<UABX GYCJJ =!?[WHZ?8V@Y."<%'"9E#EEPUE#JT6O-P.*6T:
M7C8/O((=J3Y.X8571^)W^_#RV6F>O3FW#S;4 NGT@"$!OZ]'T+5^V4>]Y[*3
M'G32\[SI7T#?D.ADA,^%J0H*K3HZ(L8KJ#KC57NW+3(3 W4Q0$:J!YA?M8"^
M7(&*#65!>>T*+M!HD!_]D60UJC#_3,='>@YI/*'.)009Q8]51K+7O22:5>C1
M?J_H./M&-JZ.OX&+OOO]-N__(9^967&2(K FUS1^<QR!Z?MR/W&Z#;VPT(XZ
M:Q@V]"M#XPWH>ZVUVTU\@/'GN/@%4$L#!!0    ( %E$;%BEV(A_5@0   (*
M   9    >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;)5676_C-A#\*PO=X7H'
M&+8LYZN);2!Q&C3%!3'B:_M0](&6UA8;B51)*H[_?8>4K#AMXN)>;$K:G9V=
MY2XYWFCS:'-F1\]EH>PDRIVKS@<#F^9<"MO7%2M\66E3"H='LQ[8RK#(@E-9
M#)(X/AF40JIH.@[OYF8ZUK4KI.*Y(5N7I3#;*R[T9A(-H]V+![G.G7\QF(XK
ML>8%NU^KN<'3H$/)9,G*2JW(\&H270[/KXZ\?3#X3?+&[JW)9[+4^M$_W&:3
M*/:$N.#4>02!OR>><5%X(-#XN\6,NI#><7^]0[\)N2.7I; \T\7O,G/Y)#J+
M*..5J OWH#<_<YO/L<=+=6'#+VT:VQ&,T]HZ7;;.8%!*U?R+YU:'/8>S^!V'
MI'5( N\F4&!Y+9R8CHW>D/'60/.+D&KP!CFI?%$6SN"KA)^;/G A'&<T%\9M
MZ9L1RHJ@EQT/'/"]U2!ML:X:K.0=K&%"=UJYW-)/*N/L-<  Q#IVR8[=57(0
M\9K3/HV&/4KB9'0 ;]1E.PIXH^_.EOZX7%IG\/3G6XDWL$=OP_K&.;>52'D2
MH3,LFR>.II\^#$_BBP.DCSK21X?0O[-$A[&&HSX=$.%>T9W8TDD0'+*[G&FF
MRTJH+;%R;. FE=,DT$]H3509RPS=:5W 3(&"?I!J36)MF&'CZ+.'^?3A+$GB
MB]F+P>7.('P:7GS!UG<Y70N%68/%9?8DK3:V1U^_SNAS"[#[O'/J454;6PO$
M :]-+M,7B![(DL@R&08 /E=&/\G,!U]))53*/8R%5->J88Q,1(8FDWXG^&E!
MJUHUTO1:WT8 -K*D-)>\:H&D*$BO5C)E##S4'POK ^X+N-S2PG&5LZ)?^G0M
MYZ(H10^"*['VX:^EP:C2!D!=!GWZMH=0"9F]Z.-KX"7,J*Z07JYK4VP)Q$%;
M^[D+)3HN395DN818O ?B+?D9(]ZRW07[;X50U[K(:,F$U"%0J#7RV4\/0!UJ
M*&0J:@N! [E13)G86H@H8;<QTCG(H+23H08@YUUP:+SR.CG@U:<[TZE(*0N?
M5DC75]+N4_O!_F_-M-_X!H(ES;!)_,[!9E;MX1$2\I"BJC3 @BBHTT*HO] P
MBSXMZJ41I5#2E^7?X6<A[$T7]KX-^SF:W=Q'7UY76:JT-K[3/E+</\+0+PI/
M =':0C7EW56VVY>H1U> K#9>!\_"X0Q]I=7F775 QN?M\^_3[4OK]!I]MC0\
M?6LRK#%"_(;8#P(5=-6U70UI42 :'O?B.":;"TP,G]$>C&_HX>F%A>QE"3\<
M?>GCJ]EQ'P"[:5%C_)@W$4 Q1J]Y_ULTN0JM/"]\99QGQL]L4@D^V%@I>QX?
M0:W_8TQ-)5I^(4"QW0G9A*<GS+HP!3 <BJ+3ZZU!/]@[ETLVZW#[\ EBX#1'
M=/>VN^!<-N?ZBWES.\+NQ)"P5/ *KG'_]#@BT]PXF@>GJW#*+[7#G2$L<US2
MV'@#?%]I[78//D!W[9O^ U!+ P04    " !91&Q8!B#YV6X@   %;0  &0
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MJ* 2>=/"0D $ )?5L!EMB1NT7M,Z0%4,N9JUL[LH$/,.^!F7$V1;BUP#+LU
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MC*Q1VU%%FZ9$<$!9+^Y)M=6]]A43$!+Z$V%A"=W0O-OR1]J?!A/, G+P:,@
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M3K#!97L-:C^TV-JKQTIHO,C8X09OCB"- :Z70NC]APG0WT47_P!02P,$%
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M%>3FV24947UR!TFNE1N?"0F2R6WHG>B-S_8T\,?Q)<%))S@9%+S LF@.L6G
MIYIL]26\/]FRX$(A!:+4K^(6I"K-5)\C@ZM<ZTAR)M5/DL@[=>25UFQ\<P^*
MCQ+$QA9Q$MG/O'FKN]&N3KRWY=')^$+7CTVY]Y6F*3X_8+$A3"(*:TWIC6*M
M4#0%7=-1O+(ESC-7NF"RS4+7P"!,@)Y?<Z[V';- 5U6G_P%02P,$%     @
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MMH[U')240K*\!JL*<D*K?_Q<"[$'&(5' $$-" X _N@(8%@#AF\%C&K Z*V
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M<!V@[J\8D[L3G:#9<IS_!U!+ P04    " !91&Q8+HFAA-$$  !P&0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6R]66UOVS80_BN$5@PML$0B9<MR
M9AM(G#8+T&!!G70?AGU@I+,M5!(]DK:;_?I1LB)9;XR5:?V2B-+=P^<YDG<'
M>K)G_)M8 TCT/0IC,3764FXN3%-X:XBH.&<;B-67)>,1E6K(5Z;8<*!^ZA2%
M)K$LQXQH$!NS2?KNGL\F;"O#((9[CL0VBBA_OH*0[:<&-EY>? E6:YF\,&>3
M#5W! N3CYIZKD9FC^$$$L0A8C#@LI\8EOI@3-W%(+;X&L!='SRB1\L38MV1P
MZT\-*V$$(7@R@:#JWP[F$(8)DN+Q=P9JY',FCL?/+^B?4O%*S!,5,&?A'X$O
MUU/#-9 /2[H-Y1>V_PTR0<,$SV.A2/^B?69K&<C;"LFBS%DQB(+X\)]^SP)Q
MY("=%@>2.9"JP[#%P<X<[%3H@5DJZYI*.IMPMD<\L59HR4,:F]1;J0GB9!D7
MDJNO@?*3LRL:TM@#M$CWS#5(&H0"G:&%VB_^-@3$ENH;X_+L 7B$;N,="*F6
M40KT/K/^H,P?%]?H_;L/Z!T*8O2P9EM!8U],3*DH)A.97D;GZD"'M-#!!-VQ
M6*X%^AC[X)<!3*4M%TA>!%X1+>(U>.?(QK\@8A&[@=#\='>BH6/G\;93/+L%
M+X_K[TMTN5/AHT]JH'8D6E#UL !ORP,9@$!_?E:NZ%9")/YJ"N1AGD'S/,GI
MOQ ;ZL'44,=; -^!,?OY)^Q8OS8%H2>P4D@&>4@&.O399:2V5_ /^&C.A&S<
M- > 80J0)*;=# _ML3V8F+MC%76S\1 /QKE5B=XPIS?4TKOA3 CT&*LD&:8L
M;U1R;&1YP'&.IA\Y%89UDT$S.R=GYW1C]UF-H9&>4YO[;%RAUV"B]GTSPU'.
M<*1E^%'(0*5;1>T3#3CZ2L,M--$;-:SQP+)PA6+=;#Q0J]S,T<TYNEJ.<Q9%
MP+V ANB>;H W\=,B=#UO/8&5Q(YSL>,?E(+&?8:D)[!22+!5E$%+NP/NJ$Q4
M/S>6+*UK5YVO$,'H&2A':C5"$$*G[:C$X_^:8/4(G27BVB$=N8.V0XI)(83T
ME(KU0)WUD%/3-B[Z *RMJ5T2MQZILQB[GN0Q;BF2N"CB6%_%3TWS>IC.8NHE
M?^3:MM.BIJCY6%_T'\\7Y^A!K8W8\N>CE-BH2 O565%/:&7A13N!G1]4'+"V
M<>D<EI[0RF$I>ABL;V*TY4'OJDOHF;:W Y3E%.T.UO<[IU0$MW:R7$O%L]*.
M-9AAQQF[+0>PZ%&PMMYW2?7C6CX;5OO:!ANKF2$I.@:B+]0=$GB&5$ZY%8I-
M-J[=0K(H_41?^D_-RJ1>L5V+8+=*LFZF5AL/6V@6A9WH"WN:;F_8#GB<W"V@
MRQ7$WC.ZAB?Y2O+5 W?-,GVAE<-0] 3D1UT.D%Y;AK[0RF$I6@NB;RUTR?<5
MU]>3KQ[@K=J*1H/H&XT3,G&&4.IQ[-&H>OFAG^BM0HK&@72\B&A-V*1^RX!'
M53'_1[DG1;DG^I+;);>/&O)V58UVMK>J*:H]T5?[DXM O9:KC794A#(UO5Y>
MF$=WUQ'P57JE+Y#'MK$\W/+F;_.?#2[3R_+*^RM\,3]<_A<PA]\B[BA?J;VH
M4L!205KG(Z60'Z[W#P/)-ND-^1.3DD7IXQJH#SPQ4-^7C,F703)!_B/+[%]0
M2P,$%     @ 641L6#HK4 :C @  M08  !D   !X;"]W;W)K<VAE971S+W-H
M965T,S8N>&ULK55=;],P%/TK5IC0)FU+FK;;--)(_6!B$A/5RN !\> FMXDU
MQPZVVPY^/==V&KJMK1#B);&O[ST^Y]HY2=92/>H2P)"GB@L]"$ICZNLPU%D)
M%=7GL@:!*PNI*FIPJHI0UPIH[HHJ'L91=!%6E(D@35QLJM)$+@UG J:*Z&55
M4?5S!%RN!T$GV 3N65$:&PC3I*8%S, \U%.%L[!%R5D%0C,IB(+%(!AVKL=]
MF^\2OC!8ZZTQL4KF4C[:R6T^"")+"#ADQB)0?*U@#)Q;(*3QH\$,VBUMX?9X
M@W[CM*.6.=4PEOPKRTTY"*X"DL."+KFYE^L/T.AQ!#/)M7N2=9,;!21;:B.K
MIA@95$SX-WUJ^K!5T+G84Q W!?'+@MZ>@FY3T'5"/3,G:T(-31,EUT39;$2S
M ]<;5XUJF+"G.#,*5QG6F71$.149D)F[,A,PE'%-SL@PSYGM,^7D5OC+8KM^
MW&2<8,K#;$*.CT[($6&"?"[E4E.1ZR0T2,N"AUE#8>0IQ'LH=&)R)X4I-7DO
M<LB? X2HIQ45;T2-XH.($\C.2;=S2N(H[NX@-/[[\O@ G6[;XZ[#Z^[!^Z0*
M*M@OU\%3,I9"2\YRWU!L&9DJT"",#\@%N6$"SX1AZV<8!/QFC";?AG-M%-[Z
M[[LZ[ GT=A.P3G"M:YK!(*CM7FH%0?KV3><B>K>K._\)[%FO>FVO>H?0TX]2
M%&<&5(67:@7:./&[%'N8OH.Q5K5*HR1<;<LXN-$_RNBW,OH'94P 0?$(W9'"
M$WJNAETJ^J]47$4O=;S.N=S*\?3"+0>H0!7.&#7)Y%(8_]VTT=9[A\YR7L1'
MZ,G>0O_ >$._HZI@0A,."X2,SB^1D?(FZ2=&ULYGYM*@:[EAB?\54#8!UQ=2
MFLW$;M#^J=+?4$L#!!0    ( %E$;%@Z+T7<1 0  %@3   9    >&PO=V]R
M:W-H965T<R]S:&5E=#,W+GAM;+U877/B-A3]*QIWI[,[TV#+!H-38(:0W30S
MR32S)-N'3A^$?0'/VA:59%CZZRM_Q#9&J)"E^Q+\<>_1.=?2N8J&6\J^\A6
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MVRCLG=I(Z5%5NXGRA>D-EX8(6",L'+Q%O&Z[M#6LJGVAKY3%MO'+$@<;:.>
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M 4F ZP#U?,&8?!KH8W3SMTGT%U!+ P04    " !91&Q85^*HCN8"   ^"
M&0   'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6RMEEUOVC 4AO^*E553)VW-
M%PEI!T@M;-HNIJ'2;A?3+DQR0JPZ<68;:/_]CI,THF!8+W9#;.><U\][[-B,
MMD(^J ) D\>25VKL%%K75ZZKT@)*JBY$#16^R84LJ<:N7+FJED"S)JGD;N!Y
ML5M25CF343,VEY.16&O.*IA+HM9E2>73#7"Q'3N^\SQPRU:%-@/N9%33%2Q
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MTQZ0),^N2L!#6\]K%WN)?NW7C[VJ</NX/Z3L@CU]S9X^O)MIG1./Z]0/GQ_
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M!TKS06D!%*WIW7UZPM(N)4]O<9P)DN$L)&A!CO2JH+F%BM;7]ZHG%')!X_)
M:3XH+8"BE28Q#G9SIH0MBYV]'(5J^E?N5ZROUKN'9\6>V1?7Y]:54^X!WF/*
M+<FWF"UCV:(E9"&1YL50ODE6[O(M3P3-BSVCCU0(FA:'*X(CPE0!^?N"4K$[
M4174>ZVG_P-02P,$%     @ 641L6)NR6Q\S!@  BB<  !D   !X;"]W;W)K
M<VAE971S+W-H965T-#4N>&ULM5IK;]LV%/TKA#<,+9#$$OU(G#D&8JG%.J1H
MT:#KAV(?&.G:%BJ)'DG'"; ?OTM)T<.1F2JCOB1Z\![R'EV1Y\B<[[GX(3<
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M\#: '->L%G2K=N^Q]>,%9DH8_X5=FQL%D-6&5-F"K8*2RV9DC^TY' #B^!E
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M/RWL^X?:)=C]M5+T%+B>[%[4]!=02P,$%     @ 641L6$%14&^:"   :D,
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MU JBEPKB5A [T"8SAS6GAJ:)DENB;#2ZV8&KC5,C#1/V%!=&X5N&.I/.I-B
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M!^'IC62;Y*3WGDG)HN1R#70!7%=0SY>,R><;W4#^[PB3_P!02P,$%     @
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MZ6BA1?R4BCP!J7XEMU\VF=Z1=V11/E4BEF1J'&U6)>1,0T*TP*'2,HO-3!D
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MH0P&YT:T;+I/,]&B<@_X3FC3#MRP, T;I4TPZRLA]&YB-^C^ I*_4$L#!!0
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M=ICKAQ0(8Z#W,\[5;F(^T#S-XK]02P,$%     @ 641L6#&++80_!   U0\
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M9]&<(9L;Q<OZ&/;,%1SJZLL=G+NIT ;P?L.Y>KW1)[OV)#__%U!+ P04
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M*LPOVI6VCH7"7$B6E&#E04+2XA_?ET+L 5S_ , K =YS0/\ H%<">J\%]$M
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M]7KJC3U(<4D*IF_%Y@M6_9Q:OD0PY3YA4\4&'B2%TB*KP*:"C/+RFSQ5.NP
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MVD)SH9<LP9%#E42C6J,S_ODG/_)^W2=9FV1Q2V0U/;N5GMTF=LJNH$)')<W
M#2)</U-IU;A/OT:>8_4KR?QRU=@JO1Y[G>[07>_JTI+%FBZ]2I=>HRZ?EF4Y
M^+0RVC"1<C$_@]]HN9GW6[)4IV2+=N+Q>Y[GU2.Z:K1Y[++YWF3H^8/>X,UH
M+?*HBCQJC/Q+\:=!6VRR1D5K@]8$JH1KA*GB"3:J$'V?5K_7&;Q3H='^L2J4
M9/T=B]U.+]POP7DEP7FC!*$',7O1L%1<*M@H;@P*$-)0_/O";F0[=FNT21:W
M1%93L5^IV/]!I;K?IIYMDL4MD=7T'%1Z#AI7Y0WC"CZS;$5[\%:L41M;MNG
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M;L01S %XP) H,N_!G?=1L'Y/!9O?:$=_ 5!+ P04    " !91&Q8EXJ[',
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MGXW_[;EZ!U!+ 0(4 Q0    ( %E$;%@'04UB@0   +$    0
M  "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ 641L6+!<>47N
M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @ 641L6)E<G",0!@  G"<  !,              ( !S $  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !91&Q8$)JWG:X'   <*0
M&               @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ 641L6$*^8T/<!0  KQ@  !@              ("!\0\  'AL
M+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( %E$;%@"5TX%G0(
M -<(   8              " @0,6  !X;"]W;W)K<VAE971S+W-H965T,RYX
M;6Q02P$"% ,4    " !91&Q88"1Q%14%  ""$P  &               @('6
M&   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ 641L6*6"
M 3LG"   C3X  !@              ("!(1X  'AL+W=O<FMS:&5E=',O<VAE
M970U+GAM;%!+ 0(4 Q0    ( %E$;%CVJG*!J@<  / A   8
M  " @7XF  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " !9
M1&Q8S4!^&$L"  "D!0  &               @(%>+@  >&PO=V]R:W-H965T
M<R]S:&5E=#<N>&UL4$L! A0#%     @ 641L6&0ZHFM# @  B@8  !@
M         ("!WS   'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0
M   ( %E$;%@U1BFDI@D  &$7   8              " @5@S  !X;"]W;W)K
M<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " !91&Q8&H@/#"T=  !06@
M&0              @($T/0  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+
M 0(4 Q0    ( %E$;%CG;[6^ZP,  .@(   9              " @9A:  !X
M;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ 641L6%A#:*U-
M!P  \A   !D              ("!NEX  'AL+W=O<FMS:&5E=',O<VAE970Q
M,BYX;6Q02P$"% ,4    " !91&Q8$TG3E*,#  #-"   &0
M@($^9@  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( %E$
M;%B8'#P'C <  '85   9              " @1AJ  !X;"]W;W)K<VAE971S
M+W-H965T,30N>&UL4$L! A0#%     @ 641L6!U[.V3X!@  RA(  !D
M         ("!VW$  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
M    " !91&Q8 FF(ID<+  ".'0  &0              @($*>0  >&PO=V]R
M:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( %E$;%@)+/-JR1$  $4X
M   9              " @8B$  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL
M4$L! A0#%     @ 641L6 3C:D@*#   6B$  !D              ("!B)8
M 'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " !91&Q8\R(L
M("@$   ["@  &0              @(')H@  >&PO=V]R:W-H965T<R]S:&5E
M=#$Y+GAM;%!+ 0(4 Q0    ( %E$;%BU0L\^. ,  "@'   9
M  " @2BG  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @
M641L6*78B']6!    @H  !D              ("!EZH  'AL+W=O<FMS:&5E
M=',O<VAE970R,2YX;6Q02P$"% ,4    " !91&Q8!B#YV6X@   %;0  &0
M            @($DKP  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4
M Q0    ( %E$;%B=II:TO@(   8&   9              " @<G/  !X;"]W
M;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ 641L6(RH;_40!0
M^PP  !D              ("!OM(  'AL+W=O<FMS:&5E=',O<VAE970R-"YX
M;6Q02P$"% ,4    " !91&Q8S[I(680#  !V"   &0              @($%
MV   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( %E$;%B;
M\'4_D (  *D%   9              " @<#;  !X;"]W;W)K<VAE971S+W-H
M965T,C8N>&UL4$L! A0#%     @ 641L6-HA"4U% P  3 <  !D
M     ("!A]X  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
M" !91&Q8O"*->0P%  !##   &0              @($#X@  >&PO=V]R:W-H
M965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( %E$;%C7]S3JCP0  )<*   9
M              " @4;G  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L!
M A0#%     @ 641L6$FKYA_+ P  8@D  !D              ("!#.P  'AL
M+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " !91&Q8R$<7.H #
M  !A"P  &0              @($.\   >&PO=V]R:W-H965T<R]S:&5E=#,Q
M+GAM;%!+ 0(4 Q0    ( %E$;%@S-M1;U 4  $HA   9              "
M@<7S  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ 641L
M6%;-&B 4 P  H@L  !D              ("!T/D  'AL+W=O<FMS:&5E=',O
M<VAE970S,RYX;6Q02P$"% ,4    " !91&Q8G+L_&!8$  !^%   &0
M        @($;_0  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0
M   ( %E$;%@NB:&$T00  ' 9   9              " @6@! 0!X;"]W;W)K
M<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ 641L6#HK4 :C @  M08
M !D              ("!< 8! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q0
M2P$"% ,4    " !91&Q8.B]%W$0$  !8$P  &0              @(%*"0$
M>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( %E$;%@#BW*$
MW (  -$'   9              " @<4- 0!X;"]W;W)K<VAE971S+W-H965T
M,S@N>&UL4$L! A0#%     @ 641L6-#J"+E# @  -@4  !D
M ("!V! ! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " !9
M1&Q8SERZXJX#  !"$0  &0              @(%2$P$ >&PO=V]R:W-H965T
M<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( %E$;%A7XJB.Y@(  #X(   9
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M970T-2YX;6Q02P$"% ,4    " !91&Q8O]F3(&("  !=!0  &0
M    @(&2, $ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    (
M %E$;%A!45!OF@@  &I#   9              " @2LS 0!X;"]W;W)K<VAE
M971S+W-H965T-#<N>&UL4$L! A0#%     @ 641L6"E0,KF$ @  KP8  !D
M             ("!_#L! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"
M% ,4    " !91&Q8\.UE][\"  #<"0  &0              @(&W/@$ >&PO
M=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( %E$;%C1Q'6*7!8
M .I& 0 9              " @:U! 0!X;"]W;W)K<VAE971S+W-H965T-3 N
M>&UL4$L! A0#%     @ 641L6#.]Q$8!!@  FB   !D              ("!
M0%@! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " !91&Q8
M9Z0O1<,#   9#P  &0              @(%X7@$ >&PO=V]R:W-H965T<R]S
M:&5E=#4R+GAM;%!+ 0(4 Q0    ( %E$;%@J0Z-JE ,  ($.   9
M      " @7)B 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%
M  @ 641L6%XVGR"4 @  #@8  !D              ("!/68! 'AL+W=O<FMS
M:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    " !91&Q8::>A_C\%   8(P
M&0              @($(:0$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+
M 0(4 Q0    ( %E$;%CSTX/U-P,  *8)   9              " @7YN 0!X
M;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ 641L6#&++80_
M!   U0\  !D              ("!['$! 'AL+W=O<FMS:&5E=',O<VAE970U
M-RYX;6Q02P$"% ,4    " !91&Q8GLY3$BT#  !&"0  &0
M@(%B=@$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( %E$
M;%A-'\^Z9 ,  #X/   9              " @<9Y 0!X;"]W;W)K<VAE971S
M+W-H965T-3DN>&UL4$L! A0#%     @ 641L6!/2>6H> P  ^@L  !D
M         ("!87T! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4
M    " !91&Q86KDLI-P#   _$0  &0              @(&V@ $ >&PO=V]R
M:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( %E$;%A)TDD04 ,  + 5
M   -              "  <F$ 0!X;"]S='EL97,N>&UL4$L! A0#%     @
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H0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !% $4 VA(  )&2 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>169</ContextCount>
  <ElementCount>361</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>56</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100060 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995455 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995465 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995475 - Disclosure - Recent Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureRecentAccountingPronouncements</Role>
      <ShortName>Recent Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995485 - Disclosure - Balance Sheet Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetails</Role>
      <ShortName>Balance Sheet Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995495 - Disclosure - Fair Value Measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurement</Role>
      <ShortName>Fair Value Measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995505 - Disclosure - License and Sponsored Research Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureLicenseAndSponsoredResearchAgreements</Role>
      <ShortName>License and Sponsored Research Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995515 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995525 - Disclosure - Convertible Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebt</Role>
      <ShortName>Convertible Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995535 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995545 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995555 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995565 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995575 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995605 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995615 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995625 - Disclosure - Balance Sheet Details (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables</Role>
      <ShortName>Balance Sheet Details (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetails</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995635 - Disclosure - Fair Value Measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementTables</Role>
      <ShortName>Fair Value Measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurement</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995645 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995655 - Disclosure - Convertible Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtTables</Role>
      <ShortName>Convertible Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebt</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995665 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquity</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995675 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995685 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShare</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995695 - Disclosure - Organization and Basis of Presentation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails</Role>
      <ShortName>Organization and Basis of Presentation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995705 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995715 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995725 - Disclosure - Recent Accounting Pronouncements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureRecentAccountingPronouncementsAdditionalInformationDetails</Role>
      <ShortName>Recent Accounting Pronouncements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995735 - Disclosure - Balance Sheet Details - Schedule of Short-Term Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfShortTermInvestmentsDetails</Role>
      <ShortName>Balance Sheet Details - Schedule of Short-Term Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995745 - Disclosure - Balance Sheet Details - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails</Role>
      <ShortName>Balance Sheet Details - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995755 - Disclosure - Balance Sheet Details - Schedule of Long-Term Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfLongTermInvestmentsDetails</Role>
      <ShortName>Balance Sheet Details - Schedule of Long-Term Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995765 - Disclosure - Balance Sheet Details - Schedule of Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Balance Sheet Details - Schedule of Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995775 - Disclosure - Balance Sheet Details - Schedule of Noncurrent Prepaid Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfNoncurrentPrepaidExpensesDetails</Role>
      <ShortName>Balance Sheet Details - Schedule of Noncurrent Prepaid Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995785 - Disclosure - Balance Sheet Details - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Balance Sheet Details - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995795 - Disclosure - Balance Sheet Details - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails</Role>
      <ShortName>Balance Sheet Details - Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995805 - Disclosure - Fair Value Measurement - Summary of Financial Assets Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementSummaryOfFinancialAssetsMeasuredAtFairValueDetails</Role>
      <ShortName>Fair Value Measurement - Summary of Financial Assets Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995815 - Disclosure - Fair Value Measurement - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurement - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995825 - Disclosure - License and Sponsored Research Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureLicenseAndSponsoredResearchAgreementsAdditionalInformationDetails</Role>
      <ShortName>License and Sponsored Research Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995835 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995845 - Disclosure - Commitments and Contingencies - Schedule of Future Lease Payments Under Non-Cancelable Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureLeasePaymentsUnderNonCancelableLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Future Lease Payments Under Non-Cancelable Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995855 - Disclosure - Convertible Debt (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails</Role>
      <ShortName>Convertible Debt (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995865 - Disclosure - Convertible Debt - Summarizes of Impact of Term Loan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtSummarizesOfImpactOfTermLoanDetails</Role>
      <ShortName>Convertible Debt - Summarizes of Impact of Term Loan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995875 - Disclosure - Convertible Debt - Future Principal Payment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtFuturePrincipalPaymentDetails</Role>
      <ShortName>Convertible Debt - Future Principal Payment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995885 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995895 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity Under Equity Incentive Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityUnderEquityIncentivePlansDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Stock Option Activity Under Equity Incentive Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995905 - Disclosure - Stockholders' Equity - Summary of Assumptions Used to Value Stock Options Granted to Employees using Black-Scholes Option-Pricing (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfAssumptionsUsedToValueStockOptionsGrantedToEmployeesUsingBlackscholesOptionpricingDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Assumptions Used to Value Stock Options Granted to Employees using Black-Scholes Option-Pricing (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995915 - Disclosure - Stockholders' Equity - Summary of Activity related to restricted stock units ("RSUs") (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityRelatedToRestrictedStockUnitsRsusDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Activity related to restricted stock units ("RSUs") (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995925 - Disclosure - Stockholders' Equity - Summary of Total Compensation Cost Recognized in Statements of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfTotalCompensationCostRecognizedInStatementsOfOperationsDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Total Compensation Cost Recognized in Statements of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995935 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>995945 - Disclosure - Income Taxes - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate to Effective Inc (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUsFederalStatutoryIncomeTaxRateToEffectiveIncDetails</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate to Effective Inc (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>995955 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Significant Components of Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>995965 - Disclosure - Net Loss per Share - Schedule of Net Loss Per Share, Basic and Diluted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/DisclosureNetLossPerShareScheduleOfNetLossPerShareBasicAndDilutedDetails</Role>
      <ShortName>Net Loss per Share - Schedule of Net Loss Per Share, Basic and Diluted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>995975 - Disclosure - Net Loss per Share - Schedule of Potential Dilutive Securities from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentialDilutiveSecuritiesFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Net Loss per Share - Schedule of Potential Dilutive Securities from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>995985 - Disclosure - Employee Benefit Plans - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetails</Role>
      <ShortName>Employee Benefit Plans - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="inzy-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>995995 - Disclosure - Related Party Transactions (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inozyme.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactions</ParentRole>
      <Position>61</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="inzy-20231231.htm">inzy-20231231.htm</File>
    <File>inzy-20231231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img187419207_0.jpg</File>
    <File>img187419207_1.jpg</File>
    <File>img187419207_10.jpg</File>
    <File>img187419207_11.jpg</File>
    <File>img187419207_12.jpg</File>
    <File>img187419207_13.jpg</File>
    <File>img187419207_14.jpg</File>
    <File>img187419207_15.jpg</File>
    <File>img187419207_16.jpg</File>
    <File>img187419207_17.jpg</File>
    <File>img187419207_18.jpg</File>
    <File>img187419207_19.jpg</File>
    <File>img187419207_2.jpg</File>
    <File>img187419207_20.jpg</File>
    <File>img187419207_21.jpg</File>
    <File>img187419207_22.jpg</File>
    <File>img187419207_23.jpg</File>
    <File>img187419207_24.jpg</File>
    <File>img187419207_25.jpg</File>
    <File>img187419207_26.jpg</File>
    <File>img187419207_3.jpg</File>
    <File>img187419207_4.jpg</File>
    <File>img187419207_5.jpg</File>
    <File>img187419207_6.jpg</File>
    <File>img187419207_7.jpg</File>
    <File>img187419207_8.jpg</File>
    <File>img187419207_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="587">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>108
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "inzy-20231231.htm": {
   "nsprefix": "inzy",
   "nsuri": "http://www.inozyme.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "inzy-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "inzy-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    }
   },
   "keyStandard": 310,
   "keyCustom": 51,
   "axisStandard": 25,
   "axisCustom": 0,
   "memberStandard": 32,
   "memberCustom": 23,
   "hidden": {
    "total": 13,
    "http://xbrl.sec.gov/dei/2023": 4,
    "http://fasb.org/us-gaap/2023": 9
   },
   "contextCount": 169,
   "entityCount": 1,
   "segmentCount": 56,
   "elementCount": 696,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 587,
    "http://xbrl.sec.gov/dei/2023": 39,
    "http://xbrl.sec.gov/ecd/2023": 4
   },
   "report": {
    "R1": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets",
     "longName": "100010 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_5c13eb3e-ee93-44a2-85e8-241a737a39d9",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5c13eb3e-ee93-44a2-85e8-241a737a39d9",
      "name": "us-gaap:ShortTermInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "100020 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_5c13eb3e-ee93-44a2-85e8-241a737a39d9",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5c13eb3e-ee93-44a2-85e8-241a737a39d9",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "100030 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit",
     "longName": "100040 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_f9151e1c-1a1c-4fd2-91c3-dfd8900bd0f6",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f9151e1c-1a1c-4fd2-91c3-dfd8900bd0f6",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
     "longName": "100060 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_6f7932b9-17b8-423d-9f3d-1d9425caa7f3",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6f7932b9-17b8-423d-9f3d-1d9425caa7f3",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentation",
     "longName": "995455 - Disclosure - Organization and Basis of Presentation",
     "shortName": "Organization and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "995465 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureRecentAccountingPronouncements",
     "longName": "995475 - Disclosure - Recent Accounting Pronouncements",
     "shortName": "Recent Accounting Pronouncements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetails",
     "longName": "995485 - Disclosure - Balance Sheet Details",
     "shortName": "Balance Sheet Details",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurement",
     "longName": "995495 - Disclosure - Fair Value Measurement",
     "shortName": "Fair Value Measurement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureLicenseAndSponsoredResearchAgreements",
     "longName": "995505 - Disclosure - License and Sponsored Research Agreements",
     "shortName": "License and Sponsored Research Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "longName": "995515 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebt",
     "longName": "995525 - Disclosure - Convertible Debt",
     "shortName": "Convertible Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquity",
     "longName": "995535 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxes",
     "longName": "995545 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShare",
     "longName": "995555 - Disclosure - Net Loss per Share",
     "shortName": "Net Loss per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlans",
     "longName": "995565 - Disclosure - Employee Benefit Plans",
     "shortName": "Employee Benefit Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactions",
     "longName": "995575 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995605 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "longName": "995615 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "inzy:PropertyAndEquipmentEstimatedUsefulLivesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "inzy:PropertyAndEquipmentEstimatedUsefulLivesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables",
     "longName": "995625 - Disclosure - Balance Sheet Details (Tables)",
     "shortName": "Balance Sheet Details (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementTables",
     "longName": "995635 - Disclosure - Fair Value Measurement (Tables)",
     "shortName": "Fair Value Measurement (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables",
     "longName": "995645 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtTables",
     "longName": "995655 - Disclosure - Convertible Debt (Tables)",
     "shortName": "Convertible Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "inzy:SummarizesOfImpactTermLoanTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "inzy:SummarizesOfImpactTermLoanTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityTables",
     "longName": "995665 - Disclosure - Stockholders' Equity (Tables)",
     "shortName": "Stockholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables",
     "longName": "995675 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareTables",
     "longName": "995685 - Disclosure - Net Loss per Share (Tables)",
     "shortName": "Net Loss per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
     "longName": "995695 - Disclosure - Organization and Basis of Presentation - Additional Information (Details)",
     "shortName": "Organization and Basis of Presentation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5c13eb3e-ee93-44a2-85e8-241a737a39d9",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "995705 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
     "longName": "995715 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Property and Equipment (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_f1b17c7a-98c5-4dda-8775-61fdebd34c84",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1b17c7a-98c5-4dda-8775-61fdebd34c84",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureRecentAccountingPronouncementsAdditionalInformationDetails",
     "longName": "995725 - Disclosure - Recent Accounting Pronouncements - Additional Information (Details)",
     "shortName": "Recent Accounting Pronouncements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_5c13eb3e-ee93-44a2-85e8-241a737a39d9",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R35": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfShortTermInvestmentsDetails",
     "longName": "995735 - Disclosure - Balance Sheet Details - Schedule of Short-Term Investments (Details)",
     "shortName": "Balance Sheet Details - Schedule of Short-Term Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_5c13eb3e-ee93-44a2-85e8-241a737a39d9",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5bb4c6de-83a3-4b5b-8ccc-2887ba662ad0",
      "name": "inzy:InvestmentMaturityPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails",
     "longName": "995745 - Disclosure - Balance Sheet Details - Additional Information (Details)",
     "shortName": "Balance Sheet Details - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_5c13eb3e-ee93-44a2-85e8-241a737a39d9",
      "name": "us-gaap:LongTermInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfLongTermInvestmentsDetails",
     "longName": "995755 - Disclosure - Balance Sheet Details - Schedule of Long-Term Investments (Details)",
     "shortName": "Balance Sheet Details - Schedule of Long-Term Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_5c13eb3e-ee93-44a2-85e8-241a737a39d9",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R38": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
     "longName": "995765 - Disclosure - Balance Sheet Details - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "shortName": "Balance Sheet Details - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_5c13eb3e-ee93-44a2-85e8-241a737a39d9",
      "name": "us-gaap:InterestReceivableCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "inzy:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5c13eb3e-ee93-44a2-85e8-241a737a39d9",
      "name": "us-gaap:InterestReceivableCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "inzy:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfNoncurrentPrepaidExpensesDetails",
     "longName": "995775 - Disclosure - Balance Sheet Details - Schedule of Noncurrent Prepaid Expenses (Details)",
     "shortName": "Balance Sheet Details - Schedule of Noncurrent Prepaid Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_5c13eb3e-ee93-44a2-85e8-241a737a39d9",
      "name": "us-gaap:PrepaidExpenseNoncurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R40": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetails",
     "longName": "995785 - Disclosure - Balance Sheet Details - Schedule of Property and Equipment (Details)",
     "shortName": "Balance Sheet Details - Schedule of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_5c13eb3e-ee93-44a2-85e8-241a737a39d9",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5c13eb3e-ee93-44a2-85e8-241a737a39d9",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails",
     "longName": "995795 - Disclosure - Balance Sheet Details - Schedule of Accrued Expenses (Details)",
     "shortName": "Balance Sheet Details - Schedule of Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_5c13eb3e-ee93-44a2-85e8-241a737a39d9",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5c13eb3e-ee93-44a2-85e8-241a737a39d9",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementSummaryOfFinancialAssetsMeasuredAtFairValueDetails",
     "longName": "995805 - Disclosure - Fair Value Measurement - Summary of Financial Assets Measured at Fair Value (Details)",
     "shortName": "Fair Value Measurement - Summary of Financial Assets Measured at Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_cc2d588b-2f3b-4c9e-8375-5d861c028af1",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cc2d588b-2f3b-4c9e-8375-5d861c028af1",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails",
     "longName": "995815 - Disclosure - Fair Value Measurement - Additional Information (Details)",
     "shortName": "Fair Value Measurement - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureLicenseAndSponsoredResearchAgreementsAdditionalInformationDetails",
     "longName": "995825 - Disclosure - License and Sponsored Research Agreements - Additional Information (Details)",
     "shortName": "License and Sponsored Research Agreements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_f0e6584f-b5b7-4d58-a88c-80a7eadaaae3",
      "name": "inzy:ResearchSupportFundingAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f0e6584f-b5b7-4d58-a88c-80a7eadaaae3",
      "name": "inzy:ResearchSupportFundingAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "longName": "995835 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "inzy:OperatingLeaseWeightedAverageIncrementalBorrowingRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "inzy:OperatingLeaseWeightedAverageIncrementalBorrowingRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureLeasePaymentsUnderNonCancelableLeasesDetails",
     "longName": "995845 - Disclosure - Commitments and Contingencies - Schedule of Future Lease Payments Under Non-Cancelable Leases (Details)",
     "shortName": "Commitments and Contingencies - Schedule of Future Lease Payments Under Non-Cancelable Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_5c13eb3e-ee93-44a2-85e8-241a737a39d9",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5c13eb3e-ee93-44a2-85e8-241a737a39d9",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails",
     "longName": "995855 - Disclosure - Convertible Debt (Additional Information) (Details)",
     "shortName": "Convertible Debt (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_5c13eb3e-ee93-44a2-85e8-241a737a39d9",
      "name": "us-gaap:LongTermDebt",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtSummarizesOfImpactOfTermLoanDetails",
     "longName": "995865 - Disclosure - Convertible Debt - Summarizes of Impact of Term Loan (Details)",
     "shortName": "Convertible Debt - Summarizes of Impact of Term Loan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_5c13eb3e-ee93-44a2-85e8-241a737a39d9",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "inzy:SummarizesOfImpactTermLoanTableTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5c13eb3e-ee93-44a2-85e8-241a737a39d9",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "inzy:SummarizesOfImpactTermLoanTableTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtFuturePrincipalPaymentDetails",
     "longName": "995875 - Disclosure - Convertible Debt - Future Principal Payment (Details)",
     "shortName": "Convertible Debt - Future Principal Payment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_5c13eb3e-ee93-44a2-85e8-241a737a39d9",
      "name": "us-gaap:LongTermDebt",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_02f9e665-ab6c-4248-ac91-2158ec322783",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
     "longName": "995885 - Disclosure - Stockholders' Equity - Additional Information (Details)",
     "shortName": "Stockholders' Equity - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_f1c3e67f-9945-41f0-944d-8d830ba9739e",
      "name": "inzy:AdditionalSharesIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1c3e67f-9945-41f0-944d-8d830ba9739e",
      "name": "inzy:AdditionalSharesIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityUnderEquityIncentivePlansDetails",
     "longName": "995895 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity Under Equity Incentive Plans (Details)",
     "shortName": "Stockholders' Equity - Summary of Stock Option Activity Under Equity Incentive Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_0d74cf94-b1f2-497c-915e-d10053a3fdac",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5c13eb3e-ee93-44a2-85e8-241a737a39d9",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfAssumptionsUsedToValueStockOptionsGrantedToEmployeesUsingBlackscholesOptionpricingDetails",
     "longName": "995905 - Disclosure - Stockholders' Equity - Summary of Assumptions Used to Value Stock Options Granted to Employees using Black-Scholes Option-Pricing (Details)",
     "shortName": "Stockholders' Equity - Summary of Assumptions Used to Value Stock Options Granted to Employees using Black-Scholes Option-Pricing (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityRelatedToRestrictedStockUnitsRsusDetails",
     "longName": "995915 - Disclosure - Stockholders' Equity - Summary of Activity related to restricted stock units (\"RSUs\") (Details)",
     "shortName": "Stockholders' Equity - Summary of Activity related to restricted stock units (\"RSUs\") (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_0d74cf94-b1f2-497c-915e-d10053a3fdac",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_095b17b0-4474-4132-8919-5e9087e56021",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfTotalCompensationCostRecognizedInStatementsOfOperationsDetails",
     "longName": "995925 - Disclosure - Stockholders' Equity - Summary of Total Compensation Cost Recognized in Statements of Operations (Details)",
     "shortName": "Stockholders' Equity - Summary of Total Compensation Cost Recognized in Statements of Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R55": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
     "longName": "995935 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUsFederalStatutoryIncomeTaxRateToEffectiveIncDetails",
     "longName": "995945 - Disclosure - Income Taxes - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate to Effective Inc (Details)",
     "shortName": "Income Taxes - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate to Effective Inc (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails",
     "longName": "995955 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets (Details)",
     "shortName": "Income Taxes - Significant Components of Deferred Tax Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_5c13eb3e-ee93-44a2-85e8-241a737a39d9",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5c13eb3e-ee93-44a2-85e8-241a737a39d9",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/DisclosureNetLossPerShareScheduleOfNetLossPerShareBasicAndDilutedDetails",
     "longName": "995965 - Disclosure - Net Loss per Share - Schedule of Net Loss Per Share, Basic and Diluted (Details)",
     "shortName": "Net Loss per Share - Schedule of Net Loss Per Share, Basic and Diluted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R59": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentialDilutiveSecuritiesFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
     "longName": "995975 - Disclosure - Net Loss per Share - Schedule of Potential Dilutive Securities from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)",
     "shortName": "Net Loss per Share - Schedule of Potential Dilutive Securities from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a654e8a2-be67-4c8a-a856-140b00703ba3",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetails",
     "longName": "995985 - Disclosure - Employee Benefit Plans - Additional Information (Details)",
     "shortName": "Employee Benefit Plans - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "C_f5346b4d-f225-4d76-a62e-df2c1fef5d1f",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f5346b4d-f225-4d76-a62e-df2c1fef5d1f",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.inozyme.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
     "longName": "995995 - Disclosure - Related Party Transactions (Additional Information) (Details)",
     "shortName": "Related Party Transactions (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "C_0492ee51-d379-44b0-9b36-2dde4f604d4e",
      "name": "us-gaap:ManagementFeeExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0492ee51-d379-44b0-9b36-2dde4f604d4e",
      "name": "us-gaap:ManagementFeeExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20231231.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingChangesAndErrorCorrectionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Changes and Error Corrections [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingStandardsUpdate201602Member",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureRecentAccountingPronouncementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASU 2016-02",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842)."
       }
      }
     },
     "auth_ref": [
      "r567"
     ]
    },
    "us-gaap_AccountingStandardsUpdate201815Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingStandardsUpdate201815Member",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureRecentAccountingPronouncementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASU 2018-15",
        "label": "Accounting Standards Update 2018-15 [Member]",
        "documentation": "Accounting Standards Update 2018-15 Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (a consensus of the FASB Emerging Issues Task Force)."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r168"
     ]
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingStandardsUpdateExtensibleList",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureRecentAccountingPronouncementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "documentation": "Indicates amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r230",
      "r231",
      "r232",
      "r282",
      "r283",
      "r317",
      "r318",
      "r319",
      "r320",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r339",
      "r450",
      "r451",
      "r452",
      "r481",
      "r482",
      "r493",
      "r494",
      "r495",
      "r505",
      "r506",
      "r507",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r543",
      "r544",
      "r547",
      "r548",
      "r549",
      "r550",
      "r563",
      "r564",
      "r568",
      "r569",
      "r570",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r984"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accounts Payable, Current, Total",
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r858"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amortization of premiums and discounts on marketable securities",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Accrued expenses",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other professional fees",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "inzy_AccruedResearchAndDevelopmentCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "AccruedResearchAndDevelopmentCostsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development costs",
        "label": "Accrued Research And Development Costs Current",
        "documentation": "Accrued research and development costs current."
       }
      }
     },
     "auth_ref": []
    },
    "inzy_AccruedResearchAndDevelopmentCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "AccruedResearchAndDevelopmentCostsPolicyTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Research and Development Costs",
        "label": "Accrued Research And Development Costs Policy [Text Block]",
        "documentation": "Accrued research and development costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "negatedLabel": "Less accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r186",
      "r654"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive (loss) income",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r99",
      "r192",
      "r650",
      "r678",
      "r682"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r13",
      "r38",
      "r510",
      "r513",
      "r588",
      "r673",
      "r674",
      "r972",
      "r973",
      "r974",
      "r981",
      "r982",
      "r983"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "inzy_AdditionalLoanAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "AdditionalLoanAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional loan amount",
        "label": "Additional loan amount",
        "terseLabel": "Additional loan amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance",
        "terseLabel": "Additional paid in-capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r451",
      "r452",
      "r701",
      "r981",
      "r982",
      "r983",
      "r1052",
      "r1082"
     ]
    },
    "inzy_AdditionalSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "AdditionalSharesIssued",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional shares issued",
        "documentation": "Additional shares issued"
       }
      }
     },
     "auth_ref": []
    },
    "inzy_AdditionalTemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "AdditionalTemporaryEquitySharesIssued",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional shares issued",
        "label": "Additional Temporary Equity Shares Issued",
        "documentation": "Additional temporary equity shares issued."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureRecentAccountingPronouncementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Standards Update",
        "label": "Accounting Standards Update [Axis]",
        "documentation": "Information by amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r230",
      "r231",
      "r232",
      "r234",
      "r246",
      "r282",
      "r283",
      "r317",
      "r318",
      "r319",
      "r320",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r339",
      "r450",
      "r451",
      "r452",
      "r479",
      "r480",
      "r481",
      "r482",
      "r493",
      "r494",
      "r495",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r515",
      "r516",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r543",
      "r544",
      "r547",
      "r548",
      "r549",
      "r550",
      "r563",
      "r564",
      "r568",
      "r569",
      "r570",
      "r571",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r631",
      "r632",
      "r633",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total",
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r68",
      "r417"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r882",
      "r894",
      "r904",
      "r930"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r885",
      "r897",
      "r907",
      "r933"
     ]
    },
    "inzy_AlexionPharmaceuticalsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "AlexionPharmaceuticalsIncMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alexion Pharmaceuticals, Inc",
        "label": "Alexion Pharmaceuticals Inc [Member]",
        "documentation": "Alexion Pharmaceuticals, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r889",
      "r898",
      "r908",
      "r925",
      "r934",
      "r938",
      "r946"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfTotalCompensationCostRecognizedInStatementsOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation expense",
        "terseLabel": "Total",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r458"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Non-cash interest expense and amortization of debt issuance costs",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r78",
      "r106",
      "r378"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentialDilutiveSecuritiesFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive shares excluded from computation of earnings per share",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r257"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentialDilutiveSecuritiesFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentialDilutiveSecuritiesFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentialDilutiveSecuritiesFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "inzy_AreaOfLeasedSpace": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "AreaOfLeasedSpace",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Area Of Leased Space",
        "documentation": "Area of leased space.",
        "terseLabel": "Area of leased space"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureLicenseAndSponsoredResearchAgreementsAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairments of long-lived assets",
        "label": "Asset Impairment Charges",
        "totalLabel": "Asset Impairment Charges, Total",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r54"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r188",
      "r219",
      "r264",
      "r275",
      "r277",
      "r315",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r498",
      "r502",
      "r545",
      "r644",
      "r743",
      "r858",
      "r871",
      "r1013",
      "r1014",
      "r1063"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r193",
      "r219",
      "r315",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r498",
      "r502",
      "r545",
      "r858",
      "r1013",
      "r1014",
      "r1063"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementSummaryOfFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets fair value disclosure",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Assets, Fair Value Disclosure, Total",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r876",
      "r877",
      "r890"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r876",
      "r877",
      "r890"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r876",
      "r877",
      "r890"
     ]
    },
    "inzy_AvailableForDebtSecuritiesEquitySecuritiesNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "AvailableForDebtSecuritiesEquitySecuritiesNonCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offer and sell",
        "label": "Available For Debt Securities Equity Securities Non current",
        "documentation": "Available For Debt Securities Equity Securities Non current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfShortTermInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfLongTermInvestmentsDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfShortTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r288"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfShortTermInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfLongTermInvestmentsDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfShortTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r289"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfShortTermInvestmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfLongTermInvestmentsDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfShortTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Costs",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r334",
      "r643"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfShortTermInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfLongTermInvestmentsDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfShortTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Securities, Available-for-sale, Total",
        "terseLabel": "Estimated Fair Value",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r286",
      "r334",
      "r637",
      "r988"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityRelatedToRestrictedStockUnitsRsusDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r420",
      "r421",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location",
        "label": "Balance Sheet Location [Axis]",
        "documentation": "Information by location on balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location",
        "label": "Balance Sheet Location [Domain]",
        "documentation": "Location in the balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r74"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "inzy_BofaSecuritiesIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "BofaSecuritiesIncMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bofa Securities Inc",
        "label": "BofA Securities, Inc [Member]",
        "documentation": "BofA Securities, Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureAcquisitionOfAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition of Assets",
        "label": "Business Combination Disclosure [Text Block]",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r492"
     ]
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment unpaid at end of period",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r47"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r183",
      "r823"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementSummaryOfFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents fair value disclosure",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Cash",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r139"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash, Cash Equivalents, and Short-term Investments, Total",
        "terseLabel": "Cash and cash equivalents and short term investments",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r971"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r109",
      "r215"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase in cash, cash equivalents, and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r109"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureRecentAccountingPronouncementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in accounting principle, accounting standards update, adopted",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]",
        "documentation": "Indicates (true false) whether accounting standards update was adopted."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r166",
      "r169",
      "r174",
      "r175",
      "r228",
      "r282",
      "r283",
      "r316",
      "r317",
      "r318",
      "r325",
      "r326",
      "r339",
      "r479",
      "r493",
      "r494",
      "r504",
      "r505",
      "r506",
      "r519",
      "r520",
      "r531",
      "r543",
      "r544",
      "r546",
      "r547",
      "r548",
      "r563",
      "r568",
      "r569",
      "r570",
      "r584",
      "r631",
      "r632",
      "r671",
      "r672"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureRecentAccountingPronouncementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in accounting principle, accounting standards update, adoption date",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date",
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r166",
      "r169",
      "r174",
      "r175",
      "r282",
      "r283",
      "r316",
      "r317",
      "r318",
      "r325",
      "r326",
      "r327",
      "r339",
      "r479",
      "r493",
      "r494",
      "r495",
      "r504",
      "r505",
      "r506",
      "r507",
      "r519",
      "r520",
      "r521",
      "r524",
      "r531",
      "r543",
      "r544",
      "r546",
      "r547",
      "r548",
      "r563",
      "r568",
      "r569",
      "r570",
      "r584",
      "r631",
      "r632",
      "r671",
      "r672",
      "r955"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureRecentAccountingPronouncementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in accounting principle, accounting standards update, immaterial effect",
        "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]",
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r230",
      "r245",
      "r321",
      "r485"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentialDilutiveSecuritiesFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r189",
      "r190",
      "r191",
      "r219",
      "r251",
      "r252",
      "r254",
      "r256",
      "r262",
      "r263",
      "r315",
      "r347",
      "r349",
      "r350",
      "r351",
      "r354",
      "r355",
      "r387",
      "r388",
      "r391",
      "r394",
      "r402",
      "r545",
      "r691",
      "r692",
      "r693",
      "r694",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r731",
      "r753",
      "r776",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r954",
      "r978",
      "r985"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Pre-funded warrant exercisable price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Class of warrant purchases",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "inzy_ClinicalExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "ClinicalExpenses",
     "crdr": "credit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical expenses",
        "label": "Clinical Expenses",
        "documentation": "Clinical Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureLicenseAndSponsoredResearchAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License and Sponsored Research Agreements",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r156",
      "r172"
     ]
    },
    "us-gaap_CollaborativeArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureLicenseAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sponsored Research Agreement",
        "label": "Collaborative Arrangement [Member]",
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity."
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureLicenseAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementSummaryOfFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial Paper",
        "label": "Commercial Paper [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r865",
      "r866",
      "r867",
      "r868"
     ]
    },
    "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfShortTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial Paper",
        "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents."
       }
      }
     },
     "auth_ref": [
      "r1019",
      "r1053"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 7)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r83",
      "r645",
      "r730"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r341",
      "r342",
      "r809",
      "r1010"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock reserved for issuance",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r861",
      "r862",
      "r863",
      "r865",
      "r866",
      "r867",
      "r868",
      "r981",
      "r982",
      "r1052",
      "r1078",
      "r1082"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r731"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "terseLabel": "Common stock, shares issued",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "terseLabel": "Common stock, shares outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r93",
      "r731",
      "r749",
      "r1082",
      "r1083"
     ]
    },
    "us-gaap_CommonStockSharesSubscriptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesSubscriptions",
     "crdr": "credit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate offering price",
        "label": "Common Stock, Value, Subscriptions",
        "documentation": "Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r93"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock, $0.0001 par value - 200,000,000 shares authorized at December 31, 2023 and December 31, 2022; 61,768,771 shares issued and outstanding at December 31, 2023 and 40,394,363 shares issued and outstanding at December 31, 2022",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "totalLabel": "Common Stock, Value, Issued, Total",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r648",
      "r858"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Benefit Plans",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r127",
      "r128",
      "r129"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r199",
      "r201",
      "r208",
      "r639",
      "r660"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "inzy_ComputerEquipmentAndSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "ComputerEquipmentAndSoftwareMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer Equipment and Software",
        "label": "Computer Equipment And Software [Member]",
        "documentation": "Computer equipment and software."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk, Sigificant Suppliers, and Off-Balance Sheet Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r158"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Off-balance sheet concentrations of credit risk description",
        "label": "Concentration Risk, Credit Risk, Financial Instruments, off-Balance-Sheet Risk",
        "documentation": "Description of financial instruments, excluding certain derivatives, with off-balance sheet credit risk (for example, standby letters of credit or financial guarantees), including (1) information about the (shared) activity, region or economic characteristic that identifies the concentration, (2) the face or contract amount of the instrument, (3) the nature and terms of the instrument, including the market risk, cash requirements and accounting policies for it, (4) the maximum amount of loss due to credit risk that would be incurred if the counterparties failed completely to perform according to the terms of the contracts, and any security or collateral that proved to be of no value, (5) the entity's policy of requiring collateral or other security to support financial instruments subject to credit risk, information about access to collateral or other security, and a brief description of the security supporting those financial instruments, and (6) the policy of entering into and a brief description of master netting arrangements to mitigate the credit risk, and the extent to which such arrangements would reduce the maximum amount of loss due to credit risk."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r138"
     ]
    },
    "inzy_ConcentrationRiskCreditRiskOffBalanceSheetRisk": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "ConcentrationRiskCreditRiskOffBalanceSheetRisk",
     "crdr": "credit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Off-balance sheet concentrations of credit risk",
        "label": "Concentration Risk Credit Risk Off Balance Sheet Risk",
        "documentation": "Concentration risk credit risk off balance sheet risk."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r828"
     ]
    },
    "us-gaap_ContractWithCustomerDurationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerDurationAxis",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Duration [Axis]",
        "documentation": "Information by duration of contract with customer. Includes, but is not limited to, short-term and long-term contracts."
       }
      }
     },
     "auth_ref": [
      "r847",
      "r1017"
     ]
    },
    "us-gaap_ContractWithCustomerDurationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerDurationDomain",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Duration [Domain]",
        "documentation": "Duration of contract with customer. Includes, but is not limited to, short-term and long-term contracts."
       }
      }
     },
     "auth_ref": [
      "r847",
      "r1017"
     ]
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of outstanding preferred stock converted",
        "label": "Conversion of Stock, Shares Converted",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r47"
     ]
    },
    "inzy_ConvertiblePreferredStockAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "ConvertiblePreferredStockAndStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock And Stockholders Equity [Abstract]",
        "documentation": "Convertible preferred stock and stockholders equity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of common stock issued upon conversion",
        "terseLabel": "Number of outstanding preferred stock converted into common stock",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r60",
      "r92",
      "r122",
      "r397"
     ]
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfShortTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate Debt Securities",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r850",
      "r852",
      "r1077"
     ]
    },
    "us-gaap_CostMaintenance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostMaintenance",
     "crdr": "debit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureLicenseAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maintenance fees",
        "label": "Cost, Maintenance",
        "documentation": "Cost of maintenance incurred and directly related to good produced and service rendered."
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureLicenseAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r221",
      "r222",
      "r360",
      "r389",
      "r594",
      "r825",
      "r827"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility",
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility",
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "inzy_CustomaryAdjustmentsPercentageOnConversion": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "CustomaryAdjustmentsPercentageOnConversion",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customary adjustments percentage on conversion.",
        "label": "Customary Adjustments Percentage on Conversion",
        "terseLabel": "Customary percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Debt instrument, amount converted to common stock upon lender's choice",
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r47"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r217",
      "r356",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r372",
      "r379",
      "r380",
      "r382"
     ]
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtSummarizesOfImpactOfTermLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Gross proceeds",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r142",
      "r383"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Debt instrument conversion price",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r359"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateBasisForEffectiveRate",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Basis for Effective Rate",
        "terseLabel": "Annual rate of interest for the debt",
        "documentation": "Description of any adjustments made to the stated rate to determine the effective rate."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r79"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Additional Interest rate for debt instrument",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r358"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtFuturePrincipalPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r363",
      "r368",
      "r369",
      "r370",
      "r371",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r381",
      "r566",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r979"
     ]
    },
    "us-gaap_DebtInstrumentPaymentTerms": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentPaymentTerms",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Payment Terms",
        "terseLabel": "Payment description for debt",
        "documentation": "Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r85"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtFuturePrincipalPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r60",
      "r61",
      "r78",
      "r79",
      "r81",
      "r84",
      "r121",
      "r123",
      "r223",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r363",
      "r368",
      "r369",
      "r370",
      "r371",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r381",
      "r566",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r979"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtSummarizesOfImpactOfTermLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedTerseLabel": "Unamortized debt issuance costs",
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r368",
      "r384",
      "r838",
      "r839"
     ]
    },
    "us-gaap_DebtPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtPolicyTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Debt and Debt Issuance Costs",
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Realized gain and losses on investments as available-for-sale",
        "label": "Debt Securities, Available-for-Sale, Realized Gain (Loss)",
        "totalLabel": "Debt Securities, Available-for-sale, Realized Gain (Loss), Total",
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfLongTermInvestmentsDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfShortTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities Available For Sale [Table]",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Short-Term Investments",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001"
     ]
    },
    "us-gaap_DebtSecuritiesHeldToMaturityThresholdPeriodPastDueWriteoff": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesHeldToMaturityThresholdPeriodPastDueWriteoff",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt securities held-to-maturity",
        "label": "Debt Securities, Held-to-Maturity, Threshold Period Past Due, Writeoff",
        "documentation": "Threshold period for when investment in debt security measured at amortized cost (held-to-maturity) is considered past due to write off as uncollectible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredChargesPolicyTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Issuance Costs",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges."
       }
      }
     },
     "auth_ref": [
      "r187"
     ]
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFinanceCostsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Debt issuance cost",
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross deferred tax liabilities",
        "totalLabel": "Gross deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Gross deferred tax liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r90",
      "r141",
      "r473"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized research and experimental expenditures",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r1050"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Non-current net deferred tax assets (liabilities)",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net deferred tax assets",
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNetOfValuationAllowanceAbstract",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets, Net of Valuation Allowance [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating losses",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r1050"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r1050"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r71",
      "r1050"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r1050"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r1050"
     ]
    },
    "inzy_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization",
        "label": "Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Amortization",
        "documentation": "Deferred tax assets tax deferred expense reserves and accruals amortization."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred rent",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Deferred Rent",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r1050"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Valuation allowance",
        "verboseLabel": "Deferred tax assets, valuation allowance",
        "terseLabel": "Less: Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities:",
        "label": "Deferred Tax Liabilities, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred issuance costs",
        "label": "Deferred Tax Liabilities, Deferred Expense, Debt Issuance Costs",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r1050"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Depreciation of fixed assets",
        "terseLabel": "Depreciation of fixed assets",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r1050"
     ]
    },
    "inzy_DeferredTaxLiabilitiesRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "DeferredTaxLiabilitiesRightOfUseAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right of use assets",
        "label": "Deferred Tax Liabilities, Right of Use Assets",
        "documentation": "Deferred Tax Liabilities, Right of Use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanDisclosureLineItems",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Contribution Plan Disclosure [Line Items]",
        "label": "Defined Contribution Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employer contribution amount",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employer matching contribution, percentage of employees base salary and bonus paid",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employer matching contribution, percentage of match",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "documentation": "Percentage employer matches of the employee's percentage contribution matched."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanTable",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Contribution Plan [Table]",
        "label": "Defined Contribution Plan [Table]",
        "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation",
        "totalLabel": "Depreciation, Total",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r55"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total",
        "verboseLabel": "Depreciation expense",
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r55"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849"
     ]
    },
    "us-gaap_Dividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Dividends",
     "crdr": "debit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Dividends, Total",
        "terseLabel": "Dividends declared on preferred stock or common stock",
        "label": "Dividends",
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r124"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r876",
      "r877",
      "r890"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r876",
      "r877",
      "r890",
      "r926"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Domestic Tax Authority [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureNetLossPerShareScheduleOfNetLossPerShareBasicAndDilutedDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Basic, Total",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share attributable to common stockholders- basic",
        "verboseLabel": "Net loss per share attributable to common stockholder - basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r235",
      "r236",
      "r238",
      "r239",
      "r241",
      "r249",
      "r251",
      "r254",
      "r255",
      "r256",
      "r260",
      "r529",
      "r530",
      "r640",
      "r661",
      "r830"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureNetLossPerShareScheduleOfNetLossPerShareBasicAndDilutedDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share attributable to common stockholders- diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r235",
      "r236",
      "r238",
      "r239",
      "r241",
      "r251",
      "r254",
      "r255",
      "r256",
      "r260",
      "r529",
      "r530",
      "r640",
      "r661",
      "r830"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r257",
      "r258",
      "r259"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "terseLabel": "Effect of foreign currency exchange rate in cash",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1058"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUsFederalStatutoryIncomeTaxRateToEffectiveIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Percent, Total",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUsFederalStatutoryIncomeTaxRateToEffectiveIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal income tax at statutory rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r466",
      "r488"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUsFederalStatutoryIncomeTaxRateToEffectiveIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1047",
      "r1051"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUsFederalStatutoryIncomeTaxRateToEffectiveIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State income tax, net of federal benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r1047",
      "r1051"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUsFederalStatutoryIncomeTaxRateToEffectiveIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal and state research and development tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r1047",
      "r1051"
     ]
    },
    "inzy_Effectiveincometaxratereconciliationpermanentdifferences": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "Effectiveincometaxratereconciliationpermanentdifferences",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUsFederalStatutoryIncomeTaxRateToEffectiveIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Permanent differences",
        "label": "EffectiveIncomeTaxRateReconciliationPermanentDifferences",
        "documentation": "Effective income tax rate reconciliation permanent differences"
       }
      }
     },
     "auth_ref": []
    },
    "inzy_EmergingGrowthCompanyAnnualGrossRevenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "EmergingGrowthCompanyAnnualGrossRevenues",
     "crdr": "credit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual gross revenues cease to be EGC",
        "label": "Emerging Growth Company Annual Gross Revenues",
        "documentation": "Emerging Growth Company Annual Gross Revenues"
       }
      }
     },
     "auth_ref": []
    },
    "inzy_EmergingGrowthCompanyMarketValueOfCommonStockHeldByNonAffiliates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "EmergingGrowthCompanyMarketValueOfCommonStockHeldByNonAffiliates",
     "crdr": "credit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market value of common stock held by non-affiliates cease to be EGC",
        "label": "Emerging Growth Company Market Value Of Common Stock Held By Non-Affiliates",
        "documentation": "Emerging Growth Company Market Value Of Common Stock Held By Non-Affiliates"
       }
      }
     },
     "auth_ref": []
    },
    "inzy_EmergingGrowthCompanyStatusIssuancePeriodOfNonConvertibleDebt": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "EmergingGrowthCompanyStatusIssuancePeriodOfNonConvertibleDebt",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance period of non-convertible debt cease to be EGC",
        "label": "Emerging growth company status issuance period of non-convertible debt",
        "documentation": "Emerging growth company status issuance period of non-convertible debt"
       }
      }
     },
     "auth_ref": []
    },
    "inzy_EmergingGrowthCompanyStatusIssuanceValueOfNonConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "EmergingGrowthCompanyStatusIssuanceValueOfNonConvertibleDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of non-convertible debt cease to be EGC",
        "label": "Emerging Growth Company Status Issuance Value Of Non-Convertible Debt",
        "documentation": "Emerging Growth Company Status Issuance Value Of Non-Convertible Debt"
       }
      }
     },
     "auth_ref": []
    },
    "inzy_EmergingGrowthCompanyStatusPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "EmergingGrowthCompanyStatusPolicyTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Emerging Growth Company Status",
        "label": "Emerging Growth Company Status Policy Text Block",
        "documentation": "Emerging Growth Company Status Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Employee-related Liabilities, Current, Total",
        "terseLabel": "Payroll and related liabilities",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total",
        "terseLabel": "Total unrecognized compensation cost related to outstanding employee awards",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r449"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total unrecognized compensation cost related to outstanding employee awards, expected to be recognized over a weighted-average period",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r449"
     ]
    },
    "inzy_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition2",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Service ShareBased Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period ForRecognition 2",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition 2",
        "documentation": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition 2"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentialDilutiveSecuritiesFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquipmentMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory Equipment and Manufacturing Equipment",
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r176",
      "r203",
      "r204",
      "r205",
      "r224",
      "r225",
      "r226",
      "r231",
      "r242",
      "r244",
      "r261",
      "r320",
      "r328",
      "r404",
      "r450",
      "r451",
      "r452",
      "r481",
      "r482",
      "r508",
      "r510",
      "r511",
      "r512",
      "r513",
      "r516",
      "r528",
      "r555",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r588",
      "r673",
      "r674",
      "r675",
      "r701",
      "r776"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r882",
      "r894",
      "r904",
      "r930"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r879",
      "r891",
      "r901",
      "r927"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "inzy_ExerciseOfPreFundedWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "ExerciseOfPreFundedWarrants",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise of pre funded warrants.",
        "label": "Exercise of Pre Funded warrants",
        "terseLabel": "Exercise of pre-funded warrants, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementSummaryOfFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r536",
      "r537",
      "r541"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementSummaryOfFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r536",
      "r537",
      "r541"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Financial Assets Measured at Fair Value",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r137"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementSummaryOfFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class",
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementSummaryOfFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class",
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r76"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementSummaryOfFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r537",
      "r602",
      "r603",
      "r604",
      "r838",
      "r839",
      "r850",
      "r851",
      "r852"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementSummaryOfFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r536",
      "r537",
      "r538",
      "r539",
      "r542"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementSummaryOfFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r407",
      "r412",
      "r537",
      "r602",
      "r850",
      "r851",
      "r852"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementSummaryOfFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Other Observable Inputs (Level 2)",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r407",
      "r412",
      "r537",
      "r603",
      "r838",
      "r839",
      "r850",
      "r851",
      "r852"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementSummaryOfFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Unobservable Inputs (Level 3)",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r537",
      "r604",
      "r838",
      "r839",
      "r850",
      "r851",
      "r852"
     ]
    },
    "us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Investment Redemption, Notice Period",
        "label": "Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Investment Redemption, Notice Period",
        "documentation": "Notice period the entity is required to deliver before it can redeem an investment calculated using net asset value per share, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, investments calculated by per unit, per membership interest, other equity or ownership interest and alternative investments."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementSummaryOfFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
     "crdr": "debit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value measurement with unobservable inputs reconciliation recurring basis asset transfers into level 3",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3",
        "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
     "crdr": "credit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value measurement with unobservable inputs reconciliation recurring basis asset transfers out of level 3",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3",
        "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementSummaryOfFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r602",
      "r603",
      "r604",
      "r838",
      "r839",
      "r850",
      "r851",
      "r852"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementSummaryOfFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r535",
      "r542"
     ]
    },
    "inzy_FederalAndStateTaxAuthorityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "FederalAndStateTaxAuthorityMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal and State",
        "label": "Federal And State Tax Authority [Member]",
        "documentation": "Federal and state tax authority."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease",
        "label": "Finance Lease, Impairment Loss",
        "documentation": "Amount of impairment loss from right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfLongTermInvestmentsDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfShortTermInvestmentsDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementSummaryOfFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r335",
      "r336",
      "r337",
      "r381",
      "r400",
      "r517",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r659",
      "r835",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r1001",
      "r1002",
      "r1003",
      "r1004"
     ]
    },
    "inzy_FirstPatientInCompanyMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "FirstPatientInCompanyMilestonesMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureLicenseAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First Patient in Company Milestones [Member]",
        "label": "First Patient in Company Milestones [Member]",
        "documentation": "First patient in company milestones member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionGainLossRealized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionGainLossRealized",
     "crdr": "credit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net foreign exchange gain (loss)",
        "label": "Realized Gain (Loss), Foreign Currency Transaction, before Tax",
        "documentation": "Amount, before tax, of realized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r751",
      "r869",
      "r1056",
      "r1057",
      "r1081"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency Transactions",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r554"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r886",
      "r898",
      "r908",
      "r934"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r886",
      "r898",
      "r908",
      "r934"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r886",
      "r898",
      "r908",
      "r934"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r886",
      "r898",
      "r908",
      "r934"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r886",
      "r898",
      "r908",
      "r934"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and Fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "inzy_FutureOfferingsOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "FutureOfferingsOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future offerings of common stock",
        "label": "Future offerings of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "General and Administrative Expense, Total",
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r755"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfTotalCompensationCostRecognizedInStatementsOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "us-gaap_GranteeStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GranteeStatusAxis",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grantee Status",
        "label": "Grantee Status [Axis]",
        "documentation": "Information by status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447"
     ]
    },
    "us-gaap_GranteeStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GranteeStatusDomain",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grantee Status",
        "label": "Grantee Status [Domain]",
        "documentation": "Status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447"
     ]
    },
    "us-gaap_HealthCareOrganizationRevenueSourcesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "HealthCareOrganizationRevenueSourcesAxis",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureLicenseAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Health Care Organization, Revenue Sources [Axis]",
        "documentation": "Information by major payor source of revenue for health care organizations."
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "us-gaap_HealthCareOrganizationRevenueSourcesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "HealthCareOrganizationRevenueSourcesDomain",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureLicenseAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Health Care Organization, Revenue Sources [Domain]",
        "documentation": "Major payor source of revenue for health care organizations."
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IPOMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IPO",
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r876",
      "r877",
      "r890"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Long-lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r115"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfTotalCompensationCostRecognizedInStatementsOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r340",
      "r760"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfTotalCompensationCostRecognizedInStatementsOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r760"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r461",
      "r467",
      "r470",
      "r477",
      "r486",
      "r489",
      "r490",
      "r491",
      "r696"
     ]
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax penalties and interest expense",
        "label": "Income Tax Examination, Penalties and Interest Expense",
        "totalLabel": "Income Tax Examination, Penalties and Interest Expense, Total",
        "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r1048"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax benefit",
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Income Tax Expense (Benefit), Total",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r170",
      "r243",
      "r244",
      "r267",
      "r465",
      "r487",
      "r663"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IncomeTaxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r463",
      "r464",
      "r470",
      "r471",
      "r476",
      "r478",
      "r690"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total",
        "terseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r956",
      "r976"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other Long term liabilities",
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total",
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "inzy_IncreaseDecreasePrepaidExpensesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "IncreaseDecreasePrepaidExpensesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses - noncurrent",
        "label": "Increase Decrease Prepaid Expenses Noncurrent",
        "documentation": "Increase (decrease) prepaid expenses, noncurrent."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r889",
      "r898",
      "r908",
      "r925",
      "r934",
      "r938",
      "r946"
     ]
    },
    "inzy_InducementPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "InducementPlanMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inducement Plan",
        "label": "Inducement Plan [Member]",
        "documentation": "Inducement Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r878",
      "r950"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r878",
      "r950"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r878",
      "r950"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "terseLabel": "Interest expense",
        "label": "Interest Expense",
        "totalLabel": "Interest Expense, Total",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r147",
      "r206",
      "r266",
      "r565",
      "r761",
      "r869",
      "r1080"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest",
        "negatedLabel": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r213",
      "r214"
     ]
    },
    "us-gaap_InterestReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest receivable",
        "label": "Interest Receivable, Current",
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r968"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r265"
     ]
    },
    "inzy_InvestmentMaturityPeriod": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "InvestmentMaturityPeriod",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfLongTermInvestmentsDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfShortTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity",
        "label": "Investment Maturity Period",
        "documentation": "Investment maturity period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-Term and Long-Term Investments",
        "label": "Investment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r662",
      "r686",
      "r687",
      "r688",
      "r689",
      "r786",
      "r787"
     ]
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfLongTermInvestmentsDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfShortTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment Type",
        "label": "Investment Type [Axis]",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r713",
      "r715",
      "r716",
      "r718",
      "r720",
      "r783",
      "r785",
      "r789",
      "r792",
      "r793",
      "r794",
      "r795",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r863"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfLongTermInvestmentsDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfShortTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investments [Domain]",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r713",
      "r715",
      "r716",
      "r718",
      "r720",
      "r783",
      "r785",
      "r789",
      "r792",
      "r793",
      "r794",
      "r795",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r863"
     ]
    },
    "inzy_IssuanceOfPreFundedWarrantsNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "IssuanceOfPreFundedWarrantsNetOfIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of pre-funded warrants, net of issuance costs",
        "label": "Issuance of pre-funded warrants, net of issuance costs",
        "terseLabel": "Issuance of pre-funded warrants, net of issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "inzy_JefferiesLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "JefferiesLlcMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jefferies LLC",
        "documentation": "Jefferies llc.",
        "label": "Jefferies LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "inzy_K2HvMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "K2HvMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "K2HV [Member]",
        "label": "K2HV [Member]",
        "terseLabel": "K2HV"
       }
      }
     },
     "auth_ref": []
    },
    "inzy_K2LoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "K2LoanAgreementMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtFuturePrincipalPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "K2 Loan Agreement [Member]",
        "label": "K2 Loan Agreement [Member]",
        "terseLabel": "K2 Loan Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "inzy_LaboratorySpaceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "LaboratorySpaceMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory Space",
        "label": "Laboratory Space [Member]",
        "documentation": "Laboratory space."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LandImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LandImprovementsMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold Improvements",
        "label": "Land Improvements [Member]",
        "documentation": "Additions or improvements to real estate held."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseIncentiveReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseIncentiveReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "label": "Lease Incentive Receivable",
        "documentation": "This item represents a receivable for an incentive or inducement contractually stipulated between parties to a lease whereby the lessor has committed to provide the entity (lessee) with a cash payment as inducement to enter the lease."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r151"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold Improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LegalFees",
     "crdr": "debit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Costs related to legal proceedings",
        "label": "Legal Fees",
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "inzy_LendersReimbursedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "LendersReimbursedAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lenders reimbursed amount",
        "label": "Lenders reimbursed amount",
        "terseLabel": "Lenders reimbursed amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee Lease Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee Lease Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease."
       }
      }
     },
     "auth_ref": [
      "r580"
     ]
    },
    "inzy_LesseeOperatingLeaseExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "LesseeOperatingLeaseExpirationYear",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee operating lease expiration year",
        "label": "Lessee Operating Lease Expiration Year",
        "documentation": "Lessee operating lease expiration year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Lease Payments Under Non-Cancelable Leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1062"
     ]
    },
    "inzy_LesseeOperatingLeaseLiabilityPaymentDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "LesseeOperatingLeaseLiabilityPaymentDue",
     "crdr": "credit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureLeasePaymentsUnderNonCancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability, Total",
        "label": "Lessee Operating Lease Liability Payment Due",
        "documentation": "Lessee Operating Lease Liability Payment Due"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureLeasePaymentsUnderNonCancelableLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureLeasePaymentsUnderNonCancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating lease liability, Total",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureLeasePaymentsUnderNonCancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureLeasePaymentsUnderNonCancelableLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureLeasePaymentsUnderNonCancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureLeasePaymentsUnderNonCancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureLeasePaymentsUnderNonCancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureLeasePaymentsUnderNonCancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureLeasePaymentsUnderNonCancelableLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureLeasePaymentsUnderNonCancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee operating lease option to extend description",
        "label": "Lessee, Operating Lease, Option to Extend",
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r580"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease renewal term",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1061"
     ]
    },
    "us-gaap_LetterOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LetterOfCreditMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Letters of Credit",
        "label": "Letter of Credit [Member]",
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r219",
      "r315",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r499",
      "r502",
      "r503",
      "r545",
      "r729",
      "r831",
      "r871",
      "r1013",
      "r1063",
      "r1064"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r143",
      "r652",
      "r858",
      "r980",
      "r1005",
      "r1055"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r182",
      "r219",
      "r315",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r499",
      "r502",
      "r503",
      "r545",
      "r858",
      "r1013",
      "r1063",
      "r1064"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "inzy_LicenseAgreementPaymentUponAchievementOfSpecifiedProductSalesOrDevelopmentAndCommercializationMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "LicenseAgreementPaymentUponAchievementOfSpecifiedProductSalesOrDevelopmentAndCommercializationMilestones",
     "crdr": "credit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureLicenseAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment upon achievement of certain milestones",
        "label": "License Agreement Payment Upon Achievement Of Specified Product Sales Or Development And Commercialization Milestones",
        "documentation": "License agreement payment upon achievement of specified product sales or development and commercialization milestones."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LicenseMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureLicenseAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License",
        "label": "License [Member]",
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r1018"
     ]
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityCommitmentFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Commitment Fee Amount",
        "terseLabel": "Lenders facility fee",
        "documentation": "Amount of the fee for available but unused credit capacity under the credit facility."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Prepayment fee percentage",
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage",
        "terseLabel": "Additional facility fee",
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility."
       }
      }
     },
     "auth_ref": []
    },
    "inzy_LoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "LoanAgreementMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Agreement Member",
        "label": "Loan Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtFuturePrincipalPaymentDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtSummarizesOfImpactOfTermLoanDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt",
        "totalLabel": "Total",
        "verboseLabel": "Carrying value",
        "terseLabel": "Long term debt, net",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r142",
      "r369",
      "r385",
      "r838",
      "r839",
      "r1074"
     ]
    },
    "us-gaap_LongTermDebtMaturingInYearsTwoAndThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturingInYearsTwoAndThree",
     "crdr": "credit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtFuturePrincipalPaymentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtFuturePrincipalPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Total",
        "label": "Long-Term Debt, Maturity, Year Two and Three",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second and third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r1016"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtFuturePrincipalPaymentDetails": {
       "parentTag": "us-gaap_LongTermDebtMaturingInYearsTwoAndThree",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtFuturePrincipalPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Long-Term Debt, Maturity, Year One",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r223",
      "r374"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtFuturePrincipalPaymentDetails": {
       "parentTag": "us-gaap_LongTermDebtMaturingInYearsTwoAndThree",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtFuturePrincipalPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Long-Term Debt, Maturity, Year Three",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r223",
      "r374"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtFuturePrincipalPaymentDetails": {
       "parentTag": "us-gaap_LongTermDebtMaturingInYearsTwoAndThree",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtFuturePrincipalPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Long-Term Debt, Maturity, Year Two",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r223",
      "r374"
     ]
    },
    "us-gaap_LongTermDebtMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturityDate",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Maturity Date",
        "terseLabel": "Loan maturity date",
        "documentation": "Maturity date of long-term debt, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r1054"
     ]
    },
    "us-gaap_LongTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Long-term Investments, Total",
        "terseLabel": "Long-term investments",
        "label": "Long-Term Investments",
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)."
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "inzy_LongTermInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "LongTermInvestmentsMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfLongTermInvestmentsDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfShortTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long Term Investments",
        "label": "Long Term Investments [Member]",
        "documentation": "Long term investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtFuturePrincipalPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtFuturePrincipalPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r57"
     ]
    },
    "inzy_LossOnDisposalOfFixedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "LossOnDisposalOfFixedAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on disposal of fixed assets",
        "label": "Loss on Disposal of Fixed Assets",
        "documentation": "Loss on Disposal of Fixed Assets"
       }
      }
     },
     "auth_ref": []
    },
    "stpr_MA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "localname": "MA",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Boston, Massachusetts",
        "label": "MASSACHUSETTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ManagementFeeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ManagementFeeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Management Fee Expense",
        "label": "Management Fee Expense",
        "documentation": "Amount of expense for investment management fee, including, but not limited to, expense in connection with research, selection, supervision, and custody of investment."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r755",
      "r869",
      "r1079"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfAssumptionsUsedToValueStockOptionsGrantedToEmployeesUsingBlackscholesOptionpricingDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344",
      "r345",
      "r346",
      "r414",
      "r629",
      "r670",
      "r721",
      "r722",
      "r784",
      "r788",
      "r790",
      "r791",
      "r796",
      "r819",
      "r820",
      "r834",
      "r842",
      "r853",
      "r860",
      "r1015",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfAssumptionsUsedToValueStockOptionsGrantedToEmployeesUsingBlackscholesOptionpricingDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Minimum",
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344",
      "r345",
      "r346",
      "r414",
      "r629",
      "r670",
      "r721",
      "r722",
      "r784",
      "r788",
      "r790",
      "r791",
      "r796",
      "r819",
      "r820",
      "r834",
      "r842",
      "r853",
      "r860",
      "r1015",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementSummaryOfFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money Market Funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1019"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r945"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r212"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r212"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r110",
      "r111"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureNetLossPerShareScheduleOfNetLossPerShareBasicAndDilutedDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "negatedLabel": "Net loss",
        "verboseLabel": "Net loss",
        "totalLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r111",
      "r146",
      "r180",
      "r197",
      "r200",
      "r205",
      "r219",
      "r230",
      "r235",
      "r236",
      "r238",
      "r239",
      "r243",
      "r244",
      "r253",
      "r264",
      "r274",
      "r276",
      "r278",
      "r315",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r530",
      "r545",
      "r657",
      "r752",
      "r774",
      "r775",
      "r832",
      "r869",
      "r1013"
     ]
    },
    "inzy_NetProductSalesMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "NetProductSalesMilestoneMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureLicenseAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Product Sales Milestone [Member]",
        "label": "Net Product Sales Milestone [Member]",
        "documentation": "Net product sales milestone member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureRecentAccountingPronouncements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r164",
      "r171",
      "r179",
      "r228",
      "r229",
      "r232",
      "r233",
      "r246",
      "r247",
      "r321",
      "r322",
      "r483",
      "r484",
      "r485",
      "r514",
      "r526",
      "r532",
      "r533",
      "r534",
      "r551",
      "r552",
      "r553",
      "r572",
      "r573",
      "r589",
      "r634",
      "r635",
      "r636",
      "r677",
      "r678",
      "r679",
      "r680",
      "r682"
     ]
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureRecentAccountingPronouncementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Accounting Pronouncements Or Change In Accounting Principle [Line Items]",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r227",
      "r230",
      "r231",
      "r232",
      "r234",
      "r238",
      "r246",
      "r260",
      "r282",
      "r283",
      "r317",
      "r318",
      "r319",
      "r320",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r339",
      "r450",
      "r451",
      "r452",
      "r479",
      "r480",
      "r481",
      "r482",
      "r493",
      "r494",
      "r495",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r515",
      "r516",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r543",
      "r544",
      "r547",
      "r548",
      "r549",
      "r550",
      "r563",
      "r564",
      "r568",
      "r569",
      "r570",
      "r571",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r631",
      "r632",
      "r633",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r685"
     ]
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureRecentAccountingPronouncementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Accounting Pronouncements Or Change In Accounting Principle [Table]",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r227",
      "r230",
      "r231",
      "r232",
      "r234",
      "r238",
      "r246",
      "r260",
      "r282",
      "r283",
      "r317",
      "r318",
      "r319",
      "r320",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r339",
      "r450",
      "r451",
      "r452",
      "r479",
      "r480",
      "r481",
      "r482",
      "r493",
      "r494",
      "r495",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r515",
      "r516",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r543",
      "r544",
      "r547",
      "r548",
      "r549",
      "r550",
      "r563",
      "r564",
      "r568",
      "r569",
      "r570",
      "r571",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r631",
      "r632",
      "r633",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r685"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Issued and Adopted Accounting Standards",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r886",
      "r898",
      "r908",
      "r925",
      "r934"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r945"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r945"
     ]
    },
    "us-gaap_NoncollaborativeArrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncollaborativeArrangementTransactionsMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureLicenseAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Arrangements",
        "label": "Arrangement Other than Collaborative [Member]",
        "documentation": "Arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other income, net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense):",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r987"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r987"
     ]
    },
    "inzy_OfficeSpaceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "OfficeSpaceMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office Space",
        "label": "Office Space [Member]",
        "documentation": "Office space."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r274",
      "r276",
      "r278",
      "r832"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease expense",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r1060"
     ]
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseImpairmentLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction in the carrying value of right-of-use assets",
        "label": "Operating Lease, Impairment Loss",
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r1059"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureRecentAccountingPronouncementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating Lease, Liability, Total",
        "terseLabel": "Operating lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, net of current portion",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included for measurement of lease liabilities",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r577",
      "r581"
     ]
    },
    "inzy_OperatingLeaseReversedLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "OperatingLeaseReversedLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureRecentAccountingPronouncementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, reversed lease liability",
        "label": "Operating Lease Reversed Lease Liability",
        "documentation": "Operating lease reversed lease liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureRecentAccountingPronouncementsAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r575"
     ]
    },
    "inzy_OperatingLeaseWeightedAverageIncrementalBorrowingRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "OperatingLeaseWeightedAverageIncrementalBorrowingRate",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average incremental borrowing rate for operating leases",
        "label": "Operating Lease Weighted Average Incremental Borrowing Rate",
        "documentation": "Operating lease weighted average incremental borrowing rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term for operating leases",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r582",
      "r857"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "totalLabel": "Operating Loss Carryforwards, Total",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "inzy_OperatingLossCarryforwardsExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards expiration year",
        "label": "Operating Loss Carryforwards Expiration Year",
        "documentation": "Operating  loss carryforwards expiration year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "inzy_OperatingLossCarryforwardsWithExpirationPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "OperatingLossCarryforwardsWithExpirationPeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards with expiration period",
        "label": "Operating Loss Carryforwards With Expiration Period",
        "documentation": "Operating loss carryforwards with expiration period."
       }
      }
     },
     "auth_ref": []
    },
    "inzy_OperatingLossCarryforwardsWithNoExpirationPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "OperatingLossCarryforwardsWithNoExpirationPeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards with no expiration period",
        "label": "Operating Loss Carryforwards With No Expiration Period",
        "documentation": "Operating loss carryforwards with no expiration period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization and Basis of Presentation",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r135",
      "r683",
      "r684"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive income:",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustment",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent, Total",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r12",
      "r136"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Unrealized loss on investments",
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r195",
      "r196"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustment",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax",
        "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax, Total",
        "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r99"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other comprehensive income (loss)",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r19",
      "r198",
      "r201",
      "r207",
      "r555",
      "r556",
      "r561",
      "r638",
      "r658",
      "r972",
      "r973"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss):",
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax",
        "terseLabel": "Unrealized (losses) on available-for-sale securities",
        "documentation": "Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r196",
      "r314"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long term liabilities",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Nonoperating Income (Expense), Total",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other expense, net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid other",
        "label": "Other Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r969",
      "r1007"
     ]
    },
    "inzy_Others": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "Others",
     "crdr": "credit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Others",
        "label": "Others",
        "terseLabel": "Others"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r884",
      "r896",
      "r906",
      "r932"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r887",
      "r899",
      "r909",
      "r935"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r887",
      "r899",
      "r909",
      "r935"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Over-Allotment Option [Member]",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "inzy_PartialUpfrontConsiderationPaymentUnderLicenseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "PartialUpfrontConsiderationPaymentUnderLicenseAgreement",
     "crdr": "debit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureLicenseAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Partial upfront consideration payment under license agreement",
        "label": "Partial Upfront Consideration Payment Under License Agreement",
        "documentation": "Partial upfront consideration payment under license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "inzy_PatentCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "PatentCostsPolicyTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patent Costs",
        "label": "Patent Costs Policy Text Block",
        "documentation": "Patent Costs Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance costs",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Payments to Acquire Marketable Securities, Total",
        "negatedLabel": "Purchases of marketable securities",
        "label": "Payments to Acquire Marketable Securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r989"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "inzy_PercentageOfBeneficialOwnershipLimitation": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "PercentageOfBeneficialOwnershipLimitation",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of beneficial ownership limitation.",
        "label": "Percentage of Beneficial Ownership Limitation",
        "terseLabel": "Beneficial ownership limitation percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045"
     ]
    },
    "inzy_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre Funded Warrants",
        "label": "Pre Funded Warrants [Member]",
        "terseLabel": "Pre-funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r387"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r731"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Preferred Stock, Shares Issued, Total",
        "terseLabel": "Preferred stock, shares issued",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r387"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "terseLabel": "Preferred stock, shares outstanding",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r731",
      "r749",
      "r1082",
      "r1083"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock, $0.0001 par value - 5,000,000 shares authorized at December 31, 2023 and December 31, 2022; No shares issued and outstanding at December 31, 2023 or December 31, 2022",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "totalLabel": "Preferred Stock, Value, Issued, Total",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r647",
      "r858"
     ]
    },
    "inzy_PrepaidClinicalTrialAndOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "PrepaidClinicalTrialAndOther",
     "crdr": "debit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfNoncurrentPrepaidExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid clinical trial and other",
        "label": "Prepaid Clinical Trial And Other",
        "documentation": "Prepaid clinical trial and other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r971"
     ]
    },
    "us-gaap_PrepaidExpenseNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfNoncurrentPrepaidExpensesDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses - noncurrent",
        "totalLabel": "Prepaid Expense, Noncurrent, Total",
        "label": "Prepaid Expense, Noncurrent",
        "verboseLabel": "Prepaid expenses, net of current portion",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid insurance",
        "label": "Prepaid Insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r824",
      "r836",
      "r1007"
     ]
    },
    "inzy_PrepaidResearchStudies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "PrepaidResearchStudies",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid research studies",
        "label": "Prepaid Research Studies",
        "documentation": "Prepaid research studies."
       }
      }
     },
     "auth_ref": []
    },
    "inzy_PrepaymentOfLoans": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "PrepaymentOfLoans",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayment of Loans",
        "label": "Prepayment of Loans",
        "terseLabel": "Prepayment of loans"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds issuance of common stock, deducting underwriting discounts and commissions",
        "label": "Proceeds from Issuance of Common Stock",
        "verboseLabel": "Net proceeds from issuance of common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "inzy_ProceedsFromIssuanceOfCommonStockForCashUnderEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "ProceedsFromIssuanceOfCommonStockForCashUnderEmployeeStockPurchasePlan",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock for cash under employee stock purchase plan",
        "label": "Proceeds from Issuance of Common Stock for Cash Under Employee Stock Purchase Plan",
        "terseLabel": "Proceeds from issuance of common stock for cash under employee stock purchase plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net proceeds from issuance of shares",
        "terseLabel": "Proceeds from issuance of Series A-2 Convertible Preferred Stock, net of issuance costs",
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Proceeds from Issuance of Long-Term Debt, Total",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Net proceeds from issuance of long-term debt",
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r691"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Net proceeds from the offering",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Net proceeds from issuance of pre-funded warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance or Sale of Equity",
        "totalLabel": "Proceeds from Issuance or Sale of Equity, Total",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r691"
     ]
    },
    "us-gaap_ProceedsFromLoans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromLoans",
     "crdr": "debit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Loans",
        "documentation": "Cash received from principal payments made on loans related to operating activities."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Proceeds from Sale and Maturity of Marketable Securities, Total",
        "terseLabel": "Maturities of marketable securities",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r18"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureLicenseAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r279",
      "r630",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r821",
      "r843",
      "r859",
      "r957",
      "r1011",
      "r1012",
      "r1017",
      "r1076"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureLicenseAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r279",
      "r630",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r821",
      "r843",
      "r859",
      "r957",
      "r1011",
      "r1012",
      "r1017",
      "r1076"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total",
        "terseLabel": "Net loss",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r197",
      "r200",
      "r211",
      "r219",
      "r230",
      "r243",
      "r244",
      "r264",
      "r274",
      "r276",
      "r278",
      "r315",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r497",
      "r500",
      "r501",
      "r530",
      "r545",
      "r641",
      "r656",
      "r700",
      "r752",
      "r774",
      "r775",
      "r832",
      "r855",
      "r856",
      "r870",
      "r974",
      "r1013"
     ]
    },
    "inzy_PropertyAndEquipmentEstimatedUsefulLivesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "PropertyAndEquipmentEstimatedUsefulLivesTableTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimated Useful Lives of Property and Equipment",
        "label": "Property And Equipment Estimated Useful Lives Table Text Block",
        "documentation": "Property And Equipment Estimated Useful Lives Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "totalLabel": "Property, Plant and Equipment, Gross, Total",
        "terseLabel": "Property and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r185",
      "r655"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property Plant And Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "totalLabel": "Total",
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r642",
      "r655",
      "r858"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r159",
      "r162",
      "r653"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Useful Life (In Years)",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]",
        "documentation": "Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value."
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfAssumptionsUsedToValueStockOptionsGrantedToEmployeesUsingBlackscholesOptionpricingDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344",
      "r345",
      "r346",
      "r406",
      "r414",
      "r444",
      "r445",
      "r446",
      "r605",
      "r629",
      "r670",
      "r721",
      "r722",
      "r784",
      "r788",
      "r790",
      "r791",
      "r796",
      "r819",
      "r820",
      "r834",
      "r842",
      "r853",
      "r860",
      "r863",
      "r1009",
      "r1015",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfAssumptionsUsedToValueStockOptionsGrantedToEmployeesUsingBlackscholesOptionpricingDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344",
      "r345",
      "r346",
      "r406",
      "r414",
      "r444",
      "r445",
      "r446",
      "r605",
      "r629",
      "r670",
      "r721",
      "r722",
      "r784",
      "r788",
      "r790",
      "r791",
      "r796",
      "r819",
      "r820",
      "r834",
      "r842",
      "r853",
      "r860",
      "r863",
      "r1009",
      "r1015",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070"
     ]
    },
    "inzy_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Issued Accounting Standards Not Yet Adopted",
        "label": "Recently Issued Accounting Standards Not Yet Adopted Policy [Text Block]",
        "documentation": "Recently issued accounting standards not yet adopted.."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r879",
      "r891",
      "r901",
      "r927"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r756",
      "r757",
      "r760"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r590",
      "r591",
      "r592",
      "r593",
      "r595",
      "r697",
      "r698",
      "r699",
      "r758",
      "r759",
      "r760",
      "r780",
      "r782"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureLicenseAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r221",
      "r222",
      "r360",
      "r389",
      "r594",
      "r826",
      "r827"
     ]
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureLicenseAndSponsoredResearchAgreementsAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Research and Development Expense, Total",
        "verboseLabel": "Research and development expenses",
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r460",
      "r1071"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfTotalCompensationCostRecognizedInStatementsOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Costs",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "inzy_ResearchSupportFundingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "ResearchSupportFundingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureLicenseAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research support funding amount",
        "label": "Research Support Funding Amount",
        "documentation": "Research support funding amount."
       }
      }
     },
     "auth_ref": []
    },
    "inzy_ResearchSupportFundingContractExtendedDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "ResearchSupportFundingContractExtendedDate",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureLicenseAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research support funding contract extended date",
        "label": "Research Support Funding Contract Extended Date",
        "documentation": "Research support funding contract extended date"
       }
      }
     },
     "auth_ref": []
    },
    "inzy_ResearchSupportFundingExpirationMonthAndYear": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "ResearchSupportFundingExpirationMonthAndYear",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureLicenseAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research support funding expiration year",
        "label": "Research Support Funding Expiration Month And Year",
        "documentation": "Research support funding expiration month and year."
       }
      }
     },
     "auth_ref": []
    },
    "inzy_ResearchSupportFundingExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "ResearchSupportFundingExpirationYear",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureLicenseAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research support funding expiration year",
        "label": "Research Support Funding Expiration Year",
        "documentation": "Research support funding expiration year."
       }
      }
     },
     "auth_ref": []
    },
    "inzy_ResearchSupportFundingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "ResearchSupportFundingPeriod",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureLicenseAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research support funding period",
        "label": "Research Support Funding Period",
        "documentation": "Research support funding period."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RestatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RestatementAxis",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureRecentAccountingPronouncementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revision of Prior Period",
        "label": "Revision of Prior Period [Axis]"
       }
      }
     },
     "auth_ref": [
      "r177",
      "r224",
      "r225",
      "r226",
      "r230",
      "r231",
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r246",
      "r260",
      "r323",
      "r324",
      "r482",
      "r523",
      "r528",
      "r529",
      "r530",
      "r571",
      "r587",
      "r588",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r685"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r880",
      "r892",
      "r902",
      "r928"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r881",
      "r893",
      "r903",
      "r929"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r888",
      "r900",
      "r910",
      "r936"
     ]
    },
    "srt_RestatementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RestatementDomain",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureRecentAccountingPronouncementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revision of Prior Period",
        "label": "Revision of Prior Period [Domain]"
       }
      }
     },
     "auth_ref": [
      "r177",
      "r224",
      "r225",
      "r226",
      "r230",
      "r231",
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r246",
      "r260",
      "r323",
      "r324",
      "r482",
      "r523",
      "r528",
      "r529",
      "r530",
      "r571",
      "r587",
      "r588",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r685"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Restricted Cash, Total",
        "label": "Restricted Cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r966",
      "r977",
      "r1072",
      "r1075"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Restricted Cash and Cash Equivalents, Total",
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash and Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r139",
      "r183",
      "r215",
      "r646"
     ]
    },
    "inzy_RestrictedCashMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "RestrictedCashMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Cash",
        "label": "Restricted Cash [Member]",
        "documentation": "Restricted cash."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash, Noncurrent",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r967",
      "r977"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityRelatedToRestrictedStockUnitsRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "RSUs",
        "terseLabel": "RSUs",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureRecentAccountingPronouncementsAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r124",
      "r651",
      "r677",
      "r682",
      "r695",
      "r732",
      "r858"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r224",
      "r225",
      "r226",
      "r231",
      "r242",
      "r244",
      "r320",
      "r328",
      "r450",
      "r451",
      "r452",
      "r481",
      "r482",
      "r508",
      "r511",
      "r512",
      "r516",
      "r528",
      "r673",
      "r675",
      "r701",
      "r1082"
     ]
    },
    "srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureRecentAccountingPronouncementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revision of Prior Period, Accounting Standards Update, Adjustment",
        "label": "Revision of Prior Period, Accounting Standards Update, Adjustment [Member]"
       }
      }
     },
     "auth_ref": [
      "r177",
      "r230",
      "r231",
      "r238",
      "r246",
      "r323",
      "r324",
      "r482",
      "r523",
      "r530",
      "r571",
      "r587",
      "r588",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r945"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r945"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock, price per shares",
        "verboseLabel": "Offering price",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentialDilutiveSecuritiesFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Potential Dilutive Securities from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfLongTermInvestmentsDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfShortTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Available For Sale Securities [Line Items]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureLicenseAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Components of Deferred Tax Assets",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Net Loss Per Share, Basic and Diluted",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r986"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate to Effective Income Tax Rate",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Total Compensation Cost Recognized in Statements of Operations",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "inzy_ScheduleOfLongTermInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "ScheduleOfLongTermInvestmentsTableTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-Term Investments",
        "label": "Schedule Of Long Term Investments Table [Text Block]",
        "documentation": "Schedule of long term investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Future Principal Payment of Loan Agreement",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "inzy_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets",
        "label": "Schedule Of Prepaid Expenses And Other Current Assets Table [Text Block]",
        "documentation": "Schedule of prepaid expenses and other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "inzy_ScheduleOfPrepaidExpensesNoncurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "ScheduleOfPrepaidExpensesNoncurrentTableTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Noncurrent Prepaid Expenses",
        "label": "Schedule Of Prepaid Expenses Noncurrent Table [Text Block]",
        "documentation": "Schedule of prepaid expenses noncurrent."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityRelatedToRestrictedStockUnitsRsusDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfAssumptionsUsedToValueStockOptionsGrantedToEmployeesUsingBlackscholesOptionpricingDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfTotalCompensationCostRecognizedInStatementsOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Activity Related to Restricted Stock Units (\"RSUs\")",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Stock Option Activity Under Equity Incentive Plans",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r65"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Assumptions Used to Value Stock Options Granted Using Black-Scholes Option-Pricing",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "inzy_Section174Adjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "Section174Adjustment",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Section 174 Adjustment",
        "label": "Section 174 Adjustment",
        "terseLabel": "Section 174 Adjustment"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "us-gaap_SecurityDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SecurityDeposit",
     "crdr": "debit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security deposits",
        "label": "Security Deposit",
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease."
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r280",
      "r281",
      "r714",
      "r717",
      "r719",
      "r785",
      "r789",
      "r793",
      "r797",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r822",
      "r844",
      "r863",
      "r1017",
      "r1076"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r280",
      "r833"
     ]
    },
    "inzy_SeriesAConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "SeriesAConvertiblePreferredStockMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentialDilutiveSecuritiesFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Convertible Preferred Stock [Member]",
        "label": "Series A Convertible Preferred Stock [Member]",
        "documentation": "Series A convertible preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "inzy_SeriesATwoConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "SeriesATwoConvertiblePreferredStockMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentialDilutiveSecuritiesFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A-2 Convertible Preferred Stock [Member]",
        "label": "Series A Two Convertible Preferred Stock [Member]",
        "documentation": "Series A two convertible preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total",
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan description",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Description",
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r64"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfAssumptionsUsedToValueStockOptionsGrantedToEmployeesUsingBlackscholesOptionpricingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfAssumptionsUsedToValueStockOptionsGrantedToEmployeesUsingBlackscholesOptionpricingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volatility rate range, maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfAssumptionsUsedToValueStockOptionsGrantedToEmployeesUsingBlackscholesOptionpricingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volatility rate range, minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfAssumptionsUsedToValueStockOptionsGrantedToEmployeesUsingBlackscholesOptionpricingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate range, maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfAssumptionsUsedToValueStockOptionsGrantedToEmployeesUsingBlackscholesOptionpricingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate range, minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityRelatedToRestrictedStockUnitsRsusDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfAssumptionsUsedToValueStockOptionsGrantedToEmployeesUsingBlackscholesOptionpricingDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfTotalCompensationCostRecognizedInStatementsOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in additional number of shares to be issued",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares authorized for issuance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of awards available for issuance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options Outstanding, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value of stock options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityRelatedToRestrictedStockUnitsRsusDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Canceled / Forfeited",
        "negatedLabel": "Options Outstanding, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityRelatedToRestrictedStockUnitsRsusDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted",
        "terseLabel": "Options Outstanding, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average grant date fair value of options granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityRelatedToRestrictedStockUnitsRsusDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation options to purchase number of common stock",
        "periodStartLabel": "Options Outstanding, Beginning Balance",
        "periodEndLabel": "Options Outstanding, Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r424"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding, Beginning Balance",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding, Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r424"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options Outstanding, Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of common stock reserved for issuance increase percentage on stock outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares purchased",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award",
        "documentation": "Number of shares purchased for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityRelatedToRestrictedStockUnitsRsusDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r420",
      "r421",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Exercised",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Forfeited",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average exercise price of options granted",
        "terseLabel": "Weighted Average Exercise Price, Granted",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Tranche One",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Tranche Two",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r422",
      "r441",
      "r442",
      "r443",
      "r444",
      "r447",
      "r453",
      "r454",
      "r455",
      "r456"
     ]
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Dividend Rate",
        "label": "Share-Based Goods and Nonemployee Services Transaction, Valuation Method, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the expected term of a nonvested share or option award issued to other than an employee."
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Term",
        "label": "Share-Based Goods and Nonemployee Services Transaction, Valuation Method, Expected Term",
        "documentation": "Period an equity-based award is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employees",
        "label": "Share-Based Payment Arrangement, Employee [Member]",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r419",
      "r420",
      "r421",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447"
     ]
    },
    "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedPaymentArrangementNonemployeeMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonemployee [Member]",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r419",
      "r420",
      "r421",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447"
     ]
    },
    "inzy_ShareBasedPaymentArrangementTrancheFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "ShareBasedPaymentArrangementTrancheFourMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Payment Arrangement, Tranche Four [Member]",
        "label": "Share-Based Payment Arrangement, Tranche Four [Member]",
        "terseLabel": "Tranche Four"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfAssumptionsUsedToValueStockOptionsGrantedToEmployeesUsingBlackscholesOptionpricingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term of options (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (in years), Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (in years), Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (in years), Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of shares vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfActivityRelatedToRestrictedStockUnitsRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested / Settled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued, price per share",
        "label": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "periodEndLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Short-term Investments, Total",
        "terseLabel": "Short-term investments",
        "label": "Short-Term Investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r145",
      "r970"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r216"
     ]
    },
    "inzy_SixtyDaysPriorWrittenNoticeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "SixtyDaysPriorWrittenNoticeMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "60 Days prior written notice",
        "label": "Sixty Days Prior Written Notice [Member]",
        "documentation": "Sixty Days Prior Written Notice [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentialDilutiveSecuritiesFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r189",
      "r190",
      "r191",
      "r219",
      "r251",
      "r252",
      "r254",
      "r256",
      "r262",
      "r263",
      "r315",
      "r347",
      "r349",
      "r350",
      "r351",
      "r354",
      "r355",
      "r387",
      "r388",
      "r391",
      "r394",
      "r402",
      "r545",
      "r691",
      "r692",
      "r693",
      "r694",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r731",
      "r753",
      "r776",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r954",
      "r978",
      "r985"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r36",
      "r176",
      "r203",
      "r204",
      "r205",
      "r224",
      "r225",
      "r226",
      "r231",
      "r242",
      "r244",
      "r261",
      "r320",
      "r328",
      "r404",
      "r450",
      "r451",
      "r452",
      "r481",
      "r482",
      "r508",
      "r510",
      "r511",
      "r512",
      "r513",
      "r516",
      "r528",
      "r555",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r588",
      "r673",
      "r674",
      "r675",
      "r701",
      "r776"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r280",
      "r281",
      "r714",
      "r717",
      "r719",
      "r785",
      "r789",
      "r793",
      "r797",
      "r808",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r822",
      "r844",
      "r863",
      "r1017",
      "r1076"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r261",
      "r630",
      "r686",
      "r712",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r731",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r750",
      "r754",
      "r755",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r776",
      "r864"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r261",
      "r630",
      "r686",
      "r712",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r731",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r750",
      "r754",
      "r755",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r776",
      "r864"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r883",
      "r895",
      "r905",
      "r931"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of convertible preferred stock into common stock, shares",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r35",
      "r60",
      "r124",
      "r373"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Shares purchased in Employee Stock Purchase Plan, Shares",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r92",
      "r93",
      "r124"
     ]
    },
    "inzy_StockIssuedDuringPeriodSharesIssuedInAtTheMarketOffering": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesIssuedInAtTheMarketOffering",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued in at-the-market offering, share",
        "label": "Stock Issued During Period, Shares issued in at-the-market offering",
        "documentation": "Stock Issued During Period, Shares issued in at-the-market offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Initial public offering, net of issuance costs, shares",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock, net of issuance costs, Share",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r92",
      "r93",
      "r124",
      "r691",
      "r776",
      "r803"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityUnderEquityIncentivePlansDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Options Outstanding, Exercised",
        "terseLabel": "Exercise of stock options, shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r92",
      "r93",
      "r124",
      "r428"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of convertible preferred stock into common stock",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r36",
      "r124"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Shares purchased in Employee Stock Purchase Plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r92",
      "r93",
      "r124"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, net of issuance costs",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r92",
      "r93",
      "r124",
      "r701",
      "r776",
      "r803",
      "r870"
     ]
    },
    "inzy_StockIssuedDuringPeriodValueSharesIssuedInAtTheMarketOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "StockIssuedDuringPeriodValueSharesIssuedInAtTheMarketOffering",
     "crdr": "credit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued in at-the-market offering",
        "label": "Stock Issued During Period, Value, Shares issued in at-the-market offering",
        "documentation": "Stock Issued During Period, Value, Shares issued in at-the-market offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r36",
      "r124"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r96",
      "r97",
      "r113",
      "r733",
      "r749",
      "r777",
      "r778",
      "r858",
      "r871",
      "r980",
      "r1005",
      "r1055",
      "r1082"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' equity",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "Stockholders' Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r218",
      "r386",
      "r388",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r398",
      "r399",
      "r401",
      "r404",
      "r518",
      "r779",
      "r781",
      "r807"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse stock split of common stock",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' equity, reverse stock split",
        "label": "Stockholders' Equity, Reverse Stock Split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r562",
      "r597"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r562",
      "r597"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r562",
      "r597"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r596",
      "r598"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "documentation": "Different names of stock transactions and the different attributes of each transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "inzy_SummarizesOfImpactTermLoanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "SummarizesOfImpactTermLoanTableTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarizes Of impact Term Loan Table Text Block",
        "label": "Summarizes Of impact Term Loan Table Text Block",
        "terseLabel": "Summarizes of Impact of Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Details",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r965"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental cash flow information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "inzy_TaxCreditCarryForwardExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "TaxCreditCarryForwardExpirationYear",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit carryforward, expiration year",
        "label": "Tax Credit Carry Forward Expiration Year",
        "documentation": "Tax credit carry forward expiration year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit carryforwards",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "inzy_TaxCutsAndJobsActFederalNetOperatingLossPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "TaxCutsAndJobsActFederalNetOperatingLossPercent",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax cuts and jobs act federal net operating loss",
        "label": "Tax Cuts And Jobs Act Federal Net Operating Loss Percent",
        "documentation": "Tax cuts and jobs act federal net operating loss percent."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock",
        "periodStartLabel": "Temporary equity, balance",
        "periodEndLabel": "Temporary equity, balance",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r349",
      "r350",
      "r351",
      "r354",
      "r355",
      "r457",
      "r649"
     ]
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityLiquidationPreference",
     "crdr": "credit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, liquidation preference",
        "label": "Temporary Equity, Liquidation Preference",
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, par value",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r58"
     ]
    },
    "inzy_TemporaryEquityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "TemporaryEquityPolicyTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock",
        "label": "Temporary Equity Policy Text Block",
        "documentation": "Temporary Equity Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityShareSubscriptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityShareSubscriptions",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares available for issuance to investors",
        "label": "Temporary Equity, Share Subscriptions",
        "documentation": "The number of securities classified as temporary equity that have been allocated to investors to buy. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "inzy_TemporaryEquityShareSubscriptionsPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "TemporaryEquityShareSubscriptionsPricePerShare",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for issuance, price per share",
        "label": "Temporary Equity Share Subscriptions Price Per Share",
        "documentation": "Temporary equity share subscriptions price per share."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesAuthorized",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, shares authorized",
        "label": "Temporary Equity, Shares Authorized",
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued",
        "verboseLabel": "Convertible preferred stock, shares issued",
        "label": "Temporary Equity, Shares Issued",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, shares outstanding",
        "periodStartLabel": "Temporary equity, shares",
        "periodEndLabel": "Temporary equity, shares",
        "label": "Temporary Equity, Shares Outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "inzy_TemporaryEquityStockIssuedDuringPeriodShareNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "TemporaryEquityStockIssuedDuringPeriodShareNewIssues",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Series A-2 Convertible Preferred Stock,net of issuance costs, shares",
        "label": "Temporary Equity Stock Issued During Period Share New Issues",
        "documentation": "Temporary equity stock issued during period share new issues."
       }
      }
     },
     "auth_ref": []
    },
    "inzy_TemporaryEquityStockIssuedDuringPeriodSharesToAcquireInProcessResearchAndDevelopment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesToAcquireInProcessResearchAndDevelopment",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares to acquire in-process research and development, shares",
        "documentation": "Temporary equity stock issued during period shares to acquire in process research And development",
        "label": "Temporary Equity Stock Issued During Period Shares To Acquire In Process Research And Development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Series A-2 Convertible Preferred Stock, net of issuance costs of $0.1 million",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "documentation": "Value of new stock classified as temporary equity issued during the period."
       }
      }
     },
     "auth_ref": []
    },
    "inzy_TemporaryEquityStockIssuedDuringPeriodValueToAcquireInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueToAcquireInProcessResearchAndDevelopment",
     "crdr": "credit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares to acquire in-process research and development",
        "documentation": "Temporary equity stock issued during period value to acquire in process research And development",
        "label": "Temporary Equity Stock Issued During Period Value To Acquire In Process Research And Development"
       }
      }
     },
     "auth_ref": []
    },
    "inzy_TermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "TermLoanMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan [Member]",
        "label": "Term Loan [Member]",
        "terseLabel": "Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "inzy_ThirtyDaysPriorWrittenNoticeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "ThirtyDaysPriorWrittenNoticeMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "30 Days prior written notice",
        "label": "Thirty Days Prior Written Notice [Member]",
        "documentation": "Thirty Days Prior Written Notice [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TimeDepositsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TimeDepositsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtSummarizesOfImpactOfTermLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying value",
        "label": "Time Deposits, at Carrying Value",
        "documentation": "Any certificate of deposit or savings account held by a bank or other financial institution for a short-term specified period of time. Because of their short-term, time deposits are considered highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months."
       }
      }
     },
     "auth_ref": [
      "r966"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfLongTermInvestmentsDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfShortTermInvestmentsDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementSummaryOfFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r381",
      "r400",
      "r517",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r659",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r1001",
      "r1002",
      "r1003",
      "r1004"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "inzy_TwoThousandSeventeenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "TwoThousandSeventeenEquityIncentivePlanMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2017 Equity Incentive Plan",
        "label": "Two Thousand Seventeen Equity Incentive Plan [Member]",
        "documentation": "Two Thousand Seventeen Equity Incentive Plan."
       }
      }
     },
     "auth_ref": []
    },
    "inzy_TwoThousandSeventeenStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "TwoThousandSeventeenStockIncentivePlanMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2017 Stock Incentive Plan",
        "label": "Two Thousand Seventeen Stock Incentive Plan [Member]",
        "documentation": "Two thousand seventeen stock incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "inzy_TwoThousandTwentyEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "TwoThousandTwentyEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2020 Employee Stock Purchase Plan",
        "label": "Two Thousand Twenty Employee Stock Purchase Plan [Member]",
        "documentation": "Two thousand twenty employee stock purchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "inzy_TwoThousandTwentyStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "TwoThousandTwentyStockIncentivePlanMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2020 Stock Incentive Plan",
        "label": "Two Thousand Twenty Stock Incentive Plan [Member]",
        "documentation": "Two thousand twenty stock incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfAdoptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfAdoptionMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureRecentAccountingPronouncementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Standards Update",
        "label": "Accounting Standards Update [Domain]",
        "documentation": "Amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r230",
      "r231",
      "r232",
      "r234",
      "r246",
      "r282",
      "r283",
      "r317",
      "r318",
      "r319",
      "r320",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r339",
      "r450",
      "r451",
      "r452",
      "r479",
      "r480",
      "r481",
      "r482",
      "r493",
      "r494",
      "r495",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r515",
      "r516",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r543",
      "r544",
      "r547",
      "r548",
      "r549",
      "r550",
      "r563",
      "r564",
      "r568",
      "r569",
      "r570",
      "r571",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r631",
      "r632",
      "r633",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureLicenseAndSponsoredResearchAgreementsAdditionalInformationDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementSummaryOfFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Government Agency Debt Securities",
        "label": "US Government Agencies Debt Securities [Member]",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r829",
      "r850",
      "r1073"
     ]
    },
    "inzy_USGovernmentAgencyDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "USGovernmentAgencyDebtSecuritiesMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfLongTermInvestmentsDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfShortTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Government Agency Debt Securities",
        "label": "U S Government Agency Debt Securities [Member]",
        "documentation": "U.S. government agency debt securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfLongTermInvestmentsDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfShortTermInvestmentsDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementSummaryOfFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Treasury Securities",
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r829",
      "r850",
      "r852",
      "r1073"
     ]
    },
    "inzy_UnderwritingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "UnderwritingAgreementMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underwriting Agreement",
        "label": "Underwriting Agreement [Member]",
        "documentation": "Underwriting Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "inzy_UnderwrittenOffering": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "UnderwrittenOffering",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwritten offering",
        "label": "Underwritten offering",
        "terseLabel": "Underwritten offering"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r943"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Unrecognized Tax Benefits, Ending Balance",
        "periodStartLabel": "Unrecognized Tax Benefits, Beginning Balance",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r469"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest or penalties",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total",
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "inzy_UnvestedRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "UnvestedRestrictedStockUnitsMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentialDilutiveSecuritiesFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested RSUs",
        "label": "Unvested Restricted Stock Units [Member]",
        "documentation": "Unvested Restricted Stock Units [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r52",
      "r53",
      "r155",
      "r157",
      "r160",
      "r161"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets, increase in valuation allowance",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045"
     ]
    },
    "inzy_WarrantsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "WarrantsPolicyTextBlock",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants [Policy Text Block]",
        "label": "Warrants [Policy Text Block]",
        "terseLabel": "Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureNetLossPerShareScheduleOfNetLossPerShareBasicAndDilutedDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares and pre-funded warrants outstanding - diluted",
        "verboseLabel": "Weighted-average common shares outstanding - diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r256"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/DisclosureNetLossPerShareScheduleOfNetLossPerShareBasicAndDilutedDetails",
      "http://www.inozyme.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares and pre-funded warrants outstanding - basic",
        "verboseLabel": "Weighted-average common shares outstanding - basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r256"
     ]
    },
    "inzy_YaleUniversityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inozyme.com/20231231",
     "localname": "YaleUniversityMember",
     "presentation": [
      "http://www.inozyme.com/20231231/taxonomy/role/Role_DisclosureLicenseAndSponsoredResearchAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Yale",
        "label": "Yale University [Member]",
        "documentation": "Yale university."
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(27)",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//710/tableOfContent"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//712/tableOfContent"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//805/tableOfContent"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481178/840-20-25-6"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481178/840-20-25-7"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "SubTopic": "20",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "SubTopic": "20",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-3"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-3"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "SubTopic": "40",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482705/350-40-65-3"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "SubTopic": "40",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482705/350-40-65-3"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-4"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//250/tableOfContent"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//808/tableOfContent"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-6"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-3"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-6"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-5"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-5"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//830/tableOfContent"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479365/842-20-25-5"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-6"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-12"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//210/tableOfContent"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482190/360-10-35-3"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479365/842-20-25-6"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>109
<FILENAME>0000950170-24-029673-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-029673-xbrl.zip
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MAXB(B(28A):4E/;Z!88+U_\__Z%K 8J3.#!\(3R<BP N!0X>!0ZZ 0!A<)[
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MH]A[(R_*,"_8:WY=D4@E?W4I?FID45,E$PV8R8E,N!A?=YD33_E(%O=$QM6
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MF95[^&<[75/OO]3]1ZASC*JA<-R_&69L>5N!^=87?S O0SPJ+>U_M#L6EI"
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MO<:3T'=/W&!#1!^2G+ D'"PG/"'7#!=));59Q0WF]4"6[TK2M(<<-KI[XV]
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M^I@6_KJ;](RM\/TBYM"$*HY.R'MQU&?-*4,J49XM-O2%;,D8XMU<XUT^;I[
M@0^+Z>1BMM2,*N6Q$@DQS-@;\ C_,;@#ECORA,GI@:B4CI8JTK;<C:+@E,\R
M)C!>)^>B" S=HF.ZZ T[N":^H]6$;>!E "FD4KF]SP5_Q3DNXQ":7CFO='!*
M1LSQ;>+B0:MDVQ/+1Z<.^\2Y:NB,BS:E&7D@7J4C!RAF)^FK30=;M5O3P\3=
MZJ7UUR+R("=J.C:.I!D]G/B<5Z31TG]?UUVA\,-&IP[F+,O/ESY/SI@WG PN
MOBD@K(;*,,A?;H?FW7K3S!12KIB-FT(=>.AWB>< V!=J=K8\WEB$H:PXI^3Q
M9 [:\>UK#]0',$/9(TU7]W+3);+BG[TZ&JVZK533K(Z^_(Q4UZ28;K@?B9*#
MO/8MP!Y,JXHU]I^@:DRC;^D>7/O:?<7M\:7J9^HSRICI!5?8/<TIU\Y97/)G
MH_8&X>EPBKCG2;-"4!F!;PG"7RXQKK4WF.-)9X=QOI_';2W5U S;\]6$2@7:
M]0+X.O4MAUP/\(^2&$VR7#$>I?_HS2+Z'P\3/5D)E=9A#[=E[G%[S 1Y=8NJ
M-TVG.J_)\:F9"9CC^H='9-B:@*3C_$RUWG+27)4<Z0FMZ0FEA18M<L.=")=^
ML>:440?N:F32580)DR%K\DW#XVA7KNYLKWOC>!J!!)^IKJY']K?F48>F.UK;
M Q.D"Q:E?BB9DJ/A?REL@5Y!%<Q.0EXK?G3\BZV0//+GT6ZU2]5\&TE?9IWJ
M;G#V&*WI)LN:T-;##(+2AIU^DO$STFQ*6 GP("_ !YI(JUZ,MO.&7E1>-@_T
MSWS_$Q&S>3RU<)'U))RRJVE$G#LO\),DPZO:0O\*GOI _ S6>R'>)_'":HXJ
MGN1DU2/9?A/YVW-D[N8#J1(W3$?<'FLR<$Q+TQ^\BZ6WK#+N6CDQCJ?%=3?Z
M,]IK&DMF!WPK:*(GNU[TV;M)L:A@3O=5AT#\')>D"7O',P,^I8WKN$DAP=GN
MD:%;I _5S;)1&;XU%P7APXAZY>E<*3DV8:T>H%#X:JCZA65WS,)F*WGP1UNG
M;P\5JKWE+@@Y9$D;*+V.A:]_T1E3@@Q0M%[\.C-X_+YB-TMR$I?3=,J+8X<2
M,!J+=P[/D7J]=6E[7G2?"A(TJ4L=[.FB45:"#W:/-E#U:*KP5:5G.&\D\BBD
M=N%SK7N4A8LZ676F2E%(L;'UZKA/^U6;8N,$;&;Y#ZDT?BPY-,F!X;_@9(K#
M.&CV6$=&GQJ_=,R+4:G/4YNLHU,B<]RD MWS(A?L0D2%;W%I<=,%+\I[IFK6
M50CHYKAZ^74=.M0Y6!+1SAIR:]S^0X#RVW&C'Q(4@U$*>X^GW+/]Q%@S2X@3
M> "=2OB!7&04I5K\T[</[=]@^[?+_[6S9+\->-/V/3(([\PV4> ]WXIP )['
M'U[U9'U=;_E7  /]E/5A\Q9W^?\_#SH]S377]#+-:J(K5YCG:$BU,OO8I9I7
M424PVU7HX1=?W-W'6<?6ZHMF1]XZ,@1@[V4'-RD;>,HZY'#Q7IIOA0I3\2U?
MFF]07ZUG<7\7*RSPP%XQ*C-]6.L.@'#  TUK![M@_3%2&PQX&@";L(5NK@$/
M-/&08;W^[MM;H&"$, N+<YO2V@F-Y&*;H\[&H_(KXAO\6R!1-8[U1<+*/4@%
M8O%(UA8(>0<^=0]66[$NB=!S6E24KE&0+XA&4=-D71>)@WY'SGJM6.)=\[26
M1PGGN\.\(*,G=;= +A[@[B"@%R^<+V18O\GUR1-%+;%_IQ<YS*@%KPSNOCG9
MA+B6'@W,JM.SV,T#SY$SWV/Q9[9 9+#O%^KPFR<@N89;(-;34Y=L])N"H-]A
M_[[K'&+7/H)<V%K64<A_,$R5:!CMAX5ABD7P/I7VJ(I+A0P_W8PEJU^=]UX[
MO4^C/9JN*R/F,_ _O/2<5B4<_9 #)D?14B$J5F__>B?TY%;E@1$)DD7N^/]F
M>CJ3[%=HCT<WD^5756 &%=DB3A_+W/>KLU=1?%O"1@HDYVD70N3_K"&F$%>=
M_?32+$:KX8*_7L"5XJR,UP>//73_[<79(M;18TX, ^UN/ )L_E?$($5T0$C_
M-[/]UI&_C:&\\4##A5JQ*WG!^M1^/AD^WG3&\G$J0M6TEYLX9B$OTZQ9OUFS
MW3OJ_?4JV1OZ\O=^$3#;_E+'*^30T->5]TH*X^S;)FISTKYZ7TNS/+/WZ.D]
MWY&UE^YY6'#E'OW#M6/$!5\+NPN^]E_]ER]<8V56W@*]^_06* VRA,.X<I/_
M1G#E_ORG=LQQ;+A^V@*E^<-&JP!#]E_^F39[CP,WOO?W[UXY@$NZ.5@!)%A:
ML?S7OW_X;=E_C^>XHW992 S^:O,<Y</U]ZMF,U834\WP3*V?L,INK24U2"NJ
M#@9+T#(-CI$ Z6]Z T_K*^$R^'2SM??XY>4B:]R85&<Z\)S/8 AK>[X%>@CN
MPV^!Y,IZ6>]X@YK6*98WCP"^@F9OWH<YKO<*K%O%3D)7@-',08[GP1+A,WM%
MK^/=FK= R5WX3Y#2S>E(YR)%'"L>-FC"L9:*&-<90");TO/O??_HRH6O<F[:
MD"7(S=^\[\1+U$(L"XD%C/"I/N,R(D)-["KUQ+5#0EU:"[ZJBN^_PGM0%3!'
MH+,@:M9Y:JJ<6$X/<"'<$[\,Z,J_PTG;V19/Z7-ML]Z)%\PKWY)PFYIUH?@7
M*X:M!2ED-9)S+?K4@JZ3K8YRD-[-V&7.C=1JM0287,3W=BC6A=M04N<$Q!)<
M6T%I&KF*2> F6)8;O-H/Z!!$O-&C6V2+]=OEAEH<T>I!S6< (ESLQAH,%$4I
MIW1=;#'*P;;T2IOUL.N7ZJQFFK#BC[407%0YR8444*##.!VVEHB%U78/\@-1
M@)AZ=/*]XG='B-PU8XWV&Z/&K+@%GO'FM&$%9"%\B)%2F+])V-F8,"".NW<.
MP"S!WR1O.5@B8*ITM:LE#46 ]$?L##Z31'9D*D&5&5V7/M->5:6>:.*-Q+%&
MYTT#1]:1!1M Q,\8\U/Z3VGEY2QG)E2!*'+LTLH/SP<4!YT_4VUSMG41*[(H
M'+Q@7VQM^/"%QGM/KFQ:1TN$ V'\^FHW2WJ+<A)+2(ED<Q3_\D>9;;&?IHHY
M3^GK"6#\+&?V2N7%Z $JH-3-&YTG.*#9)0)1'WSE%,N&5F%%\KV#S(U\6!%\
M;K.R7"H0B;(7\67A6R )8=!]''1J9*HM7G;H>25GY/L)/_ZFTG./M7B)$M\]
M!/0\T$H&T/88^ZA/[+XX9:?@R[U*X8X 2CVA%<5$K!.]OBMV\H3VI<;R'H*(
MT[I.Q.8]7SX!BM*BY/ZF_\WKKW4$2<Q;(M:_XZ -Q-:-E( 'G^!GY&#@>[MN
M(8Y#!<'==)'\&\[7"-XF#!CV5($G5R:LN 61B/7>9E[=PPSN'6MJ7:@B**$'
M#%@OO2Y@;_)F7\2FPQQ1C<=:>9M$;HYIG57H>BE$LT2A'=J -$UEF0ZT&+R$
M5\+/R'>D4_R.5Z7ZEZ% L %"$.FJ5+4KT]6I+".R%=ND2.&UW?"S 6+^60\0
MVB>)Y._/T_TFC9I]:DJ >7AQO53 <6EG=D429E>@'3"[.)8=K)8GQ++*^*M3
MK]47HZ9U!F"%+0E(5< P_EZ7]FEA.KU Q8!'ZW^99%2Z#R]<'/X&]@,,T=(N
M PIU#G+"=@N4")_> EDFR+ODGO[;*12PSG3D*!O'6N\6:%QG'=D[UM*?"M8N
M(Z2X+5!J/Y!=BC<;=PVXD5ZP!7H#B.3=$6D+B,PYR3H-&32Y7EG<-*TS##A]
M6S6NJN#9:FM#.:8^8/*P;EM[(]VS9[PY0KH /R("_66M\/-_D&, 4CU NJN"
M'X%\^"VSO7;E>6,JJ[8L"O!LW;;0/&B%GK6AVG./\&T:(EV3.'O56(>[BI6#
M\VH*D9;@>L"RM:615UEE6APVJ:PF%@WK[ZN'@6@2*;4GZG C/;2N-_D>6CU;
M[U+U$N%&;)2!#.O2_+)1<U['C2Y/3N#I)0'L19SJ8[I.99I3JM#NX?";U;SP
MZ47,[%+,C?2.6H($E9!Z3E],QEBU<"E1#QG6X?E\H^:RCBO9IW3L%L=0 W<>
M:Z4' ZKA,CG>ZU"CGK;X."H#[D70!L^OJN4::NF<6P6ZLR'QXYQZW-T;/&_G
M,%N6?.,EVS#[J6M"Y?FN+_@VA(UC]K_0X7!>5MD9M?-)M>62*I=TJ,MIR")T
MNJ-"H!/#IFWQSJ]F )U6QZ+X4+GJ>P^MP #^8 7\,<E4]M3'K$G4#D/7>B5X
MC:B%GNW(I>J-Q28:G6Y"%E_,0FZS-FY47.J/^H#Q<538%?^A'[!CH47('&Y$
M&*7FVE6GU.Z<]'S!A5,Z+@[Z@!V[)N>Y@0&/81-,.:<(,\WAL18'T1.>VQ+R
M+^%^^5'L-$"J&77X)733J;0[)S7GYO.*2WWRXH#3'(@*3+?%FR2)NXQPED3\
M7,30]1'K8SS@2L=<0S6CC.<5X$:Y%X 4LWL7=D3DWC7K02T$1M!%Z/A%$=E3
M@V>) ]WVI+\0/L+,)\R' @>?U'41*AEOSFMEV2::1NC :PFN6,HJH^8"-%1(
M=AF!O(\8*++!S ,16PU$;.1G)4*TH?A,(PLP"10[LKLB51^^(DK1B>"5ZS%O
M\3X2O$(@OJY% )KP[N/><X.SD3K!E&^L2L_.H7UJ45 *KAAP>[[7YMB[#73X
M2 WEA@!4:N_):M''JX)7T+NMZRP]Q] M">0G6>?R!7(2S@9#"N$AQ K.1\PQ
MC[5\"]OB^7P2@1R33T0%HCO0AJ[E%[0AF#NG"T,! (+/)^87)X!B5HB98!Q'
MQ"6._X \R?I[(0\QQ1!PR7I_WU@'.IXPB;9 VDAB@MJ#;8*<@?9_!S;$N;$7
MW.P(.5J[!4(0^DIA7GN_\EO?!5T8 ?","+LO<\[NLFY@]Z,8(N+BV4[(1!!"
M2NS+$LBS@IG)][@N*:Z_7S&=:D$FR!G_@Q75 ( K.0,>*.H7;1>J$//D\_3&
M#2"K5Y,#\1%<0  EM/PQ*>E^!&(T :FPGOK-W6!@ VTP<<Y7"K:TO@7O23C%
MQ+^-AI+VH1Y_GWRY#;PUV=]/QG#<13L'TX%B=1? 1OS8!:"SI@\$>''MY/I[
M_ /.P'] H. [0&9]Y_-L$2NTM!0SF8XF4H,(P(B!"(PF?N$4HB 6CTK.C5<Z
MS G\RP3V\ 8"NQM C'QE_4\(1+X/ N&(L. G#U#^ZZU1--@^PB@M9Y69\1(*
MZ@D" M))-[6<$?\7\&4;A_T#[?P5L@,J5KH I,#90?,++*T2P1*2^I^L>V -
M0=GY?=!&)PT 18O2! ,:]L$:8*X<(#\3?3[03SZ5/$>!1!#CJ[D@/AO?L.1^
M63VY^G7SU9^\ HE\,^U9T]9F9U?4%#($VJJB8N/[U-F2Y4\=I:2W&9"FI$\4
M4NI_'6(+[3M9[%;;K?9AX]M[B7/#[V]XRY%\5];[O(;P-<U!7UJ4Z87(YA?[
M38\,KO[UO)SLSN5G@8%^LL;DJ9\;9&#GNSN[QY=5/3^9ZN2WAK6=$WR0XEO=
M&70J5&AI)BROC[WYXP^_1'-<N-VK/E%O8]O'JG*UYRF9<%46OO%'FC?NA*7Y
M)\F>6EMH.I[U$$O_A?669<1! 9^EL<?+JOIOK-D.R964P)4*- 25#"^KW[!-
M-X(:/"?C=9,O)%^]_!5E:8:AI</(EQ;WFU_L]'[[^DJ^==BM?MNA:CG+:H%F
ME94FJ5*UWF9Y YRB_?+9/M'O15*;&S>'S+L+(=E]Y?$3JNE>SS?$-I,OBY\-
M?ZCPS*Z"9M6H][$8W[<9!<-V7B[CHMSA]L#T?L/F4;P8E5MZ)'__PF4_SG(^
M&D?%FC.9:)658IG2[*)BLUQ5-?1?5^W9I_HH.",&7C[]ALGEDIV+@B?*?6?M
M4?O&P'L"N 6^Q=#6\8+R8(%.[$1WOA?W)ET5MW)S6=/93-G'=V1'6#T-6J/N
M#8@>7DYE8V]LGU'PF\9(SVE4-:2F=,(?,-91!Y)>8G*M*CIEOACSE4$G]8>3
M8L+$?-9C*;N+=0L/I%.C;@=S^7ZK?.*MH5]%9>IE3II;$Z56&%1BT_X])XN"
M5LW(CZ344O,$7"&W?2@WRQWJ59%H,E^1A,J-";4]3BD47.TP="(ST3E?;&XC
M;*!YAF/2=/("VCK"1>?K>.7/='6:I24*H>2P+\IS9GY/1,ASBKY/3Y.@TP+Z
MI\Z@LV\SOB [QCCL1 .R9XXWHR[,V0(=:'(\TM"Z(*[/]*/!F:Y+&N1?^H*?
MQOQE<\'R]UQ[(9%EV4\-Y!UX1B^%]<N^#8?5.D)0XB\#QS1FWCP-P7Y=2SDC
MV2QS)>[SZ]@K;QZ R'N# PY1<=",X53UWA7%!>3%.NO0UE8=*>8/>G>+_)H0
M5LA!R=EL\$HPPNOYDLDM?O;FD;$GY1YX^?<DI"_G,YI 2]Q:=YK38^8@GMBP
MVF?>_15?C],&OAZN=8K#F9ZF^.#\<1PYZSWAQB8P,*QU-KQS0*E"YERM;Q#M
M_($J[DL]9*G6BP4=5E.A6>5FPA$MU-=3NC1P9WC/V:L[Z$2TW2UCME-5)$<\
M_\ V3&)2@2ZJ*C@5U.MCBOO,_F!&><XT.*DJ05/"U*HXSDR$+97Z7+&2E[;Y
MEY1BY_,*X--.U'IK5OT&><B\@,'SX 8J3Y,JK^?Z8>J9XR30IQA9:H6<L@)I
MYK>3+%2#UZ=ZF208Z2<9F>@Z/T^5:"6,)SL:F^"*C3M3PZR]QWMC].Z_&+]D
MP:7BT):&-!DT.V\DP!WA.;#X_ES['=?D;[3Y!Z).@AR<6;GN9;:FE3RF'<OM
M&'(UY/K:,O[ZP*W(!"/7HR0+4U),)B\$M8YHJH^+G&SF8!\Q3+N:IQP@.8YJ
MST\^] 67?T'SV(^IM!@[?>\N)<R[IT%K9]66(O*U3_RK U7^\T*B*KLZ5*:=
MB_A3[3<B,3YY,X47'/1;UZ$?-.Q0E=" BX'0PON(XO/V3UQ.:K3>I#!"A3^S
M42Q_]+DP3^K[(V@C<C9@ KE(V0J994!6PU>DK?O73HV#5\[T8]2V0+KRJ_[I
M.*LMT/LU%N_5#OPY#5N\NX 7_C OX34WQ]F+MT!BD>);H(/4&P;X6L0"/;X1
ML0"64-02V )]E4G; GW75R <ZDE\3\N5#M@HUV?83W&8+[CK(?X9N*L%KS.:
MQ(K5VMNKU 93T<SF4>O3&\?,YF+766#U[NL"L'IG"@FG56/,Z;.J=^F$-<=>
M0VR@"P<VJ+G'HDCG-AP6DY]^OBP&@[]+[PFEB_+JSD@/;8NG,_D1K$YQSSC<
MRF914>)%Q-.]W_+([WM,4MY_^8<O2BNC!Y"9Y8,M4/ICR.)YU;\=,'? X=>"
M0[_?2P__Z$NV/=]^<:?O X"D#G_Z@KG][\7[WWE-WL$7_-%G)"4 '$).K>]J
M]D8[>42\P$VJ;H3=P5&9S.UY])Q/A^8YOV&KNSFK5 LOWHDN' I"(U>*L+1)
MK1S4?J@$A;N'F'Y"H[I6,)IT%%IGC:@T M ]<>9=:N*L]@'W)RELSW]Y&. L
M2A%+5IK6;1S2#7G-=D,*]^I<:4Z[7"7KQV%_=T=;<HN;F>WBUF:6Y!;E0A8H
M^MI;?$\J.OURJEIO]"VE!$P?+9;H^7[\@#5=O,-@2<M7KC@'V,NG,M>8"@,:
M9VJB))]HT^N[\I7/K"D)'X(6S8X$IDTLXU2?=9 F-I@&7&=EE&N\>.3;((//
MVD\EQYN9$XO0X_$K(R/&Z[TBX[(LTP:3FO.4BV./,:L.L>[?A/FG663!E9HL
MK1O<F_EL(7!C\EG4E:*&%^-GSB\(^?H<0=&3&=E3G:0M9=!5-Z5_]O/9$C?V
MG!U2I=4*=DZE@B=H.8_'S:HDZT.]+#6K:?DXC8Y?5]5=#K,FSPUF]D(3'7NF
M-=^/7\;G=0\Q7)9DIC1?\3-<YVV]X7"%XFO#(/*LID2RD2I/Y-.KH9]DF/Y2
MO_=5S1W<?_VE!ZUY5$%"S>"FUJ.VR1M.$!V],<?X3]%7B_V#_J)\/<3!G/%E
MAG!.5)]WQ6Q4,>_KVP^M+4WSEA7EK^3,Q9HJC%;)G8XW?92KKT?_T?OZ?WPG
MGS+)FYF+\NM',*=>,X7<=QBD9'4I3+_4S1-C:*R'<-$+OMBS>DL[Z<((M/,S
M^H/Z;.+TE>*"D!%;CMLI&IW+S(&J(C0_JDO3U0Q3^5UEBY=?VNJ<D)?_FE5(
M<]9- 'YO5.B\HW&"75'M-,[N9[Z/=)DT&87%JU.(5&<E98R<G&"<,X4D1K8
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MJ776ZT_U1#U<[[=-SY\@S'%[A/)JILYSF/U+?("]O%9Q!WHINBEIX2TPO0N
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MI.FQNE6O;:&JJ4"!(6*AA[^PT.W_&12*W@$WH:[\Q)C'$4HB4+D\C@ E<83
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MKR3I!'E]4$:1M[5_4,Z-]3ON[JT8(856!_N7'!LW-)CMPB?#O'!/P[]1(;J
M.;(\C5[.CBS$\%4)*JR\3%#I'[\@DS!N^V"LTODS&CVCTF)@,H3]=+K#O<I2
M)FXE1/XPZJ?-]]JSKZD?<#'[#Y/TEIR:[GW90FL<W;)HO,+NI*?9Y:9U<_WZ
M#8C#X0/.SI+\,=7';@L4"Q9P3$:7Y+V8E:>JH28;EY205RD[DU704D(;]UBC
M4KO0K9EOZ(X8RQ<+OM2DFM%*(//0_]MU1Q5S)T(1]Y7&]9U@_0FIM?MWG3^
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M#^L;2L?FVU0  99^$1;V0S;$_8Q+.S=:.0$I6%I Y6:O=@9Y+I[EA#HE'4!
MHP"@&(*XE;9?Q4.H!]V'8!.G42UL=.;#IAN!=T@WKO/E6D:LF3=IFA/W5BT#
M,G@),D"1>6F6"#G^C6O.VI<VMED%3=2Q(A&6,W[$K6!EF:=<3$UFY$,.[-!7
M%-8J.5<+\TM%-'NFMJ66"1 V=T7MTI6Y\@ KQE 0#_UQVX\R$]<?M,\%-&*<
MXM3X!V*?\,PM6$B:-Q<!YHG([G1ZS=6FFZCR[,==THU?I!U'Z"Q8FCDX?3R
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M6+<K?(K^#NN);9SC"2%*1>^"%P'%JSLH)=AG!Y(,[-1A%%$OE48T42\\[;7
MG=:U]+0[K8E%\)_D?\,I(1A$9T\YI"CS7_N$^7_BY\J?'IG^?\D'O-7U/P!0
M2P,$%     @ 6D1L6'/:'\$R^ $ !T0" !(   !I;6<Q.#<T,3DR,#=?,2YJ
M<&?LO 547$&7+GIPE^#N%C2X>_#@[@[!@[L'#4Z X!#<M7%+\. .C;L%0N/.
MX__GOCOWOS-O?.Z[:\U4KZ_7JG6J^IS=NVM_WZ[:JU\67S8 3'EI.6D "AH
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M8::+JXN3(PN[3U[DL^H5VQWLI[\9M3WW>SM$KBJ3TM1A-QQ1]"U)3 !W)\8
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MJA]A]^/IAL1\C\L6N-GJ;!X4>,J)V!Q)_+0_WA:[%0R]T_#FL;5<%"4V_\R
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M]#RJ6AB-N40(BTEP14WX:+>R.^UVF.=E4=?T<=6C_DXRT2A'<%'"^7/>:5I
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MIP*/?V(\X35"5?U'"Q"#[KA'8?\M12069GJ-1#HL'->P!$ :Z='54 K7[4C
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MFE,5MX2W47%RI'W.E;FM,%!L5&YU_?A,. Y_LC%41C"OWF __;[(-;*!&C\
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M73D=79*DB<UY(;C\.Q<AC/TWGTU;9D4;F4'"DHH=7O/\NZ#$P #\($,=3)U
M7\(J-.SW#9/VBE4E&<M9P\PS_-YTKG.K\309P([;R)C9\D 7IR&G7/B5XDDK
M"^UZ<NBU3LM#R45Y$U% Q68WYD'JE+YDJ3$H[+*A-'-8;-I BMJ!A@S*'NIV
MP=.R4%_'5B#EDDY94#6%-M-Y:*6NTIPLBZ&D*]V)K@&^O/]Y"A7#L>.QW3 E
M3J9:): 1ZH>MAUY_V!T$;KLJ9:VDXC"UVPKTK586RQYS(KBEZ7IH@'VPRD=1
M=8XKT\&,Z>.I0EAS6_0A#XD?I-9RHDF&V^?OU?KP6?-CM #;DY?X"_!]'E1!
M_W/]G.&@^VH3X?F+'C#_GU</\U\2,!R]SY)ZS0^0P /HQN/_M7/PUW.*I!$2
MS([I%MDI!4[V'L"=KOQ0('C.[>"/5$="/SL+9G*XQ3,>=9,,WW$(IZZ(H*<Q
MPNKW)-AI<9C$)3(+F1=@4&?."7O5]K#&*U!VFLV\7F%=2)%:@H:QM%QZTFN"
MOH;DD@MJ7M5 <05\&ENM?_ "+&-X9'1@%V5=_ P^J:96W!840RV$60X1/JS8
MBE70.)N/(LW3=W!2:<5K1M8@;VB4>:+8N(<U$5Y407"6\K[J:J^L>:3)6#TM
MB&62;&]]WQ".NR[P_;27_W 6*KYOKK\!HG_K9T>^?#O[P=CF@:!9N<%M===M
M/6ZYV7<2P4[%:$W_<%Y]S? 757,P:A(_;)CJL) VFE/U,1D#A"[7J?B(? GL
M,/\%O8".2CM%-SM\COF=H$6"C_-\A5?<A5K==(?ZYI/TP\F!FS<;BR/1NR2X
M75UR1Z@? X@P-2# 1T!@F*B-I (0O\(YNF@_]%/>7$=?/+X1 (^/<->OV!Q#
M(PJUTLC^RA]XC-W>H\]RJ])AY5;&MO.IUSN:/FP+R!9=PC6)0DWZA8-OQ8H.
ML 0!^X1YZ%W1%Q43;[R2UI7FW"8R'"05.H-9V5A,T$]L*%;W*OUB-RS>3'R8
M-K[-^>B'_<KG7I&VR9D'E#*M8>(1;M%%I!)EI,HJ&%Q0!W-&\_?@:X6OS5]E
MYQN\L0&,H0?-NCN.W(%689WC-7Q0TUS1@M$S; 979W/&*JXN:4AJ_$<X698L
M+"]<&9D94)5DGPBCOJ')81-2.0G!Z[>S^TXJ*PT6#L9)/$EN+T@8.3%=54$0
M3H5#C@_0AK.L63/RHF7C-L:4+!QS\.8NF@-+%(Z:)R;8HR40UF)(KD/7+>MU
MSC^R;'_!.%%HW:@/-EH[LE-%K8PGI"64C^,HM 8V)A'**YA*_Z["&+'\/FPT
M50O;8-#QA@7KSWG!PRB"@4^6QQ\#[K6RL@,1_+/37#M/;W?/TA,REV6:)$FL
M <(F"@"+#T:DE;_?YM989;YH@=7!L6!V9R9@G"9N6Q6D8VBQ&I++"@.-[N,<
M*D8JE;+;E6^)MEM8P=(Q1,9K%(,AG],Z 9^=JI?=%K^R?.3)WA\<W!SP&R/?
M3!1YW\^\VL"&K8R+C.6K[;N^&7V;IE0JE2#48%;<;S!Q.BFOS_Y]RH DHZN[
MZAC,'9[MCQ;6>1K'=FIQ_CDNW9(@7LAZ#X:> O5,4=)Y*U;]YW9?DV<:@GJR
M<CC8[FV1E+2K(,&<\4<8J)X=J!\B7Z%6UM?!AQX<:VNCE,V1EBLA8OND72"K
MCH6!>YE(%C\4;^'!R)S?)\H@<=IZ9GN4:@\'J#2$8KD:F52-$/Q4+12BMU;F
MDU##7% &MJDLY4VIK%N\Q_A9#C=^FYRQBY=C3$=:JD>)A_'N6&LC;](I6"XX
M8$+$+H=K".+[B:B,]&^W%+4F;5UL%?>6F7N&FE@B?^*2) &Z[,<9!X].#M1>
MX&7]^I4;'Y'TZP,)USV*-"RV%O:& +X\#)F.CJ:9W\4='>D436$HPTQ9C*5'
MBE9KMPWB,SOA@E5*B&M>GZ=J:.K)8MX):--OCRP[X1RJ'.*I1]F7U"9KMGZ<
M0(-F-4-8RG7:*"Y=/(I0@,0E,\S4.#7?6N$NV>!=&V>Y2,O@0!T2>9285X!1
M.D6.F+XA4<AA6UBXDPV"OR=KQ=@Y'ZI2*_#'C+$;MR.[J0W.Q8F1]5U7*B,L
M&LF4VH&KQI)U),M6:6KU1'A+=>90WL$&Z<1L%9^=6LX)*7_2U7(-W'6D%M2D
M4NR.H'FF"Q+08QI5CJ9O6+CTLG]4YZFWGL6;AL EX/6\H]Y)U(8*AHD=['32
M([7K:[XOZA.8;7-(J9H!ZTLY(;-;Q6QFCX1F-8FIQB$8?80I:9AE81OK :5;
M/G"-P;8@["8ZISQR,(YY2Z=5VH(QPD'Y*9E:;1":IA!]+Y3847S6NOUDD!Q*
M#JBAY A\2103U:R3TU^YZYFFVB ;PU'Z*T$#$-\/$24"_I36L(?<]%_X\1OC
M#]=\-Y0R89/*T*<,?_]^13*)U]$$:2,(:<-9_[C4-H!F8;>NKMN!Y]<XF-#:
MJT K58[6\(>XB9A*R_" G'"=&*F_I*>GDZDU]^IL!6X'@Y$<\?=7YWUJ;EN/
MXBJH_L@N>IU:XF1->A+;$X-$AN<21X@ MX JS=X>'!VNC/7[3#F*FX6M+_D(
MG\<CK".SW3).WP80]>8I^W%)34*F"/@PUEJBEE#$A+RUBTS:[Q/HCMF?=N#6
MK)W9G#DYI4GBT]QEW1W :8;AVTGP<=LK-?2JT9UJ]#<;^N6.IK2@_D49U/(.
M;916T])*JL=*9:QGX). 59 P4?2FFZ&RD?$;G>5OH,P*I*GY(T6)8<IS'5;-
MV6H^&I/0G._MY?_@](/I;[3'?&4N2N!0P?<78.$S^3W+1QB]?TW]VW_CGP7J
M",8=FNWZG_X7( ]YIO)O>G\=@*S7E8E74VAX>(&%M<61&:%)GT^VL?&,VWO\
MS@[_F?+,CV,E6U CXB2X)%;KO4MI-P^&ANDX.N*$&=/4QSQTVPGQ=D4;]]5
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M=$(!*6@9#L%"E$U[2EE9O)];Y>U%*3E.!2>TLIK.8"LO-1,B]YQ.;$ZW(3,
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M,&,KL!?A$TL0_5/72--O-U1:!>HV ]9,U_:9=:%27V?:?-JT-B&UH;D5?=I
M6H"3CX+N-,]DFYI;[WBPP; W_\M;YLN:DS?O4OT_8"6,$"*;;@09-)T6?NJ
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M(;S^R])S+)<'2;*4>Z^A)R:?UN#P"* :]V^42-*8E?B-5.H_6]YQ@U[F_@A
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MB!\UT2/ Q'J(Q(DMUUW&IWKY7J5-'<$9V&J]SHE[Y=]3O3RZ07JP3#-O6GP
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M,]4FE*P7%):3A"NS49F&D^O'/4HRK%9IBNA=U[$R3IO;:)'G?<IH;5[GA;]
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M"',<U?&O-%)_HYGLT]XF2SU3F!_W!88.M=4OJ)@"3.1:FYOQIB9=Q2)EH<3
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MWYZQ@UHZ64._?7MY348ZU$2S;DB50T,%\CBIQ/ZNE6^@M3AZIF5:VQ12RGZ
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MQ(D'#?,CNN _>G-=8'&<W!BO>/!1:S9PJ8W9RRM&OQH'R?QLY*% 159RT/$
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MN,;5\5R_R)TZ$:KF(*W=L >I)@JT#Q1__60]UG*$#R HQ>^;FJ,\%V9OG2_
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M#M]X"D2PV7>_>9",'O#6TA0(XQ-8]GF)62F3E7BR4K/)NE8A83#]Q5>Z<.5
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MQ#HH=MONVSJ8]P_86FHIC L&>X/'LB<$6"B3+2^_$=INDX?E!3IJ7P9S+16
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M>$(WP^?(_B!MEI+)\.=CGJ,NMOJ*^X/M]/Y_N/&HAA2Q<WGDCQ+K95::A8W
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M "S>*0S]%2A7O$;FIN0$VSF')%+@BZDRB5@IB7XE;?@X)>.L0W<OO+[!0 [
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M.M*1B1E "O8[PK;CC5E!?2G5-_1ZBH].-IWZ,WH\@+SCY*:8I\@,G=M/V<2
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M ^<W8*-EEAM1>PE"1U& )7AJ<ZS'!H4BNU^P=;<"][ *NEDAY[WD%N7U[C,
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M4]$?@E%Z7Z2::4S[T]MF:@\E^Y5YVF 8?,LD*0Y>,J/1(19\59=%97/$T2D
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M/3EOS*ZKCVV8)KH=A!RC8W)<]#2 VL/OLC>-_)?[A6U^&TF+ED[B:-"/T(7
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MV)?4_H2+> 9\$)8DM>R"#%^T JVJ\5,-S6_OM(&B)S*'_9OTJJM*+N$R%KV
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M*7EF".\Q>] F^\0EX?FSK/ZI_*ZA\'+A_D?""M,3C>&L\5:%RT>!\(4H__$
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MW(8XQBG^;CK5-XQG<IP*52,\'/XT_9L7MD6_-4=QFD\[)QBJ[;7.<'-*90I
M/>CDMN#K7V)Q-R<"A9FR>E1%^A%(TRC''6FXI+47M;LF$S =*!.Y/3]*C$A
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M32B]@BW<(X?* Y.<<L#D4OR/GYAN/4TY49&VABP/;TIMP^WY-H5P!C'>B^C
M60M'%C: /7-)$ZCJVYSTI8F5@%D^8]3FIROS*5"8[9JDKNX69 L9+EI%&6X-
M.2)1)E6R,=#3RQ5OF3CU%2+AQ\K?G3T3"Q R#>"5(![+ZT\Q^2F_DCN3U I<
ME9!\N34I<8^=/P--)=-P:*K(';>J-S^1IRI*4P0"O]WN*MA75 1\P[4JY/+
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M0D7 ZG^\:@20NQ9&&X?J*D,BN0KHQ;M4J5_?B.UM&/8HRG@Y' 'K38U"']X
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MZUG7]T[W!4-A5XP#QFH(9B@8$9)Y%<M>K?W8F_L'R\S.B2Y#C@YQ_A223$X
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M@=>>]7#;;8BP))QFH<;VP!WXI.R&M2HX^;@4%?E^;\C_ )^M72JH,X&>OZU
M5W<#IG^M%E8"GD*X" GGG%/*ACEEYJ4*%< C.34[0!SD5+BP3179"%RO2F*,
M\'K5Q 5R,<5)]G5QG'-4XQM=#OW*7E[<8YH?@8Q5H1'S O49JTUJC+R*:E%[
M",U(6(#4,F[@CFM""(%MH/ J:6W3;QZ4*<+60M3*CMW!.!Q4HB(ZCFIX&!F*
M]A5UECV_-CZU'MJ:6HU%]#.%H[#(YIXM\'!'-:,;QA#@@U#<3HG/>E]9@D'(
MR);0XXIXLSC)&*=;W"R<@8-3/.%4D]*/K2<>9#Y+.Q EF2V0:F-KC@TEM<JW
MS9I]Q>B-"?UK*6,2C=E*GJ"6RD\=:=]F;G(XJI97HFD+=@:OR72HN:GZY[MV
M/DUL,$(Z 8-'E[6QU-5O[54L5&*MV\R.I/>E#&*>BT8.G8&BX!9<4!#TQFG2
MW("'/3%-LY5E=LGI5RQ*YK/<7+I<;(NW@\&EV J"&Z=JFN-CH0#CT-48)UR0
M6!(]*;Q"6[T!1[$K8/4$4IW#'<5*N)1M&*?Y"*OWCD=S5^U6ZV%8K/&W&&(/
M\Z0N0, '([8JS\IRN_D&FBWDY93G/<]ZGVEW>(6[D*.KC/!(XI2N>.<GU'%(
MKB.3##YL]#3UC#L6+$9IQ;O:($1(C/1C^-0S_,H)/.>U6)@8S@9^N.*%0!-P
MY;^=4W>\5_7R)(\'R^!ENU-+>8CKM8L.,"IF!V_/A<C\:K0PRC=B1<$YSZU$
MVVTD]!K01/*0 -N!'7)Q3;R41P%]W!'Y5,[,H*M'N]P,U52V64_.Y/.0M:[*
MR,[ZC+(&2!6G5A(PSZ598D9R-R^B]:<\;>7M)P3TXID*F-!YG^LYS0HOX8_A
MT"_5D<,CR@NX(4'C/:JMU,T,ZI'\Q?D8J^ZX0ELD,.U10(RQER@+#.">IHA%
M1BDE<)7;$C*$!'3#=\TUQM)9>5'7VIC;YWR$;CBEVI./+4["/7I4\S:M$+*^
MH\2ATR^=GK3,X^ZW'49I!!-&Y)Q*N.U)&5>X_P!20!UK1W35R0+M"P9E+!NG
M%/MK@2._R=/TI;[YH" -P/&%/(J+3+>6"$K)E0?X2<FAQ:J66P+8EN&#2("0
M1G(P:DW)(HYQ]*RM4F,,L:!7*R-@%1TJ^EO+L#$C&/N]Z5FZCTT'?0CN9FMW
M17Y5S@'WIYCG;!48!&>M2O9K<(A="K(<J32KYD*_,-V3V-3&+C=O;\AO4RKH
M*B KT%9BSB2Z"^]:-RVZ%OI6%8_\?K%O7BBKI),B.QU20H\0!':LV=5CNPF:
MMBX*IZ\5ST]\QU5<Y'.*563T'&S.OMH%D@SG@BL"8?9;]XW&,G(-;=I=HMNH
MQFL+Q$VYXI5X!.TTW-RB.QL66Z5?4&K<MB8HC)$#P,[:S]*E-O$!)T/?TJ_>
M:@L5JY4Y;:<8J'5:5I%))B6T*7<69 ,=LU5OK062B12=I./85)IEVLEJ% P1
MUJ74%>XLWB4C+=S3A+VD0>A':NB@%B3Z5>2V67YPQ4GGBN7TJ>4LUO(>%)QS
M74Q7(1 &7 QZU$9RDK35[%:;HBN%>T )*E3_ ':?:6 >0W#_ #!^<>E8.LZF
M&U&.,$A0*U])O\6H#,20<<U#JM2NT-),FU!?L862/_5G@CT-0VTAG?A@3GBI
M-4N1)92IP<J37/Z9=C<&C)R!D@GK52J-7Z7Z"ZG9I;*5R^"1W!Q5$,8YW1AN
M*GBG1WWR#&<5S\US-_:CB3<$=OE;/:HJ5*CBFEJ4N5,Z>*-)I!(RC-)>PP1!
M90VWG&.U4(;EH5"@EE-5-9N7>V7:<!6!(IWFHMAS(WK<K+\C.-G\ZGNH8Q:,
MB[00ORGIBN9TZ]D9S)C/8UI7,[3VKQ="P('M4TY5>HY.)6M[OS9%5WP3Q706
MZQ+'@G![Y%<3:EH[IK>8?.HZ@UN074HB4$DX[YZBG&<V_=%IU)+^;R;X1(V0
MW(]JT[>3Y%'0"N5FW_VNDQ?<'/0]JV8Y1MW'J*(-J=KZA?2X[4;A8;H*N%XR
MU:5J0D2^7&,'N!UKB];NFAOE??E7& *VK6XE6%-Q8<#H:GGFY62V'I;4M:K=
MQ1/$2,$Y'M18W9>4DG..GI575I4;3Y4 &D#EOZ0 X&1GK5+1I]UH&SD,>,&B
MH[5%J">AU$KHT3LZ@A1GGM5*VN8IF#;MI(Z 57N'5K21-Q&]"*YBQO9Q,(P^
M2IZ^U3B)5;Q<9%0<=4T=V6!4KA3QZ5S]U="VG\IU &<Y[XJ9KN1D ')]0:Y_
M6;P+,@)R^.1[4Y2ER*4M";J]D=/&ZJOR 'Z5D74[17)4\!N5STJ"*YD\I5!/
M ZYJ"[S=K'%G!W<GV[T?O)0%=7-2S=Y5R2"/7.:U(\8 %9UC&D,2QH %%7LX
M QT]:ZZ'NQL]R)[A<# [YJ"-YL[%7=S^%+*YW8SG-.B'%1)*;NV4IN.B'JMP
MW3 'UIA=^5<'/O5A6 XIZ3$C/;W[U<8Q6S$Y/JC($C/)M///-7FB2:W>"4;H
MY%*.OJ",&GR0Q,S2 !6/7'2HS*%C]Z48..["4^8A\(:!IOA:PDL+'S?)#&7=
M(VX[F_\ K "M@L6E9^@)R*SK0ERS$G&>F,U?\Y5ZXZ Y/I5PIJ_,_D>?B,3?
M]W'8GCF"MSG'>JM_JHBD$:GH,G%1B_@D=EB8$COCBHBA</(,%R!ROI^7M48B
MC[963:)P^,5%>]9E$7PN)#@,>>,=*N+*R1E6!VD=36+;1R1W#L#E2Y8'ZUH2
M2[HMB_,QY KH@K1L>-.I+VKG?49),]I*LD@;8>XYS5Z+4@5!SP15:: 7=H\0
M<!C@J>V:P1/Y>4S@KQCTK@JT'&2Y7H?18/&>VIWEN;,>H 7Q8#"EO6MN.^0@
M$' [UP$UPGVR,!\9Y(!K:MKG*X#$9K%1:GH[([.;34TKG4%M[W )_>=#6M:W
MRLO)RPZCTKCM2G\N]MV!R&X'UK5AE+,&W;3ZT>R]]N+LQ\^FIMZEJ4<0A(VJ
M^[&1265Y'+\Y(8BN>U9E:T+%N4^8&G6<CD(ZG:0O/O2E3DJEU+4:FN6UCH]5
MNHH['S2<%"#G/6H+*^2X!)"D<=!63>C[3:F-G([Y]ZJ6,I$$80X93BJG":DG
MS:BC-6M8ZZY>*2T=BV,*2#Z8K+L[U;@AE QV:JL\LDL#QEMNY2.*SM'=8X!$
MS9*,<X/>J:FIJ4G9BYE:R.IEDC$19_X1G/I4=E<K.&9V61#TP=PK&U6>5[!E
MA?![Y/:JFA33Q [B5C8Y ]:*TZBFFMAQY6K&_?I$D37$+;0O++VHM+KS71!(
MNTCMR*B<I+&T<@.QN"*Y^"[>"X$463M8C\*JM)QM*(HZZ';"UM]AQ&#GO6-+
M/ME\F0].HZ"IX[Y_+&TD'%8NKW>V\7<>77FI]Z<4VK>@746=+9RK(,$#';FC
M4%CBM6E5@FWJ%[UDVDHMX<1,2!USWJ#5[^1;/*_=W#(HO5<+2U\QWC>Z-NPF
MB6,=,-T[U%JA$2K,GRAN"/6LK2YF%M^\P&))I=;F1=)EF9SF/YAFKC-^S)>Y
M/:7"JI/&X^IK<MY1L 8C&,DUQ%AJ"33QAN5QG KH%N?D^7IZ5,93;O%_)C]V
MUF6=1N88;E!&Y.1EN/Z5<M+J)T4K@>Q[UQ&KWS6VH$L>JAA6GIMQ(T 9GSNY
M'I67/+FY8Z/J/2UV;&JS>05GZK]UE#?E56UNQ)*&5F&.<$U5U.X6WL7,N"#Q
MCWK+TZ\ D;D\XY[54X\CYV_5 I7]U':QW2%,ECP.36%_:WSN0Y/S'J>#4RW6
M8\=CP:Y&YNA;WDL7.%;'-372E"+;T'&5F[';6UVZIO=0,^G-3WNIM'8.!(Q!
M'W<\5A6D[&%=QR"*749XTTZ9BV %-/V*Y+MNUA.>NQ;L;SSOFSWQC-:%U>&.
MQE9P<;>U<CI<\H@1F'RMRI%;GFM*A4GJ,$'I10BFN1(<Y=64;>^+2)$&W#HI
M-<UX@\0SZF!9^6(X(G.!GDD<<U8@NF%_L'.UR#@]*Q=3A:+49PP(W-D$CJ#6
MF&A#G<K:FE-N6C*6*;R#TX[8-2;2!VIT>W>-XR/2O225FQS;0I4K&C$YW#/!
M[4F[Y<;N*L969R=OW> *!:K(<+D9K.A4EJ"I.<5)E2NR\&@6\4DQ*AY#@9Z@
M5R5S"+2W,COU.U1WS6WI$I4("1QC&*6*KRDN2!E./LWJ=CYR6UPZE@ WS*,X
MK4L[E)(<D]ZY+5[T);P9/S$U;TRZD6W#*?E85Y\W44KP>@HN-K,Z6\DV1HP9
M02<?6FDPR)@9#>M85\\MS'&R-\Z<CFK$5QNP=V">];QG437,R=.A8QLN7$R*
M0"-H/\ZL-:I(P8X0]N*Y[5;QK6X!5RV]<E3[5IV6I[XDW$\CO6;Q,Z<N6UT4
MHQDKDMW;(_[LL2XY!IT%G(8P2H#>I-4[[4!#+!( H&=I.>HJ[%>(5RS8'8CF
MK6(496:W)Y+JY6$21LQ#!LG)S39@\=N94A8(.I''%5[JZ%KJ"$9:.3D>U:2W
M =-KR(01@@U<JZT@]!*'4S;><7;;4VK@=<59EA=HB@#$$8W+66LR:9-)"_\
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MSA1W0-*=IZ\<@5TQISGJD<=2O".DCM_"0*Z/-,5QNE(W8[ "M@S;W14==['
MS6197B6VFBW@4A%'_P"LTZRFBFG,C,<HWRC/2O3A*4::A>QY<VI3;.F@MX53
M!(#]2WJ:@NG2$LLK9V^AJ"*X*XR>E<]JFH2)>E0<EG^:JE6K<MK6%:!TNGM;
MR@2R$D]@>:N7)6&/>K#CT%8-K,P;<@^4#I4]V\LUM\K9(.2/6DG5LU'8+Q6K
M+45["\F"%:KJSJZX!X]*XNSG;[6^YN!6W%.Q7@Y^M13]JG9L;E%K8GN+L1JP
MSST%&E7I"$$XW<_6N>UR:5&=!G(P1S5K3Y-MO&KGYP!DTY0=WJ)3V.EN;Q/L
MY8CVXK'2_P!]R4&-H'.*ERLL91NAK#!*W4ICY ;::4J;T=[M!S]#J(;D\8P1
MZ50O;W$DG.#4%O*<=_SK-U:01N6+9W+DC-5)*=.[T%S-/0L:9=K/,\DG+JV!
M]*V1<[>A) ]ZY#1;E'\X@Y^;%;JW "[LX HI1C**"4FF,N[DO.49CFKEM< (
M!GI7+O>?:-5!!QG(QFMN$#RQSS3A!N3Y1.5MR[?3#R,UC0NIN-V[]:L7DN+9
MOI7-65W(][(N<**FM=-!%H[:&;*8!K.U)@)ER>M107)7'7%1ZB?,C#CJ*I7<
M6K S1M9L( #Q3KIQ@$UBVURRX.:O/,)8QDTZ3;]UH4G;5%Z&YRHPQJK?3_,M
M1H0%JI?38*C'.:TE%QAJ2I79I13Y45'=SN,')Q5.&?BJEWJ ,WE9YK.2CR79
M2;N;D%X2N":8\I$VXUG6T_ YJ::4$ YHIQ2C9!*3;NS2CO#GDU7>X;SBQ/'Y
M55BE&..]0S3!WPK=.M6H)(7,:\=UN!W']::;A0W -4H6&RH)9<2_*:U2Y5=C
MYC1GN0L1(ZU2BO2 0:BED+1$'L*J1OCJ>]*=[IIB3-?SE)!S^E7!.JCK6&).
MA'_ZJ>\I4=:=1.UTQ*6I>GOT#J/>KJW2&(%37)S2%YASWK22<K$!7/34M9-E
M2DMC:BNU$F32S7N.C"L2&<,W)YI\LG%-Q<ES)AS6T-*WNF64DG@U)+>?-UXK
M(@N%SC/-/EE%'(FKAS]"[%*1(6S1<WC;3@U5BE"H<GK52YG&":FK%-681DUL
M:EK.WE'))S1//\ASS618Z@'8Q]Q4\\_!JDH\ET*[O8TK"?Y#^E2SW&5(R:R[
M*;=%@5/)@BK4'**%S69?MF CX-5[N;*X)J+SQ''P:S;BY9L\]:RJMKW4BX]V
M:^EN"IP>E6KB;C!-9E@WDVX/<TR>Y+9P:)7222!/J)YBI<$AN36[:S*+=?7%
M<,]VXU/8>E=3#+NA7'<4J-W<)-(M7DX="I-1:?=%9=JL3CK4%P (^.HK(L+X
M0:A(&/!;%.4&I)2!2TT.O-SNZDX],UBW=ZMO?1B+Y=_+5.\XQUS7/ZK<HM]#
MDX)!XJ:L8QC;H.,FW<["QO 91@[N/6K$UUP=V,>E<_I3[@[ANV,9JS<RG''Y
M4[<D$UJ%[O4L)J %RT;=.HK;BO(_)4KW]17'VX#WZ"4\L.W\JVF<*H4< <#-
M3&D[.SLV/GUV%U*^)E0CG!P:L6]RLK*,\=ZY[59&:T;RC\PYI^B3.Z[<8VKD
M@TXP:DK,'-:G6/.@7#'(]*HM>QK*57:OM5.:=@.3TK%>9S?@*V<]/>E/VKE\
M0U**6QVT(1H@[$'V(R:SKUK>!PR%MI8 @<5#!+)#;*K/EN>E4;R9AO9AGY<J
M#5RE4VEL*\>ANVY$QVH^U0,\TMQ;Q$?NRHD'1JYG1+^229<GYAD=>U;4ESD\
M=.]-5JW+9H+0&I<#:27&0VTUH):K/"'D3Y2."3BN:EEBANAL)PY+$'UK92^)
MMU5LCY>:N-:2CH[DV3?89.6MW6,L-K' YJVD:R1<=.E<_?7A_P!;NVF/[O\
M]>K.G:H'D*G)#+GFE#$33VW&XQ-"YA$4!:(G<OKZ5%:[9/EVJ 1GD43W&02"
M .@!K'LK_P J^922P#=/:M75?-J19=#?,4* LJ[3]>*8 DJX)"YXSWJ":XWK
MP=H_G6$^HR1:@(D&XY! ]:BK7J1LHK?H.,8O<Z=((8EPRECW)-9ZRXNC$ 2^
M>#UJ6>Z)4MN"\=*SH9R^HAESG81Q]:T=1WY6396NC=ECA<#<BY'\7>H(9K8W
MK1&3<5&< ]:HW%ZWE'.?>L#3[B9]?<$;< M]16?MJCJ<KT*:C:YV5Q*C ''
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M51+]997A#?-&0&Q^=-ON1-I1;9N"90WT]*AO9GGM/(CRNX8SV [U7\Q N2P
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M46\@;E=IR1Z4U)D8X/4?C2RLK1NAR1@@^_%>+1IQII<NQ]%+5,\\@!^WR,K
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M6;.XL[G=URI[BI[K45M;627.[8N<51AD48QR#6-XBN&6(Q@D(1R!WJXIJGS
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MG&>:A,NQE!XS5LXEB(/.156NW#J%[:E&W<[!D\U=1R4X-9L^8D)SC%/M+D.
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M.2>P K2E.1G=R*RM%!$;R$\' %6I)EW%2>:U48J*[DW=RI<7Z6US \C;?WF
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M>O-91<E7Y1NW)<[.YF923G/'%8>C2RC695EY#H6#&K]SAT(.0#[UEVZ[=3A
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MIBJ]*-YI7/#+KP/XETV5Y&TFYDBSN#HN[CWQ5C2-/O=5E-K96[RW"J69!@$
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MDUOR%2,@Y%07&CVT=G*D(P^WY3GO6=9WA, CWY*C!JU>+]G(G?WD9S)Y%_>
M_P 3[A^5=58OYMA$W7Y<52@T87Q:9S\S#Y0#T]S18O<6+/82QDNC?+@=0>]3
M3_=Q2EU'+WGH9WB&5D:"(8 =B2?I2^'KA=LL9_B:H-<D,\D%LD9:Z9\(HZTZ
M#1;^PLI)I)$$B'S-B^W:II^ZW)*XY:JS-J=/E(KG/"A*ZY=0KT4-N'X\5N)=
MK<1#')(!JIHMF;36KZ9XRHF12&SU.3FJ<$ZT91V%?W6F:]]*(X68YPHYQ61
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M/9,P[K_B6B!Y7(5Y53&>,FMN.17@*R<J16!XPC:31UD7[T<@:M#3Y)&LH3(
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M^L7L4,UO%T9WQCVJ_!LQ@8Q7+ZX9+C4(D"G=%U)K;T_S6B!8\TW)JMJMPM>
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M)KD&A^PE&XP[*HVL&;C&ARP5DS=L5TAIO#2K$#Z!73$/,3#SRTM#R9LJRR?
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M5/%@GQE?7(U.'(.3VD9)-2;YY3[ -,PFTB]IFJJ!13:5[T$E&\2#$8 K4I'
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M60T8]PD7-W%8 7/Y'9@*<ECH!'D[T"BG)NHA[ Z< E?H_^!E/:$HKAP8C4F
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M1 O/MDXK5[Z[IUW\F.RY-3WE*>$$4B_*W[BZ8;L@TD,](M7?;WQ6OK8ERL7
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M<P;";>#_R_YE_W^VBZG_!E!+ P04    " !:1&Q8M7SD<F7Q   F-@$ $P
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M?>>9.RK896T]DY!A4E =-Z/F\L59B5UIHC!'=ZJ?>WD#W0.%C2H+2%<&G[$
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M[\X3*';X!#,Q*OX^VAE"NPG%,_T5T^'7]A,:2P8]C J)>Q_&73*SF0I.O;X
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M>"U"MO.D_M_=(G;^O4IQPX&H7Q#EN,)+6"]YO\.#GYN<J:+G![>R@$V'9RS
M3AI*\.P_Y=#Z7Q:K_$<.K3DD.CRTOS;"0>19*OQ^",_M(I%3=XLU5S4%A54[
M'2,C =DT<S&*Y2I=_/WL#7E5/TD3.,FU2.SJ&D06CL9>>'W3>T_F%^.9AW[0
M=\\4U9ZN>8?I#'_[E93C%^'N.$!VO* ;=+W@[E6.=_$ZZ0M)F_@6%X")8TK1
M[2AS[5#7%C :E)Q"^:*7BV>V'[IU\)C(ZI;F.#V.YLLY*C8T.C=*%XJP'?V
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MTWO#A_=K_/TM"3H-#2'BXQ04EOE)!+O@Y;PN@NRK:@[<MIF+9P'+KPR9F08
M]JC^?_*N-!I*4"XW""[4J4@&Y@($%Q:C??#_7:SB(4#Y5T]*1-EVDO\9BG&=
M.FM7-E*^] +A4!&WV;%X*"["+P8F^Z9U]X?":!ZRV-JI+;IPZF98(U7/#TY)
MOJZM:#_WXI# :2?HD;OAL2S V[ B/'"E@&8%'P^;42XC&T=8-@Y_?C1V[:&-
MGE1-NC%$!,8=/K2%3:9L@ F1M% ZNI%Z;&F%>LPC<>/U[QB'J1M59W&U>SFN
M?IL,2G+@7C>:)>Q>\!#LOW';'69?.7#[@60FOY^:35N0Q;W<=RE<UT8_$SYR
MKSB'T)S1(LR)$<\48OL1TZ^#%<BRUUU7TWUO9W![?K*RO@R[X3QX[N^6U-$9
M+BS@TXEGS$_0""XTC:[S(_N&\?3\MX3E @+SN0#6O/Q/+/%#%T$SO(?Q&NU*
M4Z<K?*7;SX"WQS=D&MS5O=U/[\K4D4JQ.LS7\^5<V$O8.]]B*#$2 NC7**TM
M'@I#G'Z1[Q8.557Q\V4<57JD5MEOV]1M,/S7Z^-_95FD[2,K7S;?#_;2J$YK
M$#MKZMJ6S5@/#TTNF#2=GAXJ_)%B(*4RM<E1<QC_F2B&;0Y864&[ZYO)@]Z!
M= /9.L=%VEGM:3M)$T)F2>E;Q8?\\'" <2JWOFSS%B.W7H5FCS:LH*;&O'[L
M6A['_U[F)>=F\!NNO(?LUC>/RNXYBC_[=X (%QA-7'O4!X.BT"*0H7Z=&>VW
MO0E"2'E EL("&(^5(73I@*BN\K\;YDZHLOW!6*F!DW"R8 U%9/,6-2R%;B26
MO_,E[:&^$-&JCY<8).M?<Y237ARQD<](;M3QP\$1/EJ\J*6V()=C'Q;?&Y_.
MU'D<<R/'9O1ZIA+ZC?%&L2*3#\(I93NJ"K-Z KO@IM\'*EO3LU1:4W?F('9>
MD.[ /?3X+Z!@:\YOZ?S,H:*J.OJ;Z_W<:IS9N=,S)D^7RN5/&Y,^0#.^_]C^
MC?K39^82)$/.WQ0 ["V/RFW4?Q!321Y;=[II^W:>XSL,/#A'S_*!,'AIK9,%
MG!!O1$%P+,L"NF D(@-]C; CT!X)^[<@S_^V36;"OSG+>/Z+<!TVOG61@LFZ
ME5G[_5;GFX5D/?^$7_N^* :/7[SXQ#2!NP(CB<1T$:1OLP QP_@KX"52W/#Y
M0$5O%V^\C(Z)D"H7'[0NU\EO,)0=';A[D)33J^->9QF99MR-620IL?JSQ9"V
MN7;=X?@LN=*874DAA=?)PX:L'M34&WGJ7ZFG_;\C^0W&WNG(F;_D/H-,;]S[
MAW9ACDJ'W3>PLT/$/.R[%ABB[M#- GC::0&6MT2_V]Y[R&T "3.8!.,C=CX5
MXF<QE5!&=D*\_!,!@9TIQZ[YYTBS@)(4+8:0!@I+-_':;&8!N0@84W@"6IQD
M\?L8K\W,, /$"NN[R_5:I-58P\SLR!>+Q/QL9+S6Y724E0/OY59)KXDHA!?!
MA["M0!0D+'M\A!+D-OYHL<B,P8L.',6Z2;S*P=8_6/">E^S'SP4>A_8H'&Q:
MXS%]7P>EQ %5X,VEQJKJ;-_+.4;[8V(S]6^ZZ%J9>QZ1#1_MP57XK&2\1:M1
MG0@MJW'?A A40GNOX[AR>7GBKD.99[HNGK_SK%K&MI,C-2L*#_D1?6(*E;)T
M =Q620J88 'M2,HCB]J"UBXEK9N<+?9/;UK-F'=*<L@Z<,^'B%9TT3VHMU#<
ML_9))C:_%*7//PI!?3AMYIV0A750Y7A#\X;__H:@+9]-(QGI"EO>.K+BZ;?V
M9-,8^I((7P*<R3:/W&/B0R9*77-Y767:]JBY</& K(?CIZY\;BNEM _A6_A*
M[%6ML9Y67.E(2?&B-#S1Q(XD9>"K6)5AL)2?Y<73?O?4FVH5$X8JQ[P+O0)J
MEH3MTIK58H0.8=<EU38._C4? G;4_IKCJ$$"%MP/\7?[&"@G-UD E)0>C4W0
MR*K])"9C*0ZX:"0;VEDEKMZ:=$>SHDM0\\;Z@ZMUAXH8XR?H[XC+<XK5HFSK
M&6)S+& 7Q@0%WXRBO*'"[AK0(H/MSPM]+OEQM?*67NF%OL_)J6?Z;HQBS>'[
ML,U'$0%':8HH'[O!<AF92.?.(Z2NS9O3WYNO\5%\'NX6W[[/5R.E\'TFF"+1
M O5.7:(C4!#L&%GJ\'^-JFI-5G!]SUF2,N)D<<<W/VFWMAR'MZQ72L4JDG(1
M-DYLQ^A 48J$-/BRRO!Z@WSO^LIY_@N?TUS>WEHP GQ\U/-9 &\'RF [> 8>
M;[8??$5Z#Q, D59U(R'/QCD=)B;:+GS/*6(,R]G) U+Z;+17M&#7*>97^$?D
M_1!$_,]3'@*G._I<*R\<A9F^LY/]PIYBQ^D8NO-6#)0,'UWOH9G2#:I!!,6X
MB<G;4)VR]OO8@&=I=;9.S!VQ78S&\2^F[V.IULL2%%B'O"JN[4AAZZE]_J?O
MH!>RM715?Z"_EUDE[9DCR/9S?\)1+.&<?K6&K8'RJ+2=$5=_D0N-58DMMKJ<
M*WS5CX;"@&JWG6ACYP5+QZ_E[HC66J?7607CK@L3(?F7U2+L+K0%'8_R//AF
M!E;@I@^4.\^%T44A37[I+9V-FH\3;)2].#:-RAY12C\[O/JD-['W:< %1Y.H
MOO)H.UF!)L_GY!Z"-Q)4BT_<8 $)+LA8C&;SZZF%(^TM+LU%8ZZ,%\L_@BM,
MVJ3.)Y4 #]G<YAZ9PS^<^Q.9Z]XM_.?45&35Z(H&98MLG6QB,(N-$]_!Q]]N
M..WGRC_2KW55SZ*0K_UK2V6D>3OF638HT4$00_C;WVW4'@W(IPBF4UV;5B*#
M-%(W;^[ZI7964;)_^[B9A6>PS/JB+T<S8?8'M@+'$.9'TI4K8$PC:[H)?K,,
M0K6C?E!DC?R!?VKS]EQ_5$PTRC_;&&A4 JW;B (A(<;[77NL<I0"MILN0ED4
MY3R,$,#ZKL8A)/<Z4\)2RDWOC,'6(R(J1(HC))\)PH8<N+\3.K4FU3:SP6U*
ME1L%?M],I*+XT7MU/Y,1,[E&V\=*#Q0F+CX5= A=R&9(0@E^<[XV-9[@A8W?
MP11="BD@MCRQ<'7M<I$ZR]"\K/N!34H2D1RI\4\5_G=45K1H-JB(S4L@%IZP
ML:3&</I5_,1^<'U:5^.W^U1IF;K7QRZKN<E7"QY53H'Z=1I6KA<UEV=JTT;L
MCTR_3G!K5>;Y%I.:\=&F:R[='/X8+D /H?J1K.FB#V8-[S>J+0C,9H7(F?U<
M/4Y9@O(M(3+]V&&'KCO.E_/3FG3("C>YETZAV:AY3,=A2B"S?1Q2S>]HS"AA
MPD&,+.9+N/7*(.TTIK]1F6J80+?,1T58CHJ<'IRT;KC@],*NX^BW#]KB8O/<
MQ%[,&R3OQ)>@Z^?<GHX=]Z:]HH3.31[&?[&/QE).1 ;I]V)@$(\0KKCD@WUK
MAZDUO+?JPG^GP).M.NN%V553]I49P4)]MF6(2T 2Y9D9 &I1U2RH':EDF-3U
M)Q,G4]7%)U+R9"L'Q)/3?SHE"6MW$MR<1\U'?RH=^O9'84H <\@#H'R6UQZN
MOT0)ZQS=UZZ^D;"[=/RDMTTW]TMO7:MQ!XX#GE96?AG0S?<Q7PGEA-:_O)/X
M%:T2AD>%M>R9;)EP]=TT)M=91-4G*W=,36ZQZZW-!$U%1=K_FZ15K-D!YE=<
MN40;G&MZ/L>4JI)0 =O]A5I.N7[^]>&+&7=/XM2Q>SB#)QJ7H![(8;M$2'/_
MQ*  3-Z_]VV?_QO8B9.[HW%">4_UBI*0>[WFQZYPM0QC^YF@\V]>PKX00'=<
MY=8R+8-:V.JO1_J2P+-=(<=K/<%W;VC;9'TC?M&OF *GB_7,GGX;7NN3LHX4
M0AL.'_-/,SW1^SH!ABX5(%-/T#)KX'#T7HI]NYI*.34L5A\KU-)ZC?FUS/8"
M[*JB(D6?[>PLL5,KGBA>=)[<W*CW%7T\F2YN>'\-=CEK"C;D'((4IA_[@R70
M9:C[)Q?-A&I&S>2NTZHZS9)1 \>35V2S%"+4-&X2*5\0E8%0X/U&&X$U/E1%
MZ_A?USP4C1Z^F<_[,IT*[GY@#L^][2Q#";M ]2!0"*U'4E-NORFWEW2[:+53
MC(--19/A1_"?IWP8>1O%GZ+X3KBHLC\^8AK;^-:L0"ZY/#RYS4^TZH%P0K[E
MEV&?#ANIPYPSWJ,M2,I)V+8JLKR3D0))C3Q-M=5WH B3%]-$MV"\AG+TV /L
M?$\B0/M5G[[Y$?0A(9)P97-)]6*S=L^,3_FY5(@_ZL$L/^+4+&@^R"OET%H8
MCMM,8[RZ#1]/G7W>:$B5>['!S)(;.A0G9^I4,+U705:' V)8<E1:&W&/F1*F
MN[,#SJ6E68X3\UC8K/WV I8N,W6*XV 7A<NSISY/U@N, GZ;RW//P,']^S,Z
M6]WWM9(DVE8E/,"T+[V>5>X29]9NZ#?IGC^LZ&T<G=Y]N+N[Z36SC2C,5*##
M&04F5VAZZ*.C/ZEH:?=70R:F']QU]"3-K7@NI(66!PCR&E^49#]:7#C31Q?C
MGS5=;7DFA5%<^@V>[71Q?S>Y)&VY$?,-7:5:YY['%R/WW>=:LU0SAU2QW:96
M?PB4KUJ;Y=31%8.W\Z,><,KS3=RXO'3<QB&[$,ESJ;V=+X\;*28/>(J4]W.W
M$R4)?K").3N(,4383?NU8^2R91;.TG0[VO+%%R5C+U#A:DF72L-"NGM1$AWX
M)*PX\^"Q_$ZJL=NH 6HYVZK$_;*BI,5DV.-/27/7Y^;5=L[]_,OA%,2ZO.E*
MG-2Y/XKC(2;E_&^M#H,T4YM:#\.PR6Q_W< ].4<!W9^NIQ[4U/](2/0,,X["
M_^0X.Z2YX7]B<9-Y33.P^,JUPNS+=MV*PA>?YN2GV>(74:,M.'G$S"."@)DV
M:FVK_<BANC>@/-GA46%#2<E=E<JTJT;7A"[<DU)*,S_<9Z[*0=8"%5-JBL:9
M0Z/95Y)&.:P:^G\AS\2RZ1QJ>:T<:"$Y ]^\OXJL$IM%EA*6PV:0XRJM8:%F
MXBD1#%>'B1"!0 >%J:D5VCMM[?NZ-_-JNKM_-NZ'4ND%AIBC3X&U1:3&(@0-
M;.L-&2]VVW_P$\_S'TKKBK9,5&%R\7RRTU*JU 6^<VP89;B?^+@[WS/ZL 'N
M-<K'^NO5.^6,@QTMSC(>=J[>R4]#F@_N\J,0-I%_^;%89]"9JFAGID$]G4>V
MY_%PZQ0L\/K_J'OS>*C^OG_\B"S9LF\QLJ1(HD191ILE"<F^3$79LF4;C!F1
M1'9%BPPA2DQE2V3L0Y(L$6+&D%UFT#C,XGOZW/?UO7_7?7VN[_V][]]U78_?
M[X_Y8\[CS)QSWN_7\GR^ME/VT5\I]9BNEM%2N%KI\8[ H%B]M.'>T2A:+H6X
MU$I!8V1]J#7/KGG$60Q<"<QT^SREFI\7L_\@80\0F;N#;:DZ80HK/H+D:GZ\
MDEB]>_E*D4-/](D.K7;%4]."-SG55MDAL!T[P+!-:W\16HJT;)60DUU[N^77
M$&RBFT8OTTQG-(4?2/-AGJ*HI**4Z0ATK^>E_FL/?W<Q>@S9"TWS+#M^(1RT
M2&4O4(K<P_[E"]?D2@=N;'%*IT-#>L+7I",2EW!T32WZGFF??]XHKT/E*J[S
M9%B'5D\FYAQ]A<6#H <B:Z<NE+U$:5&9Z^]_EKM?#5CO\;FL/[_7V#;SP,/H
M&9G!,CG3[SSZ]DW;@#3^,BP%QL7PBRC4B W%B,P_,Z:+XPI&ND)W?G+<=%CB
M*'27LFOF&@Q&1&.:U?ZHD!-'B7W5MDS,@[_-.C6D\2KESJ-GGTR>BA[ZV&^N
ME?:><#7>IE.F,G4_^S0.5$V #" Y+0%3E7!7/R#HFL%PO+ZMJIO30E#;>>ON
M-]:DL#UJL752"]R$2,K*R&D2+ GCI9',VO.%H7?E:#;5K3VHU,?06?)@O@G?
MBJ([^ZV8$YE&8LP]"Z,&=SZXJZ>67/,K'3FGJ5S]W?Q@P"\[#NGR?-#>F%)>
M/S;W^.R=E #% &05W>.6U =3([:C;,_+JFTC25>?_FD^8IGBS+IX?'(;H.^W
M@#0N!?'% F-(W(G_H9@'VP;>WB9N.0RR,3GZ_IO.[*(U(A<KTRC"^OZ>T+XB
M,0$*=IPB-.=(W^_W/@;9G6SJ9E@;(\YWKV)J1XSA!N35$#P,D]>^&F)(WW-4
M_K)# W+%GGM N;%;A$F$&NH<)%>6# %J<2O12_PQ+D;;925UZF2#H9..^P^S
M=X(@C]/F(DNTEB%JSDJ &'A<%(*ED 9>)%*L85LP+A;_,@9, E:V@<E,N&]
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MXDV$=A%_&_]K#*)17R[C!E_^31H<4EW<GR2W<6G; .D^?/6:H0@D%6/; /-
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MNZ$P%?JE12PE;=/\!_-US2KJ^ZSGHS6_CBA/,5JT^C\W&OF7SQV\#,9+#"R
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MKH2ZICU#[4%$KKVO:T!S4F=(N0T]X'R:296YJVG%0.CN^%.=)E=;N60K75,
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M1YB!Q:3H8[-M(M^^;0.>"Z.N+U>>7C7V3/7Z<I,4$-CD 7'WM%YX'/S-2GM
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M]SCQP3:QKN# ^5V,JT[L;L+XWH:7U,?C*NSQN%&]LUBS^O1I:4%EE9'>;,H
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M,F!*Z'0C:VSQ"R)! @[4R]'%GFM/&GYJSG^]WR.=))"R:6M*\#&TWJI@, >
M0Z:XE?BAQ8]NGW86K>2E?6AA2QFIPB>#O.NL6*GM:X5B &.)N JI;QZ- Q O
MMG*7()(/*U4PMJ(LZU\D+OC*C'^^XW/O]8S42?'VJ:7>:60XDIKJ15P2;^8
MKR ")4.'C_C1:VB(^9>TS7-=.3[EK@J99-MT6V\-NTFDLK>A/E,M0';?6@ZP
MZ <>8AZ$.J=AS0& *>[Z_'#S#A++P8:5Q5:3?:]-'W)VZ&NO&?X1GN*[J&W1
MP.P*<^0 L!HP"IH0,Y#77EGC%NY]\@,Q49MWH/EV%Z+#5O"]V/9[:58CMA-.
MX0A#]'L#YB*&,47XOL#<;#N)CV*+, %:QDJ2D44I>&: T3EN7S[ZN%TB>WA8
MNTV'P%=IZ)#) 3JFC9RA7\AOP]PCDEU%&$[HSTXS%(\"T._HD-&N1^!EXI&7
M.5^UYM.5%V3,[ ]$;<, LZ;P@Y@V)%HW2)R\;J;#@.H0MX03C]^Z$$V@7X6Z
M?3W6=_[FAV%\'V'FYK"!/KUN17NL1ZZE>T')X]!FFU*1FJ5]1MMN/E&CV/*R
MNQ'B""_;D632Y=*) \8FBP2K+(?:1H;[][&J)A>!K2(?Q3Z'G!#H"F!!:+#-
M!#/U#KT%\PDR.EYOD!D8ZC?BJ#([?!3.%MV))1!'M$AUM=10^G6J5)21>0J^
M8E8&,_)C8/R@HA=CY/G6 %(T$#*]Y=[_MG[E__9RF.GM>HV/QDQ4X@1KG3NF
MQ^;DY=*&U_OR(;)NWI=?5?B)[?-:Q=+[6.D+B"OOX1TAQ-O+7=3ZSOP-7UA-
MAX;NR^56/>[: :0(VF\/OV9Q2+  A@3'R@]"X"P*;?BQTL4MDG"H-3L[26#3
M?NQ]"+JF-NJNV<[[%?<:^6S%#2U4%GTV+*&&LZ]XQ],([<0Q97HF]1U<%!7$
M%J4JW_8]BJ^8"S'J=HX'[T6>WGZY>][CR@;8(=/7V%HC/BK1!K2E-EE1D=%N
M#(V8Y-)X-8T9C0;5U4\KER^>S9O* ;X9F067>JZM+PXH>R]7ERY2D^9JH^-C
M21*RKI9_I6FE-X6L6NC 1*(EJ-'#6.J9#@L?F-U+C('=X"6=U:H=HZ?>^3L+
M67SY($!V1%;A(M![9_-X:>89M(5SSVDN+-;8KOJ1;)F]E_O771GSTCK5E!1D
M[#VSL)[]'E.#F??&SC5ZO!IA[B?C8M8J!EV=OZ%W/2S,M4U]OL^G)P_@CUE]
M+GCB"E\."\?<6XK28CWG !Y(.=!DPTVLU)S3P BQ(FV=0>K="9L? G9VGIO2
M/XK-.N?7SC W5_ZDWP&'GH$0T:)]:8T)N)3PY=-W23_]-V(2.K)JL'O1 OS7
M;H"!\'6X2Q">T0>7W6GU])CAFV,+8IY[5YT$8G0O.O7:S,4J%RHHANMD'HC?
MQH/T.B% PE+V0P2EA< !+F.BUDJ3:V%RGHU?:A.>=UZEE#]._/QFN^EAR>UN
M^[&%F(E8Y-_XHR&7/R(/0^KK@)CJX>[)0&8BUD[4_L0S-\U E%"2 \R1;;C'
M@JCP+<O@-#$3#=ROGH*>,R"N;;3_LQP88$V9+0BQ "6;"<CW,CXBEBJ/KM%;
M#W'S5C%OTH,0[-9E&$LMK;7EUZVCO*P6W-0'M#H'^+09R1+T_CG(WI (&>OT
M2656N )$?V]C^[A5I8[-3/:R(G9!+Y:),T9,W"$N.IKLQ'SB1;!4C@*L.W]?
MPUMT8 M#EE#!H3UY;1&"@OTIA%$,U:9W51L3 U^>N0[1U5,.7?G4<XA5F=8M
M&$(&!"$28EH'H5?U@;Q^.G,/U"GK9-;NG'"33+U5B'^OV\9J-5'G[NK:6K.P
M(6CW![S50%*NW.S'A?+6/C^7D0C!IFFAW&O7/]@.M([3E"FJU-)VPZ'QQ$J4
M&74XO<P)D77=/?AIU[87^CRC;YVW3R2)G'=AHD$!<L^8K#!1%I3JE+([NK.V
MOK&YKL%-(86WX&*P,E]2,S2^A.Z%L7BR 'ZV)MO(:C)8 U$M:19QT_2J?7UJ
MVJ2V ?R>FS%"9A&B6\[R^^2,W"=A3!E;;AF,[\I,B5/TTS2_3AMOTCQ.&+U-
MO\C'V^]6%OY@5=R>!"?MB';RDP\(&5"'O56+?IL#/+*91# %X&13>?&  ./E
M=_52.E;7K^MDI3F>K6X23^O,LU)N,4/V><Q;4T5[VI%5,^$UR;*@N$T-S:RB
MO)TN9WT\^H=$8F=YTQN[&S784X,2/Q#4IRC($1_RX(;U'"#^*V8*[S68GV4X
MH@ZR,BOU1IK7!;MY*E6E%!/'K@Z3=VI/Z_^8Y:[N/490C\/'!B=QE%VT&_;4
MK,2KY;4NFL9Z"^9/+US2>)];IB+$0-MA&R+R_(UUD"A,>S$5P1+D%O%L.P=G
MFGE?04OT-VM7E20_/NNIJKK>[$6=Y>'4OH<%E\/UO*<70-5\9K969_+:-,1L
MBZ\1/DIC(0\_48)9O(3;C)C+P+(S.DSA\EP4@9G:3W-FMY0CEE3+EI-PRHB)
M6-SB-K"" [@.P]>V#*WA_^6U/WZ[=FELX5D,I @RQ+Z;[ -KO6DW2 Y)2J '
M376GY$J@E<!#[R?FP,FOI95]SX+.'TI("/?6(OG-&TR&]B:L(;N024BQW$GD
MW1K(UV_V,1DGS-,E;3Y:BK\42.&-:.*?BD!>/&DJ?Y!Q"B5!0)N@E'/;\^1H
MB82( %6M'2]E6O*S6^P%=YE8'([IQ7H--X *Q4%E$QK8#IC,:[;*X)A%E#6N
M\5[5&_\W,MB\K6EM*RK7_"WWS;FFFZOP099 E-T)KY%J-Y;WVX#293U"5#<+
MIM5EKM7=W]549:Z8<7<5?VKE:,(B@ UDW<-<0HBB>T)$G_CH"6/%@^K/9?4.
M-UL]@1&_M%J-KC_^<=U]LF*:E2)])<?I7U.%&"&&FZ@B+@:,!K+BS^2OZ8>P
MO%B0;DQ]1F^%3-/+"] LV8S;A?G+9\*-3;AF[2YBXG%^O?Q3AOHW0T2LD=P6
M$;)/B,%#/\VBGPK/ZT[5OQ,*\I1N..&_?L#2R&'&KYT([D;@DWG =L*I8:8=
M6WO ("+@\?>4[LV6/U^;FYTQQQ^"?13K"H-^;9T_ZQX*2;M(Z,")-<M=N%[Y
MIG#4ROVIYZW4K >F9U]7FQ=EM:E+FRKSB_41IE<ZX",SD\I=D/%R!+T[3,2'
M-)=E[_+J6%VE=?'.K)N^M=5,[LW2CZ "V+<54GWR35Q</HQI/,F2?EA3X=NM
M-H?9<R'2,*8#=O(!_+J+9O\Y@U>],674&Q,K4<Q-FN]7^VZ^5G>:\S4:-N.Y
M+_KJ 7FTZ1EPS*[?#)#X&<C<XL8^AH4@=Y 9--?$' ;T?KEW0J #\R<)I\RX
M/UMD^?T0!60VD>H$CS-1HZ+CJ3.F?;5C7^#'AN070S]!.,.)5"3&O_'MP=T&
M]3V#.:R]V+=(4%.9B48I<8#*D-B?D>$F(E0(.]*2)S$Q&D86)+_8QN&FPG')
M1:V*"R+;<L^6G9^IYD4(_11<QP%B:]5R_0?/NKX:<#[VK$O.5N7;=3#2I);!
MK00".=+T750IQ@IQS4$#+8&"0'1:XB26(>S" ;[-%(CZQE%,-C(1->!3FG6'
MZ^96@@93Q[/L2T5-8^VG]6HG#AX84R_:%JA0$8JG'&3 /J$$^FJ,#[?C-M_$
MWJU"?GZSKJLUY<7Z&OL3;REU'OM\+0X.A)N<>M0B;,W*0RO-W=H[/CO.3Z@5
MWJ]3-3G<;N5V==LV[4B8WE)^!&8BNW4G37F>5,&T(>C-)0M_7_.IH'RBMGQ-
MZ_YZ)'RS:&"D 30Q8?)+/#1["<^:W&F[]^[7MFQ,NW@5-M!23]_/RDJFN-/T
M.4 [DIIF07*O'53\:+.4.1[RL,H\5W_AG,>[#S>8NCS3)KQ@V*16G+Q2'74A
M^F;V\GO?*9W#;MY1BKFGJWWX$R9X,4(K80IT*]:S9L3%.B=D).I&R4B9I"0]
MW6K+^;Q2KP9IO8$@QBMA2)9#T#-JJ/I;Q,V^-\<DAGPBOKAMS6"^_J@_[']H
MXH''@[@5!!C& 1(0W^Y?P8#:N1S@;@$L5T]KA$!_T;\TUL0@PE"F==4UT3-Y
MGEI*PMNN%&<G+Q@"@DRU4=Q$*J3XS3Y/T(.]I"8.(/X])S/VJ:>4]CE'I$LS
M+7NGT.N)_0?.^FL;1IJA"Y'@J.U=9)7[2KQ2K;-T;>^ZGB<MS_8'W"VN\M@M
MR[?=M]M[48LM"%%,Y?12S"=)KCTQ=0)8@\5_4BC]KRY5U2L%_%URGM!?[KDY
MO\V9_UVJ\A^.I_VWI2K_(>[_RR$F A'HOPJ7.WQ#_E70'4!W_D<E;:A'ZSHX
M0&H9R8(5C(0>?^U-08!*1&8VH@.VMM0 H<&G99.]H":<F8@40LR]Y8Z!^6&D
M)^2P(9V=>L/>BB$4X]D9-J;P1.3?<V]%K?\L]Y:UDQM$G\A ;#'11J%HN,0:
MG]".:[,A7PL(F;0OO=IOGYF2PA,2:)\(<A-P4 '7U2L2-->1TT*\PU2CNR!.
MUC=E]>3=\DE]6WG-Z$5ZQ)PIO#QO#YA!@L=67#4Z.9D([XB9"TS1<P8K$AJZ
M;RU<:)*6,_9^B*C);S])F R\C: &^W"QVM<5II0 VQP3;;&-E<3@ (?C<'M4
M^-;N]RU3=#I';2J?%GV7;*S,O=DTT5R5?3G&_H-VY>-(;=CAT1JUKQA0J8^/
MK@1>2%[]338ORX@HG\F#$\3U<Z,,4]^LHX,_M!)XZK*-GHS09^IND4V6>.K-
MT!"2[Z 50Z[*/!\T0C OMA#HD&)%9AI0+M!\;?EQX3B2[%BI#5K+X13#8F]5
M8C&J=JZI,O2$0#>NCDBII760>BDG:<(=KC)@])-O:Y*Y(2FCCLY=HJ_3WR0^
MU[Z]K/QT 6D KM 'P!':X7;#V!BC4S1AN^&;<@?M?<L]+ \=E8AZ<N"$O/3!
MN=$F)*AB&QW0A!O3FKQ-O3)ZN^_-DR+%U-'7]K&I\.WD5.2^+Z#'V4'*>&B%
MTMKH.L: S=7O1=\M"V"#"'#' C/61 U#J(UE1^NA7Q"F9IB;5MB'\R5P<Z.0
M#AW*P9W]]C^5&?A?NK ]OSF=2/9F:([Y6$!S-A)G5_8K9"F /<+]BD-:$=!8
MG(!\WSW0EHWSXP!+Q7/S0@#3_(^[CI;+N,>MIE\'W3C Q>E8]IVCS(R_?@98
M6N,F)1QU^H?W_=?D/3"+?X-C^)EVO[69)YA]:LM>.%7NOBW:*C67_?([_(,0
ML%;&%KR>#UY$\F!P8=R%1()&!7>'#7J=]^@0N_0:6\EQP5?Q9>JI4RZ%#^,W
MZ<"/Y7S'361R@,5+K7P< +T"(;II[#6: 86/VM,6\J4[$<LTI0['ESE3?I;[
MU9[=D6.4D/CZW8;7VW^:PE,05#OL)SR) \P7%8,R&/ZZ9P/>.BZ[>ND9??<O
MZB54?E;!C^M1B]%MF#;+&K@(FG#+A+>*"NM"QMH&//[\>97FY:I4'UZ?H[!!
M/+UAVA+?@,U"D'J1<+KD2=(MLH+,BQD.L*-/H*MN;;S(8T.<,./)3KG-^[-/
MHX%A;"Q:(:BLW;#3J2Y^TOB4]<?),Z<;:YM2%7EBMEZ2O[WM8NM=/W#7"D6^
MO(.]:?LUR]<?*ZZ%X1?48L%$QB;4=?#,><.%CA;DFQSE7(H,"GDU3@_9?"DH
M?K<;]IW%%IX>)'J **&G)AM_  N?^SGZV;S?>F-6I7U_C+1E[R%!B9E;A"S)
MJ^_]C%)T-HK+9BB&7'?.IU8RK0@,^1GX0;;>7"L/ZS9;&W5\4&,!94":,[:T
MA8VN:PYI*6BP?//*X\Z;E_OQXWQ/"F#\#8TYBS8_WROV)OBFQF\+L[%PI4%$
M3XVARPP>ULU/PL$>T]Q;L_CK')PVGMJQ]UQ*0G+#OE,1>;%@V6RR*'N ^"+_
M3O/!$D\KAI[KH17"2:?RQ&N/=P0*I_%_)NORK"E/P%?WN,#9;P8@W]&(4T=,
MI! 7@PT#61'<>; ..P*[:RCZD(2$%*TKQR3=4RXFJQ2\_&-X>%CL=HQB;<"1
MD]\ 7IPLM_;;/WZO /;EZ/_ 5D03TS\[Y8#PMU,./OQVRH%#'T1W_^1H-\._
MU05:_:TN$/!GCOC/5N7#3>[^&D+!ID!F(W_QTCC$K[$M$'H^.H7%7N%.9=ZZ
M0HQ/\<@YU_'/9IX>?K+6>IT_-N_K-W?,3@8 G72D*I%;\MK#&RY1=WM\;T/6
M5?9AKQ.S@\9Y-Q+'S[N>Q@3QJL'90@3L7(C4?.BSRF3=OL-ASYP<OVN)!M==
M["P3ZW<<UC-YB0]A*NKRL(Y=D=\^:&3_:,1K38_5^K1XO+-ZS-7)4C'NDK'T
MV6MF5QQFB$RQJ$X9>@7C0% :WBXS^&:B@<N5&IRNW).*S49/8AE-'ZY_>H'M
M._I[RJC67\1X6,)_&2@J@'V*^]M@(2"FUH!9U$.I0$*"8 5+6B2L%!J(SY Y
M5 8AHN8:"%^SUT,Y_B<0QQ,^3#<'J+=XA8V55__(U)E$W,F4N?RRI&?*9:2E
MI:/&[OSFQ^67/%+[AM&IW.V=K+P BE./S0LPM]0V-%C;N4UJI-(!E=1F[W\1
MN)2R?QG;Q8UGV<I"?8V9AOIZIKF#!&-F)*_S**7_OBV(FZ8=F8[N,C%FE>OY
M\;L&:9*M[NI>T;SXTN8HZ9%BTPZ[AC.]7_1H@<S]]>12)AMTX #KM3&T9ZRF
M1^%&@?1#H'4%2ICU@"DQX;?IC;=F]6/G'KD>Q_U!];H#EKQI/$;[* 2]893?
MS 0.(L/SR(^(I9RC/V%CC"ZGWDC,)<P=IP\1W#2^VMH:<]FQ_1O]\=ED 6]1
M\X,*R4Y,S5;6T]8]7ID&DH&8S<R3-SRORQ[6U?9*J[),V."N$+@]T@P(]@F$
M9,TV!/'T$%I\4-&KM800UYKAWBL>:>/[\9E3DK+GQ)@*.6N];$%GAC;*D/58
M#WDGA6G:E^MLHR2K7,W[_2RJ6N$8_,>>#[>TD$=!PB0BUN$@&#V9J-T]</9J
M>:UUV16%W?BKGCJ[$_*. W)7^!9@(S!NX7G"9"E%=0*V 4SODJP?E:QX$N_=
M%#! (6M&;YW0+M@^)1K3^@.2;?9&="<WX).(]5L+C<%M1YP7MB+0WX(GCFD#
M>N%6*D&L,<(<!V!NZ6$?RYJT8/G70HK0<(6/O/!_<<?_">[XQVNUB2VT%^(&
M#C0+=O-.2+YWRF9E?KWYA(^$ W= 8W$/%H>@"U=S@/XJA[D*M!GFUY6^*[\+
MXH^L'W>F;#'K-S' \P5Q<WF%S(D"V#-N <[_0!*,WY#$&PX JNH+4"IH.GSP
MV1.865W[M;;_H/OPW^D^JH/ABFG38JLP;[$>&2')#_D<J/.&YB]T[=KDICN?
M[J9$;XKAV?"]M'#!%)XY+@T9EW2K7B:KBP,4QK$SF(&T_%?$=4LB\C_Q\BJ#
MS7N]0_CU![PVSV]N.&&)/,>KMN@'#5VD/O/R\Z%YWTL$([7ICNO;$N-?WGUU
MWI99M82]"OUW]) /6XJI<N?!_66UQ\JSO$( @X\MBZ5CN$F))"P3HM5SITST
MF9940I?MB/BDQQVC'96.8)1YENG'B]9S@@;=CA?/]^2?1'Y(1'_ M"&8LD]0
MW&#]93"V0\8V3<\&R;C\EM#K\V(U.<,%+\"G>,,4GA"P@F6*);./%T$V\\5%
M:'98C U+,0V%Z;?QS. @:,*OA^YU$H80U./(3VJ3^?/O:1VG:<C$PH'M U_[
ME9XGSSN,HQ+5>L1%>1,V*MQ8*H"%8R8*,(O!^9"OG-?$+-DYI*!T(/J82K)E
M"$-Z-(6%K'4<MZQ+%%S:9*=WJQYA$"GSH1HQZMO:\^3.)+%&ZVVQJ !?R_DK
M.*HE!PA?$WUQX>F8\EV1KH>=@7MCAWA<7K?%F'_(WL*S+- -D6M);SR&#G"K
M P1BN5E*B@;,O.,/(3@+L6L6CS<]BFS!3,7)00Z&ETLLK<9Q4O^?8(GN_U<L
M\<\U!O]56()/&&\BV&^B&&1M3^V]LP36NL!.1U144I0853M6MD4:1N[GYU7[
M26>P-^12%S%;C+_@DIL/>A?6L,\/BC3;[L8_6+UX8]57Q7889S&KPI<.VE.Q
M'8AU*('BH /MAEZS(9*Y\J\O\%?O5<P,=.LYL-G*[6/.W)7?A6,D_)?[37"'
M_A,;5_ZA7 ?L#?)/@P8&B-]C!@^Y,0.D)*;M&F12O$#(I+A"+G5-6X9ARQ:$
M9K^2+;6#W:*)6'KF!:R6TF.@W[*<RY<UT0<[\&=P8KHL;:)KJW=G=:YMZKAZ
MN'XF+&JPPK\5FH:1FF!4>ZMVGUYVJ])LM5DILBV(AB^QE.[T5TO19AU76W9-
M"S<YSJK'^?&SD@*TA!SS!>KCX.?B@NOC2;X[Q#*V,A+3 D-O8N\C2" $"OIW
M^3'EDMDZCG!N:$>ZE:L9#U?8L1)H9)_ CWJ\[1V94@J$;O@)PTR'@J"+RP$(
M,<\Y=:==>;Y?UQ]XE2#E%<DT=XYX< N+MP4OV\83EZR;(1L=J89E[\1=QTWD
M8A8O<0"N^1@@0W+^BBW^QO=3G+UAC(KMQH@N^\6=@EA,#B%FLC'*UCIPJ/Q2
MW<]L)_\V@R=?PLVO?U=;RK$5^E9M.6!5].G B\_OAI]8*3]5EGAJ;2I=-RX[
M</6K8\52DUIPUH\W$HUJL$*^N%4<6\@=DJXU38']T@D"_>?TEB50+1"(TN%:
M7&Z/SU5@EBIE '"%O2$4HE>]<<1E;@<+;9#E :O<Y4]C:#K,=/FMT9]#SJT$
M.VSX7X[%_;<O['9PE7$6I</*\9E/3@J@>82%O2_)\A0_Y_+A9?=T8K!PGL&V
MC;2<MZ PPPNES"JJ]4Z$M\LPHY 1&RN*OF=2O&^>"' W9TQX/'Q,;@%"B[?8
MZ:RSLWJU+=U4V SUE.P'JM:_0O"!SWX>RNVLSZD9M@MV< @QR=_UOGRCZ ;M
M)VUM AFO)UNCP1LTM0Z$9+."VV3R!F_)T1_1(8\[@KU&I+=)G \^(_#L.7_(
M"0$;9":.>LYV=1T3@M>5H\GLJ'7HXE\/8#>%0W[UOU1[._.?:V_/.<Q#!E:)
M3,6SNWI@K$T9OP7U_N*A>SRS2W_<E_TO6T"XQY4#R 1M(.5:ALVL0U<X3&MQ
MQ8 P$<<0C ^O0D*PAVR#!C>@B!)@LU;8&3U(!\);.-4:LZJ-Y.$ ?PM6#"T!
M#A!DH)[0^C3CRGJ.4B5I:)D2EBA"89)T[VQ9.ROI2PZF#;(\VQ/0M<O1D+QF
M.8"H!5>KS03:B2O?9SC '6R_UJ=2>N 0QIT8H6^R;EC/V^;RFO!8?'WC"_.S
M+Q0NJ7R)O#X7MY+S_^Q230"'.("B'SZ?SL-U9<%JM-!?HM*LPO_$0P#KXW\'
M9SX+J7OA5C!;;YA4&NQ7^LEY1UIHV=,S^QZ=',J^'R[PLBQC=96!&D>B;K)*
M6D78'UX0SSF";@X82O(FC?)HF:![+T\K]RG:B?V8X  ;(!C6+,MP1,E"V/X(
ME0/$HA7!P#/#EWQ2'=M0N=-^1SX8Y*_<<'V!W(H>AC]'M#\\#!$*_G%1*CJ?
MA! /\CZ>;C<08+P3H72-JIKN_?RK:9MESZ6I2%'O0<QY7,(*41[AWKL>S#J3
M71G0\"C,D'UK3KUO;\+KL)%#+U:4PDTBWP=#D&5A5("$:\NJ2^YFZ_4WZ^F]
M_K)1BG"TZC5N7'#ESDJW6CGM3(M -$JG;"Y007_-YP$A[49RIJXFQ@S;BP"5
M\:_R8>C!4;]XMC'*:< 'Y3FI)3:GT^:^_EEK6,O#YB!9.WWRTT_[2"?<I'5Y
M5A;"V8I!#I-)MW-Z;Z,.EP:E6U\>HU?H3U\V)7[992OPZ:?++K3?=U>Q0<R%
M!5 %V<&PY5?PE ? 0E]ZX.@67W2OR&N?PJ)3?0)7[LC5-VR[CBQ:_1IN<O"O
MSU]TZ(=3[=]Q@ [)(&P"!RCY;7G!@;N\4(SXA) <VQ96:@-AU7#N08T:O^Q2
M+N-F@N F&HYBGJ.WU(F:#*(A PW$A)O<^3-,P5U?+4C^E-4VLO7]>&$R4SBS
MM?F_E_C1._9)G+&-Z?BJEVDY_5M8P AJ_!_C DY_G?N!^SWW8_9ON1_0]-^#
M(:F"QT/#XB'"TT?"UD".[R7\!:*=&8GHF_F=\L]RJUX9Q9/KYXNI/?2TA@%E
M,()$KK I5K_KN?-+#X^9OS#LR_/7;Y-JIS'4.;\1'/NV%8+J'< !\&IS,BI\
M]T%O*A'B@QN88H]!B_9A^$CC^BSIN&'".T]]U8OXKQ>M=MW/LPV9_?9W-A3*
M%O+X@RL407%SF;7MB"^T.A,V3LK:A>$&2 6PY%]3$9#I..KA/DR]B=JVZ_10
M&$O(BW41DK*J"L^5Q\7_8V7>__1*RTP+1QS N(E(]M#OLJI-C)B.-+T:IW=Y
M\(\Q=PMWC:[>]9!IOB/-,['',G;[-9?>4V<0$T_R)%Z A\.H]>3>F*N3 ZB3
M!6"<K'53S[YVO8^BY21W_#@'.#/7Z[EAU@Y2Q-U%["X:AB);>$ZNGIZGH60Y
MMN"&FDL'HYSAU+-SD$>)<>FOZ93]L0P3'S7C=RL3V]))7F)^X_MAH\TV/F53
MTQ+/LN]4U69)'X1_:/6&%#8-9?O19 O[M:ON1]VGXV,G/QXQ/'*JL\MU[X';
M_C"WZ07FW#?D^I$WI4&(0S7W+IY5WWX7W]A=P %VKTJQA2BE/:$,62__SO(>
M[_*S[Y7&WYXKL9V<##>VI9NR\IFJ5!S],A432S@T.)-^:N!\T]"X]\V4<5O=
M"U,_A6'W1<9,C0  ^Q!WL>'4!(+RAM8[49+52&P7[VZDI[LUW*M%-.TZ(1]U
ME8%.U0BKI@:>B#T#6DWDCMURB"0?KLJ0#I&XLBD!'4"S;<>!^9@VE];=YT;=
M"P=1VL\_6S;?#LLL@I^KGS6%W_22/T =3PZB9[%W#%RM+.H&-;4N)A*^%U>I
M_11@"SM.^L [G1S:\^<KG#I.[7W_)#CRP[22:D:4].AQG859U\,T:[;@*<;A
M[T0QE%G81J? N)V-K3DWAY6&3LK/.MX5?0N>[Y2W<!N,6V70PUF);!7VNYPS
MZ4_!!;/(;ORI;,I$WO"LIM2[$[+>$@A5A=2\!I-[/&O09."OH=7'WK3]--A>
MUYB$*_[DHC&]>L47ZY;8[8N4/G/>C+O?1-B@C5L_^QL&W O-Y3AL&_PVCGJ<
M R3B9(WX2H)Z.DSD:M,/?XS*==1<**H/ECA;22F_49-R+72YLH,MI\> <$%?
M?3%D)<9AM *1!5!]?6WI'+%6Z>&-$N3H=WW(72<Y%>8,N&?P"7J\?INFTVL;
MPCK#RD'O ,_@Z<&@C]_UR3 903)U.:[9WTM,3773]NV1G\60J1CJ+&Y4BQW=
MH@4Q72HF$4Z=Q?[C9P!-Q+2_IV)8(B%P]D8(HDX^X0#1N=R$.)DE!',KU/TN
MATD8T]";'@_A5S]K2+.;X1#C_,,-4W@]D5J-@G-+H$,"B-J* 9\A2)=!!#NF
M!6)IZ_=P )H]-PM7-(?UB -\<QZ NN0G /;_<J=/@++"5.<6%N\C<!>-N^'L
MW<F@8RO42B&6FP"8@&#:H[=#/J$$=P6W)KF$8\JVL74Q__R1AQ'VRZ 4L27]
MH#?XYLVEJ&Y0>Q+(.X@_R..OY5,V@P%5+)*-],K0W1Q O.(JRNSQ^+DW%[9:
M^BP\"G2CWTGBC7FCMYK^IUW-_4-7L9@V":;98S 0GR]^:2C VGBOXN#5(9E%
MTLZ-1[ I!F(YK/-_/AQ^_\;A6/CC<'#3*VOS% >,S *H3V:=*I)*ITL*OX8E
M32N-I*_7J7EPTSA,K1U!&D36(%G"(4BV"/3^,G_\#+ @QQWI'D3NR-&:OS#A
M['*X4\8^<:!E]HJF'S3I#?Q3,]0WD/.[6XO_KT+^2R;L"^+65H6@XS,DJ:0=
ML5TRZE5O"I&['WEMRKSH0P2 SSE,"!5$VGA+RL I8:5?O!R&1\.>]R_<>Q^P
MNS-;I4'V?D1.\A\M5]$OI@PV1@0=N7&:PNJ_BTKK%W7:A/E+7>D>9 :3*IQ^
M''"&;YHUJ+>[EN),-%.H[S]\:7@:O0/%/:OR%+M?QJ,3!AM_(_J0%$3!7LRN
MO5-[VJ-&Z%76B=CKYP6  ),,1J!,AJF@NFF;&W$\'/Y?J5*/S$>(*7@C0'5$
MQ]T?^V+([8OJ!QI]%S5CX8GH*(<N#E"/;T-L.Q>$)Q'PMM%KCH3F"Q/[>T=O
M7EF\U%JET?",IT<L:YV%HJ7EASVF)H_!6MTS."&FA^[4!K=^/Y>>FZ/;_3%'
M5P^S!7DVOD#C;_5NWZ%(\,LS2B:]%45L\HX$NQ@^01"@ SU#J7B27]N"C&/0
M8&>?W($3N6>K]CA[IB)Z]FKGP=Z>]?4IX+5U59M;&.F=^,[-_JU>B#62N-J#
M"2PZJ_.Y9^OV<R[ZL[L46H5?\+4"!2)^H]K#H0LCD!:=DWR5/44=?O1$ZJG2
MZ/%U*!;D]QXTQ/E]PG8(2QI88-!I/".M??A5,=<HA@KS.LV/HCJ!$#\'<@#2
M>WSXI?IF'^.;C!<JC-,:FR!LW&RV;S6.EMJ%*J-Z=X]K0Z/C#<9W840AH2#$
MP&I2]-=BI2(242SH5M_G^T.OWOGN U*DMJ<<YC4_R _<Q%%/ZAD0:TOG\SVN
M-F$1]3G'1$7;;GCF8?A6'2"8WG;$B(=Q:HY88UX42-I@=.%)T*X*DHPEM69P
MPTZ;J)#&3G-%8D-:1XJYJ&$HO(TH L[07[,JEY!)W/2[H@F_6/3&FBM&!J5S
M&]P:F[/KT4N%? DO+X:@GA0\$$<6W.-A?F6>!L,8YM],A)M:P.B2(#:Q_0DM
M_JX>H5$_(A[(K4][^27!HU5-8"(YBJT+YA'.8*(E332;ZJ/),E%![J5"6V-&
MO@9?NA'^J;<%8SZN3?6]2^/K,(R-;;8H<9XS5"H4B_G>33&PV)W>E_R$7^SU
M=K&S"$&T$*@P@8PA'J(JQ_H8'2BQ4LT[2XG04+_-\_++W<O[ /\@WG#$1AS)
MCOT)L[2>BZ(Q?I!)ZZ19S(\Q3@2-: QVN@J L945+Y4D/E;\\.6_M#R&V_=!
MP/8H^PY$6V;*#H+"# ?0^5B\37^S*DW+:G!2W6Z@2Y-TUVJ_XNZ4]59*-8A_
M;%P+:IP=<07ZYAQ;0HL"F2M3OSCBRN+*;W;KCW>PWR3C #8:]\<6_GU-=MB#
M.QA.<XT!W?E/@[PGT847KC4IU38R+J5:MB:46RK,.<I+L^YC/)/Y/[^_3EH
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MT6VS#D_FWMON_"D&@*GBY=81S&C'1+NJ&\VV?8?I&\38)@S-GL9-[1*@T\#
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M3MK>:"JAGB25'&@D 2\6KE0'VK,5P-\%Q@7;F2CUTO(-P<?IW2AFAM_X6(C
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MA@(-!]X("4#6N6B0B!5M]WQ2,GLYT+MXEE$[>!^-$I/Z<%DIY!7O !LBD[%
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M](&HBKL"1.OH/!)OYY  /)4PH>T7JTG\DQ['L;7PB)ZRXL1)2VX6PD/CLQ6
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MX[2VE@4O'++3T3.3^-XU0G@6$>HX$MJ?B)"UN)N].#<O_G/A*XC)0*&L (I
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M\!EY0KU_>@=8?L*HN;H"[!NT8VZ);0/-G)>*UB-;6B(NR\&NXP&QT=UFZ]@
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M;:[]"GMK1.N,+A>%]8 Y7T;V/QZ0NB1;N?&Z2NA,Q%J=\;W 5WQ^>^UZFJS
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MH1S65C.:T>>M*"_[YLQJ:]$OY4>MKZ/@0AY(=!1!+7->?[&1S:ZVC3L[0B%
M4.$*A1K\RPW@^K1_\W)4"JHOQY[=RZ"-,;0[?U;3?GLZJS0T67QW>^#.WMI-
MMA7V5 ;X1:OBR&?3:A51>)6]5PQL]>K+MF"U^PY$*K)>V;I4-^[Z5KSD$H^Q
MUK5<OA"JYSZVE&UP!63V%.$R:O2"FJU0'<^/FP_GEAU=1N1I5/8D0C7LJT#L
M2-<)EJE#X_"?M[[?>SC8<&;=KQBR7H"WT1S?=1UVXY4]^XO%L>OV@M!-'N<
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M(=WN<A;BQ;S"G1R9ULK730O/ZD>(S ,,B,'F;,3"<P0&\I $T#HUI^ZL>Y,
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M"Z"1W5?W1S:QS(D;"#?^NCA*10YB<W^!RUEV<B^_!#-Y6SU:,2_%C*XUH.)
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M7?_C;S^*Y?^W?UXC^CWS/P!02P,$%     @ 6D1L6#JV1XJ]5   M&   !,
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M-_+N.W@B2T>;EN\E3>+:F)+L[A.G7<]5>D^+E%&N<6Z#J:0*T6LY3K-S6>G
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M'BS28%]FE:3^(.=U8K99L@T2K7:-SN!_X2%H7O7(;1P"A*Z_$F8:G8K6W-N
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M B"$4PR8&#!_+(IHF-M/L] 'F+(CQA@_)5&:NRO_V<E8YXA;;!OL4I?:W_:
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M:BI\UBQG9>#=$I ?7&M]XZ"["7:>3!BZ1)P+%L&X_[O_)PB8Z*-NJ%IZ^3X
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MC9>VZDHQ[6Q#T) L^WCA<1^>RS@A"^LE2:S1J=Y((1+HDO-'?\/7+S'W-0Y
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MX<]A811#%"!MUK"_RRW]&__&_V?\F/@/4$L#!!0    ( %I$;%B_UT(699,
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M3<K',=]+6VZQ/]1&4[UR&2*@YA!&WL7\X=I?//OW.1;XG_+L'QW[?_V:!HA
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M><_+N/IE-%RFH=1<?DB.[E0O#O_;=T-;"SVEXI=*BLB4;>!-T<7'D4N_EU=
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M01!.[7Y4)^M$AGYO&A4V/@]BW\',.@Y%TM3]O)R(>;U7+71BP+$DJ>Y]IM^
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M^=8=HH#].\U2J[DVH*)!F;O7G-21K6*,/6Q54JUR8"<;/$(\@2XIJP^3_;A
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M#C<6E7XT"8RXJF1<GYOBF=N#7 4PZ<S^NI'H]< .GYDJ,=OX)1QE#&(EM>B
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MB+K"MKS-T\"\KVVMS^@/=)F_[8;MY &988%'&[R$#.'=46R!C^('SGB$H/&
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MVY4]SA6,8.EVH:RY05D]/@VKX),7@)DG6W_PA,STM2@[,^,=YT)EI=S1<@:
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MCR.04O?O=-(QJP'=5?K<?(BG:-?_Q5']%=Y-R4/;1,,Z)EM+H$KZ4"<Z>S:
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MM[V.>Z7\FUT4A^&0F,U6,!O."U:P;L)O,!93__B>,4M,XN\JTB8IO "TVBS
M3QDJ$'@*.-[^3XM!.!?/A>$Z5?J$PKVY'JM*_?GDN]O3=[#PTLO?_G%F 7]:
M18,7 -+$$-#:2U031@2$+0']=\XDD[+_SXX2^*>1MOU)&WJP?T<$!#UN9EZ+
M FK12I>8+!A'F]LV6_)J8T?-/-*U6ZZY[ *@@E.?-TV[W?K65XY8_5Z%\_9*
M=S<O*<@[0#KC+Y9LI)CJEOUDR0HE2/][W2=!],=G9<W>\VRIX2NP?UH@CO;R
MQ)BN$*'T8V74RXH::(\31UVLWD?5I?1Y;1*5_PKFFHGW=K6[HBO5?03NKEG8
M U3[?.?X.+D9-R/'W)4 T M UY2ZCP61R7GZ#?2^N-',$0_SY^*E#%UPPI%6
M(=1P2V=&W?Z8[J5X]?L%]#WA&K\.[C!9\1Q<5@L_,N*QNW,LJ3XY;1M 01;H
M;A+3^>U)3&8K1[#.VC7 VU \KZ8I(5SR VAW_=+RBC)Q[(^&^_)D/<O(C[3X
MIU>/@V%U=5)=2.]E&J+E.4RAN,LIS^]7'C;E_Q&G:.]?&I42<WO&\65@PNK_
MCL 38:TY(TUKV= X B&#P%ONJXB9,Q[TE2ITC,'_AJ6!.SAQ_8P2)@HO? 22
M1/JP6D)'&9U]J<I:KKKP?S?J*0C+*;\="B :'B!)P(DV>\^%R[+G;>I>:J#]
MH9H7XYLH[I?T*YSO3">KFA:>.\X=Z-2K72X:K4OK-*=OG5*/ (8DLR*G;S^6
M??T5FON\)-_'DR37\^#_3'0X3B^YZIS&Y39L;N@R"AL6#"H 0;YJF,JZ>0NR
M*/!<E_?Y<,@"^]Y2M0W#B[<_7!SG!OR9-J6[0BNVU0CLT'#)NLKH-TJ?/^9^
M8O';]1[%;>;-.690&<QIE:=OP"H[9\VH$U\!IN<-;>9Q-E48<"C%8+U;EQ59
M[:.V!S=$;LA1 ER!?XW4;)?\CBS.X *0%876.CN%X8H6Z]T7_'Q:#?V!(52L
MF\?$>DVF*D*OVUYP441*<B>?DM5WH5=2_ H<P100&:D=.DJPU#UA92/E&K I
MZS6 Z)^DT/MG 1J4?\]V_+,4.G\6X)")A_C7GZ=0Y9^-L7C8/I,*,(9_4+9&
MD,:LA@YUI=^-%3#MF>-[UI(]*=H\T^OYYVDM9A,90CC["T(Y=LC5EBJK]NO7
M8T6>RT9+L@5A$6J95(*7BUZM&#:HC.4^/P?A]?^L8(3.)7VO^_?'9TCLE 79
MQUO48'2PG?4""Z&]]"![IZ4M@TY)JP8_(%C&*L=1[4S=8L/)THV?:<QQ^G/*
M+^[NQU'C73H*3*"_9I89_=E0-@,',G[2?LJK.K&L$[4U4C%[[7N7[*85^5=>
MM>[</E/GN'/8);;QSWE@JDYIFL;[F.C<;$41Q7O38),?\Q_K@_KDXZW:O/62
M@2$>O;S&!L;\V[%TG@P4>D0Q)I_^P0$BVK5(^Q<M;FAE39FK.''%<G[@>JXP
MZ3Y96\1#S-UZ^B29)+BB@>/O_\<H$],R_"AU_'^)T4T+-%5P/C;QO:"'J<_G
M[9SXP?>Q#^XZO?"FRO4P>)T"X;G[DJ&#Z0MGXW5>QW^HD?K[7T%E%>J7?RTE
MQ?SM+Q\_OH*L +YQTQ1-Z<F)SZ**MSN-/!X!]/^!B=WD1,,"=WQ]%J;\1$;W
M^ S#ES3 ^OPWR-I8_"!E0TXF7>H5%;84 [_%)+"2ZA.#<HW_3Y1=QMT.HL7?
M6T@S<_ ZWAF[B]:AL&FWV*5&!<@X\I:E%1IOG/I*GOKU>-&5"ZXM1RX]+-;[
M>V:']7* U<7P"'GRRM&^>,%RAL\2G1\?"!=[TZV;)TNK,W4SDR@S&NA^5"G(
M)/G?^2!-+]5L!ZX7!=G\/:\!A^+M#A:T]3)%.-1JFVL?G1'F;K5@GDQ(%[LJ
M*+$4X"7VOY,I.F;3+7;.Q_2B*A0\(BC5%GV5&C$B =IVG"+:/WB1TN1, VG[
M;F=262_: -CXN'.9,^B@;/(?*BQ"RDO&UZ2MQT[?K],(/W!):DVX:T?,99WQ
MM!4CV4[)V>7MWO]"PU"811/"SCPT<!:TJ<!J\U<_FO+GIELY\DKH1;J/^@^[
M\.O6\5FO6QB]@Z(/[QT>YJ79W1LY;#<X^B&R][1%CZH0<;L)>8D5GNXM=LX2
MI<MIM27>--0?^N+TLVF65\83+Q\2(";DSXO++46/'6S3=1PP[A!Z(5=C,Y#F
M+(N\60UV&L.6(_S/T1Q)ZQQ\(<)-'ERN,0-C[W"F;28SC5GB%X K:2!C5)XA
MW4O"2^ S6ZD7NK(/=U1TX"9'P"M00\*M"P!Y6YYLJ\^[;?'VHH=,RE*/V-*:
MR #K]G\PZN(Y\*3#J)NYA9F2BQ/#KVZ^:]IRW9DWMI&FY./<R:@=QL7 I'OV
MJ1*=X,S%AK>TJ^T7  9-%_HPL3I*L;5R,+.IZ0.CE.(2%AO7@3.K\$*8O>\#
M/U"T/["?+7?A9+JL./^WJ4\P:,'VF/R<HIZL^$*4I2<U6B@T;KTV.LF-19$M
M:]4_M<??LDI6LGJ#AWA&+.HY*[A%D,/^&)Y@O_A1;5D-GD3*8JU_NH*G7'B"
M\0K)&I+=E7>['$KF"]E(-U764)?6VJ>7X_CXL<@X#."FMJU KN\IISRE.B3H
MR3PA6P>Q[XF5S+Q2?:Z%CH[+A28^^UH=U?1]=_&\KZ2$XKK&HK-*OOMD>6<=
M?>3E'#'@0 ;5597E1E;O1IX$R.Q0J,,M%A[1$ 47X-6Q-J7;&1&< ZMLY#%7
MZE_1=%=D'-:[R5C)&I:L,S5$-^2V%#I4D<J5;-:P:JWYW3A T-DWLD-AK57R
ME/5#)=RH^O*KWCU#O$H4))&56I9#E_R*<-NX(Q\Z9O$=<[@T!F8(9[@ 0-L_
M$X8ZW[#AG<_E"H@G_DAZY'#Q<'T$+,69W2S%ZFJBQ,]%&+\(?;$HYMW 5JXE
M:(]/N@XQ2/4"WGB7Y3ME.TAZQR_25B$_Y'X,3 ?T0@FYBPA6Q7OYT2]0X3BU
M+**M^@X'BDL*4?J(D2370QB:,-5.X,%ZO3^L^Z4JMG]5>Y([.?-'66E-( BZ
MEW^E1NJ@/XR-%M,Q%Y);A\IH2Z%0*S93)8DAW1!.?T9%3#(9(!>G,':P>\<>
MXYALWIP\J=.RDU_[=4LEUV$L$L_UK;(*FX<4"K%)P_,*+,)[/MZ*G8ZTSI1=
MW/6'/3URO)RUF!DK9:__QY]D7BMB&D5 ,M?&O$LW:2N1D3]PC%PWVV9KF"]C
MGO2;)/0O5HF=*\E*^,>EGB_FVSA7&7ZLR=B=&EB#[R*Q';N1^'NEX,E)Y=@(
MTR?[M$9E5'VBQ]$*8D1P&):\TQO\!8+>+&5Z@O'LL<^;<JN(>;#.WG4W=74(
MZ3T;5VRTF6S-%)WV.FZRKRYFF! Z<&88;M:R>,[96@Y5,=(4/2.W#]AT[[N2
MV^@::7?OVU#D02GB/5W,)!3>KK9P4G8/$_O)U"Y%QL3R^*==P?&I-@GBW\FQ
M/Y?8COH:,+XH)ZK=L%T$5K$]%A;H"3=F%Y3\RJK*JEK&UY4N,.*Q;:A^R1L6
M@Y&]NNY<<><_K,#JU-,8&"^@;5#^+D2>#>O7%2(+M8HJLQ:P+.#8_M B*_3U
M>'M@+..\THG$>%26%DU2A2I%,J\+"B*-K691S3.T-ZFXQZK$U[UG0Z]GSY]I
MTJ,E2NWNE[Y];?6]^IU<9"RPKHK5[_2F0^-US$XE=@;JTWFJE)YOE_>QDBFX
ME3]$20[0+R=#H"&2;"V>0'"-C&DII--6QKQ !4388N3WK?<FY-00:@7S52&C
M5]_-\J"#K],]&N8M. !X%/X>7=_)3!D[+R.CT?>KPXBYGLY_)QZ(&;8-X!RY
M?:K)NRXVP1E]DF5)_%.D"#<? [98Z&?92$:&%,]G4 =:H=LK$QBX7.*=29_3
M?CKH]Y<^*M6BPR':#=.%M$B@BEL#<SE A]JZ&D:CH:_$->MZON8+$!"UD?WI
ML_(24Z7%&.H$U,:U<>/$V(>@4/@01X#L4-MI2+Q?GBE.L8//X<N$?4=>P^T\
M[H9/PNR/.U7 KMT(1YQQH6-R55#"\?- @<78-V<T:L"$8N>'MXC66S;UZMD7
MSJ)@ZFIXKX5BNE'^I<OIB\D6;T6HR,+D&R #\;2W.'CT=0( S5<"Z'Z'!UFF
MGUFM;9(EC#[<OM4<S%D@'Q^\Z-/K\@Q3.D((B.E^Z_0AF=M\UMK1;4/N!X+5
M8=>7D1J;$9+LI-)J\C,.9KME7CI3_6IU8#6C>8#$'*MEZ'+;EZ>V";/UO=\^
M\;$S$_\[+.<MW 7 [A&>+P[[/H/JTK6%''GY \]HTY'4'_@7 JZFJJI>,[JI
MY1YW,J(5XL^-38B;'W62::/>E*:?O'=5&1>O=2V09161Z[F'NY>A48&5?(]G
MMLR'OO.:6W:\G6I:2+B;X2%9>5V^@J@8T]1Q6OE%X#BX7IW\?DTNSQS[DCI0
M0>UPO=_[('E1EG*^#D[URZ\$(OGNK)TIAM)3.I(C<)#&FVQK[=((%N6Y-I(3
M(KXHPIRH,G)SZCR-/@(?3GUMX7D\'[DJ1C3<7VALZH#:N#WSI-*5W2OE-2]@
MPQVLAH7I$@8PQ\&'/]#)JVVVV]SU4<J2G:Y5KP\Z(;%C,*0_J[WDT4.9C5GR
M,8'QB9YGB\X[(IGI<V,(DS$,/!QO937O)#V[W_*AU%[D-\ZH[3#;![$/?_5=
M+B4[>":FLJ*6\@(04.;$CF5))*L<'(]AIFT!2<-KE67.^08)C#C48L>D>+O)
MI^MS1D,V9W);T.9I4,34(UGO\)4=_+5"^UZ[ BA)VZEM$LPCJ39A3Y=SRIE
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M';G-4%Q5)BYZ@?]PYC9:O<!CQ=@6]=GF'ME4E14.3@QWYB%.I$^$T1W.@)V
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M3U;$%6^"KP^_.E#/?X?)FR]LB5?1ZW\5/CJ 5\_!Q0AF/*TS#48F97X*4&:
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M/3,/6"/A)L9FWJPHBB4%Q%Q& ('_X%D],ZUV)UT#>/.Q(8$AF3PD<-_M5JC
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MC.6-MWED3X,XV9(N,21OA#YV+FJ7$XD5C/>\;6H&5J-,"/OH$HOFV6^8BCP
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M,,3*\VVAV8L3UVB)3#DC@L<%@!':99'2KHNS:]5T<O&T>^6,0.Q\?4[3J0#
M)B_)@LJ@,'2DZR2N2C48KV-'#3'O>V':$EE&Q:KEG+JD?>4"T.JT8$'O,"I/
M,7KG^;!E$J&?KD[LL3O(%KP82S)4:H+IV%X-D57(H/1UN6J2D.;>E^+*2V+
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MMRT#CJ,NU$<'FNL&T19#ZS ,-!LFT0Z2E-U_ O24K2N0?D6'L^1UN<@M7;0
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MLG,!F);%>I+D:,@#"(:SVPUI0=#82@4B%:KSR;SD)+[/L!A!2T,5%ABYG'?
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M)-)5\KK;5"QAH39E4L$'4D5U>AUTZ./SGA"AT[RH=5*F.N.FX<@R6I5^W<S
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M@LW6A_G87#B':1'"ZB[+^8@]M"9MT1Z6QTFY(S5S:F'$5-V0IT%>C>DHUK:
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MPU%S-,-S^41(6MYBA?-)+>"U>:C[2D[ M8DW'$VJ@ZCE<J&ARP;5:55GA78
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MN[=MW<5LV1RG111L)F&]CL^SW!%-*EZW:."J4:,B>"8US78[4(N^Y^301*^
M -Y$1]42*H43=>#I$PI4-J,O+"AZK:C:2-U2 ZS1:8>Q]3$T-_-R!NWF66Z
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M D)4(+0G*>88MF77D2D82NHUA^^Z-)]S1_R$QQ;NBW+D0LGKQ;/2F"J0W--
M=ST"VNW,FN$(=IVNW:=AE^Q5C/E0'N)RITJA,ZP +UY;I1F,I<;22*0$@11]
M+ 8<V,IC<&0HA7$+Z+*R2_<Q;<Z6,7K0Z"1D*YZ/9*[@A+)5XD2P1D6%F=3$
M,Z^-+OPA8MIQ%3**,D@6YF6*%U2FX[2%M&T.N4Y7E'HXGR&%8FC:.1P#4:#.
M!&11S6?>AZ9[H9$WU)I1T\OMRGCQIFX;I5&['6;CG$ZD1B8J135]?.1#'JG
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MX]#^M];]7]*Z?]+U[L#-_LO": 8K!/99/BT2 _Y@AQ\FR="NY3YSVVCY$QE
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MSQ63W:#V5SQ/I&9#61[Z5F5/WV@'>O&/\':[ID]/?SHTO">_PEA<_@HC@FR
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MAZZ4-_WG,?<2Z_^\YMB0.>5%K6LNV^5]:\[Y[$M6?_7!Z<V7/_J"5SR\[AO
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M<M%?^+1^3ROFC,/.A\0-MC+D\5JOMZ0#TP^'OA]JH5.%XD40UJA*"O=#5-A
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M#^OX39N_W"U BE#7UF>).E/MR(=_;4E3*1B)7Q"9;2%)[FY5S04:3V_=3#Q
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M>QX;8::$5'ZE8XG02AI^TIF75^A.%'0Y)LE!@Q$*P(<$W=CYG$63*JRN/=P
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MM+RNF, >[[JKLOZR'V^CR0)>2]+NC!D>H1!%2'[H</DFQ<-ZYI"P\@[FP.P
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M_B)%3%^UQV"![)Q,TKG_--;^BH913%RL(%(U[%.6&I-GO)?KW*#J9<?3Q6>
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M\)^IL6\/YQ7X"IU]"V!:'P:['K#>KW*::O>ZZ5]ERM\BYTD>TKWIJNNN\8O
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M>C_GYY14E(2WQ@=8<V3A?7IJ;DP64(JI=Z(U&@S$).N\9U9="'X+:RHG'6F
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M5L_"K!3'S!ZAV*YH!L\XGNR_";]X@%=U*X:C(L$V23C>KGH-Q&FU%3CAZ,^
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MO-,EQ3ZD3BV-R1:Q_(;*U!V,*.<"QS0L)%7&-#P895"QW91*E-.<Z8)KD4W
MS7ZCQD:YP6&<GDPR-YARB LD(N=8NDS'U1!YQ94U*EA4PD\!5MO.5[M(RWC'
M.ZAK6S66^WVR0]AROUF-B*QUQMD>W N+5J!VBY;<>VO1B:=*2B(JE.FD,AES
M[HX9LWRS/IP+-!C.AON<(4S^2#69OY$VI"-/O,-B,V*SJH!24S:F-@#E,%-9
M8BPNUT4G5MW.:W&7]EIE-.\HF:'P6F?.!=; *.YVF;V>MY+$CL;L'L6Y;NQ*
MT@C0J*FKB1FBQ:8F-.P1-\5:3D($QY'5GJE8VQ01&2VGO /S2*:=4@!4!8[N
M%8X,H9+8,*AH32 %3R;!,!VP52%V"+G,F!^BK=BPL2=/X6(=B!I9*YJ8@NM@
M2" TR_)]#8VK4\3.55?9K[7$-1RGX14 E??J$/D=-O;7@-P2!<>X$B?'>&'Q
MM<J03C[).YA4YFDR=4;ID%>0?EI@+E+IYP*GT33);'8\'[MCLLO KEFUX#1O
M.CM0W64[KFON,,Y4!W.E;=>V\$?3F+::RD@*)/J8CQ-Y:NYT[UR@U($F!ZZ\
M,!"J^5ZKZC$)*33<MBN#JE@5;]688G.;[ZT>'8N1I /)VF[F!Y@$1T"A3->;
MR7$A;)F()4[H"QR"T/@ K_@EUV.LJ&.\'Z#2LC4<E=]X*\]?+([SN3Y1ZFL*
MY<IF'%A2*[C)*."%= A,8XWCS.@4;2:3/''9?#G=&YO6F9E,8H [WP_#$4*W
MJN(=#IY2+*E2"D$VQ=-B E!L<8ZEVF&VO8@>IP$B@YM9N3I%FP >#9@"!-3>
M&N,<6E&%IS&8ME:8I>W)$S>2I9K42U:+:F_IQH6$R:RJK+5,#B6<[P\JO>]&
M8T3TM^B)5B ^)@R62D=[4AG7G ;5QEBJZ3#V\^4Q5#:5"/!+G>[\92E:+(&(
M?,NO.G4=MM>P'M$,R74*Z]$IZW5 //,J8Q9O%5XZ %.[JSLW+J>->"35D8BP
M<]D:T:JP#5<:;X#; 2@"E2,T>EUL90[CW&,%!Z(:"+F^.>E0E=HYA++XOE);
M=6".>8&T(*_BJ@K \I"B#C@S&]QN=F:3?""6DZ/:1+XT0086L^Z9%EEY]5$!
M)T!Q<FRP6UN%$RS] K3!/;-.C#R#E3!4*XZC4E<D=J$8M'.:%!8FE0QNB.Z!
M\7&YAO5F;2>(:P:6G,C6OI^[)\<N-RFT7O@J1:9.A'1I@8\7 NBVVY7K'7.,
MK0]SI -*7%E--R Q<YFD].U%!OH%V="FP(U]#LC($#%A]V1E.2 ,ETL\5=9G
MNQ4ZWJ]U>=_NP6YF548X(HT"ZY?%?H\V#K#CEA:$;K> $0:8VC/,4>$ZIRYX
M.9?E(I9.Y''>.0)]L"-Y$0U*<D"&(2VI:_-5*%([PD %::[@L9=A$-O0W![M
M>1=MH56X5+F-/=7B9DB:ENF9VM0_@25YM4"T9*.M"2I7>'/A\6P2>&KLAB.3
M9\%9KV=EY<_4H.05<9*DU"J#HXR0468G9>8:H(>UQ_9+4@G0$]<;Z4A%C>55
M7E'P5 (W"#C?2LB,V[;I"@G'0]+'^#([3GIJ-NT8QRLP8SWVP'W:MEZC2R/5
MV59RSR5ZW9Y&.,PDV:I,I0[<8%J8 S:R-&R_Z=N]SJ3Z;K-0=XL.6O.N1>"J
M86$#7L%$4.K&FR$/'4, 5IP!;I741#FET80G>IFS1GXDJ/C<:53$84@H:QJ4
M5OE]!Q/3D6(YE@>&"=GO%YK$2_YZ#$ZM4!5*1"$P7..WQ! 0-J5Y\L,ADVF[
MQI$2LC&]*, $+UXQO2B*0@MO5&1=&@O$CL>R:3%)=#3:5A)KC5]>T"S7W2<R
MMQ=-'7%/&+M:*?M98O&, 4L,N*.(>#P#F0%! L:Z6@Q+&5R0QAA1?12&"1CQ
MNI'.33M9WSF&H@%VZ1Q]P=^($5UO3X#3GU2]L)_EQ;A0!_7T>K<GD2  ZP'X
M+[=6/\U&/L^.RLIL2W\A2/HAA+E5I$Y#@JUA"R^X4I7&0B77V,D/R[D-.QZ7
ME:T#C HY)*>L.:]RBP>[8AFNO=W@59N!R;7RQ.B(%O8(C4_!8CZ5=:("7'D[
M'339H#@U4*N3E=6YH*9\Y863-K5G]H9P"76W;41*V@WQ66QPI$2.03P0@(G:
M2GGBFZM)'EAPJZ(C5]YA8CT+T'SP"?Z$OBQJHRO(7L8HA>=IQETRA&42 E>)
M_FJR7R>+8J"S/ W"\IX'/3)W\W&VX8N5JGN(N"[25<.)QRPT):',3WL.7<X&
M9J+C!;^^'TE6K./&VM@T$MAM3=I*GDUB;\2F$(:J^^TX\@=\5\CCKM!F9U'9
M-CVW.]%;.]T-Y%OLO;WLC_)CL0C6"QG=$RXRB_1*06U[GZRD,%#H%)@I$JG@
M2W=2^HXW&R!S3RK+S"V@4;;7MV)P+C *1IF^CC)FVI$;N57R3AT!7E'">UKH
M%BH(\!LQ =!27^[FD]37VB:!1_LP*./)['PVR#1&9]-DB?"GM0SH?CO=[7L&
M:?EHF%>9RM:8&++ K*!*?:/QC8^IM4PE4'T6'\$ +&0#,0IJULQ$1Z&'M+K;
MJ6K JG/ZE.CY&)F!^1S,#BJW'1+8<:$8P?@\=PT)$E5E61L?YYNQLL>.>U"?
M8KV6@#"XE2;J:,AT=>,CRG2GAY,I=BZ0UY%:S/;SR1ANR.,>,.M1PFL@I8W\
M$F$X"M=YH%D!$\V@J?PX4#@W(G,[6H=+RZZ9X9>A*7(86V?3/S'Z/D%GV*[&
MUH E+'>-Q6UM<[83RZ@GR6T7Y.!>UE1&*+R:7Z6+!CVVJH6L4'#+(RV*<DX@
M6TN)YYO)[$1OIUUH0@ *'H\IE42<O5NVZ8&!H5% :NK4V2ZW2 52[D+<&3MG
M#8 31*%WFIH5@!<9%K$B%=0!1*DO2<4Y06(FG6/,D0!"/#'6#NJ9C6,6J0[Z
ML[IW=3R.U&RYX)Q#:GB"T<Z6!=Q30*STWHZ/(-V$XL#O[;6!KLW5N4#='X$A
ML4;74S=;#"%9C1!6$%6-+=G@: Q)]'! $W7XBD8D=^;PG2)J-IH9-#V!C1K<
MT&G&R[H9L\T)BC3,.-$UQ%F,.9:GJW7-C=4A(B_6\!):FPRY6FY1"SH>-$)8
M ^+."?-VBBV5''.JR@!@=<O'L0P1TUXL3GM?9D:!N+K3@KK8\,>NQ(_IE+ "
MO&#.[):ORAG% OS1@)S [OG-F/=!RL )3D^;XVQ)MX$ZLJCUG!KSQ&E#D@EG
MI$JA$:$F6U9;+#8\Q%6RS[*R D*97QRY@9AU8"UW^Y&&!!Y0(^!6K?1Z0B.(
MQ3)T&@6Q34FP1)Y&*"Y@/#+SE"D:>(#;/:P8X[;-[(3)$YD7]&"P8N%WO.EN
MYLHL#(,@,"7Q$)IX.2M-'+?",$GG!R:CYR=:D=I  *QZ-AHY @ERN]0R70,Z
M5K-X8S<[$9CH2X_:+BKGZ,:*44XB)[3<O=S8L#:5CR(1^&F[(EMQ;4;@"7 V
M,..9T]Z G99<6B60QE7KM#*;87P:6_[61_<69R"X+,P*QUIQE$@ZHLEWEC&@
M]][)4:D=28Y:I]6)T5OJDD'Z(*X02P<-AB":5;*B"6D53HL.8<DM64/@FFWT
MV0Q-![#:-/P.!74M\G4M#K4=$C#<U-KXB[5] NVNGB43E114>(;)!Y4:GRVY
M)2)[OB\:DW26C[4-+Y"JJHUB',<A?. %RWV\=Z?%SM5:VW3<11\2J-0PIP [
MH'[*7ASL^("U\A[J%R"0B9XMR[5[++6-N_>2E;]:[+<9O,Y]+O69+1W(O*(J
M-MY.QXMLUP,8VL^1.CGE9=&%&;&9Q3/IZ$Z Z9R;3O"Y=UBG_I I\7'#;N:5
M@JVCA>_T96EN:U&;#UG>M<>)3)28ASB'L21-'6YTL?>E25N0[J82NE$'5!"$
M5FP"JB#J^\);9%N$06M31@Y@@+88 6XH5Y<@,.:#!0K "X%=(,HJPA(0-_.E
M=$JC R8GM=U(;3@H,.>(UU0;( 8EL#(<%J@'7I/W"U9" Z%&1@RTR.=JH..Y
M,S)XL>0W@(LTUH@L_-Y;Q"?D0-)C=7?0%KZ_KZR$+8%)Z\NTMF( =Q@.2PN\
MM-6F(Y!NN$UD.O/=-$JU1)Q&N_3@AYM"9G.>Y3*9D^#XM.>PY8 <U4:KR<+.
MCL:@]& P0HQL3:",C86-B+7JIRMWNZSJ381MAO]H@%U*<+0FVS5JIXKK(X*8
MJ[ETLC+KT[C&J5;;S58^X8K.-CCZ)"#%FE;UI2K4><>16830:"#2(1'P;(Y"
MRGPA'75_3 ?'28*L2/VPBGS\-&6^'ZF$!%MFPC"N608ZF *E4Z.LI"IE0Y+&
M/,,W.N6A-ML8$V<%%/)^0\6,H85JG@VINM8SFF0*&[).4\ZH0=D#42B]9EOL
M06D_$.@]V /0J'"K#N- EYG8HVUKN\/*P-9$45AQWZ);8L..*&R*@&#12Y88
MHMWRM,T26IJCEG#$IUL%<'MODI9)OI\!'$//Y'6U/<#X"D#D8#+B0,*NA=%X
MB M*,C_NZU0N_%$M3E6,Q^UM I]N?\QZ.3DBRT2.VJ*1,RW6H>D(.N.O.0EJ
MHE&M&V85F@QQ"'>9JL?=@9:T!:HCA+LBQO0D1Q< "_*)L8].^#"'/9!I"Q);
M86Y%18'GDIG&2^EBWG:3(%0SJ1Z-2+W8Q+ >4Q,4AI9F8QRAG=:#'BV2ZQUE
M\MP(E)BNN2 ^ LJF8ZC;^_ "6R_*")2P46KN'!A>@ML\),)Q!D[01A:J%J$J
M%I@B2X;S?!F>5T>C(3K1ZR;^'(4N-M,4WG!=/ML97"?+CEHAO!$V5N=8_F*>
MZ1.J"VC5I/VB4]UCOSKN+.0 B.X8WO0S]2@>EKL#8_039[%=[$Y9;S':Z+$K
MRHV,*3*VTLG)[$@!HI94Q "^?7 QCY!\O/2QS0 J4&92SSJL3\LA.]8PXB+,
MGDF0 $KB0)G5YP);O]Q9.D"W_)*>S6O;$98=3A+;UC_D^[1?]Z9]Q/EZ%QUC
MO(:,75 ME-&NX9P".93TC$4BD]IL=@.!,$Z0>$C:DRFZ]^J)%6\;<(%Z$'VV
ME[3>)WO%(=!VJJ?A*AI0V5P/&E"/<G+@N@&OS8F X*ALA*\FL&*-\65Z@L3^
MMH-#5^\"J]L2P')PLGX8J\JE\EXF\E9,I!Q;MD9PW+"95[B)6>QU)RR)JN9Y
M11[K,W?B$YG319QS"K (?G 3!A51.^N.$>WGA3L&-KO,AK8K2O7UU=0E#J V
MSAO8XW9C#H[-:>4PH]),EJ.PV()-H:4%(;3K^!0<1A&5J2*Z/<:UFBS7/I^
M"PQ>S 1OQ423DI[0#@?3D*R+,Q,&+'G&25D1,]F!TJ@#L<T)HG2)W:XOE\TI
MZR%[OXW7YBRF5H0AX+/0,O4H<:&ISB?;E0T!T5Z./6='F![-4TI(>>2ZI&F>
MK&@:R:&S=& $.9\W(=2?R&/?KPPH@@N^=:5LRV=1L309=L;3!",<A6/71<+X
MN*S!Q#QD.JF[,F;6SFZ@;N!B+UN!!-<\#>3ZH ?[M%(FF"2AMN^7VHI(?-?,
MS6" -"<&5R2:Y1^)N-1,C9_U-K78"%)QG(_FM8"*D<8JW59AN7!:4^QZ>B+@
MTB3%,,4O)*SBNA58:.HNK>6L%\ 5R_O%<KI8)Y2PF=C2NJ6UI>54#E0!7EAE
M81+,V6@"+0_K39IGF\G)*+OYBH]%J3@(,U))P*!K3;/(X]B,^"' 0Y'$,U9>
MJ@6C5'*$VNAZ"+\"2[0;CYXF0PN@&Z%'?9NPG:Y>)'JI-3<]Z!@[&E'#@;%S
M(TAB#G-40(0\F(V/."PX:W6G.U!)PJ:L1<=F ]<TY,=2MF)6<]53"$*=SXP3
M^A+GY"K4W"UM2$2*'JW5T4!2-4!,LG$[T\K UN0S2399:L@HO7!<@:Q QD:=
M[:;I$&C7UHJB$'R;U==VYPP$-C?Z]@B&4;MD1BBV=45=L*343EQUEL,U!PH\
MU<PH#:SF5@L[TX+K//&H!+DLE(+00CG?!A[-C,(33_% 9YEEOCCR%9/47(1W
M2+!;J:M&#5S(UDIXOK1T5F=,.I@PJP7NQMJ(MN6)8_>[X\1T/)9GDI :W%$Z
M/3BA;SF^R+%95L'\!EW741>[2X\T.]4 "E1MEQMT+\\4F88;?R!P8V4R6_6<
M!2\.L@S%_K2PQ^KAN"QS"3IA[)4O#*B\D!DA:(EA^4CM#,W'6ZAQ3:822MXI
MPR#TQ1T0X0,/4"J<'HMV!*T4KU64*<"S"%0#Y=J8^\Z)WE:C+<B[*XY.:O?0
M'7'-#@G"-E99&=IR@($UBZ_3\0ZUP2RH!&L7=C76(^4.K:9<!A8N[&;"$;6Z
M!5F<=CC'U<3P0[L\LMV6(:BL!%E\::WW\N3 :'S0;:?P H 6=+A;FCH]4[@9
M(")N$AYVD5<5D</5A3V  ZP_^J>L-\ *0@,FP8PD5VMURE50O^TISQT G#;;
M".7( 4>@"ECZ;"#+I.6Z9I<Q!)!#6#V3ND(>0'BHE2+,3%WH1'P"V>P4!&76
M?.O@T#[I[%Z92FO:%@@L4$-E&_7RF ^G(,26]IB;C2.*'J-XS('+<;Y-6C5T
MV=12=K/ZM"$).#.6M/P9A+'S>#&OV@[>'NJ1&$OSJM:(3N"]G:3W:LY"Q+ @
M,ZWE"VL8W! @]Z!0^C;)UT9DC\D^A4\W_1/C@(2&V.+!WFE:_RB4:*;S8WLD
M<9+):BP[V^F3KA/;C-JL^Z6[61T.Y!SJ"LT7)C5Q6/46ZZ^3?+X^^2$7=X::
M->!QLSF_:S"$D?'@BOD>*V=R@^+A>&_DB<;F).9"6+#K=:>#%XOY &J5HMSB
MR]P.6,'G.,H^A2^"2$*R2FS3G6WGYI:2"=*93*9+GQ$T)5R.#&O2TLB<V(G(
M7 :<BN+S\91VYS,+W"V0*E8!3(6X3F6)X(2Q.VO/,:@ZJ\IB6.UT>;JUL3&'
M**WO44&#P:4[&@NC?*R*JCC",*F;6#6E[$DY9W<LJ7$(S4K[: HCIZPGF=5F
MSX,9,R>7N_8H2MQV :Q#?[WLU\J>CM5#BVPH',KD3%Z#^@'=SDK,18H654=9
M AF<>="])BO8L7<"2P,A]]B=4J4#V=O8'",.;A"INT#+].S0AH<9-J5M=8;-
MB"T]CE8J3X 44H-E6E!P;0F+#:PA<;3*034B3U8NR,@4G2/@^PF:PCT+;G0_
M$/ANO((V:MB)D<!,QWZ(HB74Q-,!Q>A:-K%\.%SE]+24Z=*;!#X?*9QT&J%5
MQ &PV2HM@RJ^(J.SL8)LZLXTA96'M^$VTJ>0@)2P=G9OQFK&."-OI<&QJ\0,
MAFB>S%:D I#1SI^9Z(65C8821-[V2$QH#^""G-HU[TP-EP9UT53+Q2#)XJBR
ME%L>.\L^>]I/]G07&/16C2B56-4#G=]SF]"\N$?O@OZ@^ZV\[M=2CZ.">5!T
M[."4K;--;6WETG!>C*D^G ;Z;DC\036L;AX ^K4M,OMU')AM;L?Q2KZX:Q8!
M$;>9:2Y&2&Q;TT+ &GM_1.R)XV9"0U,C/\*]B# 5MY)G%#QN*W<JH H:1N$.
MF;GP<NOHBU$I&/3,.=$*QG0/9]EA7BYC\="/5ON,*&80,='!C,>4:N?,@:ZO
M9DW?VQK?LH!:F;V.G-T"V4MVM&2SJ()"!R+=XO3<%]9'"F(KOIF%<\%"@2G/
MFYHT#6S7*O*VYA34,M$Z*N<DM8,T)O<LU4W-R(5U-B"( ]8M\;-O$CVZ)YY2
MR!)&'6H=[?I!CKG'\'I BC+D>>M^3DVA>DSS\JQ, @S/-T<Y6,U77E"2HV:D
M.6RYY?R!"<>4! -3YK12R PS1[FH36LD;;!VOI"51LNVS03QIC,Q4 X+D<;Z
MQ-SJTE%:'W#)Q2(JG(J.QLSWJI6/O(E-'NJMP.*G79&!(D>^IB06E@O!'E'J
MHS%:X,$NTA447O6[ 3]'PP7!#OL.S(51"J%8GV&@!:%(9?DF,YE8D:BT]30\
MY90)!4U#L%4]( F[48E180QN^VA_U+W2,OL&DU>@1JW':JU3<@CH>=:Y.U^>
M@LZHU@S$7Q\D3J0U<ME%%[<R^]U(3T#)ZA$'KI,^[)E\T4$E6-,'E\XX1]17
M7B,>V)DR0W9)O]B1(K&W6X^JJ\S;F3)?-!$@RZYUP4:QD@-7\]I:0_@A]#EB
M&=!5H<\V_9X$BYAGZ2%Z)+@TGR.D /1""!9"5AS< ?).*^XHM5M7:T!20!=U
MUU[3H<6Q&N'@X]8QL3):I/&14EC?6I!HY"H<!0"=.P'VO>I*TSW#K _8 *\E
M>$5"U#@7F]:--C+3;AOI-$(9W B( 6+,K.VM/JD%!N?W9IQ$_G$@2[TYJQJ>
M;%V!<L#ED5^N/8T5H\4:0.UVS@*(;5K80A20 N.R$Q0QBDG6)?L!I1>JV($*
M?2SJG14;$VM XTZF(]943+&*V -%+E. -IW ZPB:VL8L-^3N@+KL <\;8#F@
M[]-:QC; D&U<M+;D7K:GQ8#8UKY;67I!TD(ZQTA(A.8[W.GVJT71<'5BBGG5
M.#H?(%GMZ!58[PC-!!N-%4Z/)0Q\7=NM##*<PPQJJZI# 8%LH7!6-6MUMB_F
M=K,X^@TSGRYI?+D *5[*YOQ^3VH8!PPT(-\KM'%6U95.FQCEF-(V&S2<'Y9T
MP5$8Q;L(LA>A]@R\!].]VYM^N8TE#%P"7)@J?HW@EFV38WM0">I3RU4T V9&
MWLWPBZ=95,/*]HBC4;X&R -)RM@JK, V&4#^B-I,8[+EE(IRAB YG?MYEI'%
M#@8#&ZXJI*D=H:)W6>1.*Z2XR,NMOP;7UCI?LVV0[[-C7@/2L<+D0\WE+0K!
M6J;E?4.55<5;9;@3<)[HV0 O,YC!4-4:R-K$$8,Z*^1>O]@_1-?J$=592EJ$
MHG18RX18*8<9".6+#<16TYVA@6-NOP!1 (Y@3(TQ5J4S8V%H"TY=T0$O=[DY
M/M-1<7&W8N.#\QE2#(#(U4N;/ +,X+>+<BFF>4,@Q [A^R6O6\40XTE-G9 2
MK#M.53%EMHOQI 9]4X)+U2&BDV.S93Y7D,@MNK3IZ5DXQ'SM"+BCQ!RCB.MB
M7+6SIB1L"0Z['&5319J)ECY?<)M)!F0"R.,]*0PL#LRLB_O+$Q09QV16Y7$&
MR^LD@@=FE YTD(X/D@YVAI*,G=S$8G@$"*EZ=LLE*9(XGH0H-')Y_E ;VQQM
MI@0:2Q=&B4*.I7RB! I[K]HLJ-(++U#&.Q(OG!8QT:.)K<>QU6]3=!UE.PWL
ME]DJ!.8RP[*JOY1(CRKJ UM6B\6YP VXR53"M)!ET_"C0AO5(\=95T9%5RD4
M /L.Y AFN22.>.#J-EO82U0B90&8*@-G!1!")%1B""4'-L]/ 1;'+1Q?XH7+
MYDYO0UBU +">#=>L@G32FE14?JXD\(9MMKQ852:*ND9F46-@M%FB34%Y41*'
MV\TX":SHM%+68FU 5<?B:#OFX51ET\W(B\$82\HBD8N]V'0EL.#C.%JZ(>?-
M=MV,(CFGD49%T:Y4\^#E>U+(\[03IB<=(EA(1>9^)Y@,,@>FHF;:9\\9C1>U
M-CDNR$@11XF8'P"U$T I4]@"L]!L9#@V 4>R5&VK,=N$(R@B^],='QT<T!=&
M1QSETT<UC!0[P020&8%5V>6!Z\K\;O TO=L-&A5&ZI91O>V*MV%:U4=-61YX
M&A2"L!#917]ZFF4$2M79$W9N/%TA>T 6+$*C FV]&<"DT4S)^A HI8!K]$KU
M<3:<34AQQ!8[AIZD4!@:#'48D PQ5Y5%=N++S!0??'G;,_9TC!2@V'!Q"'49
MXBSP:5/(G1I$FBKL<Q3W;:(ZFH5]5*=X+H VFVZUB@<7HX9 0U>MV%,\+!L6
M)I;]/$_WAT71<A([!$ADNU8F=L]AF;01=K*?:SH088A_"-%H'(T'?5N(F50C
M9X;$0@[(:>>OV?QTY['K>+87(QV3)[&B%N(!8E-8W;/C> .5 ZU8Z*';'@ 7
M;(Q)F^_C$I7Z47P0N]#>+<FQ-]E3QW0IS@7B8N_K,&LZIX@R2QK)8V830:/@
M"(>*.42X(QM@J#<WQ70";*& U954'Q$\2D^2,"^ 91<@:V#55=FQXMERPKFG
MW3E1X6>VT'($V+(IOULM1@Q#ZVEE+BT\=XV\3!+OX(5)XABI$7%=MQF\+O>+
M=;L5SM2_U)']NHGAGCAA[&C4EH"')A"V!_I\)N])FXQ2VC+$M6"JQF9%;KSM
MH57G9I"I\%X/5P/(J3*RRI+0G&N;VHR(KA7KE;(_;4C.+( :L8*RS=V4[^5(
M4>?J /#J+:]Z/"*A!],QS2VRD7)8*]/2.LITEPNAK8A*E-"&-(^70"J)7:N2
MIY42("*8+X!M6'1BIC8IY>N*SH[1CFG'+N"+9AK*\V[&HYP-Y2* "@/D##HO
MG\;HX"P*OSP 6W$6SW50/FVF&<J@[1U[R(X2'^WBM1>JX'BG9^V<8AMIRR71
M7MQR8(1I0 WX53>1I_W@S6JFB_AAU]=RR2XRB#H>V1BZB-@XV(O5 LW-69X@
MG@DZ<)Q6ZZJQ-#"FO;6!ZRRW6H2F%^L1+9%;(0Q!?D$J.;%FZGYDK)+0ER0P
MB$[D$:VFO%FC739OMS-H0\^7',,0X]:.1@01Y?C9P]%+V8+UR6PQ1>&18^6+
ME02%00(TPBJH  V:1-X"!OW)^K29ANT@QU19((.*=I'CC;58:>+9S6B,(L<<
M&*RK(6X#1]FC-35:"'+GE@:!B2-'60(T9V%#LMZ9)&(- ?,4L?/Q)$6!^8Z3
M-F*"5A"A!#&[F8-LMCEFE&N'ECJBYUZWY;"0S;'YD3TGZNV^#Q!ZP"L1DJFM
M.PVV\^QB#[:+)S6_4<08KDW6='-*22;[1(J<>L264LT+<C^V4AI99LT ,% ;
M<$L))L*JL'MI/EH*W;Q>L@%3:\@%U]OLH2-+*@.@GB*(!U+R0-S*WM4;=A^-
MK&EARULSG^G[-%7<^=P^Y'1>H;N).B*HIK78NH8B%($-@#OMV\BD.1)G&C.I
MY*3*C';:4+(?KH5@*8[\3@PM?N(=-MLA<J^6V5J/.W;;-2G;3O<H'L$9:D>5
M.U:9:6/S)\?VU)0TU^62F*H,O<_A5ME)]>"!%0<T,L8"HZ5<;0X:6%H[ER ;
MBF7] 68;I*B=/8P8-$G?V4T\$X:@=\(V"A?(,U<3J7IIH7L8,.-"Z&Q/28]3
M@!Y[?D',$F56Z,54[W1$V&%;8"SM9&N*Y<$\U572UP\#?Q.*(5:>IMS269N)
M"EMYJF7T<D^!9T'T. %ZT>$&AZLQ%UOWQ50&H@4TDU3)Z%*6G"8S#99)90"Z
M?:ZE=L/ %X\+F@MV$D0+U^#58*U8;-#F ) S^&9;;&9C:GLPU'PNH(?\8&!\
M-6%$A$(]9K733*F&XZT")$OYL"4V,AJ=#FN40,_3&YW.)U"*9\A<3> H&=2^
MCQ(I!!JQV%D:H 9T5X #NK83:\R:\?STB&QI#WE?)E!(XS.C-T]/F=J:6EFP
MHH);<O#9WB</TXQ>*;/Y@=)+*I66,JFQ>IQUH]TLEKMAU1C3'>("L2E!: OW
MT829KQ8#C#IPIPW)26C,\PTUWHVX"1^S>>39 Z[<"Z[2T-Y8I XFS>UFC=I(
MZ[QCQ)UZ=JN8K5?!9+QJ5$E:L,LPS\W(GGK%Q:-N6W8;21K5EY8F1N!8F>TF
M$UC*/9\.#WGJ(-26E\6#6./%L&P/*4=M9&#+K$*\/</E2B;KCN@ER\X[$?"
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M>2"6$M!MV<!)?'K],E_M/U+9=>5916<&'3C^2_-Z)#*VS(DA<<-W\WA0W$K
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MKRJ8F[+5\LAW0^U&_R2-@)#!+N\,4&+(9PABEHL*$<_*%I:H2#1QOXHU/!L
M@KW\Q(L3P+,4_NO$!]-%._%;7"!'N"AP2-?7V_6WBVK49J3'Z/).04-%\^=\
MK=!)K3NU;X;OGT9[!F*OOXHM;6F8^XFMB_]LD/D9*#,H!?X'@4Q\"BUGL@WQ
MJ_FL\W FDP,9W2:39LJ<_HF#G-2HP*D]DX5J,B-8!P^^4Z-P^4NS4\VJ)#R*
M@?#N-;82_^G%;/6M%I$4-L^RS0]AA79.377U0>J)!'%YU5XD/0QH_N8+7\ 0
MOC2G5M-/J+5E#2N'.7>I<=E[QQ_G@MV5DHO*"SI56H1,]AHH5+5+A*'Z^QD@
M 4IOY(P<0DDBB+A1#2+_;=N S'5_8ABT_9J?D=*T5';TM[XE0>%( JB3(]>J
MO57^3>+YUV<YYQTMU0B%)35QXD,OS!DVIAI<V?59+Y;S<5) XR9Q&'DFBI M
M(+&&2O-$3'YT>'Y#?0S-I.WPP:=A<I+ESQX;[FU;0H;GC-<>]8O6F=G3.ENG
MMK=W;M?J2SHV%:Q8 )Z6B@+8%H+2HA]1J@ L2>*#A-DH!J(6KFS7*/MLURQ+
M?+!AZ\6RP/ \D>G%T-J;\_NZS]IY[?);VY18XFIMZE;&R?S(92Q'5*Q(+QFZ
M3$),$A['Y_;1@:<)_/6SDGN=<QK.:@M5$;2C$_GLS8NK4V\C5Y9,3*;4#J.&
MY_/6PV:[<<33.ZL8]UX=MSN2\,6:PHP6-:<T]847@\]9@H5LK.D]8&.[!.</
M"/?5UU?FD== 0NF8&5X?])?Q<YQO7H$^57A(82 MWCJ 8;I"<]3[@%3B H%2
M4R?6EI/4@%C+NNRTI>;%?_?ARHNW<\ DCR5"K;9R?2LPIH-RC-9E]<3!MP!^
M[102.[Z<U9I>(4?608=/CK<7^ &AI2O7UP.$T>-W+QF#?"T?EB*W%-6_IR-M
M(_JYG$,[02JMJ(>%0,F#E+@L%<$]-I"/16/*-%JHA*6C>0&+ZXH<+U\0LPSX
MXK'!%W_,4<]&Y!!98H8G9>!Q+3-].?D%+<[Q*"'C_<V05.S0)>Q:]O#BVTSY
MXD[0WZBBGOZ'W.(6?3K'5<ZM+<9MHS]3[8&RV)&EW$Z^&<#XYS8:?4N5F8MJ
MA+E,WIQG>N<]\1GD^6YY8CA]BCI' QH B]V.KWNX&!AN/:0J'>?,0!1>7#^M
M;GW3\?5\\#G:'^[I[H'B%LG1G%ZS6MY(TO+(6]F>_8"82Y=:O7R\725^.'&T
M=XN^U\T]-MDADL/_2=?R@A5Z<&\X[N@><[E87;F(F#2S*D5^+3)* /B . E/
M_=F&2R1,GR[6\7/!S7>74>COS;9:#WFT4$7/>[!.<P;SV;C5+63"S;B;]F_@
M'@)DTM('KMX>^Z<,AA,'L^Z^TBQ&EUA4+$P6%KEWQX,";M9TX>9?B([*@X>*
MQ&5/%/A6#8#H=JREVR2]QI%0H4C\#PRVQ_\5EXK!4R>7Y"*=7BDU9WM(ZD&Z
MKGOEXNZE"#F-?YDEH8%09B1;4<U&G)NW*.&OB>TFSL^]>Z7?18*$A=TT@T*U
MZJE,LH33DT/14'\?.N>P6LX'W8#+[G1")ZZTC6-T0RT,C346=<]J/ @'#U-Z
MY(8\W?@E94YL?4DUR%VM2T5O!U0!U%PP"0J?"Y$X= [-);$%6%%H8D<*($D<
MI%WWE/1AKUVHTJ")/?<!L3%XO^2<'OB3HA'4V0/BF+$ #7-OAR]"W[^L?BN.
M.>4=P*TW9Y16T/DVQWLHOGR-WXZ-6') BU%D+BZXEQ>%*?S*<3,ZG"] \DW-
M]J\L9<Q[%'RO)%5Z'VKL.?5)/W*D.!*-F'Z3V;A%7'YC+/\WHMKZDJ@6=.H;
MB )]J$=1<BT/F9R4@@<;<#416617AG4-6ZARPVO[Q%434T9AR[H0OL<=SDZ9
M.,NRO.6A:O.NONP&S-,DYA> $Q7XM27"#SC^@# PPQN=*9O]BE\7ER-O5 ];
M-:)>/).UELK_U2%RF,;O;$3':CTJ.L&AN*O@EQQ70J/1GC+6HO"<&#77DVSC
M$CPOW7,D)U_:@><9+ #L'!7KNPOE'OHJ4DOD/C#;O"O70!]ZS;ECIVG$N&CJ
M 5./BE('1*(2@[((++6RRLK"SK0 "*)W"M;%^EL,?Y$Y#[70375N)WN.[2@1
M1*E/C/)*MLIA+&-:Z9E;'H9[.'%^!W3(#%(E=HDYE6I%_">#PQ-GDI;=X:!P
M1/7@"&K^I6HE;9@!,!]@%VSD2<1^S/1XIN](8=X\BTQE45TF:@>PS"R[W93N
MV%Z78X%R/.9 O.H@!ABA?>B!T4CXZ!N>O%2.6HHI*P(GF Y+JE!G>]<C)AV[
M!'@'MN(R<^A%H.MQ?I6;HCWW?+W_= )^"7."[!H7E:XVTO>VD,A]PKZ5DN/K
MY,4>83RS7 CU(2EYN!,U5 ,_ZE-J,!='N[W3]K?=K0[*53S"RP9/G+*EE:&.
MEBW[JV>'+9=FW=U\D*:,H3#G^,;"$/6.&Z=0IRT-Y[NE2*Q;-"K1-P.P<TJ"
M.^G4&6&D@G7&#]KBCOFMO\K(IBMG%[X,+2'&4Z2 OP(HN^L],\E\W?P[Y87?
M/Q.7>%3,,N7VOWF/P2%2;6?Q1H!B=</9'IW; .1)B\0837(N0DYM'JT*PE?9
M&\QF!B^@EZA*'0:')X4R-<YWR$)>[]LA?D;.[!1I5K>^D^185%XX48?I\E]0
MI%"^!MBV3UNV>O44JO+F7+I#W'9 8R<.5\QX#V+)K+,?,8A2G\( C"O8I*:C
M(@*=;Q/).!JH*U'TR;;L)MK]XLQC7?IARY"(VES9X?MMUN2NZ]N30\(W H]L
MDK^Y'?/0,[CL&WDSX(D*-7^\NUY:;6E:;<."??,BOWU N""8JK>\WL +/Q_G
M3A1D;/EF)./8>"_^U.!S_X#X39SY^E<HXNR^V=]I:D.]#>"]4'][Y/96-VC]
M:X?:V'A03X*]30P^6MTY)(\"A$_43)73[U7XH[4!6D)ILRIPQ,8V_6T\3L(Z
M4Z,2)UC:BB%[S::&>%>]!6 @J:-L_1+<G<$BH_^,R*O9(FMN-N'7720NI$?@
MNIV&;N)6LXT"=W,H9/1L>M5>V6$]"UIZ<3H3DIT[)9%7*RXM!.F=5"=K::II
M;W@T3;.8&A6WKVT1@0UAH$E.2^/]%'4V,*_NY5#=/^E+645$\"F3?=70#*S=
MA6)ZHDHMPW!RH9W0<Y/ UGFQD-3K5-DE4='[!E]GD=$.%CK98+8D-!6P"(G(
M670(V. HRXM(@%55/ Q-MU[[1>GY0W>HK;U-6#P:+@?RA'6!5;?D>HVU&73Z
MP\[#Q]AIH=6F2]XF(D=.^_RA_)3&QX>*H3BG0I8(1MS;/OR.J]W/:.R&/^;P
M'FCU/S:$[G57V@6LM:IPZ]LE9.0UE-N! "S97$%)*B@:DN:)\]ZG+<<V("&&
M&JX2'"4AG^=X-3'"C>Q58S=C;>"TV;%H>1ZN&&!0?M*V&U](92E1TLES;XRP
MCZUXEN>HO+))4JL$M@;:5!E'D 8I-9*6NCK3B'OV=4U=4YA_!=WCX.S\?;;]
M3OCI^Y</B"QI]Q]$$N7)X^;):3<3%9YZ4,GIHOW1LYI=QY#,42?XNLU!"T-/
M:$74:F=94*+90\%Q5>;-6;_#=5SK"K5T)02)[1#D!4AB%8S,H')ZTCZU$?>^
M.]YL=-@(HC)F;1[5FV@D 5RB^_A$.#AGN."DUIM\I3BJL=V[.P0]R^JE(FL"
M?7 VRHQI(D%]5-)B;NL5GX3]13/+6K?05I**R^9,29LHN6,=7]UZ2,4#@[YR
M^ X>VBK7$(J8G7>?\+G-SKMC&70$8:O@S*I)J6[9\R[;Q;D^"!VIW_VS_9R>
M"/P!099L^2U?E\)"@>Y:Q.;._!1V F?"O67Z/MV:8"8$T;>'5"3Z"HSAH6/Y
MI, SU6ZPO+OO6&$87'X232%>,8A>4UY9>H^E:G*O);$I9GW!_S+U3.#:O\X5
M&AJ:V9A=?]33_P&QHZ7M2V*VZ'(L1)O1V:'%.3)V798/DF,8#%_64B-4.FX5
MLK9.VCB\?-EEI^3_44]*-LR]X[P4#]]D0]MKB:H]^ LVIL'IDN'LW,-?AI=P
MPU*/,H-^OZ^L9=Z](0% E\P+9B@MZ0$Z-ZKUK7TG+S5FM4,?1M(_<\8=&*K#
M,_J40(CP"TK8SP#%LWWR1\>&(P]S!&-DUQCH4%@9+LPTH[M"MUP'/OY&^,OP
MV,$0Z4,G.RI=VU[.7XIB'OU?M3Q>EE@\G)#P$WZY(D)IV0\8_N^HSMCW _&V
MV@DT4)2J;W$U+_(NRKZ70>-,$+O2J ;-7U>\\6-*]URL&=#EM3']K);/QLZG
M$:!_.SCOMO#B"_Q9-ZW!?GRRRE0TRCK&8X Y%E\'578@2O3I";DW74I,5VX(
MW-\Q\$D099R@B,:S"0?XXY^<!D>]\7-1-3"6?8<I_H1+OZH10<BIN HV/HQO
MY9A.&18ZSY&3O2HOY"25+426M82NDE2B>'J35G"V;BR'Q?O<*]W3LE=[5H>A
MAY^5@U8@*&%6? 8_X6NG?_;=7T#;>3B[QR9>_,#W[<6^1Z3E:E7^'[LI_J^U
M_G\I!CM/7Y<K$WB!3,_F8G+ZK!0\&IO?NRV 3 S8";@=_I ]#D(9%(*=-GC)
MBPSAL!!DZ9/#!7>100,G*WLYI)$4T?N./3T--5,R+IPR)9O$-\Y9:&+!60]%
M#?T1-Q0()&KVO<=,:#I S"Q-2UHJVCGH<E6/)H0"#E6+[:M,6.D@5;VGK.$Q
M;$MD^G&KW4/PB 8<@?KH-8U*5%14+%HGL]I.A;*$X3#Z'[9:!$=QBJ;N03O4
M_CH.\P/O>]8U?7G9H4:1"_P%N<&W[W'"]4EE,T?ZG.AC7T:(%:HB<#D%*!EE
M(%%W2;.Z5JB]%Z._Y_]_5-#_PQ[#!0DC"P>B@AIHO*)2Q"P%+]&<#$,U:2*+
ME<4K[6-(QZ\;'Q"?=K50DH=?W'1PL,#X8/W=+42;#*\1 C5Y+KJ KU3$]6T"
ML=NN:6<8T\'GKDK^T&[Z3.YC 9=2,$.K6BCN*+*> 179.[+F&"./N;^NZW^G
M\ UM3XC$6*_CQ+U<M/\7JI=[]H_&O\[M^0L/PP->)29+)>7GT)1U57:(FCS"
M)3EZ (7^G3<#ZV>8 ,X+*M[TKX-UL(W2\I _M*E/N.!,;7;))8?S[2SAQ@Z)
MH:#/.&5RT;=2^EV77?VGF>Q>1U<]@K"+':9PEA4%UKB?6^O( '[2.5\GZ ;E
MZX1P-B$]A%X1RYE=T=+?/R &C 5J#\>@J#FS$1S*$/GX8=\]JYRBAIX(]G^+
MENXO;'_UT^#39D_^1AV>O8C?"QQO!5+K)6]YE-O74V/*V,\"\%:G#*@S],Y2
M,IAJRL];TH9<U#7R__^4W2.H[^D(%KM:(6*T<'O+5]A5/ ,]ZQ[8(?.^)*DW
M&I7XTP8.[F&DRVO [:<O1SA$,,<YIS*T;J$V*TEA:GU=\+()5)OMEW)*J:'/
M*[=7(P%0<XR8V:D.0$7-*,Y-$>C+HJ#NH AK0Y,>GPFUVANNH!:#;+()Q$L=
M\(BZ8@S$U'"+"]N69ALB=)^1(HL"A.S79KELOMP?$2YW%\@&*2:78#YPG&W<
MOAF2%3..O1=$"+(^\^@-]$F*"XMN9S8Z2/F;Q-W;XKB(^+4P=:M@NZV.5<MP
M2KISM8RVR.OO*IBS+*"#Z>G/%R[B9U34!H%8):X&3.E8DH1FK@1$\B,$SK:$
M"'LSO 8_J^_<IPUM4>2K'=EGU3::@2?=+\X!8.RK&2D=YS(?A>O9?C4U'142
M(3-/#$Z;BG#"7U#[GN,QPP\\-J/_/3Q?%630E)Q4=H<7Y632%T381W,K 3FR
M6[=\[J=XEH'N0QY@^\8HVRA+@2F.6 S/T3WWA:U]E]GXQE+Z?(J2>SSIH[&-
M2#J=78!@_EZ*TS!(G$[EI07 6F\WW$=YY8I[!.D.YJ&DBP+7S_5OVY_R[\SM
MM+^1F]W D1*WG_%NV;^B/NDA[3_/-.4ML7B(TJUFNGJ+#."9P$(.9VT"#YCW
MZ2FL.\(F4NP5U?\,#?ZNE@NQMEP9D=O[K'NJ\<<\DTR?(DU]K%< B][JL$7Q
M'?]I%\X;*L?,R!)QZL4BI/E9.FU20VVU7JYXMIW^55$)L#UL'I%5M4ALY#8'
M"[/WU1(RH<]P6@9]0'M@B8?*E(8(A8:>B.0[\:P')\0^Q.]#@JL;448RCU)6
MS7IEX4L'Z_!&(70^$V_;X0<B$A!;O5LD$,:=3N37!P0+\>$WCW1!(WHW**YE
M%85&9+?CR$E5T<('SBI&3Y,X+_O1#5A/TL[%[G_SWXS.LWL> WV9=]63>3-&
M_+R=EK83X@5&);C"=ZZBQG'<J8@5-;=#:G,ZP2$3NGQL3[RHTJ_FG:FY5+'4
M9X$ENU>X/N2?2!8QVZ8_]0IAO5?[DTH2/>5Z8"<_F9KR)EKF&MG96E>GXPI9
MHB7%OE4.#0E6&?S@J"G@%>\JYK3_;-BT6R\HFR&*A49*G2 ?S"RRE^9,4@05
ME8@\D=]A*5S?-@*]Y^\?Y^/I J-P 0B36[MV-T9P&A*7G>"K1H1R!#FAUXW:
M$1<N1K42,:UU)@)8*2#W"<^VJYJ-YAFP7[[1ZCNFYPQ^%6">-@F<R/EQ>&E\
MBY@_)O$N"SOT^&)5'Y.5K&=TU*C2Z-Q>>4KN1G'G)RUE:_R6ZZ@[.[[)@OQ-
M, 3!T0#'%+K+.CQ+5%_ PY]\JI5>>2ENKF=_O-TH_K<O 9'[&]UZ$1]'T).4
M_=23HSI^D RRQ19G79.O3)IABD%RQ#P/S^? )C=?R!$< ?&AY36\R-X/B"[D
M9/L7GG5S^@KF@C48);2_@:I"WC4!X;;?*R>+VF687)3)\A7_W9(,AS@VM%W2
M,BUV52QSM:;"!LSZ,SI%:W>_N^(<!,I/]GTMK.@X*\%Z<>X&VT<=L@L@?X?^
M><*__P&!N-KU[_0YF[ AZUVT0ZCT#->3!@##(^D9A]&_7 0.\&JKK5D$&K&D
M#KXT[.,\W",U)B"VKW2RD56''P.92:@+W(3SJO0%(MHLEAMTQKR&@?^8$GU
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MV:IT 8X6+=UK$XOE;Z%9.M!GPE@<Y$ZJ>$9O69E99M1MHRIZOPN^XVG_M&M
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M333"11J\#$UO.8*OWYK7-;+4/>"J*<3Y)36X7A[^0,MT\%133[0(330([8,
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M8WREW<M&%.(C3WOI"2YPWH:[IHU#>A_Z:/7+^1CU2GE93VC$5M AA5#\?%A
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M?6O!.)Y?2)IB$G)EA#B)=!\S]@4F23&MDA(5F2R(G$][W(N-))+[&]LDAF.
MD) 0KPQ2];YI: SUN*HBN0\;!F7W"FS.S#YOQ1!SF<TM7O:B>XTVLPUUX&ZQ
M@2XI.&W@6JUY7>%47??*TM27LG!A._DD.LWGAXY<H7<FOQ!Y83<FC/P;R^+2
M9QKT#US^AP*^C#P!3!K&CY+2[*4ZT6S2^&[6VWIF#ZOH]O/";#V'40K/RA(F
MZ;,XFPD!1WB!1*.V/GVL%%:VR8HLZ)TQFCV/>F(BQO: IDCU>?W<J8/T,58Y
M7E()PP[]93F=!ZITR656!0L/9=?4WH&+,":+?"K^V'/5B!Y\ W3<ZC\P#L^B
M-6Q]_[=S[W5\G!O/Z0=&],4OL^)+P$R\/F3:DF<:3L2*PJC*<6U=4Y[NAKC=
M'!Z(6U\K<W)M17:'EN@0R=U^84L-MN!;!.$U@AHG,/0<<N1AA'R@N]&78]*5
MR;3E#-9NM]%$UG#*9>7#R._=O#%*N\>B%S'$7+*) (%7%?3#62XPS:B%A*14
M<2SNXAKI">]AF+[F)Q'W?L7T"@QY/1'[ _,URE=J3.&;SCK^7^6'AL[([O;>
MP4*]30C];G)OT@_<",YXD$QD'_55F+[1&'T^PF*-6^W['/C2DD-YO6<IH:-W
M K[NSS1*[O3SE:\Y)<-%_#DX;6SYWQUC?S!J2R1#+ F#M:(3YK1,K$21C1$]
MRH<R-:"?!4I_17(W?UE77Y&4WW%J/!I$KB2U=^)JYD68[=)J))??GS<4<=^M
M)CE3 ^ZSQ[1'AO]&UCRX4>L('6:W3\KF"W;VGDV"<@D)%8I_FS-HT/0QG7$(
M/E@I;ZX#ZCS."9(B@I$7OU;I>_3^@1%L1]1#&@+HFCA+J6YXHU4GCC";^!(6
MM@1$Q$A]UD064B=\34B( ?:G:H\?KKIK9#1J(AV#/)7MZH<CC$1YIDGL,JT@
MS:^<88!0A<#0M_S[25W^0G41B3+(B"$:GHJ6)F[>3^?XHS46%2U#1]RT<JMM
M6.E=M^4HZ:#)435/<.H3=7[1&-;X^E#SD\FC7V>S'E6];AF;:HT,)>CG+387
MYC1S&N$0*H8+H9ZWDVA^;T7'IX.16,OT:?D#&PD%/-()M35&EAE>3?H)4G@\
MW@3$[82*F[I;=;2?!;M[Q%X%<#?]VS53F6:+R?,.<U?,0K4Q"B:4U*H>5?SE
M%@JPW S5DC F4WCZO/*PAR@*H6=3TF.X]^I;WYQW"81.EM7J9=2=TFU4)H\B
M&,N*<TL"&9BRI/?4^>@&OR_DI3:!B,P=8&W'X-@^4"Z;P)^WM;CCE8IA/$$6
M"]S,IKK<*YL/C_RDWDMFIV^+ ES=^)D+J^-&CY.;%SE*;.=*UO9J/O2MRF!A
MIZ14)UPO8Q_R_(=W48*<G&3,JLT[W>3/<XR+7"7J!J;M>#_P<:,MMI[BW=4:
M=>*3P;!%2BIH9<.INQ[HZC]=TM&5) -(K4@2L1+&;M9L->U]+P<W7%<> %F/
M=IOS5@%7>K]F1!E1JM]SA_%B(:Y+)GB8>UN CVB) :E)OP8,-RAO[S].MKU+
MD98V3<33?A?=4Z3^*[Q;4ATG+$QS9P<^\6NN]_:*D,-H?*R3KL5VNAE=IG.F
ML11K8EBJM'O\1"CFH *>\0-SE7.",4!\QUCV6HH,$#.:#TDM9_J$KOE5W%1<
MFK;&;(U454#D(6]EXO7F<N@I68[]@;R.IAIMI>_QR$PVGMMV8A2VY-I?<\#8
MM3PUZF-'R.]50+=!Q3QGO#8.\6XKGP)KBRTW9 I:Q(<6<1%ECN!4AD=NKT%C
MD;VPQ\6]Q?FSX<<"!EG$N/?W]RX(1^/(P.'*/K!;B?^>6+EYP5)5J%1B&,-]
MC##:[T*W+!1-*Z+S2:G<B^\\M.#FN)Z7-K<;QUF :;XM:3-ZN\G(O4;#5JEG
MY \U;XD0+-S:T%,LNJZ-6WUD_Q-EOB%1^WPS #I#E_EY?X>4A',^_TF*Q#(_
M,7BS9J@\.^-8AI F^C)%%"0I&#S9-CGX>P^8PB6)>2<"!VPK$(3TI'^&@4B0
MRAV4'MI0QV1;,3)1E)CR)OV>4Y%]H+6MB"E-*$Q0G55MK>+SM@[;"?&,!"7'
M1H];78]<J7JW;XX@E(>*)[<75=!?!DKEB,:YK<MQZ3F/*ARP2Y[6$8@,R]*!
M=,WTH;J/#^OD\@'\JY\K[,>G9I-P9_I/-98&R9FS^$!M555094(8*<U Q'6_
MJPZ% .2LK.DWBINYJG8#HL7QS P%_1+6F9N[M3YAQN*8DF1<]'+7A.;:;Y?U
M8S[B,.9]+5FS1QKUF#IMXLB(0)T:V_3)F!C>F@JOU]0,$8S%M2%;4L&F:V^$
M5=]658P&DI!EL5G\]);A1LMUI+LLO'8F',H84+O_#0>Y7:/Z/,*%DTD+GJHL
M%7W8)=#Q<K-5>]->3*1>H[YR=BS/SBY#:DD"MMC50O9@E;]@5; $\T/$OM6S
M7=ML]\?-]O&E? 8PUS<C5.Z1OER'[/K2//PO@%'#U3"$KFKF1YRN4$/UFW9S
M=Y'-)V*NV$HR#/)H,E_?GIT 9VS #L<V2Y!(!%O:3/R+:]TX^G6)75WRZ?35
MF#Z:FQON>8PU$W%I4Z[+ #Q;( /CGN]4J\>5Y$%^<EQS:OB/+5BO:RWWV*(*
MS3E+IO266=*]>_.*!.01T?1]U[(\WU$LY8\1P(C &NNEM(S3Z<XG+290(7#E
M;HXWTPZ9>28+2?'2/ZF((Y+1:S10O@C!76FL7GG!;3/B2I!:81S$U6L+^H#M
M[,OI@Z5?/]N#4.F*'UG"'1KCUJ-\^I>J2FGYGH2?)8J;$M%H7;HW.B]LYH=;
MQ_&-=-6Q!A22/"W.ZM3)8M-2=10JN@[D(VN;]IY0<-?A ?\L*IYMD)4K7"IN
M+E,^;%E-  ^)Z\U'V.]E;UHTR&C+J?HXP5X,,%LMT_KL>IYM1BVOM_!ZJ_]+
M-")=4IBW//P0H#A<OFJ:^5>9&=.1HBQ:IWL$S2AJUGH1.;U55;A9E@\0UK\=
MY\S$\GK._=7?ZQO>^TY37=>A+V8)FB]Z@L#'DZ"J&P"Z_FZU\E[+F)HN8-H9
M>(WB@5/-@)S<KS\3(?P),*PE<0RS6 DW7F#F4NM!#W0*>JIMI(<;O18E(-FI
M4;><UNP)Y\A78A F2FW;42[YS!9^I/T(JS3HZP^@\_M8Y;5H$-N^O$_F7Y[_
MP8 'X-WWDFG.\/@^36;GBH[KRWM5XN?GAWPO6S\O# ",YT^Q[T&V>VM"SG!.
MVB\7]J02Y.6!R[V)H2UAWTY^',J88&%W?T-@*[B PS4)6=BSA<672ZN(J@"X
MLXEQ?X6/'_0XZ3LC752S]>\NZ$@F@XGI_LA<,20[E_*Y4_:WB#<=\E1ZR9/U
MFMWH;GW048;I;,(\_$H,N;$@>^TL7CQI2OCK=_D:!4U6R#"_XH%F5#;GB(>%
M(]+#-O5J\,')_S/M:;?YWXUDB0<'"Q?>G^[D^]+!H,&Q"8( >GQWS$QWT\G!
M^XO9.3M:AVIGK+GXW2M6\V.K]E,Y2&).[9E%2[0+9+%+U5J7UFS*AI?7Q:RI
M\W$;F/1999[SIA?J:.K+^NO>%%/.E')]EVU0O\GOA+H^FC?7KJUX[>;7#3'Z
MN8)568/U!WT650E51;_HA"4S.S3>*9L"XQI!PCVH-<,ZICN][5=,V@^U9<73
M_\Q>BE3&@ +?@R%TU1E8S-Z%S$7-,E0YV-4:_2:18IG:D)@/12&R[%EKN8<U
M8[Q/D,1?'HKJO%1YXS*FK!AQ[W7%2PL0/A*Q'[WN<X=<+\(#FZF5XMA$V1SB
M-)P)7EGYK=@STJ,Y)6XCR65+C%/YIV54T+%#MSI@6W,A[O;HWH8F)4,B XK4
M\Q#WOO;/9AJ%_%/,8J34E<S]UXI=B6')N ?CV;6UY)6+#+A$:;N%"C+MHL+,
MF8()S0ZTSL6%A6)EGXP<-">'&KC [V_B1# ESQM&C')8=G F@&^IW\-%U/YK
MRS2)EW%.*#=DH7_I-&K;SB7*@JC?Z6:<.^H/#)U39@"=4\[.N(@*$CRF-,4.
M5C6\,\4-I1K[T ?=.5_XI6S'Y>0R7=6'TM9+TAM]Z1?N&[%%F9[[>3OW;[",
MKU*W[*M>_4Z9G"]%.TZ99A-[+K^$SG6LB4EI6/N@R$Q_:6E>PYT>A54?!O!%
M04YL[)+8@^-%0$;DU;/%1>T"I/Q%1@Y"E0(E5<__ ],U>;A(?+#LW!&@]-9Z
MO"U-N90P<=(^\@K _%Q\WI:[([$:X#S"E%>UKTQ8OB>($-FC/PKBO(Z)>T>A
MRQOW=:%?XHI7\^1#K/H1FKJ!/F=S6"&HI;!T_0?PKP+R; 85[":"IZ32)7^4
M[FGF&"&P]"DY.O%'6Y21IY7 $ PV]\\A+SDM]77*MN\\K]-*J^=5"Y6:S+XJ
M>C8V]#$RK+=NN-_GAJW32X&J0]S4;*PV:WN\>Q\OMVENN"&NX/*6=^168WG-
M&3F?G(4M;2--KGX>#]SC*HO+)QF.*D.IW32_R)YLFJF;@F(N?_WVJCF-ER 5
MF 4RJW=#@=N:<NL:DXX^+*^OXJ2P,>+,*"2XH[%47_1DC-@6(6R6,&ZBZU^M
M?$[W%HOMH=6:GK6$:)"Z.3U*/YR2(U)UG+R([%(&N%]G["Y9.%ELQ$-R"W-U
M]NM_8 +^P%3>/;-!Z_Z%/;(7ELVVHSA92.Z1S-B95/JISSC!8]H5]U!)$)J
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MFI0*&I>4OQ3$8,+V /AG3E%2O/:W?#]>L3L]MW8Q3NPI#B7MS&X3+2KXKK9
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M:CS^'^9F.5A/N0=K?*&1"49$(JK&2M0,<LR?\#^A\A?N]@RYHWX8O-6V%*G
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MDH8)QJS=SQ('C!N>O:$=/*=;&TL>OQ2VS].LO(58@S$3T^/?4+PTXV.9H!W
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M7>D=$ H?L!62K^2NW[WS;!/&'-58YGV:-\9-KUUT"!I@1Y0G(+;]AI/I_GC
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M_"4&HWG]FO6#JM6TUIS"K>6E6<HDE^V\/M5E(>#]<;*<9X!8I=6D6S$#FD5
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M-RLY9\SQ2QAXI-I+^>_*2[L=A=RNWL%V1S3KG9*4+:O24!D8+(65,[R2H\H
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MGW/. T/+,7LF&NZNJ9EA"I8UCF&J&WX8$07(#\@!R'^\:4P_6PP3KY^[2KX
M=R7(Z,%_B%C>&R(*J+X A-6,W>IOWZ)4)NQ5MB;\J<@\_JEZ++UZ%UV\EVEH
M2W[DY2IK"NZ_.Y3\3O-ZIWK#=CPC)P/IKO]?]$*^ /\B6.>NY&D0+LXYIS%K
MESXQ+5E2G6! 5XV84]&<8QN_X@1Z)0W1/::EK7\MS^]V!+$ G?@&CH32GKX
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MIV8@*S+L]RGN0M>4Y>?Y5R"63HBWX,:0=JJ\N?C:#,W;K3ZD)G&,7$JZNO@
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MTBQ6IPF"BI;16;KKO*@>R$%(0@Z'*X#E]F'%M1;IIM-?J?I5,P&)PCT;V=-
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M/"#-F1J74$8?,SO*;O&46F6.% [&XU2^'IHC$E<R#%,?0(7_T_4.C\9W[]\
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M=@V)O=)<D)$C];W!=;]^7Y\J'5(IV0X/#2E*JC_RA^!EUI690@ETQ*O';0I
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M1MD,J-;:94SOWH[AGY7K?[@C*$//B]G@TD"ZWV[[-YUVI?943##WF@9%0=-
MQBAP10^3-M.$;A9K_S%UYE#X&:D91S$#PY%)4&L37P93XDY',\:#G\Z'H))D
M.1)UL:'A).KZ]#33D)WZYW\ I$@4%[B%2RX4";N,LWH<,MZYGVX8+-(K*GO=
M,OP )Z7FNHH.6'6N.)&/SV$=E;?N6J\4/L\S[#"9$BF6[;50"XV['R6\*]@5
MU9N((R=PGYVU7CQ:K;7O54ID,)%47!K04]@%83"?/*EDB!GTUZUWC=H7>R Z
M>FN@[I&5(0Z)T&=?4F'Y2>DX:Z(IE.S)BHR0A(*^ (+B[H17$MH76,B(U<1S
MHQC$<M(]I&B(E48F"RZ'9M#1N(D;]=-1*2XGH<=\^QH$:(PZY[_-\FD/DJ6F
MMWE<#D6KHW\B=@?\*HK5VNQ;8C^Q]"B$1X&PAHT,K0/<94XH)Q0M-*G<+CU$
M8Z8 *##):! .=2;)WT*<< 2;'L9CZ)?<2X;&)0<MR8B(LJ^\Z>+/ VR1HUU0
M84?/CP+QT([N4L0FIS:%)[4/YBPL9AFT10\E\T-JBEMJ(+3F]Y*?F6%3R,)8
MN</"?.=-L^DWRZ:I1@C89@A8??9G,B0B[C,,U5%?>KJ!I<VQ)C5 A?/53><G
MD8$0YF4&*<*3,DN.0T;]TB(7>+284>0)4Z@-44JE/<5S238+X7T@CU,G6+)(
M 0; .:_K[CP.?3??U,BE*)'!:8 GK]^FH$ XQ7G*&8[\-Z8";J9\[*HJ8W(Y
MQ>2O<<Y:>^GXF%^O-6H<F#VE^>X&>[J]Z>(!.YLU71\7A#^%2^0$GIZ>'E05
M!T8FC)#I+Q>#6"5')F][I!2SF^QVSU>HV2SF,/6[/$[--D!V6P2<*N:;C/7K
MY#'4%?7CM-4YY\4^MJ"-RWCGW.?J0B']V[90WP(B@0;Z74=5(KV4NC+^*2N;
M)D7S$]H]-T.-BKD:*U_*2#CX "]T=5R16J]9+DNCB C*.P_6U3$:#.$J:3)L
MLAFR3,%>0L-?JI3AQS%?@'PRVN!(HZKBF3GL<3&C24U<DXFL^+C2 WW4U$>;
M1>7?+17,V '[A<YC& TN\RNH3J)M0&ERZ+_O"[>A7?UOX F!2QCT77E1>D@U
M8HFE+);<23!VX[+] QUQ4>*5<5CV&.I)P_.9I:5Z4.*RNV'132968A\Y> HG
M'(9Q :I(2/X!IF<\B1PX':;1$YH'%"L"]X.=?(HJ#G)VJQUP\VF0<;7T8R+E
M)KCKAYK5N\ZO[\@BT\01?P88< S$@E1JP$E921^-J(>B4O.5U4MS;U=-\2S3
M-QQ<)"4EO7U#6@,Q_P>VG!6LD)+JLD"RC\;?SLR%\I=V[0W?W&XI^CN,,$(@
M&[\2*JOEHWN-O@S9'J!247?"() !3^(-*RR_6$]4+!)CY_)X3+C)$/\+,#PQ
M;&_[T#/?=OK:)0K.:)-%@FIKNGCK% X;) 37R,&2J9']RD 3I-^Z/XJ/.QL'
M3SQ>VRXF8CHQ9M.Z-*85&>/5-&K*,V.(X(IG6H1W/:4;5Z^'%B09)T^%9G5!
M28!G5(1^FZ63G-PQ"Q;_N4G[WM]\I0./T8]@J4]]>EZ*5_&P@N?8L$)(6PFU
MRD'^U+2/:O4D>$^ ?48^M&7.FZV%UH@WL^^!0)Z:109;>Z0"F\WA-HYC\PM;
MW@A20IHTI4,A]!L7N0U/90I<<WH(#9XK#-^^G]$[,ME)F:&0J_G_Z>LK@^+@
MMBTA2-#&">YNP=VA<??&@KM[""2X2W?C%AQ"(\$]2+#&W0D!&H?&$P*$Y-W[
M9FKFNZ^FYL]9?T_5J=I[G5I[[24PZ1/K/B'+=LI.;O5DH*/'RI.OD]SC(RD-
M8* 5@Q9@*G%F]MC2):@PZV,-=+ 94U(FCD6.1@C3D!J2<Q!"WWXR]?SQ1NA.
M7XH^U\E@LZJ*C+00;B#"9R=<Z"01Q#ZE&J=]^>A%SQ-'S/K:>#)DQ]F3G=\Q
M_RN/>KC#K\*^?FJ>S^0!X79@ GZA)V?;V[.Y<Y\@,]4Q>G)-6_V([ ZMU3)$
M]J1QV613PI?,UI:?C%*?2QZ-ZR4;+-4:C_ZBE-QEI1*N#;\'LL86 >^@K?YD
MBLO!G(WK,J$T,7<SJFD(CR.:![3.6:;ZY<5#K4#5X%FJEOG)[/."\Y.OVC^L
M$&W\&28)Y^V/MJ9\QC,D7G%YZ\:9,\*ZVNTS GNPNK.A&*?VZ1&>'.^ PLPE
MD[M'7O:<%6)F!U3B(PF9-^:CY<96EV-"$>< XH;7XD8W#/M;B04K&TH>MOYV
MY14<_-L218Z.-CX2W@A$W\ZOE'"R*-.L)<G:I-9XA8B$M&B/N_G8C3@\0C0[
M8DJ)G!N0 V1G[7ANUU"(,X.,EUFR\=J#6I)/^RQSHQ36J:D(BWW^,IO1%T6O
MO1: ;)%%=\H3$<P6B%\^6XZQ!"6HV^G8;7RF,MC5*E+F>T</FJFSSTA<X_01
MWS(PM&NAI=>P#A+@2"&-3GGXU_<1,0QX%V#U'<=W+LVZQOUN_QQ5MEOO,UI$
M)AGYE.!@[3.N("I#D9'PM3)*@CAYC+=K&T2',?!L55=!Z<TX=G*L8(KBYI@=
M Y:.[K;.D?]>\.B'L"PI:;W_S3(;<37\?K9&P(^TN!^09:V>M<$3"K6HNUJZ
M>,V3A_7P&AJ\D-^ND)PHU;K]A=+-K,&R^I?B]#0T;HK[-@;HU ^AG\6V@JS7
M'JAZ&XA-BX*-+4F7NEIKB[VY,5MD.&J=?Q]Y^.^7(B.GVVF<6MH^5@;/0UUI
MW%3@<=^''BA?*9['S4=#*;X8VBIX5/F]>*01HY#NH,8?7$M)B9)(?R$HAA&J
M'+,:L<M1<<)*0Y\KD33$U+Q)<VNS5F3FJA#?8T,ZO 5F9!@C%2E*) ]MKAM.
MM4DN^QQ )?Z.%NP0&;;\)HC^+2W1:T;Y.6+,X<--T'(%5D5#=L[B@B: SR9R
M-&GRY(CG0O_BU+S[N1!5^31 DOQ)D*P-K,,L&E'.@>KI3I-:9X*_1M(A:[.3
M3I1FXUGH);$38>(^O(5&!=,';YKH=65G6*B=MJ3OI-QH$Q6-?!KYT6S:7&:C
MD/6"W3%5C0E=#^\ZNGF1&L4SS-F5 S:C%'&#S9CG2G..R!ZBI':N"FLY2)>N
MR5F0H;;RQ[?@;F&OR+MH%*^;4*6.8;!4XDQ-^4GVBIV/G2HJB>T';"SUF%1S
M 6#1.#^#B&T/ >VY-CKM>N*4?^BSAI&9BI)QWA1;RF-I<=18VZ-J3>((MY2N
MN.H1N+DKRH[*=&;/X7KU"+Q93YUKADUB,/5_!O8#-14(' +)6LFE1.RYHP#<
M7@ORI_Q^+Z=H?CPG'-?UT1*EKEY3M (H&.O>TV.GH26,H A\S;4#B%%3+/$S
MXEW!DFKCRH'-;N-]9,9 _B2J\%/OCE6/+&.A'SFNX\B<T:ZJPD2-JBG'*T R
M@12ERJ>OGB+-]@1FK]\8-L#>L28/VU^KT1QOUG@X?>MA+N-AIZEQ28T=K8,P
M4M)-I8?,+LI]N&_?YAJP_[@VUO,9'B#]Z(QCYOL*=?BM)#6=\K6O*%D*^GFW
M(HZU*"%=AS>!S@@ NS*:)ATU&1PR6)*XWNAY>'N%M&+&%)/3\H4/LY$"6*U'
M=IO3@MY3''VT[*/I]5W-/_K9[XS(1S3S^[)!#$TBQ1D)UM1)967@5T&9\:8(
M&*.)"[Y:K $C;E-%'7GBB+,0I1838="PM935:U[T/WJ1D2,HSI>(=&GO6'R)
MZ&B2+J^"C+K73AE?RG\^XGY-,3&5T2,F$&T;MFN)5G%H5O=YMF1FC%RI<GYA
M59!J,#9& 1FM#*P/%T\SIXSCCP?&DV9$H$AWIQL>%(>(CTY<$^L:&6KSROX^
MSLYGKS+2!P;/=+NG!CXMFWHNFWZH$KCGJ'JJZ?MNU;'IV5*X#^M__T\MT^/!
M#TFY*K@:68XRX F(GTD%EHOR3CJ@%S96T:^T*T(E3WU),0(-%XJWC8!= *-A
MI[ %6^Y4,567<GL"KG;1@-^B#+5D&T+]TMZ1*<@^'P7T@+%>Y*S4SHP!.#W"
MU$1.?MG3M>!0 D1SZ&[^&A6R&@>C*_I4"EA.,R+9I'J-3]4J?/ML6[^9G2KK
M04?&G,;)E W\236!!:PP9HH*7COZ)'7^%EGT_/8HOY@\\X)@YJXNWT7O6[C5
M4&U(DF=,?Z/#AV9N\$0'L)'"QG]!.#['DM!T- >;?CX(=0JZ^)I0V<QO6,Q-
M9MS(^R\*-4PSFZSMC][Y.(9CI&B=.31MQMU4/3-%X^'<3 .7N;8&%=LAWVPN
MVE4FW6/<2UCGE*J>D5H1OG_6D^.%1Z0N_GN'-.;*K_^$<E-\W[\X&V6L(20^
MJH?+.C5JWI>A*0%*H"9'2Y(XK#6]+]7R5JQ .$XD=(T3.S&(1Z6#18%@:=SC
MNTKY6#)Y]%02IK">2O2H$%=&%D"2>O\"4G*) \O]RGM.QFX@U)08D,_,C??<
MBK(5D,MPQ+1&+B$XX] N[+F4+WFA"ZK:YQD'K[/H$]JS0!/#K/DL(RNB]X4N
MOO_:1*D?U+D5$?J2WF_*J4);?:FN>/.C4B#X-MJ;^>LARXH.(U]11Z1J97K-
M2-5B25.DNG2[XFC!-!OA<YR+2\?\XJ@D^&,>G*;O 3'NA7MXBJNDX"O&/ZD$
M6IMKTBJ;2A)V?YWEL0ND)2&R4EW6MC,AB\C%!$ZH<"<@G(DERN>_ER4LB_'Q
M=P-QTDEJ/3YD<<=U-5=@'NAUDAD%_<I<7?GM]^7%3>4?:M(6;H>N2PU)+:TS
MZ(U[R98;8_U4_8QX23QI8!%^L(5%@.;R2OJ80O_1Y</=KS=WZ7J"8C/!,V&8
MO\:L;:*[^SD*N?H^E;.,*BNA10[-<7+D$=J,<2:FX7Y@XOACR,M7$$@VYZ)2
M@2?+R<!=JTT)&+JO4/^4G=P=T!P+5'MF7_2_F O]D 4[KNC:,@>98Y (N9I@
MI<S2E$L73J+58N71-NUC$T973IWO48QDT#<91DQSX3ZXI.:I%D(Q>7BG?*XM
M\6C^Q5[0$=*W'0D'LPS@8.I:MGT^_JB;%#H&VI[2A8<[<S9K[+KG%/^04$X%
M#?4?V:*1:&D[=Y!)+#-F<Y@9X3I>OK5MXJ(AVE^43E)VT8PZ99BZQ.W8,!YG
MWMX_@]+MFR[&BW"5I]BN.#RJ--G7%*X5'&QV'.J.E\T#ARW/<J?3W128XN+7
MV6$E4*?(C6E?L_AL3<Q4YJ;PR"KLQ.@7$_+C6XC[&UJAL\C#FB'$>S*)"P8H
M]<Q6O,J(,KM_YX<WM]\M_)&%G,/;+^< /S9ZCT-]RVZDJ1JC(MQ.27)/8-N.
MR0:-WD1BK+5HVH<B<*K%%TDS*!Y"A391DOXOA\*.<HH%O^"A):L@<&A-)/'T
M9/;'BC18),C',25S(7UNXP6W,<+>9:'B' ^=A^9?WO5U66T?N[6D+EEX+JU]
MJGE5(F5MN. </]?[DUL,75'OXH2$A5[>;"G2UHK;JAE%0WJ&GJH%F34X,MR<
M)L=!%@^29W;<M4+%2IK>"P(RLT,5A -YWS_4(JB+TK8&*63DP#X*I]7.E#Y;
M8MD,\KFOP!J\FD1H]+U;6G6J.RP893=E\_AV4-%KP8@]G_UVK0)5UB;&+#F"
MI_:07P7--U_Y?@Y4H4Y4',%#0OVLQEQ_/CN.BFP^&"7;&HPWY*,&"#9Y<M-0
M*38*+<01WE4YZ<W7# WN>%8XC(ZN9K4G4SJW-DX%\4,M,B6GY0A?O/^+4LCK
MQH8V2\^$+#5Y3E:8V$C!!21E?3[7_8[!=#*[MW"?#,Y?=H(;+Q)IF@7N8 _S
M\J@S&N*-GSP<)@X?S<M]8] AX-US2&U9'8+0JKP-/3>.H1/G$L0;3CD1L%6,
M)/\]Z'<(_U>3-9NO-PZYBS2875('#TYM,I5=JDD;BTYM5I7'WB^S_-S$P(D.
M)48V]RDFCG>9XU+DQ\>2OYKYND^MR&3CQ&$J1G ]H'7J*M7N=).ZDM)?82NB
MY<3NN8#TQ_1$.>_T+=]A)/<YL88#$OH1EY>'#2\!3W3A.@A:">^B=#T?WY3#
MU0?WC)*P08S$L2';Q"XPEH;(->4F_]-H)B<N-0]TDO'*9#>#R]:H1,3:47FO
M#4N=J,L5+LQ^3$+<//.]F,<%IN-_Z']Y??_C+THEY3O<;CP38O*[ SVH3IU]
M$+H*U]1O+2DI\)"O*PL/\A,Z:]AP:WA![9X0(7-= Z\F%>1,(G_ 3+/ZJC-S
MUBRTR>YS/QD#P#EG]?MB>.*^Z/?PMGO4W\&J9PICGIO2OO43H):=>R/S^L(8
MK!57X_%(#4!>%/SH5ORQGJS 8K!<>0ZE-X\?_!4K0D0P31=SRM%0BLV8ES$X
M/DZZ]WH_[,$FA#OFGQX/,JNPZJ#8]-$E^_6L#P1A42<VZ@M!K;"^#)T:>4CC
M34ENL6)EA3OH$^5!N A8/D?Z9T\6!8THCHK\2(6^1,1#8J-VHXD+0/P!+?I@
MRKM?H;\G$"8KWA7R!,<'.6[.F8A\B=;L*Y0_W50I;=GS[XRW]B-+DP$MD;CK
MK5TQ;VWJ?X/KD@HDDB7BQ:X[\[@4U/I?(6;KNAHS6-A+)%[Z88T2Q.?T5'TC
M:X!\L%H@*V\FH &ZAWYM3N+J;J"7<*:*']J#-#W,R%&.;IS"Q?4]+-RKA& ?
MXM:[0X^A%LY4[-#/LAJ)U3\/1FZT><.!2F,S(..&O<*YW]=<.K.5RL#:+@VQ
M[6Q&KU9\9SC(:;7I+$?/C!#;FUC;U?<SPL^=2DBJOMNM.:G(SHQ'X=]35 W\
M8IMYAX!?:!Y^-T$Z\A*T0G[29U,_5D45F G7TM)2(6EHK'0;7N&YF#=^C!.:
M:=,_46&^X/DKE-V!&;7Q4NRHT:CX^ '$FCUE8APY9710=Q;@5"A(;#R5%RZH
MQF.6K^5!7%WAI#PSES85(;I=;T])30FE]61?/%9U:KDG!.&>D=-:4S^W/_IB
M1^O"H[F[",N5"[DQCR:'9O](ZVJW3'L<.XL;9/-.?X1!] TT3D_2I]Z<KP^M
MQR2$O?<XQ[.Y(^[OPA\H-\BL'0_H<8.ZZ<C194[OZ?"840Q5V6AV.U0$MJ<F
M"?JF('_Z'O3'K1L0[[2H&ODH"BE2 '959J/Q*%B&2[14[U$-6?-2W; DF"4F
MG:&JCYVF1,=/ 2NL+%P%-O;$Z[=W0E&Q2BU70M^S)]'Y'3*R5%T[@0WOC2UU
MMA<1XTOZ^8\R1 Z\",I)D/J*LR,ML<&<L5E=7*_/%WT;_]XD-,XT+<9;R0T%
M3GM[LK\HNG]1-E]ZW@""3E+L?;M>RBJ]FC=;YN].X.2_FM\4GHI8@(Z[FN+\
MX90(6SXN94J?8>%BA^&M9$[<D-6\!;%YK)T&*>\4)M[@4/"H(\I*)8SN5[[D
M</5F9MYBB "R=&*U3W5RTV=B],]P<S7KF@P8<QL^"1JGUD$?4I1.W;$?*.'O
M5)XP:)HI;CW;J-(5> X9J,'C]JP^ E$Z8C1C<>HO9[,QUS&TZ7AV.H/9E!7;
MN#R,4^W01$1YZ()$\01;O*EM[9M2W*535.R)]BHV$E-G*IJ<5BPWQ$I92_=Y
MB0D<( F]XOQP!W,68W;V/_Z3E^?[-??_;)E6[P28XKLX?D0,GEM3AT#0^-9;
M/-;'@X^;7'A?C;P"RI"]OV:LHP"H3WY9!HGRY LOAHEY)(42F7[;72'T:W:-
MESYQK3&+;1&64P1*IM6)T&:X:MRYKZCCJ*#9[D^^C+016MW7Q7>UX-.N<5D'
M@<?F2)S+5@3, CS6U5X6Q_V244W/I0WKV,>FWV;9E?^]Q6*4[;&$BFOTCM+,
MMF9,LQ"J5'O=O"Y)++&S,7PWGB2JZ4+6)(0E>OX.9$;,>4L%&X5,H ^R> &]
M2@TJ6=<WJ[9_X^&E6> WH\P*=4.^"2WP-[RII]&M] !,:!._R_WF:Z88WQ T
MVGYT@0GA$D2S'@6Q=0G=O(R.(>,[0472>O!),\S?)]KXY+BYZ&%^\'M+\*8:
M5FW.5/CE7;?-X7RVF3].7ZX)OBMP3RCIX\+"6(!Y7__' 6U0(%+3=TVD#.H:
M:"5K(#EW_C[@($M@82O' 5B=Z0ZI8%B+.)0T$7<YUGEK;Z,2S"P]BJ#@9?A5
M^QM *AS@;K.#GH+.F$TV)*"P)D(A4D4.4N6V;2%79UC&X]IU-#7%9JTB!1F3
M?3_K>_*$EM6]V]X76P:[ZQ8>2^QT>AZS3A@.7)>*2L!W&O*.X,//<R".C>0R
M&ZD$5D(3ARVG*\JE[:X )]U946RVZQ-W8VII&N43"QIQ%@>_?0! @O ]Z&@J
MT*(Z->1CWT%NN0C$#KX<@XPV&7;DCB1'W=-^V0HG;+ <8ZZ@'< $7=C@,8)[
MH.,-T4H9O>KR\AK[@X;&N>U*2=BSWR]G$>/.'<[&J\(.HR*4'_,),:48X(T+
ME'LJYI _Q&I.%>0$9IFMY6HBQB%6GI*" ZT>5N4L8:)LVQY@M1;DCV=_.V;U
M]'YZFM# &SWOW#_BNNG-3D$Y%EGNGM,M EGB9EU1+ Y(CP65\CHF!QX!##K:
MX:17.AO&HP-VV6(DVD0%"Q!UI,,+!;,R/F%^/DW2C-W&JZ>KZT-5.0Q?\5&!
M]"J!NU&Y#(JQ)X'TOR@=_QRB^7?F7X216DOY&TQ1X;<0]$TN.+BL;A-,I9#_
M> 3<D+5#BN3W>+3GS225=&NP5'7-])P4.HM?D^-ZFPV<NFV;2LDPQ0'G\(0"
M1H@;=;FI$NK96?NB]A0F<]V&:\C'Z:"]I&0L0_&"GA.7"QX4 G9N;70[2;7G
MN07%4 E@J!V1H\9I'H&D9C'P8@-3\:UXQ6%&44^8J*GIW0\;:ZX)/1QG'L -
MCWBE3>MX6_1L3JH"6\Z8Z(*H+4ANKGZRRK]35I;A.8J@R[S2V&B@QDP^_Z(M
M#2]).9K+>)*P-)])VMY4%0\"SEF/6,EGD59B9TLF#EUBB)M2P%"?P7Q!Q:_I
MY&&1I3XK8FHUO\6WH97OWR'9D0GG98C'=W$;B%8K3C9@= 4RRSMZNF%AF;X@
MJP]E>G9&S_WP"GX3\.C\4N>#A8IF$QYP>'G "$@6,7H$H1PSD Z3AX^&A64C
M]_B$)#0CT'@Z]O<K,LC+<1DI:W\RL"D9+30 IBM(F&>YQ69*^,<'XZO'*7XK
M^$D9NI+E$,<=L_6^Y>3O'%K@E,">?9UNN%L<S]@>OI:3$]ZYD!OW_G3+P"]*
M@]1ARI(14F5_Z*^\,!&SS\2MEURVN_5SR)F8+NS<KI<PN]))5WF'6=6^/1"*
MKP'[S-X[BMA_\2/N>\+&+G);*']E=VOU1"1,84E%DHP8'VTS4/AC1:BEK%[C
M4=JKJ074A::7X(+;(EZ<>7&'U(P!)L+4/&ZT"%7+IS^R:!2\4C1'N10=XL-V
MC*9*<YA$/1SGUM++3_=>5EVK6AYEDQ("C!EJ4WV&W%!AA^0H04Z'DL5J# !E
MF-;UV 7\2PC2  :;2<PHNGR$?Z$UT*(9<V@2(KH)QP6.G%<W^@>;2IG[^BDA
M6C2L'XB_1:S3$"VPZ1<"63BPP8OD4VFX#&6>Z$*TS.S+Q(UK^T]I0M&KS),Y
MBD*0>1U9VX,$.1'E*[B[VC7HI.A;1L%TY,@U@-1.Q5]!ATVWM-$*[R.ND2K;
M@JV%[K[Q.0;\DU RWE*VS1JU0?7'RR8%B1LZNF*\QZ+K=J/2?_H&_PUG9O@
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M=>P\TI2V&MO4*LMD<J9V#/Y>]A*>=2O83PIK*M'!--V*HPBAG.:ZZEMJ(ME
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M!K]3%;>6E($NR%RDY!X#88CUG'97&6*"CA(62A_/]U%B9MAOD'JBSW5W._1
M;\[$.%-7NX+LM]UP(F8!U 4%-#VT*23^'&DOMH1'2,K7^6)#GR=Q%+OS%5Z4
M"BI@">N0$0//!IIJQ,%2^( X:/P59F3V0'#IMI*?1EZ' ,S..BE,CY%VTAJ8
M%/H)V/@STW23,$9I.:85]ZQP4@FQ@(\IQ96=GGA1RNNV6/X0V$W2I&0 HG7?
ML#*0].O*JNYVG<&))9!3'FFJ+PRN@U:0)U0B=YJ57(-,IT D/J)9\D8JS+0J
MPC3'2-"A N.$8" 0C$Z0-KD64 TJX&*Z)W(9/>MR_]WR@8%%J7V(0NH7PD_B
MJ>607S<K]1?L4\_GMSWUCZO-RDLDY"=G$[LO"9IL_?4Y-<HB:QVM4+.4-64T
MC$D$26,SG+K],AH%'[W\NZ\HM7 6<=2\!L96A:I,3LP(4:\E7BY2O^M&+GE/
M<:L=75C!)"KS6MV=FO$3-:*,!ZN(*7E2(+<&/V!<:QC&Y! U,K^JE*))JQ%[
M^\!,=0.[K=:2J- >P8,5:@)UB ++[>VQ9.&=?O0^LM\<7 %Z<3!PK [.EF3'
M:R[30G"K R:5-!9LR"JL'A/(T!5YS>$QDCFH13IE[(C;8W4#<*(\"(MBIP82
M!.3=G7G8S/D\NSH+1?C%CU8:*^R1B$%YF2$;35)866VTQB.)(ED)]0[$YG4C
M.GZ4M!#X5@=DAMDL"5[<R.=DLP[+L%.TJRX$[IW;\8<4RI=T%CX@X=Y][R6N
MGF<\QD:P_T?79D\H_6[CRZNYH;_6&C3M8ZGA.S:\*<5,;TL4HJB.FE&RS-EF
MX^P:YJ:S+%Y7>I60^=G4K@"0H<(C^;.SL4Q549,195R,\R7]![DG@P$&_:8!
M!$J<9W94C*"73'1XCM^)\J:HKE'&;V=O<I\?B-3KS]O_S=JDWSC2]/CTQ!J9
M^L5NA/Q/(O&?P*%MX&/%KGWGF;,P7_C*'"3C^NAB=HI$*)4M#Y1AJ:YD)2>[
MTJ?'B=N$P;1I/,5 %7=+7RBV!GJ']U^K;:YOS1N.2(BCE3P]>IZDHU3-)OT_
M$R?_[UJUJN>=4XNRB]#\T\)SUYK00<2KRT%T1=&UP+@;P0#EJHYP3M%CM/$2
M:&!,C*O('L8.-"'1"F7&HU/?.68WFZ652!&LAA[R#-GM6X<?2Y,N+6H3+RHO
M+AHM_J]*.IKO6I4[VNU:U8V@.FOX[Z-S5&14(,6>8BSIU=G__VJYKS$6;"6G
M+ZW%!F/9WJEJ)6$3#X4LBF?Z[#<N#BV^=1=3LC^O M)K)DE;-A$2<^HGN FJ
M>E?6EW>K-S*4V!46VE\N#GGXCX8Z4W.V_%/-^#_PX>_Z?P%02P,$%     @
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M3'3UIK+ASK:)CCZ4W<VD%,H[SV%]6YV<L0F;O>0F("G"F+*7#FQXTI\C1JF
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M@L+20'I8G8"]T!JA_HWJ1-YX5W-SLI0SG[G=9V?QK<\[!S]N_DD0_^_1LEH
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M*..U'_.,Y^<GF&_4QUAE2E'H_A34YO7T=7H[:XPND1MAL> X\"R79%;9#]+
M\)T@7U2ACHMAT.Z9U36U_FN=8*3P?"NQ^B^1BH*K5(I:L!]V)<.O"!4$]AR^
MU*9HHA#X"YV<EQ?*5$TPA(VF7DJ2ACVCC25!<*'PY]XS6H.=$*8BIKJ]>>+@
M%.$XALB4:._9)7A%I3\&99<BD?*8]'D)\=+7<79XOI#Q$^L]#,ILA*53/UX8
M)T ?&#A(TA<G+C9-\+3.Z:-8F7#\\_FY/H)5AH&8ZR&W:5#\:4%A6*&H6MPZ
M<N(P??B%3,6GKX-F7^EV1\>)"LXY&4MUD@(L3(0[S?P0>DI@]'^3A]&XP_76
M4?NY26 W";6?%@>7>'G2$/JSRHZ/SJ(%@>PVEXIU\3[:9P/?>Y[9O\SY0N'G
M-B>L>4,]ZN">+F] $)Y$)QSV7)Q6I,2/PDMS%%>WYJH!FB3Q!M59A7C([Q5!
M)L\Q-XE%_*#9VEO/A:1]9=_UDNVI1T/G @@3W^+*G^M]U'OG^OI&2SDOZT\H
M0P<)B?/J+*V#'&98I>TP&YO9$'U?2CJBD B[B1..,8X$8YM0PJGIV#\:=UAT
M@FVM>WA<H(I.1=[H\FIR= \^+>63#Q;?MBGHF)P$4S+&D14I'LY*(A&;2 MB
MIOM.LSP/<LHMKZ35;5E%>A)33](UR2I2V;UCZ%A8&(&B]>Q]B%7(A$:\PT)P
MU2B^=0XX-HE-],J?>>&/DYRC*E\Y,N\G$[W_UF%-@T_'U+? O,8M8*--\)>)
M2RZ*6%--BO._G-_^,>^NE,_+P>XA-3Q9B%;):5C&-"N=Z=N@@VNMH,I2V^IY
MI@9[_W>U$P^542BD_7U* P.S93?Y6PMH:EQ8&5UP5T.'@8QZ JYRK,%! "&V
MM[68?X5X60-DF*;QKGP%!EG\L@,&HL+LR+3&9^IF'QH>'L--[Q@<]A =4+_8
MQS"8J&EP_XJ6+&>6@L :FU;NTK<QH:'F8(32^RA>^ S<5/+TX4?^98X%<+[L
M_:R%M >#->G*K$N_KCJE3:VSL0+0OS\K=%HT'6))/;9XH<D^)R.1D3BM/]?M
MX!B;U=;-,'&>!<IA! GP;^ES;R5[GL4NJ#BL2O ING*(B<'<?7DS$K,WIQK/
M\A&37>>=KH1U*?43^<F:E65&=(1*[)Y<-K</^CD/UV]8.N=N,DGK^-E<IAP+
MR(_.7<[8IS:O7FH*VH\3P8+..\G<:C+J3\A/2I[QJ3P7_-:(A;SY?;N%.GCQ
M#.7Y0NR[!! "0K!_J9A!L!";Y1F:#8+!&^:RCTB&M\#I)WDOG3KCG>NPO(8&
MQ14FW>><UQ86/T58(/4/'%]HT\5T6*3NS&5*[AD.56!#?KXEY\=07DNX@Y.X
M'$*96VY]7T@<BX5M;>!7K3<-^I]S @6]'\FM8.9AVTEW$7_)T+L 8Y/$D!.=
M44T5;?$QD6-#HA^AX1T84:Q-AD+S:DE?L@X,(-8I+R<C? "<N?7'P3\R>L+E
M-N.X!B"C'\B9J/= 06!;_(5CBVA;+)%0XBY,*2O7P6;D33=NB5*#X3C,+P\=
M RZ7H)0/QZCDCQ0U:B[M<]VYS*T91LX8,F#A/<+DVE/OORGT$RO5;!&LI2#Z
M$*'5L_ONB4CI)^A7SW]V3GLQ# IX?"3PI9"%/#8JF]PD/5>TV2Y61,EKD77L
M6\TX[LT(CZHRUGYZ"/$07)>,&19!JWJ:H5%*&5U>>3"8L8B1>?T]K8SW.[:0
MMDYM,$/*9^D&\]G&" /=O65-39([Y8\\@+W,(KXN%J?J<!9-& &H^H*MX67<
M:5'?44%UZH.%WBFZLNM 905HR@P^L[_0]14B9^JRR9O[0)Y_EO#=,8ZUQCS3
M10\VQ_-"3AO1DWKZ<:D!&VP+F:/\"=R6+"K/O>,W_H/%:/Q:S-_#P]]QG.A-
MG[B0Q?&E#J>4X:.O](S[X6GXW[Z=B82).+6FALVEX/*FA+6CQUPOFQ=1DVXZ
M?)3XZD_SF=N&T02$W?&Z;B7M%>SXVG&TWIW?=&3:V-J"[S!%FKRHISS%W)9W
M?)^_,/#UB:OGGMLGV)3IH?)'TR:DV3E3;&E,Y97YRWAM7N*3"#9U%MFU)?>B
MV,2EM!-^<K^S<F8[LGY0T(*BXBW HUPN&.WL31N=[VDE_<G U-_?E^A<C/M9
M?XNQ.,K6O@S4W=2.IT%_TNLF>5M*7K5@/!)*IO=8;.>0F[>CLBEX"-^%8,2L
MR94,#9(7*)AZ;.2G;& 0+4AI9AY&;8)P"TR7S_MG3)U:I.J]LGZ"I(ZR4!,(
MM[7)@KF-)Y(64\<L(29I6%]<$K=N.WQ=YCD:S6I_?Q+;-?5/1YWLAKA2X:J@
M[EB5Y\<;<S[NU%UAJ0)KSN*QW2R(V&/,K^&+<29(J@'HI\+3J72N>\=JQJBO
MCLYXO]A41X1"UI>Y@S_Q&;!V?WI4\WHL0GLRI0^C5_Z*O+;8@0+Z%<Q+#9>A
M;)OH_HH:YD,KET X(ROZN6%*O1 =632LF@?WCT5Y$,U!K,[$MXK:Y&'<93_P
M$ A$4R;IPZJ,0C]=_RB0SE]0RQD.'>M58H,-PTSK$9DYNCLPR;]O5M^J<]',
M.>B@9WVN0UC*8XVH$D,>.V$N<+*C]>#1SX6.68,D5BOO@Y%P\ZC5JV'&/FJQ
MSFZ8;UBL&0V&BSF2UZ.EFOY'ZS$X&<A#^*D#WY-2\F:D:3\=86;S<_:B-=;U
M[NPB\^^H+8DV%<!67Y&%OACG4A0'].>C/^+C961]=S/"3LN:)S>::EQ<RO^R
M;F;;&-6%P9ZZN^_6.!W!RL.TGV5@V=S S4GV'ODU7MKI\->0YPY^Q0M+?<]M
M^'=+^$JBQ1_8;/=8@>7H6%^@&\9/9%R4X7[1(A/O=IF8T*X0K#"*?II.CZ7&
MF -N'?ESG=GUH1=JLY)[T@5VX$S/MK]=>A!8.1))V5='B?0[W\IQ%LC*W<(J
M^]KFO<A.X??U4//B;2X#X\4<5GEY&32+H8 OCHF2^J-6H_O7=X[VTGKX%<'E
MY:2KZ'-S7FW,5\/% ]NZA)%8KIRZB4UE]H2M?*XJ?3(5S:::J;]F+AN;VI%Y
M24:/_E7S&6T'O0]!&XU:TBP0!801U0>'N:6*?-7,(7%8^8Y=[\U[3$!*S=OT
M$H$/](,YVC*4U9!<QAG&4N'>$Z/'!OIJ='DBLCZ-C)7=/VJP%(X?<<=_FT*-
M, CH*4Q!:,EM8RU%()N##5UND);ZK2U#S_)Q.6^+)#Z)2'9?G7(;OA:R2>(V
M+S04MO&-)&Z8!4(Q\<GU#2SD6P *FNS+'OHGI"]7W/%>95&Y7$Y.1KQN,#Z]
M)/]>020JDWLLW 5VRX9(2V\7(KW72W\0H=*R)%^G]=LQ<-?XH<AP>,>GMOA_
MIQ"3]L%UC]@Y_BTPJQ7Z%^] W5R:@. 33H3"][-TWZ3:XT$/-\;DX4BQGO<<
M@90I\W*T&6F3_K;([L8$Q@9M^*[M#JX[I/)/V.'X0=-48Q&AD6 6MPXU&71!
M,SE$U>U'2_ZSSX( ^G#%HF6^ 5R 0MIGT, )8ZMW/7?[":4](8ZQ0H1+G1TS
M;LCZSC'$5\VY<D!MJM'TJW> OS-#?=(H6W:]%!A[[$/",D9#:]N0LK^(=]RT
M0NW82^.7+]M%,J);/+T )XM6*6I< ==<RO4[$]<-S@M&I@W&H/<D'4H_BT:W
MT5]879.<X[&!>?&,I^2;-UWEDJ\>^2$,,>^(DM2-N>\TD/K%NSFX431@8>NN
MLN:'2Z;%<&Z-A"S>]67YYX[(/^S<:DW-/:.IBY(A-B1=PR.;%N$V>BGCBJ!+
MAHF2ZCFK*E+4"3PAR76"L8L4BV<A=C$/N"E.N>J'_1R].$MSEBF\!?1+329B
M!" >)OXRQL^9<W8[)H?<C*+QI"^HO CB#5JH#5EE1M\.FFI&WAM20X$X^^-8
M WZJ)VM&EBPI(VV";[O%7Z=N58M3>):/VF:0565T;9&R"3X(\],ATY,3VP%5
M"%LV/%+$6R)X-7O$[^ (E:\D8BYM$G,/B>T^+7$B$6^#T&G/ZA 8ADOII;3Q
M+Y!1$DVMC<+F# I\*/ X$\BOH6V UBU :7-L8-O+D+!CQ^STUKXU,DZ!_55>
M9E=#/_%U_P_L;&?#%S+J+"WC!_13PDSEO-<9]AQ)LD$1Z%GH(9 T$W]FBX8
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MHE/-5$P-KG7H"Q;([&KH/T0Z3TYA6L/-J[M((^,'XHFCR>##*40/!6*G/=R
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M'D=^*YE6RC'8J[Z8?@!QEM$'2EZ*DB&Q!/<OL=P"T\4:[:/,.'3EQC/F!(V
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M\=@R7(05H\SM?J\UI_)YXR9.<C[MX.,^E@'W52:KY.2CN<#&6-S?XFXA-JZ
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M]K_/"O^90 B/0F(X7L&*[6Q<_*QX)S^^&*,-4Y4^*!=A'K?6+P(1XHGB<\[
M=4G[>6T4ZO\FIPOI.SJ*!95,T2S*N[4@AHG415+"[#,7[F=O"_=#:-:BA=$I
M/Y*6S_J/;;U1Y0RQ)S!P-E%&H<T2S?G]8:Y_GY;^F12,*FLRU<)LV'(?KZZP
MQ-9OC'AM_38"])H)&-HSG*@*XDVRNA7UX3);/"9-S6B1Z7B-*#Q-"_1:/%%-
M/GQX\?.-Z,+ZT\+NK&U<F>8<W;:'XC[XN)VU0=/EWNN_J>4@)4F/X.BGE&.
M,GS)OSG8T2^U8=$CJU(SPTGQ<8E#<+@^_O=9YO]WBIGXC4:@+H$\:'BJUL&#
M"?Y!?>1J &X&#".T9C8S_4QS?I3]6P.):*M7J4*.+:2HUYS%R:@5'2\RX^/A
M>//OOG6)OGNY79!B7!-_'5ZU):X1NJ#E$F9!99I5+$?"(L=)@V1IJF[IQ$OP
M]&+/(<?4LS>0<=:;B_C\AA?X,FJ@CK8O7#:Z@0%J^?-?H[V0_K-0*+!Z-[A]
M6T\VJ_LE-YE?K4Y1R9GU\]&$5[^0\:E0@;Z2B?KGEPW1L#BP2"J6]:":'XA*
M;-/FU1SH?'C5[M'O?THWOR$7V[3#W'I17V_#]]W7;;9,3:9:8H]$YG_"2^F$
MVNZ(G[1.7?B*JZYYM'ZE%(&-GF[8_C[^_RKS\S]:#XVQ#",86E!:))VM?KGV
M-!# _=!* =(OGIB<<6]*T>0T"CQ9ZK*&"X!Y"*RIG<T%=Z,",=$2<YLL6O;E
MY:.OQHL,&SN\V UCL(H&M8('H2]Z)6K,L2;B?[)H#(EJM^:"(D>0I-;2JO;0
M7%CGB&S#,9U%0/F6O8B5Y((XE].R>0%8\O@.\9[\FS)%69C/P9N.)^\8GGXW
MI=OF'+DA&*Y*-,LS"0FYSW'/PAO! P/R=SX>3\U5E+R/>6WPV3<>M>@D:3CM
MVGTVIU3A\F)W(VFBQT%+Y:*%J1'2=;K0=N3O1XQ#=JJQ487$IUF8VM^W+>&3
MB;B5D!TZ%4,#1>MYG\KE):S+45PPK MLNP;H[U N<B>YU%-R^&I[9A?2Z@N/
M=N'$QT*^!7)8_R6QG'E"/^J$L\SEN2$-(S5SCSAP6K)%UN/\=L ?&'Q>.[I?
MV/8"I\"WSK@OD$$AW7(+)W3U!Y77^6O*ZZM3X3$EPDH>)":&5-WP7NF$&)61
MJ7F^'$2M(6?.L;(]Y(P3N+Y^IQ+%"/*6EV_S8DB.X$0N)VWL]Q\:C3W=;JDO
M;X7WH27 /PPWLU[:_]"&#]<UJK[P[,."'"FNE@&0"OXC,BO>@Z9^_8GMP0-G
M^]G@F++'B2&,?@A> (&A',GFV'C;4@+7%J^_.JTTHV'?;T)CGM"CMNY"]64#
MQ<[3J04S .X6F,Y"UK0E(MS#/Y]^0$8B^9!Z92HW=<P<J=V%MEP">3"QAYBJ
MD*"HC_M K?&Z(%"@5OM^CTU=Z_W_:.\ZHYK:MO4.H4E3/$%:* I2!:F:J! 0
M0R?T7I1>0DT$!$0B*&H,(,T"B &D"80N("@U@/0F*+WW(J <!82+^.X[[YQQ
MAGK;>W>\<7^L,?)CKZQOSKG6W+/MN:;H,5Z##EF_F:Y&O)45S[7N66H=#AVZ
M<2^C/9?%*A9PU/'?$^1(8;1.>;&^> HFQ1> M\%6/M$5N(G;A4VXH58CZ]DU
M;P3+S6TT'3ENR ;&B30H*4""\M\E2<0/1(B&Y"7"YLCGAWEN,-QYNGW3=;E=
M,.>HZP<BD_)RO8:?!94M1R+;&[-%@=OR 3/Y) _=HJT3M1Z#[BHEQ8#^OAO"
M>Y,D8-*=9>"=3U3A;%D>"?0B;.Y9^X%2._U2>1=?'^*79,X'\U52W]$W/S*%
M*#KNE1BL%/UI,\#H;=5X/"$Q!M2BC<VJ(0B4E]&-AE+;KH/[".L&K[IA-VIG
MU*8.@;0:*,&1#3UQB_QW++B:I,/'RP+56TS;*&9L&0@[12#UO^9B$E>+K@R>
M(81HY@BM>CFQE"TIL!>[OUL9#0LKBE:."+Y:(IIP>4Z'?  =>^>E)]K/1B>$
M'=R%$SJ^DR-2Y!;H"4GT5<6.K"Z[G*Y\8\.@];&QO2G(?PAQIFLMYM3Y]<2B
M</P@"]NR$)BF[4'36D7#VBY07CI!\M<75=]H/2+-;^L^G-);^%L,(;GH:)?]
M_:-'/<O8P>Q9S+,A.V;J0:/'<,*F7\J4XE7N2]2B(9BRC2RQH)SD5POQ%=Q/
MRP3?RQ:Z450?NG-M-O,Y>$ &U%;KERUU*W3Z/4Z"KG%$/;O02HGS9I139P&4
MFA?ZL;V/)]7[ND22PJA>A3!O_SSMKQ 06=>29?@6)/TR3;.'IF=031Y)++4X
MID%D=..##(A%PV/GI8O(_9$O_MWALWIO7R(AQKHM?Z;5_M'!\IONM/[-0S-X
MV/DW5%<E<CK>1RJM+4\&]+"4I?'&&CNH*4CYC^>=XB_(#SY<P"+%W(/OCD)(
M:M[.?L8D@5+]0.1%@L%XJ/M<0RF1%A"_YJXP$:<2$?$^QUSL<$"SL'L7V@LJ
M*"6JF:SPLE'/CT<]R3/_#IN":8J>3Z&W=2+C6;HI;\NB;&4YX:&RQHRI6#Z+
MPHS-."4(XCZY<&"=Y#XY/7W^['.TV?BX7'D=[KT_!]GA1%UB&NXP:6X]6R_&
M;FC:&JF7:B12?;V:AK>#NB7NG+M)_93<6?QE_Q-VXC.N(>O,PQG5F8-9$U.8
M!@)^3NQBVW4H[@"/!%<8H$JK6S,ZP9X.F$Q&JUR+J5C#M@)'J]CJL3J#RUO2
MM_NPM@!'0AH*JVH,KW<"XZ.$C\$BV;5+R5+E\*3P*RT8HKU<&-8L,='5@5--
M$C$DF+%!W&_:= ;6;WI$EMT!QA)X.2!8X42(K%G]!?S:Z4C\LX1)ACZDAQ]C
M#_DHU7LI$P)(X7#_@%B%*!3=_0J.,"O(+[E&I4IDT(O& ^[]>F70+G#"]'T)
M#J31)3R*'CH:L*I B^U/]G:=I'N(_?#4PP68*#X^D-&"Z&\US&G%M/K<?;J0
M@*A\:=VQWVF^=V/)LXX)XBWKCQ$C'B+OY+?1Y#U[7B),B:%N0]&2>1^G5:A8
MCP"@#AVJ+0VA3D7[P=$9;Z=GHPYQ#_G"J<YYOX8 <!AP2=\<P+;"PA\1"1M$
M!OIM=B7?9[%!!EI1Z7MOGK\J:[<Q]-T;=_SSR8 &VEKN70OZQG)#JEN_LY=Y
M[A#3GGV/Z,I%TM7A[]1D5%$\I2=<TJ%0#KG9".[9(,[( 61A,PG_A Z [3 &
MR+![>+3=)4!0*;S8:(RM;NS5+(T,2$K]0*O=0H&]C0*,/RX%[;\1!9OJC#BW
M4^3"BKX\JW,(XDND^YHQ=%9,:1:F+#7@A4[$]>47:T@T$5 HC/-S:=&W2NN@
MZQ%-.>+T7OTX0>H'\%GAE#D4!*B8]$V+,49(!<O5N]1YLG>9@FO9PGP/+4.>
MV'.I903H4&NUW:0L<S*IGYSA0MH,FVC;5:E7"L_6)I%>9;HTYJ9IFC@Z-6[
MB4RHK\HP-=@6@IN9$HS4U57@P)S?!9Q_09:D^W<8':?2RW.(.AC_"25M#/&4
M\!0"C>R\8 H4EL(NH?@W=2A_65J[Z"L:$E=-BBC),4BL88?SE'M8]^(D9S-)
M8G8EB%-TB001#D#$_(J97Z\LE[8LBS8:X^:P3A$ZP28#ZB'2LW&'0*8NL2Y8
M9#\H.?S<S&&A VI4G)@"Q>>O3WOAG,#&<%>;U'IAYE.X@Q?-O+:=@-=\(63
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MI BEA[))%I@P/#! V=D*IH$4 3%ZTX0."KV(>KQ%!R6&HK&6"QT:0Q5;-7N
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M^MSI/Q/?8R1Y+X7$7FNK,H0$,$P1F]=->PR#0XZ.U[HLM0)"=F3H VL1KU_
M _NV;\2A,6@@S*)P?U/-L/F-Y*20+.NK7#N(F[];/F)]S7@VJY\5,FG^H%FK
M!1?MAJ,I9G4N K35DC%[;0"QC^#A2?0;:DG2$+G*6)[RPRFTS6C*+V<<D[@X
MWP,YLR;[M '83-/K&0!\A0#AU;?&0&COHY#H9,V;R)*KZ6_J9E+HO[H]B!T+
M7^@,67LT:?JU+4OLU_'BSG&>\I,H80%O)FP&(VTZ#JANN'N<UO(51L<'0]&D
MA67[5+"9^=(K&$=-UV?(#"=K7>=[UJ9L7&6:V'!L"  FK_6HM*$G^PRRTR!$
ME/8*(?5CA@/9G<7)!@B= P<:)-S*]U3740"Q6I[\L^:6R8/E8Z6((\:F^>*Z
M;6>9$1__TJ]C& :FBNY<W);$7\["#8,GMGYYD<W(KQXP\A"O[ 48Q;D%.G*5
M*C@,F /XF%>XP/$1F6SQS]*>[5-&A:R+]K7'4=Q$J:Z#K9*[7*P];5[12#8_
MV0AM89+G.,:)13\J6T/\^M"'*->GGG1B,80A&8(7E9L5.GAMA=4\;*I%Q:DB
MF0/;/XA4@_A[Q*R2:^RI.YNSSZOU0MQ:CSNL:10=2X)$NX*;'_ZZ$6BX?C'Y
M<F),P&Y22'U\ RVC%R9Q+M1%X>?:UO=!L;RS!]*@+O.$T*4Q%]0Z"/&1#N\0
M-H.J40E4"X]<\[5_DYC[]=,\><0"T0!M#N^P=J&;+;=9.WQ&:B1S35NVC7,H
MFH=O;&X,X\[&CJXYO8BX5N/R,OV2Y?GC*U2!UIE0:<-KLV-.K>[+A)_;JOAV
M(\+]DZ RSIMP^&;J&A_IX:<<ON?G%[7F$TAJL.'S<:=&7S5IH;FA^M_%[\8>
M[>/Y>E:02]_WXR_]-6\LM_"^]7.Z95.J:HD;I4DD_U<-.^ $SU_K0@GA :??
MTDA<2X<,1'[+UC10JY(]Z&:2.ENVS27LX+)V*=$@S.?$NE"WV:H7%C66X8MM
ML-C(S6PNJZE5AST)*]7;(U=%'P%5_C@Q'N0_Q!^9HP\NLS'%ZQ"&WNH0*"QQ
M;[4TR:6NV+?8O@#@Q^A3T0!\D8!&HQ[Q=)U 9?F7HO=M/DMI!N76=WVFQSY7
M<VH;=]W!:14%$-@AS;=WH(B:%_<4M#,T>++G)=;O=1($T&ZK0HV?]P89W08C
MH356MT<C'1_4B<R.HSWK8">RL_ONB[YAK=%J0H\)JD<Z-D43[X4-0.?>R] R
M1#J<FN(B&*ZQIC2G!8LZ9R0BN0HZ<7ZWCCZVIJW =Q7+V&H$$1KR4((+9::K
M#D @Y@EJKZD#5J\P&IJT)+<6XMG.ES=/8:4W3(K/R5TC\5& +7^41I8E$HEL
M/="R00'X-Y+YNQ&:C11QSC#)C@/!7N6M2H^5G)(@"7WW2G&B8 /"?!!VBH=W
MA?S6]Z+-EZ+WVJ\/Q!8' JEJ3XW!0]S9I;8[+)#<3]ITF52N:%O53O*PF-YG
M.Q'J"M-20^=A+7IQ$X^IU!7&?7!GX*Q![AJDQMW>GLT/3'K:R7='S4DS ]OT
M/$C1H%>W(WVF1!V:^2S[4_.V/OO/?JJ,M520K' ?(FJ:G @7P*IK&N\M)EE:
MXR"8-D=X/\:VH/RI0QLG5[B'FPAK:+D?<PZUJNV[S_JIGKQ#4?2R-R^7E*M5
MCW!VVN)K"W?=+E=L)MW.0;7OOPW^$(?+T'S\+P# _VU[,\/\;$?7E7-23HO<
MC-GE,O83G=R%U PTAPK.$,N""),^#VIO#H96)ZU!.87%GTA[&D@.?E\6RW(Y
M,+G57O_<&'[N.W]0H%K>4U5?$31*D<?ZA0U] ,ENG\/6!,<@;Y/3\+:E.^B(
MKK6O>Y>+;<>93O_649FN;K;-_L#+- &ZF5NF;VRJ4:TL)%$Z"9L24C<'HX#?
M&2@ DO-SQ&O.4RAMCV1IL5\D6CZ5ES$$,JA '^HS$U\0)*$!#6^N'8(.ST,X
M8H;9WC:DJFJ2)600_7"%7BY_W7"HD"*"4\0^082XMV48&W2[2+;]^IXJ'F,F
M);/7<OEX+LFE^[36M;X.,E6M-?M]6=S7?71^[54%GRN8?C/2 <1U>,B=WQPM
M'A/WQ;TB3R!3 4O##Q>HDR=]A?8_9-C!@FDQ$N9PPWX#M8@X0:XGR]V]!4SM
MW(18]\(IJ\<0VE)W]+"@M")PA2\0OK!W([UJGH_8,X7SG$=DWU8GG 9R.*4$
M2\>P2DIB>I*B;3# *OS<4("\QAL4\,4"!:PW!O:4P\=NR21?(R^344#\7.V$
M#+TL"L M'90^?7.F<;VI@117O&'/I44!$Z]GI(_2I1$'/K?_L[<*Q#PZ2_=(
MH+1M&VCPJJ 3.N!:3UI3<(QC3T)CI5H0J36JD>[^@B7U</9&L2S[^8'IHK"I
MS?%-=H[&CX/8C</K6_".<=C_3)[KF"-"7B;HQ*C9%U^_^"S88WZX_SK8RYUV
M.J,&8E9H.[5B,DIR_X'2M<(F7I8U>O)0'M[I&QQO!]AE ?@<WR(5G6HG5QVB
MTVLT!7EZ"&UJP5(U#&]*T2.[7:5Z9%U[!^\V$_H1IE,4.L;/EG@6#'[]2CB\
M-&O:\E*'E! J**H ; 71?]GZX-I-E5[Y0_2)Y7%"SMU%=T [H#?(U1CH2\<Q
M?(H"*!%)**!':-;97GI'-^/HW%TL]$-9]J.-)/BI[GJ0HL9H)W]_&\%F9XD\
M?7:%:LF*X8^&;CZ+<DLDQ:L 2\E^U^=0_],,T,CTPL+=;12%"MH^="BYD*@4
MHLE9'Z[#\_"%X%Y1((&](X)LTY$9QKF"R:DW-KK@<-GV@.7,<%YCX9 ;59>2
MH35C_KZK2:,G4:XQMX7.Y)P#JZ"5>/X<:>)7@3VU;9G/6X7%ODD]RM4RUCTH
M)V?23PM[U?6K'X0P[8XK6;2KMY]:W&U>:%RSKQ]'(_Z*]N;I&#K=]KVEKH0.
M)B\W,DA7E$"K=4J?RT :NRJO"(!_]J1-[!@%1(F1)Y8,0O6K!"II]#4B]S\.
M8;8Q$:>N/W)?U2W[<Z4I>6,'!31"3,[/Y]3J4X_/P0<'^<:3JDQF;WR29>AI
MROR>SI7"?[@5_.0D*4ICL-+[?8V;C0)VYP]']?P&T:GH.$H0U:O9K_L,#(QL
M88L#YZGY@1.:"VNO$Z^+N]&'CT9]W&MJD>0:P5W;-I,H /;X#MC"DE=KKZ@%
MNF[N&P!]$WY$9;8H@,CIE IT&I,9DYR29)GLT(J^^8DV>WW^G(XC"^$%V](?
M[]#U*C,1T'7N]F"6K4V2V0"MZ:DK;>6/F<VV'R'TI7#OE$"A*@KX&E;XIZ>A
M#Q<C-&L9:)F['0)&QS-S&[Q=;\,TTI&EX@U)4HZ?QNPN(KOU9I1P9=#QQOTY
M/OUI<MO[1UQG>"*.!T^4#S9EX,-4W]MR0JF!C&BVO'O_97M:LT=-X8E;P:<?
M#Y "NQR)[8C\U6&.\/=GB][,SR%]CXL6_+\'<YC*P]7#U@3-B^R:FBT#C@=0
M -^M;ED>@<\_RVH)%+#6=>,#UD .&/)LSFR3;:$ LKO6,]43>,[W,U"H5N;/
MSVUEB#8]?BDACP),0+<<-14+\=FVE;8G\Z9?&Q9&VUFBVIZ=YA%Q(KQA4]T+
M@[VW%*^ZQO-R#GV=)[^/KM8-;8779"+)*(*ZM@V;4$!74B!<>TJ6, U:3?8X
M4MZRU. )Z<.P.+>CLXKS98YQ[D/SYN:9:N:,YQ!B"XRZTW+7:$^'65+V4>Y7
M,;;>E-*PL@Y,%""WU'Q[<]<<HPO_U8T7-=]8@"_ZNL*7B28"Z/;$XK/SNYV\
M,%3,4XR'M(P5W;;5O*0)4,!&!L(-V0U# =N,S1YJW,,&4U93$!KWEL8L-&:-
MK&<8Q%._</W#XIK2S3#C/G(0--YGBA;<KA#[BYBD?50%@HC?:3Y&DD7U8N;8
M4TM)V<H[+$I<07S<SGD"HI&?$E"35JWK;*[/4GEOF?R#ZE=AT .7$P:?G8X'
M F,/[A0]#OKV.?E5=77?N=7F.$$])J@X)6(9>T4P:IT'?\_GO)-S9+66<-=9
M,2QX<W=G4L?TO.XH8T>*UHYO5XI$0_AEPQ3U@BW7ET$;USH'D>Y3 ;39"7E2
M0%.>%.W?1+Q6&E&+ NAS'J* NM3A2X@/YI]U<B]X:S!-BJ0+TA0\P/%>P')8
M/#'>9:$]8UW">I5W;7'//K>9)O )7Z:GXYAHE?VUNL;2H8_HZQY.%?!8B.'1
MHAI$M-7/V'O="6.O+EO2/ E#K1*'VY!ULJ4+QU;LHPG7Y+*:U ZQ(VFJC1[:
ME6XMF*?[>8^T/0IX*4P?L+*Z&*MK:+1'P)[54'9FNNG[>HSM[6T- S;&SK"U
M9W.T1N"S@FB.EDN9@F@VX"\:^K<;4W][4+4]OW!\AZ(-%_5CEN*/=M]J6?&H
M78:]^CU6" HGUF%^@?-3QB,/U9@T6'8/LD;:MY;%A7QUF=;4.'I3E_FF!<7'
M'E)R.6R%O.J<"A7OFA3:CVI8D5ZJ&8.>4AN9D"N[5ZN=B1Q:)WD[;E#:LE@-
M6WB*KM-/HTW_=X.!74JK*UW67ZT_;[3TY'/I=P6/UW:=[;JR)DYP_OZ%\# )
M,?\*.;.V]\UI1CDM:W75(CVTDY+X#42O'T:^L2U:/$P=GN&O:6B:98E>]A;T
ML+34M2#_SI^89=54&8P K;7?R>)>+[)=.?(9S5<#+>N46\<UY]E4"BY:4:)A
MN"T^AW%ODHV3]FKO7C?'Z]"_BK/LHEOAL]@Y:WK0<-[6C<3@B@0M#96DBEU/
MN/%.FM#)@J(W:>)G>V_>)LV$-K=! ;3?&2L1 D,W(*Z-+]P39I.;'3&:.:.V
M'U2F&,VP5/U'P]N=T'8^V.8P))K-@""BW-S%+3F;\[6I%IY#N*0?@/7H$U5E
MEFG!;&,(0RB')U,Z"?%&3S4U!KJM^<65!QTVV0X#T8$3EY_0L&_^HDWL!9^$
MI\YN'K/%37L3O)U.#3" I\17EVT_65&>T54U9\R,J7<>NO_[/!<J<F3RVKH*
M'.Q/Y3XL_<!TJ-B.^EA?;[>>]I=D"Y5KE>++6'23PO5<O%^(WM[:PNX*J5S:
M&OS1J):V!*A$/'_"]SIIJ+$=A11]@MJTA,*QFK6 VT[S X,B4TL+2H -^OZ0
M ' 9J[6?3=5%/E1SA1<E]#W;*2\7Q?)H=FFY65FF'+ O@>5&H@ H32#9#O+1
MK",WIX#JIW.39<M?BH\H=1Y9W"PO[<XCC-$1 6NS6[JMR;HYMQY/IH.#>J !
M.WA3-K3OFFZ>0LE@9YW7)B9?2@/+-+:6?OT(<G)X"Q0&88F0HGT%KP\N4\!?
M?"&OF_"P.3Q\W2?DVFA/4XY+&1Q@B5[.D.W+XCW7+PYF;((5*N+;K,"2?N)7
M!/E ?+C^W#8&P$?=308WK)HMK3FB7(_>5M(_\SU)-/*XZ#^PFGO5VJR*=R]1
MY5M1Q!"0>+N;UL= QIRF"@G^+JYLLCE_6T46N"2ZCIYX:Q]=\B1T;4HJ%R?)
MZI,=K%Q-_TMY==O*AKN/5;(Y;*]7-Z./P,5K\T4\O)WM)I+^[+4B N)4:7?>
MA*Z4RN3R2&W3V7/K"Z\>SGK+C3)4[;GR3&G#U._C":Y%BU AL2VJTZI '!O/
MF+5.WH*YQLML:PR%&.[-0;./Z&=5QE99VA2'-^TY'UV_J6?;I<<:5M1:5U</
MERS0W\J3ZI;X/=/\IR+^*X;6OYM+7+WOL=CY9%ANUD._ZCPFBK.ZE]E!02Y)
M:8MLW(:Z=R_#IB-9K7-JOM64$2ZD/.AG7>RM4!C8L&8=E=+AY@1-*GGP6&\B
M=/WMY9"C,&&H1ZTJS&$Y()@!2<(\AP)\>@_**O)00$/8>C2P_??2.[D#3!0
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M^Z?:R/A3;1C5WNX$AB%MUM*N]P-[4(" ^\S6RA^ ; ]/NPU(N,55.:4^.8I
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MUBKHT-TO 3OUBGF%N6\U3/65CGP8$9@2]7[RX<S*?!HN0V^Z'DBMMJ8D(-
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MNZMK7[NJQ(6K)AH=%36:JZ)Q20@0\)((N$0AAH@F<HE! 94E)IB XN,2(&[
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M$EN)E]E&7CH,W#C(PW7_$A!8QIQAQ%AH)7GCIM8TB(IUE-MV6O!)44S[NBR
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MEBQ$W5@1Z 8JC0*2@D#<2FP?JB-SF=3Y$BU$D5*:&;,I^Y@N.55OSRT,RA4
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M-S/(<)%4;0A@EP90"!N3NM,'$R0I/SW/E!:I.MQW30I?HXN@(XX5#EH6(PL
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M71V)W80X+3L0-;<=@9] 2G(6ICQ<WXDQ[UT5@VM&Q\T :M-90Q]7*3@LH/J
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MQO6 \_:83H?[T:@ZE7-:L/9J745[U8K5J0E%DRK09%YS#]K<%MIV#*7 ")0
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M ;#B%NO;TE1,6/?H<')F#I-D?^'6F,-Q4SC<X*!DNML&2]ZX\!H\J<2X[N>
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MT#6@(F%62A[U $>\?UC]HOC<*ESP4W[Z-<2WPZB6T)!8?PORH>MG>%MK!?<
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M'H'!:"]F;?]$W3N&7"X7%939W]P^I(>PYQN5J'6SPO$C=SF?Y?<+BBRMG^A
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M0.YS[MVTXS_XX]-W0_L'V2/^&Q8NC6.BPE0Y,.;Z #?JSYWK\R+VA"_Y'"0
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M7Z?/6JL=RT]T9X0:E7>>GF2>/OXN"^-&:(+:2.3>\E)V6[<W)GQ3FJHIJKO
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M1^VY1&&?RR3_@0=/A&/3'S6LB;/:L&I^(?_UCU'00U/O:Z9VYM"ERGV^\!N
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M58KDX-VD/*%5UC"N0NQL+\\1"2A\41VA^)AW_W*\&S)%+569\T8RN=I)1)@
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MC9+X<SZ7"$WO=_+\)OAMI#L;G-2;_7LZ<NP48W;8L&WIW)*9/V&$ZL8Z1"A
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ME_U+B#<=V4P=G53DGBVEKY [CG)@@><<01Y=9*F 10TID%A7W+">7_]SU!L
M5T.WT)HZW<Q:F4QPSU0=0XAR_7+AT?E6<[CPR*OG+M]7KRC@[JSNME9 G*PS
MOTX$#BZM3S+C23V[,GNM6-BWP+]!:$IYH9_%#P5#D>*J+#9BZ K@<J/ESH-!
M1^;MX>3@;P"GMI<T2*<4/;^R7$P1[XH $F"%2L8?MM66LX)#9-?/N<9"W/2:
MAO(S8P5H0]TX1%1-C,J"Z9[<&M\#);S*A:\REPTNWV$;"3<K[9P_*56UM0=J
MQ _J.?'@U^R[-P[1A+Z+BDMS^Q('^9JWJ=F@-3#C%VPSO'<&.^+_-4B2KFR
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M*6=7)4-O .*IARM&+#5I>?K'_.V7;P&)6EI: :L_YH]6HBM7XRJA <X6ANE
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MJ3B_5%J^4['I"7U-V?)/CTK)&97$*",3%*.47;WM>@GZO,N=1Z(7DO<R[&^
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M]6-?.7[Z!V6N+;H]2:JKV?ONC667?A W#:V('C5]$! AG< /?&?;@PE?GLF
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MQ\BA(78X_)@(PL\ Y;*K=<_X?FW*OY8',B[O #/JB94_T:Z>$,B9@K!;]T6
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M&[!"9I8%K\[.8I1O88@3.WJ@0-/C<]-9.@-W2DQC:J75]^!H[93+%)S&-8A
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MD"@+4Q0907 @D?#=,.CYV/=U1P0YOX\/J<L[UW[363OFXUD6+IVC$U@@<Y2
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MWPN)_PWRS]S7R\$*^IW<B['F)Y"FF.8350)F_9:*IKY-)SSO#5'!ZG;RYW<
MNOA U<_$$V\%3D_/Y"AF;>Y5/03V,2***OD"6"".=7(PM/&*^'?LA_RK<_CF
MA^J,O6D0_EL4[#&/2Y/E>UIB"VW)0O6Z#%NC;I0ZYY40&XXZGCXF3;^*<OT'
M5,;H#Z=>CV:_XMMHJ)G( ^8M!CM,9T(W[\#VSR3V]]T>).WN^IF7V<)F6,W%
M7)189#;./M\*C*D"@:?E9S8XZ:W7^V'$)KKC;:D_DCRMD7TAP5F88H4=X AZ
M16XSVGDMM.MZ9;H8VY^H):_P;X"GN-KMZV^EE]^3JK^R^QQ#6[9<%?#""T86
M[##C1FI,(#?=O[]Z<Y A\0Z.C3!A!4>>PB -<R.MD?T%$\;HEB.64'?0Z'=W
MN^$HX#*)^ENM0?Q3+[8Y[Z\*[T<OW Q--\)5-GW?,(7S[HEBDG_;(G%\UHYX
MKA)@44W+/@9M:R,WHX35_2M\XJ&!C'@ZQ-!-!P5^HVD&YI*QDJ><U$#8"<'6
M2GYOIX'U3"Z]R'6WNDR%J9\/?%G-5_K^)KP^Y"]>S+&IMY.8")18N[.I7.'L
M%<:.%?CV'_F/#&$J->*Q-(RT#Y78.HRYG=[7B6FN1% ?R%^?HHM_7Y:)W@&7
MW0"CG_^_9H"9VP(#R5W3)&51\,:>+V1L@P\FFEKF(0*J0+NQ\F,%6,W#EO<N
MM,<-(N(Q?PY9"A\G]+ZF-/79[-A<<M#>[(C8;.&I50@UMN&J='V6C""%;DGG
M,#JYN4(K2ZLG3Y:&;[MM'19H::[XR&H+<PWH!+(US?*=ZAI.VL<]_E$Y?"QR
M4:Q:U@G5*5G7[DV4.JY+=9CX9KT6SL!U'#7T<S<7G[[!SP')+]P,7#_K#IP"
M[U->_<FGEG4>WF6&3S<*XBL6-MD<B1-7RCC@%H$"FA^SA^3U\2<?7\JMS[-S
M%&H<@!1:UG@_RK$84[4,*+3]EK6O'IY:SS]*>CX%.5F*=U5M+<6259GBP%TV
M"==7&=\I-QQ4T7[/U44[T4# 18\B25D(FZS'P4^)L_58"]%MLGRQI,GIL=*M
M.Y9GO%->SH M']EHF'4YM$S[C,>+ZPLNS"+LR^5@V[@-Z?JB@<."/$:Q12Q_
MCVOK=S629D'> 30UF*$PADQPPO[2.6R<W=AV%<R>RMU\Q'9K[D@>6]I) 4PN
MRN41%\J@CW;('%2H&FYHHC8?C]1C95<Z#.OK$:WB';+!3"_).N;$H*$YE6G
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M>CY$G9%/0XQ1&'@UUV R08_TEUK0G!44TQC]W"Z]%*08<9!2K]9,A2#LH])
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M!\D(O\[,)1D:-#;'' <V0VZE0M<FXZLU)-<-;<X*-<1UIFN/ W7ZO;[M:]2
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M-CG/IB4?0:<Y7Z>C2[0I&I?U,Z(]HD*/*#.:LZ#\K9_A!=UW4E^<*U5).*)
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M1WJ(\,I+>9WN:W:I7C7;SKT#MENN4:8.&/C)$IOA6V$--V"4I$',]XV"C]^
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MLMRAYN7OT)<R-S^WEKIX;;4Z_*?">'$Q?MB@^UI =IS)O\SP;%<WN5UOVSS
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M_-A^T45Z\,S"$67B>QVO6[N#$_AMX&O:#W8=<8-/9%V^ 6A23_]WASDJ\&=
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M@N?<TU:_*4KWQ':T@J>.J7**PHN[==C95;<O+_.71:V^)V72%;"KCF_L*T#
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MZCW34H(]LSY#72U@I3^+LZ<_FT,4S;]I^?<IN7X(M?&]LII>T081+/&)@>!
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M-!.>75+)EP*=/8X.@4.7%8_SCXI='?LK<.#"(\<0RULRY=\.6J5-)0$,%0Z
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MU50;CH@\\JZHO$E/&F671<9_BLGQWL9)D07+3;XI\?\)"&'$1[!(=,VW$F_
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M\T9*<CV0 0;CO8_TS=N79]:H6 J;L M!'A=<6WDZ.0X'M]1MJM1Q1Q*ZT[G
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M@F!H=G&FQ"M.0PN2A3^.A8P#7:07WH/WIWQ"M6O5AM6M\W2_I(#ID;26QJ$
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M-NMBN-\I=9WZFTM3H6UZ7"@E+_TP'3..'=A_:8S"OG,<0WHTS(,,%VY)QLB
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M/>7]$'9; B(=_6' (RN]NYL1DOG[7UE1P,CG@1F5&9>6=4V\&!)"G\?\GWM
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MI.9\=WY.SH$P* ZS$([\CA$):(0 7!BX%@RYVG(MCN3IZ_4R#YC5/HB($(T
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M>8=#5CAM=9 800GJX3 ]0\6#^I=A B4I 8B2_"6MQZE#$GU?1L@>$!B>EI0
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M)479*L(E80!$ $E<K8+V]_^9Y+#_+=<5@9%EKIG2$Y(1&T:4FU#USY]8'FY
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MYGU(QLKNXM-.S-<O!:1=1B@B5OA]@H!;[A*"A):"/;/= Q=IH@H!]>#A3G<
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MR\3JD/PL\#':9YF[7W&);]E=;. V=#=^F.(LIWG47<#S/&483/\ZNCS?ZWK
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M,R0MKHB^9KN:[V7"N(FN^&G^AA?H6JOBH@YQJ%*YI@&F.I6+XC%8\_5!S_?
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M8;J^S7P!J!WJ\:W@ISRL%Z)1F>%GNG8-<.^T__2*$;;_8X3>BGZHKGGR,_?
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M<D=_*I2$0##A:K&N;&3;!_,(-J"I6A+T]Y W^I+X"X08G%+LP!'\=4]7B\O
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MK*FCP0=PJR>2.K22),\V35TKF4XC2C9XC)EKOSRGZDZM6;^H8WXC*O!SPR-
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ME2!*5I0:'@Q36V8"YF8OP&0[)F8T7Q-!BT'28ZQ)V1ESN2]_&?1V!D5ZX&U
M[D4Z$9W4Q6W=,O,Q!7I2DSG/WLGI.F+@8'WPX0*@^TMO5S#B?GO7@Q/QQSFR
MQ\>.O6SRG!H#^Q.R"K^B0\D/;>V'!GN)I1%7K2./RFLHT3'(!?A@Y]F6/5QE
M:0 5^S@L+22E'NK7Z_=:4V.4MR/!B6@58MLO'.^]T_]. D^+A#9N(>/AV2&E
M$),3[\] /1L.K:J-,P%AIUDOI=_.A/%5^E/>0R]M3#7X.S>\?*E9,&(^6W^>
M(*)R=!R&DG4] OC+('5?XW>Y%/4P:(DN]K5WN::>N<0Z[Y38>\*D'RSROZ1
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MVMN:[B6WPCZ10_PQC<2!K"B3#>(S&<P<WOK/K=Y'"E=W.:O5#I<%,XD_CQX
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M/VO:T@I@O8&5W,5X<@PZVFCAPUT LB]K\M]YVAGX<6$_ MJ9IY=*!)(8S+^
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M.(/Z)I" _:\0M13A;W&!@9-8R&&JV[5RZLW7<2V6P%%/ID.U994Z],V]V$>
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M,]2 +_:<Z-#.I%#3'S)+ETP6#V-8 H)#E8)-#>_W73NVH B+53<\U>R?38^
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M^D[J%_KIWM]KR!39P_PCX%/3!?O\=UA@!%/N?S/K&WAVMJQ8&P^'FX1@A1A
M^-$0%UG8AX3GO2RV)E73M,C)]NAZ:9+Z/I1'0'[,\L-4TM6QNM8!#4@@X4CP
MRS=\ I^1R&SDU"&A7[6H\;H=[:&.CN[BTH"5!;J].-E27'^V.J22^'T<E-QO
MT<F2W\?S9 W681)%=I2\F._$B,")^\OZF7^::9Y_2H4'15W-B.F?B\M9*.T<
M@I\ QO]1+%+MF+-V[EWW<(Q#FZ2!(C!YGV6&.4<^ FZN.L)C<DP5=QS$H@69
M47"XL$"S*I/O2A\D)*MFT^E3WS1@(\NW&)A9?*B<;IS+GC/)E_GWD0JN18\.
MNWB]GMM6:F 268 /K>?C5Y7]P)6:4:TG?:5:.F5FP=JENO+2 W/Q7%9;<^F-
MO,O5/7GJB#(:C;=Q..:UB0&LPP#RF64V824I^H"54FY^S2IXYI+_64:N.,N/
M&JH-/)WWQP=J9Z)I\V-<'_Z7T%%V<TM]U=<Q-P>25K&-UG("ITM>7H_C?K];
M LP'GP%$:C'!;KR8V\D822\S#Q=='/]P\SN6GEF"^4R]A9[UVY<\AG?7P-$%
M61F9L:SGK$0:IWZA%P)1@K R._1.D[[T<='B)EZ.N"T;(@.V9H,\.\<#/B[0
M)__+)8^<Q*4K-)V(D=93FIB"@UB+9,^O[]8F&H:#PT=L^8$I9&7D^; U;,:4
MN3?1LBU5G>IH=*D:1J(1X].\JV\- J&U+8OE.='U38J;HK?Y!VMOIGD8 WB%
M;LI2O6\_#8T8DS_E\[_'1CS[U=)Q4M/2!V$Y;*/V@$N&=+V&WJ"8T.:)!P?@
M'>$4B6LL)? DUKP ^?D*>$.8N:WY,TE@FU#RS6#T5.P.L+]5MA.,ZVQ(?*/N
M0OGKV+C10A_L]"88X+Q15!S+D7/2LL5;GDYR.%&@SV,:>T(7OE@N_8?LI0=-
M1BA)3=ZKE<^78EYY8[_+OGV6;?EN],&>0O,Y]L50\7[Y/B&_]*4NJ?$D>S>A
MG\XY&%: I&]^]^3J3R&#OLCXAC-[[4^EO)V/#^YL)6O(%PVQ/O$=&TQ@M$P!
MC3JS2.>EY01R9;JC[HG:265;N^"8_5TS6I\1$4U[8!U&$EMYIH>&V[72%\I-
M]V'%2I'7_!:V"7GNU^RQO;RR()>*&4RZ%=>AKZ%XM)(BVM-JLV)\. -VV^WW
M4V!ROM65P[NK\I;?B@9W>UJ[+85][Z/[2?(RR[@QT"ONE[R-9@KBB?S$O1]!
M=F,_ G[N%!:0,--U7LA2#M;ABBY=X:[)]\JR>87@S0.BD!BE&I!@\(["Y"/@
M+Q 3&:D3J7$:$UHK,$KQY!LX/>21]&EFLTQT*K_=JI_(S_BTRQ&K?GCN]/%&
MLUK_*:5)N:>)"\G[[&(MB_?]VTJM@?,T/W;MLS+%,_(3T_\^:V9-"MT"?^7@
M0&<NUPUE!#17OWVX$ .6N3P?_D.NQ54Y2+M#(-]7-OE"*X/AU.#'IA"_;=U;
MH9%4179T:.,>^66!%0W[I#/V1YV,HF>MN68C=#7;"^9#%>]OVDKWF]>#G4?2
MN:XH"X,WG^58'PGAH[M@'FHJ4$UKZJ <UC<0K"Y).!$P,,>9?)#"PQHLLN(3
MHW6WDJ7;>,'?<8&B[09^B:"W<+3YO<".Z+1WQ;#'GQ,'ED%8;0?Q4B,"QZ\6
ME&MA!^-;0I$>&"K2W[DR>Y4]/.P*?HVXN7%)V!'"/:@VF/*,&'^V6BYLX2/T
MPU/UW1\!W<)NST9\#Q\,J8SOYPZ6-.KR#Y..15,\2&:EE\ES1/"X8^;+G5?<
M4!](PDO<.WKNJ/JI(1H-@49<G\?W@.IZJ<G2I^_#*U[IOU5I:'*A3"&H[/0\
M$IX]:S'HM%*6Y%TUEG(S*LZAR_!70:%/X@=9T,<91TMIIVW@%Y7>>$.S]>1>
MA^K,Y'Y+0Y?-9;]%,V#GN>OHFR ;,GLVHKO_:J>Y:'QQ&Q,E#+ZW?OO\T.P&
MF,V;(NL#48)M4\G\)G>"MT" 867I_ /0-K&+.]:D$XV$PAO='A7MP^13.=J4
M)8&HK\42 ?ZRQE0[V_7F/YY.E?;'L(_C2KW#-PV71T"[/^BR]);ZB%KLP+QX
M7C XH\ \68./4T^W8S6> 0?_$6!0.NNOCLT[]H:90H!7EMB%W]3J*SKP [?F
MX5X,JCM$X=0O[#*,EYF#Q&BD*+@[7C9N7+R,N0OZ?JW3!\7&R\HSK\SV4SI$
ME3C 'U'TUJZ,9QG2TM84L;8&;J,K)8%\&JK .2T(,KMQXLUHRCK09"62_?U[
M<"TF4(P.0"Z-&2CD-N8I5<"0N+4>$KMFE8S1/[Y%EI^DQG^V#LH7WW:C%IIQ
MGJY1E,+4-/6Q*M(><#-UH.YK36&FLTGDYQ=^$"\A"=I8QF55.*E+;X]T7G!%
M<X((4273P[SP;JF%-"[-Z,U,4"2)5?Y-12_XU)%;'>&7U%('R]"3'<W/F& V
M"[JHDC14>\NYF'[*'R+RUJV*V= ".(B+R91)1.;=$%#BAF+BAO<1 #+H0.XA
MQZT4M^.JD=TSZL,^'4=T P_';RU6;\Q,7?A[,N,[W3+H%L!5WJP>I<L_]3PX
ML4&4[9I# "K8RF[KTLA6:#0OI6&=MKNRK<T9) 6'JWG'98?BUZR*.1*592+]
M$?!KBL8'6P4LI]X1U'%&*_D(,"1\!' J?3/&6&K/DMS$CW!=0A8V*^29+/G<
MQU<A?D$^(83]U>Z?>(G.3< 6F-C<:7]_\X%M-7>Y=>'5,0<90?"MIUEFA6UB
MM[>XKD?[.PN'_6#168-%.=7:-3/RZ^7J%OP(4<ZY5F:&6)Z&<,FAY+%S$&YZ
M"^?%?7])G)-DG]TD_H</8Q1)^J5B]$YI0!D7XJ\;1'J=["2;2^ ^.Y(#^_H?
M%L;45Q7"F4VF,2\HC#-0]@[L,;WG?L10NY]W+45W(.A?.<A;<+NJH<,VM?D'
M+\ /GLN+,E=H2TSEFOTTH!\*-WX.%1:$KYVHN,3^MH0LN) /3)5,L"%\MB=(
M)*EHJ&M4V6O%5N6J"L;73\#?O%"&NNZPHYFA>O@V/QOOCTD5-V-0EBR;$>2S
MJR2XE=VDW_9@-QLF3S%:+S&_YE15MUI?IW]IFA)"N?7U)]J;JT[CEOW!L><)
MG@&'M9K/-@QI]-R+7ZP*PK&.>%O4&,E>&]:[9DCAH= \ A+!(6O\<[P/NBK3
MO#W 9?;^F^ZL#^_3R_%$L WG$_+H_6A%&"*VV^G<R_V>N]N859N0UHR^B?2$
M UR,80@<WS<%5:=T2V8]+3Y^O6SM?K]ZQZL*57['#&9YQJJI[+C*X15'G%$"
M"1'04VN[PC^N2?6>OF=OUDCW!JP[UN[\,:S,NH O>7%E]7_T9(!J9?4U1);)
MI29W'-5@'OW2H$"PCG-N8N>%#NNHM\\IILI)<M3?LL]J"8KO1WBFK"G3DAS\
M5]O_E'IU$'LK"CK=!%B_:9A!O<W0_!:*_;"%O1[EAO!453.9]NF\LMS;.DU*
MX(LT[)&>\3.G%1CU8WS14C%=+0S>>I#H:W_6TCY=MB5O^_+S&?06YSLZ048O
MS5Z9ATAM^SL@45X\J[MBN*C-:?P/\-SYNMWJ=<%SS>9D,=&8GTV&> <T;VI.
MX-E^VUB?0W1MS@+P9N[SY#*;I?]:A<VTJIX2]?N9MYT@-)*2.*%5$N@"_.,K
M]8[V4NYHJ8GR+8>5-#V23@8O.DZIX>GV&0Q5NE:##&=SB?;T>F@9V)@9VQ'[
MEA0UE<](]FAH3_%A%<*2;KDW5M):6?6OY7<&W^T!=EYU;V<$,53:>MMM5SP[
M<"W9^N%N:[TGHJQD@F-FQ8 AY4F@P\+^A$[8249OE@V:IEIQW4HM8!F.I?)$
MU7 R,^4T'UP/9.;V.K5[]3RK';X69$^<[%[]ER2@H_[XFX\ 8P5Q#G1(#__+
MS]:&KHZ7+@VGRB<3$3;30OWTA&+9Y'HXF_X;@8($1PN\BS<3?4KN$N(V'Z01
M^^E?[272[)PF1#M1Y1D59/2RG'E_IW[I*)$];3Z7B4>Z5NIOZ";=8H#0'2Y+
ME\%$WBJS;%)-5@4]] &4\P3/O0\/2M)W? 2O2CM0#XXJO(V1L^["(8U0\IQQ
MU\RWF)G===$<ZJQ7:&OF/R/V_L6:U#]*N\ "Q4;FWA2\GQ$L0_]>Q346_?W)
M5;Z44:>  !:7.YI>+XJA=(9J\+X,JFN*Z.;=(\#M='ME04*2H5S/DC]M7P5/
ML\+A4/SYGG (]7W$5*9T%&(^^LJUDU)LU R)MGPRT&XE^(F^Z!$@&SE,A3RA
M'GH$^+@B'(Y20U(%0<K2%FQ9H?HCL&+P]UPLSN\FG1,*)1<#=CTD[+PY&G3;
MZ-=4P/$X$Y7@^/>PW14H^<'[8\P#061(:B3+:UW6>?D"(>!UL4@8^!U-9\0/
M0@[[KC8T>S].)'&H,5=RS"XUMM[VZ9$8JN%Z/U9C0_ IPCXAYGYG!XG&RV7
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MHS$;AWQX!+P'"\9*'EC\Y25M2F)G<!LA?I'9TD 7XW<>T?R:J_U6.\][YY7
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MG/N2,-C]@F^[[,6Y!^+49-/=VWOMQ3E$<E5([Z]B#R<>X9[8$UQ<@I"NR!S
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M/+.@&E:&Z@L%,<.4^I4Z/Z?;Z-$6:3!S ;NG\[MG/)?[?[5PZQF',O\MBBK
M,Q4",Q73_]\2]/SW6-&B73PW_X*QIKUVK%OE@PPOPD0FZ?E.?33P<@H$#TZ9
MR$Z,E?NJRTVK2.5P:^+&^010-%YY $]A)[H0AP8O024>;:S!@BIR)?<_L JL
M$7,UND%S;D^ S;=B'3Y"2UEWSUEDMBP0K%=8[D W[,>XL"(#V=+RI$'/YAE8
MQ7FHUIGY,^Y*7%''0B')6;X63]D2\%N,[0DPP#8'/$H%W7&RE%100]EKG@!E
ML@_!ZB5AKKJ)H_9 K#7JJTC;MM,F?O@@LQFD>2?$@19C&546F'YVH"]*4$(U
M*4WA1UIKV.;D",]A1MGGOILI=*'D(UQDTY!X'D#XWRZ9#-6%!5^<Q;;H0@1,
M<+O!84+,$0@P-:@4 =Y_3A-*6XR^)65,\M=Q ;'[2[O2Z-PXRB(0YJG8H*5.
M@(R<PXF^P8V._1>DA04O3^LUX>B;93\6,K*E0M;2UQ65@:,OES!Q2RQQ,DD(
M13^D+7R1(E#]IPX8"!13,@X8(RPO/Y#27Y>30J5;[TX+)U](55O8RI\<P>9D
MML[P/*-<?LG<:CYZ(TX_ =SJT:WPYM5R(G<<8W^;,P*P+Q<OJ3$/< ^\?-PG
MF?BK(O)!.RF@\-W?I-,IWSQ_YF5IK46BLWAOHSD3W^4R[IH>!3*_1Q6@0U*C
MVJ&+(?ZI/M _9#0S5LN:\TA+F/ $\*"@'BT\M_[$^V:D4G')F!OD@J]]]Y6'
MB,/K"0"]\!E>$-5X]Q'QLG3\FGZC=/GW^LZ]G[JF-EC WB2*$ .]MU4+,4+S
M5\ITPKNSY++0@GCE""BQUWS'=(VP/O.\GG[#9]971J9QGP!%4(_03^FS-F$[
MK!5_2L#$NZJ?D*7,/=:&X2-5Y^HZ2K4=U9SMC,,&-3+J?]JFJD?4-%+4H\YW
MUA4KJ'#5'[WWG,K3"J3Q NT.UPZC"]-DW_+4RMA&?0Y5"Q1$KA#1MH^_U<FU
M).CO%?2'P\Y@6[R-.(-HER5I*ETP\X,QZ29R(//)0-X;];(0TF_X>2,S^!XX
MW89&3?#1!M"E9W2_$J3N"6#0(M?JI<'<D; >%"/E#0RZTIQY !+\21W")TF]
MBT& ?]"<J.J1OI)R=B!<*:F=RO0P>Q^5:_I*&O6W9:Y*VD;Q;YU1.Z&#&_V#
MLVUA_*%\;G(X2\1]2&G1GKVID .XQ/XZ@Q;.;<&-#5Y/"LL8E;JK* /7>!U*
M/D>?F,#_6NTI2]Q,LZM#+FRRJ\O!C#5._[B[HQVC)8S"_4!1:LA(:/'Y#B\)
M-'_YV"9];*8T-XF-^76)8M4KD_SF,]T(O?]E"@MCY_#8!B7AS^_<6N*RC/09
M;#8Z><7" !4#<G>'P@<9V*_?!US6JDM:6C]?%.&IJY,P8L2@,:( -PQ^;U!C
MRV[X$AQ,6N,9(G +?3RJ+DKUJ1^X!*99"3"5&F0ZJ$@1_OC_!FC--RA1I7O0
MRU8"(M5P9>K+R"VKU_R7^=FK[:[5:@P7(N$B::WV4U7NBO-;O#T^8H9D:+SX
MFYU+:$ITGM&"MW4F%O894RWH_(K+V)M@IMS_I[(I) :OH2'A&^YUBAH'V=X1
M">J1J>NNC(@!(_8LR,J#$DBFN*OUAF&1Z_OY4^0]&E-RQWKBQBOC=LO8DP+;
MFNJE-D0&E!/YT^7N;*7URJLZVQ$Q.8B'4KI1X*4*'LLR]OO-C.!C5KLRG4-M
MG0V1GD"F"]KHZQ#'MO!2:BR/+4FHFHB7ZQ#&-_(4M&23K6GLK0/93EG]3&:/
MI3YE&-OE55+':>N\(;DI1@7[FDE&RYVFOH$@=.[1(?0)<++U]Z!<^_>#%J3L
MI]=L_JY-@<;BB1W5CMH5/2+,O'2JF7:S*6!I%A6:%++*^ 3XYJ(?_]LT,EW7
M;J7.C=^$M _F6IS"T)(/^ZZD>\*U8_$MK2""BUH:)<8F47*] ZJ2I:L-VJ"_
M7X([<+@GIE[UNGG[U7!&'61R_+O_FV;1@S:D-MEKMM7GQCX4>[8R1-POUQ^$
M.2/D'J&GZ2@,[J#B&E_J?@) HK[_<66-K1JR:ZH][3TV$7@"8-?82$"Q?V[J
MBQ@<N--:=BP.2I/BY&#/#&5!C&"%XZ4E;9 XWY,G ']RT^"HUY:P:)O.CSZ7
M<<H=PBT@L<\7,W?T_5IB8C1O*_>?UX'%_KFN9P.$,QXRFWS!OV7R+'_S#EEC
MO?C@WNVHKY;Q"R(RY9(W-(SB*?5UE0X6]+PWP5A^3+K;E&7W'PA$6AW$4;A$
MO,B#C'5C8?2XL]E\81WX6F0XD"Z:6W@H04KY:.WYQF9)_!D(E+%LNH/-(6/!
M U6^R771V]U;19AF/[P#^J;!*M_C_R ::D++0WG>_BUL05+#:2';6?#+DJ"#
MYGR$%H3R+G23N94B55$WD9N1M@;X,T+*12 HG8] E8G-V>;W<7H#;B+]Z^R#
M+^*[.%'HTUN\R)9G_7 LW14I[D3B#MPYZXW44SX(B'W;IG8$H<_TQKDU(4Y8
MEH&Z#7C'F]DU1#]=V!XW):%.-\4>!8S[.FGQ 4E$WGJ[5(@D:S1%(27C C+"
MD;:@)3."O"[^9X6Y&IK*@QT)$8'8$@0U-&HSO#981 /EO.0)=76J!$UWZ4'@
M3FH\$9INA#*)L:)Z>&+DO^3W%/GAPMPW?$TZ=.Q6=G\V[GKPBPQQ%ULPIF,#
MY6;?A3+R^%_J4DH/?:XEYB-V7.[TP,$((;W<:C&S-N :OTQS6Y)N;GKKZ_B9
M%G4^H'[CJWC[0#DCI%N3"A76N8C5TC5@P9.N5@PB^^/P7D8A(LJOM6;%(P;&
MZ>.;VU>\.'BWG*Y2Y[I2=1;SJ\+I)N#D:O-7?D)3,<+JW^H5NLC<V$05B;_U
M790#)>*NA!UK#P:0O,0A\:KE%3N[O)/-03A2;.PI2_ZXCWPN+&6@K+HIB^MU
M-UA"0W)?HL@Q3M,2RYHEW!"\2F3';O,$J![&$T0RIB.BC]D",IV*POJV%)2^
M4Y'Y,MY_>*QY?=$<6(HR3$YZ[#2UFE&5822<PHS!TL^+0<)AE^&#W_M'>K5(
M6LKX4(QGXG(,3V<??^!M6P,3H:IHASP%9OK:AFKV:AAV"'BG60:*T@4G;KAG
MN^J.TT>(1T)K2:#ZN8^R)[^1$49&##[5F>W4CMOYW!8OXBVK,AW()7PWM9U8
M;@<X9"I_"?NYI2MJHC4E'>_Z-7M@6QN"CGEJD-Z"Y14=VDIC*<8X'1F21K_K
M1!J/]^&ST2L<8.3GW[)2'['SP5NN;6 JDO'3[>JD0]U?8?,EX794C[FN2*F8
M<%Z.T%9Z#_?NY.\6-B(5*\!E\ 8?\=VKCXQ+O&*C&BW^LU#IYG12R,EL^9NF
M3Q6VCXNUDTL_. Q[D[N$-CV2NVI3FAUY,!Q);FV7P"?&+2#T3ECI$X!^2?VN
MZPF0HYKQ+]^I:C)?^ZS8HSR#*PVC_S8]S_^@H1!"'>"R]@U/ +WGF#<1KF\7
M^A!4"CH"@U[K)?>TW;YIW'MTCGX>S1O76NIS[+_ ^.U#L%C@H58V^.U_J1\,
M2\9T].*#;KY.4$)5B/P 2@[_Z=8C9ENB"^&8E<6)T'6+AZQ NO#',;O8WN<G
MG#7PAI*<C._YPN%_/O\I<^]9?:V(H\A"CE,SS-?;FIY?ZXJQS[/TUOZ4W-:I
M3*FMQO.5=P:)1RJI+&H?X\0KY9A?E4J?)FJPOEIXJ-&D-I<Y9F:HZ6,:(->@
MBDT4O?.#?]8-W?U8%O&C]&1V$4!;$^93/.ZKU*(1>#V[\].H'JQAD$5!H9$D
MLOBC#^1D:32P;B6R/Y*V[)R_T:!G9VLQE7)X&C(P:(( 4!8+S%:K":"4&-%I
MU>NO*E].E!AK\W*KC)0[+\80"TW;3^$-#=^>/KL*PSM=-Y#']#,:BROL$3?\
MA&RM".IVMG06<9L;QW6H\/V19>[X$84M"IM% X3>/3>UO+"VLN";5:=(@?V^
MR0OB(79%V!=4:NZ=<;F4&[AGE<[Y^G;PDGXWT#-[96E\'V\#J^C3-NT?9$%1
M+FZ-[<\S/%KL)Z,71)^A,U^]-%Z6-EK3+.N;'LQN2R$!+Q9"G8]99$YNT/=-
M0&QJI[2.1:* <FKNG@D5%[/GYX\X/P!Q;6AIG/ S>WN258]>U1WWTFB0Q *)
M(DBQ(6K50T<X029B/=$IMH^VFI&H[J%IP(;#+<Q,:6/Q-^C+DBS-A:M"F=<)
M_=QW)1Q2FQ/"Z%Q7O!4"BR:;$*+K(JTZ4L)?F]J3J*67/WYP!NW]B J1G/:C
M9#ZM*HQ\L2E/CHJN6/>KX+X;]T$LL3].*^Z3[*&B+Q$.&AGNE'-_SV9+>1-E
MJ"1F,CX]YULKBA-EX93K,<P#ZOD4>HV"QR_"VW3W?4^ :99D"$[(0PU9RZ+/
M7AA!5-#]S-J<B<#D,[J-E=8,9]MI@#RNUR&><-*D4UO1O9Z[4M$E2E8Q6.AP
M1[0/\9C]N#2C9>H7\D.<)I +R]Q#MC(+0W_AGN!"!^%Q)DKZ,_5-NT[]L4+D
M(%/VS]?_$5$^%$8H8B\U)'2?UD.%OK4>Q+Y"G>^5)-;NEZN)99+YH#C'LW\5
M#?NHV*30:JMQPOV:V9-473]'-.#!218ZWK983?D$..0;F9I[FS%%>.Q$LDAO
M"?XQ&)CG95++XGTNP5.'&#Y5 \1G[+*SWM*/+*VQ$;!'^FJ'KL7JJ;D5U;#M
MU.,Y%WHU1@4;?3G),R+]L1MI0/2H7_GB1E* %#$*L'TQ[W2<_NX)$,NB_P2H
M\'D"W+$51\-HBT1(W3JDM_S64[_Z?3SHE948;'=>94GN$\.#C,:[.I<JF,MN
M@\UE^4,&EK_%<7E@S2VV.$M-;\ZZR+/)4=@V!)NVP_%DZ"""U,$JT*@P$<D-
M4<E/Z)CEI):@H^SSML*^+0.E#0XR2HX-\P;C<[NF:F&V  &!9+KHFT^[>0Y6
M6/QMN\C/<%!$M@16L.F71:]Y_@0PUKG])BZVQ;&LU/UXUCZC^^C>0\4#W7D"
MA%Z**EBYU3)(F:O5_*![:4[_5=:DG82D="VHD?':X1O6P_?P&C3,=+C.0Q'P
MD@XVPT'XP#-M.K<#)0ZNP?FS)DQ*1;O#M?=;@ZJE8RM^S+JX0[&\'HL:V])/
M<-)5_KN=C([\HYB\!>[H64-.<F3!+GF+=ZR!8=D!%6,M+"A_?NUP0JED:,>3
M6&*^R"S,P"VH8\SZ[(%PZ\1:"1_4R;;YW2AYN4B!@,4>HPD3!0EW/-J^8<0,
M-@273_X+0I>>PR[O9XJ$E9,*RK8@'A"AE:H!->X1IS4&C0IZ#M&\]%=/E1.]
MF=U$*$NW5]X"?%*1K..-6;#*=9*R(^I2DHA7[(E!]D=E61J$ 89F, X9;*CW
M;F:F[EO2XF#O\H5(/QI@^T5WT$ '#<+MK/+7^*_CZ$Y'K>P0E._'+B?NJD*1
MP0MZ594^OP7HN;^B7A[HKE$ MQ7_/#M"(&B_@>4;]"0T_-C5EQJ.IZ^Z"I>A
M[_RB9XN03/-0?**_UH=SBV_;=DR3<<<N-SN4@HD]UYEQSF@)NL8)>@)(E?+W
M\ GUYF0-.&09ODF$NK)PQR$C;)LB1@^F;2C=XE<#[U$ZG@#9LS5'/YODUGTV
M-O3INF]:N6=*>=)T6/15J?E/^#&/D7[$('>@*[$%C6L6V:PRM$*( ^RP"T1T
M0FIOP[7B:Y;HDT1>B)-<CE'5#/GP/0'B:C9!]Q[/&>Y($7;4=B)$] 2X(C?O
M%?WZ\Y%3G^OFD*F"LL"R#5]$MJ"OF#],*N:'9TSG9+6G6O\;%4<$2F[-9MRM
M2/NU'HX-)<(O974$4>: =SZF;^D"4??]TIS[?G<:6])9ROT !P9[V?617)>3
M0.T7Q(0MCVQE?OS1N:V_6HG/@&$STW%8>50CK_6LX1ZV4M6/9R@V)[V,S;-2
MY0Y@F*)">!C;T_92S.C.P%.TVZ0^ ?Y9E.=J7+SM?6<\IOR#CN1J^VHW.JKM
MR ?X!'"@OO_4$JZN\KX0/=,(\ Z0\RLIU;:NGDH&RMAS-Q<JXEF0G^'TVE^'
M/F0.2!^AWT?SU0MGL-"ZEAJ_M-I31-:Y9("HY\*T*DJUE,P[D]R#4D;/C]>B
M;^U<IYGS"6#?=B=://4@AP IJT#MYU.S@,-X;A,^V]8A#O*L$</6^L8[\O;A
M^O&=&0=UAVXA@@*"?4.Q"YZ,HB@R5NFT4,/ 9F>K+!CXL;S4_B>Q=X-3S2AB
M,96'J,2E6&^M'PJHO[SP"3!W!N^O282Z(&PY8./.88P]5A/J"#:ZC6,_ 7JK
M/-)XECR:V=!YEZ=LXS26[G,[]G:WROUL@ML@!=W?*87LE.!X!2F6RH.ST-$'
M?RYQ)#O&)<)9GP_0+ICPISJB"OJY&[-O[Y7J YR2G@<>@0,I\[X7WBS+*> =
MZ:TR,2/OU5JJMB;!=!&(N+XI.5B1$B4N)*/"AK)7;3F\.,25<:9LK4$[U]@C
MEZ WT_(7$)5!K+49L:N.QF_K/G#9K[%,-B"O,W"P*[CQ%#D96]G*<S-\ =KJ
MTWE&1K$@AD)6X/:F/6@==$=;;7"<GVPDBM))YA#&T\*^R?'JT&EMN3HOQX4^
M6 ^;2_PL9;L5&Q:D,:>F#9]N2SD:>'?K]V5T9>DBNM]/_>#D1FFRV68=]/-:
M"??6\(BOHTJL/IXPP7=?MHV&8<;';-.!Q../'4HG_IN:ZI=!RX%B1M@821V=
M>_F"P,'\2NIN!X3VE)+%\6G;F?8$[NJBAN,.?QK\7HF'(L, -N*TLF+<O5@T
MTJ.ZO;&C"#CAON$K,D((=K5%[UC5*^['K<BV,N;M:<;^)']=2%_8:RA_*%N-
MEN:7V(]Q(GLF421^H'R6G@?.S3%*6-#(1'537\JF^>K-UQ@%M/&+Z 0_B\FF
M\L C6AC>UR> :[GIV\O%C#G>< CUJ<V:+NCQ]WLYBCM;9+^\(H^]C=Y2"_;B
M(DJYP:^R6*]C*3#M]2I>ZJ9&K1E(>;O@OQEI5NMUI@BC5"JDHVWNVXJ+ADE7
MS_;17I ^ ?QYW>$4@I#>."7#2LDG0"8Z./V2H#&@X!EKT_Q;9Z9,A\P]FG\%
MR\*YGM-^8<P_:LFK_RJ6^;-,2!'^S/PW!%T1MC(H07,>WO#G@'PB="S& AK@
MF_&K> +L3Y<!M\KOSG! 2Z#' OW0'H=;AL7R6>I'LL3QVH)'5\0,F.9Z*9D2
MID2IP:*4IZM[VPL7S$KF2CV QT"O\YF6YJ(+%0EL+[\OOY=MO3Z.[SP^6(5!
MW9_JYT"/%TKGV"W#G<RDX2/950^L#RZ?'O"\--?NR-6E%:?C_(RH*7M-(;"K
M>QGX5-F>',QUHX7_ WS$EP\C^R#<(N6=J7/41U'-)4J6T']%2YR64U2+;&Z'
M9@0U73X!B#V"9+%[F:8AW@GQEL!24>#VMN[#$V HC[$+Y_8MG.$)4+MV)Z!:
M\)#Z'91QZU)*W<<ACK]5/YQ.3=5F^018=%VQHL81X<_;[U+RY5L]^>G$<]%-
MNBTZJL1RC*(T6V\8M8?GX7/GF_/WUH9Y/JJ0D>L(#GN'N%%7P]4EV;2-%N+[
MKO'H/D*<7PLR"=CD[;AU(:WLUD($7/AVC+]>H:0&WXYG. H\*.HJW0H^!VS@
M^8$ZG#R\61'*_QG*D:"Z(-)'WD2\07Q4!TS4^N>OZ,AO@C9>C/6N" UBX8V>
MLPA[G.8U=\?GRE'V]A[.#^P#F4]%V+(.B.ZH8CVQD\THYQ9H'439QL7D,-/:
M+1@9&I0B(4TPN4%UI!+WXB;*/]%CMU>E9RBPMO<M$SRZJ#5,6!=+](868Z.4
M:KM(;OM^-?%-N24H/P<\[3:HOWNEK86[[#;4UL=I!B^^NU=?8C[$04'<N=ZK
M[_%J?9X_U/1R]\>ZK+SXY6^<U17L?<K>7!")K?H1Y?@>/Q2HB-J"-3_?A_?'
MD80PW!B)WL]U%RB\>P;XX,&IK?<=&^&K^AQ[F!WA^ND&6A:-(;UHEY1>,[RC
M::<IXMX]'F-];B#^]X;K2X+4AO%/@%*#$0,0U*'+^:B5).IPE"]NMV/X%X%I
MM>F7"E$/% AO(E'"E)&;EWBDBRX"\5VE XE2_@2XR4 1\@38C$HD"G;(.ZI#
MGMV<07(:/M2FE^@\1T'"Q/85FIVM@SIW-5HS6QW?Y0V]0G(,+!(KD3E'#E?-
MX"U!3@[G64->./Q>[A&F\STPD.=>WAZ3>!*X*7)'=M$6UG@64).&:!YA!)\$
M2W%6\T42:>:\</.7%GQ@YB"H29SK;6/LGB2<C,GV/WZ/='[>?*VZE_&[. //
ME0.I8V,JW]+MSC1Y4BB6+>&C3PT2?K*AP8\1!]2%/O=;A"4/)?T@>9AZ@?7B
M][98!UO$/Y%]"+780.:")P!&?"=HK?D)T$;]Z#4!\W3 FNM29,8(,TDA#@^2
MH0W1(%\J%+6Q@.."<)X XQ@*3X#VCT^ SDH?L-)/5\0(6(T[X1.@2]>F'^W=
MLA)F9=P[MS]Q G=DN\V"T/?W"I"1I$23C=^GNX%LWYEBP74&;L%C&RF'K9R]
ML1X(=)&$N.S9ZNHD , \0./Y5_Y916BF@%!>W5=\T^?EAJBS"M0EG1-*P>'P
MEA7Z8<N&&[?N-%U=W0-P,5D,NX?+:X8 3^:> #(UWI0>>]%MVS4>)O 5T*6W
M"EK#Z%D%59^!+S3Z\R\EB'(@&CKO26<G[%#M9=@CX,%FW&:LE?- S9H*G?@5
MP^Z?>NT,2C>CWW"CQY=F<LN'ZTKKP)>6M>DX%4E[BC6-#4T!%BFR&YJ,'LO$
MJ>L \?;+TA.<SA2ED/RV9+F 3.)@G8\W9IKV3M5NU)QENNU/ %P>%$AB8FU.
MH:2%NP5Z!ZV"4SU3NY'W-@)LMY$:"S:F"#4;S2-*^?.CI!9'<,XRWNU4_"@Z
MN>7S].DI2HS/&TAB=-B535.++)&-]ZMONA6;,G;S*X?(4WU^+%,^9NLM?%L=
M0GEER04==AP/OK0=),JF$O,XZOT/-O$PG!O>L](V^'2Y<7&I('.ZOV=?QXBK
M0_/K-]\F<;@_Q93)'I";)<"]0S?TSOQCFPVA2I^AK)DU+946WT7#;^FH U_X
M93>T?+4I!WA4=>NX9I\$PE' 8ATF\4BXISDLMW-%#TP3P#\BN X\X>%G\\NM
M,L)*J,"S&)Q-Z_P$M91#E'39_YF5/FF3)KS"XU\'C5:LK)JMEK0QLT-([9_\
MD:U^@;VS4R%XZ'4W5[ZPG_(IC3.E3^%/34+9)$0WFY/J)V+!B^;B+7"SIM?+
MV4D30Q[\4W0*4(;<9:1P3PI[]286BTI=0Z.EPA!>NO@3P&8J3D!D>O0TU6X7
M1=B9N*L<U1J_YFQ>]=J"ZR.#F@A8:R^?I'!O7#/%8TP#LC/WO3I-J7,X;/#0
M_#S+,N3*\?-ZP,#UY6\X!:A3T+/,.IF*(VFEG(L,>(*,0!HN/+#289]*[16Z
MB?U[8^@)@&=5X>&VND!;*VR6M$@826_<1=).VBMT#]5]SY=6 XJA^OTOBQ:
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M<O)VHHC]4<DV%(/PX'5_58I#*:LS7+Y1ZG5ZK]\XM=? K\+ZPC0Q$Y<JTP2
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M+G3AGRR QW=*SRC,DU;H(8RUWG]S@?]_;"G\[R'Q\>@[PO=#;=>[O*(NTQ?
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M&O.D [.5L+"'%,G^H-35"A>.! 1U@\LSCJ])WO];[M():+(5(T'(3=?0P*/
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M.N1Q1O!..FP^^(&Y!_1X['B?/29OI2'P>Y^4__T10"3#FC-5JT'WO0:+5VC
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MS4(%SMDE8/T*.;O$)T0;L5!ZBEI1''3[N)V;N7Z<!ZX>Z0;Y2 ++[L%52=:
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M.EFQ-V #>UV@E)+PD(__\;;NM+S$"J_A<S0//\/DNX7WLL*(VPA(9!N<HJ@
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M8]/F].OY(:6<;N#G74\SA; J\9G:\]=;7Y#RI-*[T$G^--+3[S%MK*+9\U\
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MC$"RAO#",V#-FYUFA0V4V6L%NBWUGGA?++VE3 <X,"'X'Y^#ZWN%HP?E!'/
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M@%:8:LP_SI7H$%F 8K5X=E4/SOFOG4@JX6DM8<0[PH[&,Z8@)J+F1O;&RA=
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M'BC"#ZZ9+/ ;"UJ<BK??7JS]Q=;F[L]>%M SDD###P657@1*VE:;>@,"*R\
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MC2V94_^)^,EG8>!)?AB751M'$EP81%0[2X,?0]B_1GAF;-/E.R[IL']L%_K
M2.;K5K1A[K8S9XBETK)H96Y![^LU.>[\N\+J.2\+)R T8:0C?PCAMNI9P;I
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M^5 I1SMMBE\L[LN,*6>7O+%Z@'\-#CVEG?,S+]8OI3ECHL&2^M+6(\5[LLX
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MX1V1\C> =6!.D\,(3_C@^QVSH4A\N7- 3<N R7&2<L$($@4EWVK.#'KNG$7
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M. =.$;0"Z7SS^"T5-U5.*E_79*TDL.)E28*_NY4=OIE,JU\=W1*[3TXZV/:
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M)'X@BYW'?1LE=<5[(?Z-\B<B;MBL2(>[7SXA79^_2@B)@<Y <WVKH6:(*:H
M#-:;Z6GLVTS[X?]*04!U^F+II7Y^0=YNW**.:'L[-!;ZV^S5EP3 EV5<SNX
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ML(%.#/4=Y(Q;V;CLM4H;D92R,] 65-ZF[.8$VMX] 1SR>!.Z%C$O1,Z#4:R
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MXDJ+*/OY["9@@;UON5G?L0]%R":FJWD4 *&\N C.*\_[[1O21T5^GUHC:"^
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M-1]_1#U_5FKM%G*GE(@FZ!SR*0UG4(+BLK\<QW!5/>%QZ3HWL-4O5V]_D1@
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MBTCWYPBKY8C\,5=H^/2.JN(O=$\M9J)C+99#HXQF=]3(C 6\Q$%M4Z[!* I
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M'0_3N6D!"4ZFY\VVBB:,YI<)8"RX&R:/6RXRCM^_A^>G>M7(DG%0:("5]T(
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MG7=@NV@3EQ179V2%2&DRM_[2U[6F3/I^04-_I24%/[+5$3'[3O\)UZ$[K>8
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M]OYYWEM?71YQCY?':D>Y7>EL&U#RQ.=IDHZ/CJXU9:6(P[&8LP/_VS3U_\;
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M9S3_KE=U2O5BXU!!3Y0->\@@AZX8S<ZQ>U#)$5/2K=?UYN^2'C.G3'@_,H"
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M/PF?Q=;D-IVW/)SUG_=PR")CL@9J[.8#*+Q$#$RTU&%Y?[R)CI,_SJF3HKP
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MBM K2<%72H9-^:=3T_07C92W?1%^4E;"&2T2,R4V3E^8XHK1:";)>3@0R%X
MO:<ZS[0M,VY_4#^&*[<\?*'EMNDK)VS%5O1-NR:DDC&SWE(>Z44BVFQ364^/
M'">ZF%LF_!+Q\WS>:>N52&Y8(RY#F71'>(9--C;W(2&._DC*5,Q;^5\\PC]=
MLROM8&V"&YG ON3M"NU!IQ".I<Y5HT#GT\>R;L-/5"X)DGMK:V6?D )PF]<M
M9IG\1,V\[:P\1FI"X_*91,5[$0<+[?B&,]T_29158'3V/^/[*M@:."QP@IR
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M-7W)\OA< )'E]77WL/#0F[8W)R<;\ .YLI(LFVW0)%5&,K=J4HPN5Z9>8Z[
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M?Q-T--F$G@&7^);.?5E8XM?FQZ#)YD$^B(H7]#-B;A4RE=,$.G5U1([7,(5
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M'>4^RX@F\T>MCU)(>^X9YVU%VL3#C(UY60=*K3_JX:+Y>M72EHS),<8]A/4
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M'A /)_)"NL>V@<UK6L8N[5:2Z?.);WP'!=:@((=SM._0V*'J2V:NU[0! "\
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MK:5+DE7AJA,-N1701W+FR%F.0*-Q GQI6]76[_@U%E!"*>+F:F>O]\"I91R
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M38$Q")\9(XK9 ;N<5@+'"UO(G=:NB<"5VIM'_(3,FZ]_K%FJFY1Q#>I.6N^
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MU.%\=FU,8NW($<DG[/$',Q5?V@G\]/@1_OXC:22MRH[MCH"W:@WGE#@+#A#
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M(JO;QSF/#V)B]'A=(KV66][0O-6#],O8E<EWNJ[U=6[@#P2*K^\%N@-(I57
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M@_J@YBI->K2PN7;\S?[1/*A>BS6^CSIEYZ_(!#JH)UTO0GCU$/-A]NA9;F\
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M"X[5T)>N.46Y'36LM,U$6,Z'ER*Z<C&Y%=GJ2M+K].16P39+/[)?9,_:+>$
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MCP-TWR!7"5-J^C%8D;,'+!I*(.*8D.!#$B/DR8*P'\+=^6+5X191U,Z/AN,
M&LB&4)$A.H]_#"5$(K9,M?0I2N+F&$+HI-(HCW_*N@ PEI;%!MT.;:,9K=JH
M0&,:=[ WV!*A+L(]^H+CHT3/D\[;"# H3BKM!.:2?)=HK1(>ZNF/^]4F'^]@
MI*8VR7@"8H?C9#K?WJ<GSJH[L+PO,# !4JK  3R27KTX%V$!!#X<D"S:-B3D
M7KH2Q AGD[DOJC$!A<L51G1=/BE*[_\AR3P(L2T13U"72FI"\6DV3TB!ZQ&F
MA N\MNDK[S86U$_9M*-(K?>>VZXUW)<E=L ?G,MUNM+[>@#'FZWT?6G@GD[-
M(F[DV'W$\I4 CP+_]'R?ZVL=>[_LB+?)QK#LQD4;8J]9-Q'TSY-?U<<K;F"Z
MM##\Q_=B!]*7T!@+'L4OY4_9F>L2V,4.&MY7YB!"GD>F;LCQ.O[4(>F?FHP(
MBO)WF!1N"OWE >W/\5LWG$=-8'EP@-4F[F!46WLA1U?L U6[FOIL>CN[0',+
MTUB>AH;5G=65]GAF_BY K*R,ADXQ(% @0D67+GHTOA5:Y&ZL@3R*DJ)%;DWG
MU2^JG1_VUK^+LAU1Z@*#Q?8Z*]^@@PIAQMYXR-YD9&O@!!UXZ[%0'20P#X-G
M I^F?_*3*85>*7S6J@C_M)CS;V0<\J[4#, RWPJW(5]49*%6YO<BA@0^:RG$
MR'&UB7'@ESLR4LRTLJ\OJF;R]<&?9&U@.97)[_?Z.YS6_.#E][HY.[].?\[B
M3T:AS+B96/UJ,"]]@2BPP((MKE)MEU1:'!ST=5V*8G4WO2*I"&[A2X?M:Q *
M^YN1UDE#*';4&&5V7ODJ!T  Z*30:7!,J.ZU1E*[>,3PUYCTMRM*5U@+MDCZ
MJ8G6?W^7(B0_@%]*NM'X"WW83[H[ZY-5=,W#\%8KX;@6/.?<THL.=2A)]:_Q
M$7FO+TIJI)QA6JFR"WJ >"\>)R\>^%G0.L')J>Z:FX$L(OKP/9I;K64"PE)X
M5T1L&767,8@2],'"_CB,14RU-S[I?"4M00Q$%2Q9D<D]C#KQLPLL6NQR*C$&
M"7 F6)("SG  /%AMD7H=U%*DI8EK+!!&-N<M7?<QY'0O]-?OZN)KL^QM[MH2
M3W@V8TJAK"45J\"0Z0GCSM_2I'.=W,$'3W=*IRZ2Z.,TY2ESP_YO:3S_B_^W
MT&/?\+LO4W;27&U6WP%)Z+ET9+JH'KN)G6E>X#80V==,D13]I&.V<1R;Y1(-
M_-G\Y@O'!&A^A+TAZE>>YQ]SIA@2)ZV7^8[;+PU#3/M^OA9"/[ZNB#C!3I>R
M6UK_%;GN;<Y^N8L# &]5RW[=-["I1YD1I.]2_Q\.W0>D?<^1='>.40M1N5(4
MS?SGIY*O25?AA8OYKA1Z+VQ@*A&+K.R:_^(K;PG]=Y]T_U?@,K9$&2N&7AD!
MD_HUL:RM-X:3MS#3QBY[8F10;W)Q4\=)@C*&Q/,C17I3]!L(E]4EA/$$2TZS
M.-04@0-PH(G?--T"BGD@3)56Y+:QZNG,XJT'6P%7Y[="\#UY*(<3>W"LKJ,4
M#9*](.S S7EC_\RQD EDCHE?NLF>:-Y_7J+\(B:U2\: 19Y"^[]\;_E_ C?P
M'?)ZA2!]/($[<9!82D$*O6?X5?=MT60YHT'$[D2F_F2*,,W6Y8SX$8(RX9<\
M?B;JG_/;/FM0_M;0X;QP-&8L#YMT.*7'.E0L?]/L';.5^FNA]W19NMNS_.;>
M&)W[WZ'?+[&9:F[-O &6WU_+@3U2O4^K_MP 98X,:O74(!#._09PZ8>2M^.[
M@1'/RT?>_W\PV/D_#G[BYO\#4$L#!!0    ( %I$;%A5K'9V!UL  -JQ   3
M    :6UG,3@W-#$Y,C W7S(P+FIP9^R\!5A56_<WNFE$0 E!4J2E0[JD0;JE
M<Y,;-NP@I 05:20$"1%)0;H[I%.ZNR4%I 3D AX]>H[G'^_[WN_Y[G,9N->:
M<\PYQF_,,<<<<^VUMNMT^'0:</V^E*P4  $!$<$%P04 .%TGYE6V!,/ 4$NP
M/04G"QN 5TQ6 1D9<$;$I-7F3_ZL LQ)$70 2"0TTC_.B   HCT:*:(R !T"
M8>=B9^=E)T5$ 0@I6)E"P%"P.8Q"&>P$A"B#K>Q@%,P4[)R&%.Q<AN<5>P@8
M9&4.A!C#K,!VAHJ26H9L;!R&+/;V,.<+1)H+Q.NRKA@U-.CN>-?L>%MY7POE
M7+3Q7[0MG+>??1 N:E?M(6=JE> P>SCLK(IRSE.&PM1,P&#010]9.Q@0: >W
M_5X^/XN#(.?U:Q>R:E;.YSW$K&#G,G_J!$(4C6V!ZI(/U'^ ?1-0AH#!YFI
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M8$V["S!FGO5*B]X2UO.E'*)G;PM(=9Z\K;^"HK:%_^K.PF&@=5O6S,UL\]B
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MJQ0W.PU$&U)9ES\_V*%\_G*//6F"8 ^%Q.%F1G+DKGO%<9O67/[QC<PO!I]
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M58Y*"(UGW[D;I9(7FP&0:.KSP!!7IO9V#@PY?V0.+DS&.'&W:A-*,D6BLXM
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M3U9F ![6W_T'G[U.IOX)4$L#!!0    ( %I$;%AUXCG3X6T  -IV   3
M:6UG,3@W-#$Y,C W7S(Q+FIP9]2[951<W=8N6 3WH,$AP2D@P1U"$CQ0>.$$
M"5:X.X3@+@$"@<)="G>W0H.[!'=WIWG/Z.[;W_G><T[?.^[H,7K5F#^VC+7W
ML]=<SWSF7*N>9IZ6 2]E)64D 0@O  "$YQ_@:1[P$8"&@H**@HR&BHJ*CHZ&
M@46(C86)B46*3X!+2$E&345)1D%!0\?.2/.&E9:"@HF/F?4=!S<W-S6C@ @_
MIS [%S?G7YT@H*.C8V%BD6!CDW"^IGC-^3_=GMH >&@(LR\0$1'> %[@(2#B
M(3QU :B?WQ,9X1\-\'\VA!>(2,@HJ&CH&)C/-U2_!+Q 0$1\@82(C(R$]'S5
MZ_DZ  D/&?\UAS@*@9(!ZAL[0LYO,1EHM!_*VXF41X_IN SM_= QB%^1D)+1
M,S R,;-P\_#R\0L(?OPD(2DE+2.KHJJF#M;0U#(R_FIB:F9NX>#HY.SBZN;^
MW3\@,"@X)#0V[D=\0N+/I.3,K.R<W+S\@L**RJKJFMJZ^H:.SJ[N'GAO7__8
M^,3DU/3,[-S*ZMKZQN;6]L[NR>G9^<7EU?7-[5^X$ "("/]7^UM<>,^X7B A
M(2*A_H4+X87+7S?@(2&_YD#!%U="-; C>,/Y#8WP0TQ&>3LZ+9?R,9&A_2@&
M,1WW"OW)7]#^@>S_'3"__R5D_S>P_X%K#H"%B/ \>(AX #' U2U3IB_&_TX#
M!I\4GT41N6J-JA]"/(+JSTI*<D\'&XWZU]<=A2\*CG@BI.0GS[%192L"N7P(
M3X7T97^/^+?O*ZR=N3]R(\PHZ6!1"4S"5H[/U9V)S=T*='7FAC=[N]^\VW)@
M%Z YX*=PRNU>BS YTJ@<M=JW5'^ E5H>&L?,#^@SJW7F4Z04X>!ZGR-L$X)3
M(0U#A]7'1UU\;,*W3H_15^_D+IEEB_I(E@-[#K)?VEU33*OSS,L+R51[S#*P
M6ZFK S%;)!=BI4GNAP!62GIJ/JLB>J=7[>X7^\Z7MSI'(C.AJ Y,2H@514\
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M.C[YK+QM'&D9ZFZ!UK8X/P&:$X&UU$%:G97769E/ ",-/0L(3_&5>IJEF6'
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M(YVKE(*AV-N_R<X%EC<3\J]DF3*;'0;^"_='NKYI^+8,Y8EE)#$VB)9JEI$
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M#/S$]\VM QGX"]B^G:DW_[K+B[-QW;D7@RU=FZK53I:\V^2JT8AZ\4E$]0D
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M[>.4T+H=R,G4TRH=XU[B@0:[CH$+GJ]7\JN 7!R;FT[DK;-ZZ6#L E=9(9L
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MAYRD'0F*1M)MNKB@D\YX@)]_:3'FAODR:%?BJP+"PD$LJEB4@<YY[<1V04U
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M9G$NK_^IMFYL,W"L?]'4$_D-CXX]UV\1+I7M.9Z6"+,WP=;13X#BZ$B-)T"
M.]<@S4Y-0G-D4+!.(QE>$%Y^M-\U>3 )TO20& $[]M!";!!R=H-].L4:EL_M
MY'GJ8(M$\=@6.=ZO4Z+3O CC)T!(.![3''C+ %KL-N29*[)4PG_;6N_3SMU>
MI%+P5N(J:8]L@,PM5%F2(L768EU]&<4EO&*-=;:'8RQ".*DXB1+,9,\%9BUG
M*Y-YA6//*1;:U!!G\2B5A<9H8#5!**E92QN5!"*Y*JU=N:<R#:ZB^26N'?(S
M3?'E]&M"<^2FF")J02[?NN700U$R29\5UK'1"<^:,UD<CYBHC60FX'00[";
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M*$API'H"89S[C#':3V+IN8P,'P25FG<)GR1E)PZR?ON 0P+MI*I^(6V 7Q!
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MSB+1FGKE!X 1F1E6 PFUX+%:_ICX"$W\Z02=YT>=!&7)\T481Z&7RJDJS$%
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MY@A=O^<9SD](;KO)[ ^"&][)3\T.CU^^"5F-MS3NZ-VO^HUK0""ZE@DKU1?
M^U:8:- P[0[\N*GI2Z_6X$BA4*KAVH #*3%7V;;/H302,#$QA>OY7OJ=WSX
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MAY9O31X IPBA^[,NA")\$U6;O.NP"%52A.R_D]M;%?4 ^*I];W/[J>L4X?P
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M&T[HBPPUG/(CV%)'__^_-?KW]/#G?P%02P,$%     @ 6D1L6(,<U+6.*@
M[#$  !,   !I;6<Q.#<T,3DR,#=?,C(N:G!GI7H%6%Q+MNY&&W>"2W!H(,$2
M' +!@X7@!$GC3>.N 1+<"9 0:-Q"@""-NP8(KL'=W27 XYR9^^X[\^[,.3.W
M^OOW]W77WE6U:JU:ZU]K]]WDW0) H"BK( L@(0, TOT'N)L&I $,='00.AH&
M" 3"Q,3 PB'!Q<'&QJ$@(L8GH:&DHZ6AI*:F9^)FI6?@9*2F9GO*SOF8AY^?
MGXY52$R05Y2;CY_WMT&0,#$Q<;!QR'%QR7D?4C_D_;?;73- B(%DB&2-@L0
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MD+5=P0:"<ZL;1U?EN5IM.G?VA,A%M;7-_&#Y+>MZ/4PO%F(GK\=>NRE0]J?
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M6)A#W&KY[5_)JRW6UPO;'A7M((=_XD5C]7F?MY.>N!>526..\.<Q30J.3BX
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MWT-H:7RJW4Y_#RSQW@.*X#;$UG\L^KTJ&:/:CX],48:XFJ:?;3I1  "@!)Z
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M*K8&V-N4$[( *6F?T&_N7KE+KP36E)@VH;'M*DX/ ]X8,0]:]IC:G2\H-Z=
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MI;J(#\>I^Z'?;H$3%:3J_=BE3]2LR1''4_VL%\]0*7MOMOMYL]6'U)!8Q]J
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MIS>#ENTW4\8-=CSBJ$Y6LL&XIO6RC%NX8GY>E^3?.N9@(RZ=X+L$-^ILT#U
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MT-%;&ICN^CF?,-%)M7G8A^;HNB'8#N$,)7[$[F[9M@!E]1EJF1+@POMOR(I
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M5H[I9I?\?4^9HDT=R></^@1G:.)<"_>Z<.! VW1]A4#775@2K/Z++N95V+B
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MV8WCN:+N?>AWC=Q@-Q3S]X,QB^8R5HC@Y_HU,Q=PH%;WLP9;)'Z,$K$\C8N
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MIL%\R6&\/=^E1:T2YQJQI*2K5I;ATC_#U>=<7,F,V[27>89\*:/[@UIO!]"
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MPB&*D51RZ4R80=&Z\:QPH&-MOIMI?:>D?0BZLGI9NF+G^QCW?%P\HW117#K
MLLVHJ0K_TFA:-0RD-I8OEJ4>>4QH7:TMKF!U8B6-J355<=FC,^,5\MC<?,>G
M.[!4AX'0V')K,[@@'28(5S2Q#'UZQ'-[D+5ZW?)%D*1QAE3V1YZ%QJ?;2$SA
M#5\CFWL@!EPG">'L9ITU>^E4KKQ)N.2@7_95SWY]8(((</\1I5ZHFW6=2'29
M83I%-8S0JIYQH7H<O=94'U$0Z(M';1*AD^2_@8T0WJT7 6%-.54QN<CUUDQX
M);T7M#IAL,[&G40_'Q&$]3;@5XG)L=A08-0,H4T+\Y!H/M*K6KV6=F3/;W1
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MB]-2H]<^?PK.!Z&'13"^)G;OVGHP@A_U,T2CA;<:4U\G[/Z4KOPL5%$F-7B
MJA867P(D8;$\0>K/]XDF+PFI^=H5=]>.KQ9'Y")9U+Z/:&5O4;!1BK\)BP5.
M.;F&D5*&$,/'3F)27Z)%$^L:\3S,?+7S4G,_ C*:ZNXY7+/LJ,PN*,WD3RG&
M.M7>F1:XF6Q1[L6=YP?:\R9KKU%LZ%JL6FMV\J_3!<:F__]O,LB97E!DY)B_
M &8^(5M^(\'KQXU"DX! /]*WST/7?:U9]G]>..-@\.]*_5@?5("DCY1N$FA[
MVC_DB*(9#3/?$&,;^F3@B!+MY*HPOJ/VNVED4DH5A\62V&USJK"C<O"X;":.
MI&-]$76%#6)-F"#F<K9K&14UAT$XR4D.,YKH'O > 7EN@4$KR=2 <.A5HOSS
MAHA(7('D%'^MF;.;W8<IF)U<K?UQB<!!8)=PGH3/TD<JZ8=]+"F*N XL4;S#
M>617.6?_?0,S%-*Q5OWT5.-7+?F?J40I^U_'4:FJ*CF[6-8WR"6#OI(0R/'+
MM'$ZLJ-41(]6#!=6<2KMG!8>%R N''I<:;QD.HR"28 LT*^?E#2V<;A;:-(<
M]GF/\EGLB4AU%>4* $TMG#1.D7H/@:X2+3E<(A )NP* US@ 5L'5^M(4KS[=
MZ#YY-;V=]\A?*Z5DQ.3K<+;7E<[V?^TAR-XO_"]02P,$%     @ 6D1L6.N^
MB^+$1 $ *EL! !,   !I;6<Q.#<T,3DR,#=?,C4N:G!G[+QU4%S=UB?<! N$
M0+#@D"#!G<8;2Z"1X.X$=X*[A6"-0X#@P=UI7(*[NT/C[FX?>>9][KWO-_/.
MS#?_?#55=W>MJE-U5N_]^^V]UCIK[=U]GF:>5@!O),4DQ !P+P  N.</X&D>
M\!'P$@D)&0GQ)3(R,@K*2U0TG-=HKUZA$6!A8^"0$)*1DA 2$[^C9*)^1\Y
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MQJE[+,OG'*"XNCX>2<UZ/X1<ST$%'@&2^>OZ54<I+,@##!O4GY=K+/?/+ _
MI8-T>&ZNJ.;("Y$";8^]U5ND4ISV5(-<ZDI%!_!H!C?$,C,,2@11SSUUI28<
M2Q$6S9PQK!/#!M.#%^TW BD0PJ^+=VG@_:N/X:6/4YF1S=F[-XM;XHR#L I6
MUC$3.XZ/VFVP,#!W-"(@%PWNVQPNE^JB+R+M1][VD!1.FOX5F)%Z":6(NLD#
MP(CJLB(8\CI&*[+^"BZRG=.WT,$Y+4U_T_/M5AY_@F >Y B9U(N=<SEDB 5Z
M,]EU0I'VM@##F$-A88=NC:;Y* O!_K8;E]8C,&I%%LV<E/:XNL7"QINX3,LB
MF+)&@?;%)L>[<BVWQ,L'J?9ZIDKRWGPSE7CK3+B<[ZSPN^8'Q=G0L K-.6&<
M-^_:NK'\Y:]1 6O\JBMFC1]ARZ_-A8LUNJ6,V=M9*&M!+*P10V7+OTW:YYA#
M]FULHCQHO8KY)0C9^\T[OHEKV<&UWM-/FA$H3Q32&%$@8$:* CQ:82&+8GNK
M%ZEA3P"4\+ "C6X&>8TY]?=WGV:XM6]V(K(]V0T#^(@<O@2H39#U51;?4Z_N
M28VZVF3,B-JAKY(+_?+;Y895_W>F %<A02Q5#U;223#PE69OP[.-8\FM^P+9
M\*(4-6/^GF*C(PX[B]F,R..!U4K1,D@GO[T-**54L3CK,+1I%/V<K0?*=/--
M:2>MRQL<0/TZWH71 %GGD,7?OKWH'2\Z0HON8 V]Z+1/>W, =+4^> )4''!]
M$##1U;"-CMP?5KC[C)PU^@18%O%SM$9'.X'?:50-T]Z-N;9Z7].DM2CN<T!>
M6<RO4M_UR\J_G(E[ 5FV*V".),*)BW/%QR0(>P0/YX@3E-W8.<>;?$R_N2AJ
MW55(D7V?!.-^J<DG;69Z&Q^T:58<=Y+(I4"B=E][E:[M'^&N><=Y5_.5+.M;
M#GH1&S[FOL46C\/V2B1GDBU.JOPB35C#5:GP6*.K@54V)D?WD/"5LT+R#U$K
M2S?U*!S#>M]#,T*U26<."-Y$*GUWR2,]Z'S0PD!_' <Q(4*(]O:5KDO[IPG&
MHR-#J*OK=[PN9"C5AUO$J#U!FTKJ%X=H3X!I8?#\?FMK@Y_@Q8CJT(B+]9W$
M!&G[5NI^,A((QVWRNI&,<BZQG=6&Y52R!M<K<P.TO:R>WZ[]&R,]4B%I7E1N
MT/$E<CH;ZJFVU.KJY,%*?8!"3%>#)O*1KU9WD$/#C#$$A3Q*/]BIQ U;6GV_
MK7N$_'0BW=8>?72R)E3AH61&C/+NDR91I@V^8)C'F)4CIL&E+"@S>!X]864J
M>\^<O(N$M3B;4ZY#TFH;HUBZ-7-;L.JWJG,:Z;+V&LYPS>P38'B![.I8-7B^
M/T_7@U>*3UQ[2V5H@]_W2+VZF:2NL3KLLPVQC]=Q:M8X(O9R\[(QDO0"/LE]
MZR.'GUP%B)EQ^ &J>U**5W[\4>=FZDPP%CZ<8(BG4&&;%R/0(; BV']C/0N>
M_*S*N9/5O6G86$55KN\C+0$"L9^4^MR+C&MW&27M/,81N&T6>K'(OS?ZD:JB
MTMMY_;9E:)L]=,\F!8_2M2*"%\(T32F]#MS(B@U0\.^S@ZX&-2#DBA;IVX\>
M@G_I@-,P[B]D[[95D[!64F6G.<:.(AJ74X"OHG==2>.WVI\ (,7'6QS7$^]A
MI2= L[]KR>8"CV *;>S9U7-F:Y[ !*T!9[TJM!/'[A _:%2X.7Z>F/^F&!^/
MEVJL1/]^5WA/T<:@:^UF=+^;KEH5G/E/'=)G#%."?\8NLUM@O=\):_3&O-^^
MM*@3F+T$,0\'/KIU/P$\4?FOO;<*O)=%&D>LAQ5OQOU85MA-]L"5VMT':09C
M'O]Q,T* [&8W[6JDE*O_ROA^)ZL.)+LE.\L$NQPNW]'Y5ZX1C[>XF[7Q=]UD
M&E_1O(,BNN(KM;L*FKNS7/_@4GL"/.O-O7\"I);_\<7&+?Q'BIM1OPDL04)0
MXJ&@^1UIV&60]U:5]]5(YC\0GADK)A\*IE#PZ!1Y\SZK,5M.?QQK?$96]*R6
MK9ZA_Z+G>VJKOVMB;T/8UEDQ"(-LGK/=5I!U3: K4%K3MJ!^KMM5%$=%K/7O
M2E1\*(]M ,<M!J*QU6B\P8'5A^[1N:/\\DSB$R1FW2_>P/G@C?>PZ3^Q_A4W
M&O5VT0*/R@02\C,F7V&D! G4E>3ZURCZ&I,M@GP6?O,.DSU<TMPIM]Q?A3S>
MX:ZS\?:QD0F&B?2L' ^ IQ);E_.3*VG!^UZ"QQB&=Y_)SI8$[_;E+PN];X[P
M'B[INU[:WUL+$H9@';9&/CI*(6[*7A8^ZG8_PAVDF=<\(SCQ7M:/.7!:/COY
MH]V9H&LM5;.ERG'PPE.5CRD.>%1[)JDFWNV*A]:6M11Y[[U"VG#98'-S_8P$
MQ[-@^=&]\WD>(6>:$4B,_@VR3!FU\N,@BV34@0',)(*]Q)^K^;W:4L=T+KME
M3E__?'G^GU^NF'[T^O)L39TNW[+&D5BQYGE]7 O. N;@O07,,[^'5D=F_Y0A
MPQ'$7GR<M13<@)'=[2L\Y*#!;X']1@Z)IX>=8_B-$:FJ>=KMA^@;QA"\9ZNG
MK@"5\'6O2$/4E=I/'7G-]+5%W4FCIUF8EU)9+VPE_AX9=ZN98<QKC$%GHES$
MM75/*SENJ)C<L%0.G,WKXC)H+6VIE&^#/=\Y6$> W0&^@\7_8\5T0*8>>0IO
MNE_6[JED,38$@$#FS86;^F>DHR#=@S?/-OB7EL1ED.!?5E9*RU:FH_;H\'M(
M2Z]\.+W@-O'1@"NA[U+NSSQ _[;%W&\O$=X(']+W=O\L$C!(*W:SCDG;#^&_
M.%6]4<$UH[.PKWP=[)@DK5;W;&;(:O^:\TY%81_5EWC*T+:8!CZZ@_^8\^:]
M5J?.^.:[+Y41;76TV?/O4+O/BC,E=Z^X"V"+/$"K"/F[3X)G<\^>*__W^*7T
M9IH-R0]F&2K#R]RWDP_:&E>LKGX[9!T7-L^.N4?V<$YS]ES1IN;_Y2XA/."?
M\#$U>ZK6&@L143V"&KVMU'63J.,_7.MD]H9#'MUR_[-^QKY@6/G%KSCZJW O
MJ%>G,UL<:^YQ:M#?:R))'52R2H>Y5ZN:4!\(,UQ"%G+-MDC@AP9AY34!^.7W
M/7IO+Y/^(YH9_ D\9/^@>@9/8?#-FU?/^5#S+'>??^ )4*5[^DB=[YE!=G/P
M!_7?3%7C(EBNN&_':W#_Q(-]_F[BUI8*MZ!$]K%/@L?OA>-8IT3)PEP?T[ZN
M)#=X.=KMZO?^"9"]K;D&HXHRQ%LF6YU_A])_ALBBBIZ#E,'N)J!V9?3@S51S
MIZ9]@-IF<^].ZO\[."=61=0<E9%I&$W/Q\WT&F&FBGCM<*10UH?C=S-7N-G\
M,P9$5'U\'B?SK^Z#[E1G8DO?LPS(+B[*VWSEICY+EV]1, FW==JXEU7-R/1[
M!,&>  [>=-%E()S_;A.7:!C-"KHA:EUK#)B(W5@"+30S!'T327)\-,Y1V&!Z
ML^4$ IH$-^_G>872>LP\ ;8R_D3H=HD6BZ]XMF0?-9A=XZBTUN^F=A/-=Y)C
M2E;V1Y=N_GZ((,$PI_Z;*QC9>[Z+7"'V-,]<XO!#$R?3@'X<Z(4=C%QX0S6?
MI\FEY:A<DND]Z,.?H+W^ZN495R%QFMLHQ$F9C);T)GVD1B&.42 P]V;T/SJF
M_GN^DE&&%@A>WIM]YD(OTK?O!@KT.C.JUH^2AOV/;.!TE+[K.C+-RZRS!BV0
MTFDSK?SL/4QCV\TG%7M,[;_YXD^,^YJ(9Y_?^*8JM*KU38QWDD]M/7QT-/D(
MF2(1%%Y=FTK7=PGRT1)QDR9X OBBZG(*WFRWI+C*Q&E)]R>;3-5GJ;X7-[[?
MU>9(*<$YD?%$KQF0/2K= O],6]8=JKLGSV.3K@3U%CW(:D+:3#.#_?+W_-3Z
MY"$+NSD%TMOA[7\I2VQV/US<[_DTG.#]]*'NXP.8 YMJ3>T.9RARS&F5E$FB
MLDUE$AO Z9X9&'^9+JW */+]Y9^9VV!GS\JNF)=M>KDKYAQS/:V1T9#J46[E
M&3/9<5P.D/R>ZL.2T;@&MIKKS-6]R&S"35[M&X( M46=(J0R('2O_TXPT*5@
M#)A:+EK=[+@?>8D?@2NIC-71A[LT^VD# 0BK<$>Z(BZS5LM"LW9%HU4]+W6@
MJW&"AF533!\L>-;#\(]_AT*R()^6,1@X>ICGY:-75QJ"[<K]?+I'IKV-UA:5
MJ0TG',SX([]2AME'S4SCY>PND7"Q@3J_0Y3BY$E%&8\B@,&E<&6,) 7WS>HZ
MWRIMI]:LMV1AI5C7-G(M-5PJSE@+ ,X5@^,"PO!RO(!W$I8.28:U]989+4O*
M%_F-V)4=6,N[A-6I[*8-OO33.UJ#$V5+NXI[O)TI Q#*TU^?>N"0S<VPC?7-
MYS;\[ZJJ=\B7\6Y.KM2FP2MFI1N3:-B:<#;D40Q^OS0F ]L>2:<.].)E@P^0
M]IL?LVY5Y=$(27VS>TVPXTRT2'(3;6+]QQ:3Q[:]\,?7)JST)LO.8@(>CZ#Z
MZBZ<EV.TE.)+.TSA%';T696ZKV</;;.:.M:W[&MP[:XZ>,/&*+_2S7<TTLB/
M*--7F] =:W]N8K)";CV5L,FOO?/HK^K*3X6*2:-?GLG?J4]X#5O+;!_;^LYG
MF^8&6@/5P_HU;TI<V&K,4ZHJS45Z^MH?X@:Y<*[>3^_I;QP66PG$ +,;3!18
MOW,9.I:8@U0UQJJ> +0*?,%X63[W7=#.*BT]>YE3?9*ZG/RNN80'Q_VH&!M8
MVALI/:L/T.B9\IX$-5N-M4ZV%+BU1A\=*4SX+V3L[IOQ^V5E.S+A77"CHI*Y
M^$VHM^-&^#;GTC++EK>> UCAJC/C*U/,YZ?ZH52=+5F%/;@NLR*\--F<H[Z_
M<_N^[_5$CW<:]^&%+W_VYSK]2D<+[+^+%A$E5M_:T%)P!<!7H5T6',\/$\^O
M?U6ZQ'U-23RF?^-L7VT46_<$,,^1XC;04[,&[:I\!>00()EE4M.DIF09W)$.
MD_#'=F^HFL=%#(49/0&T5&^4Y\"63J@T&;[^./)"Q#;!$R2:,4\ ANG;:69[
M6_O7,,00C]?MF!,JTR%'HC5!RI2(RAG:16"$,W5=T[!6@JTFZTR7Y$,KB1R9
M(<FQ%WS?!*IF4EQ IE'!UFY*=ST-G>$\=B\>'8Z8J]V<<QJGG-YFP&Y7?EEC
MXAC]O$7UP I6')CI(8HLGD#-6APH8(2+@<\F/O&=2U5SR*(FDZS $E' E$$#
MT:)H?"XQ&N')[CF2:"2=,#*=P2GAH\ A=L(9 VNXZ*DNI?RV/EQ\H#F0-.A9
MT;L=)U 7W^))I_?#HW3(NHG0$'')9@"L48_%!D_"D0P#"=3*3J6:VD*#Q@L5
MV]TN@$3I_.GO;B$JS;^S2O.)W6<1PHRH<F3[*C@E< O3L1]JS&6O(DZ!B>42
MR7&,CR>#YMOFWM7%$H\GCV)IC!E]]78J?',T&77A97_7R7G65K#ZD/Y8>"9[
M/T55T!K(?$]H).PBNT&6O.=71N@Z:=7DT2^@)P'5M/]Y0_;[X@F36MSN/8$7
MJ9,:5JSWG;L&P/S5M* XM_%NQ(77)GP/(UL!)>,\6N'@TF(+PC._B;8<PN3)
M(A=+8S434R,Q";#2%S]5+/W<=(HF-[)@?D:;X@XJV47M7-IWCV*U/$5,EE2F
M3)&9X6&SA=6QIL-.KL"RTZSS&;N"O@2"6\+0-CMWI5'L\=)B&5S):/=I,#N8
M$)+:I?EI7ISZM$!!UM:ZHY6>]A96=?B1G"2G8N.;!![5[WRSSW.TX]?B9"K-
MWM&N)+Y[,8EQKS("7=Y!?#2Y#[WIHAAG,$\C93_*L(0J1V:M+[/3+G;F29=2
M/60%X[BS;*/#8WB[U6]D;=AUYQ>:Y4B11T05C,U D\7 (MUD='!7852XB ZT
MDHZ)GW--,F0+=3_A'-?RR0IKHPY%[R%U4:N8XH@Y70(S5_=0.)J0+A^/@K75
MIP7;NU_4Z;[8X?6?JIH+X0G'DFIHL=<"Y@[,[JWFGS+*"DES:DI8W=](M15&
MI7;5O9:.EI8Q^8PX:.42T2%@X!D]V@[7WON(V__>C)+/E6P)F/WRM,38;JW@
M#/HRIJ/VB\8+M@'6J5\0BBI#O:FF(D"D$$'Q%D=4)ZI5LY)A/SQ#0[*>FT*7
M.I$=NH7.[1O;R)<%;6A,8*0?AC^S4414RN6="5ZU($QG[X!YI=.? #E2]X5#
M&F\-HNTL1JNBPL@'O,=Q'Y6'(6;9!J/]$W7SGB$_Y$5M2?/^==MUP*4<OBE/
M(.R!/JZY@@ZRHZT:(G!1 B*Z5>4XK61J[RE)M%D$)T#"U@<RU(41["5(U^:J
M2."=LB&+LL"BS6B>_"]:Z]\#V+ YGEW[<#&5KFN B2XK.M92E1^THW5^0E:;
M$TW9R@\OU3=!KA'CY#XMUOUCRQ-L/8PS5G<@$V%F;7[^-;/4VERS7#YWR,2?
M]$<#^+-*?AF\*7?K%E!%38%]FN-'-QTZ7RQ_4],.(?%EH;CO$+T($<WZYTH]
MN4U>!VLC$4[".!6&1L)*1^/(L-93$%UHH&DVF6O28!]FN:X%^PJJ)=Z4,UZ8
M$28S6[CX-IUV7Y_2253HI-J[ZG*FJ1WHS/V 6V).RI A+"[S$"-.Q"^9F-!!
ML9_T!1_S74Y!PUL[M3.%$B>5<+INMN0?3:.GDF.<._C/):IY)M8+\1<)2ZD%
MR$"I3U(_LBY *AC75Q$/H_<%DN'_N#J3S='\\X^6MG\]PFD<AJ$)6%<%)@?%
MDR64?BX%G;3PCF'<&@H6V\.\7J,/O&XJ:0I7F5O-@ <5ZA-T-+@4E:,&$!1&
MU2H#,)7]?LQ-A/8EDY?BF (SAJ.:L!?SPS)9M!(RYW?I2A/G?W+:JMLN6K#H
MXH+5#R*<'C%W=/PVMUW*Y>(VNV?6Y$_%\2'&6SJYOLJ-FVQ8+<S%:I0_">HG
M"^<5"?)R34--J'Q![-K@ !@>,SLKHA \;B]]PLOYWO/2CV/OPMNET7'H*S8J
MU2='=MH*#^T&$<M/J!;PV!F^YGY.S 4ES8M9O[<Z?ON; FJV:,KKE>W).#SW
M!'"Y86"_50G+B30X7IMG[=673 R:J*SD+'S5_3'*6*57<1"(8GI[_F".]V')
M*;B;[JNY;%T-R6N'5/M/U:_O[N^F=:VX.=?#"^C#?? /??8M?DF(^^0=TO,4
MEH]YE&SJY#L".X<'NO7V7QL,O6+9*/S%J6_<RS]IT03Z(CVY :-I2)/_7OB\
M .6! W5"B^Q+-4OOU/R[ )WVY?WKXB^+DZ2^K5&&F[- E;GT[5&9W'),+*K'
MFRJR"+;R<1%3*EM-H,W'Q.O30HK#GG5%=[7W%3LZC72T:7Q!W^-"G7R9@.ZB
MW)M?1$4S: @W(I_]KU_41%T]!5]"A^'"G":CC.\?!W;>6+LH.68?-@X$)G G
M$(:]-58/'??H[Q2(),0W!3L K27CG4%D'_7$O!Q+!5D-?.C%B]'=H%K:@>V<
M\<0A[#LOQ]%S,QZ5Y@?MGRMNX='SZYDKAT'6J# .37K'@HU#PY/7Y)HVN+LC
MFE7ZK[A#'#'!/N:A5S73,]A6,^@B![\+^\U]'& _/G&MH-/F98%K?M0GC,[7
M\=>1MD,JXBPFGVL[H^I<!%^)_K#\6R6N=7#C4A'6R^L5I8PWR  EN@K:=4()
MF[6:]R0!7E!<>C&B2@UNLPFOW3I-Q?+:)CBLQ\V7=T6R/J9EXV')I*H_#WDW
MAJ1UI7XNO""PE3E[*^)4!F0M1;$<-)$L4DX<"38 Z)WG;>@EB:3SCYR2K"M%
ME5,DCMLG:!H'NJKK\(UE&9E=KQ73(/F^0W4_S[5$BA7^D"HD(P&+86*,NG&8
M$J*)7L>HIX/G8\VV^+&U0%3\3OE#9/*XO9],EP:G6T D:Z8ZQJU^2U_))"/%
MH]"4[D6G=ZQV/HAF_T\N_4441PZ9"!9F(B(M4=4D+Q'95?12QW7XX[4JQQ*9
MNG",>'.XZ>V- C%+266'%UGU!)"JP? C79YBK;WOCMKE(TG-:*JVR(A4- _8
M&GFL5'DB56DIAT[4U:RCC"UOUSZQ+#KK)U]=H:K&A,4;FJSHKX/3B4-F7,:J
M$5<FZ5UT$R5&O"J3;XW\J8Q,4-<=AKESV:T(AB4'D^0"@'WEW;EN348YGA6+
M3-!7JR:6W1L$K4"M7G(>RG/,4DQN1C^A.K.N"3%!88WX>#>,P(.U67,F2B],
MR"&35]4\QIM=O+&?Q1SXF5]&Q'_;'LGM$KIC):M<V9V658-V2(?.4])? BW4
MFJ=6Y!#BRDBSL?,*V%V:I4#<E .DJ_4LQ!">-@[E3G?-B7Z</E^Y*G\M>A/;
M?7KPYXG<<,3:"4W.*^HK#[OFB_@BET&.D'8SBQPP@_M' BT[B?-TF0?42U (
MZA;'Z5:).:.@JK;Q:!9G!@]>'GPVUIN7%(>D ?D2(#03Z8ZJF&A6!=9%;#)8
M-ZXDF[-Q<>:76F)EH+[^_$(I-D?(-Z^Z_!%T+^T9,F?NK+;X=H^Z(QD+U9!-
MIFSW+W7IY:>[H@FOK*)Q0B_G;F YGV,237H2>GH?E=)K>V'IDJW<[S>%N$G,
M'X/LBS2]&[VCBH;P3S0(T06KBV^V;!_%JIPW)H9>+8'=17%4:9?^46='P*S$
M0/0?4P^553[M8KC-E-AW3?4[KT[[_V"K+!$N@#1&8SNIFD0-YK0$22[.=/.R
M\$5VCZA,%@EP5M;(V^2_A;"GQ#C>*MX#,Q=-8;9&MC\<WHEU^YB-JNU*6!HT
M))HQJY^J8Z!"*_V:L^A"TD=,F[E::G^J+\\4#'$O82 E%5X'X-5&,6=$].LV
M5!F.J9FRS/3$:_C/:(724$<I+&X3:N\7DVL7)9#@3.1U2@G%R/ FMTXZW#"%
MVJ9\/Q_4K?99?%,N[E^YIS+>-B?1\2L@UH6GF(^1MXN )?T+3P]/\<*-6[)U
MLN&YF(<.?D.BXI;OQA;40:498PP&E\AV$ $#\M<,&R G.DEA/0'>NJE8"G!7
M,7$5W!BNV=50[*D-8W*5-[*<B,%,$^W07HE?7V;>8<A\B;+"OT4-P,#:OJ*1
MU/W$.L':FJ?;18CF_ I>MX/XF =6IIQUF^1. [1X.Q1E1KA.GH<[L,OE='D+
M$2LO))G!K8%1.-MG!HPGOU@XO"SAI/DUGKELMZE94M1Q50*Q5ARM3"PR&U/E
M)=& \5A-T8JC1/PTKIL?E&A,J]34Y_[=A1TZR=>_PZ3KEWR9MQH:A]:>N.>/
M$Y>;I(JUD26.1K5LNBLKO#"!-3=H7]QM3+ *87F%V66AC=<3/[""N91X191C
MQEN^.U/PP[7J8SH08>&*X77(NV"4=[8Q\A8JM]\KU.=GV-_%/!CZ0<5B,CB=
M#6^5RUWYNC!E$#^OS)7C%-KU]E1:6%H6?V*3,;*=#![DKN7A65'17.BI0-1S
MR4TJKR2MRD12K5:,9V=@J/M)EWCNR6(@!24[[_6.=56C]E):6VH"@Y\ D8SQ
M/ ]]9]>J N\YW+C5\[GT#W#DM7)-_S4E&[Z.8]E<2&UMR;8OQIJ6@KV/01YM
MR=:+I*?FH54GZ@JEPIFCQ6G=D1&]S._SFTM4)2GD4?J1 .5]XX?UF>%3.#3^
M@P0PG_E-\D51+U&V\Y>H->,(S9<%9K/=DGIZ8 WY!F)[;2M2=D-?GWS15CE$
M5>2I5*'?G5*B7=)X8R<^\!\*^]GYE Q,NZ2Y25DRHB%B2Z/E)WTG9]],K<24
MR)C,ZGXZ$"OI:Y<&1G#4R4U*% <GGF3+R=@O93@M]AXI^(-WQ$</\$EHLZV^
M;]!:]QW:ABII.A.6];%_7B&E&^<QL:,.3U979H50\FS;RMEUDYA5O#GVKQ#*
M[N+.+[F0YOM8'<STZ!X<_A:X#C%@B:I @B,@A:(Z.P%CT=46*R=^/0$B7)X
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M5F")\(&&&SZR>K4>>$FP9XI^07/^]S2>Y&>##+]OYMZO+%02 UI,JT=Z\1G
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M%57F#*-TF&_VNJVWYF-Y[^BH,[][]1@V_(^_?4G>&T<C>-NF-^5<YI.M&JS
MH\'/(YS(_5R"LCD(J';_B\!!,<\;A&[E@?U+FR[]&ZKW>??(R>+5-=HYS2!;
MB-H.F+L?-S:"\09N$\[1JA,Q!PYU/.("^FB=Q%[5:S77F3NP\NV//G.FJ1.8
MB)F>ZZ;UC)EB."WE*SHY;JJ+CS/#';!5OQ:NC#F]5I6PB6*JBE!3:ZOD^Z?%
MEOH.<\UQVX.16^[>_I#[$F.L==%-0*A_%FTTNRM\Y#)=Z%$R^39&/PF2/&XU
M&4PH5I3*"8PA*ZZ7)LR\\+HIV9<WF)I)CXN0/3=Q7DU+-YNHZV]+"['&04TJ
MNS9MA$#7]5,>N>S(BMI$C$S9[/5L_Y1CR36+%LK8]1%)H*8Z+R)F?-+-ODBV
MCEVKD]"YCD*V_'V<Y!00K[Q7=90S3]+H+DZX76M.GW/+&\RB57G.W5"D[[F.
M=D-P!J]8\#8V<TK+%P:2>3#<]9D=_M&&VE/HIYQN!WS@0@J-8T(O6Y"/X#<U
M*YN-"DEBQP>GW<L&CL"T$@MA!0L<;ZY@E<I3*7P_S7IR@[\G>MYHXV3X+J&T
M?Y<:N .$"'F]>RYU)"A-+)A=[THUMOZZ4:BL=S*9!V6>$7'\+^R#F':I_K);
M.?6KT*5F5 N#Z, 7['A7O/2KT%D;0VX5TW5&6^Z:$T1B-HWJ[C(F TXI5]5S
MEY'EG;(?2-K;N:6)U&Y7X L:%"SU:&RX0PO1%7,70!-*JQH@5MB/S= R3&M:
M,I G1O10X*]EZ"K1$28A2S2AV3Y42O3"<&,*#OL#,N1^,MG6B?Q>.U1'CSSQ
M]5C;2&?+\5H A"HR\PS:PI29D9;GF5?_%/$.%\Q+=R>;'Y+32'WY.8C'VD+7
M;"YI:>T'1>.70JOU2)G^Y>$%F03> @B_?$82H,O3NY\<UZ#<NS/VS/_1O?KY
M>,X,.M'3PLQD&;S,GQ'G5\9FM.]BS4SBF'IV:Q&3\?C=\VDN=15QNDRW+Y E
M-"3F3&SV\4HG=KHQH*9ZUX36[T/UUY39TCX53'"4.B$2-$UW*U&*'K7=QC15
MGB$>9:VKQ.(X8IK:DF3&'!5._''7V8=.G0$L>K0VD/3N\%2G+U5%5L_%H!9+
MF1[]Z$/9"%ZJ8Q7%M9+  $!+3EFA==$14U@GD<W"NYS\\IS\*?]1*Y'D/ZO]
M;*7_+>B<UAD2I& AU 4FK43=EZ+E&M;3HP?HI1>0S>9,D&=&&W<H\;UF4:NL
MX(#"MINH.RD+S=>)E-?,,IGNYU6]=\2_O*?'N-^549T^CQN[A5UYE1,K@\X+
M^*YDI&3[G?0#S<HZ'V$-#5/,M00!C7!MJM64.142.&Z0_K:CC%R):=@56IEV
MH[I$C%!:&>[*Q'RC_.)&F<V!A =E@-S$12A*.Z+A]&^]"YJ[ZFW76!2RVZY5
MO?3L9!&WBOMNHNQ4ZSOB(N)M8FT/)QWP5)&[\<ZRU:-_;M-,/;V_U+M8Z$*%
M+_5%?WE:UYQ#;!S  .8T IZ(^D8"[YNXZT\EY"H[<R4]=/U"9"/D!JMKF<Z<
MI^T41LLK+&COJ?AH(T^6[%A)%1/G9=F*U=V4J0I4K>/+L>#J5R7DU59:> 96
M0+*/1'Y:;EL((,XWMJE,+>NN+.<B5S_.JQG45 /*MXR9LQE7$--&P<S4Y'IM
MQ/=(1&;N7.,'8<UKZRWQM;/7N_BT9NK78?0QW& X"SLORHH=CNF,QU=#WM @
M$Q::9L&!"^@A''YZ0O7N8]YWH?%"LP:^PD"[M8S";/_PGB\&^W/@%D51;.4J
M!*!]:Z@[8:G>PD^>4RR^ZSVLA_$I X/O 'RU)E=_)*M,96>AFJ2!W/<XLB4(
M")M:?LBDWRXF"IV$V"/ZUJZD&+=4(J&']9@F,\IH]K3OB7,*"FFT<I+Z;D,X
MJ3+S*2[[  H#^E4=KA]4RN7[N8%BWXQK](EYU($<_[;M@K^)%6(>W-9FJZ[Q
M_8^-O$AP#)CDKV5\*FRF1"P15SW]MJ//"?$!W3^_T_'H<O_*I:I)2$L*@2:8
MH]>X*>6\]]9@3CR"**=$?("4#2+^F9],G"\&0-X+Y6EWD?@K$^0TCL0J?RPI
MDR=9L*JI+H.#LCX1OZ_'@#+U2#;B?%K5_,6VJR!R=# A%8/,4K*N/F TRT6@
MCU* RIS55&)MT#1K(V.^XN6!+V%)BD6(+5/FL8[T*]E%3PHGO,.,\(")<./-
M<Z^ J>:*9S2HVNXGISGIFZ*9J/XCB**ZB.B&J*I"AY_"W@[FCUA"08*2NA%B
M3+JSJS^2YZ(C'(A5Q4=DU/.5IIXF?F%_$3SGF&VLDRCW!W7^@)TUXEGG@L#!
M![IM-<7-8\R)ZM"?3NK^ZDDL:\=R,Y:L"B/.DLVPS7@'U%C0B+&+\D>7/F$:
M<Z+()#HM>A&+/%1$>V<FKL=<YX&5=B)[-DMZDU&G<W*FC-E7";5WA*1'"??8
MV:P6.I-.G7N% 5^8Q&BL49] X\<TXP=?]>6S\O\=!WL%N9<<C/T"UMB:<E"^
M,-U:9=[RUM?]>],$H@$_W&(S_B*4?3G644*EKW?PS$4__NR)(?-KOEE45EU9
MZ$1?E:04>RVF<O@[T3*7/,F5<H,^V'%3Z[:8]X1S;*<N1T$(+EU!"%JX+KU/
M<C)L&959DC@2AC:>$W0M'4'"$RKXH![#VKO'AR!U<?6ZG:B;W"45*SGVDGLU
MS^W+TAK=_GT:9Z:CIAAG3HF(#TY:;;TW<[@(;?[^ 7O2B#GCD-]W_16PZ(;&
M+UOBUC0K!"-\R&P],5J[RE(1^DR\1!1)]QI-2KS/#_0QV6P0Y&#U0/G7ZA8'
MVWK#Y<TF0"9=_!X$W8OF;)K:7B(KX5%CL9[-;N0H,TI&".H908;)CZ&;F<UB
MS<]QJ'*:SS^<%5R%PE>IY%:Z;X_EK8:.8;;Q1X-S) )#_5LA[>1;B@/K1;JR
M,8^B+J<=XM,%PB[Q-NS^8A+GHF#F> ;G2$X^3[IHVMD=HACY">JTF$\J.S13
M;]@C &7KY"9NQVI"]H+/D=HT9)A&DTLJS39UIGN?!Z<3R\>H"D>C7J$,%9IU
M_VG1?M8Q:1 D7P?DZI)1NY"E$'R? !8#/$PL+VJSFIUHE''+4E;@%BM2=D6/
M>2M>UT(AHHP&XYO1-.\KHL[>]:MZ'T7R.(Y\HGM4&TG0?6?BI#+S',UMC1!_
MK*OM\5&1/7EP0$]?L VV0)\UMZM2ZE8>>^/*.+)H9'MPQOH54:#KKI2. ZWS
M "*3)?-S;]RZJH-68X!:E'F^$#??AUPT+*-0,VY7MYS-/-XSK.JVCY.U"#U4
MR:3E=H[U(P+'FP'>9!\OQ+==,MCM&A4SU0E5(TGW7%^=,*";N#49 ;(*M4ZP
M(>\52_=E8=!G/JZ']6919&J9-56 >T1JD+E &9=\P\=6U+=%,YGTOW';$$&Q
M.I?+I>N_ARPA$Q\C>]I-PRJ)..?2-ZOJ.345T*;-I+B=$M5!VRW^I!T9[W=0
MBDNXZT+\<G\%:?Q,_;W')E&9W+<'HCDEC6X9N=+IYL_:BRHL&3(;-GF3I?D,
MD@',\RKZV]=0)1U/H*L9CQ^9FRR6Z?$%5]C@NXA%LRV^'@MN:!G/*=1,WG"J
M%4IFMYV,\5ZXU>&DLMV6F0H<Y01JK=A%#@,8V1,\S+ P#9(W^1I6BOPD.5[D
MRT-KTA6;;>3W\;'RB9/K[:*##@NIT]EA1 O1O'WS(JH5$$O;9(ME9!%9;"1H
MW(#*+%W#D[X!D,3TH0)[]+>$[DQ^:Q;GP,@I2,% 03;;\0JG<V@3Z%PN6P>.
M7;HE4[8^L"I<C1>D"7[OE'AH=+Y9FXUI'2HX5N?[%Z$3Z$E:7S_6_1<A3WR:
MXFG4$U3I>S&=<-&?4DR(-Q48?0_T,+]9A<@_DEGX"+1P0#UJ7S 5&/+:3??^
MN]6.I=FO8<N7/\M_4V%IPR- <3WF^LJN9EEC.HGRFI@J7%!-(8Z "'>3V@2+
M9$@+E@YV.B3$*IDX<T!VIIR5P8R!^D5><XQ-[4@^GI;&5]+E/;FBI;,0'?^L
MQ=+'$Z91U#V4Q$AJYH/>5-_:AB1 ]Z>AXE5*]S$Q$1H=7LRT+I]^O]V6U7[3
M&-^B0JO37YLDKQ-82^/BHJ4]:"OU,K934<[*S-16PXZ+T3))"]*UL78;FL[[
M+]8D,Q45^[-TNFSZP02@$X8XVDA'5.KY?/78:Q!#,8R[=Z@,6P/WIO-6]/ >
MG^DR6*N3] B/YO9 2(NE-UNAE:3"G9"2!0N+2> WJ57LE2/36%(ZZ\SF^U=Z
M@(>Z-H=:PKH_<1334 \[KG*1,F1U8W]R+TC[,"HQ/BYV&J8BQ,4OCBQ.O?J
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MO@9\)3(MB\1UE<9%%X'*K!U% SU<4([K4PF-BT*=G@=#FKB;H/Y]"4]"X*5
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MD88QM]\AE SHCNW,#2>JJL(R9!QKB:25GT#H";8Q"5.5);2BY97%0B-E^73
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M56HZ-H&7L-9DH\!M^36 9%S74T-MP#!A)"A-@<,!+.F8TG7"E.KIHK[GQD/
MS[D".ZD?,C\?!^^#6LIRL-8E;-[>NU:3;F @ES6#JF:@V_'FQS-&#:>;T3VI
MOQN&_G5PC=@RY9;!$_MFYT,AK'TOF!VF'A%+@S7]V59[R,7H2$H[P=29Z2M
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M'EG$GS3PR"I/=?7<?9YZ97T=ZJJ!\GSDG>;VE[9PL'>(2JC#672+6#FW 09
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MC[ /ADD<;GY]%[9FC,?2 VY/I;KZ_G)0L$L7:ZUV8+V6>UMWIVN%?M/YO"=
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M-[$RW_AAS"W.4/9GLY:!5H",=[S.8I()OWP "^VTD RO^D%.[_=[V48=:!@
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M= XD8%7N2G-MA#93?ZZMQG_%!&J?X[?3>+/S\GFI!VW1<Q:74U@71@<DPAE
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M+S;>NGE[?:7?G"6POZE<>O$**/VGHB_AB*Q9Y%3-1U<<UUMP)P&Y6EO\2N)
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MF9K?0XM6:GC;^+*[_;Z$_!TZKDU<W_(HL_Z'14LZGU(>J$8GX@3H  QA<B(
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M*ST63PZ--''5%AM%>:K8$5>+2?](],GQQ;UG\K6>9VQ\HA!/ITM9]?(6+!V
M&WZ! *GJ9XM@C*VHGV[THC0*_-4G' OY=_F5"Y6(<!HH;C%E2U+'ZRZTC=]2
M:-^\AH_3#&J;83"T0AI*3-H;'0UB1WMZ)]>9<T?=MX%)3L_WQ=V$B"XUGE0B
M95CD!.:A^4/:!3OJV+GO0OB:S<V+N[YYT326R]^H 2U"FJ2-(SB*./[7DA9^
M,J2MNK+_+C_52H'!%ZRJ#S\CG53&?>H\.A'":_1^>#N&>1HAJA]0]L0"_WMA
M"_AXO3976;9QWJN^[FF^#31EK"941.'-/RQO][)(@&JI7Z6+732+O2_V7/.M
MAY-^38S'Q#\LR\\)]%Z(ULH7J'AQ<U1TQ6</MUVHS=_>O)TYKTPQ4+^61$2D
M=G6:^F369S)!KCI*S7@"-[BP1%NTI8$X.=L3]<=T7ZJ+I#+_\TFM*FEV/<43
M4(83_6S;N 6]/ZCVV_*PZ(>7W$K#O O$/352LODB*;D?;)8=HWPQR U9#H:X
M*:L<[:HJ$L[9,Z$?U^$(?#71?1=Q8G&:B#.V>NOFFJ0-EY2GH<C.U9K<D5J=
M&&)KA',/\:6:*$CK13GS&U&JXBS5;YT].K2CV<*V6D:"Q.5-+[#%$:]BQ4@W
MZ5Z=O#?8.62Q_]K\Q ]#AUH[(C'8M=[7H*AC%P-D L8+96TK5U<Y)=RJI<N=
MF1KX7D,G](V:[9PCQ+=(!V;\E=#&0&BDT8+KNQXH[$2FH6B7JFM/0MCE4X.Q
M'V@@/0U-4P67#'B[2IO4LC#HP7?X;?V6ZIR'3[\:;4ILH$+-+$9Z!HK.50M@
M&2]YC<S70_D6=O(0GG9L;, #QKD.\!N1[@V?<P&9"1X>M&6!%@WS^X N&58U
MSU8FF#>?,0?>#XH/,2,M0]$+I,_\(E;O]9?CD$8!V1:ZG^MG%$DS9'0N>%4K
M-R#JJ=QUM5<5U4H]<IL6F[52NC8)1C6QO.K\4+._JC*T=?-;"J<"/>USE4Y;
M'O4PD=TM%Z!8;4N:M15.OZXRI6?MZ<<F/8=AP\^18C'4=316^0U8L3IG$?G,
M-UH :U9U#>#I0&YB1DRECO2264\^9;UE7?2[CU+PR[\$R-%7.^$[#A3_L'KE
MO4.&)PX4GIF+LWB5.QW/+JX@^#,OQ[/NW<$-/R(TSV3,!=/3RX95.'*:-+C_
MYV3W3C?+DM7''J7F>"MS#0A-_\.:XAI)*)1)M3+Q2ZEG'70*;%-ID[?9'>Z,
M:\';]-S8]OG;M1TY7,!/V=$G>TZULEP3%TZM1+HK(W!\@\D<[Y[[PTB0GMG0
M>PVBJ=BAHZX47%"[#.O%\04#.K03&S:F]D+-)=R3Q! P'5O75Q5:[XI7)]9;
M4"EVI[DMAE4GTDGG.?0,S_CZ:4.\R"XA]A6A*!/\5_2^K#]"RCZZ4:4T2OG8
M+[$S.U62+EV[/K!,Q&.<DL:N2D5E".>=)WTZ!]A9O$K:9FLK.9/%(ZHNGB-#
MZ4AJ%+S+W/<^).6J'3IJ-M?GR;T\E)@:-_;_)7 #DZ!MG@)]F>VG\#E,S+PH
M<#S@V<_+Q"$D<8;Z $E<2OOMS'8KAOT*1ZE^O+:4<A]VNR6,H&-N\(Y)OBQ3
M;K8LW:-CN!.R9%1LEZ<Q7VIJH:/D%;ZK=^@[PXN[*'9?;=F,UK4MFJ48+;YV
ME?S**]*G'=UZ?@#N2;[5:G](<Z VR+H(]F">:/#+>F%G=:M[]ZQ-0%9$+.]'
M.[SY#)&7/,'-7NKYI%896"J8!G7+;3B6+XR(Y_FBT2CP\ITY??8Y@E*X*0A_
MADCD\Z3RGTM$--V$-)&&GJOF:Y-B8!QRI^KZNV:5KBZ]%SS3JN;CP'R*.^+]
M$C18B8[_SH_.S4"42 P59QFEW$O:Z>WTYQ:9LLIQ:.6RSCGB-M=HI-U+)1^]
MGAR<G.H[)3U@8&<NC>IBS)NMJ!,'#MN%'JKF-$7]."^=#A31>+WX#\OZ(]5S
M=KQW>PKE>0MZ."^&3K'P06.*I+J ;9?IR]%-VC4HR*,L?GZ1-M?F MEV)^@W
M@R_ER"HM5H8_3*];DV6?3+QRK1V#:=3)K8R/2O64_G# %:LB^MV'K=9 2XU-
MA__@B10-'T)[K%F@:)#IJ,ZDOL^*U,_X. "=^.24>!)6]M6]S(YU;"Z*)?4@
M^="B-GP4]"Y()?EW]>B,PRF_/^I15]HE,_;_$)7_'> L[VDY(VV]LSJ"?KSH
MAJWB<KERFNO4 +?"ZVZV4&NY2XL^7%A!M 1<6ZV)J7+\\.!WL@#UJYA$, YR
M(4U</G\@CD,<47""+.1@+!#;)@10Q)7\?;R_F1APR5+9+!4? 57NF#H/O'9M
MV(=+C7E7_R$P?2Y:QNARR)7UG;O<'>S'&1>GMV[A8L@>TJPM&^+QS?R998[5
M37LY:,I?D[8U@_:,ZW>L._-OY*^EWC2MA8-<OEZ)!0';GJG75K\<=(\.H7R*
MWQBN?8I&UD/,OQT99J*0MM-7H<=#PQSV6+AR1CISF1E(;\=)A4F:G(&U8?8H
MW\DH@U^[4]]_HR\XO9FUDD>4$:9IK+#E'"34F<"M6^1D44$WA08;DW-<%T;<
MV6UYD/?V72'.6;>OTZ5NX=PC>J,\]6'?S8A0\\?,R<Y$XM(MG<=:B\*+[MH8
MN[;=R4T3L6XS;VV=S%&=+'4E8QM>[5>E\TLU_CXV#OX?H^F43$=15M=F#^[1
MEDA*.1\98]_I%% AC_GN]N1F!RVP+I0!=JSJ/DSS[G &5.,A^P8R)\?3S!K.
MC%T9A3<Q[:\ #TA4CZ9,ZEDN$X34]YPT[DX^Q-5X8\Q[*,6!:.&MMT-Y4^S%
M6E^(&;\=\#0D:W[O^0_GMFI:6I=19)^H*3>=C'HI?+DZWGG XHLNF'"(CN]_
M&BY*J X=S9 Q&H60FITKR@H+0L$GD/DMET ]3])="84HN'1)R3N+!$=\NHN-
M-W\7;5+47!R(4W!;?(F"[W6+_B:2CX?HBQF"ZKUG#;=ZIKRJ^(;-6;J3F!*&
M%^/B_EP6[B6,TJ5!F=F3!SSW2:=.G[M%M*.%-^$WCH56R10*%U%>P!EXY:91
M>GJC$;HGR46Z%[MU-[.@@0!76\+QM\,BC+3>&#VW1__:W;1P8?[&@6!,*YLF
MB.N,.AC?.85+W8+ZE,!UM6AGV'SFCXZN>=^H^H_.GG]87;Z.I?8#6N))Z_V;
M$1W'7WZ66V'L$2)9' ._X9PKI1*Q:'N7-8X[KF1I9 0',N%_Y:#=)ZH.XX;?
MLM+!F4/_X21O:BMIJ([N(2O"E!3IIB$^/M/Q3 /'E0S.BKXC^3:3D#3-SI'2
M9DV2\2!+?97)!<J"%-D0-SA%TD62S2G8TPXZ/\MG96VBZXMEUQO*F'#WL9[Z
M/6' WH!' ,IRYI9C0L<9T;+O)4$B,%A^8![%R%3M#UQM2HNA,MZY&NF9>S]>
M(OH)EF0UH>U0(B]@SRAI<%*6]?HZ\$@1\U:WYN&@23:UP0_<8!%W6IDT>&E,
M,U8.G&4(^^S!]F'3H$^<_L,.!#X=7O- > G@8(J^]"^EBEIM2-LK<KPH<K)W
ML-#/[U%>=D0 G%X:+=A]OWQ03&URD9FJV34NJ)F+V'U/+\'Y<Q=;3%._L:9#
M8:;D28S*_%1^*,F; BS-B,V"A-'$KV(E$0V"2>&(,?NGPL.0)Y?OY9D%X)5/
M0NBNBSS G 4-[9O5"'H/N"GK_\?>6S;% ;3;HI.00+"00'!-< T!!H<@P=UE
M@ 2'&=R=X,&#NSO#H#.#N[O;X!X@N$O(R3Y5[ZY]S_T!M^K6^;"^=W4_W;V>
M5;UZ@<O2!*VR+)<CXT[4(!HJH?BY]QH\?PQ-M5'2.C7E@MEE>\_U:F?7QY7P
MH"7H!PQ"W;]R(*M;'%PR"+<GZA\B<Q<S"(=LRA1B^DPSJM!6VNZ:J%#:S/F\
M[WY;PHH[?P%PW:DS^ID:ZUA".!2W&S>W78*UUTZJMVCU+T"XD?V"K[W(ZR22
MYQ;!;*QG9C4BZ;#T^%7_(I;XEWZP5Z:_,=*B?C%IMY7%VE5XD!U;D*&(_V(X
MDYA0;Y6T"FUH"[UVJ]F;WTT6:SCJ+0C%^+U*6-S,_D.;;J?P<T_"_L@29FN"
MNF<L+FL\J4M""S;'F?#N8=$_AWJ(R/=1BJ]ET("$55V1"P@Z[X<:8(/ '=Y%
M)<R'.'_11"Z9?U9$A:&N0%E5FZ=7.7-G)&98[*?"QI&@^"1LXBD0#BY._4!F
M6!I$)1ON9CI-H=7TFY^JXE]]OOC?5M&P'EMEB)(A>X'CP\+\JW:/;.ML_.GB
M+\GG&[(<O.OW7G/7K47[W3W.X/FPFW"[/,QM#NZI.CCY8?/ =M8UI8@<"GH3
M.U=&8P,KER$**Q1)RA;/&J[[Z+5]1;+02Q'L.\N8OM;N[.XY<V<]#4SSK=6Q
MTGTLY>SQ9TG_"\"27F!\Z.NS_B7:31X3PYU>QR;A*\&E*DP/T!*)IJG/449$
M^N"P@YY1ET+O\<-=>Z,;!P8(594YM3FA'. *LQM:\3JS^BCAAS ,)-CVV;<9
MX)W2J:A3#PEW]A["W*,)==RMYDG_DT>#5UK(6VN?#ID\=;SY06LK0-3FIGR'
MK'D9MGG55#^3I^#-QU+ \>!!':U=7V/XA:'@W?"[\//!MP>^A]4ULU\U)]/'
M=#N://X"(F]#!7>K>2CI*Z[0^; 4.6275^&&K1C&-WXD<W:K0M&??Q^]I=2[
M*RV:0)"_L.9(DKN2C-/HS#]HDF^]%(R*1D/O87$.6HJ YAW4UR??.!H1\8\M
M7Q=YLP9K).Q\JCQ&<9K&T@)QINSK(YU=UB,4#GODTG1QT#MIM&U[UEK82@0H
ML,YJ=.L_NMRS$;V47&,??A]E#,K1GY^T+6[6:%FWC&?-"E4^IXA#-6>1;8JP
M=BNYF7 KL:X_>V35"+9SJB4RVWKU6\5U8Y&A&K_C2X@R'>"<-::QKF%ZUZI0
M8C(H,WNSN55(*UOQU5MC)\>ZA[\ _9'9C^\;V@5]CPJ6#-XF\@_53[7J)R;.
MQE+CA;NL9/>+X*@:])'&Z>%ILV9J/;!_EGW;,B&?)IXLT0!,A=*'G/S4_!'I
M<@F#@%X.FVWDW-9,:"?.L]2,ZQ6QYI__:E(N*B:?;?&GUWT^] G^\* CN:&"
ML[A/5FL$ DL[TBS5@%BG:FWA94>/[TL7NI%Z%.;RV2I A0[D^2+D.H[?Y>X'
MDXH/6;T)X6I_C9H48>I_5+OGU3Y?G:\-WPQXD;ZC]EJMU-E$R_>P(14]R?X^
MY^H:Q-O-.AMQ(8#);FMW]+3X?N3MN5C%$37HPC4%:6YUM/3'",.KE7!9T#+Y
M.-LV,_(B][<(I& 2\1%CT"E_H8^#//>G$QY"\$W4>[_BA?(IIQT0)4<.YM.X
M9AH:,R6)F6:REVU6D- 22(: CTW+0<E9OR2&W>;DRZ<WG:_G.RMS5-HBU9"@
M5)6A502TL7=N6W"NC"JV>-"7F?R-)4:KYVO8EH =T+C,^GR8_-F(V*F4%T:/
M[&_ZTT,9?X$(7F'3QBK.27@JH?1']DB7R!&;Y\Q=*W+N;:&_,CTRY TESEY9
M#7[-F*OIK7@O_U&R3P3JJ#BQ.&CJ2J$6R,<JL?ABGM';G3"J9YP6?7R J-B%
M%NCFJMZG5<*A>4EWCNI;_Q"[_*\ ;%F6E!M#<.)8,UV! P>*;[\EE(\\@[52
MF2_7%#A(.4W$EVCW&[%P(%Y[@PW;;06Q:^S>X5RB^ G#*L!(7B<V9[V[_KH
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MM.,9\5>0+<N"J%VHDA"R>E"*-[8PY=['D 3OQ O'?F".OTN<OAP=M!FM>M^
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M:_AVV)&:O%-'#*M5X1170ITE,,^@Q5HD.E.=M.2)GM "M=2CC[O1@"OH/-3
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ME&+T+6PJZ-8H9=,NY%L9?\Y3?-D@:I75R]::L+.)Z!>%R\?"O,"+^Y;=&=:
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M70I!.:#B%8!N\W%E+46B\WN\T+'4D-X5&S[_VO@LE\^$E.NW%_*RU1CKRU<
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M&U=Q*DO5'QWW[B+F^,?R&Z LX>CL$I(R'19^%MXB3NP"=TH>.,$_@?I]H_&
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M9_+=^F!O-F4K?69LP0%?86-E3@(B]Z$.ZMV\%A@OX?J;(';/@_CW/>;K&BW
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M/R(UV(0Q@P1#$Y'%?O$S?D7[!15C*OT[K9PK(G5S*<;#'UJF'I'8EY;;?Y?
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MPSL"+57IOW>L*09ISR4@^_8B7CZ)GM=J[]*2]-I++EVT&JN!RU@Y(E[WP5#
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M?QB0I/\^TP$L"DXL?*J8GS <>9V^+Q+- 3,M\_P(O_D(^G6&I>PI\[U;:\?
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M5KZQ[%^7;#HS7FBUQM#1IP)6CG(.[:X2R.'PZ8C-*PAG!/:^3PW&;#*Y "F
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M1+_ 8CG/;![FANT&FHWQ:5B!-T+-]8AF7.T$E#@MACT%Q@@SBW2,M(<C/GP
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MQ'5<)*1Y,N<]LAVXG=4RS7:XHNKQUM8OL-R&8?ONX%TX/+])A.I\_GX&(;<
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MJQ6VC1/CEVN1 V]ZGRHLZVK*Y4M513LE6':I2XPEUK-E[X;T9V_0#]8$!B*
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M\2E0VY(=MI>#55*3;2,4Q.[+ZUIK$K$!9>+]J=[5H!-UX'[V6SF4]F[/%OG
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M.V'B,#I>X@&W.%D/O,8 ND)M56=AO.:^K?8FMKY;)C-)X:E]JP&1=D!&L6<
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M'W,8/*G<8ZH;"NFP,9W&\8Q[9T6 'X=?(:,U5]]CD'X# 7AD[1[NB1D7:/<
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M7;*GU1_/#DTH%,CZ=(CKV+5=&:H^8=;4F^LJ?T(_)2+@[X0';6?!PIW 8(3
ML9(OR_HGL^1 ;>&C^IJF:RT3C&P#G6]:';"8P^I@5F5'1XF$6NX"*DD8M5$C
M\13B9[MO* _=N<UY&?T>+"[PL8H%JZ=*2?>V[\30$N)&AL)'"@'_E&-%Y1DK
M%8@;D*MRI)K.F^[\6GE@K(14,FN*B,V5,)Q>LTR$S-H/EZN<#!;"ZB-N5]AN
M %1NS"';A_P68BQG1)Q/J7B9X"I0<8WA<T9.F ?TJHN#>%&1,@3T$1#T<N"W
M\FLSO(USBMTNB@218O&;QR''3(75:?M8]2+6=>:D7.>1X*1=/("FM5^L("[B
M6\41Y=X+Q!9"0_15*+[P:BT#G)?24'!\G]CSEP()\\54&_$PX6@7^&V^8O,R
MXG/-.<^7YF;YM#0T7P?PZSH(#9W=NJ<)6RO*A*N87WE1/ &<\Z6NSNB'K]_A
MFG0>2+HI=V12=*; [11SZ;=\4V>GDA@Y:L.MNT$D41\FY4Y.IJTUEOS*.JX6
MHF9@CYIE;;:11L5(JZ>4B'\A&NC185V9<,GV8:/;^D)S]:=D=<?&P+O?"=TN
M.P+]%,[X="HTI-9Q)42;[^B.O!I-/LC8%S73FJ7+KUWJ>K-ECVVO<!Z74\E#
M1]:,CF3B(M@-5^VE*ZA9T,Q$=Z_BSEJK/-\14SE:85O?%?N#E5IW9(,\P_R(
ME+YO@C:S8,$N:"A/*7CG@26$]06H52*=#YP/ BC^+?+[3SN(!5VSH[5_3';_
M<<&8^ZN2U@':_"N])@,(FKN6?(AE?R4>EG\E'MX/H$]R#P -=-TU]_Y1@1P]
MH#Y#?;+F:K36\S_??^P!05P2C_]I#TOA6]A-<F.OC\/^R ]:$^A?'!?DT.6A
M]_.H3[0$<&GIC?YJWXQOMG]C0;:W:%FA/+"R*4FGYG/U,0E6#_)DM;JPM7CX
M"(=)D*XT:AU%HC1;0"Z,&\?6:"=5]ZB7:+Y=+9KLIX).TKI3Z99CBP*?55!;
MU89>0O9PPG$7"I805<%DR4&^W3E/N/C"L!Z<[A'[G "_GUARA9'1$(0M 8W)
M4\7,4J2@\USK13MMSRAK\/PSEHSI_J#.8(F@_ L@Z]LO1!)8SX 0[H-[ ,V*
ME%*.X!:+C=W&)$G _+G >!20&QC^".UU0(1B-7R/TG Y3&%#3<LHP.G)YD;:
MTV9$?C=YCAQ?8N$PF'GUD$H7Y(,<-Q ?]X%0+P-9;"9."H/"WQ?L5OL6 5.J
MT)+[@:K^)1/*59\_)M#H49(+@;7[]2-E15[0A+W<^(8AI_PL+-.;A1X4/F.$
M*-*>R^)")NV-]5T77,:UN/8710@ IW.4"7X\!5=>3Z#SY[-]F6W1A=++1]7(
M$7*C"J-(A4=M6C'>R%336Z=-C']M@',L<G^7C@#RZ&FR/0O+4G]6W8"M0Y\2
MK2%6S*\7SO1A7^==5TCS^Y(AM:E"+P8B5?GVTS*E[3%;5Q;CV(NR0OQ\306[
MR(PG];:2##\2F>]>+K#<U.:XX8F.6(HNYU3O"NC5D9"^U4UC\S<F4V34+#O0
M(@O"@VUI2)K"*X992S5!!;X0Y<$V9SE:VBP!+6FIS20:=5A(0^Q"C$:#IM6T
M,,%/W>IXR(]'@I1 <.CGZ&M?KVW-5<)U;9] GP%S<Z]32,(\G='G^#7?IZS"
M2)O8PV>AJV 5_W5,-JE\'R),8WLSC_6]NF=CRMPQ/^$:^LE4AA2O)74LLZUF
M1ZZU*O@@=D+//"S/\QP(DDLAS^?G1-63<K_HO;R:PEG#Q;LTU/\.&J&A#SV,
MCW6$RY0VHGL9!S64DUV$%RA9EUR.7%+RP^&JO14)'B.-2$%O<PG )F'+%H#:
MM9"#-9O:LO $^\^A'9J<_'!HZZ-_2R.T"!7[\O_!<KV4&]3_Q7)6@?_H0+8*
M"U&KA;IC!AJSO/CV%LE:[G[^.G')4Y+E3]DWY<3DF[I@,B$+/IRQ[@<MA_?X
M$2(VOV2\S7;@F,L'PS4L%M>?\TQ\A[GJ2[L[M3_GY'EO<E!5],5B/OVX?1![
MU0K%.L'-S:\#2KIN[LA M.ZF7*@?[9O?XKASY2G'E!YU?+I:*8]68S-:4JRA
M^OBSK(?]NV2+C\:&1CEYOS)^134X_^X@VHTHIIA*OF$97QK,55]F"<I?;)%0
M;?*E>'H&VQ/H*+V\\Z0_\MB@:J=*!EVK"I4-0C6<IY/&2\JCV.#4@MR<9[O:
M._2CPKPL2MI>.38R7+%^L. ;DZ*]^;I7N-Y,&0V.T!F3$F;A V"5TIPQPR?H
M3=DXIK,\!0K<7(=])1U_\'24B A1:&O[A+18LA= L3Y^%O:)K/RX\L=40P@'
M<*[TZ ?%HWC\X%WACE/R=+$QHJ]>[S(S[?E@J>=#%=5QA-(7$Z4W.Q/*8V]W
MO'W(Z25ZI$);3Y-*)1FZ,WN1+"D;1GSEGAC@Z'[1]!-,4!Y?(11N_?+R\XZO
M]G!QA48$/6SFAUEM'B\K>AD,\O,<EMEUMO>=K5(XK N=8!S&],DIA=O"QG(*
M69JF$$O_I,KB'M!B(&.0K<,(EDM+R4"U"^U-;[B"N_J2_<)BFJTR?(*U-,!Q
M/6HM5-37:"4DS=YNN6\4J$3AD!C 9''4I*!70C6IZZ]C84FL 2=#\MT:7=-.
MKE<;*%$W(<^+[04R:DXSGDS?U":[R*%!S7=J][R54%C<M%RE=DU<=ML/'&*?
MR.L'3PKQ>0!IK_3/6<I"LVP%>UL<#/W<.3N1%GLA3>U@A0JY1*"J"VL7WPC[
M5% V@(@WR:37DX*[<Z"WO,5K<*5)7N*:<WKS LQJ(M@;\C+C+?]D^UF>9*WV
MK@SK=#Y>'#5M77J ^V)QS4].T\!B1@.4M4K$N,2' ]FOL5G:N?Z*'U(/#:^I
M-MFX"**0GY=;Z7]Y[Y%5(Q?QCRJ8W"AT5,0[B1,;+Z-J J?:%% KWZX]%5G7
ME3E+UB:EF4Z(E<5D;"B4+ K4KMJIC&/5%6P1Z$2\"#25V(@(<C=YNHLMD6 T
M<,ATKN-'1#%N0K@8^6CQ,;";/64(I:[_54ROI5)B+Z5B#8M2=E.,_G!+U>"K
MGK%A_W*0]X3;/KI:"M^6V.LC=/X<JA34\FR!@>BB9IU!)3H>?N2!@]5^WJ'5
MA4BYJ[J]*%J./#(QC5#7Z0H'-U_<-NZ_J6Q*O\.]HX<M7?L?A;1%V>(_MC(R
M?QNGF77G7C*2;=YZ_"EJ7*?0FUIZ$;*>[AARVO_'NRU^9]46V/-P6I842<QK
M_I%' K<DE-/5%<X*]_QAN1T!; &U1>![P,Y$*I^&GHT.1#:&63M-NO)7W*?\
MR6KZ#"UZ&<%+]]$VOI_%H7M9T2;SE@WML-A9]%B$(/2G'*$E '<5BI6'(H#;
M4W,WFB<>H-$D9B-JF:UA.OK$I"=CQL#^@L)D*A3Z]6.CB?+F=T%2F,^:U%))
MEVUQD_*!F-.)UJ%I3$G/N1.1 K;@2QT3)N4HU>JD(4T&;BN%):)PY<J/4VPZ
M<98<:WMSN *:+7I:<E;[CBV9E=OU=@'*9!0V #1%-U/+^:M@5A[-EA=D'3FD
M\@?+5#A..W6AAO+?4)7<"D*$5W/E,G;,%I7'FMMZ_*D5MS=B!$LD#>@V;",A
M,5 V68Z@\:0FUX=H^4FXJMQP0>JQ\]>X3$S00$-]!>C4E6P!1O@4W3U4A2-[
MA;]6XMC8!:7U0.S4M37;:?@+2D*$1$\NG:T(1#6Y_(7;THS6: @]4IR6-'8%
MWQ.TZ_3F#!SE#/C($CHBMANXAJBF"W41D3!V#V-9EB" ZW0F9#L%*V;0L4_L
M.V=^,34K1CLN?F+P&/5E24X]LGP/.QB#YAU),551M4:<5L*(YKS5BU\_VA,:
M6@S+^G1EZ&KT/O&E1>>$@(KB99[*S-0^/$("LB89=DPLA;RH8YROMO"IUVOL
M//NZ$&ZQ&>(2'-!2XHYC*/X(!:MW2CUXW,^>XWGFX&>*.I-BHJS\H6IAM\HS
M;J1HP.K !E(]*34^"R5CZX2=B]U&K5KP]<V;*4_7Y066Q0V;)W3W@.9),*^)
M>'QMQ>_%JC-<SXGR='#\QOMA,S\7'-W^V1>H*_ZR^R=\O"\2.@J,YHR-6 15
M8-UR9@[3SLRK&/MF+HL^KV6O)@,#I[)X!71_].'246+8GMHQ-Z9.)K#-48H2
MNJDZ=W(C31"IE<>[+IOB[L4,C<['*>D>99@.8;/RNN95<N0/%-#"&B"_^IMZ
MT*GG$6< :/.0SLXH?" )4:1A$KVM5RKNHQ42R.N<2D=>*5]X;LY44K1DT"WB
M;R'.ZC8ZP,WZ;*:@VI,NYXG[L&-F+[D\*?MXJ?&(>XJ0<;&KJS?AZZ>:PR]P
MGT7[E]#6-N3\@IC('V!B9#+Q3:C@&TH3#.PH>6U"+1P<G&R)*^(;[BC&7F6,
M0YE/>+I[\EZ4I7[RI!IQ=/=^4D4@RY@HAXG4=)O,?$F6U $$UZ=S<KAG!4[.
ME12.G>*Y;W:X(T/E18EN1#1C)G@A1 Q>-7PKT4JH_B^J>@*:PQON ;N3.'JJ
M]X"/L?U0CMYDK90^%!FO6M_4.)LD!6]LS'47)]S"MWZSC,$,F:K>J0:R/R,]
M<P/&"S1E_>1TX _(2XUGIV4G'&4T("A:BBD2;I'0;>^0:IA=G;]_-!3M1^42
M$*CKOE;C2>VM>#=LJO=4$T7U6T%>]9^>%:J2U]U7(,6 OQX=MO-G_V]N7[J6
M#.G;^%]LSZTFOHG5I3Y%_LG/R_V%=@T9PO[_F'3\^? HR "PW0*\5IO4T"Y2
MSV7;]/,9EI-7X%/$T7'*&:?EG^Y(=6C/CG%6>BR8"@69AMQLM(JQV8<.TE1J
MLEO'*_RC[P'\1C5VG_"DP,2N->)BJD3$I'O,C#T_]6-9QY12J'-5&KB??,:C
MU>)]+\FG:@3)#,D0[/H1&'OZJ$QL*G)9FN[#"*[B6,63,ZO(XQVQMQJ,<S]=
M<ED:TACN\KWX.TBCJ1[3EDF:F]?2^5B_,XAQK,0@Z1$+RV?NY;VDA/6GR#GJ
M0^W"J9F2HG7&,21(6)VIL^7):^T[=67UZF,S8^4 FAB7+:5+D<4HP[P'C#"A
M1P[*EA.\%=%:"YB+4->\9OLM'@J;##D^.F[9S*BG/N!!3V3_Q[CWDW$.+C*!
M(@1)U=[@WVK7M<<]2,IPFLB&X,/X (ML+/WY5]2?2UU654Q[*+[OS":F*@0E
M4Q*>@]VVSHT&%P;T,+^=PWY$7@*BK[4Q9 _\R^8Y'(5A+/VDB(KA)_LHAJ+>
M0 <%I@8#=/<WS>=\OH-H*;L:2O9G<:O6;B(: ^-<AI69[PZL"63G,O-,4]CG
MJI]?5C+^$L;8E:>ICPFJ5*+Z,:Y$$?/,&D/B'N (M9E@9PA6[-6-#)]--+\"
ME7J##7NZN,,M C,&$$7.8HQ6N>\.)"@A WP++JL/ 9:563W+N\R:J6+/W*-^
MM6[Z5&3!<$2DTG1# &\>@7/08N[Q-*]O^X.I/=OQT%R.+-.N+AM[07,*GN=4
MHB-K4\Z\!Y@WWV=4>N+T11-&WN>L9ZUA3<Y\;U+!^Z]T*"HS-DY$,H-I!9<O
MW=Q(IO39]^BU:.(KZZRA+T>SAGAS60S)N,PZN=]BA![.-B^MZN8"QXOR1P+,
MO<JE:D!8/[%ZZ,Y+3B.7Z\==:%DJW8_C%!MVHK\3W96;\""1Y/K1E@A0'?B-
M.=PZ^NC3M@YKRM;H3]J#I(=%'/;G#=6?AMB8$]2 MG6)S+LVL[]Z:\7CME"S
MXY<J_Q&%%-K\JZ3PU84<H>:885:GA_W./@$;R&W 4Z6(JBT&K6;4^)<O2$^C
MYH4O]^O<"<<0(GM'86[3@]0%+I:X=)1N_XB/;>M6M?> @);:KH/%8)85V&:_
M#:$N-4% L!KW<6_ZV\:XZ#7&KXV_LO04K2O=1V50JT]S+ZY"H%YBI/< '6I$
MTF)/'+%F,N$W_YC1\!KYQ\,-LR(YS+.NG\IM&U'MOEA@(IW<6*=$#>[ PN6%
M#Q?Q1^<W9\6614(I!N/3VT&LEI;6^7*N-MHEI"&>AAXS;_8'?N\;WP/"0M;&
MU:#>MH6^&A=JZ;"&@O5S;NN?^]9"07"5%:B8 EJU9"3EKD6R#R2+@)8G<29+
M^XYZO'6.32]UJY(Z@VF+:UN'0Y3).L2)L<X3_>ORGA,VXLA5_EUUANU-6"^B
MOB ! 8&'J2ADF19^W>%\CV\\U'\WF+'QNGI!6BUR@6^H4HY\&<)%KU<A=]?8
M? _HIMYY"%:+I;;0-$LF345\0YX0N8OP(E@NMEJI/QOX$8)B+.1(2R%T/[3?
M;3$_K_Q9VJTG_*S%WE-LL_PV*L)STQ=(H'Z15VK\PLC(/"KV,;*"\<CV,^S1
MB@@X9Z>^K+ZMT)N_[1@[8E?+=SY--H;!KX.D;7:1-0N5PT7^C#%++:JP!]EZ
MUL^WN!WB\_H\/ "][6B7>$7%)$O'$]?V6Y@HO<(:CI#H0E7<66:&HU]QM]T#
MY9A?%0821[:M=;>FM"\&CW;F?,N/"E<#90@ZWH;HM;"\MO&=^VG1@MLE)A*K
MI,_NLAQ?[5BC__3(F.CP)I@:ZF7ZXAX0GUYJE"TX/9Z-8^';Y@ _@(?8RM#2
M;.>PD$9$FLOXNZ88-4YI%-\#(&:%M@XAW@\S!#V5&^@!1S=H:R3/+NQ)O2IL
M(+UC(AK?]C0:=FUDG%=C"W8,;]F_.X+%=;8='0J,5Q<S>;AS&J<)NR?A60%9
M1 P2LGME*1V4S$X9J_;;UNY<H2[K(WR%,:3\IT0F,%J)H(YVJI37EMI%]P M
M@>L:]L]M04:L\F3C(?004G(6?5LB"V?:@9VYP1RLF8I^C5B'HHA[ )5..>:1
MIKW^;C'34-#MVK79=P?DI$%SS89V3DHO6A;V02OSP[(<N@<<@%:TOL*8#X*1
M3R[P"$'*6C$,-MZY,G>CU,>L#O_R F$Y6IK9_&^FO-N@93C_C\4QZ*\W2%N4
M^+$R7]O5^E\)B/?I87?<7XS^ZPVRSE*_9PU\V-M%$@\# /DB$40[XMC059MZ
MBXM>P5[#XXT=5GCK"Z_&*QVY5;F4K'M 8]^IHU^7^8=VOK=S%M22ZC,A):74
M^;>LXRT)O^+'^65(-F.-ON4E\PNB_S:DE_UU]]N>!-GP^O)+TNV$T?[#'Q\]
M+<MG5YGD31G0[&#!C+#/>$0?'8)#:]"G''A6IM"'EG2!*+]IC#MW* O9F4W=
MBV TH/<GE7@F!-8:(=/_H4BRB3R#/,P-U5*XM=$]H#SW=B>?E7%88MK%3?]*
MJ[A>WSE2FRT80Z?B\!2".]F:8A?9!,26M\GNW(AH,;WM;CQ,F"3TGK=_""Z!
M1V5F>/> WA]FA]@1>86"I4I:!C5<K!C541N'K&X8MK/<\WW'GX/.8^*>^?5^
M+W:@/MIJ.P -3K2MTQ'#M4VR?10Y>E4<_9H,K",['W>FTA;6-WWF% CC@NM2
M1[X[#FG3=7Y8YRS)L[3NS7C%Z$?B2PGJ9\_<E>L196]#7@T]>;;%8UP<);YV
M)#Y/.(QY0%W(9"B;T\,B(*QS]"*'HCQC!NA6# KG8R7?IC)Z4A+>>8OTC$;8
MI-T#:,A'KY".'T,NKI)NUVYV; 4L WCIZ$>N-#PF>,=XT0E^[P,=8HN#GZ;&
MH<)FM#US#558[R0J@QWI-*_O ;_(.E>PZ/MX?P1^GK&^KH?EJWYW[&'R66(M
M] S0TS*!A9\;_8(R.\CRJSB9FK LRCP1?B2X:ZRR2Q[5%,6>F6*$!70<"]1[
M6 9#/2&[I>"2!!(%WB\>4VJ@$50J@^1[@+L?1$XQS"C+4'X\#2V0L]]PK.T>
M$!=Y#UC@72"_U0QI=="$:T'I8?2MU-5&%O11-/X+.9@_=2UD;%_BS2UD'WF@
M6>&9)"^Y/\0'A7L ]>^0%CU>$O\!-5V/-KS#@X/N,L]OE^XQD%<4N5#_F4VA
M<MFCT9NP!U1_U[SL!=-K.!=\O9QG]PTDIS]K^.HKZE^K"N;J]7N ?IN&!+77
M?\OOX"_^A_42?OY?^2YE-^1_^4[A_Y?OGH]KYE1KD<$E JBE32=_M?W@,C'@
MS_5DR7]Y.PU4\2O^E;$KBG(/H$.G/M21G)5[9"W+\_4R+JB^P<@NPX#.@GB\
M :CV8Y>E<DZ&48Z2%08/6:=XV/AZN4:WER&+,'!,+JEJEI:OG/3*>X$T^O'2
MVZU>OGR'2L-%8:(A)P\<D8>)BGM[ HF#/QR4%?TZUS]  \LK=9K<[NHSIR%0
M X<Y+VMZ]2^D_H8CSLJR<X_)6VN@ EHG,#KMAW'E/0TV>\Y2R5:G B'56N\V
MDA@"0AUF=Q(:60^?C-+Q=6T_T#D20G>8"U7,E*WA/-(4B:SQD["Q:2>, K>L
M87SBKJ 2[=DVWKQIBBMTF7T(6:VYAN-\) V:G]GB80+X$VL'<8J9?1E6FN2#
M="64VPBSG7 CM=/<<$>")[6G+WOF7;87LZ0JK56QOIGFQM";,!=;L+'(W"B[
M!:O(\,YAT7)/[\:>,DS-FT&ICWM_@1L*:F68^7(9@4MOO[3?[<NYKF*Y%,4*
M5L8&0'P@9_> HS6F-6.5MIN(S!U'9H7YK6+"L7&S19/;[]*$%<X]GAGR4(9F
M!MM&49]'#1,/&XGN%#HL D%X.($2].371)V69CS\%0WEK-OI,GY#@&0[=T'A
M[4S9G2T$W69'-RE4:7>EK34?Q-*>F(SE'>1SS'7IGG5RCI7!Y$;KW0U]9IT4
M:([WUU19=4TCMG76KN&QV.E7(U<IQ"H6L<5V'O.!.J??$6SCXAS>5JX.7\01
M&5L<XNLXF-?P<<$=BP)$*:EZ-UB!Y;'-8](=S(#M?=[U& &T)KHLQ)L66ECJ
MX!UP:MM(QGC%FV(=%D=V]'!9TEV\+6>?IFT;&G <D>]X>5;N?/$0'*AV[_;]
MDGROIGBGFH,7]32U\JC,"PJ_?3U!34U,??^GQQ^U<M#_YDGANX-B*"%]'P1N
MW[7]T?AZ9\YO_6,(<3_S?P!02P,$%     @ 6D1L6+B#4<8&< ( E]P" !(
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M)9O(^A/$/ZC]$[/_.6)A_UO,_I78O_%:  C0T1X6#_TQ( ]<7G-6BR/D^VY
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MCF*F PF5W[I"[2,D5JSI3@K3BU3=#C6YG67%"(EB!F"-M4UEKF<C-'P:@2.
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M71!^??UL,)G5;G*-4MMGWR:8M'L9VBWQ2;6N6GX",ZE*.34U7CX03+[V* X
M&,))R[UL*ZCD;"<;0"2!/ B1+H>:'JDO&S$ZSUY^74^+G J3W2]M1JY76J4U
M38IPLC9[A-!D>'/, UVS'?UJL#0\M9@=_W*"#[H_'9V=<)J:8DC\KQRHKG3V
M^O9@)4=^Q_W";+E$NAN:52[,_-CP+/K[!OTU-7EX]!XV/=T_9/83_R0@[G'2
MC@/ ^2L$^UOI]J6D<A!OX Q"41U94P(0:2S"$KI:$SIX8,0?C@,5BTR=I-X]
ME9WYO.FK8Y<CMLWDPY20L]7!6_:9P(!4BEYOZJ):PQ,_5QP)AC;6K5N0.*
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MC=;,UE5@^Z:@9N#TLG(U'$1TG&(8V2O55[?8@ST*)BB/]&&-9#I#+SF7$#V
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MT]R"=Z2X;73[C16^;EAAMG,%%(GEESL9"2_\7G=>>P7C7 P^I6=TRVZ_H6U
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M?JIYUD3J1Z*1AQ+P[?AH>YU!805(F=]U'1)(CI" #AA@%]Z'E9LH,&:S.F$
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M"0":F]E[/GC)=&Q35?$"@]8"6S$FMVR?V4K_J,7@"_'*)\!@XA_F3,X'ER?
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M 8"?7"%MEMM?UM2=818I@Z7"=V2C6C\T=M0]2M@OO\YE!?],_9$LAX&:$YH
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M!=)JX^[5HUV><Z:B-VI+*S%Q],8\&-'PM1CEP>3CAK8!FI1=*/$'9.&F+\^
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MW[:I-]YVR&[]#/A)?%)T2:#XKS8ER>$P\W]%/TP$NP.[A,4_DDS_'_G'"T+
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M;H]^2N]V<'F:![+.WW05D0#UYX:TA-(E=QUN-:1U);NB5HS;($L7.!2ZI,\
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M5*CP@$E%LHGZ(1EZ6S*E_X3@5+#X,8?I++9-UT%#+H]C=GHG<7\^<,]3;OC
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M5$JV*7N89?_/[$EP46H1JB(^J79J4[)V2E-RJ0SQC]I/Q+&U;-JDYTC*0_:
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M9N=8"+1!OFA:W0@M& +),\]:E,^9X1N53I@5U\1L7;>BS;*F(EA6,C[SIP)
M<''W&I L=X%1*9>&'ZV3SOR87:C!<YX/, #3/D-A242)DH[I%J-:_%]&(_Y?
M#E&YV8W#5FI>WPSDJZ(+5>IVG/F888!/4Y$O8+U.SL__NAD?A5^0*KFU^.9\
MP-"4F@9ET9;US5H5N;'X/2=F&C(_,WX+&@G3V[\Q6G\_P!_&NIE#,LL0?R4)
M?-7/</OJMV):O$ZUM$@FK!]"@Z0AL;**G+A:@^#>MS]?,$>&F6?8^AU>? T-
MG*RTK'IT8'9L8ADE0:B,MA'Z>#)#)M(P<6ZV'R&766SH9X>7=P3K45G\OX%/
M^2I_N>R&V^,WQ_2-#7BL@A,D%PY@ZN0+'J'=1(W[YM2_:-T+"4L,:]F&\=:_
MJA6^NWGO!8;R_BT=P?)=9Y)]ICK-,''A#:KNY-^DOBF/O&%"-*P7D?NBB+,W
MJOX*9X\<%[@7M=O\=U$AGQG'-C\I_S@_,9,%?<KO(M30$BY3#M<V7U#9_&V.
M\:>1/NGUL0)9#LQJF:TGL448H'JFULS=@\="??7(%OJP_^VYMD#[723CXZ>7
M*?:_S77^?Z*I3#DWV\@CD!VT;Z*])>-XPM#-3C79./87I/"!KKV3XN>I/Q0R
M%_HD4WE]C+6O5;*FYY#QBD$5ZC[(?J]1-*X7,\1,:X.A!B&C2#F]0*\HTON"
MK)EY @/ @]9O9ZT@YG:&MG77E:5*[\%*STXJXYIJ%<H5O?WQ2_4O_+B*YJ_H
M*BLT6(1XNHQD>= G6-G@RG&ER-J B>D1:$X%E><,= X\76J?4M--RZ:DN=[7
M1/2WX_,)A7\1F'D?!0-LI;DG/7>X@>[?%:T@P@"Q'NL5#TC:,,!>7B;FEW]/
MBT=M"@S7#BP1>T\^':PF4MMI2:"\'QO?""=YVNJK?D]RJ1VZLX#6_XF7+;<J
MO?@P1H_/6S8O9YKP]7FZ_LU,T8P)2#QC6\UTAEHI).;[?3J2:Y(^8"+?<4Q:
MN.V!:3'>U_NY5AT4S./?Y@$5?)^=J?)D-:&Y0-!L=I"+B>G56)ZR:RO(L*]7
M\+6%^NTP15Z19,W[8706_E$SP\4Y:-S$?CK11$VB%F7]*AL,D%B=-GQ%'KR&
M9*W!0PT<:F0LH>:?;JKY$,I0P=7]OSPS*G>)UZ9_5%=Y# Y,]9D]]I4[\8GL
MO\\*95O2NBW;7@=1-#!>BM_GW/#T+WX$_WVG 3T"W7\H]%Q:9J7V/.)/[<>\
MHA"#RBL66;[Z)SRJB-(M=SD8;[&:V2JYN8?^VB=L8S^)8Y#-.U#X:>Z:'%EE
MCL<TKU@<IS?LJX%*W!7-E?"%7&T]TVMS"(WK>YJHF[0H9>@( ( .8+J%(ZBV
MW;4VRBP-)!)3VX[]9EH\-,^=F@LANGIE/:%L%CJXTR$K+0')A9^8A%A.O*FI
MB3<K1,J.#9^$LQBFLQB&)Z1+HDM)UAV#WQI/EF'T:\SABE=$ICH3?/Y8U':X
M 7PB8BZ(?[XJ2;I-@0'>JJY>G6$]A^-/#$$]IU8[OQ4\2NZU*2[+)D=Q-1;R
M IN2_BV7^6]2U;^%[/Y^^-?*IED2-\&Z;)-?%9W%$N1'CLAECY%<;T1OSO#?
M14Z[O-5_N;]2Z:8D^\)Z5-U0)".YSN]R=)#<,0)X"-Z%'%TTB4F-7'-HQ.C;
MM(5,URZL,D[.FG&/L9J+<+,%3A@@,O27*M?[.\++U?NK,!A %-^W3NBFX871
M_D_RZ[Z($M/#^Z$RPB'"OVA*O)K_W40;3E9S:GW<6>=(?=O$G67-ZQL!&QJ^
M&HLHHG\JEI)L[H'BH0!W9)%M-0MAW=F21#6 B+GP,^9KXHXK[KA-&.".7I\6
M!JC4&WT.LW3S!VVENUL]=ZBWW3-:(&3^@VNZ_Z.&D'8& SS&5>#  '.LNS
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M>2 G[$R:A:-RB7Q&(_MCSV=,33Z'C+A;;SDW3A^[>>W1P%%EE.B&\II_31
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M19A9ME<?O?HLXJOBDBQM[7 S87UCN&D.?05Y'\)DYDYLK+I^=J/"1JKKA+?
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M>#/;H722?H[]%7!=4;9P44<@;[+V)Z^","JCB'_4H,+8]%?G&(3>@P-/CM2
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MHPHJ-_*1<H%-[08GZ1G!%>?WDU_!=W$%)D>W+SXQHTQ6FXB'FUIU@)C%L^H
MTCU!4)@N&A WFTDN!R_E81F81UI7R-I52-Y:4$NE$7>"$_8T+?1,_\AXD*7*
MY ?80T+"OK-][)\#+HG[WUV!"B9RU51?^*C2&)P?(R3V-QEV36Q_5>\OK4C
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M5R7?UP-&_1Q(J0$?KA'9R05,<#-LXW.DSRFMRO1-ODR_TN:;BUWICM+_KJ]
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M0@&.'27K\=B]4 \G+.\%,,E/87\,:?CX$MH5.:268T&VF5O?>.WZL!EZ!SQ
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M:/K>WORK; 9(/Y3*CK<4!#PNJ$_?69IK]K_!F;3SK#JN @6R%'Z(J_99&WX
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M[>RMD:4C89.U'K+0B"1BU[8S%(V#(?8-R!YH79OIGV#-O(.S9*RUB6"\L7L
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M"\?Y;=G++#]TA_36*)4!/"]1S?VI"M3L1L,C)-&91[V\>'%FA*CX+76[N"\
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M2)' ^)=P\!^"M6V5/I%K/&X,MKLR$<TI 3X1] @;C_KO:S*UZO[;BLWL34C
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MK#!K:S]_IR)R$%SKNM]%]&C]^^: OX9;Z"V4])97-F6$C%(P-<64<62:@#8
M,##=-7BH5]56^KVVRL!&>>FEL2M]4A^)DX90MI- YG,(2@ON)B<,0]^$=4_G
MF(0N7P]IUP@DQGSROND_1;>^UD&I*BVRGKONM,PPVURE"$QNQ0O\$P!:5R]D
MZ)Z0*$>:%"*H>N7;O>B?>X*9K3$\#!KH9,2[&@ 35[M"27IX4FE>N(^ZK*_?
MV8QWWDP%@70N.H-O:%6GN.$ 3-F3>#W1\9@"0=ZJ =#]B\=7.M#P7L-77HY=
M-YJE[P>7C%_663\K3:WM@*6F[]@BFW5NZ]\A%,(V _?3*O4Q)R.;@E^]436D
M_[!Q!ZSA"%'&*!VF+*"A(7QYA.J%=W6[/D64I:Y<&];3Q0KSVM_5WMI5O=S8
MK@YUJ'8<C-1!"31!!?)8Q.Y,\"U**M"IF7K33F+GN8U9RL_E<EHW3>I3G@W0
MHCG.N .CO6('X( [TJ/.(_*<>P[9Q V_%B >*U""4R26,%E'<ASS8PZKR%:
M]VZP_.TZ]B,-CQ0:FJ)8SH/U>WT^.O4ZQ**<GKLK$$+O)LG+Z?>CDN<9DK&G
M*";H&A-Z6&D[>;?JFW1<B@3]CN[(J(Q3[_#J7D'9]\,.$/B0_;!MKH%AD9H;
MJS'H%'<.SWCN5]XK0F'%O#%!M"J&F]24_/.W@Q2AQB[2G@L(HV0B:P07:?^
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MV^0L"E:PQBOO2*I[12#<;F&>5\;X9(=<EW!9 X]B[1G94Q8E0[]B6J)%^7H
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M;DM?/<C5NU#(/,T&*8A4L)U_!YZP3Q>)%QM4SKSK6NPZ=AOWR+D(ON06_OW
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M/%'Q<QWW.S2WEAQ,C"BB&VOZP=O+1#?%C_'E);MPP*%\( OJEW6*MRH#Y_C
M-;M,?V3(65FGU8-[YIOJ'^/)OSPQ^+KDO3-]R '7<<3S^!(NF;C\^]R&(@3F
M=N68D<4V2U>Z8IEX+*Y[ &I8 ,R]W#N7:5JHL0EHR>+)4>\[+3Q$A(QW-=BD
M8SRE,C"N)VW>TK+DN(,37=:'5.\!H6V!5",1\UNI.._)6,AKOE[C?-5TMRIZ
MH,BV._TR^3Y>D[7(XJ7E2QRA1W-%NIP^."!@W3=>PSR,/L_*+%J'AI!.BK#B
MNKZIMK.Q)9J$1><%669MKU%4+77.-WSLF[(7K79E\T/IT2-5B'T:U$BY"%+
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M^RCMB=*P8RVIX4FD$$SACJX!/!S2<S(D;[4HC]BOEM..74GHTL@I"Q\3K N
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ME/] 3_H)%4 )]4)GP)%AG=/@9:E,*\()B'^(YZAZ,W.R[7>@,MZ_[IZCU%?
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M/H=TD9J/4%JLF)1&:DP-#/6308@E5'/C=MT \)H.F"X(Y>NJ>R)5I*96)-8
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MU!0O%MLCVX/OBK63UPKD<)]OH)F?C@,A=78S*"+BZ@T:SIK/HZ>:6XBY9*^
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MN59_.HP3)TRGA5V9\KU/C_:1 .F"MV5Z^9W+K'%&R]G#EJM4FY*\F \"%8G
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M^\ FKN_.G]#7O'XP;^#>)+ Z(,W8O #:Q 0W.7+7R,]_E6QYU@Z+:\4]2%$
M!;['W(47G5,B>]&>LXX;U.I2[S(+$<,>"CD_BK,]7SN;/W[ZU(/I6O[ST3I_
MM,1+9;:T[#YYH0K->ZOBM'\[PH?C2J^V1\.E8J6C<RL97]1H57) ,-XMZ040
M^SK:ZS.><C0G7*SO8=K_J.A#]4,<LX?N(:./ WZ"%Z-1Y-Y$@K<3Y<KE\(XO
M )3+;=*S:P_OGN0K4MGV29T7@%"YYOE8&S_7)M'RKG4]@E<)^.%@!>[N]5W/
MT'4I#Q0Z+R?1E]O^1'3X=;':/&]9IC:$_*-0@N#W\PQ[O?J.]7O\ZT\/T!?
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M!*S4**R\3[LG&=J1DFF?>V=:SQQ[ 7MY2GHA85ZT;'JCA>;2U<L#KBWVQ''
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M&6IM?$D;3ZEPQ@>@STT(O3PG"%./7T3,,2+-L:)T!9E8'QP],DT7V/N+ U\
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MJI[M4]A6J]FG9^M:,:MO*/8(^Z;7] *(T@*O<D1DQ:@K+59><50[OP!(JUX
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M9F%3W?DSQ+O>6#!(,=)PN=&<^J,, SV-%$\G7#ZOHW(OP])R:0S7$GL_H;*
M\=OGHH?R!FCUKY\@8R:K?(18M/>+0W!G0=R"H>RQE>C40JB@X!^3(7R:*M01
MC>H:2T-NVQQ&I;_@_8(&DZR7PWSA?1A:GM54N^T*UZW\'0""'#G!2F>11 (+
M'!HP^")$O))Z%3XJ%:D1F,)'*?'46C ,C@$!"P&G?&J>[I(Q6ZQ(JHJ]RPP+
M0"Z*704#XX@(![A9"/ BZG-.3-S9<OQ@5P3I_?9<DA7/R6;,;8UE.\$:M^V(
MH]H+H-HX4CT!W6_%?T_UDNT,XO@PNV3U\X;L$TPDHH*MBF3>ASK*RP_?@WU9
M,8*I7@!5Z1E^'..6/L33M=^[W6E6>VM*LW0<C"1)1Y N>YT X\_E2'R1(&YH
M^_8=^'H)U!!E+-E.SNT=KEF/E(KAL9467,RN5%L]E36Y/;6V:;,988A,S.=,
M6R]K!D>"8*QW)]"[4EO6.R,"+;<Z%>1'.8RX*%\+O$!6Q)!W8,$TFK^?B1%,
M\HUG</0'OBFR5W"4_$J#Z;>P6?I(J36LK\O_JCBPD08)KZE@FT2GK;.F3LDG
M:8*)ZB**Y:)'B%8N)*ZNRHPI&8OQ87[R"?.G&+W5/177W$&Q$T';"L*M8\AG
M<&:/Y5_NX<4,8_)B*QEW+TJLU^&1#;6A3G1;<EOJ)HNR*/Q(73_-?I^ J&/.
M1 ZR$U"6E580U)TWVJ:S>M?Y?B1&&/G#F&%$* 9&%SB1_0D&?[OS0>WG"#;7
M=.:].IGF?.-&^J/A=)Q[CF%6F&KQI3O!>XP@YA([4C%0C<IE^VUKR/U6$Y-&
MYUQ3[17KL".URV0?%?Y!#@!<I2![N[%7EQUIRP0[CMWK5R.&SWTS2'55X!U/
M@,4XR.P18B-(X?>@VL>?-]_35-6,;U E9D.1U%-QLEPG3M"_/5>9(3X5>*Y@
M_FV*=8"@V(:A^]#'0&2N+A#U/4*]YM8#>?_O<../]Y]//Y9%K=FA1+X GFS+
MU'X9EG _DH_RR%VTN SP;IQR/Z0C[5B4?DX"12_HRU!#2*8^QV  #E!QC5<V
MG(XT$)K.5O3%"0?4'838[TTT8QWW"?N'<C,&5-@<K(*L3ZD)&UL;',!!U M(
M=1HV%CJ6" XV7X,YOK9_+(><W5WWMPLJ:/JL&DZYNW+-561"AZD'"%LKTY'N
M;TNVM:<B70XY?_A!\$WX?1#SVCK/WMHP/.N65,F:F0.].T\%!WL%D*GD;B$-
MFE1$:F$;L3-1^AW&OR0+,[1D:N 4*AK:QRF&W.V]7=M@'ME$.5/B?M$V6)HD
M$><?#U0^O36$"YAW).L.9V9T_5BJ;-  V45S.70D:78V7LQX^&13D(X_<LNB
MG0\-VP[S,)5 P=Q71'WGB@[<'4EZQ@,S.;X  )V/@T6&5;6U'R=T^HFXU@S;
MV;P55)0Q>@QL6>VM+?E[7@!8!DQ(6PL#MXH693V)-EWO8F]'&J$<69VD)_0'
M;1OT&]NTX16WK*M\(B A-1I0(Q6%)#<%N&55(A/H(,[0V]JB7GD<02JOE;2;
M^A"[,D%$\$Y99]&F'O2.S7NO+N(XZ/4B@)@T@Z2-XTAP'&_GG''M=Y]BONKC
M4Z#"1,F>/MG?J6D9)2RY4Z5S::%%N%IS1\>F=5SQC-DOY[&*&M6:265K#*BJ
M"G@U'&+QO@ Z(@%'H^K!<V(&P1J5,@5WQ5<9S._.$58:'7]D!O+/&\8,>C*,
MVP51?'E/IU-$E=-P?:6_JB#H&GAGCW;1'D:M\VT6I^>=V%>([D>YBRO%EIAI
MZ@B7?H[5).8=>!G/>B!_J/\+X$"G759UQB.I\YNV.S[[QV,\"9JD#91"VY;)
MYQ"L#"J*RSI!Z%'[(_Q[M<IZ#0T0JV2&\^[78X' ?;(@WJU-Z^V5CFJ<VK?.
M+L>OXZ/T)Q.U2F/8:@(/L0)_X'&4#9608.@O]WX2J7V"/G/(Z(WM%1$Q</ ^
M-^8>:_\N8S;*:'U!5=^IC+I2I^IG G=#(QPCOJ"?M^1^9 #$G9NM$]YE\K6S
M&TUI:<)>U9]"&95HH#_\ZSLDP=2X<352:[F1=BY=I^+HL4B.HH-8+4<T\/>I
M9XHQ%Y^$RH,R?Q(YAM0!O;&L\TYZ?A%E'6E8!(SRXN(+P$+6->J*;AG]%;V3
MG UNA8\.W0XPM&QM'B).T$!E+68XD@7P&:?TU]? )@P/IQC1Z)Z8OO!07X;B
M" "2$*-FSVZ9^A+%UK]5#_G_:?\9]9%ATW,;ZY FBVZ8WT]^GK&S<,<"_8AI
MP@H?AZ+WR,JRHI%YO?=&/OR6J-@I ^C/'-<>:F)R]-[-Y[Z7N"YYJS4 N9\:
M;.S83IU:TFIAK8'@44=^%N]L)%NT!>^W/_-;U(0QY0WQI=:Y@DAK:]7*F7YT
M,4_!T9]],9R 0MZ/?>'%&RA^,'OXF^/C0748/L.(I9+H)B9])L'ES):(,5J*
M9RLR@%[P@32K^4YJ?,/\1MJLV7VY7C"LA*LN?X/^"QRF@31D#K.ZZ^U&G8-D
M]@/*4MRU0NN[B=D7P+WQ"P"F^+:NW$XQ2ZF>9["$ST>N;2$G\R'9PTMIZ)1$
MQ!#-M&:*8'L72_7!3ZVT#%1OQJRZ8Q^@06?U-XHN^/\7^W;_JZG)R2C73'VD
M:6M+'*K[3K1N;@7RY0:DYZHU[?I0@P<"BKR-7@"314*1Q>%TF4;_)/_"/ZGM
M^O]F7]=_GUE3K6J+:W/2Y/M)\)P> +TE?'(R6O5YL#7G)!=860:,)L(/2DA?
M9Q2$7ONPE\N&+[\>B2CJ-K'"5FGBR;W(_MA6OD!<([\)29<8BC6C+,8@1P#A
M',JP>NOISX<U$3"5H6@C7H5G3QRR)^AT8_O<7BLEYZ3USM+IZ$J@IL<%?7?P
MMCVHLAOS_"83/@%VZN,D3_@F(KX06\Q!]UWB\D7G7MF2!:P60LO1SLIVT)BZ
M@A/P.4TBGT56C7BBG]^36F\X-=).F.0-5;1W[X? K>0R+>T?-Y#J-[^2:B:O
M/E-5][\ 8(7C!4.S&7^75B2:Y ?4=A@D@]?A7@!?R$()1AW'@HF2OYJBR;"'
M=^Q(1DAA8'KM7XY2AT9PS"Q%.K>']MJZU!NB;_$XHAT(;\9M.-T:%'%PM/W*
M5C(IHM(96V=@+ZJE&3=TUUOKR+"Z0.(=(BC:84TMH>]4.7RS\_Z _7O?#'G*
MU+6R:01:-5U/N..,TS@2L,EC@[.4AY$R:"_,WK1G*2M]N0KNL@_( ^V^?K@N
M?4QU)"X&-TVRV Y$S N[HCWH&GRK2F)JRECKYOD8VKHH[Y#I2@(80R)>AEI5
M(D+E4@?>W6636F1D&OR\5/H2BV&J_N>IY>:&E3 ^6H8>PKU,7AR-1%4G24OZ
M>)F25I97[4@#"0Y-;:VS0SY5O%(YF8!BRTDVQ7]G$79]X_B(MJGS?,\_FS4P
ML.,1#B%R;::H;PP_9)W\S,UM0H56,!$PP"&B-@NJ3.$V"B)9=(4<"\%Q'_.<
M:3!_G-."GVP6L4.$+YJ)$B<A\"3K1DH9FJ5DZ\NP6K:VQQ=U)<=!A9OA<D:"
M*Q>)P!G3)E9N)#K"=[6L5IX6EO6^AE5LSS2Z@U,('A.M9\HUJ+FAQH.R-7B'
M1&)%D4>=0@2RJW;]]U:B>)>$,"7$F ,]3DF0YO$X?^QQEN$L(S(XT)J04>@2
MVP#94HW;-U.LF8-J(!/3P<AGB#TS6"2?]RCJ&+8/4>TSE.8KB\8BRP)N$G_X
MC1WD"/4?CJ#ZU#IL31%!2@]%PVZI56H3#R0N#CQG2$U6"W#HFP+!PYKSM[[&
M=]'>9W>83Y?2Q^/VP6L'G!,Q]5"="L$$B2/EO-B3IYV.>BBJW\->@?\64=+C
M $A#T<[.@TSDP/N'C-A".*:E76 \/<.-(F?]9><3 RRVVZ(D-S\+/]:Q^2>.
M\6I]*6N2^J1)0S[VGXB22' !Z6\>CP2V-4UM.3[>#(@3@?RZ?9!L!>Z?D_(<
MXD"ZW\A_V-<V=BCF?;>?8.8AN</=MGV',LEJ7X_$V.!!=N9ZE,*^*CVXJ^;J
MU!1MB!QK^PC_5OJ9D/H9KXQ:BA77/OYA*W[0/"?JO)3^!?#&M/D#QEG%B,]Y
MGU<56V0:@P'*E[*-)\(>Y@TMG<JON1=4NL:"4QG;WKP4&W+NZ5*YR\9L=&8=
M\!14I]N"D19@Y+(K'\R)"%NT\S0!N"HAI9#3^;M@X<?V]R70W*?L1XOP]F84
M7(B/@?X5&T*?@Q0WP)EV0GF8$FMOW-+=:N=RMW_/;!VY^9+\/80QC1.N9862
MAV"5S=KVT9/@076E55IE;5E'^FL#ZR +(8OP(\_S)0@-"G(^F\MZGJWYF*>^
MM4Y+T$ 1W[XA_--V9@/,.]XL3++3MZ9ILYT@$4U0\*7;GMH?F83-+^)<SG_J
M]%[/I]^1V)N X,^QX")3X*,K659!5@%EY40)XAAO9.8UF=)2J&D0#5064BQ4
M4L'W%NXS%<#CZLFGEK';U:6C26>Y2+_A$D26M-1^=RV''O%V@*9;BH7@TH0O
MR5NP"1B,\&'D2?)YTME)<#+K(OHJ85=R?));,'V]K]B"DD0 OB&58W=88,'K
M\B*XDP> 7N*+26X665N94E"X\"''IK(:%V1XL&%F:1B9UH=,]D/RPR]'Y37]
ML=[\EI^T=T:.V%'Y4YA[<JA%:PM%"7QAIBAL.T.]MU#0KA\0$5-E8K9S\VCK
MCBL!"FZA^ IF6I_+L#4SA^_27#W;^^&''EW1XRWC-' UC+6@5O?#%L='RSB8
M$Z*A*G8X8H>@TK/D>Q\8K4VVN0N*\[Q5NX'VM_&^GUS19@\#]DZMC17LZH!8
MJ246-?A? #7N1Q/VZJ.C*T$)1,!,#%)WV( KU-C[K<RQ.29*ZF^%X87A+,4Y
M $PA!N3RS& 1K*^7]M#"OOW]?*$#X!A2J]B-5/X+(*JDWE <S>[Y-YC%%;R]
M<)/K&MZ+OS8%?VEP*AKP3:!TX0#)\<Y!$D%7ZJWNRKJD.D&'OQ3,,@%%;O]M
MTD4QDI?-N(TY5?"X:+!,&&&ZNSRI2@)$_3B'.A6CFQ\&XI%2;VU#CC:R!IKZ
MUU;:$^!8\)?4X+R?5F9:_VF\ENO-%\E#3S.R@E:YX<A?_;0;3'J;+X# S+P*
M(]I0YIW[G25QEW/?-T^6+54SV/=D;R8'DE9^1+)-G"\'W&LDNQ$&U(<FL(!,
MYYDE58G"D&SY76Y_Z^TFO?_:4@]XRK>#%0ID,W*,LLG=N2)VE"_[]39\E^,7
M,V6=WWY:EVB (YL3;*7:J3,/_P5UO6\$+;=#V_KJN.-\Q?-YQ<2@*^6P9TT0
M7XZ?NRHP[/G2\XHDQ*-2*]>28,'*/O=SJ3VYJ))O,0L@;XR.&L4(.+ZK&I/]
M)6&\HC!=UO#UME$D8E-A$H (O-P5#N[&,[.Y0'_N,8>5RD,+'3?J&9IOF5^C
M*98_;L\WE;<7G5P?U-5-65B)RDXNT7>/M! "U3 O;3L<(:VX;R5L4<2P&<3_
MA<.O,+Q7HKU$7E\?OO1*7*H_$/%4[1!DQ/"R^OXI<_R7Q ?@KG_F7V<4%%A=
MN"E0,[@/!R]C/J7XX?_3E%3_Y>BHP7A.]2Q*(G.$^?Q#^K D_B[F!4")D7<=
M\@(0SX/E+:;+]OLG_M6_K*CZ-Z^6//6 ,ZZ2NN0_O=Y7@TD$YR736):P%MG9
M[U$14[]*4]N;-M\=F(B[?.Q3Y5((17??-EK(Q.ML%UEJDLX#Y_=[AN%%:-"Q
MQ-+M>&(]RIS<&UXJ;SMJJM9%C.17A>B2O0#4N+RBQYA.)\1XH T\6DC%Z<_;
MA0^&R0P8<:?B$6J!-@X+F^VM+X#Y(OI??O-(+X!9.7%#%T']T:>SYU: E-:M
M]E?IQD"Z;OR+00JI4V'B+.# QBVZ-OR&J:\P(1*E[V?R:7US_K@69$[D"YNO
MW3&'A/($WDC$9HCU[*T??S];#K(D:+$@H];0$7809ZB,3V6G$.S+03(-,<0]
M @XQC4_IJ=(OQB-M-DA@R*5S%M*)SCMOV=,&(;;&FKX=_C!(_NBJTPNYMM]V
M$NOX8$P'0<^(XS[<M+/:>74M]2UH1K'V(B%?4*K(G/FC^K):1VO"?')V(ZQ3
M8>8$#;P+,O)/]W)'79@&PAAP8]0FKM4)$4N8$PNRAC2UZ:_?%@H.E<&^@7_[
M-WM95EM:F14S,R[LI.@8S.^.<8$99 ,0[8(U>-\?LP"/Z+?++T?HM>#5V)[H
MLRQCHOMIGO?%VDKU"Z"245P0D(M2:5V\KLWR]+LQU#G2H/6.2_?)\<ZY>-<T
MM3R' \._[A CV=OQ:\=;V/JD$%H>$ZL=Z Z9A^99+:,[!/7 >O5G8 Q!IN-!
MX\#JL334#"_'TI%DM\85"UNI3US\S372"G%45\9'I5$<"0;&'#36B@$.ZDM7
M1K"Y>,QI@_\>ACLFEJ% 'FM[&9"#B/!SU<5JV#&-[K-6(?\@^QJM:<*(4U)J
MC<A3N]H+P++>YT0CC2KY,V5IN"?+0*9\#_:2SHKD!T*IAIY)SCGN V0R-\>)
M'4]5<9EEL?LNO3ZD-66JV M!>H%[@SSNW[SF/+S>68+7O>"N8@.QG-^%91_2
M;,9V B.YWU9[7'>0*4L<"<TUX=KVICVM02T',EL8X(3MX[ ]C%><!L8O>C6F
MKPE62C2EA9ZI34P$Y1T?U,9/Y#X^EN5PJ\PD?:6Z,E;/C)*:>=MM]C%A+,=E
MV-6-4.+7&@SI'67QR3N7B+BI\M.%'FM]7*!)7"'J*8 Z=L7^;MYHYJI4*5]/
MN,8[W[+PPO%G,I6=0&9T__,]KIGLC\_>:)-P,P9LO)AW./@*<[&N'_3/1?H3
MY[YO_/# L2>,6QC)YK"J<R'M3HGM<N5BVCC!(Z_ZJJ%0#[-G%[K>K)\T#-ZN
M<1NDB-K<:ZD[>M_[E,$);X@ #<EGF \$[\A,M!^3V+X LN<R%EFGDYH,VY(P
M6:^-2.QMWXY/.^Z007?4.;.\,9=(N<56N[.6QFQ!0:R\OCA%2.5P1WI,#K?:
M'*NED=9;4%&TWCA&P!%$"IX8%JF0YR:W;&8.W9E"I@<="M4I2Z\X5,%_#(.[
M+H/2E>77XVCKZ=98QR2DK?CS1O!P"\R.N;\C[%]D?AV(^F=1XP1/EHXB5>E3
M/'EI7G5)11=5&"MHH.V(#)L.%1<&'?STL=VDN%GFQ*>T&*P70*9IG(A7)HPG
MCN>@+03\ 8\_5@+E7?P<.W&""P"S9]:H,+<!^E%Y!>[Q6X.LQRDWO#?;52';
M##BQ$#P^6_ ,6_\"("YFD_+F#R;269VB[V[YS)!-=O/=9O"&^&&[3 L*'!U#
M7\G"(>Z$(??YU"D8O.XUFRL:SA')KBI&H*;DBU21O;TPV#1M-3?35EVHP)N.
M##'&)C,,%1*4EV/7/4!]#X?"$F$DL]2,1Z;<6%JTZUFR6!"W.R?Q0_@9 4T<
MJ4#>6V%3J;K8V'XW$G H=057Q#Z*ZYD6R(6EVU7523E(2,9(/U"P5WDU8CXG
M?PL2G1YN-.:O7P6@811$;)AFV+MI8G*"JH*:; UIP(:"(=<"'3.<$LQY1:<#
MT<O+A9!M8G\?S?X2LM\S3ZQ?ECO(5T;VI#(0I=YT6CF1=KB0S4 L>UE%_1EU
MI!8=(2Y6^S.)G8+ZYCWZ0[GXP1ANR\D8 @4 LHZ9.K7OH+UBJ<+E_#]1>U6P
MFA*7QH<>G[;$5.(SS4 &K,]*%Q6N3TL9-Y47ST(9%@)CH"4;3<EWIZ(Y6 63
MGD\*F^%B=,1FOJ>?S%XY*LUJB=O0V^?WR @<R]@:KAGA+;_C6O,W0TD9EI4I
MKO68,:VV@@<GDA+('?@%P*;P%,$%AC*Y\)1]:-V<TC]$L>3$0/J0HIO1W'']
M D QLLLA>ZZ6H@*%X 1 '+PM6$=&:WF @P=T*%/.F]Y(*@I?HQE@D4WYE-D)
M305\P:G.)9)$%0S42M7-@$R3M$A!;(O1](P/.2')VHP"69CH7*_P4Z]RS+M8
M-:4MH?/]#[)*$S?,4-:Q#G3T 6Z:>]0:)GSJ,P_#W&^LRK[*[&PZ-4780@*
MA\I!=@W/OQ6:]F_GE?^/6/$+8$3E>0%\/&OQ?WV<>5,KAJO(\@]<ES 22NH,
M#:_@HRKUM]:>:!"5]_15WK_(!T8_G*YT]!]W1$ML_SHN/[W[9JN,1/BSL _)
MVZZ;TUS6H3R_@9, _7H#7B^O/Y*5,SGG<A%".JL5D2>JWHOVW> .W\?^5O8/
MGD@A;51W9KV\&3<^49XTO6/=% 84,P@D4M2&+K]^M4QOM/M+!#TR<* V^,[4
MDE>U27SN?T1^V'GR+IGZS2+\3SKG;[RB?X%" WU/,D9V.,/@/\Y#]C^,LK$N
M^!0QV*TG)I683&F :B)@ %B"O36U+S](<VHM\5@#QRHNN 1WAFD_7GAHF9D=
MJ\',9K^PKS0EJO$C?C)8+6X'ZQ"=D<Z9H3M P^;*;HK]1IX\.5+OS8@#F3(?
MF?W1 $<J#>CG0,./S(PJ+O%;E<F00SX_Q=G(I%$9HZ%>^?E##Z[R%X#!XQ,L
M"JAP@#_^=?XYTAD*$^).2-OU,RZV]\6(Q =$% WDF^0<HA84[D2=/X.UU2/P
M5S#FKDF>VVK233NA$[B8V\]DS_7;0N@0 ILO@[-Q;R%]"R;CNBP[*E.'#PN^
M&WK]Z3G(Y&39]<]\=U/L# 9V-&2-^J^K0E\*"$(S$M8" YF,>DHLWTU1QY$Z
MI<G/L;;HXXC^KFNSL&VY[,F:_L6#-*! UMC0=T@84$2"21[>[W92CEM2+%/Q
M3 =.R9C+JJMIFI;"YQ++'/,9M4]0.BZ[37P!D)+.E,H$W5 T3Q34?9UCW!=>
MHA1RNH'_(S$/[SF+R;!-K*5W>@7E>P'P&U^7O0!.:GQAO"V![279R<:/\]'
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M 64!0?D(XBEI$2,IRNE=2Q"5&Y>+K)UA'=^T"K#!T,BWP782=]M=,'7G&1*
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MFA (E;4QO<)O00*F[;6=76+\4?S?PN<:'D=F+F3Z?3I3.D]3W4()YX<O7^-
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MYMD:K)=O-WP=CQ4V<=BN(29AH[@8*CE.4K8?P>.F5\H2IAYYMM3^ZP4!SB>
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MBN7HO.C1Y-O?&_(HJM81^Q)82(*XBO*+\K^W61+8.1Q/42(^U0U=+SQ2D-A
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MD#MN"[I4?N+$B42+Q .JW_RT%5,N&+Q:Y]5N-*VK,\P>PTQ6Z'VRYS[HJSI
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M=:DL'2=:I;&@65$7>Q+OM ?E.()-8VX/[9DY'#U*SO*;@]OZED=.A"Q.E&7
MQ^3#?=TLD+6V L.23\G&OIHR@*4:'F!4_L@K_#EM-[:S2QQ"N.["*WXJ0VG(
M]56#W/L%2SMS8<FS7N9'IV\?#.>IVIT$D!3;D*ND<,+IO"4"8\])7C&>$W$!
MGN)O&@E^<WRF1/,T@"[F,>;RZ>..?OSU &A"UD)8L,BE.%"Y8<81XTN>/7%3
M*_W'+>,BIO)"96;ZT".#0A#;B_^ *>Q_GF&+@.JUAU$06_@V#,1<0<]"<9)7
MPHZ9! )4RU#],]"U#0F@\,E#/#W%6K/OL;@S_15K,7H>T+6<HWMJ!J;X.MOD
M0;R+^@AP.\6>YA1%V8J2/]#].1_O'UHX]I>HGW8$J1J*N^+\,U;J_[UF#AM&
MO(D+1O2UT-RR5_2$]&SG^7@C^J:"]QY4^?P?J_*D/$50@C*Q_V]P-![;%N<'
M9S%E*POODK?U=NT.7^S=AM':"7D7?VN%^8#7VH[5X(I0E4]+5$-1ME^&)>C:
M.\_GPKH@Z,_"U\EJ=0JKE4O>K0S-P 6M2WT4.?'.&2J6/],SP:[16^\LDX/)
MSU71 L06+M9)I5QKI.. 2OH8660$J9_K^P"4"9T3DP&Z#>JOLQ1N(G[@# <1
MS7-Z=O%^0U#:_*@NC<M]6QW*:@G!ZD4P8M);4G=J.EZ>?FQ9X$*U]>/J') O
MB"G7/_& 1&SCT:1JM?>%^F1))DXV4PQ<O,(N2 Q24V1MO[.DKVBPI7P@\&3,
M[UG*U,6$-FR:G@;R8=B9;G1WPILT]*FU/RXDL#YOF'BO*7HK#\<6P3X3_/42
MGUO;2($R28!<  7>JU@;L[&7NGLD8M +)(#:Q[Q?V;5Q'4?Q"DKVA7L9XS,S
MF4,J3O(C]_"+"2.H\%PW0P#;;,U%CEC3W,)+N?#OZBU.%^8X3Q]/GE?60MH/
M3M"LRV#C!NUU&Q1N,%Q,<P5A>&7[+-^R,HURR^R1.8&A9!:=U&*PAM].^00;
M?ZN14N7CTPO?QL/$@,H8KS!)?"&K)=>;A<][:<%/.Y\X,L99%"T=/L>AH["%
M7RJW[2;J/>7]@>_F6VM0^%6C.=0] D+SH4F<5WVN4WJ+C,[10EW(!BQ,P.C>
M(B[*^7:#>:=-]7F T+PGYT=5\;@V$<8"/I[5UE1)(TH)*6&F\HU@8G]V8L4B
ME4WW,0D6&)/AO&>6N-+ U9"N__NF-IR7C"1BUJYD#[EI0FKEIRY&+HRQAY43
M*!SSY1M$$_]%AMX3<S@6A^VF^#@K0&O#^9>/)<;EPJZ5.CL)<=(^ Z)S#2F^
MYG35S[EFKC5 KLKQA\25C/V-;+_J/R[*\SM;C+4@FX3DKE9V%&:5+1IMBKW;
M/-;4@BY$\%.(F@K,#)DO$#JKUSEI3F7G1GVQ[R@$I9TD$^P8+$1V*F\B 91&
M/D7]S9!U.;\LIZKM1)9),CIZ;T LY:Z8>09)5*<V&$BTWYX'>I4_R[<JW+GH
M2*AV3&=)[:+JPIOMPH5)OU"FKGM,>N*2RX^ZL4J?X7[!>8%NQZ:(Z>3?UQ4W
M]EUX+O),$>*\,QWMS&5N[?)2_];,S[_,]JB?A?^STC4!NL!-TV=(0/_;]H'
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M#13-Z5E:S]_D4_^B30:2']NOJ_R^%)?>$&Y%]/Z41K]R;F*)O5IMV;D76,B
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MF4; I]@;__&YR/\?_VN"[/SG_P%02P,$%     @ 6D1L6/&Y77_DM   -=0
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M&,< )^90Y@6?W[8&LJQKGTG4].TA'\IE<0)W])44M.LN>L6]##550S'B19Q
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M=RLCWA++0ZT"X=VHJE)]-WH_)]2LZ*XUJ>WJX]5%X:R5 J+I@OJ ,(NLY2@
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M(SA[H9LI/F4H+1W-L&EZR+O9PJRG63UIH^DU& !PZQY?@#8%&<\^/%%_11W
M7J/PSN_GOB[]Y-+$WI>^E6[:=4#M5="D,$O% ]_2:A<.8W O\WETV4@MKA7$
M0Q[F^A!57ZK@E6/KR=^!<PGC^Y71O;<* B2:%3]8F79OYJ==2Y.LEHH0/+$Z
M!>H*DS58%(BDF7&F&>()IM6U-WS])&/#+O7)C,%):1[L39]QRZ6191SWHY+
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MBXN@M7 03^G_//%3=<W-MF@I9G:SP(FUIJ-B'("OLZ+MT<R? ^=SS>9_T1G
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MNJ/Y<@)C<18"4]89$@EY>F]%S;CS2^!-;SJ>A&F?6GLA0#;R6AD9'@08@(4
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M":0^Q;7,'(<Q8FJ(4&93YE-25,/%8_-B\ZH1[-XT/@4T"-V@B7_97+]#7H
MW[E>E0KMZD7?OA@4VN%C#<.ODL>_)'<T5U8>FT7)D(7GT+;[JRAM^N\LF:KO
M2 ?9.;KD%9^8B@M#)Z9G 'TEJB*=6B0^NG\\L1K)7V^5\D>37N!8^R/3*TQ*
M;";D1DX;Y=3<88&UI;7=OYDJ$T:"E6:_CD_E_?+6@@ B6F0/\/F7;@_#9\]5
MM:-<]4*((3*.F-\K<CAB^9>AQNQ,YL27^KFT9Q5\HV=FCW#6OC\)H_EZ,R]
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M*71JD)\M-^0B1J K1L^IF0&>[/([>,FI<I)"V3O7<+N6Q]@=DUHSK+[]3\3
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M&_L7T$>3;IWW$W.;X[S<AMFK="?M]N*\8W D&EX]G;UE@67Y=^A9'/Z;PH.
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M_@I_]-1XLF$BZU1]3BPG:\Q34\)##FQM*#\@O+T.\,I;MOFUP.JF+I5?;!$
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M*0L#WZ%4;=4R:U@22LDFB&++Q%2<MJ_!O7#E:"5-%]&WK01&A%W5Z^L+&IY
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M27=(WU7>TS&>5,6J]DG(JU/[!/$]*JG]"]?@GT[6"1SV\LM3,F CX:!M N.
MDQAO]@-]2XMB_D>]D0K[,L?7W-'L$T\FW?[)ORC#_747 D09TB47.N/\9'6Q
MHRL(7CJUIOPS_T1HXOQ&[:;@E8_(#X)Q ?,GU#@\S<X+;#W<:E59KU"UJ<)[
M]V,XR&B4]#S$)'90USD\T NOIL%U($-X.LCRX',AF"%.3,%M1V$IS/=D>^7G
MQTW)<Y)SQR:HPA\EX:[>:THRA:.@^BU"#YU72X&&>1*UD#JJQFUE=IK'LNR9
M^0\!_@*6M4K=13C&;9VN\; =FI<%+T[U-_3N7=F<MKEN3*3E6(MMB=D5AQK"
M.+Q[,C_:LE>@=*S/^/*X174I*L3DY\LZ6XRMJ<29:\&/'7/.+R?<Q1M<!Y=T
M/'WLV;%OJUAW+V(+%Z#CSZCT)_KRB!!T(^M9M4F^2.Z-ND,*NXC-)/[K-%@%
MSB1R\LS.XJ2ZB+&(!/\(L\NY WJRD"HJR*_>*)4Y[;HG"L!R*TBI\-?@F"+K
MK.<T"@ROF *2"[ON8&FX,DGMV;V0.4']"N8KS?KXR0O0*9+N(C(1R6U+Z6%D
M$2CV3@/<I_1G*(D:3)YH%9T/+/Q0<#5,="'#3;_I*?MT;$];YPM('E3S[#.:
M\;6\3Q%N_AUU8;;\^#Z8_L[GP=+M3;ZILRWV@#[6P$/5F!B5Q431-@9I$62^
M2:-/<O'<13@S:Z*)R >RT.ID@'26/QBC.@:TIPK 3#UG4#_'%NV_$R89H\3H
M7"7*7XY)S[O[IRW"'&2T>3V.G*'".7C%+:/?\QIJ)US985LACZ9X#;H42 OC
MSFU<BU.>2O<O//S!-9GP,%TW((+;<HND08*YY7U7D5;ELEXF9^6.4LSH83YK
M/UW-_.(M&GSV.+[P/H1Y.[5C:A?,N6>NF>V15>@=R)NI^8/-:X32&BP,VS7%
M57'$@RU*K=#>I_FOS-Y7[_7J-K!H(TQ;)'@[KT'O84P2BD&7@#NV0<^)\:;)
M@EIZ-;AA[P+YU'2(,_N!P8F.ELRJV]LAC75ORZ7X*F^Z>H/K0W^IL!AO0'*^
MRU-2@Y&?88Y.\H9@,$!N4XS'-W*U-,/P\^\87OR_.RE>;(D:PTBCI+T*[W"N
MWNQIY&JP=@W+BR_A$%/IO0G=G[=S/2FZP85,&\4Y9-&56S%]F4)>NBJ@L-+D
M$A &PP>1"?/8A'^&N@=.XO=UF1)E7TFRH-V&J>O'Y_O?1JF>YB7=-T^%>72]
MC0V=KE<,NOVJ5DB8-Q03NSKR 33D7]N[_C2I_(?!8XK]O#@T]]:363W<L$KD
MJ(_F.^P(&5@I<.T8_<]_S5*3?F-/+CB23!B=M49;V"K0REWY#(0&-&*V^8?T
M\U R[.YV%A--2C^6>/8U*,!EO+ZU)[_H9Q<^5MUAKZ%/KA'I%O8LX/:'NRN@
M[UC"_D0_F3)43D[[2T@SBL/CS"PYC.V(0(J%C;:=EC]+9"V2BP,Z>2'WOKLX
M\?C6N0\-L1();[[ ?619S6VOZ.K'7[_$QS"LT1&7P11LD1*_L.*E&GNN*T8W
M]<B$_2UQ[L@:5)].*:E[^,Z6)D3T,BD%W?1'H@J1''OX?.8#ZI :TM2<_'E9
M[C=WN/I;"K)HG7!@2T##>E>7]VQ2WU2\2UE?2%CHG(T[S+(;_Q[UMJJ,,Z@;
MD+UYO2E^L$\X!/B76/=Z@E50;%)-9"@(C1?FUJK&/D%%5KI#DWQ5SR<0N=@$
M\X+[&8)^C-C_S\M--L6.XHE/PU7J>H9)H>N8E\RUSDLB)!9D\_0V05P8<$)!
MIN &H.)ZW-JD[.\&J-H$ZRSM:J6>- 4L5" 153O%+]JFZBJECA9YG9^?Q_C*
MCO A=T]D%LP1JN;J[?E"!;9X.<$N@]=X , YZ,U.#D^E57&F4OKPD$_[#P$+
M/X]ZR@7,6GU4\M['9L;ZPKJ'F^=,\%0[!HX$<@0Z7"5XI 2X_6.P/B%82;=;
M\X$4164,Y!!U >JJFT:RWF(4V^@ <L(5 H(158.%'X$=/?FZ4.(6I)1*=@9&
MVA)9H^.OP:&GL-Y99'-+)1;/5J%O$6Y/WWR/KZ-;NR^\M9W-G,64D5Y#VE3A
MB@9)G1YTKR,['!Q:2JUTP,3" YGO]:-OE]C ^T']/9Z/+QW)PK:^JQ;8/P7!
MLB*.]'M>^T!I=?S>V'*X7!PO,@5RWOIS:P 2'ET.'&!9W[+$ZTXS3BVY]HG0
MW.[QC6"/_<=N90EL43O\VGTN$TCDHA!2E.R]@[*]>RL<KI^2].>.Z=O\>YC6
MNZ:*EQW)ZQ@0@%PRHCN9O7]5<40X*J3-Z#!V (OF.]SBMZ^_S$5Q1%B@ %[<
MGR69IB7AOH4SB@">U: 00,NGUDII/K,_?VM[NE3N$2XMRW%3-#1Y3>@6D1!\
MX42M_.H>S0==M#=&COCT'KKA] 'M\A\&H3N=HXMSWAR-+C$[S+M9ATGT0H^M
ML 8D>OI^WJ91<70%Z]0RH"7<=K[M\0OQ-%LWG>#]KEYL((58>K?0!;[E3=*5
MM5J]Y<6"*@WK'@LZMA?U0B[H]EST3-A%S#MA9/[0->+-\.LWZ3Y<?7D2U\9)
M2:\2C3I!B&[Q!#]#)?W=>;Z1B*"3DBZ5I&Y:# FV3G5$-7&<(T=$@,9 '>Q@
M9*65$QI0\"+-TK]5AVY>\ ;Q1?A$I</<A0/ABVYP$(.XU;T..]BC.\52RIL9
MK2=2VCZ$'_NV9\1(C(!CQR64;[HKT>AW">!K@[[=WH:/"_Z9S2U2G?;]N' S
MG4-Y.H8H00%+O<37EM,DI7*,$O!+PN")<F7*HP2^OXV\#9%KV?O7::((EG0%
M$\S6/ZBV!OS1U2"94[*%8D"Z/[O'3#D@8>)0=39Z2L""HXIM:#.&D)+2)_@1
MJE<A-R3F0*-.1IGMY</%346@RV(_*EYF[D01X,S0S:,:=HI'1NUS877)ZK9F
M>?:IC8C4Z9M?K[&E];JF<<T'"\.Q^S!!TS-2V$$K(- Y@Q)@;R)^3,K1"Y2J
M.7QG?BB(102:6?= V*"&YV C"8;ZM;!.VD\_^B$!=??6U^XG?.ZOGD0&N37%
M?@&YC4XS.LRDOXJ1'QV;/X4F4";9'%;,[V.:*87 Q@7^KG%^#Z;);E?9I<E/
M I"A1D/BL=W3TL7KVJZ)65@JN;/GWH,N/RA>1XY]!!\.W]1+'DC^$HR"7\+2
MR"VCT:VWG8OLCAM)BX;I0=+4,,Q=DU="T;#K;QG%K= O30E)5FSY(B)_53G.
M"'3&;"VU9UJ!K'IW'H+<1D.!LO;-T-J.6M-V?%@H>?^_*WFV7MH?+^OZOF1%
MUG",3U2/KB6<^M4UM\TFK_0W\''Z=,![^12P"::"V!,FL&C&ASNFH\Z6KLC&
MWB@)IA7NZ%@B.FPI):;)XJM5[K=:FMOQ5UA$W!M(T+1-^[>-)D8/".DI=[SI
MVO*'?^INS40JH$&V=['GEKT%Z@\^Z]!&('G[BWTN?/&]!,:BZY>RPS)S>2)9
M!!J##K[ R@BNL0TH/R(ZF&C#0U =*P!\W^U+U_"%.V.,DK2,R%QS^\ O:8/M
MQ'3^9@P/[A^K/>2[1#8>%*#>_-X^"2H$3 EY/6FOAMVHS_&U/K]O-[^;_T7J
MJ2&M]RGPUZA\O_0BZP,_LF:THO\"%-]H7K&5<]1XI*/"W4ID^H&*]5GKL< 7
M:04-X/SDRG8#^":0\ZX*:['F&'+0VFR/LNJ\J]/72(0= 1S^KA >&V_3T*6
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M4QQ*M0"'Q9P^2.L0^[$RU$( #N+S@B1E?R>PTQ!"E=2-BC?LF2(ZBTPA7PE
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MY%_%99FA"#!KKBZ4?INJ)%7)B1$S4;]0$/Y2"IF4)MZA"/EW4I_\AB)(JM)
M/^RK?E)"SSDWD-A8D=FR+6+OZX49&LNH7AY*!/._13W,P?49)^:0L20/D0X$
MO' <(I[OUM"I>_P]5+ $XB=7MEEXG+90$_812A^B\2Q$12]16W0KR1FL;OSG
M=W>F:4C?#KWXT'P3177*BPM$,P;'=%.VTADQB^ZT%16QVW7NW7ZO#6=.68_3
M31DKRQC8OIIA<(C$&P>AM^E,AJU+2Z-286FD2GU@I#UJ&*\1?>H+=JWW/R3@
MZN>;TO?BE(%#Y;:@\A:HVQ['=@4%I0LJB.9OM9?3KHV;_(@X_<X7\'#S*#=M
M*C7204?QM4=6D/ ,Y:OW!7$X?BPV2-6*/6$(X:V2 B)O,-/\_," +(8KK?TY
M %+&R?:] YJ V.9FX,'AR7#Q>,\.&?'TV..U#A2B^=S$-^ 5T=W3D@(K-330
M Y+QWB?R6I9^C3.GBIEEJ4.X/06#ZHT--C^<?1^,E=&\^5*8X?G *(W*4'N8
M*LH2*A%;U@M4%H&\W8-89GWK9]]G>.TP$@%)UKRJUMYRL.YM'"0DB2 EY=RM
M*,2^K6.8&A9OKD&F(AG'8<!;46JEI[GW@4_!+QTHJ&GFXZF+,W16><=OLCNZ
M%U*[GB3_#Q+ MVPNXR&H3<XTH?MT+38LP>MS#RG07(\- %M */??M*H\TX@$
M[>)>1UP,/EBN#XA*D80_!IDY;LND<%\G!A9^L75J<Z^1J 21\"_P0?M5/UDU
MC?3@XQGZ3%_;>XAA18R<_JRCZ<@'@EQDS V"E^M:@H#NSPPD_MZL\Y\1-"8;
M^CN(#V#+$@/;<Q#^WAEY22@_ZK;IIZSIG]2KRK2?K]I1CNF?]>58]-B[:I,1
M8*P9)S2>%HWSO(L$G(X1H:QJ*AL8N*7(ZV#V)."(!).;'OLBLGZ>L'\&#S^(
M_$)B4-7\A=3X"VDL]:LX\8R[ >>S_860PS>F=9%^5<]+*,OO^]K%'-@34%$D
M"+K :5U(I:?E]!&"YGKKTN_40[3)4$_S9U:^NLSN?"3T'[59<%BGB^Q-?1FP
M6;:3<:DPC'AX8[J.;1EXQ_,55SOI>\T&T!0DDZW-8O]NVJ4><.O9<PU\C!BF
MK +CTC":QGWLJA-_8>><30ZM%"!<,<+/I_]1V[Q3ZN-WTQW-]JU^#\(.6R@A
M,.$Z]]M_@W;+?R#5FG.AP2W:XQ"%VDKSHSJLBM< 0MHX&'_RP#8\:77V)7?M
MA . 9E,H24^0NX)\>:(C3C',.[?0NHIZO>ULP=G]TSAYSBM6-_/=%/ <6[;%
MN=->S?=FO:T;F-L#IQCQ^9);8J1/F80EFI^PL])8M$+'H\Q\X<YHO&%D[\M.
MO#E^1FO8 ".97I!,Y8ZKGK+^O=0/F-,WWWBD4:8!9%86*=9WB+4$&GCF$0]J
MH@*QKCM*BBOB'?L-I+TM(7,Q5T96,D%CC?!4%YGDM]+&J]'VME]HSC[&22/:
MWHLT:?\8WU'QDOOJ.XO/ J^GW5!VO)O3FCZ\'+[-]W1:X9"E-0$=VA^;MS3*
MTV<(-2&GXTJ('?3QQ6*"/'*8X? OK02R?HSHT^ ?]W,57G;==5Z.O4>%.?*1
MC=O6&^?$C:S99).!4=6/ HRX*BJ["P49QV6MV8$UY8*E*)@#0L3;F?],/;*;
M^I$O='71^L'VT4VXH8VL3!GH37++20K=K'B:&O]V5_8WH!'.+R[%6850Q01'
M],^T":828#0"2,D ,0#_"-MOX=-1LT51?@")6-74,6M.3B<) R)U^=88+G4=
MB=^5_W980<^ES=:/A)/X%EO:;/ZV1K9C)J-KY9!WXU,?JA^>ST)EMI#$@D*7
MLEA@A$4]&U=;M7-9<>R$KDBAUX8\HJ8(&CZBTI:?%$#EJQG-,L:AKJOH["H_
MG\U.U)LB8%9.]QHWCXM!\X#[K]D'G.$4>02C]MA1))GJF7 <B9$1_*G=(=;#
M/\G;,!3?5_@J[3O6:0>Q7<**5\SU]HBP0<=Q=U\1AOK2G <V3F4SB\?24-&2
M@_ER_.P,#Y>EV->!4EV1[_?(1;<>S]GW1UX];I\OX<0$IE??MG0-3>G9'Y.L
M/S90N;QS7:S$D&Z)P9\;^>+ ,2CJY.+MM"8R:8J3:#CT18,5)[XU:BYK<,V$
MT,OIY_-'I<%G"WHM?2_A8541T7,N)XAVO"X2BMGLHO&JI72&Y"!6PNR.:+<D
M^7LAP5+7@N,8NO.I;9.(.Z/]KTSS(5&?BA8[F>JJ]#_0\[>?41K>*\%3&E4)
M/DQ2%Y@N@XT+I:U*$-W-NLK3$&BV,#:EX+5!5ZNZ'SJP(.+3_VWM^S_63NOU
M9[C3O3EBBKZV7=[X0>YT%P.BR"? EH_=RB*JB(T.Q7!CYD77K@W1^XSEJ0?.
MTCV*[-''VH_"']N;ZY^HJ ! K=:1&0I$FS\<S/G0KFR$U:6)>VQ<5WA/CZX[
MB%._,>D5P>.^Z&V<5>/ISCP8K&%O-J:<;5W$7'UPU!4/>@#,VXW_I%^51;^.
MI(I/*!?(&%TD[P-,?M5)3"A:SY@9*M)N_HR'=QO92_&!$+20URBCUH692/;F
M2->R6.^CE6V<?GJ.$XO'B7])53>K*I8B.3JU%(H8RP\:V+!.VW:S<60=B 5$
M]+<#/N1T=W/>A>7BA9#S @U*IAP[E;__J.^_0<D@Q3!AWZK[3/D=A3L1\K9P
M[J=J43'G%D0B=^[AE/<7Q9C(1[N\Z2]TNYYQ+$WID.+^D6K!\3K(D>,=HEN^
M*>%H4JVO$T#E*+AGB-?]"PE+SZ3SKGV)SG! ARPSV<3G<F8#&%D>UMH8GK:8
MHO.)*?PG0Z=I1K^B\OVTG=*#N7@@C+?F\QW )@X:W[ T3-&<K1?XE'QC"N[.
MB6USEUTIP1<%Z".>? LX!GRJ/_.O7&O=>Q!W0%SEQ_4C,X1>TRHX^R-R.2B7
M[72K?R%Q^1^T#;;1%QKO^8LWPW+.P@)YEE5/B"YKU&M8$R7.DGQV'AAHE)SX
MI:"*3((_CP':7UCU);A"-U2:Y'7#GZR=PXO9E"G2PEDDRD7L'#\]90:(X;VM
M-NC[R9S;3<(E[X0RR#"F]=K-$&QH^0NI!Z(,D]N!OHL8>?QF\77Y(%'3QF=Y
M/%K4%-027<M?"Q#NJ4S&J!,JR'GBM@JM2(S0M;O$T!9[;O[N]&?I^G#9%<38
MPX#%$#Y?+_-VEWO/..0QN?0Q\;!@C);><3D30Z&QHBQ?"UV]$\F9Q2ZAD<[=
MQ*)1N@^+*9TS@*_<:1/J>T&2% .DKLFRSNNU6O0".F'>=JNTS##ILZV8UVL?
M^CK6F%29$-G(]@B+_"Y2R@PJC(^//S B.KNBW,J$&L<^#+JE'( M\-^^V*19
MK[_">V[K8[3D ?=4I!J/XBSQLTM)6>SU)YRB4/1MXL.V(7U%K;)%LP+[*NU9
M>=MJ8!O=L5"=(AI0:$.V]PMIOR+_4]1B8O)ZZ\>O1/M\!<"<RRIR*98!^A=3
M"-70S9FBR9?"4#I _E?U?M1B.]U<P?/!GEF1RM_ZJ\'U'^7H?W94S#62M(2T
M?G7'4HC"_!'J<EG)-WP[IX7@/2 +348&L[ >5S;5E!(7DRF U2,;B#(4#B\.
M8DGV5PAGJR]]6704]1@!%$.9832SY:=WY^L7/?6#+F5U'C+FV-;;3--[1B:?
M/]";VY7VBCW6+YD,W@\RI%F$7D(&>(WX$3].WC=$B*3>3[%^S[@$;3"?#SV/
M@0#O0&;E0WN-Q@41@"&!?_3RMK\'H0XR+S-50GT)(@$ :L_6I_=R0L2#NQ0]
M.:A-F7*(=1?"N@0A<W*,73' #"#C3#?XQ=F;N"/G"47,%USD V*5<+PP%?$^
M^-<?Y$,4%[(NT[<[;R-5!10_Q)X?/\?[XE=G./?)T>%JG C4DC4@>HXJ$P*&
M$LZ)PR;WC)],\AZ\"E24.[;H'V<K?%6IJSC)>T1.;<^N@;_#)JNI/)N/J<)[
MXCDWP,XX;?F10*IRO)AHTE*O&HXKWT_]HTJ9<NTX$SGP1B.ZF@^O@V-GB/1.
MUUH:W/]<4"J!8S5=Y6EKPYC_2R]K^="59]KF>N16[^(U _9517WF/$N[K5+J
MY*VI%"E?+ Q@T%.!5PH0O ;L'L.'\#(@UV+H=. S_09H:-<8P,!]$4<1)IM7
MD>WHHQ[IN/\+R9EY09?IM[.S\GZS 96VER+#5IRFI=F=/?E\!GGI%$"_-H+/
M%$J@I7UA++.RZ.QS.>ZSOQ,(2 .R;.C3.U9TOYAT<GI6!<!Y7N52(ZT> '#7
M88TL28$D6H^Z*C 7U/[#I^3^/_YSXM?\?P-02P,$%     @ 6D1L6,[<%@\\
M$@( @X0" !(   !I;6<Q.#<T,3DR,#=?-2YJ<&?L? 547,VVYB$0/$BPX 3W
MX X=PP,$2' ) 8)T<-=&@C722("@C0:'X"[!W=TMN+OW\-]Y<N\_[\V==]^[
M;]V9^0_KZ[6JSEE5>Y^JL_>W:^\%8A*Q".#)2<E* 4@/  #I_@] S "O '14
M5#34A^AH:&@8&.B8V(2/L+&PL$D?$^ 24I)14U&245#0T',RT="RTU%0, NR
ML'-Q\_'Q43,)BPOQB''R\O'\-@@2!@8&-A;VDT>/GO \I7C*\Q^^$$T /CJ*
M #HO,A(M\  ?"1D?"=$*4-_+^1#I3Q?P3Q?2 V24AZAHZ!B86/</E.,!#Y"0
MD1^@(#]\B()R?]?C_CZ @O_P\5/N%Z@$R@9HM#:$/-X1J>AT+XM_$JD,'=#S
M?K3UP< D)GE"2L; R,3,PLK'+R H)"SRZK6DE+2,K)SJN_=JZAJ:6H9&QI],
M3,W,[>P=')V<75Q]O_CY!P0&02.COD;'Q'Z+BT]+S\C\GI6=DUM26E9>45E5
M7=/<TMK6WM'9U3T\,CHV/C$Y-;VTO++Z:VU]8W/K\.CXY/3L_.+RZC>]D !D
MI'^^_DV]\._U>H""@HR"]IM>2 ^<?GL '^7A4V[4QR^4T0QL"&AYO-$)7T:D
M%O_$H.-5.2#Z:#N$24S/M\1P^)MJ?]+L_TPQG[])LW]1[%_UF@:PD9'N%P\9
M'P !YU?,:5Z8?^ /_#^)0OW6^--9]?"-&J&Y[('0@9!+^>U+N^3F7'Q;QU=R
M:Q6916;QTB259N0KM-S'W#=H_/X( +_,^#.Z%85K/OA6*W_C#FMDYYV"N\_5
M:76D;(/Q@#ORS0!(;F-8:%FW."WE1!G:.->A@  >U(_:@@Y*^""79PT(H-$,
M ;0I(P L.FD$  ?O7Y_!;]X[$BKW*5U"\/7$PT!WQ%(P!" QL7"^"[K(!2T9
MF2* XUT/!. Y@@"@A<U0X1P$\&R9!&9X_YA?1#H"&"@_O[U6NF.%76B2@6ZN
M]2$+90A@.>]'6I@YI.?";V5R!0'\;ICTOYQEASD]'GYT]]3Y3 @!_,4HV;^;
MHQ:3>2WKIC'P#TG_D/0/2?^0] ])_[.2HG?^_.>'A:^IR3:<!G[HNN H/7"8
M@7=D;6LO^K_M?H%BA#]?6G1"^4PU)+/OZQN;EMQ=@Q.Z^%_>#0<<.^9'XN-!
MO!;K,8'W#J7IUBQ;"H)Z&V!T)EK#4MP9]3JR_6?$*,^/C1<;9F-!2)*$;__
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MUA3"'Y49V(:2^W<-*#X99XP(E5]&S71/;+-LT #M?GAV8FX_HI@>W4"5 -[
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M3]"*UG5 L--#CH*&)$O=UU[RS,:L38XJN'031X7]'.;=4D9F9*2$Q-R]?N2
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M[<[T":%*VG66FFL4M_($MZP;]*G"#<''K%A2_0GJHR1RPX7/-!X8OLD6GSQ
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M+A1N1!' "^H;7R8$0*"ZDS45P%Y+^9!H  '\A2D&_;F05-T>WVQ[B@>5=1#
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MN\]< F-V6HP$JSH@Q&OW -0R^'7'W'2P"*M(;LE.]S4N#?80TU-DUJK4J/W
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M"+=3$*JR_9KO:),5PB3U9X^I)B/<D&)^>[HPQVRJRCQY?WEW/T/4&<@?=0_
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MKO$W' 9L1P[SMZ#<+"]^HRQ04/ZO]ITQ#6>:\6Q11+S8=XI9S5LH_=6TKB3
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M/1)5';-Q.<SEU7=&@O9+C<4@#\6>;S*'93+U82LQ#9C 42,ZMY,AIX^9<<4
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M.O5J8V$CYXO=,+29ZYEB(X]=7*X--C-4B+7H1@X9\9TM-W]/1X^]Y."Q["K
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MB-05W:?;Q'+A$W6"AZ*,#W1"8IH9J6/&PVHO,WK0]Q7H]-:]Y)A='7/!\AX
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MJA[0*&FH^C&$.RRJVTE>]E6+8C_EZ/@W/.76.2")MAX\=F0@UUB9&E-9+?3
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M^N_3?D6)^Y-D"D.C (Z>2R[KC.LI\'0B(2YWK-7S:0#I%*A'<)WTXY4U*GV
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M]+^C\Z@Y,8\**_L<#[<N)6L]@S (?7A6/WG<'3;1%(*!(JSW[B37NTQJ_1F
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MLD&RH49O/:?XE/]"Z*!(2;PR$HHJ-3H1Y[7U= Y$U$.=S$1G,^H#'6V'%B4
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MA]\SH,?KWN.H)XXD2>H90'BD/4JGLF'C97QV*&^71R'V;5V%V".RC^ PUO!
M?5[O^/YM^9&PUKK=<K:<L$U&(2W @ZP<K_)!\QF0E1SZ%R?_E+R!3.C*RI:2
MKTUH_28]=CDR:[?(0'S*<8L4Q=K:9<M8&&5I2LJVS[><>W5M7X>.WTPP?0<0
MC7< G,B5!7N.]3#B;<!?*\L!Y,TLLC);-/O?/+Y]9)LLV[@7_X[_Y[YA1OB*
M#,XU_=M\^C(&UT//8P*VUVSK#'RMB-XG3Q"/B[XW/';/<@2YU)O49^#*@;!Q
MH\B*L8GA$?U%IF3\;XF1-IYH)V UJ;?:%N$1\]]M'*2=G;'YO>#0%FGLL]I@
M9K+ C_$BP)3E#QB[S=EJO=[]M<I$I2H_RS^ORI>RWIN\G-@VOLPW'=HLJ)DN
MBRNGX(VTS9G),(][):[DBJ_?2X&R*%$[L#"XHQQ\Q3_%US_\TIT2*$-5M._\
M=<J-8T6NZP6TY/V^%;K9(LJG;VOD&G,D+TS=RTNZCC[&8P[]FHF^H(_FU7Z:
M9D"FJYQ#3JDD#J)G@O1I3@*I$D?>&LL0:PU[#!SI6KOEAI1RK\A'UXX(LNG4
M$KDQRB5SS!:^BMYFQ<8<JEMAG:W-$U56<E08TC:IC:SD2Y4YL1KXB@K8C7][
M (Q#G>A5H;/I<Y8;B:?A3:*<];E3EY!C +X_\])R4W;4NZ^;P5#BC6R96L17
M43-XW!8><6]*,VKTN0/2N*5;*VA KK]*2T_O[E!K[&9_WW%BO3S$*:B"II'P
MSR@K$S8&)TX0440*#136A(=E*/$Q?[>#JY/E+<J*1KSL*;'KURMF^#5<+^:E
MG8MR?I61F.I*O8 J0G$X.6=N>8%2%YM324G0*\29)'RDQU5GK.K8T:O1U!5H
M93DL,^0]'^/1R9A.L;?+K^;45T,+T?77V3)G\@>4[:YIY'PGG$F7#!4C=X6'
M-+RK7 SM%!_QQDW.7[(DE;>V"E#SND_I0PC\%$C=V)]TT%H^6?0&*H%P&6L*
M!>#9N7_W8V/POQ5'AWWD*FT_;NS68E*2!(T^T!OO7>@=6L;W)'2=*01LN;(.
M==,&=:*FN+DC?T?L9LUYU89<Y''/U @Q:..DB;%_]G\2Q+JE."H=$A,E64UZ
M]\!58@1$[$R!#DKFC6KUVMS?.7B:N5'_&GR< J466I$NPC)1+M-R%#V3G;@>
MI:C"A5^ZT4**2[F$G@$1((HY,17[ GU+L%G\)#ET3M5 ;J J+LH_<8\&+$0/
MGR*7H$W=%$*T%24G@2@5.2L_,YY_;DX2#W-;2R7O<P1E:[FRD=4JO3M524__
MTA2R[A2,BCFDN26\AQHBJHNT!T;/.WN#6$V+[R[$ 3"L:D+TCU%:^HY&E^U6
ME@K8IDIYNQ=)X*$U;+9TH_)Y]?4KE06TC<N]T7( 5Y/%F@.EE65L3J+Z'RE:
M@>N#KL52 <=$GK_ S#%[.A(OS-O..*&U7X)>+@8NR2P<;1>_?.3J*KV)[!FV
MM?;<M AWB7BM,J'UWK[F\]Y>HJSKD+_X!VX:#Z#L>B9>)HZ'\K!R,NJ>9=).
MF*=^TEZ;Q(FW/VM=.!4*L9KNOW?A E$V:4B6\Z>3ZD9V2B@)15*.7*.4.9A4
MO']ZX0(N^;=2HG/>P=_^P+;_ZJC!9%=8G+0QO926./=AH=ESY>=\DEB\)>FZ
MRXCY1^<Z99754B'R0?Y?E41..Q&_1YGKND>H+PTC91RL/OW@?%'(FL"HXZRG
MJ99L* ===I_?NCS%U+=JAG'4+:VDQ;^_-94\QC-RO)N52=ST_=@]AZPT2Q^7
M#4*F-D3[BG?&>7L,.6$T>O<!C;[VVZ&>;4&I[;9A?ZS$432Y2A%_6-W.M2FT
M9,/NL?R5I1_>]%QM>^C)"E-]HFE4G]9WA)5V;+T&R"@*V)G<9OIMK#*N MSP
M## ZJ9,<A#T#9.?87;U51":>OD2=U:]^/'WB=RQ8;5DD4B3,NV4H?]<7+\L;
MJ(9!G&KDABMU48J_8@)(TS"/E;M%2VF6ON3?3;PBHP?K9;R5/AJ\+N@K;%7<
M"=(@D^%<T8O?\R6+]T>GSY>I1II-9S"%4A1(X4#V8+"1XKP)B\J$?$O+N03+
M?I]W4B?BUCS(M8[:1'&Z7_)_K^27TI7L&L!-VJO/4%J:] V&.N322,8T=+7=
MZS16!WT]'8*SEU]-7SV@.'&2?P4*H5878$,UYZSAPZ^KA^^@9HQ3X^VE1T2'
MR4H,4+>]'5"'MB:\8T2$2W]7G+6VV\Y.!/BZAZ&Q*=T@V2?2]#.4&^(N7I(C
M@5Z*^:#-#=MMW6@X_RT'DV9KVU!CT_ ?4=]I\^>3M$ITRY@A8F3^/)4HWWN"
M8Z2IAX2'@'S&1J#(4*250T*T3@8LM#=SG$?DCGN!WSH["X\I YF/6C@VURIH
MJHP&/M-T[:77KEC>C4079E:-PF355ELT')@@U9:N'(E=8\B)KOO2;FH]NKII
MM8@)NR,9[RB2$0]@CZQ.5/;WKQYS#'=SBH:5\?%-8@?2O0LAQ&J:<O\"[/E_
MM[_<]L,$O.;V6/MP<WPH1.S>_,6G,5<&?+PVH>,1W1Q_":NS9T"7-1QC?JRL
MO[37W6P7T.6@_O77/'*#\W):=!CD3VBHW*2@QXJV]'+(=_]N!E,O:* D,FCA
M;$PS4WWFPAYS 9FAK,L\RG.%/CTN!K[Z#&@+\6J%AUP4^?!_RS986%I96/I0
MB9)"\B:<C".Z)RWM+@45B'@[N7J#)?73"'R'+:?_F*]:>(G:1)&;NW\E@IM,
MFEK0O;WX0:>?>G/)G=MDD.&2$:[Z[Z=0</XIVZE^&GQ.^"D@57%2?[ ^_#QZ
M0>S^'(OF!ET,F _,]'ES^\#KR^MTZK,4 Q\(NTLYZFY3T&+EN# "/W"G7<;_
MY6__91.(.B%@4(BZX/M?/#G ]Q_N(3U/T3 ^6F,6RO^PZ.:B2Q WS5/1J<Z#
M?I&?XR^V)A]\P[G):TE0M\*F;<2#PA3L@$=C$"@18CW)-M;B>^[1WQDM<=;*
MZI>Z^0P@ @49>B2/D6EZU\('YT<I!/Z2?MC']_]JQ:\D)?JG2>F">$:N)<Y,
M]>/^SOONH]^^_73E$^^IN3=5 G%0^J^2@R[1:C,$5I,F!V0FA1^7@V*]3(2?
M 5[5?&L0OW<(PTU+/Y[)W4:H3XX\ZF %%P],0A< N(_WM+HN*2VRK!.IS=6S
M(HTUU*_7V7T_?-EY^IXL@^+L-$Q,NZC)+BMP)U0I;XVA&QI7\_C;)+Z1^G)R
M+M8C85TFTTEOJSL9;B*H59^6'"DQ<IU\Z X4:F.X245L!'NUMM3?.9VUK9/G
M]M>4#F4(88,Q 7>8D#\J>#ZVB-'R.HY/BGG+U%,^9T2_U_WRD$"1EI[68+MZ
M4G>NY?</914-KO;9E*HOI_\K]1-0?:J\UI=G3Z4%*F_O2!XM?27>GTTE]=MJ
MAAAI1\\@680QWWI#W'S']O(U(]/[&5.#?K%O,6^?<C&!$O[X6ABG-<=>KTNK
M"T$R-JZ?R 6JZN\Z'_=3 ^CNHV7/4,0T+I\!>)9MC)-K*C,</17UK!T;N7:_
M"BN? 9>4T6PA;9,^:EF+CY#S+DXR"SEGLH2=YJ IM%*"#/3!9X"+=HKB]+="
M-9 &7K2+OKF'?H\?[02#QDA!OO558.'AP.EMK1)G3(T9VLC98[=CE^Z!/_<=
M:50(]0BD/]>*(C$CT<K.'F82B.] /K8JGBBK;3*/G;#8 "?PB++9JI_EM_8D
MY%H_$.&F:6_.O#&-\UR"0CE%G3!NZXH&JJ==<=1WF!#P4$ZF)K9:UU;?P?/I
M;4+_A'ZFX/[[@J:_$/L-WXIT;:OYY:6MEU20*W-7%YY6E!?S'OF#_R"QKJQC
MY'HFSLI!J6?YD;DP_[%:3S**)SX3HJ<P \W'"VETW+H\!Q)Z<D+[#_O3,""$
MHJFS3*NBA1XN;<[ <A-$@\/@L\5"R^U#K;#[[D50+E?*[@R%U+)CYE #'I6^
MKNZJ;J<9!6.O;2<8<T;/J5F\18(WO4C:RF$4W<8]'UU)+Y8UL#]!I5[+A?S0
M.B>=T^IB_K1830/(:P8M+DUZQ<-\OAS?6C+2V_*%QXHY$( J27$<A>*=86L5
MF32[7*.L0D)7A_(>/VOT-\3!P8MBU&=8QKE4/!+IIM LS9^UB7!%N 28\7;2
MI;QK\T!/[1G GG.[))'F($G(FBH/^G1 )7L3<Z\P)YVT][F!6PGME.RE]G)N
MT38-?,, \^:ZIQAJI8M<&2CYQ%AK+V9;<L3S6HFTI\ [Y \-=9N_'UAOAU^)
M[EJF08XSYWS;!1= "_65I2H=@[]E&J&"LBJU:HB,<&[:0[0WV3Q0RG]5->70
M=P]S"R$'BLRU6W(ZS7+YUG39U>$)#KYD_.U<+[8E4;NYAM4B\!%L;U HEE\D
MF2#Y!_GL"FY:]>V0#5+V>H9"PY;3,_TE<CZ(BDU@%81J+:V#+YR3XOO9JERZ
M9$[9!)I(&:=M+7'E.B^;KR7SW941\W=/FYOKFU3^D;5WO/K)ZB^4OJRA^<36
M1@FR^##/+!6/&5&^8,/=$HO3=Q_J+BI33(A.W-_88%%<Y4Z5MU#SU*&D_%HF
MS7IK0.VL6;!;4LUS\95M^JZU5E;4G;^3@=#+:T8W3=1?!!,67QF#$I'%S9_'
MJN!%-!#W;72I@V_0@"<N0^F#LG".T*K,P,LY39-A*GF]@4IKTDU<MJD6ELTB
ME_WLJI1%?J4.3W\G\1'/F<*A]^+6>OSL7&S8G]Y(NGVSH7?QGE;/FRC[QRXK
M5JIP3GQ]'I8]3J>?S^I\OGT%"VWSR],TW0S_9R[=OSM^*/9EO&J8:1LNLX#%
M>@0IB1[GBWF6KC)*A#'!*>,Z3'0RJ,Z006N&2@6?ZKSF&0[]:)KLV948A9,(
M_8XHG;RH!4W"X'(P<$\&]J28RLZPZ^MN7U*QU"7S!3X/83*[+?&8SV=!VOGY
M/TC9'U0*# VPY,VL7V\Z7HE.["BHW-,BMJ*+=+QG>SUG^J*V6@46RL56V'I%
MP #IHOXJ=7$,29:[2L;JMC&?8'H?^CJ<95EO?)4)1Y4X\1]C,M.N([SRK,ES
ME=)LSX#2,-'\A#2?(IY??OYS;)N&MHR3# USU(8T'\1M5_Q;IE\A7W^1^F7E
M',C;$-V,ZIQI9K)ELBN=>V/_'M&B[GL@KVMV%Q7T\I]1/]]D;GR_61;!RLM!
M*C"K;A2[=[=R%4X"3&\<O%S[;=0L>K#7L/?=G^AG;1]4X+J1HHK22[D'W@X<
M<]555S9(,5D'(?"/.9 (T?#_:$/J#!*:VFT?9S@GKN[[:$O59]W_R^XG4+U,
ME.*.& JEV'BPWK"O[;(O,Z&V>KRDZO6<O^-_2^WE#0NK3-HBIJG,&"O>*7H]
M K@8,31_4U*QG&#C&$HE=:PNNG$4A*6G$<,K/E19^47G;CIG(QDZ(QT?M6 S
MI[7HSE/%%QM&+C:C7T;+F,3"K>CT,HY@M;[XK39ET8_[JD;5<!C'XC^B:+*_
M+XNT8U-2A/?&?=WT103-($A7]BV: [BE?:_.ND2652"#&_CF-JP2)N(!_R;Q
M$5L:1<,P4T8#,1;.X3H?*(H.Q_<Y^P9ONHO9N<OXF1WS;<C!>DSLXP:P]KN5
M%^-V'.Y5J 1FIN;?5#$\654K^=J*(BDZB0']9RA3(BYV[A15P.G1;R$XB!(F
M<=!QQEN8;_@,X)TI7S -,8-HQ0N2:W^,E2WB_R(,$^R@"%L4D[PRB;J:).[S
M7/0S5MF4>V"#:PD-\(]I.14.N4YFUD"2G30&KXIFD=I3$DGS3X0&8=)ZNV?C
M(2:8\P\E0_V5SNKYQ5\:$)9'6":[5&R8R9%['Q(+LS7?C-&5+G=0X<J@EYO%
M%!)7+89!XX7I2G"4W[ PE$4K@Q/=.-1L$O22\7^L)#;-O/C!_^L0I+!!,A2.
MWI&/ITZRF>T8G:@L.(/E]/Z21UQ#U6NJVUFFKOEMGK[Y"!<AKUPAQ*02&;*X
MB-^,A^VL@M?[H=!?B5  55J%N=Z-@7.45^Z&KB3"<T3T%V/PHAL:E?2>&(7'
M5R%^,CM+G6U'O9]CSN-/5 O.XEO(:;8D:T!ZQ&/LOMG'%QO1TJXSAZK:!3%T
MS:W_#!"S^?J_7+OTGY=+3J-DA-[X> MRR7(I$E^E;PJM,H:E!$B\XVW[.A_2
M3AN&T8VR'_^:]3G.51+LFN $Q-7.0#\?$/H,\$^Y/CP_#?!BFA>CDB@XBG E
M'T03-XEA;;^YNKND^#^*5<;:\, #^>Y_.>/8,R!G"RX%E[@1?P;0):X]@B6?
M(J.;BL'-TY<QAY_:^/^(H_X%E>I=C7 :Z^.-=E2CM9[[=PJ>VGL-<0TO?84E
M0UQJ-R4I+[/YGWYFY06H<U_]'%/%\BG-S%H&KVNY;(TPA$+'PIY$YG+."C*M
MRZV SHM&>,P<W?$\:XZAX,6.!R6OF.@+,,GAL+$8=\G;F"33>YD#!?O1E5:D
M@]"'H[XGVL,VRI:$CYG=0.BYSE)YM=].+BTCIB"MZ?E:OB_2QH@A_RFNY5V.
MR2,CB1MRM<N7&WS9#;WIR2DY^\;U8?#6]5GR UUWC[-ONV>,^^+KX0'#%<>,
MC)DED/26$8:/Z!G.;F4YQBDOVH)9M/HNK2GF0R+9@%5'T),RWS-@;NH9L!\$
M"CDS>9)/^HO2;, 73AH)LZQ+\W@\D_J;$L4;EC[R)IOD#/7^C19Z)KOX:0DU
ML*G;N:P'MK/6O<B:I09^VBAO4PV7HNQ/D(5.6L=8S3U*%S@OHJ]U"P6AN4@=
MDC4L7G9,E]H3L/2ZP?CU21#H)P+>"<P@G+0KF*XKOSQBL?@>>C[C["]W^H=R
M:Q&25-T^0"[8^R<F]/HO9IRD>22K>08$A]'@\'6I $;FGII:>?^R@H>$R&?
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M9K9:?.5H6[BH/#'4WI+"O])_+2-,?;G'@"]'&_B/<8DTO0GQ+8<M'*"?ZE&
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M[DLH!&QKS[R^2][ E:J:U,A0P"BS5;A9IS7EWI1[2MY4&$?M%>S3H"4WV$+
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M0]KGF2Y"E*Z'S1KA7LK7 L8SA[8M#PZ;,]+\>X5>&-LR86+4 #2W_C7%@:U
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MF@ 9N<1*DR)3T#BRH4)J H!C -8;FOZ\06W-$?7EJI??XSLTB6A0[HM#P6H
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MSR/?B9X+0"GW%*L>3)6'*"14!V>G^;8\3C0M>F MG.!C+K/C38=M!Q7BD%'
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M/P8)-H:K?X GOU<R/32>L^U2A* ^/_C$NB/15.O=1 .S;ZCG93Y!O(@C?5
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MOCC@!!KGXT[YO8SFO+)N@CBM'/'0\S&:0$2(*779&F,*)=3)OG^7Y#RUID*
MOV]%<MDP1RB=F]I+&QEE97(=[UF]IE:VX_.\W-_#^H%\;?P<X^3\WNJ(X/,L
MX^T=FM3W-S)='(8+<9H#\+S75E'H[MF>F"=EWRT8XZVJ.0J%W4E@;1%UDSQM
M@4:SB:B&XHV4QNBOP_(G7,VWMGI&.K/A!#J8C1(<"&>_)1P;RCQIO[G TN"E
M72OF[Q"EOV(C\5(P<>D,QMNEII0Q&#I;\8[3Z)#W4W0KN]FFE8]B;9K.@&%+
M*N2@W)SQ32P3K" >QZ65HX94 'WR;AJ@(@7B[[^??E86O R]9H:S/FT>JPV\
M&0;S1,1$Q!WK6>Q5Z]X\FYO76F]84)?U!"2F6!S(J=2,WKG;OPWW32?S?J$\
M,.$3\F>9A=O^7>_3>Y*%CW^6G[S^OF96,N 1G^QK2EFH#AW]T'IEES3E ]*;
M)&AZZ\"%F3;T%&?M;]2P3U)Y4G859>*'.<*U_\PP"LKJ[?Y4]EW_".$LP3*?
MI($-%<NXT[G)2PG9^6U2-<'\VY7B03!P_AFK9(AI45#DK[.0M3XF]<OYQ=@V
M.Z.<3C\;QGGZ*.53C>'5*>A)6E\%:.Q:>CR0ZI%<)!'V>/(&+6*)WN^;RY*^
M1!M#H;OIRFQSQ"_;=R!W&$@FW6#( DOE:W81;37"7)H_9/ A'PQ5IC1!!SN?
M %;^1C1KS8@Q\%D6?BGV01TSM<E ?VK#:KH&IO:2853EMZJ.#^V59]=)5(;9
M]BSTI-BO<$H[V;ZO&AMH99KLF+N76L T?\(XGT8(@5QH+TJ.E7\B&KT:L!9
ME4NM91<X[<KT[E"&RP1@N%M)Q-$''L27F5$]]-7UPBQT@020$G3.,W%&W"E\
M(B!L\VF!2=PY<BW*[&=H,(IKO4/^>/=*D/_S+,:8_^K74?3*G?;Z*_P<37Y
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MB@,T'9_ZJA:Q<83FLM6#'GB;>X%ITW+2!D&P294&);HS\Q&+>E'W+4GKN_Y
M<E$S:K%XNN3P[Q;(=3K/PKAAO'(D[*[D4!3?Q7='PJ$&8023N1SU+?0.:O 9
M&/:XVBA\7&"?]#[9S41Y<6JPO*ARIC6 :T@:4^M&/G" L_<6])T%PA<"R)_<
MG+I_QC- =MS(C8]F%%"GJ+R6CME013"<IDWX<]Q.>&Y8=<*\=F(&?)\B&[7-
M6C;D%FOCO+,7UKY5RVKE44XPKHXT7<N3R4CRX)YY=H[Q53S^#PN9E>C[^R^[
M1?FL2B1_9]#>B-&%HLP]9WNZB.2L3('UI-$!X86+C7;7U3RK_?I@I:43S+DT
MTUS+Q(&%"+,O>@2E2,2!D5_A(GT9_; KM]<@)VU'LP*Y$.AU=\GK RIIR8V>
M0%@@X\'!92J7R-\GY9&*JB[0IP$>U1K3OVSDW=FF/EV:\O)"RN:P.EV-[46*
M=4(<VYI%Z@@-WNJ::E=-'LI F>%X#^ 1K"6U$EWL+<SYL.YBG1ZS0_/GO$*G
M*]G=,"\*PE4$MQ;"%R5ET3&9RW_&7BMC&<]F2(:$\ALWX/[,!G!F3=BZ!^+K
MM03"U_!+3+FK1@XVAL6GMYNKT-&)FS=M@2_:_]PKZXI:*VL6W8P>!AQ,.=]B
MTY0,#&*,3%N/)33]%.-V9EKS[S_/SIG:@6*509EM+5_?3,$7ZJ2S1M[6N5M(
M\PG\% 46$E JUAJ,/K8O(>8+[<OHF'8N]AD.#YDWX^(EP%KW\J2 5=5SALJE
MGD[MDE@\W4E-CBFG*OP]3U3YJ'V^OZ](8,[K';_02;7O2WEX^2U)"D;GC@#>
M.=%I,B'U6,QHSJE+I4:S6="Y[H4(B-<\,U'(B>BR=\_FDM[QWJ;K1%>:Z,*<
MED09:2'@:Z0F !VO%CO*!XU4U*;I^]-T?,/5"U?3KV&"PTYXNG44-M0@7 M.
M?=X=0UVNJ]]*&HIP@M9_9E;7/"S*O,R_5I>U9^P-J)#+S$]87\;+"[NI\P(+
MWR!C'V)J?<UE$AZP[1=LSHLDW"6D6GV3QA =C"Z0"G77?AN),%<F,R\IFRJN
M*D$1_Z]/J^6HA_@[7LY]/NGX!Y#9NQX$"<N?8+]'9G\GK_P'L/YZO\@)EVL;
MOL-68!RA+J;X0[8'. W>OGDB5C:3)IT+V*S!=%$%2F&O?'E?IKZZ:CX (RCN
MV:;]<P%UJYEG\L-2;5@Q+9R0KHK#_ZD+EZ.0]B2)(PQ\T].<J[5:_-,(U7;
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MRN99\<L3Z[("]JIBUH##X_RYK4XWB/B@^##-!8%3PF<[\XUGW.=AD]W;+7)
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MQ!O L$-5<NF^\D@NG79TFT4XF2<]2@?+(#CBO#Y<>PL@9[<YUICLUG8Q-W?
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M)N\E\?:R^"]EAQ$\N=$ )IF>]E>^%5:4?UX.YZ[A1\A\IT(;.$FB;I?G2:^
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M&AX\WY\YS3I9;\]58%8FZ4#&^>#""/#1G(KE=(%FY>GF#U;2)D'I;[G<B;6
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M#6?_ZJ/VCHTFMEVE163]-Q?MLTR#I;:!/Q4VM ]%(ZEF1WPNYU\YM^RQGN?
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MPO?7[Q$>T Z>Z0B.E7HZ@>/'4R+0T1]!NO%& 6'?^!H4?KOT@[/UQ_LCY;,
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M"B-BP209BX5@5$1W/(!DVM9C(.4;]W1QJKIW1$G99<(*PN%:5HD!:OT#OLN
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M2#GY[D19;;1AX>.ZJG="K.&PT\[%6D,5#T&!* 6 ,F1W9U[#$PJ?;A*4M,T
M+>GJN61!T=JQ$#XOVD1D;1,W9$[)14DXO$M_K">'2AZ=?Q:7J,T7 LFC9W1Z
M:Z$C>VHI1D1FE.X6D<Y'OM<'7!0K4(4?-6_FW'7$N)Z2P]>1MOX\!?P=WU#
MRV(V'F^C[P-F3/WA2:K>L$SAQ;/SO5$TX=/51&BB_C>=]2'52M8AG1]L")\%
M:-+DAJ\$2VIK$3-3F$MID[<^BDG,)L9\*J84<I"( .<2S'\ >5U^I9Z%OY1
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MM2?D:;LMJON)WIQ6M.Q6,&L.83I1P_Q]?AHAP[ R)AA@)EV4"0#14"G5^T;
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M&8L^9UC,\/5O2HQRA#+^!O0)_72:^!JD093E,H8;&N3P&V!1DA8]\XQG2(D
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MN#^7]7E>E;<SLAU,I'I6ZD7IO3E[F5E0RG*"HWIAW3M74F[+(UM)\ HRWS,
M$]CZ(4\V1T\V[&;V3^4/(P=WM>HN9Z=RG8[VS'C$D,Z&F&ASK;,4H_7<C'?S
MI6$TU9422H5G08;@/KZC5"2V\69@!__%;53GJ#EN5[GL8-_^KX5H-\AU?IEO
MT4?4[&MOMZO7:I"EF'H)?!!)OK*.%(R9&7&_U;CK2?*HU1QX;I+ZHK;X>KV2
M039:4QDJ\<V9U?V0#>:?+X,=(_:W^O[_QM\./9/UD\#Q_?DF:&0,V,IFQYX)
MMT "'4"BFW[5*^C8?Z+W2\)*LFEW (K^2T)&,SG/3Y"(*N#HG=EWS9-2MFWI
MK"TED4#WC51/EXVP_=W,S!R9+W')R\7@L+ *P9-UFW N*WAM,ETNZ.)GR(EP
MVT)YSUB:0MX^,&#R2I'$I;53GBEZ")R[P,M>I0Q7YSNYD="K&HFL.M\\?Z-0
M,9FI459"71^A;:N9A0EWU5Y@=;1651NYO$P;1MPS^8D850A0^D>C3R5 Q6];
M]_.6?'^SXH^U,+/9$(-8W3#=:P:K0OZX2!^W&9#!^@<B10M.;O[XA5X;E._Z
MG(0:O2H<(Y2+,ZV])E9X?6<+'1$?[GN^ %J)=V9\@!TM#+OJ]Q]"5F/_8+V?
MW__ 8;YA:BO]-8L<_>L3U^YXKQ2!:DSO^/W/!KTAO6WO $$9[L!U,LW4?8TC
MVFCF4<3H_A':KSLD=+EN&R7N]K<CG>!NIF"MBK=LL81*&F>IR"I>\1?-.:D9
M[KDZ0Q;6%^)F#W-])#@%&R(;D9UTOEUNGC_N<V"$ZKMZ[J'P])39T[/)S$R?
MDS>/; Y4#'CD-2EX(AP;TX@/Y)R-#&RM2C)F"4#N<'6P(=\>.^2KW%N!MMIE
MH%RHX$J%]D?6=RX#-O9] /!M\EE,+]=Q@W!HWJZZG$7>0K8L/I('QCG.4I3]
M=!5P*.'; ):)++><D8V1LRNE6";L3:-[#__2O)1EFJ.5-O.;^Y@V&,?E@>YG
M?=0F+G([FIS%G!X>P<5(MAX Y3- WQI8DUE?:%0TZ6Q7FP'.(;X4=CCS]KG"
M0NDG+V%R)HR3'L /31F(%/5B1:$,N.3:?4*_]5[;.;U.\78&M-3'(QX>[YC2
M(5N/VHKV\ V[CJ2GK6\F]*\13QL^V>O21>.1)Y/O")6GIIP=Z-@$>[W7,=4C
MU66S#+CHZNV/E;K[2)Z,S<<K_(AE"4K/">U:F_"??@J2_X@[>;VE5$@@BHH$
M0/!AL/"KN*U,ES,C6PXML=8,:V+,E?>G0;9%H$$6XFC?R'7Z?G839# Q?FD>
M(T.6S$C]7J%NBRWFUE?/^'?\^I4_MQKUM8F,A$M42 N=N5907L1;5\OB+$8E
M J5C*3[K)I,:6RFM%TW]ZH!(ZR3PR*8,#^]%N:RB<"=; QR&A>J1(895)7X%
MDK$%0'/Z295$1IX77[7!^=>&:D$Z3X.V(?"]Y:N(;+A(-_!T7BF6SC,@UC_O
M&=",]12HN_5O.OC\3T$07W0;)STJBR%[STO1H\:J&7+5AKCA/V0^XP]3K&FJ
M.4L9O$%]DNC(TNYS8P\$^%[R;91Y7<WY=G;B@&*M__0X?E\CRYJK\L8V<[M4
M?)_D$A? ZP@H^C"E@+6AI7:QTUFBS/D,()V7X>IHMWG;9-=8@^^7!TB[\;LJ
M2]_M64N@S&/2'55)^F'=$49?RB'^\\PFPA)&_SL[NKI[LJWB8TGMUA5=,FIX
M^S)?S9FVO+75_/PYP;+14KVF"PERY";XF/_ZHC5TYO>!'G/8=+MQ[/J21,&\
M'<4-U0]T1\28DULU=Y%@2K9*B<F,4.KZ@-B8=VVX.[[14@.+-X>>E8=,+!0&
M,\)QGOIWY+"+G0FC9?JRM"LJBML6$HS K:ONJG+/*]:0[$UP*MRN_?T]* /&
M=>9Y$E)R?,1%B+NX8&4@ FA(914]9IM9N=@N29S,D9NO@;)PJ28R+(])$+29
M_\\N5M7[%,8=*_5%@N2[D0_R=%T:Q>T:3,C"%*I9 W5/>08TT;E 6)!%W39O
M-OR[+20A!_(?R2J^O2-P<JJ4IVCZP#G.!$YG&MZ!$]V7*4OQHK9 *7;IN79A
M09\>J.%5_)HA"3YJ!-\,NT_73PHJGS'"9HNC0S+A!LV7=90OR4*VDM)*.;J=
MIT50FX0P4ZE;(TZL>9 L_(9([@%8"!>"5WM1"F%!\*#\$[HQ![;X_1)N0?>.
M>4LOZC.NA%] 3O"P!@<#"8!!T&1/7W)/2[<T(K?3X!MEWUMBRKS)-%4]S0WO
MX/+=F-+*M5DM>JM)$D,I)Y<^VCN?6 5DDLL>3["6?C@T&4JJ+8X(-D<+M&AM
M(K:/Q;\4<9YT7 6KA4#."EG")RKWMNGGX^^B3&GAXMI*.7KUV*O'./U?%<>,
MN#J2O"9H?QW@>1%51MD:Z')<NUYB 9I8K9K\ '5YX]F&#4<'0-\H%;K;G&C"
ML<$XB> <,%O#ZZ3-\S!.)F?@6XW\.;*VDL/O:IA'9:$"JJEY!OAA-B_%\NNC
MPC@GN4*L'-'VLFK+HX-?VQG'\/LA?_5JYKL<J566</T)D9<]OMBU>DU_^#*"
M]@G_GM'VW_AG,M F%;:U:K<PQT03GQG]M] N.W:*=HJ01?"*>:3K%;F]7IDW
M8J*6XU03^YW* %ZFS$A?%S869?R&%\ZI2,AAD[X)&/S]NESK#Z7FKQ]^K"[D
ML+F]'G"J1>LK8A;SV'BH%LD7FT\QAZ36<099<\RI:184S0W/ 'C,ELTKNL4+
M^8HQAQ)N4&RO?%6-\\,0.F/ T\<R91V=\QG=(::_[+8@_DL!-&9=$7/N-DV6
MFRCB+3WXK:"QM3H)X%QH9$?'W(-\0GUL<M]9<G/',@.??J/A9B>U=4,O3L)&
M$4\]V=4 ^);\[=*\L,:T)4M5Q/<-Q:8HX^ECI7O6P\Y9"(YN;6<4HO@Z;7W+
MY/2:971A5]%Y:%+*XCTZ9LJ('E!Q@QHT>9G#BON)Q6,H"YF)=]BUA]\(<C-"
M66Z&;ZLECJ]<#"Y$9_0!P.K*5'$BTZ:RK,A;Q8E5=$[ZNA41;K\QQRZ:3G?C
MU,*W)0S;#^#5/:)<[VF72Y#C,"E+EO=DH8:P J[Q[X$]/[8^A"[NRC#__>?^
M0\4ZT'.MW'T=S1-TI(W^#BMQ:T= P6V[UO3?]L/S_Q=*W//FS)5";%X47@A%
M^WL(+_(,<K-F)M1*(%TP:QW9Q[ F\"J"<.EM$!>SHPUQ&\"^6<I@'SEONN#6
M>;WKFE!9RSPA5@_1$LV7A<JDCF:;9E^DQ&WKJKQIXMCJ4P0)]'V4VY6.'[OP
MK[*?"PJ-5A*'S(86_?X5'^;BTP874K\8\;:-*,0??=5AXUP$'@P\6MNK-5&L
MN_O#E$_[PCU4%S\OV)>_H?;?&T;RIISJN*U=_W:<9QMM>KZH,5_HT85=(6 R
M28D$V-MW.]->)K^5,X5ZJ![8+7I6G^N]SE8*W66'ZS^)!M_9EQ? @*=+E](U
M9T/&NS(K^('AQI&8A]?DGN[3#OM?\R?'>*SO,Z$%[PHZ/>BJ:YK/C,=U>K[%
MHMDS2=2C+O@L7>W KF]03T'EDT\DM^7O06:93T1;*NO"^YZ]Y/;^_GMZ<UG[
MTPW+\3;Y6L*[N3H;#:D!5+9V0*9^OB%U?30*"B+@XL5*."5A5>S $^YK\9SQ
MAE[NQ>A]%\1['!\!QZMN<X_WY96UI[_J?8EU1H!H08:NC JC E\1%B:GG;OU
M\>=*8QY#+9B(\.3?LZ#6; #4D<D=#"6%?<[ZBK$"GQCC%*;B/J5,'(*L93EL
M573 (RV ]A.(4?)A@7J![TS>IMP/-?$%^LRPLV&?S'HJ;(]/XX)"!<\ DP&*
MKHM<P37<J*5-8T<:NIB)F=.2G#/*Z'E.K4;];@I(JYTFYF)R#(32/MKEFJOJ
M]Y41 1V123DCV*KHT#6Q1WMA<K+JX:.NI1;>VRO4<V/_0VGB>^N;4L6V)ZKP
M;CWJAU>=LM'96#1-EG Z7Q'Z^#8C@9E3+''KH"CJW[7?N7$\"O=?OWTS($+C
MYX8>)7M50B,V7O6:DH+E#_";?2(P=FB&Q"@6' =)Y= K/ON $1Q!D6/3.#/8
M+J:@H(O:0GI:FK1FH?GF-RZ'[%RLIC3+["X*P)9#VT%9CW.'80"J<+@K\\X8
MU%(9KC1Q;)D[$@_&^W1[$(1(M:-GE@NCQ+: USX2>_\[HI-)-MC#?ZP1<Z['
M?D3VBA^HI1'V(T[)J2[G]8!]W%0+N8N%6F4DUN]PR?!C.8L +_]2L:51QY%]
MBV&K$N1.FY"Q4&<YTT7:"+]EN;/&/$2<$00!12.]+3VCLUC\IY$)%L0/VRB:
M@FMC8B3S+OO@F!&CF5H%S*H=$2,>1V FH\2[P2AY=9#H;GM\D!@R=9C6V8=7
M,.DD24UF+J>ZQHHORH2+1"&1K!P0/[;)LRA[O1BKC6< ^N*\#/BQ@/PMU^+9
M(*J(%T#$Y6S,7E.]73T'J'700&XND7G=NBXOT.D4"LZ7[AP4,(KD6AQVW]@[
M48/Q;5  N[8U#J$:.Q!KT^]*9#94K.W4D&3'LG=GSX#P8D$U>\-Y!QY&:O2<
MW+87MJ:GFRC;4W7A/Q]H?WKC>E7K4/?Z+<ZGC$'MWS+>GS'3C2,E@35\'EYE
M3FE51\\ 0/^TQY-4_=CG(--CZDA38\VW,>(T!7U?71%)/5UVI/^C2[/_Q0"W
MFH9W7+I]EM.A"\Q6RBRI^X;VH\?N]3Z:]9..0YG.Z?>J^9O XI/W,90[9C+7
MJ>((D)@>%&+>FZ+YTL#< R5.YVO;0=EX31(XASX:1NG5"SUQOLD6PMMD]LH1
M UM)% #*!C&M<R>+=Q_7?H$XD81R6%56[:_ Y'>#UT(M81>SPA]V55&<%_0^
MJ:&]OU(AWPA<3<:;&&]JNZW4253B.2K4>4R/=D:F1G<@<S.*ZQ&85!I@G+22
M6ZH%#S<9U>2-<ZHQ4^Y;')'^.5X7833+D')H)Z8UOBJJWI'AK?E5Z#Q)_R\L
MB?U[@<^;S"5S1&S,.H,'[3&#$U$,-2UI^\[9@1<A;D3'L.EAC3E,]S9A_2P>
M;(;\!V63@QP>>91G&TBW+M^\5!MA8]SPF6G-.-"WS[AG[!F0'G/[Q1NS6H-S
MA&1AR-[VJ]\GTY3R\]A.GV5_WIU93ZE1<0SBKTG^C;&M,(2XE 9HFMB+@[G8
MT1SP^#2QWGJJD*Z'Q2[G<)%%P_>1/VV ZV)3M0EU^7,9R3=&6382Y'SAGI:H
MLX2\Q[@U9LE=5DUT2=[^WF6;'Y[@Y">"G15403XS=Z[M$E?SV)\41K5,<$K/
M -=((:D!_V.+N3;0-:^K@NS^CI"&O0RMYN@3=K=P:NQ!8ESV>?I[,JNL 2%;
M#?^X@]Z=Z90"#S)?9K0]K8 AAZ; ^IYIRE\(_B=#;BFV7@*WOB*!)X;EY=5A
M%D%10TY) J)\  !;7$SRSC.@9$@.+ZQ$9=3MZ=4?[+#)"X$5@MLRZ2!%K"%O
M>VNKGT#C=8E>":P9F\]?-XA[\1.> =@>GZ$6LZ5%#,@T@Y8DK%*B.VF]9<WZ
M$S"2$I=[8"OVNZ/, >9VE?>TUFT[Q_Z0;Z)4 Y";%M);W9P]-X>Q_3W"#'N^
M5VEFRL0(F<D[I:X;@N!N-S4PL;G#$6UR0Y$C*^3]EE<P9/DMDXSMO)^.SO#@
M>!?"250>4Q= AF]77NU7# ZBY3&%&&TIJS>'7OP9UMJ@$_<S8'Z>_ USIOCU
MS\^M#N@I&V 86]IGS&J3-:S@]-1.I<GC:89Q%2M$7)95Y%<56.2;:DT.0E%5
M"M=[DT)QV^7^IYEH_1YFY-=K3R/XBM<)R AF*@#A5NZ)*,OK,I=\9LLC2X-S
MRZ.,VG"^.70#(N$Z B&7GTV*TXSV\[T2O'; 5_C*.KF^?ZD2*NLLB+E:7]^P
M]G*RL([U9<2WI$]6*:7X=-6=!@=;%S\-O(_Z_I9"L*Z#=6\L$='A:KNI;%W$
MUPHF9(.4EXLR/Y7-P-YHC6-"!NX!3QK'+4PWM]3;A"2&FZR&GTHO\6I\P;L)
M9^V#^<**:I%#BE#'9)9/C/BC%9CNIA!C>2.9!X=%4;-HXV9!V7D=0N:?JL"N
MYD6TIM]QK;%P:&)\7O/>GWL"[=?>!YLZ')2H:VMH>8L8*_2A257;20M5-B[D
MN#DZ&W&0=.2]$V*NC^=G**H4$1^?D!ACYIQ=<:F%,'@8@?<5!(QC+3Z& ;M_
M)"?9.#GD6,&'T6?_A]=F_RM!3_&L("9KG,!$E?;[Q]&HYJJC3G?T JJGP@-!
MW8U&1=01C+*YU/U]B0MT@YI7>J*TJU<TZ9?"<Q<CF+LS+\';)"5<4!#+K-:>
MXK>F3=QE$67IB2PD[Z;!R)X[_=Y-PDL(W5Q&;E$[U16WGVF G-XX]B.!LJ0<
MK@L \ZK1IC")[$ ]3K9\Q12>..<OM\S*03:3=\HFT@&>"-_6FO$44N@JQRW3
M?R$1?O(5QUPD_UZP+XQR^E14D")YH8BK4_YJ8? K%0("-;F;E]K48Y&LRDU6
M1MKO^%JNJH79*PKVZ6M:X\CU=S%J0:\130C,D\C-T&7P30M( 86%K  *0!XH
MY,@3,_O%%%/_GV06X++&W#YVB(W5U_H0[M4X20JQO61*&/3B0X@>7$UM5:+V
M^-M(Q$!G'6WJCM\CR\JCCINVK$)N]R5*TY==TPYR0WPK7^M"TCU,S [!*\A(
M#:Q76[)F>1D<8:9G%#3KBB&<$<)HO-!E#>HUQ%W-FDT#^U1_8DJ?!W3'H[.$
MD</=,=.+JEE*PZKV+Y2WO'P4 IA/R:?VMVC=V,O5^>/?8WS;8@7QA=<:0'DN
M%FM!,7E[Y2E:<S8?%K:C*[F[:#U'X=H1)F_*](FNB'. NG?DDX]%3H*572W
M24'Y?!GF@9^KQ#@+-"EAPBDC!67BMSS.3%"%G.]*K]_\,I9J[V=Z33,1470W
M_51PNM*IE5W$4,E=G(YP_9$&8P0,<3=9KJWR).P4FXCM5?210#UWKZRUZZU_
M!EPY$ R%]HP5!'_)(/,*BLY[)_Q]X&KD-JZ]03&,E.3#]#?HF^IO@=<URRY\
MB$9T0L#TS*8Z!26/,:?O0W19C&8-5KDQ>=T&1D3Q5H1.[]=G^VG/981DBAR4
M96J69@>C\/OQ]?"FYIV )%7Q,LC(\=18@S,IL+=GB*S]]AF#Q64"=Z<\2KT
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M5:.]M#_E3-\5\<PG*&RT8L?2?E8(?][)TZ''ASN\!+U:)YP4!*XFN4O;&">
M?O;,T% '"B0A)$?Z>#G^6O-$6E!UESO0]1+SQ"M.Q,86!V!1V\<*F,2(4F9(
MN.8,#=ZG=6NL1IHA*@UFF1I!WA[;3)(*.MH+[807<PZX9HM58P<8"IO8G'8#
MW'0)MI>YSMYU-?S934CT-J[]6"38%A/K*;T#H-K1N:\T6WY3K8BU'[?<2#"
M^ U];@N\J(1<-:8'6G]4L!@AYDYR=V?.3<%C3/&)AE-RQN:_@A65GD8&0&45
MA5H*;8J/X7^6CX&3;V@XX2;^$]#MOQI*"DB*LD">+B)OP]/K#' R@6]-VG5(
MVZ-T.A;?:<I2\TQDJ2.P*"1#<7FP!!A(8N2#Y/ES.K@K16M^?[IC>GJ;(>@Z
M!E:+ 0$@@:^X$M>PD-O7@<#PI%_;H4;1DJEZ?+S]^T+=*I.7:.XBQ)U9VC*T
M^<:A)&DD U]34WM\A$B990<Z4O$FGN:[<%!]22&5+>RB5*H:8S#YFHNXD?&=
M2*0]:EL%(; O[ "O5QY<<#O,S,]>+Q%)'Q])9&]_OXG54<TB2+,NY*3];?H#
MLV&U?X"TSY](=@  L[,@'=._B_)#U6AF95R_18Q#SH01W/G9B'!]L:L7W6S)
M<M\AG0M<>Z(M\C[1,Z!,PXLM3*",:-;TK#41':?3$D7$F:YL4T+[-J2&D-#M
M>[P9ONF8M6<AGUH;@HAJVI__T=Z9OD.]L''\-TV,%DTTQ-@2#B$T*,M,8W3,
M6.I8LAW)$I(L99G!&(QT; U"%)F0D) SQQXJ628Q9(1L889HK(.LS7AZ_H7G
MN:YSWIP7G_?W==W7]\7]O;[?ZR8;)N/:X%'9SWXIT;G;HAI[U'K-+.T^L..@
M>;S]T"_>HM]^WG /5*?JY"[TRU4$OU8Q2^Z(*>QNWV\?J ;^H4&';$,_U$3)
M=Y;\[C,(-RFW5J?)?+;2AH,H<B^#MZP$BPO8]4.MIR)EGO5U$3R31.I)1=AS
MWAP3]S"IMM51CF#'W-BX6;BJJK:Y(VY(&3*_8S>.QV:OO+&L/@')ZWI/5]"_
MSZ\I+)!G1DFAQFX*T-/46\C3QW+ENF"@LU5<L"5S698IY++J:>CJ(6 5J=UC
M.74Y++1CD,B;^-P-]0_">-F[M="&($,KY7)Q]O8+=2.4 B=/=W@5'D/)V-K9
MM2>DGG0EF3_9Z N^)9UQT3SEX!\*Z$2%M?PCK6VRY_K7U3)\9YH9[R4]C0'+
MTN\;+[*BCU8L58^.%I9T5]YXL2AQ^\*^%B+_?&8O"7T'Y= V%+KYV"L;]J&@
M87NXX5;KSE!@^?#PQ UB0ZTIW$<>G\8&TCD(L,B8G!- 2&,91CH8/[1;'9%X
M.O%533JMVI.?V9N7*+Y<8GG[%>F#]:!N5VQZ2P(Z;F*P_O&E\ JD<O@S''53
M.TZY3TM[>Q+:\ZJL&<T7F8A#F*B"\(0/K@KW'5/0 A([7\F()AE6]L)W;-+B
MRV791::BH(UQ>K@>VOIJ2@/[L?#)E6&3PP\?FM_NE'Q[><ZR\J,=6J!-9WE?
M5Y3(Q7A&KJC^-A;"CW6.O[NHV]4U_WA1:9'Q+E Q8S*M,9<2VPO) 9:1*+;O
M)<+ZL&YU5IV>DMWCVWYX27;>NU*7']B:I"53=;]?FD5F0Y)&,70;/60$<RNB
M9>BL0>Y(;658^KBI5$(J4+<_(Z8759:5->&\%?U<LO!,<Q/]!LE+"7Q?B /=
M_DI&:5\88 _I/*ID)[)^/R#E2H/(1 PFVS*7F'N >4UC"OJT=[+G,&^,PJKX
M^(_[+G^+MV/!%9TS8U4G?WHTF0A[&9B;3M]F-=], J;6)Q)H'(/,FG2?@#B?
M?0%KF!$HR:/F&B?TX7DD5YV(ST!\6Q$-]:"$!O\@[P''7(I, 1D !IKA"^1<
ME6H?(B*'>4MSO;O?TJ$SC6LO7BLV19YC:;M>-6(JVN!.:@0V&%/<>-%.W\L/
MSX+/5Z?"33$A]O2+%!892:>/E'&<HNXE."D@_?43<M-R!?AOJ(2A'+_$R>&0
M47QWF><U.[DV8P^Y9+_[4&MF%AD9W!JEV-BGOK2^:R&>M3&U!Q#&9JY(S 3V
MJ%V>*BIH^/1=JA-SFQ;N61<TJ[P'8'B^_;_>D*XW.4*LU=>9!.94P/O#U%KS
M8WG9<KR-";:S/VL/\"79I\@TI$A:>4B#X$OHY[H<V"/)'OU\*(++];=HWXG*
MR=Y-R+M7ARX^E7=T4:F6*U"T=B5;_<<S9X^9;<<9:(E<3_,%L#Y=!Q%G4P[Z
M;V]SU@F74'T*;V@8J=UJKJ&89MLHT.WVQ%'Z&-UE((/=V*])>6^[9O+TY$('
MAMX3325V!^*.M@6^@&Y@U>XQ2=JE./9CZK4-O4'AU29//<59^; =./"U)CEH
MEWZ.D"5N?PE>,.9 6'[$;4C1 Z*U+V]MFD6>"8F!B]?&C6'>2 = E-'.LVN5
METV96L8GGR.IA;#R%QP[LA<*(RE(1H:VGU=IY(HUOSX-'VF7BJ&V3,C6RT!N
M$;\UF7GK/FPU-+S1]QHC\@C43\G[$2'V9;]5@3$98@0QMT%H$:T@U"WM-M_C
M\2_]TOL>?![INKVV]/YZYPD/F7">:F4KS\"BXMR53-RR4OP"E_;]Q.P>X%5Y
MT91YYJZ)]9S@J;> EJ *F([49N%6<H<^CCDB4S4^VM9VV#NO!*'F/X5(S3=;
MX.)6-\:N=&FP9\C8X\HRD7_Z&M&EM*Z;J!N(ZL,X (NOE)@:[[;ZZ5'[6\11
M ^$*RJ[WCGU4#$N+)!;I*U9(WY#"R@8LQ!%Z].BE#*(D<$=HOVQ'FK4(X:EJ
M9;X$#/351;C!'_KNU<OJV@["FHT6F7T"KT\'S_+4%%S?]),NX,$^<%NNJRF=
M<1!T))+,B=RJO Z R'K%BM8=9J8#9O/5'CJ@5H[!.ER &A=?X=,;>J#*4G<5
MVJWW%A)+P3/<PPPZ*Y'7-:M'??+["[S]&GH&5(V<-Y51*+6!)SIIA%=J4*QD
M$: ",@)"]I&10<+VMXYL#?*76'W%>=T/]BO[=,E"+==R:%/M30-\>5Q@%*4J
MWJ?(IG[TCVVLH<>,V#Q6Q_N(M<41"NXD-2:7G0-P>3['<%P&HZ/T6H"_8N:T
MT!C$?@ZS\?Y'6>E*1V.1"Z=#6-E(?(Y6A7IK=_C,:,S$_-6RCG2-81%GHA;C
M8-*]&IC*.OBGF WV@*00*O&=R:N^F7NVUK7Z8O%=O<$M:&.U\JV(DO'/8>'\
MP50YZIDTA< [QP%OF:HD#NEY]Q/OK,8]H#DEVB#R'P\S_4\!J&R6L%(- ^Z/
M"D"F:I5J5H4"L11/HCT5!LJ88@B3T,\JTAFS,C,CEQJ#+&LMW=00FH*+W&#?
MOR;"8[L10J1R#PJH$?6:6E;ZE*QO>2Q,]321>\O]U=DA>6/::/U9 ]E"P7PF
M2238IW3496)>=)Q'K5/TE/:N4\R;N9H) TT?*LX['L:V2?C-PX:I=5]C095:
M1I^Y>CYUA2-EN-[X25-XF++D^,[=3.: 8BY/[3FM3V<<$:[\5U6*I*<$P7F:
M\K5:!9S%=8CUX,*XSO3@C8B$?G>E<X+.TZ'LTO+K6RZITN$#>8Q.!"U>/EZ"
MSJ!'.ZVKJH"A;5'2]UR9A57'P@7%A:4$Q@0%M7#%PM8KR[$.N#NKAHU5A+HS
MVR9G,^U^"S+89.!MK2!/T*WZ-C[B0XXW%J<GR[#!J1?N@'X.M+(9I]Z$\OL&
M0C"4=SIS@[Z\)<@.U)D X=][6S77Z5ET6ZU?VZ8.>SZ U&(D*[8*_ERQ_&/<
M*ZTH&6$6</AE!(@?)M9GA\*9TP:>FE96#(9@QPH2)_D_91JU;V5BXTD!KRA8
M;D>FR@LTM_PY$N+ZH?E0FQ,\+-;,5_E!6R@$!]9S7YPHK3ATQ5&](OW+B%(2
M3,+6FJQZ$YC^H3OY9D$_0+&^>=>\2R2^ZZ"=<?J!Y<7?_5>^L+Y\F^['9Y]F
M!\3Z'(848R0KC7XN3P\I2@LC;EZ,Q#ID+0Y\F2S!GXBAK/4/5EV>&FAOHPE;
M7,EA"?$7W*39'T5_0ZLN/\\7FHHS#%.X SL NRD"(P!N!]/_O^^J__(O?S?@
MO>'_ %!+ P04    " !:1&Q85_:U_I1A  #Y=@  $@   &EM9S$X-S0Q.3(P
M-U\V+FIP9]2[!5B;V]8N&@I%BE/<BSO%'4I;K!0H%-<BA09WAQ1:W*%(\>(6
M-$AQBGLA0'!W=X><=.V]_KWVO[;]]SGWGG,_GOF$Y)MS,,:8[SODFP$^"5\$
MX+V259 %(#T  ) 0/P#X#. % !T5%0WU(3H:&AH&!OHC+$)L+$Q,+#*"Q[B$
M5.0TU%3DE)2T#%S,M'0<])24+$*L'$]Y^/GY:9A%)(1YQ;GX^'E_"4'"P,#
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M G?2U<@F-A"6%5;R>$)(OLXP(Z2\WP-4,-=EZI&[2$!X<A')]],>[=4!SB)
MI%3KC>*<4+>FT(X#5LUU^@Q3P++8\J.2*<VY2!75R#&R-/%TXY!;<+,MM,I-
M:7)%*L)C/:1LUHH\+[%0+G_0JN0U'/!^C%:=B6P))>JIE#0DDF^804O=I1 .
M6,[")+!0A /4/:[@ $>&C2/A_$MNE?K*$>S.N;&W"J G33.$LOS!/<A$@+@N
MIV?+I<[/; !J(S*HW_X3O_]UH"'ER##P7DHS1ZS4W6BLO(ZLHWL>2WRG +9Q
M7<8L'GQ@!=1\29[WH\\=B^"9W#I;5RT<0&\4*+53W7T?;+FQ*[72+P,'E-_"
M 3>:?@).U.[<>Q1J7SES%;T2ZBHKHL.)@'FJJ2[=#)_N>\MDB(GA@*F,J5RT
MJ<:HJGB:N9E:FGC-(\FHN_QWL;E[G3DURK99[L\STM3]HEO]100Z0UQ.K&/A
M@!\J/M\AQ&/#^\9P@"Y/]^Q-(QQPMOFD,SD=+_)<[S19>X9XPFCJ@N#QQ7JH
M&BH:E/F(:$XV15;EK78ZT2BH"K)>YS6UO]["[L(^0&C<QR+\"( <.I^92V%)
MJ"KS\!]G*4WF4'%%M #(YH$M;:R9!XI[>+B_M,1]O&I8W%KD8OQ@/?L@'+#D
ML&5TBMUX.Q%UJ>^I=8=L)R4 ;B[4JUW58HB2SVI<N">ACH<#GLT,#WZ  P*Z
M<T$_!4].="5_S:",E: +/0']U[KL/\R]SK5=B':4/PW])W\C>SN^P5>ZEWZ4
MI4SH#W*E_C:U2'/O"@VA0]%T0$1S?O[P>^>4Q;1'HC<T._IHMUP2[/=^M1G)
M(W  9M0K."#39F,=XJ-6:]<CPF"S94@UAEH.W=ZQ$%>PY-1];6?52L%RS$J*
M@B.V&B<+7II[MGVD_V'G/8KY.#BF9])&2%#WY9NG"I2NJX\Z_H4N]&)S4DK5
M4/Y+#G V)A8ZOARH\(P9K O \6]<^5=>BJK8(M1*02!@9;1ED\+C"DQS6'=:
M=HTZ[VLE-\[N>OLI5BY'U=#NCY: _C97'3QSC*- '2/CT?(OK?:4(5J' _XF
M^6^3SU[-M="NQOQ/E:@N7#H(GJ"F&U^!@G=+Z=S49E+#L1ZI8&NP5__RQ2LV
MS)G<RHKTK2^5/P+Z(O.1!386_DOD6^7P;?9.#)FF?P&AEE].Q?V_Q';5TJEM
MC!+@]%":=:*=96PG8Y4\/4=9I'HZ[Z-(7,N-1+DC\7K-W.Q9X#F0NM#Q MLQ
M481XAQ[U/7MX%8Z]'-ITYK_$L%PK/8J6V'*87O2U9K85D!$VR=4X]2Z(8NI1
M/*,T+0$OCAA,X)^X0..7"^0FOQA8KEZ&W;."7V);T)C>I/INRMTLI%SX"+DM
M7A\9#'VU/M?52"OY3.*/$A&\^:J 9K2.YE_0DN_?L^[_!N9G-<YZFXR& ("U
M7R5W#$-0LKS<\P!^=*B \YY!F5=\^271J;JSL:&+U4:AGJYQ1?J3BL;.Q])/
MGO=IH1&]_9M&EA/$Q1,+T5=D_[^@H2P<$,H-=E[ <[?</E\6\W))MQ_MFU%_
MC&G* ./+WM%]O[Q9DP [/]&' VR5N+]$8EI+V@U&*<M)GO%<=N:DU]M,W6HB
MG*W[3(3\_<*]V.^F95J*;[F!SCKA@-/'ANKB<EEWH0+W8Y!9<;:)58_L$/L6
MYIOY.2L]A-?B_N(UH-22_1;-*58#'-#]^YX>.$?+1IB@M]V(@Z[1B^/_8FC&
M_Z9X\W\JZ.E04\"6CIAB!="?Q++TQS]:M8C*M9K@#0NK8BQ^Z $'=!Y<$7'"
M 3M;H%/BLF=E4I=-< !=;LN=#_>]_W@-R65!@:U[/*&J86_='_L0M2S^R()0
MG<D #2H%B8>,2D![&VZ;_?@7_+PE'ZG7Y(7O6) SFP_!Z8G-,V^.J#/L"G-\
M377Q.B)Y"<M)>PM.X0!T0TOJQ]]AHV;:2UC]2#3BH76S<E"!L990<>'*[6M_
M2[M:U8 IR)4UINC06T (S^@WJ#<P<ZMJB]QQ6OS<M2;#//FTBDO(;]WW@$:(
MUDG?< (,T8UQ=7*E)HTTH*-Z^W9\S[G?*I'59L/_=8Z+,!5:D\88A(S_3DJI
M02]X'S73#)_C'<+A-K=.T[5,38=#%9G :Y=YL$ 8T%$^NO=<*UH%7YP21[I+
M=/R.?$=A3"4H6T%G\>>WNOIZ@B?Z+"9OG-J8(Q]J5<>.WQN@N;ZW;,8+'#]C
MK&Y@V-(\%)B,2QMM>5.WB2JG&RKU4+]W>>/GPUGI[,\JC&TH=*QO9N_?O>6'
M _#U:F*6S5OB ]:+>ADL\=*Z?564DZBKFT#+< !N[OQW+T*[ D40)7$A*C5'
M5X%0VN1*NL218GJ)\\+U\P:12?$G7D+!!Y# !);F'V3[7&8]+Z6'#CHT7<&F
M[TTYGG=KUHZ9Q"C:?<:O12.EA=EPA]U*>14,<NSQXV_76TS9N=*+U+H,05.]
MV]%JJQW(P<WQ5OP.0,^PA=+97O9G)H!S +4*4:[(D-H%Y I;: Q1JVI)2_^Q
M*#7(^'%P105&X :!/[85]JI+ T3-6=URYP1:TQF_IVPB3>^NMFHY!HQ)[<S!
M 3%E2<5;<V[WS\B#[KQ:C@5.B!P7?=&V923\0UE*5Y[]WJ")8\%DP.Z2)R]_
M6KLHY,GIQ18=L8A]XVCX:/>CDK_B@XN>2FWOVC2&^L"-HK%T[Z)+*>S-45Y(
MJ<ZE_X254*5B=*7>D,'J";4X^OUK[U0D[?'4%<:^)@6;KXGS#[WT]+J"-*O3
MM_NF;$LYGU=6=K73;N1J1;75$KC'PF1)%)J7QVU?-N",/U0TW>FTLYSGA[I8
M29@J)FQE5\9VX=OPVU=6Q,L-1/C%YAP-$PG4=K"8'@G$WM65AA#YR['<"$F^
M>XX^)$3M  UM4P?;!'B0BMKY@R#6SE>@&LYWW\>\ARMG>L")D_8>1-11BV<3
MQO%/)JQAJA$,3F;2' \H*=,_96SHZ9)$<CC/B3V#3IMPCG,17 8K7[K5]O1-
M#ME[:=@PW;2+&@65V>RY7'&ZB/T8Z76=4)/_09D1[T[*8,H4I%;4LI1ID'H1
MQ.]^UC 5ZS%-H><%Y#*/D977(%O4K,E8-!\KV:66T)T6F[FD7IX?E;$9*/+8
MR!5J;7N?J ?-$HD]4$H6YFLS07UV*V,--!2$[ED[^[!9!2KR&'.0Q#(P#_CU
M7KVJX?4Z+2X6#55Z<3UKTQS$+.@G$O::6-'!Q<DS<O[5#]G1?%*TR^;J=Y>:
M1_P*MKFA2]RC5QR=,5'KC(GV C^WFIE'GD YG"=:TK& <=,"H\^G_+ZV:6[%
M18NI-U,=V88LW2B4S+RI&T.I#98</1*M[UZSX>5RBLCW6R!,TTT8 6EA5H4%
M/9O@(E[Z!N7*T3-GYU$?^B'ZZ4#35IRY9&9+4#>F*F:Q<?EIJ")6*I=<B^4V
M)(KPP[1ME!70KK"=\IQ$K5[?0%>1.15\^XZ5AF>8=ES86\Z4*V[IPL9<4>F%
M\O>89,$:M^=D(=A^70 )4>CY.'?M.HFY4N+G,D;1B.I=OFFCF6F* EIG1(>#
MM*HEC$Z+_Q.6.VU)+GY/.R80(='B ,QY!:NDJ^\8K9'%-XH6*>,-QB= AGT8
M-&#M4YI]3"-#J+GV>_OR*,/'-ZLY&PH'K%)8P0'Z;Z\>73E(7M_)^,CEPP$]
M@K#[NOQCHK;(2Q.+MZ8;462(SU:*X !8.TCT!WCA[]Z63MZR_&3)"LU\E# Q
MK]A09_--;71@B1!G-55=HV&)ZH7RJ,#J6#63&*<ID$[F>9<"SW&DJ--\GO*(
M#3+G=CIZ_>BM3-X6MAMAB]T3TS2D:0R;'%\B1I@_^1.LA.1J\"RG-P>CF28J
MJT(7N@3HT5CMD6N0AU6.@A/R%G3K.CK-=/9D75#$J8'2:68F5*^%;&NZ7K=I
M#RK'F5#._%D.DZT?]:"Q%;<1K4R@?X\=F%](8B$X3_J5QA!UR2'[4^.N5%.[
MS3)$ /=!4QIXI[-8=U9_LK66A+A-1P<_4+IW)=>PY:AGS,9;P\;)TW!BDW>K
MA_,\5N@H%M43Y FVDN2'"J386"DF["%(.H%O)6[/6Q'S;#;"+T'-QSU[6A.J
MLO.L062G#*.;)HC+)8S3?/2*\Q'G@/VGF\K)UMZ=,0UV"2*+P[ES,$,DUELY
M.SL"+N\I_=-KDUJ!?C@ !_2#'B<NVTHYA)HQ';="H7G?4/+D$$"=/C8HN)@1
M]#@IT3G9MAA[-BR]<.=JG"UNK25IO_T>3U"(.R_"LF='@239^:C!?D7,S7F(
M'76F?;ISKEY?.F^V$9<VP@SC.(&9]':GPL;KQT0S6T9G^;80KX%\ $SYAL_V
MY-5>FV]2$5H'N5DZ;B#F3H5D+LY$M3Q=K,@3DYNO.E757SQ'(W336I ,DF#W
M!!.[ AF[5:8<, 9;%58%G*:>\Z+H3=WJSMN$IUNUW&XD"Y]EW;@G&O*/Y(*&
M@ZL;HO;H.3S!10^!>ZNLMGV@\6@<>0E?W4*ID-,]34Z3O@.]FR=UQ,MB.WH*
M1/)1(DK?YQ; CZJ5*ZBF>J0SMR_X^E'(WX_%/6]CD E?P]C$S241Q2FSL(8)
MB;X?>TI_94/?]0Q[R\ V?T6/(JGQF75IJ4GLYK2,'5.7UE?3I<F,I>$FA:++
M;J66NJ-'U7<#-3#[Z6[K%(J$YYB+^,<7&TT"NOG'"&X]G!IH6[)Y8[1U:$FL
M)6AO^#J&8U2N=198Y6ZJ+N09JCTY9S"CHZ^ J1QSZ$K =ZWUWF$Y"EN:TEYG
M?E]E3YZK96Q F^YN>7>JWV4K5(FDXYZD:BQ#->%H]&W!["OOR3SKKEW7+YBM
MPV0]@RJUA2TLW[^VS6Q.QP_&&<F9VD_(3WI]_%QT\DFKU)NS@,KPN%NQNJ%%
MSQHM^IGZ,5^/!+LF'* S*D"#NY5_8[(]ZL5B2&\2_5VGUWN#WB\&)E!!$]+(
MQQQ<3?5*KQO+[DD"<2SK*UZVC_(:W8/1'@+*D(OR_2%1)3SN@,@2!I HQ7"5
M?FM_%#?]FM10Q4[M^(%QX@]JVN:0BQ=%5NSG^N'$F+W"XC!\W=&4^'W^'Z$L
M8%E"51F 5\N/EBN"%3B@=-B@VD'J$2*"*$;=-TBXCB^;2(718]@2;< !)"VK
MZK5P0%DN'/!3M^E!(QRP?'$;F@ 'G)VV7&-J&(-"_2G2&1%IO=+VE\P_#AO@
M_..):AOQ!9UINT_KTXH!W)$-TB+")0UZBF$S=7LVWSPL8FI*+$68FBB>)X_J
M26%L6ZA"_+&I;!^N.@X0C<7%!&P[W5E%XN9O"PD>?3@TF#;JY^.;G9TKDE5?
M375FOX2)6_;VYM]YQGZ5TQ@MXS>0+K%;P9]E*^8-1 .<KFK #O/*:QVG!<JQ
M$A8LG=:QT[4,9NKQ=4%XBV^7"1LCUT?=S6M#!8Z9==!9ZJS]1DOF+OW6+K7L
M/D!ESA/K;BBBVP<%=TY,850%Y['V80;/][L)1-[(O?@Y\FD3Q'9FAV<(W,MJ
M:DK6E4P^>L:Y*L3SL-8Z/#Z*HM\S\LSB;?*@<7GHSIO:[^XN25AJC>4;??L:
M;_?S*PJOAZ.=J*5_B6 ?.VUR-)#K%.U3$,AQ+8 #S/VWR4Q"P-FSRFMS[5&Z
M)XIWG]0:\/4Q@SOVB=\!"+"[UP&>9V#6\0U7RW;E-4^6K)J_>]"O97'8<"]G
M!;I&%/I]=7V[]R2@GCU$WZ"_<*7I @KBEF6NV-,]N/TH@'M] 5JU6F>[=D-4
M6M&HW^  PX/;".]._3H:O^L8E7=9H>QUO[( X-=@U="9I2LT-_T(Z&6*S7C4
MH$3>-:-?_FBFXM/D1C7 <!PB(??"RWG,YC8H78H'KYR9K%MX2\.P;YV=I8P:
M30^HG>.(WXX_]FC[%FBVE?-!3> LK7UZ^BX=Q+5G!GI:(8'42WV6G[_]?*<M
MF5!+ZSRK:_X2?,O50]D9 WDH'I->MZ>_7;6J=L)T3>TR; _\I0NKN02 C*D)
MMTL(=*2RT%DP#X0]EK@4U=6MY)-#];AI0I6P$FJ_'OJ*&FQML_]69GQ&K)J,
MEB $38IKO^*H^T%RR:Q(+.;FN[Q/Q4QA3#7E"D1?+*A]]SZOKD1NC.9+$DQH
MR8EF3'V9X3#1?*#!A7=J\GV('217F6P75-_4F!S_-7:W:Z)78/M3M1ZSOZ_A
MYY4FW5$Z"/26I A\LI40XF1Z/*\[%UB75O_9;&_2095MT'!BELMCH<7RJ0_N
MFD%+^^;N61*WMY2O!L'S1 =)$<WGF+C?:/KJ#9@-*YJJ&\8XZ?U*,U1!@LCB
M;_8_VG],I,P#;&FHM=!;MJZ9]APZI%)Z+H?3O+C2 KM;*I+N\G'>959^MXKA
MS$AYU(W+;%GC:R'YV4&['PP13,>'[DFV\:O0I+A@A8<UQ4?^W/4]*!AD#&ZH
ME![PN.+"SYY=HJ!(9$"]CCR-'W>_RX[3KXWA'NSOM25;MI 37(T[)E;&=JRN
M%G&22[)ZDQ7*UO4[J=E\SJY#KZ-4$-"Q*;MS4%EE7^NXV3DC.J/.@ -H9XRN
MES-ZM%#%ED+2E*+2Q2T0M7QD,1Q@A'V[\ZC6^^_>-I@>9B,*=K:/OV/MUZC-
MVTI,;MK6F=2#G+3(&+:/I?\HFW$WU?X^5N9<%Z-IY4B\]GJ)T*F565@<ZLV-
M!77WA_5]CYQ3'5_S8,9G?=8:$P?;FJ\/&Q0;.+K/]2+?3/ZL0ILNO,\=KP6D
MM>V1D!4E_Y$K1Z;7DS#$=:/8!'4A<[XI=E4LN#\UC8.*K$S'*4%+7:PN=ZU'
M#)?U=S7??6\=?FOXB:EVZ<8N)!'V5IY+8T5J*Q 42[_VKJN.E#X3M?%>Z;GP
MV<L6*&=RK\E[]^P3S'CZ9I]!O$+68KU,9H>3#["):RO+QR_69DK69SA:']-N
M [8=0K]]2GVW 27:\LRKSM^6PH.@-,5";[A($RPT:+N88A08&RR$*<<;BK\T
MP" ]N<F88L&-YXI=WVN3%4AHV,*QBW=UOYF0U_+BF/;9.X53WK&TG4K%>\[M
M@X$6( ?O1&(5SV1\QMQ85HPDX:[E1CX?=JJ#R&^'VTL'9>^JDKJ@)*'R43.4
MM7/N1]_UMD8#@IMK<$R'$;[?9OFU 9KF[V7,30H4-#CL<\YHU?X0SO]]NNCR
MEA\MK083CW8-L*;MOP ,^GTL41&8FE"N@ -HDBWN7$%WQ&,%DCIY+> '8NG<
M<, C: ?HI&_A'O&;U)*N>]2]AQX<L+!D."+C>F?IDWAVPK\N;G1/E!\,!VS$
MM]S].B.%'-'<'B,24LN/IJQ0R6K)_NNK(!Y$IWL(%I># \01C>3!8?8?EA#M
M$:J>%9X;P09$HDC@@ #@LM35&B(L@@)H_KBD[$-6%%BE\K[9>,"]Y99=!1\.
M&&8'W=RR_-T2KV>K,&ZK%=3ZL;(L193[X8K8E^D'>XKQZ+S=_5V>1THFYN>*
M"'WXQ"]O>8\P*9,X0RZ^J&4$^M+1HU(X2NT4E+9ZRZ"'PT3%RSVB&3OSMH(.
M5!<L$U96SPXZK3;36<E/$W: YI,\!_6.<  '6N6GJ*3TEE>V33)@A"MH^,2G
M?$DO_7QWB;.W6!#I.,!BF6.CMV:X+)E]S.Y6X]N66U??A6HHA5\MR]25FW/O
M+FO&8>('J:FN6TO5%#O^'Z3(L2L%F.$9?8D3;*ZWG0/#3Q$R3)>Q-GI^R6"A
MP1)_AB/35 K:*2A32>R\1F&W'2[L#/MR0C>-2:R_(HP,DXI7KSS:]W/+#;OB
MBH#8\#TO9DOKB%S$F=R0:(!>=RHO)%U]W;!8B@I&;_.?0:Y-9EU >/BEJ,QO
MKG.K#XJP6:Q[:UZAKTN!ULA7%4\IK&&8-NR9,-PM^O+B9'*8U7\9+9*)@2""
M'O0HU57<20ZAIO3 L,2_V#0C2$MUR\E]_]/$GB_M3VA^K!04"TCI9IAQF?^K
M390A]/D-7#BFG7# 'V G]X<E[-,LV3MO=UO*DIRH_R50:70SWM]YMR<=@2XU
MT^GA@'1$77=QJ?5B,0-]>QHM=,^V+)8QI#USBM8T+:^).A-TA0%$U$[C+:>/
M7W2\4LA+&*"$<%M]K GPS2[T:[TM;H<ME06'^M/5MI'1-!/MZW;?^AU([<2!
MV I)KI/@@#F:OHKV<>>E?,=WN[]:N7\!YYKKL1ONG76M_^_((6.ZW4P;]&K<
MFB,WBMTQMN<XH36 7C]6SM.*2&@$9/1TW2(A*I":]FV,G25NP2]>&#YA>/RP
M@KXEF7T4+;+QZ9R N\I \<^+34_GBRW-EB66$=0B_I8]]/MIL^/;$IJF\!4)
MEK_";.W34F(PX:JT-4+0VY8_[LB7>=Z?8?J=J-^PXEHC.T4 NV3B*Z07.9 C
MUX0=%*':-S,+_ ^ QK/RX41SL9-=//,9O\C0_C7]@R^IU:ZCS9["&6^HU)+V
MY2=7[S#]ZZNL)F'W]O;U/L7A/98.GAYZ$_7 60]D6UY'D9P1<474XNQYRRH/
MU_,W*G0,N74?8)=#/D ?DWPSRH&3'1KDRY;7P.3>S(#UX(Y=!K57U)D6N6\1
M+C->QO[VFK@#R>^KC*>U+^_A:8+C7&D^30R^1DQH^;3>OC_Z0:BS+]?/]_7^
M4P*D U"_M4(UT5.T2(Q3\9&]#:_C>Y,&\=;;IT=(.W:6#G" D@SW+3LWWLE-
MF*WG_:E6$7.(,U \K?;(_'T,M* O?T$J$-NL_PA9EAM$50P9M *>9][(RZT\
M<=J!GN15$(GYFJY;/&C!:GR>O18XZ<-(V/)W.__F\"#8^O9%?LG$B2PTBWN:
M_O7]7O"0R+;$CDE<QR#PWS*M^?^5"%UQZ;!,ZA>353N=P7.WN<D^!]EW[E?Y
M57IHVL!N/8815>_,E69""J(B:?CU\35Z"0^1@7QQG)"S^WS+HH^5]A%.M@^0
MD@F#BP8(!(A3.I<<_!U]R[3A@.*,^V9&1-<SJ%L:5=(+-/MW3%+["^$HN\/@
M@#^DJ:B_$PQ1E9O(G_I%AO^=B8U8"NOV>3LV=@5UH*H"(D:U&R'36%1WW[D0
MS1M=;EE77SF/09,_+-=%3JWIC E>G+XV\]-#[KBFMU3)CY"E=TRIY1;N"X])
M_QSUJJQ$_5?0^XUA&<$?6P,G<57XU?[.H"91:&?]P^M9@9I\3'"CKW6)XX/\
M4B7]T;,(*=V0->@^2C^%M2\ZFP^Z^.CUH STA(1//-J;[PA]Z$G-1MF!#.VE
MZ3)2JM[TR2_DNHDR1^KI'B%!H2J8J%N$?4S]<N4K&Z2M<Y,6 K4%.PY;T^"T
MU$"B2.W59!V&.+N$8!%KMQVE939F*X2G)<T]M"^-EP%/.?= !YN_,N+[98*9
M<.*ILQ,93_%['JC9:'XCU):NWCTWDIMSLOM$I'6;;]A.-^7^,3;:'J\>E2PW
MY&6I 8#Y(:JV!97L7V*+$]_ /T\*X^)298A;BGHW/'1=VH4ZJ.ATU:SBZA,1
M"&W^SS#A/TIS[$O[:0XYE]:3<P\?=XH%/G(4<RLMK3PUNO)!-/8)]\^KV4.K
MFF0'<NLT_UBIC8-U1+MO?8$99U-PP*F>6NX18GJTG#VB/U3[$<J2^2"4K32[
M8'I+TWS_^ 7EDWA%I'2%UKL/9):AG2#B#P6C93-('_8E!UI9I1K;A&_]-J8K
M^1'"]88EJL$=:,/)4Z6OHXM)QT6F>JFZ??V+$PP^[N*XIN6C43[>T7_9C-8X
M9L?%=899C&[NI< 9MRNX_G3@SN!.I5I,^3+ QFLIQ$XA0H#T&P$$IZ3P1'"\
MK5NB7K.#FGN489QN-'WCG@F;.;:GH!/EHUGI?GI=WI<L5(VRSR[RR^EZ83,B
MW(B^OU?_^6O[UB;[_&+JQJ/D1-E#E7.AX/NYAS^)/U"8O7 ][_,+W$ Q>PPM
M+*R& TA YE9X6\0.T[WN1R&4<[,>/ 7, (N&Q].0,R.\K6M"S<'"/A./MLG@
MW/ZG9+2F8+'^ V3BDS9'(R-#?24G9,PF68I\5%Z5.-)E[HX3C2#_:G:KGFI,
MB>?0O3 ')]:3+$:TE' \J<9,!SWB=*'#LZW$WC'4R<R;%V+?-*9^1JOH4[,8
M47S@-!58,6AT>$$G0QO+I(4%![BMB2]>CW@$YE(];I.:A*K0-BA@5-PP<+U=
M?ZY@8=>9(DR4*HY=TFF<+X-::!8W/=EOIO]CX$'%S3;?146; )@["F)_;5^C
ME^+G9?_NZLD[TVXU.4->X8L"2 8U\"(YX Z\VHO\0KP88]H5XA!>P0F54)9@
MO;D)S)4]1,G%>GZ.CQ\Z^J !][HN<H-&4\#(X' ]'S6^:*95<]M'3DTQ3#:4
MKYX8!4__=#I3RSA_QU4T[7/B3_$0&VI%\9&D+IZT=@E9L0G.C0XJ<BJFZ_T)
M!?/8Z:<[^"&) [/V.6:..1<YJ?NH$T$YW5E /.VNSBDD((.$F:/C@&].\DBI
M[$VGFZ=1P"E8=H]62 B:1:1N7P2.]7T[]#QJJ*1WA1W-"F./*:(D7R$W;16K
MC%Q6Y,?UAC^V8GAZIC-$BYVF YMZ1;VRLEJQ4'.3SZ-9\>$;L6,1ZCO6^<='
M:67!L%Y'^F:QV9=X?FN!M._2,<XZ*6-?G2,7(#K5E[_:(")D.*!'$='_EB+(
MF)F<_L>23@F41$[^YY(-O$-SC-:(6*%T6Y1CM&T*!SB#V(*]:7CDC,=49=[\
MA4R(\=T.WUUS0V^,RU;MF"5!$=F"O/)Q>=7[E./E:I<[6TZTUT)VCP?IZSNQ
M6"<42!<?=8=U\4XN&$R[Q_9Q2H#W)C:\>:^*WM3,4HNNCLLH.O,VP?S(S9MF
M'![DK$\+/."+]^<@:%&3,=]LQA\[8[F'%BA2@2&)<8;HWEG,\U/JLSZ 54W8
M+0<VE^*5S;O K00QV>]\_!Q%3S$ GW[B\6*3<T?Q-]R1[+G58F)WJ&;/TLH"
MB(7??+^9VNKV;!BDY8$NK><S)DZ5NHCQ5DQ1"*/8ET^3^;F*'\L/K^BZ2:+'
MKBC".)MA>!FJ"7R4*;B]Y ^G@\;L/3TG0HY*/]?@SPN,A5$,V/P@U7./QHIG
M'Z-44UP!X79:V#G#2DS3%$LG)^/?V"OB+@&.!MD'L)P64RXG?BP/V8A.G$];
MQ 1'S%$XVJ#LBW!(L?GF+_5"X(# WNSL7O$1T2H(7N()SETW>VJ\Q/9\[8H7
M!=G#A/3EC3<>62%:IJ1MCL*<4&&13@6K%3U\VUC#OF\;R3*UBNI 3%EPK0?
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MXH HM8#$<3FO4[)K0H(*F#+N@O) PZD@L%:MP<*L95YZP3+S(;^3?A!)7WE
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M]<COKJ.><KM%&XA4Z_[A#VN#Z:(D[BXO*MRT/J6?NV7#D&(Y'72Z#@H0H)>
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MEEZ.[!J4<MNZX$(DEC]FT>DYN&Z4+]??L2O7CIPV^$A.1K$1SL1ZF,YF.'J
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M'^D^JC ,UU.U=C%?'.'6NFT'(QH"!9YNX;0 ,G?AC*3TEE\R.:>$'$PN8["
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M:5K869ZR<0!: !@ >OIG#: &Z )   3 !>!TKH+E]*/U=S,R#@C';Q[A6+B
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MN]F"'/^TS_&(B'(+?-\3_M#J[XV<K0INYC"0M,UIC/]IP_N5RM^;MK0]78=
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M&03K]__S#W*TDJ!UHY62/)D R *0_D,Z,_*?VD#Z^B-M;Y!I49#PO_](VVL
MU=DOKB&C_/X#;   !B;Z)20T+%1DE%.Y$1X @(YRV@,4-$QL-!Q,M&^_SP9
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M4ZF4XL,^O-=<I%7R6#*C7_-^04QOJK?W&]?55W;#0=><V"-R'9V21X>-*TX
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M;&.:QIT>\#H!U";6!]D06'=RS<VMDR;&A!2Q%;G@9N<KS5PQ7/$TSER9&YN
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M3'-HIGW58-=/\S-U[YT0GR?5ON^"3#Z< .;YQ9[[3O650,(3UK"LJ^.-X9S
MPGU2OU+V1PW@)^E#HJ+>(A@( 62%N[5WZW.Y 3.=)/Y@AKM/0P?4V5-QS)<F
M2PY3AJ0-G/,'JN9STOU4@B/)UR)5AUXG:HQ:&.N"M25L@YOU\(G5$Q40VF]2
M:H?T.:Y;+C_0%_R06\QMO-YIUN=-%'TG1BL_@G[W\LB5E?%Y]6B@Y>0BFV&+
MR(:]?O&,>.3$K8(;XSB%7_9)K:11$^&K_F$?7/T^HJ8]G]KD>8V7#M6^=$VE
M!^9A@6T?WU*;.8ZJ$KB23/8V0X3SR_+AX6(ANYN@M&6VGRCK!$$O6[$.(Z7
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M]$WS<2FL_*!.HAI>,;A?KVFBF'ZHE)Z95W_3CFT^*]-&D:SR2 U;;#*"I]=
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MA+!'6V_#N*-AW>^KQ]S >2^.\CBD=9?2568#:FO!C'JC.K(4 Y,SP1Z\G@O
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MMSWB/4P#].7/[[X,=P7T(W (90W9OISC"9ASCE[CISOBDBO\3"%VTKF=*R_
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M,N42-_.L1U;MB4[CZ7#;^3[8D>#MX%3D9?7*SE<7\8@PGB554R+%*&R0^3O
MV:>W$<Y9RB+0880N+D'-TNP\3XZQD@WGF'X\>QXF!(N(./DY;",*'B3)+?Y'
M?2/GM=^%/NN&V\RDO#>[FB D%>7YIP3L2B9$:8)%:!V YJK!#W6C5\+/?/HV
M&W7]#3;EE0]\C#.">BA=!! /_'(XZA;J2W\</6CV(9@$_PJV1<)Q-W2T3E,?
MES+MB8Y6E_JVN&?-BV<4;681]@U=A;;-SDRKQ/@85^@LTQ@-U.M\OCV1G2W*
M'?G/G'%/(SQ_VS!YJO6!'X^K\6I:K3HK3#:FL<Y%\X2A'@3U \PG^)3FLP;&
MWY\^A7+2$8BN1=BD6W^CV76L=<C6*RH1?SCL"P]/*@M J;GJB(OT5ACM-]NM
M)8#T@DAWHNZQ'I.PB" GG<L3F)$%L79$Q6B/J4N%(NSO1E'[/7K>>NZ4I\OD
M8@ 9"SX0?F15HM2IOK1X7=<+VYJ+XX=8.V[',B]V(6.RY7X.D.GZ2K7#(F7(
MW(B\U[D\"#A03E -<F\]R>2\FXPY$-4)_C%_L[:\^S2[\P:GGZR187R:]+/.
M0]5WR?(@KJ! D%"-;K$;V"ADG9R0+_4R6NX]61(+7:4,23*AS%E'TG$CZM!^
M1F07A#ES.OCT::\.G3RE9OFB)GJI'%:J^6RJN!+A/W,D/OCG2VE'JUM</81S
M<GZ;)37C-?N*HO@NTYQ'0S;*C8'%A]6,>^7NG1"$@LL*KB!\"RLTH_&3IK<-
M9@&94:,8!^V[]/(A]( T."27K/@3[&U!6+%&D?2<BHI0 GZU/4B<:==O0+D8
M4'DRK*R-G7RBVY*Y! T@YAEO%WN7@$2#Q74YP,W-\O;Y":3O>.8XM57F5O-A
M-=7[_I:*JG6Q]OL,=W_G2E+>L %N>RY@]M7TYW('4^OV\L#6>ZS&8!/;#>#F
M?Y?4_A\X>!Z,I9%"$^\"RM)/Z'7"E#[.(I4,(2\DV9PXWK]M."-\P*B!DXLU
MR/%>R3ZDZ.FW![:HIR)+S6#?Z2<392?E[$P&!FJU2G5[*>XQC/1Z7DX)VB#2
M?7MA;1!OF.ZF6?%9T*#W5"O@-AD#/N<WAOX2-.,-[7I_6!MY]3\XLW#_&WVU
M&.A'^&(J?^DILZZ0T3D5?@IG;(&=O"C R[9J3EO>NL+AEVH:,JZ!L\JB/-*B
MEDWDS3%.5/X[F4S+Y[&1G^O^4#4?KEZKNQ+2F@@_DG\%?)B$/%,A-0MD(*T:
M,#FK*3/CN:4-""A]K5.9W=UZP,*=7VF)JZ^Z(&;*([Z\<7!'^-$A[JW;QM.X
M2 E,M#S%/./XAU' H#XC%+]XLI&WAH>7E\G9UM;>1>GA1*Z3DU2V"!\;"9D!
M;F*B-M-'YH_T8R2:_UOJ>JP1=C,C3THE/%+35@93AGF]2=R&Y*G;?AEOB*>C
M^)Q 2LTT_BZU40/KF5F,A$9:U+O?"<<-T&6U]=1NSGU[0]*!?F>(913(10]B
M"%&?+HN,TJCGTF@VF*J$0 =Z8LU;/<9VT%,"&>2E!,!Y^[6[C:)$+^<1P8Y2
M^5GY$<J*GHEUDD\)UX>?Y<4#)=;O]L].SVZ('9=K[[&.K?U/GY=2U0N$WS48
MDMQC[>LM>$F<PX)7!$V/O50"].U;V0=[^75E; F:C;UH3 1O.>;).?">Z!)2
M]1FBEI=[IG%.YG^T/6THYTJ!<<'PG$H8%1VIA%#/V)RV<K271*;JC/BZQ^EF
M=^\..R; 7NPL,^#$*Q'EJ;(LPEG%7Z95^U]^N<T4H_GX(KN1T2TY92 %+[2N
M8B.486\_SX9"[<**MUESU^825,H>W2YO+7JR;%80QU]+W,S>%@-?K]I"3AI#
M-:(^UI,HWK+&U3/YN9HL); G%C#26>@K))&5K2II>#9XFGHV&VWOQ^\0T.UD
M6'DZ1^=H38"G>.@5)7(-Y=4JBC-^*U)7!JC9"Q,+.CGF&VW< DW?%X:<$6LO
M) K44\<&OJRN!@W S#D2&?71_BGEBH#5(U;J0O-7T!RF*L)FDU?ZI(J>0S6*
MFD4"G S:NI/'5&9Q:TV5[OZV;L+3 *53M$44((7X2:_<]M16SY0"Z2%N@\$*
MYDIE:^?7E;:AA^%&)J*P#0"<:-CU*:P;B2%A_*0_ 2C0J&<$\X"5OFR8*S#L
MM;Y)GR<]>#6_$L;F +^R5$+LL"&*S:U D/WBA+Z%0A]A(ETK'PN\%N**8^TU
M\KNC^+PONCXQ.<('\O2<3GR3PXDD&_&8L:#SIY8%(IX\<I.P/@4"GG)W_NTY
M5=&06 UE);GXW$:G#E'WK4TI05G=?EG?&L7B0-H,@P]I.KH%I$Z#OSF= *4[
MB[);6Z6B%DH,ED<(-_%1/T2VC<ZSJ747XG<0E2(MI_[KS[9,N^9%-\9J)9$3
M5OX='GKY"QM<\PGEZO."A!>=>?#6F86.Q0Z]^7LL["S!HWNLWQEK.5^]].](
M;%UVK6JO?2]<!"11^;^V_C'T-'LMG@P57\V%+V<4A@E.T"@_UBIX>$&@Q.GW
MQ,5$#O>1+X3/+EGY-0G9DLH49"E&)MYB'#E\QH%RA PYS:B,VN5[6::5<QM-
M]_5-PZ>"<YO  )1KK!7?<P,:J@^HK71S%^-><7%_>Z:=Q,P6YCD])[3V,+9_
M=6N9OW:K:G9_MROJ1^6PT>%_-5&AKAS\;S+/OO&3&@2/-W[*0(HX_RS;E_=J
M@VZ%WO+["L&&",-52")_4G>RL(5T?Y@SQN+;>7 0^X!NG#Q#"8L(EP>#12KZ
MKY*.X'^5=/S#O?$OBH[_GTLQA!S+[R8W5"+S;'F K+[<X?("M:N_F<.SD%W:
M3-BYHUM(-Z6BR2QB_NSM*IKZ/1Y=H@H6E&\21MOU<)"C*M(:W_RIU(L]F:7Z
M\D,&)#_I"- !$EWACF1@8+ "@7P8&%Q QGT1"V[]'-!H%@D#*W^+6"',9C]3
MG#L_U((R>A-U\/<!M)[P0&0DLK"]@@NOXJ?4QBYHMJJ5J#[CFY/&8&XB.(K2
M>N;%(P4GRLE,$/*A1:C2)S=I0;-S1(Q"RO'@4E@V@"J[9:.?N5%/9T;Q9<S+
M2@1<)+R749M4_T)ND]$X3%[.>"<Z.D-]HQ_)!ZX<Y^>K\_NN9EJ',O8"@,<G
ME\M!#27($NIU&X1NKR$^5RJ3'SOM!F-"G+S%N5%T^(_QL$._Y^$T,7YG8T%@
M5*#@F4-0CDOAQ9E#L$WEU/FF__'F,('%\?G%:T OR\;/9,''?6,?S[ 1=*HO
M$]-9V;51H:&(R%^?%8J%(+,J3%1$X<]NXK$-KVK71QS<ZC8: 3#U KG!M,^Z
M["B]:J%*LV$"<7D95-UO==&\J).^^!^78"%SM7[>O^RVYLVD_YHW^8^E=3F)
M\G0"!\/9^G*7W>G;H(4K(2DUK/KC3V\C)5T&IL]0?BY[2XV5I4$=,9/[70>K
MOXYI#VD&]S6^7Y*5L_5\D0;H9OH%AK(F&G1#)[#?VGZS7>GBA)9#45OOQTYI
MH%279F>$,PG44R Y($C-BLBGD2T9H\&6O)31>;Z%L*!@7$VH'HC5AV\(ER50
MMG+I+Q3#_/C[RMWK041]Q4U H 2TZ-M_S,($6]]CY7_ 232!YX&7Q.UF-TXD
M11?0CRM)D*T:HB9S.3)ZVR2TXUNMGR)-21*:VST-T?X@A"B<P7$OYU'>BNI>
MW1M:)P:#9?.]ZL+D:O0$.YSBO,A&=*9V1?[*Y[?\P G&GM,#L/A1%_7[=H+P
MM>SV&6&.^^QEK$W1)\3&AQ$"+OE,"0B7A+!4^N V)^6$L!3#9S7<KS%54N*Y
M.",UF[0 4]\.T:N\8R>\WUV]KPT==-S\"IN.&I_&>*6X6,HB:EJ[K]R[7^'9
M(?5_7#;/.'+N]-E-DK VN.+=AIV5S]E%@UZ4Y6/3+EL?%@9NYL?^[SH$E$,P
M^#?A:!_AVC_@U<5/4M$UT^XL'/]!=H,^3CU CS*.H\";-4[%F.1ZE-S+%LH#
MAB1ZJE(>6%S?- #"=$![6@)(!(:&V38>("@J=;<N$-NGS)PC44[:1MNE")7B
MCA8:50Y26%157O,M<)N#T((\-LXJSKS1+NY&0]84I<_8)@&7+PX4_2EOCN1A
M<LCW2!B(G/(0,(GIG -V_8(TR0#GCNZ\-C7XW<*,(6JK(UY>&M\?Q*>\4W,,
M=1[W!A*X@>5B$NG5"Y['541_F\Y^2D4<CW")*.!IPB5X\) 5U#!:[/6D,KIF
MN&Y8WK,5J#?9 MM6BY_29)KR:!=$7?-(DY#I29;Y-18[3,A[@/J:*>;E%9T]
M0?H0<K8L_"@ 1ZLV#RRJ>$UN<.&P*ZIFL<"OD$2(_AXKS%=2LMTMBTJ<*ZJD
M!43M8R2/"1/UJR.T'ITAM]O*-ADQ/H[SYNQZ:RA-P&7)!EQ$E&_4%U#@U)<K
M9#EOIV;>8SVO*LX\WK8L* Z+K>G;IF)BD_IAK_SRS1"3AI7*T+8YN$:]A(H]
MP9##)8A735GNVL@)H5 _Y)%80H2<.=M%&9T9'V*L!_BW*IP'O8F"']97.R=N
MNKSA@.M83@=L:'.]%BO^,KQ LZRGKZP'G@!D_""D"I.SF+I;2OT2TOW NII9
M)91GXXQH?7_GBZ;["YS#BE;Q52U/&T&%EPTME"I -'YN;NP;"I< 'X!_G0-A
M$1AH)!(NH+\&+/98@T11Z5+#8-5Y>>^XPCA);S,_03(*$YP.4JT&BQ1E=FR<
MSHC>$=2#Q:.F[K%6YFO*W4L7<Q;%G]]\O-.\]OF+ZS_@-GW9A<S,E3WZST^.
M_GOK.<%RIC%^,8U0^1'BD,6;Y2?_[1[KC %83[2=5$IXR7"/Q<93B+4?G,A=
M1GF/Q1IL_>W$HC. %,,Q;M!F!Q%6Q!WZ!1>^G PCYPQ=*=]49;H B5I"B/OE
M_[(X\ZA!:EWQ[ZF\ U3*YNY?:"B2A &)8L0E&4)9A&]W2E/.D9=)@XWGK*D'
MXI$!6I(X$C+(R\!2R<HV-(1'.7N5R2%MWIUEQ"W*_^98;6 $&%BROKOD*(]M
M!V$QQW-A5U)6TNA_$FHF*VC.Z]IT>7V1I7L(O+2Z,U&MO1;J[.@0>O3_KHC-
M#SM^E:4'WZH65@Y.T<BW+LY%ZY(B>]'(YN8T+=R SKG+E!)CR*Q9*4GO8SH'
MN8WR*87$H9FFZU:SN_'T3UUVW;BPVW:'.(Z?&:9^18/<Q\?&.7,]!+>7G8I+
M)<>#-VUI-N=NGX.#7''^+XH$'DY_<HZ#UDW%&E3$,H9%:8@+G!1V"N!=<W;G
MG['C3]0FFPG+:EZ%5I0FD#.$JK)OVU'V$-JVU7]TEPE-H0V>X(*W[:AR ,%^
MX8I,("C<SY=9W\  CV=/:5I./;L8X6'EP 2$S>H)]YTKQ%R5[L5,C"JB7GC"
M7-$T](8V\-B&3O&:&=_"QH9M\4_U9\ 352V,VMEP;$LJFRT"F6=9'Y\_0=93
M5\_O[/S=^@BTYG30YA#6%P!O^_Y^A,BRNG?'0!QR)FKF9";<QGE0-;&A.*\=
MQLU9E$>T%8K@V5A1IOO%J*&\K<0Q><GII[.VR$D0NQO<)*(WIJFHDSPH\T>_
M?P+<0%Y4W-A2OQ?.1D4VB:1<5P H;,U53?_>C<WF<[ARJ=P6E/$T1LPK*R.=
M,)^&Q7^U%";^ H&<3H5?NY4VS/,[4OK!\UI:,B'3/8.BZ3-J_0X,):6G4<P[
M=!*O6G9RM5;:(XZ9 ,S^LWRQ"I:0-.^ !5@S49=P.KL&33T%+J,"[S3AXNVP
M30UEDG@TZJ/%TVH_WOSF.N2,2MI./;RV% :.QA/ZM<.@)YQMZ86>FM?9%QZ(
MM0%#[4NUC>N067$8DGTGI^WF3.>(,V-+IYKOVR#;157/CJF9P'5(WTHV&\"S
M>U6U#,B&S^&05PPI@,M9(OO +/RN7S]4'JN8RKSFP3'#CQC-LE!NKWJZ.)I2
MO/RMG>: JN3.XX'- +^23,Y/QO2 )8W/?FYLIS,/564XY/RHP((F(E>["SD^
M')5)DQ,?4,*V"]T.MN)$=JE);YK,&\=OB2BC> VF@S;@$;KG&5M<FC4W@92]
MXV?<VQ!#NRU=99%)DTQGT3TOCDPGM;1I$T/?'9.UQ/*DP-\M86?/3]D*O437
MRCRMBC\\&^!V\P"!G$^MEJY^F;&GC1K&%AYNM6V4?T!B,@JYCH")3#^$G66:
M?^IL]%T[?D$5QRFB7T[_C.0<H-6% N079C!XER7&3EX$^Y,%C 7*],TMY/K=
M*?KM"0_GB^GM4913#O,<]C<6YG*#F0XY5J/UKQ0""67+WJ-1M TCUQBM4673
M/+/FA<VRTS<[D(;61/MA75-M?,!E(D1O M208NG9GJ11.C64U.6TBM/OGBZ7
M$2^A:4EF&:@6:&@NXK72'A!1WR[H&$\,YVC_/I7/!)%^7/CT*?&9]F>IHQJ^
MC+YD93VD5I:XWZ3@0#DG9UZ<MEZ_Z18?NN\J-#<<+R6,03F#:4Q+H!E6;$&+
M]D<NG>DQVK]F-V:923_UF-142-7(VJH__[J5I69X.K"C.CQG:.=<T&3,,=1T
MY5\^Y3D]'XO,4@=J.A27%,*5OE9/?J>496J(M@=$%L^3L:I\:#FVH:F@F)N]
MB6AQWV':H=:8TJ8.KVC(,OQ1H ##W"H]JS&SI4*7\ZZGYV:7/(M^*%_.^2P#
MF<:ND5.4ZUE^U6UYRIZ]@<0%%RJ;(?*]"-3XQIJK\WC+RANGA&DW\]<\7<7I
M[%O?Q# BW#?;)[.%/(TG])3*.FS;X\KTD&_*DCU)9_9E-9%E]1?1?VR0"39.
M+/ I,(L$')X*L5=".@-CFY6J_B[]=?$3/$V>@C]>QS?$L(P%1_L\O;R3I2/*
M)93NRIH>M3[' HLS^!@>-:F%^>N\#/'"<TO?L1B\;AZNH'K@)$GR_'1/@U5I
M2UW6?"IE!GE=Y\7G7@ 1-N"HA*_5 TJID'F>3K$2!2!F(^%Y7I[R&)[2Y-/G
M.7>3MR\]L\; 65O7JEL[@]Y?"Q*_,[+M.*&3&U!D\V).L17LS$;\NLHZ*0G\
MYSO6->28:R?@))@#I!:+X^2"TEU/N_3E&MU;?7)WLUF9,YI[@0RHN<?B9IZ[
M_?)^>?G+@_]0?HAN\LGQ>_W%OA^;N\!O17=.U\=@'IJ"'$CM@KR/Q=<.<]2>
M1L?74!HL&D^R*80,E\QM/7_"]F"#^L[/[27Q)!E]A-C)$8OWO]_>QUJ34/5]
M)^CM^?AEC7.!942JK8&BS+(.2^I^BVQI4YNXAX[>G]JL/-EA2,-W*=A^_3I0
MNZ#:MV]^FIG3+SDV>J*1NE="#$="(6DY7>3IB\"VZ(SM;Y .Y;Q2KZ%/%8P?
M.[!7\'P"\2WCU&2RP\G(?3U=Y<UA:_W]UH]9ZFDPDG 64MJWPIN_5BQH0<[V
M$RN_!Z>F+1^"9P])&OYL[P0^T+'KE&H^Y^&*R_M@8:2KLQ^_8A!-Q/9D1,7^
M?;':5YQ"+7U"NC%LW.'^6B4WZLIA[-<<,&(WL7LL]9=N+.WUJ78*:48]W\RL
MR?@A%-9DXHZ,6/6YV)!9^7(7P^D'=!(!7<'A1"X33W(POW%&TS5_=W%>24U>
MFV!=GN#>D<MW*%$&.WQ[+6$F^?UIX_8CS?T/CPU\N&T FQ1#EF9[.^X5T.$D
M9OIPXJ)L1-J77)9Q?+9E9F[N%]?B<4J,2\=N]*PJ%$I:] ]4O+^)?LDP2;I*
M#9V(M_<#U,<H+W+SC@D/:AL_+T#4Z@A;JC>Q,40CY[3B2L#\(&][TN+H&96J
M_+G&D-:%H,-$YL"!S(0D9TL=P\W2!&\]P@1C J A3Z'NQ7B>FYQ'VIMLIU;E
M4QR#\5&OMN4F87--, 9* #@OR<])8117>0!?9HJ5K!%.&>LBMK*=1CCZ.NC6
MP-AM7BBVL6JEV[#RV*,QILK+]$TZ=NRW--.3NGP.+Z_@KQQ5T(FIA9EYK':G
M((?T;;.4#(<$ZK_-8A#FE"?PZDGXK>J:EPHO%*@P<$YX-P5&Q5FT'P-'-II+
MPS1U<BN$&4.=N5AC5,SKXNQ.FN74EDDZE!;7@<J5HP<J+_(FR- 61L;G"]+J
ML- HK;%\9OJ@8=G/(1OD=M%RG#YG-DH8'X,I7="2)VK.6/'1UZ+P-%U9;'R'
MI1JE-?-9A(\!>X/WTF8K9ZS +\H%:H%Y9F,DZW=E4[4HQO.U@(9MV@LDRX"5
MH:LY [\0(R0RNL((T*P4IGB)>\S)=4S1;IX^^#68WZ H%E\W-_ EGT!OQFYQ
M?G0*J[XM*.SF.8QMDV,[@6QH9YL_P&IN HSB8_;0X6-+=IH9IAJ'<2MV($X#
M_8"CLM1H\O;2'99FD$(/<XL"!SMU96[&!,=8MSQV'\8.; 4K89R'(EI,$>TB
MR[P4Z%[>>4 !8V;/9+51B=;4KD!Z$B,$ZE'H3V1ISU]AQ'!ECK]!NEUI$&HX
M,[E[CS7])&=>\OK.Z&8IH\LF5O!/5O7HOQN:6O_'8_;1YA#K'S.R6SJ[VTJL
M@,O0>RQ\AF4$@63]3\*<MSF_0@U/0XK.VQZ<;)#<O(T)BN>[F_GX__ ;-+^X
MU'?PV&2\^@GICK^YL1)_S5<1RI?-_1N96.8/PM(?8+\G?UP%%1W[C-KU6WIP
M_O-??Y2BZ_MBUZ$C[=#YB6/Q[C7QIF4CA^K<I][\G4+,-G!GR#Y&>S3QPQ%'
M!9@=X?9(<ECP6"E-B#H<_,VOIS"L;X@JK8ZY6HGT4/NRO,6 #JK^#F[5X.(0
M-B([W8"8()Y=>G+]\('R=&"P8/X*?Q*^,^+CZ.Q&ZJE9=5T#K[:(<+>Y,XM\
M+,_ ..3T:L'B,]Q=?,-E+LC"FB@]SF3F=,B8&FSX=-.D,WORU1??=;EU7KG=
ME"FY#*8WS%"=Z&I.$X^?-%8AE.D_K+ULA&1! C=/AJVAXA6/[+"7H16BE[?M
M8^\K[^3%0C+LD=#>]-*P_>$@W6UGW8A:IJ2ZVMC.RH*V\(IY[PAUH\5='+?O
M"<VB7#&SA"1-=TN6,)NFML[5,I7XGC&.M,B8Y87H]@KQ-E'<QT].S)H'2;6R
M!86*76I%:#F!99NS;-/:*@FS23YWF0D>ZK](%J"1[X.H8\,A7<:IYW]T54YH
M=GN!%2SU[]B8E1\O?, _Z9T9K73C$^%MX,!KS3.X[,KZ2G40E4@)$I37WT'H
M49MD.)N5DAJ4 -;6Y8R8U9^K$_L6+YYO;0FD;=JJ>3%:F+T'L7/VSZ&(DH[_
M>%R^C!F],WNIN/;.AC]@(Q]8<JYI/ XR#CLMG& +;=]8;;GJAJMGK4^YN864
M?_IF!4$6EAW9N;UCD^WR2*BK2) S&.NC@LX286PV'A5;CS<] YF.O+7OZD^>
M6_H[6VXQS[Q@YB3VPVE:6N9_K>1?Z_3>.X\D[!F#O3EQXMTS!G42QP !M:X6
MF96%#-S.40FQGPENE8 TIKV^>;[722NQQ*TN)2+/TM^ -P]"%P+S]%<'>R%(
MI[D?E[L@]K0A,IE,=O.8B-I&AHP^R\J*'5WJL.R,8DT'ZLM/DK67'YK7IQFG
MLD&3O.PLU7YKSQVJ,%M:Q(_#P0),NXC#*^^Y'%46+R]_&_W$IWQ*I$B@?:J,
MN>XG<&-C8Q\E0Y^VL)AP_L.]9O<3Q0F@N+\'@HLIN3_&_5=S0^=&CA)/C]ZT
M31H9SL;+B=PJ>1"7?M_OZ?KJ.7:H7=1<[AQ@.@*,<'X*3'RAOG&/]4WLFU>O
MOJ_H3 +7IX(_MP<7&0+ T84\(T!Q]$D8&]^FA?;L48/>+KVD]-)Q6'7K\PH7
M(\RK1K#7D#/70&\-,#FRYV>\DA2KLZ#OX;&@#] WHGJ5:*D]4OL,(>J!UPCW
M<YXM+O\XQ.2>;I\2,&7WW=[@IZEG18G31W$ERM'T#$9IBH^:9<E.!WO!/'M6
M8YMA$0_>%.U?#-SV:F($4D#TA8O[HM5=TR6E3=GFX2[U]5^$W1;,J+;FV;4O
MG?Q'2CEQ!% EPA"695@7B[/&,:MZQ44Z-2=><CF=8RC<K& DE82*S2B$ S;3
MF>9ZP]+G5\W:W<6Q@Y%>)" (Z\10V\O_3GGV2OC;!I>H>7:AB-Q4C>$SME_Y
MSJRT#O9O^5+TUEN1>2G8+#Y!'@5!):D@A],3S]@CFFR>*)T7Y$ZR8R,I'@'6
MBIP6FY>&<B):8U&B?51I!M&YX\(<X.>X.ML8.SZ8D3I4_.;\..R3SW("\1]C
MC@?=5EJ!F9\6(O3[=G(^JT;:Z_%MD7'*:I;:KC&3#ZQE+55@O\/%"U<F J"=
M<!-(+;=3O@&^N6&!C=,VX-]JZ4K*1ZPC: <I (6[>GTR)=APH0H2R70=:F,#
M3S7H98QYYO@T"'%&W>*]BZ,T0Y(N[T.?(;.<A=CYN/05%Q*Z*1%XCZ6Q*E@2
MD.F%D+A,X%^J7W"W [&]AJ:+0=WF3A[Y)J._UZSV*,K31Q<"*BU\ZR:46;F@
MW,>AA#'F_;G[5^!$SL:'WYCRGK\F-7WN_^+4X!/T/UH%]+.E5YL%50WU'+,#
M2@I9'[3\>3Z^FN:]$2Y-P>24/"<@8O!M+][!4 V]8OB!9'<^7^?]*R&ACP^%
ME91?0">_>PMO1CP8K8LP/))%4[F^DCJXRV_?(YI7'(3I(6N<3K$LG][)SE#C
M\9PX>*!&.NDNBU_,+E.CH4IW7KO_J[*O#(J#:=8E! WN(5AP3P+!82$$E\4M
MN"^Z!'>6X.X0(-@2'!:"+ 1W=X($9W%8/"P><M^<M\ZI\^.K>^O^F^KIF>KJ
M?IZNJ9KI'LUQ^ .1I>MR_E#FU5;>J3=^X<>CY-(;N7,DH%*T$7OJTM\$Q;K;
M@MZ^][WH48[EFQ5A1>%'E@IYC8A%_&Q^(9)S[ 7AIO8,"^79$IJ":?_S@U3V
M*4R^^,>]^M[@IEJ\* O_M6MD^TEOJW?[*01\W;[8T;KV!^W5F7%-Y;!D)$,[
M\FS]00%A-D^Q^,BV81-HJG0I)=5^?+:,/+@F?M_)?MO3"J'ZS0;9^VW4-7+7
MEKH?U.F_@.B\2>SIK.)N>@#^*W3M7+GR <__%NXCKC'[NZ1O!?_O_A'L?+\G
M(0G%BA^6#PP$4K^D%ON1Y<11I!4?[Y->#J2EA9*T4-G4?/GT+.692H&P2(,]
M3NJ]#?U-UI!D%V<[GNQEJO_4F?[,\D9A53',3^V;7IVN$X4]C95RU"K&MW;-
M:7A\!KNHP67\%VZ:Y DORF.KHM86JEDQNW7"'YI3S?'Z?",Q56Z 1.!(#,R-
M2;39Y/!+7/KUM600TRII&S<#=9\Q2P+N"M%R;WBDA_/[P6+6%P 1V*+>&\6K
M4E[Z-(Y%I1#U4>(K# 0VU&\:6>D UH5[/UL4.VPYS#H\M%ET%!L^9/&H:W[>
M)R](<:HK#R>! 8>BHD-Y:9TB.!#Q93\WXY,'UL1YK#3C975'3AS^WLWX5.NS
M:",@*XB/#>SIAW:##A=P(\M+I#+U<U[J(MO!)C5K?\,2$,L'>D%<F)N/'XD]
MB[2L;]NI=X+0/I<6+4FX=#9I_5WIFF\/Z3JD^?1LE]?E_::B5V^GNL9)?^MU
M3>6"X5T3R"_PR_KF@_]#ZVCZJ<E#H/DCY'_BV1X8*#5!L7R%?$SEI^(^O%"'
M3I[Z/0C_02/%T4>%>_U!B_Y.;::?$D@H>)\W2;!\+Q)"T:G^!RVI>O)<^.G_
MUB>Y^:L/^6]UX?N\3H*EN^M_PH]\=OP'C>PC?T<-RQU!T#\H]'J<>!D.,=!W
MN<GZE([R99]RN0;DT<"1R#YBF)\?I(B[Z?QW_H'P/P<_/2S]N>U\Z9H5U UX
MK=WSGWGDX\?J]?T_:&G_PBF,[H+Z_DN"5-ZOT##_$-&4DDH_XN$J:@=<Z^JA
M1B4[MA?A-Z&[L$V:WDL$45LSO]WL< C;4WR2D"EE@SC_Z24RT8=D28Q5]7^,
M)0SJRG?N>Y-,4]C]5:[RV=$E239A P#Y^Y<@RLEP[7$<(M\Q]J^#?O\OO-?_
M-]Z#(/[+B":S^W\8\I<%JO]*W6O^LF"]II3X?=-!)_ /6@?%,LKE I+SK_61
M4O^!;/^)@/\EN_D>0O';PJ1S$_Q?7GD_4I"SKCROX>/L@AD"3>QQW"_R(B&T
M4-N\*XM0K )":?!]"\)?$58LE+'"H>@"<GEPK73;X*3,8NE!'%N< (1XZC#!
MUO^D/:R.U#G=E1F0D8%;9JK,]E+!QQ2Q>2VYOKA!#JNX'I%J9C:]$3M5'$7!
M0X%V*_[C.*RP/E"4V)1"0>([A>C(1##K-S(%DO';!&@&>]08B&Q_GX5$ !SR
M3YYT?UJ%]\2'0/^80"/#0DC"+?)*UTJC;_," TGD3%).YE0PN)#_=L/O?+BW
MCJIY+'H]ZQ"E+J0=F#(G8H!EE1*PZ?2]/>E8"!4]S:V6UN"^(QL^H9'+B3OB
M[4=2$]-CU;WWBB82S=9B$ZR!F6;38T)DF@S*%0@U&&&+SOJ]>*!Z 8\1ERZ8
MV6$K%2E,ZQQD(JJNW7[%GF9Q[ZA%?B@;E,JZ^*1K]IA>[  '=3O1A/\1:Y"Q
M+9\*GC0UZ\Z,KTM.2B;>^EF$QG;QDS^9Z(]!JN&GCH57FUD4P^%4+@#+IH9C
M(Q^!8J6^ 909X03]V@^/M1SOT5RA4V+(/M>+VJ:UES+BKNS4*[KP6VTQ3V[B
M[Q7.N!4QE/-\E:Y.SJYZ78A3IXJ%ID(#Z),8TB0+RUSB&_U$!>N?PFB^ \5L
M4_#GK'RQ6&[9+Y<RY-A!.0T4#-EIS7Z6PV^*ZZX$#I:L3W$NLQ"_V_D]JBOG
M4J3?H3&P1(;X['Y@^!BKY+O9Z)_8(G/X_-E\$Z4%IYI(. ;4K<4F+3[SJVTA
MUW>M[;;]EC1Y=L-@Y<E++<!S7N?CF\ GU\H^CLDE*-^&MM;\R@\4IC;13$U/
MB#S->8W<N,6,KWXQIZIEQPMTOP*E MH4\V>_BPERRQ=<Y.62X)ANM"MKOT,6
M!V /D'DEO1D1K2YVMV+#-=/C,!0DEP^'YV'K2$A(S==^OV,[]5"G5<+Q20+4
M)-#V&+G-]YI08H1+<R"H@JUG%$S]-R1-TX9GY)8J$KSW,GE"C!'T-5OH2\^W
M32H=UO/3! :IHY?"1].YM)K'0;4\<R?5RG.\.@[A,>HB77MCT4:_<(> NO>Y
MY>9,^V*F'?9Y<ZB19N#6^ *FZBS[O;/C$D=+F@-;<@1,I)9Y);#;./>@4SE9
M7L._8M B2;GO_GG6WL6DM\LWY!']/8(>U'""^VI+#R]^4*C-*N?4]K"H^ B/
MR]U\<6Z'<-1YD$:[KG>9;J7(>=H!;)#N^IJ  _]]LG"?=IYM7]@6VN#".NKU
MYZ!3L]D(_J#"LW@:1LPB.<(]0>:2@R^;^MRN-:)NJ[DO3 #,M6GR?@!6.*EE
M7)4^FCG_-,C4,V'HL>MG4E82E2*1>FGI6V.JR/I(B9L4WQ 2Q!(R2U:4\K7I
MU'Q<R$8YE$YG&L?11E*>M++EC@ /5HE',C=EF]E(N>%ISVD1WZND!X.BKNB%
MM<*R9#[F8$ [\U.\7<WT&_)@CX^^I]V=+L^)T-P%K)L%XPWT:QL7RJ\Y!(E'
MZ1-QKLEL*(X_$58V>[H]_\)8("H.!+WVBVWBXY$-+O$Y>(*+%*Q3I&^D!:RV
MY]X_ DJ@!V";<SJ5^?E<5(#[;W0GO;JT3H,,OF&HK(KIL^S%Q#%0&[,1J>7,
M'C8(]R$G@T+A_:2S:#%BZV<+_?0Q  '..E^_?+BYWBC*5F?9Z6B*EF-MY TB
M'BR[!W?F=BD$2,_K]T0O$TQ=9:F^,**2>XUG-^H-<L@-;V8*#IWFGE]=#'N7
MWD2+)A* S8E<G4R.E>=0(W?&CV@ RG59DH"]30")8<TZ"IIW!Z]:&H6P*S4R
MMV(/P@>WCQM5G)(&HO,+,MA(^[D,(DC#3*,'Z?^@29[07H,UK*<?I1%1N+@;
MTW<5A?'A[O"7F]G\RH6*.LV[L<8E,C)EG$].6@UAUM0.F.!D @RL*--MWT[6
M#TH*1UWI/3D]P>TJ&COG22U,KBX@@Q7V^7815B_/M<OY^6+Z.7MI0C6C^<M/
MN,6?M,:1?FJ:>9G8'N%SL!^.[Y<VP[N HXE.'V<HK+F7L%FZ>1R,YO=#\:]U
MAWM<WXLR/HY+2PNTQWW;MT ]/?W/Y:W;@;<N8 =W9RYP4#E\!//V*D)(1)A>
MKN9:D6 AD$(WF/-#;K37G)NN?EU8<#'PD*;1=EGR%5'ZA;S:I?IGEZ;U>WXY
M1"O$!13CRB\V.=+IRFMYH"38\C!,B0&$DG)*$(3D2E<RI#@IK!7&_JB=E]L9
MR?D)O?\$;O;S#DR;/,EZ5L_DF(T+UWZCPMTO'96WEQ]\>G1B\O/N-MGK\."D
M?K]E1L:&_5OQ,>6#U.!I^GZA;ZYRM)NP?E_#@M&44S)["NF@X5:Y<OIH1<8T
M&G_9K"7'5\0ITB992.2,@C@MMC4RXI&[%R)ZM"8>1'N/RVUVB:VZT"X*^@!7
MD OIKW+*2SHW4532%]'E57GJ.-A"E,VL66H$_*09H]7T[IK>L)RGOSGO35]6
MT1[L-?YGM?@>/ USM0 ?[[WZ(/?%SFB[/($[4&6+K:]3X]HS$H&&BQSG^L^P
M;5PFYZ/MGR9?2+)&T@P;:=#/6)X<0-]7#568?H41**0,,3N5\N*R-SHHG6PF
M:78.4UD3MB Y8\1YH7_0H 4$E-+5.>;TLG6TGR\<G<Q*L[A*6C'7NA/*V ^>
MX.E2;C=N&A$&Z=2NS?"]H4-^I=D\!@^I$[I._$$;VP2LK([;MNG"XXVFJFJF
M?#NUU^ L9/4JN_-]BB?9);C]HZ_==GCGD/O3\K([A-^)V^=MQKZ:$44,Z=0A
MC>S< &39@M#UPQ,F,F__ZV?%%_2I3.=&Y/"31(:\UR4:,="E.K53O<+D#[^=
M=,4#E#8UO?FRT4?C#F4W#UC1A5D2*W ;J&ERC8.SR8A$ZVZW(%)$WG2#(^>H
M/4@(4P43J'>I>>"B-W+)I!3KV OL":D=S1QBSJ4#:G+841$&D#G^OAY/48:'
MR(&NU8XYSNTS"_L56&.+_9>M_>TKAX8_UA?4.#O8N.#,;:].2@:9"D,@K4WT
M00VJMU"LFX6F.Z$4NPWEYL!O]9Y5.XK+_1JR%2D\_A7@'6%DZQ([FU>Z@X^'
M\[0317G.=^CX:4/;\.)5B[5+BB([<1.;Q[A<A964Z2E@^)CZ^.CN%=7S==1J
MK^\1E9EMYU=,/NK'@><\8W)'AF\UE>A'?P(\ $2JHT'RW=_^H*5#[4R_$*)0
MR* O"PO!;53YG[8&!U=IYG*,AK9O&4Q/Q@T6J@.DJ!5%X$9OV_W$NKZS9Q@7
MPOFEO%?2@5LL4;.HK1VG6<>MV"3&FG(K$H]3+79A&SPF7I4E8]I'DZT\"'C+
M2=B+2G65\O6;$2?)*(-I@A@/AN1'"$GRT*7O$H4G!6&YQ>1EB&]KFI\X7?C0
MMI<$V'2CES)U<+.V1-?YA9 )AHN\>\R@8 @7Z$)N$))/N.[ D,=T0;42RR[A
MJD2T2TM([$D]@KOL($K[Q %3#VXEN+,;O?/90\9&6G7[CFJ(-\J]R 0*XXLV
M)\#=.*D=+@MG";0W0+^Y]7G@6[Y-H"6;FRQ;R*!R\L6KOQGP2X#X-5/NV/CL
M[.;- [FK*C"21$TLX1 ]Q@IG$4,;UV*N#'&^YH5].=X,&$#,QKY1)[B(D]J2
M&VM(SJP&? H2'WA<L=J:!)_J5]6!Q4^6>URV"5S$)DYGF_JH=^I<O]OK IE&
M$I@F2>/ZK"XX@.&.BG,1-.;S,]25=K.<&FV9ER<YF2-F,]^ZZ'ZF8N*:AT92
MZ%[Y7[-+_M+PFDQ1.]@^R6UY">/;*H7K$EY(?DK)BV@#Z[6HCS496Y:7VHU<
M"-6BO\2_#= O9\EP#-V*BE,]+*3 41461*:4:2AB[N7<@IFWJOZ@55@N/,C&
M:A?0(:EP:E()+6M:2'WQ@U^J4WUCV%GC8U9W),H2*I%IM!BD<Y[B"1E85I55
M#:2IZI'<._+FC%:@8@>C3M3S?_0'?NEF:V-:,6&;5Q?0\-+9)XO)[D'XCE]3
M.;J'XF:K&(X@VM^U-"Z3EI<G5)JP]@U_O6"($SF15=1E=P4S;\C"!<)FV7 G
M.Z_ Z\OM(O0I9YK_MQ[##(%3=8]?-SOR]@Q_.SYU6MHKL9T[,@DH-]PFZ4O4
M$DI-@@(.K!S=6R['^W/,98NVXV,3T03;,S*[ PV82@*F SZS\KQ[D%ZM$51Q
MYK35S$DV75#P9'AM].-*1/\]"G,[8:R&:Z>>/,,C\%SP8F##B'^/8R6XR/6J
M[&I:L(V^?8A(A1B3QG>9_+ 2@B5LY%_%3^V\AC56\3W2?:*Z8'Q3KSC9>/T5
M[5UJO)%H7C9("$1@9^FE8/\VBRJZ:4)76$FK )+([&W@OAR=R/UAW/UT)T )
MB;*Z.C>5M*[)\E&&VNB;O)^*QR^D&Q+49_^IT_R1 Q/I)ETZDS7VB 37F<7G
M#EDE*N:S3QT88KK-N:/OO&4=%!^F_<$A6G9JGFO)J!0UW9?<@JQIWCTHL4B'
M>>KI/"#=M.OTGO\*RBI*.$E);.Z.J)>2*[0G41^R/.-ZQR=#:V;ZR+$ROT[C
M)&O89Q.[DOO(F4@X]2YA\MS1>YT.:+Y"W"AIFE[[P0M$\0''&<_IP-#Q,$IF
M])<\-J>GNWKV'':R,/I;2T'!:I\7^;DD=1V\+].$Q.M%PKO)>A0D;MR1)+R5
M7;^WY9QGSNSQTADX4B<0CH@W1H(]P';.!LG7<]/@3Y)67K)&MSOIKF^%=O5
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M:F[IZ>WK'QC\.O1M<FIZ9G;NQT_8*GQM?6-S:WMG%WGT^_CD] QU?O&77Q@
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MFFEA7P:9FO8F6PDUF:G\GG>'<$Z[7.E=5\Y>:/3W%R;_4*)(^\WNU'45 1;
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M/0X[:?T61UU20M,6-#],DAIEZ"KPAE_4P=M0?V6/#$SEB^BCW.<4SB")9(^
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M*R<\Y2HFC]5OP^XYZ%+%[C.GU$VN09==ZT0# N&T.S8GA.HC;=/+0ON*>W7
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M*AZC81Q&Y-"YVE818)ZYS]=&BY@UIWIYVRSL/G>DTBZ\%7C6343Y@WY5/OD
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MF<+.@.-6-QJ(]KFA1%"]$SLD=CA=8HL8_7T0]"''(B.[ZM" _2HR$-FUK\"
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MJ0-.;2BQA<?X^0H!X8HWBWM. \,2]D1"1R[ENZ:IT+HUO[Q VN\:-5_Y"]$
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M*-HX=WPE(9+84VD:/>#;$E7C[YJ_71H,MO)HG",^W8"XJ8+<WD;AK;X>NI6
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M6ND7'*7/&.8#2WLMCZ42BLV=_&02EO8\T#:3C^7P%>\!\I5@LH#DB'.K-^O
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MWPE2T(OS5MT!29!7HB0"@2.(F@M]:NLJ&W2\3%P=DS2<H9V4I1^^9CC< Z/
MR3\"4><CB!M0/47#)XM+"@*Q6ZP7N)<D+D576__9-7C^J=JW_\W.2!8ZE']M
MNBS+_?TE<""\-$VGBUII6VMPM$H08N+LWN^6> 59.+ZW\CT&/D;"20'_KJ>&
M8FD:G9;8J3[D\6LXYGZE0K\T,-.]MP L"XC>!A(I>\4ZW//F$.=A+??KRU01
M](8F:R(%G]9VK#0G_.[6Z%PH=GG=(8OT$6@\ER*J@%)K3?,>% TL"5ED3!HW
M/7](M>V;SUJ*BN:'=U3(\"!47\JLAE!],7NQ7&B"$1[>Q,CEV\B0H4)P+&_T
M$[9H1_S:)6,$(OPB!5I?F,^40.Z2:,[QD>G#1%M<CD5B+6#SW-M"W77*F>:Q
MKM*=MWRNQ4^T*[C>L4%>:=7?U!M8?DZ63'!C]MG)[",(Q?V69C83(7NQH4H6
M_O1[N=V'XV6/KBC1K9Z':)M(.R83@<'&QOZ$=-WLV$0:<'+ZS];7R)>2&M/,
MA9/V;TM7-E]="FS7&0JYI)A&+4Q%T ';;HI/">*KD,12&(<K-/:O1%IE17XW
M/LN;0/%-_^+;X]'$=7[,_9V>T 5;.PI&PZ_')K,> 7B@-(/%V@%J]^KB0OD2
M1TW32>VVZ;8Q'@AIN".E.OL9*E]N97MK^#K'X ?TY%V&!,:H=X2K)%D U-JQ
MTS'3H)?_>^27L,4+SV*(AO/W$FP)YXN*"G51L(*6DQMW@Y-XC@E>8YP=YWH^
MSS-I:*%XX^83"E0+DI@/> :@2A=4OK2SI+&/^$CF_RW%3B\!'OB:GW*P!\&%
MVJSN)<<L'^OFS&-)NPMM&]AY6I6%0LJ$ D3M7LW,_"Q(IAOQ5,TS,#'5MW:Y
M?K,^REU#DHNUF#H.8'X'[4X+>)A#:L=[N'G,2)6E37$OT9*DS,C,R,V=:8FZ
MQZNDG66?; !$<Y _H.-E1A<HCHG7X&@J/(!1<\(^A7S#+5L?Y.(!;L0.C9.3
MGO@AXBJ\CP\$\"\YI]T1)V8AD%5:4(_/:I]VRGK]L@.+8?AN%TCX+!7E'5.@
M*'_LF7T$AA2.NQ5>B6[!O78WPQ%#0!JA.,***?GQY%_DZ"4PJ&Z<4=\31$W@
M]4@%YV=R[T5J31'O'G&UOUHLU^@6QMKI2#U@EU$5^CDL7(GX/IP>Q.68^4_0
M(?%[^PMR=6%_+9-K:$5KS],$S^.!2^NFE(T[8^4C=K&+V1F,6S<NO>;??>SR
MLT0]W4=J[RNZ$P] &D&F^L6C!,<9SKK CL&AV<%A_X% Y^]+<!#V2H6'I.R=
MS*9@2.I.*QZ[,@+PWFU?^ XS"/%!)7)_<)0*'!TZ3A>E\6ZE?G2DW[YH^P?W
MS*95%]WNC-W=IQIBQ<T-*?=V9MHTSG? +=(HSJE9..0:F[2/1DX>^2@M?7+)
M95HE'.$HD=R3$<0#O11G\,#,1.].QO?3')"4%,BDX?:09A_I*_&['30S_,.B
M=W0F'2(]*-SW9@07()B='3XLM@$/D#:CY# &D#$\@+P#$\3=>^_&_"#.;,-M
MHI[UQT&/>"K%$U!"_/:8X;_9']A7X>K!](;@@;V6+XB?AWL8CM]>42K%O<C[
M?K<B]1Z%4I5+,A(3YK%_RM%[C^[&\:00;"SHO&GR;5VK9K$^D8I3T.#[9CLA
MP%]/UP[KMG5+.<UN^;^&;V^MH!^2I&N:NBY[6N*!9&9B,/!7I\PI?D2EX& P
M6AQN&O[N3\DNRW;XT=RLV<F)&XZ:NGNFW<A(N9BM>D=<23/)M],U$NAE?$B2
MV0_"K ]&UG&^A&"-?FE?4][!R^YFQ'6B&U%KD1H;)L3_<3CXBA%G6XU_+TVK
M5T^(P]%O%$2@'?# -1,-7/-/^+% :1R*=0][\5@SN%G'UB81?KA0#,XN<Y\_
M=.^$'0I,(*A:#OY/>]\=UM2RM[L0I0I($T1(W *"4I5>@R)-1(IT"+&!% ,B
M(*$&5$"*(""@@'2D@RA-BJ&7+1T$ 04"2"\)-4!(OH5GW_L=][?/]MSO.W??
M?<\Y?\SS\#"SUJS,FO7.^\ZOS(#3'M?'7A.9<>@V*ZAJ%O+'=J3RXA$K1];C
M9EBCT"MZ9. P1O8E/YL^7,#T3Q!^_%^*R:\V/ <U+&?\85/F":3ZRCA2G*X*
M#\\_TG/W:K]K%?+J(L9^C!1Z+^[LTAWOA<3;_2Z]A?_9AET**3UFUN/D6O5E
MS*:F/&H4_B3PT[SA^*;LJ8*>7][E56/U:+7W%PW:!U:!W'-:PZ@\5SWJ,*(R
M(10:Z N9'1;-Q(IQ',\3L@Y!"*E%QMU=5UI()P,!3=?)P(6X,#1.0X PF-JC
MPDEBPRL%A55+( OMZ,\-6\;1".B$T\FI1D:'&PXT>3C5,3A=>DM0RZSSR#4[
M?Z[#K5+.D=G49OIJJ\#)*G ETW(5VV&P&R,<39Y4X7(UODWDJ^38HRI9(=+K
MXM-)+'!ZTD-S=]*A+$(WU4MVD+O2BNY;3@OV+:=]1 =U.1;3 <V7<&XJXZM/
M:]=/=%/^EH87\N]U)0-<!!\G9,D>3*NB/'[3X9E'X4L+QL9QO](Q?;-.[@Z%
MX18K*-NLNMY7 X.R\#TEKN5[,"3!GPRH^+"2 <IO'H:[3HU,.Y2SR81CWQP,
MW=B5.\B !,C81Q9>DX%D\5WP[;=Q1XSXGD!W0R^":-<& U?J$3PER6]'@$2U
M'W8Z"%>#_'*1<A73]AI3)8(8V8Y"-,J7917:[QA763L@G5_E4^]QJ;LYB9^=
MUTAA[QN$8E>VSRB?)0.%]V$[(GFOL]3*>1 FV\4VS(\<"C6'9.N&D.XTY81]
M\\35KO_-3::)E* L<,/LN260 ?52UYAVU7$'+UMB%=S)HCS4^3JW28(AR[U]
M]MQAI&,8-EYT:W#,:55V03TMC^OID\7XT9$18GA2R#0H"QF@ZV=1#\%AZ"+H
M@W+1E@RDAC9""1!T?82=Q3:,#3((JD5P_6-S?;:?8^V[!@15C;W#5N#G5[M&
M8O.Z--9&2-FLB-C>(J1GI+W#?%>+KN>"S=[ 4Y.HDW'IP\8DW2;JTD9T%Z:)
MYR_QNW]52SH"ZE95CL<PG"(X)R&]Y:N^@DJ%O"0?DN"<8*'3]]507&#$#F<U
MJ#;\9XB"FS&8:/SY)6?HV@I>0TO-!?U=+2AX)='=31-,1"885J.D@)@<PN0
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MKJ^R7!_R7T\^HQ::]*I81%QXEWR_=4/R!KO[V>WC*=S15T&ZXI*)[N)1)0-
M!HBF69-%V[0H75*#,WJ6">[CO&JX^?9N3-F<;U*&<9WAJW2KQ*6N@OB:@BQ7
MEV1<XAQBK064/;6G0=5)N.):M#V9C1YG2\;">=B]8_:3TX[AKJ!O!Y- >N!'
M!C:;#Y6'E8SD91=,A! 4"YFUS5K3^2:C- Z4SZ:5/HBWVL7\/)8GG<45[+4,
M3F#?_4RVW?W_)#L9_^A2K8I=:1*C0EUJL>Q35"W4L$9)+<P=UCD<=O_%%48C
MS26K,:UB="7L#+"V0D! &="SMD'@2OKJES0N>-P@*? Q&L?E1#I90WD#[88^
M(RVP9;*:P@3[56W$KZX6ZO[6,/W;-0"X2/W[[K]Y]RE7IE (+5Z]E#$Z9:%X
M%'&9LX6N[DSL<&:$<(KKP8W"^NJ%II\Y)K,:$@&86ZXK=+U)J,?V-^W[3_&#
MQ$?5H)*[7H%9IRY\7]'U./JX.FYI056QV'R^3?C]175U(YIM678QHG !!\G'
MS8G(H4UB;\]59^=O7RJ?\C*H-VF\;ENI=Z]<>FSB-ESM'@SWI@2QO?$1@X.+
M[0LE>B$U4#C +<#%9/\H.$19%K%UFM3>3 :Z<GQ:P LVT4<D0T=F1:Z7]S=&
MMQ;G>-&RGQ>@Y NG5G+(+N"5[<*ZRSE<7]"S,PI]LAO IF]X[8\[SOO'/EU_
M@DQ!?[=)ZJ6W:I_W945W+)099:'"-=[+LG&[7*9X!%UPT6@[>;;%S_-^AQCQ
M% )<6F>?%9'88O=WU3WYV2AFT+@7WB!&I1E@" 86?\DQ88T7(P6#? 6KY;2O
MZ-/T52 @FZ:-:P0E!4@< O@QW[CQWW,W*9.KA" \M4:OXX:(*M:^R>XVY6==
M 2*?GG2_FG +Q;F[%.,F6292>%Z2%B*$#"PR@!VE6?E)E?!<W75J\'3,F]J&
M.I:$S/S\I<IFG:%<]EBS<R(=QA1R )PE3MBBW8/#X"/$%.S\/]W++H)A"!%Y
ME@L[20GCR32Z$WR]?*M.A4_6[Q?G5[0]D3D #_)]#@OTA%&CWGQH3CKVT+1O
M,I8],E[NVO,;FGQ7 ]4A*:3G*0S#?[^OU_]O)3^9W>[< HEQP-7+@^6T&SWM
MDH%&Y\?;8=D"/.\*[ 4IVUT+Z"<&(M+-[&+CRQ^%'37&CS3>*JT0-F(3;/LR
M>*!@+WJ2>N^0-Q0D W%0HI$G#SC3DF\10"%W'@'JM''^EGW^.Z0LCNXVV3_X
MA]9YWWB<"BIFCTW=,.@Z.PY-.F")QAOZ_'=OQ"WZT@&O[Z9P-7?>BMV+^=SQ
MF/+21,V>*4<Z[6O2$F'X^.7L/] U4+%K/)A7#7_9('(SFZCK+4HE[O[5L^\]
M/3  .1</06;A'5/YJY@J>[X"O",G!F*+<%E:_:6['58MQH.2<AN'?=Y))JR<
M5$BC.K=0LA9^KF+>*\HAJUN21Z:!BZ<L(LV\H" F=RE<:N:]%M^J%E^4KH$M
MI;03S;&L* 1!<V-VJQ@9['F@4%=%>CV;!&F:0EULF-82B\NQ/SU]:>0EWDO\
M V1J2ZIO,)G@8#(H2=A GAEL.#>Z%V12Q21O51\R>J?@;L5AERV!R[M3]U.8
M5-+>%2V1 1!)NA-@I,/7]@]#+2>"$'+A#CC^9Q\2;2DS_S6;5*SCPRMV&H?-
M"<J32WJU<8P8IX?'>5X:SB@7EUJ0QL 91OL6G++-3/@4QMB0:<SW-_C7:&#_
M*G62Q^6RA8O[^&X APRM$V2$P CO!!9Z_13HA.*_NSQ]%]V(63\%2N6'G+!F
M/WGS?_KZ%\HG\"<.)E-U^),!??!_>79)8H-N/J?Z#-[@?!HLK%2BZ\U)P"7Y
M0,LP?!T;Q6"/Y> F&0A&S^HDDP$J<?03Z @)%.FITF@B9QU)DJ+W7Z:!3U:8
MVX>1#PNFBM"[UJ]CKB<>)U =2S>CDIOYZI:'_E,^\A_?P%#Y[""'F8[P/C[I
M.@Y2^(Y125/177$9%!:D?/VG@M(_51,&U6:NY;@[T:,H9>Q-#VRY03D.FF1V
M5)('7;VPGH?X/WPM8K^=X"@4SS,6XH:AFZ\T5&:..BV6_ZI,P^<"0RZ<[L%=
MS\.#2)9G 6P;1L!OFQ/_KBT/#I6^PCMN8D<^N$$::_I)/12?&:=V%4\GR7NW
M-E#WEF7_.!!/4W(A [^QF=$ST0L_-_H%>O=KK]F+0/EUMYG1LMD?D* &O'*"
M6\ZI9\*3C,@-!:_@>[5(M1NF:X-S%L]^*)8H;QU*NR8?<\)8]Y&PJ&3105M/
MGU4/=^-XMVK6$]=&X#>-KD?634'4[OS8H,,9+_K2[?8$$[/E9XVRXPNMF?[E
ME#5J)9I7%,!!2+XT\J,Q9%Y?2)\DN)V%[IR<B[)X(</(_7,8E?SZU0YDSX_[
M'CW=M^RF='*47I#8QFI0_-+_FGCD%S7>)!]VSLGW0C;_@ "!P/VD(5)Y<)<&
M$CLNX[7Y?.5B5+27HI7]\'F69?>AI\?> 90M",L!W\A\0GK]&*LD&: CO#6/
M0)0,+-G$UF\MVB&%[S7**-[)68TL3]S('3M2F();:6:B1$4;/;68LW!</%49
M6<S-HODBPGF60F[F4U)_?'C.S0DR$.'+#(%4!>F%-I3%E<NLC<A&R1()C9H!
M0<>#CS6[A  ;O^N4G)5OJ667.O999<0Z<%B+N3A1W.!\7HRN:<WK/E>+#QW7
M>Q5HKM^N<#?XF;>EXZE$9 BP)D8A%DK43INMK&EI) -2R]=#IB>OZ(AV/V6D
M5]<\'N2<Q.#9@1)KXE2&GA_?]2#Q% 9SA,3/,RW>3.6,=7_:FH+GT']=/CJ9
MY;F%JN[B5UST2%#?JY$(MZ58_[UX365)#%ZI--%X]$AQN5?P@'HL:0G/$"5(
MS2]?Q4W,E1V?FBQ$-R2S?9E'4TN.L1#")Y<XJ'HM0E\\LD]X(#&UI =@O>AF
MJ\_GS54:OY#9?)7J8#US<0)6<J5XY2</2N=C\S#Y-42@KD,1J9.9X%N_.0J_
M@#PY?[0\W&V-5_26_E,Y*]-[&IY R(@!X44!BI;H83UQ7.'$P(H/$HO/XHNL
M%HK*[F/%N AVJE/I.HXF8.&>,#:4MO8 5E=$;"D*+9RX*"R'J)WR9?]*XB($
M8VMD-KT"A6HNC2I=:-%V."8Y\TRD[J5>2L0'F+069;GGROMC<R;F @U,3';#
MCVR$LH5OLC0W'.(,BU&>E"4*[N/0W]".8T<0]N:^H<([IU[LY:!C-)%A:?S\
MSQG:6]+\[GDF,@I=2JFN*>TK,)_1>Q<X\.5LI=D436BT?Q2*.U&/FA97!<=+
MYV43<EN:MLJV3,QM4EZ?*'W$Y_R0\T9>L^;!C3OQ;97]WCH%1#W\E6B[R77<
MUZ0X_C3SD>/'[;2W8^>7VA\Z;P=O+.@2K OG6%!;+<ZO\FYU>>3S6@A67+@-
MT?M*Y>M47[+1ILQB/VA>,KJ?W=S&XE.&K=-4M6DLU@RX;/V:> A@GFL"[E=*
M96Z$1SHA<^=U<N'-&=JH[GSUJU$NQ;[ZS=20F/O5,^,6"%@##==2EH-NJ>Y>
MO*-$];#3WMCH#(]STJ>ED'7[OPDCX9.=NY(8ZU7B7M"'-8GR^[*=<LT.K=76
MN=ZJ!(\L,U2T'EXMZ:WC8.1Y]XS"^*<MI2/0RJ<LVSS*-U=&V!?B9,2'AG7<
MW,^H'J3IU>9-/"-XC"^IEB(>/X)@GDUF)9HA\Q?D:P(B DHL(B1TWE16/N'#
M5%A&E&B&W<O&U&=%]^.; #>(.)X*XS'9H5 '8:X)TJY,:MHX_D5=VUG!HA9Z
M8U%U-0H1[FGHRSI8K99)U*C&Z89N<&X$.5#DF-IKW7DM&;GRJ74>(WI^?:GK
MKI"86;]PM<2NNEWE=)$;>]F+?();_HFJ6)63:['.I[ZT^,>,A'N<RNHMI7=B
M)W5'VWNR]8S:54H_NK,L]M,U?$+PJ<^\AV7Y!-OJ-E.8]'X/W#JK;UKCZ88_
MF ZZKG!\FL.9MH@TE;V$Q+_ABSPA?/"-LNE9RI<5P,Y''O<6SXZQ6J1,D[Q;
MO>U.S*ZYT.7B_%"F%^?2GQ;2--/R*D5,&A(=)O9@+?(;7?[";E5P"2W_LH7A
M9^6GF:\Q2;]>ADFPB'?TJ&LH";WM+_*F=<#R*'<9)V@X,>D(WS?.D],2T4X1
M#HZ.X61.JKYULP!0Q>H(-9ZU1SA@" %D@)8G*L>X3$=YF/^S)P\^##\'CT%E
MX @V(Y/H1WU8O[[)"F?89KNGG#Y01B.]'9)\0D[1O5,I;WCV;V_&(%C-48$[
MG?1H^OG[E88%8CMJGS=)7GPHV'SWT\RW$37-$A9&'82?=^L_6%-%3_*H*PCY
MJ#T.;:_RNL[[$X/_F3=+BN$RAW?75+B['DJML)I[&WRLYI@0L1([HHK,RESW
M##'/8&*^3?]5,V=UZF'D&*42(3-C'J)("&;,+$2Y- Z,0ONN5\6/Z)22.K4C
M2H5O.V[#M_7::>K7MUKD2/3R-@_Q;W3HL<LI4@QTRW7+&Z8#3B4%)76/U5E9
MM 1.((5UKZY'8SE"7*%4*"HRH((_58!\-68KLW7V<X.[N!;==D#,,^ZC!R$T
MU)(4GXG2^%LD29Q(4H'/@1&$(TH4:Q4L><>H>-$YN;DR=VWE@7&<N+=DX/PJ
M=1GRTO+$CNPM3NMP+=K+>R;4LVJ>#/\CZ]YYKYMV.69M=MG##>Y(P<:G79RN
MSLM9#_7F/$7C4H<3D!PZ;_M2!)Q#>@\%:VW4^YU9^D%N9'GAR#>:J3W^A_//
MT:Q+ENA1&;_$.C'-<11Y9,R:(Y_TS7AO#C@W+VU8 _$??\ [.C\2%=)0_C>X
M-B.NYSR^=X.C+$<F+O&VX[AS(F/2@_1>;R'L$A5VIKM$1$(G7NW3JME0"_VY
M&5E^E=;6.7.P9PL40L7GYJ[9NI)4J?#,TJM>"6D?]TGW!?-GOT-9C/I=/S#<
M:%HL=1#R6M 2MZ)_'JLY0LU[IO;A XH\0STJ]CC_:OY7HTT>62B$6DEE0+F&
M(I>WYJR/ZJ%6*:65 $6%G+&"S<P4.W=WA]:*I$XYOOVSU,S[]0# B$(=&*<8
M_AVJ2;,L@JTJBQV=YXNG?9H1J9D:TQ_&?@)WGOO&.Y"8FT!H0$(MTP#^*;3O
M"E(8%0)D^J3;Q2<E2NYI7RFI>L-Y8'CB4-39\.33G!/)67:Q7&KQPW;2QIO2
MK?=>CUPL3MMC5V&W_X%?];(BQ?A"U0M'T6K^U [%3BNM6WW7;>X+\ <+16G-
M2'G"&&V?SI*!(?'9'6]/1ZU=EN&4H.CHU9M.5Y-B,M4 O=X2$=X+ 6D]DGDB
MTC)RM]Z6:ZI"[Z88[?P.Q\Z=Y[(.++(=J"QX4KI1Y3/K>-WL"!FH-64VSDZA
M,[=ZDCD;.SVFUG=G?5:K+?Q_34/ZE<.V7*]2>3:S4N?*XR)O?JBH* G78N41
M;V01,@@!@-K:\3\RL<%_KSC#F-_SJ>'V)%<(,1]R:OJJVB.U2D9&FJE?G-V^
M<F'92K;3LYL:J29]VL#6P/2YHF-J3- %)M4KOPS==+7(A'81\P+DI! W?>;<
MX-BUDLCS:_Q14A"7LYWB/&5A3%@EEQ;M7Z:VL4:HV(:(6+U\4FIJP^&MS=@E
M1?TK&?D)5!/51^ZIG'#I#P$&T[)GXTO?UZ1\FA_0D-X:F'.&*K$_.\*$D?+\
MOY:XZ4]?\"^<2L58B!?P5JEV6/ID9CO]6F\%MDCX2'TNQ_0[SAA_.7?*$S>G
M%IJIWQK[!J7:O>?N'=3M0;[OL'^CF"#S-JJSZ7GL#2V^Z/YNZM#"FNSDH6GX
M4<+GD06N*ZE40>Y(MHHD(]:TQSUQO"X755IE%==">G#N#UTC".8Z$S!&E.B*
M>M\=R3(UKB=O55:MCHXWA[D?/C5ND?IEK, 5P>P+93#1>I_0,&PI8V(>LY?9
M660GTJ N17-M\H.!ENGS)QAQ2MF9@3?> N,)NXC'7#9%F00U;_970TWG1FNE
M#CV;/]1G+Q9W_)Q?P9JC(K[73]:)D7"[,4D&QT4(5Q+03C"K/M>>]%.R>;Q"
M@AUEF7@JC<KSYEIG_Q6$NAT9L".UE^ZZ\,(]3L](WCZ#H'2&#'6XR,#HB!P>
M.;I>RD''HJ95A?$9JQD2<E-OZSG5&[=^3APTSV6_D U0^ %S*A#5\61&C4GH
MT.B6YG,RD&G/BCCJSCET5_268$MX>[:]"&OC.:+. )')6E:N]QK2PBSL@?27
MBY>94]>5;2-Q7H+*&\,$Z/E^1:D<5&R]+7K"1#EC<,<5V__5YGA&A*T</)Q)
MO]7Y@4>3;B")N:*[J%JWP-[3VYAC>#E/I#: KEB3XJ1B#-^MKXEK'V<IVTN^
M4%H20$RE9<QT3IF++YW]*%IPHZ9ZX%0@4C$=>?$),TV$;=WXU\JDTH^HD(L)
MFKCDH&K]U"^HKD;=:[T)VMICHL/(5$H=7HDSY7=8F$:=].%).;BN>OG. NE,
M= :EFS.I!EL1RPS;<S6\5D0&#E#E+RA3XCHQ#C>I,C/5KU[1B;49U2AW<*T]
MKI]^INXN4"L[X:<8I!4[#7U$!MC6<TJV)?.\F"3/O])R%55NYOK,RE7!A^PZ
MP?BBR1-<CGC39\T/RMQ_+3$Z+QTIM?=Y5:+-=>2>61ML"7J9D9K=I@^[%9 O
MB=35>M/+^Z#%6"7N=0MO]K,[M(/WSP_+\1Y,C&X[E857>I_J- Z_T%4_D.1&
M!CYUU#RSNJ:7K][$_]P_H'.R\ZY"/##]GK)-$D-)E!V4&^6-44=7"CP5(\D?
M\F2W1B$NA#9 6/LDM>^/QAYM PG/2@RG""$QN;GT-VW^_R[_+G^60DD>^@]0
M2P,$%     @ 6D1L6!;8B/]SO@  .QX! !(   !I;6<Q.#<T,3DR,#=?.2YJ
M<&?LNP54'5^R+]RX0W!W#4YPMV A0(#@'B#(P?7@! ($MT 20G +&H(3W#6X
M'5P2+, ! ASTO)/_O3-S9]ZL[\V=[]VY[ZV78M6B=I_=55W5>]?^[>IN^#Q\
M#;CW2%E-&4!"0@+ B#\ OG[O1 GL\!P -#0 3@  , %4)$D &2'A(1J/HAP
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MGW_XRXC(J%?1,2FIK]/2W[Q]EY&77U!85%SRL?1S36U=?4-C4W-7=T]O7__
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MB-BQK!1O\$5FN!17F05]OC/BU3'J4:>[?4/$=%,*T'.^>'K'M9_Q-;X8YDA
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MQS7'-Z"5LJQ/T.*%P)!26-'>Z8&@N8FBG3-Y6L./3T7J'.*2#>)+FNC\&*V
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MB4K7&T'H=C?9$W/3Q1W(8VIGYYL^27F(JNF)&J/AUHF?\#ABS!A R7NN>.!
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M-GXZ+X=-I>JJT,'IU2J;Z/1N/MSV93V1@3&]R%[SS:+),Z(!25+)?SN0_/M
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M4E>0?\ZM??8.=:YP</^A+'\>=1"C$4Q'\>-2M<_WL8OBRY_/2)TDY33\)M
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M]G6AD538G3(MGH\O4* 0!F.V<1P*AO[1 "<4%88YPX+!6P\P4#U8<WLP?%E
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M-)"I7T.U6D> !AX6@H_WQ5$1GJL)^XMK:$#@:SD:\ C*@@O\9CAP_N%Z]?^
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M*1KZ]>Y!;A# ^P;V!W)5'Y! SN/X'A(H@)<@]&=KK=B30*(,?S:2W&_*V3F
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M$'&#H:DO#U=]OSA/VDO%5[',Y![ R/N%R@%H$A*(7L<SEL(P.36_;#JXX]5
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MF6A3R^0'NSY)(7Y0&P<>Q8]KTC;1)P7)S]^B$J#>\ME<C\EA" HX(QCXEO>
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M$J@3\  A9NXDD"IK9SKN A#]HV]3P?Z(3B/:QB>SII](:C>^!+JF.?3O*&@
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MSJ3K+'!8%_J/TV($+%;M \_7%^^+VOI/#Z>CO 8 :!623X@^='TF(05^9M(
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M:92^.?CKJD*T_N6NNZI9XN97 R_[ FJ,SNM&I0Y,/D;*+2;+*A  *GZGT7^
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M8VU)&H.^)E+ 6Z5$1A*;:16%NO^W8FSJBJ&O?.T6+^-XFOX!!R:IC1-'LDR
M^*8.##4A#$E-RD,E051LWS/[#2N5+-51N'FE5IK>RZ5FE4UE3 EW6*HWRD(P
M;F-.9 R&OM/"\J2_BLZ-AM*AQ81,:R>-EO[ @:4;BH3*E*(9WNM%\80A EA,
M*>R3CKA)A*.9-;T-I+^A-LL1?(S569Z*TRL&N ![P! C(G]1>D*R, .=D]&8
M152E:=S;T\HAG^&!3[8=90J-QE2$F@B5 J!*IPC7J8H2EX(>VEM5LP^'@CTH
M\.M":9E(8J(X:@]9*(E,8T6$#*FS(DT%[UV-DH<^75C?ID>X_=!QT%E2HXA.
MT5QP@A)I0@6R4H>IC&*>1+VM8=#'&))-QMB#W:9C@S?020X@&"F2:JW!FD\3
M)>.8P4;U=6N>R,64/<#)E*DDTQI>CK?7"2-"HE#4N=@)E8$%(70?4O>V<X<;
M34T<:Y<1A]:3$'%,TB0*2:PD"X76+HY[2^)]NF&O!X+$A)E+G /.D,P7T\.3
MCB0C3+-$,L%B^+BO6_D&9E)*77OHF55U =#T=E8N>8&:Z[OR+_7%6WE1?81E
M*?\&6GYM)X!<^:UU!^Z[I3[;)8SOLJ5K3>]U1T,89R83"GKTM7G##$019\0:
M#NH!I1C6WM<M[9T6_DCAY48X%VI.;$K1&VQ3C.CC1,LP3%)K=9SU5KV[)DOD
MX<.S'D<Q8-PF.DLL4=J!^B>Q;I6B@F29X3*S)F;]<RI>;T#]6CBY<(V KK=]
M=GL$1[!,92)DYH!:4F WD1FB3$*)<R+C41A&5/36U=@7']?WE,?8'X>;58XY
M&1(12LQ7,( S1DJB0BY"QPQCM+>Y:UM3Q.\!=UN/1MVHLU4:B\DI49IA0'BH
M8.\S2_!#KBP%!;YWSM9'%32KMG"RH;KM-$ZQ*EM,I,8;T;1B1$58GD8Z%G/I
ME!&]K=7V3./ROZHL_>82-%(3"HL1/A9O/61X?8V.(L)BS9E*:&;[ZY(=@K,>
MR5H(30:<9CF)F$#T2$!V\PBD1$B%4)SI5/4AI: '*Y5$C%K+4\(CAK%L&=Y!
MB<$:8"A'/(W32/6N,,KCN/1"9UV2I#&)-"R2B&-*4F$9B<&F"3/K:!KU5B+U
MU:"XK@K)[\7$7OPNRS]L_6XV,4/PP#TB( V+(N%" HHM,'B8":)4I$D6"R=U
MJ 6+>J?/]CCL?(,GFJD3$7/"$29B+$=,'5&Q#0E--* )V)A.]O:6K*VJN,U-
MLY,SL&2MN:H,SK-T3KN(:ITF@L01AH@X[8@,!7K+G)3"<A[:WH8J#]ZRIR9A
M-EENEPO-,HI58U,@7!DKHM!YI@UW.HG@]_[5WOKF^Y<>U(C>V-UNL8PHXZDE
M/*8IV$.Q(RD7DDC0[I,XE)&6O0L_^_HLX]\:8[H D!FJWW\CI5BK!*.))<"Z
M6.HDBTEF;4:8C,'(T=RR_F8Y;SUSY2M'<CEUQY/I.VM .(TP!1Z'NMSJJ1@5
M@"(A39@CFD>*",-"L">H)DH(R46:2I;TMFI*WU*M>^ $"DTBM$/+D/J$Q@3,
M0QI98F@81EQR9^365<]'4U]8;#A/8A"+&4[>1!F(Q902HV)NLI2G1O06\9Z\
MWOW=%3S<9$WK",@T2V-B*59JMEP0F;B4)$K).+-,A_VKU/R0>O=V1%]"66*Q
M#%RJ4)5V&K!228%N8$:=9F':/P7I7B?S=V;!;XP\^##9=KSHXYP7T%0FG"I%
MXD0+,(M52-(T"T&N)-RD+I':]#8$>+.IYT_3$HJ,B%/F0*D%?B="Z13]<6 8
MT21,HMC8L'_W##Z/$!P54^DHY<0JO$X#"P9)"X*-AXG@- M3E?92L/7ES/UQ
M^(5'QBHG(F*Q8"T8@8!W@AE@GXSQB"9&4-:W77L$P=CD3LREXD=YX;7V1?1'
M*Q;?%;,MW+[0 [D86PNF)OJ5.(A$D6J,S=".B,2J+(P5IL3VC4YZ6D=O93?7
M+A^[:3?7FMY/R[%)%L6,Q%EFP A)*,E<1(F+590Y&V%N<]]VLS<7A2%;\4V=
M)G,0EE0YD@$,$Y%Q0]+,Q"1R2F<VTZ"[]"X\I3\;00FE&\KBC%,;2L8BXCB-
M =\<()TS$8FYB<(DI:#^]_:LI:\NG2%.:/O>)+!08ZXTB 9EB8AM3*1,X04V
MA"= :U;W-EGG-G/5N_SW)@9/A$9_F95Y97+];"N9<VHX:ZXG$(((+/.D-)BP
MSL7:1:E/L._K3O;P4M<-5BBFRF0"N(DD%#0FP?">R!!$-K59:E(5F9CU3D;W
M/<IF$ U;%PV6.0:*/)@, F/$0R#@E(:29$R'7*69YOV]66F@E(>D%*5$HJ(X
M(DF("?;2"I+R-"2)23#H..&4;]T']-466$SH9A3_1&>,)0XL:R>),&#:9<(:
M@I7^1&Q8$LO>HOLM01%>$'\L+?*'-7^3Z*UZ.D6 4S",*4L%T49G1"@#5"DB
M1Q(AJ A386S46X_3F]*:O'XG=3ZZI-;^9FNPG#^XILVF8.M7"1J5MH>GUJZ%
M4'DJ6,1C8SVJ)W.D0",.5* )8QD DZ58;C.RQ(4N2R3E(C6]C;7O0_&6[>R*
MEDIJ!_9)E&(8F62@6*3:$FNL9D(G(MG^S3^/J0_S01]^BEH.9<9R*B0Q>(6\
MP)I0*>6.\(CR4#@%>-*[D^&^>_B&*]*WK@6%&4L8%C7A*26"QH:H6%.\FCLV
MG&62TMZ)P$=+TWB<.%R>9JP)176IQNNO(Y)&\"M83[%('=A/6>^V:)NAJ+U1
M5&0*_0F=@LG # 9(QR35J04NLDRE"C1)U=N"0 /(/B#(,D65C*$[*QVFST01
MR3"P'NQ-SL(X81$=7&5/5XG<(*2P.+0<P1UOE20BH2')9,Q)%F'&A:5X[VQ?
M*67/_&-6U7[=WQ7E>WN^IS4>X\/R?RR+"?RHFUVY=,=TVPI,VHF1I:D^3PT(
M2P:##&\['+@OCV_L%,<*$5&7,,(4&*Q"992D+I+$8HRO SDA9.^$07\B+3;(
M0M8X)^%_1&D%.E.4X%V?641HZ'B:&JY5V+O8H[Z[#[X7^ VCD*E(.T(S@_5D
M>484F$-X#7Q,$T>-3IY0&L=?K',P>5O]-GJ 4K*/D98L8I:%W)(HQ*J,_OXJ
M'E%B1!+)+!).\B<:TS"_4^R!PQK68D#OY0\+HRPT!I@GCAR62V5$)8DB::9=
MK'G*&>WM^<IW5%U@2_52.5/:,D=D1#G62TU &TH=L4I'6F5&R+2W/ORONP<5
MF/7!KD#=9*X^2TRF:$9TECBL\!=B<3]%#(MT%*8\ ^6XKQO4$Z=2#UR#J8OC
MU(01B5B(D16AQ;MA*%%,)PF/69B&O1. 5WEO\\FS]=Z&&J1JS $):0A(:'@(
M6T03T##32').,]&_RM&/>K-F#Y*1M$N<L2PA4>0P-"3.2!:E&>'&*6W2+-1Q
M[ZZ5^"YJ\#T."T=)"O)1"Y*H&,R,A&&Q:9F2*'-IDB8)Y=N/7WL4J_#.1-?'
M0+%0$"HVXA1(F$V$L,2D>.^# E,SLY029^+0Z41DTO36D/E.'4K?,J1G=N:D
M9*1B80&T0@Q'B4( +98)(@T3D;(BY&GO5,.O+<:E]6P\&T%;\Z$^M26V*^TI
M]G9FF^R?I[);FJDX3I0C2AHL(Z[A)\M2DL41J(A,,M[?], GLEN;=!,K90RW
ME,"68=!,DA')I"%<F#@22L0R[>TIW>%,5:#?2;"-Y<A^<%YW6]'NC"W/4>F;
MG.R=E'8C=T]\[W>>N=#&42J J2.58#6YE,@TU20-96*ED5+:K8?P?"VWA-&F
M7$TNE2[),A*'6 Q 4T$4MYJ$-@,V$CI*T]Y:P'=W!#=6E2WG+;"29^'J<S"J
MG@JNV00LWU!*PF.E,=M7$^5L2#+!H]A2(VG6VZ/3.]Y/>W2:E]_5!;6@0"2A
MADUT*?/U  %ZM,'C< ;[&X:)I+W=T[MSWP?G8 .'(YC52G,AM8(2*P4C(LT2
MV'AX@6#,\13S6^+>)I[U-:VXUW$0&S1'N(Y#;< 2L5CQ0806:,>QC$14,,<$
MC6G46P=HC\H^;"D_*E(A*)."8/8:%E?"ZX]#4*^ XTT:)C$7O4TTN6/40V-)
M/G#8 ]W,%94FDSS3(5&"HR4?*H+W$0(3<<-HI$/6W_M[^N?&W62TODE"A2=O
MB5(,;[N@)%,*E-LHS+)4L)C3WCK$OBHDX=VLG.0UR!YH^"[_@C\]F4VR419F
MBDK04C#7!0"-I%F8DLQP([*(9SW65GM]A<#C!.B%(F/68D0>3P ",3$R4SPF
MS!@K7!P*([9N^O?53)L!D_IE^GP\!1:=+\.X41Q_:?N '[L.NB?=[]C#%;U5
M_W3UI=YF=?D*'WQM7W@F7%TSMN;A5_:(Q\2VN>.D^N#VP$H'V^HMWGE;5OX$
M>OXRDY_!/BYW\7X&S3'8;GT\>57@_32O/A^^O6DXE[Z/'[ZUDV*<3Z[J]J[3
M7.GBY>KH;UZ-PX:?+RUP4P^V>?BU"WSX]G)W=UN?7W[*O[PJ[<@[3:K3?!J,
M\LD?GXK1*O/A%W:+\N0E"T/^LH3'+['=BP#,L_+FQFV+ET[JFKBBJ"=%;5\$
M=?')NNKG%^_>'QTK%FMJ(T4L0SF@-!Y<)9)(4'=C;2S56?0B<&4Q;K]SS"A+
MTU!QE.R&""I :%"9D-A%FFL6J53RX-TQ7D@6)1F'CA,LO9ZE1.'%5S1C"FSD
MU,I,0+/(4&JECD&]CF/,B,621DIC=:XPHS1,,HO-4I;&SF%!1PTMA$@X 7M;
M$&<%%NQ2^'+8AY=K*]I]4A6S4MNJ^?742N.A"HCFE_\5!#_!OT%57^!2 EV1
M4YN?G-:OPMTHG[Q^L=1NVK5210D]D+J8OF*[+)K6@2EF:F1?3R6(F\F)?T*G
M]6L'($2J_%_V%0WAU[$L3^ %^#1LGCDYSD>@E8-\JX+W]CSX5(SEI&NHBKHN
MQM 6D8S(47XR>36RKL9155,YZ<9S?@I<3BKTQ[R:EI:<EW*Z_.YN)->]#5YU
MGIOZ])7+:^*!<X+O^-__!IOP^J>7^"I8ANGJ(FQA;FB V')]=KH8%>6K?PO]
MG]?7S_6\V3=5C,SRY*-OG/WG]P='^V^#PZ.]H_W#[W41#O???/YT<'2P?QCL
MO7\;[/_WFS_OO?_3?O#FP^^_'QP>'GQX_]17)OS&E?G;WN&?#][_Z>C#^YW@
M[9N A9'(KEN+=D[(NJ]$^!]SF&@GN4FD:*&I^WT7P:DJ1KGI6I9^%7 4MZ[L
M+;#"'QA6XMO>]T1XZMV'3[\'W?27Q_,5?;_PRL.DF'@E*]=>&WEW[%B2VCBR
M1'.0MT(P05(3A232CD?4\B2*0)JWJC$(=&^IQY&PJ61$V3@!2ST%X9]&()!%
MJ,(P";F2_$4PD6@3X,GRVT+[(' TA?NQH#0D?YV3T\JR_#)P9$\Y\BHUYG[D
MDW[CY'_ 7/K@P\3^N+8 M025;DWEP^$ G>!<\"D9R8MB5D./7ZQYW?1.PW 7
M]K+]@D9;:UK95Y6=2K"&++P1.H?>RZ[KL[S*E2\M]ZIKW3:"5F:^];YS\1^O
M7[R\YED6SQ_^]+(NUU_3JK6X3.<P-J)**_]XY?\F^,'5"WYY(&>VK/& KMU(
MH /<QVW*_:MH977?KX'#6(8A]3>AT BO\P:0DYD%='0F%3H4(1@2FX+#O<ED
M)D>?[+0H:S"8BG(LZY]?Y#")RFJ@U6*DY&A4U*KXL@&ROYZ3LT3$KV]'0Z 0
M\^U;FVYQ9S>Y''OOWW_>^RWXM/_QPZ>CX./G3X>?]]X?!4<? E!LCT![#2@/
M/GP*:/2#^3'X\"XX^O-^L*3SSO7=O3='^)AF7%RUB!V_P;\("T]4H_E6!'U7
ME$%]:@.75T \P86596#QT.(6+>>V]UW'U1&WCH'03V7*B0!KGJA(2)*)5$:Q
M5$92MRFN_NB=BON-JW&%K5]AT0PRAK><XM>(D1<$9T[LI!>;\M;JQG?.Z<YV
M]D'BK>6*A;"<D28 IA')%&B<+(JMB+A.TG!C^_#.D];?87W?P2=5+U88G?>W
M >W=M-%-(02V[BE&?/@T:%?/3;MB$4_ IB2Q2O F!<WPFGK,"HQ2:V)M=&PW
M9FR6<E+Y@[Q>:%ABT+#:Y3CZM/?^\,"K4H.6]2!:5CUGA: Y\O2G,\'Q57^"
MNKCZP=/WOGVKWQ83S/(*8PF"=SE((.!<T))>W>:0N^UUUV D2Q* -<=(:")#
M!%<)R223Q'&>&%!:8YJD]\7()LL#)]/,I1_K#)8WX1G/DL$S][0\<U?/;^E5
MWV@NJ"S!DG"<)-H)(@RS)(T$UMDUCE,;"Q/'FV&%3_8DKQ F:PQ^W"P[?"MZ
M'[S_\#]__WT_^/CGO4^_[^T$!^_?[&[,2NC5B=HW^V'WOTA=^\T,"A>4\TT,
M9!544ZLQPL@$^23(ZRK0I[*$H:_[; <8Z<=)_C=$*6QT;BO6Y3(MR%E=O-Z<
MN;FRP[[O>QF@47B#!;KT<',6Z.4]N\5D:79[VT;I;4+H!K,T35@L0A 2&<6@
M5F5BDH8T)9F(8J&2Q)G$;$;.8.Y#.2V:K#<?8^?+NY87;PIC+UNH%;; VF78
MST:\A-?[_D82,R$W8Z3V?L>SS H1QI1H8T"?D#&&F<>2I))FTH4BM))M9L>/
MY)>#-MBUN91I8QKW=5O)84(A$Q%+OV(S;X"'Y#'A(>F=VG*M,N+9.0"3N\#J
M"<$_EC*70#M97O0-SW,WB;;EQ;UNLODRCODYER=RDO_+__[C)M'B"1' P>ZG
MW</=8'\\'147MOQ)E2]_6>7]X'VQ>^7J/!7I?*O&M16TEHEC-,+:3CJV8 =2
MO,<CSDAL0#Q'@FHEZ6;0>L^8TE95^\]O^<32;2(UH\'A#*L7!8=U:6U]"V!O
MUN*Z;E1W.?N[;J-"'4F=4D*Y@(W22A.IM2%6:ZLL52DU?%L;Q;:X48<S^'8@
MPO .$K6G&D_H4A4F2A#I_-:(D,@LXB1R<1QS21-FU4:WY@W\^*$\*LZWJ;;^
M6E1U,7GJ;!/'@C+A8%O","8"+SE->6Q(%*<,-5&5:KG1O?&JRH?R(U@6(,D?
MU?#X75:5U*>SRM9UU8N-#)Z;L4/3Q'!J(V)9J(BPAI-,A8(817E&XS!2D=XH
M>7T$KI2C_\FGWJK='NV$C-&[0/)@Y&Q,QVUW&-VMTQ*P(Y_*46"_6.W+T<+'
M6.:E^EXM "#Y &G^1AW_*\^B-SS?Y^(N[M,YQ.+TZ'__6\IH\KH*:CNRT]-B
M8H.)]_?L!, LHQD>* 02P 7@UMBKCY ?Z2QE*P%_J;9&9S8E-LM LY%"$Z4C
M093*N'"I#86]=\ ?*II[L*0;$C;W7\HTNNT$^_''^.-V CR53#*5"+P%E0N"
MECF129@2K8Q3+$YURK/[[K>O"_01>6L+P0O?NIZ<XPV]X@[:R'#F^(U"Q(\J
MGZ!#[978C3C_CQO6YAZ.JO[D&2WJKK9GV[:T)IC.RFJ&A]QU$4 +[U>D[ ?U
M(RIE&.ZUI^M7_4&:X &5@L<^0W[.<^MC]#7/;CC\IC<\8S>=FM_TQ:4W/KXU
M>3VD/W5+ZBBO1SZFQTI]&F@L^O]M)N6U2Q3\F_-_0OXHBW7E\MR9'S>Q $^?
M1DKIS:G#BS&T^^%;G0X#A3Q;"GG?!@9Z$+%?]"G>:A: N@3=PB<+G:IGSL('
M2.&YS9V<7.].CB)**4\M49&31%@\K:#4$)%&H<NXXI3?.W:FU7PO*%->%'P]
MD=P4S%]@1X7^8R< )20XPVK P;^#FA*&%!,D E]0[ $BH9X)@/275/'&=T59
M0A*94B+")",*[[EU+F.I82Y)[A_8UXJA1@IMCDX/WO_/WP<2?/HDF' 69DF$
MIVW*ISP#;E(3$L&H2S+I.'/W]HAU:+G?BCB?PW#I3!<%X+<>YUXO82LC_QG\
M:50H.0H.[<CJ.L#J*+?&LMSY9&39[1/M\IO=/D_6NOY>CDJ^RJ5U<J5+J_<K
M=J\%>E],[. M_CZ\Q?<BE(.)P:A2&ZB+0)]:_4<PQJI4><,P2[E0>17(X-R.
M1N2/27$.@[2R B(S\*":X<FDK )C73YI4J4^S488ZA9UK+?$L<"%N\'?X8<V
MHWT[9T@\51'SMZ&$"D,^4_@IB?&ZHT0;O)095+C-A*O\#1;EK[@FA^V2'/@5
M6=M-O]D^A1HEZJO9%$P$+2O[^F'PX#Z>_'N]N=C"(>;]3A+62U4-+'\]RT^*
M.L ;<'*4KR!6'6:NE[X21G6UO.48Q]\47%A(W=W@ 1C>QG&444>HM&"E::N)
M5%R3*$[2-,("E-F&PKO_JQC-)K4L?>I[N5X3:&#T@=%[S>CGI]:G%JUQ^P_T
MQ^ 4A#BRN GD:#3G\V4 4+9M 'W>P/-+XKXS)Q$'\#$660G,#._)\DUAPMIZ
M%SQE@2]K5@4_0'_ /4$UTZ=!=5I@QG57=*0^E?7ZV,]E=1FF_)?;.?P(^LG$
M!#^P9HX*S%=XKOZ!AB:T]TWA2SB*MA]_HY<?A!^DK.H@"P,C+ZK=P#L3MH%A
M@K%(92XE.N: 1U(KDLE0DR2,%!>QBT44;@;#WLS*$F;8%#5"QU,MZV\N;W8O
M*OV[W4; ]OV0HX,.W.CW11"LUUX:D.0F)$$. ^8:XYV;)O#>G+*8H+MM=!'8
M,UM>! =HX4GMHWW?REHV)7'6@&;1Q[*FL6Q9?+(GL^;2A>"0' 4_H#&7O&:<
M[<Y-C]R7;)ABR89MHTXSWCF8V.K'+4(%C30+8\&)"S.P:J2A1,76D4@R)I5S
M46(WE.VQM%>X52UR/!)4!+W#B@$J[@$5WJLP@FG80&H-4('1/,9S#[H4)E=^
M"E;)A%SQH!H#PL [RDZH ?F/8?X7.ZB?0&<@U''!3H*3LCBO3[O'NZ"N6#\R
M[\#P)<Y\;@+&8;/P]77C\X_IZZ[9K0VN'U_7$'64MO$U8^U:=BX6RA1AG=:U
MK&KM/KJC<RB[<FOD&8T  I*;@LAV;PPCVV793;%K4;2;I3<U8##;I?JB7QG]
MMILE=XICH^'NPY4GS1ZW?N5U5/O;U1BRL;*=/9WVUV9!/KD)7A;WSW*:P;/?
MR+V!-9_9!&]@S1N$%=^-'TQ6\8<.._C&H!G8!'SR\POV8ICC,,>^SO$&KLX>
MC*<?J#Q^=GVLF%(BX2&+"&..$Y&)E,@H5B04*7SJ'%/LWMFR^_/2S^4;$)DG
M17EQ1:B8;^2%J6X;;31J["HOP+;+X_=4UGT?PCP>].PG/\/#ZYQ@SWWBF]O9
MQQ<QAJ<L%C0E7',0,5&8$L4R2A)!$Q71) G=O:_[;$2,)Y=?9U4^L56U\<M7
M-G>;W56ZQV!$W(?*AWD-\QKF-<SK&<ZK%X;J-M6DQ]S_85[#O)[[O.ZAVNY?
M'5?P)*;]F-OY^$:7Y"JU,N)$1GC;A(TSDB;*$6L=95G&$VXW%.#>T<B?/(F\
M:2CD"1A?#U43LS=IGE\53?8H5WG>+Y;,W1"UA;4P[YC(@@&I/@S5&I_14A?!
MK&HBOF"6S8WA5]QN693^7:,+?/EY#J^&UP83&':!_JNSO/)>YXF<Z%R.,+@#
M;^'!QE4M)T:6I@JP^G5NKDM.Y3_('Z\,WMI.S&@F4N="RDFJA"$B#BF1(A7$
M61>SB*4NSC94O7W_R^+BW.8J\^U<G'LO\KKSC;H]X;G^0\SS#UA=RI!I7=A8
M"0CC-F5=6RQXCXP-/(YW!<)KY8G/))E7])559:L*/^KXWCIG?7#UI*V(C=_,
M,:!R J""XRR+45" HK*$-0OO^0RVIIPCB@C%4@G'0UDJ"=V2#U]&]L(GX/Q
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ML,S&D]<FKZ8C>?$*GZZ7NPYWH[QY7QN!VWSPCUE5Y^ZB>[7_*@'>APW_@G/
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M69#F#@I+6.R=EBHG9H;&A_-,AEH>JOFWX-%5K'P=(BUX9OD%'63<\J(.FU;
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M[#SJZ?P4C$#L"^V3TILH=>T3K-&FL.6XVNF\FMX0;)TUZ-.UL!0[C06,MCB
ME&W"_4H8NW=-S<JYE=0F6YS943'U40T &R>E''O'T))3]G)XLW7 ^8T#Z03-
MS,"7!F_<RDU_RUZ.JY(=6Y^'K^^W<$)AX0)T2E_=#XP=R![,_Z<"*=NJ-#U
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MH=N8M7R$HZ.T&(6$\X63P4-<A5X"U]_>?$.CR6 )C"O2L$T^9(D>9EXB>DB
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M/=IUC>1Z:FN7U2;CQ#LW$)[%N=+M@NG_@W9EG&Z*&N0V(/.,DR7<;;XLZ!_
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M(ED8I:UO[Y;:$BK;=?MYY@SYME7K3IMRVR$K5G>I%3TU7A5LN,(\>*\J;TE
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M.#N.' %I)-OM?CCB1JAE=]NSQ]T*VWTGXGX#25#"- GPX"&9^]??RI6/R@)
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M4HL[605SWW%68?C3#J(U2&4Z0F\.C.G4_)R[>G=<#QYUSL0HF^S!]GK7$BM
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MQ[9H/5]K(,BM48YG:$/LRH0;]MP!K5.AF#"5+Z+ 0#X&0SPY:[O911A%'TS
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MP980DK$I5,<>1RW4QDUZJP14&]/W62DF>@*DV]%@^8$A/R8NI[=6)D)^"#+
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M/T-Y?,8X)#)@9BA_X\IHS+!-6]3L4XLB'(4*CECO) 7'408C!ILM!3.N1YH
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M=55NBEMTJNV>SLB_0#S,..R^4.CJ,ZX,CN@!U4$(!VN>B\FE-D$G<Q4EK06
MQOTH+J>'%)%0+WQ*;"@1$T*BO@8IIZ;Q/*M>B16]3XC(-!J(Q48/=TH.!^-
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MDZ"?WI$[P78W^9;_AY("8#:48]*VJ')]:#C5<3]-%I$&0+*2OHM+2((> >1
MB%JH);3?)H>IPY$^=!:CPJ%^5HHZ6[G!+RE<5Z!RY'0$E:,KR#I+-U\B/XW7
MQ4P@7O(X;FPL*CP8.6'OE&5T5&=R[?W/V$Z*:XH>DB(BGNA<' E0:.\?RPU7
MC]ZE=-T9_<+/5BCIDT4?W9?N(NYO/JW_^<!R#I4MB&!N]"KR^56-\@^STF],
M/%FE.-O=DC:JK:NT[L.N0]=" 7^U-/N\^1[)_P>")?UBH3*G@2,QDQ/P'L6U
M,U& E"K.7:R4=;?@<!<[=/XFX/''5Q,/>YOK=)'Q@>>OOIYKT @&.> $I_\$
MI#, ?Z&6 3L/ 9&L.[X=KIG8[OG 40*H\7-YG_*F%[*O822Z%JG44,B\JG7R
M'?+G_!Y717X5C4\*C["9C@BNU B!'A(=!;Q:O"3-D>2C\KE,0)HP37(<D8*+
M[&+*C93+^KJSE=J*T(BZ<!T=)< I)..U;_ETB"<^@X4-+6(4"OU&X( G:LUT
M'O?-4$OLYK/G9'F<G0:97SW%39FXK/O\HP'0.[>FS  M PMX5:\2_O(P6QNE
MC*=[C6HCLG?H,NDZ<*7Q;+@0K=V'W:LUU&88.-#4-\3(O HIB2L+KBB_K_=T
M7^>MY+2:LHOIO9+;X>KK=8HOMM:<L=8)MMC>J0\8#\=5?S5HU9H3@E5^S8RP
M$?TA.51N([';B&B%:U> [THAXMAZM-,XO&?VX$AQ[Q//E;;J\(S4XP>-677Y
MY39(V[5H99Z^Q)PV4V_2#::,6-INP05MB\@KL6LDW;5G%%//3-(%,>U<%>06
M9.QN0^.7;]OH5WQ2?8R[RICI.LSX')EPK?QN3X17 V:J43$NPCE1BN8+4Z,K
M8#8E0#UVBV9^Z,5T[_+F59V\;W0]]%J#8-&1DM!&?[+8<2LBO$(+<; KZK[-
MPT^B^8N1(?X3=W'U'K#4OFU*2G$#X%F"NP49MBQ:'8Q?W35X4?IZI9U+QAT$
MZYR&+4DZ&1Y1NG3B&^^$,.XU^R?Y@5SB/XIFI4M82BR5]VW(K"*<:6C50/MH
ME?MCTW';MG_S]Z=#/"**/C>BZ&Q$%(V(HM^6Q0=/^=CGT>9P?Y6_-:]_9%&>
M^/2N#QM*$;VO''*R3T0_S&"KX#69V^XND8GKD6N^^)ORG!M>^*LO\\*O95%.
MZ]7\\_0*+R#?3)LPO]\9Z)>%&;M<3W=-BR#VM^PRG_T&'G*S\X/#ZO@2@))
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MVM*?I5?$3:&C55U_#&1DVIG]4#! C6*ODSO$+@J3<GR6W+%R-9/#9U) *SU
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MH.'N0+D0HLBJ=(M(Y:.#78DX;Q%CPGF=N6]V=WGG%9*!\4KD4@[5">]A;/
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M9$DB+1A /A;'Z9Q%F 4"VZ_M6+)%C@DH],(ZH329K@Z])=<0]$M2U595K?H
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M)M"*/QRQCEK()2AK0%7P'?&V+PJ-\N .\/OV[F<<0/@R$\]\<Q0=P$6$#'O
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MFH$#_RANX#MQ W#8DFDU7-G=HCQ'CX;RC%GZ2?&-] B*RGV6D:ID0<E''W(
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M/3_,-(]U],^CFC\[/OOZU1>CFC\[?GGVXN79\Z=G3Y^?O#A[>OKR7YEJ?HA
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MD<7R-K9*96/!4W+-A5IIW ,/X;)2;GB,QW>I+0]-]D0PK?C-Q'?:9 8:(^O
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M$['1EL K(B%#./ PSY1C'9%T[HHAO(/<*(' ?M1HO*<[X4\!+Q@1D14<,IT
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M[LGIB.THR/9R=U<%4E2DR2_FR62L*Z&$\@=="H9LA!SAK)7)( N*?G4&Z2I
M5!&AA=);8"BC;=( W#X;+SUA? D[U4L$>KX\"WIV%):(;E*2Q--FU%4+]-;B
MCV@$8_V.73^&1TR'X<>6VQ/X6' YN_)$%_+OL&'4]K1_GGW5@;FWHN$:OQ(O
MG'8HX)%,AH91JB [,!117;V-^\1=V^XE1=N][YS:BH5[QM7H1*$)RZ;VE]P)
M(\PQSTH(6#-,FAM*\M'1398=Y^.W72GCLI=X.!]"PHK!FDROP5GA!.,O0Q#Q
MT^&VY3'QFH:6XM*H>(#"1B!(WYE&8I:9.GJU8O[[S/09'D).F&(T/!BU;S]5
MJH".F\W7M WSD\&T12NK<!_OBR<]$DA_%&64I;5YSV%@/KI*FS*/8=DRE+TE
MNV>^#)J=I=VHV? L*4]N"(K07A1^Y]DA'GMQE]Z3S::<JU#OM4DBEQ_W*KFE
M%%SP[.^^I2^5F'?E$6J;5ID.[]I(-CHT-.6OMT]=F4<V5#$<S&DT*#'=$:D4
M75,'Q](S=KP<%B&273O>8@"RKLMMRYMG$1?)#D4MWO'9AKKV7$(@O>PZ(-19
MPXN@I'UP/ O14IGBBFQJ"W@^<Y#L[^/.'M<8 >U;Y4CH K%8]6V=<QAQ7*!/
MJ/JW:$K8[2P/(M]L_A*-#D: D9Y:B!#33D-X)F^-4C^N!'#O)8^/0*=V/-K,
M(-C&1O:5IK)YJ;/**]+SN9&>GZY(SX\>Z?E+1,_711"O*=-'?\_\\ZK]/A-^
M3Z-!$)'778ZS.9[H6QQLSB8)R!%K-+"&P2\V#'[<E#QMX&6+2:-Q3YG&]@>E
M4,81['SQ]V^^^=03[$1K^F+L8@I/9ODF1N3[LGCOT\QX?.PTB0%E<OSM(X<7
M;:S';L-FFYG C3F/F.1_1H8\2)3UR(JUJ6,*=6,"40]W%+_Y1?P."_B::\B*
M.EPEHD/&9-@-3ELMID=41)/[P@D4+V=")&#1X@-EU>D"D?. EFKV6#IF'H@K
MDWES0G=/7 <T4XF8<5OV%7O!A;$[>5C_N/GNIK G1 $=\]P@>">/=Y),B/5
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MJ$F,C.;XC"Y6>I_E[2V(QH8@_,\E6.'07*OV09GKL?C=*50TW$L%*1S4I!=
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M5:BA\[]$N[J@6?!F+TMXT'&V=UCG6BG'*KU"XLGL5FAY;AXP1,>JSCJ- 89
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M33D5F\9</94J1%QYFNR\9E4$9(0-@8QKMH,L.V+61UZY.EZ&E;TW]3\#TG<
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M-=2:P*5M*H3[PQ2S@SRZTJ%22G.40.O9BF?1#EOOG.$MB)_'S^VKGB*_)7$
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M5/:Z" #U;)A;;IA+"2LX.H)6%>7\(U??Z[QM23I$2A471'C-U,L7C%6PW,Z
M+L9C*>]4+$3SH?3R3=\.1;!Q\]RTHVLW=PG1HN0?K!-ZP#^O,AE%!<HUS3VG
M?($#GYZBA/3/R@9:?J09VVSSLAWS  @@TL/47(;"0\^&/#B>E(!KR%,4*(G
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MN1&_ZIA5S;X+U//X_B).K+<_C-*>'-"Z6!5**8".#+[E%/UK&M*WD>5624R
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MBXY!Y] YN(HS>L0L'Q:%V3M8Y1V]2'TP=\CPRV/Z@1@7R$ED&[LM_J%2[6L
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MEEO.EP7D3"!NU-T2PIN2VC]G^7MYP];[B?8B 7$(>PWEN3"<R$- -'4"4>-
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M^CFN'UX_UJ51E/_;MP7+<QX7QW%QT$#+^A]]'?'Y:EDZ(S->EM<E,ZBVY09
M0(/@G\ZMHH<$+GH39J7*VQ0+QH*B M&=(=\RE9IO^[;9D@SN+[71CUXUU:H0
M+3#G3R:RW:6C)!V@BT@[B91!T=_E"EQ.V5X&-^CNFJ)G9/1N7N%RX$/B9:"@
M-ND7%FCAWT8HN?$S1G)- YYOB4$Z7S;7Y659*36UM'X:P^."U'QCLSYQ S.
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M*29C\4JLXYN>8 %UX5>S7*0;,J/9*I7UZ)9KEJQ7DTL$G3I:/<2'^>7TS>F
ME%C\._K]#WVXX^*-6&-V*W]XDR4N%, ,7)X3"]\Y((5FW9@#.*]87\)#44:
M"P=9@7]7D#1!V)173;<ET(\J6]R$"!'*E$Q*2HA&57,M"$E-+EFU2E5YG19&
MN:'9 3<]WG68+,*N"MHWHB,NVR:<C5)"Y5SB95Z+>W@T 4<3H!W!FLB>8*=F
M$MUU#@F6S;;@!$>2VE9XDM'&,XXG/-:R\,)>6)WQ/U$!LO)5M0>*S\9P7)['
MY2G+DU3HFTOB@NT,G#_&F&HPR]])X3. @,8B95J905%2.U8@W9SR+HXP<'*-
M8+>;ZAKF/9X 4_5+$=B&/2>RZE@0I2-WA ;T:0<D#@CD 09F/5<T6>&F YM)
MH>[235+T.QRA(LA<=!,]#,/O$F*GV[G$9WA&RM0D^DA>7ER[.,)96EQ3)7GP
M-?R#FCKZZA*'K:1PQ@5M"#Y(Y9A/>WH:F@5R%08.1/0&;CO0QQ)T_M@>I#'2
M-^\D-[O?US=X-$G_-TU2)VUOMZ--YSJ2>!'^HV_+;E4J1B9N?-?TY=WP51$V
M?L7:DA0!"BY6-,=7R:J?I+&'V"2--"7VEP0EPT(D1XGV1[$TXA"@Q\JV6[2Y
M=(GOT1U3+5[DNYQ4/]2!>&W38:"^[U^\>CU,P+IV-&W&&?&:DL28=TN8UI3K
MV"(XFBB$>*A1U2P/](@]BC,O=H$N]OC8XAEN^4U!Z"O#*E*M>46L\&OI@;.%
M3Y_6X;2D\*8S# VG_"AS;G4K;75;%^3S70 !?QW6-04MF6 /PJKH2G1JTLG6
M-9M"&T@-J>Y\R2GQK1#TA.5"?: <O'II0BK(T=KE/K\?^<*Q^XDQ7DU?KP1Q
M%E9- CN*"EC\^,.V+M%1'.'(1D!\<SSZ.;&? Z [^ *CON0L-LD(U4^8^*I'
MD0$0*BY>DN87^FAK/\#!J0CX:W88_YK1'@YFK!%8FBZ%8$7(6"GP#ANZ=^VE
MZ91G.J>W*O_]'VUG>P"6Y%MH<(X$PM)-/=TOPXNV,,%/U^P=\QVWG<;X+;OM
MJ;8Z24*2'9BP/(FS[@4P5<]'VTF&#\)H@&6Z;YOI!KX##NHPKT0&@G#E?@H$
MIPE8(W<=146M)$8"DI9-M@M?#K05&1;VEJG]8S94#Y$9JSE07[(&IMMMIT>X
MPF1F9B\SZ9=%NR"DN)F+\8XVU)G,=8_2]$3?P*V&\_>92J=GNBK62A\I\&J:
M0+ZK^$[4?'Y1B IUAF[G$TZR:,L]S9N&C@-,<$>UL2IV1J//N2W"-@X'=2':
MW20^2S_MER1NL>XK5K>Z=63V(B_(JZ!&LIU]F5YILIWD>^&HR8GR 0O.G<)N
M!]F:3:(ZJX1CQ]Q<A7<H4IB\5%:-MT'IRJ7]AD)ARNS@]@WG$Z!T.%Z%<<G)
M&J1UGBX\U_X:C84MN>X]UMSIXC\$!\XYM@)P\![8YJ[/:TV?ZY[3)GDZ-.DA
MDRU#9I%W)<<;;;]5G\&?K?[(%IU<*\?*$3ZKE_M_X0P_PF _. SVV1$&^^?
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M@+1BA]_'+7O_]N<'Q[V_C2<J(').C6Y8=)G:87HBC!'BTHD7>\^DML%=:@.
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MJ)= /G%'I-P>LX<_K\6"/^(.SE4O30A/GSW^VG=EL,&4ZUMUZS+?FE6*C48
M.L.XZ6<"W<?'HPGZ[#%;67HG# +BF[TA$5M@1XATGW&.%C+22W/,7BY^U2-
M>8&1>6BVG'!(8M8L>C7H=*^D@_/8G_AQ.I!$?IP.JK'<U7CCN0X?E:3R_<+A
M-[:])"DB.]#G!IBQC-JU+ZOP4" @8R-"BU_E(F+2!-O'=W\(7WU8S9?$34M*
M*'2(EXV4!:/_ZCBZY[<R[[#3!:)P*93*,[C1AQEC#!_88-A,(54!!V(_,@B@
M/G8FB58^>?9\9)]]IM_C*_&7OLCL@V_HD2:^\F4FK7.'O_85SV6Q;VJTO_N&
M*E471)@9?G-_7(0CO.N#P[L^.\*[CO"N/_3,J5UV':H:^P//0LB3/!C*KZ3I
MUYOVT4^IR:?NY*=GS[1UFV*ADDQ_&!=JH,H+RI;NX"73T<AALVBY3:<#TQ>
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MPF1DL:$6"D\7YP*[4:H/S**$\-A20G>TKGHI:'+$!#X3 0MWZ'6E> J"*V:
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M\A!2D#&Q#S5G.SW9?0Y@DMH9G:KU92.6EU3M.NJ^[$=1MSL6XA--/<T$6,H
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MG!NU+DB%U@%>:61DJRC^0VFI*'"](D)O>'5" 1CU.MV3WSZ13HS(JFL1NI;
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M19I7X-%CUL>)QV)ZP192MD%Z[0UTWB/\<*/Q6S0W$N>+E*E@8GE*.+Q*.T
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MHLBXMP Q=R23(X$59$S+-0[W)!4JY30WY@-(EK$>. AA]1_J$0)*B-6LYH?
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M:341@]B0P@SG5YD"+AVPDVPS*AU?BS[4H=[A=!RA%"\7'NZE,; !SJYB6:6
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MVY(G9[\GT/$B>5F1Q,/,$3_6M5*<$R7%K+9,$1]9+[\2YNW3F)#?\.$?,%A
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M3A>EQ62!M5BR^%AN18R3Z&  )R"U[I)SB"/82QW]92+N%MH2XTKHJFS+K6)
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M"ZM*P1">.7FGWKJIYZT%UXN LCV3'. 79U X>61CA#PN+69(>Q'8*>F1*LX
M4S)"+#3WZ*)!]\G_PI/8ZET>QJ*M%\F[*C'^V!M[>CC8W7$=-_?#C=1%"09=
M6(_B2I\,3DY8D>WP?S(R'K%*%><:TM<Y(S?YV/O<8T&[V)K]HDXV+D9>'*FZ
M2)@XU&AD*82OPO^W:'1*"%RR>R9MW(TWAEH\4SQ8.#-'-5W\1TQ-TDZ2]+-L
MQE1K%51%P[*($MB%G, 3/4@O9/4T;;(ZG=$I:L*DNE(KFIILISMAK&I22N=%
M&*M/),>/8ZG(->/>3:Z+)'>.-)?) FZR-!KO^<BI [M**/[G8G0:?#9+'0;O
M\G@0+HW'XR\?4U0PG^$_,_C?_Q5-9R_AJ@%Y*"4E?N#IY(\8')@**RI FYB1
MX-+F(!$)>]UIOCK4+W4QK8C_?KAW1)MBI:KD<UQ@Y4#!A<?MF]*J0F.#SDD<
MJ0[)H*B1RA='JS5R_JK4NAQ.U-\YD>45G'7@9<+:+)UTN&S\?\%RW5L5T>N^
MAR-Q^X/C;7LN7"_(MC_8OZ4@VP9OX(OJ.3%6&'+5$.KELRC#8UL(Z1%KB0NK
M6=_RD8Z43NVEVSD^[M04RM.?[E_*1,$E&(*ZI_KU904W9/,N$&NI[Q)]NL:'
M1/USPUZ=XIQ\0_X.!AUL>=4H*\Y;YKB-(_9VZ1S8RCX*B7!_#@R#)I#2XZ E
MIC-I!= F-J'W2B#BO"QTR:"3*,9)Q,XAO%I8_R);U\9XF5B6$\5X5 945)C7
ML&)-_BT'RXM#%0/0SRJ@-K#ME^]3^*PD%2K!5U)[]$ES?P[HLIVEC3(;L*.^
MM ONG":.(3/$T0(2#.QB92'7';AEF[H$@0\2<8RQO )$ @[9+OFI(_BZJE=P
M3;GRHNW-@#-/7AY6&KY8RSRO[]S<@,Y-S0_<#[&[ HV8R%$70/N6\3S>//J/
M^\1+47TLQ^G5FKL]OJNTQZ_H+'WIR93\3L.!4E"MI Z*T'1+AV(FVTUX"2#P
MQ>[@U9O/HH*[+]";YH(7R38,A97I2JSA=F_IEUX,/;'X<5WL";^C_(YJG5VZ
M #1L];C6JK+-/!<>9,;J PM98]=[0?."=@."MJ2][5+BY6LM;Z?6<M_76GHD
M8Z\J;UX45#Z.F+''J2&BG"XWWSEL0V]?GX:628@L1=*4SHU14T\*3D^\]&>Q
M%S!X)9$.U2WRI32CG">WFJIO/]AUGHZ"M';0)3)J@9UE"IL=.\>[MQ"]5+)4
M@DQ@R8WN.+7P IQK(XP0L@^C&9=^>I7FA4>?F1ID*8@N@46!$9DR@G\W#+I$
MM4<.])6+?.6HM1%UH$K!/&:EED)T>*7FY9+D$A>8<"(()"F**:OJQDIJ%4]R
M&,HXY0[GZ_FX7I8V0):FT3?13+J,&_36O_'0_"/G[NQZ'CQ[@K\\>>Z"B(@
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MPQL>YS6H-![8"O&EE\%Y_^2B6KUV4*W>2'7I/:S;Y4>_R>ATGRX&9J>.*LR
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MZD7.BYRTXG3B6E2;2[0W&B+.(<>V.! ^T>2%R"96"9RPB WMDH!9HA8B >N
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MV-DYLORS;54AU(=$L30EMG!N.C;L7$3!I(@H-'AZ>-+B];3/@>_1UR]]D/"
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M :X](N:! !=3)&!E/(C_E1&$7 0AA&%$(J05YU8[+@8R?+<+7&A$6)FY7F+
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M$90, 2.\ P1CY1'2F#"WQ3CRX%W*%#KX,<4%O0HQ#P2]$(*&.\Y 0AU C=5
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MB43;HYFWT05J1Y7_:GWJ^9)S!*,TZ!^'I]5=E_R0I'IT0[E+S%QX4MU"\Q0
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M_OYV<C3[>.)_S6)YW$OE +<7C)%1W%2YO2A(=KB$/ @D"UHKFT!,6\T!)8@
MQ3T%3$*#3404QMRVD"RGX'P?G-VCU+N 60&SPR7D08 9<YABHA&0'.$(9DH#
M@Z0%%B*$'?-$.7:?JJ>= 3.,1I@4\^S)QG *R.TO;4M\[F!(7<1X?VE;Q+CX
M%T5FBW]Q(5B"M:!0!R"=]-%7< X8"S706F%GI(0";715^)ZRI]WR+[;86/\I
M"$*I:+IG15.;&+EJSA+KE%JF?1:5HC.NUQD0,0VUTX!RRZ/.8!1(P36 5(1
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MBNEZ-0%2E+**$I-JCIM6CU.1=:Z@J73;^EFY>]UO*2L*XX+"H%A 'R+:2X$
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ML/# O&*YH"D3!5$J 5S+<T5DDE'"3"RSO"QB(_;"W/N06$@S.BF?67NIXW%
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M"#4OQ'ZNVGG=BND_ $OG\ WX-PZXFBV-?C<W@!68$KIO4G'ZO!3[T&DA@&T
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MIZ9C@  #%-T:T;P!Y+5=BF2TJ''C&S@L[EUNR%-GO2JQQ&,Q6*K:R&I:(:[
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M?@\*DO\NPLV?('_A7\[<<QM_ZC961-]W*O*?)Q].HG^<GK[OE>23Z!1$=V,
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M3%'$=-D'N&QWT+ZOT'X>4?GI)6F[M#YR[^($=MD=C54_Q0;GV'1XABD F.H
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M+0SA'Q=\.8>#WG_RGR!^,/*R>T!KDQNEAX_6JC&N>+MV"H+UI2<?4?HN&V]
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MG4/'&=HCUPM^Z23ZL&J7YG[23@;NDR[&ZKL_K34$L!%-^NXY?=.VOIB[OKA
MVW_P.W2.DDY%[*JH49/!OCD#B>R&*^NJ.,(JL-P/9)C_272J=>6KZ:>7&TW*
M:N/3XGN"\OZ4=&%M_Z^AG["W:=$GX=?AY*7>O--NG?ZYA)&XOM9KYZF["*YB
MO=\+3__ORH&P-U!3B<X[M^A/R.HZCK?OQ^C[Z@?\9V/\/8;-G[76$_/47V:@
MNIY7\[6O=&P$SILWVNS.1C<SO?9I=V(F\!;_FI6R"X"-,- G,\#3^C9D.U[E
MO @+[W$0+9PU.;T<<G[AJ^:K:52%'<S@1=V;1C>GZHX6:./_@]J4:(8DC,9<
M"%]4 M=@5E^ JC!NL#$>!C[\LW]V#U9#RH9KY;%T5\._=RXNNZ(8W$5W7WUG
M-"RXD0AZB\IQ5HQ\<.M9(#M>W[U])IRG>=>FP$Q=0G77=[C;HWE=S=96<>Q!
M[8ISNF>U+8QT5L.P7,*V<QPM/;)?N;V  3@)!XP=A&VV#=\ P)=[MW_I+O&&
M0][CXJWB#;VCK0?/#=Q?$[8[S^G& 1VP?71A5B&5GOC"N<+1.PBZ4C5(Z4X$
MO.WNTOI'//;#A=6P0(,015?UNIA8+JJIE]&SH>2K)U,!U&K<Y,0TDG73>(QS
M+[I^'4ZB=U>L;H.AFL;3=K@:KRZ& VOE*@T0*/IZK[65VG[DL(9K91,WM!,2
M'>SUCQJ"^-O[<!+]LH;YHRFL6@EA2&G<VZA_WFV[&FUT(+JIRU#?E^CJ4:ZM
MBJQ@L97[.F!0[<2-<"W]'.IW[N$Q5%2.FE2O[-]^0G@OG!S9^'YC]%)U[NM!
M1@Y:'0RZQJ7I:Q)'QW9-PSW"AJJP(")5:4J4I G6O96$RY21/-:\*$1>VGBK
MB]Q=G"_=]CEC;,5A\FO='M1[K*V*X\P:0@LPPUD,?RMI&A/#.14Z-HP7R>;L
MF#&EBBDG:9&!_:YC2X1TECQ,-S=<%FJ+K/30LSMN!_*HC>R:_CBZ<_4.E]*&
M$>0<2\?D,3XB(I<'<UU)N+YE0I*,"<($,T301,/%B?,R30PUL=J'ZZH/_'<4
M1L%[=;5K:,B1>-NV2W==0OW6T2K>8V$/)]@M$RJ=O17I*JR0A*2V8 0Y?\8H
M8N[+I^K.]U,UFJ 1>>D+5/N<^*Z,:[JM=,"8X,$*'3:8F;_HP1B>[(S[(?NB
MZD^2+]+"ET]]U=;X"]CS'LO +AR?"9A?F.R\^E%GY/L:L-G6&R=K?!";EIKP
M^M384^"&CI:KKQ%;K#[H*/JZ3]68I ./=\XM=(F!F@9"!$/YFR-P!'L25K2&
MWT[6\T\V5F @Y!O4ZPHT?8UKZ];9I^P 4KD*X4VE>F!CN5=YVM$KBB9F22YM
M2DIM0>D3/"%<ZX(@;VU><)OK8BO'X&Z=JOTF?11??UT9J/U/N]A<_\]?^MUV
MH'A(33+F>:J4XD2+ E,L=$X$2QC)8I,FW,@L3K:B.G=)L7CTZ3\95?.JV[P"
MFJ-+0-C\X3&HED<9D TE5R^DY(K&5]1<A8JK@U5<[=5DI"7(-FTQ6T?FA!4)
M!4/09"03H!TH)80NMSPL=S$9WX@&(RCM>].XNO-@,UYM?_UN%A'ZGB)8K,BM
M5C 7C]%<_$FT<(]FIN,X!QLA:L^=XWVCG ,C#_7,5V9C4-,E^[7.C%AV%)AP
MJ2O=.^.'1][F05U0U6^ST40@#SO8.J 42N^R=X-R=LSX^SXU$9;#+AT'\Q>7
M(H'VSG*!L4=/.N(9,U?%#!-GK,)'/)N3[NPB'QVI<6%\R%)7TZ4+#()^"L_P
M='@_XP_A53N6['B7P_W\^IE=OV2KW)!QW >3+-IE<TE6;Z\L'BYL3P.?]"&8
M'>69(P-[M3*5JQOI7C@DRAC]RL?M87>Z@)IT9]9EK%R]&;=99_R<"PT!S'<5
MH3[=N!U[!6Y8MQ65/GR*])\X;MUVK^)7T=*F)=4D4PI,S#BGA)=*$YMJJ3.N
MDSS;[E-Y%ZX7XS@S_^C)+KWX_3;:Z]N,]<737G<+_80<O$^)5_?61_#AD6,5
M]V_-V2JVK8UUP"_:<1*;+YUR-(673G1V-59]#MRJSK.:>6=/5TRUJN3SQ9Q]
M:/QL.17-M.\+XV6HRY\XKXP=Y23\;%3E /HW\0G@_ONNYNKUNY]_ZVJL?O!$
MNLJ+W_/Z"PH K$ETG6% KM3+QD72:YP"DC>"I$9&VF[: P>P:X[2\>JZ.<R4
MV5U#@6]W29NP,G[ ;[Z"C'#"XIVUE3+-MA@<"=5JT3EHNPJW^_I>-\[/5A<\
M3LM<<X$19@RNB;@@@K*4\#RG19H)6$;]2)P5L-[3P5I8_^,1A&F]>2?<X3C&
M&A9=B#PQA20B1\XU^!?2!X,RF,L4 ":S<;J7[C:_.RWTG?6"&"]R+S#6O+_=
M#\=^W[>__W*]XQ>@Y8@<O1VOMH.J;O-]"N!VQZI.5UPE9*-9T0=E_H1%@8]^
M<-6G+XO2FIE<9#I)B<XHG,E<&%(RIHC6PLBLR&5LMB(V=SF3K\?1+%]D=1OU
M\&7K>6N+=L/IP[:Y1Z#L'>4ZHI_KJ ?X8KU;8X6K&O5@='6NB.T=L^U8J=T.
MC(\9;'M/PZ0']Y6:.PJWKW-GC @_S.5&FO-)]'J[<+%JQSJWB^L/=!U=CD'G
MH1'].WSE"Q8U>+'9CA(YNK:)V[5([DM8H>(J(*).+=XYI([W?%/2#?KO:EVP
MDKM+RW?<'S[/NT95^BI*\FJ&Y&!NZ7P""OIZX.1$CFAXIB[]S*8=N8C+9EZU
MSZA&OJ(Q=6^@ZKV5B.:\*!+*2U(6#"P!:3B12H$6F0I>\I3JK-B+VOB+W]/7
MW99^')W5TYG^N-K@D(MW#91WJQCURQB-US$(H6,70EB$M7"HV$.<%+-/*[8;
M6(?:\0+XHD^S;&H/41^^5"T"-@!WUS1HUO$M8.W3&/>]J/%^F[6'?18@*99M
M#ZHNFO'+3J =1(CC3J\ZY_>0U-+[9?JZEB$>8+YV<LK[,6 1T=7CY)0O8M%=
MR8L/'@QO JMJT7GVQ^G8^.G)ZK47(*,7R)/5?6IKM3:D1E]3-%2_P$K]>?+A
M)-+U=(I$7*N!>R&*V1?=T!T3F9_,2?2FG]:6/(,5=<\8NO>.Y13VQ=U<7CAA
M%]N<])V8]HE5$R=+@PS[)KKYV*8@LRB)&3+TE(D@998+PE4*HD@EMJ1Z+S),
M5,U_8HW9;YX.#C<CV)DWRBRL]W3+%HW6+4BKHY=6Z"X_JQN7/^[ZP^TNW!RX
M$0'E1[6].XC:'./!C61M+B2P:K+G<I^]^8'N5Y"!%\;U[,.@@W^WP^#AS=Z&
M #B%/UI7V0EPZ%A_7;-/[)CG"Z1WL2-T<[Z\:E98>5CYJDH430#L^')73#Q;
M_;NGEQ^MQI9-9[Y6"Y"1E7)"KC-A!HK/$:_<$&&&YQOG=<1^4JYUU&Q5K-BW
MCQHJV\5H5IY PN6;3=>$_$#-"8?Q$SP(T_TK5<V%*P0]]6T3)VO;VKH"<_QT
M1YE_L;K4'>_BP!4QBG ,!;LPXN7%W$LN]_$=K^[FO/2]0'&1G!8QFNXP-]_L
ML"-PP WNDSI6_6%6+_0)!,-)6S]DB_/&& )'NAG/]QS^C:VV+B>=:@6CP?/K
M;H7/&)@OL8:A]<)\UXET/;X<=4'[XY%(Y9'\[7 (,<>A6O:W]7S634S;F;D*
M*]DL7CGT(D[+^1$W'"MQMW!N-;[T)$W3OST6\*4G>9XE6<;B)*%Q6JRF7<UP
MX,3-_IK98K(C3Y)\R'8<+:I_!8WCS:<^#JS_BCWB(NH(*BE]%?TY&]3B?RYK
M_,,A44>OZ:#97\M1V0]@-89#7>36Z^OCF^\;?"!;I^.MP5[&?7"D&8N+5ZMC
MZ/-"-]7!<!Q?RG%,AN/X_ZV=0=<YNX('BN8JG6/KF$ZVS_'6 4:>!O\M1T/4
M ??*8*XE]H+QS V=D!]*W=SG^W]-_!#7"$X\-S8(Y3%WT+:X>H7_"C<@W !W
M ]+A!KSWQ[9N1C3:"Z/.9]4_EWWM91>_Z _N<*YA(\_7^DMW?#@C!62,U'B7
MEK/588^^KT[,R03.\QQC(M[# V=U,35>L>TUM*ZYZ.4/)SM/<*BC>=EU-#34
MT3SI.AHI*,@:61*;QR5AIJ2D9)0145 J65SFL;E7'8UKE/L&W@C+>_:/IOZR
M..\\#9@:LPQQGVO\4?VR17[=!A>-7[G@2CMV5UKEV+"Z5%73;^:9WTRUBH=C
MAX ^H_7-/UX/":UBY3[J0@/_L;R8.ZTG>K=LHI\PF(&\"Q_P1\MY&YWZ]@9)
M3)/H>_Q"]]3_>/?3!_QE_^A5\]U5D JT6?$)(R?8A@ K3S OHB.0,%]-[[UQ
M88\^K-3T>?F]FN(C%2OK<:U!B@]YS)<2?M;-?VAVWJOJ,'_O@X*5@[^OLZDI
M3#[&+E^^W<KF:+V##38"0RS.W^6;.73I$L+:M5A6ORA#EQND=_.$;'TL9P;[
M73<N.]GQ$*X<EZYLQK>3V<SP'?4A6W:,C]>,RGNOX,VN*X[SF-[BK7X#MY@J
MJN[M\/RUE=M-G+\SC04/0M<7Q6U1,RJF&6^8'W/7 7J\I9?1+Z<??EH-M7MW
MU[ &K3?M<B+7ULVU8_%\E=W.=_P@FZ7KV03I&\_KY=DYTH0ZAX175-=X +?G
M/:J8ZM//S\W4'0;,AH'# :::BP/V7);_<FS)OK&PB:29)0K^![*ZT*2,M292
MI5+FF<JRI-R4U<IF7&0\)U)82EAF$IBJR> 195S*6*@,F[+=)*M_<TOLPCGO
M[&NWEJXO[;_#"OYT^7L].QV6[THVB'R-#2)?2PK&A&"BZP7I/O'=WXLX/J:L
M8/CTU.4A=340EP#%,Q.E,=P3#/CZ,[6H?.^A:CTS^-S1(LZPV # OT78_&QF
M2Q]R/KI39IC.4Z-S."*QQC9^<'8,G+(LL3:-;6'5=FF7,HS%QG7]*Y#-+[6$
MYX4BDG+!BJ*TL38WG[)3MT;_P"7ZHUNA*T]3^4VGB9XD:79,YTEVYPFC677C
MXV:.Q@ZGYWJ&K4L^'QI1GI>R]I6'#B7]@1RAY."%6HE>?-P&W'H2HVE;[WIF
M93V5;KMT&1C^=,^.[Z26DN>ER)*.0])F*2ES.*Y%*E21QAE/XZV&\_LYJ5X#
M[ZG1.EP$&'SMRV#17?ZSD8M;GM[RIM-[E"?7.KFI5C.&*<F%YU[=1RG33J)
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MVSW'J:2%*@0IN<H(TUI@0DA&<FJUD3IEBK-;^V9<LZ.]]>0(B=4!P(Y^2P.
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MR1T0:]C25XE8FE)O;2B$*H.'(7B 8A4'] G&Z""]81V/8P%@$U@/UG"X4HK
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MMM/E#826"%)I8E4&Z<68(AX#5'FQT6J5J ^=+-%']V!P=J+$T$!XZ-(^@.P
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M+3@/O%!J,\G!<.Q!K0EHSYIDYKE707HA.J<,#SU)7U=P_DOMN+4K1C!4G%S
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MR(*^NL2LMLX%2TF@BA$9%"?6,4VP)+5P*J!Q^1"76+4N?EAA\M#/I62L0K0
M>*T:Y&_+6I?Z)?O .A6<X(-25P,;_C3+48LK[7FWXDZU:A@67(<F0Z-O;Y21
M1N%8IUB..YZSMFT$O"G,9SY-L%O&_)]YV08AUM>W^22@#HPO)VNUI?:/:C6*
MA;]H$TM/=K-**R"#8E@/5$II^L?!D^K(FIY38_3U54L$ZTW!<&ID?=-[#JLO
MODI'^^L]7MCD,FW:,H :#O;F8E5E5].]H8_^VR@LSPE=;TQPK-042. &U% ,
M'$TQ196[9?M=",PA++($>J?*6#@$D#4J+"E6F,O)=_VW#9O_T'1G_ X7Y-_G
ML\6!OAWW DC:STI/C0">-B%*C0ISS0NRUS^N];34,M8(FTTIUSW8J_'1ZXK:
MV\3TG3HBO:0SZI4),02BBI98+J80JV4B+ K/4S)&,-^)(XR44RT*\8P*(I.@
MQ!IF"'-6>2&8DR9_=ASA46MOTM.;^ZP_']75>N0?,X;E+_I'"3$*[K)EA/F2
MP=(5F#^B%:&41:N%U#YW8I0_AQ+:OL:5,W[-XXN 72G3D;>]5\<_NR>2C>ZT
M;HRU$4?A:A\PJAFY7IOUMVN(>?-5:]!^WS[GJV]JO['>&8O1SYN>H=CG+*\5
MQ.LF\.7E?/;'^*+V0:M'_7X\W[]C \=5"UR,4VY[*M6J7VT2\,:AU'P,MO<8
MYN#G;1X-%C3!FQHMM'J=%H,6>$./H?LF/X-JX:--@!H!?@C  D^C),K[S'V4
MILA.:NCG.,DJ=/RVNH!EA6&"(?<C,$2L:?)(5+^C]^0.'8=>^@8WA>\FDZ:X
M3^U*CFG.[:HU::1UX3K\M;:[NM$/-S?E[A7NO.T91S]9Z/"Z"7V[V\W;V\'B
MP-[ZU7+VKHVCQO%@6#4,'R\G$W\U6RWA%7_D]*YY':/TE'Z]OJ$V3[E<Y+?K
M$\/U.E1O5//LK]9C@$%LHL&QPV1S3O-V_8R="^'*M%FI^EHE3[7\&H/%;[GF
M5.A/7,(^\;VPG_6 /_]I.3\TNS9<W<(F!A__>38''2:1EO1+_>\==C%LXN'?
M-E'Q^,%AACB\,-45 UI02V4-Y1VBNP,1D?9(I'TXX>&SE,T#P>[+]!D3?MP)
MWIEW'S ]H O\MH8OW3K53;;#.BGF<CFJ\#M:XVD?=O\^_>H^.Q__\^GDEL5K
M.)**7BS?$:EK@*<!GIX0GOJPM\<$GS?UE&2V6H#5O?CF_B30AW5Y.E2IJFL7
M5B( ;(DWP,H-FM^A,5];8EBJY\C\>X!SK3K/-P7,[T)5=UF'6]'FZ2V9AZ/I
M[F.GLWY->7_W;YKK_SCRWA[D\<><>K7ACDCY-[0IL90%DREAEE(B@^-8BCZ1
M(@0/R8026"<1044F<A"9Y.RP2;WGQ*IL"9?,&V&\<,E](A&A]4!^PKTL]MS+
MXA/N9:E.Z"U!4E\JN3^EF+A5^WQ-8N(?0+TSF,-_'SZ3'N3&0QGIT\;T%\-J
M]]STSW(G?)DBY\T]7="?)\(8M2)J54A4(8 XLI'X(".AR3M!+<,BT<<783L(
M\9?QHB98_-+45'L_3?72%C%JS,9/^5A2CHN;#U$?FS,WGIIG!_.;*.1&.W$P
MFQ[$>=_M'1D/XN^X3,9/.7)9FJWPE.@9!>#SF%9W68PO7A;>D,9I4F!<*.(<
MYG0++4E@/A&?A8DY:*&/([ONU$+G,\TM>6+TS<F:C\\FSRF-'FZ4P>]XR'N@
M[&TM-O6:#LF/'.WB@S=!<)*I]D2Z9(AWU)+"I4[::</-4<HK_Q;/<UI-\L^E
M;1@RQM"7748; E_:VGA-:D.WH<2F#%--.6WRD#=5FDYNB@*^'JC6MXRLFEWA
M%VVLSV+T)M7*&9@-N\+TJ[USC2$R9HB,>161,4]_$GO,P\@?QJ@CC?Y/]O/A
M,/H+.8Q^TD"#%S;AP5WR(&,/U  Y.$E>S6';<*2\Z],HL3!F8R;9:@T&&)A5
MWBA/*-;$5\(4G3IMT2DO+FNMB ]8+Y]+2WQTC'"F;(Z"<V.[-3FZ/1O!!/MU
MG7@/QM@O:XOCQ^E/\*[?/^;)A_SW&;:^NY\3I"J<Y+_S?(8D83GC[X;SY@<(
MC.&\>2LPU" P7@VW# )CK]J(X29R5PAEV+J)LTB\=YPXD0)-,E%:.DU^'UU@
MH*GW^\?9D9SE3)XH:@=9,1@71Y$5>I 50P#2$(!T[W9OPILD!>$%98<M(&I<
M<<057;3BPL?8*1KX-/+F?)[SD22.$">"WES<Y26'"@T63!]<YK_/EGXRR*DA
M4FB(%#I*QPAJC9"J$"\3"*"4!;$Y,)(2U9D71J-3CR.TIF>-=%J .?1^FHXI
MI*0YL>SF]K9##-$=8XAZ*"?J$V"C9_-:OO?M9#S-9'D.PO/L_!@!!7\.\S_=
MMWK48X_MP X>#/(Z^"GL[9_KMX>"FSA+3E&1B"I"$.FD)#:@Z@I<'H,!#39W
MNES?*[AIIR[_][6DZ$^S9<9 ]\ELL9K?):KI9E)\KB+!NUK+$7;9G8Y^.]"^
MH%FNA\0C'7F<G]N?[=C;\W1QA#V$P8=L:',IONKM&'3I<;QQ*9IFZQA[]@^L
M0/<1+$WX9K2NK3RLT8UL\ JJF_\\'37T80Y5C*\J<DY-%PKL:;DFH%K%>1-E
M6:,OOYV5]Z/?-J6E3T8_3N/I"3SJ8Y[6XHCM0T]&?_O;=_6#7\;8)^ W^'4"
M__Z__N+R'5QT6DMM[K8P^; M5+W(H,?YR78@6'D1I5,MNC[/X^GH#8;F-?TV
M)U?-=!!].7WWCYV;ZD?LW3<G\*9)4W3ZVA211RY!$03QNJZ[?5,LZ6?LP_%S
MM(WRTGE+BF.@QH<8B?,.=  6$[=<!^>ZYR,AI"0R(]J D2"9<<1SGXB0"=2!
M(+6WY:#0Q[2UG/Y2]?Y?8$EFJ79\6\#\ZE?[)^=-=[Y=G9]^^B1$F-LSM9^>
M10YW&?RWZ_T%]Z*5^]<3S -Y,,8%*1ES^1T%$]'X3(RV@BJ=DW:=JOV%10%J
M8<$$% 5T4B@!I3(1F^">X)T1;K]$[/M-,YB&+AIZ>2A1G-C>TL3SC6!<EW:T
M6C?RV30XJ>T")I-U =H]I&Q(>#Q?-^_",JOK;D0[C7S:R;W!^[_:J@_-GF+A
M6JQ6N2ZDW3SS&;=B5W3O=F'?31R9Y#](&L^;; $,WEY=3-]AMZF)OWJ+W[Y;
M-[??^JL/];?'+H?C<K5^?;V5Y&EZ4./[AV@.#RNU],#4#?)\N\[,G@7=VL;H
M]CC?..<O_5EN_.[$%UBEMW[RT5\M,!9^ESC6.U^UV\/;_I#=_3(S,':<$!N&
MZK'U_K#9;_2[YZ/GY6SVSQ&@$?9AFX[>K\X :$9MSM#IZ/UDTP+Y.AR//H+:
MBP=KUTN.-RB]F=JFW?'AA_2QJKV1TF0A&+&@FQ"IHR!>1T:2T2$;GIRDG:-8
M57S*!7U@UH'*8FD@+KE,\$,1,HN\V]_@-X^)>E7!K?V.0;-M&QD_?MMC>6I[
MI==LVAZ?PM7+32VT;;/1A6\[JFV*WMQ*F#N5XN'KWI$89S))$RUQ2EGL2T6)
M#5D1ZKG01=G$>$<KYB*;Z R(EE@$D2 ]B M,@I*<A'>@2'/3:;7]2[N./\ R
MKFM_U!/^#[ POR#;HR%]I%8*6O:UA09*89A)6L5J<>^Y$U);**7II("V%5#8
MIG74!L?6?1@.]P'HGV1Z=-?5>T#V"3(>_PS_WNOP;*W%:"-'V;YOJXPGV-<,
M60Y;&E>S)T_*:)[/L&=KTXEX@7C?=.J;CGX IAO]1L3:UD>AV?:F3*,,RUV=
M3COR&]UIS8L;4^K7W4?_MGXT&E3_V'1=/'S-_M"Q*69EB,H:"^Q*T]->@=XP
MGT)T1!B.Z1[.@RH>"C$N)2]#28;'Z_AJ0S0F:(!6$3W@JW#$2B,)#UPIH907
M>;\3^7OL$X)GG;!!>#*]=4(VQRW;OW^:3;^K[6Z/!;4<$XM[B+6U.>_H@Y^/
M\Q)I9:?GWWX3YUT/UK6^@2>P$)=@XR^QI73C$CAIZMWM/JSM*PV_+59A$>?C
MQK/PC$O0MG6=S>L6KU47;/^%+;[PW\O5'$5P[>DYF]86T!>SO?Z*?MDHS(WP
MJ=T,V_[K.UW<KW466VM'I\\X>02]*@^8K-##[^_/_VNNJP&O7?OK#[OR;_>@
M;^3VZA,(UT??>E+!9.X<,4PZ(G,NQ(<220@Y.N4<%=U.IY%E)Z+QA-H,Z,6Y
M(XY:1@P/1?*2HMKZUBMZ[0KMM<S^A,?TQY]^^)3/5)]PHT^<-7T"IX..])V&
M-5LP:@7FVN.(1%=+?DS&>76]^>EN9]Z==J0X\H)4ES88M>?O[!NQ.<<4TR ;
M@_- .-2CV]VBW2MD#IQQ;CH'.<I8H,(H"<A+L'8-Y\1&;XERQ1IK#!."7S=%
MOIOX!5BP_]FLR<_S7Q$N?UIAE1(P@C?(_IV?@'[T[55[W:*]\%,G/)\F37&B
M0"^BMT1V/2ME[E+6(4?W%M&NN6P:V'4-[-[F?.FSR\5E48H1GB07*9&I@)4+
M:A@I69EL&.-%=ETNHE"CI"&:<;2A$YC",D>25,3\K*)85GURN8C36RJ3/:?+
MI=$U;J2;0X#62R)*CF<KG":L6$FDDIK8[ S)3CIL91M\[/2_O0^2/281R4\3
M$0RXGV145:U)K<B9/=BI7<(Y':UA?72!AFK8GA]6-_)%]M-%8T-$OSB?Y,5B
M<\%-CL$-T7X)?K\D@[*6*<(H8X!S";2T%$#L"A,R-5X$WB'1S]'LGL?O9T][
M)50?U^_WS"?-K\R5]M<5V,F,'C(J<9LJSC2QKK>)JWW[\R+7;YO&N=73E@[>
MM9A-$$3@ECP9PQCAPDTPV)1<95^[\XY;BQ(;7MXRAM/1]SC6.[X<>]).9Q_7
MX%?+T0$/]@_0=.)%T.! TF)A2T%5$\<=N+&*F:*+RM<!+01I@@)Q:R@#.\-G
M2:RPE)AD0E#1"'9'Z^'[5C14*;SY<F,RL*<0R/045K)7+:2W OFZP;J5F?/Q
M62UIN2;:S:$: "*8$WA-6I/[8>K<RNTV\*<]+:Y-JQO'U2T,.<\7:#:OIF 3
M3\]R:NR60U?BQ/!28)5I\G/@G(3!,-5U Z(>2R,B9H_+QA:/L_DE)E& ;O$A
M5V45%0/@XG-0#O+T.8'\U2+Y3;N+5!J1M<=EC*BX0,T/\'TV;5US0,SP7/PC
M5Y]Z!<ZZH7-,E4E;=^B&A"OAKJKI[%L?X8>]3N%^,IG%!K0O\O)\=@OUX?C:
M%^\,,^3H5XO*'5?UDC+/N1(HOK0 9TWC&+AKO&G,L&@ZC>.UDWP& [A"ARX(
MA(KLS6E*4Q,4OMD#_37+MJ/8>>1)?=SXXB*G<>?&DU&:@02!9;L(LX3+-IH%
M(()FVBA*=D4I,,<\;SQ4Z+Q>^]UQ:+@'XV:1V[22YH:8<6']J!:@&DVK*Z?Z
M_ \Z-9J0P:TV_^-T$_J'/OR#]L)B/8O*Z0E7ZFITMO+X7:[ U?9^G\-PEJOY
M%$"HOOAZ_5M0'?HF.971A6+$2);HY TI$,<+@Q]49,6!Q%3'%- F.LY-(5P4
MD+:)"G1Y)")<#A)$L=&^4V7]223G9T35.G/"5;\$Y@&Z._?(YGEZ@WW:L4Y1
M"N8_&FFV8:_=4)6^D9\IAO,(EJA&MQM8E99X[PL&.5'G&5!4[KA][T-^E4"^
M!5A)"#9@2E4$>H_+?%:-T&^OMI?\TA2A> _;D#:NX8HF[U< U-B3_E-1W7<X
MHT *E+TZ/;U+I/]-T-:FSC0:U4W!A,\*="(Q:H&T+%6)R*PL<<%YHB-7T6M=
MN.JDA[+DO$!7<)"B$*EI(,$P@$DJ$F<J4MY-#^T9T(D3P=6)T;Q/A/8JH4XP
M)K1@ '#9 3$)SHA5,8/YR8U2S%MN.OU,[D. _8.ZA@:U[%58WIW ;HBR:UU@
M0$>CO_OY/_-RA.<.VQX3K]64_/%P XXRGNP<EMX4Z_&)V+SK<2HWK_Z!6)6:
M/XJ!.& VGM78N=UXGR9T[Q/1=%O6&"^O!2;4]\&0_!D,X:QQVUP_K>MI,!ZL
M<W3!2I*L%: V.D!B93PQW@DI4[2>NX<$XVT4@+I>]5RN0=+?=B+#;BZN_'F'
M':JG@7=-G!.\ODTZ]DL"Q$8N*O&V6<>[)#,[F_N+M4[9HT8USS>4?2BHF2U]
MXZ3L%2M<*]!*&!IMJF!.+"/"*I]"2%)VC3:J* \J%L)<$@TG!:R\I+/6S!26
MHKDM3&)?-VD2:W^<_@XZS:(9V@.S;,4)\/.)<S=7!7Q6%:6#P[N8CO1RBXA
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MA^3*)Q-IL(K:_,-M\J5=G T#7Z\[^FR0TD>!1T6DGDI/6 8>EU([8H6F1&3
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M]63* ]0=P9\J@@5]F1-G0R'2:D6\XHYH395E@&F./0W4+3X+ZY[;IRH'G^H
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M72PI(P0UAJ-$@G]2L(WB,%(D9;$4491D5)N=%9>Y2BSMJUA,@/D-NXS;O)K
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MN:6)@UG5Q2*2?KEA*^F>6&VH0@F&&5=87P>#*(!>=9.VV<B:<U F0> HK*0
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M?,*CU >)J16101"0,(E40D,94;D6B7L;4V9H$C-T$M-)3'<(<C]18FM3]XY
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ME"3YPU0E$DG,&7^S3W2^1#2'Q.>G[E\=3&Z]$YW/6G1F&9,Z,RF8!"8@0HB
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MGOJ!3G:=B[5' <EB)R%=G85#:OF_XJJB>C^OC5/N'R_7.>P:'G8I&BD3ZXB
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M<Q<EAYQ<U+D=\W(V[117GX$CMZ<,3323#:=:NV5U5E9#\EHE#]Z .P0K@X@
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M";]4N/;J$FS;CZKVSV0_(*'"2SN6L.[@Z$V]PELVD!5IJ:5E9+&1-Y_BUTB
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M?W)BG^[0E;(JJ@8WI%O+WO[XX_=__OY[4-]R3\ 14FDR?8Y11>$:J71?=W?
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M[9W=_7J"C 7I#3XW^]+J."U5 VY[0-_K"3%U0G+I]"Q-X.*@-SV^<EY8X[O
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M(]=OBJ%F J1W%SA;@";Z'> V8W: KR*\]=,MJ^]#FZK%SMO0@\=1M8>!)(6
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M4H:RZ^MM;*[YI3L/O)1#9K9["VO;S=2[UAH?LA<)W;Y;>@= R>06YVRQA=6
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MI$)W=9P9O'?EVZ;+^-VGYYPRO46"DL ![ : 'T1B7E]W%D72CBC8IZL]_4I
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M7NIM0:/]^L[@?N^5Y 9HR*X0R,MI; RWK_\+H'L\NY]1)>2W&@UXWXU8= X
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MX$FLO$\XP&L_ 1Q)/6 FDC 2E!E$I1%GVU3<*=ZWS.'* OUK.34*?0+B]'E
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MFJNVH9D[TGLG)[UWJ)"+G<A]N$EWNS!*SE(VY.GSSN?IGE#Z8J0*P.BCF ^
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MGHIQ-1ZX-^O&8X+U<Z\**+WY-B*?:.3U1\YK@#?06W"KLN9Q@@?$4ET2R=?
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M>SQE4Z.9+1\/3@SS Q$8")D!RC/!+JER&B$Y6,;UA<*U35CH5?* (SBV$7X
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MC?(. E&2,U"VUA\;3W!]5378SQM7U61G#;7O@F9&RMK^C0R+'.[^DO )! =
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M"38(:!1  85(B(B^)+C\QHPD_12 ''F%(JD6'4P#9SX"<;B%KORU,A\J?1M
MT5V.#TM=-![#($VH*QU?@#OJ;S",STFVV8!@ ]X0O''GKD K+$;",_32L3C?
M?W=W_YA\-WJ T<R,XDNI-3!"R:63@J'3^8=0"^HU"L&EYPX%FZ>,3#6H2;+N
M>I"*79NWZL1YLXY+VST$6G+CS@'34+:PS4'(PVOTL(ZRA!RI]^1$A6<M ]6_
M"L&[+W@! *"POU'JRX^?_\IW4MXRU:<=+'7B(?D:.:(/)^]$2>HT0-!CTEPY
M/X#V5-">Y+0SE(<@IWU+^AO?[U.X:O='2,R=OJ<"-^PU=#S7J%LN<KKF>)C
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MX'3ZM;UIJ.O8)A@^?=?<!V_I[MS=)31NX9<X2%,4WD1I,$1:Q;_\Z$#39+-
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MXV*L3M'6-#J$(<9?$5$H'5G>YNA"2"4D_M:-ES$U2_GT;A:*X]&  +9N[+Q
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M&6UIYCK%@CUTVK'!,34GD.BML'-*KB9L:OI( WFK%3<3UO)$8L& I,F:^&K
M$,?E"FC+AT,3-IFI.<CAY]_OXTR3F[=^6+2U3-=B,K(H2!(\5V.T)B]6\CHE
MSU1R?P%0PF44H^ Y9,B=GHS;2UZS]%^8^<CZ_YTQP?04K4@=<NWUNO%9MX['
M^V5*:M:5X^9]'0EG^$IA8%:EX3AL/,[W,*(?3AS!-S$J.7"+7LS2P)QB9"?.
M$QT;2"M'PM,2+/TDC)WLC@3(G'0'&B;PR,B],[[&A)2^<7&B]1.:E8CY8^0]
MG#BTCZGCX<:@6 Z$,Z-Y\@"X8<DNRWHF!!_@:BZ+$ZQE2ATJJ'N.1T07&X<L
M;#YMMD?0@%L/\LLYM/O,,FO/^:-SC](4CR]+V4"_PD#0-W:(#>NDEH%^'G.*
MC%C*^5G+)<:'3N[M%0K2#!Y5(7-\K>1KYV%1"'*@]=);BG8=WK (N +02M(T
ME2%@+!,M0HNYUF&!)J8K5!HRZ#^%CW/+I(QI3[I&SRYF$3K[^#F6\^R2IAS6
MEL5#QO71CNR?F?L2!2$1N0(7%ZA(?7F>-RDA+1T(&5A/P43S<1V$:+EB_B>7
MKD>3MD"46D!?19>H'TH\M$YC%9C#B>C@Q"FZ@(PC(X/ CTRK*L_VBC</V6'F
MC%:1$W6* [67;B\_E<FLLNB<:#L-HL#85(J[KCT.IYRU->]P_,!491[*7K/)
MCGY-VLD#(0C/28NQ)-<BR(E5E(MQ]-%>QB88!K8AR $%F']R=2,[:.P%;3//
M1GB2Y<.4Q=V)81VD8$&]&>MQ&X5%C&&_8/[B_2D';G)+G9.1GGC(9S*!K]\$
MU)?\8G+:HR*TOQ;5RB->*4[/Q/&M$_"#[R,Y2+79W,G6Q-GH:P(NGP79ISZ5
M^;#;&=&A=*J*AAQHR=HAXRE'FV-LNF],U)8AW/M+V/PI44)K/R!2^%30C!*,
M$KG-L=-AU>&Y>!+(<>#%)8QMD6Q2Y&$Y7 JQGKAY ,-I2,D=2I ;>^O[;+N-
MXO0RHY<..4YIF/#%6PH/4_^<"(#]/,A8+T["NG%6K!^XS&A'1'AD/3G@ZGB@
M%.,*L;P'AW?AB#X<T8ES?KC$5J*%;)KA?Z 5$1C(9KK&7G_?U+PUY_KZS/)Q
M5R:E&#K&WK@9=?J/'2O8/5%NU/S,KR3]6H0^<V9AJ;A8BH=Q[KE:VC.P[7*W
M%=;[R.DT)N=$]3Y<*IBPT##!89?D%(G>)^=+-;&NM$BJ>>+H(HDH?WBV.!;Q
M/3YFU]7MLO_)2AJQ=IPX'^)TJ8M?W ##TKF,8@CAA"0@!4 3D16S388!_I+Z
M>3R&,6)0L^# UMU+3HFH25MVBJ9I2J\)D#(GI5R1:D5&4<L'\XDT_ F&<^)(
M0W"4/)K2O_*!%"+/$Y_I7?MOPX:8HT,@!;=2,5D(-,6#H"]'$9PR="@.[8'+
M"XFX) Z3+%RAJ&A^SM@:*8>8]"H? B8LSQ:6NF\.+MK^C\,B"5>H 8V4U"SW
M0IP :8P*9I=!G*2W9!>0O7 5<IO=MP"C)(U"- !.+>W X3V (8;WX12=3/-(
M&852? Q$5@1J1NRV(-;CQ&X*8C>TH]&EZ)^)")&NS]P8+>-G-^28W7?H!849
MNJ<U^^6C9!V JIB\KZ0N ,2(=N+P7D:_(H4V*HT#R",$B3KZ;\ZB/9KYP_JQ
M8^6PI]E:0XR_KO,3=$ VF5'1.IF7QB79HLQ*.H#W"C3&_9UM'CF>>M"%M1>3
M7R( @'I!LL<N2V7F:3Y+<5/)];YY,,OXJE)'9=?A!4MGYNE*R$%<R219-&U@
M'F[A&PO@E_[-5&SIVH6;7ZXT)<=JV7M[1SDQ2=27Y6YWDI3$PY"BDK19<U.&
M^O3PLV(Q)1#\)'(91O"3E*8F]RX;PV&MEF>(APK1<#"1SS"-' #<^6#EV*%%
M+%A-8CO\7,E9I)V["5+UT 0YA 08"=?F]SE[1(L.;_)$6# F"JL<B**ZFC A
M3Z?=%*FZAJ$ MTS'^%>!G!><+&M$*J1W9(U3Q==E%%^L5F1/D-OV;G^7@TJ^
M<.HF2CMRH-$3!E3KK*+8R7NC7PZ<^G*FES!SL1/#Z1&MP#>2,0"()N(-$0.>
M)ICLRKV?)]*%1(6O$#/>SSYSC9+D/Z3TO*YH]I H4_K]GM>EM!/J:'[XA);C
M?-[/!#;)IP6%BP.F4+[03<F<Z'[G*5G#9^&)T(<VEA,V$DWF_@76$\&78-[.
M9&ZB OH3+KAO;LJ-QW=HRV3@!!Q%*"@CQ)7<H+?TX17A%_0M"M-U+V7(EQ^_
M_.E=$<>GL$! A5Y/'-[O[H3EA5B&HT9R+S(_2*/XFB<3WE?(9*TXHAEKH2CR
MQ SD',LV(BB*/RS)'/1*]%N\\6 V(9B%QX=]OR,SF?QP/%P9[BU=Y*QPI,&=
M%.]I&-]<*LW^=IS[+:$F@LLU=R->/,<(31&1/RQ5K:K7J9S):*C4.L(050X0
M0>D.+'Z$Y2Q>:XN#7LH N?G_3<&5X*B.61<\4"V!3@Z03JPB\8*3R%OGL=SW
M8Y)8&(\6OD_*)/P_UT&(O@Q@_^+-G8@_'&C8>7B-#H(@/"\M:L30WMKK6JSC
M__?C'W[\\<?/SM85>:$^.7\^(3_!_]<!4ATW)0*41\\8YZ?/)PZ1%W^BJM?J
MKU_^?^<F*@/A,G=B*?14V1@1<&IM'0"7ZSB'%4YS(X& .YX:X7 @ LNPALTD
MS@!HV'^S-"%65^B; ;&ZC\VEF9SQ#^7[C8OQ:9:0D[,?\"(_DVE[CFC0\O'C
M>8>^1A@/A\M"FYL.C:7/Z/'T \_3"' ,QEQ[=(^>>R>BD3 <<J54PML]&()P
ME99"P78_$2UR<K025B8[#:]"R5-FB#1I=>1+@2\1A+(7T>@!2WG^'XB-Z MQ
M5[3F0'/V#QXKQSTCIMUCF($FR=V2?U=0WVY1#'E1W.=]+_QK'<H=Z]01O=9@
M[XJ>WPU+2J9<G_1&]IJ+)\'#H^ZQL-E!!*81GA FC_Q?7-#;I,D-2I<K\9WF
MC^[I-RO:XB&=GU:T.^>5]W?BA(CFCPU$.6_T%.*CDB\V]9&173J(K:(]UWUB
M-TF6*T[R,KX#*-T2\&_^,>%?DWVUX+0O()$W"'H$VN))!;%7*I/DA=X'*RJ:
MGLHJ$ !Z-+1].R9XL2#ZPHWA^9^08YO*/(.$*)*-0T-B'2(S,E'J8,@0CQ'>
M'MRSC())D 8*B\1F PO!Q;<NX6%_\TK1H$-;/ @"L'KLHQM0FI34_>RB39KJ
MD>W;@Q%DHG4?D99\A;G)>A'22"8PS+R0EQPYEW,#[GF0>#A*LKB7&$ICLT E
M#L%-U,;%^R%2:2"T\7[>U<'2C"ODTC^D+DKFY_/)Z%V0->8'. ,3:H'/</'F
MX8Q<FI=QM $]4<:$ZN6J>@F<[M0-]'U2RZU*N!%'Q W<R(B)WNH :(:I2=W%
MW'IQOT8H+=9G,A#@ FW;H8T[YRAU SR^\FM$XH3R2^K"J1!9]#(=PE*N8;Q&
M;H*XE=VG_Q#H KTTXX4&$T.;N:^"S_Z= S*,IG4>C4I<)9 V)QP5?/[/ZX.E
MKZ(\J4RD=AY'#]XO!U3WL6-6XL$G,ESV&S]6#GW4Q?6 -MLH=N,=\\71)':@
MU]T->J5?!M/9W#-(PL6G+TX3-+52BR/RV!X\<_B<YUUQIRA'G_J"OYXADS;K
M\N!Y4#F-"EXP'[@R7+W/>,$\,]@J<$+""_IY/) ^RHQ':D)!?K%#*3\>PR =
M !9'M.[<W3^..ZG#TX&K)!1G&%O)M.UI4#F&IZZR0.>FTCB'TGC6-*N,9R.8
MRR@D*7,77Q'ZMI/1=Y\])>38(YU=O'";;R^THJ(]AS;(;;\3@??M':*OBANX
M"Y+?+F.$Y)#7;T$8;+)-+\ CTNRG%6FWB&^E :]TC"?.AO5PK)P2RVB\> L8
MK .CK098?YN&\RQG^3TYW"D5(M"HOYL(386>MSM9!-. ]. 64B;22S$T:#G1
M/!M1@1?[<X3!L_@K.=/ 3+8,)6U<'"3DDRRM]H6W79Y=G3A&&+<2HBT?H@-C
M=+Z'4?Z0 ]PN_/_.N&L.*(LGP+NUAJ5E 3CGUO>8@B3_X$ \=XFQ"7B8)9/I
MB#O%;4)8Y<.:'&4]HU'_\CZH$D)D<Q@J;?KPKU?W;6Q!A/5PK)R:4Q"9AO.+
M312G'$QTN8*] E8#@-@AKY%-L#?+Y';A,4=O+M&T\SUO?/08XL')*SG(1.$G
M:E+.MP['6Z 7JEOA .#63.D2]PB)B%_)F9<B0CJD8@D[YXVKZ2"*)@E)K$WK
MB<C51(<X^+*H,C4%%YLMCG8(W:/X)0#;I>J8OHFX:HH>=0FU><C?P>?R)DI_
M1>D=\J+G$&0M)L!=1C'_"<KU"X7E(W7X4)UBK.4C.Q\M.YD39J,IEX$1DX(I
MD17(<9P/6NC"R\-V1@N:/( IP$W<=T9CO_/!?^4!_3[G00L,1?X0OW&\(("=
MB%]H.B>:D]'%23W]8T_P1)KI<2IDI;EHYAM;"98%?^<?^"!.'#$,!DK,!W*B
M2HUY4*\)@<QR'KP$/@K]OO"&HAUG%R!L;X;UL5@Q_HLJA]+).3T%0";H&U*N
MW.@9,U=574P8.'<;1ZL@O>X)UPV! UQ]*W2.Y)\XHZK(6W@5P42G:1P\92D-
MDD@CAOX>IJ0Q#,7$:WBRX/^]":]$3. )\+SW'RT>?H9&WUF(7#NH[)"6^Z#Q
M,R$YSQ#H]2Z#E[YJT+\=.CWB%*'=G#@5=\*3PH'P!";U"9%S-?"Y6A3Z&S?_
M)J+!UY__^J?"_- WKR9KTB%M2C8-ZZD0%^%ACKX$(38I"1)<"Z10O0J3+.X+
MYBO2U0:B,=L'C\OCOIIJW+E4>!5NLS2Y1B\(?QD -C @;\A5X+EY"I/E$SPF
MZ,W#NB+W%'3F?!E=93P@C7R:"DGUA%-#3F%&S70P@GGBXP$2VM"\R+TF7,H5
M/5Q6(#JL(^ D7U9#I 6:AF7E[ %G;ASOB$"RV( =9J!'TB1Y=(:D0]X.++_1
M-HX\A/S1J$CB%%X.?N:ERY@K"/LZ'/'VZ(KC3=H^?*P=^<B/;"I\\2O[CL/C
MWJ?DS=5/(RF$@%@@[B:LS0,@HR+&B-:<^X.AH/(6T<W%J!D5N8_4[O.7IX<@
M[7<QTP; 6OWYR_=//PA7LU&AY_H.'\\R<G$E?'-#E]VREPAQ77B?"2C:HS[N
MO,5#H +/24 E8JA\-<N*K(?HUNV;0$L.'-OF@6,T8.C@Z:R#SU8CHTZ<IVE
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MZ^-JB@>G2SSQYZ3G.O# BI#G$N5NDH_;*%QXZP"]T%^7J_LM\H)5@'QNW05
MA&09GX.S3;2ESNVA7R!1BW=S0$JE4=C/#INWX@@0GVP+0 +%^"C+4)P"&,,F
M[_,H&<<7%1]>D20V=_*'$3K2$.'5E _2$<9[.DQG"8D,\X%2KZ':4)UOQ\WP
MRNDD&._FC&]:M$G.^"UG?$(93UX7OL1X"K%=8WRQTD='\N0YK>[0%ES8B?P1
MX<#;L?\=1L$[5=*L,0C!)1J<O/$3AS7L_!?_[X1Z6;+ZM^1$W-V2!F#%@UUJ
M*[2;^RF.Y/FB7F+7P0L-8 N?J<66ZJ</D"[<0M)D6ELU?GT9A;;^G:VM7E E
MTT#4SD&F4';JD?LKQ&M*3;^1&5[K.B!K_=S=);?DV17_PB *;J*4W#+]7S@_
M_>A TY!)AUPX O\@I*T?&%E\GEG#C"K:M,/;=ECCTSQ^AB>OBJEK!YE&8,+4
M>/D0+3Q2*$97X2TXXR:)< \D&UT2S88"H^9)N].("%RT7R<(/VU9SX4/(6QU
M2<QZ[\SJ <S,,KF4V.G4V+DX+G:*(Z<#UC<+JGZ('#XBYRIT^)@*']T%344_
M#1MS)]UL"S(KY/?+F==3HN!NNJQA9\5:YNOI8&C"%7)XFPYOE,_KP9!3.0%:
M9FE<\^,E\E'L8K+:J;828#BR=!V!:W%_R88WSF(0QM3CCD,*+E.Q$%0PL!#1
M]D2:W*&)JZISI:E**)$I(=(5?8RNVCA'JR $%(^0^6>20<';D@/^Q(!J%R.:
M:S?>R87Z!R>)+AQ/:A;0[;+Q@WRGI9JO9]ZI(S?H0+<G3LZ+4L_EDHM).$,-
M6T_MP"Y/56"7I<!RR5.4_H(@"2KR%R]DA3^C.P1:!'!7X*XWF8LAT*Y7SD31
MA\,[<?)>'*D;AP;T?4^DMATY\0&50AKF!T<'!,]9%F@Y^:A/G ZS-$7J46ZP
M8C;<998FX-NVA[VXZN?/VN:9?KB)F+"DZ("PA4D8I]/X_P]/K!S 84#N*7H.
MPO! *:YFR!4629&NR8F*M@^)+FPX?3-A^_?7SMN6K:"77KXA7X$M>4\2'=@;
MOPV^TJ3H5R%[M54NL5(*]:X\(DT\135AX)/+KQDD\L9O1=[XB(W(>88AH?EA
M\N9C7:,4)5IV:-. @G#L[.H@(B6F,A(;+2@3A5M9RT2,ZV% $V.0!\@V2ER\
M7%T&;X1U-.BFGZDT22!6Q^<-PRY<0=..2]L^%)IPF9QSB1S:*H]/.A1RJGX;
M,Y%E$N?1(X"E/<ICU"@6@"$XYXP& WTO?%?>#H7MM'7 >,*Q%CZD#=[!+*0^
MH5D:I/#Z(FBT?[Q^PO,P>/KH?4CD$)6\&L=.^3H/<\0EV>HX?>*4>2<C']Q/
ME@Z)PE=Q:!6.)W&6Q7U1' 162P2M'PX)?.X8I)>@(0?AYHW:$_LR7<S+X=)<
MQ4ZF.66^SP2Q6XD%P82!3@"X=8>VY,O:E3Q:ST"]C>*M&Z>[&W<S@)>>W*(#
M31XD15A#S'1^>5$(^6*9Q 1YI5C"6IH.2Z 1%.AUR7*UXLJ^^S5"M%B?223-
M?>)P*>3.1+",Y?&P> &6T3>&G%<^2KPXV$ZA[IF>,8586W1,4WV=B*S&[!\%
M2H34_PD$67SB0_A$QT"+C^]TS""SSA%Y6@1](8%I4V26:5L3.$SW&CNN#)LW
M,].5PE?%X%>*?)&L1!_S1\P.0*Z9U)!W-('4P (B:SJP,@JLMT:7I/(@#@I*
M15;1W8G#.W2@QVE\,D8E7Z'H.P:R2V"-$FFSJWQU&M^;#,A<KA:^3]-$N9@]
M+;E[SN^HEP??54AD"M(E#>W->W!"VFG9Q?8)<:?1(V)5!VUXBS+\)N=H,3H1
M75V,;TQ]UT68DJOY,L HYK!'O:))6',.;<\1#5H^?CS#T)L2D3%9EF((KJ*8
MYI$3SIJ#N.56/-_Y^V&6G&L#DBJ4K[K4:OR%4.KK)'>\GM1?'?;W??:4O]02
M:MZZ13'],@"*1YYFW2&4YMEQ3[@A>$O6]_@H'N,2S6>[[G]/,S.6^F'&0U#!
MLJ\'3'5K$ >E/BE17YGST5UJVT+Y^KRYS,+U)DEM-CB9ZI!,;X*0S*%)P>:3
M-39ILL9I. \KWJK#E$A3N5<-1PMN(F,RQ:IX9)PC]M^K<("<LM)AD3]BOA<]
M_ #O&47FU(F.C%$(GC&)[ACTX*YS-[J)L911\&JS=8.8>3?V2VIYAP#Q _8;
MH2M=(W+2<\QP%FY)GH0Q>$-]BE:?,H 4F<0194AJA4FUFBFQ:-6YGB"[T#UY
M1*?@6R]!\?8Y5FA[GR IK2.U.-$1,@@QI?="3DPP'=KR$%1@F8"'RFR,CD/"
M\XGFT<4,><_MYULC+3+1 6C81+APT4<)]7V:1+Z#$OQW1G"(GETB'0J2N?V8
MFC0W!:W)9 XQH\PJ[CBAX^K0*9)^\#M*EBLXACVZ"Z\C-Z30\7MC(%6-)GDW
M@"\6T(Y8$!ITY51AZ@^29''^' &I]5P,E%ZR35DO\%=.\F2I%TYW5+MWAHED
MU!O(GB(]T:8.9ORX-O2)0.EOHC 2,AT+S]DW09=TX3''NX V=^*$XT.)#48%
MGP>YO3P)/&]RM.2Z=-M+WJ.WPO&6^J#2J'WRWW6$?;+8F4:R)VJV[*J:]\91
M3QA20=&AT,E.A)H]#1\J5UU#TC(.:B#Q@VEI1]? GKG;@.PLNOC\ /!E(><0
MN+#ZIUEZ$Z6_HA2RT_?,4$J1^"B12,#P.5E('6?=U"%=P[TP+N3+V!2+1<^:
M=^3V'=&!\Y2E@+SE[!#@K :C$SN0>HR^&QP\G2:EOU9H0K5/D8Y:CSDY9+KN
M?#_1;NA1FG<T?0KN86G&Y2/CA-/H3DFCRC@W(()MP[5X0!3QB:H956NXEP=$
MD]9D.C5M2;J-__UMT2__(B ^GSC?B+#O>NN,2/[CZ;KV'"]?0]\6]_>+LY\?
M[R\>'NY'72XJMQ+Q&Y>_P<DC?J$I@J@%P<7)8@,HS0Q+N]?+46KGG9')9U+A
M4$/_S'_GO3NB>WIYB0$X[YA!E:,E9PB%,&.,@C]]\3NWRU',3,HHN %=P2A7
M&LGH3P3*H<(0<[9VX^=^QL>B,:H9PH"GC2F>]C26JV$H*BE5)$,5;^XPB)"E
M?!TE4]FK:N_N_D\6^4G]O_F;VGXZZ@!2$V%"#37T NCK8 ;.=[/(RCUM$FX9
M3 "T$5$,@F<* 3IW<",@PL)!WAYY)X[<"SB>Y_T<)(W8F#SR>)PNM\8-.:&I
M>K>33X32Y F!57@"%XC]AJP$F3J((5?#]"89L,Z>,$0B3MDZXGS/Y<@?_N/@
M:#*QE4R83?4*0LI1DG:U_"@WLVA,B/FV#EX9[G500\>545\<Q*C+KJGEH8\L
MC=/W\6V, #X>^;^X,45>&R0^EK3JL&8=T>XA4)&KI&NCGR:8=2 R*L [GU;3
MS(38$1>K%:3 ?D'L#']PW^[(@7B' *(BP %=(J4<IWFY?KH&!H?/K\/4?:,.
M Q19C\/)/Z$0K<8'&IB2?O&6$5V*>Q-4<="K4^[VQ*FF@2W*P^O_%L7>!(A&
M9T)@/T=/:>'DUG^UYPT[T/*$J%F#4H1;B!G],"IB,V5B?D;8?XB^N2F%[7A8
MD\KP#F<@9K=NDIYG"').H6BUZO5R!6H+_TYG3?K]E$:?-KSG]T,UE@B6G7=_
MYA2+7HD@(/H5:8.@9X=T?>*(SB=S4?N&W"2+6<+5:."<G] )3XDD=3.=^]W0
MM.$FLN;,!9I#9P-@*L=%N@48'D!/Z/>.*U"Y*5ZJ %T2K4_XDJM@'0O(A_,
M9^37_ECXDNQ> RDN,!QX]'4I!P ?PD3Z]I'Y@/NPX,!I5R&&YU#K MR4A]^'
MD-(Y%\=?Q=-"RIC@?'+\=\&6%@SZ,F-F84#AUF0BKP_H*B_<N\BV*/<!OSS^
MX?X/CDA_!0=IED;QKB;5IY&C%?G?$^-PG6>F3QWN.C;EG<JP1"Y=&$.ZZQM]
MP)%)1'/V#QXKQSUR^$%#/L2+MVW T""_16$*" :_DE*CI+!$>5<TF=;!$HLK
M=%9S6Q:].+0;ZM3SZR%3;)K^4IKA#:4<;G.8Z]&=<MA=S(##AT8$8AAMDR$
M#4X2+E%SQ:F9"-FG6=\'61:","-KAX>Z1V&OZZ"X]PH-IQ-/<-^/1UYGY>5$
MZLD1)U1Z,78F>Z+'XD*@A%U&\;V+*QI-[AD)<(M)>NHF>\@XLA^::,V!YL9W
MI!N9-)T^+^_WTRJ*/T'/)TZ9]&D1/'0I,^G'X=*/BM=>G">VQ!2]A0)+  1=
M8>ZG'R;&,1F>"WS^:]@F#:D^:8E1DWQ2$>IB@^)GTM_7.'I-UP!+ZH8[AC1
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M#^L8*>>E<R-6D"Y)A/PX9%-TQ^'<B01UF1&) @EK3(M8:=:(%:0O/"_;9-0
M2@]]Q5.^(8K2M+(5I)YF"1%\DX2,\BD(Z9&H2'.F-*@:U;2"2-T\@+*Z285C
M4L]J LGV0L%SR$0W3S;DDWN/_@NS6S"_]P59MY 3EWQ(TSAXRBB(RT-TZS9&
M-TTU "M8KJ<L*9/6Y%32NS$K6"&I=R3#JM;QND5#9-+$_-(V?1;0FWNYNH[<
ML.ZJ42LQNX*T9"@^ T"H^"%Z+3T'&HI9L=0T;DF-VI^V.E80IE*1+E=U+W23
M)ZQI&_/O(K+(*!Z#BV&'U+WQM86LF#.57']''I&O#.# ]"D@5;&"+'A&&LJ
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M[;-#X#*(-U>J4ZW\?=I!"4@W_;#R$M,.3/,,D+\J!B3;O@8Q-6YICM5/WCK
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ML*G/'FOT,AR%>^_IA#)0E_[E@WGMQ[O&,U0 '(Z_>VW$P+FEW%^C-/" 3,[
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MA;D+*7NT-Q5M-U'HL6'T($C;B'T!I7N'DEI 5,%_;KV_#MRG ---;G0N=&C
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M%A$W%'I 6QA*>*OFSGGC%>[0*BWFO@SRCM/6DSBU^VWV (DB<!SU9DD8C7U
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M!!6=["/FXB"XJB33TSZR\-2X=V)D>AHCZS@9[L6!;BN33[#7[S;5%V+1?T>
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MTHVWK_-.S!L=6]EW;RJXSP;<0(?:D%&EWMRI5N9L^DVX,JU'?*H5.-N'$ZX
M^[6@:CG.%J6YY>B_1%2MRMGLG'!5>,\;50NBU5R=O??[]*34 4\G57=0SO%,
M\[M'XOFE:KG.5O;TBR7W>%.U0F?#7'V%1GP%JEJ6LTVOZ)Z:^@&J:J'.W@"+
M]@_C":MJK<[^@>E/(\H+6-5RG)T%!JQ3WNM:U<*<W083+DRQ#)3WNJK5.+L+
M!J[&JWC45X;48C\&5JW*.<2MOBJR+XQ5UZ8G,?;_YX<>R(B(WQH-J+^7Y/40
M#^/D=P3'G_QD]T/U3.H/F?>9Q,GN4,SD*DS]*$ES"/J/1SSENYT'#^75L((;
M5WX6OJ/?2!4H2O6[] ID7AC5D(<9GE1WQG]H,0[XS !^0N@/QM[KDWHX(RJ6
M5K*3>Z\UGM\)/3]8K[YM6 \R-83&T0W$?/E3?2!G>04I51L0XG#^<1E'XA7:
MEYR%S9A4^O6_W 6MW"XX]#<J:/WO. M9H6VOX@!K@+CZR'."_S05^TE_WEF
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M/D7HE(=?5+',A:;2,:X6<T\+?A_KMA5B=1!NX^*BJ-]\(7$5!^1?4?%:8U^
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M.W<C8U+NU59X0*L/T_&(PD WP3$ 1W416HV)7*B-[T7LLA/#W>4(#MPJ/QJ
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MXOQLA8OTN0QM#NJ>+_J-?=%/WM-&93^>R\<1=+BUAT>#9S;58T<7=0K^M[E
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M\[6;FXN;P,0'($AO8++#N@B^9TD2X]Z]##-_ 34KGB+7V:Z-<_T)H!^F@"S
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M>TU'=RYW%QMMX[OW0M-1MC;VTF.8_G8# 4"6.D"G7O:()$M9M$@W=ZE^7B_
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M<:NLMIAGZZ,C9W$7D/95"%H-G"^.9*'IY9(RFE6"0=L[7ZS,WU('HA] EQW
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M8#X?RS2GQ^]9S34O%-V,[D-/;6?/3BI-8DFMBS263G8H?\7_\XH6I?CS__R
MYO/?WGX?QIL$_ZG\0QPG&1F!_ W_"43DC?C_%P8EE.T7%+Z!W2N>>NSM$%ST
MWPHH@PS^$?]7^M]!LO/"^#8#NV?T[S_\OS1_3;,PR_%WD9*<[__W#QC:\+]+
M]P/Y[SUYG^&Y&"J'Y2:+PXADP__O'S*(TX4]-!+T_*S\]P]L,G1L\8)H'2,5
M$!64[I(89!X\G !0&*>9AW<"&Y\-F@.H^KX6UR81LN US'BP%7FKZPTB#^G]
M::>B?P$(OXUF4F5X82"M__?U+O'BU18"\D.;U1D_6LGK=SB3"2)5-=R]YA!I
M78CY<L(>A!3FS]8LE4],&?Y:_?S>7:#Z+U:NRO4.P"W:(.B#']D;5H2]^+"*
M8R0=B*O@$9D3<8X5RH(@^?8.K=L]R) A%>1^ANN1I=]"]#\9FG)[+46MK%S?
MI_ S.UQYA_0!C0N_PS#+0'R?9*'?H4ZBH94$MN]E?"=>?"0\WM%?MX!4M,7M
MO>@B@8AE43O\>%)%],#.72#0*%C)G(2[.5!<(IT2+0D\U.HE?E$*3PV1LXZ+
MVQ]I0VM0Z6$IT<4[6$B_#XF//?,^T:   C^)?62MD@^@C^X\G.(:A%@? $@L
MU )M<']+ >&^\%*>M;PFULAMH6J$E#LDG9[V7E>647ZP4G8]0'"3X_SNZK6?
M-AG,GZTDYC9&1R/Y&X[]M"FA_V8I&55%\.J5J>)1OIH4UN_-C8,MT'AK6A0\
M>,BZ\Z*7_08F.-$_3L, %..6=_W(E>X[M%EPC;_*C#CRW]#N[HB0RRB,0]^+
MJG(\QX.Q]W=;C&.Q-DN[KXKH" L0\3V5VN82MVS2O<5_,L[4L+J @U^U\N*T
M(2Z[/UAZ1..X6$Z*+_PS>4U7?G8#\,:*D(71BF:6JEA%H'(W_>1+LRV'>G%5
MD(<D"OW#,_C,+J*&2V= QRX"6?63:1:H'Y#JG?)X.3?5[X2LX]FCULD=,8QO
MV>$MV]8:NG^U4E]@5ORNGTUYQB/WN'E 1VNYN5%7 !%3>)V)IQ7M4?+_WY((
M>_=P-E!V6)4#'P_;@;TG5[@D]'EJ,=W&^43YU1;-0F*7[O8)1+,K%H(L#18Y
M(+@BU\$+19B$U>_!!_DEK??RD+ZM%<:_I:8Y_0FGI<+P=Y B<;M#%F9622G&
M+I=N;^WF5G@YJS*1I#M8<T2)U6JJY_LI0T9@6IV[!1.O-[A&5KO2"M=]+C](
M$ZZ*5M/L(4$2SN(%)\+"&<,A)KH)89H]H.&Q&AZ7A!XC"1W_CV1C*]4BV5S)
M7O2:V]J6HU*\T'5R6>DJ66$]?4M:/>-*_F_@)LEA)P:CULG*A5=[ 4=1-98:
MP]J#E!/(=R>,SQ'5#+-=I8>U:Z?K6>G*%- SFC4GG]!V8"C\Y%1_*C1[\N-M
MO,J>W\ W#_Z&/1I%]LY1+IPVB#5HB8^/BV3CU2^A(86Z+2Z8/ULI,AH1Y4V1
M?.V'7K3^B)%-_Q;N[\)=F+62V10Z6.KA/>Y9 -]Q*)*::GZ?D%@2"%;D7L1S
MDGE1-Q7]/LE^ ?C=HF0;XR< "XY'XJ'\$V[WM9:TTW[51G.DN@521H++?[FC
M.+;OS-P4=V;HX1NIIM;%;ZCJ0"&J2QNO<0[^#*+@XH!8=K79D&P,02::TCCN
M,$6M$%<UZ1H/5XMT:(DNUJI=R-;'XKP8Z3%,?RL8'O\7.M>;#ZW@/S4<RDJ]
MW&&$!\2Y_" 9KX6UR]P.0>,<4IP!W*ZT3,_98[6U94G%24S,ZZMTH2_?WCK)
MSW/ZGZ#^*VK^=L01%.(A2$5;^:@5+N IN#:J'&M1&-L^#%<1^,2Y2&@R.\\'
MZ.L^ZM(SEH3-K#2:CF'"?(\6,\/1?K1T[3L3_#:VB$#QJ;8* F)2>%&7=1M;
M^[B<<HVULJN.M!>VX/X>9F^U\&ZG&ZKVLF71E8/)>(F>T/1\&)+*._@> @F&
MD5]8HDW4B^(>(+\8YH7GMQ#*7<N0:6FE_"ISTT@*!U))\;W$/'M+<,)L)\HE
M;F@E@<\?R?-;DJ<>FCB^])0!$!=<>;QRW$^$5NQD)>'$*?V!78_HK*&',[A-
MK"2*+V?ODV'RF=;/&0E-UR[H5HE<6^LLDL9V?/Y OQR8L1;F-I;L9R73TU<-
M/PB'^U^7CP]<-2[,J?1H>8?17TPO-NV=]&LTCQU^%O(E!9L\ND/RE^%/&]K;
M6I]+&5JO;CH\PY <PF45B%;*(J.-,Y)L]>Z%9,2;!.*4H3IT5JJ1QW_C]*)V
M,MNPOLY @_WF>0;@D:>Q'I9L,G2$=311F9962KDG-!Y(5\PLXTX.CF1K2TFE
M5:*I"*/]Y@RC_A,0;QY([Z*.?X?VBY6K\_+T4X*8*B:;!S^X>F@+E(X.+=G:
M2E)_\2+P$H?D\GC7X*/_9B49M:^))&BUG&_TWVS93\.N"7:?M22OG[+O"E*;
MNX/ 2YD(41>,(A(>\6;W)K9,2\L9F.]*'=%W.F&XA,3]QXF6* ZM>1.,F6J&
MZ^+%670H:%[Y/A9DB.XGM.T"[,@HDH%60;)'?,^(.I\XB+5&$LU?5W"(FH^/
MW<=.L2&\:=NUDN0[N',^T)T=;?\?OTW+!6))@IS(54<>\$0+J.+>:_?IN?G(
MSZ;IOO->D9C/$GB@5(QA_&CEYJRN?#-$,?-G>X5L^P1FT"5J92UY*PB\]88H
MS 'AKJ/0[/_0)0+I7I[A6.7U)X!^F-**#AQ3,7E-[%,FNP5KJF(V^R1>^6\A
M.KB*(B)/>^"'FQ#I*XVR?VO8.-F0R,-)IIAZ+RKKJ-87](["9;+ON7.V4I)2
MNS>BF VLE,JEWQ I?VJ.1ID.5A+<BX$IZ,6B#E82? QJ9R#NIB;2?S,G^HI*
MVJG_!G;>__?_ U!+ P04    " !:1&Q84N!D70E0  !$9P0 $    &EN>GDM
M97@Q,%\Q,2YH=&WM?>E7(SFR[_?W5^CU3,^A[C%N+RP%S)US7."JHE\5< P]
M??LN'^1,&:LKG>F;"^#YZU]$2,I,VVDP8'"FK5FZC9V+% K%IHA?_'T8C[Q_
M_!_V]Z'@+OR;_3V6L2?^T?V/W6:CWFS^_1?U-USQB[[D[_W G; HGGCBWW\:
M\?!6^L>,)W'P?^5H'(0Q]^.3,7==Z=\>LX_CAY.?Z+FNO$MODO[N4,C;87S<
ME#[\_O=?X%>Z:FRN&01^O!O)?XGC9F,<GZCW[,;!^+AQ0K\-^$AZD^,;.1(1
MNQ#WK!>,N&\N[ =Q'(S@VE@\Q+O<D[?^<8AOQ+?A_>8]3N %X?%?&O2?D_NA
MC,5N-.:..!Z'8O<^Y&/UNGLUWG[@N2>YL;5@;(\.!\9R+]UX>#R0\:X#5PH?
MQ]!]&,J^C)DF,CX"J#!^<QHX\'H1SA)A\;2SM[]DEG_[2_.@<;+VZ2V[QJ];
MTE,!O"]])EWX6PZD<)GT!T$XXK$,?#;D$>L+X3,8_@_ZC<5#P81FA+YP>!()
M!A\E7!C$0[8C/S _B.$&F)/D'N.^"U_"M_=!XKG,DS^$-V'J/B<8C07L57DG
MX%7AB,4!/?\4ON?^I,;D@(V3OB<=N,65D>,%D7#K9FW>GUQL2]CB+ "J"\8C
M7,3H1\2 /8)8L& DHP@8(ZJ_(R$\,9B3@%7>_+0J)5GH\XO+__SC>Y==?>WT
MOG=J[/SBM,Y.+R\^GY]U+V[..]^J1(H5J[L_.M^Z[+>+\W]V>]?G-W]4E1+T
M4%<X04@R_3CQ71%ZTA<KT1^7O:O+7N>FRZZO+B^N+WO=,];K7G<[O=.OK/.E
MU^U^!SY:1#H:FO11]QP?UO</?I[=PF\E/MYG<]T,02O.4X/MQ/C#W_[RT&HT
MG9/7:+-W6^?.;2C$"#ZO3_<J>KDG']#6H-U!!@F8#&"D! /V*_<3'D[808W!
M=8=(95$M(G<' ^&0,70&UE,)*%UC_0D9<'T1WZ,9N"HRKD(Z<S!0?O.!6F$D
MX\GZJ%5C'"Q>?W<<!O #V+3A6','"\);[L/#72*B>)!1# XF(Z91=)VP.QG&
MB4 &YBP:"P=M9@>,8>!O=AN"7RKH,F3F+\(7(?S<B2(QZH-)##<I<]D+?+50
MUS&/Z6&G@>\C,SE)7,&=4(9US>T"I&R)6/_<#_XU&0EVA3X3K[%OWT[7R_YG
MPN/W/!3@W8TD,JPG>5]ZL'SDXI$K-^1WR/LRCM@XE+XCQ\#)P6 @'7@-CUEK
MK\$^><E@P/XIX:5G(7! C7U)I ?NJ%N;8NC&07NOB@+^>@RN4Q"6@*??V'\K
MDXOS.SMG-^R"@8D*_^W"YZ_L>*T6Z9\)Z('!9$WD^-KM=3O7-8SEC),P2D!G
M@;[ ?2G<Q"&NAYT)/XV#2$0U!@-QAG"UXR6N8*&(! _A"Y2)<<BE#[NZ1FHH
M$]I*P\7\!XPH<H:!QT,/1("YMZ;5X5B$$FU*C!*AW2-C"3? N#B[XZ$4,6DX
M[G!7C*1# 2 YQKT8Z>&@0,$W]R60[C;5AZ/ 33RM@6%FOE+##AM/PF \#*+Q
M$)4DCL'AGB-!!*F+0<V"A G\Q/%$$$N8;?X.'HE?U.? A7$"/\,W$=NIE 3J
M7EQ=1260/R=(_BUU"],=B+RJ50*[E]$0[@9O9@ +3LSIBDB&^!TPW\(-!GLE
MW9)@@8+%.#)1VH$4GHL[@!:]AFX2/-()91\T]"@ =3U(/+ BY8OM^K=E51UD
M[M36&._E<<R=(=!K".YF'$RQ[1J&L^T[!EAUD(3 W. 8.<+HK84J1OI1'":.
M5FF28@91',VI*QG!_O,\4B=!;F]%">RJ='LEL%7I3GC,*%+Z(_!=B8^'08B8
M@:4:#\%9]H)[RREKX92+R]]K[ ;9Y?-EKTL, S]&H,O#U"# )81WCB2J;S)C
MT&9(X@0][^!.^.!T1[3AU=UX0"9<Q31C<,S12%'B@'$,BZ%@'00>+'HT:U?F
MSH\'GGC8=4&@$SL> SF2D7\"-LW8XY-C_-4<0*<DK>]+-=/<N;.V'<V4Z<9=
MX;LG_> !:8<'V'UPF$0(C\%C[,T]FLD.X(>A>?F8WXK=?BCXCUT^@'UZS+U[
M/HF>=9R?NVIZMTQMEL8T 0O7)8J!7>;HETT0'MEH_;RJG?-.1F2>)HV4@:6/
M3]\E/G[&*QXC6_KV9GWO8/]G($LS=5MS:Z2O:31^GAE,R>GXTS^NG6!,2JRG
M54R)8DSU5P6\7GGZG(3&LT-5JV0VZ.CT$&).@4=#[GD,4PI@ZT>@[?'T6@Q0
M'Y--#9XF)C70;7/F<F84E]T27FN4;]H2UO:5B7;K[X& ;Q*56\$,5K''5G6
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MUS)];80] ;"GR,&PL)@D2+H\B6;FHYJXH7*@P85IG\J4BICWRW731>0^!VR
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MJ@58I#44K'<RC),",5@SSGRNRB KI:OE9#LH!.$,?>EP+X_U23(Y-DYG&OK
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M]SP4S G"<1!R]$9JV ,&$^VQY]0XE+XCQ]S3K5PBQF/6;C79=3(:B9!=QZ'
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M'U,)/6DR5S'1 H\/2Q2L85[++1DL[,3(5HLT$W)R05\K[^LBORB+V8Y7QRZ
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M"3VE0<]V_-YQF!!1YJ@.TAQ?W89T@LQTN$;"$A)Q&1KH+(5)(8(("9P3BA?
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M=&7&;\ZBCK 5<8R^6"B5F <H'Z-:F$.KP[8^ZGKZ8M@VAV3_ U!+ P04
M" !:1&Q8!(T![Y<(  #M-@  #P   &EN>GDM97@S,5\Q+FAT;>U;;5/C.!+^
MO/LK=#,U6U"5A"2$VQV'FZH,9':IVX,I"%5S'Q5;3G3(EE>R$[*__IZ6[+Q
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MS/F8-, )V:XN:/UZW[3;O1#  *&_$3><]:\'%^\NSGJ#BZM+]O[#]<V'WN6
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M[K8>> _*.2C]55#N3"EKV-R=C':&*& ]EB$ACQN5<F)=;H!:JH<)CER'%30
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M,_!2X/!3V0%_Z1SDBW_/8W^:59YFG1[1-^#>_'AZ9+\[]W]02P,$%     @
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ML7EN?3SLIAQ8M;F>N:6Y-FM01/A*2K6\UG6C9GKEBO"_MXH_HX)L$^HI"B:
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MA"](5=C5J]\VCV9/GO7;]J'N/U!+ P04    " !:1&Q8VI1\W.T$  !3'@
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MS39"-^Z.(&6VT-C]BM&P"N5[GNOM-0U0/H+D!0L*EA-DF34<V!URU;?=M",
MU41_QPO<L0JNRZ!I7SNA%UVS8\/U7KB'_I[=V&NZQ><N>]?M].[RZ3U'IZ,;
M3OA!W8;>_-8PLIB1Z.U<90M)G7H6Q?85+I$;9Z88>1O8_X[Y8O/<^G#833FP
M:G,]\ZOFG5F#(B)J*57R6M>-BNG:%>%_;Q5_0@79)M03%$P ?Q$5)>!W[,K>
MNR;;C>GZ/_$#7TX&6GX&)EZ6P5<31EVZ&M1NYS!'B)G@%!IL&QG;,+I[^3-I
M&X?MHHT[3_F&E#!9S!3!^)S(3;3N*M\#F-D[,JZ1D7)*!7M(9'QPF/&#I/)0
MJMHG\[4K<3_-K-Z1\:#)V)6XKR.>8<)9#*?K@XYQ'/.(J8:T;R'1!\7/_H7B
MR$R.U'Q DCT+NK(/H@AKND:)- X''UL=\-V<@]S+TZ'//8O;>#IT[4HU%FSE
M4*ZJ<U%S0K-(94AYD0M2!L8:WKIUK6\EFAC6QV&2WKB.3=359)ZS:@5U2(Q*
M"(A8DK*PRV6_;:Z$CQ_UV_8R^5]02P,$%     @ 6D1L6 O(%:K0#@  S&4
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M7S N:G!G4$L! A0#%     @ 6D1L6'/:'\$R^ $ !T0" !(
M ( !+X0  &EM9S$X-S0Q.3(P-U\Q+FIP9U!+ 0(4 Q0    ( %I$;%BU?.1R
M9?$  "8V 0 3              "  9%\ @!I;6<Q.#<T,3DR,#=?,3 N:G!G
M4$L! A0#%     @ 6D1L6"U4H*YDI@  J\8  !,              ( !)VX#
M &EM9S$X-S0Q.3(P-U\Q,2YJ<&=02P$"% ,4    " !:1&Q8.K9'BKU4  "T
M8   $P              @ &\% 0 :6UG,3@W-#$Y,C W7S$R+FIP9U!+ 0(4
M Q0    ( %I$;%B_UT(699,  &*T   3              "  :II! !I;6<Q
M.#<T,3DR,#=?,3,N:G!G4$L! A0#%     @ 6D1L6,?7[OU;VP  [Q$! !,
M             ( !0/T$ &EM9S$X-S0Q.3(P-U\Q-"YJ<&=02P$"% ,4
M" !:1&Q8X8;VS:$G  !4+0  $P              @ ',V 4 :6UG,3@W-#$Y
M,C W7S$U+FIP9U!+ 0(4 Q0    ( %I$;%@=G-DW+V@! -F9 0 3
M      "  9X !@!I;6<Q.#<T,3DR,#=?,38N:G!G4$L! A0#%     @ 6D1L
M6(7\"4H4F0  =;X  !,              ( !_F@' &EM9S$X-S0Q.3(P-U\Q
M-RYJ<&=02P$"% ,4    " !:1&Q8X_B$^7$[   410  $P
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M-S0Q.3(P-U\R,2YJ<&=02P$"% ,4    " !:1&Q8@QS4M8XJ  #L,0  $P
M            @ %[%@T :6UG,3@W-#$Y,C W7S(R+FIP9U!+ 0(4 Q0    (
M %I$;%@M@B%,\SX  +)*   3              "  3I!#0!I;6<Q.#<T,3DR
M,#=?,C,N:G!G4$L! A0#%     @ 6D1L6-:SK@FD:@  =G8  !,
M     ( !7H - &EM9S$X-S0Q.3(P-U\R-"YJ<&=02P$"% ,4    " !:1&Q8
MZ[Z+XL1$ 0 J6P$ $P              @ $SZPT :6UG,3@W-#$Y,C W7S(U
M+FIP9U!+ 0(4 Q0    ( %I$;%BP[19'RS,!  )" 0 3              "
M 2@P#P!I;6<Q.#<T,3DR,#=?,C8N:G!G4$L! A0#%     @ 6D1L6+B#4<8&
M< ( E]P" !(              ( !)&00 &EM9S$X-S0Q.3(P-U\S+FIP9U!+
M 0(4 Q0    ( %I$;%CQN5U_Y+0  #74   2              "  5K4$@!I
M;6<Q.#<T,3DR,#=?-"YJ<&=02P$"% ,4    " !:1&Q8SMP6#SP2 @"#A (
M$@              @ %NB1, :6UG,3@W-#$Y,C W7S4N:G!G4$L! A0#%
M  @ 6D1L6%?VM?Z480  ^78  !(              ( !VIL5 &EM9S$X-S0Q
M.3(P-U\V+FIP9U!+ 0(4 Q0    ( %I$;%C5!27<UIX  .CQ   2
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M+3(P,C,Q,C,Q+GAS9%!+ 0(4 Q0    ( %I$;%A2X&1="5   $1G!  0
M          "  1X*'@!I;GIY+65X,3!?,3$N:'1M4$L! A0#%     @ 6D1L
M6,5[(-]:&@  12\! !               ( !55H> &EN>GDM97@Q,%\R-RYH
M=&U02P$"% ,4    " !:1&Q8'_>W61(#  "-&   #P              @ '=
M=!X :6YZ>2UE>#(Q7S$N:'1M4$L! A0#%     @ 6D1L6':+\#R,!   *RL
M  \              ( !''@> &EN>GDM97@R,U\Q+FAT;5!+ 0(4 Q0    (
M %I$;%@$C0'OEP@  .TV   /              "  =5\'@!I;GIY+65X,S%?
M,2YH=&U02P$"% ,4    " !:1&Q8-6UC6J$(  !"-P  #P
M@ &9A1X :6YZ>2UE>#,Q7S(N:'1M4$L! A0#%     @ 6D1L6 9;RW;<!
MVQT   \              ( !9XX> &EN>GDM97@S,E\Q+FAT;5!+ 0(4 Q0
M   ( %I$;%C:E'S<[00  %,>   /              "  7"3'@!I;GIY+65X
M,S)?,BYH=&U02P$"% ,4    " !:1&Q8"\@5JM .  #,90  #P
M    @ &*F!X :6YZ>2UE>#DW7S$N:'1M4$L%!@     F "8 =@D  (>G'@
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>inzy-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:inzy="http://www.inozyme.com/20231231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="inzy-20231231.xsd" xlink:type="simple"/>
    <context id="C_471a56d8-9599-49a3-ac22-3a686ca9ff8d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0ff899d6-441a-422c-b0bd-1738ae7e6c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e9fc3ff4-5b7b-4b15-a31d-763d0bfe62db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inzy:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4c84ce21-27ad-466f-a52b-53d2b027d662">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_be56dd08-7be1-43d7-b997-dbab1bf7f427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inzy:YaleUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d18b316d-5084-434e-a439-1915ad6efe10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inzy:K2HvMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-25</instant>
        </period>
    </context>
    <context id="C_196b61ab-ba69-4401-87d4-819541ae1871">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inzy:YaleUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ce440ee2-4c72-4b3f-867c-b18a4779f0de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_fc80a413-7ca1-4fd4-9918-01e35939d5b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_9cdf7217-5d9d-4e8f-a508-7e31ed97b29e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_db0a0e7f-8b7b-448c-940d-e857265ac0d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inzy:YaleUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="C_cad8e074-adf8-454f-b55e-9b9e5c164673">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="C_1bb0cd98-9386-44b8-b7ca-6ea13928be77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
        </entity>
        <period>
            <instant>2022-07-25</instant>
        </period>
    </context>
    <context id="C_1b475cba-fda5-4a60-90f8-717eba9366b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e6f1df46-623b-42c5-95a7-877ba9f99313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_bdaa54b5-eb56-4511-8115-339fb1fdafab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inzy:K2HvMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-25</instant>
        </period>
    </context>
    <context id="C_5bc7e1b8-abf2-44b5-9b32-535f64c92fa2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inzy:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-01</instant>
        </period>
    </context>
    <context id="C_a654e8a2-be67-4c8a-a856-140b00703ba3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_aa1d3c56-5369-4d66-b7ef-2331a4328983">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_53f07547-6128-43d4-94ec-d5cd4d0f51e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inzy:JefferiesLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-14</instant>
        </period>
    </context>
    <context id="C_cf58a586-baf1-45e2-afe5-cc909b0ac57a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_909f663f-1f61-4e6b-b9d6-919c23e28089">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0e40adfd-e61b-4fd5-8fdb-f07aeb03f570">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">inzy:ShareBasedPaymentArrangementTrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-25</startDate>
            <endDate>2022-07-25</endDate>
        </period>
    </context>
    <context id="C_afa7e7f7-939c-4d45-98c6-aac2333bb8a1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_ecaeeeb0-1d3a-46e8-a993-a422899cf67d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inzy:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-23</startDate>
            <endDate>2020-07-23</endDate>
        </period>
    </context>
    <context id="C_fd818a77-dcd6-4172-b69f-ef9f6f65f940">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ebb0e8ce-192c-4794-b110-e57d539bd7f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4ee9c018-375e-4d0f-ab9e-435246e8b7ce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_41e6d162-5110-43e5-831b-9b8060b23a84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inzy:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-23</instant>
        </period>
    </context>
    <context id="C_bbdbd94c-6c63-4c85-99b0-648d3794ad11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b8ef8150-b682-4318-bd34-79e0eb945521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inzy:K2HvMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-25</startDate>
            <endDate>2022-07-25</endDate>
        </period>
    </context>
    <context id="C_580be68e-23a1-4156-859f-97d143db13e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3d6d281a-1b18-436a-aaa0-c7bcf2e894fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_cc2d588b-2f3b-4c9e-8375-5d861c028af1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_52088c66-3520-4604-9fd3-bc8ff48b99dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inzy:K2HvMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_095b17b0-4474-4132-8919-5e9087e56021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8f92c86f-a41e-44a3-8900-38efa4b160f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_93d69508-3aa9-4327-a66a-00b902adeda8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">inzy:ShareBasedPaymentArrangementTrancheFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inzy:K2HvMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-25</instant>
        </period>
    </context>
    <context id="C_c1e93c7a-08ea-4229-9081-72bf42fdc58f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inzy:JefferiesLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-14</startDate>
            <endDate>2022-04-14</endDate>
        </period>
    </context>
    <context id="C_9c13b456-85ec-4115-a24f-2f8c865d0abb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f4d73906-7252-43b1-b4b1-204a7275742a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_560a8eac-a2ea-4e9e-8e4c-468159d80f18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_94c35e60-92f5-4512-bce8-5ad4b2e3d95d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3f4c43df-91a9-4dcb-a518-2b872f3cab86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inzy:USGovernmentAgencyDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_9dcd98d2-cef7-49c2-a825-548d1468b4ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inzy:USGovernmentAgencyDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6218f8b0-72c4-4511-8848-700fe16326a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f2eb39b0-33a2-4aff-a77e-446a7f20b7ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_dac8f012-8074-43e0-b610-ec3ed404d713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b766d812-c104-4ba8-94cb-06af03d52200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_02f9e665-ab6c-4248-ac91-2158ec322783">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inzy:K2LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_405879f4-cccf-412e-9ad8-4013cd3d818b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
        </entity>
        <period>
            <instant>2020-03-27</instant>
        </period>
    </context>
    <context id="C_f5346b4d-f225-4d76-a62e-df2c1fef5d1f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="C_58e1da8f-d797-45d5-94a7-e1c0672c5b37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8bc77b63-43ca-4a39-8474-2b255355a3eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inzy:JefferiesLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-11</instant>
        </period>
    </context>
    <context id="C_c7103008-51fd-4024-8f26-143b54185554">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b5a7dbf5-13da-420d-8cd7-0ede5acf17cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inzy:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-01</instant>
        </period>
    </context>
    <context id="C_263cecd1-5504-45b5-bec1-fb7bb72fed3f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inzy:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_08242d46-09fa-4d0f-acdd-9a2a331c3f18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f468c3aa-9d5e-4348-b6a5-6d3b6072b370">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ca6446c0-a789-468c-9c42-d76f1a43d7b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">inzy:OfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_ba3b1d97-e28d-4318-9ed8-6d65ffffa8e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_da086e8a-c936-404a-b841-ba2c9c0e2bfa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_01add2ad-475c-4cb0-a885-6e7db27bc554">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
        </entity>
        <period>
            <startDate>2020-07-17</startDate>
            <endDate>2020-07-17</endDate>
        </period>
    </context>
    <context id="C_6f3ac30a-0134-4683-b65a-b99db351909d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inzy:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-23</instant>
        </period>
    </context>
    <context id="C_031bf463-89a7-40b9-950c-5f55540d3e85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inzy:YaleUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-01</instant>
        </period>
    </context>
    <context id="C_e8c0a014-c50e-4051-b4de-b6a88a7006fe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_577acb1e-1a50-479e-a43c-9ea32fcb780c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a74fde5d-3b11-4279-84b0-6eaf17b9fed8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
        </entity>
        <period>
            <startDate>2021-05-17</startDate>
            <endDate>2021-05-17</endDate>
        </period>
    </context>
    <context id="C_86c60b96-dc4e-40d1-8dc6-75af50996958">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_36317d60-ef8e-4485-8be4-dbe28ed900be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2ad74538-b479-4925-9f60-b6af61969b3d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inzy:YaleUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c219104e-7f65-4cfb-a306-535fab73fbae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5ea75401-6aea-4087-a31b-3b37976549a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6f7932b9-17b8-423d-9f3d-1d9425caa7f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
        </entity>
        <period>
            <startDate>2023-09-30</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c0269d4f-7dd7-4002-9ff8-a6effc16399e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_46f9ae16-b8c7-4213-9f64-dc61525d4c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_bc04799a-6e65-4820-b17f-b1036be4e528">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d9d28d21-3347-4c53-a22e-f87f54964ee4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inzy:K2HvMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-25</instant>
        </period>
    </context>
    <context id="C_f9151e1c-1a1c-4fd2-91c3-dfd8900bd0f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b6643dbc-a9cd-41a0-9331-c15dc4781614">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">inzy:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_fe23324a-e605-4ce7-a370-83d0da0161d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inzy:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="C_b69eb069-0d70-4c35-82e1-af14e7470196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f1b17c7a-98c5-4dda-8775-61fdebd34c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f619a243-7caf-4810-be59-b9733e6d8eae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inzy:YaleUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="C_93fed2f2-49b6-4337-8584-7a6a8c8c936e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d2a5c6ce-86e7-4875-bb49-7e9cb50c94fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f1c3e67f-9945-41f0-944d-8d830ba9739e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
        </entity>
        <period>
            <startDate>2023-07-27</startDate>
            <endDate>2023-07-27</endDate>
        </period>
    </context>
    <context id="C_bebe8a61-3f52-4590-a963-a6915fc4e374">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inzy:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="C_a9bb1918-b1d7-45e7-8152-c53d74f19eda">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inzy:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-25</instant>
        </period>
    </context>
    <context id="C_639eb17d-d451-4e67-9099-b216251b8867">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5f12b8c5-840c-4b80-aafb-3c8b57f8ed2e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f0ae2476-b345-490a-a86b-4a01fe48843b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inzy:K2HvMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-25</startDate>
            <endDate>2022-07-25</endDate>
        </period>
    </context>
    <context id="C_f33f58db-c8e7-4f41-ad0b-b1c08a56375f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5bb4c6de-83a3-4b5b-8ccc-2887ba662ad0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_82b79cc2-0604-4d40-bafb-f6f4b9a694c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_18d66cf9-fa61-4466-8750-6ba204ccf660">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-25</startDate>
            <endDate>2022-07-25</endDate>
        </period>
    </context>
    <context id="C_d09f7ff2-1a27-45d2-8579-2c27a2426a27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerDurationAxis">inzy:SixtyDaysPriorWrittenNoticeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-06</startDate>
            <endDate>2021-05-06</endDate>
        </period>
    </context>
    <context id="C_3069d94b-0504-4b09-8332-ed3b1c11af61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_cd4ff0c3-e817-48e8-b8c3-ca0078eec69f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_23e7c97e-bcf3-4add-9b14-99d3a9ed6274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inzy:BofaSecuritiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-27</startDate>
            <endDate>2023-07-27</endDate>
        </period>
    </context>
    <context id="C_a8a74a9f-0187-449d-bd71-ff493500514a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5ebf2fa0-40a8-42d4-9daa-b0340f2d221d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inzy:K2HvMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5fadef3d-5895-480b-9d9e-def33be1c27e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inzy:BofaSecuritiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-27</instant>
        </period>
    </context>
    <context id="C_16876f16-aca9-4cb2-b583-baf263afbd49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b8d04e02-0ef5-4212-8c55-26c32b719e5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inzy:YaleUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0d9dede3-5249-4c7a-b353-10144b32c8b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_7521ee38-3522-499f-9163-aff0538685b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
        </entity>
        <period>
            <startDate>2022-07-25</startDate>
            <endDate>2022-07-25</endDate>
        </period>
    </context>
    <context id="C_0fef7786-5c9f-4661-84e2-6bd709ef1859">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_dd2554f0-5fa2-4094-bb5c-964fac0c425e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8f452f4f-2469-461f-b6e0-17cef1221fa3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inzy:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f51cc874-6545-4fcf-a041-fffaa4e330ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_034c291a-b985-4a6b-bfa0-cd3fc75a6bbe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="C_6a51238e-3618-4c6f-834a-a5b8760a5cab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">inzy:LaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_eeb4217e-fc77-4296-9ee9-2a609ec3e2d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">inzy:FederalAndStateTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6180172f-c35b-4d20-961c-b44a3488a278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0d74cf94-b1f2-497c-915e-d10053a3fdac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_26d33768-49f2-4d59-a581-db63d9838d45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a5581986-e14e-4e34-a7f8-7bba69e2c058">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7127e8c7-8b18-4fcc-9ba4-6bd21fc208d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inzy:K2HvMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-25</startDate>
            <endDate>2022-07-25</endDate>
        </period>
    </context>
    <context id="C_18a731bb-67c4-4ab0-8890-db73d8f7acd7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_5d4682fc-b7e8-4bc8-a04e-f170756de070">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inzy:K2HvMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b61af113-eb50-4b3e-aef8-307431908b88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inzy:YaleUniversityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_35debf45-eff8-4880-842d-b7923517d412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">inzy:ShareBasedPaymentArrangementTrancheFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inzy:K2HvMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-25</startDate>
            <endDate>2022-07-25</endDate>
        </period>
    </context>
    <context id="C_6eef9496-93b0-48ca-b3cf-47eb906b4a01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inzy:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-23</startDate>
            <endDate>2020-07-23</endDate>
        </period>
    </context>
    <context id="C_18e79562-699d-4e71-9f51-f6b59fe5e488">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inzy:YaleUniversityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_83b501bf-9deb-493d-89d6-5fbc9e9ca049">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inzy:YaleUniversityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="C_68e0a225-f316-48f6-9fd5-63d50781b73b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a4ab63bc-07be-46e6-aa82-1e04ab169eca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_31d32f64-dc44-41d7-bce8-ff6cf58b79cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inzy:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="C_1bd944ab-7162-429e-a0bf-1e98d8b5d629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e2f25e47-2422-40ab-810a-92c03b89c3a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_bb47b565-7017-4ae4-8380-7d7bb5c73132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
        </entity>
        <period>
            <instant>2022-06-10</instant>
        </period>
    </context>
    <context id="C_67c9227f-23fa-4d03-94ed-39eb46d276a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inzy:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_85011284-cdc9-4bd4-845f-74414084de51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">inzy:RestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b153501c-2297-4e17-905e-f0f97a1348d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_cabacfd7-585b-4a2b-88ce-edec24c747f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_12de314a-d4b0-494b-813f-351304fba130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_809272a0-4381-416d-b6c1-4926d329a113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_38923768-4f8c-4cf5-8568-d7b648fc7393">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a82024c8-742d-4976-8c8e-41e2b8b05ebd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2b1ba612-eaf7-4255-9f94-845320672517">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_260e3568-2332-4710-9a63-9553a3e1f87f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="C_e4451f72-2b2b-4b91-8f5a-e4ab0f0244ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inzy:YaleUniversityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_edffafaf-bcb8-4571-af95-10f388d3cb08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0502b5cf-19d3-4a39-bb6c-6e6617f1dc75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inzy:JefferiesLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e462903e-5095-4918-b351-d475a954fa3c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inzy:TwoThousandSeventeenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-23</instant>
        </period>
    </context>
    <context id="C_10590ddc-665f-42d2-b77b-89cf6c383211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">inzy:LaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_532bce2f-a513-4807-8f8f-ebc5cb9d4a86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_627d9b19-c97f-4990-affb-d25c50839022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8f668d05-5207-4a0e-8751-b2c77362080c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0c02063f-a103-4d30-8717-1985a331947e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inzy:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-25</startDate>
            <endDate>2022-07-25</endDate>
        </period>
    </context>
    <context id="C_cf7fde27-55f9-4b69-9589-3dfbcd890c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inzy:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_578990c4-7b65-4722-8ca8-59f878771332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inzy:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inzy:JefferiesLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-14</instant>
        </period>
    </context>
    <context id="C_072e744e-d8a8-4b95-9e11-fd60fc749ad1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ba5b64e4-70b0-4502-8294-ad245be4038c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c2b667bf-badf-46cf-be28-9653192a233b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0bbdd3e1-67b1-4179-a2ad-34d654b46a8f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inzy:UnderwritingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inzy:BofaSecuritiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-27</startDate>
            <endDate>2023-07-27</endDate>
        </period>
    </context>
    <context id="C_f0e6584f-b5b7-4d58-a88c-80a7eadaaae3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="C_6f8af799-609d-4c14-b3ec-0e9bdd4c588e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">inzy:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e7cf70aa-36bc-46ec-bfe0-94356e1da198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerDurationAxis">inzy:ThirtyDaysPriorWrittenNoticeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-06</startDate>
            <endDate>2021-05-06</endDate>
        </period>
    </context>
    <context id="C_65370ce0-f82e-4e38-acd5-1026ec007a18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">inzy:OfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_18a01e41-ea42-4897-ac23-422f3897a169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3c60cddf-e6e6-40e7-af29-5142f2416154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c5b05844-1535-4e7e-bc09-618ad8076340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inzy:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-17</instant>
        </period>
    </context>
    <context id="C_1d9a39c0-b43f-460b-b719-403d215c02a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inzy:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ad70b717-7bb2-4c61-9bb0-95099842631c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e5909b1a-428c-48ad-8908-9d3d49539a18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0492ee51-d379-44b0-9b36-2dde4f604d4e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
        </entity>
        <period>
            <startDate>2021-05-06</startDate>
            <endDate>2021-05-06</endDate>
        </period>
    </context>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_Segment">
        <measure>inzy:Segment</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="C_4ee9c018-375e-4d0f-ab9e-435246e8b7ce"
      id="F_76a60ac7-93d6-4c32-bfce-f6d2d8cea252">http://fasb.org/us-gaap/2023#AccountingStandardsUpdate201912Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <dei:AmendmentFlag
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_a15aaf36-3d5b-4787-b975-a3a77b3b6827">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_1cbeff8c-ad11-4b0e-bbd2-c155d4757782">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_5309203e-500a-4126-b22b-ec8d64db6d1d">0001693011</dei:EntityCentralIndexKey>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_01add2ad-475c-4cb0-a885-6e7db27bc554"
      decimals="4"
      id="F_0fc9b8f5-e2f0-43c6-b068-1c4c8f53dfd8"
      unitRef="U_pure">0.1338</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      id="F_e90451bb-00b0-4267-9f72-24a543a3e860">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_260e3568-2332-4710-9a63-9553a3e1f87f"
      id="F_e1dd4c93-e457-45e0-b6c0-ca83dbd27efa">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_026d8e7b-ffcc-47b8-ac91-c8959a4e7883">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      id="F_dce1800e-309e-4f55-9e0c-343addd78c00">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      id="F_6360d63f-17d5-4de6-a919-fd4922754e06"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      id="F_639d92d0-6f7f-4b32-af29-72c21c77075a"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration
      contextRef="C_532bce2f-a513-4807-8f8f-ebc5cb9d4a86"
      id="F_163a734f-613d-45f6-b523-f3a90ba56209">http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentNet</us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="INF"
      id="F_8196d8a8-372d-4a07-a143-8661735a221d"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <dei:DocumentType
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_f278e65e-c398-4424-8d50-5cf351e37555">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_6a001ff8-4155-4fa2-a9ee-cfd84c040447">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_653ef210-8a83-4ead-b54a-948a56abda1f">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_a760ab20-4c5c-4045-9b24-256e453c780f">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_62537e37-6b72-42c2-9ee7-2558ed6cdc6e">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_277007f2-0d5d-43b7-9a2a-f337d54a6178">001-39397</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_b97f3883-7cf4-4d2e-8548-4fdf31e64d66">INOZYME PHARMA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_87264056-918c-4bd6-8018-94564b77fd7d">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_99e44061-cdd8-4a60-956a-8a19af040ea2">38-4024528</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_a7f215a8-4c6e-4d16-8c69-6d64b541cba1">321 Summer Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_a0c5ac81-134e-4cbc-accd-eccebe1b81d3">Suite 400</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_0f8b07b4-af4e-4c40-a953-5f6663a172eb">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_664124fe-4006-445f-836d-56820ea2b8ca">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_187d31e5-e20b-4ed3-9b04-db1391605b5c">02210</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_8cedc9e8-e996-4a4c-bc54-bb934f8e04ef">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_ba79b74c-4c34-41cb-a708-cbdfb268c839">330-4340</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_5511138e-b5fa-4e5f-811d-4850f93b3132">Common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_451fb127-7a81-4079-b2d2-ff928d2f777d">INZY</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_73209754-dbbc-404e-b1d0-421f79af32f9">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_38b52897-a0b8-4c87-a76c-467cd985ab2d">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_3e66591f-1ae1-4cec-ab3c-567885755591">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_4225b9f8-c637-4acb-9a0c-705b346f6450">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_15c20643-f09c-4ad1-b6ef-5a22abff57ea">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_bb473025-22f3-4948-a56b-048025ff2b2f">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_d3826418-3c33-4508-b291-7417b51770f5">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_a3b8ea53-a5d8-4e69-87bf-eef1299373e1">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_948ff013-8b4d-4601-a484-fef62528f69b">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_15618657-b7c0-4424-9245-514029b365be">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_a0041ef5-58be-4ef5-a309-115a15f86284">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_56c65502-2b6a-4efd-abff-ee9d133257da">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_82b79cc2-0604-4d40-bafb-f6f4b9a694c4"
      decimals="-3"
      id="F_29433588-2711-41a8-86de-4b0fb02745d0"
      unitRef="U_USD">199465749000</dei:EntityPublicFloat>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_6d693039-939f-4fb6-99c3-3542c4ac4cf7">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;The registrant intends to file a definitive proxy statement pursuant to Regulation 14A within 120 days of the end of the fiscal year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Portions of such definitive proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_81ae238e-c3bd-4352-a75f-39950655b221">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_e0a6b3ff-9811-477f-9229-bf2454e25a20">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_f6d7f264-e60a-460c-a79b-72db2bf850db">Boston, Massachusetts</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_e87668de-7fbe-4f13-b70c-a39444163d40"
      unitRef="U_USD">34588000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_48b79c04-2545-4109-a95c-6649004d0d72"
      unitRef="U_USD">32915000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_1afc5b19-36fb-4032-a596-25e307cfdeed"
      unitRef="U_USD">154001000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_f3213c74-a2c3-4a72-ae77-7cab01e0e54d"
      unitRef="U_USD">94951000</us-gaap:ShortTermInvestments>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_53dfb213-bcf3-4f8c-9649-ed73d2f60580"
      unitRef="U_USD">7661000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_87fa15d8-e895-4c59-a47e-e12e2f48744f"
      unitRef="U_USD">3527000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_492262ee-37c4-429c-8ae4-653d18f70fe9"
      unitRef="U_USD">196250000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_d0ef99c4-dd29-43b9-a688-9118400f992c"
      unitRef="U_USD">131393000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_d455e92d-a0af-4f20-a70b-a0903544179e"
      unitRef="U_USD">1466000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_20cd13dd-eaef-428b-9739-486d70783746"
      unitRef="U_USD">2018000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_a3024496-de63-471c-8115-8be10c656cef"
      unitRef="U_USD">1126000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_96bb6b0c-75a0-486d-a6cb-2a911e3c3249"
      unitRef="U_USD">1620000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_6d480a6a-cd5b-458f-9130-9a13e7af5815"
      unitRef="U_USD">311000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_d702e491-3906-421c-abea-71594a95d803"
      unitRef="U_USD">354000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_3cc8d760-cab7-4e49-8a8f-c3e95e0662d4"
      unitRef="U_USD">1694000</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_6a061735-0c48-46af-b459-517772b19028"
      unitRef="U_USD">3810000</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:Assets
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_54f195f5-e4c5-4572-a0bd-8812370959cb"
      unitRef="U_USD">200847000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_ffd40d43-f450-47fb-9ffd-5eea7106e28e"
      unitRef="U_USD">139195000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_02a22c66-9872-45a2-afa4-674485502ae0"
      unitRef="U_USD">1166000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_6c08b599-0a12-4f42-9242-8bec07389748"
      unitRef="U_USD">2544000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_aca09502-86ff-4394-8649-c095da1d84c1"
      unitRef="U_USD">12610000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_593f29be-f298-44d2-8120-851a966cad67"
      unitRef="U_USD">11355000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_aa29ef63-0318-4457-b6e7-dd2f252a46d6"
      unitRef="U_USD">910000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_65b5cbc2-79f9-4adc-aa0f-9ae752d5d180"
      unitRef="U_USD">816000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_1ecc6f7d-bacb-47d3-b903-74d2c9ab0b9a"
      unitRef="U_USD">14686000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_bee10824-20bd-4675-8d7d-6ec1696bbb08"
      unitRef="U_USD">14715000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_7531cb34-c39f-4f51-b7ed-3229e11a235d"
      unitRef="U_USD">913000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_110b6d65-37a3-4bca-ae36-f7e3e8f19fe2"
      unitRef="U_USD">1823000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermDebt
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_dd7ccee9-b828-4bb8-8182-451fa54ec280"
      unitRef="U_USD">44769000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_967f9abc-ddc1-4ce0-9aca-9008d9c1eb41"
      unitRef="U_USD">4139000</us-gaap:LongTermDebt>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_689539cd-f0c7-4d21-aacd-6150cefcfc11"
      unitRef="U_USD">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_0ff3e796-513b-4f0a-83cf-24365d365e09"
      unitRef="U_USD">124000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_c6d3e260-4364-44e0-9745-185194c597ab"
      unitRef="U_USD">60368000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_af3e8487-4f15-4092-aa0e-6b0b39e92a86"
      unitRef="U_USD">20801000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="4"
      id="F_606c3ac6-4c39-407b-944e-08a1c9db856a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="4"
      id="F_c2ed5047-0821-4ecc-9cbb-4a3aa9d727aa"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="0"
      id="F_4e405eab-416f-4c71-a1b4-9ed05b24a10a"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="0"
      id="F_f61499b0-ddee-4f23-b561-c216e2fc455a"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="0"
      id="F_bc1e19b9-79af-4ca9-b71d-e1aac2af5d59"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="0"
      id="F_f144b5da-225b-43c8-9593-a37cf02c122b"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="0"
      id="F_a4572e8a-f8a9-49e0-9fa6-e399b29aa9b2"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="0"
      id="F_c20a6f0b-af7e-44c1-a687-6b60c8bbab35"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_e41c39a3-3064-4010-8db3-4a694d0ea4d1"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_2767c2f2-b9c9-4164-8094-2dd3e2497b22"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="4"
      id="F_845648c7-7088-490f-8d2b-498e35805cf6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="4"
      id="F_9160af8c-5bd3-4693-91c9-dfbfb4428fb8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="0"
      id="F_4cfeaf90-a3de-435f-95c2-c20b3d41ed30"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="0"
      id="F_db642a05-ba43-431e-878f-2f1d5b68ef19"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="0"
      id="F_7ac81c27-fc95-4ec1-a7e6-84215eb316bc"
      unitRef="U_shares">61768771</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="0"
      id="F_d8ed6275-9c4d-4a76-b470-ff7284a4c4d8"
      unitRef="U_shares">61768771</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="0"
      id="F_44e268ea-16b7-4097-8f74-6e8dd700f25d"
      unitRef="U_shares">40394363</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="0"
      id="F_7d40ae9c-02f8-466d-853a-8c2307a56966"
      unitRef="U_shares">40394363</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_662a5fea-b9fb-41c2-acf7-bf1c4d674966"
      unitRef="U_USD">6000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_ebc340e0-ccfb-410d-9347-6854569138ba"
      unitRef="U_USD">4000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_8c7c30c8-c676-4ebf-b1a5-04430d4f88b3"
      unitRef="U_USD">426362000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_5f54d4b9-cb69-4e0e-9502-e0daa4cff21d"
      unitRef="U_USD">333356000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_8a22a98a-8bc6-4603-9a05-37172c4d116c"
      unitRef="U_USD">41000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_db1cfa16-d27f-4a27-8b94-dcc425388e6b"
      unitRef="U_USD">-205000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_d5d76e65-9d85-4fca-91a1-f733554f243f"
      unitRef="U_USD">-285930000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_93cde37f-2e0d-4cf1-bebb-331eb8cfe310"
      unitRef="U_USD">-214761000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_d466fa9e-039f-49e8-8328-1e2a0ed9eca7"
      unitRef="U_USD">140479000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_60f2d72e-e385-4ab3-a3f7-0da3ac09790e"
      unitRef="U_USD">118394000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_10666dca-8343-48da-843c-9dac5b3fbbd0"
      unitRef="U_USD">200847000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_1da499e2-bf09-453d-b169-831406b88acd"
      unitRef="U_USD">139195000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_127f0459-376d-4eea-89b4-ff072a47a6a8"
      unitRef="U_USD">54847000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_44126002-cbe5-42fc-bf5b-6751c112dd14"
      unitRef="U_USD">47849000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_11940b97-832a-46b6-b1d5-31d6f4f5d715"
      unitRef="U_USD">20798000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_f16ea773-c439-4a78-896f-36c1504b820e"
      unitRef="U_USD">20826000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_1f9dcb64-9ef6-4de2-a75d-f4c9fdb90f0b"
      unitRef="U_USD">75645000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_5a2bba18-ca30-4fb8-91b7-8bf2146d326e"
      unitRef="U_USD">68675000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_735165d3-f545-4b22-b454-408652d30a16"
      unitRef="U_USD">-75645000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_b863e69b-df4a-4df2-ab57-eeacd3221b5a"
      unitRef="U_USD">-68675000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_0d19c8fb-5d4e-49bb-a4fa-8ea07293b97b"
      unitRef="U_USD">7837000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_7fa7c9db-8a18-4080-bece-17e1d16cc4e9"
      unitRef="U_USD">2195000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_74e1b48d-d4f5-407d-919a-433271f4eb3f"
      unitRef="U_USD">3333000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_5bd157e9-182c-45f8-8e48-0f9f4dbaf3eb"
      unitRef="U_USD">262000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_b95b1d97-7456-457a-9037-ba0f87533657"
      unitRef="U_USD">-28000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_7e43e834-f835-4511-9ae9-669fe079d311"
      unitRef="U_USD">-319000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_efb5c671-d799-4eb2-8a9f-56ed2659ab30"
      unitRef="U_USD">4476000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_767d9b5a-083c-43b6-96b1-913f3a017bed"
      unitRef="U_USD">1614000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_326ad914-556d-4a3a-8e7e-eebe4d6863e1"
      unitRef="U_USD">-71169000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_6fa7983e-d11d-4581-9586-9a74c16394ad"
      unitRef="U_USD">-67061000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_7192d4c1-3a23-4c2e-8d15-ba6e4893e3d7"
      unitRef="U_USD">264000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_f3f5a970-87e0-49a9-86e9-0c11ab11a03f"
      unitRef="U_USD">-198000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_9a3bc603-68f9-4b8a-9106-d1763903a032"
      unitRef="U_USD">-18000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_a3669cf6-a8dd-4276-9289-98ec6f552638"
      unitRef="U_USD">-25000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_e25f2ff4-ef61-4c17-ae3b-59341f66e8d8"
      unitRef="U_USD">246000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_c7751aee-4fa5-491d-a73f-309f419a8b81"
      unitRef="U_USD">-223000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_32657b80-ca26-4890-b79c-a7c8bbf0bc70"
      unitRef="U_USD">-70923000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_1ba8c427-3555-44cf-852d-9da09d6289aa"
      unitRef="U_USD">-67284000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_d248df69-7094-4f33-be1f-c8ff75b18397"
      unitRef="U_USD">-71169000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_5167bdbb-d435-4124-aa47-415cf4ba5c7c"
      unitRef="U_USD">-67061000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="2"
      id="F_45a8b82d-64de-4a11-9eea-9b62cdb2335d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="2"
      id="F_202dbc0b-b402-4f3e-a55b-009855c54ba2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="2"
      id="F_15d1915c-e993-4389-8a9b-187f082ee295"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.78</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="2"
      id="F_28b1feea-9f96-47b1-a195-056e4818f172"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.78</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="INF"
      id="F_7be21c9b-a21c-4b89-b8f2-dd56f4a1bc6d"
      unitRef="U_shares">51839131</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="INF"
      id="F_fa58d197-3b71-4a7f-a9c6-cb8be1da4145"
      unitRef="U_shares">51839131</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="INF"
      id="F_4d9452b4-d9fe-42ae-9e0c-d268efda91bc"
      unitRef="U_shares">37763168</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="INF"
      id="F_9d0cf1b0-a4f8-410f-9982-994df02e64ed"
      unitRef="U_shares">37763168</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_ba3b1d97-e28d-4318-9ed8-6d65ffffa8e5"
      decimals="INF"
      id="F_bd80d53d-3fb4-4a14-a608-174d023864d5"
      unitRef="U_shares">23668747</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_ba3b1d97-e28d-4318-9ed8-6d65ffffa8e5"
      decimals="-3"
      id="F_df435f95-f36f-42ee-96cc-699d77aeb68c"
      unitRef="U_USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b69eb069-0d70-4c35-82e1-af14e7470196"
      decimals="-3"
      id="F_0f81fa93-6ec5-4812-b191-bf34ce9ec983"
      unitRef="U_USD">256948000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_471a56d8-9599-49a3-ac22-3a686ca9ff8d"
      decimals="-3"
      id="F_b94b75e9-4578-4af5-8e83-e9ae1443d3dd"
      unitRef="U_USD">18000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0ff899d6-441a-422c-b0bd-1738ae7e6c26"
      decimals="-3"
      id="F_4fa5713e-aab7-44b3-bac7-9b8aac459d4b"
      unitRef="U_USD">-147700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f9151e1c-1a1c-4fd2-91c3-dfd8900bd0f6"
      decimals="-3"
      id="F_27ae67b9-a672-4e13-92ed-4bd11c168875"
      unitRef="U_USD">109268000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_6180172f-c35b-4d20-961c-b44a3488a278"
      decimals="-3"
      id="F_f24179ed-6493-4003-8da6-ba188776df15"
      unitRef="U_USD">7672000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_5a3c7630-bf5c-4d79-88a5-23dd43f3b8b9"
      unitRef="U_USD">7672000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_5f12b8c5-840c-4b80-aafb-3c8b57f8ed2e"
      decimals="INF"
      id="F_379369d9-afa5-4b22-b513-5332fe506cff"
      unitRef="U_shares">210977</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_6180172f-c35b-4d20-961c-b44a3488a278"
      decimals="-3"
      id="F_8620f425-f1f0-4f42-933e-e0802764e1d8"
      unitRef="U_USD">359000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_ea4d9ac3-5e4b-4471-95eb-d2789990766a"
      unitRef="U_USD">359000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_5f12b8c5-840c-4b80-aafb-3c8b57f8ed2e"
      decimals="INF"
      id="F_3ef83508-e517-46c5-8f74-d73fa32667fb"
      unitRef="U_shares">16276987</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_5f12b8c5-840c-4b80-aafb-3c8b57f8ed2e"
      decimals="-3"
      id="F_99e21bd4-7be7-4fa8-ab38-1f3da141da49"
      unitRef="U_USD">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_6180172f-c35b-4d20-961c-b44a3488a278"
      decimals="-3"
      id="F_0f852d1f-a800-47d0-816b-023ea46a3646"
      unitRef="U_USD">56135000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_60cf068b-ac72-4ecb-a916-caf60a1b081a"
      unitRef="U_USD">56137000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <inzy:IssuanceOfPreFundedWarrantsNetOfIssuanceCosts
      contextRef="C_6180172f-c35b-4d20-961c-b44a3488a278"
      decimals="-3"
      id="F_efeedcbe-3607-4bec-9742-52ed56297357"
      unitRef="U_USD">12150000</inzy:IssuanceOfPreFundedWarrantsNetOfIssuanceCosts>
    <inzy:IssuanceOfPreFundedWarrantsNetOfIssuanceCosts
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_08162773-9aab-4964-8260-eafb4d951e83"
      unitRef="U_USD">12150000</inzy:IssuanceOfPreFundedWarrantsNetOfIssuanceCosts>
    <inzy:ExerciseOfPreFundedWarrants
      contextRef="C_5f12b8c5-840c-4b80-aafb-3c8b57f8ed2e"
      decimals="INF"
      id="F_097e73a4-1827-4225-9a5d-7dadd7c29ac6"
      unitRef="U_shares">197240</inzy:ExerciseOfPreFundedWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_5f12b8c5-840c-4b80-aafb-3c8b57f8ed2e"
      decimals="INF"
      id="F_426fbe2b-60ed-4f49-abfd-aaee768a7740"
      unitRef="U_shares">40412</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_6180172f-c35b-4d20-961c-b44a3488a278"
      decimals="-3"
      id="F_b89d57b5-d921-4274-9f44-4a6b5200fa89"
      unitRef="U_USD">92000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_f05c5888-3c71-44cc-b60b-21e1864016fa"
      unitRef="U_USD">92000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_94c35e60-92f5-4512-bce8-5ad4b2e3d95d"
      decimals="-3"
      id="F_e9fdc45f-4eb7-4198-9367-f31e9c3a9e99"
      unitRef="U_USD">-198000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_b28e338b-9428-4895-8abc-a316a2da644f"
      unitRef="U_USD">-198000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_94c35e60-92f5-4512-bce8-5ad4b2e3d95d"
      decimals="-3"
      id="F_757e0bd8-552c-4da2-bdac-20e2dd2b7cbf"
      unitRef="U_USD">-25000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_dfd45012-4d83-4417-b5a7-442e130c081c"
      unitRef="U_USD">-25000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="C_4c84ce21-27ad-466f-a52b-53d2b027d662"
      decimals="-3"
      id="F_79306643-c87f-4ed9-8f06-d7ff83cd9e38"
      unitRef="U_USD">-67061000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_b23fb535-fd40-47da-8b7a-c83dd66683f1"
      unitRef="U_USD">-67061000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_c0269d4f-7dd7-4002-9ff8-a6effc16399e"
      decimals="INF"
      id="F_bd397cde-5007-45a0-a1eb-ba6a48a06d01"
      unitRef="U_shares">40394363</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_c0269d4f-7dd7-4002-9ff8-a6effc16399e"
      decimals="-3"
      id="F_7f528d80-007b-4832-b534-427d57342747"
      unitRef="U_USD">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_577acb1e-1a50-479e-a43c-9ea32fcb780c"
      decimals="-3"
      id="F_996760ad-2e2e-4c05-9dab-72c419b72d44"
      unitRef="U_USD">333356000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ba5b64e4-70b0-4502-8294-ad245be4038c"
      decimals="-3"
      id="F_5973a9a1-adbf-4630-844c-171b70b42b4b"
      unitRef="U_USD">-205000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f33f58db-c8e7-4f41-ad0b-b1c08a56375f"
      decimals="-3"
      id="F_7e290c9f-f210-420e-9de0-41206c0ae7b1"
      unitRef="U_USD">-214761000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_a52f98bf-e2dc-4416-9a47-88340aeac0e8"
      unitRef="U_USD">118394000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_e5909b1a-428c-48ad-8908-9d3d49539a18"
      decimals="-3"
      id="F_fab1bbfc-5ac9-4a16-b247-28a0913c5cca"
      unitRef="U_USD">7037000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_6f88dc4d-f69e-476c-8094-3f4c62d4de61"
      unitRef="U_USD">7037000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <inzy:ExerciseOfPreFundedWarrants
      contextRef="C_3069d94b-0504-4b09-8332-ed3b1c11af61"
      decimals="INF"
      id="F_665d6f54-1411-4d1b-bf37-35b4fe842fc9"
      unitRef="U_shares">3325644</inzy:ExerciseOfPreFundedWarrants>
    <inzy:StockIssuedDuringPeriodSharesIssuedInAtTheMarketOffering
      contextRef="C_3069d94b-0504-4b09-8332-ed3b1c11af61"
      decimals="INF"
      id="F_a3d67d61-1bbe-4995-bdcb-1a42c108b256"
      unitRef="U_shares">3553995</inzy:StockIssuedDuringPeriodSharesIssuedInAtTheMarketOffering>
    <inzy:StockIssuedDuringPeriodValueSharesIssuedInAtTheMarketOffering
      contextRef="C_3069d94b-0504-4b09-8332-ed3b1c11af61"
      decimals="-3"
      id="F_faa9cbbe-aca6-4313-96e4-580b2bffe55d"
      unitRef="U_USD">1000</inzy:StockIssuedDuringPeriodValueSharesIssuedInAtTheMarketOffering>
    <inzy:StockIssuedDuringPeriodValueSharesIssuedInAtTheMarketOffering
      contextRef="C_e5909b1a-428c-48ad-8908-9d3d49539a18"
      decimals="-3"
      id="F_5d2423a1-8612-439a-b18c-c0112d5e39d5"
      unitRef="U_USD">21235000</inzy:StockIssuedDuringPeriodValueSharesIssuedInAtTheMarketOffering>
    <inzy:StockIssuedDuringPeriodValueSharesIssuedInAtTheMarketOffering
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_f2a740af-8d8e-48dd-bc0a-aa92db88071a"
      unitRef="U_USD">21236000</inzy:StockIssuedDuringPeriodValueSharesIssuedInAtTheMarketOffering>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_3069d94b-0504-4b09-8332-ed3b1c11af61"
      decimals="INF"
      id="F_015a0ada-46c6-4854-876a-047ff3df746d"
      unitRef="U_shares">43209</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_3069d94b-0504-4b09-8332-ed3b1c11af61"
      decimals="-3"
      id="F_3ae56836-4449-42aa-b772-d5cbcd351183"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_e5909b1a-428c-48ad-8908-9d3d49539a18"
      decimals="-3"
      id="F_beb07fce-0b97-4bf9-8cb6-855f6347c7cb"
      unitRef="U_USD">116000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_89793a84-da66-47da-aaff-3a28079af62f"
      unitRef="U_USD">117000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_3069d94b-0504-4b09-8332-ed3b1c11af61"
      decimals="INF"
      id="F_f1b32b55-5ab4-4984-b4a6-eb008acf4491"
      unitRef="U_shares">14375000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <inzy:IssuanceOfPreFundedWarrantsNetOfIssuanceCosts
      contextRef="C_e5909b1a-428c-48ad-8908-9d3d49539a18"
      decimals="-3"
      id="F_c0281e41-7a72-4d4d-85f4-40868afd27f7"
      unitRef="U_USD">64412000</inzy:IssuanceOfPreFundedWarrantsNetOfIssuanceCosts>
    <inzy:IssuanceOfPreFundedWarrantsNetOfIssuanceCosts
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_371a11a3-619d-4634-8406-a1f13a3be007"
      unitRef="U_USD">64412000</inzy:IssuanceOfPreFundedWarrantsNetOfIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_3069d94b-0504-4b09-8332-ed3b1c11af61"
      decimals="INF"
      id="F_609bab41-509c-499e-bdad-b77723b637f9"
      unitRef="U_shares">76560</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_e5909b1a-428c-48ad-8908-9d3d49539a18"
      decimals="-3"
      id="F_1fba7cf7-0c43-4218-a2ec-026997a566a5"
      unitRef="U_USD">206000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_e3d418c3-8e2e-43b3-91c5-78b85be3a05a"
      unitRef="U_USD">206000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_46f9ae16-b8c7-4213-9f64-dc61525d4c66"
      decimals="-3"
      id="F_8bccd545-45d7-4fee-9552-28a3a46f2a7d"
      unitRef="U_USD">-264000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_5b71a7b4-d4ff-46cd-a349-79a2a9c25435"
      unitRef="U_USD">264000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_46f9ae16-b8c7-4213-9f64-dc61525d4c66"
      decimals="-3"
      id="F_f3c0ed44-541c-4159-9f3d-d205006ec392"
      unitRef="U_USD">-18000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_840543b8-ce7d-4803-a78d-a5ec527686a4"
      unitRef="U_USD">-18000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="C_8f92c86f-a41e-44a3-8900-38efa4b160f5"
      decimals="-3"
      id="F_06302b53-4e35-478a-91e4-2f28d505544b"
      unitRef="U_USD">-71169000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_11b129ab-6eea-4b16-9279-130ba9052d43"
      unitRef="U_USD">-71169000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_b153501c-2297-4e17-905e-f0f97a1348d3"
      decimals="INF"
      id="F_4c41c10d-be39-49d9-bdc9-a6462fb1ab30"
      unitRef="U_shares">61768771</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_b153501c-2297-4e17-905e-f0f97a1348d3"
      decimals="-3"
      id="F_e3d4e7ff-84e3-48f0-a4c0-a45f816d9c03"
      unitRef="U_USD">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_dac8f012-8074-43e0-b610-ec3ed404d713"
      decimals="-3"
      id="F_46794457-acaa-48ad-af9e-728fb743e113"
      unitRef="U_USD">426362000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c2b667bf-badf-46cf-be28-9653192a233b"
      decimals="-3"
      id="F_fd2bf402-dff6-40e5-b6c9-ccd92919b054"
      unitRef="U_USD">41000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5ea75401-6aea-4087-a31b-3b37976549a7"
      decimals="-3"
      id="F_54d81ea0-00bb-4646-8a1a-20138937b2c0"
      unitRef="U_USD">-285930000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_ca3ec5f6-37b7-4a76-adb9-3e859ab27a07"
      unitRef="U_USD">140479000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_8dabfdcf-b136-4481-b943-342b1c4d3d4e"
      unitRef="U_USD">-71169000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_b655c7dd-89fa-4ab9-9d03-7d2d7dd18865"
      unitRef="U_USD">-67061000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_bf9466bb-6f33-42fa-bb59-8aab48c53983"
      unitRef="U_USD">833000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_99ab82f2-994e-478a-8b01-597d67954897"
      unitRef="U_USD">744000</us-gaap:Depreciation>
    <inzy:LossOnDisposalOfFixedAssets
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_94270ef3-1871-4e4e-9398-42b84a90de6b"
      unitRef="U_USD">20000</inzy:LossOnDisposalOfFixedAssets>
    <inzy:LossOnDisposalOfFixedAssets
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_68fedc62-4604-4864-b2e9-c02889e621a3"
      unitRef="U_USD">17000</inzy:LossOnDisposalOfFixedAssets>
    <us-gaap:ShareBasedCompensation
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_c9d6dd90-6188-46c1-a7f0-48ebce27e68e"
      unitRef="U_USD">7037000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_f9e4b251-7e8e-4d73-bdab-4c24500a93ca"
      unitRef="U_USD">7672000</us-gaap:ShareBasedCompensation>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_adea295a-8386-4273-b197-31e06ccf51bf"
      unitRef="U_USD">5438000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_55efbf99-9b39-4288-bf64-b29b57c247cb"
      unitRef="U_USD">1671000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_34bc10a9-d6f0-45f4-af44-b227e31bac04"
      unitRef="U_USD">494000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_88ad3e15-de9e-4aac-8552-1b64bd3138f4"
      unitRef="U_USD">433000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_51ade35b-80ed-4daf-a9c4-dc1ab5b58ff7"
      unitRef="U_USD">630000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_c078f9f9-1eb8-4353-8177-e615b7b1ec48"
      unitRef="U_USD">93000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_f840f3a8-0b74-4bf8-8ecc-4ccf3183be22"
      unitRef="U_USD">4134000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_f48eac49-4999-42e8-aee6-8a6b4edaab04"
      unitRef="U_USD">-14000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_0f67f21d-5071-4647-9651-0866cea42980"
      unitRef="U_USD">-1378000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_d0c29e5f-25a4-4ebf-8fe7-7f78d54b8066"
      unitRef="U_USD">150000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_f5dc8449-43da-4a08-b357-95322622242d"
      unitRef="U_USD">1255000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_fb473435-4aad-497d-adb6-b67982f9ba9d"
      unitRef="U_USD">2857000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_9357950b-ee0c-4ddf-93ee-37e1838ef381"
      unitRef="U_USD">-816000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_e1dfe9d0-3210-49e9-a73b-870d7fe8ca8a"
      unitRef="U_USD">-732000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <inzy:IncreaseDecreasePrepaidExpensesNoncurrent
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_f53353dc-5c28-4ffb-97cd-c06b9cb8443e"
      unitRef="U_USD">-2115000</inzy:IncreaseDecreasePrepaidExpensesNoncurrent>
    <inzy:IncreaseDecreasePrepaidExpensesNoncurrent
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_f4b5de5d-95a4-46d4-ab09-d3542a13a50f"
      unitRef="U_USD">401000</inzy:IncreaseDecreasePrepaidExpensesNoncurrent>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_62d25b03-8105-4ef7-b22f-5e47d08c2091"
      unitRef="U_USD">-124000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_e4fba57d-a289-496a-8551-781ca2039fe7"
      unitRef="U_USD">124000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_36300ebe-9936-454b-93bc-c536c5b62de1"
      unitRef="U_USD">-70675000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_1a265017-ebdf-464a-8d25-e4baec885b55"
      unitRef="U_USD">-57761000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_85bb95c4-5b9c-41b2-b629-23c19a3a339a"
      unitRef="U_USD">269330000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_d6a134a7-cc27-466c-b251-4e0b56970ea4"
      unitRef="U_USD">151993000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_c25100d3-bc9c-4604-be6d-e64d4b0dd751"
      unitRef="U_USD">215982000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_cc7745f5-f64f-4650-aa63-bcda120db6a3"
      unitRef="U_USD">147000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_5a6b276e-1cb8-442a-96c3-55dc67953044"
      unitRef="U_USD">298000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_e4c5abc1-0998-4b0d-b267-f87a731b4029"
      unitRef="U_USD">410000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_82766f4c-1aa7-407d-a899-438a11879db8"
      unitRef="U_USD">-53646000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_507c22a3-4266-4c2e-ab6f-ee7022786daf"
      unitRef="U_USD">-5403000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_50fe506b-ed4c-48bf-b26e-16ac8067599e"
      unitRef="U_USD">85647000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_40050ddd-5f1c-4182-b540-b1e265ce494b"
      unitRef="U_USD">56137000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_444a1e2c-6d67-4e0e-9f1d-d45dfe8abd94"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_b813e302-47c8-4891-8da3-0336678ddf7c"
      unitRef="U_USD">12150000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_f3c7cf18-0af5-4c8e-bf77-af07da47b1ec"
      unitRef="U_USD">40000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_1f9f7c57-70f8-4957-9a51-6efc45410348"
      unitRef="U_USD">4050000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_f66bb3fc-ddab-4c78-ac7d-c7e88d9b56be"
      unitRef="U_USD">116000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_84d46bc4-9641-4498-9e54-1db02b7112d2"
      unitRef="U_USD">359000</us-gaap:ProceedsFromStockOptionsExercised>
    <inzy:ProceedsFromIssuanceOfCommonStockForCashUnderEmployeeStockPurchasePlan
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_b268e79b-e3fd-4405-801a-a0ab3acbc454"
      unitRef="U_USD">206000</inzy:ProceedsFromIssuanceOfCommonStockForCashUnderEmployeeStockPurchasePlan>
    <inzy:ProceedsFromIssuanceOfCommonStockForCashUnderEmployeeStockPurchasePlan
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_9bfc398d-ba9f-4644-98e3-890e29833503"
      unitRef="U_USD">92000</inzy:ProceedsFromIssuanceOfCommonStockForCashUnderEmployeeStockPurchasePlan>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_0bbd4335-0191-41c7-b6fd-24ed337ab01b"
      unitRef="U_USD">125969000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_829c4724-d72e-4b1d-8942-45ce29299658"
      unitRef="U_USD">72788000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_d6c5b588-52b0-4232-9733-7206df1b3f62"
      unitRef="U_USD">1648000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_cf375bd0-2c0a-49b1-9c2d-22079358773b"
      unitRef="U_USD">9624000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_a31d13a5-d68d-4945-bbeb-b442cc51326a"
      unitRef="U_USD">-18000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_cf08d0c6-3a87-41b1-a7f5-eed05450b555"
      unitRef="U_USD">-25000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_12f05863-c917-40a5-a679-d3ea1f384155"
      unitRef="U_USD">33269000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_f9151e1c-1a1c-4fd2-91c3-dfd8900bd0f6"
      decimals="-3"
      id="F_fdf27bd8-dd25-4853-85ab-a1ee3d609848"
      unitRef="U_USD">23670000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_d2c3e0ab-47c7-46aa-b6df-edb6b9eee35c"
      unitRef="U_USD">34899000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_d70cb0f9-371b-415b-a2e0-3489e9d90518"
      unitRef="U_USD">33269000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_41381aed-caa6-43f3-8b20-b4d831f9b58d"
      unitRef="U_USD">34588000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_420775c4-0a6d-4051-890b-3bd52ca487c6"
      unitRef="U_USD">32915000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_1a607bd5-f6c9-4299-874e-a0641817d997"
      unitRef="U_USD">311000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_2a4a4edc-86c9-4479-84af-0e96abb81d64"
      unitRef="U_USD">354000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_36886876-c2e1-4df9-bdd2-5d7db500a066"
      unitRef="U_USD">34899000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_21351119-5ca3-4a4a-add8-d89b215dbb55"
      unitRef="U_USD">33269000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_ae2b523f-7412-4c4e-a9d3-d76bb90b3df8"
      unitRef="U_USD">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_8f9fdb78-21f1-467b-bb98-ea0a8b35a6e5"
      unitRef="U_USD">14000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:InterestPaidNet
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_5d8e96d7-b577-42e9-a066-aa4b76078f9d"
      unitRef="U_USD">2347000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_50c38078-d1d6-4b19-a641-c61fc4c8f897"
      unitRef="U_USD">170000</us-gaap:InterestPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_eabf6ce2-b078-40e9-a6bb-ba06695ad864">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;1. Organization and Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Inozyme Pharma, Inc. (the &#x201c;Company&#x201d;) is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Through the Company&#x2019;s in-depth understanding of a key biological pathway, the Company is pursuing the development of therapeutics that address pathologic mineralization and intimal proliferation to improve the underlying causes of these debilitating diseases. It is well established that low levels of plasma pyrophosphate drive pathologic mineralization and low levels of adenosine drive intimal proliferation in a number of rare diseases. The Company is initially focused on developing a novel therapy to treat for ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s lead product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to metabolize extracellular adenosine triphosphate to generate plasma pyrophosphate and adenosine monophosphate, which can be processed to phosphate and adenosine. This process is central to the regulation of calcium deposition throughout the body and is further associated with the inhibition of intimal proliferation, or narrowing and obstruction of blood vessels.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Liquidity, Capital Resources, and Going Concern&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Since the Company&#x2019;s incorporation in 2017 and through December 31, 2023, the Company has devoted substantially all of its efforts to raising capital, building infrastructure, developing intellectual property and conducting research and development. The Company incurred net losses of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in the years ended December 31, 2023 and 2022, respectively, and had an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;285.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as of December 31, 2023. The Company had cash, cash equivalents, and short-term investments of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;188.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as of December 31, 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Because of the numerous risks and uncertainties associated with product development, the Company is unable to predict the timing or amount of increased expenses or when or if the Company will be able to achieve or maintain profitability. Even if the Company is able to generate revenue from product sales, the Company may not become profitable. If the Company fails to become profitable or is unable to sustain profitability on a continuing basis, then the Company may be unable to continue its operations at planned levels and be forced to reduce or terminate its operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets, and the satisfaction of liabilities and commitments in the ordinary course of business. The Company has incurred recurring losses and negative cash flows from operations since inception and has primarily funded its operations with proceeds from the issuance of convertible preferred stock, offerings of common stock and pre-funded warrants, and its loan and security agreement (the "Loan Agreement") with K2 HealthVentures LLC (see Note 8). The Company expects its operating losses and negative operating cash flows to continue into the foreseeable future as it continues to expand its research and development efforts.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company believes that its cash, cash equivalents, and short-term investments as of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; will be sufficient to fund its cash flow requirements for at least 12 months from the date of filing this Annual Report on Form 10-K. Management&#x2019;s expectations with respect to its ability to fund current and long-term planned operations are based on estimates that are subject to risks and uncertainties. The Company will need additional funding to support its planned operating activities. However, there is no guarantee that any financing opportunities will be executed on favorable terms, or at all, and some could be dilutive to existing stockholders. If the Company is unable to obtain additional funding, it would be forced to delay, reduce or eliminate some or all of its research and development programs, portfolio expansion, or commercialization efforts, which could adversely affect its business prospects.&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_972cff08-2c4e-4d4b-b78e-248b51f6b2b2">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-5"
      id="F_0a9d7e65-378a-4a61-b692-775f5ae008b8"
      unitRef="U_USD">-71200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-5"
      id="F_5f431a06-b3bd-45d2-89ce-77ba6fe1c3e7"
      unitRef="U_USD">-67100000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-5"
      id="F_8cb0867c-4733-49bb-b654-b275715db2f8"
      unitRef="U_USD">-285900000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-5"
      id="F_a52cc5c6-dc9d-495a-9622-18e6f33acc81"
      unitRef="U_USD">188600000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_c27a5c50-8d22-40ab-8e08-0e78ecf1d1b6">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2. Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Inozyme Securities Corp., which is a Massachusetts subsidiary created to buy, sell, and hold securities; Inozyme Ireland Limited; and Inozyme Pharma Switzerland GmbH. All intercompany transactions and balances have been eliminated.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The preparation of the Company&#x2019;s financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and judgments are based on historical information and other market-specific or various relevant assumptions, including, in certain circumstances, future projections that management believes to be reasonable under the circumstances. Actual results could differ materially from estimates. Significant estimates and assumptions are used for, but not limited to the accruals for research and development expenses. The Company evaluates its estimates and assumptions on an ongoing basis. All revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Concentration of Credit Risk, Significant Suppliers, and Off-Balance Sheet Risk&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and short-term investments and, from time to time, long-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits and limits its exposure to credit risk by placing its cash with high credit quality financial institutions. The Company&#x2019;s investments are composed of U.S. Treasury and U.S. government agency debt securities and commercial paper of corporations. The Company mitigates credit risk by maintaining a diversified portfolio and limiting the amount of investment exposure as to institution, maturity, and investment type.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is dependent on third-party manufacturers and contract research organizations ("CROs") to supply product candidates and provide services for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. The Company also relies on CROs to conduct its clinical trials. The Company&#x2019;s programs could be adversely affected if a third-party manufacturer or a CRO is unable to successfully carry out their contractual obligations or meet expected deadlines. If a third-party manufacturer or a CRO needs to be replaced, the Company may not be able to complete its program development on its anticipated timelines and the Company may incur additional expenses as a result, which could be significant.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; significant off-balance sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts, money market accounts, and certain marketable securities. Cash is carried at cost, which approximates its fair value. Cash equivalents are carried at fair market value.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Restricted cash is composed of amounts held to collateralize the letters of credit related to the Company&#x2019;s lease arrangements. Restricted cash is classified as either current or non-current based on the terms of the underlying lease arrangement.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Short-Term and Long-Term Investments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company classifies its investments as available-for-sale and records such assets at estimated fair value on the balance sheet, with unrealized gains and losses on marketable securities, if any, reported as a component of accumulated other comprehensive (loss) income. Realized gains and losses are calculated based on the specific-identification method and are recorded as a component of interest income. There have been &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; realized gains and losses for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022. The Company periodically reviews available-for-sale securities for other-than-temporary declines in fair value below the cost basis whenever events&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Marketable securities with a maturity date of one year or less from the balance sheet date are classified by the Company as short-term investments. Marketable securities with a maturity date of greater than one year from the balance sheet date are classified as long-term investments and are available to fund operations as needed. As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t have any long-term investments. In accordance with the Company&#x2019;s investment policy, at the time of purchase, the final maturity of each security within the portfolio shall not exceed &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;18&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; months and the weighted average maturity of the portfolio will be no greater than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; months.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the related asset. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The estimated useful lives of the Company&#x2019;s property and equipment are as follows: &lt;/span&gt;&lt;/span&gt;&lt;span style=""&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:73.34%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:24.66%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated Useful Life (In Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Laboratory equipment and manufacturing equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_163a734f-613d-45f6-b523-f3a90ba56209;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lesser of asset life or lease term&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Impairment of Long-lived Assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As required under the applicable accounting guidance, the Company periodically reevaluates the original assumptions and rationale used in the establishment of the carrying value and estimated lives of all of its long-lived assets, including property and equipment. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. An impairment loss is recognized when the total of estimated future undiscounted cash flows, expected to result from the use of the asset and its eventual disposition, are less than its carrying amount. Impairment, if any, would be assessed using discounted cash flows or other appropriate measures of fair value. There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; impairments for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Accrued Research and Development Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company records accrued liabilities for estimated costs of research and development activities conducted by service providers for sponsored research, preclinical studies, clinical operations, and contract manufacturing activities based upon the estimated amount of services provided but not yet invoiced and includes these costs in accrued expenses in the accompanying consolidated balance sheets and within research and development expense in the accompanying consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with service providers. The Company makes significant judgments and estimates in determining the accrued liabilities balance in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. The Company has not experienced any material differences between accrued costs and actual costs incurred since its inception.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Research and Development Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. Research and development costs consist of direct and indirect internal costs related to specific projects as well as fees paid to other entities that conduct certain research and development activities on the Company&#x2019;s behalf.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Patent Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company expenses all costs as incurred in connection with patent applications, including direct application fees, and the legal and consulting expenses related to making such applications, and such costs are included in general and administrative expenses within the Company&#x2019;s consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-based &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;compensation expense represents the cost of the grant date fair value of employee and non-employee stock option grants recognized over the requisite service period of the awards on a straight-line basis. For service-based awards that are&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;subject &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;to graded vesting, the Company has elected to recognize compensation expense on a straight-line basis. The Company has elected to recognize forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income taxes have been accounted for using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates applicable to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. A valuation allowance against deferred tax assets is recorded if, based upon the weight of all available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounts for income taxes in accordance with authoritative accounting guidance which states the impact of an uncertain income tax position is recognized at the largest amount that is &#x201c;more likely than not&#x201d; to be sustained upon audit by the relevant taxing authority. There are &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; unrecognized tax benefits included in the Company&#x2019;s consolidated balance sheets at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 or 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Company&#x2019;s policy is to recognize interest and penalties related to income tax matters in income tax expense. The Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t recognized any interest or penalties in its consolidated statements of operations and comprehensive loss since inception.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company determines if an arrangement is a lease at contract inception based on the facts and circumstances present in the arrangement. If a lease is identified in an arrangement, the Company recognizes a right-of-use asset and liability on its balance sheet and determines whether the lease should be classified as a finance or operating lease. Short-term leases, or leases that have a lease term of 12 months or less at the commencement date are excluded from this treatment and are recognized on a straight-line basis over the term of the lease. Additionally, the Company does not separate lease and non-lease components for all leases.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded as operating leases.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Finance and operating lease assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount rate implicit in the lease. If the rate implicit is not readily determinable, the Company utilizes an estimate of its incremental borrowing rate at the lease commencement date. Operating lease assets are further adjusted for prepaid or accrued lease payments. Operating lease payments are expensed using the straight-line method as an operating expense over the lease term. Finance lease assets are amortized to depreciation expense using the straight-line method over the shorter of the useful life of the related asset or the lease term. Finance lease payments are bifurcated into (i) a portion that is recorded as imputed interest expense and (ii) a portion that reduces the finance liability associated with the lease. The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t have any finance leases recorded on its consolidated balance sheet as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Deferred Issuance Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company capitalizes certain legal, professional accounting, and other third-party fees that are directly associated with in-process equity financings as deferred issuance costs until such financings are consummated. After consummation of such an equity financing, these costs are recorded as a reduction of the proceeds generated as a result of the offering. Should a planned equity financing be abandoned, the deferred issuance costs would be expensed immediately as a charge to operating expenses in the consolidated statements of operations and comprehensive loss. The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t have any deferred issuance costs recorded at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 or December 31, 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock and pre-funded warrants outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock and pre-funded warrants and potentially dilutive securities outstanding during the period determined using the treasury-stock and if-converted methods. The Company has generated a net loss in all periods presented; therefore, the basic and diluted net loss per share attributable to common stockholders are the same as the inclusion of the potentially dilutive securities would be anti-dilutive.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (&#x201c;CODM&#x201d;) in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#x2019;s CODM is its Chief Executive Officer. The Company has determined it operates in a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_8196d8a8-372d-4a07-a143-8661735a221d;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;single&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; operating segment and has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; reportable segment. All long-lived assets of the Company reside in the United States.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Comprehensive&lt;/span&gt;&lt;span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Loss&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is required to report all components of comprehensive loss, including net loss, in the financial statements in the period in which they are recognized. Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Comprehensive loss consists of the Company&#x2019;s net loss, unrealized gains and losses on the Company&#x2019;s investments, and foreign currency translation adjustments and is presented within the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Foreign Currency Transactions&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company maintains foreign bank accounts denominated in euros and Swiss francs and enters into transactions which are denominated in various currencies. Foreign currency transactions are initially recorded by the Company using the exchange rates prevailing at the date of the transaction. At the balance sheet date, recorded monetary balances denominated in foreign currencies are adjusted to U.S. dollars using the period-end rates of exchange. Exchange gains and losses arising from the translation of foreign currency items are included in other expense, net in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company categorizes its assets and liabilities measured at fair value in accordance with the authoritative accounting guidance that establishes a consistent framework for measuring fair value, and expands disclosures for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.66525540221037%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 1 &#x2013; Unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets or liabilities; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.66525540221037%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 2 &#x2013; Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; or &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.66525540221037%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 3 &#x2013; Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Emerging Growth Company Status&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is an &#x201c;emerging growth company&#x201d; (&#x201c;EGC&#x201d;) as defined in the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;), and the Company may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs. As an EGC, the Company can elect to take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to use the extended transition period for complying with new or revised accounting standards, and as a result of this election, the Company&#x2019;s consolidated financial statements may not be comparable to companies that comply with public company FASB standards&#x2019; effective dates. The Company will remain an EGC until December 31, 2025, although if the market value of the Company&#x2019;s common stock that is held by non-affiliates exceeds $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;700&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as of any June 30 before that time or if the Company has annual gross revenues of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.235&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; billion or more in any fiscal year, the Company would cease to be an EGC as of December 31 of the applicable year. The Company would also cease to be an EGC if it issued more than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; billion of non-convertible debt over a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;three-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; period.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Debt and Debt Issuance Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Debt issuance costs are presented on the consolidated balance sheet as a direct deduction from the related debt liability. Debt issuance costs represent legal and other direct costs incurred in connection with the Company&#x2019;s term loan under the Loan Agreement. These costs are amortized as a non-cash component of interest expense using the effective interest method over the term of the loan. Any final payments are included in the cash flows to determine the effective interest rate and are recognized using the effective interest method over the term of the loan.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company determines the accounting classification of warrants that are issued, as either liability or equity, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Accounting for Certain Financial Instruments with Characteristics of Both Liabilities and Equity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, and then in accordance with ASC 815-40, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#x2019;s Own Stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Under ASC 480-10, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate the issuer to settle the warrants or the underlying shares by paying cash or other assets, or must or may require settlement by issuing variable number of shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;If warrants do not meet liability classification under ASC 480-10, the Company assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability classification under ASC 815-40, in order to conclude equity classification, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable U.S. GAAP. After all relevant assessments are made, the Company concludes whether the warrants are classified as liability or equity. Liability classified warrants are required to be accounted for at fair value both on the date of issuance and on subsequent accounting period ending dates, with all changes in fair value after the issuance date recorded in the statements of operations as a gain or loss. Equity classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_d6107755-60f2-46fe-82bc-95779d65a9c1">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Inozyme Securities Corp., which is a Massachusetts subsidiary created to buy, sell, and hold securities; Inozyme Ireland Limited; and Inozyme Pharma Switzerland GmbH. All intercompany transactions and balances have been eliminated.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_8e4c76b5-cc5c-4f7f-9973-24c9689bbd9e">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The preparation of the Company&#x2019;s financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and judgments are based on historical information and other market-specific or various relevant assumptions, including, in certain circumstances, future projections that management believes to be reasonable under the circumstances. Actual results could differ materially from estimates. Significant estimates and assumptions are used for, but not limited to the accruals for research and development expenses. The Company evaluates its estimates and assumptions on an ongoing basis. All revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_eedb7b0a-805b-4d1b-8bdc-cf386849f8a3">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Concentration of Credit Risk, Significant Suppliers, and Off-Balance Sheet Risk&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and short-term investments and, from time to time, long-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits and limits its exposure to credit risk by placing its cash with high credit quality financial institutions. The Company&#x2019;s investments are composed of U.S. Treasury and U.S. government agency debt securities and commercial paper of corporations. The Company mitigates credit risk by maintaining a diversified portfolio and limiting the amount of investment exposure as to institution, maturity, and investment type.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is dependent on third-party manufacturers and contract research organizations ("CROs") to supply product candidates and provide services for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. The Company also relies on CROs to conduct its clinical trials. The Company&#x2019;s programs could be adversely affected if a third-party manufacturer or a CRO is unable to successfully carry out their contractual obligations or meet expected deadlines. If a third-party manufacturer or a CRO needs to be replaced, the Company may not be able to complete its program development on its anticipated timelines and the Company may incur additional expenses as a result, which could be significant.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; significant off-balance sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_1f249596-1768-4942-956d-a0289ed24f1e">The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.</us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk>
    <inzy:ConcentrationRiskCreditRiskOffBalanceSheetRisk
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_cd53fb91-72d2-4a9d-bf37-34f41f2db4f7"
      unitRef="U_USD">0</inzy:ConcentrationRiskCreditRiskOffBalanceSheetRisk>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_cdab6c2d-c273-4bd4-9b8b-4827278c7364">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts, money market accounts, and certain marketable securities. Cash is carried at cost, which approximates its fair value. Cash equivalents are carried at fair market value.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_7862449a-f5fd-46c9-927d-6e50d63f4075">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Restricted cash is composed of amounts held to collateralize the letters of credit related to the Company&#x2019;s lease arrangements. Restricted cash is classified as either current or non-current based on the terms of the underlying lease arrangement.&lt;/span&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_1ca69b15-13b1-4abe-9587-eea7b8525626">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Short-Term and Long-Term Investments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company classifies its investments as available-for-sale and records such assets at estimated fair value on the balance sheet, with unrealized gains and losses on marketable securities, if any, reported as a component of accumulated other comprehensive (loss) income. Realized gains and losses are calculated based on the specific-identification method and are recorded as a component of interest income. There have been &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; realized gains and losses for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022. The Company periodically reviews available-for-sale securities for other-than-temporary declines in fair value below the cost basis whenever events&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Marketable securities with a maturity date of one year or less from the balance sheet date are classified by the Company as short-term investments. Marketable securities with a maturity date of greater than one year from the balance sheet date are classified as long-term investments and are available to fund operations as needed. As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t have any long-term investments. In accordance with the Company&#x2019;s investment policy, at the time of purchase, the final maturity of each security within the portfolio shall not exceed &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;18&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; months and the weighted average maturity of the portfolio will be no greater than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; months.&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_4caf2bb2-0fd5-456e-8896-e3375b1186f2"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_0e50a852-f9d2-46b6-9e43-9be55d6dcbe3"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:LongTermInvestments
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_6e800d23-b1d6-40f5-98e1-eff482fb8b38"
      unitRef="U_USD">0</us-gaap:LongTermInvestments>
    <us-gaap:DebtSecuritiesHeldToMaturityThresholdPeriodPastDueWriteoff
      contextRef="C_a5581986-e14e-4e34-a7f8-7bba69e2c058"
      id="F_a5fabd00-4fea-4de6-9b45-325e57fe2224">P18M</us-gaap:DebtSecuritiesHeldToMaturityThresholdPeriodPastDueWriteoff>
    <us-gaap:DebtSecuritiesHeldToMaturityThresholdPeriodPastDueWriteoff
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      id="F_ba748a34-72a7-46e6-94eb-4e571aa72cdf">P12M</us-gaap:DebtSecuritiesHeldToMaturityThresholdPeriodPastDueWriteoff>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_fa219f20-0467-4aac-b831-4c2de6b83bf6">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the related asset. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The estimated useful lives of the Company&#x2019;s property and equipment are as follows: &lt;/span&gt;&lt;/span&gt;&lt;span style=""&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:73.34%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:24.66%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated Useful Life (In Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Laboratory equipment and manufacturing equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_163a734f-613d-45f6-b523-f3a90ba56209;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lesser of asset life or lease term&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <inzy:PropertyAndEquipmentEstimatedUsefulLivesTableTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_d2f16701-f627-425a-a1a2-b8e31ac5b7a5">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The estimated useful lives of the Company&#x2019;s property and equipment are as follows: &lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:73.34%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:24.66%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated Useful Life (In Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Laboratory equipment and manufacturing equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_163a734f-613d-45f6-b523-f3a90ba56209;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lesser of asset life or lease term&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</inzy:PropertyAndEquipmentEstimatedUsefulLivesTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_f1b17c7a-98c5-4dda-8775-61fdebd34c84"
      id="F_1a500c19-a89d-497d-bb5b-295521e84e68">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_ad70b717-7bb2-4c61-9bb0-95099842631c"
      id="F_c1e78596-3a49-4d9a-9e2d-b8566f98bad1">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_6f8af799-609d-4c14-b3ec-0e9bdd4c588e"
      id="F_9f5b3fb7-1708-40ea-b5b0-100d8e64f3af">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_a6f6a2cf-c8e9-4316-bef8-8a1b04d24b4a">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Impairment of Long-lived Assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As required under the applicable accounting guidance, the Company periodically reevaluates the original assumptions and rationale used in the establishment of the carrying value and estimated lives of all of its long-lived assets, including property and equipment. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. An impairment loss is recognized when the total of estimated future undiscounted cash flows, expected to result from the use of the asset and its eventual disposition, are less than its carrying amount. Impairment, if any, would be assessed using discounted cash flows or other appropriate measures of fair value. There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; impairments for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_cc9b1d3e-7386-4ab4-b63d-b297d8a6dfa0"
      unitRef="U_USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_e78542c8-f710-4714-af37-c253f76b4603"
      unitRef="U_USD">0</us-gaap:AssetImpairmentCharges>
    <inzy:AccruedResearchAndDevelopmentCostsPolicyTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_4195e7fc-7d3c-41cb-bfc4-dce56ae94fd0">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Accrued Research and Development Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company records accrued liabilities for estimated costs of research and development activities conducted by service providers for sponsored research, preclinical studies, clinical operations, and contract manufacturing activities based upon the estimated amount of services provided but not yet invoiced and includes these costs in accrued expenses in the accompanying consolidated balance sheets and within research and development expense in the accompanying consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with service providers. The Company makes significant judgments and estimates in determining the accrued liabilities balance in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. The Company has not experienced any material differences between accrued costs and actual costs incurred since its inception.&lt;/span&gt;</inzy:AccruedResearchAndDevelopmentCostsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_51526752-1537-4b00-b05a-bbc22a0685d7">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Research and Development Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. Research and development costs consist of direct and indirect internal costs related to specific projects as well as fees paid to other entities that conduct certain research and development activities on the Company&#x2019;s behalf.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <inzy:PatentCostsPolicyTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_f176e6a1-c03c-4acd-bdd6-0b803bf9905e">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Patent Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company expenses all costs as incurred in connection with patent applications, including direct application fees, and the legal and consulting expenses related to making such applications, and such costs are included in general and administrative expenses within the Company&#x2019;s consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</inzy:PatentCostsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_d4268b36-b7af-4ba4-8a46-b82e48202a73">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-based &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;compensation expense represents the cost of the grant date fair value of employee and non-employee stock option grants recognized over the requisite service period of the awards on a straight-line basis. For service-based awards that are&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;subject &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;to graded vesting, the Company has elected to recognize compensation expense on a straight-line basis. The Company has elected to recognize forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_3019682d-b2e2-4cdc-9fa5-ce9ad873197a">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income taxes have been accounted for using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates applicable to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. A valuation allowance against deferred tax assets is recorded if, based upon the weight of all available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounts for income taxes in accordance with authoritative accounting guidance which states the impact of an uncertain income tax position is recognized at the largest amount that is &#x201c;more likely than not&#x201d; to be sustained upon audit by the relevant taxing authority. There are &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; unrecognized tax benefits included in the Company&#x2019;s consolidated balance sheets at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 or 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Company&#x2019;s policy is to recognize interest and penalties related to income tax matters in income tax expense. The Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t recognized any interest or penalties in its consolidated statements of operations and comprehensive loss since inception.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_58ffbc56-102e-48cf-9b3e-86eb02652968"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_f9151e1c-1a1c-4fd2-91c3-dfd8900bd0f6"
      decimals="-3"
      id="F_99158650-21ab-43f8-8f2d-3b0b1a909dcb"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_87988723-f5e6-4f4f-afa2-b825e435b044"
      unitRef="U_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_5a01ffdd-c19e-431b-8dc6-2bebc3e1e235">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company determines if an arrangement is a lease at contract inception based on the facts and circumstances present in the arrangement. If a lease is identified in an arrangement, the Company recognizes a right-of-use asset and liability on its balance sheet and determines whether the lease should be classified as a finance or operating lease. Short-term leases, or leases that have a lease term of 12 months or less at the commencement date are excluded from this treatment and are recognized on a straight-line basis over the term of the lease. Additionally, the Company does not separate lease and non-lease components for all leases.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded as operating leases.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Finance and operating lease assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount rate implicit in the lease. If the rate implicit is not readily determinable, the Company utilizes an estimate of its incremental borrowing rate at the lease commencement date. Operating lease assets are further adjusted for prepaid or accrued lease payments. Operating lease payments are expensed using the straight-line method as an operating expense over the lease term. Finance lease assets are amortized to depreciation expense using the straight-line method over the shorter of the useful life of the related asset or the lease term. Finance lease payments are bifurcated into (i) a portion that is recorded as imputed interest expense and (ii) a portion that reduces the finance liability associated with the lease. The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t have any finance leases recorded on its consolidated balance sheet as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:FinanceLeaseImpairmentLoss
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_deda3c33-cb12-4b09-8b34-60d877a69f06"
      unitRef="U_USD">0</us-gaap:FinanceLeaseImpairmentLoss>
    <us-gaap:FinanceLeaseImpairmentLoss
      contextRef="C_4ee9c018-375e-4d0f-ab9e-435246e8b7ce"
      decimals="-3"
      id="F_dfc005fe-171b-40fe-9130-e881ad0e4872"
      unitRef="U_USD">0</us-gaap:FinanceLeaseImpairmentLoss>
    <us-gaap:DeferredChargesPolicyTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_5abb3292-254a-4a4e-a12d-4006932e1e0c">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Deferred Issuance Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company capitalizes certain legal, professional accounting, and other third-party fees that are directly associated with in-process equity financings as deferred issuance costs until such financings are consummated. After consummation of such an equity financing, these costs are recorded as a reduction of the proceeds generated as a result of the offering. Should a planned equity financing be abandoned, the deferred issuance costs would be expensed immediately as a charge to operating expenses in the consolidated statements of operations and comprehensive loss. The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t have any deferred issuance costs recorded at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 or December 31, 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_e0426bf3-9df9-4a82-8dd7-f6a2678f6d78"
      unitRef="U_USD">0</us-gaap:DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_0863ccc8-da7e-48d6-a424-50e328eb5025"
      unitRef="U_USD">0</us-gaap:DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_191f2df2-b8b6-4721-bee5-5a8ddccaad92">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock and pre-funded warrants outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock and pre-funded warrants and potentially dilutive securities outstanding during the period determined using the treasury-stock and if-converted methods. The Company has generated a net loss in all periods presented; therefore, the basic and diluted net loss per share attributable to common stockholders are the same as the inclusion of the potentially dilutive securities would be anti-dilutive.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_c19f391d-5cc2-4061-89cd-f3dbd58d2651">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (&#x201c;CODM&#x201d;) in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#x2019;s CODM is its Chief Executive Officer. The Company has determined it operates in a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_8196d8a8-372d-4a07-a143-8661735a221d;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;single&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; operating segment and has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; reportable segment. All long-lived assets of the Company reside in the United States.&lt;/span&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="INF"
      id="F_d7a62e7b-a6af-47a6-b05e-f6b39cd5f030"
      unitRef="U_Segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_4e6a5d23-d51f-46ae-944c-ddaeb576b0e8">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Comprehensive&lt;/span&gt;&lt;span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Loss&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is required to report all components of comprehensive loss, including net loss, in the financial statements in the period in which they are recognized. Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Comprehensive loss consists of the Company&#x2019;s net loss, unrealized gains and losses on the Company&#x2019;s investments, and foreign currency translation adjustments and is presented within the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_88772189-974d-4be8-bccb-a3a89831d570">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Foreign Currency Transactions&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company maintains foreign bank accounts denominated in euros and Swiss francs and enters into transactions which are denominated in various currencies. Foreign currency transactions are initially recorded by the Company using the exchange rates prevailing at the date of the transaction. At the balance sheet date, recorded monetary balances denominated in foreign currencies are adjusted to U.S. dollars using the period-end rates of exchange. Exchange gains and losses arising from the translation of foreign currency items are included in other expense, net in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_d0f3ccb1-04ab-492a-956a-8c33bac2f91d">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company categorizes its assets and liabilities measured at fair value in accordance with the authoritative accounting guidance that establishes a consistent framework for measuring fair value, and expands disclosures for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.66525540221037%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 1 &#x2013; Unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets or liabilities; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.66525540221037%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 2 &#x2013; Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; or &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.66525540221037%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 3 &#x2013; Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <inzy:EmergingGrowthCompanyStatusPolicyTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_ba1065b9-f609-4e91-9414-a711b40960e2">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Emerging Growth Company Status&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is an &#x201c;emerging growth company&#x201d; (&#x201c;EGC&#x201d;) as defined in the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;), and the Company may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs. As an EGC, the Company can elect to take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to use the extended transition period for complying with new or revised accounting standards, and as a result of this election, the Company&#x2019;s consolidated financial statements may not be comparable to companies that comply with public company FASB standards&#x2019; effective dates. The Company will remain an EGC until December 31, 2025, although if the market value of the Company&#x2019;s common stock that is held by non-affiliates exceeds $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;700&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as of any June 30 before that time or if the Company has annual gross revenues of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.235&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; billion or more in any fiscal year, the Company would cease to be an EGC as of December 31 of the applicable year. The Company would also cease to be an EGC if it issued more than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; billion of non-convertible debt over a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;three-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; period.&lt;/span&gt;&lt;/p&gt;</inzy:EmergingGrowthCompanyStatusPolicyTextBlock>
    <inzy:EmergingGrowthCompanyMarketValueOfCommonStockHeldByNonAffiliates
      contextRef="C_cf58a586-baf1-45e2-afe5-cc909b0ac57a"
      decimals="-6"
      id="F_0af2b15f-cccc-4e7d-90dd-bc3bb65c5529"
      unitRef="U_USD">700000000</inzy:EmergingGrowthCompanyMarketValueOfCommonStockHeldByNonAffiliates>
    <inzy:EmergingGrowthCompanyAnnualGrossRevenues
      contextRef="C_ce440ee2-4c72-4b3f-867c-b18a4779f0de"
      decimals="-6"
      id="F_e4d63ed6-cc0d-4cd6-bedd-52ff30f7fc51"
      unitRef="U_USD">1235000000</inzy:EmergingGrowthCompanyAnnualGrossRevenues>
    <inzy:EmergingGrowthCompanyStatusIssuanceValueOfNonConvertibleDebt
      contextRef="C_ce440ee2-4c72-4b3f-867c-b18a4779f0de"
      decimals="-9"
      id="F_9b869a52-cb12-4f53-96d6-73ac73058303"
      unitRef="U_USD">1000000000</inzy:EmergingGrowthCompanyStatusIssuanceValueOfNonConvertibleDebt>
    <inzy:EmergingGrowthCompanyStatusIssuancePeriodOfNonConvertibleDebt
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_5c153743-1110-4c5c-ad66-e2b1226470f1">P3Y</inzy:EmergingGrowthCompanyStatusIssuancePeriodOfNonConvertibleDebt>
    <us-gaap:DebtPolicyTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_ee33bed4-fab4-463a-8233-52228d81e7c8">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Debt and Debt Issuance Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Debt issuance costs are presented on the consolidated balance sheet as a direct deduction from the related debt liability. Debt issuance costs represent legal and other direct costs incurred in connection with the Company&#x2019;s term loan under the Loan Agreement. These costs are amortized as a non-cash component of interest expense using the effective interest method over the term of the loan. Any final payments are included in the cash flows to determine the effective interest rate and are recognized using the effective interest method over the term of the loan.&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtPolicyTextBlock>
    <inzy:WarrantsPolicyTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_b72f35d5-9d0a-43b0-b424-521afad43418">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company determines the accounting classification of warrants that are issued, as either liability or equity, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Accounting for Certain Financial Instruments with Characteristics of Both Liabilities and Equity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, and then in accordance with ASC 815-40, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#x2019;s Own Stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Under ASC 480-10, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate the issuer to settle the warrants or the underlying shares by paying cash or other assets, or must or may require settlement by issuing variable number of shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;If warrants do not meet liability classification under ASC 480-10, the Company assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability classification under ASC 815-40, in order to conclude equity classification, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable U.S. GAAP. After all relevant assessments are made, the Company concludes whether the warrants are classified as liability or equity. Liability classified warrants are required to be accounted for at fair value both on the date of issuance and on subsequent accounting period ending dates, with all changes in fair value after the issuance date recorded in the statements of operations as a gain or loss. Equity classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.&lt;/span&gt;&lt;/p&gt;</inzy:WarrantsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_dbd09f33-c1bf-4344-b794-5d396792e3c1">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;3. Recent Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recently Adopted Accounting Standard&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (&#x201c;Topic 326&#x201d;): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 and its subsequent related updates establish a new forward-looking &#x201c;expected loss model&#x201d; that requires entities to estimate current expected credit losses on accounts receivable and financial instruments by using all practical and relevant information. The Company adopted this standard effective January 1, 2023. There was no impact to the Company's financial statements upon adoption.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_f675882e-d3f9-4b10-a718-ec7cb74d6d79">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recently Adopted Accounting Standard&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (&#x201c;Topic 326&#x201d;): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 and its subsequent related updates establish a new forward-looking &#x201c;expected loss model&#x201d; that requires entities to estimate current expected credit losses on accounts receivable and financial instruments by using all practical and relevant information. The Company adopted this standard effective January 1, 2023. There was no impact to the Company's financial statements upon adoption.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_75615bea-0589-4e84-ad57-3569ce57b8e0">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;4. Balance Sheet Details&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Short-term investments consisted of the following (dollar amounts in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.24%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.9%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.120000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.82%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="16" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Maturity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1 year or less&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;80,160&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;80,218&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government agency debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1 year or less&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;73,774&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;73,783&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;153,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;154,001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.269%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.902%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.282%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.282%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.122%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.822%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="16" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Maturity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1 year or less&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;78,451&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;119&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;78,336&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1 year or less&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,615&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;95,149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;202&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;94,951&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company concluded that the declines in market value of available-for-sale securities were temporary in nature and did not consider any of the investments to be other-than-temporarily impaired. In accordance with its investment policy, the Company invests in investment grade securities with high credit quality issuers, and generally limits the amount of credit exposure to any one issuer. The Company evaluates securities for other-than-temporary impairment at the end of each reporting period. Impairment is evaluated considering numerous factors, and their relative significance varies depending on the situation. Factors considered include the length of time and extent to which fair value has been less than the cost basis, the financial condition and near-term prospects of the issuer, and the Company&#x2019;s intent and ability to hold the investment to allow for an anticipated recovery in fair value. Furthermore, the aggregate of individual unrealized losses that had been outstanding for 12 months or less was not significant as of December 31, 2023 and December 31, 2022. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before a recovery of their amortized cost bases, which may be maturity. The Company also believes that it will be able to collect both principal and interest amounts due at maturity.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Prepaid expenses and other current assets consisted of the following (dollar amounts in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;At December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;At December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Interest receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,067&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,293&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid research studies&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,339&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,397&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;870&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,661&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment consisted of the following (dollar amounts in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;At December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;At December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Laboratory equipment and manufacturing equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;805&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;284&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;258&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;491&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;558&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,129&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,879&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,413&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,732&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,466&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,018&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Depreciation expense for the years ended December 31, 2023 and 2022 totaled &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued expenses consisted of the following (dollar amounts in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;At December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;At December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Payroll and related liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,838&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,229&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Clinical expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,986&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,917&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,345&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;883&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;485&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,610&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,355&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_ba561aad-8a59-4dd1-97fd-9e8f32df55fb">&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Short-term investments consisted of the following (dollar amounts in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.24%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.9%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.120000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.82%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="16" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Maturity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1 year or less&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;80,160&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;80,218&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government agency debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1 year or less&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;73,774&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;73,783&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;153,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;154,001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.269%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.902%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.282%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.282%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.122%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.822%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="16" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Maturity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1 year or less&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;78,451&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;119&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;78,336&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1 year or less&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,615&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;95,149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;202&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;94,951&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <inzy:InvestmentMaturityPeriod
      contextRef="C_afa7e7f7-939c-4d45-98c6-aac2333bb8a1"
      id="F_6a4f7699-70ea-4c01-8193-7cedaeef4501">1 year or less</inzy:InvestmentMaturityPeriod>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_38923768-4f8c-4cf5-8568-d7b648fc7393"
      decimals="-3"
      id="F_3a324e0c-3823-400e-913f-afc7f1f70b28"
      unitRef="U_USD">80160000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_38923768-4f8c-4cf5-8568-d7b648fc7393"
      decimals="-3"
      id="F_b76c4797-6fd1-465b-aa45-39d443751694"
      unitRef="U_USD">59000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_38923768-4f8c-4cf5-8568-d7b648fc7393"
      decimals="-3"
      id="F_8db0e6fb-5812-4b1e-b6fb-57c6391d0f12"
      unitRef="U_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_38923768-4f8c-4cf5-8568-d7b648fc7393"
      decimals="-3"
      id="F_a6b57b33-69b2-49c7-a87d-69c4c6a657c3"
      unitRef="U_USD">80218000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <inzy:InvestmentMaturityPeriod
      contextRef="C_3f4c43df-91a9-4dcb-a518-2b872f3cab86"
      id="F_95760b22-3931-4e62-bf1b-ddcd87235066">1 year or less</inzy:InvestmentMaturityPeriod>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_9dcd98d2-cef7-49c2-a825-548d1468b4ee"
      decimals="-3"
      id="F_2dc854df-1b93-401f-ad1b-52e114e6a34c"
      unitRef="U_USD">73774000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_9dcd98d2-cef7-49c2-a825-548d1468b4ee"
      decimals="-3"
      id="F_6cf4046f-6294-443c-9fe1-17aa84ce3b84"
      unitRef="U_USD">17000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_9dcd98d2-cef7-49c2-a825-548d1468b4ee"
      decimals="-3"
      id="F_cbaf0672-e391-4e6a-b16a-c505f81cee16"
      unitRef="U_USD">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_9dcd98d2-cef7-49c2-a825-548d1468b4ee"
      decimals="-3"
      id="F_a9a6c309-d83d-4d33-aea3-7c1d80bbd60d"
      unitRef="U_USD">73783000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_3f0c6589-a71e-4c33-b69e-3bf7f2ea153c"
      unitRef="U_USD">153934000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_03247cdf-2651-492d-9cd9-7d4bc2c10dd9"
      unitRef="U_USD">76000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_2517baed-2492-481c-8171-e4a39a46174c"
      unitRef="U_USD">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_28702be3-1b85-46bd-b37d-8f1c3536e9c1"
      unitRef="U_USD">154001000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <inzy:InvestmentMaturityPeriod
      contextRef="C_5bb4c6de-83a3-4b5b-8ccc-2887ba662ad0"
      id="F_6549c39a-5101-42d7-ad05-5dd6d67d88b5">1 year or less</inzy:InvestmentMaturityPeriod>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_580be68e-23a1-4156-859f-97d143db13e7"
      decimals="-3"
      id="F_7d98ba3f-46e0-467f-b9af-9b5a777ed751"
      unitRef="U_USD">78451000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_580be68e-23a1-4156-859f-97d143db13e7"
      decimals="-3"
      id="F_0ea408cb-ac80-4657-bf2c-0e8cc9bafd06"
      unitRef="U_USD">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_580be68e-23a1-4156-859f-97d143db13e7"
      decimals="-3"
      id="F_273171c0-4b36-496b-8e56-9f20e1d1c3db"
      unitRef="U_USD">119000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_580be68e-23a1-4156-859f-97d143db13e7"
      decimals="-3"
      id="F_aba0dec2-9076-40b5-b6c2-90e5cf1e8632"
      unitRef="U_USD">78336000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <inzy:InvestmentMaturityPeriod
      contextRef="C_627d9b19-c97f-4990-affb-d25c50839022"
      id="F_43a69409-ed43-4003-b770-0fe1a5b7c65b">1 year or less</inzy:InvestmentMaturityPeriod>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_fd818a77-dcd6-4172-b69f-ef9f6f65f940"
      decimals="-3"
      id="F_aaba097a-20fd-478c-bd5f-d0791542c02a"
      unitRef="U_USD">16698000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_fd818a77-dcd6-4172-b69f-ef9f6f65f940"
      decimals="-3"
      id="F_12bf9d0e-d901-4d1c-90bb-3ae19f858785"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_fd818a77-dcd6-4172-b69f-ef9f6f65f940"
      decimals="-3"
      id="F_b625c180-430f-4f0d-9e0d-8f21c6546056"
      unitRef="U_USD">83000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_fd818a77-dcd6-4172-b69f-ef9f6f65f940"
      decimals="-3"
      id="F_33e56427-115c-4446-a4e3-811e1db929ec"
      unitRef="U_USD">16615000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_5194c989-4edd-4ece-ae7a-5d2de8832ce1"
      unitRef="U_USD">95149000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_6010e46b-88d6-4739-a79d-295971ec7474"
      unitRef="U_USD">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_cadcd1bc-df01-4d58-ba06-8cd179e09a9b"
      unitRef="U_USD">202000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_20447c2a-da39-459c-96fd-75518c32b138"
      unitRef="U_USD">94951000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <inzy:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_7944f43b-f4a5-4fa2-a054-6b018fe537a2">&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Prepaid expenses and other current assets consisted of the following (dollar amounts in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;At December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;At December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Interest receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,067&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,293&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid research studies&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,339&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,397&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;870&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,661&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</inzy:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock>
    <us-gaap:InterestReceivableCurrent
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_6e9c4371-6635-4932-8f60-0af4811fe786"
      unitRef="U_USD">385000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_c1a0493f-fabc-4781-b940-5283367227fd"
      unitRef="U_USD">115000</us-gaap:InterestReceivableCurrent>
    <us-gaap:PrepaidInsurance
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_ea9a0431-7e22-439b-8292-6d336f4b1cb7"
      unitRef="U_USD">1067000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_54d5e46a-5d0c-496d-9129-52a718b6db20"
      unitRef="U_USD">1293000</us-gaap:PrepaidInsurance>
    <inzy:PrepaidResearchStudies
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_cced3f7f-0470-4e3f-ae6a-e0f4d27eb842"
      unitRef="U_USD">5339000</inzy:PrepaidResearchStudies>
    <inzy:PrepaidResearchStudies
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_7d061d5a-19f1-4e5f-b644-f5aff50919b1"
      unitRef="U_USD">1397000</inzy:PrepaidResearchStudies>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_6a7ab929-3f25-4068-a81f-5e57498ae18d"
      unitRef="U_USD">870000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_7a738084-a9b2-46c6-877c-add1e93c623a"
      unitRef="U_USD">722000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_1db435db-5a8a-4758-8aae-852d2710d4bc"
      unitRef="U_USD">7661000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_33fb43e0-7aab-4054-81f1-12b1ad35899b"
      unitRef="U_USD">3527000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_9d84b2d6-94a4-4406-9766-a5eced1dcda3">&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment consisted of the following (dollar amounts in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;At December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;At December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Laboratory equipment and manufacturing equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;805&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;284&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;258&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;491&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;558&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,129&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,879&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,413&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,732&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,466&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,018&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_f1b17c7a-98c5-4dda-8775-61fdebd34c84"
      decimals="-3"
      id="F_7a180909-4acb-4ee5-abc6-60a9f238cd0c"
      unitRef="U_USD">947000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_dd2554f0-5fa2-4094-bb5c-964fac0c425e"
      decimals="-3"
      id="F_6b89f4bb-01a1-4028-88e8-b07755258f79"
      unitRef="U_USD">805000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_ad70b717-7bb2-4c61-9bb0-95099842631c"
      decimals="-3"
      id="F_b0af0e3a-5a1f-4ebb-aa04-bd76e87d4b92"
      unitRef="U_USD">284000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_e8c0a014-c50e-4051-b4de-b6a88a7006fe"
      decimals="-3"
      id="F_247135a4-e80d-448f-8a90-895064342e80"
      unitRef="U_USD">258000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_6f8af799-609d-4c14-b3ec-0e9bdd4c588e"
      decimals="-3"
      id="F_a8241500-6190-49f7-934b-08683cb3b851"
      unitRef="U_USD">491000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_b6643dbc-a9cd-41a0-9331-c15dc4781614"
      decimals="-3"
      id="F_5a7c6270-220d-4816-8b1e-b4a99206db71"
      unitRef="U_USD">558000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_1b475cba-fda5-4a60-90f8-717eba9366b4"
      decimals="-3"
      id="F_a5840710-747f-4d1f-a4b7-6e59d791c598"
      unitRef="U_USD">2157000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_93fed2f2-49b6-4337-8584-7a6a8c8c936e"
      decimals="-3"
      id="F_4d4c6845-d089-4127-9d7f-92003d5dcf92"
      unitRef="U_USD">2129000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_f02bc506-c512-466a-9021-d2a523bc299d"
      unitRef="U_USD">3879000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_7cf7afe2-b5f7-417d-8539-5e8af6ce2f22"
      unitRef="U_USD">3750000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_c001e5f5-c3cf-4b12-8e08-5a389c4b8d13"
      unitRef="U_USD">2413000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_45483f42-3ae5-465c-bfd6-c67aceeb7acc"
      unitRef="U_USD">1732000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_a9186b7f-6ad7-4010-9896-1195815b5d0b"
      unitRef="U_USD">1466000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_b925a626-57f4-45eb-ad3d-d59df68f7af8"
      unitRef="U_USD">2018000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-5"
      id="F_a1d40243-a74f-45e4-ab5f-cff2d2350176"
      unitRef="U_USD">800000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-5"
      id="F_2ac468cb-4640-4965-8b86-73bc37436eb7"
      unitRef="U_USD">700000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_7b7be5af-6de9-4272-9898-c53130a8e84e">&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued expenses consisted of the following (dollar amounts in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;At December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;At December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Payroll and related liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,838&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,229&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Clinical expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,986&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,917&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,345&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;883&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;485&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,610&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,355&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_f23e1aab-3397-4bd8-9c11-2f19056efef1"
      unitRef="U_USD">3838000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_45b79002-86cd-475f-8ba0-a08a20d30db3"
      unitRef="U_USD">3229000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_c530eb52-8f6d-4a14-a6d6-864f774b8932"
      unitRef="U_USD">1377000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_f343e244-87e6-431e-8511-f8c76ff1b25f"
      unitRef="U_USD">1310000</us-gaap:AccruedProfessionalFeesCurrent>
    <inzy:ClinicalExpenses
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_4b34f705-b6e4-4f3d-8f24-6f80e51ebe09"
      unitRef="U_USD">3595000</inzy:ClinicalExpenses>
    <inzy:ClinicalExpenses
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_cf396902-0662-40fc-bc7c-40c3c0f7c646"
      unitRef="U_USD">3986000</inzy:ClinicalExpenses>
    <inzy:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_01b16efc-a2c4-44ad-bc9b-9aec6231e1e8"
      unitRef="U_USD">2917000</inzy:AccruedResearchAndDevelopmentCostsCurrent>
    <inzy:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_add3af88-af7f-4cad-bc22-24b897829a2f"
      unitRef="U_USD">2345000</inzy:AccruedResearchAndDevelopmentCostsCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_6cd3c4b3-b5d5-4ae7-84a1-b336b5519cde"
      unitRef="U_USD">883000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_86258d39-85c8-44e1-a3ef-e399bcfcd6e4"
      unitRef="U_USD">485000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_985c80d7-ec1d-4222-9d66-18e346aada6f"
      unitRef="U_USD">12610000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_217bac8a-02bf-412e-8906-f90768cd1279"
      unitRef="U_USD">11355000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_98567677-f8bc-466f-9b1f-be4fa4336db4">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;5. Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following tables represent the Company&#x2019;s financial assets measured at fair value on a recurring basis and indicate the level of fair value hierarchy utilized to determine such fair values (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value Measurements at Reporting Date&lt;br/&gt;Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Quoted&lt;br/&gt;Prices in&lt;br/&gt;Active&lt;br/&gt;Markets for&lt;br/&gt;Identical&lt;br/&gt;Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds (included in cash and cash&lt;br/&gt;&#160;&#160;&#160;equivalents)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government agency debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;73,783&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;73,783&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;80,218&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;80,218&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;187,831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;114,048&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;73,783&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value Measurements at Reporting Date&lt;br/&gt;Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Quoted&lt;br/&gt;Prices in&lt;br/&gt;Active&lt;br/&gt;Markets for&lt;br/&gt;Identical&lt;br/&gt;Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds (included in cash and cash&lt;br/&gt;&#160;&#160;&#160;equivalents)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;78,336&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;78,336&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,615&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,615&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;121,538&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43,202&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;78,336&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;There have been &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; transfers between fair value levels during the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and December 31, 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_0b2a973c-6f03-46a0-b781-1344da8be933">&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following tables represent the Company&#x2019;s financial assets measured at fair value on a recurring basis and indicate the level of fair value hierarchy utilized to determine such fair values (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value Measurements at Reporting Date&lt;br/&gt;Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Quoted&lt;br/&gt;Prices in&lt;br/&gt;Active&lt;br/&gt;Markets for&lt;br/&gt;Identical&lt;br/&gt;Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds (included in cash and cash&lt;br/&gt;&#160;&#160;&#160;equivalents)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government agency debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;73,783&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;73,783&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;80,218&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;80,218&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;187,831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;114,048&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;73,783&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value Measurements at Reporting Date&lt;br/&gt;Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Quoted&lt;br/&gt;Prices in&lt;br/&gt;Active&lt;br/&gt;Markets for&lt;br/&gt;Identical&lt;br/&gt;Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds (included in cash and cash&lt;br/&gt;&#160;&#160;&#160;equivalents)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;78,336&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;78,336&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,615&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,615&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;121,538&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43,202&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;78,336&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_2b1ba612-eaf7-4255-9f94-845320672517"
      decimals="-3"
      id="F_85f9b5c4-783c-4d4a-b617-a83eb90f48ed"
      unitRef="U_USD">33830000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_aa1d3c56-5369-4d66-b7ef-2331a4328983"
      decimals="-3"
      id="F_7a10c747-5c81-4998-b750-0991fb836596"
      unitRef="U_USD">33830000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0fef7786-5c9f-4661-84e2-6bd709ef1859"
      decimals="-3"
      id="F_c7085863-ef18-4ccf-af1b-583b004052d2"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_ebb0e8ce-192c-4794-b110-e57d539bd7f5"
      decimals="-3"
      id="F_16d35fb0-3ef0-4087-8d8c-2cd87a4a1669"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_f468c3aa-9d5e-4348-b6a5-6d3b6072b370"
      decimals="-3"
      id="F_4b7420a3-9507-497a-96bb-6a69cfa9df31"
      unitRef="U_USD">73783000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_08242d46-09fa-4d0f-acdd-9a2a331c3f18"
      decimals="-3"
      id="F_808acd06-4993-4d76-9314-97a90b2164ff"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_f4d73906-7252-43b1-b4b1-204a7275742a"
      decimals="-3"
      id="F_600a88bf-0579-4d98-b852-9ab776b4a712"
      unitRef="U_USD">73783000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_b766d812-c104-4ba8-94cb-06af03d52200"
      decimals="-3"
      id="F_1a27c44a-df52-4809-a90d-1918c9ab5aec"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_639eb17d-d451-4e67-9099-b216251b8867"
      decimals="-3"
      id="F_03e0ec99-bb1e-44f1-b83c-76b6907f160f"
      unitRef="U_USD">80218000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_f2eb39b0-33a2-4aff-a77e-446a7f20b7ba"
      decimals="-3"
      id="F_274c5d66-3707-4aae-bddc-836e424e1495"
      unitRef="U_USD">80218000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a8a74a9f-0187-449d-bd71-ff493500514a"
      decimals="-3"
      id="F_edfcca4f-470b-43db-85d5-0f8cbcdcb04e"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_58e1da8f-d797-45d5-94a7-e1c0672c5b37"
      decimals="-3"
      id="F_711319d2-ffe9-4372-b681-b06279dc393b"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_cc2d588b-2f3b-4c9e-8375-5d861c028af1"
      decimals="-3"
      id="F_3a15cff4-ea8f-4228-8b4e-b8d4f85768ed"
      unitRef="U_USD">187831000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_c219104e-7f65-4cfb-a306-535fab73fbae"
      decimals="-3"
      id="F_b6ef7c01-4d95-4d24-9ae7-4ae9ab94de70"
      unitRef="U_USD">114048000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_560a8eac-a2ea-4e9e-8e4c-468159d80f18"
      decimals="-3"
      id="F_0628ab97-fd1b-4b3a-a53e-a15a31abfe28"
      unitRef="U_USD">73783000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_edffafaf-bcb8-4571-af95-10f388d3cb08"
      decimals="-3"
      id="F_f423c01e-c523-48bf-82e1-45d61264a646"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_e2f25e47-2422-40ab-810a-92c03b89c3a7"
      decimals="-3"
      id="F_875506a5-dcb4-4422-82cd-c27672b6ff23"
      unitRef="U_USD">26587000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_68e0a225-f316-48f6-9fd5-63d50781b73b"
      decimals="-3"
      id="F_aea5b585-e44f-42b0-b260-4f653500dd23"
      unitRef="U_USD">26587000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_1bd944ab-7162-429e-a0bf-1e98d8b5d629"
      decimals="-3"
      id="F_6a1e21df-8435-43ad-bed9-3feb541ee405"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_cabacfd7-585b-4a2b-88ce-edec24c747f6"
      decimals="-3"
      id="F_cd67773d-c830-4e8b-b171-85bbd5bf0fa3"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a82024c8-742d-4976-8c8e-41e2b8b05ebd"
      decimals="-3"
      id="F_1dcfe138-524f-46f9-9077-5dbdbb76a5cd"
      unitRef="U_USD">78336000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_12de314a-d4b0-494b-813f-351304fba130"
      decimals="-3"
      id="F_b43b7102-0e0c-4366-a5ff-aea8983180b3"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_86c60b96-dc4e-40d1-8dc6-75af50996958"
      decimals="-3"
      id="F_22beddd1-5c4a-4a26-b27d-f158107e8110"
      unitRef="U_USD">78336000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_072e744e-d8a8-4b95-9e11-fd60fc749ad1"
      decimals="-3"
      id="F_4fc0dafb-dd31-49d5-b4bd-96553bf7b1cc"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_da086e8a-c936-404a-b841-ba2c9c0e2bfa"
      decimals="-3"
      id="F_fe9ebe8b-6bea-4e62-adb5-0c9c1e6e4c72"
      unitRef="U_USD">16615000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_26d33768-49f2-4d59-a581-db63d9838d45"
      decimals="-3"
      id="F_9388960f-2f94-4b6f-b421-8946fddf01ca"
      unitRef="U_USD">16615000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_f51cc874-6545-4fcf-a041-fffaa4e330ec"
      decimals="-3"
      id="F_e2e18ada-37a5-4a2b-b470-77af1129a55d"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_e6f1df46-623b-42c5-95a7-877ba9f99313"
      decimals="-3"
      id="F_d7fce6db-9c1c-45bb-80a5-29ee0eddf60f"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9c13b456-85ec-4115-a24f-2f8c865d0abb"
      decimals="-3"
      id="F_bc56f26a-e898-4b91-8dd2-0cf783f59586"
      unitRef="U_USD">121538000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_6218f8b0-72c4-4511-8848-700fe16326a0"
      decimals="-3"
      id="F_bd6353f9-34a4-4b95-8b26-acae2d77145f"
      unitRef="U_USD">43202000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_18a01e41-ea42-4897-ac23-422f3897a169"
      decimals="-3"
      id="F_c3406394-ccde-4b41-986d-d13479841c31"
      unitRef="U_USD">78336000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9cdf7217-5d9d-4e8f-a508-7e31ed97b29e"
      decimals="-3"
      id="F_3423adb9-7d96-4dd0-8cab-dd188875c96b"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_04fff231-739d-4832-b1c1-6cde6ca29b32"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_5b6c5793-03a8-4a6f-8d0a-5196c92f098a"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_d02c0538-2140-4d22-85f6-8476295af697"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_0b65395b-951b-4b8c-b917-0cdb46c5d6e0"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_2a455ab1-3fba-4afa-bfd8-21627ffedc4f">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;6. License and Sponsored Research Agreements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In January 2017, the Company entered into a license agreement with Yale University (&#x201c;Yale&#x201d;), which was amended in May 2020 and July 2020, under which the Company licensed certain intellectual property related to ectonucleotide pyrophosphatase/phosphodiesterase enzymes that is the basis for the Company&#x2019;s INZ-701 development program. Pursuant to the license agreement, as partial upfront consideration, the Company made a payment of approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million to Yale, which&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;amount reflected unreimbursed patent expenses incurred by Yale prior to the date of the license agreement. The Company is responsible for paying Yale an annual license maintenance fee in varying amounts throughout the term ranging from the low tens of thousands of dollars to the high tens of thousands of dollars. For the years ended December 31, 2023 and 2022, the Company incurred a total of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively, in license maintenance fees to Yale.  The Company is required to pay Yale up to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, based on the achievement of a specified net product sales milestone or specified development and commercialization milestones, for each therapeutic and prophylactic licensed product developed. In January 2022, the Company paid Yale an approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million milestone payment following dosing of the first patient in Company&#x2019;s Phase 1/2 clinical trial of INZ-701 in adult patients with ENPP1 Deficiency in November 2021. In March 2022, the Company paid Yale an approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million milestone payment following completion of the first cohort of the Company's Phase 1/2 clinical trial of INZ-701 in adult patients with ENPP1 Deficiency in January 2022. In addition, the Company is required to pay Yale an amount in the several hundreds of thousands of dollars, based on the achievement of a specified net product sales milestone or specified development and commercialization milestones, for each diagnostic licensed product developed. While the agreement remains in effect, the Company is required to pay Yale low single-digit percentage royalties on aggregate worldwide net sales of certain licensed products. Yale is guaranteed a minimum royalty payment amount (ranging in dollar amounts from the mid six figures to low seven figures) for each year after the first sale of a therapeutic or prophylactic licensed product that results in net sales. Yale is guaranteed a minimum royalty payment amount (ranging from the low tens of thousands of dollars to the mid tens of thousands of dollars) for each year after the first sale of a diagnostic licensed product that results in net sales. The Company must also pay Yale a percentage in the twenties of certain types of income it receives from sublicensees. The Company is also responsible for costs relating to the prosecution and maintenance of the licensed patents. Finally, subject to certain conditions, all payments due by the Company to Yale will be tripled following any patent challenge or challenge to a claim by Yale that a product is a licensed product under the agreement, made by the Company against Yale if Yale prevails in such challenge.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In January 2017, the Company also entered into a corporate sponsored research agreement with Yale (the "Sponsored Research Agreement"), which was amended in February 2019, under which the Company agreed to provide research support funding in the aggregate amount of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million over the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;five-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; period from contract inception through &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Sponsored Research Agreement was amended in February 2022, under which the contract was extended through June 30, 2022 subject to the terms of the existing agreement. The Sponsored Research Agreement was amended again in May 2022, March 2023, and January 2024, such that the agreement now extends through December 2024, with approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of Company-provided research support funding for the most recent extension. The aggregate amount of agreed upon research support funding under the Sponsored Research Agreement is &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The Company recorded research and development expenses associated with this arrangement of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in each of the years ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <inzy:PartialUpfrontConsiderationPaymentUnderLicenseAgreement
      contextRef="C_b61af113-eb50-4b3e-aef8-307431908b88"
      decimals="-5"
      id="F_7e9bde8b-b499-4ea6-8ee5-69d1f738cc06"
      unitRef="U_USD">100000</inzy:PartialUpfrontConsiderationPaymentUnderLicenseAgreement>
    <us-gaap:CostMaintenance
      contextRef="C_be56dd08-7be1-43d7-b997-dbab1bf7f427"
      decimals="-5"
      id="F_99329919-954f-4f28-8128-99bb3db7ba48"
      unitRef="U_USD">100000</us-gaap:CostMaintenance>
    <us-gaap:CostMaintenance
      contextRef="C_196b61ab-ba69-4401-87d4-819541ae1871"
      decimals="-5"
      id="F_9a0d0311-9185-44b9-862b-e2fb1d1efb42"
      unitRef="U_USD">100000</us-gaap:CostMaintenance>
    <inzy:LicenseAgreementPaymentUponAchievementOfSpecifiedProductSalesOrDevelopmentAndCommercializationMilestones
      contextRef="C_e4451f72-2b2b-4b91-8f5a-e4ab0f0244ad"
      decimals="-5"
      id="F_204af1a8-0052-4ec5-9347-e0bd6070a7ef"
      unitRef="U_USD">3000000</inzy:LicenseAgreementPaymentUponAchievementOfSpecifiedProductSalesOrDevelopmentAndCommercializationMilestones>
    <inzy:LicenseAgreementPaymentUponAchievementOfSpecifiedProductSalesOrDevelopmentAndCommercializationMilestones
      contextRef="C_83b501bf-9deb-493d-89d6-5fbc9e9ca049"
      decimals="-5"
      id="F_89f8baf6-ab8a-4163-901a-7e0a1778daed"
      unitRef="U_USD">300000</inzy:LicenseAgreementPaymentUponAchievementOfSpecifiedProductSalesOrDevelopmentAndCommercializationMilestones>
    <inzy:LicenseAgreementPaymentUponAchievementOfSpecifiedProductSalesOrDevelopmentAndCommercializationMilestones
      contextRef="C_18e79562-699d-4e71-9f51-f6b59fe5e488"
      decimals="-5"
      id="F_c6a7806f-857d-4dc1-94aa-67cb2b47ff9e"
      unitRef="U_USD">300000</inzy:LicenseAgreementPaymentUponAchievementOfSpecifiedProductSalesOrDevelopmentAndCommercializationMilestones>
    <inzy:ResearchSupportFundingAmount
      contextRef="C_031bf463-89a7-40b9-950c-5f55540d3e85"
      decimals="-5"
      id="F_0d3e6b8a-8467-4b2a-8970-f95d308b5d6a"
      unitRef="U_USD">2400000</inzy:ResearchSupportFundingAmount>
    <inzy:ResearchSupportFundingPeriod
      contextRef="C_f619a243-7caf-4810-be59-b9733e6d8eae"
      id="F_c64c2000-7860-4660-93c2-1b072c7f2fda">P5Y</inzy:ResearchSupportFundingPeriod>
    <inzy:ResearchSupportFundingExpirationMonthAndYear
      contextRef="C_cad8e074-adf8-454f-b55e-9b9e5c164673"
      id="F_56879eb2-4668-4b58-a909-3a7844dfff6f">2021-12</inzy:ResearchSupportFundingExpirationMonthAndYear>
    <inzy:ResearchSupportFundingAmount
      contextRef="C_db0a0e7f-8b7b-448c-940d-e857265ac0d7"
      decimals="-5"
      id="F_69e5ef67-55f6-47e3-b0e1-d80d29936555"
      unitRef="U_USD">300000</inzy:ResearchSupportFundingAmount>
    <inzy:ResearchSupportFundingAmount
      contextRef="C_f0e6584f-b5b7-4d58-a88c-80a7eadaaae3"
      decimals="-5"
      id="F_818c3757-7176-4ac5-9cda-1a508464a0a1"
      unitRef="U_USD">3000000</inzy:ResearchSupportFundingAmount>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_2ad74538-b479-4925-9f60-b6af61969b3d"
      decimals="-5"
      id="F_d5f3d3c5-6cce-4901-b475-905305e3e401"
      unitRef="U_USD">100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_b8d04e02-0ef5-4212-8c55-26c32b719e5f"
      decimals="-5"
      id="F_6f908250-7a40-4bd4-9a6a-6576d7ffcfdf"
      unitRef="U_USD">100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_c6932093-232f-4c81-8cd3-a1ead01f2db6">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;7. Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company held the following significant operating leases of office and laboratory space as of December 31, 2023:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;An operating lease for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,499&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; square feet of office space in Boston, Massachusetts that expires in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, with an &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;option to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;extend&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; the term for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Exercise of the option was determined not to be reasonably certain and thus was not included in the operating lease liability on the consolidated balance sheet as of December 31, 2023 or 2022; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;An operating lease for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,244&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; square feet of laboratory space in Boston, Massachusetts that expires in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, with an &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;option to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;extend&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; the term for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Exercise of the option was determined not to be reasonably certain and thus was not included in the operating lease liability on the consolidated balance sheet as of December 31, 2023 or 2022.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:10.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Both leases are subject to yearly rent escalations. In connection with the Company&#x2019;s leases of office space and laboratory space, the Company provided security deposits to the landlords in the form of letters of credit totaling $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023. The cash collateralizing the letters of credit is included in restricted cash in the accompanying balance sheets as of December 31, 2023 and December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;        &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;At December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the weighted average incremental borrowing rate and the weighted average remaining lease term for the operating leases held by the Company were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;years, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the year ended December 31, 2023, cash paid for amounts included for the measurement of lease liabilities was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and the Company recorded operating lease expense of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. During the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, cash paid for amounts included for the measurement of lease liabilities was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and the Company recorded operating lease expense of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Future lease payments under non-cancelable leases as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 are as follows (dollar amounts in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.84%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;"&gt;Year Ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,016&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;944&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company did not have any finance leases recorded on its consolidated balance sheet as of December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Indemnification Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:10.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters arising out of the relationship between such parties and the Company. In addition, the Company has entered into indemnification agreements with members of its board of directors and senior management that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any claims under indemnification arrangements, and it has not accrued any liabilities related to such obligations as of December 31, 2023 or December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Legal Proceedings&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:10.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is not currently a party to any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses the costs related to its legal proceedings as they are incurred. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; such costs have been incurred during the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <inzy:AreaOfLeasedSpace
      contextRef="C_65370ce0-f82e-4e38-acd5-1026ec007a18"
      decimals="INF"
      id="F_c7f2470c-8dae-488c-b977-7007f81c8865"
      unitRef="U_sqft">8499</inzy:AreaOfLeasedSpace>
    <inzy:LesseeOperatingLeaseExpirationYear
      contextRef="C_ca6446c0-a789-468c-9c42-d76f1a43d7b9"
      id="F_d02c98e5-f1fc-4880-839b-4ff6be5d137f">2025</inzy:LesseeOperatingLeaseExpirationYear>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_ca6446c0-a789-468c-9c42-d76f1a43d7b9"
      id="F_1a27f382-16bc-4613-976d-026eaf8cd0c7">option to extend the term for five years.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_ca6446c0-a789-468c-9c42-d76f1a43d7b9"
      id="F_93b402af-d0d7-49a3-be2e-a1b7c49ff76b">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_65370ce0-f82e-4e38-acd5-1026ec007a18"
      id="F_802216cf-b36f-4d46-bdae-18b1a357ac5e">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <inzy:AreaOfLeasedSpace
      contextRef="C_10590ddc-665f-42d2-b77b-89cf6c383211"
      decimals="INF"
      id="F_9c021174-0dba-465d-a96a-0bcdfb83c4f0"
      unitRef="U_sqft">6244</inzy:AreaOfLeasedSpace>
    <inzy:LesseeOperatingLeaseExpirationYear
      contextRef="C_6a51238e-3618-4c6f-834a-a5b8760a5cab"
      id="F_32fffb91-3851-4278-8d33-23553bb51f40">2025</inzy:LesseeOperatingLeaseExpirationYear>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_6a51238e-3618-4c6f-834a-a5b8760a5cab"
      id="F_667d5b6c-bdf9-49c4-b446-69194c0641b4">option to extend the term for five years.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_6a51238e-3618-4c6f-834a-a5b8760a5cab"
      id="F_820996fc-7505-4562-b2b7-4db8f4a08da9">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_10590ddc-665f-42d2-b77b-89cf6c383211"
      id="F_0244c1ad-87f3-4579-9acd-65cb9370d989">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:SecurityDeposit
      contextRef="C_85011284-cdc9-4bd4-845f-74414084de51"
      decimals="-5"
      id="F_006beaca-571b-414c-97cd-91742860dac8"
      unitRef="U_USD">300000</us-gaap:SecurityDeposit>
    <inzy:OperatingLeaseWeightedAverageIncrementalBorrowingRate
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="2"
      id="F_3d8f71af-2b2a-4d72-bde2-182da70af6c7"
      unitRef="U_pure">0.08</inzy:OperatingLeaseWeightedAverageIncrementalBorrowingRate>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      id="F_bccd7aff-ed31-4e1e-b442-b317757c0e6d">P1Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-5"
      id="F_08e8e5c0-14e2-4226-932b-e3dcf9a7ea77"
      unitRef="U_USD">700000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-5"
      id="F_dc03371e-6d7a-4e33-9fa1-4982fad45963"
      unitRef="U_USD">900000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-5"
      id="F_8676f171-80dd-4ef9-8323-6e28cb660d0a"
      unitRef="U_USD">900000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-5"
      id="F_cfb65d33-f648-4129-9c09-3fa96055d714"
      unitRef="U_USD">700000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_bae67349-64df-4f65-8da4-b2e2268c27ba">&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Future lease payments under non-cancelable leases as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 are as follows (dollar amounts in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.84%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;"&gt;Year Ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,016&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;944&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_4aa02391-e389-44dc-94b3-ad59f8f7b15a"
      unitRef="U_USD">1016000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_a8f42ac1-e12d-4b2c-9728-765ccbbb0c4b"
      unitRef="U_USD">944000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <inzy:LesseeOperatingLeaseLiabilityPaymentDue
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_de57d7f6-afc7-4d2b-aabe-e5e686c865c1"
      unitRef="U_USD">1960000</inzy:LesseeOperatingLeaseLiabilityPaymentDue>
    <us-gaap:LegalFees
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="0"
      id="F_e888f09d-64fd-4d18-b5a3-c0751f9cb208"
      unitRef="U_USD">0</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="0"
      id="F_60a28c2c-6763-443b-a63e-520aa3a8681b"
      unitRef="U_USD">0</us-gaap:LegalFees>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_d78c51bd-29f8-4cf7-9023-653e04fec1f6">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;8. Convertible Debt&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Loan Agreement with K2 HealthVentures LLC&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On July 25, 2022, the Company, as borrower, entered into the Loan Agreement with K2 HealthVentures LLC (&#x201c;K2HV&#x201d;, together with any other lender from time to time, the &#x201c;Lenders&#x201d;), K2HV, as administrative agent for the Lenders, and Ankura Trust Company, LLC, as collateral agent for the Lenders. The Loan Agreement provides up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million principal in term loans, subject to certain customary conditions. The Company received $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million from the first tranche commitment upon closing. The first tranche commitment contained an additional $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million available to be drawn at the Company&#x2019;s option through March 31, 2023. The Company elected to borrow the remaining $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in February 2023. Two subsequent tranche commitments totaling $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in the aggregate were available to be drawn at the Company&#x2019;s option during certain availability periods, subject to the achievement of certain clinical and regulatory milestones relating to INZ-701. The Company elected to borrow $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million under the second tranche commitment in June 2023 and elected to borrow $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million under the third tranche commitment in December 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A fourth tranche commitment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million may be made available to be drawn down at the Company&#x2019;s option through August 31, 2025, subject to use of proceeds limitations and Lender's consent at its discretion. The fourth tranche commitment is subject to an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.75&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% facility fee.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, a total of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of borrowing capacity remained available under the Loan Agreement, subject to the terms and conditions set forth therein. As security for its obligations under the Loan Agreement, the Company granted the Lenders a first priority security interest on substantially all of the Company&#x2019;s assets (other than intellectual property), subject to certain exceptions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The term loan matures on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;August 1, 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the Company is obligated to make interest only payments for the first 36 months and then interest and equal principal payments through the maturity date. The term loan bears a variable interest rate equal to the greater of (i) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;7.85&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%, and (ii) the sum of (A) the prime rate last quoted in The Wall Street Journal (or a comparable replacement rate if The Wall Street Journal ceases to quote such rate) and (B) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.85&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%; provided that the interest rate cannot exceed 9.60%&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The interest rate as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;9.60&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%. The Company has the option to prepay all, but not less than, the outstanding principal balance and all accrued and unpaid interest with respect to the principal balance being repaid of the term loans, subject to a prepayment premium to which the Lenders are entitled. The prepayment fee is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% prior to the second anniversary of the July 25, 2022 funding date, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% after the second anniversary but prior to the third anniversary of the funding date, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;thereafter if prior to the&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;maturity &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;date. Upon final payment or prepayment of the loans, the Company must pay a final payment equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the loans borrowed ("Final Fee"), which is being accrued as interest expense over the term of the loan using the effective interest method.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Lenders may elect, prior to the full repayment of the term loans, to convert up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of outstanding principal of the term loans into shares of the Company&#x2019;s common stock, at a conversion price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.21&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, subject to customary adjustments and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.99&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19.99&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% beneficial ownership limitations. The Company determined that the embedded conversion option was not required to be separated from the term loan. The embedded conversion option met the derivative accounting scope exception since the embedded conversion option is indexed to the Company&#x2019;s own common stock and qualifies for classification within stockholders&#x2019; equity.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Loan Agreement contains customary representations and warranties, events of default and affirmative and negative covenants, including covenants that limit or restrict the Company&#x2019;s ability to, among other things, dispose of assets, make changes to the Company&#x2019;s business, management, ownership or business locations, merge or consolidate, incur additional indebtedness, incur additional liens, pay dividends or other distributions or repurchase equity, make investments, and enter into certain transactions with affiliates, in each case subject to certain exceptions. Upon the occurrence of an event of default, a default interest rate of an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% per annum may be applied to the outstanding loan balances, and the Lender may declare all outstanding obligations immediately due and payable and exercise all of its rights and remedies as set forth in the Loan Agreement and under applicable law. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, the Company was in compliance with all covenants under the Loan Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Subject to certain conditions, the Company granted the Lenders the right, prior to repayment of the term loans, to invest up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in the aggregate in future offerings of common stock, convertible preferred stock or other equity securities of the Company that are broadly marketed and offered to multiple investors, on the same terms, conditions and pricing afforded to others participating in any such financing.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company incurred debt issuance costs of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in connection with the term loan. In addition, at the time of closing the Company paid to the Lenders a facility fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, as well as $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of other expenses incurred by the Lenders and reimbursed by the Company ("Lender Expenses"). At &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, the carrying value of the Loan Agreement approximates the fair value of the term loan, considering that it bears interest that is similar to prevailing market rates.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the impact of the term loan on the Company&#x2019;s consolidated balance sheet at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:54.64%;"&gt;&lt;/td&gt;
        &lt;td style="width:5.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Gross proceeds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Carrying value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44,769&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Future principal payments, which include the Final Fee, in connection with the Loan Agreement as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 are as follows (dollar amounts in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:54.64%;"&gt;&lt;/td&gt;
        &lt;td style="width:5.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fiscal Year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,305&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;47,813&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;text-decoration:line-through;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;text-decoration:line-through;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LongTermDebt
      contextRef="C_d9d28d21-3347-4c53-a22e-f87f54964ee4"
      decimals="-5"
      id="F_998c31ae-760d-48ee-af60-e68058727f99"
      unitRef="U_USD">70000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="C_bdaa54b5-eb56-4511-8115-339fb1fdafab"
      decimals="-5"
      id="F_3b4e20b9-7826-4ed5-9456-5a74a9f214e8"
      unitRef="U_USD">5000000</us-gaap:LongTermDebt>
    <inzy:AdditionalLoanAmount
      contextRef="C_bdaa54b5-eb56-4511-8115-339fb1fdafab"
      decimals="-5"
      id="F_a2921ab7-834f-4c37-a610-591367ab4d8b"
      unitRef="U_USD">20000000</inzy:AdditionalLoanAmount>
    <inzy:AdditionalLoanAmount
      contextRef="C_bdaa54b5-eb56-4511-8115-339fb1fdafab"
      decimals="-5"
      id="F_abeb86ca-0b0a-4b13-b34b-f8ad95eac97b"
      unitRef="U_USD">20000000</inzy:AdditionalLoanAmount>
    <us-gaap:LongTermDebt
      contextRef="C_d18b316d-5084-434e-a439-1915ad6efe10"
      decimals="-5"
      id="F_51f2f0fb-42d8-48e7-b18a-6eefc010ead0"
      unitRef="U_USD">20000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="C_5ebf2fa0-40a8-42d4-9daa-b0340f2d221d"
      decimals="-5"
      id="F_02e3d740-ed94-43c3-a5ce-d6d91010ada5"
      unitRef="U_USD">7500000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="C_52088c66-3520-4604-9fd3-bc8ff48b99dc"
      decimals="-5"
      id="F_efef1339-66a8-4468-896b-87567cac8ea6"
      unitRef="U_USD">12500000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="C_93d69508-3aa9-4327-a66a-00b902adeda8"
      decimals="-5"
      id="F_33db14f9-2722-4550-8ae9-c6e19b142746"
      unitRef="U_USD">25000000</us-gaap:LongTermDebt>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="C_35debf45-eff8-4880-842d-b7923517d412"
      decimals="4"
      id="F_73a46437-81be-45f2-9ef7-ce4c2d6a2890"
      unitRef="U_pure">0.0075</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:LongTermDebt
      contextRef="C_5d4682fc-b7e8-4bc8-a04e-f170756de070"
      decimals="-5"
      id="F_cb770ce7-f985-443a-9197-ee327eacbffe"
      unitRef="U_USD">25000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtMaturityDate
      contextRef="C_d9d28d21-3347-4c53-a22e-f87f54964ee4"
      id="F_2b2f008e-eb72-4c66-bf46-e1a2a5b4a33b">2026-08-01</us-gaap:LongTermDebtMaturityDate>
    <us-gaap:DebtInstrumentPaymentTerms
      contextRef="C_7521ee38-3522-499f-9163-aff0538685b8"
      id="F_24b62f6b-6a74-42d6-a04f-c94fe3c36c65">the Company is obligated to make interest only payments for the first 36 months and then interest and equal principal payments through the maturity date. The term loan bears a variable interest rate equal to the greater of (i) 7.85%, and (ii) the sum of (A) the prime rate last quoted in The Wall Street Journal (or a comparable replacement rate if The Wall Street Journal ceases to quote such rate) and (B) 3.85%; provided that the interest rate cannot exceed 9.60%</us-gaap:DebtInstrumentPaymentTerms>
    <us-gaap:DebtInstrumentInterestRateBasisForEffectiveRate
      contextRef="C_7521ee38-3522-499f-9163-aff0538685b8"
      id="F_da091b37-4c25-494d-98e8-9d8257e273d8">7.85</us-gaap:DebtInstrumentInterestRateBasisForEffectiveRate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_1bb0cd98-9386-44b8-b7ca-6ea13928be77"
      decimals="4"
      id="F_a43b16a9-4c3c-4961-83ab-a47a5220c4b9"
      unitRef="U_pure">0.0385</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateBasisForEffectiveRate
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_0adea806-885e-4459-a7d9-103ef315688f">9.60</us-gaap:DebtInstrumentInterestRateBasisForEffectiveRate>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="C_7127e8c7-8b18-4fcc-9ba4-6bd21fc208d5"
      decimals="2"
      id="F_852ae480-acab-4ba0-b22c-e47de35067c2"
      unitRef="U_pure">0.03</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="C_18d66cf9-fa61-4466-8750-6ba204ccf660"
      decimals="2"
      id="F_6af69d8c-8c5f-4cfa-a410-907505f75ed1"
      unitRef="U_pure">0.02</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="C_0e40adfd-e61b-4fd5-8fdb-f07aeb03f570"
      decimals="2"
      id="F_c462e082-c86c-4956-836c-ff7653160aec"
      unitRef="U_pure">0.01</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <inzy:PrepaymentOfLoans
      contextRef="C_7521ee38-3522-499f-9163-aff0538685b8"
      decimals="4"
      id="F_cd230d24-1d82-4e25-ae1f-0d0f927dc8b3"
      unitRef="U_pure">0.0625</inzy:PrepaymentOfLoans>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="C_b8ef8150-b682-4318-bd34-79e0eb945521"
      decimals="-5"
      id="F_083f3f2b-5306-471f-a9be-3bf5f3f827b8"
      unitRef="U_USD">5000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="C_d9d28d21-3347-4c53-a22e-f87f54964ee4"
      decimals="2"
      id="F_2e834631-c57b-4a61-85c6-c90506f843ad"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.21</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <inzy:CustomaryAdjustmentsPercentageOnConversion
      contextRef="C_f0ae2476-b345-490a-a86b-4a01fe48843b"
      decimals="4"
      id="F_3edefc12-d9ad-4a5e-8f87-fe9015f87d34"
      unitRef="U_pure">0.0999</inzy:CustomaryAdjustmentsPercentageOnConversion>
    <inzy:PercentageOfBeneficialOwnershipLimitation
      contextRef="C_f0ae2476-b345-490a-a86b-4a01fe48843b"
      decimals="4"
      id="F_9f2ff211-b7b6-4eaf-bf2b-681d04a001b6"
      unitRef="U_pure">0.1999</inzy:PercentageOfBeneficialOwnershipLimitation>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="4"
      id="F_769de3fa-e0e5-4e49-ab1d-8b02d06a8224"
      unitRef="U_pure">0.05</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <inzy:FutureOfferingsOfCommonStock
      contextRef="C_b8ef8150-b682-4318-bd34-79e0eb945521"
      decimals="-5"
      id="F_86899b80-b051-4b52-8916-e04f395b5f87"
      unitRef="U_USD">5000000</inzy:FutureOfferingsOfCommonStock>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="C_a9bb1918-b1d7-45e7-8152-c53d74f19eda"
      decimals="-5"
      id="F_c382ed12-d132-460b-b27a-ed21fdcdc5e6"
      unitRef="U_USD">500000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:LineOfCreditFacilityCommitmentFeeAmount
      contextRef="C_0c02063f-a103-4d30-8717-1985a331947e"
      decimals="-5"
      id="F_0a57bcbb-5f64-488f-864d-1c3a2dd7731a"
      unitRef="U_USD">400000</us-gaap:LineOfCreditFacilityCommitmentFeeAmount>
    <inzy:LendersReimbursedAmount
      contextRef="C_0c02063f-a103-4d30-8717-1985a331947e"
      decimals="-5"
      id="F_cc329e81-1afe-4e36-8865-001c86346ae1"
      unitRef="U_USD">100000</inzy:LendersReimbursedAmount>
    <inzy:SummarizesOfImpactTermLoanTableTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_d19eac8d-4ebd-4303-a0c4-5aae2ac47f49">&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the impact of the term loan on the Company&#x2019;s consolidated balance sheet at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:54.64%;"&gt;&lt;/td&gt;
        &lt;td style="width:5.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Gross proceeds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Carrying value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44,769&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</inzy:SummarizesOfImpactTermLoanTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_e801b7e0-1800-4b92-b79d-f332bd7bfb1d"
      unitRef="U_USD">45000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_1083c65f-c5bb-448c-ab4c-0da930814a33"
      unitRef="U_USD">231000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_97db1235-9947-4364-b1ad-ae37ceb63633"
      unitRef="U_USD">44769000</us-gaap:LongTermDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_daba7b32-e06a-49d7-a908-f246d696727f">&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Future principal payments, which include the Final Fee, in connection with the Loan Agreement as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 are as follows (dollar amounts in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:54.64%;"&gt;&lt;/td&gt;
        &lt;td style="width:5.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fiscal Year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,305&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;47,813&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;text-decoration:line-through;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;text-decoration:line-through;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="C_02f9e665-ab6c-4248-ac91-2158ec322783"
      decimals="-3"
      id="F_fcf118ce-e866-49a2-a75a-0462e537f6d0"
      unitRef="U_USD">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="C_02f9e665-ab6c-4248-ac91-2158ec322783"
      decimals="-3"
      id="F_8727c29f-01ab-421c-aa92-93db0d4d00fb"
      unitRef="U_USD">14508000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="C_02f9e665-ab6c-4248-ac91-2158ec322783"
      decimals="-3"
      id="F_6a3a7d43-2f6c-48f2-99f9-9f6f6523acc4"
      unitRef="U_USD">33305000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturingInYearsTwoAndThree
      contextRef="C_02f9e665-ab6c-4248-ac91-2158ec322783"
      decimals="-3"
      id="F_2087345f-a4dc-4de3-8eb1-dd06e2f10c95"
      unitRef="U_USD">47813000</us-gaap:LongTermDebtMaturingInYearsTwoAndThree>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_21d9503d-5f33-4944-8bf9-9665cb79f6e2">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;9. Stockholders&#x2019; Equity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;July 2023 Underwritten Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On July 27, 2023, the Company entered into an underwriting agreement with BofA Securities, Inc., Cowen and Company, LLC and Piper Sandler &amp;amp; Co., as representatives of the several underwriters named therein (collectively, the &#x201c;Underwriters&#x201d;), relating to an underwritten public offering of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,375,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company's common stock, which included &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,875,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;issued upon the exercise in full by the underwriters of their option to purchase additional shares (the "July 2023 Shares"). The closing of the&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;offering &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;took place on August 1, 2023. All of the July 2023 Shares were sold by the Company. The offering price of the July 2023 Shares was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.80&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share. Net proceeds from the sale and issuance of the July 2023 Shares were approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;64.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, after deducting underwriting discounts and commissions and offering expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;April 2022 Underwritten Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On August 11, 2021, the Company filed a universal shelf registration statement on Form S-3, which was declared effective on August 23, 2021, (the "Registration Statement"). Under the Registration Statement, the Company may offer and sell up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;200.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of a variety of securities, including common stock, preferred stock, depositary shares, debt securities, warrants, subscription &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; rights or units from time to time pursuant to one or more offerings at prices and terms to be determined at the time of the sale. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On April 14, 2022, the Company entered into an underwriting agreement with Jefferies LLC and Cowen and Company, LLC, relating to an underwritten offering under the Registration Statement of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,276,987&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock (the "Shares") and, in lieu of common stock to certain investors, pre-funded warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,523,013&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock. The closing of the offering took place on April 19, 2022. The offering price of the Shares was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.69&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share and the offering price of the pre-funded warrants was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.6899&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share underlying each pre-funded warrant. Warrants must be exercised by means of a cashless exercise. Net proceeds from the offering were approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;68.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, after deducting underwriting discounts and commissions and offering expenses.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On June 10, 2022, the Company and each holder of the pre-funded warrants entered into amended and restated pre-funded warrants solely to eliminate the seven-year expiration date of the pre-funded warrants. Each amended and restated pre-funded warrant is now exercisable for $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share of common stock from the original date of issuance until the date the pre-funded warrant is exercised in full. All other terms of the pre-funded warrants remain unchanged. The pre-funded warrants contain standard adjustment provisions if certain corporate events were to happen.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The pre-funded warrants are classified as a component of permanent equity and were recorded at the issuance date using a relative fair value allocation method. The pre-funded warrants are equity classified because they are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the holders to receive a fixed number of shares of common stock upon exercise. In addition, such pre-funded warrants do not provide any guarantee of value or return. As of December 31, 2022, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;197,251&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; pre-funded warrants had been exercised by means of cashless exercise in exchange for the issuance of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;197,240&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company's common stock. As of December 31, 2023, the remaining &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,325,762&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; pre-funded warrants had been exercised by means of cashless exercise in exchange for the issuance of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,325,644&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company's common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Open Market Sale Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In connection with the filing of the Registration Statement on August 11, 2021, the Company entered into an Open Market Sale Agreement with Jefferies LLC, as sales agent, pursuant to which the Company may offer and sell shares of its common stock with an aggregate offering price of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million under an &#x201c;at-the-market&#x201d; offering program. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company sold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,553,995&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of its common stock pursuant to the Open Market Sale Agreement for aggregate net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Equity Incentive Plans&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In January 2017, the Company&#x2019;s board of directors and stockholders adopted the 2017 Equity Incentive Plan, which was amended and restated in July 2017, (as so amended and restated, the &#x201c;2017 Plan&#x201d;), which provided for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards and other stock awards. The maximum number of shares of common stock that were authorized for issuance under the 2017 Plan was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,730,496&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On July 17, 2020, the Company&#x2019;s stockholders approved the 2020 Stock Incentive Plan (the &#x201c;2020 Plan&#x201d;), which became effective on July 23, 2020. The 2020 Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock units, and other stock-based awards. The number of shares of the Company&#x2019;s common stock reserved for issuance under the 2020 Plan&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,588,315&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares, plus the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;426,065&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock remaining available for issuance under the 2017 Plan as of July 23, 2020. The number of shares reserved under the 2020 Plan will be annually increased on each January 1 through January 1, 2030 by the lower of (i) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the number of shares of common stock outstanding on the first day of such fiscal year and (ii) an amount determined by the Company&#x2019;s board of directors.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of the effective date of the 2020 Plan, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; further &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;awards will be made under the 2017 Plan. Any options or awards outstanding under the 2017 Plan are governed by their existing terms. The shares of the Company&#x2019;s common stock subject to outstanding awards under the 2017 Plan that expire, terminate, or are otherwise surrendered, cancelled, forfeited, or repurchased by&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Company at their original issuance price pursuant to a contractual repurchase right will be added back to the shares of common stock available for issuance under the 2020 Plan. No more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,588,315&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock may be granted subject to incentive stock options under the 2020 Plan. On January 1, 2024 and 2023, the number of shares of common stock reserved under the 2020 Plan was increased by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,470,750&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,615,774&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On February 27, 2023, the Company's board of directors adopted the 2023 Inducement Stock Incentive Plan (the "Inducement Plan"). The Inducement Plan provides for the grant of non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock units, and other stock-based awards to persons who (a) were not previously an employee or director or (b) are commencing employment with the Company following a bona fide period of non-employment, in either case, as an inducement material to such person&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2019;s entry into employment with the Company and in accordance with the requirements of the Nasdaq Stock Market Rule 5635(c)(4). As of December 31, 2023, the maximum number of shares of the Company's common stock reserved for issuance under the Inducement Plan is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For the years ended December 31, 2023 and 2022, the Company recognized stock-based compensation expense of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively. The fair value of shares vested for the years ended December 31, 2023 and 2022 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes stock option activity under the Company&#x2019;s equity incentive plans since &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2022:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.11%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.662%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.942%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.662%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value (1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,687,811&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.06&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,019,590&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43,209&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;627,526&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,036,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.71&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,615&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercisable at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,370,210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.05&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.37&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested and expected to vest at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,036,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.71&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,615&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#x2019;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The weighted average grant date fair value of stock options granted in the years ended December 31, 2023 and 2022 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.47&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.45&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, respectively. The aggregate intrinsic value of stock options exercised during the years ended December 31, 2023 and 2022 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The total unrecognized compensation cost related to outstanding employee option awards as of December 31, 2023 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and is expected to be recognized over a weighted average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For purposes of calculating stock-based compensation expense, the Company estimates the fair value of stock options using the Black-Scholes option-pricing model. This model incorporates various assumptions, including the expected volatility, expected term, and interest rates. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The underlying assumptions used to value stock options granted to participants using the Black-Scholes option-pricing were as follows: &lt;/span&gt;&lt;/span&gt;&lt;span style=""&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.883%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.883%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free interest rate range&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.36&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.67&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.59&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.30&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term of options (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.48&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.08&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.48&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Volatility rate range&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;87.26&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;89.67&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;84.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;87.15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Expected Term &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The expected term of stock options represents the weighted average period the stock options are expected to be outstanding. The Company uses the simplified method for estimating the expected term, which calculates the expected term as the average time-to-vesting and the contractual life of the options for stock options issued to participants.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Expected Volatility &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Due to the Company&#x2019;s limited operating history and lack of company-specific historical or implied volatility, the expected volatility assumption was determined by examining the historical volatilities of a group of industry peers whose share prices are publicly available. The Company expects to continue using this approach until such time as it has adequate historical data regarding the volatility of its own traded stock price.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Risk-Free Interest Rate &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The risk-free rate assumption is based on U.S. Treasury instruments, the terms of which were consistent with the expected term of the Company&#x2019;s stock options.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Expected Dividend &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The expected dividend assumption is based on the Company&#x2019;s history and expectation of dividend payouts. The Company has not paid any dividends to date and does not intend to pay dividends.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value of Common Stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;&#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Following the Company's initial public offering, the fair value of the Company&#x2019;s common stock has been determined based on the closing price of the Company&#x2019;s common stock on the Nasdaq Global Select Market on the grant date, with consideration of whether there is material nonpublic information that could impact that estimated fair value when it is released.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;RSUs&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Activity related to restricted stock units ("RSUs") for the year ended December 31, 2023 is summarized in the table below:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding as of January 1, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Canceled / Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested / Settled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The weighted-average grant date fair value of RSUs granted in the year ended December 31, 2023 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"&gt;5.73&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share. The total unrecognized compensation cost related to outstanding RSUs as of December 31, 2023 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and is expected to be recognized over a weighted-average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;3.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;years.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On July 17, 2020, the Company&#x2019;s stockholders approved the 2020 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;), which became effective on July 23, 2020. The ESPP initially provided participating employees with the opportunity to purchase up to an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;198,539&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The number of shares of common stock reserved for issuance under the ESPP will increase each January 1 through January 1, 2031, in an amount equal to the lowest of (1) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;397,079&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock, (2) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the number of shares of the Company&#x2019;s common stock outstanding on the first day of such fiscal year, and (3) an amount determined by the Company&#x2019;s board of directors.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; On January 1, 2024 and 2023, the number of shares of common stock reserved under the ESPP was increased by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"&gt;397,079&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"&gt;397,079&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares, respectively. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company activated its first six month offering period under the ESPP on April 1, 2022. As of December 31, 2023, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"&gt;116,972&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares have been purchased by employees under the ESPP.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0bbdd3e1-67b1-4179-a2ad-34d654b46a8f"
      decimals="0"
      id="F_e75a49a8-f91c-4bcc-9a9d-51cd2826b99b"
      unitRef="U_shares">14375000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <inzy:AdditionalSharesIssued
      contextRef="C_f1c3e67f-9945-41f0-944d-8d830ba9739e"
      decimals="0"
      id="F_a91c1123-fe00-4903-87ae-7683056ed697"
      unitRef="U_shares">1875000</inzy:AdditionalSharesIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_5fadef3d-5895-480b-9d9e-def33be1c27e"
      decimals="2"
      id="F_7447e331-8697-46c3-a6c1-d76be72d9404"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.8</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_23e7c97e-bcf3-4add-9b14-99d3a9ed6274"
      decimals="-5"
      id="F_214d47c8-9558-4310-8be5-0a236f58d127"
      unitRef="U_USD">64400000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <inzy:AvailableForDebtSecuritiesEquitySecuritiesNonCurrent
      contextRef="C_8bc77b63-43ca-4a39-8474-2b255355a3eb"
      decimals="-5"
      id="F_a71adbc9-3726-499a-afbf-79dda4bfd72c"
      unitRef="U_USD">200000000</inzy:AvailableForDebtSecuritiesEquitySecuritiesNonCurrent>
    <inzy:UnderwrittenOffering
      contextRef="C_c1e93c7a-08ea-4229-9081-72bf42fdc58f"
      decimals="INF"
      id="F_d5b7e299-7149-4eef-abfc-bbec95990387"
      unitRef="U_shares">16276987</inzy:UnderwrittenOffering>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_578990c4-7b65-4722-8ca8-59f878771332"
      decimals="INF"
      id="F_991516bf-b9aa-40af-9987-4634eb21227b"
      unitRef="U_shares">3523013</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_53f07547-6128-43d4-94ec-d5cd4d0f51e5"
      decimals="2"
      id="F_9e3ff73a-d9c0-4dfe-b43c-fe57e7112f44"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.69</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_578990c4-7b65-4722-8ca8-59f878771332"
      decimals="4"
      id="F_d92e8396-1f84-4546-8e97-e9494f19bac6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.6899</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_c1e93c7a-08ea-4229-9081-72bf42fdc58f"
      decimals="-5"
      id="F_d4b58815-1011-4dd9-9dba-437be07a3b26"
      unitRef="U_USD">68300000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_bb47b565-7017-4ae4-8380-7d7bb5c73132"
      decimals="4"
      id="F_6d2f30b9-8e6a-4305-a856-b278517f6f5e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_67c9227f-23fa-4d03-94ed-39eb46d276a9"
      decimals="0"
      id="F_576f0f3d-e449-4bdb-92f1-9203e52eca56"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">197251</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_67c9227f-23fa-4d03-94ed-39eb46d276a9"
      decimals="INF"
      id="F_7f722c15-673a-4228-aaaf-d7609a139eeb"
      unitRef="U_shares">197240</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_1d9a39c0-b43f-460b-b719-403d215c02a3"
      decimals="0"
      id="F_53d108af-805d-4e58-9b9a-6c25ca66f252"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3325762</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_1d9a39c0-b43f-460b-b719-403d215c02a3"
      decimals="INF"
      id="F_31136318-ae9f-4321-85ce-7027551a8273"
      unitRef="U_shares">3325644</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockSharesSubscriptions
      contextRef="C_8bc77b63-43ca-4a39-8474-2b255355a3eb"
      decimals="-5"
      id="F_202c9b84-d883-4d98-a57a-7a9344dc8a29"
      unitRef="U_USD">50000000</us-gaap:CommonStockSharesSubscriptions>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_0502b5cf-19d3-4a39-bb6c-6e6617f1dc75"
      decimals="0"
      id="F_ea51f265-b41a-425f-8d81-385adbbd44eb"
      unitRef="U_shares">3553995</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="C_0502b5cf-19d3-4a39-bb6c-6e6617f1dc75"
      decimals="-5"
      id="F_1726532e-bb0a-44c4-845d-030264d24fd9"
      unitRef="U_USD">21200000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_bebe8a61-3f52-4590-a963-a6915fc4e374"
      decimals="INF"
      id="F_f394a5ba-8f67-47fd-b8fd-d07a8a231f66"
      unitRef="U_shares">2730496</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_29802e4b-9def-4267-9561-f1e6310a9710">On July 17, 2020, the Company&#x2019;s stockholders approved the 2020 Stock Incentive Plan (the &#x201c;2020 Plan&#x201d;), which became effective on July 23, 2020. The 2020 Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock units, and other stock-based awards. The number of shares of the Company&#x2019;s common stock reserved for issuance under the 2020 Plan</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_6f3ac30a-0134-4683-b65a-b99db351909d"
      decimals="INF"
      id="F_03c0a04a-1ea2-4469-8360-3e9de5452b0d"
      unitRef="U_shares">1588315</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_e462903e-5095-4918-b351-d475a954fa3c"
      decimals="INF"
      id="F_22a4276e-8641-46e2-baef-b1e4ba0668bf"
      unitRef="U_shares">426065</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_ecaeeeb0-1d3a-46e8-a993-a422899cf67d"
      decimals="2"
      id="F_414d9d84-ec40-4d1f-85ce-18a19b901c2a"
      unitRef="U_pure">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_c5b05844-1535-4e7e-bc09-618ad8076340"
      decimals="INF"
      id="F_2a9c101e-678b-4167-9acf-8278e6bcc45c"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_6f3ac30a-0134-4683-b65a-b99db351909d"
      decimals="INF"
      id="F_baa2f23a-1454-4d79-b8df-767c14e736e0"
      unitRef="U_shares">1588315</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_5bc7e1b8-abf2-44b5-9b32-535f64c92fa2"
      decimals="0"
      id="F_8aaa1ce0-78de-45b4-8efb-b4829a3300a4"
      unitRef="U_shares">2470750</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_31d32f64-dc44-41d7-bce8-ff6cf58b79cc"
      decimals="0"
      id="F_2dd33430-c1b7-455c-8d96-8de3605eb4ff"
      unitRef="U_shares">1615774</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_e9fc3ff4-5b7b-4b15-a31d-763d0bfe62db"
      decimals="0"
      id="F_346207fa-f98f-41ea-a412-8fc780f07f4d"
      unitRef="U_shares">1000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-5"
      id="F_7be9dce1-e3d1-4f12-abec-34400967ce0f"
      unitRef="U_USD">7000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-5"
      id="F_f8ad34b8-7279-4e38-b242-d357f8d94dc6"
      unitRef="U_USD">7700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-5"
      id="F_ba5979b9-d669-40da-a411-345fd6b12648"
      unitRef="U_USD">7600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-5"
      id="F_de172955-7615-4661-bd1c-b75554e29536"
      unitRef="U_USD">9000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_daa4ccaa-c364-4d34-9bad-612142fa100a">&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes stock option activity under the Company&#x2019;s equity incentive plans since &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2022:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.11%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.662%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.942%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.662%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value (1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,687,811&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.06&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,019,590&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43,209&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;627,526&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,036,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.71&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,615&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercisable at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,370,210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.05&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.37&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested and expected to vest at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,036,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.71&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,615&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#x2019;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="INF"
      id="F_7f434c12-d687-4baa-94c8-c60a8c2843f5"
      unitRef="U_shares">4687811</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="2"
      id="F_91e36684-c288-4bef-976d-6d313ef002b0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      id="F_49c62019-4213-4431-9f3a-1b152c902b27">P8Y21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_212880b3-7bbd-414d-81a7-6f5c3c25b8a3"
      unitRef="U_USD">18000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="0"
      id="F_8b566164-6bd3-45d2-ad61-ebe864595bbf"
      unitRef="U_shares">3019590</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="2"
      id="F_93b814d2-98bf-4865-a529-66058165491f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.53</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="0"
      id="F_b96d059a-55cf-4b85-b1ad-f2c2f18d0eff"
      unitRef="U_shares">43209</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="2"
      id="F_d724af64-dac3-4617-9196-f02134e0826b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.7</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="0"
      id="F_9e96a3b2-30ac-4833-8be4-3ec7d3eef215"
      unitRef="U_shares">627526</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="2"
      id="F_9a9cb34c-cba6-4f22-92d5-121ee07f8215"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.43</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="INF"
      id="F_09ca56cb-9fdd-4d28-a19c-9170fd0de9c0"
      unitRef="U_shares">7036666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="2"
      id="F_40ed48fa-de60-4afa-a347-0ca5cc3a8e9d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_9cd50fe9-9e2d-455e-b4ad-7f69cb055ea3">P7Y8M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_8286ff25-fc6a-4473-a014-fe4d629b6f5c"
      unitRef="U_USD">4615000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="0"
      id="F_566225b0-2e32-4d22-8134-9a270e41da65"
      unitRef="U_shares">3370210</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="2"
      id="F_dc8900e4-109f-4b69-856a-a71d51fb9de6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_84c591d6-4dc6-4aa5-862c-487ea244c898">P6Y4M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_5d11eac6-1566-416a-92bc-7160911079e4"
      unitRef="U_USD">3007000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="INF"
      id="F_17935371-a703-406d-a3ba-6f9fbef32384"
      unitRef="U_shares">7036666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="2"
      id="F_dda6459c-1e3e-4e23-ba20-758679f9d638"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_d3cd3473-47a5-4cdc-8b8e-0d3fa50ace31">P7Y8M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_34c25793-e274-4a98-b618-192bea48ea94"
      unitRef="U_USD">4615000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_909f663f-1f61-4e6b-b9d6-919c23e28089"
      decimals="2"
      id="F_9725b4f1-8389-4576-af55-c27a17f9c0aa"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_cd4ff0c3-e817-48e8-b8c3-ca0078eec69f"
      decimals="2"
      id="F_503757dd-a258-460f-a34e-64ff99b1bd88"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_909f663f-1f61-4e6b-b9d6-919c23e28089"
      decimals="-5"
      id="F_311f19dc-32dc-4d85-9829-6b974259d819"
      unitRef="U_USD">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_cd4ff0c3-e817-48e8-b8c3-ca0078eec69f"
      decimals="-5"
      id="F_b93bc725-3f79-406c-b01f-e82657d3450f"
      unitRef="U_USD">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-5"
      id="F_96c2e989-4dc2-49fa-94a0-213232ff9de2"
      unitRef="U_USD">11600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_af7ec8d1-b036-43a4-8e4e-400b68d221bb">P2Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_b0deff98-ee90-44e0-a82e-3a868f7f0bbb">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The underlying assumptions used to value stock options granted to participants using the Black-Scholes option-pricing were as follows: &lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.883%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.883%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free interest rate range&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.36&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.67&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.59&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.30&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term of options (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.48&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.08&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.48&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Volatility rate range&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;87.26&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;89.67&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;84.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;87.15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="4"
      id="F_76111b75-6fad-4cfb-b2cc-5b1260497528"
      unitRef="U_pure">0.0336</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="4"
      id="F_3d579463-fb19-48c4-978b-f8e06cb87550"
      unitRef="U_pure">0.0467</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="4"
      id="F_5f863a87-cc34-40c4-bcd1-5d0c5639ec99"
      unitRef="U_pure">0.0159</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="4"
      id="F_0f50d03f-efa6-4aa8-a24a-ea2e1a1bc035"
      unitRef="U_pure">0.043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="2"
      id="F_a4fe7cbf-6b16-4a14-86df-d3ba96d0a5c1"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="2"
      id="F_07244c18-368b-4f2d-8bf2-eb1c017bc529"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_ce440ee2-4c72-4b3f-867c-b18a4779f0de"
      id="F_37da54b5-c4a0-4940-8f5f-6831086aad29">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_fc80a413-7ca1-4fd4-9918-01e35939d5b6"
      id="F_cb862c2e-67a7-46cb-b544-ca3ad52b9b51">P6Y5M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_8f668d05-5207-4a0e-8751-b2c77362080c"
      id="F_47d38b36-1388-48f6-a7a8-33f49778d360">P5Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_809272a0-4381-416d-b6c1-4926d329a113"
      id="F_516d44c8-0d75-42cb-beee-6b686b2b766f">P6Y5M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="4"
      id="F_572fbc7a-2486-4da1-9d1e-d7aff73557f9"
      unitRef="U_pure">0.8726</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="4"
      id="F_c876b390-23ee-4f1c-8dab-707ddcba5b7e"
      unitRef="U_pure">0.8967</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="4"
      id="F_12b595ea-1c1c-482e-9da4-b7286b1d69d8"
      unitRef="U_pure">0.845</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="4"
      id="F_975293f8-77c9-4c0d-8b45-61bbeabc01e0"
      unitRef="U_pure">0.8715</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_bbf3a3f3-9d4d-4980-9ac1-327a9b82958d">&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Activity related to restricted stock units ("RSUs") for the year ended December 31, 2023 is summarized in the table below:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding as of January 1, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Canceled / Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested / Settled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_c7103008-51fd-4024-8f26-143b54185554"
      decimals="0"
      id="F_dbf05ff7-8344-4dc5-b37f-b513960ad11c"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_095b17b0-4474-4132-8919-5e9087e56021"
      decimals="0"
      id="F_4e1a1a1e-609e-42f1-aa65-b7685c7a7783"
      unitRef="U_shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_095b17b0-4474-4132-8919-5e9087e56021"
      decimals="0"
      id="F_e6e2e8e8-f793-4430-8e64-04a5ea581530"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="C_095b17b0-4474-4132-8919-5e9087e56021"
      decimals="0"
      id="F_a5841c09-1984-4925-90ec-0210e403dfce"
      unitRef="U_shares">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_36317d60-ef8e-4485-8be4-dbe28ed900be"
      decimals="0"
      id="F_b15311a0-263a-46f0-bb11-4897616eeeeb"
      unitRef="U_shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_095b17b0-4474-4132-8919-5e9087e56021"
      decimals="2"
      id="F_1a2d3a8c-83fa-4d0b-8a79-557d0233d8a7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_36317d60-ef8e-4485-8be4-dbe28ed900be"
      decimals="-5"
      id="F_c1e67522-781b-4371-867c-0ffcc7fec9ed"
      unitRef="U_USD">500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <inzy:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition2
      contextRef="C_095b17b0-4474-4132-8919-5e9087e56021"
      id="F_6094ef1a-6359-44fe-8c10-0ac18c6292cd">P3Y2M12D</inzy:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_41e6d162-5110-43e5-831b-9b8060b23a84"
      decimals="INF"
      id="F_7684a5d9-c6d8-4e6d-87e8-7e1fc9cad2a2"
      unitRef="U_shares">198539</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
      contextRef="C_6eef9496-93b0-48ca-b3cf-47eb906b4a01"
      id="F_5ab628ea-25bc-43d9-b34d-af552c7c07bc">The number of shares of common stock reserved for issuance under the ESPP will increase each January 1 through January 1, 2031, in an amount equal to the lowest of (1) 397,079 shares of the Company&#x2019;s common stock, (2) 1% of the number of shares of the Company&#x2019;s common stock outstanding on the first day of such fiscal year, and (3) an amount determined by the Company&#x2019;s board of directors.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_6eef9496-93b0-48ca-b3cf-47eb906b4a01"
      decimals="INF"
      id="F_24f8c329-e27b-4b27-ab27-92a041df5326"
      unitRef="U_shares">397079</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_6eef9496-93b0-48ca-b3cf-47eb906b4a01"
      decimals="2"
      id="F_62df0eb3-b31c-4b80-895a-b7a138489765"
      unitRef="U_pure">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_b5a7dbf5-13da-420d-8cd7-0ede5acf17cc"
      decimals="0"
      id="F_4f066e64-94c9-4d85-854b-dcbf2531890d"
      unitRef="U_shares">397079</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_fe23324a-e605-4ce7-a370-83d0da0161d5"
      decimals="0"
      id="F_e18de26a-adc5-4835-a769-7a35b3ba3714"
      unitRef="U_shares">397079</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_263cecd1-5504-45b5-bec1-fb7bb72fed3f"
      decimals="0"
      id="F_0a6226ed-59fb-4248-bb93-3422fc39076d"
      unitRef="U_shares">116972</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_61095702-f03a-48ca-96e2-0b215a58b6a7">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;10. Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the years ended December 31, 2023 and 2022, the Company recorded pre-tax net losses of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively. Since it maintains a full valuation allowance on its deferred tax assets, the Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t record an income tax provision for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A reconciliation of the U.S. federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:59.088%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.277%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.44%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.277%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.92%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="8" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal income tax at statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State income tax, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal and state research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Effective income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;     &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Deferred taxes are recognized for temporary differences between the bases of assets and liabilities for financial statement and income tax purposes. &lt;/span&gt;&lt;span style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The significant components of the Company&#x2019;s deferred tax assets as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 are composed of the following (dollar amounts in thousands): &lt;/span&gt;&lt;/span&gt;&lt;span style=""&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net operating losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;42,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,903&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,220&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,930&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,604&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;916&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;758&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,759&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;499&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Capitalized research and experimental expenditures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,959&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,467&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;351&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;297&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;89,316&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63,077&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;88,906&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;62,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;410&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Depreciation of fixed assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Right of use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;308&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;422&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;38&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Gross deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;410&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non-current net deferred tax assets (liabilities)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, the Company had gross federal net operating loss carryforwards ("NOLs") of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"&gt;164.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which may be available to offset future taxable income. Of the federal NOLs, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"&gt;5.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2037&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;158.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million do not expire. As of December 31, 2023, the Company had gross state NOLs of  &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"&gt;135.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which may be available to offset future taxable income and which begin to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2037&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As required by FASB ASC Topic 740, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, management of the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, which are composed principally of capitalized research and experimental ("R&amp;amp;E") expenditures, NOLs, and research and development credits. Under the applicable accounting standards, management has considered the Company&#x2019;s history of losses and concluded that it is more likely than not that the Company will not recognize the benefits of federal and state deferred tax assets. Accordingly, a full valuation allowance of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"&gt;88.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"&gt;62.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million has been established at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and December 31, 2022, respectively. The increase in the valuation allowance of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"&gt;26.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million during &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2023 was primarily due to increases in capitalized R&amp;amp;E expenditures, NOLs, and research and development credits generated by the Company.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company also has federal and state research and development credit carryforwards totaling &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"&gt;17.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The federal research and development credit carryforwards will begin to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2038&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, unless previously utilized. The state research and development credit carryforwards will begin to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2032&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;unless previously utilized. The Company has generated research and development credits but has not conducted a study to document the qualified activity. This study&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;may &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;result in an adjustment to the Company&#x2019;s research and development credit carryforwards; however, until a study is completed and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#x2019;s research and development credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the deferred tax asset established for the research and development credit carryforwards and the valuation allowance.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Effective January 1, 2022, a provision of the Tax Cuts and Jobs Act ("TCJA") changed the treatment of R&amp;amp;E expenditures under Section 174 of the United States Internal Revenue Code (the "Internal Revenue Code"). Prior to the TCJA being effective, businesses have had the option of deducting Section 174 expenses in the year incurred or capitalizing and amortizing the costs over five years. The new TCJA provision, however, eliminates this option and requires Section 174 expenses associated with research conducted in the United States to be capitalized and amortized over a five-year period. For expenses associated with research outside of the United States, Section 174 expenses will be capitalized and amortized over a 15-year period.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s ability to use its NOLs and tax credit carryforwards to offset taxable income is subject to restrictions under Sections 382 and 383 of the Internal Revenue Code. Under the Internal Revenue Code provisions, certain substantial changes in the Company&#x2019;s ownership, including the sale of the Company or significant changes in ownership due to sales of equity, have limited and may limit in the future, the amount of NOLs which could be used annually to offset future taxable income. The Company has not yet conducted an analysis of ownership changes. The Company may also experience ownership changes in the future as a result of subsequent shifts in its stock ownership, some of which may be outside the Company&#x2019;s control. As a result, the Company&#x2019;s ability to use its pre-change NOLs to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to the Company. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. Under the TCJA, the use of federal NOLs arising in taxable years beginning after December 31, 2017 is limited to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;80&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of current year taxable income and NOLs arising in taxable years ending after December 31, 2017 may not be carried back (though any such NOLs may be carried forward indefinitely).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company establishes reserves for uncertain tax positions based on management&#x2019;s assessment of exposures associated with tax positions taken on tax return filings. The tax reserves are analyzed periodically and adjustments are made as events occur that warrant adjustment to the reserves. The Company does not have any reserves for uncertain tax positions as of December 31, 2023 and any change in position would result in a change in the valuation allowance maintained against its net deferred tax assets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Interest and penalty charges, if any, related to unrecognized tax benefits are classified as income tax expense in the accompanying consolidated statements of operations and comprehensive loss. As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company had no accrued interest related to uncertain tax positions. Since the Company is in a loss carryforward position, the Company is generally subject to examination by the U.S. federal, state, and local income tax authorities for all tax years in which a loss carryforward is available.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-5"
      id="F_1470d594-ffef-44bd-9e05-d7f4e197b539"
      unitRef="U_USD">-71200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-5"
      id="F_97362368-b5cf-4591-952c-66fff35a8fd2"
      unitRef="U_USD">-67100000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-6"
      id="F_4250fd7a-fbea-4648-9a25-a9111075a3f8"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-6"
      id="F_37f06261-6c64-43fd-b727-3787addba09f"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_ac29af33-b8a0-4c3a-adf5-087a20f7b7e5">&lt;p style="text-indent:9.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A reconciliation of the U.S. federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:59.088%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.277%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.44%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.277%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.92%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="8" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal income tax at statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State income tax, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal and state research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Effective income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="3"
      id="F_e1cb889b-fd85-40a0-98dc-fb49ffbd3af1"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="3"
      id="F_410d9c31-72b7-4734-9640-2f3fbac3848c"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <inzy:Effectiveincometaxratereconciliationpermanentdifferences
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="3"
      id="F_b9615d6a-10d9-424c-8ba5-c7539021006d"
      unitRef="U_pure">-0.01</inzy:Effectiveincometaxratereconciliationpermanentdifferences>
    <inzy:Effectiveincometaxratereconciliationpermanentdifferences
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="3"
      id="F_2c092843-27b3-42dc-a555-697c906a70a8"
      unitRef="U_pure">-0.016</inzy:Effectiveincometaxratereconciliationpermanentdifferences>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="3"
      id="F_1778e033-aa70-4498-bad2-e4676eb77999"
      unitRef="U_pure">0.081</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="3"
      id="F_3f3a5c87-a571-49cd-b4e4-2e1d1ff12f78"
      unitRef="U_pure">0.054</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="3"
      id="F_e6d33a90-246d-47ec-8234-f3dc21a258e7"
      unitRef="U_pure">0.091</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="3"
      id="F_0905f88e-c54c-4211-9ffb-9c5b77e3b4ab"
      unitRef="U_pure">0.055</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="3"
      id="F_4cfba11d-da0b-4ee8-8fdb-b8d2af288ab9"
      unitRef="U_pure">-0.372</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="3"
      id="F_3d4a0203-b219-46bf-88af-4e584981b346"
      unitRef="U_pure">-0.303</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="2"
      id="F_35590ff5-b7c1-4fcc-884d-171819bad8cd"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="2"
      id="F_ff1adfeb-dee5-4445-a580-16ad2715d442"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_f9eb7fec-181d-49b7-8945-18d89b9a184e">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The significant components of the Company&#x2019;s deferred tax assets as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 are composed of the following (dollar amounts in thousands): &lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net operating losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;42,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,903&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,220&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,930&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,604&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;916&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;758&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,759&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;499&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Capitalized research and experimental expenditures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,959&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,467&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;351&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;297&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;89,316&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63,077&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;88,906&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;62,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;410&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Depreciation of fixed assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Right of use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;308&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;422&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;38&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Gross deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;410&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non-current net deferred tax assets (liabilities)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_cd8528d7-ae94-4242-b663-10ce29275bdc"
      unitRef="U_USD">42999000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_3fc847ab-859c-4549-bfa4-8b488188b890"
      unitRef="U_USD">36144000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_d7ca8458-4c47-44b9-9c6f-ab6190118d71"
      unitRef="U_USD">16903000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_d1729eb1-e084-49d4-b729-a86fbca90587"
      unitRef="U_USD">9220000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_671de964-2d70-4a26-b893-162d82f750b5"
      unitRef="U_USD">1930000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_d1bb6a57-017a-4ef5-a531-5c5a253372cb"
      unitRef="U_USD">1604000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_6ed4e904-62fb-4e05-9825-8192bbfc69e8"
      unitRef="U_USD">916000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_af5c5921-5240-4f79-ab92-ce130eaa3745"
      unitRef="U_USD">758000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <inzy:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_7e5e67ee-ce68-4202-9a2c-fb34456e3a4e"
      unitRef="U_USD">3759000</inzy:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization>
    <inzy:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_56796d58-be4f-49a7-b046-40cc5602e301"
      unitRef="U_USD">3899000</inzy:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization>
    <us-gaap:LeaseIncentiveReceivable
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_6a179603-7970-452a-8d48-c06bfecc2999"
      unitRef="U_USD">499000</us-gaap:LeaseIncentiveReceivable>
    <us-gaap:LeaseIncentiveReceivable
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_71cd708a-a0fd-4304-bce5-5d67297d43ff"
      unitRef="U_USD">688000</us-gaap:LeaseIncentiveReceivable>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_e3736e8b-2b4f-4867-87a9-06138ddde595"
      unitRef="U_USD">21959000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_5e59960d-1fa9-4ff7-86d6-99345eb17ca6"
      unitRef="U_USD">10467000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_fb29c884-f53b-4239-aa61-88312757fd42"
      unitRef="U_USD">351000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_2d684b46-d5fb-4e6d-80ce-82fca8aba04f"
      unitRef="U_USD">297000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_75b390b9-db00-4322-be0e-119cb0a099ec"
      unitRef="U_USD">89316000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_83a4afd0-5b00-4e32-816b-c40c9802d052"
      unitRef="U_USD">63077000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_641decec-727b-47ff-afb7-748d244e665a"
      unitRef="U_USD">88906000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_7ffefd55-6bbf-4371-a171-997acff86831"
      unitRef="U_USD">62468000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_3ae4c811-83ba-4d94-ae1f-a19a7833478b"
      unitRef="U_USD">410000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_fdb837a3-f8e5-4e3b-a2bb-0785e944b9b0"
      unitRef="U_USD">609000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_cabb3f4e-9bf3-4fd9-8edd-4cdc67cff1b1"
      unitRef="U_USD">64000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_214c807f-b62a-42af-bd58-59bce2b35d9f"
      unitRef="U_USD">184000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <inzy:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_c07ce8d7-bb3a-476a-af7e-222d8b190f34"
      unitRef="U_USD">-308000</inzy:DeferredTaxLiabilitiesRightOfUseAssets>
    <inzy:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_20e4102f-ecc2-4552-8007-af750722b42b"
      unitRef="U_USD">-422000</inzy:DeferredTaxLiabilitiesRightOfUseAssets>
    <inzy:Others
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_203fbbf8-6168-4c27-ac7f-90c394781003"
      unitRef="U_USD">-38000</inzy:Others>
    <inzy:Others
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_db506265-853a-4098-b749-fe84119a8bdd"
      unitRef="U_USD">-3000</inzy:Others>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_c4e06f93-0e8c-410f-b70c-0610a3147a7c"
      unitRef="U_USD">410000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_757a50d1-43c1-4613-907c-a3d700f8ade4"
      unitRef="U_USD">609000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-3"
      id="F_56e5d483-9eab-403d-85c4-2d5936db432a"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-3"
      id="F_7e0f8fe0-a82a-428d-a236-d46cf399ee12"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_bbdbd94c-6c63-4c85-99b0-648d3794ad11"
      decimals="-5"
      id="F_f86a9473-44a9-4f9e-bdad-b08a65345ffd"
      unitRef="U_USD">164500000</us-gaap:OperatingLossCarryforwards>
    <inzy:OperatingLossCarryforwardsWithExpirationPeriod
      contextRef="C_bbdbd94c-6c63-4c85-99b0-648d3794ad11"
      decimals="-5"
      id="F_c5c3960d-0d05-4789-8297-6a96de9fcb65"
      unitRef="U_USD">5600000</inzy:OperatingLossCarryforwardsWithExpirationPeriod>
    <inzy:OperatingLossCarryforwardsExpirationYear
      contextRef="C_18a731bb-67c4-4ab0-8890-db73d8f7acd7"
      id="F_39322d91-0126-4af2-9f63-91f89fce511b">2037</inzy:OperatingLossCarryforwardsExpirationYear>
    <inzy:OperatingLossCarryforwardsWithNoExpirationPeriod
      contextRef="C_bbdbd94c-6c63-4c85-99b0-648d3794ad11"
      decimals="-5"
      id="F_882adb88-7dee-4bfc-b213-e135c6551933"
      unitRef="U_USD">158900000</inzy:OperatingLossCarryforwardsWithNoExpirationPeriod>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_3c60cddf-e6e6-40e7-af29-5142f2416154"
      decimals="-5"
      id="F_beb8b4c4-b8ab-4dd6-a4e6-a08165659de2"
      unitRef="U_USD">135600000</us-gaap:OperatingLossCarryforwards>
    <inzy:OperatingLossCarryforwardsExpirationYear
      contextRef="C_a4ab63bc-07be-46e6-aa82-1e04ab169eca"
      id="F_b88aa229-9331-4b54-887e-60698f0f82b0">2037</inzy:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_5c13eb3e-ee93-44a2-85e8-241a737a39d9"
      decimals="-5"
      id="F_535af447-7cf3-4536-b3ee-90e095c99aa3"
      unitRef="U_USD">88900000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0d74cf94-b1f2-497c-915e-d10053a3fdac"
      decimals="-5"
      id="F_e7dd0d9b-dbcb-4e30-84cd-5e6e91b90fc5"
      unitRef="U_USD">62500000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-5"
      id="F_30b3294a-33b0-4c05-9768-354b123221e1"
      unitRef="U_USD">26400000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_eeb4217e-fc77-4296-9ee9-2a609ec3e2d5"
      decimals="-5"
      id="F_8ea1b5ae-4e6b-4bf7-ae16-e206a5f34c8f"
      unitRef="U_USD">17300000</us-gaap:TaxCreditCarryforwardAmount>
    <inzy:TaxCreditCarryForwardExpirationYear
      contextRef="C_d2a5c6ce-86e7-4875-bb49-7e9cb50c94fc"
      id="F_0ab2d1d2-9328-4c04-8db2-fe34692ab2e5">2038</inzy:TaxCreditCarryForwardExpirationYear>
    <inzy:TaxCreditCarryForwardExpirationYear
      contextRef="C_3d6d281a-1b18-436a-aaa0-c7bcf2e894fc"
      id="F_8181dcd0-b9f9-4841-96a6-955a6d8a9e54">2032</inzy:TaxCreditCarryForwardExpirationYear>
    <inzy:TaxCutsAndJobsActFederalNetOperatingLossPercent
      contextRef="C_405879f4-cccf-412e-9ad8-4013cd3d818b"
      decimals="2"
      id="F_ec767be5-4a6c-4a52-bf88-0fa8991140bb"
      unitRef="U_pure">0.80</inzy:TaxCutsAndJobsActFederalNetOperatingLossPercent>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_b183568c-cf0f-4405-92df-3396c7e7a78b">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;11. Net Loss per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Net Loss per Share Attributable to Common Stockholders&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table sets forth the computation of basic and diluted net loss per share for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 (in thousands, except share and per share amounts):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.64%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.64%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="8" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss attributable to common stockholders&#x2014;basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71,169&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67,061&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss per share attributable to common stockholders&#x2014;basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average common shares and pre-funded warrants outstanding&#x2014;basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;51,839,131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37,763,168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has generated a net loss in all periods presented; therefore, the basic and diluted net loss per share attributable to common stockholders are the same as the inclusion of the potentially dilutive securities would be anti-dilutive. Since the shares underlying the pre-funded warrants are issuable for nominal consideration, they are considered outstanding for both basic and diluted earnings per share from the date of issuance. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company excluded the following potential dilutive securities, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated: &lt;/span&gt;&lt;/span&gt;&lt;span style=""&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,036,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,687,811&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,136,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,687,811&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_0fe4cb27-d04d-4909-b902-5c661e2339f1">&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table sets forth the computation of basic and diluted net loss per share for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 (in thousands, except share and per share amounts):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.64%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.64%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="8" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss attributable to common stockholders&#x2014;basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71,169&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67,061&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss per share attributable to common stockholders&#x2014;basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average common shares and pre-funded warrants outstanding&#x2014;basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;51,839,131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37,763,168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-3"
      id="F_6e96a55b-238a-4b4d-8c61-3622ba2710c6"
      unitRef="U_USD">-71169000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-3"
      id="F_ae90facc-7ab7-452d-ab76-6b3b07e69b4f"
      unitRef="U_USD">-67061000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="2"
      id="F_8f72099f-1e51-4f94-9d9e-ce8646b0ff14"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="2"
      id="F_b42c5abb-0d95-42ac-8cd6-d32059308b83"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="2"
      id="F_1922eb0d-b145-4e0c-8f98-1104e2089471"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.78</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="2"
      id="F_86410aed-2ea6-4869-a9cd-7639abdd4444"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.78</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="0"
      id="F_18b1f359-72c3-475d-98d7-880dc26c0bde"
      unitRef="U_shares">51839131</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="0"
      id="F_822da900-f4b0-493d-b8ac-3e450ba2b470"
      unitRef="U_shares">51839131</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="0"
      id="F_a75c828d-a601-47f9-a9f2-8df988da3001"
      unitRef="U_shares">37763168</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="0"
      id="F_6f2eb53e-f55e-44b5-b55c-38937da66a04"
      unitRef="U_shares">37763168</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_7efa4164-af8b-4c52-98d3-f4460bc8c708">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company excluded the following potential dilutive securities, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated: &lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,036,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,687,811&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,136,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,687,811&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_bc04799a-6e65-4820-b17f-b1036be4e528"
      decimals="INF"
      id="F_30004a71-86e0-46b2-852a-cded42cab0a1"
      unitRef="U_shares">7036666</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_16876f16-aca9-4cb2-b583-baf263afbd49"
      decimals="INF"
      id="F_6be484a5-654a-4557-b576-a9729a48414f"
      unitRef="U_shares">4687811</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_8f452f4f-2469-461f-b6e0-17cef1221fa3"
      decimals="INF"
      id="F_201a8c3e-a6f3-4838-8b9e-fc4b62b57656"
      unitRef="U_shares">100000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_cf7fde27-55f9-4b69-9589-3dfbcd890c64"
      decimals="0"
      id="F_0f203645-9b6b-4b17-8437-120a581a7551"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="INF"
      id="F_157f482a-561a-4a60-907d-3cf644cf3101"
      unitRef="U_shares">7136666</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_4ee9c018-375e-4d0f-ab9e-435246e8b7ce"
      decimals="INF"
      id="F_904e492d-22a7-43f8-aab6-831a28222613"
      unitRef="U_shares">4687811</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_b330207d-078a-4874-a796-79424cdcd5b0">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;12. Employee Benefit Plans&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company established a defined contribution savings plan in 2018 for all eligible U.S. employees under Section 401(k) of the Internal Revenue Code. Employees can designate the investment of their 401(k) accounts into several mutual funds. Effective January 1, 2021, the Company implemented a matching policy under which the Company matches &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of an employee&#x2019;s contributions to the 401(k) plan, up to a maximum of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the employee&#x2019;s base salary and bonus paid during the year. For each of the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022, the Company made employer contributions to the 401(k) plan of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="C_f5346b4d-f225-4d76-a62e-df2c1fef5d1f"
      decimals="2"
      id="F_3f01628e-5fb7-4123-ae4a-7fda08762212"
      unitRef="U_pure">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="C_034c291a-b985-4a6b-bfa0-cd3fc75a6bbe"
      decimals="2"
      id="F_efc76103-aa48-4600-be1f-f8c7803f624d"
      unitRef="U_pure">0.06</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      decimals="-5"
      id="F_2124cae2-dbc8-43ae-a9f9-eba99f6e613f"
      unitRef="U_USD">300000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_0d9dede3-5249-4c7a-b353-10144b32c8b6"
      decimals="-5"
      id="F_dfa4490e-b40d-4d92-a57a-1a61953bf441"
      unitRef="U_USD">300000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_a654e8a2-be67-4c8a-a856-140b00703ba3"
      id="F_fc735d02-8587-409e-8f06-c608191fa5cb">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;13. Related Party Transactions&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On May 6, 2021, the Company entered into an amended and restated consulting agreement (the &#x201c;Consulting Agreement&#x201d;) with Danforth Advisors, LLC (&#x201c;Danforth&#x201d;), pursuant to which Danforth, in addition to providing finance, accounting and administrative functions, provided interim chief financial officer services to the Company by Stephen J. DiPalma, Managing Director of Danforth. The Company paid Danforth an agreed upon hourly rate for such services and reimbursed Danforth for expenses. The Consulting Agreement could be terminated by the Company or Danforth with cause, upon &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; days prior written notice, and without cause, upon &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;60&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; days prior written notice. Mr. DiPalma ceased serving as the Company's interim chief financial officer on March 21, 2022 in connection with the appointment of Sanjay S. Subramanian as the Company's Chief Financial Officer ("CFO"). The Company incurred $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of expense for services provided by Danforth during the time Mr. DiPalma was the Company's interim CFO in 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In addition, on May 17, 2021, the Company granted Mr. DiPalma an option to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock (the &#x201c;Option&#x201d;) under the Company&#x2019;s 2020 Stock Incentive Plan at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.90&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The shares underlying the Option vested in full in 2022.&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1
      contextRef="C_e7cf70aa-36bc-46ec-bfe0-94356e1da198"
      id="F_0a2a6272-1c8b-4b4e-8a89-ef7b78fcd6f9">P30D</us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1>
    <us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1
      contextRef="C_d09f7ff2-1a27-45d2-8579-2c27a2426a27"
      id="F_6bb996db-13ee-41bc-89d7-d5a7b63ddcca">P60D</us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1>
    <us-gaap:ManagementFeeExpense
      contextRef="C_0492ee51-d379-44b0-9b36-2dde4f604d4e"
      decimals="-5"
      id="F_2b77ca4f-460b-41eb-8014-6e602c14e1d2"
      unitRef="U_USD">400000</us-gaap:ManagementFeeExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_a74fde5d-3b11-4279-84b0-6eaf17b9fed8"
      decimals="0"
      id="F_116f1246-90ff-4a5c-826e-e5b1978cc3ba"
      unitRef="U_shares">15000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_a74fde5d-3b11-4279-84b0-6eaf17b9fed8"
      decimals="2"
      id="F_832cc156-748a-4086-a8b8-82a6b712de9d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.9</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_6f7932b9-17b8-423d-9f3d-1d9425caa7f3"
      id="F_3941164c-636b-4268-815d-adb0047ba30f">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_6f7932b9-17b8-423d-9f3d-1d9425caa7f3"
      id="F_8afd13af-2d96-4a9e-9a88-d0f8c21990be">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_6f7932b9-17b8-423d-9f3d-1d9425caa7f3"
      id="F_d1ae1f4d-c3ca-4615-a0f2-73d8549ca2d7">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_6f7932b9-17b8-423d-9f3d-1d9425caa7f3"
      id="F_a56a17e5-3f46-4166-83c0-e053126f6806">false</ecd:NonRule10b51ArrAdoptedFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_8286ff25-fc6a-4473-a014-fe4d629b6f5c"
          xlink:label="F_8286ff25-fc6a-4473-a014-fe4d629b6f5c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_34c25793-e274-4a98-b618-192bea48ea94"
          xlink:label="F_34c25793-e274-4a98-b618-192bea48ea94"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_5d11eac6-1566-416a-92bc-7160911079e4"
          xlink:label="F_5d11eac6-1566-416a-92bc-7160911079e4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_212880b3-7bbd-414d-81a7-6f5c3c25b8a3"
          xlink:label="F_212880b3-7bbd-414d-81a7-6f5c3c25b8a3"
          xlink:type="locator"/>
        <link:footnote id="FNT_b26c1e5b-e21a-4bc2-827a-a1536cde1c95" xlink:label="FNT_b26c1e5b-e21a-4bc2-827a-a1536cde1c95" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#x2019;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#x2019;s common stock.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_8286ff25-fc6a-4473-a014-fe4d629b6f5c"
          xlink:to="FNT_b26c1e5b-e21a-4bc2-827a-a1536cde1c95"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_34c25793-e274-4a98-b618-192bea48ea94"
          xlink:to="FNT_b26c1e5b-e21a-4bc2-827a-a1536cde1c95"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_5d11eac6-1566-416a-92bc-7160911079e4"
          xlink:to="FNT_b26c1e5b-e21a-4bc2-827a-a1536cde1c95"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_212880b3-7bbd-414d-81a7-6f5c3c25b8a3"
          xlink:to="FNT_b26c1e5b-e21a-4bc2-827a-a1536cde1c95"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
